### 18653395
Methotrexate	0	12		|O
and	13	16		|O
leucovorin	17	27		|O
double	28	34		|O
-	34	35		|O
modulated	35	44		|O
5	45	46		|O
-	46	47		|O
fluorouracil	47	59		|O
combined	60	68		|O
with	69	73		|O
cisplatin	74	83		|O
(	84	85		|O
MPFL	85	89		|O
)	89	90		|O
in	91	93		|O
metastatic	94	104	metastatic/recurrent head and neck cancer	|B-DISEASE
/	104	105		|I-DISEASE
recurrent	105	114		|I-DISEASE
head	115	119		|I-DISEASE
and	120	123		|I-DISEASE
neck	124	128		|I-DISEASE
cancer	129	135		|I-DISEASE
.	135	136		|O
BACKGROUND	138	148		|O
:	148	149		|O
To	150	152		|O
determine	153	162		|O
the	163	166		|O
efficacy	167	175		|O
and	176	179		|O
safety	180	186		|O
profile	187	194		|O
of	195	197		|O
the	198	201		|O
combination	202	213		|O
of	214	216		|O
cisplatin	217	226		|O
and	227	230		|O
5	231	232		|O
-	232	233		|O
fluorouracil	233	245		|O
modulated	246	255		|O
both	256	260		|O
by	261	263		|O
methotrexate	264	276		|O
and	277	280		|O
leucovorin	281	291		|O
in	292	294		|O
metastatic	295	305	metastatic/recurrent squamous cell carcinoma of the head and neck	|B-DISEASE
/	305	306		|I-DISEASE
recurrent	306	315		|I-DISEASE
squamous	316	324		|I-DISEASE
cell	325	329		|I-DISEASE
carcinoma	330	339		|I-DISEASE
of	340	342		|I-DISEASE
the	343	346		|I-DISEASE
head	347	351		|I-DISEASE
and	352	355		|I-DISEASE
neck	356	360		|I-DISEASE
.	360	361		|O
METHODS	362	369		|O
:	369	370		|O
Twenty	371	377		|O
-	377	378		|O
eight	378	383		|O
patients	384	392		|O
were	393	397		|O
treated	398	405		|O
with	406	410		|O
cisplatin	411	420		|O
40	421	423		|O
mg	424	426		|O
/	426	427		|O
m2	427	429		|O
/	429	430		|O
day	430	433		|O
continuous	434	444		|O
infusion	445	453		|O
for	454	457		|O
24	458	460		|O
hours	461	466		|O
on	467	469		|O
day	470	473		|O
1	474	475		|O
;	475	476		|O
high	477	481		|O
-	481	482		|O
dose	482	486		|O
5	487	488		|O
-	488	489		|O
fluorouracil	489	501		|O
2,000	502	507		|O
mg	508	510		|O
/	510	511		|O
m2	511	513		|O
/	513	514		|O
day	514	517		|O
and	518	521		|O
leucovorin	522	532		|O
100	533	536		|O
mg	537	539		|O
/	539	540		|O
m2	540	542		|O
/	542	543		|O
day	543	546		|O
continuous	547	557		|O
infusion	558	566		|O
for	567	570		|O
48	571	573		|O
hours	574	579		|O
on	580	582		|O
days	583	587		|O
1	588	589		|O
and	590	593		|O
2	594	595		|O
;	595	596		|O
methotrexate	597	609		|O
40	610	612		|O
mg	613	615		|O
/	615	616		|O
m2	616	618		|O
/	618	619		|O
day	619	622		|O
as	623	625		|O
a	626	627		|O
bolus	628	633		|O
infusion	634	642		|O
4	643	644		|O
hours	645	650		|O
before	651	657		|O
5	658	659		|O
-	659	660		|O
fluorouracil	660	672		|O
and	673	676		|O
leucovorin	677	687		|O
on	688	690		|O
day	691	694		|O
1	695	696		|O
.	696	697		|O
The	698	701		|O
treatment	702	711		|O
was	712	715		|O
repeated	716	724		|O
every	725	730		|O
2	731	732		|O
weeks	733	738		|O
in	739	741		|O
a	742	743		|O
cycle	744	749		|O
.	749	750		|O
RESULTS	751	758		|O
:	758	759		|O
The	760	763		|O
overall	764	771		|O
response	772	780		|O
rate	781	785		|O
was	786	789		|O
25%	790	793		|O
,	793	794		|O
and	795	798		|O
14%	799	802		|O
of	803	805		|O
the	806	809		|O
patients	810	818		|O
achieved	819	827		|O
stable	828	834		|O
disease	835	842		|O
status	843	849		|O
.	849	850		|O
Subgroup	851	859		|O
analysis	860	868		|O
demonstrated	869	881		|O
significantly	882	895		|O
improved	896	904		|O
overall	905	912		|O
survival	913	921		|O
in	922	924		|O
the	925	928		|O
disease	929	936		|O
-	936	937		|O
control	937	944		|O
group	945	950		|O
(	951	952		|O
12.0	952	956		|O
months	957	963		|O
vs.	964	967		|O
5.3	968	971		|O
months	972	978		|O
,	978	979		|O
p	980	981		|O
<	981	982		|O
0.001	982	987		|O
)	987	988		|O
.	988	989		|O
Only	990	994		|O
3	995	996		|O
(	997	998		|O
10.7%	998	1003		|O
)	1003	1004		|O
patients	1005	1013		|O
developed	1014	1023		|O
grade	1024	1029		|O
3-4	1030	1033		|O
neutropenia	1034	1045	neutropenia	|B-ADVERSE
,	1045	1046		|O
and	1047	1050		|O
none	1051	1055		|O
developed	1056	1065		|O
grade	1066	1071		|O
3-4	1072	1075		|O
non	1076	1079	non-hematologic toxicity	|B-ADVERSE
-	1079	1080		|I-ADVERSE
hematologic	1080	1091		|I-ADVERSE
toxicity	1092	1100		|I-ADVERSE
.	1100	1101		|O
CONCLUSION	1102	1112		|O
:	1112	1113		|O
This	1114	1118		|O
multiagent	1119	1129		|O
-	1129	1130		|O
containing	1130	1140		|O
regimen	1141	1148		|O
has	1149	1152		|O
an	1153	1155		|O
excellent	1156	1165		|O
safety	1166	1172		|O
profile	1173	1180		|O
and	1181	1184		|O
improved	1185	1193		|O
survival	1194	1202		|O
in	1203	1205		|O
disease	1206	1213		|O
-	1213	1214		|O
control	1214	1221		|O
group	1222	1227		|O
of	1228	1230		|O
patients	1231	1239		|O
with	1240	1244		|O
metastatic	1245	1255	metastatic/recurrent squamous cell carcinoma of the head and neck	|B-DISEASE
/	1255	1256		|I-DISEASE
recurrent	1256	1265		|I-DISEASE
squamous	1266	1274		|I-DISEASE
cell	1275	1279		|I-DISEASE
carcinoma	1280	1289		|I-DISEASE
of	1290	1292		|I-DISEASE
the	1293	1296		|I-DISEASE
head	1297	1301		|I-DISEASE
and	1302	1305		|I-DISEASE
neck	1306	1310		|I-DISEASE
.	1310	1311		|O

### 18556142
Dose	0	4		|O
escalation	5	15		|O
of	16	18		|O
gemcitabine	19	30		|O
is	31	33		|O
possible	34	42		|O
with	43	47		|O
concurrent	48	58		|O
chest	59	64		|O
three	65	70		|O
-	70	71		|O
dimensional	71	82		|O
rather	83	89		|O
than	90	94		|O
two	95	98		|O
-	98	99		|O
dimensional	99	110		|O
radiotherapy	111	123		|O
:	123	124		|O
a	125	126		|O
phase	127	132		|O
I	133	134		|O
trial	135	140		|O
in	141	143		|O
patients	144	152		|O
with	153	157		|O
stage	158	163		|O
III	164	167		|O
non	168	171	non-small-cell lung cancer	|B-DISEASE
-	171	172		|I-DISEASE
small	172	177		|I-DISEASE
-	177	178		|I-DISEASE
cell	178	182		|I-DISEASE
lung	183	187		|I-DISEASE
cancer	188	194		|I-DISEASE
.	194	195		|O
PURPOSE	197	204		|O
:	204	205		|O
To	206	208		|O
determine	209	218		|O
in	219	221		|O
a	222	223		|O
Phase	224	229		|O
I	230	231		|O
study	232	237		|O
the	238	241		|O
maximum	242	249		|O
tolerated	250	259		|O
dose	260	264		|O
of	265	267		|O
weekly	268	274		|O
gemcitabine	275	286		|O
concurrent	287	297		|O
with	298	302		|O
radiotherapy	303	315		|O
in	316	318		|O
locally	319	326		|O
advanced	327	335		|O
non	336	339	non-small-cell lung cancer	|B-DISEASE
-	339	340		|I-DISEASE
small	340	345		|I-DISEASE
-	345	346		|I-DISEASE
cell	346	350		|I-DISEASE
lung	351	355		|I-DISEASE
cancer	356	362		|I-DISEASE
(	363	364		|O
NSCLC	364	369	NSCLC	|B-DISEASE
)	369	370		|O
,	370	371		|O
as	372	374		|O
well	375	379		|O
as	380	382		|O
the	383	386		|O
relationship	387	399		|O
between	400	407		|O
the	408	411		|O
volume	412	418		|O
of	419	421		|O
the	422	425		|O
esophagus	426	435		|O
irradiated	436	446		|O
and	447	450		|O
severe	451	457		|O
esophagitis	458	469	esophagitis	|B-DISEASE
.	469	470		|O
METHODS	471	478		|O
AND	479	482		|O
MATERIALS	483	492		|O
:	492	493		|O
Twenty	494	500		|O
-	500	501		|O
one	501	504		|O
patients	505	513		|O
with	514	518		|O
Stage	519	524		|O
III	525	528		|O
NSCLC	529	534	NSCLC	|B-DISEASE
received	535	543		|O
gemcitabine	544	555		|O
initially	556	565		|O
at	566	568		|O
150	569	572		|O
mg	573	575		|O
/	575	576		|O
m	576	577		|O
(	577	578		|O
2	578	579		|O
)	579	580		|O
/	580	581		|O
wk	581	583		|O
over	584	588		|O
7	589	590		|O
weeks	591	596		|O
concurrently	597	609		|O
with	610	614		|O
chest	615	620		|O
radiotherapy	621	633		|O
to	634	636		|O
63	637	639		|O
Gy	640	642		|O
in	643	645		|O
34	646	648		|O
fractions	649	658		|O
.	658	659		|O
The	660	663		|O
first	664	669		|O
9	670	671		|O
patients	672	680		|O
underwent	681	690		|O
treatment	691	700		|O
with	701	705		|O
two	706	709		|O
-	709	710		|O
dimensional	710	721		|O
(	722	723		|O
2D	723	725		|O
)	725	726		|O
radiotherapy	727	739		|O
;	739	740		|O
the	741	744		|O
remaining	745	754		|O
12	755	757		|O
patients	758	766		|O
,	766	767		|O
with	768	772		|O
three	773	778		|O
-	778	779		|O
dimensional	779	790		|O
conformal	791	800		|O
radiotherapy	801	813		|O
(	814	815		|O
3D	815	817		|O
-	817	818		|O
CRT	818	821		|O
)	821	822		|O
and	823	826		|O
target	827	833		|O
volume	834	840		|O
reduced	841	848		|O
to	849	851		|O
clinically	852	862		|O
apparent	863	871		|O
disease	872	879		|O
.	879	880		|O
Consolidation	881	894		|O
was	895	898		|O
4	899	900		|O
cycles	901	907		|O
of	908	910		|O
gemcitabine	911	922		|O
at	923	925		|O
1000	926	930		|O
mg	931	933		|O
/	933	934		|O
m	934	935		|O
(	935	936		|O
2	936	937		|O
)	937	938		|O
/	938	939		|O
wk	939	941		|O
and	942	945		|O
cisplatin	946	955		|O
60	956	958		|O
mg	959	961		|O
/	961	962		|O
m	962	963		|O
(	963	964		|O
2	964	965		|O
)	965	966		|O
.	966	967		|O
RESULTS	968	975		|O
:	975	976		|O
In	977	979		|O
the	980	983		|O
2D	984	986		|O
group	987	992		|O
,	992	993		|O
the	994	997		|O
dose	998	1002	dose-limiting toxicity	|B-ADVERSE
-	1002	1003		|I-ADVERSE
limiting	1003	1011		|I-ADVERSE
toxicity	1012	1020		|I-ADVERSE
,	1020	1021		|O
Grade	1022	1027		|O
3	1028	1029		|O
esophagitis	1030	1041	esophagitis	|B-ADVERSE
,	1041	1042		|O
occurred	1043	1051		|O
in	1052	1054		|O
3	1055	1056		|O
of	1057	1059		|O
6	1060	1061		|O
patients	1062	1070		|O
in	1071	1073		|O
the	1074	1077		|O
150	1078	1081		|O
-	1081	1082		|O
mg	1082	1084		|O
/	1084	1085		|O
m	1085	1086		|O
(	1086	1087		|O
2	1087	1088		|O
)	1088	1089		|O
/	1089	1090		|O
wk	1090	1092		|O
cohort	1093	1099		|O
and	1100	1103		|O
2	1104	1105		|O
of	1106	1108		|O
3	1109	1110		|O
patients	1111	1119		|O
in	1120	1122		|O
the	1123	1126		|O
125	1127	1130		|O
-	1130	1131		|O
mg	1131	1133		|O
/	1133	1134		|O
m	1134	1135		|O
(	1135	1136		|O
2	1136	1137		|O
)	1137	1138		|O
/	1138	1139		|O
wk	1139	1141		|O
cohort	1142	1148		|O
.	1148	1149		|O
No	1150	1152		|O
cases	1153	1158		|O
of	1159	1161		|O
Grade	1162	1167		|O
3	1168	1169		|O
esophagitis	1170	1181	esophagitis	|B-ADVERSE
occurred	1182	1190		|O
at	1191	1193		|O
these	1194	1199		|O
doses	1200	1205		|O
in	1206	1208		|O
the	1209	1212		|O
3D	1213	1215		|O
group	1216	1221		|O
.	1221	1222		|O
At	1223	1225		|O
gemcitabine	1226	1237		|O
190	1238	1241		|O
mg	1242	1244		|O
/	1244	1245		|O
m	1245	1246		|O
(	1246	1247		|O
2	1247	1248		|O
)	1248	1249		|O
/	1249	1250		|O
wk	1250	1252		|O
,	1252	1253		|O
2	1254	1255		|O
of	1256	1258		|O
6	1259	1260		|O
patients	1261	1269		|O
in	1270	1272		|O
the	1273	1276		|O
3D	1277	1279		|O
cohort	1280	1286		|O
had	1287	1290		|O
Grade	1291	1296		|O
3	1297	1298		|O
esophagitis	1299	1310	esophagitis	|B-ADVERSE
.	1310	1311		|O
The	1312	1315		|O
mean	1316	1320		|O
percentages	1321	1332		|O
of	1333	1335		|O
esophagus	1336	1345		|O
irradiated	1346	1356		|O
to	1357	1359		|O
60	1360	1362		|O
Gy	1363	1365		|O
were	1366	1370		|O
68%	1371	1374		|O
in	1375	1377		|O
the	1378	1381		|O
2D	1382	1384		|O
cohort	1385	1391		|O
and	1392	1395		|O
18%	1396	1399		|O
in	1400	1402		|O
the	1403	1406		|O
3D	1407	1409		|O
cohort	1410	1416		|O
.	1416	1417		|O
CONCLUSIONS	1418	1429		|O
:	1429	1430		|O
We	1431	1433		|O
could	1434	1439		|O
not	1440	1443		|O
escalate	1444	1452		|O
the	1453	1456		|O
dose	1457	1461		|O
of	1462	1464		|O
gemcitabine	1465	1476		|O
with	1477	1481		|O
concurrent	1482	1492		|O
radiotherapy	1493	1505		|O
when	1506	1510		|O
using	1511	1516		|O
2D	1517	1519		|O
planning	1520	1528		|O
because	1529	1536		|O
of	1537	1539		|O
severe	1540	1546		|O
acute	1547	1552	acute esophagitis	|B-ADVERSE
esophagitis	1553	1564		|I-ADVERSE
.	1564	1565		|O
However	1566	1573		|O
,	1573	1574		|O
we	1575	1577		|O
could	1578	1583		|O
escalate	1584	1592		|O
the	1593	1596		|O
dose	1597	1601		|O
of	1602	1604		|O
gemcitabine	1605	1616		|O
to	1617	1619		|O
190	1620	1623		|O
mg	1624	1626		|O
/	1626	1627		|O
m	1627	1628		|O
(	1628	1629		|O
2	1629	1630		|O
)	1630	1631		|O
/	1631	1632		|O
wk	1632	1634		|O
when	1635	1639		|O
using	1640	1645		|O
3D	1646	1648		|O
planning	1649	1657		|O
.	1657	1658		|O
The	1659	1662		|O
Phase	1663	1668		|O
II	1669	1671		|O
dose	1672	1676		|O
is	1677	1679		|O
150	1680	1683		|O
mg	1684	1686		|O
/	1686	1687		|O
m	1687	1688		|O
(	1688	1689		|O
2	1689	1690		|O
)	1690	1691		|O
/	1691	1692		|O
wk	1692	1694		|O
.	1694	1695		|O
Three	1696	1701		|O
-	1701	1702		|O
dimensional	1702	1713		|O
CRT	1714	1717		|O
permitted	1718	1727		|O
the	1728	1731		|O
use	1732	1735		|O
of	1736	1738		|O
higher	1739	1745		|O
doses	1746	1751		|O
of	1752	1754		|O
gemcitabine	1755	1766		|O
.	1766	1767		|O

### 18600584
Morphine	0	8		|O
-	8	9		|O
6	9	10		|O
-	10	11		|O
glucuronide	11	22		|O
,	22	23		|O
an	24	26		|O
active	27	33		|O
morphine	34	42		|O
metabolite	43	53		|O
for	54	57		|O
the	58	61		|O
potential	62	71		|O
treatment	72	81		|O
of	82	84		|O
post	85	89	post-operative pain	|B-DISEASE
-	89	90		|I-DISEASE
operative	90	99		|I-DISEASE
pain	100	104		|I-DISEASE
.	104	105		|O
Morphine	107	115		|O
-	115	116		|O
6	116	117		|O
-	117	118		|O
glucuronide	118	129		|O
(	130	131		|O
M6G	131	134		|O
)	134	135		|O
is	136	138		|O
an	139	141		|O
active	142	148		|O
metabolite	149	159		|O
of	160	162		|O
morphine	163	171		|O
that	172	176		|O
is	177	179		|O
being	180	185		|O
developed	186	195		|O
by	196	198		|O
CeNeS	199	204		|O
Pharmaceuticals	205	220		|O
as	221	223		|O
an	224	226		|O
alternative	227	238		|O
to	239	241		|O
morphine	242	250		|O
(	251	252		|O
the	252	255		|O
most	256	260		|O
commonly	261	269		|O
used	270	274		|O
opioid	275	281		|O
)	281	282		|O
for	283	286		|O
the	287	290		|O
management	291	301		|O
of	302	304		|O
postoperative	305	318	postoperative pain	|B-DISEASE
pain	319	323		|I-DISEASE
.	323	324		|O
M6G	325	328		|O
is	329	331		|O
currently	332	341		|O
undergoing	342	352		|O
phase	353	358		|O
III	359	362		|O
clinical	363	371		|O
trials	372	378		|O
in	379	381		|O
patients	382	390		|O
with	391	395		|O
postoperative	396	409	postoperative pain	|B-DISEASE
pain	410	414		|I-DISEASE
.	414	415		|O

### 18773883
La3+	0	4		|O
binds	5	10		|O
to	11	13		|O
BiP	14	17		|O
/	17	18		|O
GRP78	18	23		|O
and	24	27		|O
induces	28	35		|O
unfolded	36	44		|O
protein	45	52		|O
response	53	61		|O
in	62	64		|O
HepG2	65	70		|O
cells	71	76		|O
.	76	77		|O
The	79	82		|O
effects	83	90		|O
of	91	93		|O
La3+	94	98		|O
on	99	101		|O
the	102	105		|O
unfolded	106	114		|O
protein	115	122		|O
response	123	131		|O
signaling	132	141		|O
pathways	142	150		|O
were	151	155		|O
investigated	156	168		|O
in	169	171		|O
human	172	177		|O
hepatoblastoma	178	192		|O
HepG2	193	198		|O
cells	199	204		|O
.	204	205		|O
Our	206	209		|O
data	210	214		|O
showed	215	221		|O
that	222	226		|O
La3+	227	231		|O
could	232	237		|O
induce	238	244		|O
unfolded	245	253		|O
protein	254	261		|O
response	262	270		|O
in	271	273		|O
HepG2	274	279		|O
cells	280	285		|O
,	285	286		|O
including	287	296		|O
a	297	298		|O
significant	299	310		|O
increase	311	319		|O
of	320	322		|O
BiP	323	326		|O
/	326	327		|O
GRP78	327	332		|O
level	333	338		|O
,	338	339		|O
which	340	345		|O
is	346	348		|O
an	349	351		|O
important	352	361		|O
ER	362	364		|O
residential	365	376		|O
chaperone	377	386		|O
and	387	390		|O
an	391	393		|O
ER	394	396		|O
stress	397	403		|O
hallmark	404	412		|O
,	412	413		|O
in	414	416		|O
a	417	418		|O
concentration	419	432		|O
and	433	436		|O
time	437	441		|O
-	441	442		|O
dependent	442	451		|O
manner	452	458		|O
,	458	459		|O
UPR	460	463		|O
transducer	464	474		|O
IRE1	475	479		|O
phosphorylation	480	495		|O
and	496	499		|O
splicing	500	508		|O
activation	509	519		|O
IRE1	520	524		|O
downstream	525	535		|O
substrate	536	545		|O
XBP1	546	550		|O
mRNA	551	555		|O
.	555	556		|O
By	557	559		|O
using	560	565		|O
La3+	566	570		|O
-	570	571		|O
affinity	571	579		|O
chromatography	580	594		|O
,	594	595		|O
the	596	599		|O
possible	600	608		|O
cellular	609	617		|O
target	618	624		|O
of	625	627		|O
La3+	628	632		|O
leading	633	640		|O
to	641	643		|O
UPR	644	647		|O
events	648	654		|O
was	655	658		|O
shown	659	664		|O
to	665	667		|O
be	668	670		|O
the	671	674		|O
ER	675	677		|O
residential	678	689		|O
chaperone	690	699		|O
BiP	700	703		|O
/	703	704		|O
GRP78	704	709		|O
.	709	710		|O
BiP	711	714		|O
/	714	715		|O
GRP78	715	720		|O
was	721	724		|O
shown	725	730		|O
to	731	733		|O
be	734	736		|O
a	737	738		|O
La3+	739	743		|O
binding	744	751		|O
protein	752	759		|O
and	760	763		|O
the	764	767		|O
interaction	768	779		|O
of	780	782		|O
La3+	783	787		|O
with	788	792		|O
BiP	793	796		|O
/	796	797		|O
GRP78	797	802		|O
resulted	803	811		|O
in	812	814		|O
dissociation	815	827		|O
of	828	830		|O
BiP	831	834		|O
-	834	835		|O
IRE1	835	839		|O
complexes	840	849		|O
.	849	850		|O
La3+	851	855		|O
induced	856	863		|O
dissociation	864	876		|O
of	877	879		|O
the	880	883		|O
BiP	884	887		|O
/	887	888		|O
GRP78	888	893		|O
-	893	894		|O
IRE1	894	898		|O
complex	899	906		|O
was	907	910		|O
in	911	913		|O
a	914	915		|O
time	916	920		|O
and	921	924		|O
concentration	925	938		|O
manner	939	945		|O
.	945	946		|O
The	947	950		|O
apparent	951	959		|O
dissociation	960	972		|O
constant	973	981		|O
was	982	985		|O
estimated	986	995		|O
to	996	998		|O
be	999	1001		|O
4	1002	1003		|O
nM	1004	1006		|O
.	1006	1007		|O
In	1008	1010		|O
addition	1011	1019		|O
,	1019	1020		|O
La3+	1021	1025		|O
was	1026	1029		|O
observed	1030	1038		|O
to	1039	1041		|O
slightly	1042	1050		|O
stimulate	1051	1060		|O
the	1061	1064		|O
production	1065	1075		|O
of	1076	1078		|O
cellular	1079	1087		|O
ROS	1088	1091		|O
and	1092	1095		|O
cause	1096	1101		|O
alteration	1102	1112		|O
of	1113	1115		|O
intracellular	1116	1129		|O
Ca2+	1130	1134		|O
,	1134	1135		|O
indicating	1136	1146		|O
the	1147	1150		|O
possible	1151	1159		|O
involvement	1160	1171		|O
of	1172	1174		|O
ROS	1175	1178		|O
and	1179	1182		|O
Ca2+	1183	1187		|O
alteration	1188	1198		|O
in	1199	1201		|O
La3+	1202	1206		|O
induced	1207	1214		|O
UPR	1215	1218		|O
.	1218	1219		|O
The	1220	1223		|O
present	1224	1231		|O
work	1232	1236		|O
provides	1237	1245		|O
a	1246	1247		|O
new	1248	1251		|O
perspective	1252	1263		|O
for	1264	1267		|O
understanding	1268	1281		|O
the	1282	1285		|O
biological	1286	1296		|O
and	1297	1300		|O
toxicological	1301	1314		|O
effects	1315	1322		|O
of	1323	1325		|O
La3+	1326	1330		|O
.	1330	1331		|O

### 18778717
The	0	3		|O
effects	4	11		|O
of	12	14		|O
1,4	15	18		|O
-	18	19		|O
benzoquinone	19	31		|O
on	32	34		|O
c	35	36		|O
-	36	37		|O
Myb	37	40		|O
and	41	44		|O
topoisomerase	45	58		|O
II	59	61		|O
in	62	64		|O
K	65	66		|O
-	66	67		|O
562	67	70		|O
cells	71	76		|O
.	76	77		|O
Exposure	79	87		|O
to	88	90		|O
benzene	91	98		|O
,	98	99		|O
a	100	101		|O
ubiquitous	102	112		|O
environmental	113	126		|O
pollutant	127	136		|O
,	136	137		|O
has	138	141		|O
been	142	146		|O
linked	147	153		|O
to	154	156		|O
leukemia	157	165	leukemia	|B-ADVERSE
,	165	166		|O
although	167	175		|O
the	176	179		|O
mechanism	180	189		|O
of	190	192		|O
benzene	193	200		|O
-	200	201		|O
initiated	201	210		|O
leukemogenesis	211	225		|O
remains	226	233		|O
unclear	234	241		|O
.	241	242		|O
Benzene	243	250		|O
can	251	254		|O
be	255	257		|O
bioactivated	258	270		|O
to	271	273		|O
toxic	274	279		|O
metabolites	280	291		|O
such	292	296		|O
as	297	299		|O
1,4	300	303		|O
benzoquinone	304	316		|O
(	317	318		|O
BQ	318	320		|O
)	320	321		|O
,	321	322		|O
which	323	328		|O
can	329	332		|O
alter	333	338		|O
signaling	339	348		|O
pathways	349	357		|O
and	358	361		|O
affect	362	368		|O
chromosomal	369	380		|O
integrity	381	390		|O
.	390	391		|O
BQ	392	394		|O
has	395	398		|O
been	399	403		|O
shown	404	409		|O
to	410	412		|O
increase	413	421		|O
the	422	425		|O
activity	426	434		|O
of	435	437		|O
c	438	439		|O
-	439	440		|O
Myb	440	443		|O
,	443	444		|O
which	445	450		|O
is	451	453		|O
an	454	456		|O
important	457	466		|O
transcription	467	480		|O
factor	481	487		|O
involved	488	496		|O
in	497	499		|O
hematopoiesis	500	513		|O
,	513	514		|O
cell	515	519		|O
proliferation	520	533		|O
,	533	534		|O
and	535	538		|O
cell	539	543		|O
differentiation	544	559		|O
.	559	560		|O
The	561	564		|O
c	565	566		|O
-	566	567		|O
Myb	567	570		|O
protein	571	578		|O
has	579	582		|O
also	583	587		|O
been	588	592		|O
shown	593	598		|O
to	599	601		|O
increase	602	610		|O
topoisomerase	611	624		|O
IIalpha	625	632		|O
(	633	634		|O
Topo	634	638		|O
IIalpha	639	646		|O
)	646	647		|O
promoter	648	656		|O
activity	657	665		|O
specifically	666	678		|O
in	679	681		|O
cell	682	686		|O
lines	687	692		|O
with	693	697		|O
hematopoietic	698	711		|O
origin	712	718		|O
.	718	719		|O
Topo	720	724		|O
IIalpha	725	732		|O
is	733	735		|O
a	736	737		|O
critical	738	746		|O
nuclear	747	754		|O
enzyme	755	761		|O
that	762	766		|O
removes	767	774		|O
torsional	775	784		|O
strain	785	791		|O
by	792	794		|O
cleaving	795	803		|O
,	803	804		|O
untangling	805	815		|O
and	816	819		|O
religating	820	830		|O
double	831	837		|O
-	837	838		|O
stranded	838	846		|O
DNA	847	850		|O
.	850	851		|O
Since	852	857		|O
Topo	858	862		|O
IIalpha	863	870		|O
mediates	871	879		|O
DNA	880	883		|O
strand	884	890		|O
breaks	891	897		|O
,	897	898		|O
aberrant	899	907		|O
Topo	908	912		|O
IIalpha	913	920		|O
activity	921	929		|O
or	930	932		|O
increased	933	942		|O
protein	943	950		|O
levels	951	957		|O
may	958	961		|O
increase	962	970		|O
the	971	974		|O
formation	975	984		|O
of	985	987		|O
DNA	988	991		|O
strand	992	998		|O
breaks	999	1005		|O
,	1005	1006		|O
leaving	1007	1014		|O
the	1015	1018		|O
cell	1019	1023		|O
susceptible	1024	1035		|O
to	1036	1038		|O
mutational	1039	1049		|O
events	1050	1056		|O
.	1056	1057		|O
We	1058	1060		|O
hypothesized	1061	1073		|O
that	1074	1078		|O
BQ	1079	1081		|O
can	1082	1085		|O
increase	1086	1094		|O
c	1095	1096		|O
-	1096	1097		|O
Myb	1097	1100		|O
activity	1101	1109		|O
,	1109	1110		|O
which	1111	1116		|O
in	1117	1119		|O
turn	1120	1124		|O
increases	1125	1134		|O
Topo	1135	1139		|O
IIalpha	1140	1147		|O
promoter	1148	1156		|O
activity	1157	1165		|O
resulting	1166	1175		|O
in	1176	1178		|O
increased	1179	1188		|O
DNA	1189	1192		|O
strand	1193	1199		|O
breaks	1200	1206		|O
.	1206	1207		|O
Using	1208	1213		|O
luciferase	1214	1224		|O
reporter	1225	1233		|O
assays	1234	1240		|O
in	1241	1243		|O
K	1244	1245		|O
-	1245	1246		|O
562	1246	1249		|O
cells	1250	1255		|O
we	1256	1258		|O
demonstrated	1259	1271		|O
that	1272	1276		|O
BQ	1277	1279		|O
(	1280	1281		|O
25	1281	1283		|O
and	1284	1287		|O
37microM	1288	1296		|O
)	1296	1297		|O
exposure	1298	1306		|O
caused	1307	1313		|O
an	1314	1316		|O
increase	1317	1325		|O
in	1326	1328		|O
c	1329	1330		|O
-	1330	1331		|O
Myb	1331	1334		|O
activity	1335	1343		|O
after	1344	1349		|O
24h	1350	1353		|O
.	1353	1354		|O
Contradictory	1355	1368		|O
to	1369	1371		|O
previous	1372	1380		|O
findings	1381	1389		|O
,	1389	1390		|O
overexpression	1391	1405		|O
of	1406	1408		|O
exogenous	1409	1418		|O
c	1419	1420		|O
-	1420	1421		|O
Myb	1421	1424		|O
or	1425	1427		|O
a	1428	1429		|O
polypeptide	1430	1441		|O
consisting	1442	1452		|O
of	1453	1455		|O
c	1456	1457		|O
-	1457	1458		|O
Myb	1458	1461		|O
's	1461	1463		|O
DNA	1464	1467		|O
binding	1468	1475		|O
domain	1476	1482		|O
(	1483	1484		|O
DBD	1484	1487		|O
)	1487	1488		|O
,	1488	1489		|O
which	1490	1495		|O
competitively	1496	1509		|O
inhibits	1510	1518		|O
the	1519	1522		|O
binding	1523	1530		|O
of	1531	1533		|O
endogenous	1534	1544		|O
c	1545	1546		|O
-	1546	1547		|O
Myb	1547	1550		|O
to	1551	1553		|O
DNA	1554	1557		|O
,	1557	1558		|O
did	1559	1562		|O
not	1563	1566		|O
affect	1567	1573		|O
Topo	1574	1578		|O
IIalpha	1579	1586		|O
promoter	1587	1595		|O
activity	1596	1604		|O
.	1604	1605		|O
However	1606	1613		|O
,	1613	1614		|O
BQ	1615	1617		|O
(	1618	1619		|O
37microM	1619	1627		|O
for	1628	1631		|O
24h	1632	1635		|O
)	1635	1636		|O
exposure	1637	1645		|O
caused	1646	1652		|O
a	1653	1654		|O
significant	1655	1666		|O
increase	1667	1675		|O
in	1676	1678		|O
Topo	1679	1683		|O
IIalpha	1684	1691		|O
promoter	1692	1700		|O
activity	1701	1709		|O
,	1709	1710		|O
which	1711	1716		|O
could	1717	1722		|O
be	1723	1725		|O
blocked	1726	1733		|O
by	1734	1736		|O
the	1737	1740		|O
overexpression	1741	1755		|O
of	1756	1758		|O
the	1759	1762		|O
DBD	1763	1766		|O
polypeptide	1767	1778		|O
,	1778	1779		|O
suggesting	1780	1790		|O
that	1791	1795		|O
BQ	1796	1798		|O
exposure	1799	1807		|O
increases	1808	1817		|O
Topo	1818	1822		|O
IIalpha	1823	1830		|O
promoter	1831	1839		|O
activity	1840	1848		|O
through	1849	1856		|O
the	1857	1860		|O
c	1861	1862		|O
-	1862	1863		|O
Myb	1863	1866		|O
signaling	1867	1876		|O
pathway	1877	1884		|O
.	1884	1885		|O

### 18640217
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
alpha	29	34		|O
-	34	35		|O
bisabolol	35	44		|O
.	44	45		|O
A	47	48		|O
toxicologic	49	60		|O
and	61	64		|O
dermatologic	65	77		|O
review	78	84		|O
of	85	87		|O
alpha	88	93		|O
-	93	94		|O
bisabolol	94	103		|O
when	104	108		|O
used	109	113		|O
as	114	116		|O
a	117	118		|O
fragrance	119	128		|O
ingredient	129	139		|O
is	140	142		|O
presented	143	152		|O
.	152	153		|O

### 18704008
Experimental	0	12		|O
models	13	19		|O
of	20	22		|O
sepsis	23	29	sepsis	|B-DISEASE
and	30	33		|O
their	34	39		|O
clinical	40	48		|O
relevance	49	58		|O
.	58	59		|O
Sepsis	61	67	Sepsis	|B-DISEASE
remains	68	75		|O
a	76	77		|O
major	78	83		|O
cause	84	89		|O
of	90	92		|O
morbidity	93	102		|O
and	103	106		|O
mortality	107	116		|O
mainly	117	123		|O
because	124	131		|O
of	132	134		|O
sepsis	135	141	sepsis	|B-DISEASE
-	141	142		|O
induced	142	149		|O
multiple	150	158	multiple organ dysfunction	|B-DISEASE
organ	159	164		|I-DISEASE
dysfunction	165	176		|I-DISEASE
.	176	177		|O
In	178	180		|O
contrast	181	189		|O
to	190	192		|O
preclinical	193	204		|O
studies	205	212		|O
,	212	213		|O
most	214	218		|O
clinical	219	227		|O
trials	228	234		|O
of	235	237		|O
promising	238	247		|O
new	248	251		|O
treatment	252	261		|O
strategies	262	272		|O
for	273	276		|O
sepsis	277	283	sepsis	|B-DISEASE
have	284	288		|O
failed	289	295		|O
to	296	298		|O
demonstrate	299	310		|O
efficacy	311	319		|O
.	319	320		|O
Although	321	329		|O
many	330	334		|O
reasons	335	342		|O
could	343	348		|O
account	349	356		|O
for	357	360		|O
this	361	365		|O
discrepancy	366	377		|O
,	377	378		|O
the	379	382		|O
misinterpretation	383	400		|O
of	401	403		|O
preclinical	404	415		|O
data	416	420		|O
obtained	421	429		|O
from	430	434		|O
experimental	435	447		|O
studies	448	455		|O
and	456	459		|O
especially	460	470		|O
the	471	474		|O
use	475	478		|O
of	479	481		|O
animal	482	488		|O
models	489	495		|O
that	496	500		|O
do	501	503		|O
not	504	507		|O
adequately	508	518		|O
mimic	519	524		|O
human	525	530		|O
sepsis	531	537	sepsis	|B-DISEASE
may	538	541		|O
have	542	546		|O
been	547	551		|O
contributing	552	564		|O
factors	565	572		|O
.	572	573		|O
In	574	576		|O
this	577	581		|O
review	582	588		|O
,	588	589		|O
the	590	593		|O
potentials	594	604		|O
and	605	608		|O
limitations	609	620		|O
of	621	623		|O
various	624	631		|O
animal	632	638		|O
models	639	645		|O
of	646	648		|O
sepsis	649	655	sepsis	|B-DISEASE
are	656	659		|O
discussed	660	669		|O
to	670	672		|O
clarify	673	680		|O
to	681	683		|O
which	684	689		|O
extent	690	696		|O
these	697	702		|O
findings	703	711		|O
are	712	715		|O
relevant	716	724		|O
to	725	727		|O
human	728	733		|O
sepsis	734	740	sepsis	|B-DISEASE
.	740	741		|O
Such	742	746		|O
models	747	753		|O
include	754	761		|O
intravascular	762	775		|O
infusion	776	784		|O
of	785	787		|O
endotoxin	788	797		|O
or	798	800		|O
live	801	805		|O
bacteria	806	814		|O
,	814	815		|O
bacterial	816	825	bacterial peritonitis	|B-DISEASE
peritonitis	826	837		|I-DISEASE
,	837	838		|O
cecal	839	844		|O
ligation	845	853		|O
and	854	857		|O
perforation	858	869		|O
,	869	870		|O
soft	871	875	soft tissue infection	|B-DISEASE
tissue	876	882		|I-DISEASE
infection	883	892		|I-DISEASE
,	892	893		|O
pneumonia	894	903	pneumonia	|B-DISEASE
or	904	906		|O
meningitis	907	917	meningitis	|B-DISEASE
models	918	924		|O
using	925	930		|O
different	931	940		|O
animal	941	947		|O
species	948	955		|O
including	956	965		|O
rats	966	970		|O
,	970	971		|O
mice	972	976		|O
,	976	977		|O
rabbits	978	985		|O
,	985	986		|O
dogs	987	991		|O
,	991	992		|O
pigs	993	997		|O
,	997	998		|O
sheep	999	1004		|O
,	1004	1005		|O
and	1006	1009		|O
nonhuman	1010	1018		|O
primates	1019	1027		|O
.	1027	1028		|O
Despite	1029	1036		|O
several	1037	1044		|O
limitations	1045	1056		|O
,	1056	1057		|O
animal	1058	1064		|O
models	1065	1071		|O
remain	1072	1078		|O
essential	1079	1088		|O
in	1089	1091		|O
the	1092	1095		|O
development	1096	1107		|O
of	1108	1110		|O
all	1111	1114		|O
new	1115	1118		|O
therapies	1119	1128		|O
for	1129	1132		|O
sepsis	1133	1139	sepsis	|B-DISEASE
and	1140	1143		|O
septic	1144	1150	septic shock	|B-DISEASE
shock	1151	1156		|I-DISEASE
because	1157	1164		|O
they	1165	1169		|O
provide	1170	1177		|O
fundamental	1178	1189		|O
information	1190	1201		|O
about	1202	1207		|O
the	1208	1211		|O
pharmacokinetics	1212	1228		|O
,	1228	1229		|O
toxicity	1230	1238		|O
,	1238	1239		|O
and	1240	1243		|O
mechanism	1244	1253		|O
of	1254	1256		|O
drug	1257	1261		|O
action	1262	1268		|O
that	1269	1273		|O
cannot	1274	1280		|O
be	1281	1283		|O
replaced	1284	1292		|O
by	1293	1295		|O
other	1296	1301		|O
methods	1302	1309		|O
.	1309	1310		|O
New	1311	1314		|O
therapeutic	1315	1326		|O
agents	1327	1333		|O
should	1334	1340		|O
be	1341	1343		|O
studied	1344	1351		|O
in	1352	1354		|O
infection	1355	1364	infection	|B-DISEASE
models	1365	1371		|O
,	1371	1372		|O
even	1373	1377		|O
after	1378	1383		|O
the	1384	1387		|O
initiation	1388	1398		|O
of	1399	1401		|O
the	1402	1405		|O
septic	1406	1412		|O
process	1413	1420		|O
.	1420	1421		|O
Furthermore	1422	1433		|O
,	1433	1434		|O
debility	1435	1443		|O
conditions	1444	1454		|O
need	1455	1459		|O
to	1460	1462		|O
be	1463	1465		|O
reproduced	1466	1476		|O
to	1477	1479		|O
avoid	1480	1485		|O
the	1486	1489		|O
exclusive	1490	1499		|O
use	1500	1503		|O
of	1504	1506		|O
healthy	1507	1514		|O
animals	1515	1522		|O
,	1522	1523		|O
which	1524	1529		|O
often	1530	1535		|O
do	1536	1538		|O
not	1539	1542		|O
represent	1543	1552		|O
the	1553	1556		|O
human	1557	1562		|O
septic	1563	1569		|O
patient	1570	1577		|O
.	1577	1578		|O

### 18606837
Efficient	0	9		|O
clearance	10	19		|O
of	20	22		|O
Aspergillus	23	34		|O
fumigatus	35	44		|O
in	45	47		|O
murine	48	54		|O
lungs	55	60		|O
by	61	63		|O
an	64	66		|O
ultrashort	67	77		|O
antimicrobial	78	91		|O
lipopeptide	92	103		|O
,	103	104		|O
palmitoyl	105	114		|O
-	114	115		|O
lys	115	118		|O
-	118	119		|O
ala	119	122		|O
-	122	123		|O
DAla	123	127		|O
-	127	128		|O
lys	128	131		|O
.	131	132		|O
Aspergillus	134	145		|O
fumigatus	146	155		|O
is	156	158		|O
an	159	161		|O
opportunistic	162	175		|O
fungal	176	182		|O
pathogen	183	191		|O
responsible	192	203		|O
for	204	207		|O
invasive	208	216		|O
aspergillosis	217	230	aspergillosis	|B-DISEASE
in	231	233		|O
immunocompromised	234	251		|O
individuals	252	263		|O
.	263	264		|O
The	265	268		|O
inefficiency	269	281		|O
of	282	284		|O
antifungal	285	295		|O
agents	296	302		|O
and	303	306		|O
high	307	311		|O
mortality	312	321		|O
rate	322	326		|O
resulting	327	336		|O
from	337	341		|O
invasive	342	350		|O
aspergillosis	351	364	aspergillosis	|B-DISEASE
remain	365	371		|O
major	372	377		|O
clinical	378	386		|O
concerns	387	395		|O
.	395	396		|O
Recently	397	405		|O
,	405	406		|O
we	407	409		|O
reported	410	418		|O
on	419	421		|O
a	422	423		|O
new	424	427		|O
family	428	434		|O
of	435	437		|O
ultrashort	438	448		|O
cationic	449	457		|O
lipopeptides	458	470		|O
active	471	477		|O
in	478	480		|O
vitro	481	486		|O
against	487	494		|O
fungi	495	500		|O
.	500	501		|O
Mode	502	506		|O
of	507	509		|O
action	510	516		|O
studies	517	524		|O
supported	525	534		|O
a	535	536		|O
membranolytic	537	550		|O
or	551	553		|O
a	554	555		|O
detergent	556	565		|O
-	565	566		|O
like	566	570		|O
effect	571	577		|O
.	577	578		|O
Here	579	583		|O
,	583	584		|O
we	585	587		|O
screened	588	596		|O
several	597	604		|O
lipopeptides	605	617		|O
in	618	620		|O
vitro	621	626		|O
for	627	630		|O
their	631	636		|O
anti	637	641		|O
-	641	642		|O
A	642	643		|O
.	643	644		|O
fumigatus	645	654		|O
activity	655	663		|O
.	663	664		|O
To	665	667		|O
investigate	668	679		|O
the	680	683		|O
therapeutic	684	695		|O
properties	696	706		|O
of	707	709		|O
the	710	713		|O
selected	714	722		|O
peptides	723	731		|O
in	732	734		|O
vivo	735	739		|O
,	739	740		|O
we	741	743		|O
challenged	744	754		|O
immunosuppressed	755	771		|O
C57BL	772	777		|O
/	777	778		|O
6	778	779		|O
wild	780	784		|O
-	784	785		|O
type	785	789		|O
mice	790	794		|O
intranasally	795	807		|O
with	808	812		|O
DsRed	813	818		|O
-	818	819		|O
labeled	819	826		|O
A	827	828		|O
.	828	829		|O
fumigatus	830	839		|O
conidia	840	847		|O
and	848	851		|O
subsequently	852	864		|O
treated	865	872		|O
the	873	876		|O
animals	877	884		|O
locally	885	892		|O
with	893	897		|O
the	898	901		|O
lipopeptides	902	914		|O
.	914	915		|O
Confocal	916	924		|O
microscopic	925	936		|O
analysis	937	945		|O
revealed	946	954		|O
the	955	958		|O
degradation	959	970		|O
of	971	973		|O
DsRed	974	979		|O
-	979	980		|O
labeled	980	987		|O
hyphal	988	994		|O
forms	995	1000		|O
and	1001	1004		|O
residual	1005	1013		|O
conidia	1014	1021		|O
in	1022	1024		|O
the	1025	1028		|O
lungs	1029	1034		|O
of	1035	1037		|O
the	1038	1041		|O
mice	1042	1046		|O
.	1046	1047		|O
The	1048	1051		|O
most	1052	1056		|O
efficient	1057	1066		|O
peptide	1067	1074		|O
was	1075	1078		|O
tested	1079	1085		|O
further	1086	1093		|O
using	1094	1099		|O
a	1100	1101		|O
survival	1102	1110		|O
assay	1111	1116		|O
and	1117	1120		|O
was	1121	1124		|O
found	1125	1130		|O
to	1131	1133		|O
significantly	1134	1147		|O
prolong	1148	1155		|O
the	1156	1159		|O
life	1160	1164		|O
of	1165	1167		|O
the	1168	1171		|O
treated	1172	1179		|O
animals	1180	1187		|O
,	1187	1188		|O
whereas	1189	1196		|O
no	1197	1199		|O
mice	1200	1204		|O
survived	1205	1213		|O
with	1214	1218		|O
the	1219	1222		|O
current	1223	1230		|O
standard	1231	1239		|O
antifungal	1240	1250		|O
treatment	1251	1260		|O
with	1261	1265		|O
amphotericin	1266	1278		|O
B	1279	1280		|O
.	1280	1281		|O
Moreover	1282	1290		|O
,	1290	1291		|O
as	1292	1294		|O
opposed	1295	1302		|O
to	1303	1305		|O
the	1306	1309		|O
drug	1310	1314		|O
-	1314	1315		|O
treated	1315	1322		|O
lungs	1323	1328		|O
,	1328	1329		|O
the	1330	1333		|O
peptide	1334	1341		|O
-	1341	1342		|O
treated	1342	1349		|O
lungs	1350	1355		|O
did	1356	1359		|O
not	1360	1363		|O
display	1364	1371		|O
any	1372	1375		|O
toxicity	1376	1384		|O
of	1385	1387		|O
the	1388	1391		|O
peptide	1392	1399		|O
.	1399	1400		|O
Our	1401	1404		|O
results	1405	1412		|O
highlight	1413	1422		|O
the	1423	1426		|O
potential	1427	1436		|O
of	1437	1439		|O
this	1440	1444		|O
family	1445	1451		|O
of	1452	1454		|O
lipopeptides	1455	1467		|O
for	1468	1471		|O
the	1472	1475		|O
treatment	1476	1485		|O
of	1486	1488		|O
pulmonary	1489	1498		|O
invasive	1499	1507		|O
aspergillosis	1508	1521	aspergillosis	|B-DISEASE
.	1521	1522		|O

### 18711350
Allogeneic	0	10		|O
SCT	11	14		|O
in	15	17		|O
refractory	18	28		|O
or	29	31		|O
relapsed	32	40	relapsed adult ALL	|B-DISEASE
adult	41	46		|I-DISEASE
ALL	47	50		|I-DISEASE
is	51	53		|O
effective	54	63		|O
without	64	71		|O
prior	72	77		|O
reinduction	78	89		|O
chemotherapy	90	102		|O
.	102	103		|O
We	105	107		|O
present	108	115		|O
60	116	118		|O
patients	119	127		|O
with	128	132		|O
refractory	133	143		|O
(	144	145		|O
n	145	146		|O
=	146	147		|O
8	147	148		|O
)	148	149		|O
or	150	152		|O
relapsed	153	161		|O
(	162	163		|O
n	163	164		|O
=	164	165		|O
52	165	167		|O
)	167	168		|O
adult	169	174		|O
ALL	175	178	ALL	|B-DISEASE
who	179	182		|O
received	183	191		|O
allogeneic	192	202		|O
hematopoietic	203	216		|O
SCT	217	220		|O
(	221	222		|O
HSCT	222	226		|O
)	226	227		|O
with	228	232		|O
(	233	234		|O
n	234	235		|O
=	235	236		|O
41	236	238		|O
)	238	239		|O
or	240	242		|O
without	243	250		|O
(	251	252		|O
n	252	253		|O
=	253	254		|O
19	254	256		|O
)	256	257		|O
prior	258	263		|O
reinduction	264	275		|O
chemotherapy	276	288		|O
.	288	289		|O
In	290	292		|O
our	293	296		|O
center	297	303		|O
,	303	304		|O
omission	305	313		|O
of	314	316		|O
reinduction	317	328		|O
is	329	331		|O
recommended	332	343		|O
if	344	346		|O
a	347	348		|O
suitable	349	357		|O
donor	358	363		|O
is	364	366		|O
promptly	367	375		|O
available	376	385		|O
,	385	386		|O
tumor	387	392	tumor	|B-DISEASE
burden	393	399		|O
is	400	402		|O
moderate	403	411		|O
and	412	415		|O
disease	416	423		|O
features	424	432		|O
suggest	433	440		|O
a	441	442		|O
highly	443	449		|O
aggressive	450	460		|O
course	461	467		|O
.	467	468		|O
Overall	469	476		|O
survival	477	485		|O
(	486	487		|O
OS	487	489		|O
)	489	490		|O
of	491	493		|O
the	494	497		|O
whole	498	503		|O
cohort	504	510		|O
at	511	513		|O
1	514	515		|O
,	515	516		|O
2	517	518		|O
and	519	522		|O
5	523	524		|O
years	525	530		|O
was	531	534		|O
42	535	537		|O
,	537	538		|O
33	539	541		|O
and	542	545		|O
28%	546	549		|O
,	549	550		|O
respectively	551	563		|O
.	563	564		|O
Leukemia	565	573	Leukemia	|B-DISEASE
-	573	574		|O
free	574	578		|O
survival	579	587		|O
at	588	590		|O
1	591	592		|O
,	592	593		|O
2	594	595		|O
and	596	599		|O
5	600	601		|O
years	602	607		|O
was	608	611		|O
37	612	614		|O
,	614	615		|O
33	616	618		|O
and	619	622		|O
24%	623	626		|O
.	626	627		|O
Deaths	628	634		|O
were	635	639		|O
due	640	643		|O
to	644	646		|O
relapse	647	654		|O
(	655	656		|O
n	656	657		|O
=	657	658		|O
25	658	660		|O
)	660	661		|O
,	661	662		|O
acute	663	668		|O
or	669	671		|O
chronic	672	679	chronic GVHD	|B-DISEASE
GVHD	680	684		|I-DISEASE
(	685	686		|O
n	686	687		|O
=	687	688		|O
7	688	689		|O
)	689	690		|O
,	690	691		|O
infections	692	702	infections	|B-DISEASE
(	703	704		|O
n	704	705		|O
=	705	706		|O
8	706	707		|O
)	707	708		|O
or	709	711		|O
toxicity	712	720		|O
(	721	722		|O
n	722	723		|O
=	723	724		|O
4	724	725		|O
)	725	726		|O
.	726	727		|O
Interestingly	728	741		|O
,	741	742		|O
patients	743	751		|O
who	752	755		|O
did	756	759		|O
not	760	763		|O
receive	764	771		|O
reinduction	772	783		|O
before	784	790		|O
HSCT	791	795		|O
had	796	799		|O
better	800	806		|O
outcomes	807	815		|O
than	816	820		|O
patients	821	829		|O
who	830	833		|O
received	834	842		|O
reinduction	843	854		|O
with	855	859		|O
OS	860	862		|O
at	863	865		|O
1	866	867		|O
,	867	868		|O
2	869	870		|O
and	871	874		|O
5	875	876		|O
years	877	882		|O
being	883	888		|O
58	889	891		|O
vs	892	894		|O
34%	895	898		|O
,	898	899		|O
47	900	902		|O
vs	903	905		|O
25%	906	909		|O
and	910	913		|O
47	914	916		|O
vs	917	919		|O
18%	920	923		|O
,	923	924		|O
respectively	925	937		|O
(	938	939		|O
P	939	940		|O
=	940	941		|O
0.039	941	946		|O
)	946	947		|O
.	947	948		|O
Importantly	949	960		|O
,	960	961		|O
even	962	966		|O
achievement	967	978		|O
of	979	981		|O
a	982	983		|O
second	984	990		|O
CR	991	993		|O
after	994	999		|O
reinduction	1000	1011		|O
was	1012	1015		|O
not	1016	1019		|O
associated	1020	1030		|O
with	1031	1035		|O
improved	1036	1044		|O
survival	1045	1053		|O
compared	1054	1062		|O
to	1063	1065		|O
patients	1066	1074		|O
directly	1075	1083		|O
proceeding	1084	1094		|O
to	1095	1097		|O
HSCT	1098	1102		|O
.	1102	1103		|O
We	1104	1106		|O
conclude	1107	1115		|O
that	1116	1120		|O
patients	1121	1129		|O
who	1130	1133		|O
undergo	1134	1141		|O
HSCT	1142	1146		|O
for	1147	1150		|O
refractory	1151	1161		|O
or	1162	1164		|O
relapsed	1165	1173	relapsed ALL	|B-DISEASE
ALL	1174	1177		|I-DISEASE
can	1178	1181		|O
achieve	1182	1189		|O
long	1190	1194		|O
-	1194	1195		|O
term	1195	1199		|O
survival	1200	1208		|O
.	1208	1209		|O
In	1210	1212		|O
selected	1213	1221		|O
patients	1222	1230		|O
,	1230	1231		|O
reinduction	1232	1243		|O
chemotherapy	1244	1256		|O
can	1257	1260		|O
be	1261	1263		|O
omitted	1264	1271		|O
if	1272	1274		|O
immediate	1275	1284		|O
HSCT	1285	1289		|O
is	1290	1292		|O
feasible	1293	1301		|O
.	1301	1302		|O

### 18590766
Perception	0	10		|O
of	11	13		|O
validity	14	22		|O
of	23	25		|O
clinical	26	34		|O
and	35	38		|O
preclinical	39	50		|O
methods	51	58		|O
for	59	62		|O
assessment	63	73		|O
of	74	76		|O
torsades	77	85	torsades de pointes	|B-DISEASE
de	86	88		|I-DISEASE
pointes	89	96		|I-DISEASE
liability	97	106		|O
.	106	107		|O
In	109	111		|O
2007	112	116		|O
a	117	118		|O
meeting	119	126		|O
on	127	129		|O
drug	130	134		|O
-	134	135		|O
induced	135	142		|O
torsades	143	151	torsades de pointes	|B-ADVERSE
de	152	154		|I-ADVERSE
pointes	155	162		|I-ADVERSE
(	163	164		|O
TdP	164	167	TdP	|B-ADVERSE
)	167	168		|O
was	169	172		|O
held	173	177		|O
in	178	180		|O
London	181	187		|O
,	187	188		|O
UK	189	191		|O
,	191	192		|O
under	193	198		|O
the	199	202		|O
auspices	203	211		|O
of	212	214		|O
the	215	218		|O
British	219	226		|O
Society	227	234		|O
for	235	238		|O
Cardiovascular	239	253		|O
Research	254	262		|O
(	263	264		|O
BSCR	264	268		|O
)	268	269		|O
.	269	270		|O
One	271	274		|O
of	275	277		|O
the	278	281		|O
objectives	282	292		|O
was	293	296		|O
to	297	299		|O
explore	300	307		|O
the	308	311		|O
validity	312	320		|O
of	321	323		|O
available	324	333		|O
biomarkers	334	344		|O
,	344	345		|O
risk	346	350		|O
factors	351	358		|O
and	359	362		|O
preclinical	363	374		|O
investigational	375	390		|O
methods	391	398		|O
for	399	402		|O
the	403	406		|O
detection	407	416		|O
of	417	419		|O
drug	420	424		|O
-	424	425		|O
induced	425	432		|O
TdP	433	436	TdP	|B-ADVERSE
liability	437	446		|O
-	447	448		|O
preclinical	449	460		|O
methods	461	468		|O
and	469	472		|O
clinical	473	481		|O
't	482	484		|O
horough	484	491		|O
QT	492	494		|O
'	494	495		|O
testing	496	503		|O
.	503	504		|O
The	505	508		|O
first	509	514		|O
symposium	515	524		|O
was	525	528		|O
entitled	529	537		|O
"	538	539		|O
How	539	542		|O
validated	543	552		|O
are	553	556		|O
current	557	564		|O
models	565	571		|O
and	572	575		|O
biomarkers	576	586		|O
for	587	590		|O
testing	591	598		|O
drug	599	603		|O
-	603	604		|O
induced	604	611		|O
torsades	612	620	torsades de pointes	|B-ADVERSE
de	621	623		|I-ADVERSE
pointes	624	631		|I-ADVERSE
liability	632	641		|O
?	641	642		|O
"	642	643		|O
Validation	644	654		|O
,	654	655		|O
as	656	658		|O
far	659	662		|O
as	663	665		|O
the	666	669		|O
symposium	670	679		|O
was	680	683		|O
concerned	684	693		|O
,	693	694		|O
meant	695	700		|O
that	701	705		|O
the	706	709		|O
endpoints	710	719		|O
measured	720	728		|O
in	729	731		|O
the	732	735		|O
method	736	742		|O
predict	743	750		|O
TdP	751	754	TdP	|B-ADVERSE
liability	755	764		|O
specifically	765	777		|O
,	777	778		|O
selectively	779	790		|O
and	791	794		|O
quantitatively	795	809		|O
.	809	810		|O
Topics	811	817		|O
(	818	819		|O
and	819	822		|O
the	823	826		|O
publications	827	839		|O
derived	840	847		|O
from	848	852		|O
the	853	856		|O
presentations	857	870		|O
)	870	871		|O
were	872	876		|O
:	876	877		|O
human	878	883		|O
volunteer	884	893		|O
phase	894	899		|O
1	900	901		|O
studies	902	909		|O
[	910	911		|O
Vik	911	914		|O
,	914	915		|O
T	916	917		|O
.	917	918		|O
,	918	919		|O
Pollard	920	927		|O
,	927	928		|O
C	929	930		|O
.	930	931		|O
,	931	932		|O
&	933	934		|O
Sager	935	940		|O
,	940	941		|O
P	942	943		|O
.	943	944		|O
(	945	946		|O
2008	946	950		|O
-	950	951		|O
this	951	955		|O
issue	956	961		|O
)	961	962		|O
,	962	963		|O
the	964	967		|O
anaesthetized	968	981		|O
rabbit	982	988		|O
TDP	989	992		|O
model	993	998		|O
[	999	1000		|O
Carlsson	1000	1008		|O
,	1008	1009		|O
L	1010	1011		|O
.	1011	1012		|O
(	1013	1014		|O
2008	1014	1018		|O
-	1018	1019		|O
this	1019	1023		|O
issue	1024	1029		|O
)	1029	1030		|O
,	1030	1031		|O
the	1032	1035		|O
AV	1036	1038		|O
blocked	1039	1046		|O
canine	1047	1053		|O
preparation	1054	1065		|O
[	1066	1067		|O
Oros	1067	1071		|O
,	1071	1072		|O
A	1073	1074		|O
.	1074	1075		|O
,	1075	1076		|O
Beekman	1077	1084		|O
,	1084	1085		|O
J	1086	1087		|O
.	1087	1088		|O
D	1089	1090		|O
.	1090	1091		|O
M	1092	1093		|O
.	1093	1094		|O
,	1094	1095		|O
&	1096	1097		|O
Vos	1098	1101		|O
,	1101	1102		|O
M	1103	1104		|O
.	1104	1105		|O
A	1106	1107		|O
.	1107	1108		|O
(	1109	1110		|O
2008	1110	1114		|O
-	1114	1115		|O
this	1115	1119		|O
issue	1120	1125		|O
)	1125	1126		|O
,	1126	1127		|O
QT	1128	1130		|O
interval	1131	1139		|O
and	1140	1143		|O
its	1144	1147		|O
corrections	1148	1159		|O
in	1160	1162		|O
the	1163	1166		|O
in	1167	1169		|O
vivo	1170	1174		|O
conscious	1175	1184		|O
canine	1185	1191		|O
[	1192	1193		|O
Fossa	1193	1198		|O
,	1198	1199		|O
A	1200	1201		|O
.	1201	1202		|O
A	1203	1204		|O
.	1204	1205		|O
(	1206	1207		|O
2008	1207	1211		|O
-	1211	1212		|O
this	1212	1216		|O
issue	1217	1222		|O
)	1222	1223		|O
,	1223	1224		|O
the	1225	1228		|O
rabbit	1229	1235		|O
heart	1236	1241	heart failure	|B-DISEASE
failure	1242	1249		|I-DISEASE
model	1250	1255		|O
[	1256	1257		|O
Hamlin	1257	1263		|O
,	1263	1264		|O
R	1265	1266		|O
.	1266	1267		|O
L	1268	1269		|O
.	1269	1270		|O
,	1270	1271		|O
&	1272	1273		|O
Kijtawornrat	1274	1286		|O
,	1286	1287		|O
A	1288	1289		|O
.	1289	1290		|O
(	1291	1292		|O
2008	1292	1296		|O
-	1296	1297		|O
this	1297	1301		|O
issue	1302	1307		|O
)	1307	1308		|O
,	1308	1309		|O
the	1310	1313		|O
rabbit	1314	1320		|O
Langendorff	1321	1332		|O
preparation	1333	1344		|O
and	1345	1348		|O
the	1349	1352		|O
Screenit	1353	1361		|O
approach	1362	1370		|O
[	1371	1372		|O
Dumotier	1372	1380		|O
,	1380	1381		|O
B	1382	1383		|O
.	1383	1384		|O
M	1385	1386		|O
.	1386	1387		|O
,	1387	1388		|O
Deurinck	1389	1397		|O
,	1397	1398		|O
M	1399	1400		|O
.	1400	1401		|O
,	1401	1402		|O
Yang	1403	1407		|O
,	1407	1408		|O
Y	1409	1410		|O
.	1410	1411		|O
,	1411	1412		|O
Traebert	1413	1421		|O
,	1421	1422		|O
M	1423	1424		|O
.	1424	1425		|O
,	1425	1426		|O
&	1427	1428		|O
Suter	1429	1434		|O
,	1434	1435		|O
W	1436	1437		|O
.	1437	1438		|O
(	1439	1440		|O
2008	1440	1444		|O
-	1444	1445		|O
this	1445	1449		|O
issue	1450	1455		|O
)	1455	1456		|O
,	1456	1457		|O
the	1458	1461		|O
wedge	1462	1467		|O
preparation	1468	1479		|O
[	1480	1481		|O
Yan	1481	1484		|O
G	1485	1486		|O
.	1486	1487		|O
-	1487	1488		|O
X	1488	1489		|O
.	1489	1490		|O
(	1491	1492		|O
2008	1492	1496		|O
-	1496	1497		|O
this	1497	1501		|O
issue	1502	1507		|O
)	1507	1508		|O
]	1508	1509		|O
and	1510	1513		|O
hERG	1514	1518		|O
screens	1519	1526		|O
[	1527	1528		|O
Hancox	1528	1534		|O
,	1534	1535		|O
J	1536	1537		|O
.	1537	1538		|O
C	1539	1540		|O
.	1540	1541		|O
,	1541	1542		|O
McPate	1543	1549		|O
,	1549	1550		|O
M	1551	1552		|O
.	1552	1553		|O
J	1554	1555		|O
.	1555	1556		|O
,	1556	1557		|O
El	1558	1560		|O
Harchi	1561	1567		|O
,	1567	1568		|O
A	1569	1570		|O
.	1570	1571		|O
,	1571	1572		|O
&	1573	1574		|O
Zhang	1575	1580		|O
,	1580	1581		|O
Y	1582	1583		|O
.	1583	1584		|O
h	1585	1586		|O
.	1586	1587		|O
(	1588	1589		|O
2008	1589	1593		|O
-	1593	1594		|O
this	1594	1598		|O
issue	1599	1604		|O
)	1604	1605		|O
.	1605	1606		|O
Unbeknownst	1607	1618		|O
to	1619	1621		|O
the	1622	1625		|O
speakers	1626	1634		|O
before	1635	1641		|O
the	1642	1645		|O
start	1646	1651		|O
of	1652	1654		|O
the	1655	1658		|O
sessions	1659	1667		|O
,	1667	1668		|O
the	1669	1672		|O
audience	1673	1681		|O
were	1682	1686		|O
invited	1687	1694		|O
,	1694	1695		|O
during	1696	1702		|O
the	1703	1706		|O
session	1707	1714		|O
,	1714	1715		|O
to	1716	1718		|O
rate	1719	1723		|O
each	1724	1728		|O
approach	1729	1737		|O
on	1738	1740		|O
a	1741	1742		|O
0	1743	1744		|O
to	1745	1747		|O
10	1748	1750		|O
scale	1751	1756		|O
in	1757	1759		|O
terms	1760	1765		|O
of	1766	1768		|O
the	1769	1772		|O
extent	1773	1779		|O
to	1780	1782		|O
which	1783	1788		|O
each	1789	1793		|O
approach	1794	1802		|O
appeared	1803	1811		|O
to	1812	1814		|O
be	1815	1817		|O
validated	1818	1827		|O
.	1827	1828		|O
The	1829	1832		|O
outcome	1833	1840		|O
of	1841	1843		|O
this	1844	1848		|O
exercise	1849	1857		|O
forms	1858	1863		|O
the	1864	1867		|O
basis	1868	1873		|O
of	1874	1876		|O
this	1877	1881		|O
article	1882	1889		|O
.	1889	1890		|O
We	1891	1893		|O
invite	1894	1900		|O
you	1901	1904		|O
to	1905	1907		|O
evaluate	1908	1916		|O
for	1917	1920		|O
yourselves	1921	1931		|O
the	1932	1935		|O
accompanying	1936	1948		|O
reviews	1949	1956		|O
in	1957	1959		|O
this	1960	1964		|O
edition	1965	1972		|O
of	1973	1975		|O
Pharmacology	1976	1988		|O
and	1989	1992		|O
Therapeutics	1993	2005		|O
.	2005	2006		|O

### 18942662
Patient	0	7		|O
willingness	8	19		|O
to	20	22		|O
undergo	23	30		|O
chemotherapy	31	43		|O
and	44	47		|O
thoracic	48	56		|O
radiotherapy	57	69		|O
for	70	73		|O
locally	74	81		|O
advanced	82	90		|O
non	91	94	non-small cell lung cancer	|B-DISEASE
-	94	95		|I-DISEASE
small	95	100		|I-DISEASE
cell	101	105		|I-DISEASE
lung	106	110		|I-DISEASE
cancer	111	117		|I-DISEASE
.	117	118		|O
OBJECTIVES	120	130		|O
:	130	131		|O
To	132	134		|O
determine	135	144		|O
how	145	148		|O
Japanese	149	157		|O
patients	158	166		|O
with	167	171		|O
lung	172	176	lung cancer	|B-DISEASE
cancer	177	183		|I-DISEASE
weigh	184	189		|O
the	190	193		|O
chance	194	200		|O
of	201	203		|O
cure	204	208		|O
and	209	212		|O
potential	213	222		|O
survival	223	231		|O
against	232	239		|O
the	240	243		|O
potential	244	253		|O
toxicity	254	262		|O
of	263	265		|O
different	266	275		|O
treatment	276	285		|O
strategies	286	296		|O
for	297	300		|O
locally	301	308		|O
advanced	309	317		|O
non	318	321	non-small cell lung cancer	|B-DISEASE
-	321	322		|I-DISEASE
small	322	327		|I-DISEASE
cell	328	332		|I-DISEASE
lung	333	337		|I-DISEASE
cancer	338	344		|I-DISEASE
(	345	346		|O
NSCLC	346	351		|O
)	351	352		|O
.	352	353		|O
METHODS	354	361		|O
:	361	362		|O
We	363	365		|O
used	366	370		|O
a	371	372		|O
questionnaire	373	386		|O
describing	387	397		|O
a	398	399		|O
hypothetical	400	412		|O
situation	413	422		|O
involving	423	432		|O
locally	433	440		|O
advanced	441	449		|O
NSCLC	450	455		|O
.	455	456		|O
Seventy	457	464		|O
-	464	465		|O
three	465	470		|O
patients	471	479		|O
with	480	484		|O
lung	485	489	lung cancer	|B-DISEASE
cancer	490	496		|I-DISEASE
who	497	500		|O
had	501	504		|O
received	505	513		|O
chemotherapy	514	526		|O
and	527	530		|O
a	531	532		|O
control	533	540		|O
group	541	546		|O
of	547	549		|O
120	550	553		|O
patients	554	562		|O
without	563	570		|O
cancer	571	577	cancer	|B-DISEASE
were	578	582		|O
asked	583	588		|O
to	589	591		|O
state	592	597		|O
the	598	601		|O
minimal	602	609		|O
benefit	610	617		|O
that	618	622		|O
would	623	628		|O
make	629	633		|O
two	634	637		|O
hypothetical	638	650		|O
treatments	651	661		|O
acceptable	662	672		|O
.	672	673		|O
RESULTS	674	681		|O
:	681	682		|O
Patients	683	691		|O
with	692	696		|O
lung	697	701	lung cancer	|B-DISEASE
cancer	702	708		|I-DISEASE
were	709	713		|O
significantly	714	727		|O
more	728	732		|O
likely	733	739		|O
than	740	744		|O
were	745	749		|O
patients	750	758		|O
without	759	766		|O
cancer	767	773	cancer	|B-DISEASE
to	774	776		|O
accept	777	783		|O
either	784	790		|O
intensive	791	800		|O
or	801	803		|O
less	804	808		|O
-	808	809		|O
intensive	809	818		|O
chemoradiotherapy	819	836		|O
for	837	840		|O
a	841	842		|O
potentially	843	854		|O
small	855	860		|O
benefit	861	868		|O
for	869	872		|O
'	873	874		|O
chance	874	880		|O
of	881	883		|O
cure	884	888		|O
'	888	889		|O
and	890	893		|O
're	894	897		|O
sponse	897	903		|O
but	904	907		|O
not	908	911		|O
cure	912	916		|O
'	916	917		|O
.	917	918		|O
The	919	922		|O
percentages	923	934		|O
of	935	937		|O
patients	938	946		|O
who	947	950		|O
would	951	956		|O
accept	957	963		|O
intensive	964	973		|O
or	974	976		|O
less	977	981		|O
-	981	982		|O
intensive	982	991		|O
chemoradiotherapy	992	1009		|O
to	1010	1012		|O
prolong	1013	1020		|O
survival	1021	1029		|O
did	1030	1033		|O
not	1034	1037		|O
differ	1038	1044		|O
significantly	1045	1058		|O
between	1059	1066		|O
the	1067	1070		|O
two	1071	1074		|O
groups	1075	1081		|O
.	1081	1082		|O
When	1083	1087		|O
the	1088	1091		|O
chance	1092	1098		|O
of	1099	1101		|O
cure	1102	1106		|O
was	1107	1110		|O
20%	1111	1114		|O
,	1114	1115		|O
56	1116	1118		|O
and	1119	1122		|O
64%	1123	1126		|O
of	1127	1129		|O
patients	1130	1138		|O
with	1139	1143		|O
lung	1144	1148	lung cancer	|B-DISEASE
cancer	1149	1155		|I-DISEASE
were	1156	1160		|O
willing	1161	1168		|O
to	1169	1171		|O
receive	1172	1179		|O
intensive	1180	1189		|O
and	1190	1193		|O
less	1194	1198		|O
-	1198	1199		|O
intensive	1199	1208		|O
chemoradiotherapy	1209	1226		|O
,	1226	1227		|O
respectively	1228	1240		|O
.	1240	1241		|O
If	1242	1244		|O
their	1245	1250		|O
lives	1251	1256		|O
were	1257	1261		|O
prolonged	1262	1271		|O
by	1272	1274		|O
6	1275	1276		|O
months	1277	1283		|O
,	1283	1284		|O
20	1285	1287		|O
and	1288	1291		|O
30%	1292	1295		|O
of	1296	1298		|O
patients	1299	1307		|O
with	1308	1312		|O
lung	1313	1317	lung cancer	|B-DISEASE
cancer	1318	1324		|I-DISEASE
would	1325	1330		|O
choose	1331	1337		|O
to	1338	1340		|O
receive	1341	1348		|O
intensive	1349	1358		|O
and	1359	1362		|O
less	1363	1367		|O
-	1367	1368		|O
intensive	1368	1377		|O
chemoradiotherapy	1378	1395		|O
,	1395	1396		|O
respectively	1397	1409		|O
.	1409	1410		|O
The	1411	1414		|O
chance	1415	1421		|O
of	1422	1424		|O
cure	1425	1429		|O
and	1430	1433		|O
the	1434	1437		|O
survival	1438	1446		|O
advantage	1447	1456		|O
that	1457	1461		|O
patients	1462	1470		|O
require	1471	1478		|O
for	1479	1482		|O
accepting	1483	1492		|O
chemoradiotherapy	1493	1510		|O
varied	1511	1517		|O
widely	1518	1524		|O
.	1524	1525		|O
No	1526	1528		|O
factors	1529	1536		|O
were	1537	1541		|O
associated	1542	1552		|O
with	1553	1557		|O
the	1558	1561		|O
choice	1562	1568		|O
of	1569	1571		|O
chemoradiotherapy	1572	1589		|O
in	1590	1592		|O
patients	1593	1601		|O
with	1602	1606		|O
lung	1607	1611	lung cancer	|B-DISEASE
cancer	1612	1618		|I-DISEASE
.	1618	1619		|O
CONCLUSIONS	1620	1631		|O
:	1631	1632		|O
Physicians	1633	1643		|O
must	1644	1648		|O
consider	1649	1657		|O
the	1658	1661		|O
substantial	1662	1673		|O
range	1674	1679		|O
of	1680	1682		|O
attitudes	1683	1692		|O
to	1693	1695		|O
chemoradiotherapy	1696	1713		|O
among	1714	1719		|O
patients	1720	1728		|O
when	1729	1733		|O
selecting	1734	1743		|O
treatment	1744	1753		|O
and	1754	1757		|O
give	1758	1762		|O
patients	1763	1771		|O
opportunities	1772	1785		|O
to	1786	1788		|O
be	1789	1791		|O
included	1792	1800		|O
in	1801	1803		|O
the	1804	1807		|O
treatment	1808	1817		|O
-	1817	1818		|O
selection	1818	1827		|O
process	1828	1835		|O
.	1835	1836		|O

### 18698850
Identification	0	14		|O
and	15	18		|O
characterization	19	35		|O
of	36	38		|O
thiosemicarbazones	39	57		|O
with	58	62		|O
antifungal	63	73		|O
and	74	77		|O
antitumor	78	87		|O
effects	88	95		|O
:	95	96		|O
cellular	97	105		|O
iron	106	110		|O
chelation	111	120		|O
mediating	121	130		|O
cytotoxic	131	140	cytotoxic activity	|B-ADVERSE
activity	141	149		|I-ADVERSE
.	149	150		|O
Thiosemicarbazones	152	170		|O
derived	171	178		|O
from	179	183		|O
acetylpyrazines	184	199		|O
were	200	204		|O
prepared	205	213		|O
by	214	216		|O
condensing	217	227		|O
an	228	230		|O
acetylpyrazine	231	245		|O
or	246	248		|O
a	249	250		|O
ring	251	255		|O
-	255	256		|O
substituted	256	267		|O
acetylpyrazine	268	282		|O
with	283	287		|O
thiosemicarbazide	288	305		|O
.	305	306		|O
Using	307	312		|O
the	313	316		|O
same	317	321		|O
procedure	322	331		|O
,	331	332		|O
N	333	334		|O
,	334	335		|O
N	336	337		|O
-	337	338		|O
dimethylthiosemicarbazones	338	364		|O
were	365	369		|O
synthesized	370	381		|O
from	382	386		|O
acetylpyrazines	387	402		|O
and	403	406		|O
N	407	408		|O
,	408	409		|O
N	410	411		|O
-	411	412		|O
dimethylthiosemicarbazide	412	437		|O
.	437	438		|O
A	439	440		|O
total	441	446		|O
of	447	449		|O
20	450	452		|O
compounds	453	462		|O
(	463	464		|O
16	464	466		|O
novel	467	472		|O
)	472	473		|O
were	474	478		|O
chemically	479	489		|O
characterized	490	503		|O
and	504	507		|O
then	508	512		|O
tested	513	519		|O
for	520	523		|O
antifungal	524	534		|O
effects	535	542		|O
on	543	545		|O
eight	546	551		|O
strains	552	559		|O
of	560	562		|O
fungi	563	568		|O
and	569	572		|O
also	573	577		|O
for	578	581		|O
antitumor	582	591		|O
activity	592	600		|O
against	601	608		|O
SK	609	611		|O
-	611	612		|O
N	612	613		|O
-	613	614		|O
MC	614	616		|O
neuroepithelioma	617	633		|O
cells	634	639		|O
.	639	640		|O
The	641	644		|O
most	645	649		|O
effective	650	659		|O
compound	660	668		|O
identified	669	679		|O
in	680	682		|O
terms	683	688		|O
of	689	691		|O
both	692	696		|O
antifungal	697	707		|O
and	708	711		|O
antitumor	712	721		|O
activity	722	730		|O
was	731	734		|O
N	735	736		|O
,	736	737		|O
N	738	739		|O
-	739	740		|O
dimethyl	740	748		|O
-	748	749		|O
2	749	750		|O
-	750	751		|O
(	751	752		|O
1	752	753		|O
-	753	754		|O
pyrazin	754	761		|O
-	761	762		|O
2	762	763		|O
-	763	764		|O
ylethylidene	764	776		|O
)	776	777		|O
hydrazinecarbothioamide	777	800		|O
(	801	802		|O
5a	802	804		|O
)	804	805		|O
.	805	806		|O
The	807	810		|O
mechanism	811	820		|O
of	821	823		|O
action	824	830		|O
of	831	833		|O
this	834	838		|O
and	839	842		|O
its	843	846		|O
related	847	854		|O
thiosemicarbazones	855	873		|O
was	874	877		|O
due	878	881		|O
,	881	882		|O
at	883	885		|O
least	886	891		|O
in	892	894		|O
part	895	899		|O
,	899	900		|O
to	901	903		|O
its	904	907		|O
ability	908	915		|O
to	916	918		|O
act	919	922		|O
as	923	925		|O
a	926	927		|O
tridentate	928	938		|O
ligand	939	945		|O
that	946	950		|O
binds	951	956		|O
metal	957	962		|O
ions	963	967		|O
.	967	968		|O
This	969	973		|O
was	974	977		|O
deduced	978	985		|O
from	986	990		|O
preparation	991	1002		|O
of	1003	1005		|O
the	1006	1009		|O
related	1010	1017		|O
thiosemicarbazones	1018	1036		|O
[	1037	1038		|O
acetophenone	1038	1050		|O
thiosemicarbazone	1051	1068		|O
(	1069	1070		|O
6	1070	1071		|O
)	1071	1072		|O
and	1073	1076		|O
acetophenone	1077	1089		|O
N	1090	1091		|O
,	1091	1092		|O
N	1093	1094		|O
-	1094	1095		|O
dimethylthiosemicarbazone	1095	1120		|O
(	1121	1122		|O
7	1122	1123		|O
)	1123	1124		|O
]	1124	1125		|O
that	1126	1130		|O
do	1131	1133		|O
not	1134	1137		|O
possess	1138	1145		|O
a	1146	1147		|O
coordinating	1148	1160		|O
ring	1161	1165		|O
-	1165	1166		|O
N	1166	1167		|O
,	1167	1168		|O
which	1169	1174		|O
plays	1175	1180		|O
a	1181	1182		|O
vital	1183	1188		|O
role	1189	1193		|O
in	1194	1196		|O
metal	1197	1202		|O
ion	1203	1206		|O
chelation	1207	1216		|O
.	1216	1217		|O
Furthermore	1218	1229		|O
,	1229	1230		|O
5a	1231	1233		|O
and	1234	1237		|O
several	1238	1245		|O
other	1246	1251		|O
thiosemicarbazones	1252	1270		|O
that	1271	1275		|O
showed	1276	1282		|O
high	1283	1287		|O
antiproliferative	1288	1305		|O
activity	1306	1314		|O
were	1315	1319		|O
demonstrated	1320	1332		|O
to	1333	1335		|O
have	1336	1340		|O
marked	1341	1347		|O
iron	1348	1352		|O
(	1353	1354		|O
Fe	1354	1356		|O
)	1356	1357		|O
chelation	1358	1367		|O
efficacy	1368	1376		|O
.	1376	1377		|O
In	1378	1380		|O
fact	1381	1385		|O
,	1385	1386		|O
these	1387	1392		|O
agents	1393	1399		|O
were	1400	1404		|O
highly	1405	1411		|O
effective	1412	1421		|O
at	1422	1424		|O
mobilizing	1425	1435		|O
(	1436	1437		|O
59	1437	1439		|O
)	1439	1440		|O
Fe	1440	1442		|O
from	1443	1447		|O
prelabeled	1448	1458		|O
SK	1459	1461		|O
-	1461	1462		|O
N	1462	1463		|O
-	1463	1464		|O
MC	1464	1466		|O
cells	1467	1472		|O
and	1473	1476		|O
preventing	1477	1487		|O
(	1488	1489		|O
59	1489	1491		|O
)	1491	1492		|O
Fe	1492	1494		|O
uptake	1495	1501		|O
from	1502	1506		|O
the	1507	1510		|O
serum	1511	1516		|O
Fe	1517	1519		|O
transport	1520	1529		|O
protein	1530	1537		|O
,	1537	1538		|O
transferrin	1539	1550		|O
.	1550	1551		|O
In	1552	1554		|O
contrast	1555	1563		|O
,	1563	1564		|O
compounds	1565	1574		|O
6	1575	1576		|O
and	1577	1580		|O
7	1581	1582		|O
that	1583	1587		|O
do	1588	1590		|O
not	1591	1594		|O
possess	1595	1602		|O
a	1603	1604		|O
tridentate	1605	1615		|O
metal	1616	1621		|O
-	1621	1622		|O
binding	1622	1629		|O
site	1630	1634		|O
showed	1635	1641		|O
little	1642	1648		|O
activity	1649	1657		|O
.	1657	1658		|O
Further	1659	1666		|O
studies	1667	1674		|O
examining	1675	1684		|O
ascorbate	1685	1694		|O
oxidation	1695	1704		|O
demonstrated	1705	1717		|O
that	1718	1722		|O
the	1723	1726		|O
Fe	1727	1729		|O
complexes	1730	1739		|O
of	1740	1742		|O
the	1743	1746		|O
most	1747	1751		|O
effective	1752	1761		|O
compounds	1762	1771		|O
were	1772	1776		|O
redox	1777	1782		|O
-	1782	1783		|O
inactive	1783	1791		|O
.	1791	1792		|O
Thus	1793	1797		|O
,	1797	1798		|O
in	1799	1801		|O
contrast	1802	1810		|O
to	1811	1813		|O
other	1814	1819		|O
thiosemicarbazones	1820	1838		|O
with	1839	1843		|O
potent	1844	1850		|O
antiproliferative	1851	1868		|O
activity	1869	1877		|O
,	1877	1878		|O
Fe	1879	1881		|O
chelation	1882	1891		|O
and	1892	1895		|O
mobilization	1896	1908		|O
rather	1909	1915		|O
than	1916	1920		|O
free	1921	1925		|O
radical	1926	1933		|O
generation	1934	1944		|O
played	1945	1951		|O
a	1952	1953		|O
significant	1954	1965		|O
role	1966	1970		|O
in	1971	1973		|O
the	1974	1977		|O
cytotoxic	1978	1987	cytotoxic effects	|B-ADVERSE
effects	1988	1995		|I-ADVERSE
of	1996	1998		|O
the	1999	2002		|O
current	2003	2010		|O
ligands	2011	2018		|O
.	2018	2019		|O

### 18560533
Transcriptome	0	13		|O
analyses	14	22		|O
in	23	25		|O
normal	26	32		|O
prostate	33	41		|O
epithelial	42	52		|O
cells	53	58		|O
exposed	59	66		|O
to	67	69		|O
low	70	73		|O
-	73	74		|O
dose	74	78		|O
cadmium	79	86		|O
:	86	87		|O
oncogenic	88	97		|O
and	98	101		|O
immunomodulations	102	119		|O
involving	120	129		|O
the	130	133		|O
action	134	140		|O
of	141	143		|O
tumor	144	149		|O
necrosis	150	158		|O
factor	159	165		|O
.	165	166		|O
BACKGROUND	168	178		|O
:	178	179		|O
Cadmium	180	187		|O
is	188	190		|O
implicated	191	201		|O
in	202	204		|O
prostate	205	213	prostate carcinogenesis	|B-ADVERSE
carcinogenesis	214	228		|I-ADVERSE
,	228	229		|O
but	230	233		|O
its	234	237		|O
oncogenic	238	247		|O
action	248	254		|O
remains	255	262		|O
unclear	263	270		|O
.	270	271		|O
OBJECTIVES	272	282		|O
:	282	283		|O
In	284	286		|O
this	287	291		|O
study	292	297		|O
we	298	300		|O
aimed	301	306		|O
to	307	309		|O
decipher	310	318		|O
changes	319	326		|O
in	327	329		|O
cell	330	334		|O
growth	335	341		|O
and	342	345		|O
the	346	349		|O
transcriptome	350	363		|O
in	364	366		|O
an	367	369		|O
immortalized	370	382		|O
human	383	388		|O
normal	389	395		|O
prostate	396	404		|O
epithelial	405	415		|O
cell	416	420		|O
line	421	425		|O
(	426	427		|O
NPrEC	427	432		|O
)	432	433		|O
following	434	443		|O
exposure	444	452		|O
to	453	455		|O
low	456	459		|O
-	459	460		|O
dose	460	464		|O
Cd	465	467		|O
.	467	468		|O
METHODS	469	476		|O
:	476	477		|O
Synchronized	478	490		|O
NPrEC	491	496		|O
cells	497	502		|O
were	503	507		|O
exposed	508	515		|O
to	516	518		|O
different	519	528		|O
doses	529	534		|O
of	535	537		|O
Cd	538	540		|O
and	541	544		|O
assayed	545	552		|O
for	553	556		|O
cell	557	561		|O
viability	562	571		|O
and	572	575		|O
cell	576	580		|O
-	580	581		|O
cycle	581	586		|O
progression	587	598		|O
.	598	599		|O
We	600	602		|O
investigated	603	615		|O
changes	616	623		|O
in	624	626		|O
transcriptome	627	640		|O
by	641	643		|O
global	644	650		|O
profiling	651	660		|O
and	661	664		|O
used	665	669		|O
Ingenuity	670	679		|O
Pathways	680	688		|O
Analysis	689	697		|O
software	698	706		|O
to	707	709		|O
develop	710	717		|O
propositions	718	730		|O
about	731	736		|O
functional	737	747		|O
connections	748	759		|O
among	760	765		|O
differentially	766	780		|O
expressed	781	790		|O
genes	791	796		|O
.	796	797		|O
A	798	799		|O
neutralizing	800	812		|O
antibody	813	821		|O
was	822	825		|O
used	826	830		|O
to	831	833		|O
negate	834	840		|O
the	841	844		|O
effect	845	851		|O
of	852	854		|O
Cd	855	857		|O
-	857	858		|O
induced	858	865		|O
up	866	868		|O
-	868	869		|O
regulation	869	879		|O
of	880	882		|O
tumor	883	888		|O
necrosis	889	897		|O
factor	898	904		|O
(	905	906		|O
TNF	906	909		|O
)	909	910		|O
in	911	913		|O
NPrEC	914	919		|O
cells	920	925		|O
.	925	926		|O
RESULTS	927	934		|O
:	934	935		|O
Exposure	936	944		|O
of	945	947		|O
NPrEC	948	953		|O
to	954	956		|O
2.5	957	960		|O
microM	961	967		|O
Cd	968	970		|O
enhanced	971	979		|O
cell	980	984		|O
viability	985	994		|O
and	995	998		|O
accelerated	999	1010		|O
cell	1011	1015		|O
-	1015	1016		|O
cycle	1016	1021		|O
progression	1022	1033		|O
.	1033	1034		|O
Global	1035	1041		|O
expression	1042	1052		|O
profiling	1053	1062		|O
identified	1063	1073		|O
48	1074	1076		|O
genes	1077	1082		|O
that	1083	1087		|O
exhibited	1088	1097		|O
>	1098	1099		|O
or	1099	1101		|O
=	1101	1102		|O
1.5	1103	1106		|O
-	1106	1107		|O
fold	1107	1111		|O
changes	1112	1119		|O
in	1120	1122		|O
expression	1123	1133		|O
after	1134	1139		|O
4	1140	1141		|O
,	1141	1142		|O
8	1143	1144		|O
,	1144	1145		|O
16	1146	1148		|O
,	1148	1149		|O
and	1150	1153		|O
32	1154	1156		|O
hr	1157	1159		|O
of	1160	1162		|O
Cd	1163	1165		|O
treatment	1166	1175		|O
.	1175	1176		|O
Pathway	1177	1184		|O
analyses	1185	1193		|O
inferred	1194	1202		|O
a	1203	1204		|O
functional	1205	1215		|O
connection	1216	1226		|O
among	1227	1232		|O
35	1233	1235		|O
of	1236	1238		|O
these	1239	1244		|O
genes	1245	1250		|O
in	1251	1253		|O
one	1254	1257		|O
major	1258	1263		|O
network	1264	1271		|O
,	1271	1272		|O
with	1273	1277		|O
TNF	1278	1281		|O
as	1282	1284		|O
the	1285	1288		|O
most	1289	1293		|O
prominent	1294	1303		|O
node	1304	1308		|O
.	1308	1309		|O
Fourteen	1310	1318		|O
of	1319	1321		|O
the	1322	1325		|O
35	1326	1328		|O
genes	1329	1334		|O
are	1335	1338		|O
related	1339	1346		|O
to	1347	1349		|O
TNF	1350	1353		|O
,	1353	1354		|O
and	1355	1358		|O
11	1359	1361		|O
exhibited	1362	1371		|O
an	1372	1374		|O
average	1375	1382		|O
of	1383	1385		|O
>	1386	1387		|O
2	1387	1388		|O
-	1388	1389		|O
fold	1389	1393		|O
changes	1394	1401		|O
in	1402	1404		|O
gene	1405	1409		|O
expression	1410	1420		|O
.	1420	1421		|O
Real	1422	1426		|O
-	1426	1427		|O
time	1427	1431		|O
reverse	1432	1439		|O
transcriptase	1440	1453		|O
-	1453	1454		|O
polymerase	1454	1464		|O
chain	1465	1470		|O
reaction	1471	1479		|O
confirmed	1480	1489		|O
the	1490	1493		|O
up	1494	1496		|O
-	1496	1497		|O
regulation	1497	1507		|O
of	1508	1510		|O
7	1511	1512		|O
of	1513	1515		|O
the	1516	1519		|O
11	1520	1522		|O
genes	1523	1528		|O
(	1529	1530		|O
ADAM8	1530	1535		|O
,	1535	1536		|O
EDN1	1537	1541		|O
,	1541	1542		|O
IL8	1543	1546		|O
,	1546	1547		|O
IL24	1548	1552		|O
,	1552	1553		|O
IL13RA2	1554	1561		|O
,	1561	1562		|O
COX2	1563	1567		|O
/	1567	1568		|O
PTGS2	1568	1573		|O
,	1573	1574		|O
and	1575	1578		|O
SERPINB2	1579	1587		|O
)	1587	1588		|O
and	1589	1592		|O
uncovered	1593	1602		|O
a	1603	1604		|O
28	1605	1607		|O
-	1607	1608		|O
fold	1608	1612		|O
transient	1613	1622		|O
increase	1623	1631		|O
in	1632	1634		|O
TNF	1635	1638		|O
expression	1639	1649		|O
in	1650	1652		|O
Cd	1653	1655		|O
-	1655	1656		|O
treated	1656	1663		|O
NPrEC	1664	1669		|O
cells	1670	1675		|O
.	1675	1676		|O
A	1677	1678		|O
TNF	1679	1682		|O
-	1682	1683		|O
neutralizing	1683	1695		|O
antibody	1696	1704		|O
effectively	1705	1716		|O
blocked	1717	1724		|O
Cd	1725	1727		|O
-	1727	1728		|O
induced	1728	1735		|O
elevations	1736	1746		|O
in	1747	1749		|O
the	1750	1753		|O
expression	1754	1764		|O
of	1765	1767		|O
these	1768	1773		|O
genes	1774	1779		|O
.	1779	1780		|O
CONCLUSIONS	1781	1792		|O
:	1792	1793		|O
Noncytotoxic	1794	1806		|O
,	1806	1807		|O
low	1808	1811		|O
-	1811	1812		|O
dose	1812	1816		|O
Cd	1817	1819		|O
has	1820	1823		|O
growth	1824	1830		|O
-	1830	1831		|O
promoting	1831	1840		|O
effects	1841	1848		|O
on	1849	1851		|O
NPrEC	1852	1857		|O
cells	1858	1863		|O
and	1864	1867		|O
induces	1868	1875		|O
transient	1876	1885		|O
overexpression	1886	1900		|O
of	1901	1903		|O
TNF	1904	1907		|O
,	1907	1908		|O
leading	1909	1916		|O
to	1917	1919		|O
up	1920	1922		|O
-	1922	1923		|O
regulation	1923	1933		|O
of	1934	1936		|O
genes	1937	1942		|O
with	1943	1947		|O
oncogenic	1948	1957		|O
and	1958	1961		|O
immunomodulation	1962	1978		|O
functions	1979	1988		|O
.	1988	1989		|O

### 18826176
Methylated	0	10		|O
bismuth	11	18		|O
,	18	19		|O
but	20	23		|O
not	24	27		|O
bismuth	28	35		|O
citrate	36	43		|O
or	44	46		|O
bismuth	47	54		|O
glutathione	55	66		|O
,	66	67		|O
induces	68	75		|O
cyto	76	80		|O
-	80	81		|O
and	82	85		|O
genotoxic	86	95	genotoxic effects	|B-ADVERSE
effects	96	103		|I-ADVERSE
in	104	106		|O
human	107	112		|O
cells	113	118		|O
in	119	121		|O
vitro	122	127		|O
.	127	128		|O
Bismuth	130	137		|O
compounds	138	147		|O
are	148	151		|O
widely	152	158		|O
used	159	163		|O
in	164	166		|O
industrial	167	177		|O
processes	178	187		|O
and	188	191		|O
products	192	200		|O
.	200	201		|O
In	202	204		|O
medicine	205	213		|O
,	213	214		|O
bismuth	215	222		|O
salts	223	228		|O
have	229	233		|O
been	234	238		|O
applied	239	246		|O
in	247	249		|O
combination	250	261		|O
with	262	266		|O
antibiotics	267	278		|O
for	279	282		|O
the	283	286		|O
treatment	287	296		|O
of	297	299		|O
Helicobacter	300	312	Helicobacter pylori infections	|B-DISEASE
pylori	313	319		|I-DISEASE
infections	320	330		|I-DISEASE
,	330	331		|O
for	332	335		|O
the	336	339		|O
prevention	340	350		|O
of	351	353		|O
diarrhea	354	362	diarrhea	|B-DISEASE
,	362	363		|O
and	364	367		|O
in	368	370		|O
radioimmunotherapy	371	389		|O
.	389	390		|O
In	391	393		|O
the	394	397		|O
environment	398	409		|O
,	409	410		|O
bismuth	411	418		|O
ions	419	423		|O
can	424	427		|O
be	428	430		|O
biotransformed	431	445		|O
to	446	448		|O
the	449	452		|O
volatile	453	461		|O
bismuth	462	469		|O
compound	470	478		|O
trimethylbismuth	479	495		|O
(	496	497		|O
Me3Bi	497	502		|O
)	502	503		|O
by	504	506		|O
methanobacteria	507	522		|O
.	522	523		|O
Preliminary	524	535		|O
in	536	538		|O
-	538	539		|O
house	539	544		|O
studies	545	552		|O
have	553	557		|O
indicated	558	567		|O
that	568	572		|O
bismuth	573	580		|O
ions	581	585		|O
are	586	589		|O
methylated	590	600		|O
in	601	603		|O
the	604	607		|O
human	608	613		|O
colon	614	619		|O
by	620	622		|O
intestinal	623	633		|O
microflora	634	644		|O
following	645	654		|O
ingestion	655	664		|O
of	665	667		|O
bismuth	668	675		|O
-	675	676		|O
containing	676	686		|O
salts	687	692		|O
.	692	693		|O
Information	694	705		|O
concerning	706	716		|O
cyto	717	721		|O
-	721	722		|O
and	723	726		|O
genotoxicity	727	739	genotoxicity	|B-ADVERSE
of	740	742		|O
these	743	748		|O
biomethylated	749	762		|O
products	763	771		|O
is	772	774		|O
limited	775	782		|O
.	782	783		|O
In	784	786		|O
the	787	790		|O
present	791	798		|O
study	799	804		|O
,	804	805		|O
we	806	808		|O
investigated	809	821		|O
the	822	825		|O
cellular	826	834		|O
uptake	835	841		|O
of	842	844		|O
an	845	847		|O
organic	848	855		|O
bismuth	856	863		|O
compound	864	872		|O
[	873	874		|O
monomethylbismuth	874	891		|O
(	891	892		|O
III	892	895		|O
)	895	896		|O
,	896	897		|O
MeBi	898	902		|O
(	902	903		|O
III	903	906		|O
)	906	907		|O
]	907	908		|O
and	909	912		|O
two	913	916		|O
other	917	922		|O
bismuth	923	930		|O
compounds	931	940		|O
[	941	942		|O
bismuth	942	949		|O
citrate	950	957		|O
(	958	959		|O
Bi	959	961		|O
-	961	962		|O
Cit	962	965		|O
)	965	966		|O
and	967	970		|O
bismuth	971	978		|O
glutathione	979	990		|O
(	991	992		|O
Bi	992	994		|O
-	994	995		|O
GS	995	997		|O
)	997	998		|O
]	998	999		|O
in	1000	1002		|O
human	1003	1008		|O
hepatocytes	1009	1020		|O
,	1020	1021		|O
lymphocytes	1022	1033		|O
,	1033	1034		|O
and	1035	1038		|O
erythrocytes	1039	1051		|O
using	1052	1057		|O
ICP	1058	1061		|O
-	1061	1062		|O
MS	1062	1064		|O
.	1064	1065		|O
We	1066	1068		|O
also	1069	1073		|O
analyzed	1074	1082		|O
the	1083	1086		|O
cyto	1087	1091		|O
-	1091	1092		|O
and	1093	1096		|O
genotoxic	1097	1106	genotoxic effects	|B-ADVERSE
effects	1107	1114		|I-ADVERSE
of	1115	1117		|O
these	1118	1123		|O
compounds	1124	1133		|O
to	1134	1136		|O
investigate	1137	1148		|O
their	1149	1154		|O
toxic	1155	1160		|O
potential	1161	1170		|O
.	1170	1171		|O
Our	1172	1175		|O
results	1176	1183		|O
show	1184	1188		|O
that	1189	1193		|O
the	1194	1197		|O
methylbismuth	1198	1211		|O
compound	1212	1220		|O
was	1221	1224		|O
better	1225	1231		|O
taken	1232	1237		|O
up	1238	1240		|O
by	1241	1243		|O
the	1244	1247		|O
cells	1248	1253		|O
than	1254	1258		|O
Bi	1259	1261		|O
-	1261	1262		|O
Cit	1262	1265		|O
and	1266	1269		|O
Bi	1270	1272		|O
-	1272	1273		|O
GS	1273	1275		|O
.	1275	1276		|O
All	1277	1280		|O
intracellularly	1281	1296		|O
detected	1297	1305		|O
bismuth	1306	1313		|O
compounds	1314	1323		|O
were	1324	1328		|O
located	1329	1336		|O
in	1337	1339		|O
the	1340	1343		|O
cytosol	1344	1351		|O
of	1352	1354		|O
the	1355	1358		|O
cells	1359	1364		|O
.	1364	1365		|O
MeBi	1366	1370		|O
(	1370	1371		|O
III	1371	1374		|O
)	1374	1375		|O
was	1376	1379		|O
best	1380	1384		|O
taken	1385	1390		|O
up	1391	1393		|O
by	1394	1396		|O
erythrocytes	1397	1409		|O
(	1410	1411		|O
36%	1411	1414		|O
)	1414	1415		|O
,	1415	1416		|O
followed	1417	1425		|O
by	1426	1428		|O
lymphocytes	1429	1440		|O
(	1441	1442		|O
17%	1442	1445		|O
)	1445	1446		|O
and	1447	1450		|O
hepatocytes	1451	1462		|O
(	1463	1464		|O
0.04%	1464	1469		|O
)	1469	1470		|O
.	1470	1471		|O
Erythrocytes	1472	1484		|O
and	1485	1488		|O
hepatocytes	1489	1500		|O
were	1501	1505		|O
more	1506	1510		|O
susceptible	1511	1522		|O
to	1523	1525		|O
MeBi	1526	1530		|O
(	1530	1531		|O
III	1531	1534		|O
)	1534	1535		|O
exposure	1536	1544		|O
than	1545	1549		|O
lymphocytes	1550	1561		|O
.	1561	1562		|O
Cytotoxic	1563	1572	Cytotoxic effects	|B-ADVERSE
effects	1573	1580		|I-ADVERSE
of	1581	1583		|O
MeBi	1584	1588		|O
(	1588	1589		|O
III	1589	1592		|O
)	1592	1593		|O
were	1594	1598		|O
detectable	1599	1609		|O
in	1610	1612		|O
erythrocytes	1613	1625		|O
at	1626	1628		|O
concentrations	1629	1643		|O
>	1644	1645		|O
4	1645	1646		|O
microM	1647	1653		|O
,	1653	1654		|O
in	1655	1657		|O
hepatocytes	1658	1669		|O
at	1670	1672		|O
>	1673	1674		|O
130	1674	1677		|O
microM	1678	1684		|O
,	1684	1685		|O
and	1686	1689		|O
in	1690	1692		|O
lymphocytes	1693	1704		|O
at	1705	1707		|O
>	1708	1709		|O
430	1709	1712		|O
microM	1713	1719		|O
after	1720	1725		|O
24	1726	1728		|O
h	1729	1730		|O
of	1731	1733		|O
exposure	1734	1742		|O
.	1742	1743		|O
Cytotoxic	1744	1753	Cytotoxic effects	|B-ADVERSE
effects	1754	1761		|I-ADVERSE
for	1762	1765		|O
Bi	1766	1768		|O
-	1768	1769		|O
Cit	1769	1772		|O
and	1773	1776		|O
Bi	1777	1779		|O
-	1779	1780		|O
GS	1780	1782		|O
were	1783	1787		|O
much	1788	1792		|O
lower	1793	1798		|O
or	1799	1801		|O
not	1802	1805		|O
detectable	1806	1816		|O
in	1817	1819		|O
the	1820	1823		|O
used	1824	1828		|O
cell	1829	1833		|O
lines	1834	1839		|O
up	1840	1842		|O
to	1843	1845		|O
a	1846	1847		|O
tested	1848	1854		|O
concentration	1855	1868		|O
of	1869	1871		|O
500	1872	1875		|O
microM	1876	1882		|O
.	1882	1883		|O
Exposure	1884	1892		|O
of	1893	1895		|O
lymphocytes	1896	1907		|O
to	1908	1910		|O
MeBi	1911	1915		|O
(	1915	1916		|O
III	1916	1919		|O
)	1919	1920		|O
(	1921	1922		|O
250	1922	1925		|O
microM	1926	1932		|O
for	1933	1936		|O
1	1937	1938		|O
h	1939	1940		|O
and	1941	1944		|O
25	1945	1947		|O
microM	1948	1954		|O
/	1954	1955		|O
50	1955	1957		|O
microM	1958	1964		|O
for	1965	1968		|O
24	1969	1971		|O
h	1972	1973		|O
)	1973	1974		|O
resulted	1975	1983		|O
in	1984	1986		|O
significantly	1987	2000		|O
increased	2001	2010		|O
frequencies	2011	2022		|O
of	2023	2025		|O
chromosomal	2026	2037		|O
aberrations	2038	2049		|O
(	2050	2051		|O
CA	2051	2053		|O
)	2053	2054		|O
and	2055	2058		|O
sister	2059	2065		|O
chromatid	2066	2075		|O
exchanges	2076	2085		|O
(	2086	2087		|O
SCE	2087	2090		|O
)	2090	2091		|O
,	2091	2092		|O
whereas	2093	2100		|O
Bi	2101	2103		|O
-	2103	2104		|O
Cit	2104	2107		|O
and	2108	2111		|O
Bi	2112	2114		|O
-	2114	2115		|O
GS	2115	2117		|O
induced	2118	2125		|O
neither	2126	2133		|O
CA	2134	2136		|O
nor	2137	2140		|O
SCE	2141	2144		|O
.	2144	2145		|O
Our	2146	2149		|O
study	2150	2155		|O
also	2156	2160		|O
showed	2161	2167		|O
an	2168	2170		|O
intracellular	2171	2184		|O
production	2185	2195		|O
of	2196	2198		|O
free	2199	2203		|O
radicals	2204	2212		|O
caused	2213	2219		|O
by	2220	2222		|O
MeBi	2223	2227		|O
(	2227	2228		|O
III	2228	2231		|O
)	2231	2232		|O
in	2233	2235		|O
hepatocytes	2236	2247		|O
but	2248	2251		|O
not	2252	2255		|O
in	2256	2258		|O
lymphocytes	2259	2270		|O
.	2270	2271		|O
These	2272	2277		|O
data	2278	2282		|O
suggest	2283	2290		|O
that	2291	2295		|O
biomethylation	2296	2310		|O
of	2311	2313		|O
bismuth	2314	2321		|O
ions	2322	2326		|O
by	2327	2329		|O
the	2330	2333		|O
intestinal	2334	2344		|O
microflora	2345	2355		|O
of	2356	2358		|O
the	2359	2362		|O
human	2363	2368		|O
colon	2369	2374		|O
leads	2375	2380		|O
to	2381	2383		|O
an	2384	2386		|O
increase	2387	2395		|O
in	2396	2398		|O
the	2399	2402		|O
toxicity	2403	2411		|O
of	2412	2414		|O
the	2415	2418		|O
primary	2419	2426		|O
bismuth	2427	2434		|O
salt	2435	2439		|O
.	2439	2440		|O

### 18636394
Integrated	0	10		|O
disinfection	11	23		|O
by	24	26		|O
-	26	27		|O
products	27	35		|O
research	36	44		|O
:	44	45		|O
assessing	46	55		|O
reproductive	56	68		|O
and	69	72		|O
developmental	73	86		|O
risks	87	92		|O
posed	93	98		|O
by	99	101		|O
complex	102	109		|O
disinfection	110	122		|O
by	123	125		|O
-	125	126		|O
product	126	133		|O
mixtures	134	142		|O
.	142	143		|O
This	145	149		|O
article	150	157		|O
presents	158	166		|O
a	167	168		|O
toxicologically	169	184		|O
-	184	185		|O
based	185	190		|O
risk	191	195		|O
assessment	196	206		|O
strategy	207	215		|O
for	216	219		|O
identifying	220	231		|O
the	232	235		|O
individual	236	246		|O
components	247	257		|O
or	258	260		|O
fractions	261	270		|O
of	271	273		|O
a	274	275		|O
complex	276	283		|O
mixture	284	291		|O
that	292	296		|O
are	297	300		|O
associated	301	311		|O
with	312	316		|O
its	317	320		|O
toxicity	321	329		|O
.	329	330		|O
The	331	334		|O
strategy	335	343		|O
relies	344	350		|O
on	351	353		|O
conventional	354	366		|O
component	367	376		|O
-	376	377		|O
based	377	382		|O
mixtures	383	391		|O
risk	392	396		|O
approaches	397	407		|O
such	408	412		|O
as	413	415		|O
dose	416	420		|O
addition	421	429		|O
,	429	430		|O
response	431	439		|O
addition	440	448		|O
,	448	449		|O
and	450	453		|O
analyses	454	462		|O
of	463	465		|O
interactions	466	478		|O
.	478	479		|O
Developmental	480	493	Developmental toxicity	|B-ADVERSE
toxicity	494	502		|I-ADVERSE
data	503	507		|O
from	508	512		|O
two	513	516		|O
drinking	517	525		|O
-	525	526		|O
water	526	531		|O
concentrates	532	544		|O
containing	545	555		|O
disinfection	556	568		|O
by	569	571		|O
-	571	572		|O
products	572	580		|O
(	581	582		|O
DBP	582	585		|O
)	585	586		|O
mixtures	587	595		|O
were	596	600		|O
used	601	605		|O
to	606	608		|O
illustrate	609	619		|O
the	620	623		|O
strategy	624	632		|O
.	632	633		|O
The	634	637		|O
results	638	645		|O
of	646	648		|O
this	649	653		|O
study	654	659		|O
showed	660	666		|O
that	667	671		|O
future	672	678		|O
studies	679	686		|O
of	687	689		|O
DBP	690	693		|O
concentrates	694	706		|O
using	707	712		|O
the	713	716		|O
Chernoff	717	725		|O
-	725	726		|O
Kavlock	726	733		|O
bioassay	734	742		|O
need	743	747		|O
to	748	750		|O
consider	751	759		|O
evaluating	760	770		|O
DBP	771	774		|O
that	775	779		|O
are	780	783		|O
concentrated	784	796		|O
more	797	801		|O
than	802	806		|O
130	807	810		|O
-	810	811		|O
fold	811	815		|O
and	816	819		|O
using	820	825		|O
a	826	827		|O
rat	828	831		|O
strain	832	838		|O
that	839	843		|O
is	844	846		|O
more	847	851		|O
sensitive	852	861		|O
to	862	864		|O
chemically	865	875		|O
-	875	876		|O
induced	876	883		|O
pregnancy	884	893		|O
loss	894	898		|O
than	899	903		|O
Sprague	904	911		|O
-	911	912		|O
Dawley	912	918		|O
rats	919	923		|O
.	923	924		|O
The	925	928		|O
results	929	936		|O
support	937	944		|O
the	945	948		|O
planned	949	956		|O
experimental	957	969		|O
design	970	976		|O
of	977	979		|O
a	980	981		|O
multigeneration	982	997		|O
reproductive	998	1010		|O
and	1011	1014		|O
developmental	1015	1028		|O
study	1029	1034		|O
of	1035	1037		|O
DBP	1038	1041		|O
concentrates	1042	1054		|O
.	1054	1055		|O
Finally	1056	1063		|O
,	1063	1064		|O
this	1065	1069		|O
article	1070	1077		|O
discusses	1078	1087		|O
the	1088	1091		|O
need	1092	1096		|O
for	1097	1100		|O
a	1101	1102		|O
systematic	1103	1113		|O
evaluation	1114	1124		|O
of	1125	1127		|O
DBP	1128	1131		|O
concentrates	1132	1144		|O
obtained	1145	1153		|O
from	1154	1158		|O
multiple	1159	1167		|O
source	1168	1174		|O
waters	1175	1181		|O
and	1182	1185		|O
treatment	1186	1195		|O
types	1196	1201		|O
.	1201	1202		|O
The	1203	1206		|O
development	1207	1218		|O
of	1219	1221		|O
such	1222	1226		|O
a	1227	1228		|O
database	1229	1237		|O
could	1238	1243		|O
be	1244	1246		|O
useful	1247	1253		|O
in	1254	1256		|O
evaluating	1257	1267		|O
whether	1268	1275		|O
a	1276	1277		|O
specific	1278	1286		|O
DBP	1287	1290		|O
concentrate	1291	1302		|O
is	1303	1305		|O
sufficiently	1306	1318		|O
similar	1319	1326		|O
to	1327	1329		|O
tested	1330	1336		|O
combinations	1337	1349		|O
of	1350	1352		|O
source	1353	1359		|O
waters	1360	1366		|O
and	1367	1370		|O
treatment	1371	1380		|O
alternatives	1381	1393		|O
so	1394	1396		|O
that	1397	1401		|O
health	1402	1408		|O
risks	1409	1414		|O
for	1415	1418		|O
the	1419	1422		|O
former	1423	1429		|O
may	1430	1433		|O
be	1434	1436		|O
estimated	1437	1446		|O
using	1447	1452		|O
data	1453	1457		|O
on	1458	1460		|O
the	1461	1464		|O
latter	1465	1471		|O
.	1471	1472		|O

### 18596603
Chemoprevention	0	15		|O
in	16	18		|O
postmenopausal	19	33		|O
women	34	39		|O
.	39	40		|O
Several	42	49		|O
large	50	55		|O
,	55	56		|O
prospective	57	68		|O
trials	69	75		|O
have	76	80		|O
evaluated	81	90		|O
tamoxifen	91	100		|O
compared	101	109		|O
with	110	114		|O
placebo	115	122		|O
for	123	126		|O
breast	127	133	breast cancer	|B-DISEASE
cancer	134	140		|I-DISEASE
risk	141	145		|O
reduction	146	155		|O
in	156	158		|O
women	159	164		|O
at	165	167		|O
increased	168	177		|O
risk	178	182		|O
of	183	185		|O
breast	186	192	breast cancer	|B-DISEASE
cancer	193	199		|I-DISEASE
.	199	200		|O
Combined	201	209		|O
results	210	217		|O
from	218	222		|O
these	223	228		|O
trials	229	235		|O
demonstrate	236	247		|O
that	248	252		|O
tamoxifen	253	262		|O
at	263	265		|O
20	266	268		|O
mg	269	271		|O
/	271	272		|O
d	272	273		|O
reduced	274	281		|O
the	282	285		|O
incidence	286	295		|O
of	296	298		|O
breast	299	305	breast cancer	|B-DISEASE
cancer	306	312		|I-DISEASE
by	313	315		|O
38%	316	319		|O
.	319	320		|O
The	321	324		|O
risk	325	329		|O
of	330	332		|O
developing	333	343		|O
breast	344	350	breast cancer	|B-DISEASE
cancer	351	357		|I-DISEASE
is	358	360		|O
the	361	364		|O
primary	365	372		|O
determinant	373	384		|O
of	385	387		|O
net	388	391		|O
benefit	392	399		|O
,	399	400		|O
with	401	405		|O
greater	406	413		|O
benefits	414	422		|O
accrued	423	430		|O
to	431	433		|O
women	434	439		|O
with	440	444		|O
the	445	448		|O
highest	449	456		|O
risk	457	461		|O
of	462	464		|O
breast	465	471	breast cancer	|B-DISEASE
cancer	472	478		|I-DISEASE
.	478	479		|O
Age	480	483		|O
and	484	487		|O
the	488	491		|O
presence	492	500		|O
of	501	503		|O
risk	504	508		|O
factors	509	516		|O
for	517	520		|O
increased	521	530		|O
toxicity	531	539		|O
also	540	544		|O
have	545	549		|O
an	550	552		|O
effect	553	559		|O
on	560	562		|O
the	563	566		|O
net	567	570		|O
benefit	571	578		|O
associated	579	589		|O
with	590	594		|O
tamoxifen	595	604		|O
.	604	605		|O
The	606	609		|O
greatest	610	618		|O
clinical	619	627		|O
benefit	628	635		|O
from	636	640		|O
tamoxifen	641	650		|O
is	651	653		|O
evident	654	661		|O
for	662	665		|O
younger	666	673		|O
women	674	679		|O
who	680	683		|O
are	684	687		|O
at	688	690		|O
lower	691	696		|O
risk	697	701		|O
of	702	704		|O
thromboembolic	705	719	thromboembolic complications	|B-DISEASE
complications	720	733		|I-DISEASE
and	734	737		|O
uterine	738	745	uterine cancer	|B-DISEASE
cancer	746	752		|I-DISEASE
,	752	753		|O
women	754	759		|O
without	760	767		|O
a	768	769		|O
uterus	770	776		|O
,	776	777		|O
and	778	781		|O
women	782	787		|O
with	788	792		|O
breast	793	799		|O
biopsy	800	806		|O
results	807	814		|O
indicative	815	825		|O
of	826	828		|O
atypical	829	837	atypical hyperplasia	|B-DISEASE
hyperplasia	838	849		|I-DISEASE
or	850	852		|O
lobular	853	860	lobular carcinoma	|B-DISEASE
carcinoma	861	870		|I-DISEASE
in	871	873		|O
situ	874	878		|O
.	878	879		|O
Raloxifene	880	890		|O
has	891	894		|O
also	895	899		|O
been	900	904		|O
shown	905	910		|O
to	911	913		|O
reduce	914	920		|O
the	921	924		|O
risk	925	929		|O
of	930	932		|O
invasive	933	941		|O
breast	942	948	breast cancer	|B-DISEASE
cancer	949	955		|I-DISEASE
in	956	958		|O
women	959	964		|O
with	965	969		|O
osteoporosis	970	982	osteoporosis	|B-DISEASE
and	983	986		|O
is	987	989		|O
as	990	992		|O
effective	993	1002		|O
as	1003	1005		|O
tamoxifen	1006	1015		|O
for	1016	1019		|O
reducing	1020	1028		|O
the	1029	1032		|O
risk	1033	1037		|O
of	1038	1040		|O
invasive	1041	1049		|O
breast	1050	1056	breast cancer	|B-DISEASE
cancer	1057	1063		|I-DISEASE
in	1064	1066		|O
postmenopausal	1067	1081		|O
women	1082	1087		|O
at	1088	1090		|O
increased	1091	1100		|O
risk	1101	1105		|O
of	1106	1108		|O
breast	1109	1115	breast cancer	|B-DISEASE
cancer	1116	1122		|I-DISEASE
.	1122	1123		|O
In	1124	1126		|O
high	1127	1131		|O
-	1131	1132		|O
risk	1132	1136		|O
younger	1137	1144		|O
,	1144	1145		|O
postmenopausal	1146	1160		|O
women	1161	1166		|O
,	1166	1167		|O
raloxifene	1168	1178		|O
seems	1179	1184		|O
to	1185	1187		|O
offer	1188	1193		|O
a	1194	1195		|O
net	1196	1199		|O
benefit	1200	1207		|O
when	1208	1212		|O
comparing	1213	1222		|O
the	1223	1226		|O
reduction	1227	1236		|O
of	1237	1239		|O
risk	1240	1244		|O
of	1245	1247		|O
breast	1248	1254	breast cancer	|B-DISEASE
cancer	1255	1261		|I-DISEASE
and	1262	1265		|O
prevention	1266	1276		|O
of	1277	1279		|O
fractures	1280	1289		|O
with	1290	1294		|O
the	1295	1298		|O
risk	1299	1303		|O
of	1304	1306		|O
stroke	1307	1313	stroke	|B-ADVERSE
,	1313	1314		|O
venous	1315	1321	venous thromboembolic events	|B-ADVERSE
thromboembolic	1322	1336		|I-ADVERSE
events	1337	1343		|I-ADVERSE
,	1343	1344		|O
uterine	1345	1352	uterine events	|B-ADVERSE
events	1353	1359		|I-ADVERSE
,	1359	1360		|O
and	1361	1364		|O
symptomatic	1365	1376	symptomatic side effects	|B-ADVERSE
side	1377	1381		|I-ADVERSE
effects	1382	1389		|I-ADVERSE
.	1389	1390		|O
Raloxifene	1391	1401		|O
offers	1402	1408		|O
an	1409	1411		|O
acceptable	1412	1422		|O
option	1423	1429		|O
for	1430	1433		|O
breast	1434	1440	breast cancer	|B-DISEASE
cancer	1441	1447		|I-DISEASE
risk	1448	1452		|O
reduction	1453	1462		|O
in	1463	1465		|O
postmenopausal	1466	1480		|O
women	1481	1486		|O
.	1486	1487		|O

### 18664513
DNA	0	3		|O
damage	4	10		|O
and	11	14		|O
repair	15	21		|O
detected	22	30		|O
by	31	33		|O
the	34	37		|O
comet	38	43		|O
assay	44	49		|O
in	50	52		|O
lymphocytes	53	64		|O
of	65	67		|O
african	68	75		|O
petrol	76	82		|O
attendants	83	93		|O
:	93	94		|O
a	95	96		|O
pilot	97	102		|O
study	103	108		|O
.	108	109		|O
Petrol	111	117		|O
attendants	118	128		|O
are	129	132		|O
exposed	133	140		|O
to	141	143		|O
petrol	144	150		|O
volatile	151	159		|O
organic	160	167		|O
compounds	168	177		|O
(	178	179		|O
VOCs	179	183		|O
)	183	184		|O
which	185	190		|O
may	191	194		|O
have	195	199		|O
genotoxic	200	209		|O
and	210	213		|O
carcinogenic	214	226	carcinogenic effects	|B-ADVERSE
effects	227	234		|I-ADVERSE
.	234	235		|O
The	236	239		|O
single	240	246		|O
-	246	247		|O
cell	247	251		|O
gel	252	255		|O
electrophoresis	256	271		|O
assay	272	277		|O
(	278	279		|O
comet	279	284		|O
assay	285	290		|O
)	290	291		|O
is	292	294		|O
a	295	296		|O
method	297	303		|O
highly	304	310		|O
sensitive	311	320		|O
to	321	323		|O
DNA	324	327		|O
damage	328	334		|O
induced	335	342		|O
by	343	345		|O
environmental	346	359		|O
and	360	363		|O
occupational	364	376		|O
exposure	377	385		|O
to	386	388		|O
carcinogenic	389	401		|O
and	402	405		|O
mutagenic	406	415		|O
agents	416	422		|O
.	422	423		|O
The	424	427		|O
aim	428	431		|O
of	432	434		|O
this	435	439		|O
study	440	445		|O
was	446	449		|O
to	450	452		|O
evaluate	453	461		|O
the	462	465		|O
level	466	471		|O
of	472	474		|O
exposure	475	483		|O
of	484	486		|O
petrol	487	493		|O
attendants	494	504		|O
to	505	507		|O
petrol	508	514		|O
VOCs	515	519		|O
and	520	523		|O
also	524	528		|O
to	529	531		|O
determine	532	541		|O
their	542	547		|O
effect	548	554		|O
on	555	557		|O
DNA	558	561		|O
damage	562	568		|O
and	569	572		|O
repair	573	579		|O
in	580	582		|O
lymphocytes	583	594		|O
of	595	597		|O
African	598	605		|O
petrol	606	612		|O
attendants	613	623		|O
.	623	624		|O
The	625	628		|O
exposed	629	636		|O
group	637	642		|O
consisted	643	652		|O
of	653	655		|O
20	656	658		|O
subjects	659	667		|O
,	667	668		|O
randomly	669	677		|O
selected	678	686		|O
from	687	691		|O
three	692	697		|O
petrol	698	704		|O
stations	705	713		|O
.	713	714		|O
A	715	716		|O
control	717	724		|O
group	725	730		|O
of	731	733		|O
20	734	736		|O
unexposed	737	746		|O
subjects	747	755		|O
was	756	759		|O
also	760	764		|O
chosen	765	771		|O
and	772	775		|O
matched	776	783		|O
for	784	787		|O
age	788	791		|O
and	792	795		|O
smoking	796	803		|O
habits	804	810		|O
with	811	815		|O
the	816	819		|O
exposed	820	827		|O
group	828	833		|O
.	833	834		|O
Sorbent	835	842		|O
tubes	843	848		|O
were	849	853		|O
used	854	858		|O
to	859	861		|O
assess	862	868		|O
personal	869	877		|O
exposure	878	886		|O
of	887	889		|O
petrol	890	896		|O
attendants	897	907		|O
.	907	908		|O
The	909	912		|O
comet	913	918		|O
assay	919	924		|O
was	925	928		|O
used	929	933		|O
to	934	936		|O
investigate	937	948		|O
the	949	952		|O
basal	953	958		|O
DNA	959	962		|O
damage	963	969		|O
and	970	973		|O
repair	974	980		|O
capacity	981	989		|O
in	990	992		|O
isolated	993	1001		|O
lymphocytes	1002	1013		|O
of	1014	1016		|O
petrol	1017	1023		|O
attendants	1024	1034		|O
and	1035	1038		|O
unexposed	1039	1048		|O
subjects	1049	1057		|O
.	1057	1058		|O
Blood	1059	1064		|O
samples	1065	1072		|O
were	1073	1077		|O
taken	1078	1083		|O
from	1084	1088		|O
the	1089	1092		|O
petrol	1093	1099		|O
attendants	1100	1110		|O
at	1111	1113		|O
the	1114	1117		|O
end	1118	1121		|O
of	1122	1124		|O
their	1125	1130		|O
8	1131	1132		|O
-	1132	1133		|O
h	1133	1134		|O
working	1135	1142		|O
shift	1143	1148		|O
and	1149	1152		|O
also	1153	1157		|O
from	1158	1162		|O
the	1163	1166		|O
unexposed	1167	1176		|O
subjects	1177	1185		|O
.	1185	1186		|O
The	1187	1190		|O
petrol	1191	1197		|O
attendants	1198	1208		|O
were	1209	1213		|O
found	1214	1219		|O
to	1220	1222		|O
be	1223	1225		|O
exposed	1226	1233		|O
to	1234	1236		|O
levels	1237	1243		|O
of	1244	1246		|O
petrol	1247	1253		|O
VOCs	1254	1258		|O
lower	1259	1264		|O
than	1265	1269		|O
the	1270	1273		|O
South	1274	1279		|O
African	1280	1287		|O
occupational	1288	1300		|O
exposure	1301	1309		|O
limit	1310	1315		|O
for	1316	1319		|O
constituent	1320	1331		|O
chemicals	1332	1341		|O
.	1341	1342		|O
A	1343	1344		|O
significant	1345	1356		|O
relationship	1357	1369		|O
was	1370	1373		|O
found	1374	1379		|O
between	1380	1387		|O
the	1388	1391		|O
volume	1392	1398		|O
of	1399	1401		|O
petrol	1402	1408		|O
sold	1409	1413		|O
during	1414	1420		|O
the	1421	1424		|O
shift	1425	1430		|O
and	1431	1434		|O
the	1435	1438		|O
average	1439	1446		|O
concentrations	1447	1461		|O
of	1462	1464		|O
benzene	1465	1472		|O
,	1472	1473		|O
toluene	1474	1481		|O
and	1482	1485		|O
the	1486	1489		|O
total	1490	1495		|O
VOCs	1496	1500		|O
measured	1501	1509		|O
.	1509	1510		|O
However	1511	1518		|O
,	1518	1519		|O
relative	1520	1528		|O
humidity	1529	1537		|O
had	1538	1541		|O
a	1542	1543		|O
negative	1544	1552		|O
correlation	1553	1564		|O
with	1565	1569		|O
the	1570	1573		|O
average	1574	1581		|O
concentrations	1582	1596		|O
of	1597	1599		|O
benzene	1600	1607		|O
,	1607	1608		|O
toluene	1609	1616		|O
,	1616	1617		|O
xylene	1618	1624		|O
and	1625	1628		|O
the	1629	1632		|O
total	1633	1638		|O
VOCs	1639	1643		|O
.	1643	1644		|O
Significantly	1645	1658		|O
higher	1659	1665		|O
basal	1666	1671		|O
DNA	1672	1675		|O
damage	1676	1682		|O
was	1683	1686		|O
observed	1687	1695		|O
with	1696	1700		|O
the	1701	1704		|O
exposed	1705	1712		|O
group	1713	1718		|O
compared	1719	1727		|O
to	1728	1730		|O
the	1731	1734		|O
unexposed	1735	1744		|O
group	1745	1750		|O
.	1750	1751		|O
The	1752	1755		|O
period	1756	1762		|O
of	1763	1765		|O
exposure	1766	1774		|O
influenced	1775	1785		|O
the	1786	1789		|O
level	1790	1795		|O
of	1796	1798		|O
DNA	1799	1802		|O
damage	1803	1809		|O
and	1810	1813		|O
the	1814	1817		|O
calculated	1818	1828		|O
repair	1829	1835		|O
capacity	1836	1844		|O
.	1844	1845		|O
Smoking	1846	1853		|O
and	1854	1857		|O
age	1858	1861		|O
had	1862	1865		|O
a	1866	1867		|O
significant	1868	1879		|O
influence	1880	1889		|O
on	1890	1892		|O
the	1893	1896		|O
level	1897	1902		|O
of	1903	1905		|O
DNA	1906	1909		|O
damage	1910	1916		|O
.	1916	1917		|O
DNA	1918	1921		|O
repair	1922	1928		|O
capacity	1929	1937		|O
was	1938	1941		|O
delayed	1942	1949		|O
in	1950	1952		|O
smokers	1953	1960		|O
of	1961	1963		|O
both	1964	1968		|O
exposed	1969	1976		|O
and	1977	1980		|O
unexposed	1981	1990		|O
group	1991	1996		|O
.	1996	1997		|O

### 18569277
Menorrhagia	0	11	Menorrhagia	|B-ADVERSE
and	12	15		|O
severe	16	22		|O
menstrual	23	32	menstrual pain	|B-ADVERSE
pain	33	37		|I-ADVERSE
related	38	45		|O
to	46	48		|O
the	49	52		|O
use	53	56		|O
of	57	59		|O
adalimumab	60	70		|O
in	71	73		|O
a	74	75		|O
psoriatic	76	85		|O
.	85	86		|O
The	88	91		|O
case	92	96		|O
is	97	99		|O
reported	100	108		|O
of	109	111		|O
a	112	113		|O
32	114	116		|O
-	116	117		|O
year	117	121		|O
-	121	122		|O
old	122	125		|O
morbidly	126	134		|O
obese	135	140		|O
white	141	146		|O
woman	147	152		|O
who	153	156		|O
used	157	161		|O
adalimumab	162	172		|O
40	173	175		|O
mg	176	178		|O
every	179	184		|O
other	185	190		|O
week	191	195		|O
for	196	199		|O
4	200	201		|O
months	202	208		|O
for	209	212		|O
psoriatic	213	222	psoriatic arthritis	|B-DISEASE
arthritis	223	232		|I-DISEASE
,	232	233		|O
psoriasis	234	243	psoriasis vulgaris	|B-DISEASE
vulgaris	244	252		|I-DISEASE
and	253	256		|O
inverse	257	264	inverse psoriasis	|B-DISEASE
psoriasis	265	274		|I-DISEASE
with	275	279		|O
total	280	285		|O
clearance	286	295		|O
of	296	298		|O
her	299	302		|O
psoriasis	303	312	psoriasis	|B-DISEASE
who	313	316		|O
developed	317	326		|O
menorrhagia	327	338	menorrhagia	|B-ADVERSE
(	339	340		|O
at	340	342		|O
least	343	348		|O
twice	349	354		|O
the	355	358		|O
number	359	365		|O
of	366	368		|O
pads	369	373		|O
used	374	378		|O
daily	379	384		|O
for	385	388		|O
4-6	389	392		|O
days	393	397		|O
as	398	400		|O
opposed	401	408		|O
to	409	411		|O
3-5	412	415		|O
days	416	420		|O
previously	421	431		|O
)	431	432		|O
and	433	436		|O
severe	437	443		|O
menstrual	444	453	menstrual pain	|B-ADVERSE
pain	454	458		|I-ADVERSE
.	458	459		|O
Treatment	460	469		|O
with	470	474		|O
Aviane	475	481		|O
(	482	483		|O
ethinyl	483	490		|O
estradiol	491	500		|O
and	501	504		|O
levonorgestrel	505	519		|O
)	519	520		|O
abated	521	527		|O
some	528	532		|O
of	533	535		|O
these	536	541		|O
menstrual	542	551	menstrual symptoms	|B-ADVERSE
symptoms	552	560		|I-ADVERSE
.	560	561		|O
The	562	565		|O
symptoms	566	574		|O
resolved	575	583		|O
altogether	584	594		|O
when	595	599		|O
the	600	603		|O
adalimumab	604	614		|O
was	615	618		|O
discontinued	619	631		|O
.	631	632		|O
Menstrual	633	642		|O
disorders	643	652		|O
are	653	656		|O
listed	657	663		|O
as	664	666		|O
possible	667	675		|O
side	676	680		|O
effects	681	688		|O
from	689	693		|O
the	694	697		|O
use	698	701		|O
of	702	704		|O
infliximab	705	715		|O
and	716	719		|O
adalimumab	720	730		|O
in	731	733		|O
their	734	739		|O
respective	740	750		|O
package	751	758		|O
inserts	759	766		|O
and	767	770		|O
also	771	775		|O
for	776	779		|O
adalimumab	780	790		|O
and	791	794		|O
etanercept	795	805		|O
in	806	808		|O
the	809	812		|O
United	813	819		|O
Kingdom	820	827		|O
's	827	829		|O
Medicines	830	839		|O
and	840	843		|O
Healthcare	844	854		|O
products	855	863		|O
Regulatory	864	874		|O
Agency	875	881		|O
's	881	883		|O
drug	884	888		|O
side	889	893		|O
-	893	894		|O
effect	894	900		|O
database	901	909		|O
,	909	910		|O
but	911	914		|O
few	915	918		|O
case	919	923		|O
reports	924	931		|O
of	932	934		|O
menstrual	935	944	menstrual side effects	|B-ADVERSE
side	945	949		|I-ADVERSE
effects	950	957		|I-ADVERSE
exist	958	963		|O
from	964	968		|O
including	969	978		|O
tumor	979	984		|O
necrosis	985	993		|O
alpha	994	999		|O
(	1000	1001		|O
TNFalpha	1001	1009		|O
)	1009	1010		|O
blockers	1011	1019		|O
.	1019	1020		|O
Physicians	1021	1031		|O
should	1032	1038		|O
be	1039	1041		|O
aware	1042	1047		|O
of	1048	1050		|O
the	1051	1054		|O
menstrual	1055	1064	menstrual side effects	|B-ADVERSE
side	1065	1069		|I-ADVERSE
effects	1070	1077		|I-ADVERSE
of	1078	1080		|O
adalimumab	1081	1091		|O
and	1092	1095		|O
the	1096	1099		|O
role	1100	1104		|O
of	1105	1107		|O
oral	1108	1112		|O
contraceptive	1113	1126		|O
pills	1127	1132		|O
in	1133	1135		|O
treating	1136	1144		|O
such	1145	1149		|O
menstrual	1150	1159	menstrual side effects	|B-ADVERSE
side	1160	1164		|I-ADVERSE
effects	1165	1172		|I-ADVERSE
.	1172	1173		|O

### 18636785
Effects	0	7		|O
of	8	10		|O
stratification	11	25		|O
on	26	28		|O
data	29	33		|O
mining	34	40		|O
in	41	43		|O
the	44	47		|O
US	48	50		|O
Vaccine	51	58		|O
Adverse	59	66		|O
Event	67	72		|O
Reporting	73	82		|O
System	83	89		|O
(	90	91		|O
VAERS	91	96		|O
)	96	97		|O
.	97	98		|O
BACKGROUND	100	110		|O
:	110	111		|O
Vaccines	112	120		|O
are	121	124		|O
administered	125	137		|O
differentially	138	152		|O
according	153	162		|O
to	163	165		|O
age	166	169		|O
and	170	173		|O
sex	174	177		|O
,	177	178		|O
and	179	182		|O
disease	183	190		|O
patterns	191	199		|O
also	200	204		|O
vary	205	209		|O
among	210	215		|O
people	216	222		|O
of	223	225		|O
different	226	235		|O
age	236	239		|O
and	240	243		|O
sex	244	247		|O
groups	248	254		|O
.	254	255		|O
Estimates	256	265		|O
of	266	268		|O
disproportionality	269	287		|O
should	288	294		|O
be	295	297		|O
calculated	298	308		|O
based	309	314		|O
on	315	317		|O
comparisons	318	329		|O
of	330	332		|O
groups	333	339		|O
that	340	344		|O
have	345	349		|O
a	350	351		|O
similar	352	359		|O
likelihood	360	370		|O
of	371	373		|O
receiving	374	383		|O
similar	384	391		|O
vaccines	392	400		|O
and	401	404		|O
experiencing	405	417		|O
similar	418	425		|O
adverse	426	433		|O
events	434	440		|O
,	440	441		|O
to	442	444		|O
prevent	445	452		|O
false	453	458		|O
disproportionality	459	477		|O
from	478	482		|O
occurring	483	492		|O
.	492	493		|O
Stratified	494	504		|O
empirical	505	514		|O
Bayesian	515	523		|O
(	524	525		|O
EB	525	527		|O
)	527	528		|O
methods	529	536		|O
have	537	541		|O
been	542	546		|O
compared	547	555		|O
with	556	560		|O
crude	561	566		|O
,	566	567		|O
but	568	571		|O
not	572	575		|O
stratified	576	586		|O
,	586	587		|O
proportional	588	600		|O
reporting	601	610		|O
ratios	611	617		|O
(	618	619		|O
PRRs	619	623		|O
)	623	624		|O
in	625	627		|O
their	628	633		|O
performance	634	645		|O
on	646	648		|O
adverse	649	656		|O
event	657	662		|O
data	663	667		|O
.	667	668		|O
OBJECTIVES	669	679		|O
:	679	680		|O
(	681	682		|O
i	682	683		|O
)	683	684		|O
to	685	687		|O
implement	688	697		|O
stratification	698	712		|O
of	713	715		|O
PRR	716	719		|O
;	719	720		|O
(	721	722		|O
ii	722	724		|O
)	724	725		|O
to	726	728		|O
quantify	729	737		|O
and	738	741		|O
compare	742	749		|O
vaccine	750	757		|O
-	757	758		|O
event	758	763		|O
pairs	764	769		|O
that	770	774		|O
are	775	778		|O
highlighted	779	790		|O
by	791	793		|O
PRR	794	797		|O
and	798	801		|O
EB05	802	806		|O
(	807	808		|O
the	808	811		|O
lower	812	817		|O
bound	818	823		|O
of	824	826		|O
the	827	830		|O
90%	831	834		|O
CI	835	837		|O
of	838	840		|O
the	841	844		|O
EB	845	847		|O
geometric	848	857		|O
mean	858	862		|O
)	862	863		|O
,	863	864		|O
for	865	868		|O
both	869	873		|O
crude	874	879		|O
and	880	883		|O
stratified	884	894		|O
;	894	895		|O
and	896	899		|O
(	900	901		|O
iii	901	904		|O
)	904	905		|O
to	906	908		|O
evaluate	909	917		|O
the	918	921		|O
effects	922	929		|O
of	930	932		|O
stratification	933	947		|O
by	948	950		|O
age	951	954		|O
and	955	958		|O
sex	959	962		|O
,	962	963		|O
in	964	966		|O
identifying	967	978		|O
adverse	979	986		|O
events	987	993		|O
that	994	998		|O
are	999	1002		|O
accepted	1003	1011		|O
to	1012	1014		|O
be	1015	1017		|O
caused	1018	1024		|O
by	1025	1027		|O
vaccines	1028	1036		|O
.	1036	1037		|O
METHODS	1038	1045		|O
:	1045	1046		|O
We	1047	1049		|O
applied	1050	1057		|O
EB	1058	1060		|O
and	1061	1064		|O
PRR	1065	1068		|O
data	1069	1073		|O
mining	1074	1080		|O
methods	1081	1088		|O
to	1089	1091		|O
data	1092	1096		|O
from	1097	1101		|O
the	1102	1105		|O
US	1106	1108		|O
Vaccine	1109	1116		|O
Adverse	1117	1124		|O
Event	1125	1130		|O
Reporting	1131	1140		|O
System	1141	1147		|O
(	1148	1149		|O
VAERS	1149	1154		|O
)	1154	1155		|O
.	1155	1156		|O
We	1157	1159		|O
stratified	1160	1170		|O
PRR	1171	1174		|O
and	1175	1178		|O
EB05	1179	1183		|O
by	1184	1186		|O
age	1187	1190		|O
and	1191	1194		|O
sex	1195	1198		|O
.	1198	1199		|O
To	1200	1202		|O
study	1203	1208		|O
the	1209	1212		|O
effects	1213	1220		|O
of	1221	1223		|O
stratification	1224	1238		|O
,	1238	1239		|O
we	1240	1242		|O
compared	1243	1251		|O
the	1252	1255		|O
crude	1256	1261		|O
PRR	1262	1265		|O
and	1266	1269		|O
stratified	1270	1280		|O
PRR	1281	1284		|O
.	1284	1285		|O
We	1286	1288		|O
also	1289	1293		|O
assessed	1294	1302		|O
the	1303	1306		|O
crude	1307	1312		|O
EB05	1313	1317		|O
and	1318	1321		|O
stratified	1322	1332		|O
EB05	1333	1337		|O
,	1337	1338		|O
and	1339	1342		|O
then	1343	1347		|O
compared	1348	1356		|O
the	1357	1360		|O
effects	1361	1368		|O
of	1369	1371		|O
stratification	1372	1386		|O
on	1387	1389		|O
EB05	1390	1394		|O
and	1395	1398		|O
PRR	1399	1402		|O
.	1402	1403		|O
RESULTS	1404	1411		|O
:	1411	1412		|O
Stratification	1413	1427		|O
not	1428	1431		|O
only	1432	1436		|O
changed	1437	1444		|O
the	1445	1448		|O
number	1449	1455		|O
of	1456	1458		|O
vaccine	1459	1466		|O
-	1466	1467		|O
event	1467	1472		|O
pairs	1473	1478		|O
that	1479	1483		|O
were	1484	1488		|O
highlighted	1489	1500		|O
,	1500	1501		|O
but	1502	1505		|O
also	1506	1510		|O
changed	1511	1518		|O
which	1519	1524		|O
pairs	1525	1530		|O
were	1531	1535		|O
highlighted	1536	1547		|O
.	1547	1548		|O
There	1549	1554		|O
were	1555	1559		|O
283	1560	1563		|O
vaccine	1564	1571		|O
-	1571	1572		|O
event	1572	1577		|O
pairs	1578	1583		|O
that	1584	1588		|O
were	1589	1593		|O
highlighted	1594	1605		|O
by	1606	1608		|O
the	1609	1612		|O
crude	1613	1618		|O
EB05	1619	1623		|O
,	1623	1624		|O
but	1625	1628		|O
not	1629	1632		|O
the	1633	1636		|O
stratified	1637	1647		|O
;	1647	1648		|O
12	1649	1651		|O
that	1652	1656		|O
were	1657	1661		|O
highlighted	1662	1673		|O
by	1674	1676		|O
the	1677	1680		|O
stratified	1681	1691		|O
EB05	1692	1696		|O
,	1696	1697		|O
but	1698	1701		|O
not	1702	1705		|O
the	1706	1709		|O
crude	1710	1715		|O
;	1715	1716		|O
and	1717	1720		|O
162	1721	1724		|O
that	1725	1729		|O
were	1730	1734		|O
highlighted	1735	1746		|O
by	1747	1749		|O
both	1750	1754		|O
.	1754	1755		|O
Similarly	1756	1765		|O
,	1765	1766		|O
there	1767	1772		|O
were	1773	1777		|O
701	1778	1781		|O
vaccine	1782	1789		|O
-	1789	1790		|O
event	1790	1795		|O
pairs	1796	1801		|O
that	1802	1806		|O
were	1807	1811		|O
highlighted	1812	1823		|O
by	1824	1826		|O
the	1827	1830		|O
crude	1831	1836		|O
PRR	1837	1840		|O
,	1840	1841		|O
but	1842	1845		|O
not	1846	1849		|O
the	1850	1853		|O
stratified	1854	1864		|O
;	1864	1865		|O
139	1866	1869		|O
that	1870	1874		|O
were	1875	1879		|O
highlighted	1880	1891		|O
by	1892	1894		|O
the	1895	1898		|O
stratified	1899	1909		|O
PRR	1910	1913		|O
,	1913	1914		|O
but	1915	1918		|O
not	1919	1922		|O
the	1923	1926		|O
crude	1927	1932		|O
;	1932	1933		|O
and	1934	1937		|O
895	1938	1941		|O
that	1942	1946		|O
were	1947	1951		|O
highlighted	1952	1963		|O
by	1964	1966		|O
both	1967	1971		|O
.	1971	1972		|O
There	1973	1978		|O
were	1979	1983		|O
1466	1984	1988		|O
vaccine	1989	1996		|O
-	1996	1997		|O
event	1997	2002		|O
pairs	2003	2008		|O
in	2009	2011		|O
which	2012	2017		|O
the	2018	2021		|O
effect	2022	2028		|O
of	2029	2031		|O
stratification	2032	2046		|O
was	2047	2050		|O
different	2051	2060		|O
for	2061	2064		|O
EB05	2065	2069		|O
and	2070	2073		|O
PRR	2074	2077		|O
.	2077	2078		|O
CONCLUSION	2079	2089		|O
:	2089	2090		|O
To	2091	2093		|O
our	2094	2097		|O
knowledge	2098	2107		|O
,	2107	2108		|O
this	2109	2113		|O
is	2114	2116		|O
the	2117	2120		|O
first	2121	2126		|O
published	2127	2136		|O
analysis	2137	2145		|O
using	2146	2151		|O
stratified	2152	2162		|O
PRRs	2163	2167		|O
.	2167	2168		|O
In	2169	2171		|O
this	2172	2176		|O
analysis	2177	2185		|O
of	2186	2188		|O
passive	2189	2196		|O
surveillance	2197	2209		|O
data	2210	2214		|O
,	2214	2215		|O
stratification	2216	2230		|O
revealed	2231	2239		|O
and	2240	2243		|O
reduced	2244	2251		|O
confounding	2252	2263		|O
in	2264	2266		|O
EB	2267	2269		|O
and	2270	2273		|O
PRR	2274	2277		|O
,	2277	2278		|O
and	2279	2282		|O
also	2283	2287		|O
unmasked	2288	2296		|O
some	2297	2301		|O
vaccine	2302	2309		|O
-	2309	2310		|O
event	2310	2315		|O
pairs	2316	2321		|O
that	2322	2326		|O
the	2327	2330		|O
crude	2331	2336		|O
values	2337	2343		|O
did	2344	2347		|O
not	2348	2351		|O
highlight	2352	2361		|O
.	2361	2362		|O
Stratification	2363	2377		|O
should	2378	2384		|O
be	2385	2387		|O
applied	2388	2395		|O
if	2396	2398		|O
confounding	2399	2410		|O
is	2411	2413		|O
suspected	2414	2423		|O
.	2423	2424		|O
By	2425	2427		|O
decreasing	2428	2438		|O
the	2439	2442		|O
total	2443	2448		|O
number	2449	2455		|O
of	2456	2458		|O
highlighted	2459	2470		|O
vaccine	2471	2478		|O
-	2478	2479		|O
event	2479	2484		|O
pairs	2485	2490		|O
,	2490	2491		|O
stratification	2492	2506		|O
is	2507	2509		|O
likely	2510	2516		|O
to	2517	2519		|O
increase	2520	2528		|O
efficiency	2529	2539		|O
and	2540	2543		|O
therefore	2544	2553		|O
might	2554	2559		|O
reduce	2560	2566		|O
workload	2567	2575		|O
.	2575	2576		|O

### 18803960
Brain	0	5		|O
development	6	17		|O
:	17	18		|O
anatomy	19	26		|O
,	26	27		|O
connectivity	28	40		|O
,	40	41		|O
adaptive	42	50		|O
plasticity	51	61		|O
,	61	62		|O
and	63	66		|O
toxicity	67	75		|O
.	75	76		|O
The	78	81		|O
developing	82	92		|O
brain	93	98		|O
is	99	101		|O
inherently	102	112		|O
more	113	117		|O
vulnerable	118	128		|O
to	129	131		|O
injury	132	138		|O
than	139	143		|O
the	144	147		|O
adult	148	153		|O
brain	154	159		|O
because	160	167		|O
brain	168	173		|O
development	174	185		|O
is	186	188		|O
extraordinarily	189	204		|O
complex	205	212		|O
,	212	213		|O
with	214	218		|O
periods	219	226		|O
of	227	229		|O
unique	230	236		|O
susceptibility	237	251		|O
.	251	252		|O
When	253	257		|O
brain	258	263		|O
developmental	264	277		|O
processes	278	287		|O
are	288	291		|O
suspended	292	301		|O
or	302	304		|O
delayed	305	312		|O
by	313	315		|O
any	316	319		|O
external	320	328		|O
influence	329	338		|O
,	338	339		|O
virtually	340	349		|O
no	350	352		|O
potential	353	362		|O
exists	363	369		|O
for	370	373		|O
subsequent	374	384		|O
regeneration	385	397		|O
and	398	401		|O
repair	402	408		|O
.	408	409		|O
This	410	414		|O
inevitably	415	425		|O
leads	426	431		|O
to	432	434		|O
long	435	439		|O
-	439	440		|O
lasting	440	447		|O
or	448	450		|O
permanent	451	460		|O
consequences	461	473		|O
.	473	474		|O
Recent	475	481		|O
genetic	482	489		|O
studies	490	497		|O
have	498	502		|O
contributed	503	514		|O
to	515	517		|O
a	518	519		|O
better	520	526		|O
understanding	527	540		|O
of	541	543		|O
the	544	547		|O
dynamic	548	555		|O
adaptive	556	564		|O
changes	565	572		|O
that	573	577		|O
occur	578	583		|O
in	584	586		|O
the	587	590		|O
developing	591	601		|O
brain	602	607		|O
as	608	610		|O
a	611	612		|O
consequence	613	624		|O
of	625	627		|O
genetic	628	635		|O
and	636	639		|O
environmental	640	653		|O
processes	654	663		|O
.	663	664		|O
Many	665	669		|O
industrial	670	680		|O
and	681	684		|O
environmental	685	698		|O
chemicals	699	708		|O
such	709	713		|O
as	714	716		|O
lead	717	721		|O
,	721	722		|O
methyl	723	729		|O
-	729	730		|O
mercury	730	737		|O
,	737	738		|O
polychlorinated	739	754		|O
biphenyls	755	764		|O
,	764	765		|O
arsenic	766	773		|O
,	773	774		|O
and	775	778		|O
toluene	779	786		|O
are	787	790		|O
recognized	791	801		|O
causes	802	808		|O
of	809	811		|O
neurodevelopmental	812	830	neurodevelopmental disorders	|B-ADVERSE
disorders	831	840		|I-ADVERSE
that	841	845		|O
lead	846	850		|O
to	851	853		|O
clinical	854	862		|O
or	863	865		|O
subclinical	866	877	subclinical brain dysfunction	|B-ADVERSE
brain	878	883		|I-ADVERSE
dysfunction	884	895		|I-ADVERSE
.	895	896		|O
A	897	898		|O
number	899	905		|O
of	906	908		|O
these	909	914		|O
developmental	915	928		|O
disabilities	929	941		|O
arise	942	947		|O
from	948	952		|O
interactions	953	965		|O
between	966	973		|O
environmental	974	987		|O
factors	988	995		|O
and	996	999		|O
individual	1000	1010		|O
gene	1011	1015		|O
susceptibility	1016	1030		|O
.	1030	1031		|O
In	1032	1034		|O
addition	1035	1043		|O
,	1043	1044		|O
neurodevelopmental	1045	1063	neurodevelopmental disorders	|B-DISEASE
disorders	1064	1073		|I-DISEASE
of	1074	1076		|O
unknown	1077	1084		|O
origin	1085	1091		|O
,	1091	1092		|O
such	1093	1097		|O
as	1098	1100		|O
mental	1101	1107	mental retardation	|B-DISEASE
retardation	1108	1119		|I-DISEASE
,	1119	1120		|O
attention	1121	1130	attention deficit disorder	|B-DISEASE
deficit	1131	1138		|I-DISEASE
disorder	1139	1147		|I-DISEASE
,	1147	1148		|O
cerebral	1149	1157	cerebral palsy	|B-DISEASE
palsy	1158	1163		|I-DISEASE
,	1163	1164		|O
and	1165	1168		|O
autism	1169	1175	autism	|B-DISEASE
are	1176	1179		|O
becoming	1180	1188		|O
increasingly	1189	1201		|O
prevalent	1202	1211		|O
,	1211	1212		|O
with	1213	1217		|O
costly	1218	1224		|O
consequences	1225	1237		|O
for	1238	1241		|O
the	1242	1245		|O
family	1246	1252		|O
and	1253	1256		|O
society	1257	1264		|O
.	1264	1265		|O
The	1266	1269		|O
aim	1270	1273		|O
of	1274	1276		|O
this	1277	1281		|O
review	1282	1288		|O
is	1289	1291		|O
examine	1292	1299		|O
brain	1300	1305		|O
developmental	1306	1319		|O
anatomy	1320	1327		|O
,	1327	1328		|O
connectivity	1329	1341		|O
,	1341	1342		|O
adaptive	1343	1351		|O
plasticity	1352	1362		|O
,	1362	1363		|O
and	1364	1367		|O
toxicity	1368	1376		|O
in	1377	1379		|O
the	1380	1383		|O
context	1384	1391		|O
of	1392	1394		|O
current	1395	1402		|O
knowledge	1403	1412		|O
and	1413	1416		|O
future	1417	1423		|O
trends	1424	1430		|O
.	1430	1431		|O

### 18642029
Impact	0	6		|O
of	7	9		|O
different	10	19		|O
anticancer	20	30		|O
regimens	31	39		|O
on	40	42		|O
biomarkers	43	53		|O
of	54	56		|O
angiogenesis	57	69		|O
in	70	72		|O
patients	73	81		|O
with	82	86		|O
advanced	87	95		|O
hepatocellular	96	110	hepatocellular cancer	|B-DISEASE
cancer	111	117		|I-DISEASE
.	117	118		|O
OBJECTIVE	120	129		|O
:	129	130		|O
Advanced	131	139		|O
hepatocellular	140	154	hepatocellular cancer	|B-DISEASE
cancer	155	161		|I-DISEASE
(	162	163		|O
HCC	163	166	HCC	|B-DISEASE
)	166	167		|O
is	168	170		|O
a	171	172		|O
highly	173	179		|O
vascularised	180	192		|O
tumor	193	198		|O
with	199	203		|O
limited	204	211		|O
treatment	212	221		|O
options	222	229		|O
.	229	230		|O
We	231	233		|O
wanted	234	240		|O
to	241	243		|O
evaluate	244	252		|O
the	253	256		|O
impact	257	263		|O
of	264	266		|O
different	267	276		|O
treatments	277	287		|O
on	288	290		|O
systemic	291	299		|O
biomarkers	300	310		|O
linked	311	317		|O
to	318	320		|O
angiogenesis	321	333		|O
.	333	334		|O
METHODS	335	342		|O
:	342	343		|O
Two	344	347		|O
subsequent	348	358		|O
prospective	359	370		|O
,	370	371		|O
randomised	372	382		|O
,	382	383		|O
phase	384	389		|O
-	389	390		|O
I	390	391		|O
/	391	392		|O
II	392	394		|O
trials	395	401		|O
in	402	404		|O
patients	405	413		|O
with	414	418		|O
advanced	419	427		|O
HCC	428	431	HCC	|B-DISEASE
were	432	436		|O
performed	437	446		|O
.	446	447		|O
A	448	449		|O
total	450	455		|O
of	456	458		|O
38	459	461		|O
patients	462	470		|O
was	471	474		|O
randomised	475	485		|O
to	486	488		|O
a	489	490		|O
total	491	496		|O
of	497	499		|O
4	500	501		|O
regimens	502	510		|O
consisting	511	521		|O
of	522	524		|O
3	525	526		|O
cycles	527	533		|O
of	534	536		|O
4	537	538		|O
weeks	539	544		|O
each	545	549		|O
:	549	550		|O
Trial	551	556		|O
1	557	558		|O
included	559	567		|O
group	568	573		|O
1	574	575		|O
receiving	576	585		|O
octreotide	586	596		|O
30	597	599		|O
mg	600	602		|O
im	603	605		|O
on	606	608		|O
day	609	612		|O
1	613	614		|O
,	614	615		|O
and	616	619		|O
group	620	625		|O
2	626	627		|O
octreotide	628	638		|O
30	639	641		|O
mg	642	644		|O
on	645	647		|O
day	648	651		|O
1	652	653		|O
plus	654	658		|O
Imatinib	659	667		|O
400	668	671		|O
mg	672	674		|O
po	675	677		|O
daily	678	683		|O
;	683	684		|O
Trial	685	690		|O
2	691	692		|O
included	693	701		|O
group	702	707		|O
3	708	709		|O
with	710	714		|O
oxaliplatin	715	726		|O
on	727	729		|O
day	730	733		|O
1	734	735		|O
(	736	737		|O
60	737	739		|O
mg	740	742		|O
-	742	743		|O
90	743	745		|O
mg	746	748		|O
/	748	749		|O
m	749	750		|O
(	750	751		|O
2	751	752		|O
)	752	753		|O
)	753	754		|O
,	754	755		|O
and	756	759		|O
group	760	765		|O
4	766	767		|O
with	768	772		|O
oxaliplatin	773	784		|O
on	785	787		|O
day	788	791		|O
1	792	793		|O
,	793	794		|O
8	795	796		|O
,	796	797		|O
15	798	800		|O
(	801	802		|O
20	802	804		|O
mg	805	807		|O
-	807	808		|O
30	808	810		|O
mg	811	813		|O
/	813	814		|O
m	814	815		|O
(	815	816		|O
2	816	817		|O
)	817	818		|O
)	818	819		|O
in	820	822		|O
combination	823	834		|O
with	835	839		|O
octreotide	840	850		|O
30	851	853		|O
mg	854	856		|O
on	857	859		|O
day	860	863		|O
1	864	865		|O
plus	866	870		|O
imatinib	871	879		|O
400	880	883		|O
mg	884	886		|O
po	887	889		|O
daily	890	895		|O
.	895	896		|O
Primary	897	904		|O
outcome	905	912		|O
measure	913	920		|O
was	921	924		|O
the	925	928		|O
relative	929	937		|O
changes	938	945		|O
in	946	948		|O
plasma	949	955		|O
biomarkers	956	966		|O
over	967	971		|O
time	972	976		|O
.	976	977		|O
RESULTS	978	985		|O
:	985	986		|O
Time	987	991		|O
-	991	992		|O
to	992	994		|O
-	994	995		|O
progression	995	1006		|O
and	1007	1010		|O
overall	1011	1018		|O
survival	1019	1027		|O
was	1028	1031		|O
not	1032	1035		|O
different	1036	1045		|O
between	1046	1053		|O
the	1054	1057		|O
the	1058	1061		|O
two	1062	1065		|O
study	1066	1071		|O
trials	1072	1078		|O
.	1078	1079		|O
Within	1080	1086		|O
group	1087	1092		|O
1-4	1093	1096		|O
,	1096	1097		|O
the	1098	1101		|O
mean	1102	1106		|O
relative	1107	1115		|O
increase	1116	1124		|O
from	1125	1129		|O
baseline	1130	1138		|O
to	1139	1141		|O
week	1142	1146		|O
12	1147	1149		|O
of	1150	1152		|O
treatment	1153	1162		|O
was	1163	1166		|O
17	1167	1169		|O
,	1169	1170		|O
18	1171	1173		|O
,	1173	1174		|O
37	1175	1177		|O
,	1177	1178		|O
and	1179	1182		|O
2%	1183	1185		|O
for	1186	1189		|O
s	1190	1191		|O
-	1191	1192		|O
E	1192	1193		|O
-	1193	1194		|O
selectin	1194	1202		|O
;	1202	1203		|O
-	1204	1205		|O
1	1205	1206		|O
,	1206	1207		|O
90	1208	1210		|O
,	1210	1211		|O
10	1212	1214		|O
,	1214	1215		|O
and	1216	1219		|O
-	1220	1221		|O
9%	1221	1223		|O
for	1224	1227		|O
VEGF	1228	1232		|O
-	1232	1233		|O
A	1233	1234		|O
;	1234	1235		|O
18	1236	1238		|O
,	1238	1239		|O
84	1240	1242		|O
,	1242	1243		|O
141	1244	1247		|O
,	1247	1248		|O
and	1249	1252		|O
74%	1253	1256		|O
for	1257	1260		|O
PDGF	1261	1265		|O
-	1265	1266		|O
BB	1266	1268		|O
,	1268	1269		|O
and	1270	1273		|O
111	1274	1277		|O
,	1277	1278		|O
142	1279	1282		|O
,	1282	1283		|O
30	1284	1286		|O
,	1286	1287		|O
and	1288	1291		|O
7%	1292	1294		|O
for	1295	1298		|O
serum	1299	1304		|O
AFP	1305	1308		|O
,	1308	1309		|O
respectively	1310	1322		|O
.	1322	1323		|O
CONCLUSIONS	1324	1335		|O
:	1335	1336		|O
The	1337	1340		|O
increase	1341	1349		|O
of	1350	1352		|O
plasma	1353	1359		|O
levels	1360	1366		|O
for	1367	1370		|O
s	1371	1372		|O
-	1372	1373		|O
E	1373	1374		|O
-	1374	1375		|O
selectin	1375	1383		|O
and	1384	1387		|O
PDGF	1388	1392		|O
-	1392	1393		|O
BB	1393	1395		|O
seen	1396	1400		|O
in	1401	1403		|O
patients	1404	1412		|O
receiving	1413	1422		|O
chemotherapy	1423	1435		|O
alone	1436	1441		|O
may	1442	1445		|O
reflect	1446	1453		|O
activation	1454	1464		|O
of	1465	1467		|O
angiogenesis	1468	1480		|O
.	1480	1481		|O
In	1482	1484		|O
contrast	1485	1493		|O
,	1493	1494		|O
low	1495	1498		|O
-	1498	1499		|O
dose	1499	1503		|O
metronomic	1504	1514		|O
chemotherapy	1515	1527		|O
in	1528	1530		|O
combination	1531	1542		|O
with	1543	1547		|O
anti	1548	1552		|O
-	1552	1553		|O
angiogenic	1553	1563		|O
drugs	1564	1569		|O
seems	1570	1575		|O
to	1576	1578		|O
correlate	1579	1588		|O
with	1589	1593		|O
the	1594	1597		|O
least	1598	1603		|O
increase	1604	1612		|O
in	1613	1615		|O
biomarkers	1616	1626		|O
.	1626	1627		|O
Imatinib	1628	1636		|O
-	1636	1637		|O
octreotide	1637	1647		|O
temporarily	1648	1659		|O
leads	1660	1665		|O
to	1666	1668		|O
a	1669	1670		|O
decrease	1671	1679		|O
in	1680	1682		|O
PDGF	1683	1687		|O
-	1687	1688		|O
BB	1688	1690		|O
,	1690	1691		|O
whereas	1692	1699		|O
octreotide	1700	1710		|O
alone	1711	1716		|O
had	1717	1720		|O
no	1721	1723		|O
effect	1724	1730		|O
on	1731	1733		|O
PDGF	1734	1738		|O
-	1738	1739		|O
BB	1739	1741		|O
plasma	1742	1748		|O
levels	1749	1755		|O
.	1755	1756		|O

### 18835419
In	0	2		|O
vitro	3	8		|O
investigation	9	22		|O
of	23	25		|O
oxide	26	31		|O
nanoparticle	32	44		|O
and	45	48		|O
carbon	49	55		|O
nanotube	56	64		|O
toxicity	65	73		|O
and	74	77		|O
intracellular	78	91		|O
accumulation	92	104		|O
in	105	107		|O
A549	108	112		|O
human	113	118		|O
pneumocytes	119	130		|O
.	130	131		|O
If	133	135		|O
released	136	144		|O
in	145	147		|O
the	148	151		|O
environment	152	163		|O
,	163	164		|O
nanomaterials	165	178		|O
might	179	184		|O
be	185	187		|O
inhaled	188	195		|O
by	196	198		|O
populations	199	210		|O
and	211	214		|O
cause	215	220		|O
damage	221	227		|O
to	228	230		|O
the	231	234		|O
deepest	235	242		|O
regions	243	250		|O
of	251	253		|O
the	254	257		|O
respiratory	258	269		|O
tract	270	275		|O
,	275	276		|O
i.e.	277	281		|O
,	281	282		|O
the	283	286		|O
alveolar	287	295		|O
compartment	296	307		|O
.	307	308		|O
To	309	311		|O
model	312	317		|O
this	318	322		|O
situation	323	332		|O
,	332	333		|O
we	334	336		|O
studied	337	344		|O
the	345	348		|O
response	349	357		|O
of	358	360		|O
A549	361	365		|O
human	366	371		|O
pneumocytes	372	383		|O
after	384	389		|O
exposure	390	398		|O
to	399	401		|O
aluminium	402	411		|O
oxide	412	417		|O
or	418	420		|O
titanium	421	429		|O
oxide	430	435		|O
nanoparticles	436	449		|O
,	449	450		|O
and	451	454		|O
to	455	457		|O
multi	458	463		|O
-	463	464		|O
walled	464	470		|O
carbon	471	477		|O
nanotubes	478	487		|O
.	487	488		|O
The	489	492		|O
influence	493	502		|O
of	503	505		|O
size	506	510		|O
,	510	511		|O
crystalline	512	523		|O
structure	524	533		|O
and	534	537		|O
chemical	538	546		|O
composition	547	558		|O
was	559	562		|O
investigated	563	575		|O
.	575	576		|O
After	577	582		|O
a	583	584		|O
detailed	585	593		|O
identification	594	608		|O
of	609	611		|O
nanomaterial	612	624		|O
physico	625	632		|O
-	632	633		|O
chemical	633	641		|O
characteristics	642	657		|O
,	657	658		|O
cells	659	664		|O
were	665	669		|O
exposed	670	677		|O
in	678	680		|O
vitro	681	686		|O
and	687	690		|O
viability	691	700		|O
and	701	704		|O
intracellular	705	718		|O
accumulation	719	731		|O
were	732	736		|O
assessed	737	745		|O
.	745	746		|O
In	747	749		|O
our	750	753		|O
conditions	754	764		|O
,	764	765		|O
carbon	766	772		|O
nanotubes	773	782		|O
were	783	787		|O
more	788	792		|O
toxic	793	798		|O
than	799	803		|O
metal	804	809		|O
oxide	810	815		|O
nanoparticles	816	829		|O
.	829	830		|O
Our	831	834		|O
results	835	842		|O
confirmed	843	852		|O
that	853	857		|O
both	858	862		|O
nanotubes	863	872		|O
and	873	876		|O
nanoparticles	877	890		|O
are	891	894		|O
able	895	899		|O
to	900	902		|O
rapidly	903	910		|O
enter	911	916		|O
into	917	921		|O
cells	922	927		|O
,	927	928		|O
and	929	932		|O
distribute	933	943		|O
in	944	946		|O
the	947	950		|O
cytoplasm	951	960		|O
and	961	964		|O
intracellular	965	978		|O
vesicles	979	987		|O
.	987	988		|O
Among	989	994		|O
nanoparticles	995	1008		|O
,	1008	1009		|O
we	1010	1012		|O
demonstrate	1013	1024		|O
significant	1025	1036		|O
difference	1037	1047		|O
in	1048	1050		|O
biological	1051	1061		|O
response	1062	1070		|O
as	1071	1073		|O
a	1074	1075		|O
function	1076	1084		|O
of	1085	1087		|O
size	1088	1092		|O
,	1092	1093		|O
crystalline	1094	1105		|O
phase	1106	1111		|O
and	1112	1115		|O
chemical	1116	1124		|O
composition	1125	1136		|O
.	1136	1137		|O
Their	1138	1143		|O
toxicity	1144	1152		|O
was	1153	1156		|O
globally	1157	1165		|O
lower	1166	1171		|O
than	1172	1176		|O
nanotubes	1177	1186	nanotubes toxicity	|B-ADVERSE
toxicity	1187	1195		|I-ADVERSE
.	1195	1196		|O
Among	1197	1202		|O
nanotubes	1203	1212		|O
,	1212	1213		|O
the	1214	1217		|O
length	1218	1224		|O
did	1225	1228		|O
not	1229	1232		|O
influence	1233	1242		|O
cytotoxicity	1243	1255	cytotoxicity	|B-ADVERSE
,	1255	1256		|O
neither	1257	1264		|O
the	1265	1268		|O
presence	1269	1277		|O
of	1278	1280		|O
metal	1281	1286		|O
catalyst	1287	1295		|O
impurities	1296	1306		|O
.	1306	1307		|O

### 18544904
Points	0	6		|O
to	7	9		|O
consider	10	18		|O
on	19	21		|O
the	22	25		|O
non	26	29		|O
-	29	30		|O
clinical	30	38		|O
safety	39	45		|O
evaluation	46	56		|O
of	57	59		|O
anticancer	60	70		|O
drugs	71	76		|O
.	76	77		|O
Since	79	84		|O
malignant	85	94	malignant tumors	|B-DISEASE
tumors	95	101		|I-DISEASE
are	102	105		|O
life	106	110		|O
-	110	111		|O
threatening	111	122		|O
,	122	123		|O
the	124	127		|O
death	128	133		|O
rate	134	138		|O
from	139	143		|O
these	144	149		|O
diseases	150	158		|O
is	159	161		|O
high	162	166		|O
,	166	167		|O
and	168	171		|O
existing	172	180		|O
therapies	181	190		|O
have	191	195		|O
limited	196	203		|O
effectiveness	204	217		|O
,	217	218		|O
it	219	221		|O
is	222	224		|O
desired	225	232		|O
to	233	235		|O
provide	236	243		|O
new	244	247		|O
effective	248	257		|O
anticancer	258	268		|O
drugs	269	274		|O
to	275	277		|O
tumor	278	283		|O
patients	284	292		|O
sooner	293	299		|O
.	299	300		|O
However	301	308		|O
,	308	309		|O
there	310	315		|O
is	316	318		|O
no	319	321		|O
guideline	322	331		|O
regarding	332	341		|O
non	342	345		|O
-	345	346		|O
clinical	346	354		|O
safety	355	361		|O
studies	362	369		|O
on	370	372		|O
the	373	376		|O
development	377	388		|O
of	389	391		|O
anticancer	392	402		|O
drugs	403	408		|O
required	409	417		|O
for	418	421		|O
the	422	425		|O
first	426	431		|O
in	432	434		|O
human	435	440		|O
clinical	441	449		|O
trials	450	456		|O
and	457	460		|O
for	461	464		|O
the	465	468		|O
approval	469	477		|O
applications	478	490		|O
in	491	493		|O
Japan	494	499		|O
.	499	500		|O
Then	501	505		|O
,	505	506		|O
the	507	510		|O
Ministry	511	519		|O
of	520	522		|O
Health	523	529		|O
,	529	530		|O
Labour	531	537		|O
and	538	541		|O
Welfare	542	549		|O
(	550	551		|O
MHLW	551	555		|O
)	555	556		|O
established	557	568		|O
the	569	572		|O
collaboration	573	586		|O
group	587	592		|O
including	593	602		|O
regulatory	603	613		|O
,	613	614		|O
academic	615	623		|O
and	624	627		|O
industrial	628	638		|O
scientists	639	649		|O
to	650	652		|O
prepare	653	660		|O
the	661	664		|O
guideline	665	674		|O
on	675	677		|O
the	678	681		|O
non	682	685		|O
-	685	686		|O
clinical	686	694		|O
safety	695	701		|O
evaluation	702	712		|O
of	713	715		|O
anticancer	716	726		|O
drugs	727	732		|O
in	733	735		|O
2004	736	740		|O
.	740	741		|O
As	742	744		|O
a	745	746		|O
guide	747	752		|O
for	753	756		|O
basic	757	762		|O
concept	763	770		|O
of	771	773		|O
non	774	777		|O
-	777	778		|O
clinical	778	786		|O
safety	787	793		|O
studies	794	801		|O
on	802	804		|O
anticancer	805	815		|O
drugs	816	821		|O
,	821	822		|O
the	823	826		|O
"	827	828		|O
Points	828	834		|O
to	835	837		|O
Consider	838	846		|O
"	846	847		|O
document	848	856		|O
was	857	860		|O
prepared	861	869		|O
by	870	872		|O
this	873	877		|O
group	878	883		|O
in	884	886		|O
2007	887	891		|O
.	891	892		|O

### 18812021
Delivery	0	8		|O
of	9	11		|O
daunorubicin	12	24		|O
to	25	27		|O
cancer	28	34		|O
cells	35	40		|O
with	41	45		|O
decreased	46	55		|O
toxicity	56	64		|O
by	65	67		|O
association	68	79		|O
with	80	84		|O
a	85	86		|O
lipidic	87	94		|O
nanoemulsion	95	107		|O
that	108	112		|O
binds	113	118		|O
to	119	121		|O
LDL	122	125		|O
receptors	126	135		|O
.	135	136		|O
A	138	139		|O
lipidic	140	147		|O
nanoemulsion	148	160		|O
termed	161	167		|O
LDE	168	171		|O
concentrates	172	184		|O
in	185	187		|O
neoplastic	188	198		|O
cells	199	204		|O
after	205	210		|O
injection	211	220		|O
into	221	225		|O
the	226	229		|O
bloodstream	230	241		|O
and	242	245		|O
thus	246	250		|O
can	251	254		|O
be	255	257		|O
used	258	262		|O
as	263	265		|O
a	266	267		|O
drug	268	272		|O
carrier	273	280		|O
to	281	283		|O
tumour	284	290		|O
sites	291	296		|O
.	296	297		|O
The	298	301		|O
chemotherapeutic	302	318		|O
agent	319	324		|O
daunorubicin	325	337		|O
associates	338	348		|O
poorly	349	355		|O
with	356	360		|O
LDE	361	364		|O
;	364	365		|O
the	366	369		|O
aim	370	373		|O
of	374	376		|O
this	377	381		|O
study	382	387		|O
was	388	391		|O
to	392	394		|O
clarify	395	402		|O
whether	403	410		|O
the	411	414		|O
derivatization	415	429		|O
of	430	432		|O
daunorubicin	433	445		|O
by	446	448		|O
the	449	452		|O
attachment	453	463		|O
of	464	466		|O
an	467	469		|O
oleyl	470	475		|O
group	476	481		|O
increases	482	491		|O
the	492	495		|O
association	496	507		|O
with	508	512		|O
LDE	513	516		|O
,	516	517		|O
and	518	521		|O
to	522	524		|O
test	525	529		|O
the	530	533		|O
cytotoxicity	534	546	cytotoxicity	|B-ADVERSE
and	547	550		|O
animal	551	557	animal toxicity	|B-ADVERSE
toxicity	558	566		|I-ADVERSE
of	567	569		|O
the	570	573		|O
new	574	577		|O
preparation	578	589		|O
.	589	590		|O
The	591	594		|O
association	595	606		|O
of	607	609		|O
oleyl	610	615		|O
-	615	616		|O
daunorubicin	616	628		|O
(	629	630		|O
oDNR	630	634		|O
)	634	635		|O
to	636	638		|O
LDE	639	642		|O
showed	643	649		|O
high	650	654		|O
yield	655	660		|O
(	661	662		|O
93	662	664		|O
+	665	666		|O
/	666	667		|O
-	667	668		|O
2%	669	671		|O
and	672	675		|O
84	676	678		|O
+	679	680		|O
/	680	681		|O
-	681	682		|O
4%	683	685		|O
at	686	688		|O
1	689	690		|O
:	690	691		|O
10	691	693		|O
and	694	697		|O
1	698	699		|O
:	699	700		|O
5	700	701		|O
drug	702	706		|O
:	706	707		|O
lipid	707	712		|O
mass	713	717		|O
,	717	718		|O
respectively	719	731		|O
)	731	732		|O
and	733	736		|O
was	737	740		|O
stable	741	747		|O
for	748	751		|O
at	752	754		|O
least	755	760		|O
20	761	763		|O
days	764	768		|O
.	768	769		|O
Association	770	781		|O
with	782	786		|O
oDNR	787	791		|O
increased	792	801		|O
the	802	805		|O
LDE	806	809		|O
particle	810	818		|O
diameter	819	827		|O
from	828	832		|O
42	833	835		|O
+	836	837		|O
/	837	838		|O
-	838	839		|O
4	840	841		|O
nm	842	844		|O
to	845	847		|O
75	848	850		|O
+	851	852		|O
/	852	853		|O
-	853	854		|O
6	855	856		|O
nm	857	859		|O
.	859	860		|O
Cytotoxicity	861	873		|O
of	874	876		|O
LDE	877	880		|O
-	880	881		|O
oDNR	881	885		|O
was	886	889		|O
reduced	890	897		|O
two	898	901		|O
-	901	902		|O
fold	902	906		|O
in	907	909		|O
HL	910	912		|O
-	912	913		|O
60	913	915		|O
and	916	919		|O
K	920	921		|O
-	921	922		|O
562	922	925		|O
cell	926	930		|O
lines	931	936		|O
,	936	937		|O
fourteen	938	946		|O
-	946	947		|O
fold	947	951		|O
in	952	954		|O
B16	955	958		|O
cells	959	964		|O
and	965	968		|O
nine	969	973		|O
-	973	974		|O
fold	974	978		|O
in	979	981		|O
L1210	982	987		|O
cells	988	993		|O
when	994	998		|O
compared	999	1007		|O
with	1008	1012		|O
commercial	1013	1023		|O
daunorubicin	1024	1036		|O
.	1036	1037		|O
When	1038	1042		|O
tested	1043	1049		|O
in	1050	1052		|O
mice	1053	1057		|O
,	1057	1058		|O
LDE	1059	1062		|O
-	1062	1063		|O
oDNR	1063	1067		|O
showed	1068	1074		|O
remarkable	1075	1085		|O
reduced	1086	1093		|O
toxicity	1094	1102		|O
(	1103	1104		|O
maximum	1104	1111		|O
tolerated	1112	1121		|O
dose	1122	1126		|O
>	1127	1128		|O
253	1129	1132		|O
micromol	1133	1141		|O
kg	1142	1144		|O
(	1144	1145		|O
-	1145	1146		|O
1	1146	1147		|O
)	1147	1148		|O
,	1148	1149		|O
compared	1150	1158		|O
with	1159	1163		|O
<	1164	1165		|O
3	1165	1166		|O
micromol	1167	1175		|O
kg	1176	1178		|O
(	1178	1179		|O
-	1179	1180		|O
1	1180	1181		|O
)	1181	1182		|O
for	1183	1186		|O
commercial	1187	1197		|O
daunorubicin	1198	1210		|O
)	1210	1211		|O
.	1211	1212		|O
At	1213	1215		|O
high	1216	1220		|O
doses	1221	1226		|O
,	1226	1227		|O
the	1228	1231		|O
cardiac	1232	1239		|O
tissue	1240	1246		|O
of	1247	1249		|O
LDE	1250	1253		|O
-	1253	1254		|O
oDNR	1254	1258		|O
-	1258	1259		|O
treated	1259	1266		|O
animals	1267	1274		|O
had	1275	1278		|O
much	1279	1283		|O
smaller	1284	1291		|O
structural	1292	1302		|O
lesions	1303	1310		|O
than	1311	1315		|O
with	1316	1320		|O
commercial	1321	1331		|O
daunorubicin	1332	1344		|O
.	1344	1345		|O
LDE	1346	1349		|O
-	1349	1350		|O
oDNR	1350	1354		|O
is	1355	1357		|O
therefore	1358	1367		|O
a	1368	1369		|O
promising	1370	1379		|O
new	1380	1383		|O
preparation	1384	1395		|O
that	1396	1400		|O
may	1401	1404		|O
offer	1405	1410		|O
superior	1411	1419		|O
tolerability	1420	1432		|O
compared	1433	1441		|O
with	1442	1446		|O
commercial	1447	1457		|O
daunorubicin	1458	1470		|O
.	1470	1471		|O

### 18751929
The	0	3		|O
novel	4	9		|O
cholinesterase	10	24		|O
-	24	25		|O
monoamine	25	34		|O
oxidase	35	42		|O
inhibitor	43	52		|O
and	53	56		|O
antioxidant	57	68		|O
,	68	69		|O
ladostigil	70	80		|O
,	80	81		|O
confers	82	89		|O
neuroprotection	90	105		|O
in	106	108		|O
neuroblastoma	109	122		|O
cells	123	128		|O
and	129	132		|O
aged	133	137		|O
rats	138	142		|O
.	142	143		|O
The	145	148		|O
current	149	156		|O
therapeutic	157	168		|O
advance	169	176		|O
in	177	179		|O
which	180	185		|O
future	186	192		|O
drugs	193	198		|O
are	199	202		|O
designed	203	211		|O
to	212	214		|O
possess	215	222		|O
varied	223	229		|O
pharmacological	230	245		|O
properties	246	256		|O
and	257	260		|O
act	261	264		|O
on	265	267		|O
multiple	268	276		|O
targets	277	284		|O
has	285	288		|O
stimulated	289	299		|O
the	300	303		|O
development	304	315		|O
of	316	318		|O
the	319	322		|O
multimodal	323	333		|O
drug	334	338		|O
,	338	339		|O
ladostigil	340	350		|O
(	351	352		|O
TV3326	352	358		|O
;	358	359		|O
(	360	361		|O
N	361	362		|O
-	362	363		|O
propargyl	363	372		|O
-	372	373		|O
(	373	374		|O
3R	374	376		|O
)	376	377		|O
aminoindan	378	388		|O
-	388	389		|O
5yl	389	392		|O
)	392	393		|O
-	393	394		|O
ethyl	394	399		|O
methyl	400	406		|O
carbamate	407	416		|O
)	416	417		|O
.	417	418		|O
Ladostigil	419	429		|O
combines	430	438		|O
neuroprotective	439	454		|O
effects	455	462		|O
with	463	467		|O
monoamine	468	477		|O
oxidase	478	485		|O
(	486	487		|O
MAO	487	490		|O
)	490	491		|O
-	491	492		|O
A	492	493		|O
and	494	497		|O
MAO	498	501		|O
-	501	502		|O
B	502	503		|O
and	504	507		|O
cholinesterase	508	522		|O
(	523	524		|O
ChE	524	527		|O
)	527	528		|O
inhibitory	529	539		|O
activities	540	550		|O
in	551	553		|O
a	554	555		|O
single	556	562		|O
molecule	563	571		|O
,	571	572		|O
as	573	575		|O
a	576	577		|O
potential	578	587		|O
treatment	588	597		|O
for	598	601		|O
Alzheimer	602	611	Alzheimer's disease	|B-DISEASE
's	611	613		|I-DISEASE
disease	614	621		|I-DISEASE
(	622	623		|O
AD	623	625	AD	|B-DISEASE
)	625	626		|O
and	627	630		|O
Lewy	631	635	Lewy body disease	|B-DISEASE
body	636	640		|I-DISEASE
disease	641	648		|I-DISEASE
.	648	649		|O
In	650	652		|O
the	653	656		|O
present	657	664		|O
study	665	670		|O
,	670	671		|O
we	672	674		|O
demonstrate	675	686		|O
that	687	691		|O
ladostigil	692	702		|O
(	703	704		|O
10	704	706		|O
(	706	707		|O
-	707	708		|O
6	708	709		|O
)	709	710		|O
-	710	711		|O
10	711	713		|O
muM	714	717		|O
)	717	718		|O
dose	719	723		|O
-	723	724		|O
dependently	724	735		|O
increased	736	745		|O
cell	746	750		|O
viability	751	760		|O
,	760	761		|O
associated	762	772		|O
with	773	777		|O
increased	778	787		|O
activity	788	796		|O
of	797	799		|O
catalase	800	808		|O
and	809	812		|O
glutathione	813	824		|O
reductase	825	834		|O
and	835	838		|O
decrease	839	847		|O
of	848	850		|O
intracellular	851	864		|O
reactive	865	873		|O
oxygen	874	880		|O
species	881	888		|O
production	889	899		|O
in	900	902		|O
a	903	904		|O
cytotoxic	905	914		|O
model	915	920		|O
of	921	923		|O
human	924	929		|O
SH	930	932		|O
-	932	933		|O
SY5Y	933	937		|O
neuroblastoma	938	951		|O
cells	952	957		|O
exposed	958	965		|O
to	966	968		|O
hydrogen	969	977		|O
peroxide	978	986		|O
(	987	988		|O
H	988	989		|O
(	989	990		|O
2	990	991		|O
)	991	992		|O
O	992	993		|O
(	993	994		|O
2	994	995		|O
)	995	996		|O
)	996	997		|O
.	997	998		|O
In	999	1001		|O
addition	1002	1010		|O
,	1010	1011		|O
ladostigil	1012	1022		|O
significantly	1023	1036		|O
upregulated	1037	1048		|O
mRNA	1049	1053		|O
levels	1054	1060		|O
of	1061	1063		|O
several	1064	1071		|O
antioxidant	1072	1083		|O
enzymes	1084	1091		|O
(	1092	1093		|O
catalase	1093	1101		|O
,	1101	1102		|O
NAD	1103	1106		|O
(	1106	1107		|O
P	1107	1108		|O
)	1108	1109		|O
H	1109	1110		|O
quinone	1111	1118		|O
oxidoreductase	1119	1133		|O
1	1134	1135		|O
and	1136	1139		|O
peroxiredoxin	1140	1153		|O
1	1154	1155		|O
)	1155	1156		|O
in	1157	1159		|O
both	1160	1164		|O
H	1165	1166		|O
(	1166	1167		|O
2	1167	1168		|O
)	1168	1169		|O
O	1169	1170		|O
(	1170	1171		|O
2	1171	1172		|O
)	1172	1173		|O
-	1173	1174		|O
treated	1174	1181		|O
SH	1182	1184		|O
-	1184	1185		|O
SY5Y	1185	1189		|O
cells	1190	1195		|O
,	1195	1196		|O
as	1197	1199		|O
well	1200	1204		|O
as	1205	1207		|O
in	1208	1210		|O
the	1211	1214		|O
high	1215	1219		|O
-	1219	1220		|O
density	1220	1227		|O
human	1228	1233		|O
SK	1234	1236		|O
-	1236	1237		|O
N	1237	1238		|O
-	1238	1239		|O
SH	1239	1241		|O
neuroblastoma	1242	1255		|O
cultured	1256	1264		|O
apoptotic	1265	1274		|O
models	1275	1281		|O
.	1281	1282		|O
In	1283	1285		|O
vivo	1286	1290		|O
chronic	1291	1298		|O
treatment	1299	1308		|O
with	1309	1313		|O
ladostigil	1314	1324		|O
(	1325	1326		|O
1	1326	1327		|O
mg	1328	1330		|O
/	1330	1331		|O
kg	1331	1333		|O
per	1334	1337		|O
os	1338	1340		|O
per	1341	1344		|O
day	1345	1348		|O
for	1349	1352		|O
30	1353	1355		|O
days	1356	1360		|O
)	1360	1361		|O
markedly	1362	1370		|O
upregulated	1371	1382		|O
mRNA	1383	1387		|O
expression	1388	1398		|O
levels	1399	1405		|O
of	1406	1408		|O
various	1409	1416		|O
enzymes	1417	1424		|O
involved	1425	1433		|O
in	1434	1436		|O
metabolism	1437	1447		|O
and	1448	1451		|O
oxidation	1452	1461		|O
processes	1462	1471		|O
in	1472	1474		|O
aged	1475	1479		|O
rat	1480	1483		|O
hippocampus	1484	1495		|O
.	1495	1496		|O
In	1497	1499		|O
addition	1500	1508		|O
to	1509	1511		|O
its	1512	1515		|O
unique	1516	1522		|O
combination	1523	1534		|O
of	1535	1537		|O
ChE	1538	1541		|O
and	1542	1545		|O
MAO	1546	1549		|O
enzyme	1550	1556		|O
inhibition	1557	1567		|O
,	1567	1568		|O
these	1569	1574		|O
results	1575	1582		|O
indicate	1583	1591		|O
that	1592	1596		|O
ladostigil	1597	1607		|O
displays	1608	1616		|O
neuroprotective	1617	1632		|O
activity	1633	1641		|O
against	1642	1649		|O
oxidative	1650	1659		|O
stress	1660	1666		|O
-	1666	1667		|O
induced	1667	1674		|O
cell	1675	1679		|O
apoptosis	1680	1689		|O
,	1689	1690		|O
which	1691	1696		|O
might	1697	1702		|O
be	1703	1705		|O
valuable	1706	1714		|O
for	1715	1718		|O
aging	1719	1724		|O
and	1725	1728		|O
age	1729	1732		|O
-	1732	1733		|O
associated	1733	1743		|O
neurodegenerative	1744	1761	neurodegenerative diseases	|B-DISEASE
diseases	1762	1770		|I-DISEASE
.	1770	1771		|O

### 18555464
High	0	4		|O
dose	5	9		|O
chemotherapy	10	22		|O
and	23	26		|O
autologous	27	37		|O
stem	38	42		|O
cell	43	47		|O
transplantation	48	63		|O
in	64	66		|O
patients	67	75		|O
with	76	80		|O
multiple	81	89	multiple myeloma	|B-DISEASE
myeloma	90	97		|I-DISEASE
:	97	98		|O
the	99	102		|O
experience	103	113		|O
of	114	116		|O
a	117	118		|O
single	119	125		|O
haematological	126	140		|O
unit	141	145		|O
.	145	146		|O
PURPOSE	148	155		|O
:	155	156		|O
To	157	159		|O
study	160	165		|O
the	166	169		|O
toxicity	170	178		|O
of	179	181		|O
high	182	186		|O
dose	187	191		|O
chemotherapy	192	204		|O
(	205	206		|O
HDCT	206	210		|O
)	210	211		|O
in	212	214		|O
multiple	215	223	multiple myeloma	|B-DISEASE
myeloma	224	231		|I-DISEASE
(	232	233		|O
MM	233	235	MM	|B-DISEASE
)	235	236		|O
patients	237	245		|O
and	246	249		|O
its	250	253		|O
impact	254	260		|O
on	261	263		|O
event	264	269		|O
free	270	274		|O
survival	275	283		|O
(	284	285		|O
EFS	285	288		|O
)	288	289		|O
and	290	293		|O
overall	294	301		|O
survival	302	310		|O
(	311	312		|O
OS	312	314		|O
)	314	315		|O
,	315	316		|O
and	317	320		|O
also	321	325		|O
the	326	329		|O
impact	330	336		|O
of	337	339		|O
thalidomide	340	351		|O
maintenance	352	363		|O
therapy	364	371		|O
on	372	374		|O
EFS	375	378		|O
and	379	382		|O
OS	383	385		|O
after	386	391		|O
HDCT	392	396		|O
.	396	397		|O
PATIENTS	398	406		|O
AND	407	410		|O
METHODS	411	418		|O
:	418	419		|O
From	420	424		|O
April	425	430		|O
1999	431	435		|O
to	436	438		|O
November	439	447		|O
2006	448	452		|O
37	453	455		|O
patients	456	464		|O
(	465	466		|O
29	466	468		|O
males	469	474		|O
,	474	475		|O
8	476	477		|O
females	478	485		|O
)	485	486		|O
out	487	490		|O
of	491	493		|O
a	494	495		|O
total	496	501		|O
of	502	504		|O
38	505	507		|O
scheduled	508	517		|O
were	518	522		|O
treated	523	530		|O
with	531	535		|O
HDCT	536	540		|O
and	541	544		|O
autologous	545	555		|O
peripheral	556	566		|O
stem	567	571		|O
cell	572	576		|O
transplantation	577	592		|O
(	593	594		|O
APSCT	594	599		|O
)	599	600		|O
,	600	601		|O
as	602	604		|O
consolidation	605	618		|O
treatment	619	628		|O
after	629	634		|O
first	635	640		|O
-	640	641		|O
or	642	644		|O
second	645	651		|O
-	651	652		|O
line	652	656		|O
chemotherapy	657	669		|O
.	669	670		|O
Their	671	676		|O
median	677	683		|O
age	684	687		|O
was	688	691		|O
55	692	694		|O
years	695	700		|O
(	701	702		|O
range	702	707		|O
38-71	708	713		|O
)	713	714		|O
.	714	715		|O
HDCT	716	720		|O
regimen	721	728		|O
used	729	733		|O
was	734	737		|O
melphalan	738	747		|O
200	748	751		|O
mg	752	754		|O
/	754	755		|O
m	755	756		|O
(	756	757		|O
2	757	758		|O
)	758	759		|O
.	759	760		|O
Following	761	770		|O
HDCT	771	775		|O
thalidomide	776	787		|O
100	788	791		|O
mg	792	794		|O
/	794	795		|O
day	795	798		|O
was	799	802		|O
administered	803	815		|O
as	816	818		|O
maintenance	819	830		|O
therapy	831	838		|O
to	839	841		|O
28	842	844		|O
patients	845	853		|O
in	854	856		|O
a	857	858		|O
random	859	865		|O
fashion	866	873		|O
.	873	874		|O
RESULTS	875	882		|O
:	882	883		|O
All	884	887		|O
patients	888	896		|O
tolerated	897	906		|O
well	907	911		|O
HDCT	912	916		|O
and	917	920		|O
APSCT	921	926		|O
.	926	927		|O
There	928	933		|O
was	934	937		|O
no	938	940		|O
treatment	941	950		|O
-	950	951		|O
related	951	958		|O
mortality	959	968		|O
.	968	969		|O
The	970	973		|O
median	974	980		|O
time	981	985		|O
interval	986	994		|O
for	995	998		|O
neutrophil	999	1009		|O
recovery	1010	1018		|O
(	1019	1020		|O
>	1020	1021		|O
500	1021	1024		|O
/	1024	1025		|O
mm	1025	1027		|O
(	1027	1028		|O
3	1028	1029		|O
)	1029	1030		|O
)	1030	1031		|O
was	1032	1035		|O
10	1036	1038		|O
days	1039	1043		|O
(	1044	1045		|O
range	1045	1050		|O
8-20	1051	1055		|O
)	1055	1056		|O
,	1056	1057		|O
while	1058	1063		|O
the	1064	1067		|O
median	1068	1074		|O
time	1075	1079		|O
interval	1080	1088		|O
for	1089	1092		|O
platelets	1093	1102		|O
to	1103	1105		|O
recover	1106	1113		|O
to	1114	1116		|O
>	1117	1118		|O
20.000	1118	1124		|O
/	1124	1125		|O
mm	1125	1127		|O
(	1127	1128		|O
3	1128	1129		|O
)	1129	1130		|O
was	1131	1134		|O
14	1135	1137		|O
days	1138	1142		|O
(	1143	1144		|O
range	1144	1149		|O
9-32	1150	1154		|O
)	1154	1155		|O
.	1155	1156		|O
Twenty	1157	1163		|O
(	1164	1165		|O
54%	1165	1168		|O
)	1168	1169		|O
patients	1170	1178		|O
achieved	1179	1187		|O
complete	1188	1196		|O
response	1197	1205		|O
(	1206	1207		|O
CR	1207	1209		|O
)	1209	1210		|O
,	1210	1211		|O
15	1212	1214		|O
(	1215	1216		|O
40%	1216	1219		|O
)	1219	1220		|O
partial	1221	1228		|O
response	1229	1237		|O
(	1238	1239		|O
PR	1239	1241		|O
)	1241	1242		|O
,	1242	1243		|O
and	1244	1247		|O
2	1248	1249		|O
(	1250	1251		|O
6%	1251	1253		|O
)	1253	1254		|O
stable	1255	1261		|O
disease	1262	1269		|O
(	1270	1271		|O
SD	1271	1273		|O
)	1273	1274		|O
.	1274	1275		|O
Before	1276	1282		|O
receiving	1283	1292		|O
thalidomide	1293	1304		|O
as	1305	1307		|O
maintenance	1308	1319		|O
treatment	1320	1329		|O
12	1330	1332		|O
(	1333	1334		|O
42%	1334	1337		|O
)	1337	1338		|O
patients	1339	1347		|O
were	1348	1352		|O
in	1353	1355		|O
CR	1356	1358		|O
,	1358	1359		|O
while	1360	1365		|O
all	1366	1369		|O
the	1370	1373		|O
others	1374	1380		|O
,	1380	1381		|O
except	1382	1388		|O
one	1389	1392		|O
who	1393	1396		|O
had	1397	1400		|O
progressive	1401	1412		|O
disease	1413	1420		|O
(	1421	1422		|O
PD	1422	1424		|O
)	1424	1425		|O
,	1425	1426		|O
were	1427	1431		|O
in	1432	1434		|O
PR	1435	1437		|O
.	1437	1438		|O
CR	1439	1441		|O
correlated	1442	1452		|O
with	1453	1457		|O
better	1458	1464		|O
EFS	1465	1468		|O
and	1469	1472		|O
probably	1473	1481		|O
OS	1482	1484		|O
.	1484	1485		|O
Thalidomide	1486	1497		|O
maintenance	1498	1509		|O
treatment	1510	1519		|O
correlated	1520	1530		|O
with	1531	1535		|O
better	1536	1542		|O
EFS	1543	1546		|O
.	1546	1547		|O
CONCLUSION	1548	1558		|O
:	1558	1559		|O
In	1560	1562		|O
our	1563	1566		|O
series	1567	1573		|O
of	1574	1576		|O
patients	1577	1585		|O
HDCT	1586	1590		|O
appears	1591	1598		|O
to	1599	1601		|O
be	1602	1604		|O
a	1605	1606		|O
totally	1607	1614		|O
feasible	1615	1623		|O
,	1623	1624		|O
safe	1625	1629		|O
and	1630	1633		|O
without	1634	1641		|O
treatment	1642	1651		|O
-	1651	1652		|O
related	1652	1659		|O
mortality	1660	1669		|O
procedure	1670	1679		|O
,	1679	1680		|O
even	1681	1685		|O
in	1686	1688		|O
patients	1689	1697		|O
older	1698	1703		|O
than	1704	1708		|O
60	1709	1711		|O
years	1712	1717		|O
of	1718	1720		|O
age	1721	1724		|O
.	1724	1725		|O
It	1726	1728		|O
has	1729	1732		|O
a	1733	1734		|O
major	1735	1740		|O
impact	1741	1747		|O
in	1748	1750		|O
terms	1751	1756		|O
of	1757	1759		|O
CR	1760	1762		|O
achievement	1763	1774		|O
,	1774	1775		|O
which	1776	1781		|O
seems	1782	1787		|O
to	1788	1790		|O
strongly	1791	1799		|O
correlate	1800	1809		|O
with	1810	1814		|O
a	1815	1816		|O
prolonged	1817	1826		|O
EFS	1827	1830		|O
and	1831	1834		|O
OS	1835	1837		|O
.	1837	1838		|O
The	1839	1842		|O
use	1843	1846		|O
of	1847	1849		|O
thalidomide	1850	1861		|O
as	1862	1864		|O
a	1865	1866		|O
maintenance	1867	1878		|O
therapy	1879	1886		|O
induces	1887	1894		|O
a	1895	1896		|O
greater	1897	1904		|O
EFS	1905	1908		|O
which	1909	1914		|O
could	1915	1920		|O
possibly	1921	1929		|O
yield	1930	1935		|O
an	1936	1938		|O
improved	1939	1947		|O
OS	1948	1950		|O
.	1950	1951		|O

### 18612759
Clinical	0	8		|O
and	9	12		|O
radiological	13	25		|O
features	26	34		|O
of	35	37		|O
brain	38	43	brain neurotoxicity	|B-ADVERSE
neurotoxicity	44	57		|I-ADVERSE
caused	58	64		|O
by	65	67		|O
antitumor	68	77		|O
and	78	81		|O
immunosuppressant	82	99		|O
treatments	100	110		|O
.	110	111		|O
Antitumor	113	122		|O
and	123	126		|O
immunosuppressant	127	144		|O
treatment	145	154		|O
-	154	155		|O
related	155	162		|O
neurotoxicity	163	176	neurotoxicity	|B-ADVERSE
can	177	180		|O
determine	181	190		|O
nonspecific	191	202		|O
clinical	203	211		|O
syndromes	212	221		|O
.	221	222		|O
Exclusion	223	232		|O
of	233	235		|O
other	236	241		|O
possible	242	250		|O
causes	251	257		|O
,	257	258		|O
among	259	264		|O
which	265	270		|O
tumor	271	276	tumor progression	|B-ADVERSE
progression	277	288		|I-ADVERSE
,	288	289		|O
appearance	290	300		|O
of	301	303		|O
paraneoplastic	304	318	paraneoplastic disease	|B-ADVERSE
disease	319	326		|I-ADVERSE
,	326	327		|O
renal	328	333		|O
or	334	336		|O
hepatic	337	344	hepatic failure	|B-ADVERSE
failure	345	352		|I-ADVERSE
,	352	353		|O
diabetes	354	362	diabetes	|B-ADVERSE
or	363	365		|O
hypertension	366	378	hypertension	|B-ADVERSE
,	378	379		|O
is	380	382		|O
relevant	383	391		|O
.	391	392		|O
We	393	395		|O
report	396	402		|O
clinical	403	411		|O
and	412	415		|O
neuroradiological	416	433		|O
features	434	442		|O
in	443	445		|O
five	446	450		|O
patients	451	459		|O
with	460	464		|O
neurotoxic	465	475	neurotoxic syndromes	|B-ADVERSE
syndromes	476	485		|I-ADVERSE
due	486	489		|O
to	490	492		|O
chemotherapy	493	505		|O
/	505	506		|O
radiotherapy	506	518		|O
or	519	521		|O
immunosuppression	522	539		|O
in	540	542		|O
the	543	546		|O
context	547	554		|O
of	555	557		|O
neoplastic	558	568		|O
disease	569	576		|O
/	576	577		|O
organ	577	582		|O
transplantation	583	598		|O
.	598	599		|O
Acute	600	605	Acute neurological syndrome	|B-ADVERSE
neurological	606	618		|I-ADVERSE
syndrome	619	627		|I-ADVERSE
developed	628	637		|O
in	638	640		|O
three	641	646		|O
patients	647	655		|O
after	656	661		|O
methotrexate	662	674		|O
(	675	676		|O
MTX	676	679		|O
)	679	680		|O
,	680	681		|O
cyclosporine	682	694		|O
A	695	696		|O
,	696	697		|O
and	698	701		|O
L	702	703		|O
-	703	704		|O
asparaginase	704	716		|O
therapy	717	724		|O
,	724	725		|O
respectively	726	738		|O
.	738	739		|O
MRI	740	743		|O
showed	744	750		|O
posterior	751	760	posterior reversible encephalopathy	|B-ADVERSE
reversible	761	771		|I-ADVERSE
encephalopathy	772	786		|I-ADVERSE
in	787	789		|O
two	790	793		|O
cases	794	799		|O
and	800	803		|O
venous	804	810	venous thrombosis	|B-ADVERSE
thrombosis	811	821		|I-ADVERSE
with	822	826		|O
intraparenchymal	827	843	intraparenchymal hematoma	|B-ADVERSE
hematoma	844	852		|I-ADVERSE
in	853	855		|O
the	856	859		|O
third	860	865		|O
patient	866	873		|O
.	873	874		|O
Late	875	879		|O
onset	880	885		|O
clinical	886	894		|O
syndrome	895	903		|O
occurred	904	912		|O
in	913	915		|O
the	916	919		|O
last	920	924		|O
two	925	928		|O
patients	929	937		|O
,	937	938		|O
treated	939	946		|O
with	947	951		|O
MTX	952	955		|O
or	956	958		|O
radiation	959	968		|O
therapy	969	976		|O
for	977	980		|O
breast	981	987	breast cancer metastasis	|B-DISEASE
cancer	988	994		|I-DISEASE
metastasis	995	1005		|I-DISEASE
and	1006	1009		|O
pituitary	1010	1019	pituitary adenoma	|B-DISEASE
adenoma	1020	1027		|I-DISEASE
.	1027	1028		|O
Neuroimaging	1029	1041		|O
showed	1042	1048		|O
brain	1049	1054		|O
diffuse	1055	1062		|O
abnormalities	1063	1076		|O
.	1076	1077		|O
Patients	1078	1086		|O
affected	1087	1095		|O
by	1096	1098		|O
tumors	1099	1105	tumors	|B-DISEASE
suffer	1106	1112		|O
from	1113	1117		|O
increased	1118	1127		|O
risk	1128	1132		|O
for	1133	1136		|O
treatment	1137	1146		|O
-	1146	1147		|O
related	1147	1154		|O
toxicities	1155	1165		|O
.	1165	1166		|O
Appearance	1167	1177		|O
or	1178	1180		|O
worsening	1181	1190		|O
of	1191	1193		|O
neurological	1194	1206		|O
signs	1207	1212		|O
and	1213	1216		|O
symptoms	1217	1225		|O
challenge	1226	1235		|O
the	1236	1239		|O
clinician	1240	1249		|O
to	1250	1252		|O
discriminate	1253	1265		|O
between	1266	1273		|O
CNS	1274	1277		|O
involvement	1278	1289		|O
by	1290	1292		|O
the	1293	1296		|O
tumor	1297	1302		|O
,	1302	1303		|O
toxicity	1304	1312		|O
of	1313	1315		|O
drugs	1316	1321		|O
,	1321	1322		|O
parane	1323	1329		|O
-	1329	1330		|O
oplastic	1330	1338		|O
disease	1339	1346		|O
and	1347	1350		|O
infections	1351	1361		|O
.	1361	1362		|O
MRI	1363	1366		|O
has	1367	1370		|O
a	1371	1372		|O
key	1373	1376		|O
role	1377	1381		|O
in	1382	1384		|O
differential	1385	1397		|O
diagnosis	1398	1407		|O
.	1407	1408		|O
Close	1409	1414		|O
interaction	1415	1426		|O
between	1427	1434		|O
the	1435	1438		|O
neurologist	1439	1450		|O
,	1450	1451		|O
the	1452	1455		|O
oncologist	1456	1466		|O
and	1467	1470		|O
the	1471	1474		|O
neuroradiologist	1475	1491		|O
leads	1492	1497		|O
to	1498	1500		|O
the	1501	1504		|O
optimal	1505	1512		|O
management	1513	1523		|O
of	1524	1526		|O
patients	1527	1535		|O
.	1535	1536		|O

### 18690972
Drotrecogin	0	11		|O
alfa	12	16		|O
(	17	18		|O
activated	18	27		|O
)	27	28		|O
in	29	31		|O
the	32	35		|O
treatment	36	45		|O
of	46	48		|O
severe	49	55		|O
sepsis	56	62	sepsis	|B-DISEASE
.	62	63		|O
Severe	65	71		|O
sepsis	72	78	sepsis	|B-DISEASE
and	79	82		|O
septic	83	89	septic shock	|B-DISEASE
shock	90	95		|I-DISEASE
are	96	99		|O
common	100	106		|O
in	107	109		|O
the	110	113		|O
critically	114	124		|O
ill	125	128		|O
patient	129	136		|O
and	137	140		|O
account	141	148		|O
for	149	152		|O
considerable	153	165		|O
morbidity	166	175		|O
and	176	179		|O
mortality	180	189		|O
not	190	193		|O
to	194	196		|O
mention	197	204		|O
the	205	208		|O
high	209	213		|O
associated	214	224		|O
costs	225	230		|O
.	230	231		|O
Advances	232	240		|O
in	241	243		|O
our	244	247		|O
understanding	248	261		|O
of	262	264		|O
sepsis	265	271	sepsis	|B-DISEASE
pathophysiology	272	287		|O
and	288	291		|O
in	292	294		|O
the	295	298		|O
important	299	308		|O
link	309	313		|O
between	314	321		|O
the	322	325		|O
inflammatory	326	338		|O
response	339	347		|O
to	348	350		|O
sepsis	351	357	sepsis	|B-DISEASE
and	358	361		|O
activation	362	372		|O
of	373	375		|O
coagulation	376	387		|O
led	388	391		|O
to	392	394		|O
the	395	398		|O
development	399	410		|O
and	411	414		|O
licensing	415	424		|O
of	425	427		|O
the	428	431		|O
first	432	437		|O
ever	438	442		|O
,	442	443		|O
specific	444	452		|O
,	452	453		|O
immunomodulatory	454	470		|O
anti	471	475		|O
-	475	476		|O
sepsis	476	482		|O
drug	483	487		|O
.	487	488		|O
Drotrecogin	489	500		|O
alfa	501	505		|O
(	506	507		|O
activated	507	516		|O
)	516	517		|O
,	517	518		|O
a	519	520		|O
recombinant	521	532		|O
version	533	540		|O
of	541	543		|O
activated	544	553		|O
protein	554	561		|O
C	562	563		|O
,	563	564		|O
was	565	568		|O
shown	569	574		|O
in	575	577		|O
a	578	579		|O
large	580	585		|O
randomized	586	596		|O
controlled	597	607		|O
clinical	608	616		|O
trial	617	622		|O
to	623	625		|O
reduce	626	632		|O
mortality	633	642		|O
rates	643	648		|O
from	649	653		|O
30.8%	654	659		|O
in	660	662		|O
the	663	666		|O
placebo	667	674		|O
group	675	680		|O
to	681	683		|O
24.7%	684	689		|O
in	690	692		|O
the	693	696		|O
treatment	697	706		|O
group	707	712		|O
,	712	713		|O
which	714	719		|O
equated	720	727		|O
to	728	730		|O
one	731	734		|O
additional	735	745		|O
life	746	750		|O
saved	751	756		|O
for	757	760		|O
every	761	766		|O
16	767	769		|O
patients	770	778		|O
treated	779	786		|O
.	786	787		|O
Vasopressor	788	799		|O
requirements	800	812		|O
and	813	816		|O
duration	817	825		|O
of	826	828		|O
mechanical	829	839		|O
ventilation	840	851		|O
were	852	856		|O
also	857	861		|O
reduced	862	869		|O
.	869	870		|O
Apart	871	876		|O
from	877	881		|O
an	882	884		|O
expected	885	893		|O
increased	894	903		|O
risk	904	908		|O
of	909	911		|O
severe	912	918		|O
bleeding	919	927	bleeding	|B-DISEASE
,	927	928		|O
mostly	929	935		|O
associated	936	946		|O
with	947	951		|O
interventions	952	965		|O
,	965	966		|O
drotrecogin	967	978		|O
alfa	979	983		|O
(	984	985		|O
activated	985	994		|O
)	994	995		|O
was	996	999		|O
not	1000	1003		|O
associated	1004	1014		|O
with	1015	1019		|O
any	1020	1023		|O
other	1024	1029		|O
adverse	1030	1037		|O
reactions	1038	1047		|O
.	1047	1048		|O
In	1049	1051		|O
this	1052	1056		|O
article	1057	1064		|O
,	1064	1065		|O
I	1066	1067		|O
will	1068	1072		|O
briefly	1073	1080		|O
summarize	1081	1090		|O
the	1091	1094		|O
events	1095	1101		|O
leading	1102	1109		|O
to	1110	1112		|O
the	1113	1116		|O
development	1117	1128		|O
of	1129	1131		|O
drotrecogin	1132	1143		|O
alfa	1144	1148		|O
(	1149	1150		|O
activated	1150	1159		|O
)	1159	1160		|O
including	1161	1170		|O
aspects	1171	1178		|O
of	1179	1181		|O
sepsis	1182	1188	sepsis	|B-DISEASE
epidemiology	1189	1201		|O
and	1202	1205		|O
pathophysiology	1206	1221		|O
and	1222	1225		|O
the	1226	1229		|O
results	1230	1237		|O
of	1238	1240		|O
early	1241	1246		|O
animal	1247	1253		|O
and	1254	1257		|O
clinical	1258	1266		|O
studies	1267	1274		|O
.	1274	1275		|O
The	1276	1279		|O
results	1280	1287		|O
of	1288	1290		|O
the	1291	1294		|O
large	1295	1300		|O
multicenter	1301	1312		|O
phase	1313	1318		|O
III	1319	1322		|O
PROWESS	1323	1330		|O
study	1331	1336		|O
will	1337	1341		|O
then	1342	1346		|O
be	1347	1349		|O
reviewed	1350	1358		|O
,	1358	1359		|O
along	1360	1365		|O
with	1366	1370		|O
results	1371	1378		|O
from	1379	1383		|O
subsequent	1384	1394		|O
open	1395	1399		|O
-	1399	1400		|O
label	1400	1405		|O
studies	1406	1413		|O
.	1413	1414		|O
Finally	1415	1422		|O
,	1422	1423		|O
I	1424	1425		|O
will	1426	1430		|O
focus	1431	1436		|O
on	1437	1439		|O
the	1440	1443		|O
key	1444	1447		|O
side	1448	1452		|O
effect	1453	1459		|O
issue	1460	1465		|O
with	1466	1470		|O
drotrecogin	1471	1482		|O
alfa	1483	1487		|O
(	1488	1489		|O
activated	1489	1498		|O
)	1498	1499		|O
,	1499	1500		|O
that	1501	1505		|O
of	1506	1508		|O
increased	1509	1518		|O
bleeding	1519	1527	bleeding	|B-DISEASE
,	1527	1528		|O
drawing	1529	1536		|O
data	1537	1541		|O
from	1542	1546		|O
the	1547	1550		|O
available	1551	1560		|O
clinical	1561	1569		|O
studies	1570	1577		|O
,	1577	1578		|O
and	1579	1582		|O
highlighting	1583	1595		|O
the	1596	1599		|O
contraindications	1600	1617		|O
and	1618	1621		|O
precautions	1622	1633		|O
when	1634	1638		|O
prescribing	1639	1650		|O
this	1651	1655		|O
drug	1656	1660		|O
.	1660	1661		|O

### 18614266
Current	0	7		|O
regulatory	8	18		|O
toxicology	19	29		|O
perspectives	30	42		|O
on	43	45		|O
the	46	49		|O
development	50	61		|O
of	62	64		|O
herbal	65	71		|O
medicines	72	81		|O
to	82	84		|O
prescription	85	97		|O
drug	98	102		|O
products	103	111		|O
in	112	114		|O
the	115	118		|O
United	119	125		|O
States	126	132		|O
.	132	133		|O
Toxicological	135	148		|O
studies	149	156		|O
constitute	157	167		|O
an	168	170		|O
essential	171	180		|O
part	181	185		|O
of	186	188		|O
the	189	192		|O
effort	193	199		|O
in	200	202		|O
developing	203	213		|O
an	214	216		|O
herbal	217	223		|O
medicine	224	232		|O
into	233	237		|O
a	238	239		|O
drug	240	244		|O
product	245	252		|O
.	252	253		|O
The	254	257		|O
US	258	260		|O
food	261	265		|O
and	266	269		|O
drug	270	274		|O
administration	275	289		|O
(	290	291		|O
FDA	291	294		|O
)	294	295		|O
published	296	305		|O
a	306	307		|O
guidance	308	316		|O
to	317	319		|O
assist	320	326		|O
academic	327	335		|O
and	336	339		|O
industry	340	348		|O
sponsors	349	357		|O
in	358	360		|O
the	361	364		|O
development	365	376		|O
of	377	379		|O
this	380	384		|O
unique	385	391		|O
group	392	397		|O
of	398	400		|O
drug	401	405		|O
products	406	414		|O
,	414	415		|O
and	416	419		|O
has	420	423		|O
recently	424	432		|O
approved	433	441		|O
an	442	444		|O
new	445	448		|O
drug	449	453		|O
application	454	465		|O
(	466	467		|O
NDA	467	470		|O
)	470	471		|O
based	472	477		|O
on	478	480		|O
green	481	486		|O
tea	487	490		|O
extract	491	498		|O
(	499	500		|O
Veregen	500	507		|O
)	507	508		|O
for	509	512		|O
topical	513	520		|O
treatment	521	530		|O
of	531	533		|O
genital	534	541		|O
and	542	545		|O
perianal	546	554	perianal warts	|B-DISEASE
warts	555	560		|I-DISEASE
.	560	561		|O
In	562	564		|O
this	565	569		|O
article	570	577		|O
,	577	578		|O
current	579	586		|O
regulatory	587	597		|O
views	598	603		|O
on	604	606		|O
issues	607	613		|O
related	614	621		|O
to	622	624		|O
requirements	625	637		|O
and	638	641		|O
recommendations	642	657		|O
on	658	660		|O
various	661	668		|O
types	669	674		|O
of	675	677		|O
nonclinical	678	689		|O
toxicity	690	698		|O
studies	699	706		|O
in	707	709		|O
support	710	717		|O
of	718	720		|O
clinical	721	729		|O
trials	730	736		|O
and	737	740		|O
filing	741	747		|O
an	748	750		|O
NDA	751	754		|O
for	755	758		|O
a	759	760		|O
herbal	761	767		|O
medicine	768	776		|O
,	776	777		|O
including	778	787		|O
pharm	788	793		|O
/	793	794		|O
tox	794	797		|O
aspects	798	805		|O
of	806	808		|O
green	809	814		|O
tea	815	818		|O
extract	819	826		|O
(	827	828		|O
Veregen	828	835		|O
)	835	836		|O
NDA	837	840		|O
,	840	841		|O
are	842	845		|O
discussed	846	855		|O
.	855	856		|O
Topics	857	863		|O
include	864	871		|O
nonclinical	872	883		|O
pharmacology	884	896		|O
/	896	897		|O
toxicology	897	907		|O
perspectives	908	920		|O
on	921	923		|O
herbal	924	930		|O
nomenclature	931	943		|O
and	944	947		|O
its	948	951		|O
identification	952	966		|O
,	966	967		|O
previous	968	976		|O
human	977	982		|O
experience	983	993		|O
and	994	997		|O
initial	998	1005		|O
clinical	1006	1014		|O
trial	1015	1020		|O
proposal	1021	1029		|O
,	1029	1030		|O
regulatory	1031	1041		|O
aspects	1042	1049		|O
of	1050	1052		|O
acute	1053	1058	acute toxicity	|B-ADVERSE
toxicity	1059	1067		|I-ADVERSE
studies	1068	1075		|O
,	1075	1076		|O
chronic	1077	1084	chronic toxicity	|B-ADVERSE
toxicity	1085	1093		|I-ADVERSE
studies	1094	1101		|O
,	1101	1102		|O
mutagenicity	1103	1115	mutagenicity	|B-ADVERSE
studies	1116	1123		|O
,	1123	1124		|O
reproductive	1125	1137	reproductive toxicity	|B-ADVERSE
toxicity	1138	1146		|I-ADVERSE
studies	1147	1154		|O
,	1154	1155		|O
and	1156	1159		|O
carcinogenicity	1160	1175	carcinogenicity	|B-ADVERSE
studies	1176	1183		|O
on	1184	1186		|O
botanicals	1187	1197		|O
.	1197	1198		|O
Certain	1199	1206		|O
regulatory	1207	1217		|O
review	1218	1224		|O
-	1224	1225		|O
related	1225	1232		|O
issues	1233	1239		|O
are	1240	1243		|O
also	1244	1248		|O
presented	1249	1258		|O
.	1258	1259		|O
It	1260	1262		|O
is	1263	1265		|O
anticipated	1266	1277		|O
that	1278	1282		|O
through	1283	1290		|O
a	1291	1292		|O
proactive	1293	1302		|O
two	1303	1306		|O
-	1306	1307		|O
way	1307	1310		|O
communication	1311	1324		|O
between	1325	1332		|O
the	1333	1336		|O
Agency	1337	1343		|O
and	1344	1347		|O
the	1348	1351		|O
sponsor	1352	1359		|O
,	1359	1360		|O
toxicological	1361	1374		|O
development	1375	1386		|O
of	1387	1389		|O
botanical	1390	1399		|O
drug	1400	1404		|O
product	1405	1412		|O
can	1413	1416		|O
be	1417	1419		|O
significantly	1420	1433		|O
facilitated	1434	1445		|O
.	1445	1446		|O

### 18840496
Genotoxicity	0	12		|O
of	13	15		|O
topoisomerase	16	29		|O
II	30	32		|O
inhibitors	33	43		|O
:	43	44		|O
an	45	47		|O
anti	48	52		|O
-	52	53		|O
infective	53	62		|O
perspective	63	74		|O
.	74	75		|O
At	77	79		|O
present	80	87		|O
,	87	88		|O
an	89	91		|O
inevitable	92	102		|O
consequence	103	114		|O
of	115	117		|O
a	118	119		|O
chemical	120	128		|O
's	128	130		|O
inhibitory	131	141		|O
activity	142	150		|O
on	151	153		|O
key	154	157		|O
regulators	158	168		|O
of	169	171		|O
DNA	172	175		|O
topology	176	184		|O
in	185	187		|O
bacteria	188	196		|O
,	196	197		|O
the	198	201		|O
type	202	206		|O
II	207	209		|O
topoisomerases	210	224		|O
,	224	225		|O
is	226	228		|O
a	229	230		|O
less	231	235		|O
pronounced	236	246		|O
effect	247	253		|O
on	254	256		|O
their	257	262		|O
eukaryotic	263	273		|O
counterparts	274	286		|O
.	286	287		|O
In	288	290		|O
the	291	294		|O
context	295	302		|O
of	303	305		|O
anti	306	310		|O
-	310	311		|O
infectives	311	321		|O
drug	322	326		|O
development	327	338		|O
,	338	339		|O
this	340	344		|O
may	345	348		|O
pose	349	353		|O
a	354	355		|O
risk	356	360		|O
to	361	363		|O
patient	364	371		|O
safety	372	378		|O
as	379	381		|O
inhibition	382	392		|O
of	393	395		|O
eukaryotic	396	406		|O
type	407	411		|O
II	412	414		|O
topoisomerases	415	429		|O
(	430	431		|O
TOPO	431	435		|O
II	436	438		|O
)	438	439		|O
can	440	443		|O
result	444	450		|O
in	451	453		|O
the	454	457		|O
generation	458	468		|O
of	469	471		|O
DNA	472	475		|O
double	476	482		|O
-	482	483		|O
strand	483	489		|O
breaks	490	496		|O
(	497	498		|O
DSBs	498	502		|O
)	502	503		|O
,	503	504		|O
which	505	510		|O
have	511	515		|O
the	516	519		|O
potential	520	529		|O
to	530	532		|O
manifest	533	541		|O
as	542	544		|O
mutations	545	554		|O
,	554	555		|O
chromosome	556	566		|O
breakage	567	575		|O
or	576	578		|O
cell	579	583		|O
death	584	589		|O
.	589	590		|O
The	591	594		|O
biological	595	605		|O
effects	606	613		|O
of	614	616		|O
several	617	624		|O
TOPO	625	629		|O
II	630	632		|O
inhibitors	633	643		|O
in	644	646		|O
mammalian	647	656		|O
cells	657	662		|O
are	663	666		|O
described	667	676		|O
herein	677	683		|O
;	683	684		|O
their	685	690		|O
modulation	691	701		|O
of	702	704		|O
DSB	705	708		|O
damage	709	715		|O
response	716	724		|O
parameters	725	735		|O
is	736	738		|O
examined	739	747		|O
and	748	751		|O
evidence	752	760		|O
for	761	764		|O
the	765	768		|O
existence	769	778		|O
of	779	781		|O
a	782	783		|O
threshold	784	793		|O
concept	794	801		|O
for	802	805		|O
genotoxicity	806	818	genotoxicity	|B-ADVERSE
and	819	822		|O
its	823	826		|O
relevance	827	836		|O
in	837	839		|O
safety	840	846		|O
assessment	847	857		|O
is	858	860		|O
discussed	861	870		|O
.	870	871		|O
The	872	875		|O
potential	876	885		|O
utility	886	893		|O
of	894	896		|O
gammaH2AX	897	906		|O
,	906	907		|O
a	908	909		|O
promising	910	919		|O
and	920	923		|O
highly	924	930		|O
sensitive	931	940		|O
molecular	941	950		|O
marker	951	957		|O
for	958	961		|O
DSBs	962	966		|O
,	966	967		|O
in	968	970		|O
a	971	972		|O
novel	973	978		|O
genotoxicity	979	991	genotoxicity	|B-ADVERSE
'	992	993		|O
pre	993	996		|O
-	996	997		|O
screen	997	1003		|O
'	1003	1004		|O
to	1005	1007		|O
conventional	1008	1020		|O
assays	1021	1027		|O
is	1028	1030		|O
also	1031	1035		|O
highlighted	1036	1047		|O
.	1047	1048		|O

### 18790714
Study	0	5		|O
of	6	8		|O
cytotoxic	9	18		|O
and	19	22		|O
apoptogenic	23	34		|O
properties	35	45		|O
of	46	48		|O
saffron	49	56		|O
extract	57	64		|O
in	65	67		|O
human	68	73		|O
cancer	74	80		|O
cell	81	85		|O
lines	86	91		|O
.	91	92		|O
Saffron	94	101		|O
(	102	103		|O
dried	103	108		|O
stigmas	109	116		|O
of	117	119		|O
Crocus	120	126		|O
sativus	127	134		|O
L	135	136		|O
.	136	137		|O
)	137	138		|O
has	139	142		|O
been	143	147		|O
used	148	152		|O
as	153	155		|O
a	156	157		|O
spice	158	163		|O
,	163	164		|O
food	165	169		|O
colorant	170	178		|O
and	179	182		|O
medicinal	183	192		|O
plant	193	198		|O
for	199	202		|O
millennia	203	212		|O
.	212	213		|O
In	214	216		|O
this	217	221		|O
study	222	227		|O
cytotoxic	228	237	cytotoxic effect	|B-ADVERSE
effect	238	244		|I-ADVERSE
of	245	247		|O
saffron	248	255		|O
extract	256	263		|O
was	264	267		|O
evaluated	268	277		|O
in	278	280		|O
HepG2	281	286		|O
and	287	290		|O
HeLa	291	295		|O
cell	296	300		|O
lines	301	306		|O
.	306	307		|O
Meanwhile	308	317		|O
role	318	322		|O
of	323	325		|O
apoptosis	326	335		|O
and	336	339		|O
ROS	340	343		|O
were	344	348		|O
explored	349	357		|O
.	357	358		|O
Malignant	359	368		|O
and	369	372		|O
non	373	376		|O
-	376	377		|O
malignant	377	386		|O
cells	387	392		|O
(	393	394		|O
L929	394	398		|O
)	398	399		|O
were	400	404		|O
cultured	405	413		|O
in	414	416		|O
DMEM	417	421		|O
medium	422	428		|O
and	429	432		|O
incubated	433	442		|O
with	443	447		|O
different	448	457		|O
concentrations	458	472		|O
of	473	475		|O
ethanolic	476	485		|O
saffron	486	493		|O
extract	494	501		|O
.	501	502		|O
Cell	503	507		|O
viability	508	517		|O
was	518	521		|O
quantitated	522	533		|O
by	534	536		|O
MTT	537	540		|O
assay	541	546		|O
.	546	547		|O
Apoptotic	548	557		|O
cells	558	563		|O
were	564	568		|O
determined	569	579		|O
using	580	585		|O
PI	586	588		|O
staining	589	597		|O
of	598	600		|O
DNA	601	604		|O
fragmentation	605	618		|O
by	619	621		|O
flow	622	626		|O
cytometry	627	636		|O
(	637	638		|O
sub	638	641		|O
-	641	642		|O
G1	642	644		|O
peak	645	649		|O
)	649	650		|O
.	650	651		|O
ROS	652	655		|O
was	656	659		|O
measured	660	668		|O
using	669	674		|O
DCF	675	678		|O
-	678	679		|O
DA	679	681		|O
by	682	684		|O
flow	685	689		|O
cytometry	690	699		|O
analysis	700	708		|O
.	708	709		|O
Saffron	710	717		|O
could	718	723		|O
decrease	724	732		|O
cell	733	737		|O
viability	738	747		|O
in	748	750		|O
malignant	751	760		|O
cells	761	766		|O
as	767	769		|O
a	770	771		|O
concentration	772	785		|O
and	786	789		|O
time	790	794		|O
-	794	795		|O
dependent	795	804		|O
manner	805	811		|O
.	811	812		|O
The	813	816		|O
IC50	817	821		|O
values	822	828		|O
against	829	836		|O
HeLa	837	841		|O
and	842	845		|O
HepG2	846	851		|O
were	852	856		|O
determined	857	867		|O
800	868	871		|O
and	872	875		|O
950	876	879		|O
microg	880	886		|O
/	886	887		|O
ml	887	889		|O
after	890	895		|O
48	896	898		|O
h	899	900		|O
,	900	901		|O
respectively	902	914		|O
.	914	915		|O
Saffron	916	923		|O
induced	924	931		|O
a	932	933		|O
sub	934	937		|O
-	937	938		|O
G1	938	940		|O
peak	941	945		|O
in	946	948		|O
flow	949	953		|O
cytometry	954	963		|O
histogram	964	973		|O
of	974	976		|O
treated	977	984		|O
cells	985	990		|O
compared	991	999		|O
to	1000	1002		|O
control	1003	1010		|O
indicating	1011	1021		|O
apoptotic	1022	1031		|O
cell	1032	1036		|O
death	1037	1042		|O
is	1043	1045		|O
involved	1046	1054		|O
in	1055	1057		|O
saffron	1058	1065	saffron toxicity	|B-ADVERSE
toxicity	1066	1074		|I-ADVERSE
.	1074	1075		|O
This	1076	1080		|O
toxicity	1081	1089		|O
was	1090	1093		|O
also	1094	1098		|O
independent	1099	1110		|O
of	1111	1113		|O
ROS	1114	1117		|O
production	1118	1128		|O
.	1128	1129		|O
It	1130	1132		|O
might	1133	1138		|O
be	1139	1141		|O
concluded	1142	1151		|O
that	1152	1156		|O
saffron	1157	1164		|O
could	1165	1170		|O
cause	1171	1176		|O
cell	1177	1181		|O
death	1182	1187		|O
in	1188	1190		|O
HeLa	1191	1195		|O
and	1196	1199		|O
HepG2	1200	1205		|O
cells	1206	1211		|O
,	1211	1212		|O
in	1213	1215		|O
which	1216	1221		|O
apoptosis	1222	1231		|O
or	1232	1234		|O
programmed	1235	1245		|O
cell	1246	1250		|O
death	1251	1256		|O
plays	1257	1262		|O
an	1263	1265		|O
important	1266	1275		|O
role	1276	1280		|O
.	1280	1281		|O
Saffron	1282	1289		|O
could	1290	1295		|O
be	1296	1298		|O
also	1299	1303		|O
considered	1304	1314		|O
as	1315	1317		|O
a	1318	1319		|O
promising	1320	1329		|O
chemotherapeutic	1330	1346		|O
agent	1347	1352		|O
in	1353	1355		|O
cancer	1356	1362	cancer	|B-DISEASE
treatment	1363	1372		|O
in	1373	1375		|O
future	1376	1382		|O
.	1382	1383		|O

### 18951238
Synthesis	0	9		|O
of	10	12		|O
some	13	17		|O
pyrazolyl	18	27		|O
benzenesulfonamide	28	46		|O
derivatives	47	58		|O
as	59	61		|O
dual	62	66		|O
anti	67	71		|O
-	71	72		|O
inflammatory	72	84		|O
antimicrobial	85	98		|O
agents	99	105		|O
.	105	106		|O
Four	108	112		|O
series	113	119		|O
of	120	122		|O
pyrazolylbenzenesulfonamide	123	150		|O
derivatives	151	162		|O
were	163	167		|O
synthesized	168	179		|O
and	180	183		|O
evaluated	184	193		|O
for	194	197		|O
their	198	203		|O
anti	204	208		|O
-	208	209		|O
inflammatory	209	221		|O
activity	222	230		|O
using	231	236		|O
cotton	237	243		|O
pellet	244	250		|O
induced	251	258		|O
granuloma	259	268	granuloma	|B-ADVERSE
and	269	272		|O
carrageenan	273	284		|O
-	284	285		|O
induced	285	292		|O
rat	293	296		|O
paw	297	300		|O
edema	301	306	edema	|B-ADVERSE
bioassays	307	316		|O
.	316	317		|O
Moreover	318	326		|O
,	326	327		|O
COX	328	331		|O
-	331	332		|O
1	332	333		|O
and	334	337		|O
COX	338	341		|O
-	341	342		|O
2	342	343		|O
inhibitory	344	354		|O
activity	355	363		|O
,	363	364		|O
ulcerogenic	365	376	ulcerogenic effect	|B-ADVERSE
effect	377	383		|I-ADVERSE
and	384	387		|O
acute	388	393	acute toxicity	|B-ADVERSE
toxicity	394	402		|I-ADVERSE
were	403	407		|O
also	408	412		|O
determined	413	423		|O
.	423	424		|O
Furthermore	425	436		|O
,	436	437		|O
the	438	441		|O
target	442	448		|O
compounds	449	458		|O
were	459	463		|O
screened	464	472		|O
for	473	476		|O
their	477	482		|O
in	483	485		|O
-	485	486		|O
vitro	486	491		|O
antimicrobial	492	505		|O
activity	506	514		|O
against	515	522		|O
Eischerichia	523	535		|O
coli	536	540		|O
,	540	541		|O
Staphylococcus	542	556		|O
aureus	557	563		|O
and	564	567		|O
Candida	568	575		|O
albicans	576	584		|O
.	584	585		|O
Compounds	586	595		|O
4	596	597		|O
-	597	598		|O
(	598	599		|O
3	599	600		|O
-	600	601		|O
Phenyl	601	607		|O
-	607	608		|O
4	608	609		|O
-	609	610		|O
cyano	610	615		|O
-	615	616		|O
1H	616	618		|O
-	618	619		|O
pyrazol	619	626		|O
-	626	627		|O
1	627	628		|O
-	628	629		|O
yl	629	631		|O
)	631	632		|O
benzenesulfonamide	632	650		|O
9a	651	653		|O
and	654	657		|O
4	658	659		|O
-	659	660		|O
(	660	661		|O
3	661	662		|O
-	662	663		|O
Tolyl	663	668		|O
-	668	669		|O
4	669	670		|O
-	670	671		|O
cyano	671	676		|O
-	676	677		|O
1H	677	679		|O
-	679	680		|O
pyrazol	680	687		|O
-	687	688		|O
1	688	689		|O
-	689	690		|O
yl	690	692		|O
)	692	693		|O
benzenesulfonamide	693	711		|O
9b	712	714		|O
were	715	719		|O
not	720	723		|O
only	724	728		|O
found	729	734		|O
to	735	737		|O
be	738	740		|O
the	741	744		|O
most	745	749		|O
active	750	756		|O
dual	757	761		|O
anti	762	766		|O
-	766	767		|O
inflammatory	767	779		|O
antimicrobial	780	793		|O
agents	794	800		|O
in	801	803		|O
the	804	807		|O
present	808	815		|O
study	816	821		|O
with	822	826		|O
good	827	831		|O
safety	832	838		|O
margin	839	845		|O
and	846	849		|O
minimal	850	857		|O
ulcerogenic	858	869		|O
effect	870	876		|O
but	877	880		|O
also	881	885		|O
exhibited	886	895		|O
good	896	900		|O
selective	901	910		|O
inhibitory	911	921		|O
activity	922	930		|O
towards	931	938		|O
COX	939	942		|O
-	942	943		|O
2	943	944		|O
.	944	945		|O
A	946	947		|O
docking	948	955		|O
pose	956	960		|O
for	961	964		|O
9a	965	967		|O
and	968	971		|O
9b	972	974		|O
separately	975	985		|O
in	986	988		|O
the	989	992		|O
active	993	999		|O
site	1000	1004		|O
of	1005	1007		|O
the	1008	1011		|O
human	1012	1017		|O
COX	1018	1021		|O
-	1021	1022		|O
2	1022	1023		|O
enzyme	1024	1030		|O
was	1031	1034		|O
also	1035	1039		|O
obtained	1040	1048		|O
.	1048	1049		|O
Therefore	1050	1059		|O
,	1059	1060		|O
these	1061	1066		|O
compounds	1067	1076		|O
would	1077	1082		|O
represent	1083	1092		|O
a	1093	1094		|O
fruitful	1095	1103		|O
matrix	1104	1110		|O
for	1111	1114		|O
the	1115	1118		|O
development	1119	1130		|O
of	1131	1133		|O
dual	1134	1138		|O
anti	1139	1143		|O
-	1143	1144		|O
inflammatory	1144	1156		|O
antimicrobial	1157	1170		|O
candidates	1171	1181		|O
with	1182	1186		|O
remarkable	1187	1197		|O
COX	1198	1201		|O
-	1201	1202		|O
2	1202	1203		|O
selectivity	1204	1215		|O
.	1215	1216		|O

### 18690095
Multicenter	0	11		|O
phase	12	17		|O
II	18	20		|O
study	21	26		|O
of	27	29		|O
capecitabine	30	42		|O
plus	43	47		|O
oxaliplatin	48	59		|O
as	60	62		|O
a	63	64		|O
first	65	70		|O
-	70	71		|O
line	71	75		|O
therapy	76	83		|O
in	84	86		|O
Chinese	87	94		|O
patients	95	103		|O
with	104	108		|O
advanced	109	117		|O
gastric	118	125	gastric cancer	|B-DISEASE
cancer	126	132		|I-DISEASE
.	132	133		|O
The	135	138		|O
efficacy	139	147		|O
of	148	150		|O
chemotherapy	151	163		|O
for	164	167		|O
advanced	168	176		|O
gastric	177	184	gastric cancer	|B-DISEASE
cancer	185	191		|I-DISEASE
with	192	196		|O
palliative	197	207		|O
intent	208	214		|O
compared	215	223		|O
with	224	228		|O
supportive	229	239		|O
care	240	244		|O
alone	245	250		|O
is	251	253		|O
now	254	257		|O
widely	258	264		|O
accepted	265	273		|O
.	273	274		|O
However	275	282		|O
,	282	283		|O
the	284	287		|O
survival	288	296		|O
advantage	297	306		|O
is	307	309		|O
small	310	315		|O
,	315	316		|O
and	317	320		|O
no	321	323		|O
internationally	324	339		|O
accepted	340	348		|O
standard	349	357		|O
regimen	358	365		|O
has	366	369		|O
emerged	370	377		|O
.	377	378		|O
This	379	383		|O
study	384	389		|O
is	390	392		|O
performed	393	402		|O
to	403	405		|O
evaluate	406	414		|O
the	415	418		|O
response	419	427		|O
rate	428	432		|O
,	432	433		|O
time	434	438		|O
to	439	441		|O
progression	442	453		|O
,	453	454		|O
and	455	458		|O
safety	459	465		|O
of	466	468		|O
the	469	472		|O
combination	473	484		|O
of	485	487		|O
capecitabine	488	500		|O
(	501	502		|O
1000	502	506		|O
mg	507	509		|O
/	509	510		|O
m	510	511		|O
twice	512	517		|O
daily	518	523		|O
,	523	524		|O
days	525	529		|O
1-14	530	534		|O
)	534	535		|O
plus	536	540		|O
oxaliplatin	541	552		|O
(	553	554		|O
130	554	557		|O
mg	558	560		|O
/	560	561		|O
m	561	562		|O
as	563	565		|O
a	566	567		|O
2	568	569		|O
-	569	570		|O
h	570	571		|O
intravenous	572	583		|O
infusion	584	592		|O
on	593	595		|O
day	596	599		|O
1	600	601		|O
)	601	602		|O
every	603	608		|O
3	609	610		|O
weeks	611	616		|O
,	616	617		|O
in	618	620		|O
previously	621	631		|O
untreated	632	641		|O
Chinese	642	649		|O
patients	650	658		|O
with	659	663		|O
advanced	664	672		|O
gastric	673	680	gastric cancer	|B-DISEASE
cancer	681	687		|I-DISEASE
.	687	688		|O
Sixty	689	694		|O
-	694	695		|O
five	695	699		|O
(	700	701		|O
95.6%	701	706		|O
)	706	707		|O
of	708	710		|O
the	711	714		|O
68	715	717		|O
patients	718	726		|O
were	727	731		|O
assessable	732	742		|O
for	743	746		|O
response	747	755		|O
.	755	756		|O
Three	757	762		|O
cases	763	768		|O
of	769	771		|O
complete	772	780		|O
response	781	789		|O
and	790	793		|O
34	794	796		|O
cases	797	802		|O
of	803	805		|O
partial	806	813		|O
response	814	822		|O
were	823	827		|O
confirmed	828	837		|O
,	837	838		|O
giving	839	845		|O
an	846	848		|O
overall	849	856		|O
response	857	865		|O
rate	866	870		|O
of	871	873		|O
54.4%	874	879		|O
[	880	881		|O
95%	881	884		|O
confidence	885	895		|O
interval	896	904		|O
(	905	906		|O
CI	906	908		|O
)	908	909		|O
,	909	910		|O
42.6-66.2%	911	921		|O
]	921	922		|O
.	922	923		|O
The	924	927		|O
median	928	934		|O
time	935	939		|O
to	940	942		|O
progression	943	954		|O
and	955	958		|O
overall	959	966		|O
survival	967	975		|O
for	976	979		|O
all	980	983		|O
patients	984	992		|O
were	993	997		|O
5.7	998	1001		|O
months	1002	1008		|O
(	1009	1010		|O
95%	1010	1013		|O
CI	1014	1016		|O
,	1016	1017		|O
2.0-8.8	1018	1025		|O
months	1026	1032		|O
)	1032	1033		|O
and	1034	1037		|O
10.5	1038	1042		|O
months	1043	1049		|O
(	1050	1051		|O
95%	1051	1054		|O
CI	1055	1057		|O
,	1057	1058		|O
5.0-15.1	1059	1067		|O
months	1068	1074		|O
)	1074	1075		|O
.	1075	1076		|O
The	1077	1080		|O
most	1081	1085		|O
severe	1086	1092		|O
hematologic	1093	1104		|O
adverse	1105	1112		|O
event	1113	1118		|O
was	1119	1122		|O
neutropenia	1123	1134	neutropenia	|B-ADVERSE
,	1134	1135		|O
which	1136	1141		|O
occurred	1142	1150		|O
with	1151	1155		|O
grade	1156	1161		|O
3	1162	1163		|O
intensity	1164	1173		|O
in	1174	1176		|O
three	1177	1182		|O
(	1183	1184		|O
4.6%	1184	1188		|O
)	1188	1189		|O
patients	1190	1198		|O
and	1199	1202		|O
grade	1203	1208		|O
4	1209	1210		|O
in	1211	1213		|O
one	1214	1217		|O
(	1218	1219		|O
1.5%	1219	1223		|O
)	1223	1224		|O
patient	1225	1232		|O
.	1232	1233		|O
Thrombocytopenia	1234	1250	Thrombocytopenia	|B-ADVERSE
and	1251	1254		|O
leukopenia	1255	1265	leukopenia	|B-ADVERSE
occurred	1266	1274		|O
with	1275	1279		|O
grade	1280	1285		|O
3	1286	1287		|O
intensity	1288	1297		|O
in	1298	1300		|O
five	1301	1305		|O
(	1306	1307		|O
7.7%	1307	1311		|O
)	1311	1312		|O
and	1313	1316		|O
three	1317	1322		|O
(	1323	1324		|O
4.6%	1324	1328		|O
)	1328	1329		|O
patients	1330	1338		|O
,	1338	1339		|O
respectively	1340	1352		|O
.	1352	1353		|O
However	1354	1361		|O
,	1361	1362		|O
no	1363	1365		|O
grade	1366	1371		|O
4	1372	1373		|O
thrombocytopenia	1374	1390	thrombocytopenia	|B-ADVERSE
and	1391	1394		|O
leukopenia	1395	1405	leukopenia	|B-ADVERSE
were	1406	1410		|O
observed	1411	1419		|O
.	1419	1420		|O
Grade	1421	1426		|O
1/2	1427	1430		|O
nausea	1431	1437	nausea	|B-ADVERSE
/	1437	1438		|O
vomiting	1438	1446	vomiting	|B-ADVERSE
and	1447	1450		|O
diarrhea	1451	1459	diarrhea	|B-ADVERSE
were	1460	1464		|O
observed	1465	1473		|O
in	1474	1476		|O
33	1477	1479		|O
(	1480	1481		|O
50.8%	1481	1486		|O
)	1486	1487		|O
,	1487	1488		|O
17	1489	1491		|O
(	1492	1493		|O
26.2%	1493	1498		|O
)	1498	1499		|O
,	1499	1500		|O
26	1501	1503		|O
(	1504	1505		|O
40%	1505	1508		|O
)	1508	1509		|O
,	1509	1510		|O
44	1511	1513		|O
(	1514	1515		|O
67.7%	1515	1520		|O
)	1520	1521		|O
,	1521	1522		|O
and	1523	1526		|O
13	1527	1529		|O
(	1530	1531		|O
20%	1531	1534		|O
)	1534	1535		|O
patients	1536	1544		|O
,	1544	1545		|O
respectively	1546	1558		|O
,	1558	1559		|O
and	1560	1563		|O
grade	1564	1569		|O
3	1570	1571		|O
nausea	1572	1578	nausea	|B-ADVERSE
/	1578	1579		|O
vomiting	1579	1587	vomiting	|B-ADVERSE
and	1588	1591		|O
diarrhea	1592	1600	diarrhea	|B-ADVERSE
were	1601	1605		|O
observed	1606	1614		|O
in	1615	1617		|O
one	1618	1621		|O
(	1622	1623		|O
1.5%	1623	1627		|O
)	1627	1628		|O
and	1629	1632		|O
four	1633	1637		|O
(	1638	1639		|O
6.2%	1639	1643		|O
)	1643	1644		|O
patients	1645	1653		|O
.	1653	1654		|O
Yet	1655	1658		|O
,	1658	1659		|O
no	1660	1662		|O
grade	1663	1668		|O
4	1669	1670		|O
nonhematologic	1671	1685	nonhematologic toxicity	|B-ADVERSE
toxicity	1686	1694		|I-ADVERSE
was	1695	1698		|O
observed	1699	1707		|O
.	1707	1708		|O
Capecitabine	1709	1721		|O
/	1721	1722		|O
oxaliplatin	1722	1733		|O
combination	1734	1745		|O
chemotherapy	1746	1758		|O
is	1759	1761		|O
active	1762	1768		|O
in	1769	1771		|O
Chinese	1772	1779		|O
patients	1780	1788		|O
with	1789	1793		|O
previously	1794	1804		|O
untreated	1805	1814		|O
advanced	1815	1823		|O
gastric	1824	1831	gastric cancer	|B-DISEASE
cancer	1832	1838		|I-DISEASE
.	1838	1839		|O

### 18854394
Lack	0	4		|O
of	5	7		|O
therapeutic	8	19		|O
effect	20	26		|O
of	27	29		|O
the	30	33		|O
histone	34	41		|O
deacetylase	42	53		|O
inhibitor	54	63		|O
vorinostat	64	74		|O
in	75	77		|O
patients	78	86		|O
with	87	91		|O
metastatic	92	102	metastatic radioiodine-refractory thyroid carcinoma	|B-DISEASE
radioiodine	103	114		|I-DISEASE
-	114	115		|I-DISEASE
refractory	115	125		|I-DISEASE
thyroid	126	133		|I-DISEASE
carcinoma	134	143		|I-DISEASE
.	143	144		|O
CONTEXT	146	153		|O
:	153	154		|O
Aberrant	155	163		|O
histone	164	171		|O
deacetylase	172	183		|O
activity	184	192		|O
is	193	195		|O
seen	196	200		|O
in	201	203		|O
a	204	205		|O
variety	206	213		|O
of	214	216		|O
malignancies	217	229		|O
,	229	230		|O
and	231	234		|O
histone	235	242		|O
deacetylase	243	254		|O
inhibitors	255	265		|O
such	266	270		|O
as	271	273		|O
vorinostat	274	284		|O
have	285	289		|O
been	290	294		|O
shown	295	300		|O
to	301	303		|O
induce	304	310		|O
cell	311	315		|O
death	316	321		|O
and	322	325		|O
sensitize	326	335		|O
cells	336	341		|O
to	342	344		|O
cytotoxic	345	354		|O
chemotherapy	355	367		|O
in	368	370		|O
thyroid	371	378		|O
cancer	379	385		|O
cell	386	390		|O
lines	391	396		|O
.	396	397		|O
This	398	402		|O
phase	403	408		|O
II	409	411		|O
study	412	417		|O
was	418	421		|O
undertaken	422	432		|O
to	433	435		|O
assess	436	442		|O
objective	443	452		|O
response	453	461		|O
to	462	464		|O
vorinostat	465	475		|O
in	476	478		|O
patients	479	487		|O
with	488	492		|O
advanced	493	501		|O
thyroid	502	509	thyroid cancer	|B-DISEASE
cancer	510	516		|I-DISEASE
.	516	517		|O
EXPERIMENTAL	518	530		|O
DESIGN	531	537		|O
:	537	538		|O
A	539	540		|O
total	541	546		|O
of	547	549		|O
19	550	552		|O
patients	553	561		|O
with	562	566		|O
differentiated	567	581	differentiated thyroid cancer	|B-DISEASE
thyroid	582	589		|I-DISEASE
cancer	590	596		|I-DISEASE
(	597	598		|O
n	598	599		|O
=	600	601		|O
16	602	604		|O
)	604	605		|O
and	606	609		|O
medullary	610	619	medullary thyroid cancer	|B-DISEASE
thyroid	620	627		|I-DISEASE
cancer	628	634		|I-DISEASE
(	635	636		|O
n	636	637		|O
=	638	639		|O
3	640	641		|O
)	641	642		|O
were	643	647		|O
enrolled	648	656		|O
in	657	659		|O
the	660	663		|O
study	664	669		|O
.	669	670		|O
Patients	671	679		|O
received	680	688		|O
oral	689	693		|O
vorinostat	694	704		|O
at	705	707		|O
a	708	709		|O
starting	710	718		|O
dose	719	723		|O
of	724	726		|O
200	727	730		|O
mg	731	733		|O
twice	734	739		|O
daily	740	745		|O
,	745	746		|O
with	747	751		|O
dose	752	756		|O
adjustments	757	768		|O
allowed	769	776		|O
as	777	779		|O
necessary	780	789		|O
for	790	793		|O
toxicity	794	802		|O
.	802	803		|O
Patients	804	812		|O
were	813	817		|O
treated	818	825		|O
for	826	829		|O
2	830	831		|O
wk	832	834		|O
,	834	835		|O
followed	836	844		|O
by	845	847		|O
1	848	849		|O
wk	850	852		|O
off	853	856		|O
therapy	857	864		|O
(	865	866		|O
3	866	867		|O
-	867	868		|O
wk	868	870		|O
cycle	871	876		|O
)	876	877		|O
until	878	883		|O
disease	884	891		|O
progression	892	903		|O
or	904	906		|O
study	907	912		|O
withdrawal	913	923		|O
.	923	924		|O
Responses	925	934		|O
were	935	939		|O
measured	940	948		|O
by	949	951		|O
Response	952	960		|O
Evaluation	961	971		|O
Criteria	972	980		|O
in	981	983		|O
Solid	984	989		|O
Tumors	990	996		|O
criteria	997	1005		|O
and	1006	1009		|O
correlated	1010	1020		|O
with	1021	1025		|O
tumor	1026	1031		|O
markers	1032	1039		|O
.	1039	1040		|O
RESULTS	1041	1048		|O
:	1048	1049		|O
No	1050	1052		|O
patient	1053	1060		|O
achieved	1061	1069		|O
a	1070	1071		|O
partial	1072	1079		|O
or	1080	1082		|O
complete	1083	1091		|O
response	1092	1100		|O
.	1100	1101		|O
Median	1102	1108		|O
duration	1109	1117		|O
of	1118	1120		|O
therapy	1121	1128		|O
in	1129	1131		|O
patients	1132	1140		|O
with	1141	1145		|O
differentiated	1146	1160	differentiated thyroid cancer	|B-DISEASE
thyroid	1161	1168		|I-DISEASE
cancer	1169	1175		|I-DISEASE
was	1176	1179		|O
17	1180	1182		|O
wk	1183	1185		|O
,	1185	1186		|O
whereas	1187	1194		|O
in	1195	1197		|O
medullary	1198	1207	medullary thyroid cancer	|B-DISEASE
thyroid	1208	1215		|I-DISEASE
cancer	1216	1222		|I-DISEASE
patients	1223	1231		|O
it	1232	1234		|O
was	1235	1238		|O
25	1239	1241		|O
wk	1242	1244		|O
.	1244	1245		|O
Reasons	1246	1253		|O
for	1254	1257		|O
termination	1258	1269		|O
included	1270	1278		|O
progression	1279	1290		|O
of	1291	1293		|O
disease	1294	1301		|O
by	1302	1304		|O
RECIST	1305	1311		|O
criteria	1312	1320		|O
(	1321	1322		|O
n	1322	1323		|O
=	1324	1325		|O
7	1326	1327		|O
)	1327	1328		|O
,	1328	1329		|O
clinical	1330	1338		|O
progression	1339	1350		|O
(	1351	1352		|O
n	1352	1353		|O
=	1354	1355		|O
3	1356	1357		|O
)	1357	1358		|O
,	1358	1359		|O
and	1360	1363		|O
adverse	1364	1371		|O
events	1372	1378		|O
(	1379	1380		|O
AEs	1380	1383		|O
)	1383	1384		|O
(	1385	1386		|O
n	1386	1387		|O
=	1388	1389		|O
9	1390	1391		|O
)	1391	1392		|O
.	1392	1393		|O
AEs	1394	1397		|O
were	1398	1402		|O
primarily	1403	1412		|O
grade	1413	1418		|O
1-3	1419	1422		|O
;	1422	1423		|O
no	1424	1426		|O
clinical	1427	1435		|O
grade	1436	1441		|O
4	1442	1443		|O
or	1444	1446		|O
grade	1447	1452		|O
5	1453	1454		|O
events	1455	1461		|O
were	1462	1466		|O
observed	1467	1475		|O
.	1475	1476		|O
Clinical	1477	1485		|O
grade	1486	1491		|O
3	1492	1493		|O
AEs	1494	1497		|O
consisted	1498	1507		|O
of	1508	1510		|O
fatigue	1511	1518	fatigue	|B-ADVERSE
,	1518	1519		|O
dehydration	1520	1531	dehydration	|B-ADVERSE
,	1531	1532		|O
ataxia	1533	1539	ataxia	|B-ADVERSE
,	1539	1540		|O
pneumonia	1541	1550	pneumonia	|B-ADVERSE
,	1550	1551		|O
bruises	1552	1559	bruises	|B-ADVERSE
,	1559	1560		|O
and	1561	1564		|O
deep	1565	1569	deep vein thrombosis	|B-ADVERSE
vein	1570	1574		|I-ADVERSE
thrombosis	1575	1585		|I-ADVERSE
.	1585	1586		|O
Severe	1587	1593		|O
thrombocytopenia	1594	1610	thrombocytopenia	|B-ADVERSE
was	1611	1614		|O
seen	1615	1619		|O
in	1620	1622		|O
seven	1623	1628		|O
patients	1629	1637		|O
(	1638	1639		|O
grade	1639	1644		|O
3	1645	1646		|O
,	1646	1647		|O
n	1648	1649		|O
=	1650	1651		|O
5	1652	1653		|O
;	1653	1654		|O
grade	1655	1660		|O
4	1661	1662		|O
,	1662	1663		|O
n	1664	1665		|O
=	1666	1667		|O
2	1668	1669		|O
)	1669	1670		|O
and	1671	1674		|O
was	1675	1678		|O
associated	1679	1689		|O
with	1690	1694		|O
minor	1695	1700		|O
bleeding	1701	1709	bleeding	|B-ADVERSE
or	1710	1712		|O
bruises	1713	1720	bruises	|B-ADVERSE
.	1720	1721		|O
CONCLUSIONS	1722	1733		|O
:	1733	1734		|O
Vorinostat	1735	1745		|O
at	1746	1748		|O
this	1749	1753		|O
dose	1754	1758		|O
and	1759	1762		|O
schedule	1763	1771		|O
is	1772	1774		|O
not	1775	1778		|O
an	1779	1781		|O
effective	1782	1791		|O
treatment	1792	1801		|O
for	1802	1805		|O
advanced	1806	1814		|O
thyroid	1815	1822	thyroid cancer	|B-DISEASE
cancer	1823	1829		|I-DISEASE
.	1829	1830		|O

### 18585919
Cyclin	0	6		|O
D1	7	9		|O
in	10	12		|O
excitatory	13	23		|O
neurons	24	31		|O
of	32	34		|O
the	35	38		|O
adult	39	44		|O
brain	45	50		|O
enhances	51	59		|O
kainate	60	67		|O
-	67	68		|O
induced	68	75		|O
neurotoxicity	76	89	neurotoxicity	|B-ADVERSE
.	89	90		|O
G1	92	94		|O
-	94	95		|O
phase	95	100		|O
cyclin	101	107		|O
D1	108	110		|O
(	111	112		|O
cD1	112	115		|O
)	115	116		|O
expression	117	127		|O
has	128	131		|O
been	132	136		|O
documented	137	147		|O
in	148	150		|O
post	151	155		|O
-	155	156		|O
mitotic	156	163		|O
neurons	164	171		|O
undergoing	172	182		|O
apoptosis	183	192		|O
,	192	193		|O
leading	194	201		|O
others	202	208		|O
to	209	211		|O
propose	212	219		|O
that	220	224		|O
attempted	225	234		|O
cell	235	239		|O
cycle	240	245		|O
re	246	248		|O
-	248	249		|O
entry	249	254		|O
may	255	258		|O
induce	259	265		|O
cell	266	270		|O
death	271	276		|O
.	276	277		|O
Here	278	282		|O
,	282	283		|O
cD1	284	287		|O
immunoreactivity	288	304		|O
was	305	308		|O
found	309	314		|O
in	315	317		|O
a	318	319		|O
subpopulation	320	333		|O
of	334	336		|O
healthy	337	344		|O
excitatory	345	355		|O
neurons	356	363		|O
throughout	364	374		|O
the	375	378		|O
brain	379	384		|O
.	384	385		|O
Most	386	390		|O
striking	391	399		|O
was	400	403		|O
the	404	407		|O
selective	408	417		|O
cD1	418	421		|O
expression	422	432		|O
in	433	435		|O
hippocampal	436	447		|O
pyramidal	448	457		|O
neurons	458	465		|O
,	465	466		|O
an	467	469		|O
especially	470	480		|O
vulnerable	481	491		|O
cell	492	496		|O
group	497	502		|O
.	502	503		|O
Seizure	504	511	Seizure	|B-ADVERSE
threshold	512	521		|O
,	521	522		|O
cD1	523	526		|O
induction	527	536		|O
and	537	540		|O
CA1	541	544		|O
neuron	545	551		|O
death	552	557		|O
were	558	562		|O
examined	563	571		|O
following	572	581		|O
application	582	593		|O
of	594	596		|O
kainate	597	604		|O
(	605	606		|O
KA	606	608		|O
)	608	609		|O
or	610	612		|O
pentylenetetrazole	613	631		|O
(	632	633		|O
PTZ	633	636		|O
)	636	637		|O
in	638	640		|O
cD1	641	644		|O
heterozygous	645	657		|O
(	658	659		|O
+	659	660		|O
/	660	661		|O
-	661	662		|O
)	662	663		|O
and	664	667		|O
wildtype	668	676		|O
mice	677	681		|O
to	682	684		|O
determine	685	694		|O
whether	695	702		|O
baseline	703	711		|O
cD1	712	715		|O
correlates	716	726		|O
with	727	731		|O
pathology	732	741		|O
.	741	742		|O
cD1+	743	747		|O
/	747	748		|O
-	748	749		|O
mice	750	754		|O
displayed	755	764		|O
resistance	765	775		|O
to	776	778		|O
KA	779	781		|O
,	781	782		|O
but	783	786		|O
not	787	790		|O
PTZ	791	794		|O
-	794	795		|O
induced	795	802		|O
seizures	803	811	seizures	|B-ADVERSE
and	812	815		|O
had	816	819		|O
reduced	820	827		|O
or	828	830		|O
equivalent	831	841		|O
cytotoxicity	842	854	cytotoxicity	|B-ADVERSE
respectively	855	867		|O
,	867	868		|O
compared	869	877		|O
with	878	882		|O
wildtype	883	891		|O
.	891	892		|O
KA	893	895		|O
administration	896	910		|O
,	910	911		|O
but	912	915		|O
not	916	919		|O
PTZ	920	923		|O
,	923	924		|O
induced	925	932		|O
cD1	933	936		|O
expression	937	947		|O
.	947	948		|O
These	949	954		|O
findings	955	963		|O
suggest	964	971		|O
that	972	976		|O
basal	977	982		|O
cD1	983	986		|O
expression	987	997		|O
may	998	1001		|O
render	1002	1008		|O
hippocampal	1009	1020		|O
circuits	1021	1029		|O
more	1030	1034		|O
susceptible	1035	1046		|O
to	1047	1049		|O
particular	1050	1060		|O
epileptogenic	1061	1074		|O
agents	1075	1081		|O
and	1082	1085		|O
excitotoxic	1086	1097		|O
cell	1098	1102		|O
death	1103	1108		|O
,	1108	1109		|O
though	1110	1116		|O
cD1	1117	1120		|O
is	1121	1123		|O
not	1124	1127		|O
a	1128	1129		|O
direct	1130	1136		|O
precipitant	1137	1148		|O
in	1149	1151		|O
apoptosis	1152	1161		|O
.	1161	1162		|O

### 18627268
Aging	0	5		|O
and	6	9		|O
infectious	10	20	infectious diseases	|B-DISEASE
diseases	21	29		|I-DISEASE
:	29	30		|O
workshop	31	39		|O
on	40	42		|O
HIV	43	46	HIV infection	|B-DISEASE
infection	47	56		|I-DISEASE
and	57	60		|O
aging	61	66		|O
:	66	67		|O
what	68	72		|O
is	73	75		|O
known	76	81		|O
and	82	85		|O
future	86	92		|O
research	93	101		|O
directions	102	112		|O
.	112	113		|O
Highly	115	121		|O
active	122	128		|O
antiretroviral	129	143		|O
treatment	144	153		|O
has	154	157		|O
resulted	158	166		|O
in	167	169		|O
dramatically	170	182		|O
increased	183	192		|O
life	193	197		|O
expectancy	198	208		|O
among	209	214		|O
patients	215	223		|O
with	224	228		|O
HIV	229	232	HIV infection	|B-DISEASE
infection	233	242		|I-DISEASE
who	243	246		|O
are	247	250		|O
now	251	254		|O
aging	255	260		|O
while	261	266		|O
receiving	267	276		|O
treatment	277	286		|O
and	287	290		|O
are	291	294		|O
at	295	297		|O
risk	298	302		|O
of	303	305		|O
developing	306	316		|O
chronic	317	324	chronic diseases	|B-DISEASE
diseases	325	333		|I-DISEASE
associated	334	344		|O
with	345	349		|O
advanced	350	358		|O
age	359	362		|O
.	362	363		|O
Similarities	364	376		|O
between	377	384		|O
aging	385	390		|O
and	391	394		|O
the	395	398		|O
courses	399	406		|O
of	407	409		|O
human	410	415	human immunodeficiency virus (HIV) infection	|B-DISEASE
immunodeficiency	416	432		|I-DISEASE
virus	433	438		|I-DISEASE
(	439	440		|I-DISEASE
HIV	440	443		|I-DISEASE
)	443	444		|I-DISEASE
infection	445	454		|I-DISEASE
and	455	458		|O
acquired	459	467	acquired immunodeficiency syndrome	|B-DISEASE
immunodeficiency	468	484		|I-DISEASE
syndrome	485	493		|I-DISEASE
suggest	494	501		|O
that	502	506		|O
HIV	507	510	HIV infection	|B-DISEASE
infection	511	520		|I-DISEASE
compresses	521	531		|O
the	532	535		|O
aging	536	541		|O
process	542	549		|O
,	549	550		|O
perhaps	551	558		|O
accelerating	559	571		|O
comorbidities	572	585	comorbidities	|B-DISEASE
and	586	589		|O
frailty	590	597	frailty	|B-DISEASE
.	597	598		|O
In	599	601		|O
a	602	603		|O
workshop	604	612		|O
organized	613	622		|O
by	623	625		|O
the	626	629		|O
Association	630	641		|O
of	642	644		|O
Specialty	645	654		|O
Professors	655	665		|O
,	665	666		|O
the	667	670		|O
Infectious	671	681	Infectious Diseases	|B-DISEASE
Diseases	682	690		|I-DISEASE
Society	691	698		|O
of	699	701		|O
America	702	709		|O
,	709	710		|O
the	711	714		|O
HIV	715	718		|O
Medical	719	726		|O
Association	727	738		|O
,	738	739		|O
the	740	743		|O
National	744	752		|O
Institute	753	762		|O
on	763	765		|O
Aging	766	771		|O
,	771	772		|O
and	773	776		|O
the	777	780		|O
National	781	789		|O
Institute	790	799		|O
on	800	802		|O
Allergy	803	810	Allergy	|B-DISEASE
and	811	814		|O
Infectious	815	825	Infectious Diseases	|B-DISEASE
Diseases	826	834		|I-DISEASE
,	834	835		|O
researchers	836	847		|O
in	848	850		|O
infectious	851	861	infectious diseases	|B-DISEASE
diseases	862	870		|I-DISEASE
,	870	871		|O
geriatrics	872	882		|O
,	882	883		|O
immunology	884	894		|O
,	894	895		|O
and	896	899		|O
gerontology	900	911		|O
met	912	915		|O
to	916	918		|O
review	919	925		|O
what	926	930		|O
is	931	933		|O
known	934	939		|O
about	940	945		|O
HIV	946	949	HIV infection	|B-DISEASE
infection	950	959		|I-DISEASE
and	960	963		|O
aging	964	969		|O
,	969	970		|O
to	971	973		|O
identify	974	982		|O
research	983	991		|O
gaps	992	996		|O
,	996	997		|O
and	998	1001		|O
to	1002	1004		|O
suggest	1005	1012		|O
high	1013	1017		|O
priority	1018	1026		|O
topics	1027	1033		|O
for	1034	1037		|O
future	1038	1044		|O
research	1045	1053		|O
.	1053	1054		|O
Answers	1055	1062		|O
to	1063	1065		|O
the	1066	1069		|O
questions	1070	1079		|O
posed	1080	1085		|O
are	1086	1089		|O
likely	1090	1096		|O
to	1097	1099		|O
help	1100	1104		|O
prioritize	1105	1115		|O
and	1116	1119		|O
balance	1120	1127		|O
strategies	1128	1138		|O
to	1139	1141		|O
slow	1142	1146		|O
the	1147	1150		|O
progression	1151	1162		|O
of	1163	1165		|O
HIV	1166	1169	HIV infection	|B-DISEASE
infection	1170	1179		|I-DISEASE
,	1179	1180		|O
to	1181	1183		|O
address	1184	1191		|O
comorbidities	1192	1205		|O
and	1206	1209		|O
drug	1210	1214	drug toxicity	|B-ADVERSE
toxicity	1215	1223		|I-ADVERSE
,	1223	1224		|O
and	1225	1228		|O
to	1229	1231		|O
enhance	1232	1239		|O
understanding	1240	1253		|O
about	1254	1259		|O
both	1260	1264		|O
HIV	1265	1268	HIV infection	|B-DISEASE
infection	1269	1278		|I-DISEASE
and	1279	1282		|O
aging	1283	1288		|O
.	1288	1289		|O

### 18693154
Adapalene	0	9		|O
0.1%	10	14		|O
and	15	18		|O
benzoyl	19	26		|O
peroxide	27	35		|O
2.5%	36	40		|O
as	41	43		|O
a	44	45		|O
fixed	46	51		|O
-	51	52		|O
dose	52	56		|O
combination	57	68		|O
gel	69	72		|O
is	73	75		|O
as	76	78		|O
well	79	83		|O
tolerated	84	93		|O
as	94	96		|O
the	97	100		|O
individual	101	111		|O
components	112	122		|O
alone	123	128		|O
in	129	131		|O
terms	132	137		|O
of	138	140		|O
cumulative	141	151		|O
irritancy	152	161		|O
.	161	162		|O
International	164	177		|O
guidelines	178	188		|O
recommend	189	198		|O
the	199	202		|O
combination	203	214		|O
of	215	217		|O
retinoids	218	227		|O
(	228	229		|O
e.g.	229	233		|O
adapalene	234	243		|O
,	243	244		|O
tazarotene	245	255		|O
)	255	256		|O
and	257	260		|O
benzoyl	261	268		|O
peroxide	269	277		|O
for	278	281		|O
treating	282	290		|O
acne	291	295	acne	|B-DISEASE
because	296	303		|O
of	304	306		|O
their	307	312		|O
complementary	313	326		|O
mechanisms	327	337		|O
of	338	340		|O
action	341	347		|O
.	347	348		|O
A	349	350		|O
new	351	354		|O
fixed	355	360		|O
-	360	361		|O
dose	361	365		|O
combination	366	377		|O
gel	378	381		|O
of	382	384		|O
adapalene	385	394		|O
0.1%	395	399		|O
and	400	403		|O
benzoyl	404	411		|O
peroxide	412	420		|O
(	421	422		|O
BPO	422	425		|O
)	425	426		|O
2.5%	427	431		|O
(	432	433		|O
adapalene	433	442		|O
/	442	443		|O
BPO	443	446		|O
*	446	447		|O
)	447	448		|O
is	449	451		|O
an	452	454		|O
effective	455	464		|O
acne	465	469	acne	|B-DISEASE
treatment	470	479		|O
and	480	483		|O
offers	484	490		|O
the	491	494		|O
advantage	495	504		|O
of	505	507		|O
a	508	509		|O
once	510	514		|O
daily	515	520		|O
application	521	532		|O
.	532	533		|O
This	534	538		|O
paper	539	544		|O
reports	545	552		|O
the	553	556		|O
results	557	564		|O
of	565	567		|O
a	568	569		|O
cumulative	570	580		|O
irritancy	581	590		|O
study	591	596		|O
in	597	599		|O
healthy	600	607		|O
volunteers	608	618		|O
comparing	619	628		|O
adapalene	629	638		|O
/	638	639		|O
BPO	639	642		|O
to	643	645		|O
adapalene	646	655		|O
0.1%	656	660		|O
and	661	664		|O
BPO	665	668		|O
2.5%	669	673		|O
applied	674	681		|O
separately	682	692		|O
,	692	693		|O
BPO	694	697		|O
10%	698	701		|O
gel	702	705		|O
,	705	706		|O
tazarotene	707	717		|O
0.1%	718	722		|O
gel	723	726		|O
and	727	730		|O
the	731	734		|O
gel	735	738		|O
vehicle	739	746		|O
as	747	749		|O
a	750	751		|O
control	752	759		|O
.	759	760		|O
There	760	765		|O
was	766	769		|O
no	770	772		|O
significant	773	784		|O
difference	785	795		|O
between	796	803		|O
the	804	807		|O
mean	808	812		|O
cumulative	813	823		|O
irritation	824	834		|O
index	835	840		|O
(	841	842		|O
MCII	842	846		|O
)	846	847		|O
for	848	851		|O
adapalene	852	861		|O
/	861	862		|O
BPO	862	865		|O
and	866	869		|O
any	870	873		|O
test	874	878		|O
product	879	886		|O
except	887	893		|O
tazarotene	894	904		|O
0.1%	905	909		|O
gel	910	913		|O
,	913	914		|O
which	915	920		|O
had	921	924		|O
a	925	926		|O
significantly	927	940		|O
greater	941	948		|O
MCII	949	953		|O
than	954	958		|O
all	959	962		|O
other	963	968		|O
test	969	973		|O
products	974	982		|O
(	983	984		|O
p	984	985		|O
<	986	987		|O
0.05	988	992		|O
)	992	993		|O
.	993	994		|O
This	995	999		|O
study	1000	1005		|O
showed	1006	1012		|O
that	1013	1017		|O
adapalene	1018	1027		|O
/	1027	1028		|O
BPO	1028	1031		|O
as	1032	1034		|O
a	1035	1036		|O
fixed	1037	1042		|O
-	1042	1043		|O
dose	1043	1047		|O
combination	1048	1059		|O
is	1060	1062		|O
as	1063	1065		|O
well	1066	1070		|O
tolerated	1071	1080		|O
as	1081	1083		|O
BPO	1084	1087		|O
2.5%	1088	1092		|O
gel	1093	1096		|O
alone	1097	1102		|O
or	1103	1105		|O
adapalene	1106	1115		|O
0.1%	1116	1120		|O
gel	1121	1124		|O
alone	1125	1130		|O
in	1131	1133		|O
terms	1134	1139		|O
of	1140	1142		|O
cumulative	1143	1153		|O
irritancy	1154	1163		|O
.	1163	1164		|O
*	1164	1165		|O
Epiduo	1165	1171		|O
,	1171	1172		|O
Galderma	1173	1181		|O
S	1182	1183		|O
.	1183	1184		|O
A	1184	1185		|O
.	1185	1186		|O

### 18602129
Gene	0	4		|O
expression	5	15		|O
profiles	16	24		|O
in	25	27		|O
the	28	31		|O
cerebellum	32	42		|O
and	43	46		|O
hippocampus	47	58		|O
following	59	68		|O
exposure	69	77		|O
to	78	80		|O
a	81	82		|O
neurotoxicant	83	96		|O
,	96	97		|O
Aroclor	98	105		|O
1254	106	110		|O
:	110	111		|O
developmental	112	125		|O
effects	126	133		|O
.	133	134		|O
The	136	139		|O
developmental	140	153		|O
consequences	154	166		|O
of	167	169		|O
exposure	170	178		|O
to	179	181		|O
the	182	185		|O
polychlorinated	186	201		|O
biphenyls	202	211		|O
(	212	213		|O
PCBs	213	217		|O
)	217	218		|O
have	219	223		|O
been	224	228		|O
widely	229	235		|O
studied	236	243		|O
,	243	244		|O
making	245	251		|O
PCBs	252	256		|O
a	257	258		|O
unique	259	265		|O
model	266	271		|O
to	272	274		|O
understand	275	285		|O
issues	286	292		|O
related	293	300		|O
to	301	303		|O
environmental	304	317		|O
mixture	318	325		|O
of	326	328		|O
persistent	329	339		|O
chemicals	340	349		|O
.	349	350		|O
PCB	351	354		|O
exposure	355	363		|O
in	364	366		|O
humans	367	373		|O
adversely	374	383		|O
affects	384	391		|O
neurocognitive	392	406		|O
development	407	418		|O
,	418	419		|O
causes	420	426		|O
psychomotor	427	438		|O
difficulties	439	451		|O
,	451	452		|O
and	453	456		|O
contributes	457	468		|O
to	469	471		|O
attention	472	481		|O
deficits	482	490		|O
in	491	493		|O
children	494	502		|O
,	502	503		|O
all	504	507		|O
of	508	510		|O
which	511	516		|O
seem	517	521		|O
to	522	524		|O
be	525	527		|O
associated	528	538		|O
with	539	543		|O
altered	544	551		|O
patterns	552	560		|O
of	561	563		|O
neuronal	564	572		|O
connectivity	573	585		|O
.	585	586		|O
In	587	589		|O
the	590	593		|O
present	594	601		|O
study	602	607		|O
,	607	608		|O
we	609	611		|O
examined	612	620		|O
gene	621	625		|O
expression	626	636		|O
profiles	637	645		|O
in	646	648		|O
the	649	652		|O
rat	653	656		|O
nervous	657	664		|O
system	665	671		|O
following	672	681		|O
PCB	682	685		|O
developmental	686	699		|O
exposure	700	708		|O
.	708	709		|O
Pregnant	710	718		|O
rats	719	723		|O
(	724	725		|O
Long	725	729		|O
-	729	730		|O
Evans	730	735		|O
)	735	736		|O
were	737	741		|O
dosed	742	747		|O
perinatally	748	759		|O
with	760	764		|O
0	765	766		|O
or	767	769		|O
6	770	771		|O
mg	772	774		|O
/	774	775		|O
kg	775	777		|O
/	777	778		|O
day	778	781		|O
of	782	784		|O
Aroclor	785	792		|O
1254	793	797		|O
from	798	802		|O
gestation	803	812		|O
day	813	816		|O
6	817	818		|O
through	819	826		|O
postnatal	827	836		|O
day	837	840		|O
(	841	842		|O
PND	842	845		|O
)	845	846		|O
21	847	849		|O
.	849	850		|O
Gene	851	855		|O
expression	856	866		|O
in	867	869		|O
cerebellum	870	880		|O
and	881	884		|O
hippocampus	885	896		|O
from	897	901		|O
PND7	902	906		|O
and	907	910		|O
PND14	911	916		|O
animals	917	924		|O
was	925	928		|O
analyzed	929	937		|O
with	938	942		|O
an	943	945		|O
emphasis	946	954		|O
on	955	957		|O
developmental	958	971		|O
aspects	972	979		|O
.	979	980		|O
Changes	981	988		|O
in	989	991		|O
gene	992	996		|O
expression	997	1007		|O
(	1008	1009		|O
>	1009	1010		|O
or	1011	1013		|O
=	1014	1015		|O
1.5	1015	1018		|O
fold	1019	1023		|O
)	1023	1024		|O
in	1025	1027		|O
control	1028	1035		|O
animals	1036	1043		|O
identified	1044	1054		|O
normal	1055	1061		|O
developmental	1062	1075		|O
changes	1076	1083		|O
.	1083	1084		|O
These	1085	1090		|O
basal	1091	1096		|O
levels	1097	1103		|O
of	1104	1106		|O
expression	1107	1117		|O
were	1118	1122		|O
compared	1123	1131		|O
to	1132	1134		|O
data	1135	1139		|O
from	1140	1144		|O
Aroclor	1145	1152		|O
1254	1153	1157		|O
-	1157	1158		|O
treated	1158	1165		|O
animals	1166	1173		|O
to	1174	1176		|O
determine	1177	1186		|O
the	1187	1190		|O
impact	1191	1197		|O
of	1198	1200		|O
gestational	1201	1212		|O
PCB	1213	1216		|O
exposure	1217	1225		|O
on	1226	1228		|O
developmental	1229	1242		|O
parameters	1243	1253		|O
.	1253	1254		|O
The	1255	1258		|O
results	1259	1266		|O
indicate	1267	1275		|O
that	1276	1280		|O
the	1281	1284		|O
expression	1285	1295		|O
of	1296	1298		|O
a	1299	1300		|O
number	1301	1307		|O
of	1308	1310		|O
developmental	1311	1324		|O
genes	1325	1330		|O
related	1331	1338		|O
to	1339	1341		|O
cell	1342	1346		|O
cycle	1347	1352		|O
,	1352	1353		|O
synaptic	1354	1362		|O
function	1363	1371		|O
,	1371	1372		|O
cell	1373	1377		|O
maintenance	1378	1389		|O
,	1389	1390		|O
and	1391	1394		|O
neurogenesis	1395	1407		|O
is	1408	1410		|O
significantly	1411	1424		|O
altered	1425	1432		|O
from	1433	1437		|O
PND7	1438	1442		|O
to	1443	1445		|O
PND14	1446	1451		|O
.	1451	1452		|O
Aroclor	1453	1460		|O
1254	1461	1465		|O
treatment	1466	1475		|O
appears	1476	1483		|O
to	1484	1486		|O
dampen	1487	1493		|O
the	1494	1497		|O
overall	1498	1505		|O
growth	1506	1512		|O
-	1512	1513		|O
related	1513	1520		|O
gene	1521	1525		|O
expression	1526	1536		|O
levels	1537	1543		|O
in	1544	1546		|O
both	1547	1551		|O
regions	1552	1559		|O
with	1560	1564		|O
the	1565	1568		|O
effect	1569	1575		|O
being	1576	1581		|O
more	1582	1586		|O
pronounced	1587	1597		|O
in	1598	1600		|O
the	1601	1604		|O
cerebellum	1605	1615		|O
.	1615	1616		|O
Functional	1617	1627		|O
analysis	1628	1636		|O
suggests	1637	1645		|O
that	1646	1650		|O
Aroclor	1651	1658		|O
1254	1659	1663		|O
delays	1664	1670		|O
maturation	1671	1681		|O
of	1682	1684		|O
the	1685	1688		|O
developing	1689	1699		|O
nervous	1700	1707		|O
system	1708	1714		|O
,	1714	1715		|O
with	1716	1720		|O
the	1721	1724		|O
consequences	1725	1737		|O
dependent	1738	1747		|O
on	1748	1750		|O
the	1751	1754		|O
ontological	1755	1766		|O
state	1767	1772		|O
of	1773	1775		|O
the	1776	1779		|O
brain	1780	1785		|O
area	1786	1790		|O
and	1791	1794		|O
the	1795	1798		|O
functional	1799	1809		|O
role	1810	1814		|O
of	1815	1817		|O
the	1818	1821		|O
individual	1822	1832		|O
gene	1833	1837		|O
.	1837	1838		|O
Such	1839	1843		|O
changes	1844	1851		|O
may	1852	1855		|O
underlie	1856	1864		|O
learning	1865	1873		|O
and	1874	1877		|O
memory	1878	1884		|O
deficits	1885	1893		|O
observed	1894	1902		|O
in	1903	1905		|O
PCB	1906	1909		|O
exposed	1910	1917		|O
animals	1918	1925		|O
and	1926	1929		|O
humans	1930	1936		|O
.	1936	1937		|O

### 18666210
Cognitive	0	9		|O
effects	10	17		|O
of	18	20		|O
hormone	21	28		|O
therapy	29	36		|O
in	37	39		|O
men	40	43		|O
with	44	48		|O
prostate	49	57	prostate cancer	|B-DISEASE
cancer	58	64		|I-DISEASE
:	64	65		|O
a	66	67		|O
review	68	74		|O
.	74	75		|O
BACKGROUND	77	87		|O
:	87	88		|O
Men	89	92		|O
who	93	96		|O
receive	97	104		|O
androgen	105	113		|O
-	113	114		|O
deprivation	114	125		|O
therapy	126	133		|O
(	134	135		|O
ADT	135	138		|O
)	138	139		|O
for	140	143		|O
prostate	144	152	prostate cancer	|B-DISEASE
cancer	153	159		|I-DISEASE
experience	160	170		|O
several	171	178		|O
side	179	183		|O
effects	184	191		|O
from	192	196		|O
this	197	201		|O
treatment	202	211		|O
.	211	212		|O
A	213	214		|O
few	215	218		|O
recent	219	225		|O
studies	226	233		|O
have	234	238		|O
examined	239	247		|O
the	248	251		|O
cognitive	252	261		|O
implications	262	274		|O
of	275	277		|O
ADT	278	281		|O
and	282	285		|O
how	286	289		|O
they	290	294		|O
impact	295	301		|O
a	302	303		|O
patient	304	311		|O
's	311	313		|O
treatment	314	323		|O
decision	324	332		|O
-	332	333		|O
making	333	339		|O
,	339	340		|O
occupational	341	353		|O
pursuits	354	362		|O
,	362	363		|O
and	364	367		|O
quality	368	375		|O
of	376	378		|O
life	379	383		|O
.	383	384		|O
For	385	388		|O
this	389	393		|O
report	394	400		|O
,	400	401		|O
the	402	405		|O
authors	406	413		|O
explored	414	422		|O
possible	423	431		|O
mechanisms	432	442		|O
for	443	446		|O
this	447	451		|O
association	452	463		|O
,	463	464		|O
reviewed	465	473		|O
research	474	482		|O
in	483	485		|O
animal	486	492		|O
studies	493	500		|O
and	501	504		|O
aging	505	510		|O
men	511	514		|O
,	514	515		|O
and	516	519		|O
examined	520	528		|O
the	529	532		|O
growing	533	540		|O
literature	541	551		|O
focused	552	559		|O
on	560	562		|O
the	563	566		|O
relation	567	575		|O
between	576	583		|O
ADT	584	587		|O
and	588	591		|O
cognitive	592	601		|O
functioning	602	613		|O
in	614	616		|O
patients	617	625		|O
with	626	630		|O
prostate	631	639	prostate cancer	|B-DISEASE
cancer	640	646		|I-DISEASE
.	646	647		|O
METHODS	648	655		|O
:	655	656		|O
A	657	658		|O
systematic	659	669		|O
literature	670	680		|O
search	681	687		|O
was	688	691		|O
conducted	692	701		|O
using	702	707		|O
the	708	711		|O
PubMed	712	718		|O
and	719	722		|O
Information	723	734		|O
Sciences	735	743		|O
Institute	744	753		|O
Web	754	757		|O
of	758	760		|O
Knowledge	761	770		|O
-	770	771		|O
Web	771	774		|O
of	775	777		|O
Science	778	785		|O
databases	786	795		|O
to	796	798		|O
identify	799	807		|O
relevant	808	816		|O
studies	817	824		|O
that	825	829		|O
investigated	830	842		|O
the	843	846		|O
relation	847	855		|O
between	856	863		|O
ADT	864	867		|O
in	868	870		|O
men	871	874		|O
with	875	879		|O
prostate	880	888	prostate cancer	|B-DISEASE
cancer	889	895		|I-DISEASE
and	896	899		|O
its	900	903		|O
cognitive	904	913		|O
effects	914	921		|O
.	921	922		|O
RESULTS	923	930		|O
:	930	931		|O
Testosterone	932	944		|O
and	945	948		|O
its	949	952		|O
derivatives	953	964		|O
may	965	968		|O
have	969	973		|O
an	974	976		|O
impact	977	983		|O
on	984	986		|O
cognition	987	996		|O
through	997	1004		|O
several	1005	1012		|O
mechanisms	1013	1023		|O
in	1024	1026		|O
the	1027	1030		|O
brain	1031	1036		|O
,	1036	1037		|O
as	1038	1040		|O
supported	1041	1050		|O
by	1051	1053		|O
studies	1054	1061		|O
of	1062	1064		|O
animals	1065	1072		|O
and	1073	1076		|O
in	1077	1079		|O
aging	1080	1085		|O
men	1086	1089		|O
.	1089	1090		|O
Studies	1091	1098		|O
that	1099	1103		|O
researched	1104	1114		|O
the	1115	1118		|O
impact	1119	1125		|O
of	1126	1128		|O
ADT	1129	1132		|O
on	1133	1135		|O
cognition	1136	1145		|O
in	1146	1148		|O
patients	1149	1157		|O
with	1158	1162		|O
prostate	1163	1171	prostate cancer	|B-DISEASE
cancer	1172	1178		|I-DISEASE
patients	1179	1187		|O
were	1188	1192		|O
designed	1193	1201		|O
relatively	1202	1212		|O
well	1213	1217		|O
but	1218	1221		|O
suffered	1222	1230		|O
from	1231	1235		|O
small	1236	1241		|O
sample	1242	1248		|O
sizes	1249	1254		|O
.	1254	1255		|O
Between	1256	1263		|O
47%	1264	1267		|O
and	1268	1271		|O
69%	1272	1275		|O
of	1276	1278		|O
men	1279	1282		|O
on	1283	1285		|O
ADT	1286	1289		|O
declined	1290	1298		|O
in	1299	1301		|O
at	1302	1304		|O
least	1305	1310		|O
1	1311	1312		|O
cognitive	1313	1322		|O
area	1323	1327		|O
,	1327	1328		|O
most	1329	1333		|O
commonly	1334	1342		|O
in	1343	1345		|O
visuospatial	1346	1358		|O
abilities	1359	1368		|O
and	1369	1372		|O
executive	1373	1382		|O
functioning	1383	1394		|O
.	1394	1395		|O
Some	1396	1400		|O
studies	1401	1408		|O
reported	1409	1417		|O
contradictory	1418	1431		|O
results	1432	1439		|O
with	1440	1444		|O
increased	1445	1454		|O
functioning	1455	1466		|O
in	1467	1469		|O
verbal	1470	1476		|O
memory	1477	1483		|O
.	1483	1484		|O
CONCLUSIONS	1485	1496		|O
:	1496	1497		|O
There	1498	1503		|O
is	1504	1506		|O
a	1507	1508		|O
strong	1509	1515		|O
argument	1516	1524		|O
that	1525	1529		|O
androgen	1530	1538		|O
-	1538	1539		|O
ablation	1539	1547		|O
therapy	1548	1555		|O
is	1556	1558		|O
linked	1559	1565		|O
to	1566	1568		|O
subtle	1569	1575		|O
but	1576	1579		|O
significant	1580	1591		|O
cognitive	1592	1601		|O
declines	1602	1610		|O
in	1611	1613		|O
men	1614	1617		|O
with	1618	1622		|O
prostate	1623	1631	prostate cancer	|B-DISEASE
cancer	1632	1638		|I-DISEASE
.	1638	1639		|O
The	1640	1643		|O
authors	1644	1651		|O
believe	1652	1659		|O
that	1660	1664		|O
clinicians	1665	1675		|O
should	1676	1682		|O
become	1683	1689		|O
aware	1690	1695		|O
of	1696	1698		|O
this	1699	1703		|O
correlation	1704	1715		|O
as	1716	1718		|O
the	1719	1722		|O
use	1723	1726		|O
of	1727	1729		|O
ADT	1730	1733		|O
increases	1734	1743		|O
and	1744	1747		|O
should	1748	1754		|O
inform	1755	1761		|O
and	1762	1765		|O
monitor	1766	1773		|O
patients	1774	1782		|O
for	1783	1786		|O
this	1787	1791		|O
possible	1792	1800		|O
side	1801	1805		|O
effect	1806	1812		|O
of	1813	1815		|O
treatment	1816	1825		|O
.	1825	1826		|O

### 18751444
Paclitaxel	0	10		|O
and	11	14		|O
pegylated	15	24		|O
liposomal	25	34		|O
doxorubicin	35	46		|O
in	47	49		|O
recurrent	50	59	recurrent head and neck cancer	|B-DISEASE
head	60	64		|I-DISEASE
and	65	68		|I-DISEASE
neck	69	73		|I-DISEASE
cancer	74	80		|I-DISEASE
:	80	81		|O
clinical	82	90		|O
and	91	94		|O
unexpected	95	105		|O
pharmacokinetic	106	121		|O
interactions	122	134		|O
.	134	135		|O
BACKGROUND	137	147		|O
:	147	148		|O
The	149	152		|O
combination	153	164		|O
of	165	167		|O
paclitaxel	168	178		|O
(	179	180		|O
PTX	180	183		|O
)	183	184		|O
with	185	189		|O
pegylated	190	199		|O
liposomal	200	209		|O
doxorubicin	210	221		|O
(	222	223		|O
PLD	223	226		|O
)	226	227		|O
is	228	230		|O
an	231	233		|O
interesting	234	245		|O
treatment	246	255		|O
for	256	259		|O
recurrent	260	269	recurrent head and neck cancer	|B-DISEASE
head	270	274		|I-DISEASE
and	275	278		|I-DISEASE
neck	279	283		|I-DISEASE
cancer	284	290		|I-DISEASE
.	290	291		|O
The	292	295		|O
pharmacokinetic	296	311		|O
behavior	312	320		|O
may	321	324		|O
depend	325	331		|O
on	332	334		|O
the	335	338		|O
interval	339	347		|O
between	348	355		|O
the	356	359		|O
intravenous	360	371		|O
administration	372	386		|O
of	387	389		|O
the	390	393		|O
two	394	397		|O
drugs	398	403		|O
.	403	404		|O
This	405	409		|O
study	410	415		|O
evaluates	416	425		|O
the	426	429		|O
clinical	430	438		|O
efficacy	439	447		|O
,	447	448		|O
toxicity	449	457		|O
and	458	461		|O
any	462	465		|O
possible	466	474		|O
interval	475	483		|O
-	483	484		|O
dependent	484	493		|O
pharmacokinetic	494	509		|O
interactions	510	522		|O
.	522	523		|O
PATIENTS	524	532		|O
AND	533	536		|O
METHODS	537	544		|O
:	544	545		|O
Thirty	546	552		|O
patients	553	561		|O
were	562	566		|O
randomized	567	577		|O
to	578	580		|O
receive	581	588		|O
80	589	591		|O
mg	592	594		|O
/	594	595		|O
m2	595	597		|O
PTX	598	601		|O
weekly	602	608		|O
and	609	612		|O
12.5	613	617		|O
mg	618	620		|O
/	620	621		|O
m2	621	623		|O
PLD	624	627		|O
every	628	633		|O
two	634	637		|O
weeks	638	643		|O
at	644	646		|O
administration	647	661		|O
intervals	662	671		|O
of	672	674		|O
0	675	676		|O
,	676	677		|O
1	678	679		|O
,	679	680		|O
3	681	682		|O
,	682	683		|O
12	684	686		|O
or	687	689		|O
24	690	692		|O
hours	693	698		|O
.	698	699		|O
Blood	700	705		|O
sampling	706	714		|O
was	715	718		|O
performed	719	728		|O
at	729	731		|O
day	732	735		|O
1	736	737		|O
and	738	741		|O
15	742	744		|O
and	745	748		|O
pharmacokinetics	749	765		|O
of	766	768		|O
PTX	769	772		|O
,	772	773		|O
PLD	774	777		|O
and	778	781		|O
Cremophor	782	791		|O
EL	792	794		|O
were	795	799		|O
evaluated	800	809		|O
by	810	812		|O
non	813	816		|O
-	816	817		|O
compartmental	817	830		|O
analysis	831	839		|O
.	839	840		|O
RESULTS	841	848		|O
:	848	849		|O
Neutropenia	850	861	Neutropenia	|B-ADVERSE
was	862	865		|O
the	866	869		|O
most	870	874		|O
frequent	875	883		|O
side	884	888		|O
-	888	889		|O
effect	889	895		|O
(	896	897		|O
100%	897	901		|O
of	902	904		|O
patients	905	913		|O
;	913	914		|O
30%	915	918		|O
grade	919	924		|O
3-4	925	928		|O
)	928	929		|O
.	929	930		|O
Hand	931	935	Hand-foot syndrome	|B-ADVERSE
-	935	936		|I-ADVERSE
foot	936	940		|I-ADVERSE
syndrome	941	949		|I-ADVERSE
was	950	953		|O
severe	954	960		|O
in	961	963		|O
only	964	968		|O
3%	969	971		|O
of	972	974		|O
patients	975	983		|O
.	983	984		|O
Overall	985	992		|O
response	993	1001		|O
rate	1002	1006		|O
was	1007	1010		|O
30%	1011	1014		|O
,	1014	1015		|O
with	1016	1020		|O
3%	1021	1023		|O
complete	1024	1032		|O
responses	1033	1042		|O
and	1043	1046		|O
27%	1047	1050		|O
partial	1051	1058		|O
responses	1059	1068		|O
.	1068	1069		|O
Stable	1070	1076		|O
disease	1077	1084		|O
and	1085	1088		|O
progression	1089	1100		|O
were	1101	1105		|O
43%	1106	1109		|O
and	1110	1113		|O
27%	1114	1117		|O
,	1117	1118		|O
respectively	1119	1131		|O
.	1131	1132		|O
Median	1133	1139		|O
response	1140	1148		|O
duration	1149	1157		|O
and	1158	1161		|O
overall	1162	1169		|O
median	1170	1176		|O
survival	1177	1185		|O
were	1186	1190		|O
5.5	1191	1194		|O
and	1195	1198		|O
10	1199	1201		|O
months	1202	1208		|O
respectively	1209	1221		|O
.	1221	1222		|O
Co	1223	1225		|O
-	1225	1226		|O
administration	1226	1240		|O
of	1241	1243		|O
PLD	1244	1247		|O
markedly	1248	1256		|O
reduced	1257	1264		|O
Cmax	1265	1269		|O
and	1270	1273		|O
the	1274	1277		|O
area	1278	1282		|O
under	1283	1288		|O
the	1289	1292		|O
curve	1293	1298		|O
(	1299	1300		|O
AUC	1300	1303		|O
)	1303	1304		|O
,	1304	1305		|O
and	1306	1309		|O
increased	1310	1319		|O
PTX	1320	1323		|O
clearance	1324	1333		|O
.	1333	1334		|O
The	1335	1338		|O
differences	1339	1350		|O
in	1351	1353		|O
the	1354	1357		|O
PTX	1358	1361		|O
AUC	1362	1365		|O
and	1366	1369		|O
clearance	1370	1379		|O
between	1380	1387		|O
the	1388	1391		|O
0	1392	1393		|O
h	1394	1395		|O
and	1396	1399		|O
the	1400	1403		|O
24	1404	1406		|O
h	1407	1408		|O
experimental	1409	1421		|O
arms	1422	1426		|O
were	1427	1431		|O
statistically	1432	1445		|O
significant	1446	1457		|O
.	1457	1458		|O
CONCLUSION	1459	1469		|O
:	1469	1470		|O
The	1471	1474		|O
PTX	1475	1478		|O
/	1478	1479		|O
PLD	1479	1482		|O
combination	1483	1494		|O
plays	1495	1500		|O
a	1501	1502		|O
palliative	1503	1513		|O
role	1514	1518		|O
(	1519	1520		|O
clinical	1520	1528		|O
benefit	1529	1536		|O
in	1537	1539		|O
73%	1540	1543		|O
of	1544	1546		|O
patients	1547	1555		|O
)	1555	1556		|O
and	1557	1560		|O
has	1561	1564		|O
good	1565	1569		|O
tolerability	1570	1582		|O
.	1582	1583		|O
The	1584	1587		|O
PTX	1588	1591		|O
pharmacokinetic	1592	1607		|O
profile	1608	1615		|O
was	1616	1619		|O
unexpectedly	1620	1632		|O
affected	1633	1641		|O
by	1642	1644		|O
different	1645	1654		|O
administration	1655	1669		|O
time	1670	1674		|O
intervals	1675	1684		|O
;	1684	1685		|O
in	1686	1688		|O
the	1689	1692		|O
0	1693	1694		|O
h	1695	1696		|O
arm	1697	1700		|O
the	1701	1704		|O
AUC	1705	1708		|O
was	1709	1712		|O
reduced	1713	1720		|O
to	1721	1723		|O
one	1724	1727		|O
fourth	1728	1734		|O
,	1734	1735		|O
therefore	1736	1745		|O
a	1746	1747		|O
schedule	1748	1756		|O
with	1757	1761		|O
PTX	1762	1765		|O
on	1766	1768		|O
day	1769	1772		|O
one	1773	1776		|O
,	1776	1777		|O
PLD	1778	1781		|O
on	1782	1784		|O
day	1785	1788		|O
two	1789	1792		|O
may	1793	1796		|O
be	1797	1799		|O
preferred	1800	1809		|O
.	1809	1810		|O

### 18607570
Denbinobin	0	10		|O
induces	11	18		|O
apoptosis	19	28		|O
by	29	31		|O
apoptosis	32	41		|O
-	41	42		|O
inducing	42	50		|O
factor	51	57		|O
releasing	58	67		|O
and	68	71		|O
DNA	72	75		|O
damage	76	82		|O
in	83	85		|O
human	86	91		|O
colorectal	92	102		|O
cancer	103	109		|O
HCT	110	113		|O
-	113	114		|O
116	114	117		|O
cells	118	123		|O
.	123	124		|O
Denbinobin	126	136		|O
is	137	139		|O
a	140	141		|O
phenanthraquinone	142	159		|O
derivative	160	170		|O
present	171	178		|O
in	179	181		|O
the	182	185		|O
stems	186	191		|O
of	192	194		|O
Ephemerantha	195	207		|O
lonchophylla	208	220		|O
.	220	221		|O
We	222	224		|O
showed	225	231		|O
that	232	236		|O
denbinobin	237	247		|O
induces	248	255		|O
apoptosis	256	265		|O
in	266	268		|O
human	269	274		|O
colorectal	275	285		|O
cancer	286	292		|O
cells	293	298		|O
(	299	300		|O
HCT	300	303		|O
-	303	304		|O
116	304	307		|O
)	307	308		|O
in	309	311		|O
a	312	313		|O
concentration	314	327		|O
-	327	328		|O
dependent	328	337		|O
manner	338	344		|O
.	344	345		|O
The	346	349		|O
addition	350	358		|O
of	359	361		|O
a	362	363		|O
pan	364	367		|O
-	367	368		|O
caspase	368	375		|O
inhibitor	376	385		|O
(	386	387		|O
zVAD	387	391		|O
-	391	392		|O
fmk	392	395		|O
)	395	396		|O
did	397	400		|O
not	401	404		|O
suppress	405	413		|O
the	414	417		|O
denbinobin	418	428		|O
-	428	429		|O
induced	429	436		|O
apoptotic	437	446		|O
effect	447	453		|O
,	453	454		|O
and	455	458		|O
denbinobin	459	469		|O
-	469	470		|O
induced	470	477		|O
apoptosis	478	487		|O
was	488	491		|O
not	492	495		|O
accompanied	496	507		|O
by	508	510		|O
processing	511	521		|O
of	522	524		|O
procaspase	525	535		|O
-	535	536		|O
3	536	537		|O
,	537	538		|O
-	539	540		|O
6	540	541		|O
,	541	542		|O
-	543	544		|O
7	544	545		|O
,	545	546		|O
-	547	548		|O
9	548	549		|O
,	549	550		|O
and	551	554		|O
-	555	556		|O
8	556	557		|O
.	557	558		|O
However	559	566		|O
,	566	567		|O
denbinobin	568	578		|O
triggered	579	588		|O
the	589	592		|O
translocation	593	606		|O
of	607	609		|O
the	610	613		|O
apoptosis	614	623		|O
-	623	624		|O
inducing	624	632		|O
factor	633	639		|O
(	640	641		|O
AIF	641	644		|O
)	644	645		|O
from	646	650		|O
the	651	654		|O
mitochondria	655	667		|O
into	668	672		|O
the	673	676		|O
nucleus	677	684		|O
.	684	685		|O
Small	686	691		|O
interfering	692	703		|O
RNA	704	707		|O
targeting	708	717		|O
of	718	720		|O
AIF	721	724		|O
effectively	725	736		|O
protected	737	746		|O
HCT	747	750		|O
-	750	751		|O
116	751	754		|O
cells	755	760		|O
against	761	768		|O
denbinobin	769	779		|O
-	779	780		|O
induced	780	787		|O
apoptosis	788	797		|O
.	797	798		|O
Denbinobin	799	809		|O
treatment	810	819		|O
also	820	824		|O
caused	825	831		|O
DNA	832	835		|O
damage	836	842		|O
,	842	843		|O
activation	844	854		|O
of	855	857		|O
the	858	861		|O
p53	862	865		|O
tumor	866	871		|O
suppressor	872	882		|O
gene	883	887		|O
,	887	888		|O
and	889	892		|O
upregulation	893	905		|O
of	906	908		|O
numerous	909	917		|O
downstream	918	928		|O
effectors	929	938		|O
(	939	940		|O
p21WAF1	940	947		|O
/	947	948		|O
CIP1	948	952		|O
,	952	953		|O
Bax	954	957		|O
,	957	958		|O
PUMA	959	963		|O
,	963	964		|O
and	965	968		|O
NOXA	969	973		|O
)	973	974		|O
.	974	975		|O
A	976	977		|O
HCT	978	981		|O
-	981	982		|O
116	982	985		|O
xenograft	986	995		|O
model	996	1001		|O
demonstrated	1002	1014		|O
the	1015	1018		|O
in	1019	1021		|O
vivo	1022	1026		|O
efficacy	1027	1035		|O
and	1036	1039		|O
low	1040	1043		|O
toxicity	1044	1052		|O
of	1053	1055		|O
denbinobin	1056	1066		|O
.	1066	1067		|O
Taken	1068	1073		|O
together	1074	1082		|O
,	1082	1083		|O
our	1084	1087		|O
findings	1088	1096		|O
suggest	1097	1104		|O
that	1105	1109		|O
denbinobin	1110	1120		|O
induces	1121	1128		|O
apoptosis	1129	1138		|O
of	1139	1141		|O
human	1142	1147		|O
colorectal	1148	1158		|O
cancer	1159	1165		|O
HCT	1166	1169		|O
-	1169	1170		|O
116	1170	1173		|O
cells	1174	1179		|O
via	1180	1183		|O
DNA	1184	1187		|O
damage	1188	1194		|O
and	1195	1198		|O
an	1199	1201		|O
AIF	1202	1205		|O
-	1205	1206		|O
mediated	1206	1214		|O
pathway	1215	1222		|O
.	1222	1223		|O
These	1224	1229		|O
results	1230	1237		|O
indicate	1238	1246		|O
that	1247	1251		|O
denbinobin	1252	1262		|O
has	1263	1266		|O
potential	1267	1276		|O
as	1277	1279		|O
a	1280	1281		|O
novel	1282	1287		|O
anticancer	1288	1298		|O
agent	1299	1304		|O
.	1304	1305		|O

### 18542079
Effect	0	6		|O
of	7	9		|O
treatment	10	19		|O
with	20	24		|O
epoetin	25	32		|O
-	32	33		|O
beta	33	37		|O
on	38	40		|O
survival	41	49		|O
,	49	50		|O
tumour	51	57	tumour progression	|B-DISEASE
progression	58	69		|I-DISEASE
and	70	73		|O
thromboembolic	74	88	thromboembolic events	|B-DISEASE
events	89	95		|I-DISEASE
in	96	98		|O
patients	99	107		|O
with	108	112		|O
cancer	113	119	cancer	|B-DISEASE
:	119	120		|O
an	121	123		|O
updated	124	131		|O
meta	132	136		|O
-	136	137		|O
analysis	137	145		|O
of	146	148		|O
12	149	151		|O
randomised	152	162		|O
controlled	163	173		|O
studies	174	181		|O
including	182	191		|O
2301	192	196		|O
patients	197	205		|O
.	205	206		|O
Epoetin	208	215		|O
-	215	216		|O
beta	216	220		|O
is	221	223		|O
used	224	228		|O
to	229	231		|O
treat	232	237		|O
patients	238	246		|O
with	247	251		|O
metastatic	252	262	metastatic cancer	|B-DISEASE
cancer	263	269		|I-DISEASE
undergoing	270	280		|O
chemotherapy	281	293		|O
to	294	296		|O
alleviate	297	306		|O
the	307	310		|O
symptoms	311	319		|O
of	320	322		|O
anaemia	323	330	anaemia	|B-DISEASE
,	330	331		|O
reduce	332	338		|O
the	339	342		|O
risk	343	347		|O
of	348	350		|O
blood	351	356		|O
transfusions	357	369		|O
and	370	373		|O
improve	374	381		|O
quality	382	389		|O
of	390	392		|O
life	393	397		|O
.	397	398		|O
This	399	403		|O
meta	404	408		|O
-	408	409		|O
analysis	409	417		|O
of	418	420		|O
12	421	423		|O
randomised	424	434		|O
,	434	435		|O
controlled	436	446		|O
studies	447	454		|O
evaluated	455	464		|O
the	465	468		|O
impact	469	475		|O
of	476	478		|O
epoetin	479	486		|O
-	486	487		|O
beta	487	491		|O
on	492	494		|O
overall	495	502		|O
survival	503	511		|O
,	511	512		|O
tumour	513	519	tumour progression	|B-DISEASE
progression	520	531		|I-DISEASE
and	532	535		|O
thromboembolic	536	550	thromboembolic events	|B-DISEASE
events	551	557		|I-DISEASE
(	558	559		|O
TEEs	559	563	TEEs	|B-DISEASE
)	563	564		|O
.	564	565		|O
A	566	567		|O
total	568	573		|O
of	574	576		|O
2297	577	581		|O
patients	582	590		|O
were	591	595		|O
included	596	604		|O
in	605	607		|O
the	608	611		|O
analysis	612	620		|O
(	621	622		|O
epoetin	622	629		|O
-	629	630		|O
beta	630	634		|O
,	634	635		|O
n	636	637		|O
=	637	638		|O
1244	638	642		|O
;	642	643		|O
control	644	651		|O
,	651	652		|O
n	653	654		|O
=	654	655		|O
1053	655	659		|O
;	659	660		|O
65%	661	664		|O
solid	665	670		|O
and	671	674		|O
35%	675	678		|O
nonmyeloid	679	689	nonmyeloid haematological malignancies	|B-DISEASE
haematological	690	704		|I-DISEASE
malignancies	705	717		|I-DISEASE
)	717	718		|O
.	718	719		|O
A	720	721		|O
prespecified	722	734		|O
subgroup	735	743		|O
analysis	744	752		|O
assessed	753	761		|O
the	762	765		|O
effects	766	773		|O
in	774	776		|O
patients	777	785		|O
with	786	790		|O
a	791	792		|O
baseline	793	801		|O
Hb	802	804		|O
<	804	805		|O
or	805	807		|O
=	807	808		|O
11	808	810		|O
g	811	812		|O
dl	813	815		|O
(	815	816		|O
-	816	817		|O
1	817	818		|O
)	818	819		|O
,	819	820		|O
corresponding	821	834		|O
to	835	837		|O
current	838	845		|O
European	846	854		|O
Organisation	855	867		|O
for	868	871		|O
Research	872	880		|O
and	881	884		|O
Treatment	885	894		|O
of	895	897		|O
Cancer	898	904	Cancer	|B-DISEASE
(	905	906		|O
EORTC	906	911		|O
)	911	912		|O
guidelines	913	923		|O
.	923	924		|O
No	925	927		|O
statistically	928	941		|O
significant	942	953		|O
effect	954	960		|O
on	961	963		|O
mortality	964	973		|O
was	974	977		|O
observed	978	986		|O
with	987	991		|O
epoetin	992	999		|O
-	999	1000		|O
beta	1000	1004		|O
vs	1005	1007		|O
control	1008	1015		|O
,	1015	1016		|O
both	1017	1021		|O
overall	1022	1029		|O
(	1030	1031		|O
hazard	1031	1037		|O
ratio	1038	1043		|O
(	1044	1045		|O
HR	1045	1047		|O
)	1047	1048		|O
=	1048	1049		|O
1.13	1049	1053		|O
;	1053	1054		|O
95%	1055	1058		|O
CI	1059	1061		|O
:	1061	1062		|O
0.87	1063	1067		|O
,	1067	1068		|O
1.46	1069	1073		|O
;	1073	1074		|O
P	1075	1076		|O
=	1076	1077		|O
0.355	1077	1082		|O
)	1082	1083		|O
and	1084	1087		|O
in	1088	1090		|O
patients	1091	1099		|O
with	1100	1104		|O
baseline	1105	1113		|O
Hb	1114	1116		|O
<	1116	1117		|O
or	1117	1119		|O
=	1119	1120		|O
11	1120	1122		|O
g	1123	1124		|O
dl	1125	1127		|O
(	1127	1128		|O
-	1128	1129		|O
1	1129	1130		|O
)	1130	1131		|O
(	1132	1133		|O
HR	1133	1135		|O
=	1135	1136		|O
1.09	1136	1140		|O
;	1140	1141		|O
95%	1142	1145		|O
CI	1146	1148		|O
:	1148	1149		|O
0.80	1150	1154		|O
,	1154	1155		|O
1.47	1156	1160		|O
;	1160	1161		|O
P	1162	1163		|O
=	1163	1164		|O
0.579	1164	1169		|O
)	1169	1170		|O
.	1170	1171		|O
A	1172	1173		|O
trend	1174	1179		|O
for	1180	1183		|O
a	1184	1185		|O
beneficial	1186	1196		|O
effect	1197	1203		|O
on	1204	1206		|O
tumour	1207	1213	tumour progression	|B-DISEASE
progression	1214	1225		|I-DISEASE
was	1226	1229		|O
seen	1230	1234		|O
overall	1235	1242		|O
(	1243	1244		|O
HR	1244	1246		|O
=	1246	1247		|O
0.85	1247	1251		|O
;	1251	1252		|O
95%	1253	1256		|O
CI	1257	1259		|O
:	1259	1260		|O
0.72	1261	1265		|O
,	1265	1266		|O
1.01	1267	1271		|O
;	1271	1272		|O
P	1273	1274		|O
=	1274	1275		|O
0.072	1275	1280		|O
)	1280	1281		|O
and	1282	1285		|O
in	1286	1288		|O
patients	1289	1297		|O
with	1298	1302		|O
an	1303	1305		|O
Hb	1306	1308		|O
<	1308	1309		|O
or	1309	1311		|O
=	1311	1312		|O
11	1312	1314		|O
g	1315	1316		|O
dl	1317	1319		|O
(	1319	1320		|O
-	1320	1321		|O
1	1321	1322		|O
)	1322	1323		|O
(	1324	1325		|O
HR	1325	1327		|O
=	1327	1328		|O
0.80	1328	1332		|O
;	1332	1333		|O
95%	1334	1337		|O
CI	1338	1340		|O
:	1340	1341		|O
0.65	1342	1346		|O
,	1346	1347		|O
0.99	1348	1352		|O
;	1352	1353		|O
P	1354	1355		|O
=	1355	1356		|O
0.041	1356	1361		|O
)	1361	1362		|O
.	1362	1363		|O
An	1364	1366		|O
increased	1367	1376		|O
frequency	1377	1386		|O
of	1387	1389		|O
TEEs	1390	1394	TEEs	|B-DISEASE
was	1395	1398		|O
seen	1399	1403		|O
with	1404	1408		|O
epoetin	1409	1416		|O
-	1416	1417		|O
beta	1417	1421		|O
vs	1422	1424		|O
control	1425	1432		|O
(	1433	1434		|O
7	1434	1435		|O
vs	1436	1438		|O
4%	1439	1441		|O
of	1442	1444		|O
patients	1445	1453		|O
)	1453	1454		|O
;	1454	1455		|O
however	1456	1463		|O
,	1463	1464		|O
TEEs	1465	1469	TEEs	|B-DISEASE
-	1469	1470		|O
related	1470	1477		|O
mortality	1478	1487		|O
was	1488	1491		|O
similar	1492	1499		|O
in	1500	1502		|O
both	1503	1507		|O
groups	1508	1514		|O
(	1515	1516		|O
1%	1516	1518		|O
each	1519	1523		|O
)	1523	1524		|O
.	1524	1525		|O
The	1526	1529		|O
results	1530	1537		|O
of	1538	1540		|O
this	1541	1545		|O
meta	1546	1550		|O
-	1550	1551		|O
analysis	1551	1559		|O
indicate	1560	1568		|O
that	1569	1573		|O
when	1574	1578		|O
used	1579	1583		|O
within	1584	1590		|O
current	1591	1598		|O
EORTC	1599	1604		|O
treatment	1605	1614		|O
guidelines	1615	1625		|O
,	1625	1626		|O
epoetin	1627	1634		|O
-	1634	1635		|O
beta	1635	1639		|O
has	1640	1643		|O
no	1644	1646		|O
negative	1647	1655		|O
impact	1656	1662		|O
on	1663	1665		|O
survival	1666	1674		|O
,	1674	1675		|O
tumour	1676	1682	tumour progression	|B-DISEASE
progression	1683	1694		|I-DISEASE
or	1695	1697		|O
TEEs	1698	1702	TEEs	|B-DISEASE
-	1702	1703		|O
related	1703	1710		|O
mortality	1711	1720		|O
.	1720	1721		|O

### 18614347
Effect	0	6		|O
of	7	9		|O
fluticasone	10	21		|O
propionate	22	32		|O
/	32	33		|O
salmeterol	33	43		|O
(	44	45		|O
250/50	45	51		|O
microg	52	58		|O
)	58	59		|O
or	60	62		|O
salmeterol	63	73		|O
(	74	75		|O
50	75	77		|O
microg	78	84		|O
)	84	85		|O
on	86	88		|O
COPD	89	93	COPD exacerbations	|B-DISEASE
exacerbations	94	107		|I-DISEASE
.	107	108		|O
OBJECTIVES	110	120		|O
:	120	121		|O
COPD	122	126	COPD exacerbations	|B-DISEASE
exacerbations	127	140		|I-DISEASE
are	141	144		|O
associated	145	155		|O
with	156	160		|O
significant	161	172		|O
morbidity	173	182		|O
and	183	186		|O
mortality	187	196		|O
.	196	197		|O
This	198	202		|O
randomized	203	213		|O
,	213	214		|O
double	215	221		|O
-	221	222		|O
blind	222	227		|O
,	227	228		|O
parallel	229	237		|O
-	237	238		|O
group	238	243		|O
,	243	244		|O
multicenter	245	256		|O
study	257	262		|O
evaluated	263	272		|O
the	273	276		|O
effect	277	283		|O
of	284	286		|O
fluticasone	287	298		|O
propionate	299	309		|O
/	309	310		|O
salmeterol	310	320		|O
250/50	321	327		|O
and	328	331		|O
salmeterol	332	342		|O
50	343	345		|O
microg	346	352		|O
twice	353	358		|O
daily	359	364		|O
on	365	367		|O
moderate	368	376		|O
to	377	379		|O
severe	380	386		|O
exacerbations	387	400		|O
.	400	401		|O
METHODS	402	409		|O
:	409	410		|O
Patients	411	419		|O
received	420	428		|O
standardized	429	441		|O
treatment	442	451		|O
with	452	456		|O
fluticasone	457	468		|O
propionate	469	479		|O
/	479	480		|O
salmeterol	480	490		|O
250/50	491	497		|O
during	498	504		|O
a	505	506		|O
1	507	508		|O
-	508	509		|O
month	509	514		|O
run	515	518		|O
-	518	519		|O
in	519	521		|O
,	521	522		|O
followed	523	531		|O
by	532	534		|O
randomization	535	548		|O
to	549	551		|O
fluticasone	552	563		|O
propionate	564	574		|O
/	574	575		|O
salmeterol	575	585		|O
250/50	586	592		|O
or	593	595		|O
salmeterol	596	606		|O
for	607	610		|O
12	611	613		|O
months	614	620		|O
.	620	621		|O
Moderate	622	630		|O
to	631	633		|O
severe	634	640		|O
exacerbations	641	654		|O
were	655	659		|O
defined	660	667		|O
as	668	670		|O
worsening	671	680		|O
symptoms	681	689		|O
of	690	692		|O
COPD	693	697	COPD	|B-DISEASE
requiring	698	707		|O
treatment	708	717		|O
with	718	722		|O
oral	723	727		|O
corticosteroids	728	743		|O
,	743	744		|O
antibiotics	745	756		|O
,	756	757		|O
or	758	760		|O
hospitalization	761	776		|O
.	776	777		|O
RESULTS	778	785		|O
:	785	786		|O
In	787	789		|O
782	790	793		|O
patients	794	802		|O
with	803	807		|O
COPD	808	812	COPD	|B-DISEASE
(	813	814		|O
mean	814	818		|O
FEV	819	822		|O
(	822	823		|O
1	823	824		|O
)	824	825		|O
=	825	826		|O
0.94	826	830		|O
+	830	831		|O
/	831	832		|O
-	832	833		|O
0.36	833	837		|O
L	838	839		|O
,	839	840		|O
33%	841	844		|O
predicted	845	854		|O
normal	855	861		|O
)	861	862		|O
,	862	863		|O
treatment	864	873		|O
with	874	878		|O
fluticasone	879	890		|O
propionate	891	901		|O
/	901	902		|O
salmeterol	902	912		|O
250/50	913	919		|O
significantly	920	933		|O
reduced	934	941		|O
(	942	943		|O
1	943	944		|O
)	944	945		|O
the	946	949		|O
annual	950	956		|O
rate	957	961		|O
of	962	964		|O
moderate	965	973		|O
to	974	976		|O
severe	977	983		|O
exacerbations	984	997		|O
by	998	1000		|O
30.5%	1001	1006		|O
compared	1007	1015		|O
with	1016	1020		|O
salmeterol	1021	1031		|O
(	1032	1033		|O
1.06	1033	1037		|O
and	1038	1041		|O
1.53	1042	1046		|O
per	1047	1050		|O
subject	1051	1058		|O
per	1059	1062		|O
year	1063	1067		|O
,	1067	1068		|O
respectively	1069	1081		|O
,	1081	1082		|O
p	1083	1084		|O
<	1084	1085		|O
0.001	1085	1090		|O
)	1090	1091		|O
,	1091	1092		|O
(	1093	1094		|O
2	1094	1095		|O
)	1095	1096		|O
the	1097	1100		|O
risk	1101	1105		|O
of	1106	1108		|O
time	1109	1113		|O
to	1114	1116		|O
first	1117	1122		|O
exacerbation	1123	1135		|O
by	1136	1138		|O
25%	1139	1142		|O
(	1143	1144		|O
hazard	1144	1150		|O
ratio	1151	1156		|O
=	1156	1157		|O
0.750	1157	1162		|O
,	1162	1163		|O
p	1164	1165		|O
=	1165	1166		|O
0.003	1166	1171		|O
)	1171	1172		|O
and	1173	1176		|O
(	1177	1178		|O
3	1178	1179		|O
)	1179	1180		|O
the	1181	1184		|O
annual	1185	1191		|O
rate	1192	1196		|O
of	1197	1199		|O
exacerbations	1200	1213		|O
requiring	1214	1223		|O
oral	1224	1228		|O
corticosteroids	1229	1244		|O
by	1245	1247		|O
40%	1248	1251		|O
(	1252	1253		|O
p	1253	1254		|O
<	1254	1255		|O
0.001	1255	1260		|O
)	1260	1261		|O
.	1261	1262		|O
Clinical	1263	1271		|O
improvements	1272	1284		|O
observed	1285	1293		|O
during	1294	1300		|O
run	1301	1304		|O
-	1304	1305		|O
in	1305	1307		|O
treatment	1308	1317		|O
with	1318	1322		|O
fluticasone	1323	1334		|O
propionate	1335	1345		|O
/	1345	1346		|O
salmeterol	1346	1356		|O
250/50	1357	1363		|O
were	1364	1368		|O
better	1369	1375		|O
maintained	1376	1386		|O
over	1387	1391		|O
12	1392	1394		|O
months	1395	1401		|O
with	1402	1406		|O
fluticasone	1407	1418		|O
propionate	1419	1429		|O
/	1429	1430		|O
salmeterol	1430	1440		|O
250/50	1441	1447		|O
than	1448	1452		|O
salmeterol	1453	1463		|O
.	1463	1464		|O
Adverse	1465	1472		|O
events	1473	1479		|O
were	1480	1484		|O
reported	1485	1493		|O
for	1494	1497		|O
a	1498	1499		|O
similar	1500	1507		|O
percentage	1508	1518		|O
of	1519	1521		|O
subjects	1522	1530		|O
across	1531	1537		|O
groups	1538	1544		|O
.	1544	1545		|O
A	1546	1547		|O
higher	1548	1554		|O
reporting	1555	1564		|O
of	1565	1567		|O
pneumonia	1568	1577	pneumonia	|B-ADVERSE
was	1578	1581		|O
observed	1582	1590		|O
with	1591	1595		|O
fluticasone	1596	1607		|O
propionate	1608	1618		|O
/	1618	1619		|O
salmeterol	1619	1629		|O
250/50	1630	1636		|O
than	1637	1641		|O
salmeterol	1642	1652		|O
(	1653	1654		|O
7%	1654	1656		|O
vs.	1657	1660		|O
4%	1661	1663		|O
)	1663	1664		|O
.	1664	1665		|O
CONCLUSIONS	1666	1677		|O
:	1677	1678		|O
We	1679	1681		|O
conclude	1682	1690		|O
that	1691	1695		|O
fluticasone	1696	1707		|O
propionate	1708	1718		|O
/	1718	1719		|O
salmeterol	1719	1729		|O
250/50	1730	1736		|O
is	1737	1739		|O
more	1740	1744		|O
effective	1745	1754		|O
than	1755	1759		|O
salmeterol	1760	1770		|O
at	1771	1773		|O
reducing	1774	1782		|O
the	1783	1786		|O
rate	1787	1791		|O
of	1792	1794		|O
moderate	1795	1803		|O
to	1804	1806		|O
severe	1807	1813		|O
exacerbations	1814	1827		|O
over	1828	1832		|O
1	1833	1834		|O
year	1835	1839		|O
.	1839	1840		|O
The	1841	1844		|O
benefits	1845	1853		|O
of	1854	1856		|O
this	1857	1861		|O
reduction	1862	1871		|O
relative	1872	1880		|O
to	1881	1883		|O
the	1884	1887		|O
risk	1888	1892		|O
of	1893	1895		|O
a	1896	1897		|O
higher	1898	1904		|O
incidence	1905	1914		|O
of	1915	1917		|O
reported	1918	1926		|O
pneumonia	1927	1936	pneumonia	|B-ADVERSE
should	1937	1943		|O
be	1944	1946		|O
considered	1947	1957		|O
.	1957	1958		|O
This	1959	1963		|O
study	1964	1969		|O
supports	1970	1978		|O
the	1979	1982		|O
use	1983	1986		|O
of	1987	1989		|O
fluticasone	1990	2001		|O
propionate	2002	2012		|O
/	2012	2013		|O
salmeterol	2013	2023		|O
250/50	2024	2030		|O
for	2031	2034		|O
the	2035	2038		|O
reduction	2039	2048		|O
of	2049	2051		|O
COPD	2052	2056	COPD exacerbations	|B-DISEASE
exacerbations	2057	2070		|I-DISEASE
in	2071	2073		|O
patients	2074	2082		|O
with	2083	2087		|O
COPD	2088	2092	COPD	|B-DISEASE
.	2092	2093		|O

### 18759760
Efficacy	0	8		|O
of	9	11		|O
fractionated	12	24		|O
gemtuzumab	25	35		|O
ozogamicin	36	46		|O
combined	47	55		|O
with	56	60		|O
cytarabine	61	71		|O
in	72	74		|O
advanced	75	83		|O
childhood	84	93		|O
myeloid	94	101	myeloid leukaemia	|B-DISEASE
leukaemia	102	111		|I-DISEASE
.	111	112		|O
Gemtuzumab	114	124		|O
ozogamicin	125	135		|O
(	136	137		|O
GO	137	139		|O
)	139	140		|O
monotherapy	141	152		|O
is	153	155		|O
reported	156	164		|O
to	165	167		|O
yield	168	173		|O
a	174	175		|O
20-30%	176	182		|O
response	183	191		|O
rate	192	196		|O
in	197	199		|O
advanced	200	208		|O
acute	209	214	acute myeloid leukaemia	|B-DISEASE
myeloid	215	222		|I-DISEASE
leukaemia	223	232		|I-DISEASE
(	233	234		|O
AML	234	237	AML	|B-DISEASE
)	237	238		|O
.	238	239		|O
This	240	244		|O
study	245	250		|O
examined	251	259		|O
the	260	263		|O
efficacy	264	272		|O
and	273	276		|O
tolerability	277	289		|O
of	290	292		|O
GO	293	295		|O
combined	296	304		|O
with	305	309		|O
cytarabine	310	320		|O
(	321	322		|O
GOCYT	322	327		|O
)	327	328		|O
in	329	331		|O
children	332	340		|O
with	341	345		|O
refractory	346	356		|O
/	356	357		|O
relapsed	357	365		|O
CD33	366	370		|O
(	370	371		|O
+	371	372		|O
)	372	373		|O
AML	374	377	AML	|B-DISEASE
.	377	378		|O
Seventeen	379	388		|O
children	389	397		|O
received	398	406		|O
GO	407	409		|O
3	410	411		|O
mg	412	414		|O
/	414	415		|O
m	415	416		|O
(	416	417		|O
2	417	418		|O
)	418	419		|O
on	420	422		|O
days	423	427		|O
1	428	429		|O
,	429	430		|O
4	431	432		|O
and	433	436		|O
7	437	438		|O
plus	439	443		|O
cytarabine	444	454		|O
100	455	458		|O
mg	459	461		|O
/	461	462		|O
m	462	463		|O
(	463	464		|O
2	464	465		|O
)	465	466		|O
/	466	467		|O
d	467	468		|O
for	469	472		|O
7	473	474		|O
d	475	476		|O
on	477	479		|O
a	480	481		|O
compassionate	482	495		|O
-	495	496		|O
use	496	499		|O
basis	500	505		|O
.	505	506		|O
Seven	507	512		|O
patients	513	521		|O
then	522	526		|O
received	527	535		|O
GO	536	538		|O
-	538	539		|O
based	539	544		|O
consolidation	545	558		|O
.	558	559		|O
At	560	562		|O
the	563	566		|O
outset	567	573		|O
of	574	576		|O
GOCYT	577	582		|O
,	582	583		|O
two	584	587		|O
patients	588	596		|O
were	597	601		|O
refractory	602	612		|O
;	612	613		|O
eight	614	619		|O
patients	620	628		|O
were	629	633		|O
in	634	636		|O
refractory	637	647		|O
first	648	653		|O
relapse	654	661		|O
;	661	662		|O
six	663	666		|O
patients	667	675		|O
had	676	679		|O
relapsed	680	688		|O
after	689	694		|O
stem	695	699		|O
cell	700	704		|O
transplantation	705	720		|O
(	721	722		|O
SCT	722	725		|O
)	725	726		|O
;	726	727		|O
and	728	731		|O
one	732	735		|O
patient	736	743		|O
[	744	745		|O
del	745	748		|O
(	748	749		|O
5q	749	751		|O
)	751	752		|O
therapy	753	760		|O
-	760	761		|O
related	761	768		|O
AML	769	772	AML	|B-DISEASE
(	773	774		|O
t	774	775		|O
-	775	776		|O
AML	776	779		|O
)	779	780		|O
]	780	781		|O
had	782	785		|O
not	786	789		|O
yet	790	793		|O
been	794	798		|O
treated	799	806		|O
.	806	807		|O
Mean	808	812		|O
follow	813	819		|O
-	819	820		|O
up	820	822		|O
was	823	826		|O
17	827	829		|O
months	830	836		|O
(	837	838		|O
8-33	838	842		|O
months	843	849		|O
)	849	850		|O
.	850	851		|O
Ten	852	855		|O
responses	856	865		|O
were	866	870		|O
obtained	871	879		|O
after	880	885		|O
GOCYT	886	891		|O
induction	892	901		|O
,	901	902		|O
including	903	912		|O
complete	913	921		|O
remission	922	931		|O
(	932	933		|O
CR	933	935		|O
)	935	936		|O
or	937	939		|O
CR	940	942		|O
without	943	950		|O
complete	951	959		|O
recovery	960	968		|O
of	969	971		|O
platelets	972	981		|O
(	982	983		|O
CRp	983	986		|O
)	986	987		|O
in	988	990		|O
six	991	994		|O
patients	995	1003		|O
(	1004	1005		|O
35%	1005	1008		|O
)	1008	1009		|O
.	1009	1010		|O
The	1011	1014		|O
responses	1015	1024		|O
improved	1025	1033		|O
in	1034	1036		|O
three	1037	1042		|O
children	1043	1051		|O
who	1052	1055		|O
received	1056	1064		|O
GOCYT	1065	1070		|O
consolidation	1071	1084		|O
,	1084	1085		|O
increasing	1086	1096		|O
the	1097	1100		|O
CR	1101	1103		|O
+	1104	1105		|O
CRp	1106	1109		|O
rate	1110	1114		|O
to	1115	1117		|O
53%	1118	1121		|O
.	1121	1122		|O
SCT	1123	1126		|O
was	1127	1130		|O
subsequently	1131	1143		|O
performed	1144	1153		|O
in	1154	1156		|O
eight	1157	1162		|O
responders	1163	1173		|O
.	1173	1174		|O
Grade	1175	1180		|O
3-4	1181	1184		|O
adverse	1185	1192		|O
events	1193	1199		|O
consisted	1200	1209		|O
of	1210	1212		|O
haematological	1213	1227	haematological disorders	|B-ADVERSE
disorders	1228	1237		|I-ADVERSE
(	1238	1239		|O
n	1239	1240		|O
=	1241	1242		|O
17	1243	1245		|O
,	1245	1246		|O
100%	1247	1251		|O
)	1251	1252		|O
and	1253	1256		|O
documented	1257	1267		|O
infections	1268	1278	infections	|B-ADVERSE
(	1279	1280		|O
n	1280	1281		|O
=	1282	1283		|O
5	1284	1285		|O
,	1285	1286		|O
29%	1287	1290		|O
)	1290	1291		|O
.	1291	1292		|O
No	1293	1295		|O
cases	1296	1301		|O
of	1302	1304		|O
sinusoidal	1305	1315	sinusoidal obstructive syndrome	|B-DISEASE
obstructive	1316	1327		|I-DISEASE
syndrome	1328	1336		|I-DISEASE
occurred	1337	1345		|O
.	1345	1346		|O
Three	1347	1352		|O
patients	1353	1361		|O
were	1362	1366		|O
alive	1367	1372		|O
at	1373	1375		|O
the	1376	1379		|O
cut	1380	1383		|O
-	1383	1384		|O
off	1384	1387		|O
date	1388	1392		|O
for	1393	1396		|O
this	1397	1401		|O
analysis	1402	1410		|O
,	1410	1411		|O
all	1412	1415		|O
of	1416	1418		|O
whom	1419	1423		|O
had	1424	1427		|O
responded	1428	1437		|O
to	1438	1440		|O
GOCYT	1441	1446		|O
.	1446	1447		|O
GOCYT	1448	1453		|O
combination	1454	1465		|O
therapy	1466	1473		|O
yielded	1474	1481		|O
a	1482	1483		|O
high	1484	1488		|O
response	1489	1497		|O
rate	1498	1502		|O
(	1503	1504		|O
53%	1504	1507		|O
)	1507	1508		|O
and	1509	1512		|O
showed	1513	1519		|O
acceptable	1520	1530		|O
toxicity	1531	1539		|O
in	1540	1542		|O
heavily	1543	1550		|O
pretreated	1551	1561		|O
children	1562	1570		|O
with	1571	1575		|O
refractory	1576	1586	refractory/relapsed AML	|B-DISEASE
/	1586	1587		|I-DISEASE
relapsed	1587	1595		|I-DISEASE
AML	1596	1599		|I-DISEASE
.	1599	1600		|O
These	1601	1606		|O
results	1607	1614		|O
warrant	1615	1622		|O
a	1623	1624		|O
larger	1625	1631		|O
prospective	1632	1643		|O
study	1644	1649		|O
.	1649	1650		|O

### 18622679
Effect	0	6		|O
of	7	9		|O
linezolid	10	19		|O
against	20	27		|O
postneurosurgical	28	45	postneurosurgical meningitis	|B-ADVERSE
meningitis	46	56		|I-ADVERSE
caused	57	63		|O
by	64	66		|O
methicillin	67	78		|O
-	78	79		|O
resistant	79	88		|O
Staphylococcus	89	103		|O
epidermidis	104	115		|O
:	115	116		|O
case	117	121		|O
report	122	128		|O
.	128	129		|O
A	131	132		|O
67	133	135		|O
-	135	136		|O
year	136	140		|O
-	140	141		|O
old	141	144		|O
man	145	148		|O
who	149	152		|O
had	153	156		|O
twice	157	162		|O
previously	163	173		|O
undergone	174	183		|O
operations	184	194		|O
for	195	198		|O
a	199	200		|O
tuberculum	201	211	tuberculum sellae meningioma	|B-DISEASE
sellae	212	218		|I-DISEASE
meningioma	219	229		|I-DISEASE
was	230	233		|O
admitted	234	242		|O
to	243	245		|O
hospital	246	254		|O
for	255	258		|O
further	259	266		|O
treatment	267	276		|O
.	276	277		|O
After	278	283		|O
the	284	287		|O
third	288	293		|O
surgical	294	302		|O
intervention	303	315		|O
,	315	316		|O
the	317	320		|O
patient	321	328		|O
developed	329	338		|O
persistent	339	349		|O
low	350	353		|O
-	353	354		|O
grade	354	359		|O
fever	360	365	fever	|B-ADVERSE
and	366	369		|O
impaired	370	378	impaired consciousness	|B-ADVERSE
consciousness	379	392		|I-ADVERSE
.	392	393		|O
Computed	394	402		|O
tomography	403	413		|O
,	413	414		|O
1	415	416		|O
week	417	421		|O
after	422	427		|O
surgery	428	435		|O
,	435	436		|O
showed	437	443		|O
postsurgical	444	456	postsurgical hydrocephalus	|B-ADVERSE
hydrocephalus	457	470		|I-ADVERSE
.	470	471		|O
Cerebrospinal	472	485		|O
fluid	486	491		|O
(	492	493		|O
CSF	493	496		|O
)	496	497		|O
studies	498	505		|O
revealed	506	514		|O
high	515	519		|O
intracranial	520	532		|O
pressure	533	541		|O
(	542	543		|O
above	543	548		|O
30	549	551		|O
cm	552	554		|O
H2O	555	558		|O
)	558	559		|O
,	559	560		|O
and	561	564		|O
increased	565	574		|O
cell	575	579		|O
count	580	585		|O
(	586	587		|O
1232/3	587	593		|O
)	593	594		|O
.	594	595		|O
One	596	599		|O
week	600	604		|O
after	605	610		|O
the	611	614		|O
ventricular	615	626		|O
drainage	627	635		|O
,	635	636		|O
coagulase	637	646		|O
-	646	647		|O
negative	647	655		|O
Staphylococcus	656	670		|O
epidermidis	671	682		|O
was	683	686		|O
recovered	687	696		|O
from	697	701		|O
his	702	705		|O
CSF	706	709		|O
,	709	710		|O
and	711	714		|O
antimicrobial	715	728		|O
susceptibility	729	743		|O
results	744	751		|O
indicated	752	761		|O
that	762	766		|O
the	767	770		|O
organism	771	779		|O
was	780	783		|O
methicillin	784	795		|O
-	795	796		|O
resistant	796	805		|O
.	805	806		|O
After	807	812		|O
14	813	815		|O
days	816	820		|O
of	821	823		|O
intravenous	824	835		|O
vancomycin	836	846		|O
(	847	848		|O
VCM	848	851		|O
)	851	852		|O
administration	853	867		|O
failed	868	874		|O
,	874	875		|O
linezolid	876	885		|O
(	886	887		|O
LZD	887	890		|O
)	890	891		|O
was	892	895		|O
initialized	896	907		|O
intravenously	908	921		|O
,	921	922		|O
resulting	923	932		|O
in	933	935		|O
a	936	937		|O
resolution	938	948		|O
of	949	951		|O
the	952	955		|O
meningitis	956	966	meningitis	|B-ADVERSE
.	966	967		|O
After	968	973		|O
a	974	975		|O
ventriculoperitoneal	976	996		|O
shunt	997	1002		|O
procedure	1003	1012		|O
was	1013	1016		|O
performed	1017	1026		|O
,	1026	1027		|O
LZD	1028	1031		|O
was	1032	1035		|O
continued	1036	1045		|O
orally	1046	1052		|O
,	1052	1053		|O
which	1054	1059		|O
resulted	1060	1068		|O
in	1069	1071		|O
a	1072	1073		|O
cure	1074	1078		|O
.	1078	1079		|O
CSF	1080	1083		|O
penetration	1084	1095		|O
by	1096	1098		|O
VCM	1099	1102		|O
is	1103	1105		|O
reported	1106	1114		|O
to	1115	1117		|O
be	1118	1120		|O
poor	1121	1125		|O
,	1125	1126		|O
i.e.	1127	1131		|O
,	1131	1132		|O
approximately	1133	1146		|O
10%	1147	1150		|O
of	1151	1153		|O
serum	1154	1159		|O
concentration	1160	1173		|O
,	1173	1174		|O
which	1175	1180		|O
may	1181	1184		|O
explain	1185	1192		|O
its	1193	1196		|O
lack	1197	1201		|O
of	1202	1204		|O
efficacy	1205	1213		|O
.	1213	1214		|O
In	1215	1217		|O
this	1218	1222		|O
case	1223	1227		|O
,	1227	1228		|O
the	1229	1232		|O
penetration	1233	1244		|O
of	1245	1247		|O
LZD	1248	1251		|O
into	1252	1256		|O
the	1257	1260		|O
CSF	1261	1264		|O
was	1265	1268		|O
58.9%	1269	1274		|O
of	1275	1277		|O
the	1278	1281		|O
peak	1282	1286		|O
value	1287	1292		|O
and	1293	1296		|O
133%	1297	1301		|O
of	1302	1304		|O
the	1305	1308		|O
trough	1309	1315		|O
value	1316	1321		|O
of	1322	1324		|O
serum	1325	1330		|O
concentrations	1331	1345		|O
.	1345	1346		|O
LZD	1347	1350		|O
must	1351	1355		|O
be	1356	1358		|O
considered	1359	1369		|O
one	1370	1373		|O
of	1374	1376		|O
the	1377	1380		|O
first	1381	1386		|O
-	1386	1387		|O
line	1387	1391		|O
treatments	1392	1402		|O
against	1403	1410		|O
surgical	1411	1419	surgical-site infection	|B-ADVERSE
-	1419	1420		|I-ADVERSE
site	1420	1424		|I-ADVERSE
infection	1425	1434		|I-ADVERSE
in	1435	1437		|O
neurosurgery	1438	1450		|O
caused	1451	1457		|O
by	1458	1460		|O
methicillin	1461	1472		|O
-	1472	1473		|O
resistant	1473	1482		|O
Staphylococci	1483	1496		|O
.	1496	1497		|O

### 18628507
Angio	0	5	Angio-oedema	|B-DISEASE
-	5	6		|I-DISEASE
oedema	6	12		|I-DISEASE
as	13	15		|O
an	16	18		|O
unusual	19	26		|O
tolerable	27	36		|O
side	37	41		|O
effect	42	48		|O
of	49	51		|O
voriconazole	52	64		|O
therapy	65	72		|O
.	72	73		|O
Voriconazole	75	87		|O
(	88	89		|O
VRC	89	92		|O
)	92	93		|O
has	94	97		|O
not	98	101		|O
previously	102	112		|O
been	113	117		|O
reported	118	126		|O
to	127	129		|O
cause	130	135		|O
angio	136	141	angio-oedema	|B-DISEASE
-	141	142		|I-DISEASE
oedema	142	148		|I-DISEASE
.	148	149		|O
Here	150	154		|O
,	154	155		|O
we	156	158		|O
report	159	165		|O
a	166	167		|O
case	168	172		|O
of	173	175		|O
angio	176	181	angio-oedema	|B-DISEASE
-	181	182		|I-DISEASE
oedema	182	188		|I-DISEASE
associated	189	199		|O
with	200	204		|O
VRC	205	208		|O
therapy	209	216		|O
.	216	217		|O
A	218	219		|O
37	220	222		|O
-	222	223		|O
year	223	227		|O
-	227	228		|O
old	228	231		|O
woman	232	237		|O
with	238	242		|O
relapsing	243	252		|O
invasive	253	261		|O
vertebral	262	271		|O
aspergillosis	272	285	aspergillosis	|B-DISEASE
received	286	294		|O
intravenous	295	306		|O
VRC	307	310		|O
and	311	314		|O
developed	315	324		|O
angio	325	330		|O
-	330	331		|O
oedema	331	337		|O
10	338	340		|O
days	341	345		|O
after	346	351		|O
starting	352	360		|O
therapy	361	368		|O
.	368	369		|O
This	370	374		|O
condition	375	384		|O
rapidly	385	392		|O
diminished	393	403		|O
after	404	409		|O
administration	410	424		|O
of	425	427		|O
intravenous	428	439		|O
antihistaminics	440	455		|O
and	456	459		|O
did	460	463		|O
not	464	467		|O
necessitate	468	479		|O
cessation	480	489		|O
of	490	492		|O
VRC	493	496		|O
treatment	497	506		|O
.	506	507		|O
The	508	511		|O
treatment	512	521		|O
was	522	525		|O
continued	526	535		|O
for	536	539		|O
6	540	541		|O
months	542	548		|O
without	549	556		|O
recurrence	557	567		|O
of	568	570		|O
the	571	574		|O
symptoms	575	583		|O
.	583	584		|O
After	585	590		|O
18	591	593		|O
months	594	600		|O
,	600	601		|O
the	602	605		|O
patient	606	613		|O
was	614	617		|O
in	618	620		|O
good	621	625		|O
health	626	632		|O
.	632	633		|O
To	634	636		|O
our	637	640		|O
knowledge	641	650		|O
,	650	651		|O
this	652	656		|O
is	657	659		|O
the	660	663		|O
first	664	669		|O
report	670	676		|O
of	677	679		|O
an	680	682		|O
angio	683	688	angio-oedema	|B-DISEASE
-	688	689		|I-DISEASE
oedema	689	695		|I-DISEASE
associated	696	706		|O
with	707	711		|O
VRC	712	715		|O
.	715	716		|O

### 18657019
Extended	0	8		|O
-	8	9		|O
and	10	13		|O
continuous	14	24		|O
-	24	25		|O
cycle	25	30		|O
oral	31	35		|O
contraceptives	36	50		|O
.	50	51		|O
Five	53	57		|O
new	58	61		|O
oral	62	66		|O
contraceptives	67	81		|O
,	81	82		|O
classified	83	93		|O
as	94	96		|O
extended	97	105		|O
-	105	106		|O
or	107	109		|O
continuous	110	120		|O
-	120	121		|O
cycle	121	126		|O
oral	127	131		|O
contraceptives	132	146		|O
,	146	147		|O
have	148	152		|O
been	153	157		|O
approved	158	166		|O
by	167	169		|O
the	170	173		|O
United	174	180		|O
States	181	187		|O
Food	188	192		|O
and	193	196		|O
Drug	197	201		|O
Administration	202	216		|O
.	216	217		|O
These	218	223		|O
agents	224	230		|O
have	231	235		|O
various	236	243		|O
combinations	244	256		|O
of	257	259		|O
estrogen	260	268		|O
and	269	272		|O
progestin	273	282		|O
,	282	283		|O
and	284	287		|O
different	288	297		|O
effects	298	305		|O
on	306	308		|O
the	309	312		|O
length	313	319		|O
of	320	322		|O
women	323	328		|O
's	328	330		|O
menstrual	331	340		|O
cycles	341	347		|O
.	347	348		|O
Usually	349	356		|O
they	357	361		|O
shorten	362	369		|O
the	370	373		|O
duration	374	382		|O
of	383	385		|O
menses	386	392		|O
,	392	393		|O
decrease	394	402		|O
the	403	406		|O
frequency	407	416		|O
of	417	419		|O
menses	420	426		|O
to	427	429		|O
4	430	431		|O
times	432	437		|O
/	437	438		|O
year	438	442		|O
,	442	443		|O
or	444	446		|O
completely	447	457		|O
eliminate	458	467		|O
menses	468	474		|O
.	474	475		|O
These	476	481		|O
new	482	485		|O
oral	486	490		|O
contraceptives	491	505		|O
are	506	509		|O
given	510	515		|O
in	516	518		|O
the	519	522		|O
following	523	532		|O
regimens	533	541		|O
:	541	542		|O
24	543	545		|O
days	546	550		|O
followed	551	559		|O
by	560	562		|O
placebo	563	570		|O
for	571	574		|O
4	575	576		|O
days	577	581		|O
(	582	583		|O
24/4	583	587		|O
)	587	588		|O
,	588	589		|O
84	590	592		|O
days	593	597		|O
followed	598	606		|O
by	607	609		|O
placebo	610	617		|O
for	618	621		|O
7	622	623		|O
days	624	628		|O
(	629	630		|O
84/7	630	634		|O
)	634	635		|O
,	635	636		|O
or	637	639		|O
continuously	640	652		|O
(	653	654		|O
without	654	661		|O
placebo	662	669		|O
)	669	670		|O
.	670	671		|O
These	672	677		|O
agents	678	684		|O
contain	685	692		|O
ethinyl	693	700		|O
estradiol	701	710		|O
20	711	713		|O
microg	714	720		|O
-	720	721		|O
drospirenone	721	733		|O
3	734	735		|O
mg	736	738		|O
(	739	740		|O
24/4	740	744		|O
)	744	745		|O
;	745	746		|O
ethinyl	747	754		|O
estradiol	755	764		|O
20	765	767		|O
microg	768	774		|O
-	774	775		|O
norethindrone	775	788		|O
1	789	790		|O
mg	791	793		|O
(	794	795		|O
24/4	795	799		|O
)	799	800		|O
;	800	801		|O
ethinyl	802	809		|O
estradiol	810	819		|O
30	820	822		|O
microg	823	829		|O
-	829	830		|O
levonorgestrel	830	844		|O
150	845	848		|O
microg	849	855		|O
(	856	857		|O
84/7	857	861		|O
)	861	862		|O
;	862	863		|O
ethinyl	864	871		|O
estradiol	872	881		|O
30	882	884		|O
microg	885	891		|O
-	891	892		|O
levonorgestrel	892	906		|O
150	907	910		|O
microg	911	917		|O
(	918	919		|O
84/7	919	923		|O
)	923	924		|O
with	925	929		|O
very	930	934		|O
low	935	938		|O
-	938	939		|O
dose	939	943		|O
ethinyl	944	951		|O
estradiol	952	961		|O
(	962	963		|O
10	963	965		|O
microg	966	972		|O
/	972	973		|O
day	973	976		|O
)	976	977		|O
for	978	981		|O
7	982	983		|O
days	984	988		|O
;	988	989		|O
and	990	993		|O
ethinyl	994	1001		|O
estradiol	1002	1011		|O
20	1012	1014		|O
microg	1015	1021		|O
-	1021	1022		|O
levonorgestrel	1022	1036		|O
90	1037	1039		|O
microg	1040	1046		|O
continuously	1047	1059		|O
.	1059	1060		|O
Clinical	1061	1069		|O
trials	1070	1076		|O
have	1077	1081		|O
demonstrated	1082	1094		|O
that	1095	1099		|O
extended	1100	1108		|O
-	1108	1109		|O
and	1110	1113		|O
continuous	1114	1124		|O
-	1124	1125		|O
cycle	1125	1130		|O
oral	1131	1135		|O
contraceptives	1136	1150		|O
are	1151	1154		|O
as	1155	1157		|O
effective	1158	1167		|O
in	1168	1170		|O
preventing	1171	1181		|O
pregnancy	1182	1191		|O
as	1192	1194		|O
traditional	1195	1206		|O
oral	1207	1211		|O
contraceptives	1212	1226		|O
.	1226	1227		|O
These	1228	1233		|O
new	1234	1237		|O
agents	1238	1244		|O
also	1245	1249		|O
have	1250	1254		|O
similar	1255	1262		|O
adverse	1263	1270		|O
effects	1271	1278		|O
;	1278	1279		|O
however	1280	1287		|O
,	1287	1288		|O
the	1289	1292		|O
only	1293	1297		|O
significantly	1298	1311		|O
different	1312	1321		|O
adverse	1322	1329		|O
effect	1330	1336		|O
compared	1337	1345		|O
with	1346	1350		|O
traditional	1351	1362		|O
oral	1363	1367		|O
contraceptives	1368	1382		|O
in	1383	1385		|O
clinical	1386	1394		|O
trials	1395	1401		|O
was	1402	1405		|O
change	1406	1412	change in bleeding pattern	|B-ADVERSE
in	1413	1415		|I-ADVERSE
bleeding	1416	1424		|I-ADVERSE
pattern	1425	1432		|I-ADVERSE
.	1432	1433		|O
These	1434	1439		|O
oral	1440	1444		|O
contraceptives	1445	1459		|O
are	1460	1463		|O
associated	1464	1474		|O
with	1475	1479		|O
more	1480	1484		|O
breakthrough	1485	1497	breakthrough bleeding	|B-ADVERSE
bleeding	1498	1506		|I-ADVERSE
and	1507	1510		|O
spotting	1511	1519		|O
than	1520	1524		|O
the	1525	1528		|O
traditional	1529	1540		|O
pills	1541	1546		|O
.	1546	1547		|O
Long	1548	1552		|O
-	1552	1553		|O
term	1553	1557		|O
effects	1558	1565		|O
on	1566	1568		|O
efficacy	1569	1577		|O
and	1578	1581		|O
safety	1582	1588		|O
are	1589	1592		|O
not	1593	1596		|O
known	1597	1602		|O
,	1602	1603		|O
as	1604	1606		|O
these	1607	1612		|O
new	1613	1616		|O
products	1617	1625		|O
generally	1626	1635		|O
have	1636	1640		|O
been	1641	1645		|O
used	1646	1650		|O
for	1651	1654		|O
only	1655	1659		|O
1-2	1660	1663		|O
years	1664	1669		|O
.	1669	1670		|O
Extended	1671	1679		|O
-	1679	1680		|O
and	1681	1684		|O
continuous	1685	1695		|O
-	1695	1696		|O
cycle	1696	1701		|O
oral	1702	1706		|O
contraceptives	1707	1721		|O
are	1722	1725		|O
a	1726	1727		|O
new	1728	1731		|O
option	1732	1738		|O
for	1739	1742		|O
women	1743	1748		|O
desiring	1749	1757		|O
decreased	1758	1767		|O
menses	1768	1774		|O
or	1775	1777		|O
for	1778	1781		|O
whom	1782	1786		|O
decreased	1787	1796		|O
menses	1797	1803		|O
may	1804	1807		|O
alleviate	1808	1817		|O
symptoms	1818	1826		|O
of	1827	1829		|O
coexisting	1830	1840		|O
medical	1841	1848		|O
conditions	1849	1859		|O
.	1859	1860		|O

### 18828020
Phase	0	5		|O
II	6	8		|O
trial	9	14		|O
of	15	17		|O
S	18	19		|O
-	19	20		|O
1	20	21		|O
and	22	25		|O
concurrent	26	36		|O
radiotherapy	37	49		|O
in	50	52		|O
patients	53	61		|O
with	62	66		|O
locally	67	74		|O
advanced	75	83		|O
pancreatic	84	94	pancreatic cancer	|B-DISEASE
cancer	95	101		|I-DISEASE
.	101	102		|O
PURPOSE	104	111		|O
:	111	112		|O
S	113	114		|O
-	114	115		|O
1	115	116		|O
has	117	120		|O
a	121	122		|O
favorable	123	132		|O
effect	133	139		|O
in	140	142		|O
unresectable	143	155		|O
pancreatic	156	166	pancreatic cancer	|B-DISEASE
cancer	167	173		|I-DISEASE
and	174	177		|O
a	178	179		|O
potential	180	189		|O
radiosensitizer	190	205		|O
.	205	206		|O
In	207	209		|O
addition	210	218		|O
,	218	219		|O
daily	220	225		|O
oral	226	230		|O
administration	231	245		|O
of	246	248		|O
S	249	250		|O
-	250	251		|O
1	251	252		|O
is	253	255		|O
more	256	260		|O
convenient	261	271		|O
than	272	276		|O
continuous	277	287		|O
infusion	288	296		|O
of	297	299		|O
5	300	301		|O
-	301	302		|O
fluorouracil	302	314		|O
.	314	315		|O
This	316	320		|O
study	321	326		|O
was	327	330		|O
designed	331	339		|O
to	340	342		|O
evaluate	343	351		|O
the	352	355		|O
efficacy	356	364		|O
and	365	368		|O
safety	369	375		|O
of	376	378		|O
S	379	380		|O
-	380	381		|O
1	381	382		|O
and	383	386		|O
concurrent	387	397		|O
radiotherapy	398	410		|O
in	411	413		|O
patients	414	422		|O
with	423	427		|O
locally	428	435		|O
advanced	436	444		|O
pancreatic	445	455	pancreatic cancer	|B-DISEASE
cancer	456	462		|I-DISEASE
.	462	463		|O
METHODS	464	471		|O
:	471	472		|O
Eligibility	473	484		|O
criteria	485	493		|O
were	494	498		|O
histologically	499	513		|O
proven	514	520		|O
pancreatic	521	531	pancreatic adenocarcinoma	|B-DISEASE
adenocarcinoma	532	546		|I-DISEASE
,	546	547		|O
locally	548	555		|O
advanced	556	564		|O
disease	565	572		|O
,	572	573		|O
and	574	577		|O
no	578	580		|O
previous	581	589		|O
treatment	590	599		|O
.	599	600		|O
S	601	602		|O
-	602	603		|O
1	603	604		|O
was	605	608		|O
administered	609	621		|O
orally	622	628		|O
at	629	631		|O
a	632	633		|O
dose	634	638		|O
of	639	641		|O
40	642	644		|O
mg	645	647		|O
/	647	648		|O
m	648	649		|O
(	649	650		|O
2	650	651		|O
)	651	652		|O
twice	653	658		|O
daily	659	664		|O
from	665	669		|O
day	670	673		|O
1	674	675		|O
to	676	678		|O
14	679	681		|O
and	682	685		|O
from	686	690		|O
day	691	694		|O
22	695	697		|O
to	698	700		|O
35	701	703		|O
,	703	704		|O
and	705	708		|O
concurrent	709	719		|O
radiotherapy	720	732		|O
(	733	734		|O
a	734	735		|O
total	736	741		|O
dose	742	746		|O
of	747	749		|O
50.4	750	754		|O
Gy	755	757		|O
)	757	758		|O
was	759	762		|O
delivered	763	772		|O
in	773	775		|O
28	776	778		|O
fractions	779	788		|O
.	788	789		|O
One	790	793		|O
month	794	799		|O
after	800	805		|O
treatment	806	815		|O
completion	816	826		|O
,	826	827		|O
tumor	828	833		|O
response	834	842		|O
was	843	846		|O
evaluated	847	856		|O
by	857	859		|O
computed	860	868		|O
tomography	869	879		|O
(	880	881		|O
CT	881	883		|O
)	883	884		|O
.	884	885		|O
RESULTS	886	893		|O
:	893	894		|O
A	895	896		|O
total	897	902		|O
of	903	905		|O
25	906	908		|O
patients	909	917		|O
were	918	922		|O
evaluable	923	932		|O
for	933	936		|O
efficacy	937	945		|O
and	946	949		|O
toxicity	950	958		|O
on	959	961		|O
the	962	965		|O
basis	966	971		|O
of	972	974		|O
the	975	978		|O
intention	979	988		|O
-	988	989		|O
to	989	991		|O
-	991	992		|O
treat	992	997		|O
analysis	998	1006		|O
.	1006	1007		|O
The	1008	1011		|O
response	1012	1020		|O
rate	1021	1025		|O
and	1026	1029		|O
disease	1030	1037		|O
control	1038	1045		|O
rate	1046	1050		|O
were	1051	1055		|O
24.0	1056	1060		|O
and	1061	1064		|O
68.0%	1065	1070		|O
,	1070	1071		|O
respectively	1072	1084		|O
.	1084	1085		|O
There	1086	1091		|O
was	1092	1095		|O
no	1096	1098		|O
treatment	1099	1108		|O
-	1108	1109		|O
related	1109	1116		|O
death	1117	1122		|O
or	1123	1125		|O
grade	1126	1131		|O
4	1132	1133		|O
toxicity	1134	1142		|O
.	1142	1143		|O
The	1144	1147		|O
most	1148	1152		|O
common	1153	1159		|O
grade	1160	1165		|O
3	1166	1167		|O
hematologic	1168	1179		|O
and	1180	1183		|O
non	1184	1187		|O
-	1187	1188		|O
hematologic	1188	1199		|O
toxicities	1200	1210		|O
were	1211	1215		|O
thrombocytopenia	1216	1232	thrombocytopenia	|B-ADVERSE
(	1233	1234		|O
4.0%	1234	1238		|O
)	1238	1239		|O
and	1240	1243		|O
anorexia	1244	1252	anorexia	|B-ADVERSE
(	1253	1254		|O
20%	1254	1257		|O
)	1257	1258		|O
,	1258	1259		|O
respectively	1260	1272		|O
.	1272	1273		|O
All	1274	1277		|O
toxicities	1278	1288		|O
were	1289	1293		|O
tolerable	1294	1303		|O
and	1304	1307		|O
transient	1308	1317		|O
.	1317	1318		|O
The	1319	1322		|O
median	1323	1329		|O
time	1330	1334		|O
-	1334	1335		|O
to	1335	1337		|O
-	1337	1338		|O
progression	1338	1349		|O
and	1350	1353		|O
median	1354	1360		|O
overall	1361	1368		|O
survival	1369	1377		|O
were	1378	1382		|O
6.5	1383	1386		|O
months	1387	1393		|O
(	1394	1395		|O
95%	1395	1398		|O
confidence	1399	1409		|O
interval	1410	1418		|O
,	1418	1419		|O
4.1-9.0	1420	1427		|O
months	1428	1434		|O
)	1434	1435		|O
and	1436	1439		|O
12.9	1440	1444		|O
months	1445	1451		|O
(	1452	1453		|O
95%	1453	1456		|O
confidence	1457	1467		|O
interval	1468	1476		|O
,	1476	1477		|O
6.7-19.0	1478	1486		|O
months	1487	1493		|O
)	1493	1494		|O
,	1494	1495		|O
respectively	1496	1508		|O
,	1508	1509		|O
and	1510	1513		|O
the	1514	1517		|O
1	1518	1519		|O
-	1519	1520		|O
year	1520	1524		|O
survival	1525	1533		|O
rate	1534	1538		|O
was	1539	1542		|O
estimated	1543	1552		|O
to	1553	1555		|O
be	1556	1558		|O
43%	1559	1562		|O
.	1562	1563		|O
CONCLUSIONS	1564	1575		|O
:	1575	1576		|O
S	1577	1578		|O
-	1578	1579		|O
1	1579	1580		|O
and	1581	1584		|O
concurrent	1585	1595		|O
radiotherapy	1596	1608		|O
shows	1609	1614		|O
favorable	1615	1624		|O
efficacy	1625	1633		|O
for	1634	1637		|O
disease	1638	1645		|O
control	1646	1653		|O
against	1654	1661		|O
locally	1662	1669		|O
advanced	1670	1678		|O
pancreatic	1679	1689	pancreatic cancer	|B-DISEASE
cancer	1690	1696		|I-DISEASE
and	1697	1700		|O
was	1701	1704		|O
well	1705	1709		|O
tolerated	1710	1719		|O
with	1720	1724		|O
no	1725	1727		|O
severe	1728	1734		|O
toxicities	1735	1745		|O
.	1745	1746		|O

### 18938110
Induction	0	9		|O
of	10	12		|O
mucosal	13	20		|O
tolerance	21	30		|O
in	31	33		|O
SLE	34	37	SLE	|B-DISEASE
:	37	38		|O
a	39	40		|O
sniff	41	46		|O
or	47	49		|O
a	50	51		|O
sip	52	55		|O
away	56	60		|O
from	61	65		|O
ameliorating	66	78		|O
lupus	79	84		|O
?	84	85		|O
Systemic	87	95	Systemic lupus erythematosus	|B-DISEASE
lupus	96	101		|I-DISEASE
erythematosus	102	115		|I-DISEASE
(	116	117		|O
SLE	117	120	SLE	|B-DISEASE
)	120	121		|O
is	122	124		|O
an	125	127		|O
autoimmune	128	138	autoimmune disease	|B-DISEASE
disease	139	146		|I-DISEASE
characterized	147	160		|O
by	161	163		|O
aberrant	164	172		|O
immune	173	179		|O
responses	180	189		|O
against	190	197		|O
intracellularly	198	213		|O
derived	214	221		|O
self	222	226		|O
antigens	227	235		|O
.	235	236		|O
Treatment	237	246		|O
for	247	250		|O
SLE	251	254	SLE	|B-DISEASE
relies	255	261		|O
on	262	264		|O
the	265	268		|O
use	269	272		|O
of	273	275		|O
aggressive	276	286		|O
immunosuppressants	287	305		|O
and	306	309		|O
steroids	310	318		|O
that	319	323		|O
are	324	327		|O
nonspecific	328	339		|O
and	340	343		|O
can	344	347		|O
cause	348	353		|O
serious	354	361		|O
adverse	362	369		|O
effects	370	377		|O
.	377	378		|O
The	379	382		|O
observation	383	394		|O
that	395	399		|O
a	400	401		|O
systemic	402	410		|O
immune	411	417		|O
tolerance	418	427		|O
to	428	430		|O
self	431	435		|O
antigens	436	444		|O
or	445	447		|O
generation	448	458		|O
of	459	461		|O
regulatory	462	472		|O
T	473	474		|O
cells	475	480		|O
may	481	484		|O
follow	485	491		|O
mucosal	492	499		|O
(	500	501		|O
nasal	501	506		|O
or	507	509		|O
oral	510	514		|O
)	514	515		|O
exposure	516	524		|O
to	525	527		|O
self	528	532		|O
proteins	533	541		|O
or	542	544		|O
monoclonal	545	555		|O
antibody	556	564		|O
against	565	572		|O
CD3	573	576		|O
respectively	577	589		|O
suggests	590	598		|O
that	599	603		|O
induction	604	613		|O
of	614	616		|O
mucosal	617	624		|O
tolerance	625	634		|O
offers	635	641		|O
the	642	645		|O
basis	646	651		|O
of	652	654		|O
a	655	656		|O
side	657	661		|O
effect	662	668		|O
-	668	669		|O
free	669	673		|O
therapy	674	681		|O
that	682	686		|O
could	687	692		|O
re	693	695		|O
-	695	696		|O
establish	696	705		|O
the	706	709		|O
ability	710	717		|O
to	718	720		|O
distinguish	721	732		|O
self	733	737		|O
from	738	742		|O
non	743	746		|O
-	746	747		|O
self	747	751		|O
and	752	755		|O
restore	756	763		|O
peripheral	764	774		|O
tolerance	775	784		|O
in	785	787		|O
individuals	788	799		|O
susceptible	800	811		|O
to	812	814		|O
developing	815	825		|O
autoimmune	826	836	autoimmune diseases	|B-DISEASE
diseases	837	845		|I-DISEASE
.	845	846		|O
Here	847	851		|O
I	852	853		|O
review	854	860		|O
studies	861	868		|O
on	869	871		|O
mucosal	872	879		|O
tolerance	880	889		|O
in	890	892		|O
autoimmune	893	903	autoimmune diseases	|B-DISEASE
diseases	904	912		|I-DISEASE
and	913	916		|O
discuss	917	924		|O
the	925	928		|O
therapeutic	929	940		|O
potential	941	950		|O
of	951	953		|O
inducing	954	962		|O
tolerance	963	972		|O
for	973	976		|O
the	977	980		|O
treatment	981	990		|O
of	991	993		|O
SLE	994	997	SLE	|B-DISEASE
.	997	998		|O

### 18759348
Biochemical	0	11		|O
mechanism	12	21		|O
of	22	24		|O
acetaminophen	25	38		|O
(	39	40		|O
APAP	40	44		|O
)	44	45		|O
induced	46	53		|O
toxicity	54	62		|O
in	63	65		|O
melanoma	66	74		|O
cell	75	79		|O
lines	80	85		|O
.	85	86		|O
In	88	90		|O
this	91	95		|O
work	96	100		|O
,	100	101		|O
we	102	104		|O
investigated	105	117		|O
the	118	121		|O
biochemical	122	133		|O
mechanism	134	143		|O
of	144	146		|O
acetaminophen	147	160		|O
(	161	162		|O
APAP	162	166		|O
)	166	167		|O
induced	168	175		|O
toxicity	176	184		|O
in	185	187		|O
SK	188	190		|O
-	190	191		|O
MEL	191	194		|O
-	194	195		|O
28	195	197		|O
melanoma	198	206		|O
cells	207	212		|O
using	213	218		|O
tyrosinase	219	229		|O
enzyme	230	236		|O
as	237	239		|O
a	240	241		|O
molecular	242	251		|O
cancer	252	258	cancer	|B-DISEASE
therapeutic	259	270		|O
target	271	277		|O
.	277	278		|O
Our	279	282		|O
results	283	290		|O
showed	291	297		|O
that	298	302		|O
APAP	303	307		|O
was	308	311		|O
metabolized	312	323		|O
87%	324	327		|O
by	328	330		|O
tyrosinase	331	341		|O
at	342	344		|O
2	345	346		|O
h	347	348		|O
incubation	349	359		|O
.	359	360		|O
AA	361	363		|O
and	364	367		|O
NADH	368	372		|O
,	372	373		|O
quinone	374	381		|O
reducing	382	390		|O
agents	391	397		|O
,	397	398		|O
were	399	403		|O
significantly	404	417		|O
depleted	418	426		|O
during	427	433		|O
APAP	434	438		|O
oxidation	439	448		|O
by	449	451		|O
tyrosinase	452	462		|O
.	462	463		|O
The	464	467		|O
IC	468	470		|O
(	470	471		|O
50	471	473		|O
)	473	474		|O
(	475	476		|O
48	476	478		|O
h	479	480		|O
)	480	481		|O
of	482	484		|O
APAP	485	489		|O
towards	490	497		|O
SK	498	500		|O
-	500	501		|O
MEL	501	504		|O
-	504	505		|O
28	505	507		|O
,	507	508		|O
MeWo	509	513		|O
,	513	514		|O
SK	515	517		|O
-	517	518		|O
MEL	518	521		|O
-	521	522		|O
5	522	523		|O
,	523	524		|O
B16	525	528		|O
-	528	529		|O
F0	529	531		|O
,	531	532		|O
and	533	536		|O
B16	537	540		|O
-	540	541		|O
F10	541	544		|O
melanoma	545	553		|O
cells	554	559		|O
was	560	563		|O
100	564	567		|O
microM	568	574		|O
whereas	575	582		|O
it	583	585		|O
showed	586	592		|O
no	593	595		|O
significant	596	607		|O
toxicity	608	616		|O
towards	617	624		|O
BJ	625	627		|O
,	627	628		|O
Saos	629	633		|O
-	633	634		|O
2	634	635		|O
,	635	636		|O
SW	637	639		|O
-	639	640		|O
620	640	643		|O
,	643	644		|O
and	645	648		|O
PC	649	651		|O
-	651	652		|O
3	652	653		|O
nonmelanoma	654	665		|O
cells	666	671		|O
,	671	672		|O
demonstrating	673	686		|O
selective	687	696		|O
toxicity	697	705		|O
towards	706	713		|O
melanoma	714	722		|O
cells	723	728		|O
.	728	729		|O
Dicoumarol	730	740		|O
,	740	741		|O
a	742	743		|O
diaphorase	744	754		|O
inhibitor	755	764		|O
,	764	765		|O
and	766	769		|O
1	770	771		|O
-	771	772		|O
bromoheptane	772	784		|O
,	784	785		|O
a	786	787		|O
GSH	788	791		|O
depleting	792	801		|O
agent	802	807		|O
,	807	808		|O
enhanced	809	817		|O
APAP	818	822		|O
toxicity	823	831		|O
towards	832	839		|O
SK	840	842		|O
-	842	843		|O
MEL	843	846		|O
-	846	847		|O
28	847	849		|O
cells	850	855		|O
.	855	856		|O
AA	857	859		|O
and	860	863		|O
GSH	864	867		|O
were	868	872		|O
effective	873	882		|O
in	883	885		|O
preventing	886	896		|O
APAP	897	901		|O
induced	902	909		|O
melanoma	910	918	melanoma cell toxicity	|B-ADVERSE
cell	919	923		|I-ADVERSE
toxicity	924	932		|I-ADVERSE
.	932	933		|O
Trifluoperazine	934	949		|O
and	950	953		|O
cyclosporin	954	965		|O
A	966	967		|O
,	967	968		|O
inhibitors	969	979		|O
of	980	982		|O
permeability	983	995		|O
transition	996	1006		|O
pore	1007	1011		|O
in	1012	1014		|O
mitochondria	1015	1027		|O
,	1027	1028		|O
significantly	1029	1042		|O
prevented	1043	1052		|O
APAP	1053	1057	APAP melanoma cell toxicity	|B-ADVERSE
melanoma	1058	1066		|I-ADVERSE
cell	1067	1071		|I-ADVERSE
toxicity	1072	1080		|I-ADVERSE
.	1080	1081		|O
APAP	1082	1086		|O
caused	1087	1093		|O
time	1094	1098		|O
and	1099	1102		|O
dose	1103	1107		|O
-	1107	1108		|O
dependent	1108	1117		|O
decline	1118	1125		|O
in	1126	1128		|O
intracellular	1129	1142		|O
GSH	1143	1146		|O
content	1147	1154		|O
in	1155	1157		|O
SK	1158	1160		|O
-	1160	1161		|O
MEL	1161	1164		|O
-	1164	1165		|O
28	1165	1167		|O
,	1167	1168		|O
which	1169	1174		|O
preceded	1175	1183		|O
cell	1184	1188	cell toxicity	|B-ADVERSE
toxicity	1189	1197		|I-ADVERSE
.	1197	1198		|O
APAP	1199	1203		|O
led	1204	1207		|O
to	1208	1210		|O
ROS	1211	1214		|O
formation	1215	1224		|O
in	1225	1227		|O
SK	1228	1230		|O
-	1230	1231		|O
MEL	1231	1234		|O
-	1234	1235		|O
28	1235	1237		|O
cells	1238	1243		|O
which	1244	1249		|O
was	1250	1253		|O
exacerbated	1254	1265		|O
by	1266	1268		|O
dicoumarol	1269	1279		|O
and	1280	1283		|O
1	1284	1285		|O
-	1285	1286		|O
bromoheptane	1286	1298		|O
whereas	1299	1306		|O
cyslosporin	1307	1318		|O
A	1319	1320		|O
and	1321	1324		|O
trifluoperazine	1325	1340		|O
prevented	1341	1350		|O
it	1351	1353		|O
.	1353	1354		|O
Our	1355	1358		|O
investigation	1359	1372		|O
suggests	1373	1381		|O
that	1382	1386		|O
APAP	1387	1391		|O
is	1392	1394		|O
a	1395	1396		|O
tyrosinase	1397	1407		|O
substrate	1408	1417		|O
,	1417	1418		|O
and	1419	1422		|O
that	1423	1427		|O
intracellular	1428	1441		|O
GSH	1442	1445		|O
depletion	1446	1455		|O
,	1455	1456		|O
ROS	1457	1460		|O
formation	1461	1470		|O
and	1471	1474		|O
induced	1475	1482		|O
mitochondrial	1483	1496	mitochondrial toxicity	|B-ADVERSE
toxicity	1497	1505		|I-ADVERSE
contributed	1506	1517		|O
towards	1518	1525		|O
APAP	1526	1530		|O
's	1530	1532		|O
selective	1533	1542		|O
toxicity	1543	1551		|O
in	1552	1554		|O
SK	1555	1557		|O
-	1557	1558		|O
MEL	1558	1561		|O
-	1561	1562		|O
28	1562	1564		|O
cells	1565	1570		|O
.	1570	1571		|O

### 18952618
Hepatic	0	7		|O
safety	8	14		|O
of	15	17		|O
tipranavir	18	28		|O
plus	29	33		|O
ritonavir	34	43		|O
(	44	45		|O
TPV	45	48		|O
/	48	49		|O
r	49	50		|O
)	50	51		|O
-	51	52		|O
based	52	57		|O
antiretroviral	58	72		|O
combinations	73	85		|O
:	85	86		|O
effect	87	93		|O
of	94	96		|O
hepatitis	97	106	hepatitis virus co-infection	|B-DISEASE
virus	107	112		|I-DISEASE
co	113	115		|I-DISEASE
-	115	116		|I-DISEASE
infection	116	125		|I-DISEASE
and	126	129		|O
pre	130	133		|O
-	133	134		|O
existing	134	142		|O
fibrosis	143	151	fibrosis	|B-DISEASE
.	151	152		|O
OBJECTIVES	154	164		|O
:	164	165		|O
The	166	169		|O
aim	170	173		|O
of	174	176		|O
this	177	181		|O
study	182	187		|O
was	188	191		|O
to	192	194		|O
evaluate	195	203		|O
the	204	207		|O
incidence	208	217		|O
and	218	221		|O
risk	222	226		|O
factors	227	234		|O
of	235	237		|O
severe	238	244		|O
liver	245	250		|O
events	251	257		|O
among	258	263		|O
HIV	264	267		|O
-	267	268		|O
infected	268	276		|O
patients	277	285		|O
treated	286	293		|O
with	294	298		|O
drug	299	303		|O
combinations	304	316		|O
including	317	326		|O
tipranavir	327	337		|O
boosted	338	345		|O
with	346	350		|O
ritonavir	351	360		|O
(	361	362		|O
TPV	362	365		|O
/	365	366		|O
r	366	367		|O
)	367	368		|O
.	368	369		|O
METHODS	370	377		|O
:	377	378		|O
One	379	382		|O
hundred	383	390		|O
and	391	394		|O
fifty	395	400		|O
patients	401	409		|O
were	410	414		|O
selected	415	423		|O
because	424	431		|O
they	432	436		|O
started	437	444		|O
a	445	446		|O
regimen	447	454		|O
that	455	459		|O
included	460	468		|O
TPV	469	472		|O
/	472	473		|O
r	473	474		|O
(	475	476		|O
500/200	476	483		|O
mg	484	486		|O
twice	487	492		|O
a	493	494		|O
day	495	498		|O
)	498	499		|O
and	500	503		|O
had	504	507		|O
clinical	508	516		|O
visits	517	523		|O
at	524	526		|O
least	527	532		|O
every	533	538		|O
3	539	540		|O
months	541	547		|O
.	547	548		|O
Patients	549	557		|O
who	558	561		|O
discontinued	562	574		|O
TPV	575	578		|O
/	578	579		|O
r	579	580		|O
before	581	587		|O
their	588	593		|O
first	594	599		|O
visit	600	605		|O
were	606	610		|O
included	611	619		|O
.	619	620		|O
RESULTS	621	628		|O
:	628	629		|O
Twelve	630	636		|O
(	637	638		|O
8%	638	640		|O
)	640	641		|O
individuals	642	653		|O
developed	654	663		|O
grade	664	669		|O
>	669	670		|O
or	670	672		|O
=	672	673		|O
3	673	674		|O
transaminase	675	687		|O
elevation	688	697		|O
(	698	699		|O
G	699	700		|O
>	700	701		|O
or	701	703		|O
=	703	704		|O
3TE	704	707		|O
)	707	708		|O
.	708	709		|O
Nine	710	714		|O
(	715	716		|O
6%	716	718		|O
)	718	719		|O
patients	720	728		|O
discontinued	729	741		|O
TPV	742	745		|O
/	745	746		|O
r	746	747		|O
due	748	751		|O
to	752	754		|O
liver	755	760		|O
events	761	767		|O
.	767	768		|O
Six	769	772		|O
(	773	774		|O
8.6%	774	778		|O
)	778	779		|O
of	780	782		|O
70	783	785		|O
hepatitis	786	795		|O
C	796	797		|O
virus	798	803		|O
(	804	805		|O
HCV	805	808		|O
)	808	809		|O
co	810	812		|O
-	812	813		|O
infected	813	821		|O
patients	822	830		|O
and	831	834		|O
6	835	836		|O
(	837	838		|O
7.5%	838	842		|O
)	842	843		|O
of	844	846		|O
80	847	849		|O
subjects	850	858		|O
without	859	866		|O
HCV	867	870		|O
co	871	873		|O
-	873	874		|O
infection	874	883		|O
developed	884	893		|O
G	894	895		|O
>	895	896		|O
or	896	898		|O
=	898	899		|O
3TE	899	902		|O
(	903	904		|O
P	904	905		|O
=	905	906		|O
1	906	907		|O
)	907	908		|O
.	908	909		|O
Liver	910	915	Liver fibrosis	|B-DISEASE
fibrosis	916	924		|I-DISEASE
was	925	928		|O
evaluable	929	938		|O
in	939	941		|O
48	942	944		|O
(	945	946		|O
63%	946	949		|O
)	949	950		|O
of	951	953		|O
76	954	956		|O
individuals	957	968		|O
with	969	973		|O
hepatitis	974	983		|O
B	984	985		|O
virus	986	991		|O
and	992	995		|O
/	995	996		|O
or	996	998		|O
HCV	999	1002	HCV infection	|B-DISEASE
infection	1003	1012		|I-DISEASE
.	1012	1013		|O
Four	1014	1018		|O
(	1019	1020		|O
13%	1020	1023		|O
)	1023	1024		|O
of	1025	1027		|O
30	1028	1030		|O
subjects	1031	1039		|O
with	1040	1044		|O
moderate	1045	1053		|O
-	1053	1054		|O
to	1054	1056		|O
-	1056	1057		|O
severe	1057	1063		|O
fibrosis	1064	1072	fibrosis	|B-ADVERSE
and	1073	1076		|O
none	1077	1081		|O
of	1082	1084		|O
18	1085	1087		|O
with	1088	1092		|O
mild	1093	1097		|O
fibrosis	1098	1106	fibrosis	|B-ADVERSE
showed	1107	1113		|O
G	1114	1115		|O
>	1115	1116		|O
or	1116	1118		|O
=	1118	1119		|O
3TE	1119	1122		|O
(	1123	1124		|O
P	1124	1125		|O
=	1125	1126		|O
0.3	1126	1129		|O
)	1129	1130		|O
.	1130	1131		|O
None	1132	1136		|O
of	1137	1139		|O
nine	1140	1144		|O
patients	1145	1153		|O
with	1154	1158		|O
cirrhosis	1159	1168	cirrhosis	|B-DISEASE
showed	1169	1175		|O
G	1176	1177		|O
>	1177	1178		|O
or	1178	1180		|O
=	1180	1181		|O
3TE	1181	1184		|O
.	1184	1185		|O
CONCLUSIONS	1186	1197		|O
:	1197	1198		|O
Liver	1199	1204		|O
tolerability	1205	1217		|O
of	1218	1220		|O
TPV	1221	1224		|O
/	1224	1225		|O
r	1225	1226		|O
was	1227	1230		|O
generally	1231	1240		|O
good	1241	1245		|O
in	1246	1248		|O
a	1249	1250		|O
cohort	1251	1257		|O
of	1258	1260		|O
patients	1261	1269		|O
with	1270	1274		|O
a	1275	1276		|O
high	1277	1281		|O
proportion	1282	1292		|O
of	1293	1295		|O
HCV	1296	1299	HCV co-infection	|B-DISEASE
co	1300	1302		|I-DISEASE
-	1302	1303		|I-DISEASE
infection	1303	1312		|I-DISEASE
,	1312	1313		|O
including	1314	1323		|O
subjects	1324	1332		|O
with	1333	1337		|O
advanced	1338	1346		|O
fibrosis	1347	1355	fibrosis	|B-DISEASE
.	1355	1356		|O
The	1357	1360		|O
presence	1361	1369		|O
of	1370	1372		|O
HCV	1373	1376	HCV co-infection	|B-DISEASE
co	1377	1379		|I-DISEASE
-	1379	1380		|I-DISEASE
infection	1380	1389		|I-DISEASE
was	1390	1393		|O
not	1394	1397		|O
associated	1398	1408		|O
with	1409	1413		|O
an	1414	1416		|O
increased	1417	1426		|O
risk	1427	1431		|O
of	1432	1434		|O
severe	1435	1441		|O
transaminase	1442	1454		|O
elevations	1455	1465		|O
.	1465	1466		|O

### 18721818
18beta	0	6		|O
-	6	7		|O
Glycyrrhetinic	7	21		|O
acid	22	26		|O
induces	27	34		|O
apoptotic	35	44		|O
cell	45	49		|O
death	50	55		|O
in	56	58		|O
SiHa	59	63		|O
cells	64	69		|O
and	70	73		|O
exhibits	74	82		|O
a	83	84		|O
synergistic	85	96		|O
effect	97	103		|O
against	104	111		|O
antibiotic	112	122		|O
anti	123	127		|O
-	127	128		|O
cancer	128	134		|O
drug	135	139	drug toxicity	|B-ADVERSE
toxicity	140	148		|I-ADVERSE
.	148	149		|O
Defects	151	158		|O
in	159	161		|O
mitochondrial	162	175		|O
function	176	184		|O
have	185	189		|O
been	190	194		|O
shown	195	200		|O
to	201	203		|O
participate	204	215		|O
in	216	218		|O
the	219	222		|O
induction	223	232		|O
of	233	235		|O
cell	236	240		|O
death	241	246		|O
in	247	249		|O
cancer	250	256		|O
cells	257	262		|O
.	262	263		|O
The	264	267		|O
present	268	275		|O
study	276	281		|O
was	282	285		|O
designed	286	294		|O
to	295	297		|O
assess	298	304		|O
the	305	308		|O
toxic	309	314		|O
effect	315	321		|O
of	322	324		|O
18beta	325	331		|O
-	331	332		|O
glycyrrhetinic	332	346		|O
acid	347	351		|O
against	352	359		|O
human	360	365		|O
cervix	366	372		|O
and	373	376		|O
uterus	377	383		|O
tumor	384	389		|O
cell	390	394		|O
line	395	399		|O
SiHa	400	404		|O
cells	405	410		|O
in	411	413		|O
relation	414	422		|O
to	423	425		|O
the	426	429		|O
mitochondria	430	442		|O
-	442	443		|O
mediated	443	451		|O
cell	452	456		|O
-	456	457		|O
death	457	462		|O
process	463	470		|O
and	471	474		|O
evaluate	475	483		|O
the	484	487		|O
combined	488	496		|O
toxic	497	502		|O
effect	503	509		|O
of	510	512		|O
18beta	513	519		|O
-	519	520		|O
glycyrrhetinic	520	534		|O
acid	535	539		|O
and	540	543		|O
anti	544	548		|O
-	548	549		|O
cancer	549	555		|O
drugs	556	561		|O
.	561	562		|O
18beta	563	569		|O
-	569	570		|O
Glycyrrhetinic	570	584		|O
acid	585	589		|O
induced	590	597		|O
the	598	601		|O
nuclear	602	609		|O
damage	610	616		|O
,	616	617		|O
changes	618	625		|O
in	626	628		|O
the	629	632		|O
mitochondrial	633	646		|O
membrane	647	655		|O
permeability	656	668		|O
,	668	669		|O
formation	670	679		|O
of	680	682		|O
reactive	683	691		|O
oxygen	692	698		|O
species	699	706		|O
and	707	710		|O
depletion	711	720		|O
of	721	723		|O
glutathione	724	735		|O
in	736	738		|O
SiHa	739	743		|O
cells	744	749		|O
.	749	750		|O
It	751	753		|O
caused	754	760		|O
cell	761	765		|O
death	766	771		|O
by	772	774		|O
inducing	775	783		|O
the	784	787		|O
increase	788	796		|O
in	797	799		|O
the	800	803		|O
pro	804	807		|O
-	807	808		|O
apoptotic	808	817		|O
Bax	818	821		|O
protein	822	829		|O
and	830	833		|O
cytochrome	834	844		|O
c	845	846		|O
levels	847	853		|O
,	853	854		|O
reduction	855	864		|O
in	865	867		|O
anti	868	872		|O
-	872	873		|O
apoptotic	873	882		|O
Bcl	883	886		|O
-	886	887		|O
2	887	888		|O
level	889	894		|O
,	894	895		|O
subsequent	896	906		|O
caspase	907	914		|O
-	914	915		|O
3	915	916		|O
activation	917	927		|O
and	928	931		|O
loss	932	936		|O
of	937	939		|O
the	940	943		|O
mitochondrial	944	957		|O
transmembrane	958	971		|O
potential	972	981		|O
.	981	982		|O
Unlike	983	989		|O
18beta	990	996		|O
-	996	997		|O
glycyrrhetinic	997	1011		|O
acid	1012	1016		|O
,	1016	1017		|O
a	1018	1019		|O
pro	1020	1023		|O
-	1023	1024		|O
compound	1024	1032		|O
glycyrrhizin	1033	1045		|O
up	1046	1048		|O
to	1049	1051		|O
100	1052	1055		|O
microM	1056	1062		|O
did	1063	1066		|O
not	1067	1070		|O
induce	1071	1077		|O
cell	1078	1082		|O
death	1083	1088		|O
and	1089	1092		|O
depletion	1093	1102		|O
of	1103	1105		|O
glutathione	1106	1117		|O
.	1117	1118		|O
Combined	1119	1127		|O
treatment	1128	1137		|O
of	1138	1140		|O
mitomycin	1141	1150		|O
c	1151	1152		|O
(	1153	1154		|O
or	1154	1156		|O
doxorubicin	1157	1168		|O
)	1168	1169		|O
and	1170	1173		|O
18beta	1174	1180		|O
-	1180	1181		|O
glycyrrhetinic	1181	1195		|O
acid	1196	1200		|O
revealed	1201	1209		|O
a	1210	1211		|O
synergistic	1212	1223	synergistic toxic effect	|B-ADVERSE
toxic	1224	1229		|I-ADVERSE
effect	1230	1236		|I-ADVERSE
.	1236	1237		|O
Meanwhile	1238	1247		|O
,	1247	1248		|O
combination	1249	1260		|O
of	1261	1263		|O
camptothecin	1264	1276		|O
and	1277	1280		|O
18beta	1281	1287		|O
-	1287	1288		|O
glycyrrhetinic	1288	1302		|O
acid	1303	1307		|O
exhibited	1308	1317		|O
an	1318	1320		|O
additive	1321	1329		|O
cytotoxic	1330	1339	cytotoxic effect	|B-ADVERSE
effect	1340	1346		|I-ADVERSE
.	1346	1347		|O
Results	1348	1355		|O
suggest	1356	1363		|O
that	1364	1368		|O
18beta	1369	1375		|O
-	1375	1376		|O
glycyrrhetinic	1376	1390		|O
acid	1391	1395		|O
may	1396	1399		|O
cause	1400	1405		|O
cell	1406	1410		|O
death	1411	1416		|O
in	1417	1419		|O
SiHa	1420	1424		|O
cells	1425	1430		|O
by	1431	1433		|O
inducing	1434	1442		|O
the	1443	1446		|O
mitochondrial	1447	1460		|O
membrane	1461	1469		|O
permeability	1470	1482		|O
change	1483	1489		|O
,	1489	1490		|O
leading	1491	1498		|O
to	1499	1501		|O
cytochrome	1502	1512		|O
c	1513	1514		|O
release	1515	1522		|O
and	1523	1526		|O
caspase	1527	1534		|O
-	1534	1535		|O
3	1535	1536		|O
activation	1537	1547		|O
.	1547	1548		|O
The	1549	1552		|O
effect	1553	1559		|O
may	1560	1563		|O
be	1564	1566		|O
associated	1567	1577		|O
with	1578	1582		|O
increased	1583	1592		|O
formation	1593	1602		|O
of	1603	1605		|O
reactive	1606	1614		|O
oxygen	1615	1621		|O
species	1622	1629		|O
and	1630	1633		|O
depletion	1634	1643		|O
of	1644	1646		|O
glutathione	1647	1658		|O
.	1658	1659		|O
Combined	1660	1668		|O
treatment	1669	1678		|O
of	1679	1681		|O
antibiotic	1682	1692		|O
anti	1693	1697		|O
-	1697	1698		|O
cancer	1698	1704		|O
drug	1705	1709		|O
and	1710	1713		|O
18beta	1714	1720		|O
-	1720	1721		|O
glycyrrhetinic	1721	1735		|O
acid	1736	1740		|O
seems	1741	1746		|O
to	1747	1749		|O
exhibit	1750	1757		|O
a	1758	1759		|O
synergistic	1760	1771	synergistic toxic effect	|B-ADVERSE
toxic	1772	1777		|I-ADVERSE
effect	1778	1784		|I-ADVERSE
.	1784	1785		|O

### 18759504
Role	0	4		|O
of	5	7		|O
the	8	11		|O
nitro	12	17		|O
functionality	18	31		|O
in	32	34		|O
the	35	38		|O
DNA	39	42		|O
binding	43	50		|O
of	51	53		|O
3	54	55		|O
-	55	56		|O
nitro	56	61		|O
-	61	62		|O
10	62	64		|O
-	64	65		|O
methylbenzothiazolo	65	84		|O
[	84	85		|O
3,2	85	88		|O
-	88	89		|O
a	89	90		|O
]	90	91		|O
quinolinium	91	102		|O
chloride	103	111		|O
.	111	112		|O
Interest	114	122		|O
in	123	125		|O
DNA	126	129		|O
binding	130	137		|O
drugs	138	143		|O
has	144	147		|O
increased	148	157		|O
in	158	160		|O
recent	161	167		|O
years	168	173		|O
due	174	177		|O
to	178	180		|O
their	181	186		|O
importance	187	197		|O
in	198	200		|O
the	201	204		|O
treatment	205	214		|O
of	215	217		|O
genome	218	224	genome-related diseases	|B-DISEASE
-	224	225		|I-DISEASE
related	225	232		|I-DISEASE
diseases	233	241		|I-DISEASE
,	241	242		|O
like	243	247		|O
cancer	248	254	cancer	|B-DISEASE
.	254	255		|O
A	256	257		|O
new	258	261		|O
family	262	268		|O
of	269	271		|O
water	272	277		|O
-	277	278		|O
soluble	278	285		|O
DNA	286	289		|O
binding	290	297		|O
compounds	298	307		|O
,	307	308		|O
the	309	312		|O
benzothiazolo	313	326		|O
[	326	327		|O
3,2	327	330		|O
-	330	331		|O
a	332	333		|O
]	333	334		|O
quinolinium	334	345		|O
chlorides	346	355		|O
(	356	357		|O
BQCls	357	362		|O
)	362	363		|O
,	363	364		|O
is	365	367		|O
studied	368	375		|O
here	376	380		|O
as	381	383		|O
potential	384	393		|O
candidates	394	404		|O
for	405	408		|O
chemical	409	417		|O
treatment	418	427		|O
of	428	430		|O
solid	431	436		|O
tumor	437	442		|O
cells	443	448		|O
that	449	453		|O
may	454	457		|O
encounter	458	467		|O
low	468	471		|O
-	471	472		|O
oxygen	472	478		|O
environments	479	491		|O
,	491	492		|O
a	493	494		|O
condition	495	504		|O
known	505	510		|O
as	511	513		|O
hypoxia	514	521	hypoxia	|B-DISEASE
.	521	522		|O
These	523	528		|O
compounds	529	538		|O
are	539	542		|O
good	543	547		|O
DNA	548	551		|O
intercalators	552	565		|O
;	565	566		|O
however	567	574		|O
,	574	575		|O
no	576	578		|O
studies	579	586		|O
have	587	591		|O
been	592	596		|O
made	597	601		|O
of	602	604		|O
these	605	610		|O
compounds	611	620		|O
under	621	626		|O
hypoxic	627	634		|O
conditions	635	645		|O
.	645	646		|O
This	647	651		|O
work	652	656		|O
demonstrates	657	669		|O
the	670	673		|O
importance	674	684		|O
of	685	687		|O
the	688	691		|O
nitro	692	697		|O
-	697	698		|O
functionality	698	711		|O
in	712	714		|O
the	715	718		|O
DNA	719	722		|O
binding	723	730		|O
of	731	733		|O
3	734	735		|O
-	735	736		|O
nitro	736	741		|O
-	741	742		|O
10	742	744		|O
-	744	745		|O
methylbenzothiazolo	745	764		|O
[	764	765		|O
3,2	765	768		|O
-	768	769		|O
a	770	771		|O
]	771	772		|O
quinolinium	772	783		|O
chloride	784	792		|O
(	793	794		|O
NBQ	794	797		|O
-	797	798		|O
91	798	800		|O
)	800	801		|O
,	801	802		|O
which	803	808		|O
possesses	809	818		|O
nitro	819	824		|O
-	824	825		|O
functionality	825	838		|O
,	838	839		|O
and	840	843		|O
10	844	846		|O
-	846	847		|O
methylbenzothiazolo	847	866		|O
[	866	867		|O
3,2	867	870		|O
-	870	871		|O
a	872	873		|O
]	873	874		|O
quinolinium	874	885		|O
chloride	886	894		|O
(	895	896		|O
BQ	896	898		|O
-	898	899		|O
106	899	902		|O
)	902	903		|O
,	903	904		|O
which	905	910		|O
does	911	915		|O
not	916	919		|O
.	919	920		|O
Both	921	925		|O
NBQ	926	929		|O
-	929	930		|O
91	930	932		|O
and	933	936		|O
BQ	937	939		|O
-	939	940		|O
106	940	943		|O
have	944	948		|O
similar	949	956		|O
noncovalent	957	968		|O
binding	969	976		|O
affinity	977	985		|O
toward	986	992		|O
DNA	993	996		|O
.	996	997		|O
Dialysis	998	1006		|O
experiments	1007	1018		|O
show	1019	1023		|O
that	1024	1028		|O
NBQ	1029	1032		|O
-	1032	1033		|O
91	1033	1035		|O
binds	1036	1041		|O
DNA	1042	1045		|O
under	1046	1051		|O
N2	1052	1054		|O
-	1054	1055		|O
saturated	1055	1064		|O
conditions	1065	1075		|O
with	1076	1080		|O
increasing	1081	1091		|O
concentrations	1092	1106		|O
of	1107	1109		|O
reducing	1110	1118		|O
agent	1119	1124		|O
,	1124	1125		|O
presumably	1126	1136		|O
due	1137	1140		|O
to	1141	1143		|O
reduction	1144	1153		|O
of	1154	1156		|O
the	1157	1160		|O
nitro	1161	1166		|O
-	1166	1167		|O
functionality	1167	1180		|O
.	1180	1181		|O
Conversely	1182	1192		|O
,	1192	1193		|O
because	1194	1201		|O
of	1202	1204		|O
the	1205	1208		|O
lack	1209	1213		|O
of	1214	1216		|O
nitro	1217	1222		|O
-	1222	1223		|O
functionality	1223	1236		|O
,	1236	1237		|O
the	1238	1241		|O
presence	1242	1250		|O
of	1251	1253		|O
a	1254	1255		|O
reducing	1256	1264		|O
agent	1265	1270		|O
had	1271	1274		|O
no	1275	1277		|O
effect	1278	1284		|O
on	1285	1287		|O
BQ	1288	1290		|O
-	1290	1291		|O
106	1291	1294		|O
binding	1295	1302		|O
to	1303	1305		|O
DNA	1306	1309		|O
under	1310	1315		|O
both	1316	1320		|O
aerobic	1321	1328		|O
and	1329	1332		|O
N2	1333	1335		|O
-	1335	1336		|O
saturated	1336	1345		|O
conditions	1346	1356		|O
.	1356	1357		|O
Clonogenic	1358	1368		|O
assays	1369	1375		|O
were	1376	1380		|O
performed	1381	1390		|O
to	1391	1393		|O
determine	1394	1403		|O
the	1404	1407		|O
quinolinium	1408	1419		|O
chloride	1420	1428		|O
cytotoxicities	1429	1443		|O
under	1444	1449		|O
both	1450	1454		|O
aerobic	1455	1462		|O
(	1463	1464		|O
95%	1464	1467		|O
air	1468	1471		|O
and	1472	1475		|O
5%	1476	1478		|O
CO2	1479	1482		|O
)	1482	1483		|O
and	1484	1487		|O
hypoxic	1488	1495		|O
(	1496	1497		|O
80%	1497	1500		|O
N2	1501	1503		|O
and	1504	1507		|O
20%	1508	1511		|O
CO2	1512	1515		|O
)	1515	1516		|O
conditions	1517	1527		|O
.	1527	1528		|O
The	1529	1532		|O
calculated	1533	1543		|O
ratios	1544	1550		|O
of	1551	1553		|O
cellular	1554	1562	cellular toxicity	|B-ADVERSE
toxicity	1563	1571		|I-ADVERSE
under	1572	1577		|O
aerobic	1578	1585		|O
to	1586	1588		|O
hypoxic	1589	1596		|O
conditions	1597	1607		|O
caused	1608	1614		|O
by	1615	1617		|O
the	1618	1621		|O
same	1622	1626		|O
concentration	1627	1640		|O
of	1641	1643		|O
test	1644	1648		|O
agent	1649	1654		|O
(	1655	1656		|O
CTR	1656	1659		|O
values	1660	1666		|O
)	1666	1667		|O
show	1668	1672		|O
greater	1673	1680		|O
levels	1681	1687		|O
of	1688	1690		|O
cell	1691	1695		|O
death	1696	1701		|O
under	1702	1707		|O
hypoxia	1708	1715	hypoxia	|B-DISEASE
than	1716	1720		|O
under	1721	1726		|O
aerobic	1727	1734		|O
conditions	1735	1745		|O
for	1746	1749		|O
mitomycin	1750	1759		|O
C	1760	1761		|O
(	1762	1763		|O
MC	1763	1765		|O
)	1765	1766		|O
(	1767	1768		|O
CTR	1768	1771		|O
=	1772	1773		|O
0.7	1774	1777		|O
at	1778	1780		|O
1	1781	1782		|O
microM	1783	1789		|O
)	1789	1790		|O
and	1791	1794		|O
NBQ	1795	1798		|O
-	1798	1799		|O
91	1799	1801		|O
(	1802	1803		|O
CTR	1803	1806		|O
=	1807	1808		|O
0.4	1809	1812		|O
at	1813	1815		|O
200	1816	1819		|O
microM	1820	1826		|O
)	1826	1827		|O
than	1828	1832		|O
for	1833	1836		|O
BQ	1837	1839		|O
-	1839	1840		|O
106	1840	1843		|O
(	1844	1845		|O
CTR	1845	1848		|O
=	1849	1850		|O
1.0	1851	1854		|O
at	1855	1857		|O
200	1858	1861		|O
microM	1862	1868		|O
)	1868	1869		|O
,	1869	1870		|O
which	1871	1876		|O
agreed	1877	1883		|O
with	1884	1888		|O
the	1889	1892		|O
previously	1893	1903		|O
reported	1904	1912		|O
data	1913	1917		|O
for	1918	1921		|O
MC	1922	1924		|O
and	1925	1928		|O
confirmed	1929	1938		|O
the	1939	1942		|O
importance	1943	1953		|O
of	1954	1956		|O
nitro	1957	1962		|O
-	1962	1963		|O
functionality	1963	1976		|O
for	1977	1980		|O
reactivity	1981	1991		|O
under	1992	1997		|O
hypoxic	1998	2005		|O
conditions	2006	2016		|O
.	2016	2017		|O
There	2018	2023		|O
was	2024	2027		|O
no	2028	2030		|O
correlation	2031	2042		|O
between	2043	2050		|O
noncovalent	2051	2062		|O
binding	2063	2070		|O
affinity	2071	2079		|O
constants	2080	2089		|O
and	2090	2093		|O
their	2094	2099		|O
cytotoxicity	2100	2112	cytotoxicity	|B-ADVERSE
under	2113	2118		|O
hypoxic	2119	2126		|O
conditions	2127	2137		|O
.	2137	2138		|O
Adduct	2139	2145		|O
formation	2146	2155		|O
between	2156	2163		|O
the	2164	2167		|O
NBQ	2168	2171		|O
-	2171	2172		|O
91	2172	2174		|O
and	2175	2178		|O
2'	2179	2181		|O
-	2181	2182		|O
dG	2182	2184		|O
was	2185	2188		|O
also	2189	2193		|O
assessed	2194	2202		|O
by	2203	2205		|O
reacting	2206	2214		|O
2'	2215	2217		|O
-	2217	2218		|O
dG	2218	2220		|O
or	2221	2223		|O
DNA	2224	2227		|O
with	2228	2232		|O
NBQ	2233	2236		|O
-	2236	2237		|O
91	2237	2239		|O
and	2240	2243		|O
BQ	2244	2246		|O
-	2246	2247		|O
106	2247	2250		|O
under	2251	2256		|O
N2	2257	2259		|O
-	2259	2260		|O
saturated	2260	2269		|O
conditions	2270	2280		|O
in	2281	2283		|O
the	2284	2287		|O
presence	2288	2296		|O
of	2297	2299		|O
hypoxanthine	2300	2312		|O
and	2313	2316		|O
xanthine	2317	2325		|O
oxidase	2326	2333		|O
(	2334	2335		|O
HX	2335	2337		|O
/	2337	2338		|O
XO	2338	2340		|O
)	2340	2341		|O
.	2341	2342		|O
DNA	2343	2346		|O
covalent	2347	2355		|O
adduct	2356	2362		|O
formation	2363	2372		|O
was	2373	2376		|O
analyzed	2377	2385		|O
by	2386	2388		|O
two	2389	2392		|O
techniques	2393	2403		|O
:	2403	2404		|O
LC	2405	2407		|O
-	2407	2408		|O
ESI	2408	2411		|O
-	2411	2412		|O
MS	2412	2414		|O
and	2415	2418		|O
Sephadex	2419	2427		|O
size	2428	2432		|O
exclusion	2433	2442		|O
chromatography	2443	2457		|O
.	2457	2458		|O
LC	2459	2461		|O
-	2461	2462		|O
ESI	2462	2465		|O
-	2465	2466		|O
MS	2466	2468		|O
results	2469	2476		|O
clearly	2477	2484		|O
indicate	2485	2493		|O
the	2494	2497		|O
formation	2498	2507		|O
of	2508	2510		|O
a	2511	2512		|O
prominent	2513	2522		|O
molecular	2523	2532		|O
ion	2533	2536		|O
at	2537	2539		|O
masses	2540	2546		|O
of	2547	2549		|O
266.0	2550	2555		|O
and	2556	2559		|O
530.58	2560	2566		|O
Da	2567	2569		|O
,	2569	2570		|O
corresponding	2571	2584		|O
to	2585	2587		|O
the	2588	2591		|O
[	2592	2593		|O
M	2593	2594		|O
+	2595	2596		|O
H	2597	2598		|O
]	2598	2599		|O
(	2599	2600		|O
+	2600	2601		|O
2	2601	2602		|O
)	2602	2603		|O
and	2604	2607		|O
[	2608	2609		|O
M	2609	2610		|O
]	2610	2611		|O
(	2611	2612		|O
+	2612	2613		|O
)	2613	2614		|O
molecular	2615	2624		|O
ions	2625	2629		|O
of	2630	2632		|O
the	2633	2636		|O
monitored	2637	2646		|O
2'	2647	2649		|O
-	2649	2650		|O
dG	2650	2652		|O
-	2652	2653		|O
NBQ	2653	2656		|O
-	2656	2657		|O
91	2657	2659		|O
adduct	2660	2666		|O
.	2666	2667		|O
Results	2668	2675		|O
from	2676	2680		|O
the	2681	2684		|O
Sephadex	2685	2693		|O
size	2694	2698		|O
exclusion	2699	2708		|O
chromatography	2709	2723		|O
support	2724	2731		|O
these	2732	2737		|O
findings	2738	2746		|O
because	2747	2754		|O
the	2755	2758		|O
NBQ	2759	2762		|O
-	2762	2763		|O
91	2763	2765		|O
elution	2766	2773		|O
percentage	2774	2784		|O
increases	2785	2794		|O
in	2795	2797		|O
the	2798	2801		|O
presence	2802	2810		|O
of	2811	2813		|O
HX	2814	2816		|O
/	2816	2817		|O
XO	2817	2819		|O
due	2820	2823		|O
to	2824	2826		|O
the	2827	2830		|O
reduction	2831	2840		|O
of	2841	2843		|O
the	2844	2847		|O
nitro	2848	2853		|O
-	2853	2854		|O
functionality	2854	2867		|O
,	2867	2868		|O
which	2869	2874		|O
results	2875	2882		|O
in	2883	2885		|O
covalent	2886	2894		|O
binding	2895	2902		|O
to	2903	2905		|O
DNA	2906	2909		|O
.	2909	2910		|O
This	2911	2915		|O
study	2916	2921		|O
reports	2922	2929		|O
evidence	2930	2938		|O
of	2939	2941		|O
the	2942	2945		|O
DNA	2946	2949		|O
binding	2950	2957		|O
capacity	2958	2966		|O
of	2967	2969		|O
this	2970	2974		|O
bioreductive	2975	2987		|O
drug	2988	2992		|O
.	2992	2993		|O
The	2994	2997		|O
preferential	2998	3010		|O
N2	3011	3013		|O
-	3013	3014		|O
saturated	3014	3023		|O
over	3024	3028		|O
aerobic	3029	3036		|O
conditions	3037	3047		|O
for	3048	3051		|O
DNA	3052	3055		|O
binding	3056	3063		|O
makes	3064	3069		|O
NBQ	3070	3073		|O
-	3073	3074		|O
91	3074	3076		|O
a	3077	3078		|O
potential	3079	3088		|O
bioreductive	3089	3101		|O
compound	3102	3110		|O
for	3111	3114		|O
hypoxic	3115	3122		|O
cell	3123	3127		|O
killing	3128	3135		|O
.	3135	3136		|O

### 18641546
AcylMPAG	0	8		|O
plasma	9	15		|O
concentrations	16	30		|O
and	31	34		|O
mycophenolic	35	47	mycophenolic acid-related side effects	|B-ADVERSE
acid	48	52		|I-ADVERSE
-	52	53		|I-ADVERSE
related	53	60		|I-ADVERSE
side	61	65		|I-ADVERSE
effects	66	73		|I-ADVERSE
in	74	76		|O
patients	77	85		|O
undergoing	86	96		|O
renal	97	102		|O
transplantation	103	118		|O
are	119	122		|O
not	123	126		|O
related	127	134		|O
to	135	137		|O
the	138	141		|O
UGT2B7	142	148		|O
-	148	149		|O
840G	149	153		|O
>	153	154		|O
A	154	155		|O
gene	156	160		|O
polymorphism	161	173		|O
.	173	174		|O
Mycophenolic	176	188		|O
acid	189	193		|O
(	194	195		|O
MPA	195	198		|O
)	198	199		|O
is	200	202		|O
metabolized	203	214		|O
primarily	215	224		|O
by	225	227		|O
glucuronidation	228	243		|O
to	244	246		|O
form	247	251		|O
the	252	255		|O
biologically	256	268		|O
inactive	269	277		|O
7	278	279		|O
-	279	280		|O
O	280	281		|O
-	281	282		|O
glucuronide	282	293		|O
conjugate	294	303		|O
(	304	305		|O
MPAG	305	309		|O
)	309	310		|O
,	310	311		|O
which	312	317		|O
is	318	320		|O
the	321	324		|O
major	325	330		|O
urinary	331	338		|O
excretion	339	348		|O
product	349	356		|O
.	356	357		|O
MPA	358	361		|O
is	362	364		|O
also	365	369		|O
converted	370	379		|O
to	380	382		|O
acyl	383	387		|O
-	387	388		|O
glucuronide	388	399		|O
metabolite	400	410		|O
(	411	412		|O
AcylMPAG	412	420		|O
)	420	421		|O
,	421	422		|O
which	423	428		|O
has	429	432		|O
been	433	437		|O
suggested	438	447		|O
to	448	450		|O
be	451	453		|O
involved	454	462		|O
in	463	465		|O
the	466	469		|O
generation	470	480		|O
of	481	483		|O
MPA	484	487		|O
-	487	488		|O
related	488	495		|O
adverse	496	503		|O
events	504	510		|O
such	511	515		|O
as	516	518		|O
diarrhea	519	527	diarrhea	|B-ADVERSE
or	528	530		|O
leucopenia	531	541	leucopenia	|B-ADVERSE
.	541	542		|O
This	543	547		|O
conversion	548	558		|O
of	559	561		|O
MPA	562	565		|O
to	566	568		|O
AcylMPAG	569	577		|O
is	578	580		|O
catalyzed	581	590		|O
by	591	593		|O
UDP	594	597		|O
-	597	598		|O
glucuronosyltransferase	598	621		|O
2B7	622	625		|O
(	626	627		|O
UGT2B7	627	633		|O
)	633	634		|O
.	634	635		|O
We	636	638		|O
studied	639	646		|O
the	647	650		|O
impact	651	657		|O
of	658	660		|O
the	661	664		|O
-	665	666		|O
840G	666	670		|O
>	670	671		|O
A	671	672		|O
polymorphisms	673	686		|O
in	687	689		|O
the	690	693		|O
UGT2B7	694	700		|O
gene	701	705		|O
on	706	708		|O
the	709	712		|O
pharmacokinetics	713	729		|O
of	730	732		|O
AcylMPAG	733	741		|O
.	741	742		|O
We	743	745		|O
also	746	750		|O
investigated	751	763		|O
whether	764	771		|O
the	772	775		|O
plasma	776	782		|O
concentrations	783	797		|O
of	798	800		|O
AcylMPAG	801	809		|O
are	810	813		|O
correlated	814	824		|O
with	825	829		|O
MPA	830	833	MPA-related toxicity	|B-ADVERSE
-	833	834		|I-ADVERSE
related	834	841		|I-ADVERSE
toxicity	842	850		|I-ADVERSE
to	851	853		|O
further	854	861		|O
evaluate	862	870		|O
its	871	874		|O
potential	875	884		|O
clinical	885	893		|O
significance	894	906		|O
.	906	907		|O
In	908	910		|O
a	911	912		|O
randomized	913	923		|O
,	923	924		|O
controlled	925	935		|O
trial	936	941		|O
,	941	942		|O
comparing	943	952		|O
fixed	953	958		|O
-	958	959		|O
dose	959	963		|O
mycophenolate	964	977		|O
mofetil	978	985		|O
(	986	987		|O
MMF	987	990		|O
)	990	991		|O
with	992	996		|O
concentration	997	1010		|O
-	1010	1011		|O
controlled	1011	1021		|O
MMF	1022	1025		|O
therapy	1026	1033		|O
,	1033	1034		|O
patients	1035	1043		|O
undergoing	1044	1054		|O
renal	1055	1060		|O
transplantation	1061	1076		|O
were	1077	1081		|O
treated	1082	1089		|O
with	1090	1094		|O
a	1095	1096		|O
calcineurin	1097	1108		|O
inhibitor	1109	1118		|O
,	1118	1119		|O
MMF	1120	1123		|O
,	1123	1124		|O
and	1125	1128		|O
corticosteroids	1129	1144		|O
.	1144	1145		|O
Informed	1146	1154		|O
consent	1155	1162		|O
was	1163	1166		|O
obtained	1167	1175		|O
from	1176	1180		|O
332	1181	1184		|O
patients	1185	1193		|O
for	1194	1197		|O
genotyping	1198	1208		|O
.	1208	1209		|O
In	1210	1212		|O
all	1213	1216		|O
patients	1217	1225		|O
,	1225	1226		|O
blood	1227	1232		|O
samples	1233	1240		|O
were	1241	1245		|O
drawn	1246	1251		|O
(	1252	1253		|O
three	1253	1258		|O
samples	1259	1266		|O
within	1267	1273		|O
the	1274	1277		|O
first	1278	1283		|O
2	1284	1285		|O
hours	1286	1291		|O
after	1292	1297		|O
administration	1298	1312		|O
)	1312	1313		|O
on	1314	1316		|O
Day	1317	1320		|O
3	1321	1322		|O
,	1322	1323		|O
Day	1324	1327		|O
10	1328	1330		|O
,	1330	1331		|O
Week	1332	1336		|O
4	1337	1338		|O
,	1338	1339		|O
and	1340	1343		|O
Months	1344	1350		|O
3	1351	1352		|O
,	1352	1353		|O
6	1354	1355		|O
,	1355	1356		|O
and	1357	1360		|O
12	1361	1363		|O
to	1364	1366		|O
measure	1367	1374		|O
MPA	1375	1378		|O
and	1379	1382		|O
AcylMPAG	1383	1391		|O
plasma	1392	1398		|O
concentrations	1399	1413		|O
.	1413	1414		|O
The	1415	1418		|O
pharmacokinetics	1419	1435		|O
of	1436	1438		|O
AcylMPAG	1439	1447		|O
were	1448	1452		|O
correlated	1453	1463		|O
with	1464	1468		|O
the	1469	1472		|O
-	1473	1474		|O
840G	1474	1478		|O
>	1478	1479		|O
A	1479	1480		|O
single	1481	1487		|O
nucleotide	1488	1498		|O
polymorphism	1499	1511		|O
(	1512	1513		|O
SNP	1513	1516		|O
)	1516	1517		|O
in	1518	1520		|O
the	1521	1524		|O
UGT2B7	1525	1531		|O
gene	1532	1536		|O
.	1536	1537		|O
Heterozygosity	1538	1552		|O
for	1553	1556		|O
the	1557	1560		|O
-	1561	1562		|O
840G	1562	1566		|O
>	1566	1567		|O
A	1567	1568		|O
SNP	1569	1572		|O
in	1573	1575		|O
the	1576	1579		|O
UGT2B7	1580	1586		|O
gene	1587	1591		|O
was	1592	1595		|O
found	1596	1601		|O
in	1602	1604		|O
145	1605	1608		|O
patients	1609	1617		|O
(	1618	1619		|O
145	1619	1622		|O
of	1623	1625		|O
332	1626	1629		|O
[	1630	1631		|O
44%	1631	1634		|O
]	1634	1635		|O
)	1635	1636		|O
and	1637	1640		|O
93	1641	1643		|O
(	1644	1645		|O
93	1645	1647		|O
of	1648	1650		|O
332	1651	1654		|O
[	1655	1656		|O
28%	1656	1659		|O
]	1659	1660		|O
)	1660	1661		|O
patients	1662	1670		|O
were	1671	1675		|O
homozygous	1676	1686		|O
for	1687	1690		|O
the	1691	1694		|O
-	1695	1696		|O
840G	1696	1700		|O
>	1700	1701		|O
A	1701	1702		|O
allele	1703	1709		|O
.	1709	1710		|O
No	1711	1713		|O
difference	1714	1724		|O
was	1725	1728		|O
found	1729	1734		|O
in	1735	1737		|O
the	1738	1741		|O
dose	1742	1746		|O
-	1746	1747		|O
normalized	1747	1757		|O
AcylMPAG	1758	1766		|O
trough	1767	1773		|O
(	1774	1775		|O
C0	1775	1777		|O
)	1777	1778		|O
levels	1779	1785		|O
and	1786	1789		|O
dose	1790	1794		|O
-	1794	1795		|O
normalized	1795	1805		|O
AcylMPAG	1806	1814		|O
areas	1815	1820		|O
under	1821	1826		|O
the	1827	1830		|O
concentration	1831	1844		|O
-	1844	1845		|O
time	1845	1849		|O
curve	1850	1855		|O
(	1856	1857		|O
AUCs	1857	1861		|O
)	1861	1862		|O
at	1863	1865		|O
each	1866	1870		|O
visit	1871	1876		|O
between	1877	1884		|O
carriers	1885	1893		|O
and	1894	1897		|O
noncarriers	1898	1909		|O
of	1910	1912		|O
the	1913	1916		|O
-	1917	1918		|O
840G	1918	1922		|O
>	1922	1923		|O
A	1923	1924		|O
SNP	1925	1928		|O
.	1928	1929		|O
Also	1930	1934		|O
,	1934	1935		|O
metabolic	1936	1945		|O
ratios	1946	1952		|O
,	1952	1953		|O
expressed	1954	1963		|O
as	1964	1966		|O
AcylMPAG	1967	1975		|O
/	1975	1976		|O
MPA	1976	1979		|O
and	1980	1983		|O
AcylMPAG	1984	1992		|O
/	1992	1993		|O
MPAG	1993	1997		|O
,	1997	1998		|O
were	1999	2003		|O
not	2004	2007		|O
related	2008	2015		|O
to	2016	2018		|O
UGT2B7	2019	2025		|O
genotype	2026	2034		|O
.	2034	2035		|O
The	2036	2039		|O
dose	2040	2044		|O
-	2044	2045		|O
normalized	2045	2055		|O
AcylMPAG	2056	2064		|O
-	2064	2065		|O
C0	2065	2067		|O
and	2068	2071		|O
AcylMPAG	2072	2080		|O
AUC	2081	2084		|O
were	2085	2089		|O
higher	2090	2096		|O
in	2097	2099		|O
the	2100	2103		|O
cyclosporine	2104	2116		|O
-	2116	2117		|O
treated	2117	2124		|O
group	2125	2130		|O
compared	2131	2139		|O
with	2140	2144		|O
the	2145	2148		|O
tacrolimus	2149	2159		|O
-	2159	2160		|O
treated	2160	2167		|O
patients	2168	2176		|O
at	2177	2179		|O
each	2180	2184		|O
visit	2185	2190		|O
.	2190	2191		|O
There	2192	2197		|O
was	2198	2201		|O
no	2202	2204		|O
difference	2205	2215		|O
in	2216	2218		|O
AcylMPAG	2219	2227		|O
concentrations	2228	2242		|O
(	2243	2244		|O
trough	2244	2250		|O
or	2251	2253		|O
AUC	2254	2257		|O
)	2257	2258		|O
or	2259	2261		|O
AcylMPAG	2262	2270		|O
/	2270	2271		|O
MPAG	2271	2275		|O
ratio	2276	2281		|O
between	2282	2289		|O
patients	2290	2298		|O
with	2299	2303		|O
compared	2304	2312		|O
with	2313	2317		|O
patients	2318	2326		|O
without	2327	2334		|O
diarrhea	2335	2343	diarrhea	|B-ADVERSE
.	2343	2344		|O
None	2345	2349		|O
of	2350	2352		|O
the	2353	2356		|O
-	2357	2358		|O
840G	2358	2362		|O
>	2362	2363		|O
A	2363	2364		|O
UGT2B7	2365	2371		|O
SNPs	2372	2376		|O
was	2377	2380		|O
disproportionately	2381	2399		|O
present	2400	2407		|O
among	2408	2413		|O
the	2414	2417		|O
patients	2418	2426		|O
with	2427	2431		|O
diarrhea	2432	2440	diarrhea	|B-ADVERSE
.	2440	2441		|O
There	2442	2447		|O
was	2448	2451		|O
a	2452	2453		|O
higher	2454	2460		|O
incidence	2461	2470		|O
of	2471	2473		|O
diarrhea	2474	2482	diarrhea	|B-ADVERSE
in	2483	2485		|O
tacrolimus	2486	2496		|O
-	2496	2497		|O
treated	2497	2504		|O
patients	2505	2513		|O
[	2514	2515		|O
26	2515	2517		|O
of	2518	2520		|O
163	2521	2524		|O
(	2525	2526		|O
16.0%	2526	2531		|O
)	2531	2532		|O
]	2532	2533		|O
compared	2534	2542		|O
with	2543	2547		|O
cyclosporine	2548	2560		|O
-	2560	2561		|O
treated	2561	2568		|O
individuals	2569	2580		|O
[	2581	2582		|O
five	2582	2586		|O
of	2587	2589		|O
51	2590	2592		|O
(	2593	2594		|O
9.8%	2594	2598		|O
)	2598	2599		|O
]	2599	2600		|O
,	2600	2601		|O
although	2602	2610		|O
AcylMPAG	2611	2619		|O
concentrations	2620	2634		|O
were	2635	2639		|O
lower	2640	2645		|O
in	2646	2648		|O
tacrolimus	2649	2659		|O
-	2659	2660		|O
treated	2660	2667		|O
patients	2668	2676		|O
.	2676	2677		|O
In	2678	2680		|O
this	2681	2685		|O
study	2686	2691		|O
,	2691	2692		|O
we	2693	2695		|O
have	2696	2700		|O
found	2701	2706		|O
no	2707	2709		|O
influence	2710	2719		|O
of	2720	2722		|O
the	2723	2726		|O
-	2727	2728		|O
840G	2728	2732		|O
>	2732	2733		|O
A	2733	2734		|O
UGT2B7	2735	2741		|O
SNP	2742	2745		|O
on	2746	2748		|O
AcylMPAG	2749	2757		|O
exposure	2758	2766		|O
in	2767	2769		|O
patients	2770	2778		|O
undergoing	2779	2789		|O
renal	2790	2795		|O
transplantation	2796	2811		|O
.	2811	2812		|O
There	2813	2818		|O
also	2819	2823		|O
was	2824	2827		|O
no	2828	2830		|O
association	2831	2842		|O
between	2843	2850		|O
this	2851	2855		|O
variant	2856	2863		|O
genotype	2864	2872		|O
and	2873	2876		|O
the	2877	2880		|O
incidence	2881	2890		|O
of	2891	2893		|O
diarrhea	2894	2902	diarrhea	|B-ADVERSE
or	2903	2905		|O
leucopenia	2906	2916	leucopenia	|B-ADVERSE
,	2916	2917		|O
two	2918	2921		|O
adverse	2922	2929		|O
events	2930	2936		|O
for	2937	2940		|O
which	2941	2946		|O
a	2947	2948		|O
role	2949	2953		|O
for	2954	2957		|O
AcylMPAG	2958	2966		|O
has	2967	2970		|O
been	2971	2975		|O
suggested	2976	2985		|O
.	2985	2986		|O

### 18704471
Relationship	0	12		|O
between	13	20		|O
airborne	21	29		|O
pollen	30	36		|O
count	37	42		|O
and	43	46		|O
treatment	47	56		|O
outcome	57	64		|O
in	65	67		|O
Japanese	68	76		|O
cedar	77	82		|O
pollinosis	83	93	pollinosis	|B-DISEASE
patients	94	102		|O
.	102	103		|O
In	105	107		|O
Japan	108	113		|O
,	113	114		|O
information	115	126		|O
on	127	129		|O
daily	130	135		|O
Japanese	136	144		|O
cedar	145	150		|O
pollen	151	157		|O
counts	158	164		|O
is	165	167		|O
made	168	172		|O
public	173	179		|O
during	180	186		|O
pollen	187	193		|O
season	194	200		|O
.	200	201		|O
If	202	204		|O
symptom	205	212		|O
severity	213	221		|O
and	222	225		|O
treatment	226	235		|O
outcome	236	243		|O
are	244	247		|O
predictable	248	259		|O
according	260	269		|O
to	270	272		|O
these	273	278		|O
pollen	279	285		|O
counts	286	292		|O
,	292	293		|O
management	294	304		|O
of	305	307		|O
seasonal	308	316	seasonal allergic rhinitis	|B-DISEASE
allergic	317	325		|I-DISEASE
rhinitis	326	334		|I-DISEASE
may	335	338		|O
become	339	345		|O
more	346	350		|O
precise	351	358		|O
.	358	359		|O
The	360	363		|O
aims	364	368		|O
of	369	371		|O
the	372	375		|O
study	376	381		|O
were	382	386		|O
to	387	389		|O
evaluate	390	398		|O
the	399	402		|O
relationship	403	415		|O
between	416	423		|O
airborne	424	432		|O
pollen	433	439		|O
counts	440	446		|O
,	446	447		|O
symptom	448	455		|O
severity	456	464		|O
and	465	468		|O
treatment	469	478		|O
outcome	479	486		|O
in	487	489		|O
Japanese	490	498		|O
cedar	499	504		|O
pollinosis	505	515	pollinosis	|B-DISEASE
patients	516	524		|O
.	524	525		|O
In	526	528		|O
the	529	532		|O
randomized	533	543		|O
study	544	549		|O
,	549	550		|O
patients	551	559		|O
with	560	564		|O
moderate	565	573		|O
to	574	576		|O
most	577	581		|O
severe	582	588		|O
Japanese	589	597		|O
pollinosis	598	608	pollinosis	|B-DISEASE
were	609	613		|O
treated	614	621		|O
with	622	626		|O
fexofenadine	627	639		|O
(	640	641		|O
60	641	643		|O
mg	644	646		|O
BD	647	649		|O
)	649	650		|O
or	651	653		|O
fexofenadine	654	666		|O
and	667	670		|O
nasal	671	676		|O
corticosteroids	677	692		|O
for	693	696		|O
2	697	698		|O
weeks	699	704		|O
.	704	705		|O
During	706	712		|O
the	713	716		|O
same	717	721		|O
period	722	728		|O
daily	729	734		|O
airborne	735	743		|O
pollen	744	750		|O
counts	751	757		|O
were	758	762		|O
measured	763	771		|O
.	771	772		|O
A	773	774		|O
total	775	780		|O
of	781	783		|O
105	784	787		|O
adult	788	793		|O
patients	794	802		|O
were	803	807		|O
enrolled	808	816		|O
.	816	817		|O
No	818	820		|O
difference	821	831		|O
of	832	834		|O
treatment	835	844		|O
efficacy	845	853		|O
was	854	857		|O
seen	858	862		|O
among	863	868		|O
groups	869	875		|O
.	875	876		|O
Detailed	877	885		|O
results	886	893		|O
of	894	896		|O
efficacy	897	905		|O
and	906	909		|O
safety	910	916		|O
were	917	921		|O
previously	922	932		|O
described	933	942		|O
elsewhere	943	952		|O
.	952	953		|O
In	954	956		|O
univariate	957	967		|O
analysis	968	976		|O
,	976	977		|O
the	978	981		|O
mean	982	986		|O
cumulative	987	997		|O
amount	998	1004		|O
of	1005	1007		|O
airborne	1008	1016		|O
pollen	1017	1023		|O
exposure	1024	1032		|O
for	1033	1036		|O
4	1037	1038		|O
days	1039	1043		|O
prior	1044	1049		|O
to	1050	1052		|O
the	1053	1056		|O
study	1057	1062		|O
tended	1063	1069		|O
to	1070	1072		|O
affect	1073	1079		|O
symptom	1080	1087		|O
severity	1088	1096		|O
(	1097	1098		|O
P	1098	1099		|O
=	1100	1101		|O
0.053	1102	1107		|O
)	1107	1108		|O
and	1109	1112		|O
the	1113	1116		|O
mean	1117	1121		|O
cumulative	1122	1132		|O
amount	1133	1139		|O
of	1140	1142		|O
airborne	1143	1151		|O
pollen	1152	1158		|O
during	1159	1165		|O
the	1166	1169		|O
treatment	1170	1179		|O
period	1180	1186		|O
tended	1187	1193		|O
to	1194	1196		|O
show	1197	1201		|O
difference	1202	1212		|O
among	1213	1218		|O
five	1219	1223		|O
treatment	1224	1233		|O
outcome	1234	1241		|O
categories	1242	1252		|O
(	1253	1254		|O
P	1254	1255		|O
=	1256	1257		|O
0.066	1258	1263		|O
)	1263	1264		|O
.	1264	1265		|O
In	1266	1268		|O
multivariate	1269	1281		|O
analysis	1282	1290		|O
,	1290	1291		|O
the	1292	1295		|O
mean	1296	1300		|O
cumulative	1301	1311		|O
amount	1312	1318		|O
of	1319	1321		|O
airborne	1322	1330		|O
pollen	1331	1337		|O
exposure	1338	1346		|O
for	1347	1350		|O
4	1351	1352		|O
days	1353	1357		|O
prior	1358	1363		|O
to	1364	1366		|O
the	1367	1370		|O
study	1371	1376		|O
was	1377	1380		|O
identified	1381	1391		|O
as	1392	1394		|O
the	1395	1398		|O
only	1399	1403		|O
significant	1404	1415		|O
factor	1416	1422		|O
of	1423	1425		|O
symptom	1426	1433		|O
severity	1434	1442		|O
(	1443	1444		|O
P	1444	1445		|O
=	1446	1447		|O
0.0327	1448	1454		|O
)	1454	1455		|O
and	1456	1459		|O
cumulative	1460	1470		|O
amount	1471	1477		|O
of	1478	1480		|O
airborne	1481	1489		|O
pollen	1490	1496		|O
during	1497	1503		|O
the	1504	1507		|O
treatment	1508	1517		|O
period	1518	1524		|O
(	1525	1526		|O
P	1526	1527		|O
=	1528	1529		|O
0.027	1530	1535		|O
)	1535	1536		|O
and	1537	1540		|O
allergic	1541	1549		|O
history	1550	1557		|O
(	1558	1559		|O
P	1559	1560		|O
=	1561	1562		|O
0.027	1563	1568		|O
)	1568	1569		|O
were	1570	1574		|O
significant	1575	1586		|O
factors	1587	1594		|O
of	1595	1597		|O
treatment	1598	1607		|O
outcomes	1608	1616		|O
.	1616	1617		|O
No	1618	1620		|O
serious	1621	1628		|O
adverse	1629	1636		|O
effect	1637	1643		|O
was	1644	1647		|O
reported	1648	1656		|O
during	1657	1663		|O
the	1664	1667		|O
study	1668	1673		|O
.	1673	1674		|O
The	1675	1678		|O
amount	1679	1685		|O
of	1686	1688		|O
airborne	1689	1697		|O
pollen	1698	1704		|O
may	1705	1708		|O
be	1709	1711		|O
predictive	1712	1722		|O
of	1723	1725		|O
both	1726	1730		|O
symptom	1731	1738		|O
severity	1739	1747		|O
and	1748	1751		|O
treatment	1752	1761		|O
outcome	1762	1769		|O
.	1769	1770		|O

### 18690337
Clinical	0	8		|O
implications	9	21		|O
of	22	24		|O
clopidogrel	25	36		|O
resistance	37	47		|O
.	47	48		|O
The	50	53		|O
benefits	54	62		|O
of	63	65		|O
clopidogrel	66	77		|O
in	78	80		|O
the	81	84		|O
treatment	85	94		|O
and	95	98		|O
prevention	99	109		|O
of	110	112		|O
coronary	113	121	coronary artery disease	|B-DISEASE
artery	122	128		|I-DISEASE
disease	129	136		|I-DISEASE
are	137	140		|O
well	141	145		|O
established	146	157		|O
,	157	158		|O
however	159	166		|O
,	166	167		|O
not	168	171		|O
all	172	175		|O
individuals	176	187		|O
respond	188	195		|O
in	196	198		|O
the	199	202		|O
same	203	207		|O
way	208	211		|O
to	212	214		|O
clopidogrel	215	226		|O
;	226	227		|O
there	228	233		|O
are	234	237		|O
patients	238	246		|O
who	247	250		|O
suffer	251	257		|O
adverse	258	265		|O
events	266	272		|O
despite	273	280		|O
clopidogrel	281	292		|O
treatment	293	302		|O
.	302	303		|O
This	304	308		|O
review	309	315		|O
focuses	316	323		|O
on	324	326		|O
the	327	330		|O
definition	331	341		|O
,	341	342		|O
potential	343	352		|O
mechanisms	353	363		|O
for	364	367		|O
and	368	371		|O
clinical	372	380		|O
implications	381	393		|O
of	394	396		|O
clopidogrel	397	408		|O
resistance	409	419		|O
,	419	420		|O
as	421	423		|O
well	424	428		|O
as	429	431		|O
the	432	435		|O
strategies	436	446		|O
to	447	449		|O
improve	450	457		|O
the	458	461		|O
response	462	470		|O
to	471	473		|O
this	474	478		|O
antiplatelet	479	491		|O
drug	492	496		|O
.	496	497		|O
There	498	503		|O
is	504	506		|O
an	507	509		|O
inter	510	515		|O
-	515	516		|O
individual	516	526		|O
variability	527	538		|O
in	539	541		|O
response	542	550		|O
to	551	553		|O
clopidogrel	554	565		|O
therapy	566	573		|O
,	573	574		|O
and	575	578		|O
a	579	580		|O
sub	581	584		|O
-	584	585		|O
optimal	585	592		|O
response	593	601		|O
(	602	603		|O
clopidogrel	603	614		|O
resistance	615	625		|O
)	625	626		|O
has	627	630		|O
been	631	635		|O
associated	636	646		|O
with	647	651		|O
adverse	652	659	adverse cardiovascular events	|B-ADVERSE
cardiovascular	660	674		|I-ADVERSE
events	675	681		|I-ADVERSE
.	681	682		|O
Nevertheless	683	695		|O
,	695	696		|O
there	697	702		|O
is	703	705		|O
no	706	708		|O
clear	709	714		|O
and	715	718		|O
consensual	719	729		|O
definition	730	740		|O
of	741	743		|O
clopidogrel	744	755		|O
resistance	756	766		|O
.	766	767		|O
Response	768	776		|O
to	777	779		|O
clopidogrel	780	791		|O
therapy	792	799		|O
follows	800	807		|O
a	808	809		|O
normal	810	816		|O
,	816	817		|O
bell	818	822		|O
-	822	823		|O
shaped	823	829		|O
distribution	830	842		|O
,	842	843		|O
so	844	846		|O
a	847	848		|O
more	849	853		|O
appropriate	854	865		|O
description	866	877		|O
would	878	883		|O
be	884	886		|O
variable	887	895		|O
response	896	904		|O
rather	905	911		|O
than	912	916		|O
clopidogrel	917	928		|O
resistance	929	939		|O
.	939	940		|O
Independent	941	952		|O
of	953	955		|O
the	956	959		|O
term	960	964		|O
used	965	969		|O
,	969	970		|O
lower	971	976		|O
response	977	985		|O
to	986	988		|O
clopidogrel	989	1000		|O
therapy	1001	1008		|O
seems	1009	1014		|O
to	1015	1017		|O
be	1018	1020		|O
associated	1021	1031		|O
with	1032	1036		|O
a	1037	1038		|O
higher	1039	1045		|O
probability	1046	1057		|O
of	1058	1060		|O
suffering	1061	1070		|O
thrombotic	1071	1081	thrombotic events	|B-ADVERSE
events	1082	1088		|I-ADVERSE
.	1088	1089		|O
Due	1090	1093		|O
to	1094	1096		|O
the	1097	1100		|O
misleading	1101	1111		|O
definition	1112	1122		|O
of	1123	1125		|O
resistance	1126	1136		|O
and	1137	1140		|O
non	1141	1144		|O
-	1144	1145		|O
standardized	1145	1157		|O
method	1158	1164		|O
for	1165	1168		|O
assessing	1169	1178		|O
platelet	1179	1187		|O
inhibition	1188	1198		|O
,	1198	1199		|O
current	1200	1207		|O
guidelines	1208	1218		|O
do	1219	1221		|O
not	1222	1225		|O
recommend	1226	1235		|O
the	1236	1239		|O
use	1240	1243		|O
of	1244	1246		|O
platelet	1247	1255		|O
function	1256	1264		|O
assays	1265	1271		|O
to	1272	1274		|O
monitor	1275	1282		|O
the	1283	1286		|O
inhibitory	1287	1297		|O
effect	1298	1304		|O
of	1305	1307		|O
antiplatelet	1308	1320		|O
drugs	1321	1326		|O
.	1326	1327		|O
Current	1328	1335		|O
guidelines	1336	1346		|O
also	1347	1351		|O
do	1352	1354		|O
not	1355	1358		|O
recommend	1359	1368		|O
clopidogrel	1369	1380		|O
loading	1381	1388		|O
doses	1389	1394		|O
higher	1395	1401		|O
than	1402	1406		|O
300	1407	1410		|O
mg	1411	1413		|O
and	1414	1417		|O
daily	1418	1423		|O
maintenance	1424	1435		|O
doses	1436	1441		|O
higher	1442	1448		|O
than	1449	1453		|O
75	1454	1456		|O
mg	1457	1459		|O
,	1459	1460		|O
even	1461	1465		|O
though	1466	1472		|O
a	1473	1474		|O
regimen	1475	1482		|O
of	1483	1485		|O
600	1486	1489		|O
mg	1490	1492		|O
clopidogrel	1493	1504		|O
loading	1505	1512		|O
dose	1513	1517		|O
seems	1518	1523		|O
to	1524	1526		|O
be	1527	1529		|O
preferred	1530	1539		|O
for	1540	1543		|O
patients	1544	1552		|O
undergoing	1553	1563		|O
percutaneous	1564	1576		|O
coronary	1577	1585		|O
interventions	1586	1599		|O
.	1599	1600		|O

### 18844846
Vitamin	0	7		|O
D	8	9		|O
:	9	10		|O
criteria	11	19		|O
for	20	23		|O
safety	24	30		|O
and	31	34		|O
efficacy	35	43		|O
.	43	44		|O
The	46	49		|O
functional	50	60		|O
status	61	67		|O
indicator	68	77		|O
for	78	81		|O
vitamin	82	89		|O
D	90	91		|O
,	91	92		|O
for	93	96		|O
both	97	101		|O
safety	102	108		|O
and	109	112		|O
efficacy	113	121		|O
,	121	122		|O
is	123	125		|O
serum	126	131		|O
25	132	134		|O
-	134	135		|O
hydroxyvitamin	135	149		|O
D	150	151		|O
concentration	152	165		|O
.	165	166		|O
Efficacy	167	175		|O
for	176	179		|O
several	180	187		|O
health	188	194		|O
endpoints	195	204		|O
requires	205	213		|O
levels	214	220		|O
of	221	223		|O
80	224	226		|O
nmol	227	231		|O
/	231	232		|O
L	232	233		|O
or	234	236		|O
higher	237	243		|O
.	243	244		|O
Toxicity	245	253		|O
occurs	254	260		|O
at	261	263		|O
levels	264	270		|O
of	271	273		|O
500	274	277		|O
nmol	278	282		|O
/	282	283		|O
L	283	284		|O
or	285	287		|O
higher	288	294		|O
.	294	295		|O
The	296	299		|O
input	300	305		|O
needed	306	312		|O
for	313	316		|O
efficacy	317	325		|O
,	325	326		|O
in	327	329		|O
addition	330	338		|O
to	339	341		|O
typical	342	349		|O
food	350	354		|O
and	355	358		|O
cutaneous	359	368		|O
inputs	369	375		|O
,	375	376		|O
will	377	381		|O
usually	382	389		|O
be	390	392		|O
1000-2000	393	402		|O
IU	403	405		|O
/	405	406		|O
day	406	409		|O
of	410	412		|O
supplemental	413	425		|O
cholecalciferol	426	441		|O
.	441	442		|O
Toxicity	443	451		|O
is	452	454		|O
associated	455	465		|O
only	466	470		|O
with	471	475		|O
excessive	476	485		|O
supplemental	486	498		|O
intake	499	505		|O
(	506	507		|O
usually	507	514		|O
well	515	519		|O
above	520	525		|O
20,000	526	532		|O
IU	533	535		|O
/	535	536		|O
day	536	539		|O
)	539	540		|O
.	540	541		|O

### 18774727
Synergistic	0	11		|O
cytotoxic	12	21	cytotoxic effect	|B-ADVERSE
effect	22	28		|I-ADVERSE
of	29	31		|O
different	32	41		|O
sized	42	47		|O
ZnO	48	51		|O
nanoparticles	52	65		|O
and	66	69		|O
daunorubicin	70	82		|O
against	83	90		|O
leukemia	91	99		|O
cancer	100	106		|O
cells	107	112		|O
under	113	118		|O
UV	119	121		|O
irradiation	122	133		|O
.	133	134		|O
Failure	136	143		|O
of	144	146		|O
chemotherapy	147	159		|O
to	160	162		|O
the	163	166		|O
malignant	167	176	malignant tumor	|B-DISEASE
tumor	177	182		|I-DISEASE
is	183	185		|O
usually	186	193		|O
induced	194	201		|O
by	202	204		|O
multidrug	205	214		|O
resistance	215	225		|O
(	226	227		|O
MDR	227	230		|O
)	230	231		|O
.	231	232		|O
The	233	236		|O
development	237	248		|O
of	249	251		|O
anti	252	256		|O
-	256	257		|O
MDR	257	260		|O
agents	261	267		|O
for	268	271		|O
efficient	272	281		|O
drug	282	286		|O
delivery	287	295		|O
is	296	298		|O
of	299	301		|O
great	302	307		|O
importance	308	318		|O
in	319	321		|O
cancer	322	328	cancer	|B-DISEASE
therapy	329	336		|O
.	336	337		|O
Recent	338	344		|O
reports	345	352		|O
have	353	357		|O
demonstrated	358	370		|O
that	371	375		|O
some	376	380		|O
anticancer	381	391		|O
drugs	392	397		|O
could	398	403		|O
be	404	406		|O
readily	407	414		|O
self	415	419		|O
-	419	420		|O
assembled	420	429		|O
on	430	432		|O
some	433	437		|O
biocompatible	438	451		|O
nanomaterials	452	465		|O
covalently	466	476		|O
or	477	479		|O
non	480	483		|O
-	483	484		|O
covalently	484	494		|O
,	494	495		|O
which	496	501		|O
could	502	507		|O
effectively	508	519		|O
afford	520	526		|O
the	527	530		|O
sustained	531	540		|O
drug	541	545		|O
delivery	546	554		|O
for	555	558		|O
the	559	562		|O
target	563	569		|O
cancer	570	576		|O
cells	577	582		|O
and	583	586		|O
reduce	587	593		|O
the	594	597		|O
relevant	598	606		|O
toxicity	607	615		|O
towards	616	623		|O
normal	624	630		|O
cells	631	636		|O
and	637	640		|O
tissues	641	648		|O
.	648	649		|O
Thus	650	654		|O
these	655	660		|O
biocompatible	661	674		|O
nanomaterials	675	688		|O
may	689	692		|O
play	693	697		|O
an	698	700		|O
important	701	710		|O
role	711	715		|O
in	716	718		|O
the	719	722		|O
relevant	723	731		|O
biological	732	742		|O
and	743	746		|O
biomedical	747	757		|O
system	758	764		|O
.	764	765		|O
In	766	768		|O
this	769	773		|O
paper	774	779		|O
,	779	780		|O
we	781	783		|O
have	784	788		|O
explored	789	797		|O
the	798	801		|O
cytotoxic	802	811		|O
effect	812	818		|O
of	819	821		|O
anticancer	822	832		|O
drug	833	837		|O
daunorubicin	838	850		|O
on	851	853		|O
leukemia	854	862		|O
cancer	863	869		|O
cells	870	875		|O
in	876	878		|O
the	879	882		|O
absence	883	890		|O
and	891	894		|O
presence	895	903		|O
of	904	906		|O
different	907	916		|O
sized	917	922		|O
ZnO	923	926		|O
nanoparticles	927	940		|O
via	941	944		|O
fluorescence	945	957		|O
microscopy	958	968		|O
,	968	969		|O
UV	970	972		|O
-	972	973		|O
Vis	973	976		|O
absorption	977	987		|O
spectroscopy	988	1000		|O
,	1000	1001		|O
electrochemical	1002	1017		|O
analysis	1018	1026		|O
as	1027	1029		|O
well	1030	1034		|O
as	1035	1037		|O
MTT	1038	1041		|O
assay	1042	1047		|O
.	1047	1048		|O
Meanwhile	1049	1058		|O
,	1058	1059		|O
the	1060	1063		|O
cytotoxicity	1064	1076	cytotoxicity	|B-ADVERSE
suppression	1077	1088		|O
of	1089	1091		|O
daunorubicin	1092	1104		|O
together	1105	1113		|O
with	1114	1118		|O
different	1119	1128		|O
sized	1129	1134		|O
ZnO	1135	1138		|O
nanoparticles	1139	1152		|O
in	1153	1155		|O
the	1156	1159		|O
absence	1160	1167		|O
and	1168	1171		|O
presence	1172	1180		|O
of	1181	1183		|O
UV	1184	1186		|O
irradiation	1187	1198		|O
on	1199	1201		|O
leukemia	1202	1210		|O
cancer	1211	1217		|O
cells	1218	1223		|O
were	1224	1228		|O
also	1229	1233		|O
investigated	1234	1246		|O
using	1247	1252		|O
MTT	1253	1256		|O
assay	1257	1262		|O
.	1262	1263		|O
The	1264	1267		|O
results	1268	1275		|O
indicate	1276	1284		|O
that	1285	1289		|O
the	1290	1293		|O
combination	1294	1305		|O
of	1306	1308		|O
the	1309	1312		|O
different	1313	1322		|O
sized	1323	1328		|O
ZnO	1329	1332		|O
nanoparticles	1333	1346		|O
and	1347	1350		|O
daunorubicin	1351	1363		|O
under	1364	1369		|O
UV	1370	1372		|O
irradiation	1373	1384		|O
could	1385	1390		|O
have	1391	1395		|O
synergistic	1396	1407		|O
cytotoxic	1408	1417	cytotoxic effect	|B-ADVERSE
effect	1418	1424		|I-ADVERSE
on	1425	1427		|O
leukemia	1428	1436		|O
cancer	1437	1443		|O
cells	1444	1449		|O
,	1449	1450		|O
indicating	1451	1461		|O
the	1462	1465		|O
great	1466	1471		|O
potential	1472	1481		|O
of	1482	1484		|O
ZnO	1485	1488		|O
nanoparticles	1489	1502		|O
in	1503	1505		|O
relevant	1506	1514		|O
clinical	1515	1523		|O
and	1524	1527		|O
biomedical	1528	1538		|O
applications	1539	1551		|O
.	1551	1552		|O

### 18560212
Partial	0	7		|O
peroxisome	8	18		|O
proliferator	19	31		|O
-	31	32		|O
activated	32	41		|O
receptor	42	50		|O
agonist	51	58		|O
angiotensin	59	70		|O
receptor	71	79		|O
blockers	80	88		|O
.	88	89		|O
Potential	90	99		|O
multipronged	100	112		|O
strategy	113	121		|O
in	122	124		|O
stroke	125	131	stroke	|B-DISEASE
prevention	132	142		|O
.	142	143		|O
BACKGROUND	145	155		|O
AND	156	159		|O
PURPOSE	160	167		|O
:	167	168		|O
Although	169	177		|O
their	178	183		|O
primary	184	191		|O
mechanism	192	201		|O
of	202	204		|O
action	205	211		|O
is	212	214		|O
blood	215	220		|O
pressure	221	229		|O
lowering	230	238		|O
,	238	239		|O
emerging	240	248		|O
data	249	253		|O
suggest	254	261		|O
that	262	266		|O
select	267	273		|O
angiotensin	274	285		|O
receptor	286	294		|O
blockers	295	303		|O
(	304	305		|O
ARBs	305	309		|O
)	309	310		|O
,	310	311		|O
which	312	317		|O
partially	318	327		|O
activate	328	336		|O
the	337	340		|O
peroxisome	341	351		|O
proliferator	352	364		|O
-	364	365		|O
activated	365	374		|O
receptor	375	383		|O
gamma	384	389		|O
(	390	391		|O
PPAR	391	395		|O
-	395	396		|O
gamma	396	401		|O
)	401	402		|O
,	402	403		|O
may	404	407		|O
effectively	408	419		|O
treat	420	425		|O
insulin	426	433	insulin resistance	|B-DISEASE
resistance	434	444		|I-DISEASE
and	445	448		|O
dyslipidemia	449	461	dyslipidemia	|B-DISEASE
without	462	469		|O
the	470	473		|O
toxicity	474	482		|O
sometimes	483	492		|O
associated	493	503		|O
with	504	508		|O
full	509	513		|O
PPAR	514	518		|O
-	518	519		|O
gamma	519	524		|O
agonists	525	533		|O
.	533	534		|O
Since	535	540		|O
up	541	543		|O
to	544	546		|O
50%	547	550		|O
of	551	553		|O
the	554	557		|O
patients	558	566		|O
with	567	571		|O
ischemic	572	580	ischemic stroke	|B-DISEASE
stroke	581	587		|I-DISEASE
and	588	591		|O
transient	592	601	transient ischemic attack	|B-DISEASE
ischemic	602	610		|I-DISEASE
attack	611	617		|I-DISEASE
harbor	618	624		|O
insulin	625	632	insulin resistance	|B-DISEASE
resistance	633	643		|I-DISEASE
,	643	644		|O
drugs	645	650		|O
that	651	655		|O
simultaneously	656	670		|O
control	671	678		|O
hypertension	679	691	hypertension	|B-DISEASE
and	692	695		|O
insulin	696	703	insulin resistance	|B-DISEASE
resistance	704	714		|I-DISEASE
could	715	720		|O
be	721	723		|O
particularly	724	736		|O
useful	737	743		|O
for	744	747		|O
stroke	748	754	stroke	|B-DISEASE
prevention	755	765		|O
.	765	766		|O
SUMMARY	767	774		|O
OF	775	777		|O
REVIEW	778	784		|O
:	784	785		|O
This	786	790		|O
review	791	797		|O
presents	798	806		|O
the	807	810		|O
experimental	811	823		|O
and	824	827		|O
preliminary	828	839		|O
clinical	840	848		|O
evidence	849	857		|O
supporting	858	868		|O
a	869	870		|O
promising	871	880		|O
role	881	885		|O
for	886	889		|O
partial	890	897		|O
PPAR	898	902		|O
-	902	903		|O
gamma	903	908		|O
agonist	909	916		|O
ARBs	917	921		|O
in	922	924		|O
treating	925	933		|O
insulin	934	941	insulin resistance	|B-DISEASE
resistance	942	952		|I-DISEASE
and	953	956		|O
the	957	960		|O
metabolic	961	970	metabolic syndrome	|B-DISEASE
syndrome	971	979		|I-DISEASE
in	980	982		|O
patients	983	991		|O
with	992	996		|O
ischemic	997	1005	ischemic cerebrovascular disease	|B-DISEASE
cerebrovascular	1006	1021		|I-DISEASE
disease	1022	1029		|I-DISEASE
.	1029	1030		|O
CONCLUSION	1031	1041		|O
:	1041	1042		|O
Partial	1043	1050		|O
PPAR	1051	1055		|O
-	1055	1056		|O
gamma	1056	1061		|O
agonist	1062	1069		|O
ARBs	1070	1074		|O
by	1075	1077		|O
virtue	1078	1084		|O
of	1085	1087		|O
their	1088	1093		|O
multiple	1094	1102		|O
beneficial	1103	1113		|O
mechanisms	1114	1124		|O
of	1125	1127		|O
action	1128	1134		|O
could	1135	1140		|O
provide	1141	1148		|O
a	1149	1150		|O
single	1151	1157		|O
multipronged	1158	1170		|O
strategy	1171	1179		|O
for	1180	1183		|O
reducing	1184	1192		|O
future	1193	1199		|O
vascular	1200	1208		|O
events	1209	1215		|O
in	1216	1218		|O
persons	1219	1226		|O
with	1227	1231		|O
,	1231	1232		|O
or	1233	1235		|O
at	1236	1238		|O
risk	1239	1243		|O
for	1244	1247		|O
,	1247	1248		|O
stroke	1249	1255	stroke	|B-DISEASE
.	1255	1256		|O

### 18821393
Nonclinical	0	11		|O
aspects	12	19		|O
of	20	22		|O
biopharmaceutical	23	40		|O
development	41	52		|O
:	52	53		|O
discussion	54	64		|O
of	65	67		|O
case	68	72		|O
studies	73	80		|O
at	81	83		|O
a	84	85		|O
PhRMA	86	91		|O
-	91	92		|O
FDA	92	95		|O
workshop	96	104		|O
.	104	105		|O
Robust	107	113		|O
assessments	114	125		|O
of	126	128		|O
the	129	132		|O
nonclinical	133	144		|O
safety	145	151		|O
profile	152	159		|O
of	160	162		|O
biopharmaceuticals	163	181		|O
are	182	185		|O
best	186	190		|O
developed	191	200		|O
on	201	203		|O
a	204	205		|O
scientifically	206	220		|O
justified	221	230		|O
,	230	231		|O
case	232	236		|O
-	236	237		|O
by	237	239		|O
-	239	240		|O
case	240	244		|O
basis	245	250		|O
,	250	251		|O
with	252	256		|O
consideration	257	270		|O
of	271	273		|O
the	274	277		|O
therapeutic	278	289		|O
molecule	290	298		|O
,	298	299		|O
molecular	300	309		|O
target	310	316		|O
,	316	317		|O
and	318	321		|O
differences	322	333		|O
/	333	334		|O
similarities	334	346		|O
between	347	354		|O
nonclinical	355	366		|O
species	367	374		|O
and	375	378		|O
humans	379	385		|O
(	386	387		|O
ICH	387	390		|O
S6	391	393		|O
)	393	394		|O
.	394	395		|O
Significant	396	407		|O
experience	408	418		|O
has	419	422		|O
been	423	427		|O
gained	428	434		|O
in	435	437		|O
the	438	441		|O
10	442	444		|O
years	445	450		|O
ensuing	451	458		|O
since	459	464		|O
publication	465	476		|O
of	477	479		|O
the	480	483		|O
ICH	484	487		|O
S6	488	490		|O
guidance	491	499		|O
.	499	500		|O
In	501	503		|O
a	504	505		|O
PhRMA	506	511		|O
-	511	512		|O
FDA	512	515		|O
-	515	516		|O
sponsored	516	525		|O
workshop	526	534		|O
,	534	535		|O
"	536	537		|O
Nonclinical	537	548		|O
Aspects	549	556		|O
of	557	559		|O
Biopharmaceutical	560	577		|O
Development	578	589		|O
,	589	590		|O
"	590	591		|O
industry	592	600		|O
and	601	604		|O
US	605	607		|O
regulatory	608	618		|O
representatives	619	634		|O
engaged	635	642		|O
in	643	645		|O
exploration	646	657		|O
of	658	660		|O
current	661	668		|O
scientific	669	679		|O
and	680	683		|O
regulatory	684	694		|O
issues	695	701		|O
relating	702	710		|O
to	711	713		|O
the	714	717		|O
nonclinical	718	729		|O
development	730	741		|O
of	742	744		|O
biopharmaceuticals	745	763		|O
in	764	766		|O
order	767	772		|O
to	773	775		|O
share	776	781		|O
scientific	782	792		|O
learning	793	801		|O
and	802	805		|O
experience	806	816		|O
and	817	820		|O
to	821	823		|O
work	824	828		|O
towards	829	836		|O
establishing	837	849		|O
consistency	850	861		|O
in	862	864		|O
application	865	876		|O
of	877	879		|O
general	880	887		|O
principles	888	898		|O
and	899	902		|O
approaches	903	913		|O
.	913	914		|O
The	915	918		|O
proceedings	919	930		|O
and	931	934		|O
discussions	935	946		|O
of	947	949		|O
this	950	954		|O
workshop	955	963		|O
confirm	964	971		|O
general	972	979		|O
alignment	980	989		|O
of	990	992		|O
strategy	993	1001		|O
and	1002	1005		|O
tactics	1006	1013		|O
in	1014	1016		|O
development	1017	1028		|O
of	1029	1031		|O
biopharmaceuticals	1032	1050		|O
with	1051	1055		|O
regard	1056	1062		|O
to	1063	1065		|O
such	1066	1070		|O
areas	1071	1076		|O
as	1077	1079		|O
species	1080	1087		|O
selection	1088	1097		|O
,	1097	1098		|O
selection	1099	1108		|O
of	1109	1111		|O
high	1112	1116		|O
doses	1117	1122		|O
in	1123	1125		|O
toxicology	1126	1136		|O
studies	1137	1144		|O
,	1144	1145		|O
selection	1146	1155		|O
of	1156	1158		|O
clinical	1159	1167		|O
doses	1168	1173		|O
,	1173	1174		|O
the	1175	1178		|O
conduct	1179	1186		|O
of	1187	1189		|O
developmental	1190	1203		|O
and	1204	1207		|O
reproductive	1208	1220	reproductive toxicity	|B-ADVERSE
toxicity	1221	1229		|I-ADVERSE
(	1230	1231		|O
DART	1231	1235		|O
)	1235	1236		|O
studies	1237	1244		|O
,	1244	1245		|O
and	1246	1249		|O
assessment	1250	1260		|O
of	1261	1263		|O
carcinogenic	1264	1276		|O
potential	1277	1286		|O
.	1286	1287		|O
However	1288	1295		|O
,	1295	1296		|O
several	1297	1304		|O
important	1305	1314		|O
aspects	1315	1322		|O
,	1322	1323		|O
including	1324	1333		|O
,	1333	1334		|O
for	1335	1338		|O
example	1339	1346		|O
,	1346	1347		|O
appropriate	1348	1359		|O
use	1360	1363		|O
of	1364	1366		|O
homologues	1367	1377		|O
,	1377	1378		|O
nonhuman	1379	1387		|O
primates	1388	1396		|O
,	1396	1397		|O
and	1398	1401		|O
/	1401	1402		|O
or	1402	1404		|O
in	1405	1407		|O
vitro	1408	1413		|O
models	1414	1420		|O
in	1421	1423		|O
the	1424	1427		|O
assessment	1428	1438		|O
of	1439	1441		|O
risk	1442	1446		|O
for	1447	1450		|O
potential	1451	1460		|O
developmental	1461	1474		|O
and	1475	1478		|O
carcinogenic	1479	1491		|O
effects	1492	1499		|O
,	1499	1500		|O
were	1501	1505		|O
identified	1506	1516		|O
as	1517	1519		|O
requiring	1520	1529		|O
further	1530	1537		|O
scientific	1538	1548		|O
exploration	1549	1560		|O
and	1561	1564		|O
discussion	1565	1575		|O
.	1575	1576		|O

### 18755865
Clinical	0	8		|O
features	9	17		|O
and	18	21		|O
therapeutic	22	33		|O
management	34	44		|O
of	45	47		|O
subglottic	48	58	subglottic stenosis	|B-DISEASE
stenosis	59	67		|I-DISEASE
in	68	70		|O
patients	71	79		|O
with	80	84		|O
Wegener	85	92	Wegener's granulomatosis	|B-DISEASE
's	92	94		|I-DISEASE
granulomatosis	95	109		|I-DISEASE
.	109	110		|O
The	112	115		|O
objective	116	125		|O
of	126	128		|O
the	129	132		|O
study	133	138		|O
was	139	142		|O
to	143	145		|O
evaluate	146	154		|O
the	155	158		|O
clinical	159	167		|O
features	168	176		|O
,	176	177		|O
response	178	186		|O
to	187	189		|O
treatment	190	199		|O
,	199	200		|O
and	201	204		|O
long	205	209		|O
-	209	210		|O
term	210	214		|O
outcome	215	222		|O
of	223	225		|O
subglottic	226	236	subglottic stenosis	|B-DISEASE
stenosis	237	245		|I-DISEASE
(	246	247		|O
SGS	247	250	SGS	|B-DISEASE
)	250	251		|O
in	252	254		|O
a	255	256		|O
series	257	263		|O
of	264	266		|O
patients	267	275		|O
diagnosed	276	285		|O
as	286	288		|O
having	289	295		|O
Wegener	296	303	Wegener's granulomatosis	|B-DISEASE
's	303	305		|I-DISEASE
granulomatosis	306	320		|I-DISEASE
(	321	322		|O
WG	322	324	WG	|B-DISEASE
)	324	325		|O
at	326	328		|O
a	329	330		|O
single	331	337		|O
institution	338	349		|O
.	349	350		|O
Subglottic	351	361	Subglottic stenosis	|B-DISEASE
stenosis	362	370		|I-DISEASE
developed	371	380		|O
in	381	383		|O
6	384	385		|O
out	386	389		|O
of	390	392		|O
51	393	395		|O
(	396	397		|O
11.7%	397	402		|O
)	402	403		|O
patients	404	412		|O
,	412	413		|O
in	414	416		|O
four	417	421		|O
of	422	424		|O
them	425	429		|O
in	430	432		|O
the	433	436		|O
absence	437	444		|O
of	445	447		|O
other	448	453		|O
features	454	462		|O
of	463	465		|O
active	466	472		|O
disease	473	480		|O
,	480	481		|O
and	482	485		|O
was	486	489		|O
the	490	493		|O
symptom	494	501		|O
that	502	506		|O
leads	507	512		|O
to	513	515		|O
WG	516	518	WG	|B-DISEASE
diagnosis	519	528		|O
in	529	531		|O
three	532	537		|O
cases	538	543		|O
.	543	544		|O
In	545	547		|O
two	548	551		|O
cases	552	557		|O
,	557	558		|O
SGS	559	562	SGS	|B-DISEASE
began	563	568		|O
while	569	574		|O
the	575	578		|O
patients	579	587		|O
were	588	592		|O
receiving	593	602		|O
systemic	603	611		|O
immunosuppressive	612	629		|O
therapy	630	637		|O
for	638	641		|O
disease	642	649		|O
activity	650	658		|O
involving	659	668		|O
other	669	674		|O
sites	675	680		|O
.	680	681		|O
PR3	682	685		|O
-	685	686		|O
ANCAs	686	691		|O
were	692	696		|O
positive	697	705		|O
in	706	708		|O
four	709	713		|O
cases	714	719		|O
.	719	720		|O
An	721	723		|O
urgent	724	730		|O
tracheostomy	731	743		|O
was	744	747		|O
needed	748	754		|O
in	755	757		|O
two	758	761		|O
patients	762	770		|O
.	770	771		|O
Four	772	776		|O
patients	777	785		|O
achieved	786	794		|O
SGS	795	798	SGS	|B-DISEASE
clinical	799	807		|O
remission	808	817		|O
on	818	820		|O
standard	821	829		|O
treatment	830	839		|O
with	840	844		|O
glucocorticoids	845	860		|O
and	861	864		|O
cyclophosphamide	865	881		|O
,	881	882		|O
but	883	886		|O
three	887	892		|O
of	893	895		|O
them	896	900		|O
experienced	901	912		|O
repeated	913	921		|O
local	922	927		|O
relapses	928	936		|O
and	937	940		|O
required	941	949		|O
additional	950	960		|O
immunosuppressive	961	978		|O
therapy	979	986		|O
and	987	990		|O
mechanical	991	1001		|O
dilations	1002	1011		|O
.	1011	1012		|O
In	1013	1015		|O
one	1016	1019		|O
case	1020	1024		|O
,	1024	1025		|O
a	1026	1027		|O
local	1028	1033		|O
relapse	1034	1041		|O
was	1042	1045		|O
successfully	1046	1058		|O
managed	1059	1066		|O
with	1067	1071		|O
endotracheal	1072	1084		|O
dilation	1085	1093		|O
of	1094	1096		|O
the	1097	1100		|O
stenotic	1101	1109		|O
segment	1110	1117		|O
and	1118	1121		|O
intralesional	1122	1135		|O
injection	1136	1145		|O
of	1146	1148		|O
a	1149	1150		|O
long	1151	1155		|O
-	1155	1156		|O
acting	1156	1162		|O
corticosteroid	1163	1177		|O
plus	1178	1182		|O
mechanical	1183	1193		|O
dilation	1194	1202		|O
of	1203	1205		|O
the	1206	1209		|O
stenotic	1210	1218		|O
segment	1219	1226		|O
(	1227	1228		|O
ILCD	1228	1232		|O
)	1232	1233		|O
without	1234	1241		|O
adding	1242	1248		|O
supplemental	1249	1261		|O
immunosuppressant	1262	1279		|O
drugs	1280	1285		|O
.	1285	1286		|O
Two	1287	1290		|O
patients	1291	1299		|O
with	1300	1304		|O
isolated	1305	1313		|O
SGS	1314	1317	SGS	|B-DISEASE
were	1318	1322		|O
also	1323	1327		|O
successfully	1328	1340		|O
managed	1341	1348		|O
with	1349	1353		|O
ILCD	1354	1358		|O
alone	1359	1364		|O
and	1365	1368		|O
did	1369	1372		|O
not	1373	1376		|O
require	1377	1384		|O
the	1385	1388		|O
institution	1389	1400		|O
of	1401	1403		|O
systemic	1404	1412		|O
immunosuppressive	1413	1430		|O
therapy	1431	1438		|O
.	1438	1439		|O
One	1440	1443		|O
patient	1444	1451		|O
underwent	1452	1461		|O
open	1462	1466		|O
surgical	1467	1475		|O
repair	1476	1482		|O
when	1483	1487		|O
the	1488	1491		|O
disease	1492	1499		|O
was	1500	1503		|O
under	1504	1509		|O
control	1510	1517		|O
.	1517	1518		|O
Our	1519	1522		|O
data	1523	1527		|O
suggest	1528	1535		|O
that	1536	1540		|O
Subglottic	1541	1551	Subglottic stenosis	|B-DISEASE
stenosis	1552	1560		|I-DISEASE
often	1561	1566		|O
occurs	1567	1573		|O
or	1574	1576		|O
progresses	1577	1587		|O
independently	1588	1601		|O
of	1602	1604		|O
other	1605	1610		|O
features	1611	1619		|O
of	1620	1622		|O
active	1623	1629		|O
WG	1630	1632	WG	|B-DISEASE
,	1632	1633		|O
and	1634	1637		|O
that	1638	1642		|O
ILCD	1643	1647		|O
may	1648	1651		|O
be	1652	1654		|O
a	1655	1656		|O
safe	1657	1661		|O
alternative	1662	1673		|O
to	1674	1676		|O
conventional	1677	1689		|O
immunosuppressive	1690	1707		|O
therapy	1708	1715		|O
in	1716	1718		|O
patients	1719	1727		|O
who	1728	1731		|O
develop	1732	1739		|O
SGS	1740	1743	SGS	|B-DISEASE
in	1744	1746		|O
the	1747	1750		|O
absence	1751	1758		|O
of	1759	1761		|O
other	1762	1767		|O
features	1768	1776		|O
of	1777	1779		|O
active	1780	1786		|O
disease	1787	1794		|O
,	1794	1795		|O
allowing	1796	1804		|O
reducing	1805	1813		|O
the	1814	1817		|O
treatment	1818	1827	treatment-related toxicity	|B-ADVERSE
-	1827	1828		|I-ADVERSE
related	1828	1835		|I-ADVERSE
toxicity	1836	1844		|I-ADVERSE
.	1844	1845		|O

### 18620786
Recent	0	6		|O
developments	7	19		|O
in	20	22		|O
the	23	26		|O
treatment	27	36		|O
of	37	39		|O
aggressive	40	50		|O
non	51	54	non-Hodgkin lymphoma	|B-DISEASE
-	54	55		|I-DISEASE
Hodgkin	55	62		|I-DISEASE
lymphoma	63	71		|I-DISEASE
.	71	72		|O
SUMMARY	74	81		|O
:	81	82		|O
Options	83	90		|O
for	91	94		|O
treating	95	103		|O
aggressive	104	114		|O
non	115	118	non-Hodgkin lymphoma	|B-DISEASE
-	118	119		|I-DISEASE
Hodgkin	119	126		|I-DISEASE
lymphoma	127	135		|I-DISEASE
(	136	137		|O
NHL	137	140	NHL	|B-DISEASE
)	140	141		|O
have	142	146		|O
expanded	147	155		|O
in	156	158		|O
recent	159	165		|O
years	166	171		|O
.	171	172		|O
In	173	175		|O
phase	176	181		|O
3	182	183		|O
clinical	184	192		|O
trials	193	199		|O
,	199	200		|O
giving	201	207		|O
rituximab	208	217		|O
with	218	222		|O
cyclophosphamide	223	239		|O
,	239	240		|O
vincristine	241	252		|O
,	252	253		|O
doxorubicin	254	265		|O
,	265	266		|O
and	267	270		|O
prednisone	271	281		|O
(	282	283		|O
CHOP	283	287		|O
)	287	288		|O
every	289	294		|O
3	295	296		|O
weeks	297	302		|O
(	303	304		|O
R	304	305		|O
-	305	306		|O
CHOP	306	310		|O
-	310	311		|O
21	311	313		|O
)	313	314		|O
has	315	318		|O
been	319	323		|O
associated	324	334		|O
with	335	339		|O
improved	340	348		|O
survival	349	357		|O
,	357	358		|O
without	359	366		|O
increased	367	376		|O
toxicity	377	385		|O
,	385	386		|O
in	387	389		|O
all	390	393		|O
patient	394	401		|O
groups	402	408		|O
studied	409	416		|O
.	416	417		|O
Giving	418	424		|O
dose	425	429		|O
-	429	430		|O
dense	430	435		|O
CHOP	436	440		|O
-	440	441		|O
-	441	442		|O
CHOP	442	446		|O
every	447	452		|O
2	453	454		|O
weeks	455	460		|O
(	461	462		|O
CHOP	462	466		|O
-	466	467		|O
14	467	469		|O
)	469	470		|O
-	470	471		|O
-	471	472		|O
has	472	475		|O
also	476	480		|O
proved	481	487		|O
appropriate	488	499		|O
for	500	503		|O
all	504	507		|O
patients	508	516		|O
18-75	517	522		|O
years	523	528		|O
old	529	532		|O
.	532	533		|O
Studies	534	541		|O
combining	542	551		|O
these	552	557		|O
approaches	558	568		|O
-	568	569		|O
-	569	570		|O
dose	570	574		|O
-	574	575		|O
dense	575	580		|O
CHOP	581	585		|O
with	586	590		|O
rituximab	591	600		|O
(	601	602		|O
R	602	603		|O
-	603	604		|O
CHOP	604	608		|O
-	608	609		|O
14	609	611		|O
)	611	612		|O
-	612	613		|O
-	613	614		|O
have	614	618		|O
shown	619	624		|O
improved	625	633		|O
survival	634	642		|O
over	643	647		|O
CHOP	648	652		|O
-	652	653		|O
14	653	655		|O
in	656	658		|O
patients	659	667		|O
60-81	668	673		|O
years	674	679		|O
old	680	683		|O
.	683	684		|O
These	685	690		|O
results	691	698		|O
also	699	703		|O
indicate	704	712		|O
the	713	716		|O
importance	717	727		|O
of	728	730		|O
delivering	731	741		|O
chemotherapy	742	754		|O
at	755	757		|O
full	758	762		|O
dose	763	767		|O
and	768	771		|O
on	772	774		|O
schedule	775	783		|O
,	783	784		|O
which	785	790		|O
can	791	794		|O
improve	795	802		|O
survival	803	811		|O
in	812	814		|O
aggressive	815	825		|O
NHL	826	829	NHL	|B-DISEASE
.	829	830		|O
Effective	831	840		|O
delivery	841	849		|O
of	850	852		|O
dose	853	857		|O
-	857	858		|O
dense	858	863		|O
regimens	864	872		|O
requires	873	881		|O
granulocyte	882	893		|O
colony	894	900		|O
-	900	901		|O
stimulating	901	912		|O
factor	913	919		|O
support	920	927		|O
,	927	928		|O
which	929	934		|O
should	935	941		|O
also	942	946		|O
be	947	949		|O
considered	950	960		|O
for	961	964		|O
standard	965	973		|O
CHOP	974	978		|O
.	978	979		|O
A	980	981		|O
key	982	985		|O
question	986	994		|O
for	995	998		|O
the	999	1002		|O
future	1003	1009		|O
is	1010	1012		|O
whether	1013	1020		|O
R	1021	1022		|O
-	1022	1023		|O
CHOP	1023	1027		|O
-	1027	1028		|O
14	1028	1030		|O
is	1031	1033		|O
superior	1034	1042		|O
to	1043	1045		|O
R	1046	1047		|O
-	1047	1048		|O
CHOP	1048	1052		|O
-	1052	1053		|O
21	1053	1055		|O
.	1055	1056		|O

### 18753950
Factors	0	7		|O
affecting	8	17		|O
sensitivity	18	29		|O
of	30	32		|O
distortion	33	43		|O
-	43	44		|O
product	44	51		|O
otoacoustic	52	63		|O
emissions	64	73		|O
to	74	76		|O
ototoxic	77	85	ototoxic hearing loss	|B-ADVERSE
hearing	86	93		|I-ADVERSE
loss	94	98		|I-ADVERSE
.	98	99		|O
OBJECTIVES	101	111		|O
:	111	112		|O
(	113	114		|O
1	114	115		|O
)	115	116		|O
To	117	119		|O
determine	120	129		|O
the	130	133		|O
ototoxicity	134	145	ototoxicity	|B-ADVERSE
detection	146	155		|O
rate	156	160		|O
(	161	162		|O
sensitivity	162	173		|O
)	173	174		|O
for	175	178		|O
distortion	179	189		|O
-	189	190		|O
product	190	197		|O
otoacoustic	198	209		|O
emissions	210	219		|O
(	220	221		|O
DPOAEs	221	227		|O
)	227	228		|O
testing	229	236		|O
in	237	239		|O
adults	240	246		|O
who	247	250		|O
received	251	259		|O
ototoxic	260	268		|O
medications	269	280		|O
and	281	284		|O
experienced	285	296		|O
pure	297	301		|O
-	301	302		|O
tone	302	306		|O
threshold	307	316		|O
changes	317	324		|O
during	325	331		|O
the	332	335		|O
course	336	342		|O
of	343	345		|O
treatment	346	355		|O
;	355	356		|O
(	357	358		|O
2	358	359		|O
)	359	360		|O
to	361	363		|O
determine	364	373		|O
the	374	377		|O
extent	378	384		|O
to	385	387		|O
which	388	393		|O
DPOAE	394	399		|O
sensitivity	400	411		|O
to	412	414		|O
ototoxicity	415	426	ototoxicity	|B-ADVERSE
depends	427	434		|O
on	435	437		|O
the	438	441		|O
type	442	446		|O
of	447	449		|O
drug	450	454		|O
administered	455	467		|O
(	468	469		|O
platinum	469	477		|O
or	478	480		|O
antibiotic	481	491		|O
)	491	492		|O
,	492	493		|O
magnitude	494	503		|O
of	504	506		|O
ototoxic	507	515		|O
threshold	516	525		|O
shifts	526	532		|O
,	532	533		|O
pre	534	537		|O
-	537	538		|O
exposure	538	546		|O
pure	547	551		|O
-	551	552		|O
tone	552	556		|O
threshold	557	566		|O
,	566	567		|O
and	568	571		|O
DPOAE	572	577		|O
data	578	582		|O
;	582	583		|O
and	584	587		|O
(	588	589		|O
3	589	590		|O
)	590	591		|O
to	592	594		|O
build	595	600		|O
a	601	602		|O
model	603	608		|O
to	609	611		|O
predict	612	619		|O
DPOAE	620	625		|O
sensitivity	626	637		|O
.	637	638		|O
DESIGN	639	645		|O
:	645	646		|O
DPOAE	647	652		|O
and	653	656		|O
audiometric	657	668		|O
data	669	673		|O
were	674	678		|O
obtained	679	687		|O
as	688	690		|O
part	691	695		|O
of	696	698		|O
a	699	700		|O
prospective	701	712		|O
Veterans	713	721		|O
Affairs	722	729		|O
study	730	735		|O
investigating	736	749		|O
methods	750	757		|O
of	758	760		|O
ototoxicity	761	772	ototoxicity	|B-ADVERSE
monitoring	773	783		|O
.	783	784		|O
Data	785	789		|O
were	790	794		|O
analyzed	795	803		|O
from	804	808		|O
90	809	811		|O
ears	812	816		|O
of	817	819		|O
53	820	822		|O
subjects	823	831		|O
receiving	832	841		|O
ototoxic	842	850		|O
medications	851	862		|O
and	863	866		|O
showing	867	874		|O
significant	875	886		|O
hearing	887	894		|O
changes	895	902		|O
in	903	905		|O
at	906	908		|O
least	909	914		|O
one	915	918		|O
ear	919	922		|O
.	922	923		|O
Pure	924	928		|O
-	928	929		|O
tone	929	933		|O
threshold	934	943		|O
data	944	948		|O
were	949	953		|O
obtained	954	962		|O
at	963	965		|O
frequencies	966	977		|O
from	978	982		|O
0.5	983	986		|O
to	987	989		|O
20	990	992		|O
kHz	993	996		|O
,	996	997		|O
using	998	1003		|O
1/6	1004	1007		|O
-	1007	1008		|O
octave	1008	1014		|O
precision	1015	1024		|O
near	1025	1029		|O
the	1030	1033		|O
upper	1034	1039		|O
frequency	1040	1049		|O
limit	1050	1055		|O
of	1056	1058		|O
hearing	1059	1066		|O
.	1066	1067		|O
DPOAE	1068	1073		|O
data	1074	1078		|O
are	1079	1082		|O
reported	1083	1091		|O
for	1092	1095		|O
f2	1096	1098		|O
's	1098	1100		|O
from	1101	1105		|O
0.8	1106	1109		|O
to	1110	1112		|O
8.0	1113	1116		|O
kHz	1117	1120		|O
in	1121	1123		|O
1/6	1124	1127		|O
-	1127	1128		|O
octave	1128	1134		|O
increments	1135	1145		|O
using	1146	1151		|O
primary	1152	1159		|O
levels	1160	1166		|O
(	1167	1168		|O
L1	1168	1170		|O
/	1170	1171		|O
L2	1171	1173		|O
)	1173	1174		|O
of	1175	1177		|O
65/59	1178	1183		|O
dB	1184	1186		|O
SPL	1187	1190		|O
and	1191	1194		|O
a	1195	1196		|O
primary	1197	1204		|O
frequency	1205	1214		|O
ratio	1215	1220		|O
(	1221	1222		|O
f2	1222	1224		|O
/	1224	1225		|O
f1	1225	1227		|O
)	1227	1228		|O
of	1229	1231		|O
1.2	1232	1235		|O
.	1235	1236		|O
Test	1237	1241		|O
results	1242	1249		|O
were	1250	1254		|O
evaluated	1255	1264		|O
at	1265	1267		|O
various	1268	1275		|O
times	1276	1281		|O
during	1282	1288		|O
drug	1289	1293		|O
treatment	1294	1303		|O
to	1304	1306		|O
determine	1307	1316		|O
whether	1317	1324		|O
DPOAE	1325	1330		|O
level	1331	1336		|O
changes	1337	1344		|O
were	1345	1349		|O
associated	1350	1360		|O
with	1361	1365		|O
behavioral	1366	1376		|O
hearing	1377	1384		|O
changes	1385	1392		|O
.	1392	1393		|O
Univariate	1394	1404		|O
and	1405	1408		|O
multivariate	1409	1421		|O
analysis	1422	1430		|O
techniques	1431	1441		|O
were	1442	1446		|O
used	1447	1451		|O
to	1452	1454		|O
determine	1455	1464		|O
factors	1465	1472		|O
that	1473	1477		|O
affected	1478	1486		|O
DPOAE	1487	1492		|O
sensitivity	1493	1504		|O
to	1505	1507		|O
ototoxic	1508	1516	ototoxic damage	|B-ADVERSE
damage	1517	1523		|I-ADVERSE
.	1523	1524		|O
RESULTS	1525	1532		|O
:	1532	1533		|O
Of	1534	1536		|O
the	1537	1540		|O
90	1541	1543		|O
ears	1544	1548		|O
examined	1549	1557		|O
,	1557	1558		|O
82	1559	1561		|O
(	1562	1563		|O
91%	1563	1566		|O
)	1566	1567		|O
had	1568	1571		|O
DPOAEs	1572	1578		|O
that	1579	1583		|O
could	1584	1589		|O
be	1590	1592		|O
monitored	1593	1602		|O
for	1603	1606		|O
changes	1607	1614		|O
.	1614	1615		|O
Sixty	1616	1621		|O
-	1621	1622		|O
four	1622	1626		|O
of	1627	1629		|O
these	1630	1635		|O
82	1636	1638		|O
ears	1639	1643		|O
(	1644	1645		|O
78%	1645	1648		|O
)	1648	1649		|O
had	1650	1653		|O
DPOAEs	1654	1660		|O
that	1661	1665		|O
were	1666	1670		|O
reduced	1671	1678		|O
or	1679	1681		|O
absent	1682	1688		|O
following	1689	1698		|O
drug	1699	1703		|O
treatment	1704	1713		|O
.	1713	1714		|O
DPOAE	1715	1720		|O
sensitivity	1721	1732		|O
to	1733	1735		|O
ototoxicity	1736	1747	ototoxicity	|B-ADVERSE
was	1748	1751		|O
unrelated	1752	1761		|O
to	1762	1764		|O
the	1765	1768		|O
type	1769	1773		|O
of	1774	1776		|O
ototoxic	1777	1785		|O
drug	1786	1790		|O
administered	1791	1803		|O
.	1803	1804		|O
Rather	1805	1811		|O
,	1811	1812		|O
DPOAE	1813	1818		|O
sensitivity	1819	1830		|O
depended	1831	1839		|O
on	1840	1842		|O
the	1843	1846		|O
magnitude	1847	1856		|O
of	1857	1859		|O
postexposure	1860	1872		|O
hearing	1873	1880		|O
changes	1881	1888		|O
and	1889	1892		|O
on	1893	1895		|O
variables	1896	1905		|O
related	1906	1913		|O
to	1914	1916		|O
pre	1917	1920		|O
-	1920	1921		|O
exposure	1921	1929		|O
audiogram	1930	1939		|O
and	1940	1943		|O
DPOAE	1944	1949		|O
measurements	1950	1962		|O
.	1962	1963		|O
Behavioral	1964	1974		|O
hearing	1975	1982		|O
changes	1983	1990		|O
not	1991	1994		|O
detected	1995	2003		|O
by	2004	2006		|O
DPOAEs	2007	2013		|O
were	2014	2018		|O
small	2019	2024		|O
on	2025	2027		|O
average	2028	2035		|O
(	2036	2037		|O
<	2037	2038		|O
7	2038	2039		|O
dB	2040	2042		|O
)	2042	2043		|O
.	2043	2044		|O
DPOAE	2045	2050		|O
sensitivity	2051	2062		|O
was	2063	2066		|O
reduced	2067	2074		|O
in	2075	2077		|O
ears	2078	2082		|O
with	2083	2087		|O
poorer	2088	2094		|O
pre	2095	2098		|O
-	2098	2099		|O
exposure	2099	2107		|O
hearing	2108	2115		|O
,	2115	2116		|O
and	2117	2120		|O
in	2121	2123		|O
ears	2124	2128		|O
with	2129	2133		|O
measurable	2134	2144		|O
DPOAE	2145	2150		|O
frequencies	2151	2162		|O
limited	2163	2170		|O
to	2171	2173		|O
f2	2174	2176		|O
's	2176	2178		|O
below	2179	2184		|O
2.5	2185	2188		|O
kHz	2189	2192		|O
or	2193	2195		|O
more	2196	2200		|O
than	2201	2205		|O
one	2206	2209		|O
octave	2210	2216		|O
from	2217	2221		|O
the	2222	2225		|O
frequency	2226	2235		|O
region	2236	2242		|O
where	2243	2248		|O
hearing	2249	2256		|O
change	2257	2263		|O
occurred	2264	2272		|O
.	2272	2273		|O
Results	2274	2281		|O
of	2282	2284		|O
logistic	2285	2293		|O
regression	2294	2304		|O
modeling	2305	2313		|O
showed	2314	2320		|O
that	2321	2325		|O
DPOAEs	2326	2332		|O
present	2333	2340		|O
at	2341	2343		|O
f2	2344	2346		|O
's	2346	2348		|O
greater	2349	2356		|O
than	2357	2361		|O
2.5	2362	2365		|O
kHz	2366	2369		|O
were	2370	2374		|O
associated	2375	2385		|O
with	2386	2390		|O
the	2391	2394		|O
eventual	2395	2403		|O
success	2404	2411		|O
of	2412	2414		|O
ototoxicity	2415	2426	ototoxicity	|B-ADVERSE
monitoring	2427	2437		|O
with	2438	2442		|O
DPOAEs	2443	2449		|O
.	2449	2450		|O
However	2451	2458		|O
,	2458	2459		|O
independent	2460	2471		|O
variables	2472	2481		|O
examined	2482	2490		|O
could	2491	2496		|O
not	2497	2500		|O
explain	2501	2508		|O
differences	2509	2520		|O
in	2521	2523		|O
the	2524	2527		|O
relative	2528	2536		|O
timing	2537	2543		|O
of	2544	2546		|O
behavioral	2547	2557		|O
and	2558	2561		|O
DPOAE	2562	2567		|O
changes	2568	2575		|O
.	2575	2576		|O
A	2577	2578		|O
roughly	2579	2586		|O
equivalent	2587	2597		|O
proportion	2598	2608		|O
of	2609	2611		|O
ears	2612	2616		|O
experienced	2617	2628		|O
DPOAE	2629	2634		|O
changes	2635	2642		|O
before	2643	2649		|O
,	2649	2650		|O
during	2651	2657		|O
,	2657	2658		|O
or	2659	2661		|O
after	2662	2667		|O
behavioral	2668	2678		|O
hearing	2679	2686		|O
changes	2687	2694		|O
.	2694	2695		|O
CONCLUSIONS	2696	2707		|O
:	2707	2708		|O
DPOAEs	2709	2715		|O
are	2716	2719		|O
a	2720	2721		|O
useful	2722	2728		|O
screening	2729	2738		|O
tool	2739	2743		|O
for	2744	2747		|O
ototoxicity	2748	2759	ototoxicity	|B-DISEASE
in	2760	2762		|O
adults	2763	2769		|O
with	2770	2774		|O
pre	2775	2778		|O
-	2778	2779		|O
exposure	2779	2787		|O
hearing	2788	2795	hearing loss	|B-ADVERSE
loss	2796	2800		|I-ADVERSE
,	2800	2801		|O
but	2802	2805		|O
are	2806	2809		|O
less	2810	2814		|O
sensitive	2815	2824		|O
compared	2825	2833		|O
with	2834	2838		|O
a	2839	2840		|O
behavioral	2841	2851		|O
test	2852	2856		|O
method	2857	2863		|O
that	2864	2868		|O
targets	2869	2876		|O
thresholds	2877	2887		|O
near	2888	2892		|O
the	2893	2896		|O
upper	2897	2902		|O
limit	2903	2908		|O
of	2909	2911		|O
a	2912	2913		|O
subject	2914	2921		|O
's	2921	2923		|O
audible	2924	2931		|O
frequency	2932	2941		|O
range	2942	2947		|O
.	2947	2948		|O
Ears	2949	2953		|O
successfully	2954	2966		|O
monitored	2967	2976		|O
for	2977	2980		|O
ototoxicity	2981	2992	ototoxicity	|B-ADVERSE
with	2993	2997		|O
DPOAEs	2998	3004		|O
are	3005	3008		|O
those	3009	3014		|O
with	3015	3019		|O
better	3020	3026		|O
pre	3027	3030		|O
-	3030	3031		|O
exposure	3031	3039		|O
hearing	3040	3047		|O
,	3047	3048		|O
greater	3049	3056		|O
postexposure	3057	3069		|O
hearing	3070	3077		|O
changes	3078	3085		|O
,	3085	3086		|O
and	3087	3090		|O
baseline	3091	3099		|O
DPOAEs	3100	3106		|O
near	3107	3111		|O
the	3112	3115		|O
highest	3116	3123		|O
behavioral	3124	3134		|O
test	3135	3139		|O
frequencies	3140	3151		|O
and	3152	3155		|O
present	3156	3163		|O
at	3164	3166		|O
high	3167	3171		|O
f2	3172	3174		|O
's	3174	3176		|O
.	3176	3177		|O
Results	3178	3185		|O
suggest	3186	3193		|O
that	3194	3198		|O
successful	3199	3209		|O
monitoring	3210	3220		|O
of	3221	3223		|O
ototoxicity	3224	3235	ototoxicity	|B-ADVERSE
with	3236	3240		|O
DPOAEs	3241	3247		|O
may	3248	3251		|O
be	3252	3254		|O
predicted	3255	3264		|O
clinically	3265	3275		|O
by	3276	3278		|O
assessing	3279	3288		|O
the	3289	3292		|O
measurable	3293	3303		|O
DPOAE	3304	3309		|O
f2	3310	3312		|O
frequency	3313	3322		|O
range	3323	3328		|O
and	3329	3332		|O
its	3333	3336		|O
relation	3337	3345		|O
to	3346	3348		|O
the	3349	3352		|O
highest	3353	3360		|O
behavioral	3361	3371		|O
test	3372	3376		|O
frequencies	3377	3388		|O
.	3388	3389		|O

### 18671473
A	0	1		|O
new	2	5		|O
lipoglycopeptide	6	22		|O
:	22	23		|O
telavancin	24	34		|O
.	34	35		|O
The	37	40		|O
increase	41	49		|O
in	50	52		|O
infections	53	63		|O
caused	64	70		|O
by	71	73		|O
resistant	74	83		|O
Gram	84	88		|O
-	88	89		|O
positive	89	97		|O
organisms	98	107		|O
has	108	111		|O
led	112	115		|O
to	116	118		|O
an	119	121		|O
urgent	122	128		|O
need	129	133		|O
for	134	137		|O
new	138	141		|O
antibiotics	142	153		|O
.	153	154		|O
Telavancin	155	165		|O
is	166	168		|O
a	169	170		|O
rapidly	171	178		|O
bactericidal	179	191		|O
lipoglycopeptide	192	208		|O
with	209	213		|O
multiple	214	222		|O
mechanisms	223	233		|O
of	234	236		|O
action	237	243		|O
,	243	244		|O
including	245	254		|O
concentration	255	268		|O
-	268	269		|O
dependent	269	278		|O
inhibition	279	289		|O
of	290	292		|O
bacterial	293	302		|O
cell	303	307		|O
wall	308	312		|O
synthesis	313	322		|O
and	323	326		|O
disruption	327	337		|O
of	338	340		|O
the	341	344		|O
functional	345	355		|O
integrity	356	365		|O
of	366	368		|O
the	369	372		|O
cell	373	377		|O
membrane	378	386		|O
.	386	387		|O
Telavancin	388	398		|O
is	399	401		|O
active	402	408		|O
against	409	416		|O
a	417	418		|O
wide	419	423		|O
variety	424	431		|O
of	432	434		|O
Gram	435	439		|O
-	439	440		|O
positive	440	448		|O
organisms	449	458		|O
including	459	468		|O
Staphylococcus	469	483		|O
aureus	484	490		|O
with	491	495		|O
resistance	496	506		|O
to	507	509		|O
methicillin	510	521		|O
,	521	522		|O
reduced	523	530		|O
susceptibility	531	545		|O
to	546	548		|O
vancomycin	549	559		|O
,	559	560		|O
and	561	564		|O
full	565	569		|O
resistance	570	580		|O
to	581	583		|O
vancomycin	584	594		|O
.	594	595		|O
Telavacin	596	605		|O
is	606	608		|O
approximately	609	622		|O
90%	623	626		|O
protein	627	634		|O
bound	635	640		|O
;	640	641		|O
it	642	644		|O
has	645	648		|O
a	649	650		|O
serum	651	656		|O
half	657	661		|O
-	661	662		|O
life	662	666		|O
of	667	669		|O
around	670	676		|O
8	677	678		|O
h	679	680		|O
and	681	684		|O
a	685	686		|O
prolonged	687	696		|O
postantibiotic	697	711		|O
effect	712	718		|O
,	718	719		|O
allowing	720	728		|O
once	729	733		|O
daily	734	739		|O
administration	740	754		|O
.	754	755		|O
Telavancin	756	766		|O
is	767	769		|O
eliminated	770	780		|O
principally	781	792		|O
through	793	800		|O
the	801	804		|O
urine	805	810		|O
,	810	811		|O
requiring	812	821		|O
dose	822	826		|O
adjustment	827	837		|O
in	838	840		|O
patients	841	849		|O
with	850	854		|O
renal	855	860	renal impairment	|B-DISEASE
impairment	861	871		|I-DISEASE
.	871	872		|O
The	873	876		|O
efficacy	877	885		|O
and	886	889		|O
safety	890	896		|O
of	897	899		|O
telavancin	900	910		|O
was	911	914		|O
demonstrated	915	927		|O
in	928	930		|O
a	931	932		|O
large	933	938		|O
program	939	946		|O
of	947	949		|O
patients	950	958		|O
with	959	963		|O
complicated	964	975		|O
skin	976	980		|O
and	981	984		|O
skin	985	989		|O
structure	990	999		|O
infections	1000	1010		|O
.	1010	1011		|O
Development	1012	1023		|O
of	1024	1026		|O
resistance	1027	1037		|O
has	1038	1041		|O
not	1042	1045		|O
been	1046	1050		|O
detected	1051	1059		|O
in	1060	1062		|O
clinical	1063	1071		|O
strains	1072	1079		|O
.	1079	1080		|O
Adverse	1081	1088		|O
events	1089	1095		|O
include	1096	1103		|O
taste	1104	1109	taste disturbance	|B-ADVERSE
disturbance	1110	1121		|I-ADVERSE
,	1121	1122		|O
nausea	1123	1129	nausea	|B-ADVERSE
and	1130	1133		|O
vomiting	1134	1142	vomiting	|B-ADVERSE
;	1142	1143		|O
a	1144	1145		|O
small	1146	1151		|O
proportion	1152	1162		|O
of	1163	1165		|O
patients	1166	1174		|O
experienced	1175	1186		|O
reversible	1187	1197		|O
increase	1198	1206		|O
in	1207	1209		|O
serum	1210	1215		|O
creatinine	1216	1226		|O
.	1226	1227		|O
Two	1228	1231		|O
large	1232	1237		|O
Phase	1238	1243		|O
III	1244	1247		|O
studies	1248	1255		|O
in	1256	1258		|O
patients	1259	1267		|O
with	1268	1272		|O
healthcare	1273	1283		|O
associated	1284	1294		|O
pneumonia	1295	1304	pneumonia	|B-DISEASE
were	1305	1309		|O
recently	1310	1318		|O
completed	1319	1328		|O
.	1328	1329		|O
Telavancin	1330	1340		|O
has	1341	1344		|O
the	1345	1348		|O
potential	1349	1358		|O
to	1359	1361		|O
become	1362	1368		|O
an	1369	1371		|O
important	1372	1381		|O
therapeutic	1382	1393		|O
option	1394	1400		|O
to	1401	1403		|O
treat	1404	1409		|O
serious	1410	1417		|O
infections	1418	1428	infections	|B-DISEASE
produced	1429	1437		|O
by	1438	1440		|O
resistant	1441	1450		|O
Gram	1451	1455		|O
-	1455	1456		|O
positive	1456	1464		|O
cocci	1465	1470		|O
,	1470	1471		|O
particularly	1472	1484		|O
those	1485	1490		|O
caused	1491	1497		|O
by	1498	1500		|O
methicillin	1501	1512		|O
-	1512	1513		|O
resistant	1513	1522		|O
S	1523	1524		|O
.	1524	1525		|O
aureus	1526	1532		|O
.	1532	1533		|O

### 18581028
Acute	0	5	Acute generalised exanthematous pustulosis	|B-ADVERSE
generalised	6	17		|I-ADVERSE
exanthematous	18	31		|I-ADVERSE
pustulosis	32	42		|I-ADVERSE
and	43	46		|O
toxic	47	52	toxic epidermal necrolysis	|B-ADVERSE
epidermal	53	62		|I-ADVERSE
necrolysis	63	73		|I-ADVERSE
induced	74	81		|O
by	82	84		|O
carbamazepine	85	98		|O
.	98	99		|O
Acute	101	106	Acute generalised exanthematous pustulosis	|B-ADVERSE
generalised	107	118		|I-ADVERSE
exanthematous	119	132		|I-ADVERSE
pustulosis	133	143		|I-ADVERSE
and	144	147		|O
Stevens	148	155	Stevens-Johnson syndrome	|B-ADVERSE
-	155	156		|I-ADVERSE
Johnson	156	163		|I-ADVERSE
syndrome	164	172		|I-ADVERSE
(	173	174		|O
toxic	174	179	toxic epidermal necrolysis	|B-ADVERSE
epidermal	180	189		|I-ADVERSE
necrolysis	190	200		|I-ADVERSE
spectrum	201	209		|O
of	210	212		|O
severe	213	219		|O
cutaneous	220	229		|O
drug	230	234		|O
reactions	235	244		|O
)	244	245		|O
are	246	249		|O
believed	250	258		|O
to	259	261		|O
have	262	266		|O
distinct	267	275		|O
underlying	276	286		|O
pathophysiologies	287	304		|O
.	304	305		|O
Our	306	309		|O
patient	310	317		|O
,	317	318		|O
a	319	320		|O
28	321	323		|O
-	323	324		|O
year	324	328		|O
-	328	329		|O
old	329	332		|O
Chinese	333	340		|O
woman	341	346		|O
,	346	347		|O
represents	348	358		|O
the	359	362		|O
first	363	368		|O
known	369	374		|O
reported	375	383		|O
case	384	388		|O
of	389	391		|O
clinically	392	402		|O
-	402	403		|O
consistent	403	413		|O
and	414	417		|O
histologically	418	432		|O
-	432	433		|O
proven	433	439		|O
acute	440	445	acute generalised exanthematous pustulosis	|B-ADVERSE
generalised	446	457		|I-ADVERSE
exanthematous	458	471		|I-ADVERSE
pustulosis	472	482		|I-ADVERSE
and	483	486		|O
toxic	487	492	toxic epidermal necrolysis	|B-ADVERSE
epidermal	493	502		|I-ADVERSE
necrolysis	503	513		|I-ADVERSE
overlap	514	521		|O
induced	522	529		|O
by	530	532		|O
carbamazepine	533	546		|O
in	547	549		|O
the	550	553		|O
English	554	561		|O
literature	562	572		|O
.	572	573		|O

### 18549882
Proteasome	0	10		|O
activation	11	21		|O
by	22	24		|O
hepatitis	25	34		|O
C	35	36		|O
core	37	41		|O
protein	42	49		|O
is	50	52		|O
reversed	53	61		|O
by	62	64		|O
ethanol	65	72		|O
-	72	73		|O
induced	73	80		|O
oxidative	81	90		|O
stress	91	97		|O
.	97	98		|O
BACKGROUND	100	110		|O
&	111	112		|O
AIMS	113	117		|O
:	117	118		|O
The	119	122		|O
proteasome	123	133		|O
is	134	136		|O
a	137	138		|O
major	139	144		|O
cellular	145	153		|O
proteinase	154	164		|O
.	164	165		|O
Its	166	169		|O
activity	170	178		|O
is	179	181		|O
modulated	182	191		|O
by	192	194		|O
cellular	195	203		|O
oxidants	204	212		|O
.	212	213		|O
Hepatitis	214	223		|O
C	224	225		|O
core	226	230		|O
protein	231	238		|O
and	239	242		|O
ethanol	243	250		|O
exposure	251	259		|O
both	260	264		|O
cause	265	270		|O
enhanced	271	279		|O
oxidant	280	287		|O
generation	288	298		|O
.	298	299		|O
The	300	303		|O
aim	304	307		|O
was	308	311		|O
to	312	314		|O
investigate	315	326		|O
whether	327	334		|O
core	335	339		|O
protein	340	347		|O
,	347	348		|O
by	349	351		|O
its	352	355		|O
ability	356	363		|O
to	364	366		|O
generate	367	375		|O
oxidants	376	384		|O
,	384	385		|O
alters	386	392		|O
proteasome	393	403		|O
activity	404	412		|O
and	413	416		|O
whether	417	424		|O
these	425	430		|O
alterations	431	442		|O
are	443	446		|O
further	447	454		|O
affected	455	463		|O
by	464	466		|O
ethanol	467	474		|O
exposure	475	483		|O
.	483	484		|O
METHODS	485	492		|O
:	492	493		|O
These	494	499		|O
interactions	500	512		|O
were	513	517		|O
examined	518	526		|O
in	527	529		|O
Huh	530	533		|O
-	533	534		|O
7	534	535		|O
cell	536	540		|O
lines	541	546		|O
that	547	551		|O
expressed	552	561		|O
inducible	562	571		|O
HCV	572	575		|O
core	576	580		|O
protein	581	588		|O
and	589	592		|O
/	592	593		|O
or	593	595		|O
constitutive	596	608		|O
cytochrome	609	619		|O
P450	620	624		|O
2E1	625	628		|O
(	629	630		|O
CYP2E1	630	636		|O
)	636	637		|O
and	638	641		|O
as	642	644		|O
purified	645	653		|O
components	654	664		|O
in	665	667		|O
a	668	669		|O
cell	670	674		|O
-	674	675		|O
free	675	679		|O
system	680	686		|O
.	686	687		|O
Chymotrypsin	688	700		|O
-	700	701		|O
like	701	705		|O
proteasome	706	716		|O
activity	717	725		|O
was	726	729		|O
measured	730	738		|O
fluorometrically	739	755		|O
.	755	756		|O
RESULTS	757	764		|O
:	764	765		|O
Proteasome	766	776		|O
activity	777	785		|O
in	786	788		|O
core	789	793		|O
-	793	794		|O
positive	794	802		|O
191-20	803	809		|O
cells	810	815		|O
was	816	819		|O
20%	820	823		|O
higher	824	830		|O
than	831	835		|O
that	836	840		|O
in	841	843		|O
core	844	848		|O
-	848	849		|O
negative	849	857		|O
cells	858	863		|O
and	864	867		|O
was	868	871		|O
enhanced	872	880		|O
3	881	882		|O
-	882	883		|O
fold	883	887		|O
in	888	890		|O
CYP2E1	891	897		|O
-	897	898		|O
expressing	898	908		|O
L14	909	912		|O
cells	913	918		|O
.	918	919		|O
Exposure	920	928		|O
of	929	931		|O
core	932	936		|O
-	936	937		|O
positive	937	945		|O
cells	946	951		|O
to	952	954		|O
glutathione	955	966		|O
ethyl	967	972		|O
ester	973	978		|O
,	978	979		|O
catalase	980	988		|O
,	988	989		|O
or	990	992		|O
the	993	996		|O
CYP2E1	997	1003		|O
inhibitor	1004	1013		|O
diallyl	1014	1021		|O
sulfide	1022	1029		|O
partially	1030	1039		|O
reversed	1040	1048		|O
the	1049	1052		|O
elevation	1053	1062		|O
of	1063	1065		|O
proteasome	1066	1076		|O
activity	1077	1085		|O
in	1086	1088		|O
core	1089	1093		|O
-	1093	1094		|O
positive	1094	1102		|O
cells	1103	1108		|O
,	1108	1109		|O
whereas	1110	1117		|O
ethanol	1118	1125		|O
exposure	1126	1134		|O
suppressed	1135	1145		|O
proteasome	1146	1156		|O
activity	1157	1165		|O
.	1165	1166		|O
The	1167	1170		|O
results	1171	1178		|O
indicate	1179	1187		|O
that	1188	1192		|O
proteasome	1193	1203		|O
activity	1204	1212		|O
was	1213	1216		|O
up	1217	1219		|O
-	1219	1220		|O
regulated	1220	1229		|O
by	1230	1232		|O
low	1233	1236		|O
levels	1237	1243		|O
of	1244	1246		|O
core	1247	1251		|O
-	1251	1252		|O
induced	1252	1259		|O
oxidative	1260	1269		|O
stress	1270	1276		|O
but	1277	1280		|O
down	1281	1285		|O
-	1285	1286		|O
regulated	1286	1295		|O
by	1296	1298		|O
high	1299	1303		|O
levels	1304	1310		|O
of	1311	1313		|O
ethanol	1314	1321		|O
-	1321	1322		|O
elicited	1322	1330		|O
stress	1331	1337		|O
.	1337	1338		|O
These	1339	1344		|O
findings	1345	1353		|O
were	1354	1358		|O
partially	1359	1368		|O
mimicked	1369	1377		|O
in	1378	1380		|O
a	1381	1382		|O
cell	1383	1387		|O
-	1387	1388		|O
free	1388	1392		|O
system	1393	1399		|O
.	1399	1400		|O
Addition	1401	1409		|O
of	1410	1412		|O
core	1413	1417		|O
protein	1418	1425		|O
enhanced	1426	1434		|O
the	1435	1438		|O
peptidase	1439	1448		|O
activity	1449	1457		|O
of	1458	1460		|O
purified	1461	1469		|O
20S	1470	1473		|O
proteasome	1474	1484		|O
containing	1485	1495		|O
the	1496	1499		|O
proteasome	1500	1510		|O
activator	1511	1520		|O
PA28	1521	1525		|O
and	1526	1529		|O
was	1530	1533		|O
further	1534	1541		|O
potentiated	1542	1553		|O
by	1554	1556		|O
addition	1557	1565		|O
of	1566	1568		|O
liver	1569	1574		|O
mitochondrial	1575	1588		|O
and	1589	1592		|O
/	1592	1593		|O
or	1593	1595		|O
microsome	1596	1605		|O
fractions	1606	1615		|O
.	1615	1616		|O
However	1617	1624		|O
,	1624	1625		|O
proteasome	1626	1636		|O
activation	1637	1647		|O
was	1648	1651		|O
significantly	1652	1665		|O
attenuated	1666	1676		|O
when	1677	1681		|O
fractions	1682	1691		|O
were	1692	1696		|O
obtained	1697	1705		|O
from	1706	1710		|O
ethanol	1711	1718		|O
-	1718	1719		|O
fed	1719	1722		|O
animals	1723	1730		|O
.	1730	1731		|O
CONCLUSIONS	1732	1743		|O
:	1743	1744		|O
HCV	1745	1748		|O
core	1749	1753		|O
protein	1754	1761		|O
interacts	1762	1771		|O
with	1772	1776		|O
PA28	1777	1781		|O
,	1781	1782		|O
mitochondrial	1783	1796		|O
,	1796	1797		|O
and	1798	1801		|O
endoplasmic	1802	1813		|O
reticulum	1814	1823		|O
proteins	1824	1832		|O
to	1833	1835		|O
cause	1836	1841		|O
low	1842	1845		|O
levels	1846	1852		|O
of	1853	1855		|O
oxidant	1856	1863		|O
stress	1864	1870		|O
and	1871	1874		|O
proteasome	1875	1885		|O
activation	1886	1896		|O
,	1896	1897		|O
which	1898	1903		|O
is	1904	1906		|O
dampened	1907	1915		|O
during	1916	1922		|O
ethanol	1923	1930		|O
metabolism	1931	1941		|O
when	1942	1946		|O
oxidant	1947	1954		|O
generation	1955	1965		|O
is	1966	1968		|O
higher	1969	1975		|O
.	1975	1976		|O

### 18798698
Evolving	0	8		|O
concepts	9	17		|O
in	18	20		|O
liver	21	26		|O
tissue	27	33		|O
modeling	34	42		|O
and	43	46		|O
implications	47	59		|O
for	60	63		|O
in	64	66		|O
vitro	67	72		|O
toxicology	73	83		|O
.	83	84		|O
The	86	89		|O
development	90	101		|O
of	102	104		|O
human	105	110		|O
cell	111	115		|O
models	116	122		|O
stably	123	129		|O
expressing	130	140		|O
functional	141	151		|O
properties	152	162		|O
of	163	165		|O
the	166	169		|O
in	170	172		|O
vivo	173	177		|O
cells	178	183		|O
they	184	188		|O
are	189	192		|O
derived	193	200		|O
from	201	205		|O
for	206	209		|O
predicting	210	220		|O
toxicity	221	229		|O
of	230	232		|O
chemicals	233	242		|O
is	243	245		|O
a	246	247		|O
major	248	253		|O
challenge	254	263		|O
.	263	264		|O
For	265	268		|O
mimicking	269	278		|O
the	279	282		|O
liver	283	288		|O
,	288	289		|O
a	290	291		|O
major	292	297		|O
target	298	304		|O
of	305	307		|O
toxic	308	313		|O
chemicals	314	323		|O
,	323	324		|O
primary	325	332		|O
hepatocytes	333	344		|O
represent	345	354		|O
the	355	358		|O
most	359	363		|O
pertinent	364	373		|O
model	374	379		|O
.	379	380		|O
Their	381	386		|O
use	387	390		|O
is	391	393		|O
limited	394	401		|O
by	402	404		|O
interdonor	405	415		|O
functional	416	426		|O
variability	427	438		|O
and	439	442		|O
early	443	448		|O
phenotypic	449	459		|O
changes	460	467		|O
although	468	476		|O
their	477	482		|O
lifespan	483	491		|O
can	492	495		|O
be	496	498		|O
extended	499	507		|O
not	508	511		|O
only	512	516		|O
by	517	519		|O
culturing	520	529		|O
in	530	532		|O
a	533	534		|O
2D	535	537		|O
dimension	538	547		|O
under	548	553		|O
sophisticated	554	567		|O
conditions	568	578		|O
but	579	582		|O
also	583	587		|O
by	588	590		|O
the	591	594		|O
use	595	598		|O
of	599	601		|O
synthetic	602	611		|O
and	612	615		|O
natural	616	623		|O
scaffolds	624	633		|O
as	634	636		|O
3D	637	639		|O
supporting	640	650		|O
templates	651	660		|O
that	661	665		|O
allow	666	671		|O
cells	672	677		|O
to	678	680		|O
have	681	685		|O
a	686	687		|O
more	688	692		|O
stable	693	699		|O
microenvironment	700	716		|O
.	716	717		|O
Hepatocytes	718	729		|O
derived	730	737		|O
from	738	742		|O
stem	743	747		|O
cells	748	753		|O
could	754	759		|O
be	760	762		|O
the	763	766		|O
most	767	771		|O
appropriate	772	783		|O
alternative	784	795		|O
but	796	799		|O
up	800	802		|O
to	803	805		|O
now	806	809		|O
only	810	814		|O
liver	815	820		|O
progenitors	821	832		|O
/	832	833		|O
hepatoblasts	833	845		|O
are	846	849		|O
obtained	850	858		|O
in	859	861		|O
vitro	862	867		|O
.	867	868		|O
A	869	870		|O
few	871	874		|O
hepatocyte	875	885		|O
cell	886	890		|O
lines	891	896		|O
have	897	901		|O
retained	902	910		|O
a	911	912		|O
variable	913	921		|O
set	922	925		|O
of	926	928		|O
liver	929	934		|O
-	934	935		|O
specific	935	943		|O
functions	944	953		|O
.	953	954		|O
Among	955	960		|O
them	961	965		|O
are	966	969		|O
the	970	973		|O
human	974	979		|O
hepatoma	980	988		|O
HepaRG	989	995		|O
cells	996	1001		|O
that	1002	1006		|O
express	1007	1014		|O
drug	1015	1019		|O
metabolism	1020	1030		|O
capacity	1031	1039		|O
at	1040	1042		|O
levels	1043	1049		|O
close	1050	1055		|O
to	1056	1058		|O
those	1059	1064		|O
found	1065	1070		|O
in	1071	1073		|O
primary	1074	1081		|O
hepatocytes	1082	1093		|O
making	1094	1100		|O
them	1101	1105		|O
a	1106	1107		|O
suitable	1108	1116		|O
model	1117	1122		|O
for	1123	1126		|O
both	1127	1131		|O
acute	1132	1137		|O
and	1138	1141		|O
chronic	1142	1149	chronic toxicity	|B-ADVERSE
toxicity	1150	1158		|I-ADVERSE
studies	1159	1166		|O
.	1166	1167		|O
New	1168	1171		|O
screening	1172	1181		|O
strategies	1182	1192		|O
are	1193	1196		|O
now	1197	1200		|O
proposed	1201	1209		|O
based	1210	1215		|O
on	1216	1218		|O
miniaturized	1219	1231		|O
and	1232	1235		|O
automated	1236	1245		|O
systems	1246	1253		|O
;	1253	1254		|O
they	1255	1259		|O
include	1260	1267		|O
the	1268	1271		|O
use	1272	1275		|O
of	1276	1278		|O
microfluidic	1279	1291		|O
chips	1292	1297		|O
and	1298	1301		|O
cell	1302	1306		|O
chips	1307	1312		|O
coupled	1313	1320		|O
with	1321	1325		|O
high	1326	1330		|O
content	1331	1338		|O
imaging	1339	1346		|O
analysis	1347	1355		|O
.	1355	1356		|O
Toxicogenomics	1357	1371		|O
technologies	1372	1384		|O
(	1385	1386		|O
particularly	1386	1398		|O
toxicotranscriptomics	1399	1420		|O
)	1420	1421		|O
have	1422	1426		|O
emerged	1427	1434		|O
as	1435	1437		|O
promising	1438	1447		|O
in	1448	1450		|O
vitro	1451	1456		|O
approaches	1457	1467		|O
for	1468	1471		|O
better	1472	1478		|O
identification	1479	1493		|O
and	1494	1497		|O
discrimination	1498	1512		|O
of	1513	1515		|O
cellular	1516	1524		|O
responses	1525	1534		|O
to	1535	1537		|O
chemicals	1538	1547		|O
.	1547	1548		|O
They	1549	1553		|O
should	1554	1560		|O
allow	1561	1566		|O
to	1567	1569		|O
discriminate	1570	1582		|O
compounds	1583	1592		|O
on	1593	1595		|O
the	1596	1599		|O
basis	1600	1605		|O
of	1606	1608		|O
the	1609	1612		|O
identification	1613	1627		|O
of	1628	1630		|O
a	1631	1632		|O
set	1633	1636		|O
of	1637	1639		|O
markers	1640	1647		|O
and	1648	1651		|O
/	1651	1652		|O
specific	1652	1660		|O
signaling	1661	1670		|O
pathways	1671	1679		|O
.	1679	1680		|O

### 18763324
Mycophenolate	0	13		|O
mofetil	14	21		|O
-	21	22		|O
related	22	29		|O
gastrointestinal	30	46	gastrointestinal mucosal injury	|B-ADVERSE
mucosal	47	54		|I-ADVERSE
injury	55	61		|I-ADVERSE
:	61	62		|O
variable	63	71		|O
injury	72	78		|O
patterns	79	87		|O
,	87	88		|O
including	89	98		|O
graft	99	104	graft-versus-host disease	|B-ADVERSE
-	104	105		|I-ADVERSE
versus	105	111		|I-ADVERSE
-	111	112		|I-ADVERSE
host	112	116		|I-ADVERSE
disease	117	124		|I-ADVERSE
-	124	125		|O
like	125	129		|O
changes	130	137		|O
.	137	138		|O
Mycophenolate	140	153		|O
mofetil	154	161		|O
(	162	163		|O
MMF	163	166		|O
)	166	167		|O
is	168	170		|O
a	171	172		|O
commonly	173	181		|O
used	182	186		|O
immunosuppressive	187	204		|O
drug	205	209		|O
used	210	214		|O
in	215	217		|O
the	218	221		|O
management	222	232		|O
of	233	235		|O
transplant	236	246		|O
recipients	247	257		|O
.	257	258		|O
Although	259	267		|O
gastrointestinal	268	284	gastrointestinal (GI) toxicity	|B-ADVERSE
(	285	286		|I-ADVERSE
GI	286	288		|I-ADVERSE
)	288	289		|I-ADVERSE
toxicity	290	298		|I-ADVERSE
is	299	301		|O
a	302	303		|O
known	304	309		|O
complication	310	322		|O
of	323	325		|O
MMF	326	329		|O
,	329	330		|O
the	331	334		|O
literature	335	345		|O
characterizing	346	360		|O
the	361	364		|O
pathologic	365	375		|O
features	376	384		|O
of	385	387		|O
MMF	388	391		|O
in	392	394		|O
the	395	398		|O
GI	399	401		|O
tract	402	407		|O
is	408	410		|O
sparse	411	417		|O
.	417	418		|O
This	419	423		|O
study	424	429		|O
characterizes	430	443		|O
the	444	447		|O
pathologic	448	458		|O
features	459	467		|O
of	468	470		|O
MMF	471	474	MMF toxicity	|B-ADVERSE
toxicity	475	483		|I-ADVERSE
in	484	486		|O
both	487	491		|O
the	492	495		|O
upper	496	501		|O
and	502	505		|O
lower	506	511		|O
GI	512	514		|O
tract	515	520		|O
,	520	521		|O
correlating	522	533		|O
it	534	536		|O
with	537	541		|O
clinical	542	550		|O
and	551	554		|O
endoscopic	555	565		|O
findings	566	574		|O
.	574	575		|O
Seventy	576	583		|O
-	583	584		|O
five	584	588		|O
GI	589	591		|O
biopsies	592	600		|O
(	601	602		|O
9	602	603		|O
esophageal	604	614		|O
,	614	615		|O
15	616	618		|O
gastric	619	626		|O
,	626	627		|O
16	628	630		|O
duodenal	631	639		|O
,	639	640		|O
5	641	642		|O
ileal	643	648		|O
,	648	649		|O
30	650	652		|O
colonic	653	660		|O
)	660	661		|O
from	662	666		|O
46	667	669		|O
transplant	670	680		|O
recipients	681	691		|O
from	692	696		|O
2002	697	701		|O
to	702	704		|O
2006	705	709		|O
were	710	714		|O
obtained	715	723		|O
and	724	727		|O
assessed	728	736		|O
for	737	740		|O
multiple	741	749		|O
histologic	750	760		|O
features	761	769		|O
.	769	770		|O
Clinical	771	779		|O
features	780	788		|O
were	789	793		|O
recorded	794	802		|O
for	803	806		|O
all	807	810		|O
cases	811	816		|O
and	817	820		|O
endoscopic	821	831		|O
findings	832	840		|O
.	840	841		|O
Only	842	846		|O
MMF	847	850		|O
patients	851	859		|O
showed	860	866		|O
ulcerative	867	877	ulcerative esophagitis	|B-ADVERSE
esophagitis	878	889		|I-ADVERSE
(	890	891		|O
5/7	891	894		|O
cases	895	900		|O
)	900	901		|O
and	902	905		|O
reactive	906	914	reactive gastropathy	|B-ADVERSE
gastropathy	915	926		|I-ADVERSE
(	927	928		|O
4/10	928	932		|O
cases	933	938		|O
)	938	939		|O
.	939	940		|O
Only	941	945		|O
MMF	946	949		|O
patients	950	958		|O
showed	959	965		|O
graft	966	971	graft-versus-host disease	|B-ADVERSE
-	971	972		|I-ADVERSE
versus	972	978		|I-ADVERSE
-	978	979		|I-ADVERSE
host	979	983		|I-ADVERSE
disease	984	991		|I-ADVERSE
(	992	993		|O
GVHD	993	997	GVHD	|B-ADVERSE
)	997	998		|O
-	998	999		|O
like	999	1003		|O
features	1004	1012		|O
in	1013	1015		|O
duodenal	1016	1024		|O
(	1025	1026		|O
4/12	1026	1030		|O
cases	1031	1036		|O
)	1036	1037		|O
and	1038	1041		|O
ileal	1042	1047		|O
(	1048	1049		|O
1/5	1049	1052		|O
cases	1053	1058		|O
)	1058	1059		|O
biopsies	1060	1068		|O
.	1068	1069		|O
GVHD	1070	1074	GVHD	|B-ADVERSE
-	1074	1075		|O
like	1075	1079		|O
changes	1080	1087		|O
were	1088	1092		|O
seen	1093	1097		|O
more	1098	1102		|O
frequently	1103	1113		|O
among	1114	1119		|O
patients	1120	1128		|O
on	1129	1131		|O
MMF	1132	1135		|O
compared	1136	1144		|O
with	1145	1149		|O
those	1150	1155		|O
not	1156	1159		|O
on	1160	1162		|O
MMF	1163	1166		|O
[	1167	1168		|O
9	1168	1169		|O
(	1170	1171		|O
56%	1171	1174		|O
)	1174	1175		|O
vs.	1176	1179		|O
2	1180	1181		|O
(	1182	1183		|O
14%	1183	1186		|O
)	1186	1187		|O
;	1187	1188		|O
P	1189	1190		|O
=	1190	1191		|O
0.017	1191	1196		|O
]	1196	1197		|O
.	1197	1198		|O
Crypt	1199	1204	Crypt architectural disarray	|B-ADVERSE
architectural	1205	1218		|I-ADVERSE
disarray	1219	1227		|I-ADVERSE
[	1228	1229		|O
12	1229	1231		|O
(	1232	1233		|O
75%	1233	1236		|O
)	1236	1237		|O
vs.	1238	1241		|O
2	1242	1243		|O
(	1244	1245		|O
14%	1245	1248		|O
)	1248	1249		|O
;	1249	1250		|O
P	1251	1252		|O
=	1252	1253		|O
0.001	1253	1258		|O
]	1258	1259		|O
,	1259	1260		|O
lamina	1261	1267	lamina propria edema	|B-ADVERSE
propria	1268	1275		|I-ADVERSE
edema	1276	1281		|I-ADVERSE
[	1282	1283		|O
9	1283	1284		|O
(	1285	1286		|O
56%	1286	1289		|O
)	1289	1290		|O
vs.	1291	1294		|O
2	1295	1296		|O
(	1297	1298		|O
14%	1298	1301		|O
)	1301	1302		|O
;	1302	1303		|O
P	1304	1305		|O
=	1305	1306		|O
0.017	1306	1311		|O
]	1311	1312		|O
,	1312	1313		|O
increased	1314	1323		|O
lamina	1324	1330	lamina propria inflammation	|B-ADVERSE
propria	1331	1338		|I-ADVERSE
inflammation	1339	1351		|I-ADVERSE
[	1352	1353		|O
13	1353	1355		|O
(	1356	1357		|O
81%	1357	1360		|O
)	1360	1361		|O
vs.	1362	1365		|O
3	1366	1367		|O
(	1368	1369		|O
21%	1369	1372		|O
)	1372	1373		|O
;	1373	1374		|O
P	1375	1376		|O
=	1376	1377		|O
0.001	1377	1382		|O
]	1382	1383		|O
,	1383	1384		|O
dilated	1385	1392	dilated damaged crypts	|B-ADVERSE
damaged	1393	1400		|I-ADVERSE
crypts	1401	1407		|I-ADVERSE
[	1408	1409		|O
7	1409	1410		|O
(	1411	1412		|O
44%	1412	1415		|O
)	1415	1416		|O
vs.	1417	1420		|O
1	1421	1422		|O
(	1423	1424		|O
7%	1424	1426		|O
)	1426	1427		|O
;	1427	1428		|O
P	1429	1430		|O
=	1430	1431		|O
0.024	1431	1436		|O
]	1436	1437		|O
,	1437	1438		|O
and	1439	1442		|O
increased	1443	1452		|O
crypt	1453	1458		|O
epithelial	1459	1469		|O
apoptosis	1470	1479		|O
[	1480	1481		|O
9	1481	1482		|O
(	1483	1484		|O
56%	1484	1487		|O
)	1487	1488		|O
vs.	1489	1492		|O
2	1493	1494		|O
(	1495	1496		|O
14%	1496	1499		|O
)	1499	1500		|O
;	1500	1501		|O
P	1502	1503		|O
=	1503	1504		|O
0.017	1504	1509		|O
]	1509	1510		|O
were	1511	1515		|O
more	1516	1520		|O
common	1521	1527		|O
with	1528	1532		|O
MMF	1533	1536		|O
patients	1537	1545		|O
compared	1546	1554		|O
with	1555	1559		|O
non	1560	1563		|O
-	1563	1564		|O
MMF	1564	1567		|O
patients	1568	1576		|O
.	1576	1577		|O
In	1578	1580		|O
conclusion	1581	1591		|O
,	1591	1592		|O
pathologists	1593	1605		|O
should	1606	1612		|O
be	1613	1615		|O
aware	1616	1621		|O
of	1622	1624		|O
the	1625	1628		|O
potential	1629	1638		|O
manifestations	1639	1653		|O
of	1654	1656		|O
MMF	1657	1660	MMF toxicity	|B-ADVERSE
toxicity	1661	1669		|I-ADVERSE
throughout	1670	1680		|O
the	1681	1684		|O
GI	1685	1687		|O
tract	1688	1693		|O
,	1693	1694		|O
including	1695	1704		|O
ulcerative	1705	1715	ulcerative esophagitis	|B-ADVERSE
esophagitis	1716	1727		|I-ADVERSE
,	1727	1728		|O
reactive	1729	1737	reactive gastropathy	|B-ADVERSE
gastropathy	1738	1749		|I-ADVERSE
,	1749	1750		|O
and	1751	1754		|O
GVHD	1755	1759	GVHD	|B-ADVERSE
-	1759	1760		|O
like	1760	1764		|O
features	1765	1773		|O
in	1774	1776		|O
intestinal	1777	1787		|O
biopsies	1788	1796		|O
.	1796	1797		|O

### 18775466
Broccoli	0	8		|O
flower	9	15		|O
head	16	20		|O
extract	21	28		|O
reduces	29	36		|O
mitomycin	37	46		|O
-	46	47		|O
C	47	48		|O
induced	49	56		|O
sister	57	63		|O
chromatid	64	73		|O
exchange	74	82		|O
in	83	85		|O
cultured	86	94		|O
human	95	100		|O
lymphocytes	101	112		|O
.	112	113		|O
This	115	119		|O
study	120	125		|O
is	126	128		|O
a	129	130		|O
continuation	131	143		|O
of	144	146		|O
our	147	150		|O
previous	151	159		|O
work	160	164		|O
[	165	166		|O
Murugan	166	173		|O
,	173	174		|O
S	175	176		|O
.	176	177		|O
S	177	178		|O
.	178	179		|O
,	179	180		|O
Balakrishnamurthy	181	198		|O
,	198	199		|O
P	200	201		|O
.	201	202		|O
,	202	203		|O
Mathew	204	210		|O
,	210	211		|O
Y	212	213		|O
.	213	214		|O
J	214	215		|O
.	215	216		|O
,	216	217		|O
2007	218	222		|O
.	222	223		|O
Antimutagenic	224	237		|O
effect	238	244		|O
of	245	247		|O
broccoli	248	256		|O
flower	257	263		|O
head	264	268		|O
by	269	271		|O
the	272	275		|O
Ames	276	280		|O
Salmonella	281	291		|O
reverse	292	299		|O
mutation	300	308		|O
assay	309	314		|O
.	314	315		|O
Phytother	316	325		|O
.	325	326		|O
Res.	327	331		|O
21	332	334		|O
,	334	335		|O
545-547	336	343		|O
]	343	344		|O
,	344	345		|O
in	346	348		|O
search	349	355		|O
of	356	358		|O
possible	359	367		|O
antimutagenic	368	381		|O
properties	382	392		|O
in	393	395		|O
broccoli	396	404		|O
flower	405	411		|O
head	412	416		|O
extracts	417	425		|O
.	425	426		|O
In	427	429		|O
the	430	433		|O
present	434	441		|O
investigation	442	455		|O
,	455	456		|O
the	457	460		|O
effect	461	467		|O
of	468	470		|O
addition	471	479		|O
of	480	482		|O
ethanol	483	490		|O
extract	491	498		|O
of	499	501		|O
broccoli	502	510		|O
flower	511	517		|O
head	518	522		|O
on	523	525		|O
mitomycin	526	535		|O
-	535	536		|O
C	536	537		|O
(	538	539		|O
MMC	539	542		|O
)	542	543		|O
induced	544	551		|O
sister	552	558		|O
chromatid	559	568		|O
exchange	569	577		|O
(	578	579		|O
SCE	579	582		|O
)	582	583		|O
in	584	586		|O
cultured	587	595		|O
human	596	601		|O
peripheral	602	612		|O
blood	613	618		|O
lymphocytes	619	630		|O
was	631	634		|O
investigated	635	647		|O
.	647	648		|O
Broccoli	649	657		|O
flower	658	664		|O
head	665	669		|O
was	670	673		|O
extracted	674	683		|O
in	684	686		|O
ethanol	687	694		|O
using	695	700		|O
either	701	707		|O
acetone	708	715		|O
or	716	718		|O
ethanol	719	726		|O
as	727	729		|O
solvents	730	738		|O
.	738	739		|O
The	740	743		|O
extract	744	751		|O
was	752	755		|O
tested	756	762		|O
at	763	765		|O
final	766	771		|O
concentrations	772	786		|O
of	787	789		|O
200	790	793		|O
and	794	797		|O
400	798	801		|O
microg	802	808		|O
/	808	809		|O
ml	809	811		|O
culture	812	819		|O
and	820	823		|O
set	824	827		|O
for	828	831		|O
SCE	832	835		|O
assay	836	841		|O
.	841	842		|O
MMC	843	846		|O
at	847	849		|O
a	850	851		|O
concentration	852	865		|O
of	866	868		|O
1	869	870		|O
microg	871	877		|O
/	877	878		|O
ml	878	880		|O
and	881	884		|O
the	885	888		|O
test	889	893		|O
concentrations	894	908		|O
of	909	911		|O
broccoli	912	920		|O
flower	921	927		|O
head	928	932		|O
were	933	937		|O
added	938	943		|O
to	944	946		|O
the	947	950		|O
culture	951	958		|O
following	959	968		|O
48	969	971		|O
h	972	973		|O
from	974	978		|O
the	979	982		|O
initiation	983	993		|O
of	994	996		|O
culture	997	1004		|O
.	1004	1005		|O
Enumeration	1006	1017		|O
of	1018	1020		|O
SCE	1021	1024		|O
in	1025	1027		|O
second	1028	1034		|O
division	1035	1043		|O
mitotic	1044	1051		|O
cells	1052	1057		|O
indicated	1058	1067		|O
that	1068	1072		|O
broccoli	1073	1081		|O
flower	1082	1088		|O
head	1089	1093		|O
extract	1094	1101		|O
significantly	1102	1115		|O
reduced	1116	1123		|O
MMC	1124	1127		|O
induced	1128	1135		|O
SCEs	1136	1140		|O
at	1141	1143		|O
both	1144	1148		|O
the	1149	1152		|O
concentrations	1153	1167		|O
tested	1168	1174		|O
.	1174	1175		|O
This	1176	1180		|O
observation	1181	1192		|O
is	1193	1195		|O
in	1196	1198		|O
line	1199	1203		|O
with	1204	1208		|O
our	1209	1212		|O
earlier	1213	1220		|O
finding	1221	1228		|O
and	1229	1232		|O
confirms	1233	1241		|O
to	1242	1244		|O
the	1245	1248		|O
presence	1249	1257		|O
of	1258	1260		|O
antimutagenic	1261	1274		|O
principles	1275	1285		|O
in	1286	1288		|O
broccoli	1289	1297		|O
flower	1298	1304		|O
head	1305	1309		|O
extract	1310	1317		|O
.	1317	1318		|O

### 18793295
Establishing	0	12		|O
causality	13	22		|O
in	23	25		|O
the	26	29		|O
assessment	30	40		|O
of	41	43		|O
safety	44	50		|O
of	51	53		|O
medicines	54	63		|O
for	64	67		|O
children	68	76		|O
.	76	77		|O
BACKGROUND	79	89		|O
:	89	90		|O
Data	91	95		|O
on	96	98		|O
safety	99	105		|O
of	106	108		|O
medicines	109	118		|O
in	119	121		|O
children	122	130		|O
typically	131	140		|O
arises	141	147		|O
from	148	152		|O
various	153	160		|O
sources	161	168		|O
,	168	169		|O
rendering	170	179		|O
assessment	180	190		|O
of	191	193		|O
causality	194	203		|O
challenging	204	215		|O
.	215	216		|O
METHODS	217	224		|O
:	224	225		|O
We	226	228		|O
outline	229	236		|O
these	237	242		|O
sources	243	250		|O
,	250	251		|O
together	252	260		|O
with	261	265		|O
their	266	271		|O
strengths	272	281		|O
and	282	285		|O
weaknesses	286	296		|O
.	296	297		|O
Bradford	298	306		|O
Hill	307	311		|O
proposed	312	320		|O
criteria	321	329		|O
for	330	333		|O
assessment	334	344		|O
of	345	347		|O
causality	348	357		|O
of	358	360		|O
observed	361	369		|O
associations	370	382		|O
;	382	383		|O
we	384	386		|O
explore	387	394		|O
their	395	400		|O
utility	401	408		|O
in	409	411		|O
this	412	416		|O
context	417	424		|O
.	424	425		|O
CONCLUSION	426	436		|O
:	436	437		|O
Collaborations	438	452		|O
between	453	460		|O
clinicians	461	471		|O
,	471	472		|O
epidemiologists	473	488		|O
and	489	492		|O
clinical	493	501		|O
pharmacologists	502	517		|O
,	517	518		|O
making	519	525		|O
intelligent	526	537		|O
use	538	541		|O
of	542	544		|O
both	545	549		|O
older	550	555		|O
and	556	559		|O
newer	560	565		|O
methodologies	566	579		|O
,	579	580		|O
can	581	584		|O
help	585	589		|O
make	590	594		|O
the	595	598		|O
use	599	602		|O
of	603	605		|O
medicines	606	615		|O
in	616	618		|O
children	619	627		|O
safer	628	633		|O
.	633	634		|O

### 18695700
The	0	3		|O
effect	4	10		|O
of	11	13		|O
thiazolidinediones	14	32		|O
on	33	35		|O
BMD	36	39	BMD	|B-DISEASE
and	40	43		|O
osteoporosis	44	56	osteoporosis	|B-DISEASE
.	56	57		|O
Thiazolidinediones	59	77		|O
,	77	78		|O
also	79	83		|O
known	84	89		|O
as	90	92		|O
glitazones	93	103		|O
,	103	104		|O
are	105	108		|O
insulin	109	116		|O
-	116	117		|O
sensitizing	117	128		|O
medications	129	140		|O
that	141	145		|O
account	146	153		|O
for	154	157		|O
approximately	158	171		|O
21%	172	175		|O
of	176	178		|O
oral	179	183		|O
antihyperglycemic	184	201		|O
drugs	202	207		|O
used	208	212		|O
in	213	215		|O
the	216	219		|O
US	220	222		|O
.	222	223		|O
Although	224	232		|O
the	233	236		|O
main	237	241		|O
therapeutic	242	253		|O
effects	254	261		|O
occur	262	267		|O
in	268	270		|O
adipose	271	278		|O
tissue	279	285		|O
,	285	286		|O
muscles	287	294		|O
and	295	298		|O
the	299	302		|O
liver	303	308		|O
,	308	309		|O
studies	310	317		|O
suggest	318	325		|O
effects	326	333		|O
in	334	336		|O
bone	337	341		|O
as	342	344		|O
well	345	349		|O
.	349	350		|O
Currently	351	360		|O
,	360	361		|O
two	362	365		|O
thiazolidinediones	366	384		|O
are	385	388		|O
marketed	389	397		|O
in	398	400		|O
the	401	404		|O
US	405	407		|O
-	407	408		|O
rosiglitazone	408	421		|O
and	422	425		|O
pioglitazone	426	438		|O
-	438	439		|O
and	439	442		|O
several	443	450		|O
others	451	457		|O
are	458	461		|O
under	462	467		|O
investigation	468	481		|O
.	481	482		|O
This	483	487		|O
Review	488	494		|O
examines	495	503		|O
the	504	507		|O
evidence	508	516		|O
regarding	517	526		|O
the	527	530		|O
effects	531	538		|O
of	539	541		|O
thiazolidinediones	542	560		|O
on	561	563		|O
skeletal	564	572		|O
health	573	579		|O
.	579	580		|O
These	581	586		|O
drugs	587	592		|O
appear	593	599		|O
to	600	602		|O
trigger	603	610		|O
preferential	611	623		|O
differentiation	624	639		|O
of	640	642		|O
mesenchymal	643	654		|O
stem	655	659		|O
cells	660	665		|O
into	666	670		|O
adipocytes	671	681		|O
rather	682	688		|O
than	689	693		|O
osteoblasts	694	705		|O
,	705	706		|O
leading	707	714		|O
to	715	717		|O
decreased	718	727		|O
bone	728	732		|O
formation	733	742		|O
and	743	746		|O
increased	747	756		|O
adipogenesis	757	769		|O
.	769	770		|O
Although	771	779		|O
only	780	784		|O
a	785	786		|O
few	787	790		|O
small	791	796		|O
,	796	797		|O
randomized	798	808		|O
studies	809	816		|O
have	817	821		|O
examined	822	830		|O
the	831	834		|O
effects	835	842		|O
of	843	845		|O
thiazolidinediones	846	864		|O
on	865	867		|O
bone	868	872		|O
in	873	875		|O
humans	876	882		|O
,	882	883		|O
the	884	887		|O
available	888	897		|O
data	898	902		|O
suggest	903	910		|O
that	911	915		|O
these	916	921		|O
agents	922	928		|O
contribute	929	939		|O
to	940	942		|O
bone	943	947	bone loss	|B-ADVERSE
loss	948	952		|I-ADVERSE
in	953	955		|O
postmenopausal	956	970		|O
women	971	976		|O
;	976	977		|O
the	978	981		|O
relationship	982	994		|O
is	995	997		|O
less	998	1002		|O
clear	1003	1008		|O
in	1009	1011		|O
men	1012	1015		|O
.	1015	1016		|O
On	1017	1019		|O
the	1020	1023		|O
basis	1024	1029		|O
of	1030	1032		|O
this	1033	1037		|O
limited	1038	1045		|O
evidence	1046	1054		|O
,	1054	1055		|O
the	1056	1059		|O
absolute	1060	1068		|O
increase	1069	1077		|O
in	1078	1080		|O
fracture	1081	1089	fracture	|B-ADVERSE
risk	1090	1094		|O
associated	1095	1105		|O
with	1106	1110		|O
thiazolidinediones	1111	1129		|O
seems	1130	1135		|O
to	1136	1138		|O
be	1139	1141		|O
small	1142	1147		|O
.	1147	1148		|O
Pending	1149	1156		|O
data	1157	1161		|O
from	1162	1166		|O
future	1167	1173		|O
randomized	1174	1184		|O
,	1184	1185		|O
controlled	1186	1196		|O
trials	1197	1203		|O
of	1204	1206		|O
the	1207	1210		|O
association	1211	1222		|O
between	1223	1230		|O
thiazolidinediones	1231	1249		|O
and	1250	1253		|O
low	1254	1257		|O
bone	1258	1262		|O
mass	1263	1267		|O
,	1267	1268		|O
prescribers	1269	1280		|O
should	1281	1287		|O
consider	1288	1296		|O
use	1297	1300		|O
of	1301	1303		|O
these	1304	1309		|O
drugs	1310	1315		|O
as	1316	1318		|O
a	1319	1320		|O
risk	1321	1325		|O
factor	1326	1332		|O
for	1333	1336		|O
the	1337	1340		|O
development	1341	1352		|O
of	1353	1355		|O
osteoporosis	1356	1368	osteoporosis	|B-ADVERSE
in	1369	1371		|O
postmenopausal	1372	1386		|O
women	1387	1392		|O
.	1392	1393		|O

### 18707870
Raltitrexed	0	11		|O
(	12	13		|O
Tomudex	13	20		|O
)	20	21		|O
versus	22	28		|O
standard	29	37		|O
leucovorin	38	48		|O
-	48	49		|O
modulated	49	58		|O
bolus	59	64		|O
5	65	66		|O
-	66	67		|O
fluorouracil	67	79		|O
:	79	80		|O
Results	81	88		|O
from	89	93		|O
the	94	97		|O
randomised	98	108		|O
phase	109	114		|O
III	115	118		|O
Pan	119	122		|O
-	122	123		|O
European	123	131		|O
Trial	132	137		|O
in	138	140		|O
Adjuvant	141	149		|O
Colon	150	155	Colon Cancer	|B-DISEASE
Cancer	156	162		|I-DISEASE
01	163	165		|O
(	166	167		|O
PETACC	167	173		|O
-	173	174		|O
1	174	175		|O
)	175	176		|O
.	176	177		|O
OBJECTIVES	179	189		|O
:	189	190		|O
PETACC	191	197		|O
-	197	198		|O
1	198	199		|O
assessed	200	208		|O
if	209	211		|O
raltitrexed	212	223		|O
is	224	226		|O
non	227	230		|O
-	230	231		|O
inferior	231	239		|O
to	240	242		|O
5	243	244		|O
-	244	245		|O
fluorouracil	245	257		|O
and	258	261		|O
leucovorin	262	272		|O
for	273	276		|O
relapse	277	284		|O
-	284	285		|O
free	285	289		|O
survival	290	298		|O
(	299	300		|O
RFS	300	303		|O
)	303	304		|O
and	305	308		|O
overall	309	316		|O
survival	317	325		|O
(	326	327		|O
OS	327	329		|O
)	329	330		|O
in	331	333		|O
adjuvant	334	342		|O
stage	343	348		|O
III	349	352		|O
colon	353	358	colon cancer	|B-DISEASE
cancer	359	365		|I-DISEASE
.	365	366		|O
METHODS	367	374		|O
:	374	375		|O
Non	376	379		|O
-	379	380		|O
inferiority	380	391		|O
required	392	400		|O
both	401	405		|O
HR	406	408		|O
for	409	412		|O
RFS	413	416		|O
and	417	420		|O
OS	421	423		|O
<	423	424		|O
1.25	424	428		|O
at	429	431		|O
1	432	433		|O
-	433	434		|O
sided	434	439		|O
alpha	440	445		|O
=	445	446		|O
0.05	446	450		|O
.	450	451		|O
Patients	452	460		|O
(	461	462		|O
1921	462	466		|O
)	466	467		|O
were	468	472		|O
randomised	473	483		|O
to	484	486		|O
six	487	490		|O
cycles	491	497		|O
of	498	500		|O
5	501	502		|O
-	502	503		|O
FU	503	505		|O
/	505	506		|O
LV	506	508		|O
(	509	510		|O
n	510	511		|O
=	511	512		|O
969	512	515		|O
)	515	516		|O
or	517	519		|O
eight	520	525		|O
cycles	526	532		|O
of	533	535		|O
raltitrexed	536	547		|O
(	548	549		|O
n	549	550		|O
=	550	551		|O
952	551	554		|O
)	554	555		|O
.	555	556		|O
We	557	559		|O
report	560	566		|O
the	567	570		|O
final	571	576		|O
results	577	584		|O
in	585	587		|O
993	588	591		|O
eligible	592	600		|O
patients	601	609		|O
who	610	613		|O
started	614	621		|O
and	622	625		|O
completed	626	635		|O
the	636	639		|O
allocated	640	649		|O
treatment	650	659		|O
(	660	661		|O
489	661	664		|O
5	665	666		|O
-	666	667		|O
FU	667	669		|O
/	669	670		|O
LV	670	672		|O
and	673	676		|O
n	677	678		|O
=	678	679		|O
504	679	682		|O
Raltitrexed	683	694		|O
)	694	695		|O
of	696	698		|O
whom	699	703		|O
respectively	704	716		|O
146	717	720		|O
and	721	724		|O
148	725	728		|O
died	729	733		|O
,	733	734		|O
respectively	735	747		|O
.	747	748		|O
RESULTS	749	756		|O
:	756	757		|O
The	758	761		|O
trial	762	767		|O
closed	768	774		|O
prematurely	775	786		|O
when	787	791		|O
17	792	794		|O
(	795	796		|O
1.9%	796	800		|O
)	800	801		|O
raltitrexed	802	813		|O
-	813	814		|O
related	814	821		|O
deaths	822	828		|O
were	829	833		|O
reported	834	842		|O
.	842	843		|O
Haematological	844	858		|O
and	859	862		|O
gastrointestinal	863	879	gastrointestinal toxicities	|B-ADVERSE
toxicities	880	890		|I-ADVERSE
were	891	895		|O
more	896	900		|O
frequent	901	909		|O
with	910	914		|O
5	915	916		|O
-	916	917		|O
FU	917	919		|O
/	919	920		|O
LV	920	922		|O
,	922	923		|O
liver	924	929	liver toxicities	|B-ADVERSE
toxicities	930	940		|I-ADVERSE
with	941	945		|O
raltitrexed	946	957		|O
.	957	958		|O
Raltitrexed	959	970		|O
was	971	974		|O
stopped	975	982		|O
for	983	986		|O
toxicity	987	995		|O
in	996	998		|O
13.2%	999	1004		|O
and	1005	1008		|O
5	1009	1010		|O
-	1010	1011		|O
FU	1011	1013		|O
/	1013	1014		|O
LV	1014	1016		|O
in	1017	1019		|O
8.5%	1020	1024		|O
.	1024	1025		|O
Sixty	1026	1031		|O
-	1031	1032		|O
day	1032	1035		|O
mortality	1036	1045		|O
was	1046	1049		|O
9%	1050	1052		|O
versus	1053	1059		|O
7%	1060	1062		|O
.	1062	1063		|O
With	1064	1068		|O
4.1	1069	1072		|O
years	1073	1078		|O
median	1079	1085		|O
follow	1086	1092		|O
-	1092	1093		|O
up	1093	1095		|O
,	1095	1096		|O
the	1097	1100		|O
HR	1101	1103		|O
for	1104	1107		|O
RFS	1108	1111		|O
was	1112	1115		|O
1.16	1116	1120		|O
(	1121	1122		|O
90%	1122	1125		|O
CI	1126	1128		|O
0.99-1.37	1129	1138		|O
)	1138	1139		|O
and	1140	1143		|O
that	1144	1148		|O
for	1149	1152		|O
OS	1153	1155		|O
was	1156	1159		|O
1.01	1160	1164		|O
(	1165	1166		|O
90%	1166	1169		|O
CI	1170	1172		|O
0.84-1.23	1173	1182		|O
)	1182	1183		|O
.	1183	1184		|O
CONCLUSION	1185	1195		|O
:	1195	1196		|O
The	1197	1200		|O
trial	1201	1206		|O
failed	1207	1213		|O
to	1214	1216		|O
demonstrate	1217	1228		|O
non	1229	1232		|O
-	1232	1233		|O
inferiority	1233	1244		|O
of	1245	1247		|O
raltitrexed	1248	1259		|O
.	1259	1260		|O
FUNDING	1261	1268		|O
:	1268	1269		|O
Free	1270	1274		|O
drugs	1275	1280		|O
and	1281	1284		|O
financial	1285	1294		|O
support	1295	1302		|O
from	1303	1307		|O
AstraZeneca	1308	1319		|O
.	1319	1320		|O

### 18636418
Identifying	0	11		|O
patterns	12	20		|O
of	21	23		|O
adverse	24	31		|O
event	32	37		|O
reporting	38	47		|O
for	48	51		|O
four	52	56		|O
members	57	64		|O
of	65	67		|O
the	68	71		|O
angiotensin	72	83		|O
II	84	86		|O
receptor	87	95		|O
blockers	96	104		|O
class	105	110		|O
of	111	113		|O
drugs	114	119		|O
:	119	120		|O
revisiting	121	131		|O
the	132	135		|O
Weber	136	141		|O
effect	142	148		|O
.	148	149		|O
PURPOSE	151	158		|O
:	158	159		|O
To	160	162		|O
evaluate	163	171		|O
the	172	175		|O
evidence	176	184		|O
for	185	188		|O
temporal	189	197		|O
reporting	198	207		|O
patterns	208	216		|O
,	216	217		|O
such	218	222		|O
as	223	225		|O
the	226	229		|O
Weber	230	235		|O
effect	236	242		|O
,	242	243		|O
in	244	246		|O
spontaneous	247	258		|O
post	259	263		|O
-	263	264		|O
marketing	264	273		|O
adverse	274	281		|O
event	282	287		|O
(	288	289		|O
AE	289	291		|O
)	291	292		|O
reports	293	300		|O
submitted	301	310		|O
to	311	313		|O
the	314	317		|O
Food	318	322		|O
and	323	326		|O
Drug	327	331		|O
Administration	332	346		|O
(	347	348		|O
FDA	348	351		|O
)	351	352		|O
,	352	353		|O
for	354	357		|O
four	358	362		|O
members	363	370		|O
of	371	373		|O
the	374	377		|O
angiotensin	378	389		|O
II	390	392		|O
receptor	393	401		|O
blockers	402	410		|O
drug	411	415		|O
class	416	421		|O
(	422	423		|O
ARBs	423	427		|O
)	427	428		|O
.	428	429		|O
METHODS	430	437		|O
:	437	438		|O
For	439	442		|O
losartan	443	451		|O
,	451	452		|O
valsartan	453	462		|O
,	462	463		|O
irbesartan	464	474		|O
,	474	475		|O
and	476	479		|O
candesartan	480	491		|O
,	491	492		|O
we	493	495		|O
evaluated	496	505		|O
temporal	506	514		|O
trends	515	521		|O
in	522	524		|O
reporting	525	534		|O
for	535	538		|O
the	539	542		|O
total	543	548		|O
number	549	555		|O
of	556	558		|O
AE	559	561		|O
reports	562	569		|O
,	569	570		|O
serious	571	578		|O
AE	579	581		|O
reports	582	589		|O
,	589	590		|O
and	591	594		|O
direct	595	601		|O
reports	602	609		|O
from	610	614		|O
consumers	615	624		|O
or	625	627		|O
health	628	634		|O
care	635	639		|O
providers	640	649		|O
(	650	651		|O
direct	651	657		|O
reports	658	665		|O
)	665	666		|O
to	667	669		|O
FDA	670	673		|O
.	673	674		|O
Reporting	675	684		|O
patterns	685	693		|O
were	694	698		|O
considered	699	709		|O
consistent	710	720		|O
with	721	725		|O
the	726	729		|O
Weber	730	735		|O
effect	736	742		|O
when	743	747		|O
the	748	751		|O
peak	752	756		|O
occurred	757	765		|O
2	766	767		|O
years	768	773		|O
after	774	779		|O
US	780	782		|O
marketing	783	792		|O
and	793	796		|O
the	797	800		|O
number	801	807		|O
of	808	810		|O
reports	811	818		|O
declined	819	827		|O
thereafter	828	838		|O
.	838	839		|O
We	840	842		|O
tabulated	843	852		|O
the	853	856		|O
number	857	863		|O
of	864	866		|O
reports	867	874		|O
by	875	877		|O
year	878	882		|O
since	883	888		|O
the	889	892		|O
first	893	898		|O
report	899	905		|O
.	905	906		|O
We	907	909		|O
adjusted	910	918		|O
the	919	922		|O
total	923	928		|O
number	929	935		|O
of	936	938		|O
reports	939	946		|O
,	946	947		|O
number	948	954		|O
of	955	957		|O
serious	958	965		|O
AE	966	968		|O
reports	969	976		|O
,	976	977		|O
and	978	981		|O
number	982	988		|O
of	989	991		|O
direct	992	998		|O
reports	999	1006		|O
by	1007	1009		|O
the	1010	1013		|O
number	1014	1020		|O
of	1021	1023		|O
US	1024	1026		|O
dispensed	1027	1036		|O
prescriptions	1037	1050		|O
.	1050	1051		|O
RESULTS	1052	1059		|O
:	1059	1060		|O
There	1061	1066		|O
were	1067	1071		|O
no	1072	1074		|O
clear	1075	1080		|O
temporal	1081	1089		|O
reporting	1090	1099		|O
patterns	1100	1108		|O
for	1109	1112		|O
the	1113	1116		|O
total	1117	1122		|O
number	1123	1129		|O
of	1130	1132		|O
reports	1133	1140		|O
,	1140	1141		|O
direct	1142	1148		|O
reports	1149	1156		|O
,	1156	1157		|O
or	1158	1160		|O
serious	1161	1168		|O
AE	1169	1171		|O
reports	1172	1179		|O
.	1179	1180		|O
We	1181	1183		|O
observed	1184	1192		|O
a	1193	1194		|O
consistent	1195	1205		|O
trend	1206	1211		|O
for	1212	1215		|O
the	1216	1219		|O
adjusted	1220	1228		|O
number	1229	1235		|O
of	1236	1238		|O
direct	1239	1245		|O
and	1246	1249		|O
serious	1250	1257		|O
AE	1258	1260		|O
reports	1261	1268		|O
.	1268	1269		|O
The	1270	1273		|O
adjusted	1274	1282		|O
number	1283	1289		|O
was	1290	1293		|O
highest	1294	1301		|O
in	1302	1304		|O
the	1305	1308		|O
first	1309	1314		|O
year	1315	1319		|O
and	1320	1323		|O
continually	1324	1335		|O
decreased	1336	1345		|O
over	1346	1350		|O
time	1351	1355		|O
for	1356	1359		|O
all	1360	1363		|O
four	1364	1368		|O
ARBs	1369	1373		|O
.	1373	1374		|O
For	1375	1378		|O
the	1379	1382		|O
adjusted	1383	1391		|O
total	1392	1397		|O
number	1398	1404		|O
of	1405	1407		|O
reports	1408	1415		|O
,	1415	1416		|O
the	1417	1420		|O
decline	1421	1428		|O
was	1429	1432		|O
not	1433	1436		|O
constant	1437	1445		|O
over	1446	1450		|O
time	1451	1455		|O
.	1455	1456		|O
CONCLUSION	1457	1467		|O
:	1467	1468		|O
A	1469	1470		|O
characteristic	1471	1485		|O
temporal	1486	1494		|O
pattern	1495	1502		|O
in	1503	1505		|O
the	1506	1509		|O
adjusted	1510	1518		|O
number	1519	1525		|O
of	1526	1528		|O
reports	1529	1536		|O
,	1536	1537		|O
in	1538	1540		|O
which	1541	1546		|O
the	1547	1550		|O
adjusted	1551	1559		|O
number	1560	1566		|O
was	1567	1570		|O
highest	1571	1578		|O
in	1579	1581		|O
the	1582	1585		|O
first	1586	1591		|O
year	1592	1596		|O
and	1597	1600		|O
declined	1601	1609		|O
thereafter	1610	1620		|O
,	1620	1621		|O
was	1622	1625		|O
identified	1626	1636		|O
.	1636	1637		|O
However	1638	1645		|O
,	1645	1646		|O
we	1647	1649		|O
did	1650	1653		|O
not	1654	1657		|O
observe	1658	1665		|O
a	1666	1667		|O
pattern	1668	1675		|O
consistent	1676	1686		|O
with	1687	1691		|O
the	1692	1695		|O
Weber	1696	1701		|O
effect	1702	1708		|O
for	1709	1712		|O
these	1713	1718		|O
four	1719	1723		|O
ARBs	1724	1728		|O
.	1728	1729		|O

### 18597652
Pharmacogenetics	0	16		|O
of	17	19		|O
Crohn	20	25	Crohn's disease	|B-DISEASE
's	25	27		|I-DISEASE
disease	28	35		|I-DISEASE
.	35	36		|O
The	38	41		|O
considerable	42	54		|O
interindividual	55	70		|O
differences	71	82		|O
in	83	85		|O
efficacy	86	94		|O
and	95	98		|O
side	99	103		|O
effects	104	111		|O
of	112	114		|O
commonly	115	123		|O
used	124	128		|O
medications	129	140		|O
in	141	143		|O
Crohn	144	149	Crohn's disease	|B-DISEASE
's	149	151		|I-DISEASE
disease	152	159		|I-DISEASE
are	160	163		|O
partly	164	170		|O
owing	171	176		|O
to	177	179		|O
genetic	180	187		|O
polymorphisms	188	201		|O
.	201	202		|O
Many	203	207		|O
genetic	208	215		|O
variants	216	224		|O
have	225	229		|O
been	230	234		|O
studied	235	242		|O
in	243	245		|O
genes	246	251		|O
possibly	252	260		|O
involved	261	269		|O
in	270	272		|O
the	273	276		|O
metabolism	277	287		|O
or	288	290		|O
mechanism	291	300		|O
of	301	303		|O
action	304	310		|O
of	311	313		|O
therapeutic	314	325		|O
agents	326	332		|O
such	333	337		|O
as	338	340		|O
glucocorticosteroids	341	361		|O
,	361	362		|O
azathioprine	363	375		|O
/	375	376		|O
6	376	377		|O
-	377	378		|O
mercaptopurine	378	392		|O
,	392	393		|O
methotrexate	394	406		|O
,	406	407		|O
calcineurin	408	419		|O
inhibitors	420	430		|O
or	431	433		|O
anti	434	438		|O
-	438	439		|O
TNF	439	442		|O
agents	443	449		|O
.	449	450		|O
However	451	458		|O
,	458	459		|O
the	460	463		|O
only	464	468		|O
test	469	473		|O
translated	474	484		|O
into	485	489		|O
clinical	490	498		|O
practice	499	507		|O
is	508	510		|O
thiopurine	511	521		|O
S	522	523		|O
-	523	524		|O
methyltransferase	524	541		|O
(	542	543		|O
TPMT	543	547		|O
)	547	548		|O
genotyping	549	559		|O
for	560	563		|O
hematological	564	577	hematological toxicity	|B-ADVERSE
toxicity	578	586		|I-ADVERSE
of	587	589		|O
thiopurine	590	600		|O
treatment	601	610		|O
.	610	611		|O
To	612	614		|O
date	615	619		|O
,	619	620		|O
there	621	626		|O
are	627	630		|O
no	631	633		|O
other	634	639		|O
meaningful	640	650		|O
applications	651	663		|O
for	664	667		|O
pharmacogenomics	668	684		|O
in	685	687		|O
clinical	688	696		|O
practice	697	705		|O
of	706	708		|O
Crohn	709	714	Crohn's disease	|B-DISEASE
's	714	716		|I-DISEASE
disease	717	724		|I-DISEASE
.	724	725		|O
In	726	728		|O
the	729	732		|O
future	733	739		|O
,	739	740		|O
designed	741	749		|O
therapeutic	750	761		|O
trials	762	768		|O
should	769	775		|O
possibly	776	784		|O
permit	785	791		|O
the	792	795		|O
development	796	807		|O
of	808	810		|O
predictive	811	821		|O
models	822	828		|O
including	829	838		|O
genotypic	839	848		|O
markers	849	856		|O
,	856	857		|O
such	858	862		|O
as	863	865		|O
that	866	870		|O
proposed	871	879		|O
for	880	883		|O
the	884	887		|O
clinical	888	896		|O
outcome	897	904		|O
after	905	910		|O
infliximab	911	921		|O
therapy	922	929		|O
,	929	930		|O
which	931	936		|O
includes	937	945		|O
an	946	948		|O
apoptotic	949	958		|O
pharmacogenetic	959	974		|O
index	975	980		|O
.	980	981		|O
The	982	985		|O
recent	986	992		|O
identification	993	1007		|O
of	1008	1010		|O
new	1011	1014		|O
susceptibility	1015	1029		|O
genes	1030	1035		|O
provides	1036	1044		|O
additional	1045	1055		|O
candidate	1056	1065		|O
markers	1066	1073		|O
that	1074	1078		|O
have	1079	1083		|O
possible	1084	1092		|O
effects	1093	1100		|O
on	1101	1103		|O
the	1104	1107		|O
outcomes	1108	1116		|O
of	1117	1119		|O
therapies	1120	1129		|O
,	1129	1130		|O
and	1131	1134		|O
prioritizes	1135	1146		|O
new	1147	1150		|O
therapeutic	1151	1162		|O
targets	1163	1170		|O
,	1170	1171		|O
such	1172	1176		|O
as	1177	1179		|O
the	1180	1183		|O
IL	1184	1186		|O
-	1186	1187		|O
23	1187	1189		|O
pathway	1190	1197		|O
.	1197	1198		|O
Further	1199	1206		|O
innovative	1207	1217		|O
approaches	1218	1228		|O
might	1229	1234		|O
be	1235	1237		|O
relevant	1238	1246		|O
for	1247	1250		|O
the	1251	1254		|O
pharmacogenetic	1255	1270		|O
investigation	1271	1284		|O
of	1285	1287		|O
gene	1288	1292		|O
variants	1293	1301		|O
implied	1302	1309		|O
in	1310	1312		|O
innate	1313	1319		|O
immune	1320	1326		|O
pattern	1327	1334		|O
recognition	1335	1346		|O
and	1347	1350		|O
autophagy	1351	1360		|O
.	1360	1361		|O

### 18840369
Pharmacokinetic	0	15		|O
and	16	19		|O
safety	20	26		|O
profile	27	34		|O
of	35	37		|O
rupatadine	38	48		|O
when	49	53		|O
coadministered	54	68		|O
with	69	73		|O
azithromycin	74	86		|O
at	87	89		|O
steady	90	96		|O
-	96	97		|O
state	97	102		|O
levels	103	109		|O
:	109	110		|O
a	111	112		|O
randomized	113	123		|O
,	123	124		|O
open	125	129		|O
-	129	130		|O
label	130	135		|O
,	135	136		|O
two	137	140		|O
-	140	141		|O
way	141	144		|O
,	144	145		|O
crossover	146	155		|O
,	155	156		|O
Phase	157	162		|O
I	163	164		|O
study	165	170		|O
.	170	171		|O
BACKGROUND	173	183		|O
:	183	184		|O
Rupatadine	185	195		|O
is	196	198		|O
an	199	201		|O
oral	202	206		|O
active	207	213		|O
antihistamine	214	227		|O
and	228	231		|O
platelet	232	240		|O
-	240	241		|O
activating	241	251		|O
factor	252	258		|O
antagonist	259	269		|O
indicated	270	279		|O
for	280	283		|O
the	284	287		|O
management	288	298		|O
of	299	301		|O
allergic	302	310	allergic rhinitis	|B-DISEASE
rhinitis	311	319		|I-DISEASE
and	320	323		|O
chronic	324	331	chronic urticaria	|B-DISEASE
urticaria	332	341		|I-DISEASE
in	342	344		|O
Europe	345	351		|O
.	351	352		|O
OBJECTIVE	353	362		|O
:	362	363		|O
The	364	367		|O
purpose	368	375		|O
of	376	378		|O
this	379	383		|O
study	384	389		|O
was	390	393		|O
to	394	396		|O
describe	397	405		|O
the	406	409		|O
effect	410	416		|O
of	417	419		|O
the	420	423		|O
concomitant	424	435		|O
administration	436	450		|O
of	451	453		|O
azithromycin	454	466		|O
and	467	470		|O
rupatadine	471	481		|O
on	482	484		|O
the	485	488		|O
pharmacokinetics	489	505		|O
of	506	508		|O
rupatadine	509	519		|O
and	520	523		|O
its	524	527		|O
metabolites	528	539		|O
after	540	545		|O
repeated	546	554		|O
doses	555	560		|O
.	560	561		|O
METHODS	562	569		|O
:	569	570		|O
This	571	575		|O
was	576	579		|O
a	580	581		|O
multiple	582	590		|O
-	590	591		|O
dose	591	595		|O
,	595	596		|O
randomized	597	607		|O
,	607	608		|O
open	609	613		|O
-	613	614		|O
label	614	619		|O
,	619	620		|O
2	621	622		|O
-	622	623		|O
way	623	626		|O
,	626	627		|O
crossover	628	637		|O
,	637	638		|O
Phase	639	644		|O
I	645	646		|O
study	647	652		|O
in	653	655		|O
which	656	661		|O
healthy	662	669		|O
male	670	674		|O
and	675	678		|O
female	679	685		|O
volunteers	686	696		|O
received	697	705		|O
rupatadine	706	716		|O
10	717	719		|O
mg	720	722		|O
once	723	727		|O
a	728	729		|O
day	730	733		|O
for	734	737		|O
6	738	739		|O
days	740	744		|O
either	745	751		|O
alone	752	757		|O
or	758	760		|O
with	761	765		|O
azithromycin	766	778		|O
500	779	782		|O
mg	783	785		|O
on	786	788		|O
day	789	792		|O
2	793	794		|O
and	795	798		|O
250	799	802		|O
mg	803	805		|O
from	806	810		|O
day	811	814		|O
3	815	816		|O
to	817	819		|O
day	820	823		|O
6	824	825		|O
.	825	826		|O
Treatments	827	837		|O
were	838	842		|O
administered	843	855		|O
after	856	861		|O
a	862	863		|O
fasting	864	871		|O
period	872	878		|O
of	879	881		|O
10	882	884		|O
hours	885	890		|O
with	891	895		|O
240	896	899		|O
mL	900	902		|O
of	903	905		|O
water	906	911		|O
,	911	912		|O
and	913	916		|O
fasting	917	924		|O
conditions	925	935		|O
were	936	940		|O
kept	941	945		|O
until	946	951		|O
3	952	953		|O
hours	954	959		|O
postmedication	960	974		|O
.	974	975		|O
A	976	977		|O
washout	978	985		|O
period	986	992		|O
of	993	995		|O
at	996	998		|O
least	999	1004		|O
21	1005	1007		|O
days	1008	1012		|O
between	1013	1020		|O
the	1021	1024		|O
2	1025	1026		|O
active	1027	1033		|O
periods	1034	1041		|O
was	1042	1045		|O
observed	1046	1054		|O
.	1054	1055		|O
Blood	1056	1061		|O
samples	1062	1069		|O
were	1070	1074		|O
collected	1075	1084		|O
and	1085	1088		|O
plasma	1089	1095		|O
concentrations	1096	1110		|O
of	1111	1113		|O
rupatadine	1114	1124		|O
and	1125	1128		|O
its	1129	1132		|O
metabolites	1133	1144		|O
desloratadine	1145	1158		|O
and	1159	1162		|O
3	1163	1164		|O
-	1164	1165		|O
hydroxydesloratadine	1165	1185		|O
were	1186	1190		|O
determined	1191	1201		|O
by	1202	1204		|O
liquid	1205	1211		|O
chromatography	1212	1226		|O
tandem	1227	1233		|O
mass	1234	1238		|O
spectrometry	1239	1251		|O
.	1251	1252		|O
Tolerability	1253	1265		|O
was	1266	1269		|O
based	1270	1275		|O
on	1276	1278		|O
the	1279	1282		|O
recording	1283	1292		|O
of	1293	1295		|O
adverse	1296	1303		|O
events	1304	1310		|O
(	1311	1312		|O
AEs	1312	1315		|O
)	1315	1316		|O
,	1316	1317		|O
physical	1318	1326		|O
examination	1327	1338		|O
,	1338	1339		|O
electrocardiograms	1340	1358		|O
,	1358	1359		|O
and	1360	1363		|O
laboratory	1364	1374		|O
screen	1375	1381		|O
controls	1382	1390		|O
at	1391	1393		|O
baseline	1394	1402		|O
and	1403	1406		|O
the	1407	1410		|O
final	1411	1416		|O
study	1417	1422		|O
visit	1423	1428		|O
.	1428	1429		|O
RESULTS	1430	1437		|O
:	1437	1438		|O
Twenty	1439	1445		|O
-	1445	1446		|O
four	1446	1450		|O
healthy	1451	1458		|O
volunteers	1459	1469		|O
(	1470	1471		|O
15	1471	1473		|O
males	1474	1479		|O
,	1479	1480		|O
9	1481	1482		|O
females	1483	1490		|O
;	1490	1491		|O
mean	1492	1496		|O
[	1497	1498		|O
SD	1498	1500		|O
]	1500	1501		|O
age	1502	1505		|O
,	1505	1506		|O
25.67	1507	1512		|O
[	1513	1514		|O
5.58	1514	1518		|O
]	1518	1519		|O
years	1520	1525		|O
;	1525	1526		|O
weight	1527	1533		|O
,	1533	1534		|O
65.96	1535	1540		|O
[	1541	1542		|O
8.57	1542	1546		|O
]	1546	1547		|O
kg	1548	1550		|O
)	1550	1551		|O
completed	1552	1561		|O
the	1562	1565		|O
study	1566	1571		|O
.	1571	1572		|O
Except	1573	1579		|O
for	1580	1583		|O
maximum	1584	1591		|O
observed	1592	1600		|O
concentration	1601	1614		|O
during	1615	1621		|O
a	1622	1623		|O
dosing	1624	1630		|O
interval	1631	1639		|O
(	1640	1641		|O
Cmax	1641	1645		|O
,	1645	1646		|O
ss	1646	1648		|O
)	1648	1649		|O
of	1650	1652		|O
3	1653	1654		|O
-	1654	1655		|O
hydroxydesloratadine	1655	1675		|O
,	1675	1676		|O
on	1677	1679		|O
average	1680	1687		|O
,	1687	1688		|O
there	1689	1694		|O
were	1695	1699		|O
no	1700	1702		|O
statistically	1703	1716		|O
significant	1717	1728		|O
differences	1729	1740		|O
in	1741	1743		|O
mean	1744	1748		|O
plasma	1749	1755		|O
concentrations	1756	1770		|O
in	1771	1773		|O
any	1774	1777		|O
of	1778	1780		|O
the	1781	1784		|O
main	1785	1789		|O
pharmacokinetic	1790	1805		|O
parameters	1806	1816		|O
of	1817	1819		|O
rupatadine	1820	1830		|O
,	1830	1831		|O
desloratadine	1832	1845		|O
,	1845	1846		|O
and	1847	1850		|O
3	1851	1852		|O
-	1852	1853		|O
hydroxydesloratadine	1853	1873		|O
when	1874	1878		|O
administered	1879	1891		|O
in	1892	1894		|O
combination	1895	1906		|O
with	1907	1911		|O
azithromycin	1912	1924		|O
or	1925	1927		|O
alone	1928	1933		|O
.	1933	1934		|O
The	1935	1938		|O
Cmax	1939	1943		|O
,	1943	1944		|O
ss	1944	1946		|O
ratio	1947	1952		|O
was	1953	1956		|O
111	1957	1960		|O
(	1961	1962		|O
90%	1962	1965		|O
CI	1966	1968		|O
,	1968	1969		|O
91-136	1970	1976		|O
)	1976	1977		|O
and	1978	1981		|O
area	1982	1986		|O
under	1987	1992		|O
the	1993	1996		|O
plasma	1997	2003		|O
concentration	2004	2017		|O
-	2017	2018		|O
time	2018	2022		|O
curve	2023	2028		|O
during	2029	2035		|O
a	2036	2037		|O
dosing	2038	2044		|O
interval	2045	2053		|O
(	2054	2055		|O
AUC0	2055	2059		|O
-	2059	2060		|O
tau	2060	2063		|O
)	2063	2064		|O
ratio	2065	2070		|O
had	2071	2074		|O
a	2075	2076		|O
value	2077	2082		|O
of	2083	2085		|O
103	2086	2089		|O
(	2090	2091		|O
90%	2091	2094		|O
CI	2095	2097		|O
,	2097	2098		|O
91-117	2099	2105		|O
)	2105	2106		|O
.	2106	2107		|O
The	2108	2111		|O
corresponding	2112	2125		|O
ratios	2126	2132		|O
for	2133	2136		|O
the	2137	2140		|O
rupatadine	2141	2151		|O
metabolites	2152	2163		|O
were	2164	2168		|O
109	2169	2172		|O
(	2173	2174		|O
90%	2174	2177		|O
CI	2178	2180		|O
,	2180	2181		|O
100-120	2182	2189		|O
)	2189	2190		|O
for	2191	2194		|O
Cmax	2195	2199		|O
,	2199	2200		|O
ss	2200	2202		|O
and	2203	2206		|O
103	2207	2210		|O
(	2211	2212		|O
90%	2212	2215		|O
CI	2216	2218		|O
,	2218	2219		|O
96-110	2220	2226		|O
)	2226	2227		|O
for	2228	2231		|O
AUC0	2232	2236		|O
-	2236	2237		|O
tau	2237	2240		|O
for	2241	2244		|O
desloratadine	2245	2258		|O
and	2259	2262		|O
109	2263	2266		|O
(	2267	2268		|O
90%	2268	2271		|O
CI	2272	2274		|O
,	2274	2275		|O
103-115	2276	2283		|O
)	2283	2284		|O
for	2285	2288		|O
Cmax	2289	2293		|O
,	2293	2294		|O
ss	2294	2296		|O
and	2297	2300		|O
104	2301	2304		|O
(	2305	2306		|O
90%	2306	2309		|O
CI	2310	2312		|O
,	2312	2313		|O
100-108	2314	2321		|O
)	2321	2322		|O
for	2323	2326		|O
AUC0	2327	2331		|O
-	2331	2332		|O
tau	2332	2335		|O
for	2336	2339		|O
3	2340	2341		|O
-	2341	2342		|O
hydroxydesloratadine	2342	2362		|O
.	2362	2363		|O
Point	2364	2369		|O
estimates	2370	2379		|O
for	2380	2383		|O
Cmax	2384	2388		|O
,	2388	2389		|O
ss	2389	2391		|O
ratios	2392	2398		|O
using	2399	2404		|O
paired	2405	2411		|O
data	2412	2416		|O
were	2417	2421		|O
111%	2422	2426		|O
for	2427	2430		|O
rupatadine	2431	2441		|O
,	2441	2442		|O
109%	2443	2447		|O
for	2448	2451		|O
desloratadine	2452	2465		|O
,	2465	2466		|O
and	2467	2470		|O
109%	2471	2475		|O
for	2476	2479		|O
3	2480	2481		|O
-	2481	2482		|O
hydroxydesloratadine	2482	2502		|O
.	2502	2503		|O
The	2504	2507		|O
90%	2508	2511		|O
CIs	2512	2515		|O
were	2516	2520		|O
included	2521	2529		|O
in	2530	2532		|O
the	2533	2536		|O
interval	2537	2545		|O
80%	2546	2549		|O
to	2550	2552		|O
125%	2553	2557		|O
for	2558	2561		|O
desloratadine	2562	2575		|O
and	2576	2579		|O
3	2580	2581		|O
-	2581	2582		|O
hydroxydesloratadine	2582	2602		|O
,	2602	2603		|O
whereas	2604	2611		|O
90%	2612	2615		|O
CI	2616	2618		|O
for	2619	2622		|O
rupatadine	2623	2633		|O
was	2634	2637		|O
shifted	2638	2645		|O
to	2646	2648		|O
the	2649	2652		|O
right	2653	2658		|O
of	2659	2661		|O
the	2662	2665		|O
interval	2666	2674		|O
used	2675	2679		|O
for	2680	2683		|O
comparing	2684	2693		|O
bioavailability	2694	2709		|O
of	2710	2712		|O
the	2713	2716		|O
drugs	2717	2722		|O
.	2722	2723		|O
A	2724	2725		|O
total	2726	2731		|O
of	2732	2734		|O
5	2735	2736		|O
subjects	2737	2745		|O
reported	2746	2754		|O
9	2755	2756		|O
AEs	2757	2760		|O
;	2760	2761		|O
5	2762	2763		|O
of	2764	2766		|O
these	2767	2772		|O
were	2773	2777		|O
thought	2778	2785		|O
to	2786	2788		|O
be	2789	2791		|O
related	2792	2799		|O
to	2800	2802		|O
the	2803	2806		|O
drug	2807	2811		|O
administration	2812	2826		|O
and	2827	2830		|O
all	2831	2834		|O
were	2835	2839		|O
categorized	2840	2851		|O
as	2852	2854		|O
mild	2855	2859		|O
or	2860	2862		|O
moderate	2863	2871		|O
.	2871	2872		|O
The	2873	2876		|O
reported	2877	2885		|O
AEs	2886	2889		|O
were	2890	2894		|O
somnolence	2895	2905	somnolence	|B-ADVERSE
(	2906	2907		|O
1/24	2907	2911		|O
in	2912	2914		|O
the	2915	2918		|O
rupatadine	2919	2929		|O
group	2930	2935		|O
and	2936	2939		|O
1/24	2940	2944		|O
in	2945	2947		|O
the	2948	2951		|O
rupatadine	2952	2962		|O
plus	2963	2967		|O
azithromycin	2968	2980		|O
group	2981	2986		|O
)	2986	2987		|O
,	2987	2988		|O
diarrhea	2989	2997	diarrhea	|B-ADVERSE
(	2998	2999		|O
1/24	2999	3003		|O
in	3004	3006		|O
the	3007	3010		|O
rupatadine	3011	3021		|O
plus	3022	3026		|O
azithromycin	3027	3039		|O
group	3040	3045		|O
)	3045	3046		|O
,	3046	3047		|O
and	3048	3051		|O
gastric	3052	3059	gastric discomfort	|B-ADVERSE
discomfort	3060	3070		|I-ADVERSE
(	3071	3072		|O
2/24	3072	3076		|O
in	3077	3079		|O
the	3080	3083		|O
rupatadine	3084	3094		|O
plus	3095	3099		|O
azithromycin	3100	3112		|O
group	3113	3118		|O
)	3118	3119		|O
.	3119	3120		|O
Four	3121	3125		|O
AEs	3126	3129		|O
were	3130	3134		|O
considered	3135	3145		|O
not	3146	3149		|O
to	3150	3152		|O
be	3153	3155		|O
related	3156	3163		|O
(	3164	3165		|O
2	3165	3166		|O
episodes	3167	3175		|O
of	3176	3178		|O
headache	3179	3187	headache	|B-ADVERSE
,	3187	3188		|O
1	3189	3190		|O
anemia	3191	3197	anemia	|B-ADVERSE
,	3197	3198		|O
1	3199	3200		|O
cheilitis	3201	3210	cheilitis	|B-ADVERSE
)	3210	3211		|O
.	3211	3212		|O
All	3213	3216		|O
were	3217	3221		|O
resolved	3222	3230		|O
spontaneously	3231	3244		|O
.	3244	3245		|O
No	3246	3248		|O
serious	3249	3256		|O
AEs	3257	3260		|O
were	3261	3265		|O
reported	3266	3274		|O
.	3274	3275		|O
CONCLUSIONS	3276	3287		|O
:	3287	3288		|O
The	3289	3292		|O
results	3293	3300		|O
of	3301	3303		|O
this	3304	3308		|O
study	3309	3314		|O
in	3315	3317		|O
these	3318	3323		|O
healthy	3324	3331		|O
volunteers	3332	3342		|O
found	3343	3348		|O
no	3349	3351		|O
significant	3352	3363		|O
differences	3364	3375		|O
in	3376	3378		|O
pharmacokinetic	3379	3394		|O
parameters	3395	3405		|O
other	3406	3411		|O
than	3412	3416		|O
Cmax	3417	3421		|O
,	3421	3422		|O
ss	3422	3424		|O
of	3425	3427		|O
3	3428	3429		|O
-	3429	3430		|O
hydroxydesloratadine	3430	3450		|O
between	3451	3458		|O
rupatadine	3459	3469		|O
10	3470	3472		|O
mg	3473	3475		|O
administered	3476	3488		|O
alone	3489	3494		|O
or	3495	3497		|O
with	3498	3502		|O
azithromycin	3503	3515		|O
500	3516	3519		|O
mg	3520	3522		|O
on	3523	3525		|O
day	3526	3529		|O
2	3530	3531		|O
and	3532	3535		|O
250	3536	3539		|O
mg	3540	3542		|O
from	3543	3547		|O
day	3548	3551		|O
3	3552	3553		|O
to	3554	3556		|O
day	3557	3560		|O
6	3561	3562		|O
.	3562	3563		|O
The	3564	3567		|O
administration	3568	3582		|O
of	3583	3585		|O
rupatadine	3586	3596		|O
compared	3597	3605		|O
with	3606	3610		|O
rupatadine	3611	3621		|O
plus	3622	3626		|O
azithromycin	3627	3639		|O
met	3640	3643		|O
the	3644	3647		|O
regulatory	3648	3658		|O
definition	3659	3669		|O
of	3670	3672		|O
bioequivalence	3673	3687		|O
in	3688	3690		|O
terms	3691	3696		|O
of	3697	3699		|O
exposure	3700	3708		|O
and	3709	3712		|O
rate	3713	3717		|O
parameters	3718	3728		|O
;	3728	3729		|O
however	3730	3737		|O
,	3737	3738		|O
Cmax	3739	3743		|O
,	3743	3744		|O
ss	3744	3746		|O
of	3747	3749		|O
rupatadine	3750	3760		|O
was	3761	3764		|O
outside	3765	3772		|O
the	3773	3776		|O
conventional	3777	3789		|O
confidence	3790	3800		|O
interval	3801	3809		|O
.	3809	3810		|O

### 18676805
Pluripotent	0	11		|O
stem	12	16		|O
cell	17	21		|O
lines	22	27		|O
.	27	28		|O
The	30	33		|O
derivation	34	44		|O
of	45	47		|O
human	48	53		|O
embryonic	54	63		|O
stem	64	68		|O
cells	69	74		|O
10	75	77		|O
years	78	83		|O
ago	84	87		|O
ignited	88	95		|O
an	96	98		|O
explosion	99	108		|O
of	109	111		|O
public	112	118		|O
interest	119	127		|O
in	128	130		|O
stem	131	135		|O
cells	136	141		|O
,	141	142		|O
yet	143	146		|O
this	147	151		|O
achievement	152	163		|O
depended	164	172		|O
on	173	175		|O
prior	176	181		|O
decades	182	189		|O
of	190	192		|O
research	193	201		|O
on	202	204		|O
mouse	205	210		|O
embryonic	211	220		|O
carcinoma	221	230		|O
cells	231	236		|O
and	237	240		|O
embryonic	241	250		|O
stem	251	255		|O
cells	256	261		|O
.	261	262		|O
In	263	265		|O
turn	266	270		|O
,	270	271		|O
the	272	275		|O
recent	276	282		|O
derivation	283	293		|O
of	294	296		|O
mouse	297	302		|O
and	303	306		|O
human	307	312		|O
induced	313	320		|O
pluripotent	321	332		|O
stem	333	337		|O
cells	338	343		|O
depended	344	352		|O
on	353	355		|O
the	356	359		|O
prior	360	365		|O
studies	366	373		|O
on	374	376		|O
mouse	377	382		|O
and	383	386		|O
human	387	392		|O
embryonic	393	402		|O
stem	403	407		|O
cells	408	413		|O
.	413	414		|O
Both	415	419		|O
human	420	425		|O
embryonic	426	435		|O
stem	436	440		|O
cells	441	446		|O
and	447	450		|O
induced	451	458		|O
pluripotent	459	470		|O
stem	471	475		|O
cells	476	481		|O
can	482	485		|O
self	486	490		|O
-	490	491		|O
renew	491	496		|O
indefinitely	497	509		|O
in	510	512		|O
vitro	513	518		|O
while	519	524		|O
maintaining	525	536		|O
the	537	540		|O
ability	541	548		|O
to	549	551		|O
differentiate	552	565		|O
into	566	570		|O
advanced	571	579		|O
derivatives	580	591		|O
of	592	594		|O
all	595	598		|O
three	599	604		|O
germ	605	609		|O
layers	610	616		|O
,	616	617		|O
features	618	626		|O
very	627	631		|O
useful	632	638		|O
for	639	642		|O
understanding	643	656		|O
the	657	660		|O
differentiation	661	676		|O
and	677	680		|O
function	681	689		|O
of	690	692		|O
human	693	698		|O
tissues	699	706		|O
,	706	707		|O
for	708	711		|O
drug	712	716		|O
screen	717	723		|O
and	724	727		|O
toxicity	728	736		|O
testing	737	744		|O
,	744	745		|O
and	746	749		|O
for	750	753		|O
cellular	754	762		|O
transplantation	763	778		|O
therapies	779	788		|O
.	788	789		|O
Here	790	794		|O
we	795	797		|O
review	798	804		|O
the	805	808		|O
family	809	815		|O
of	816	818		|O
pluripotent	819	830		|O
cell	831	835		|O
lines	836	841		|O
derived	842	849		|O
from	850	854		|O
early	855	860		|O
embryos	861	868		|O
and	869	872		|O
from	873	877		|O
germ	878	882		|O
cells	883	888		|O
,	888	889		|O
and	890	893		|O
compare	894	901		|O
them	902	906		|O
with	907	911		|O
the	912	915		|O
more	916	920		|O
recently	921	929		|O
described	930	939		|O
induced	940	947		|O
pluripotent	948	959		|O
stem	960	964		|O
cells	965	970		|O
.	970	971		|O

### 18789051
Advances	0	8		|O
in	9	11		|O
plasma	12	18		|O
skin	19	23		|O
regeneration	24	36		|O
.	36	37		|O
Plasma	39	45		|O
skin	46	50		|O
regeneration	51	63		|O
(	64	65		|O
PSR	65	68		|O
)	68	69		|O
is	70	72		|O
a	73	74		|O
novel	75	80		|O
method	81	87		|O
of	88	90		|O
resurfacing	91	102		|O
that	103	107		|O
uses	108	112		|O
plasma	113	119		|O
energy	120	126		|O
to	127	129		|O
create	130	136		|O
a	137	138		|O
thermal	139	146		|O
effect	147	153		|O
on	154	156		|O
the	157	160		|O
skin	161	165		|O
.	165	166		|O
PSR	167	170		|O
is	171	173		|O
different	174	183		|O
from	184	188		|O
lasers	189	195		|O
,	195	196		|O
light	197	202		|O
sources	203	210		|O
,	210	211		|O
and	212	215		|O
ablative	216	224		|O
lasers	225	231		|O
in	232	234		|O
that	235	239		|O
it	240	242		|O
is	243	245		|O
not	246	249		|O
chromophore	250	261		|O
dependent	262	271		|O
and	272	275		|O
does	276	280		|O
not	281	284		|O
vaporize	285	293		|O
tissue	294	300		|O
,	300	301		|O
but	302	305		|O
leaves	306	312		|O
a	313	314		|O
layer	315	320		|O
of	321	323		|O
intact	324	330		|O
,	330	331		|O
desiccated	332	342		|O
epidermis	343	352		|O
that	353	357		|O
acts	358	362		|O
as	363	365		|O
a	366	367		|O
natural	368	375		|O
biologic	376	384		|O
dressing	385	393		|O
and	394	397		|O
promotes	398	406		|O
wound	407	412	wound	|B-DISEASE
healing	413	420		|O
and	421	424		|O
rapid	425	430		|O
recovery	431	439		|O
.	439	440		|O
Histological	441	453		|O
studies	454	461		|O
performed	462	471		|O
on	472	474		|O
plasma	475	481		|O
resurfacing	482	493		|O
patients	494	502		|O
have	503	507		|O
confirmed	508	517		|O
continued	518	527		|O
collagen	528	536		|O
production	537	547		|O
,	547	548		|O
reduction	549	558		|O
of	559	561		|O
elastosis	562	571		|O
,	571	572		|O
and	573	576		|O
progressive	577	588		|O
skin	589	593		|O
rejuvenation	594	606		|O
beyond	607	613		|O
1	614	615		|O
year	616	620		|O
after	621	626		|O
treatment	627	636		|O
.	636	637		|O
PSR	638	641		|O
has	642	645		|O
received	646	654		|O
US	655	657		|O
Food	658	662		|O
and	663	666		|O
Drug	667	671		|O
Administration	672	686		|O
510	687	690		|O
(	691	692		|O
k	692	693		|O
)	693	694		|O
clearance	695	704		|O
for	705	708		|O
treatment	709	718		|O
of	719	721		|O
rhytides	722	730	rhytides of the body	|B-DISEASE
of	731	733		|I-DISEASE
the	734	737		|I-DISEASE
body	738	742		|I-DISEASE
,	742	743		|O
superficial	744	755	superficial skin lesions	|B-DISEASE
skin	756	760		|I-DISEASE
lesions	761	768		|I-DISEASE
,	768	769		|O
actinic	770	777	actinic keratoses	|B-DISEASE
keratoses	778	787		|I-DISEASE
,	787	788		|O
viral	789	794	viral papillomata	|B-DISEASE
papillomata	795	806		|I-DISEASE
,	806	807		|O
and	808	811		|O
seborrheic	812	822	seborrheic keratoses	|B-DISEASE
keratoses	823	832		|I-DISEASE
.	832	833		|O
PSR	834	837		|O
also	838	842		|O
has	843	846		|O
beneficial	847	857		|O
effects	858	865		|O
in	866	868		|O
the	869	872		|O
treatment	873	882		|O
of	883	885		|O
other	886	891		|O
conditions	892	902		|O
including	903	912		|O
dyschromias	913	924	dyschromias	|B-DISEASE
,	924	925		|O
photoaging	926	936	photoaging	|B-DISEASE
,	936	937		|O
skin	938	942	skin laxity	|B-DISEASE
laxity	943	949		|I-DISEASE
,	949	950		|O
and	951	954		|O
acne	955	959	acne scars	|B-DISEASE
scars	960	965		|I-DISEASE
.	965	966		|O
The	967	970		|O
safety	971	977		|O
profile	978	985		|O
of	986	988		|O
PSR	989	992		|O
is	993	995		|O
excellent	996	1005		|O
,	1005	1006		|O
and	1007	1010		|O
there	1011	1016		|O
have	1017	1021		|O
been	1022	1026		|O
no	1027	1029		|O
reports	1030	1037		|O
of	1038	1040		|O
demarcation	1041	1052		|O
lines	1053	1058		|O
in	1059	1061		|O
perioral	1062	1070		|O
,	1070	1071		|O
periorbital	1072	1083		|O
,	1083	1084		|O
or	1085	1087		|O
jawline	1088	1095		|O
areas	1096	1101		|O
,	1101	1102		|O
as	1103	1105		|O
can	1106	1109		|O
sometimes	1110	1119		|O
be	1120	1122		|O
observed	1123	1131		|O
following	1132	1141		|O
CO2	1142	1145		|O
resurfacing	1146	1157		|O
.	1157	1158		|O
PSR	1159	1162		|O
is	1163	1165		|O
effective	1166	1175		|O
in	1176	1178		|O
improving	1179	1188		|O
facial	1189	1195		|O
and	1196	1199		|O
periorbital	1200	1211		|O
rhytides	1212	1220		|O
and	1221	1224		|O
can	1225	1228		|O
be	1229	1231		|O
used	1232	1236		|O
on	1237	1239		|O
nonfacial	1240	1249		|O
sites	1250	1255		|O
,	1255	1256		|O
including	1257	1266		|O
the	1267	1270		|O
hands	1271	1276		|O
,	1276	1277		|O
neck	1278	1282		|O
,	1282	1283		|O
and	1284	1287		|O
chest	1288	1293		|O
.	1293	1294		|O
Numerous	1295	1303		|O
treatment	1304	1313		|O
protocols	1314	1323		|O
with	1324	1328		|O
variable	1329	1337		|O
energy	1338	1344		|O
settings	1345	1353		|O
allow	1354	1359		|O
for	1360	1363		|O
individualized	1364	1378		|O
treatments	1379	1389		|O
and	1390	1393		|O
provide	1394	1401		|O
the	1402	1405		|O
operator	1406	1414		|O
with	1415	1419		|O
fine	1420	1424		|O
control	1425	1432		|O
over	1433	1437		|O
the	1438	1441		|O
degree	1442	1448		|O
of	1449	1451		|O
injury	1452	1458		|O
and	1459	1462		|O
length	1463	1469		|O
of	1470	1472		|O
subsequent	1473	1483		|O
recovery	1484	1492		|O
time	1493	1497		|O
.	1497	1498		|O

### 18634931
Hydrogen	0	8		|O
peroxide	9	17		|O
induces	18	25		|O
heme	26	30		|O
oxygenase	31	40		|O
-	40	41		|O
1	41	42		|O
and	43	46		|O
dentin	47	53		|O
sialophosphoprotein	54	73		|O
mRNA	74	78		|O
in	79	81		|O
human	82	87		|O
pulp	88	92		|O
cells	93	98		|O
.	98	99		|O
Although	101	109		|O
the	110	113		|O
induction	114	123		|O
of	124	126		|O
heme	127	131		|O
oxygenase	132	141		|O
-	141	142		|O
1	142	143		|O
(	144	145		|O
HO	145	147		|O
-	147	148		|O
1	148	149		|O
)	149	150		|O
by	151	153		|O
hydrogen	154	162		|O
peroxide	163	171		|O
(	172	173		|O
H2O2	173	177		|O
)	177	178		|O
has	179	182		|O
been	183	187		|O
reported	188	196		|O
,	196	197		|O
the	198	201		|O
HO	202	204		|O
-	204	205		|O
1	205	206		|O
and	207	210		|O
odontoblastic	211	224		|O
differentiation	225	240		|O
-	240	241		|O
inducing	241	249		|O
effects	250	257		|O
against	258	265		|O
H2O2	266	270		|O
have	271	275		|O
not	276	279		|O
been	280	284		|O
clarified	285	294		|O
in	295	297		|O
human	298	303		|O
pulp	304	308		|O
cells	309	314		|O
.	314	315		|O
In	316	318		|O
this	319	323		|O
study	324	329		|O
,	329	330		|O
we	331	333		|O
investigated	334	346		|O
whether	347	354		|O
HO	355	357		|O
-	357	358		|O
1	358	359		|O
is	360	362		|O
involved	363	371		|O
in	372	374		|O
the	375	378		|O
protective	379	389		|O
mechanisms	390	400		|O
against	401	408		|O
the	409	412		|O
cytotoxic	413	422		|O
effects	423	430		|O
of	431	433		|O
H2O2	434	438		|O
by	439	441		|O
using	442	447		|O
a	448	449		|O
cell	450	454		|O
viability	455	464		|O
assay	465	470		|O
,	470	471		|O
and	472	475		|O
we	476	478		|O
examined	479	487		|O
the	488	491		|O
production	492	502		|O
of	503	505		|O
dentin	506	512		|O
sialophosphoprotein	513	532		|O
(	533	534		|O
DSPP	534	538		|O
)	538	539		|O
and	540	543		|O
other	544	549		|O
mineralization	550	564		|O
markers	565	572		|O
by	573	575		|O
using	576	581		|O
reverse	582	589		|O
transcriptase	590	603		|O
-	603	604		|O
polymerase	604	614		|O
chain	615	620		|O
reaction	621	629		|O
in	630	632		|O
human	633	638		|O
pulp	639	643		|O
cells	644	649		|O
.	649	650		|O
H2O2	651	655		|O
decreased	656	665		|O
cell	666	670		|O
viability	671	680		|O
but	681	684		|O
increased	685	694		|O
HO	695	697		|O
-	697	698		|O
1	698	699		|O
and	700	703		|O
DSPP	704	708		|O
expression	709	719		|O
in	720	722		|O
a	723	724		|O
concentration	725	738		|O
-	738	739		|O
and	740	743		|O
time	744	748		|O
-	748	749		|O
dependent	749	758		|O
manner	759	765		|O
.	765	766		|O
Antioxidants	767	779		|O
and	780	783		|O
inhibitors	784	794		|O
of	795	797		|O
HO	798	800		|O
-	800	801		|O
1	801	802		|O
,	802	803		|O
phosphatidylinositol	804	824		|O
-	824	825		|O
3'	825	827		|O
-	827	828		|O
kinase	828	834		|O
,	834	835		|O
extracellular	836	849		|O
signal	850	856		|O
-	856	857		|O
regulated	857	866		|O
kinase	867	873		|O
,	873	874		|O
and	875	878		|O
p38	879	882		|O
mitogen	883	890		|O
-	890	891		|O
activated	891	900		|O
protein	901	908		|O
kinase	909	915		|O
blocked	916	923		|O
H2O2	924	928		|O
-	928	929		|O
induced	929	936		|O
cytotoxicity	937	949		|O
and	950	953		|O
the	954	957		|O
expression	958	968		|O
of	969	971		|O
HO	972	974		|O
-	974	975		|O
1	975	976		|O
and	977	980		|O
DSPP	981	985		|O
mRNA	986	990		|O
in	991	993		|O
pulp	994	998		|O
cells	999	1004		|O
.	1004	1005		|O
These	1006	1011		|O
data	1012	1016		|O
suggest	1017	1024		|O
that	1025	1029		|O
the	1030	1033		|O
induction	1034	1043		|O
of	1044	1046		|O
HO	1047	1049		|O
-	1049	1050		|O
1	1050	1051		|O
by	1052	1054		|O
H2O2	1055	1059		|O
in	1060	1062		|O
pulp	1063	1067		|O
cells	1068	1073		|O
plays	1074	1079		|O
a	1080	1081		|O
protective	1082	1092		|O
role	1093	1097		|O
against	1098	1105		|O
the	1106	1109		|O
cytotoxic	1110	1119		|O
effects	1120	1127		|O
of	1128	1130		|O
H2O2	1131	1135		|O
and	1136	1139		|O
stimulates	1140	1150		|O
DSPP	1151	1155		|O
expression	1156	1166		|O
,	1166	1167		|O
resulting	1168	1177		|O
in	1178	1180		|O
premature	1181	1190		|O
odontoblast	1191	1202		|O
differentiation	1203	1218		|O
through	1219	1226		|O
pathways	1227	1235		|O
that	1236	1240		|O
involve	1241	1248		|O
phosphatidylinositol	1249	1269		|O
-	1269	1270		|O
3'	1270	1272		|O
-	1272	1273		|O
kinase	1273	1279		|O
,	1279	1280		|O
p38	1281	1284		|O
,	1284	1285		|O
and	1286	1289		|O
extracellular	1290	1303		|O
signal	1304	1310		|O
-	1310	1311		|O
regulated	1311	1320		|O
kinase	1321	1327		|O
.	1327	1328		|O

### 18761239
Pharmacokinetics	0	16		|O
of	17	19		|O
levobupivacaine	20	35		|O
0.5%	36	40		|O
after	41	46		|O
superficial	47	58		|O
or	59	61		|O
combined	62	70		|O
(	71	72		|O
deep	72	76		|O
and	77	80		|O
superficial	81	92		|O
)	92	93		|O
cervical	94	102		|O
plexus	103	109		|O
block	110	115		|O
in	116	118		|O
patients	119	127		|O
undergoing	128	138		|O
minimally	139	148		|O
invasive	149	157		|O
parathyroidectomy	158	175		|O
.	175	176		|O
STUDY	178	183		|O
OBJECTIVE	184	193		|O
:	193	194		|O
To	195	197		|O
evaluate	198	206		|O
the	207	210		|O
pharmacokinetic	211	226		|O
profile	227	234		|O
of	235	237		|O
0.35	238	242		|O
mL	243	245		|O
/	245	246		|O
kg	246	248		|O
of	249	251		|O
0.5%	252	256		|O
levobupivacaine	257	272		|O
during	273	279		|O
superficial	280	291		|O
and	292	295		|O
combined	296	304		|O
(	305	306		|O
deep	306	310		|O
and	311	314		|O
superficial	315	326		|O
)	326	327		|O
cervical	328	336		|O
plexus	337	343		|O
block	344	349		|O
(	350	351		|O
CPB	351	354		|O
)	354	355		|O
in	356	358		|O
patients	359	367		|O
undergoing	368	378		|O
minimally	379	388		|O
invasive	389	397		|O
parathyroidectomy	398	415		|O
.	415	416		|O
DESIGN	417	423		|O
:	423	424		|O
Prospective	425	436		|O
randomized	437	447		|O
study	448	453		|O
.	453	454		|O
SETTING	455	462		|O
:	462	463		|O
Operating	464	473		|O
theater	474	481		|O
of	482	484		|O
a	485	486		|O
university	487	497		|O
hospital	498	506		|O
.	506	507		|O
PATIENTS	508	516		|O
:	516	517		|O
12	518	520		|O
ASA	521	524		|O
physical	525	533		|O
status	534	540		|O
II	541	543		|O
and	544	547		|O
III	548	551		|O
patients	552	560		|O
(	561	562		|O
11	562	564		|O
women	565	570		|O
and	571	574		|O
1	575	576		|O
man	577	580		|O
)	580	581		|O
,	581	582		|O
scheduled	583	592		|O
for	593	596		|O
minimally	597	606		|O
invasive	607	615		|O
parathyroidectomy	616	633		|O
.	633	634		|O
INTERVENTIONS	635	648		|O
:	648	649		|O
Seven	650	655		|O
and	656	659		|O
5	660	661		|O
patients	662	670		|O
were	671	675		|O
randomly	676	684		|O
assigned	685	693		|O
to	694	696		|O
receive	697	704		|O
either	705	711		|O
superficial	712	723		|O
or	724	726		|O
combined	727	735		|O
CPB	736	739		|O
,	739	740		|O
respectively	741	753		|O
.	753	754		|O
The	755	758		|O
superficial	759	770		|O
CPB	771	774		|O
was	775	778		|O
performed	779	788		|O
with	789	793		|O
an	794	796		|O
injection	797	806		|O
of	807	809		|O
0.35	810	814		|O
mL	815	817		|O
/	817	818		|O
kg	818	820		|O
of	821	823		|O
0.5%	824	828		|O
levobupivacaine	829	844		|O
subcutaneously	845	859		|O
along	860	865		|O
the	866	869		|O
posterior	870	879		|O
border	880	886		|O
of	887	889		|O
the	890	893		|O
sternocleidomastoid	894	913		|O
muscle	914	920		|O
and	921	924		|O
deeper	925	931		|O
on	932	934		|O
its	935	938		|O
medial	939	945		|O
surface	946	953		|O
.	953	954		|O
The	955	958		|O
combined	959	967		|O
CPB	968	971		|O
was	972	975		|O
initiated	976	985		|O
by	986	988		|O
the	989	992		|O
deep	993	997		|O
block	998	1003		|O
at	1004	1006		|O
the	1007	1010		|O
C3	1011	1013		|O
level	1014	1019		|O
vertebra	1020	1028		|O
by	1029	1031		|O
injecting	1032	1041		|O
0.2	1042	1045		|O
mL	1046	1048		|O
/	1048	1049		|O
kg	1049	1051		|O
of	1052	1054		|O
0.5%	1055	1059		|O
levobupivacaine	1060	1075		|O
,	1075	1076		|O
followed	1077	1085		|O
by	1086	1088		|O
the	1089	1092		|O
superficial	1093	1104		|O
block	1105	1110		|O
with	1111	1115		|O
an	1116	1118		|O
injection	1119	1128		|O
of	1129	1131		|O
the	1132	1135		|O
remaining	1136	1145		|O
0.15	1146	1150		|O
mL	1151	1153		|O
/	1153	1154		|O
kg	1154	1156		|O
.	1156	1157		|O
After	1158	1163		|O
completion	1164	1174		|O
of	1175	1177		|O
the	1178	1181		|O
block	1182	1187		|O
,	1187	1188		|O
venous	1189	1195		|O
blood	1196	1201		|O
was	1202	1205		|O
sampled	1206	1213		|O
at	1214	1216		|O
the	1217	1220		|O
intervals	1221	1230		|O
of	1231	1233		|O
5	1234	1235		|O
,	1235	1236		|O
10	1237	1239		|O
,	1239	1240		|O
15	1241	1243		|O
,	1243	1244		|O
20	1245	1247		|O
,	1247	1248		|O
30	1249	1251		|O
,	1251	1252		|O
45	1253	1255		|O
,	1255	1256		|O
and	1257	1260		|O
60	1261	1263		|O
minutes	1264	1271		|O
.	1271	1272		|O
MEASUREMENTS	1273	1285		|O
AND	1286	1289		|O
MAIN	1290	1294		|O
RESULTS	1295	1302		|O
:	1302	1303		|O
Venous	1304	1310		|O
plasma	1311	1317		|O
concentrations	1318	1332		|O
were	1333	1337		|O
measured	1338	1346		|O
using	1347	1352		|O
gas	1353	1356		|O
chromatography	1357	1371		|O
-	1371	1372		|O
mass	1372	1376		|O
spectroscopy	1377	1389		|O
.	1389	1390		|O
Mean	1391	1395		|O
+	1396	1397		|O
/	1397	1398		|O
-	1398	1399		|O
SD	1400	1402		|O
of	1403	1405		|O
maximal	1406	1413		|O
concentrations	1414	1428		|O
of	1429	1431		|O
levobupivacaine	1432	1447		|O
was	1448	1451		|O
0.58	1452	1456		|O
+	1457	1458		|O
/	1458	1459		|O
-	1459	1460		|O
0.41	1461	1465		|O
mg	1466	1468		|O
/	1468	1469		|O
L	1469	1470		|O
in	1471	1473		|O
group	1474	1479		|O
superficial	1480	1491		|O
and	1492	1495		|O
0.52	1496	1500		|O
+	1501	1502		|O
/	1502	1503		|O
-	1503	1504		|O
0.28	1505	1509		|O
mg	1510	1512		|O
/	1512	1513		|O
L	1513	1514		|O
in	1515	1517		|O
group	1518	1523		|O
combined	1524	1532		|O
(	1533	1534		|O
P	1534	1535		|O
=	1536	1537		|O
0.71	1538	1542		|O
)	1542	1543		|O
.	1543	1544		|O
The	1545	1548		|O
median	1549	1555		|O
(	1556	1557		|O
range	1557	1562		|O
)	1562	1563		|O
time	1564	1568		|O
required	1569	1577		|O
to	1578	1580		|O
reach	1581	1586		|O
the	1587	1590		|O
maximal	1591	1598		|O
concentrations	1599	1613		|O
was	1614	1617		|O
30	1618	1620		|O
minutes	1621	1628		|O
(	1629	1630		|O
20-30	1630	1635		|O
min	1636	1639		|O
)	1639	1640		|O
in	1641	1643		|O
group	1644	1649		|O
superficial	1650	1661		|O
and	1662	1665		|O
20	1666	1668		|O
minutes	1669	1676		|O
(	1677	1678		|O
15-30	1678	1683		|O
min	1684	1687		|O
)	1687	1688		|O
in	1689	1691		|O
group	1692	1697		|O
combined	1698	1706		|O
(	1707	1708		|O
P	1708	1709		|O
=	1710	1711		|O
0.45	1712	1716		|O
)	1716	1717		|O
.	1717	1718		|O
The	1719	1722		|O
areas	1723	1728		|O
under	1729	1734		|O
the	1735	1738		|O
drug	1739	1743		|O
concentration	1744	1757		|O
/	1757	1758		|O
time	1758	1762		|O
curve	1763	1768		|O
(	1769	1770		|O
AUC	1770	1773		|O
(	1773	1774		|O
10-60	1774	1779		|O
)	1779	1780		|O
)	1780	1781		|O
were	1782	1786		|O
also	1787	1791		|O
similar	1792	1799		|O
in	1800	1802		|O
both	1803	1807		|O
groups	1808	1814		|O
.	1814	1815		|O
No	1816	1818		|O
signs	1819	1824		|O
of	1825	1827		|O
central	1828	1835		|O
nervous	1836	1843		|O
system	1844	1850		|O
or	1851	1853		|O
cardiovascular	1854	1868	cardiovascular toxicity	|B-ADVERSE
toxicity	1869	1877		|I-ADVERSE
or	1878	1880		|O
other	1881	1886		|O
untoward	1887	1895		|O
events	1896	1902		|O
were	1903	1907		|O
observed	1908	1916		|O
in	1917	1919		|O
any	1920	1923		|O
patient	1924	1931		|O
.	1931	1932		|O
CONCLUSION	1933	1943		|O
:	1943	1944		|O
With	1945	1949		|O
the	1950	1953		|O
given	1954	1959		|O
dose	1960	1964		|O
regimen	1965	1972		|O
,	1972	1973		|O
levobupivacaine	1974	1989		|O
plasma	1990	1996		|O
concentrations	1997	2011		|O
were	2012	2016		|O
within	2017	2023		|O
safe	2024	2028		|O
ranges	2029	2035		|O
.	2035	2036		|O

### 18575136
Genotoxicity	0	12	Genotoxicity	|B-ADVERSE
evaluation	13	23		|O
of	24	26		|O
drinking	27	35		|O
water	36	41		|O
sources	42	49		|O
in	50	52		|O
human	53	58		|O
peripheral	59	69		|O
blood	70	75		|O
lymphocytes	76	87		|O
using	88	93		|O
the	94	97		|O
comet	98	103		|O
assay	104	109		|O
.	109	110		|O
The	112	115		|O
potential	116	125		|O
harm	126	130		|O
of	131	133		|O
organic	134	141		|O
pollutants	142	152		|O
in	153	155		|O
drinking	156	164		|O
water	165	170		|O
to	171	173		|O
human	174	179		|O
health	180	186		|O
is	187	189		|O
widely	190	196		|O
focused	197	204		|O
on	205	207		|O
in	208	210		|O
the	211	214		|O
world	215	220		|O
;	220	221		|O
more	222	226		|O
and	227	230		|O
more	231	235		|O
pollutants	236	246		|O
with	247	251		|O
genotoxic	252	261		|O
substances	262	272		|O
are	273	276		|O
released	277	285		|O
into	286	290		|O
the	291	294		|O
aquatic	295	302		|O
environment	303	314		|O
.	314	315		|O
Water	316	321		|O
source	322	328		|O
samples	329	336		|O
were	337	341		|O
collected	342	351		|O
from	352	356		|O
7	357	358		|O
different	359	368		|O
localities	369	379		|O
of	380	382		|O
Nanjing	383	390		|O
City	391	395		|O
.	395	396		|O
The	397	400		|O
potential	401	410		|O
genotoxicity	411	423	genotoxicity	|B-ADVERSE
of	424	426		|O
organic	427	434		|O
extracts	435	443		|O
from	444	448		|O
drinking	449	457		|O
water	458	463		|O
sources	464	471		|O
were	472	476		|O
investigated	477	489		|O
by	490	492		|O
means	493	498		|O
of	499	501		|O
the	502	505		|O
comet	506	511		|O
assay	512	517		|O
in	518	520		|O
human	521	526		|O
peripheral	527	537		|O
lymphocytes	538	549		|O
.	549	550		|O
The	551	554		|O
results	555	562		|O
showed	563	569		|O
that	570	574		|O
all	575	578		|O
the	579	582		|O
organic	583	590		|O
extracts	591	599		|O
from	600	604		|O
all	605	608		|O
the	609	612		|O
water	613	618		|O
source	619	625		|O
samples	626	633		|O
could	634	639		|O
induce	640	646		|O
DNA	647	650		|O
damages	651	658		|O
of	659	661		|O
human	662	667		|O
peripheral	668	678		|O
blood	679	684		|O
lymphocytes	685	696		|O
at	697	699		|O
different	700	709		|O
levels	710	716		|O
.	716	717		|O
A	718	719		|O
significant	720	731		|O
difference	732	742		|O
(	743	744		|O
P	744	745		|O
<	746	747		|O
0.01	748	752		|O
)	752	753		|O
was	754	757		|O
observed	758	766		|O
when	767	771		|O
compared	772	780		|O
with	781	785		|O
the	786	789		|O
solvent	790	797		|O
control	798	805		|O
.	805	806		|O
The	807	810		|O
DNA	811	814		|O
damage	815	821		|O
increased	822	831		|O
with	832	836		|O
the	837	840		|O
increase	841	849		|O
of	850	852		|O
the	853	856		|O
dosage	857	863		|O
of	864	866		|O
the	867	870		|O
original	871	879		|O
water	880	885		|O
source	886	892		|O
.	892	893		|O
Significant	894	905		|O
differences	906	917		|O
of	918	920		|O
DNA	921	924		|O
damage	925	931		|O
were	932	936		|O
observed	937	945		|O
in	946	948		|O
different	949	958		|O
drinking	959	967		|O
water	968	973		|O
sources	974	981		|O
,	981	982		|O
as	983	985		|O
shown	986	991		|O
by	992	994		|O
the	995	998		|O
multiple	999	1007		|O
comparisons	1008	1019		|O
analysis	1020	1028		|O
at	1029	1031		|O
the	1032	1035		|O
dosage	1036	1042		|O
of	1043	1045		|O
100x	1046	1050		|O
;	1050	1051		|O
the	1052	1055		|O
degree	1056	1062		|O
of	1063	1065		|O
DNA	1066	1069		|O
damage	1070	1076		|O
treated	1077	1084		|O
by	1085	1087		|O
Hushu	1088	1093		|O
waterworks	1094	1104		|O
(	1105	1106		|O
at	1106	1108		|O
town	1109	1113		|O
level	1114	1119		|O
)	1119	1120		|O
was	1121	1124		|O
the	1125	1128		|O
most	1129	1133		|O
serious	1134	1141		|O
,	1141	1142		|O
the	1143	1146		|O
arbitrary	1147	1156		|O
units	1157	1162		|O
(	1163	1164		|O
AU	1164	1166		|O
)	1166	1167		|O
was	1168	1171		|O
141.62	1172	1178		|O
+	1179	1180		|O
/	1180	1181		|O
-	1181	1182		|O
6.96	1183	1187		|O
,	1187	1188		|O
however	1189	1196		|O
,	1196	1197		|O
that	1198	1202		|O
of	1203	1205		|O
Shangyuanmen	1206	1218		|O
waterworks	1219	1229		|O
(	1230	1231		|O
at	1231	1233		|O
city	1234	1238		|O
level	1239	1244		|O
)	1244	1245		|O
was	1246	1249		|O
only	1250	1254		|O
109.64	1255	1261		|O
+	1262	1263		|O
/	1263	1264		|O
-	1264	1265		|O
2.97	1266	1270		|O
.	1270	1271		|O
The	1272	1275		|O
analysis	1276	1284		|O
also	1285	1289		|O
revealed	1290	1298		|O
that	1299	1303		|O
the	1304	1307		|O
genotoxicity	1308	1320	genotoxicity	|B-ADVERSE
of	1321	1323		|O
town	1324	1328		|O
's	1328	1330		|O
water	1331	1336		|O
sources	1337	1344		|O
was	1345	1348		|O
higher	1349	1355		|O
than	1356	1360		|O
that	1361	1365		|O
of	1366	1368		|O
the	1369	1372		|O
city	1373	1377		|O
.	1377	1378		|O
The	1379	1382		|O
results	1383	1390		|O
demonstrated	1391	1403		|O
that	1404	1408		|O
the	1409	1412		|O
comet	1413	1418		|O
assay	1419	1424		|O
can	1425	1428		|O
be	1429	1431		|O
successfully	1432	1444		|O
applied	1445	1452		|O
to	1453	1455		|O
the	1456	1459		|O
genotoxicity	1460	1472	genotoxicity	|B-ADVERSE
monitoring	1473	1483		|O
programs	1484	1492		|O
of	1493	1495		|O
drinking	1496	1504		|O
water	1505	1510		|O
sources	1511	1518		|O
.	1518	1519		|O

### 18843612
WITHDRAWN	0	9		|O
:	9	10		|O
Multi	11	16		|O
-	16	17		|O
agent	17	22		|O
chemotherapy	23	35		|O
for	36	39		|O
early	40	45		|O
breast	46	52	breast cancer	|B-DISEASE
cancer	53	59		|I-DISEASE
.	59	60		|O
BACKGROUND	62	72		|O
:	72	73		|O
There	74	79		|O
have	80	84		|O
been	85	89		|O
many	90	94		|O
randomised	95	105		|O
trials	106	112		|O
of	113	115		|O
adjuvant	116	124		|O
prolonged	125	134		|O
polychemotherapy	135	151		|O
among	152	157		|O
women	158	163		|O
with	164	168		|O
early	169	174		|O
breast	175	181	breast cancer	|B-DISEASE
cancer	182	188		|I-DISEASE
,	188	189		|O
and	190	193		|O
an	194	196		|O
updated	197	204		|O
overview	205	213		|O
of	214	216		|O
their	217	222		|O
results	223	230		|O
is	231	233		|O
presented	234	243		|O
.	243	244		|O
OBJECTIVES	245	255		|O
:	255	256		|O
In	257	259		|O
this	260	264		|O
report	265	271		|O
,	271	272		|O
the	273	276		|O
Early	277	282		|O
Breast	283	289	Breast Cancer	|B-DISEASE
Cancer	290	296		|I-DISEASE
Trialists	297	306		|O
'	306	307		|O
Collaborative	308	321		|O
Group	322	327		|O
present	328	335		|O
their	336	341		|O
updated	342	349		|O
systematic	350	360		|O
overview	361	369		|O
(	370	371		|O
meta	371	375		|O
-	375	376		|O
analysis	376	384		|O
)	384	385		|O
of	386	388		|O
treatment	389	398		|O
with	399	403		|O
polychemotherapy	404	420		|O
.	420	421		|O
SEARCH	422	428		|O
STRATEGY	429	437		|O
:	437	438		|O
Trial	439	444		|O
identification	445	459		|O
procedures	460	470		|O
for	471	474		|O
the	475	478		|O
EBCTCG	479	485		|O
overviews	486	495		|O
have	496	500		|O
been	501	505		|O
described	506	515		|O
elsewhere	516	525		|O
.	525	526		|O
See	527	530		|O
under	531	536		|O
"	537	538		|O
EBCTCG	538	544		|O
"	544	545		|O
in	546	548		|O
the	549	552		|O
Breast	553	559	Breast Cancer	|B-DISEASE
Cancer	560	566		|I-DISEASE
Collaborative	567	580		|O
Review	581	587		|O
Group	588	593		|O
module	594	600		|O
.	600	601		|O
SELECTION	602	611		|O
CRITERIA	612	620		|O
:	620	621		|O
All	622	625		|O
randomised	626	636		|O
trials	637	643		|O
that	644	648		|O
began	649	654		|O
before	655	661		|O
1990	662	666		|O
and	667	670		|O
involved	671	679		|O
treatment	680	689		|O
groups	690	696		|O
that	697	701		|O
differed	702	710		|O
only	711	715		|O
with	716	720		|O
respect	721	728		|O
to	729	731		|O
the	732	735		|O
chemotherapy	736	748		|O
regimens	749	757		|O
that	758	762		|O
were	763	767		|O
being	768	773		|O
compared	774	782		|O
.	782	783		|O
DATA	784	788		|O
COLLECTION	789	799		|O
AND	800	803		|O
ANALYSIS	804	812		|O
:	812	813		|O
In	814	816		|O
1995	817	821		|O
,	821	822		|O
information	823	834		|O
was	835	838		|O
sought	839	845		|O
on	846	848		|O
each	849	853		|O
woman	854	859		|O
in	860	862		|O
any	863	866		|O
randomised	867	877		|O
trial	878	883		|O
that	884	888		|O
began	889	894		|O
before	895	901		|O
1990	902	906		|O
and	907	910		|O
involved	911	919		|O
treatment	920	929		|O
groups	930	936		|O
that	937	941		|O
differed	942	950		|O
only	951	955		|O
with	956	960		|O
respect	961	968		|O
to	969	971		|O
the	972	975		|O
chemotherapy	976	988		|O
regimens	989	997		|O
that	998	1002		|O
were	1003	1007		|O
being	1008	1013		|O
compared	1014	1022		|O
.	1022	1023		|O
Analyses	1024	1032		|O
involved	1033	1041		|O
about	1042	1047		|O
18,000	1048	1054		|O
women	1055	1060		|O
in	1061	1063		|O
47	1064	1066		|O
trials	1067	1073		|O
of	1074	1076		|O
prolonged	1077	1086		|O
polychemotherapy	1087	1103		|O
versus	1104	1110		|O
no	1111	1113		|O
chemotherapy	1114	1126		|O
,	1126	1127		|O
about	1128	1133		|O
6000	1134	1138		|O
in	1139	1141		|O
11	1142	1144		|O
trials	1145	1151		|O
of	1152	1154		|O
longer	1155	1161		|O
versus	1162	1168		|O
shorter	1169	1176		|O
polychemotherapy	1177	1193		|O
,	1193	1194		|O
and	1195	1198		|O
about	1199	1204		|O
6000	1205	1209		|O
in	1210	1212		|O
11	1213	1215		|O
trials	1216	1222		|O
of	1223	1225		|O
anthracycline	1226	1239		|O
-	1239	1240		|O
containing	1240	1250		|O
regimens	1251	1259		|O
versus	1260	1266		|O
CMF	1267	1270		|O
(	1271	1272		|O
cyclophosphamide	1272	1288		|O
,	1288	1289		|O
methotrexate	1290	1302		|O
,	1302	1303		|O
and	1304	1307		|O
fluorouracil	1308	1320		|O
)	1320	1321		|O
.	1321	1322		|O
MAIN	1323	1327		|O
RESULTS	1328	1335		|O
:	1335	1336		|O
For	1337	1340		|O
recurrence	1341	1351		|O
,	1351	1352		|O
polychemotherapy	1353	1369		|O
produced	1370	1378		|O
substantial	1379	1390		|O
and	1391	1394		|O
highly	1395	1401		|O
significant	1402	1413		|O
proportional	1414	1426		|O
reductions	1427	1437		|O
both	1438	1442		|O
among	1443	1448		|O
women	1449	1454		|O
aged	1455	1459		|O
under	1460	1465		|O
50	1466	1468		|O
at	1469	1471		|O
randomisation	1472	1485		|O
(	1486	1487		|O
35%	1487	1490		|O
[	1491	1492		|O
SD	1492	1494		|O
4	1495	1496		|O
]	1496	1497		|O
reduction	1498	1507		|O
;	1507	1508		|O
2p	1509	1511		|O
<	1511	1512		|O
0.00001	1512	1519		|O
)	1519	1520		|O
and	1521	1524		|O
among	1525	1530		|O
those	1531	1536		|O
aged	1537	1541		|O
50-69	1542	1547		|O
(	1548	1549		|O
20%	1549	1552		|O
[	1553	1554		|O
SD	1554	1556		|O
3	1557	1558		|O
]	1558	1559		|O
reduction	1560	1569		|O
;	1569	1570		|O
2p	1571	1573		|O
<	1573	1574		|O
0.00001	1574	1581		|O
)	1581	1582		|O
;	1582	1583		|O
few	1584	1587		|O
women	1588	1593		|O
aged	1594	1598		|O
70	1599	1601		|O
or	1602	1604		|O
over	1605	1609		|O
had	1610	1613		|O
been	1614	1618		|O
studied	1619	1626		|O
.	1626	1627		|O
For	1628	1631		|O
mortality	1632	1641		|O
,	1641	1642		|O
the	1643	1646		|O
reductions	1647	1657		|O
were	1658	1662		|O
also	1663	1667		|O
significant	1668	1679		|O
both	1680	1684		|O
among	1685	1690		|O
women	1691	1696		|O
aged	1697	1701		|O
under	1702	1707		|O
50	1708	1710		|O
(	1711	1712		|O
27%	1712	1715		|O
[	1716	1717		|O
SD	1717	1719		|O
5	1720	1721		|O
]	1721	1722		|O
reduction	1723	1732		|O
;	1732	1733		|O
2p	1734	1736		|O
<	1736	1737		|O
0.00001	1737	1744		|O
)	1744	1745		|O
and	1746	1749		|O
among	1750	1755		|O
those	1756	1761		|O
aged	1762	1766		|O
50-69	1767	1772		|O
(	1773	1774		|O
11%	1774	1777		|O
[	1778	1779		|O
SD	1779	1781		|O
3	1782	1783		|O
]	1783	1784		|O
reduction	1785	1794		|O
;	1794	1795		|O
2p	1796	1798		|O
=	1798	1799		|O
0.0001	1799	1805		|O
)	1805	1806		|O
.	1806	1807		|O
The	1808	1811		|O
recurrence	1812	1822		|O
reductions	1823	1833		|O
emerged	1834	1841		|O
chiefly	1842	1849		|O
during	1850	1856		|O
the	1857	1860		|O
first	1861	1866		|O
5	1867	1868		|O
years	1869	1874		|O
of	1875	1877		|O
follow	1878	1884		|O
-	1884	1885		|O
up	1885	1887		|O
,	1887	1888		|O
whereas	1889	1896		|O
the	1897	1900		|O
difference	1901	1911		|O
in	1912	1914		|O
survival	1915	1923		|O
grew	1924	1928		|O
throughout	1929	1939		|O
the	1940	1943		|O
first	1944	1949		|O
10	1950	1952		|O
years	1953	1958		|O
.	1958	1959		|O
After	1960	1965		|O
standardisation	1966	1981		|O
for	1982	1985		|O
age	1986	1989		|O
and	1990	1993		|O
time	1994	1998		|O
since	1999	2004		|O
randomisation	2005	2018		|O
,	2018	2019		|O
the	2020	2023		|O
proportional	2024	2036		|O
reductions	2037	2047		|O
in	2048	2050		|O
risk	2051	2055		|O
were	2056	2060		|O
similar	2061	2068		|O
for	2069	2072		|O
women	2073	2078		|O
with	2079	2083		|O
node	2084	2088		|O
-	2088	2089		|O
negative	2089	2097		|O
and	2098	2101		|O
node	2102	2106		|O
-	2106	2107		|O
positive	2107	2115		|O
disease	2116	2123		|O
.	2123	2124		|O
Applying	2125	2133		|O
the	2134	2137		|O
proportional	2138	2150		|O
mortality	2151	2160		|O
reduction	2161	2170		|O
observed	2171	2179		|O
in	2180	2182		|O
all	2183	2186		|O
women	2187	2192		|O
aged	2193	2197		|O
under	2198	2203		|O
50	2204	2206		|O
at	2207	2209		|O
randomisation	2210	2223		|O
would	2224	2229		|O
typically	2230	2239		|O
change	2240	2246		|O
a	2247	2248		|O
10	2249	2251		|O
-	2251	2252		|O
year	2252	2256		|O
survival	2257	2265		|O
of	2266	2268		|O
71%	2269	2272		|O
for	2273	2276		|O
those	2277	2282		|O
with	2283	2287		|O
node	2288	2292		|O
-	2292	2293		|O
negative	2293	2301		|O
disease	2302	2309		|O
to	2310	2312		|O
78%	2313	2316		|O
(	2317	2318		|O
an	2318	2320		|O
absolute	2321	2329		|O
benefit	2330	2337		|O
of	2338	2340		|O
7%	2341	2343		|O
)	2343	2344		|O
,	2344	2345		|O
and	2346	2349		|O
of	2350	2352		|O
42%	2353	2356		|O
for	2357	2360		|O
those	2361	2366		|O
with	2367	2371		|O
node	2372	2376		|O
-	2376	2377		|O
positive	2377	2385		|O
disease	2386	2393		|O
to	2394	2396		|O
53%	2397	2400		|O
(	2401	2402		|O
an	2402	2404		|O
absolute	2405	2413		|O
benefit	2414	2421		|O
of	2422	2424		|O
11%	2425	2428		|O
)	2428	2429		|O
.	2429	2430		|O
The	2431	2434		|O
smaller	2435	2442		|O
proportional	2443	2455		|O
mortality	2456	2465		|O
reduction	2466	2475		|O
observed	2476	2484		|O
in	2485	2487		|O
all	2488	2491		|O
women	2492	2497		|O
aged	2498	2502		|O
50-69	2503	2508		|O
at	2509	2511		|O
randomisation	2512	2525		|O
would	2526	2531		|O
translate	2532	2541		|O
into	2542	2546		|O
smaller	2547	2554		|O
absolute	2555	2563		|O
benefits	2564	2572		|O
,	2572	2573		|O
changing	2574	2582		|O
a	2583	2584		|O
10	2585	2587		|O
-	2587	2588		|O
year	2588	2592		|O
survival	2593	2601		|O
of	2602	2604		|O
67%	2605	2608		|O
for	2609	2612		|O
those	2613	2618		|O
with	2619	2623		|O
node	2624	2628		|O
-	2628	2629		|O
negative	2629	2637		|O
disease	2638	2645		|O
to	2646	2648		|O
69%	2649	2652		|O
(	2653	2654		|O
an	2654	2656		|O
absolute	2657	2665		|O
gain	2666	2670		|O
of	2671	2673		|O
2%	2674	2676		|O
)	2676	2677		|O
and	2678	2681		|O
of	2682	2684		|O
46%	2685	2688		|O
for	2689	2692		|O
those	2693	2698		|O
with	2699	2703		|O
node	2704	2708		|O
-	2708	2709		|O
positive	2709	2717		|O
disease	2718	2725		|O
to	2726	2728		|O
49%	2729	2732		|O
(	2733	2734		|O
an	2734	2736		|O
absolute	2737	2745		|O
gain	2746	2750		|O
of	2751	2753		|O
3%	2754	2756		|O
)	2756	2757		|O
.	2757	2758		|O
The	2759	2762		|O
age	2763	2766		|O
-	2766	2767		|O
specific	2767	2775		|O
benefits	2776	2784		|O
of	2785	2787		|O
polychemotherapy	2788	2804		|O
appeared	2805	2813		|O
to	2814	2816		|O
be	2817	2819		|O
largely	2820	2827		|O
irrespective	2828	2840		|O
of	2841	2843		|O
menopausal	2844	2854		|O
status	2855	2861		|O
at	2862	2864		|O
presentation	2865	2877		|O
,	2877	2878		|O
oestrogen	2879	2888		|O
receptor	2889	2897		|O
status	2898	2904		|O
of	2905	2907		|O
the	2908	2911		|O
primary	2912	2919		|O
tumour	2920	2926		|O
,	2926	2927		|O
and	2928	2931		|O
of	2932	2934		|O
whether	2935	2942		|O
adjuvant	2943	2951		|O
tamoxifen	2952	2961		|O
had	2962	2965		|O
been	2966	2970		|O
given	2971	2976		|O
.	2976	2977		|O
In	2978	2980		|O
terms	2981	2986		|O
of	2987	2989		|O
other	2990	2995		|O
outcomes	2996	3004		|O
,	3004	3005		|O
there	3006	3011		|O
was	3012	3015		|O
a	3016	3017		|O
reduction	3018	3027		|O
of	3028	3030		|O
about	3031	3036		|O
one	3037	3040		|O
-	3040	3041		|O
fifth	3041	3046		|O
(	3047	3048		|O
2p	3048	3050		|O
=	3050	3051		|O
0.05	3051	3055		|O
)	3055	3056		|O
in	3057	3059		|O
contralateral	3060	3073	contralateral breast cancer	|B-DISEASE
breast	3074	3080		|I-DISEASE
cancer	3081	3087		|I-DISEASE
,	3087	3088		|O
which	3089	3094		|O
has	3095	3098		|O
already	3099	3106		|O
been	3107	3111		|O
included	3112	3120		|O
in	3121	3123		|O
the	3124	3127		|O
analyses	3128	3136		|O
of	3137	3139		|O
recurrence	3140	3150		|O
,	3150	3151		|O
and	3152	3155		|O
no	3156	3158		|O
apparent	3159	3167		|O
adverse	3168	3175		|O
effect	3176	3182		|O
on	3183	3185		|O
deaths	3186	3192		|O
from	3193	3197		|O
causes	3198	3204		|O
other	3205	3210		|O
than	3211	3215		|O
breast	3216	3222	breast cancer	|B-DISEASE
cancer	3223	3229		|I-DISEASE
(	3230	3231		|O
death	3231	3236		|O
rate	3237	3241		|O
ratio	3242	3247		|O
0.89	3248	3252		|O
[	3253	3254		|O
SD	3254	3256		|O
0.09	3257	3261		|O
]	3261	3262		|O
)	3262	3263		|O
.	3263	3264		|O
The	3265	3268		|O
directly	3269	3277		|O
randomised	3278	3288		|O
comparisons	3289	3300		|O
of	3301	3303		|O
longer	3304	3310		|O
versus	3311	3317		|O
shorter	3318	3325		|O
durations	3326	3335		|O
of	3336	3338		|O
polychemotherapy	3339	3355		|O
did	3356	3359		|O
not	3360	3363		|O
indicate	3364	3372		|O
any	3373	3376		|O
survival	3377	3385		|O
advantage	3386	3395		|O
with	3396	3400		|O
the	3401	3404		|O
use	3405	3408		|O
of	3409	3411		|O
more	3412	3416		|O
than	3417	3421		|O
about	3422	3427		|O
3-6	3428	3431		|O
months	3432	3438		|O
of	3439	3441		|O
polychemotherapy	3442	3458		|O
.	3458	3459		|O
By	3460	3462		|O
contrast	3463	3471		|O
,	3471	3472		|O
directly	3473	3481		|O
randomised	3482	3492		|O
comparisons	3493	3504		|O
did	3505	3508		|O
suggest	3509	3516		|O
that	3517	3521		|O
,	3521	3522		|O
compared	3523	3531		|O
with	3532	3536		|O
CMF	3537	3540		|O
alone	3541	3546		|O
,	3546	3547		|O
the	3548	3551		|O
anthracycline	3552	3565		|O
-	3565	3566		|O
containing	3566	3576		|O
regimens	3577	3585		|O
studied	3586	3593		|O
produced	3594	3602		|O
somewhat	3603	3611		|O
greater	3612	3619		|O
effects	3620	3627		|O
on	3628	3630		|O
recurrence	3631	3641		|O
(	3642	3643		|O
2p	3643	3645		|O
=	3645	3646		|O
0.006	3646	3651		|O
)	3651	3652		|O
and	3653	3656		|O
mortality	3657	3666		|O
(	3667	3668		|O
69%	3668	3671		|O
vs	3672	3674		|O
72%	3675	3678		|O
5	3679	3680		|O
-	3680	3681		|O
year	3681	3685		|O
survival	3686	3694		|O
;	3694	3695		|O
log	3696	3699		|O
-	3699	3700		|O
rank	3700	3704		|O
2p	3705	3707		|O
=	3707	3708		|O
0.02	3708	3712		|O
)	3712	3713		|O
.	3713	3714		|O
But	3715	3718		|O
this	3719	3723		|O
comparison	3724	3734		|O
is	3735	3737		|O
one	3738	3741		|O
of	3742	3744		|O
many	3745	3749		|O
that	3750	3754		|O
could	3755	3760		|O
have	3761	3765		|O
been	3766	3770		|O
selected	3771	3779		|O
for	3780	3783		|O
emphasis	3784	3792		|O
,	3792	3793		|O
the	3794	3797		|O
99%	3798	3801		|O
CI	3802	3804		|O
reaches	3805	3812		|O
zero	3813	3817		|O
,	3817	3818		|O
and	3819	3822		|O
the	3823	3826		|O
results	3827	3834		|O
of	3835	3837		|O
several	3838	3845		|O
of	3846	3848		|O
the	3849	3852		|O
relevant	3853	3861		|O
trials	3862	3868		|O
are	3869	3872		|O
not	3873	3876		|O
yet	3877	3880		|O
available	3881	3890		|O
.	3890	3891		|O
AUTHORS	3892	3899		|O
'	3899	3900		|O
CONCLUSIONS	3901	3912		|O
:	3912	3913		|O
Some	3914	3918		|O
months	3919	3925		|O
of	3926	3928		|O
adjuvant	3929	3937		|O
polychemotherapy	3938	3954		|O
(	3955	3956		|O
eg	3956	3958		|O
,	3958	3959		|O
with	3960	3964		|O
CMF	3965	3968		|O
or	3969	3971		|O
an	3972	3974		|O
anthracycline	3975	3988		|O
-	3988	3989		|O
containing	3989	3999		|O
regimen	4000	4007		|O
)	4007	4008		|O
typically	4009	4018		|O
produces	4019	4027		|O
an	4028	4030		|O
absolute	4031	4039		|O
improvement	4040	4051		|O
of	4052	4054		|O
about	4055	4060		|O
7-11%	4061	4066		|O
in	4067	4069		|O
10	4070	4072		|O
-	4072	4073		|O
year	4073	4077		|O
survival	4078	4086		|O
for	4087	4090		|O
women	4091	4096		|O
aged	4097	4101		|O
under	4102	4107		|O
50	4108	4110		|O
at	4111	4113		|O
presentation	4114	4126		|O
with	4127	4131		|O
early	4132	4137		|O
breast	4138	4144	breast cancer	|B-DISEASE
cancer	4145	4151		|I-DISEASE
,	4151	4152		|O
and	4153	4156		|O
of	4157	4159		|O
about	4160	4165		|O
2-3%	4166	4170		|O
for	4171	4174		|O
those	4175	4180		|O
aged	4181	4185		|O
50-69	4186	4191		|O
(	4192	4193		|O
unless	4193	4199		|O
their	4200	4205		|O
prognosis	4206	4215		|O
is	4216	4218		|O
likely	4219	4225		|O
to	4226	4228		|O
be	4229	4231		|O
extremely	4232	4241		|O
good	4242	4246		|O
even	4247	4251		|O
without	4252	4259		|O
such	4260	4264		|O
treatment	4265	4274		|O
)	4274	4275		|O
.	4275	4276		|O
Treatment	4277	4286		|O
decisions	4287	4296		|O
involve	4297	4304		|O
consideration	4305	4318		|O
not	4319	4322		|O
only	4323	4327		|O
of	4328	4330		|O
improvements	4331	4343		|O
in	4344	4346		|O
cancer	4347	4353	cancer	|B-DISEASE
recurrence	4354	4364		|O
and	4365	4368		|O
survival	4369	4377		|O
but	4378	4381		|O
also	4382	4386		|O
of	4387	4389		|O
adverse	4390	4397		|O
side	4398	4402		|O
-	4402	4403		|O
effects	4403	4410		|O
of	4411	4413		|O
treatment	4414	4423		|O
,	4423	4424		|O
and	4425	4428		|O
this	4429	4433		|O
report	4434	4440		|O
makes	4441	4446		|O
no	4447	4449		|O
recommendations	4450	4465		|O
as	4466	4468		|O
to	4469	4471		|O
who	4472	4475		|O
should	4476	4482		|O
or	4483	4485		|O
should	4486	4492		|O
not	4493	4496		|O
be	4497	4499		|O
treated	4500	4507		|O
.	4507	4508		|O

### 18854788
Changes	0	7		|O
in	8	10		|O
retinal	11	18		|O
sensitivity	19	30		|O
from	31	35		|O
retained	36	44		|O
subretinal	45	55		|O
perfluorocarbon	56	71		|O
liquid	72	78		|O
.	78	79		|O
PURPOSE	81	88		|O
:	88	89		|O
To	90	92		|O
study	93	98		|O
the	99	102		|O
effect	103	109		|O
of	110	112		|O
retained	113	121		|O
subretinal	122	132		|O
perfluorocarbon	133	148		|O
liquid	149	155		|O
(	156	157		|O
PFCL	157	161		|O
)	161	162		|O
on	163	165		|O
retinal	166	173		|O
function	174	182		|O
.	182	183		|O
METHODS	184	191		|O
:	191	192		|O
Scanning	193	201		|O
laser	202	207		|O
ophthalmoscope	208	222		|O
microperimetry	223	237		|O
was	238	241		|O
performed	242	251		|O
on	252	254		|O
four	255	259		|O
eyes	260	264		|O
with	265	269		|O
retained	270	278		|O
subretinal	279	289		|O
PFCL	290	294		|O
after	295	300		|O
vitreoretinal	301	314		|O
surgery	315	322		|O
for	323	326		|O
complicated	327	338		|O
retinal	339	346		|O
detachments	347	358		|O
with	359	363		|O
and	364	367		|O
without	368	375		|O
proliferative	376	389	proliferative vitreoretinopathy	|B-DISEASE
vitreoretinopathy	390	407		|I-DISEASE
.	407	408		|O
RESULTS	409	416		|O
:	416	417		|O
Scotomas	418	426		|O
to	427	429		|O
the	430	433		|O
highest	434	441		|O
intensity	442	451		|O
stimulus	452	460		|O
were	461	465		|O
noted	466	471		|O
in	472	474		|O
the	475	478		|O
area	479	483		|O
of	484	486		|O
the	487	490		|O
subretinal	491	501		|O
PFCL	502	506		|O
in	507	509		|O
all	510	513		|O
four	514	518		|O
eyes	519	523		|O
.	523	524		|O
All	525	528		|O
scotomas	529	537		|O
encompassed	538	549		|O
approximately	550	563		|O
the	564	567		|O
same	568	572		|O
area	573	577		|O
as	578	580		|O
the	581	584		|O
retained	585	593		|O
PFCL	594	598		|O
droplets	599	607		|O
.	607	608		|O
In	609	611		|O
the	612	615		|O
area	616	620		|O
vacated	621	628		|O
by	629	631		|O
a	632	633		|O
migrating	634	643		|O
PFCL	644	648		|O
droplet	649	656		|O
in	657	659		|O
one	660	663		|O
eye	664	667		|O
,	667	668		|O
the	669	672		|O
highest	673	680		|O
intensity	681	690		|O
stimulus	691	699		|O
could	700	705		|O
be	706	708		|O
perceived	709	718		|O
,	718	719		|O
but	720	723		|O
a	724	725		|O
relative	726	734		|O
scotoma	735	742	scotoma	|B-DISEASE
(	743	744		|O
to	744	746		|O
a	747	748		|O
lower	749	754		|O
intensity	755	764		|O
stimulus	765	773		|O
)	773	774		|O
was	775	778		|O
present	779	786		|O
.	786	787		|O
CONCLUSIONS	788	799		|O
:	799	800		|O
There	801	806		|O
is	807	809		|O
a	810	811		|O
local	812	817		|O
reduction	818	827		|O
in	828	830		|O
retinal	831	838		|O
function	839	847		|O
in	848	850		|O
the	851	854		|O
area	855	859		|O
of	860	862		|O
retained	863	871		|O
subretinal	872	882		|O
PFCL	883	887		|O
.	887	888		|O
There	889	894		|O
may	895	898		|O
be	899	901		|O
partial	902	909		|O
recovery	910	918		|O
of	919	921		|O
retinal	922	929		|O
function	930	938		|O
in	939	941		|O
an	942	944		|O
area	945	949		|O
vacated	950	957		|O
by	958	960		|O
the	961	964		|O
subretinal	965	975		|O
PFCL	976	980		|O
.	980	981		|O
Subretinal	982	992		|O
PFCL	993	997		|O
beneath	998	1005		|O
the	1006	1009		|O
fovea	1010	1015		|O
or	1016	1018		|O
at	1019	1021		|O
risk	1022	1026		|O
for	1027	1030		|O
migration	1031	1040		|O
beneath	1041	1048		|O
the	1049	1052		|O
fovea	1053	1058		|O
should	1059	1065		|O
be	1066	1068		|O
considered	1069	1079		|O
for	1080	1083		|O
removal	1084	1091		|O
.	1091	1092		|O

### 18623206
Dose	0	4		|O
intensive	5	14		|O
melphalan	15	24		|O
and	25	28		|O
cyclophosphamide	29	45		|O
with	46	50		|O
autologous	51	61		|O
hematopoietic	62	75		|O
stem	76	80		|O
cells	81	86		|O
for	87	90		|O
recurrent	91	100	recurrent medulloblastoma	|B-DISEASE
medulloblastoma	101	116		|I-DISEASE
or	117	119		|O
germinoma	120	129	germinoma	|B-DISEASE
.	129	130		|O
PURPOSE	132	139		|O
:	139	140		|O
To	141	143		|O
determine	144	153		|O
the	154	157		|O
response	158	166		|O
,	166	167		|O
toxicity	168	176		|O
,	176	177		|O
and	178	181		|O
survival	182	190		|O
for	191	194		|O
children	195	203		|O
with	204	208		|O
progressive	209	220		|O
or	221	223		|O
recurrent	224	233	recurrent medulloblastoma	|B-DISEASE
medulloblastoma	234	249		|I-DISEASE
and	250	253		|O
germinoma	254	263	germinoma	|B-DISEASE
using	264	269		|O
a	270	271		|O
single	272	278		|O
myeloablative	279	292		|O
course	293	299		|O
of	300	302		|O
chemotherapy	303	315		|O
supported	316	325		|O
by	326	328		|O
autologous	329	339		|O
hematopoietic	340	353		|O
stem	354	358		|O
cells	359	364		|O
.	364	365		|O
PATIENTS	366	374		|O
AND	375	378		|O
METHODS	379	386		|O
:	386	387		|O
Subjects	388	396		|O
were	397	401		|O
in	402	404		|O
second	405	411		|O
remission	412	421		|O
or	422	424		|O
had	425	428		|O
minimal	429	436		|O
residual	437	445		|O
disease	446	453		|O
at	454	456		|O
the	457	460		|O
time	461	465		|O
of	466	468		|O
study	469	474		|O
entry	475	480		|O
.	480	481		|O
The	482	485		|O
conditioning	486	498		|O
regimen	499	506		|O
consisted	507	516		|O
of	517	519		|O
cyclophosphamide	520	536		|O
6,000	537	542		|O
mg	543	545		|O
/	545	546		|O
m	546	547		|O
(	547	548		|O
2	548	549		|O
)	549	550		|O
plus	551	555		|O
melphalan	556	565		|O
180	566	569		|O
mg	570	572		|O
/	572	573		|O
m	573	574		|O
(	574	575		|O
2	575	576		|O
)	576	577		|O
.	577	578		|O
RESULTS	579	586		|O
:	586	587		|O
Twenty	588	594		|O
-	594	595		|O
nine	595	599		|O
evaluable	600	609		|O
pediatric	610	619		|O
patients	620	628		|O
were	629	633		|O
accrued	634	641		|O
.	641	642		|O
The	643	646		|O
most	647	651		|O
frequent	652	660		|O
major	661	666		|O
toxicities	667	677		|O
were	678	682		|O
myelosuppression	683	699	myelosuppression	|B-ADVERSE
,	699	700		|O
infections	701	711	infections	|B-ADVERSE
,	711	712		|O
and	713	716		|O
stomatitis	717	727	stomatitis	|B-ADVERSE
,	727	728		|O
but	729	732		|O
no	733	735		|O
toxic	736	741		|O
deaths	742	748		|O
were	749	753		|O
recorded	754	762		|O
.	762	763		|O
Best	764	768		|O
responses	769	778		|O
were	779	783		|O
:	783	784		|O
CR	785	787		|O
=	788	789		|O
6	790	791		|O
,	791	792		|O
CCR	793	796		|O
=	797	798		|O
13	799	801		|O
,	801	802		|O
PR	803	805		|O
=	806	807		|O
6	808	809		|O
,	809	810		|O
SD	811	813		|O
=	814	815		|O
2	816	817		|O
,	817	818		|O
and	819	822		|O
PD	823	825		|O
=	826	827		|O
2	828	829		|O
.	829	830		|O
There	831	836		|O
were	837	841		|O
6	842	843		|O
medulloblastoma	844	859	medulloblastoma	|B-DISEASE
and	860	863		|O
3	864	865		|O
germinoma	866	875	germinoma	|B-DISEASE
survivors	876	885		|O
with	886	890		|O
a	891	892		|O
median	893	899		|O
follow	900	906		|O
-	906	907		|O
up	907	909		|O
of	910	912		|O
7.5	913	916		|O
years	917	922		|O
(	923	924		|O
range	924	929		|O
=	930	931		|O
2.8-10	932	938		|O
)	938	939		|O
.	939	940		|O
Two	941	944		|O
germinoma	945	954	germinoma	|B-DISEASE
survivors	955	964		|O
received	965	973		|O
radiotherapy	974	986		|O
after	987	992		|O
autografting	993	1005		|O
for	1006	1009		|O
presumptive	1010	1021		|O
progressive	1022	1033		|O
disease	1034	1041		|O
.	1041	1042		|O
CONCLUSION	1043	1053		|O
:	1053	1054		|O
Myeloablative	1055	1068		|O
chemotherapy	1069	1081		|O
consisting	1082	1092		|O
of	1093	1095		|O
cyclophosphamide	1096	1112		|O
and	1113	1116		|O
melphalan	1117	1126		|O
was	1127	1130		|O
tolerable	1131	1140		|O
in	1141	1143		|O
the	1144	1147		|O
relapsed	1148	1156	relapsed brain tumor	|B-DISEASE
brain	1157	1162		|I-DISEASE
tumor	1163	1168		|I-DISEASE
setting	1169	1176		|O
with	1177	1181		|O
19/29	1182	1187		|O
cases	1188	1193		|O
achieving	1194	1203		|O
CR	1204	1206		|O
or	1207	1209		|O
CCR	1210	1213		|O
status	1214	1220		|O
and	1221	1224		|O
9/29	1225	1229		|O
becoming	1230	1238		|O
long	1239	1243		|O
-	1243	1244		|O
term	1244	1248		|O
survivors	1249	1258		|O
.	1258	1259		|O

### 18703135
Cadmium	0	7		|O
activates	8	17		|O
the	18	21		|O
mitogen	22	29		|O
-	29	30		|O
activated	30	39		|O
protein	40	47		|O
kinase	48	54		|O
(	55	56		|O
MAPK	56	60		|O
)	60	61		|O
pathway	62	69		|O
via	70	73		|O
induction	74	83		|O
of	84	86		|O
reactive	87	95		|O
oxygen	96	102		|O
species	103	110		|O
and	111	114		|O
inhibition	115	125		|O
of	126	128		|O
protein	129	136		|O
phosphatases	137	149		|O
2A	150	152		|O
and	153	156		|O
5	157	158		|O
.	158	159		|O
Cadmium	161	168		|O
(	169	170		|O
Cd	170	172		|O
)	172	173		|O
,	173	174		|O
a	175	176		|O
highly	177	183		|O
toxic	184	189		|O
environmental	190	203		|O
pollutant	204	213		|O
,	213	214		|O
induces	215	222		|O
neurodegenerative	223	240	neurodegenerative diseases	|B-ADVERSE
diseases	241	249		|I-ADVERSE
.	249	250		|O
Recently	251	259		|O
we	260	262		|O
have	263	267		|O
demonstrated	268	280		|O
that	281	285		|O
Cd	286	288		|O
may	289	292		|O
induce	293	299		|O
neuronal	300	308		|O
apoptosis	309	318		|O
in	319	321		|O
part	322	326		|O
through	327	334		|O
activation	335	345		|O
of	346	348		|O
c	349	350		|O
-	350	351		|O
Jun	351	354		|O
N	355	356		|O
-	356	357		|O
terminal	357	365		|O
kinase	366	372		|O
(	373	374		|O
JNK	374	377		|O
)	377	378		|O
and	379	382		|O
extracellular	383	396		|O
signal	397	403		|O
-	403	404		|O
regulated	404	413		|O
kinase	414	420		|O
1/2	421	424		|O
(	425	426		|O
Erk1/2	426	432		|O
)	432	433		|O
pathways	434	442		|O
.	442	443		|O
However	444	451		|O
,	451	452		|O
the	453	456		|O
underlying	457	467		|O
mechanism	468	477		|O
remains	478	485		|O
enigmatic	486	495		|O
.	495	496		|O
Here	497	501		|O
we	502	504		|O
show	505	509		|O
that	510	514		|O
Cd	515	517		|O
induced	518	525		|O
generation	526	536		|O
of	537	539		|O
reactive	540	548		|O
oxygen	549	555		|O
species	556	563		|O
(	564	565		|O
ROS	565	568		|O
)	568	569		|O
,	569	570		|O
leading	571	578		|O
to	579	581		|O
apoptosis	582	591		|O
of	592	594		|O
PC12	595	599		|O
and	600	603		|O
SH	604	606		|O
-	606	607		|O
SY5Y	607	611		|O
cells	612	617		|O
.	617	618		|O
Pretreatment	619	631		|O
with	632	636		|O
N	637	638		|O
-	638	639		|O
acetyl	639	645		|O
-	645	646		|O
L	646	647		|O
-	647	648		|O
cysteine	648	656		|O
(	657	658		|O
NAC	658	661		|O
)	661	662		|O
scavenged	663	672		|O
Cd	673	675		|O
-	675	676		|O
induced	676	683		|O
ROS	684	687		|O
,	687	688		|O
and	689	692		|O
prevented	693	702		|O
cell	703	707		|O
death	708	713		|O
,	713	714		|O
suggesting	715	725		|O
that	726	730		|O
Cd	731	733		|O
-	733	734		|O
induced	734	741		|O
apoptosis	742	751		|O
is	752	754		|O
attributed	755	765		|O
to	766	768		|O
its	769	772		|O
induction	773	782		|O
of	783	785		|O
ROS	786	789		|O
.	789	790		|O
Furthermore	791	802		|O
,	802	803		|O
we	804	806		|O
found	807	812		|O
that	813	817		|O
Cd	818	820		|O
-	820	821		|O
induced	821	828		|O
ROS	829	832		|O
inhibited	833	842		|O
serine	843	849		|O
/	849	850		|O
threonine	850	859		|O
protein	860	867		|O
phosphatases	868	880		|O
2A	881	883		|O
(	884	885		|O
PP2A	885	889		|O
)	889	890		|O
and	891	894		|O
5	895	896		|O
(	897	898		|O
PP5	898	901		|O
)	901	902		|O
,	902	903		|O
leading	904	911		|O
to	912	914		|O
activation	915	925		|O
of	926	928		|O
Erk1/2	929	935		|O
and	936	939		|O
JNK	940	943		|O
,	943	944		|O
which	945	950		|O
was	951	954		|O
abrogated	955	964		|O
by	965	967		|O
NAC	968	971		|O
.	971	972		|O
Overexpression	973	987		|O
of	988	990		|O
PP2A	991	995		|O
or	996	998		|O
PP5	999	1002		|O
partially	1003	1012		|O
prevented	1013	1022		|O
Cd	1023	1025		|O
-	1025	1026		|O
induced	1026	1033		|O
activation	1034	1044		|O
of	1045	1047		|O
Erk1/2	1048	1054		|O
and	1055	1058		|O
JNK	1059	1062		|O
,	1062	1063		|O
as	1064	1066		|O
well	1067	1071		|O
as	1072	1074		|O
cell	1075	1079		|O
death	1080	1085		|O
.	1085	1086		|O
Cd	1087	1089		|O
-	1089	1090		|O
induced	1090	1097		|O
ROS	1098	1101		|O
was	1102	1105		|O
also	1106	1110		|O
linked	1111	1117		|O
to	1118	1120		|O
the	1121	1124		|O
activation	1125	1135		|O
of	1136	1138		|O
caspase	1139	1146		|O
-	1146	1147		|O
3	1147	1148		|O
.	1148	1149		|O
Pretreatment	1150	1162		|O
with	1163	1167		|O
inhibitors	1168	1178		|O
of	1179	1181		|O
JNK	1182	1185		|O
(	1186	1187		|O
SP600125	1187	1195		|O
)	1195	1196		|O
and	1197	1200		|O
Erk1/2	1201	1207		|O
(	1208	1209		|O
U0126	1209	1214		|O
)	1214	1215		|O
partially	1216	1225		|O
blocked	1226	1233		|O
Cd	1234	1236		|O
-	1236	1237		|O
induced	1237	1244		|O
cleavage	1245	1253		|O
of	1254	1256		|O
caspase	1257	1264		|O
-	1264	1265		|O
3	1265	1266		|O
and	1267	1270		|O
prevented	1271	1280		|O
cell	1281	1285		|O
death	1286	1291		|O
.	1291	1292		|O
However	1293	1300		|O
,	1300	1301		|O
zVAD	1302	1306		|O
-	1306	1307		|O
fmk	1307	1310		|O
,	1310	1311		|O
a	1312	1313		|O
pan	1314	1317		|O
caspase	1318	1325		|O
inhibitor	1326	1335		|O
,	1335	1336		|O
only	1337	1341		|O
partially	1342	1351		|O
prevented	1352	1361		|O
Cd	1362	1364		|O
-	1364	1365		|O
induced	1365	1372		|O
apoptosis	1373	1382		|O
.	1382	1383		|O
The	1384	1387		|O
results	1388	1395		|O
indicate	1396	1404		|O
that	1405	1409		|O
Cd	1410	1412		|O
induction	1413	1422		|O
of	1423	1425		|O
ROS	1426	1429		|O
inhibits	1430	1438		|O
PP2A	1439	1443		|O
and	1444	1447		|O
PP5	1448	1451		|O
,	1451	1452		|O
leading	1453	1460		|O
to	1461	1463		|O
activation	1464	1474		|O
of	1475	1477		|O
JNK	1478	1481		|O
and	1482	1485		|O
Erk1/2	1486	1492		|O
pathways	1493	1501		|O
,	1501	1502		|O
and	1503	1506		|O
consequently	1507	1519		|O
resulting	1520	1529		|O
in	1530	1532		|O
caspase	1533	1540		|O
-	1540	1541		|O
dependent	1541	1550		|O
and	1551	1554		|O
-	1555	1556		|O
independent	1556	1567		|O
apoptosis	1568	1577		|O
of	1578	1580		|O
neuronal	1581	1589		|O
cells	1590	1595		|O
.	1595	1596		|O
The	1597	1600		|O
findings	1601	1609		|O
strongly	1610	1618		|O
suggest	1619	1626		|O
that	1627	1631		|O
the	1632	1635		|O
inhibitors	1636	1646		|O
of	1647	1649		|O
JNK	1650	1653		|O
,	1653	1654		|O
Erk1/2	1655	1661		|O
,	1661	1662		|O
or	1663	1665		|O
antioxidants	1666	1678		|O
may	1679	1682		|O
be	1683	1685		|O
exploited	1686	1695		|O
for	1696	1699		|O
prevention	1700	1710		|O
of	1711	1713		|O
Cd	1714	1716		|O
-	1716	1717		|O
induced	1717	1724		|O
neurodegenerative	1725	1742	neurodegenerative diseases	|B-ADVERSE
diseases	1743	1751		|I-ADVERSE
.	1751	1752		|O

### 18815938
Management	0	10		|O
of	11	13		|O
cocaine	14	21		|O
-	21	22		|O
induced	22	29		|O
cardiac	30	37	cardiac arrhythmias	|B-ADVERSE
arrhythmias	38	49		|I-ADVERSE
due	50	53		|O
to	54	56		|O
cardiac	57	64	cardiac ion channel dysfunction	|B-ADVERSE
ion	65	68		|I-ADVERSE
channel	69	76		|I-ADVERSE
dysfunction	77	88		|I-ADVERSE
.	88	89		|O
Cocaine	91	98		|O
use	99	102		|O
is	103	105		|O
common	106	112		|O
in	113	115		|O
many	116	120		|O
areas	121	126		|O
of	127	129		|O
the	130	133		|O
world	134	139		|O
,	139	140		|O
particularly	141	153		|O
the	154	157		|O
United	158	164		|O
States	165	171		|O
and	172	175		|O
Western	176	183		|O
Europe	184	190		|O
.	190	191		|O
Toxicity	192	200		|O
following	201	210		|O
the	211	214		|O
use	215	218		|O
of	219	221		|O
cocaine	222	229		|O
is	230	232		|O
associated	233	243		|O
with	244	248		|O
a	249	250		|O
wide	251	255		|O
range	256	261		|O
of	262	264		|O
clinical	265	273		|O
features	274	282		|O
.	282	283		|O
In	284	286		|O
this	287	291		|O
review	292	298		|O
,	298	299		|O
we	300	302		|O
will	303	307		|O
focus	308	313		|O
on	314	316		|O
the	317	320		|O
cocaine	321	328		|O
-	328	329		|O
associated	329	339		|O
cardiac	340	347	cardiac arrhythmias	|B-ADVERSE
arrhythmias	348	359		|I-ADVERSE
and	360	363		|O
,	363	364		|O
in	365	367		|O
particular	368	378		|O
,	378	379		|O
some	380	384		|O
of	385	387		|O
the	388	391		|O
controversies	392	405		|O
in	406	408		|O
their	409	414		|O
etiology	415	423		|O
and	424	427		|O
management	428	438		|O
.	438	439		|O
Cocaine	440	447		|O
can	448	451		|O
produce	452	459		|O
arrhythmias	460	471	arrhythmias	|B-ADVERSE
either	472	478		|O
through	479	486		|O
the	487	490		|O
production	491	501		|O
of	502	504		|O
myocardial	505	515	myocardial ischemia	|B-ADVERSE
ischemia	516	524		|I-ADVERSE
or	525	527		|O
as	528	530		|O
a	531	532		|O
direct	533	539		|O
result	540	546		|O
of	547	549		|O
ion	550	553		|O
channel	554	561		|O
alterations	562	573		|O
.	573	574		|O
Excessive	575	584		|O
catecholamines	585	599		|O
,	599	600		|O
combined	601	609		|O
with	610	614		|O
sodium	615	621		|O
and	622	625		|O
potassium	626	635		|O
channel	636	643		|O
blockades	644	653		|O
,	653	654		|O
give	655	659		|O
rise	660	664		|O
to	665	667		|O
a	668	669		|O
wide	670	674		|O
variety	675	682		|O
of	683	685		|O
supra	686	691		|O
-	691	692		|O
ventricular	692	703		|O
and	704	707		|O
ventricular	708	719		|O
rhythms	720	727		|O
.	727	728		|O
The	729	732		|O
animal	733	739		|O
and	740	743		|O
human	744	749		|O
evidence	750	758		|O
for	759	762		|O
ion	763	766	ion channel dysfunction	|B-ADVERSE
channel	767	774		|I-ADVERSE
dysfunction	775	786		|I-ADVERSE
is	787	789		|O
reviewed	790	798		|O
,	798	799		|O
and	800	803		|O
the	804	807		|O
effects	808	815		|O
of	816	818		|O
catecholamines	819	833		|O
are	834	837		|O
followed	838	846		|O
from	847	851		|O
the	852	855		|O
cardiac	856	863		|O
action	864	870		|O
potential	871	880		|O
to	881	883		|O
the	884	887		|O
development	888	899		|O
of	900	902		|O
arrhythmias	903	914	arrhythmias	|B-ADVERSE
.	914	915		|O
Finally	916	923		|O
,	923	924		|O
theoretical	925	936		|O
constructs	937	947		|O
are	948	951		|O
combined	952	960		|O
with	961	965		|O
existing	966	974		|O
evidence	975	983		|O
to	984	986		|O
develop	987	994		|O
a	995	996		|O
rational	997	1005		|O
treatment	1006	1015		|O
strategy	1016	1024		|O
for	1025	1028		|O
patients	1029	1037		|O
with	1038	1042		|O
cocaine	1043	1050		|O
-	1050	1051		|O
induced	1051	1058		|O
cardiac	1059	1066	cardiac arrhythmias	|B-ADVERSE
arrhythmias	1067	1078		|I-ADVERSE
.	1078	1079		|O
In	1080	1082		|O
particular	1083	1093		|O
,	1093	1094		|O
we	1095	1097		|O
review	1098	1104		|O
the	1105	1108		|O
evidence	1109	1117		|O
concerning	1118	1128		|O
the	1129	1132		|O
controversies	1133	1146		|O
relating	1147	1155		|O
to	1156	1158		|O
the	1159	1162		|O
use	1163	1166		|O
of	1167	1169		|O
lidocaine	1170	1179		|O
in	1180	1182		|O
comparison	1183	1193		|O
with	1194	1198		|O
sodium	1199	1205		|O
bicarbonate	1206	1217		|O
,	1217	1218		|O
in	1219	1221		|O
terms	1222	1227		|O
of	1228	1230		|O
QRS	1231	1234		|O
prolongation	1235	1247		|O
secondary	1248	1257		|O
to	1258	1260		|O
sodium	1261	1267		|O
channel	1268	1275		|O
blockade	1276	1284		|O
.	1284	1285		|O

### 18670875
Venlafaxine	0	11		|O
versus	12	18		|O
clonidine	19	28		|O
for	29	32		|O
the	33	36		|O
treatment	37	46		|O
of	47	49		|O
hot	50	53	hot flashes	|B-DISEASE
flashes	54	61		|I-DISEASE
in	62	64		|O
breast	65	71	breast cancer	|B-DISEASE
cancer	72	78		|I-DISEASE
patients	79	87		|O
:	87	88		|O
a	89	90		|O
double	91	97		|O
-	97	98		|O
blind	98	103		|O
,	103	104		|O
randomized	105	115		|O
cross	116	121		|O
-	121	122		|O
over	122	126		|O
study	127	132		|O
.	132	133		|O
PURPOSE	135	142		|O
:	142	143		|O
Breast	144	150	Breast cancer	|B-DISEASE
cancer	151	157		|I-DISEASE
patients	158	166		|O
with	167	171		|O
treatment	172	181		|O
-	181	182		|O
induced	182	189		|O
menopause	190	199		|O
experience	200	210		|O
frequent	211	219		|O
and	220	223		|O
severe	224	230		|O
hot	231	234	hot flashes	|B-DISEASE
flashes	235	242		|I-DISEASE
(	243	244		|O
HF	244	246	HF	|B-DISEASE
)	246	247		|O
.	247	248		|O
We	249	251		|O
compared	252	260		|O
venlafaxine	261	272		|O
and	273	276		|O
clonidine	277	286		|O
for	287	290		|O
the	291	294		|O
treatment	295	304		|O
of	305	307		|O
HF	308	310		|O
with	311	315		|O
regard	316	322		|O
to	323	325		|O
side	326	330		|O
effects	331	338		|O
,	338	339		|O
efficacy	340	348		|O
,	348	349		|O
quality	350	357		|O
of	358	360		|O
life	361	365		|O
and	366	369		|O
sexual	370	376		|O
functioning	377	388		|O
.	388	389		|O
METHODS	390	397		|O
:	397	398		|O
In	399	401		|O
a	402	403		|O
double	404	410		|O
-	410	411		|O
blind	411	416		|O
,	416	417		|O
cross	418	423		|O
-	423	424		|O
over	424	428		|O
study	429	434		|O
,	434	435		|O
60	436	438		|O
breast	439	445	breast cancer	|B-DISEASE
cancer	446	452		|I-DISEASE
patients	453	461		|O
experiencing	462	474		|O
HF	475	477	HF	|B-DISEASE
were	478	482		|O
randomized	483	493		|O
to	494	496		|O
8	497	498		|O
weeks	499	504		|O
venlafaxine	505	516		|O
followed	517	525		|O
by	526	528		|O
2	529	530		|O
weeks	531	536		|O
wash	537	541		|O
-	541	542		|O
out	542	545		|O
,	545	546		|O
and	547	550		|O
8	551	552		|O
weeks	553	558		|O
clonidine	559	568		|O
or	569	571		|O
vice	572	576		|O
versa	577	582		|O
.	582	583		|O
HF	584	586	HF	|B-DISEASE
frequency	587	596		|O
and	597	600		|O
severity	601	609		|O
,	609	610		|O
side	611	615		|O
effects	616	623		|O
,	623	624		|O
quality	625	632		|O
of	633	635		|O
life	636	640		|O
and	641	644		|O
sexuality	645	654		|O
were	655	659		|O
assessed	660	668		|O
.	668	669		|O
RESULTS	670	677		|O
:	677	678		|O
Thirty	679	685		|O
patients	686	694		|O
started	695	702		|O
with	703	707		|O
venlafaxine	708	719		|O
and	720	723		|O
30	724	726		|O
with	727	731		|O
clonidine	732	741		|O
.	741	742		|O
Premature	743	752		|O
discontinuation	753	768		|O
for	769	772		|O
toxicity	773	781		|O
occurred	782	790		|O
in	791	793		|O
14/59	794	799		|O
during	800	806		|O
venlafaxine	807	818		|O
and	819	822		|O
5/53	823	827		|O
during	828	834		|O
clonidine	835	844		|O
(	845	846		|O
P	846	847		|O
=	848	849		|O
.038	850	854		|O
)	854	855		|O
.	855	856		|O
Venlafaxine	857	868		|O
induced	869	876		|O
more	877	881		|O
side	882	886		|O
effects	887	894		|O
.	894	895		|O
Median	896	902		|O
reduction	903	912		|O
in	913	915		|O
HF	916	918	HF	|B-DISEASE
score	919	924		|O
was	925	928		|O
49%	929	932		|O
for	933	936		|O
venlafaxine	937	948		|O
and	949	952		|O
55%	953	956		|O
for	957	960		|O
clonidine	961	970		|O
(	971	972		|O
ns	972	974		|O
)	974	975		|O
.	975	976		|O
CONCLUSION	977	987		|O
:	987	988		|O
Venlafaxine	989	1000		|O
and	1001	1004		|O
clonidine	1005	1014		|O
are	1015	1018		|O
equally	1019	1026		|O
,	1026	1027		|O
but	1028	1031		|O
moderately	1032	1042		|O
effective	1043	1052		|O
in	1053	1055		|O
HF	1056	1058	HF	|B-DISEASE
reduction	1059	1068		|O
.	1068	1069		|O
Side	1070	1074		|O
effects	1075	1082		|O
are	1083	1086		|O
the	1087	1090		|O
main	1091	1095		|O
reason	1096	1102		|O
for	1103	1106		|O
drug	1107	1111		|O
discontinuation	1112	1127		|O
,	1127	1128		|O
occurring	1129	1138		|O
more	1139	1143		|O
often	1144	1149		|O
with	1150	1154		|O
venlafaxine	1155	1166		|O
.	1166	1167		|O

### 18586117
Increased	0	9		|O
circulating	10	21		|O
pro	22	25		|O
-	25	26		|O
inflammatory	26	38		|O
cytokines	39	48		|O
and	49	52		|O
imbalanced	53	63		|O
regulatory	64	74		|O
T	75	76		|O
-	76	77		|O
cell	77	81		|O
cytokines	82	91		|O
production	92	102		|O
in	103	105		|O
chronic	106	113	chronic idiopathic urticaria	|B-DISEASE
idiopathic	114	124		|I-DISEASE
urticaria	125	134		|I-DISEASE
.	134	135		|O
The	137	140		|O
immunologic	141	152		|O
characterization	153	169		|O
of	170	172		|O
chronic	173	180	chronic idiopathic urticaria	|B-DISEASE
idiopathic	181	191		|I-DISEASE
urticaria	192	201		|I-DISEASE
(	202	203		|O
CIU	203	206	CIU	|B-DISEASE
)	206	207		|O
,	207	208		|O
mainly	209	215		|O
regarding	216	225		|O
cytokine	226	234		|O
profile	235	242		|O
needs	243	248		|O
more	249	253		|O
investigation	254	267		|O
.	267	268		|O
We	269	271		|O
examined	272	280		|O
circulating	281	292		|O
inflammatory	293	305		|O
cytokine	306	314		|O
levels	315	321		|O
,	321	322		|O
T	323	324		|O
-	324	325		|O
cell	325	329		|O
induced	330	337		|O
secretion	338	347		|O
,	347	348		|O
and	349	352		|O
cytokine	353	361		|O
mRNA	362	366		|O
expression	367	377		|O
in	378	380		|O
patients	381	389		|O
with	390	394		|O
CIU	395	398	CIU	|B-DISEASE
subjected	399	408		|O
to	409	411		|O
the	412	415		|O
intradermal	416	427		|O
autologous	428	438		|O
serum	439	444		|O
skin	445	449		|O
test	450	454		|O
(	455	456		|O
ASST	456	460		|O
)	460	461		|O
.	461	462		|O
Increased	463	472		|O
levels	473	479		|O
of	480	482		|O
circulating	483	494		|O
pro	495	498		|O
-	498	499		|O
inflammatory	499	511		|O
cytokines	512	521		|O
,	521	522		|O
such	523	527		|O
as	528	530		|O
TNF	531	534		|O
-	534	535		|O
alpha	535	540		|O
,	540	541		|O
IL	542	544		|O
-	544	545		|O
1beta	545	550		|O
,	550	551		|O
IL	552	554		|O
-	554	555		|O
12p70	555	560		|O
,	560	561		|O
and	562	565		|O
IL	566	568		|O
-	568	569		|O
6	569	570		|O
have	571	575		|O
been	576	580		|O
observed	581	589		|O
in	590	592		|O
most	593	597		|O
of	598	600		|O
patients	601	609		|O
with	610	614		|O
CIU	615	618	CIU	|B-DISEASE
,	618	619		|O
together	620	628		|O
with	629	633		|O
an	634	636		|O
enhancement	637	648		|O
of	649	651		|O
IL	652	654		|O
-	654	655		|O
2	655	656		|O
secretion	657	666		|O
following	667	676		|O
T	677	678		|O
-	678	679		|O
cell	679	683		|O
stimulation	684	695		|O
.	695	696		|O
Highlighting	697	709		|O
the	710	713		|O
inflammatory	714	726		|O
profile	727	734		|O
in	735	737		|O
CIU	738	741	CIU	|B-DISEASE
found	742	747		|O
in	748	750		|O
ASST	751	755		|O
positive	756	764		|O
,	764	765		|O
is	766	768		|O
the	769	772		|O
enhanced	773	781		|O
B	782	783		|O
-	783	784		|O
cell	784	788		|O
proliferative	789	802		|O
responsiveness	803	817		|O
and	818	821		|O
increased	822	831		|O
IL	832	834		|O
-	834	835		|O
17	835	837		|O
secretion	838	847		|O
levels	848	854		|O
.	854	855		|O
ASST	856	860		|O
-	860	861		|O
positive	861	869		|O
patients	870	878		|O
also	879	883		|O
exhibited	884	893		|O
impaired	894	902		|O
IL	903	905		|O
-	905	906		|O
4	906	907		|O
secretion	908	917		|O
associated	918	928		|O
with	929	933		|O
increased	934	943		|O
IL	944	946		|O
-	946	947		|O
10	947	949		|O
production	950	960		|O
.	960	961		|O
Altered	962	969		|O
cytokine	970	978		|O
expression	979	989		|O
in	990	992		|O
patients	993	1001		|O
with	1002	1006		|O
ASST	1007	1011		|O
-	1011	1012		|O
negative	1012	1020		|O
,	1020	1021		|O
was	1022	1025		|O
the	1026	1029		|O
down	1030	1034		|O
-	1034	1035		|O
modulation	1035	1045		|O
of	1046	1048		|O
spontaneous	1049	1060		|O
IL	1061	1063		|O
-	1063	1064		|O
10	1064	1066		|O
mRNA	1067	1071		|O
expression	1072	1082		|O
levels	1083	1089		|O
in	1090	1092		|O
peripheral	1093	1103		|O
blood	1104	1109		|O
mononuclear	1110	1121		|O
cells	1122	1127		|O
.	1127	1128		|O
Our	1129	1132		|O
findings	1133	1141		|O
support	1142	1149		|O
the	1150	1153		|O
concept	1154	1161		|O
of	1162	1164		|O
immunologic	1165	1176		|O
dysregulation	1177	1190		|O
in	1191	1193		|O
CIU	1194	1197	CIU	|B-DISEASE
,	1197	1198		|O
revealing	1199	1208		|O
a	1209	1210		|O
systemic	1211	1219		|O
inflammatory	1220	1232		|O
profile	1233	1240		|O
associated	1241	1251		|O
with	1252	1256		|O
disturbed	1257	1266		|O
cytokine	1267	1275		|O
production	1276	1286		|O
by	1287	1289		|O
T	1290	1291		|O
cells	1292	1297		|O
,	1297	1298		|O
mainly	1299	1305		|O
related	1306	1313		|O
to	1314	1316		|O
IL	1317	1319		|O
-	1319	1320		|O
17	1320	1322		|O
and	1323	1326		|O
IL	1327	1329		|O
-	1329	1330		|O
10	1330	1332		|O
production	1333	1343		|O
.	1343	1344		|O

### 18646134
Target	0	6		|O
-	6	7		|O
controlled	7	17		|O
infusion	18	26		|O
versus	27	33		|O
manually	34	42		|O
-	42	43		|O
controlled	43	53		|O
infusion	54	62		|O
of	63	65		|O
propofol	66	74		|O
for	75	78		|O
general	79	86		|O
anaesthesia	87	98		|O
or	99	101		|O
sedation	102	110		|O
in	111	113		|O
adults	114	120		|O
.	120	121		|O
BACKGROUND	123	133		|O
:	133	134		|O
Continuous	135	145		|O
infusions	146	155		|O
of	156	158		|O
the	159	162		|O
intravenous	163	174		|O
anaesthetic	175	186		|O
propofol	187	195		|O
are	196	199		|O
commonly	200	208		|O
used	209	213		|O
to	214	216		|O
induce	217	223		|O
and	224	227		|O
maintain	228	236		|O
sedation	237	245		|O
and	246	249		|O
general	250	257		|O
anaesthesia	258	269		|O
.	269	270		|O
Infusion	271	279		|O
devices	280	287		|O
can	288	291		|O
be	292	294		|O
manually	295	303		|O
controlled	304	314		|O
(	315	316		|O
MCI	316	319		|O
)	319	320		|O
where	321	326		|O
the	327	330		|O
anaesthetist	331	343		|O
makes	344	349		|O
each	350	354		|O
change	355	361		|O
to	362	364		|O
the	365	368		|O
infusion	369	377		|O
rate	378	382		|O
or	383	385		|O
target	386	392		|O
-	392	393		|O
controlled	393	403		|O
(	404	405		|O
TCI	405	408		|O
)	408	409		|O
where	410	415		|O
the	416	419		|O
anaesthetist	420	432		|O
sets	433	437		|O
a	438	439		|O
target	440	446		|O
blood	447	452		|O
or	453	455		|O
effect	456	462		|O
-	462	463		|O
site	463	467		|O
concentration	468	481		|O
and	482	485		|O
the	486	489		|O
computerised	490	502		|O
infusion	503	511		|O
device	512	518		|O
makes	519	524		|O
the	525	528		|O
necessary	529	538		|O
changes	539	546		|O
to	547	549		|O
the	550	553		|O
infusion	554	562		|O
rate	563	567		|O
.	567	568		|O
Randomized	569	579		|O
trials	580	586		|O
have	587	591		|O
explored	592	600		|O
the	601	604		|O
differences	605	616		|O
in	617	619		|O
quality	620	627		|O
of	628	630		|O
anaesthesia	631	642		|O
,	642	643		|O
adverse	644	651		|O
event	652	657		|O
rate	658	662		|O
and	663	666		|O
cost	667	671		|O
between	672	679		|O
TCI	680	683		|O
and	684	687		|O
MCI	688	691		|O
but	692	695		|O
the	696	699		|O
effectiveness	700	713		|O
of	714	716		|O
TCI	717	720		|O
compared	721	729		|O
with	730	734		|O
MCI	735	738		|O
remains	739	746		|O
controversial	747	760		|O
.	760	761		|O
As	762	764		|O
TCI	765	768		|O
is	769	771		|O
in	772	774		|O
widespread	775	785		|O
international	786	799		|O
use	800	803		|O
,	803	804		|O
and	805	808		|O
potentially	809	820		|O
may	821	824		|O
be	825	827		|O
more	828	832		|O
expensive	833	842		|O
without	843	850		|O
added	851	856		|O
benefit	857	864		|O
,	864	865		|O
a	866	867		|O
systematic	868	878		|O
review	879	885		|O
of	886	888		|O
randomized	889	899		|O
controlled	900	910		|O
trials	911	917		|O
comparing	918	927		|O
TCI	928	931		|O
and	932	935		|O
MCI	936	939		|O
is	940	942		|O
warranted	943	952		|O
.	952	953		|O
OBJECTIVES	954	964		|O
:	964	965		|O
To	966	968		|O
assess	969	975		|O
whether	976	983		|O
TCI	984	987		|O
of	988	990		|O
propofol	991	999		|O
is	1000	1002		|O
as	1003	1005		|O
effective	1006	1015		|O
as	1016	1018		|O
MCI	1019	1022		|O
of	1023	1025		|O
propofol	1026	1034		|O
with	1035	1039		|O
respect	1040	1047		|O
to	1048	1050		|O
quality	1051	1058		|O
of	1059	1061		|O
anaesthesia	1062	1073		|O
or	1074	1076		|O
sedation	1077	1085		|O
,	1085	1086		|O
adverse	1087	1094		|O
events	1095	1101		|O
and	1102	1105		|O
propofol	1106	1114		|O
drug	1115	1119		|O
cost	1120	1124		|O
.	1124	1125		|O
SEARCH	1126	1132		|O
STRATEGY	1133	1141		|O
:	1141	1142		|O
We	1143	1145		|O
searched	1146	1154		|O
the	1155	1158		|O
Cochrane	1159	1167		|O
Central	1168	1175		|O
Register	1176	1184		|O
of	1185	1187		|O
Controlled	1188	1198		|O
Trials	1199	1205		|O
(	1206	1207		|O
CENTRAL	1207	1214		|O
)	1214	1215		|O
(	1216	1217		|O
The	1217	1220		|O
Cochrane	1221	1229		|O
Library	1230	1237		|O
2007	1238	1242		|O
,	1242	1243		|O
Issue	1244	1249		|O
3	1250	1251		|O
)	1251	1252		|O
;	1252	1253		|O
PubMED	1254	1260		|O
(	1261	1262		|O
1950	1262	1266		|O
to	1267	1269		|O
July	1270	1274		|O
week	1275	1279		|O
2	1280	1281		|O
2007	1282	1286		|O
)	1286	1287		|O
;	1287	1288		|O
and	1289	1292		|O
EMBASE	1293	1299		|O
via	1300	1303		|O
OVID	1304	1308		|O
(	1309	1310		|O
1980	1310	1314		|O
to	1315	1317		|O
week	1318	1322		|O
28	1323	1325		|O
2007	1326	1330		|O
)	1330	1331		|O
.	1331	1332		|O
We	1333	1335		|O
also	1336	1340		|O
searched	1341	1349		|O
LILACS	1350	1356		|O
,	1356	1357		|O
CINAHL	1358	1364		|O
,	1364	1365		|O
ISI	1366	1369		|O
Web	1370	1373		|O
Knowledge	1374	1383		|O
,	1383	1384		|O
Panteleimon	1385	1396		|O
,	1396	1397		|O
KoreaMed	1398	1406		|O
and	1407	1410		|O
IndMed	1411	1417		|O
.	1417	1418		|O
We	1419	1421		|O
searched	1422	1430		|O
for	1431	1434		|O
ongoing	1435	1442		|O
trials	1443	1449		|O
via	1450	1453		|O
the	1454	1457		|O
National	1458	1466		|O
Research	1467	1475		|O
Register	1476	1484		|O
and	1485	1488		|O
metaRegister	1489	1501		|O
of	1502	1504		|O
Controlled	1505	1515		|O
Trials	1516	1522		|O
.	1522	1523		|O
SELECTION	1524	1533		|O
CRITERIA	1534	1542		|O
:	1542	1543		|O
We	1544	1546		|O
planned	1547	1554		|O
to	1555	1557		|O
include	1558	1565		|O
all	1566	1569		|O
published	1570	1579		|O
and	1580	1583		|O
unpublished	1584	1595		|O
randomized	1596	1606		|O
controlled	1607	1617		|O
trials	1618	1624		|O
that	1625	1629		|O
compared	1630	1638		|O
TCI	1639	1642		|O
of	1643	1645		|O
propofol	1646	1654		|O
with	1655	1659		|O
MCI	1660	1663		|O
of	1664	1666		|O
propofol	1667	1675		|O
for	1676	1679		|O
general	1680	1687		|O
anaesthesia	1688	1699		|O
or	1700	1702		|O
sedation	1703	1711		|O
in	1712	1714		|O
adult	1715	1720		|O
surgical	1721	1729		|O
patients	1730	1738		|O
.	1738	1739		|O
Only	1740	1744		|O
published	1745	1754		|O
studies	1755	1762		|O
were	1763	1767		|O
included	1768	1776		|O
as	1777	1779		|O
no	1780	1782		|O
unpublished	1783	1794		|O
studies	1795	1802		|O
were	1803	1807		|O
identified	1808	1818		|O
.	1818	1819		|O
DATA	1820	1824		|O
COLLECTION	1825	1835		|O
AND	1836	1839		|O
ANALYSIS	1840	1848		|O
:	1848	1849		|O
Two	1850	1853		|O
authors	1854	1861		|O
independently	1862	1875		|O
assessed	1876	1884		|O
trial	1885	1890		|O
quality	1891	1898		|O
and	1899	1902		|O
extracted	1903	1912		|O
outcome	1913	1920		|O
data	1921	1925		|O
.	1925	1926		|O
We	1927	1929		|O
contacted	1930	1939		|O
study	1940	1945		|O
authors	1946	1953		|O
and	1954	1957		|O
the	1958	1961		|O
pharmaceutical	1962	1976		|O
industry	1977	1985		|O
for	1986	1989		|O
additional	1990	2000		|O
information	2001	2012		|O
.	2012	2013		|O
MAIN	2014	2018		|O
RESULTS	2019	2026		|O
:	2026	2027		|O
Twenty	2028	2034		|O
trials	2035	2041		|O
of	2042	2044		|O
poor	2045	2049		|O
quality	2050	2057		|O
that	2058	2062		|O
involved	2063	2071		|O
1759	2072	2076		|O
patients	2077	2085		|O
were	2086	2090		|O
included	2091	2099		|O
.	2099	2100		|O
Heterogeneity	2101	2114		|O
was	2115	2118		|O
high	2119	2123		|O
(	2124	2125		|O
that	2125	2129		|O
is	2130	2132		|O
the	2133	2136		|O
trials	2137	2143		|O
were	2144	2148		|O
not	2149	2152		|O
comparing	2153	2162		|O
the	2163	2166		|O
same	2167	2171		|O
things	2172	2178		|O
)	2178	2179		|O
.	2179	2180		|O
TCI	2181	2184		|O
was	2185	2188		|O
associated	2189	2199		|O
with	2200	2204		|O
higher	2205	2211		|O
total	2212	2217		|O
doses	2218	2223		|O
of	2224	2226		|O
propofol	2227	2235		|O
than	2236	2240		|O
was	2241	2244		|O
MCI	2245	2248		|O
resulting	2249	2258		|O
in	2259	2261		|O
marginally	2262	2272		|O
higher	2273	2279		|O
propofol	2280	2288		|O
drug	2289	2293		|O
costs	2294	2299		|O
.	2299	2300		|O
However	2301	2308		|O
,	2308	2309		|O
fewer	2310	2315		|O
interventions	2316	2329		|O
were	2330	2334		|O
required	2335	2343		|O
by	2344	2346		|O
the	2347	2350		|O
anaesthetist	2351	2363		|O
during	2364	2370		|O
the	2371	2374		|O
use	2375	2378		|O
of	2379	2381		|O
TCI	2382	2385		|O
compared	2386	2394		|O
with	2395	2399		|O
MCI	2400	2403		|O
.	2403	2404		|O
No	2405	2407		|O
clinically	2408	2418		|O
significant	2419	2430		|O
differences	2431	2442		|O
were	2443	2447		|O
demonstrated	2448	2460		|O
in	2461	2463		|O
terms	2464	2469		|O
of	2470	2472		|O
quality	2473	2480		|O
of	2481	2483		|O
anaesthesia	2484	2495		|O
or	2496	2498		|O
adverse	2499	2506		|O
events	2507	2513		|O
.	2513	2514		|O
AUTHORS	2515	2522		|O
'	2522	2523		|O
CONCLUSIONS	2524	2535		|O
:	2535	2536		|O
This	2537	2541		|O
systematic	2542	2552		|O
review	2553	2559		|O
does	2560	2564		|O
not	2565	2568		|O
provide	2569	2576		|O
sufficient	2577	2587		|O
evidence	2588	2596		|O
for	2597	2600		|O
us	2601	2603		|O
to	2604	2606		|O
make	2607	2611		|O
firm	2612	2616		|O
recommendations	2617	2632		|O
about	2633	2638		|O
the	2639	2642		|O
use	2643	2646		|O
of	2647	2649		|O
TCI	2650	2653		|O
versus	2654	2660		|O
MCI	2661	2664		|O
in	2665	2667		|O
clinical	2668	2676		|O
anaesthetic	2677	2688		|O
practice	2689	2697		|O
.	2697	2698		|O

### 18553993
Kinetic	0	7		|O
analysis	8	16		|O
of	17	19		|O
superoxide	20	30		|O
anion	31	36		|O
radical	37	44		|O
-	44	45		|O
scavenging	45	55		|O
and	56	59		|O
hydroxyl	60	68		|O
radical	69	76		|O
-	76	77		|O
scavenging	77	87		|O
activities	88	98		|O
of	99	101		|O
platinum	102	110		|O
nanoparticles	111	124		|O
.	124	125		|O
There	127	132		|O
are	133	136		|O
few	137	140		|O
reports	141	148		|O
on	149	151		|O
the	152	155		|O
physiological	156	169		|O
effects	170	177		|O
of	178	180		|O
metal	181	186		|O
nanoparticles	187	200		|O
(	201	202		|O
nps	202	205		|O
)	205	206		|O
,	206	207		|O
especially	208	218		|O
with	219	223		|O
respect	224	231		|O
to	232	234		|O
their	235	240		|O
functions	241	250		|O
as	251	253		|O
scavengers	254	264		|O
for	265	268		|O
superoxide	269	279		|O
anion	280	285		|O
radical	286	293		|O
(	294	295		|O
O2	295	297		|O
(	297	298		|O
.	298	299		|O
-	299	300		|O
)	300	301		|O
)	301	302		|O
and	303	306		|O
hydroxyl	307	315		|O
radical	316	323		|O
(	324	325		|O
.	325	326		|O
OH	326	328		|O
)	328	329		|O
.	329	330		|O
We	331	333		|O
tried	334	339		|O
to	340	342		|O
detect	343	349		|O
the	350	353		|O
scavenging	354	364		|O
activity	365	373		|O
of	374	376		|O
Pt	377	379		|O
nps	380	383		|O
using	384	389		|O
a	390	391		|O
hypoxanthine	392	404		|O
-	404	405		|O
xanthine	405	413		|O
oxidase	414	421		|O
system	422	428		|O
for	429	432		|O
O2	433	435		|O
(	435	436		|O
.	436	437		|O
-	437	438		|O
)	438	439		|O
and	440	443		|O
using	444	449		|O
a	450	451		|O
Fenton	452	458		|O
and	459	462		|O
a	463	464		|O
UV	465	467		|O
/	467	468		|O
H2O2	468	472		|O
system	473	479		|O
for	480	483		|O
.	484	485		|O
OH	485	487		|O
.	487	488		|O
Electron	489	497		|O
spin	498	502		|O
resonance	503	512		|O
analysis	513	521		|O
revealed	522	530		|O
that	531	535		|O
2	536	537		|O
nm	538	540		|O
particle	541	549		|O
size	550	554		|O
Pt	555	557		|O
nps	558	561		|O
have	562	566		|O
the	567	570		|O
ability	571	578		|O
to	579	581		|O
scavenge	582	590		|O
O2	591	593		|O
(	593	594		|O
.	594	595		|O
-	595	596		|O
)	596	597		|O
and	598	601		|O
.	602	603		|O
OH	603	605		|O
.	605	606		|O
The	607	610		|O
calculated	611	621		|O
rate	622	626		|O
constant	627	635		|O
for	636	639		|O
the	640	643		|O
O2	644	646		|O
(	646	647		|O
.	647	648		|O
-	648	649		|O
)	649	650		|O
-	650	651		|O
scavenging	651	661		|O
reaction	662	670		|O
was	671	674		|O
5.03	675	679		|O
+	680	681		|O
/	681	682		|O
-	682	683		|O
0.03	684	688		|O
x	689	690		|O
10	691	693		|O
(	693	694		|O
7	694	695		|O
)	695	696		|O
M	697	698		|O
(	699	700		|O
-	700	701		|O
1	701	702		|O
)	702	703		|O
s	704	705		|O
(	706	707		|O
-	707	708		|O
1	708	709		|O
)	709	710		|O
.	710	711		|O
However	712	719		|O
,	719	720		|O
the	721	724		|O
analysis	725	733		|O
of	734	736		|O
the	737	740		|O
Fenton	741	747		|O
and	748	751		|O
UV	752	754		|O
/	754	755		|O
H	755	756		|O
2O	757	759		|O
2	760	761		|O
system	762	768		|O
in	769	771		|O
the	772	775		|O
presence	776	784		|O
of	785	787		|O
Pt	788	790		|O
nps	791	794		|O
suggested	795	804		|O
that	805	809		|O
the	810	813		|O
.	814	815		|O
OH	815	817		|O
-	817	818		|O
scavenging	818	828		|O
reaction	829	837		|O
cannot	838	844		|O
be	845	847		|O
determined	848	858		|O
in	859	861		|O
both	862	866		|O
systems	867	874		|O
.	874	875		|O
Among	876	881		|O
particle	882	890		|O
sizes	891	896		|O
tested	897	903		|O
from	904	908		|O
1	909	910		|O
to	911	913		|O
5	914	915		|O
nm	916	918		|O
,	918	919		|O
1	920	921		|O
nm	922	924		|O
Pt	925	927		|O
nps	928	931		|O
showed	932	938		|O
the	939	942		|O
highest	943	950		|O
O2	951	953		|O
(	953	954		|O
.	954	955		|O
-	955	956		|O
)	956	957		|O
-	957	958		|O
scavenging	958	968		|O
ability	969	976		|O
.	976	977		|O
Almost	978	984		|O
no	985	987		|O
cytotoxicity	988	1000		|O
was	1001	1004		|O
observed	1005	1013		|O
even	1014	1018		|O
after	1019	1024		|O
adherent	1025	1033		|O
cells	1034	1039		|O
(	1040	1041		|O
TIG	1041	1044		|O
-	1044	1045		|O
1	1045	1046		|O
,	1046	1047		|O
HeLa	1048	1052		|O
,	1052	1053		|O
HepG2	1054	1059		|O
,	1059	1060		|O
WI	1061	1063		|O
-	1063	1064		|O
38	1064	1066		|O
,	1066	1067		|O
and	1068	1071		|O
MRC	1072	1075		|O
-	1075	1076		|O
5	1076	1077		|O
)	1077	1078		|O
were	1079	1083		|O
exposed	1084	1091		|O
to	1092	1094		|O
Pt	1095	1097		|O
nps	1098	1101		|O
at	1102	1104		|O
concentrations	1105	1119		|O
as	1120	1122		|O
high	1123	1127		|O
as	1128	1130		|O
50	1131	1133		|O
mg	1134	1136		|O
/	1136	1137		|O
L	1137	1138		|O
.	1138	1139		|O
Pt	1140	1142		|O
nps	1143	1146		|O
scavenged	1147	1156		|O
intrinsically	1157	1170		|O
generated	1171	1180		|O
reactive	1181	1189		|O
oxygen	1190	1196		|O
species	1197	1204		|O
(	1205	1206		|O
ROS	1206	1209		|O
)	1209	1210		|O
in	1211	1213		|O
HeLa	1214	1218		|O
cells	1219	1224		|O
.	1224	1225		|O
Additionally	1226	1238		|O
,	1238	1239		|O
Pt	1240	1242		|O
nps	1243	1246		|O
significantly	1247	1260		|O
reduced	1261	1268		|O
the	1269	1272		|O
levels	1273	1279		|O
of	1280	1282		|O
intracellular	1283	1296		|O
O2	1297	1299		|O
(	1299	1300		|O
.	1300	1301		|O
-	1301	1302		|O
)	1302	1303		|O
generated	1304	1313		|O
by	1314	1316		|O
UVA	1317	1320		|O
irradiation	1321	1332		|O
and	1333	1336		|O
subsequently	1337	1349		|O
protected	1350	1359		|O
HeLa	1360	1364		|O
cells	1365	1370		|O
from	1371	1375		|O
ROS	1376	1379		|O
damage	1380	1386		|O
-	1386	1387		|O
induced	1387	1394		|O
cell	1395	1399		|O
death	1400	1405		|O
.	1405	1406		|O
These	1407	1412		|O
findings	1413	1421		|O
suggest	1422	1429		|O
that	1430	1434		|O
Pt	1435	1437		|O
nps	1438	1441		|O
may	1442	1445		|O
be	1446	1448		|O
a	1449	1450		|O
new	1451	1454		|O
type	1455	1459		|O
of	1460	1462		|O
antioxidant	1463	1474		|O
capable	1475	1482		|O
of	1483	1485		|O
circumventing	1486	1499		|O
the	1500	1503		|O
paradoxical	1504	1515		|O
effects	1516	1523		|O
of	1524	1526		|O
conventional	1527	1539		|O
antioxidants	1540	1552		|O
.	1552	1553		|O

### 18613215
Association	0	11		|O
between	12	19		|O
serious	20	27		|O
ischemic	28	36		|O
cardiac	37	44		|O
outcomes	45	53		|O
and	54	57		|O
medications	58	69		|O
used	70	74		|O
to	75	77		|O
treat	78	83		|O
diabetes	84	92	diabetes	|B-DISEASE
.	92	93		|O
PURPOSE	95	102		|O
:	102	103		|O
Data	104	108		|O
on	109	111		|O
cardiovascular	112	126		|O
outcomes	127	135		|O
among	136	141		|O
treated	142	149		|O
diabetics	150	159		|O
have	160	164		|O
been	165	169		|O
inconsistent	170	182		|O
.	182	183		|O
Our	184	187		|O
goal	188	192		|O
was	193	196		|O
to	197	199		|O
compare	200	207		|O
cardiovascular	208	222		|O
outcomes	223	231		|O
associated	232	242		|O
with	243	247		|O
different	248	257		|O
treatments	258	268		|O
for	269	272		|O
diabetes	273	281	diabetes	|B-DISEASE
.	281	282		|O
METHODS	283	290		|O
:	290	291		|O
This	292	296		|O
is	297	299		|O
a	300	301		|O
retrospective	302	315		|O
cohort	316	322		|O
study	323	328		|O
of	329	331		|O
diabetic	332	340		|O
patients	341	349		|O
at	350	352		|O
least	353	358		|O
40	359	361		|O
years	362	367		|O
of	368	370		|O
age	371	374		|O
treated	375	382		|O
in	383	385		|O
general	386	393		|O
practices	394	403		|O
participating	404	417		|O
in	418	420		|O
The	421	424		|O
Health	425	431		|O
Information	432	443		|O
Network	444	451		|O
(	452	453		|O
THIN	453	457		|O
)	457	458		|O
data	459	463		|O
system	464	470		|O
between	471	478		|O
2002	479	483		|O
and	484	487		|O
2006	488	492		|O
.	492	493		|O
Our	494	497		|O
primary	498	505		|O
outcome	506	513		|O
was	514	517		|O
serious	518	525		|O
atherosclerotic	526	541	atherosclerotic vascular disease	|B-DISEASE
vascular	542	550		|I-DISEASE
disease	551	558		|I-DISEASE
of	559	561		|O
the	562	565		|O
heart	566	571		|O
.	571	572		|O
RESULTS	573	580		|O
:	580	581		|O
Among	582	587		|O
all	588	591		|O
diabetics	592	601		|O
(	602	603		|O
N	603	604		|O
=	605	606		|O
63	607	609		|O
579	610	613		|O
)	613	614		|O
,	614	615		|O
the	616	619		|O
fully	620	625		|O
adjusted	626	634		|O
hazard	635	641		|O
ratios	642	648		|O
of	649	651		|O
association	652	663		|O
with	664	668		|O
our	669	672		|O
outcome	673	680		|O
were	681	685		|O
1.2	686	689		|O
(	690	691		|O
1.1	691	694		|O
,	694	695		|O
1.3	696	699		|O
)	699	700		|O
for	701	704		|O
insulin	705	712		|O
,	712	713		|O
1.03	714	718		|O
(	719	720		|O
0.97	720	724		|O
,	724	725		|O
1.09	726	730		|O
)	730	731		|O
for	732	735		|O
sulfonylureas	736	749		|O
,	749	750		|O
0.8	751	754		|O
(	755	756		|O
0.7	756	759		|O
,	759	760		|O
0.8	761	764		|O
)	764	765		|O
for	766	769		|O
biguanide	770	779		|O
,	779	780		|O
1.2	781	784		|O
(	785	786		|O
0.99	786	790		|O
,	790	791		|O
1.5	792	795		|O
)	795	796		|O
for	797	800		|O
meglitinide	801	812		|O
,	812	813		|O
0.5	814	817		|O
(	818	819		|O
0.5	819	822		|O
,	822	823		|O
0.6	824	827		|O
)	827	828		|O
for	829	832		|O
thiazolidinediones	833	851		|O
,	851	852		|O
and	853	856		|O
individually	857	869		|O
0.6	870	873		|O
(	874	875		|O
0.5	875	878		|O
,	878	879		|O
0.6	880	883		|O
)	883	884		|O
for	885	888		|O
rosiglitazone	889	902		|O
,	902	903		|O
and	904	907		|O
0.5	908	911		|O
(	912	913		|O
0.4	913	916		|O
,	916	917		|O
0.7	918	921		|O
)	921	922		|O
for	923	926		|O
pioglitazone	927	939		|O
.	939	940		|O
Among	941	946		|O
those	947	952		|O
individuals	953	964		|O
newly	965	970		|O
diagnosed	971	980		|O
and	981	984		|O
treated	985	992		|O
for	993	996		|O
diabetes	997	1005	diabetes	|B-DISEASE
after	1006	1011		|O
2002	1012	1016		|O
(	1017	1018		|O
N	1018	1019		|O
=	1020	1021		|O
13	1022	1024		|O
576	1025	1028		|O
)	1028	1029		|O
,	1029	1030		|O
the	1031	1034		|O
adjusted	1035	1043		|O
hazard	1044	1050		|O
ratios	1051	1057		|O
of	1058	1060		|O
association	1061	1072		|O
with	1073	1077		|O
our	1078	1081		|O
outcome	1082	1089		|O
were	1090	1094		|O
2.4	1095	1098		|O
(	1099	1100		|O
2.0	1100	1103		|O
,	1103	1104		|O
2.9	1105	1108		|O
)	1108	1109		|O
for	1110	1113		|O
insulin	1114	1121		|O
,	1121	1122		|O
1.4	1123	1126		|O
(	1127	1128		|O
1.2	1128	1131		|O
,	1131	1132		|O
1.7	1133	1136		|O
)	1136	1137		|O
for	1138	1141		|O
sulfonylureas	1142	1155		|O
,	1155	1156		|O
0.5	1157	1160		|O
(	1161	1162		|O
0.4	1162	1165		|O
,	1165	1166		|O
0.5	1167	1170		|O
)	1170	1171		|O
for	1172	1175		|O
biguanide	1176	1185		|O
,	1185	1186		|O
0.9	1187	1190		|O
(	1191	1192		|O
0.4	1192	1195		|O
,	1195	1196		|O
2.1	1197	1200		|O
)	1200	1201		|O
for	1202	1205		|O
meglitinide	1206	1217		|O
,	1217	1218		|O
0.8	1219	1222		|O
(	1223	1224		|O
0.7	1224	1227		|O
,	1227	1228		|O
1.0	1229	1232		|O
)	1232	1233		|O
for	1234	1237		|O
thiazolidinediones	1238	1256		|O
,	1256	1257		|O
and	1258	1261		|O
individually	1262	1274		|O
0.8	1275	1278		|O
(	1279	1280		|O
0.6	1280	1283		|O
,	1283	1284		|O
1.0	1285	1288		|O
)	1288	1289		|O
for	1290	1293		|O
rosiglitazone	1294	1307		|O
,	1307	1308		|O
and	1309	1312		|O
0.9	1313	1316		|O
(	1317	1318		|O
0.6	1318	1321		|O
,	1321	1322		|O
1.4	1323	1326		|O
)	1326	1327		|O
for	1328	1331		|O
pioglitazone	1332	1344		|O
.	1344	1345		|O
Risk	1346	1350		|O
increased	1351	1360		|O
as	1361	1363		|O
total	1364	1369		|O
duration	1370	1378		|O
of	1379	1381		|O
therapy	1382	1389		|O
increased	1390	1399		|O
for	1400	1403		|O
insulin	1404	1411		|O
,	1411	1412		|O
sulfonylureas	1413	1426		|O
,	1426	1427		|O
and	1428	1431		|O
biguanide	1432	1441		|O
,	1441	1442		|O
but	1443	1446		|O
decreased	1447	1456		|O
with	1457	1461		|O
duration	1462	1470		|O
for	1471	1474		|O
rosiglitazone	1475	1488		|O
and	1489	1492		|O
pioglitazone	1493	1505		|O
.	1505	1506		|O
CONCLUSIONS	1507	1518		|O
:	1518	1519		|O
Overall	1520	1527		|O
,	1527	1528		|O
insulin	1529	1536		|O
was	1537	1540		|O
associated	1541	1551		|O
with	1552	1556		|O
an	1557	1559		|O
increased	1560	1569		|O
risk	1570	1574		|O
of	1575	1577		|O
myocardial	1578	1588	myocardial infarction	|B-ADVERSE
infarction	1589	1599		|I-ADVERSE
.	1599	1600		|O
Its	1601	1604		|O
risk	1605	1609		|O
increased	1610	1619		|O
with	1620	1624		|O
longer	1625	1631		|O
use	1632	1635		|O
,	1635	1636		|O
and	1637	1640		|O
risk	1641	1645		|O
emerged	1646	1653		|O
with	1654	1658		|O
longer	1659	1665		|O
use	1666	1669		|O
of	1670	1672		|O
sulfonylureas	1673	1686		|O
and	1687	1690		|O
biguanide	1691	1700		|O
.	1700	1701		|O
Conversely	1702	1712		|O
,	1712	1713		|O
a	1714	1715		|O
protective	1716	1726		|O
effect	1727	1733		|O
emerged	1734	1741		|O
with	1742	1746		|O
longer	1747	1753		|O
use	1754	1757		|O
of	1758	1760		|O
rosiglitazone	1761	1774		|O
or	1775	1777		|O
pioglitazone	1778	1790		|O
.	1790	1791		|O

### 18772046
Serotonin	0	9		|O
-	9	10		|O
dopamine	10	18		|O
interaction	19	30		|O
in	31	33		|O
the	34	37		|O
induction	38	47		|O
and	48	51		|O
maintenance	52	63		|O
of	64	66		|O
L	67	68		|O
-	68	69		|O
DOPA	69	73		|O
-	73	74		|O
induced	74	81		|O
dyskinesias	82	93	dyskinesias	|B-ADVERSE
.	93	94		|O
Appearance	96	106		|O
of	107	109		|O
dyskinesia	110	120	dyskinesia	|B-ADVERSE
is	121	123		|O
a	124	125		|O
common	126	132		|O
problem	133	140		|O
of	141	143		|O
long	144	148		|O
-	148	149		|O
term	149	153		|O
Levodopa	154	162		|O
(	163	164		|O
L	164	165		|O
-	165	166		|O
DOPA	166	170		|O
)	170	171		|O
treatment	172	181		|O
in	182	184		|O
Parkinson	185	194	Parkinson's disease	|B-DISEASE
's	194	196		|I-DISEASE
disease	197	204		|I-DISEASE
(	205	206		|O
PD	206	208	PD	|B-DISEASE
)	208	209		|O
patients	210	218		|O
and	219	222		|O
represents	223	233		|O
a	234	235		|O
major	236	241		|O
limitation	242	252		|O
for	253	256		|O
the	257	260		|O
pharmacological	261	276		|O
management	277	287		|O
of	288	290		|O
the	291	294		|O
motor	295	300		|O
symptoms	301	309		|O
in	310	312		|O
the	313	316		|O
advanced	317	325		|O
stages	326	332		|O
of	333	335		|O
disease	336	343		|O
.	343	344		|O
An	345	347		|O
increasing	348	358		|O
body	359	363		|O
of	364	366		|O
evidence	367	375		|O
points	376	382		|O
to	383	385		|O
dopamine	386	394		|O
released	395	403		|O
as	404	406		|O
a	407	408		|O
false	409	414		|O
neurotransmitter	415	431		|O
from	432	436		|O
the	437	440		|O
striatal	441	449		|O
serotonin	450	459		|O
terminals	460	469		|O
as	470	472		|O
the	473	476		|O
main	477	481		|O
pre	482	485		|O
-	485	486		|O
synaptic	486	494		|O
determinant	495	506		|O
of	507	509		|O
L	510	511		|O
-	511	512		|O
DOPA	512	516		|O
-	516	517		|O
induced	517	524		|O
dyskinesia	525	535	dyskinesia	|B-ADVERSE
.	535	536		|O
Here	537	541		|O
we	542	544		|O
review	545	551		|O
the	552	555		|O
animal	556	562		|O
experimental	563	575		|O
and	576	579		|O
human	580	585		|O
clinical	586	594		|O
data	595	599		|O
in	600	602		|O
support	603	610		|O
of	611	613		|O
this	614	618		|O
view	619	623		|O
,	623	624		|O
which	625	630		|O
point	631	636		|O
to	637	639		|O
the	640	643		|O
serotonin	644	653		|O
system	654	660		|O
as	661	663		|O
a	664	665		|O
promising	666	675		|O
target	676	682		|O
for	683	686		|O
anti	687	691		|O
-	691	692		|O
dyskinetic	692	702		|O
therapy	703	710		|O
in	711	713		|O
PD	714	716	PD	|B-DISEASE
patients	717	725		|O
under	726	731		|O
L	732	733		|O
-	733	734		|O
DOPA	734	738		|O
medication	739	749		|O
.	749	750		|O

### 18679398
Somatic	0	7		|O
pharmacogenomics	8	24		|O
in	25	27		|O
cancer	28	34	cancer	|B-DISEASE
.	34	35		|O
Many	37	41		|O
of	42	44		|O
the	45	48		|O
initial	49	56		|O
examples	57	65		|O
of	66	68		|O
the	69	72		|O
clinical	73	81		|O
utility	82	89		|O
of	90	92		|O
pharmacogenetics	93	109		|O
were	110	114		|O
elucidated	115	125		|O
in	126	128		|O
the	129	132		|O
field	133	138		|O
of	139	141		|O
oncology	142	150		|O
.	150	151		|O
Those	152	157		|O
examples	158	166		|O
were	167	171		|O
largely	172	179		|O
based	180	185		|O
on	186	188		|O
the	189	192		|O
existence	193	202		|O
of	203	205		|O
germline	206	214		|O
genetic	215	222		|O
variation	223	232		|O
that	233	237		|O
influences	238	248		|O
the	249	252		|O
metabolism	253	263		|O
of	264	266		|O
cytotoxic	267	276		|O
drugs	277	282		|O
.	282	283		|O
However	284	291		|O
,	291	292		|O
with	293	297		|O
the	298	301		|O
development	302	313		|O
of	314	316		|O
kinase	317	323		|O
inhibitors	324	334		|O
,	334	335		|O
drugs	336	341		|O
designed	342	350		|O
to	351	353		|O
preferentially	354	368		|O
target	369	375		|O
altered	376	383		|O
proteins	384	392		|O
driving	393	400		|O
oncogenesis	401	412		|O
,	412	413		|O
pharmacogenetics	414	430		|O
in	431	433		|O
cancer	434	440	cancer	|B-DISEASE
has	441	444		|O
shifted	445	452		|O
to	453	455		|O
understanding	456	469		|O
the	470	473		|O
somatic	474	481		|O
differences	482	493		|O
that	494	498		|O
determine	499	508		|O
response	509	517		|O
to	518	520		|O
these	521	526		|O
targeted	527	535		|O
agents	536	542		|O
.	542	543		|O
It	544	546		|O
is	547	549		|O
becoming	550	558		|O
increasingly	559	571		|O
clear	572	577		|O
that	578	582		|O
understanding	583	596		|O
the	597	600		|O
molecular	601	610		|O
genetics	611	619		|O
of	620	622		|O
cancer	623	629	cancer	|B-DISEASE
will	630	634		|O
lead	635	639		|O
to	640	642		|O
the	643	646		|O
further	647	654		|O
development	655	666		|O
of	667	669		|O
targeted	670	678		|O
therapeutics	679	691		|O
.	691	692		|O
Therefore	693	702		|O
,	702	703		|O
it	704	706		|O
is	707	709		|O
imperative	710	720		|O
that	721	725		|O
pharmacogenomics	726	742		|O
researchers	743	754		|O
understand	755	765		|O
the	766	769		|O
motivations	770	781		|O
and	782	785		|O
challenges	786	796		|O
of	797	799		|O
developing	800	810		|O
targeted	811	819		|O
therapies	820	829		|O
to	830	832		|O
treat	833	838		|O
cancer	839	845	cancer	|B-DISEASE
as	846	848		|O
a	849	850		|O
paradigm	851	859		|O
for	860	863		|O
personalized	864	876		|O
medicine	877	885		|O
.	885	886		|O
However	887	894		|O
,	894	895		|O
much	896	900		|O
of	901	903		|O
the	904	907		|O
discussion	908	918		|O
in	919	921		|O
the	922	925		|O
pharmacogenomics	926	942		|O
community	943	952		|O
in	953	955		|O
cancer	956	962	cancer	|B-DISEASE
is	963	965		|O
still	966	971		|O
largely	972	979		|O
focused	980	987		|O
on	988	990		|O
the	991	994		|O
germline	995	1003		|O
variants	1004	1012		|O
as	1013	1015		|O
predictors	1016	1026		|O
of	1027	1029		|O
drug	1030	1034	drug toxicity	|B-ADVERSE
toxicity	1035	1043		|I-ADVERSE
.	1043	1044		|O
In	1045	1047		|O
light	1048	1053		|O
of	1054	1056		|O
that	1057	1061		|O
fact	1062	1066		|O
,	1066	1067		|O
this	1068	1072		|O
review	1073	1079		|O
presents	1080	1088		|O
a	1089	1090		|O
detailed	1091	1099		|O
discussion	1100	1110		|O
of	1111	1113		|O
the	1114	1117		|O
development	1118	1129		|O
of	1130	1132		|O
commonly	1133	1141		|O
used	1142	1146		|O
targeted	1147	1155		|O
therapies	1156	1165		|O
for	1166	1169		|O
the	1170	1173		|O
treatment	1174	1183		|O
of	1184	1186		|O
hematological	1187	1200		|O
and	1201	1204		|O
solid	1205	1210		|O
tumors	1211	1217		|O
,	1217	1218		|O
the	1219	1222		|O
somatic	1223	1230		|O
mutations	1231	1240		|O
that	1241	1245		|O
determine	1246	1255		|O
response	1256	1264		|O
to	1265	1267		|O
those	1268	1273		|O
therapies	1274	1283		|O
,	1283	1284		|O
and	1285	1288		|O
the	1289	1292		|O
mechanisms	1293	1303		|O
of	1304	1306		|O
drug	1307	1311		|O
resistance	1312	1322		|O
.	1322	1323		|O

### 18751414
Weekly	0	6		|O
irinotecan	7	17		|O
plus	18	22		|O
protracted	23	33		|O
venous	34	40		|O
fluorouracil	41	53		|O
infusion	54	62		|O
(	63	64		|O
WI	64	66		|O
-	66	67		|O
FI	67	69		|O
)	69	70		|O
in	71	73		|O
advanced	74	82		|O
colorectal	83	93	colorectal cancer	|B-DISEASE
cancer	94	100		|I-DISEASE
:	100	101		|O
a	102	103		|O
phase	104	109		|O
II	110	112		|O
study	113	118		|O
.	118	119		|O
BACKGROUND	121	131		|O
:	131	132		|O
Irinotecan	133	143		|O
(	144	145		|O
IRI	145	148		|O
)	148	149		|O
is	150	152		|O
a	153	154		|O
topoisomerase	155	168		|O
I	169	170		|O
inhibitor	171	180		|O
active	181	187		|O
as	188	190		|O
first	191	196		|O
-	196	197		|O
or	198	200		|O
second	201	207		|O
-	207	208		|O
line	208	212		|O
chemotherapy	213	225		|O
in	226	228		|O
advanced	229	237		|O
colorectal	238	248	colorectal cancer	|B-DISEASE
cancer	249	255		|I-DISEASE
(	256	257		|O
ACRC	257	261	ACRC	|B-DISEASE
)	261	262		|O
.	262	263		|O
Its	264	267		|O
combination	268	279		|O
with	280	284		|O
fluorouracil	285	297		|O
(	298	299		|O
FU	299	301		|O
)	301	302		|O
increases	303	312		|O
the	313	316		|O
response	317	325		|O
rate	326	330		|O
and	331	334		|O
prolongs	335	343		|O
survival	344	352		|O
.	352	353		|O
In	354	356		|O
order	357	362		|O
to	363	365		|O
identify	366	374		|O
a	375	376		|O
new	377	380		|O
effective	381	390		|O
and	391	394		|O
less	395	399		|O
toxic	400	405		|O
schedule	406	414		|O
of	415	417		|O
administration	418	432		|O
,	432	433		|O
we	434	436		|O
planned	437	444		|O
this	445	449		|O
phase	450	455		|O
II	456	458		|O
study	459	464		|O
with	465	469		|O
weekly	470	476		|O
IRI	477	480		|O
and	481	484		|O
protracted	485	495		|O
venous	496	502		|O
infusion	503	511		|O
of	512	514		|O
FU	515	517		|O
(	518	519		|O
WI	519	521		|O
-	521	522		|O
FI	522	524		|O
regimen	525	532		|O
)	532	533		|O
.	533	534		|O
The	535	538		|O
primary	539	546		|O
endpoint	547	555		|O
was	556	559		|O
the	560	563		|O
objective	564	573		|O
response	574	582		|O
rate	583	587		|O
.	587	588		|O
Secondary	589	598		|O
aims	599	603		|O
were	604	608		|O
to	609	611		|O
detect	612	618		|O
toxicity	619	627		|O
,	627	628		|O
progression	629	640		|O
-	640	641		|O
free	641	645		|O
survival	646	654		|O
(	655	656		|O
PFS	656	659		|O
)	659	660		|O
and	661	664		|O
overall	665	672		|O
survival	673	681		|O
(	682	683		|O
OS	683	685		|O
)	685	686		|O
of	687	689		|O
patients	690	698		|O
(	699	700		|O
pts	700	703		|O
)	703	704		|O
.	704	705		|O
MATERIALS	706	715		|O
AND	716	719		|O
METHODS	720	727		|O
:	727	728		|O
On	729	731		|O
May	732	735		|O
2000	736	740		|O
,	740	741		|O
a	742	743		|O
monoinstitutional	744	761		|O
study	762	767		|O
commenced	768	777		|O
with	778	782		|O
the	783	786		|O
following	787	796		|O
schedule	797	805		|O
of	806	808		|O
administration	809	823		|O
:	823	824		|O
IRI	825	828		|O
80	829	831		|O
mg	832	834		|O
/	834	835		|O
m2	835	837		|O
on	838	840		|O
days	841	845		|O
1	846	847		|O
,	847	848		|O
8	849	850		|O
,	850	851		|O
15	852	854		|O
,	854	855		|O
22	856	858		|O
,	858	859		|O
29	860	862		|O
plus	863	867		|O
a	868	869		|O
28	870	872		|O
-	872	873		|O
day	873	876		|O
protracted	877	887		|O
venous	888	894		|O
infusion	895	903		|O
of	904	906		|O
FU	907	909		|O
200	910	913		|O
mg	914	916		|O
/	916	917		|O
m2	917	919		|O
/	919	920		|O
day	920	923		|O
.	923	924		|O
The	925	928		|O
treatment	929	938		|O
was	939	942		|O
repeated	943	951		|O
every	952	957		|O
35	958	960		|O
days	961	965		|O
.	965	966		|O
Cycles	967	973		|O
were	974	978		|O
administered	979	991		|O
until	992	997		|O
a	998	999		|O
maximum	1000	1007		|O
of	1008	1010		|O
6	1011	1012		|O
courses	1013	1020		|O
,	1020	1021		|O
disease	1022	1029		|O
progression	1030	1041		|O
or	1042	1044		|O
unacceptable	1045	1057		|O
toxicity	1058	1066		|O
.	1066	1067		|O
RESULTS	1068	1075		|O
:	1075	1076		|O
By	1077	1079		|O
March	1080	1085		|O
2005	1086	1090		|O
,	1090	1091		|O
52	1092	1094		|O
patients	1095	1103		|O
(	1104	1105		|O
30	1105	1107		|O
males	1108	1113		|O
and	1114	1117		|O
22	1118	1120		|O
females	1121	1128		|O
)	1128	1129		|O
had	1130	1133		|O
entered	1134	1141		|O
the	1142	1145		|O
study	1146	1151		|O
.	1151	1152		|O
Their	1153	1158		|O
median	1159	1165		|O
age	1166	1169		|O
was	1170	1173		|O
61.5	1174	1178		|O
years	1179	1184		|O
and	1185	1188		|O
the	1189	1192		|O
median	1193	1199		|O
ECOG	1200	1204		|O
PS	1205	1207		|O
was	1208	1211		|O
1	1212	1213		|O
.	1213	1214		|O
In	1215	1217		|O
total	1218	1223		|O
,	1223	1224		|O
223	1225	1228		|O
courses	1229	1236		|O
were	1237	1241		|O
administered	1242	1254		|O
(	1255	1256		|O
median	1256	1262		|O
5	1263	1264		|O
cycles	1265	1271		|O
/	1271	1272		|O
patient	1272	1279		|O
)	1279	1280		|O
.	1280	1281		|O
Toxicity	1282	1290		|O
was	1291	1294		|O
low	1295	1298		|O
:	1298	1299		|O
neutropenia	1300	1311	neutropenia	|B-ADVERSE
G3	1312	1314		|O
and	1315	1318		|O
asthenia	1319	1327	asthenia	|B-ADVERSE
G3	1328	1330		|O
were	1331	1335		|O
the	1336	1339		|O
most	1340	1344		|O
observed	1345	1353		|O
toxicities	1354	1364		|O
(	1365	1366		|O
5	1366	1367		|O
pts	1368	1371		|O
each	1372	1376		|O
)	1376	1377		|O
.	1377	1378		|O
No	1379	1381		|O
other	1382	1387		|O
grade	1388	1393		|O
3-4	1394	1397		|O
toxic	1398	1403		|O
side	1404	1408		|O
-	1408	1409		|O
effects	1409	1416		|O
were	1417	1421		|O
seen	1422	1426		|O
.	1426	1427		|O
Weekly	1428	1434		|O
IRI	1435	1438		|O
was	1439	1442		|O
interrupted	1443	1454		|O
in	1455	1457		|O
11	1458	1460		|O
pts	1461	1464		|O
,	1464	1465		|O
mostly	1466	1472		|O
related	1473	1480		|O
to	1481	1483		|O
problems	1484	1492		|O
with	1493	1497		|O
the	1498	1501		|O
central	1502	1509		|O
venous	1510	1516		|O
catheter	1517	1525		|O
.	1525	1526		|O
Following	1527	1536		|O
RECIST	1537	1543		|O
criteria	1544	1552		|O
,	1552	1553		|O
we	1554	1556		|O
observed	1557	1565		|O
5	1566	1567		|O
complete	1568	1576		|O
responses	1577	1586		|O
,	1586	1587		|O
15	1588	1590		|O
partial	1591	1598		|O
responses	1599	1608		|O
,	1608	1609		|O
17	1610	1612		|O
pts	1613	1616		|O
had	1617	1620		|O
stable	1621	1627		|O
disease	1628	1635		|O
,	1635	1636		|O
while	1637	1642		|O
in	1643	1645		|O
15	1646	1648		|O
disease	1649	1656		|O
progressed	1657	1667		|O
.	1667	1668		|O
The	1669	1672		|O
overall	1673	1680		|O
response	1681	1689		|O
rate	1690	1694		|O
was	1695	1698		|O
38.5%	1699	1704		|O
and	1705	1708		|O
the	1709	1712		|O
disease	1713	1720		|O
control	1721	1728		|O
rate	1729	1733		|O
was	1734	1737		|O
71.2%	1738	1743		|O
.	1743	1744		|O
Thirteen	1745	1753		|O
pts	1754	1757		|O
underwent	1758	1767		|O
surgical	1768	1776		|O
resection	1777	1786		|O
of	1787	1789		|O
their	1790	1795		|O
relapsing	1796	1805		|O
disease	1806	1813		|O
.	1813	1814		|O
The	1815	1818		|O
median	1819	1825		|O
PFS	1826	1829		|O
was	1830	1833		|O
8.2	1834	1837		|O
months	1838	1844		|O
and	1845	1848		|O
the	1849	1852		|O
median	1853	1859		|O
OS	1860	1862		|O
was	1863	1866		|O
16.3	1867	1871		|O
months	1872	1878		|O
.	1878	1879		|O
CONCLUSION	1880	1890		|O
:	1890	1891		|O
The	1892	1895		|O
WI	1896	1898		|O
-	1898	1899		|O
FI	1899	1901		|O
regimen	1902	1909		|O
is	1910	1912		|O
an	1913	1915		|O
active	1916	1922		|O
treatment	1923	1932		|O
with	1933	1937		|O
a	1938	1939		|O
good	1940	1944		|O
safety	1945	1951		|O
profile	1952	1959		|O
in	1960	1962		|O
patients	1963	1971		|O
with	1972	1976		|O
CRC	1977	1980	CRC	|B-DISEASE
.	1980	1981		|O
The	1982	1985		|O
low	1986	1989		|O
incidence	1990	1999		|O
of	2000	2002		|O
grade	2003	2008		|O
3-4	2009	2012		|O
toxicities	2013	2023		|O
justifies	2024	2033		|O
further	2034	2041		|O
evaluation	2042	2052		|O
of	2053	2055		|O
this	2056	2060		|O
combination	2061	2072		|O
.	2072	2073		|O

### 18803413
Selectins	0	9		|O
ligand	10	16		|O
decorated	17	26		|O
drug	27	31		|O
carriers	32	40		|O
for	41	44		|O
activated	45	54		|O
endothelial	55	66		|O
cell	67	71		|O
targeting	72	81		|O
.	81	82		|O
New	84	87		|O
active	88	94		|O
particulate	95	106		|O
polymeric	107	116		|O
vectors	117	124		|O
based	125	130		|O
on	131	133		|O
branched	134	142		|O
polyester	143	152		|O
copolymers	153	163		|O
of	164	166		|O
hydroxy	167	174		|O
-	174	175		|O
acid	175	179		|O
and	180	183		|O
allyl	184	189		|O
glycidyl	190	198		|O
ether	199	204		|O
were	205	209		|O
developed	210	219		|O
to	220	222		|O
target	223	229		|O
drugs	230	235		|O
to	236	238		|O
the	239	242		|O
inflammatory	243	255		|O
endothelial	256	267		|O
cell	268	272		|O
surface	273	280		|O
.	280	281		|O
The	282	285		|O
hydroxyl	286	294		|O
and	295	298		|O
carboxyl	299	307		|O
derivatives	308	319		|O
of	320	322		|O
these	323	328		|O
polymers	329	337		|O
allow	338	343		|O
grafting	344	352		|O
of	353	355		|O
ligand	356	362		|O
molecules	363	372		|O
on	373	375		|O
the	376	379		|O
polyester	380	389		|O
backbones	390	399		|O
at	400	402		|O
different	403	412		|O
densities	413	422		|O
.	422	423		|O
A	424	425		|O
known	426	431		|O
potent	432	438		|O
nonselective	439	451		|O
selectin	452	460		|O
ligand	461	467		|O
was	468	471		|O
selected	472	480		|O
and	481	484		|O
synthesized	485	496		|O
using	497	502		|O
a	503	504		|O
new	505	508		|O
scheme	509	515		|O
.	515	516		|O
This	517	521		|O
synthesis	522	531		|O
allowed	532	539		|O
the	540	543		|O
grafting	544	552		|O
of	553	555		|O
the	556	559		|O
ligand	560	566		|O
to	567	569		|O
the	570	573		|O
polyester	574	583		|O
polymers	584	592		|O
,	592	593		|O
preserving	594	604		|O
its	605	608		|O
binding	609	616		|O
activity	617	625		|O
as	626	628		|O
assessed	629	637		|O
by	638	640		|O
docking	641	648		|O
simulations	649	660		|O
.	660	661		|O
Selectin	662	670		|O
expression	671	681		|O
on	682	684		|O
human	685	690		|O
umbilical	691	700		|O
cord	701	705		|O
vascular	706	714		|O
endothelial	715	726		|O
cells	727	732		|O
(	733	734		|O
HUVEC	734	739		|O
)	739	740		|O
was	741	744		|O
induced	745	752		|O
with	753	757		|O
the	758	761		|O
pro	762	765		|O
-	765	766		|O
inflammatory	766	778		|O
bacterial	779	788		|O
lipopolysaccharide	789	807		|O
(	808	809		|O
LPS	809	812		|O
)	812	813		|O
or	814	816		|O
with	817	821		|O
the	822	825		|O
nonselective	826	838		|O
inhibitor	839	848		|O
of	849	851		|O
nitric	852	858		|O
oxide	859	864		|O
synthase	865	873		|O
L	874	875		|O
-	875	876		|O
NAME	876	880		|O
.	880	881		|O
Strong	882	888		|O
adhesion	889	897		|O
of	898	900		|O
the	901	904		|O
ligand	905	911		|O
decorated	912	921		|O
nanoparticles	922	935		|O
was	936	939		|O
evidenced	940	949		|O
in	950	952		|O
vitro	953	958		|O
on	959	961		|O
activated	962	971		|O
HUVEC	972	977		|O
.	977	978		|O
Binding	979	986		|O
of	987	989		|O
nanoparticles	990	1003		|O
bearing	1004	1011		|O
ligand	1012	1018		|O
molecules	1019	1028		|O
could	1029	1034		|O
be	1035	1037		|O
efficiently	1038	1049		|O
inhibited	1050	1059		|O
by	1060	1062		|O
prior	1063	1068		|O
incubation	1069	1079		|O
of	1080	1082		|O
cells	1083	1088		|O
with	1089	1093		|O
free	1094	1098		|O
ligand	1099	1105		|O
,	1105	1106		|O
demonstrating	1107	1120		|O
that	1121	1125		|O
adhesion	1126	1134		|O
of	1135	1137		|O
the	1138	1141		|O
nanoparticles	1142	1155		|O
is	1156	1158		|O
mediated	1159	1167		|O
by	1168	1170		|O
specific	1171	1179		|O
interaction	1180	1191		|O
between	1192	1199		|O
the	1200	1203		|O
ligand	1204	1210		|O
and	1211	1214		|O
the	1215	1218		|O
selectin	1219	1227		|O
receptors	1228	1237		|O
.	1237	1238		|O
These	1239	1244		|O
nanoparticles	1245	1258		|O
could	1259	1264		|O
be	1265	1267		|O
used	1268	1272		|O
for	1273	1276		|O
specific	1277	1285		|O
drug	1286	1290		|O
delivery	1291	1299		|O
to	1300	1302		|O
the	1303	1306		|O
activated	1307	1316		|O
vascular	1317	1325		|O
endothelium	1326	1337		|O
,	1337	1338		|O
suggesting	1339	1349		|O
their	1350	1355		|O
application	1356	1367		|O
in	1368	1370		|O
the	1371	1374		|O
treatment	1375	1384		|O
of	1385	1387		|O
diseases	1388	1396		|O
with	1397	1401		|O
an	1402	1404		|O
inflammatory	1405	1417		|O
component	1418	1427		|O
such	1428	1432		|O
as	1433	1435		|O
rheumatoid	1436	1446	rheumatoid arthritis	|B-DISEASE
arthritis	1447	1456		|I-DISEASE
and	1457	1460		|O
cancer	1461	1467	cancer	|B-DISEASE
.	1467	1468		|O

### 18640133
Radiation	0	9		|O
-	9	10		|O
induced	10	17		|O
bystander	18	27		|O
effects	28	35		|O
enhanced	36	44		|O
by	45	47		|O
elevated	48	56		|O
sodium	57	63		|O
chloride	64	72		|O
through	73	80		|O
sensitizing	81	92		|O
cells	93	98		|O
to	99	101		|O
bystander	102	111		|O
factors	112	119		|O
.	119	120		|O
Radiation	122	131		|O
-	131	132		|O
induced	132	139		|O
bystander	140	149		|O
effects	150	157		|O
(	158	159		|O
RIBE	159	163		|O
)	163	164		|O
have	165	169		|O
been	170	174		|O
demonstrated	175	187		|O
to	188	190		|O
occur	191	196		|O
widely	197	203		|O
in	204	206		|O
various	207	214		|O
cell	215	219		|O
lines	220	225		|O
.	225	226		|O
However	227	234		|O
,	234	235		|O
very	236	240		|O
little	241	247		|O
data	248	252		|O
is	253	255		|O
available	256	265		|O
on	266	268		|O
the	269	272		|O
genotoxic	273	282		|O
effects	283	290		|O
of	291	293		|O
RIBE	294	298		|O
combined	299	307		|O
with	308	312		|O
other	313	318		|O
factor	319	325		|O
(	325	326		|O
s	326	327		|O
)	327	328		|O
.	328	329		|O
We	330	332		|O
reported	333	341		|O
previously	342	352		|O
that	353	357		|O
with	358	362		|O
a	363	364		|O
low	365	368		|O
dose	369	373		|O
of	374	376		|O
alpha	377	382		|O
-	382	383		|O
particle	383	391		|O
irradiation	392	403		|O
,	403	404		|O
the	405	408		|O
fraction	409	417		|O
of	418	420		|O
gamma	421	426		|O
-	426	427		|O
H2AX	427	431		|O
foci	432	436		|O
-	436	437		|O
positive	437	445		|O
cells	446	451		|O
in	452	454		|O
non	455	458		|O
-	458	459		|O
irradiated	459	469		|O
bystander	470	479		|O
cells	480	485		|O
was	486	489		|O
significantly	490	503		|O
increased	504	513		|O
under	514	519		|O
elevated	520	528		|O
NaCl	529	533		|O
culture	534	541		|O
conditions	542	552		|O
.	552	553		|O
In	554	556		|O
this	557	561		|O
study	562	567		|O
,	567	568		|O
we	569	571		|O
further	572	579		|O
investigated	580	592		|O
the	593	596		|O
functional	597	607		|O
role	608	612		|O
of	613	615		|O
NaCl	616	620		|O
in	621	623		|O
the	624	627		|O
enhancement	628	639		|O
of	640	642		|O
RIBE	643	647		|O
using	648	653		|O
a	654	655		|O
specially	656	665		|O
designed	666	674		|O
co	675	677		|O
-	677	678		|O
culture	678	685		|O
system	686	692		|O
and	693	696		|O
micronucleus	697	709		|O
(	710	711		|O
MN	711	713		|O
)	713	714		|O
test	715	719		|O
.	719	720		|O
It	721	723		|O
was	724	727		|O
shown	728	733		|O
that	734	738		|O
the	739	742		|O
MN	743	745		|O
frequency	746	755		|O
was	756	759		|O
not	760	763		|O
increased	764	773		|O
significantly	774	787		|O
by	788	790		|O
elevated	791	799		|O
NaCl	800	804		|O
(	805	806		|O
9.0	806	809		|O
g	810	811		|O
/	811	812		|O
L	812	813		|O
)	813	814		|O
alone	815	820		|O
or	821	823		|O
by	824	826		|O
medium	827	833		|O
exposure	834	842		|O
.	842	843		|O
However	844	851		|O
,	851	852		|O
with	853	857		|O
1.0	858	861		|O
cGy	862	865		|O
alpha	866	871		|O
-	871	872		|O
particle	872	880		|O
irradiation	881	892		|O
,	892	893		|O
the	894	897		|O
induced	898	905		|O
MN	906	908		|O
frequency	909	918		|O
increased	919	928		|O
significantly	929	942		|O
in	943	945		|O
both	946	950		|O
irradiated	951	961		|O
and	962	965		|O
non	966	969		|O
-	969	970		|O
irradiated	970	980		|O
bystander	981	990		|O
regions	991	998		|O
.	998	999		|O
Additional	1000	1010		|O
studies	1011	1018		|O
showed	1019	1025		|O
that	1026	1030		|O
elevated	1031	1039		|O
NaCl	1040	1044		|O
made	1045	1049		|O
the	1050	1053		|O
non	1054	1057		|O
-	1057	1058		|O
irradiated	1058	1068		|O
bystander	1069	1078		|O
cells	1079	1084		|O
more	1085	1089		|O
vulnerable	1090	1100		|O
to	1101	1103		|O
bystander	1104	1113		|O
factors	1114	1121		|O
.	1121	1122		|O
Furthermore	1123	1134		|O
,	1134	1135		|O
it	1136	1138		|O
was	1139	1142		|O
found	1143	1148		|O
that	1149	1153		|O
the	1154	1157		|O
induced	1158	1165		|O
MN	1166	1168		|O
frequency	1169	1178		|O
in	1179	1181		|O
cells	1182	1187		|O
both	1188	1192		|O
in	1193	1195		|O
irradiated	1196	1206		|O
and	1207	1210		|O
non	1211	1214		|O
-	1214	1215		|O
irradiated	1215	1225		|O
bystander	1226	1235		|O
regions	1236	1243		|O
was	1244	1247		|O
weakened	1248	1256		|O
when	1257	1261		|O
the	1262	1265		|O
hypertonic	1266	1276		|O
medium	1277	1283		|O
was	1284	1287		|O
changed	1288	1295		|O
to	1296	1298		|O
normotonic	1299	1309		|O
medium	1310	1316		|O
for	1317	1320		|O
2h	1321	1323		|O
before	1324	1330		|O
irradiation	1331	1342		|O
.	1342	1343		|O
Such	1344	1348		|O
observations	1349	1361		|O
were	1362	1366		|O
quite	1367	1372		|O
similar	1373	1380		|O
to	1381	1383		|O
the	1384	1387		|O
co	1388	1390		|O
-	1390	1391		|O
effect	1391	1397		|O
of	1398	1400		|O
NaCl	1401	1405		|O
and	1406	1409		|O
hydrogen	1410	1418		|O
peroxide	1419	1427		|O
(	1428	1429		|O
H	1429	1430		|O
(	1430	1431		|O
2	1431	1432		|O
)	1432	1433		|O
O	1433	1434		|O
(	1434	1435		|O
2	1435	1436		|O
)	1436	1437		|O
)	1437	1438		|O
,	1438	1439		|O
indicating	1440	1450		|O
that	1451	1455		|O
elevated	1456	1464		|O
NaCl	1465	1469		|O
might	1470	1475		|O
sensitize	1476	1485		|O
non	1486	1489		|O
-	1489	1490		|O
irradiated	1490	1500		|O
cells	1501	1506		|O
to	1507	1509		|O
bystander	1510	1519		|O
factors	1520	1527		|O
-	1527	1528		|O
induced	1528	1535		|O
oxidative	1536	1545		|O
stress	1546	1552		|O
.	1552	1553		|O

### 18585544
Cabergoline	0	11		|O
-	11	12		|O
induced	12	19		|O
psychotic	20	29	psychotic exacerbation	|B-ADVERSE
exacerbation	30	42		|I-ADVERSE
in	43	45		|O
schizophrenic	46	59		|O
patients	60	68		|O
.	68	69		|O
INTRODUCTION	71	83		|O
:	83	84		|O
Hyperprolactinemia	85	103	Hyperprolactinemia	|B-ADVERSE
is	104	106		|O
a	107	108		|O
well	109	113		|O
-	113	114		|O
recognized	114	124		|O
side	125	129		|O
effect	130	136		|O
of	137	139		|O
antipsychotic	140	153		|O
treatment	154	163		|O
.	163	164		|O
Cabergoline	165	176		|O
,	176	177		|O
a	178	179		|O
dopamine	180	188		|O
agonist	189	196		|O
,	196	197		|O
has	198	201		|O
been	202	206		|O
introduced	207	217		|O
on	218	220		|O
the	221	224		|O
market	225	231		|O
to	232	234		|O
treat	235	240		|O
hyperprolactinemia	241	259	hyperprolactinemia	|B-ADVERSE
,	259	260		|O
even	261	265		|O
secondary	266	275		|O
to	276	278		|O
antipsychotic	279	292		|O
use	293	296		|O
.	296	297		|O
CASE	298	302		|O
REPORT	303	309		|O
:	309	310		|O
In	311	313		|O
this	314	318		|O
article	319	326		|O
,	326	327		|O
we	328	330		|O
described	331	340		|O
two	341	344		|O
schizophrenic	345	358		|O
patients	359	367		|O
who	368	371		|O
received	372	380		|O
cabergoline	381	392		|O
to	393	395		|O
treat	396	401		|O
their	402	407		|O
antipsychotic	408	421		|O
-	421	422		|O
induced	422	429		|O
hyperprolactinemia	430	448	hyperprolactinemia	|B-ADVERSE
and	449	452		|O
developed	453	462		|O
a	463	464		|O
subsequent	465	475		|O
psychotic	476	485	psychotic exacerbation	|B-ADVERSE
exacerbation	486	498		|I-ADVERSE
.	498	499		|O
The	500	503		|O
first	504	509		|O
patient	510	517		|O
received	518	526		|O
amisulpride	527	538		|O
as	539	541		|O
antipsychotic	542	555		|O
medication	556	566		|O
,	566	567		|O
and	568	571		|O
the	572	575		|O
second	576	582		|O
one	583	586		|O
took	587	591		|O
risperidone	592	603		|O
and	604	607		|O
fluoxetine	608	618		|O
for	619	622		|O
her	623	626		|O
psychotic	627	636		|O
and	637	640		|O
depressive	641	651	depressive symptoms	|B-ADVERSE
symptoms	652	660		|I-ADVERSE
,	660	661		|O
respectively	662	674		|O
.	674	675		|O
Both	676	680		|O
patients	681	689		|O
improved	690	698		|O
significantly	699	712		|O
their	713	718		|O
psychotic	719	728	psychotic symptoms	|B-ADVERSE
symptoms	729	737		|I-ADVERSE
in	738	740		|O
1	741	742		|O
week	743	747		|O
without	748	755		|O
changing	756	764		|O
their	765	770		|O
former	771	777		|O
antipsychotic	778	791		|O
regimens	792	800		|O
.	800	801		|O
DISCUSSION	802	812		|O
:	812	813		|O
To	814	816		|O
the	817	820		|O
best	821	825		|O
of	826	828		|O
our	829	832		|O
knowledge	833	842		|O
,	842	843		|O
we	844	846		|O
found	847	852		|O
no	853	855		|O
previous	856	864		|O
report	865	871		|O
of	872	874		|O
cabergoline	875	886		|O
-	886	887		|O
induced	887	894		|O
psychotic	895	904	psychotic exacerbation	|B-ADVERSE
exacerbation	905	917		|I-ADVERSE
in	918	920		|O
schizophrenic	921	934		|O
patients	935	943		|O
who	944	947		|O
received	948	956		|O
antipsychotics	957	971		|O
.	971	972		|O
We	973	975		|O
brought	976	983		|O
up	984	986		|O
questions	987	996		|O
whether	997	1004		|O
schizophrenic	1005	1018		|O
patients	1019	1027		|O
on	1028	1030		|O
amisulpride	1031	1042		|O
or	1043	1045		|O
with	1046	1050		|O
the	1051	1054		|O
addition	1055	1063		|O
of	1064	1066		|O
fluoxetine	1067	1077		|O
may	1078	1081		|O
have	1082	1086		|O
higher	1087	1093		|O
risk	1094	1098		|O
to	1099	1101		|O
experience	1102	1112		|O
psychotic	1113	1122	psychotic worsening	|B-ADVERSE
worsening	1123	1132		|I-ADVERSE
.	1132	1133		|O
We	1134	1136		|O
also	1137	1141		|O
highlighted	1142	1153		|O
the	1154	1157		|O
possible	1158	1166		|O
role	1167	1171		|O
of	1172	1174		|O
dose	1175	1179		|O
-	1179	1180		|O
dependent	1180	1189		|O
nature	1190	1196		|O
in	1197	1199		|O
cabergoline	1200	1211		|O
-	1211	1212		|O
induced	1212	1219		|O
psychotic	1220	1229	psychotic exacerbation	|B-ADVERSE
exacerbation	1230	1242		|I-ADVERSE
,	1242	1243		|O
suggesting	1244	1254		|O
that	1255	1259		|O
the	1260	1263		|O
single	1264	1270		|O
starting	1271	1279		|O
dose	1280	1284		|O
of	1285	1287		|O
0.5	1288	1291		|O
mg	1292	1294		|O
or	1295	1297		|O
higher	1298	1304		|O
might	1305	1310		|O
be	1311	1313		|O
unsafe	1314	1320		|O
in	1321	1323		|O
schizophrenic	1324	1337		|O
patients	1338	1346		|O
.	1346	1347		|O
CONCLUSION	1348	1358		|O
:	1358	1359		|O
These	1360	1365		|O
cases	1366	1371		|O
suggest	1372	1379		|O
that	1380	1384		|O
cabergoline	1385	1396		|O
,	1396	1397		|O
like	1398	1402		|O
other	1403	1408		|O
dopaminergic	1409	1421		|O
agents	1422	1428		|O
,	1428	1429		|O
should	1430	1436		|O
be	1437	1439		|O
used	1440	1444		|O
with	1445	1449		|O
caution	1450	1457		|O
in	1458	1460		|O
psychotic	1461	1470		|O
patients	1471	1479		|O
and	1480	1483		|O
the	1484	1487		|O
dose	1488	1492		|O
should	1493	1499		|O
be	1500	1502		|O
as	1503	1505		|O
low	1506	1509		|O
as	1510	1512		|O
possible	1513	1521		|O
.	1521	1522		|O

### 18840370
Bioequivalence	0	14		|O
and	15	18		|O
pharmacokinetic	19	34		|O
comparison	35	45		|O
of	46	48		|O
a	49	50		|O
single	51	57		|O
200	58	61		|O
-	61	62		|O
mg	62	64		|O
dose	65	69		|O
of	70	72		|O
meclofenoxate	73	86		|O
hydrochloride	87	100		|O
capsule	101	108		|O
and	109	112		|O
tablet	113	119		|O
formulations	120	132		|O
in	133	135		|O
healthy	136	143		|O
Chinese	144	151		|O
adult	152	157		|O
male	158	162		|O
volunteers	163	173		|O
:	173	174		|O
a	175	176		|O
randomized	177	187		|O
sequence	188	196		|O
,	196	197		|O
open	198	202		|O
-	202	203		|O
label	203	208		|O
,	208	209		|O
two	210	213		|O
-	213	214		|O
period	214	220		|O
crossover	221	230		|O
study	231	236		|O
.	236	237		|O
BACKGROUND	239	249		|O
:	249	250		|O
Meclofenoxate	251	264		|O
hydrochloride	265	278		|O
is	279	281		|O
a	282	283		|O
psychostimulant	284	299		|O
in	300	302		|O
the	303	306		|O
nootropic	307	316		|O
agent	317	322		|O
group	323	328		|O
available	329	338		|O
in	339	341		|O
capsule	342	349		|O
and	350	353		|O
tablet	354	360		|O
formulations	361	373		|O
approved	374	382		|O
for	383	386		|O
traumatic	387	396	traumatic cataphora	|B-DISEASE
cataphora	397	406		|I-DISEASE
,	406	407		|O
alcoholic	408	417	alcoholic poisoning	|B-DISEASE
poisoning	418	427		|I-DISEASE
,	427	428		|O
anoxia	429	435	anoxia neonatorum	|B-DISEASE
neonatorum	436	446		|I-DISEASE
,	446	447		|O
and	448	451		|O
children	452	460		|O
's	460	462		|O
enuresis	463	471	enuresis	|B-DISEASE
in	472	474		|O
China	475	480		|O
.	480	481		|O
Although	482	490		|O
these	491	496		|O
2	497	498		|O
generic	499	506		|O
formulations	507	519		|O
are	520	523		|O
marketed	524	532		|O
in	533	535		|O
China	536	541		|O
,	541	542		|O
information	543	554		|O
regarding	555	564		|O
their	565	570		|O
pharmacokinetics	571	587		|O
and	588	591		|O
bioequivalence	592	606		|O
in	607	609		|O
humans	610	616		|O
has	617	620		|O
not	621	624		|O
been	625	629		|O
published	630	639		|O
.	639	640		|O
OBJECTIVE	641	650		|O
:	650	651		|O
The	652	655		|O
aim	656	659		|O
of	660	662		|O
this	663	667		|O
study	668	673		|O
was	674	677		|O
to	678	680		|O
compare	681	688		|O
the	689	692		|O
pharmacokinetic	693	708		|O
properties	709	719		|O
and	720	723		|O
bioequivalence	724	738		|O
of	739	741		|O
the	742	745		|O
capsule	746	753		|O
(	754	755		|O
test	755	759		|O
)	759	760		|O
and	761	764		|O
tablet	765	771		|O
(	772	773		|O
reference	773	782		|O
)	782	783		|O
formulations	784	796		|O
of	797	799		|O
meclofenoxate	800	813		|O
hydrochloride	814	827		|O
200	828	831		|O
mg	832	834		|O
in	835	837		|O
healthy	838	845		|O
Chinese	846	853		|O
volunteers	854	864		|O
.	864	865		|O
METHODS	866	873		|O
:	873	874		|O
This	875	879		|O
single	880	886		|O
-	886	887		|O
dose	887	891		|O
,	891	892		|O
randomized	893	903		|O
-	903	904		|O
sequence	904	912		|O
,	912	913		|O
open	914	918		|O
-	918	919		|O
label	919	924		|O
,	924	925		|O
2	926	927		|O
-	927	928		|O
period	928	934		|O
crossover	935	944		|O
study	945	950		|O
was	951	954		|O
performed	955	964		|O
at	965	967		|O
the	968	971		|O
Nanjing	972	979		|O
First	980	985		|O
Hospital	986	994		|O
of	995	997		|O
Nanjing	998	1005		|O
Medical	1006	1013		|O
University	1014	1024		|O
,	1024	1025		|O
Nanjing	1026	1033		|O
,	1033	1034		|O
China	1035	1040		|O
.	1040	1041		|O
Eligible	1042	1050		|O
subjects	1051	1059		|O
were	1060	1064		|O
healthy	1065	1072		|O
male	1073	1077		|O
volunteers	1078	1088		|O
who	1089	1092		|O
were	1093	1097		|O
randomly	1098	1106		|O
assigned	1107	1115		|O
at	1116	1118		|O
a	1119	1120		|O
1	1121	1122		|O
:	1122	1123		|O
1	1123	1124		|O
ratio	1125	1130		|O
to	1131	1133		|O
receive	1134	1141		|O
a	1142	1143		|O
single	1144	1150		|O
200	1151	1154		|O
-	1154	1155		|O
mg	1155	1157		|O
dose	1158	1162		|O
of	1163	1165		|O
the	1166	1169		|O
test	1170	1174		|O
or	1175	1177		|O
reference	1178	1187		|O
formulation	1188	1199		|O
,	1199	1200		|O
followed	1201	1209		|O
by	1210	1212		|O
a	1213	1214		|O
1	1215	1216		|O
-	1216	1217		|O
week	1217	1221		|O
washout	1222	1229		|O
period	1230	1236		|O
and	1237	1240		|O
administration	1241	1255		|O
of	1256	1258		|O
the	1259	1262		|O
alternate	1263	1272		|O
formulation	1273	1284		|O
.	1284	1285		|O
The	1286	1289		|O
study	1290	1295		|O
drugs	1296	1301		|O
were	1302	1306		|O
administered	1307	1319		|O
after	1320	1325		|O
a	1326	1327		|O
12	1328	1330		|O
-	1330	1331		|O
hour	1331	1335		|O
overnight	1336	1345		|O
fast	1346	1350		|O
.	1350	1351		|O
As	1352	1354		|O
a	1355	1356		|O
prodrug	1357	1364		|O
,	1364	1365		|O
meclofenoxate	1366	1379		|O
is	1380	1382		|O
hydrolyzed	1383	1393		|O
into	1394	1398		|O
4	1399	1400		|O
-	1400	1401		|O
chlorophenoxyacetic	1401	1420		|O
acid	1421	1425		|O
and	1426	1429		|O
is	1430	1432		|O
not	1433	1436		|O
detected	1437	1445		|O
in	1446	1448		|O
plasma	1449	1455		|O
.	1455	1456		|O
The	1457	1460		|O
active	1461	1467		|O
metabolite	1468	1478		|O
of	1479	1481		|O
meclofenoxate	1482	1495		|O
,	1495	1496		|O
chlorophenoxyacetic	1497	1516		|O
acid	1517	1521		|O
,	1521	1522		|O
was	1523	1526		|O
assayed	1527	1534		|O
using	1535	1540		|O
a	1541	1542		|O
high	1543	1547		|O
-	1547	1548		|O
performance	1548	1559		|O
liquid	1560	1566		|O
chromatography	1567	1581		|O
method	1582	1588		|O
.	1588	1589		|O
For	1590	1593		|O
analysis	1594	1602		|O
of	1603	1605		|O
pharmacokinetic	1606	1621		|O
properties	1622	1632		|O
,	1632	1633		|O
including	1634	1643		|O
Cmax	1644	1648		|O
,	1648	1649		|O
AUC0	1650	1654		|O
-	1654	1655		|O
24	1655	1657		|O
,	1657	1658		|O
and	1659	1662		|O
AUC0	1663	1667		|O
-	1667	1668		|O
infinity	1668	1676		|O
,	1676	1677		|O
blood	1678	1683		|O
samples	1684	1691		|O
were	1692	1696		|O
obtained	1697	1705		|O
at	1706	1708		|O
0.33	1709	1713		|O
,	1713	1714		|O
0.67	1715	1719		|O
,	1719	1720		|O
1	1721	1722		|O
,	1722	1723		|O
1.5	1724	1727		|O
,	1727	1728		|O
2	1729	1730		|O
,	1730	1731		|O
2.5	1732	1735		|O
,	1735	1736		|O
3	1737	1738		|O
,	1738	1739		|O
4	1740	1741		|O
,	1741	1742		|O
6	1743	1744		|O
,	1744	1745		|O
8	1746	1747		|O
,	1747	1748		|O
10	1749	1751		|O
,	1751	1752		|O
14	1753	1755		|O
,	1755	1756		|O
and	1757	1760		|O
24	1761	1763		|O
hours	1764	1769		|O
after	1770	1775		|O
administration	1776	1790		|O
.	1790	1791		|O
The	1792	1795		|O
formulations	1796	1808		|O
were	1809	1813		|O
considered	1814	1824		|O
bioequivalent	1825	1838		|O
if	1839	1841		|O
the	1842	1845		|O
log	1846	1849		|O
-	1849	1850		|O
transformed	1850	1861		|O
ratios	1862	1868		|O
of	1869	1871		|O
Cmax	1872	1876		|O
and	1877	1880		|O
AUC	1881	1884		|O
were	1885	1889		|O
within	1890	1896		|O
the	1897	1900		|O
predetermined	1901	1914		|O
equivalence	1915	1926		|O
range	1927	1932		|O
(	1933	1934		|O
80%	1934	1937		|O
-	1937	1938		|O
125%	1938	1942		|O
)	1942	1943		|O
as	1944	1946		|O
established	1947	1958		|O
by	1959	1961		|O
the	1962	1965		|O
US	1966	1968		|O
Food	1969	1973		|O
and	1974	1977		|O
Drug	1978	1982		|O
Administration	1983	1997		|O
(	1998	1999		|O
FDA	1999	2002		|O
)	2002	2003		|O
.	2003	2004		|O
Subjects	2005	2013		|O
were	2014	2018		|O
interviewed	2019	2030		|O
concerning	2031	2041		|O
the	2042	2045		|O
occurrence	2046	2056		|O
of	2057	2059		|O
adverse	2060	2067		|O
events	2068	2074		|O
including	2075	2084		|O
excitement	2085	2095	excitement	|B-ADVERSE
,	2095	2096		|O
insomnia	2097	2105	insomnia	|B-ADVERSE
,	2105	2106		|O
lassitude	2107	2116	lassitude	|B-ADVERSE
,	2116	2117		|O
and	2118	2121		|O
headache	2122	2130	headache	|B-ADVERSE
.	2130	2131		|O
Tolerability	2132	2144		|O
was	2145	2148		|O
assessed	2149	2157		|O
at	2158	2160		|O
baseline	2161	2169		|O
(	2170	2171		|O
before	2171	2177		|O
administration	2178	2192		|O
)	2192	2193		|O
and	2194	2197		|O
at	2198	2200		|O
1	2201	2202		|O
,	2202	2203		|O
2	2204	2205		|O
,	2205	2206		|O
6	2207	2208		|O
,	2208	2209		|O
and	2210	2213		|O
12	2214	2216		|O
hours	2217	2222		|O
after	2223	2228		|O
administration	2229	2243		|O
by	2244	2246		|O
monitoring	2247	2257		|O
vital	2258	2263		|O
signs	2264	2269		|O
and	2270	2273		|O
laboratory	2274	2284		|O
tests	2285	2290		|O
(	2291	2292		|O
hematology	2292	2302		|O
,	2302	2303		|O
blood	2304	2309		|O
biochemistry	2310	2322		|O
,	2322	2323		|O
hepatic	2324	2331		|O
function	2332	2340		|O
,	2340	2341		|O
and	2342	2345		|O
urinalysis	2346	2356		|O
)	2356	2357		|O
.	2357	2358		|O
RESULTS	2359	2366		|O
:	2366	2367		|O
Twenty	2368	2374		|O
-	2374	2375		|O
four	2375	2379		|O
Chinese	2380	2387		|O
male	2388	2392		|O
subjects	2393	2401		|O
(	2402	2403		|O
mean	2403	2407		|O
[	2408	2409		|O
range	2409	2414		|O
]	2414	2415		|O
age	2415	2418		|O
,	2418	2419		|O
23.5	2419	2423		|O
[	2423	2424		|O
22-30	2424	2429		|O
]	2429	2430		|O
years	2430	2435		|O
;	2435	2436		|O
weight	2436	2442		|O
,	2442	2443		|O
63.3	2443	2447		|O
[	2447	2448		|O
56-68	2448	2453		|O
]	2453	2454		|O
kg	2454	2456		|O
;	2456	2457		|O
height	2458	2464		|O
,	2464	2465		|O
171	2466	2469		|O
[	2470	2471		|O
165-184	2471	2478		|O
]	2478	2479		|O
cm	2480	2482		|O
)	2482	2483		|O
were	2484	2488		|O
enrolled	2489	2497		|O
;	2497	2498		|O
all	2499	2502		|O
completed	2503	2512		|O
the	2513	2516		|O
study	2517	2522		|O
.	2522	2523		|O
No	2524	2526		|O
period	2527	2533		|O
or	2534	2536		|O
sequence	2537	2545		|O
effect	2546	2552		|O
was	2553	2556		|O
observed	2557	2565		|O
.	2565	2566		|O
The	2567	2570		|O
90%	2571	2574		|O
CIs	2575	2578		|O
for	2579	2582		|O
the	2583	2586		|O
log	2587	2590		|O
-	2590	2591		|O
transformed	2591	2602		|O
ratios	2603	2609		|O
of	2610	2612		|O
chlorophenoxyacetic	2613	2632		|O
acid	2633	2637		|O
Cmax	2638	2642		|O
,	2642	2643		|O
AUC0	2644	2648		|O
-	2648	2649		|O
24	2649	2651		|O
,	2651	2652		|O
and	2653	2656		|O
AUC0	2657	2661		|O
-	2661	2662		|O
infinity	2662	2670		|O
were	2671	2675		|O
95.7	2676	2680		|O
to	2681	2683		|O
122.9	2684	2689		|O
,	2689	2690		|O
97.6	2691	2695		|O
to	2696	2698		|O
111.9	2699	2704		|O
,	2704	2705		|O
and	2706	2709		|O
97.8	2710	2714		|O
to	2715	2717		|O
111.7	2718	2723		|O
,	2723	2724		|O
respectively	2725	2737		|O
(	2738	2739		|O
all	2739	2742		|O
,	2742	2743		|O
P	2744	2745		|O
>	2745	2746		|O
0.05	2746	2750		|O
)	2750	2751		|O
.	2751	2752		|O
Similar	2753	2760		|O
results	2761	2768		|O
were	2769	2773		|O
found	2774	2779		|O
for	2780	2783		|O
the	2784	2787		|O
data	2788	2792		|O
without	2793	2800		|O
log	2801	2804		|O
-	2804	2805		|O
transformation	2805	2819		|O
.	2819	2820		|O
No	2821	2823		|O
adverse	2824	2831		|O
events	2832	2838		|O
were	2839	2843		|O
reported	2844	2852		|O
or	2853	2855		|O
observed	2856	2864		|O
during	2865	2871		|O
this	2872	2876		|O
single	2877	2883		|O
-	2883	2884		|O
dose	2884	2888		|O
study	2889	2894		|O
.	2894	2895		|O
CONCLUSIONS	2896	2907		|O
:	2907	2908		|O
In	2909	2911		|O
this	2912	2916		|O
small	2917	2922		|O
study	2923	2928		|O
in	2929	2931		|O
healthy	2932	2939		|O
Chinese	2940	2947		|O
adult	2948	2953		|O
male	2954	2958		|O
volunteers	2959	2969		|O
,	2969	2970		|O
a	2971	2972		|O
single	2973	2979		|O
200	2980	2983		|O
-	2983	2984		|O
mg	2984	2986		|O
dose	2987	2991		|O
of	2992	2994		|O
the	2995	2998		|O
capsule	2999	3006		|O
formulation	3007	3018		|O
was	3019	3022		|O
found	3023	3028		|O
to	3029	3031		|O
be	3032	3034		|O
bioequivalent	3035	3048		|O
to	3049	3051		|O
a	3052	3053		|O
single	3054	3060		|O
200	3061	3064		|O
-	3064	3065		|O
mg	3065	3067		|O
dose	3068	3072		|O
of	3073	3075		|O
the	3076	3079		|O
tablet	3080	3086		|O
formulation	3087	3098		|O
based	3099	3104		|O
on	3105	3107		|O
the	3108	3111		|O
US	3112	3114		|O
FDA	3115	3118		|O
's	3118	3120		|O
regulatory	3121	3131		|O
definition	3132	3142		|O
(	3143	3144		|O
rate	3144	3148		|O
and	3149	3152		|O
extent	3153	3159		|O
of	3160	3162		|O
absorption	3163	3173		|O
)	3173	3174		|O
.	3174	3175		|O
Both	3176	3180		|O
formulations	3181	3193		|O
were	3194	3198		|O
well	3199	3203		|O
tolerated	3204	3213		|O
.	3213	3214		|O

### 18652871
Cumulative	0	10		|O
risk	11	15		|O
assessment	16	26		|O
of	27	29		|O
the	30	33		|O
exposure	34	42		|O
to	43	45		|O
organophosphorus	46	62		|O
and	63	66		|O
carbamate	67	76		|O
insecticides	77	89		|O
in	90	92		|O
the	93	96		|O
Dutch	97	102		|O
diet	103	107		|O
.	107	108		|O
We	110	112		|O
report	113	119		|O
the	120	123		|O
acute	124	129		|O
cumulative	130	140		|O
exposure	141	149		|O
to	150	152		|O
organophosphorus	153	169		|O
insecticides	170	182		|O
(	183	184		|O
OPs	184	187		|O
)	187	188		|O
and	189	192		|O
carbamates	193	203		|O
in	204	206		|O
the	207	210		|O
Dutch	211	216		|O
population	217	227		|O
and	228	231		|O
young	232	237		|O
children	238	246		|O
(	247	248		|O
1-6	248	251		|O
years	252	257		|O
)	257	258		|O
via	259	262		|O
the	263	266		|O
diet	267	271		|O
.	271	272		|O
Residue	273	280		|O
data	281	285		|O
were	286	290		|O
derived	291	298		|O
from	299	303		|O
Dutch	304	309		|O
monitoring	310	320		|O
programmes	321	331		|O
performed	332	341		|O
during	342	348		|O
2003-2005	349	358		|O
,	358	359		|O
and	360	363		|O
food	364	368		|O
consumption	369	380		|O
levels	381	387		|O
from	388	392		|O
the	393	396		|O
Dutch	397	402		|O
National	403	411		|O
Food	412	416		|O
Consumption	417	428		|O
Survey	429	435		|O
1997/1998	436	445		|O
.	445	446		|O
The	447	450		|O
relative	451	459		|O
potency	460	467		|O
factor	468	474		|O
(	475	476		|O
RPF	476	479		|O
)	479	480		|O
approach	481	489		|O
was	490	493		|O
used	494	498		|O
to	499	501		|O
cumulate	502	510		|O
the	511	514		|O
exposure	515	523		|O
to	524	526		|O
OPs	527	530		|O
and	531	534		|O
carbamates	535	545		|O
using	546	551		|O
acephate	552	560		|O
and	561	564		|O
oxamyl	565	571		|O
as	572	574		|O
index	575	580		|O
compound	581	589		|O
respectively	590	602		|O
.	602	603		|O
The	604	607		|O
exposure	608	616		|O
was	617	620		|O
estimated	621	630		|O
using	631	636		|O
the	637	640		|O
probabilistic	641	654		|O
approach	655	663		|O
,	663	664		|O
including	665	674		|O
unit	675	679		|O
variability	680	691		|O
and	692	695		|O
processing	696	706		|O
effects	707	714		|O
.	714	715		|O
We	716	718		|O
demonstrate	719	730		|O
that	731	735		|O
about	736	741		|O
3%	742	744		|O
of	745	747		|O
the	748	751		|O
composite	752	761		|O
samples	762	769		|O
analysed	770	778		|O
for	779	782		|O
OPs	783	786		|O
and	787	790		|O
0.2%	791	795		|O
for	796	799		|O
carbamates	800	810		|O
contain	811	818		|O
combinations	819	831		|O
of	832	834		|O
these	835	840		|O
pesticides	841	851		|O
.	851	852		|O
The	853	856		|O
P99	857	860		|O
.9	860	862		|O
of	863	865		|O
exposure	866	874		|O
to	875	877		|O
OPs	878	881		|O
and	882	885		|O
carbamates	886	896		|O
in	897	899		|O
the	900	903		|O
total	904	909		|O
Dutch	910	915		|O
population	916	926		|O
equals	927	933		|O
23	934	936		|O
and	937	940		|O
0.64	941	945		|O
microg	945	951		|O
/	951	952		|O
kg	952	954		|O
BW	955	957		|O
/	957	958		|O
d	958	959		|O
respectively	960	972		|O
.	972	973		|O
For	974	977		|O
young	978	983		|O
children	984	992		|O
the	993	996		|O
corresponding	997	1010		|O
exposure	1011	1019		|O
levels	1020	1026		|O
are	1027	1030		|O
57	1031	1033		|O
and	1034	1037		|O
1.47	1038	1042		|O
microg	1042	1048		|O
/	1048	1049		|O
kg	1049	1051		|O
BW	1052	1054		|O
/	1054	1055		|O
d	1055	1056		|O
.	1056	1057		|O
When	1058	1062		|O
comparing	1063	1072		|O
the	1073	1076		|O
P99	1077	1080		|O
.9	1080	1082		|O
of	1083	1085		|O
exposure	1086	1094		|O
with	1095	1099		|O
the	1100	1103		|O
ARfD	1104	1108		|O
,	1108	1109		|O
50	1110	1112		|O
and	1113	1116		|O
9microg	1117	1124		|O
/	1124	1125		|O
kg	1125	1127		|O
BW	1128	1130		|O
/	1130	1131		|O
d	1131	1132		|O
for	1133	1136		|O
acephate	1137	1145		|O
and	1146	1149		|O
oxamyl	1150	1156		|O
respectively	1157	1169		|O
,	1169	1170		|O
there	1171	1176		|O
is	1177	1179		|O
only	1180	1184		|O
a	1185	1186		|O
possible	1187	1195		|O
health	1196	1202		|O
risk	1203	1207		|O
for	1208	1211		|O
young	1212	1217		|O
children	1218	1226		|O
.	1226	1227		|O
Spinach	1228	1235		|O
contributed	1236	1247		|O
most	1248	1252		|O
to	1253	1255		|O
the	1256	1259		|O
exposure	1260	1268		|O
to	1269	1271		|O
OPs	1272	1275		|O
in	1276	1278		|O
both	1279	1283		|O
age	1284	1287		|O
groups	1288	1294		|O
,	1294	1295		|O
followed	1296	1304		|O
by	1305	1307		|O
orange	1308	1314		|O
and	1315	1318		|O
mandarin	1319	1327		|O
.	1327	1328		|O
For	1329	1332		|O
carbamates	1333	1343		|O
apple	1344	1349		|O
(	1350	1351		|O
sauce	1351	1356		|O
)	1356	1357		|O
was	1358	1361		|O
the	1362	1365		|O
main	1366	1370		|O
product	1371	1378		|O
determining	1379	1390		|O
the	1391	1394		|O
exposure	1395	1403		|O
.	1403	1404		|O

### 18850280
Hg2+	0	4		|O
and	5	8		|O
Cd2+	9	13		|O
interact	14	22		|O
differently	23	34		|O
with	35	39		|O
biomimetic	40	50		|O
erythrocyte	51	62		|O
membranes	63	72		|O
.	72	73		|O
In	75	77		|O
order	78	83		|O
to	84	86		|O
characterize	87	99		|O
the	100	103		|O
potentially	104	115		|O
deleterious	116	127		|O
effects	128	135		|O
of	136	138		|O
toxic	139	144		|O
Hg	145	147		|O
(	147	148		|O
2+	148	150		|O
)	150	151		|O
and	152	155		|O
Cd	156	158		|O
(	158	159		|O
2+	159	161		|O
)	161	162		|O
on	163	165		|O
lipid	166	171		|O
membranes	172	181		|O
,	181	182		|O
we	183	185		|O
have	186	190		|O
studied	191	198		|O
their	199	204		|O
binding	205	212		|O
to	213	215		|O
liposomes	216	225		|O
whose	226	231		|O
composition	232	243		|O
mimicked	244	252		|O
erythrocyte	253	264		|O
membranes	265	274		|O
.	274	275		|O
Fluorescence	276	288		|O
spectroscopy	289	301		|O
utilizing	302	311		|O
the	312	315		|O
concentration	316	329		|O
dependent	330	339		|O
quenching	340	349		|O
of	350	352		|O
Phen	353	357		|O
Green	358	363		|O
SK	364	366		|O
by	367	369		|O
Hg	370	372		|O
(	372	373		|O
2+	373	375		|O
)	375	376		|O
and	377	380		|O
Cd	381	383		|O
(	383	384		|O
2+	384	386		|O
)	386	387		|O
was	388	391		|O
found	392	397		|O
to	398	400		|O
be	401	403		|O
a	404	405		|O
sensitive	406	415		|O
tool	416	420		|O
to	421	423		|O
probe	424	429		|O
these	430	435		|O
interactions	436	448		|O
at	449	451		|O
metal	452	457		|O
concentrations	458	472		|O
<	473	474		|O
or	475	477		|O
=	478	479		|O
1	479	480		|O
microM	481	487		|O
.	487	488		|O
We	489	491		|O
have	492	496		|O
systematically	497	511		|O
developed	512	521		|O
a	522	523		|O
metal	524	529		|O
binding	530	537		|O
affinity	538	546		|O
assay	547	552		|O
to	553	555		|O
screen	556	562		|O
for	563	566		|O
the	567	570		|O
interactions	571	583		|O
of	584	586		|O
Hg	587	589		|O
(	589	590		|O
2+	590	592		|O
)	592	593		|O
or	594	596		|O
Cd	597	599		|O
(	599	600		|O
2+	600	602		|O
)	602	603		|O
with	604	608		|O
certain	609	616		|O
lipid	617	622		|O
classes	623	630		|O
.	630	631		|O
A	632	633		|O
biomimetic	634	644		|O
liposome	645	653		|O
system	654	660		|O
was	661	664		|O
developed	665	674		|O
that	675	679		|O
contained	680	689		|O
four	690	694		|O
major	695	700		|O
lipid	701	706		|O
classes	707	714		|O
of	715	717		|O
erythrocyte	718	729		|O
membranes	730	739		|O
(	740	741		|O
zwitterionic	741	753		|O
lipids	754	760		|O
:	760	761		|O
phosphatidylcholine	762	781		|O
and	782	785		|O
phosphatidylethanolamine	786	810		|O
;	810	811		|O
negatively	812	822		|O
charged	823	830		|O
:	830	831		|O
phosphatidylserine	832	850		|O
and	851	854		|O
neutral	855	862		|O
:	862	863		|O
cholesterol	864	875		|O
)	875	876		|O
.	876	877		|O
In	878	880		|O
contrast	881	889		|O
to	890	892		|O
Hg	893	895		|O
(	895	896		|O
2+	896	898		|O
)	898	899		|O
,	899	900		|O
which	901	906		|O
preferentially	907	921		|O
bound	922	927		|O
to	928	930		|O
the	931	934		|O
negatively	935	945		|O
charged	946	953		|O
phosphatidylserine	954	972		|O
compared	973	981		|O
to	982	984		|O
the	985	988		|O
zwitterionic	989	1001		|O
components	1002	1012		|O
,	1012	1013		|O
Cd	1014	1016		|O
(	1016	1017		|O
2+	1017	1019		|O
)	1019	1020		|O
bound	1021	1026		|O
stronger	1027	1035		|O
to	1036	1038		|O
the	1039	1042		|O
two	1043	1046		|O
zwitterionic	1047	1059		|O
lipids	1060	1066		|O
.	1066	1067		|O
Thus	1068	1072		|O
,	1072	1073		|O
the	1074	1077		|O
observed	1078	1086		|O
distinct	1087	1095		|O
differences	1096	1107		|O
in	1108	1110		|O
the	1111	1114		|O
binding	1115	1122		|O
affinity	1123	1131		|O
of	1132	1134		|O
Hg	1135	1137		|O
(	1137	1138		|O
2+	1138	1140		|O
)	1140	1141		|O
and	1142	1145		|O
Cd	1146	1148		|O
(	1148	1149		|O
2+	1149	1151		|O
)	1151	1152		|O
for	1153	1156		|O
certain	1157	1164		|O
lipid	1165	1170		|O
classes	1171	1178		|O
together	1179	1187		|O
with	1188	1192		|O
their	1193	1198		|O
known	1199	1204		|O
effects	1205	1212		|O
on	1213	1215		|O
membrane	1216	1224		|O
properties	1225	1235		|O
represent	1236	1245		|O
an	1246	1248		|O
important	1249	1258		|O
first	1259	1264		|O
step	1265	1269		|O
toward	1270	1276		|O
a	1277	1278		|O
better	1279	1285		|O
understanding	1286	1299		|O
the	1300	1303		|O
role	1304	1308		|O
of	1309	1311		|O
these	1312	1317		|O
interactions	1318	1330		|O
in	1331	1333		|O
the	1334	1337		|O
chronic	1338	1345	chronic toxicity	|B-ADVERSE
toxicity	1346	1354		|I-ADVERSE
of	1355	1357		|O
these	1358	1363		|O
metals	1364	1370		|O
.	1370	1371		|O

### 18554312
Efavirenz	0	9		|O
replacement	10	21		|O
by	22	24		|O
immediate	25	34		|O
full	35	39		|O
-	39	40		|O
dose	40	44		|O
nevirapine	45	55		|O
is	56	58		|O
safe	59	63		|O
in	64	66		|O
HIV	67	70		|O
-	70	71		|O
1	71	72		|O
-	72	73		|O
infected	73	81		|O
patients	82	90		|O
in	91	93		|O
Cambodia	94	102		|O
.	102	103		|O
BACKGROUND	105	115		|O
:	115	116		|O
Efavirenz	117	126		|O
is	127	129		|O
used	130	134		|O
for	135	138		|O
the	139	142		|O
antiretroviral	143	157		|O
treatment	158	167		|O
of	168	170		|O
HIV	171	174	HIV	|B-DISEASE
/	174	175		|O
tuberculosis	175	187	tuberculosis	|B-DISEASE
-	187	188		|O
coinfected	188	198		|O
patients	199	207		|O
in	208	210		|O
developing	211	221		|O
countries	222	231		|O
.	231	232		|O
A	233	234		|O
switch	235	241		|O
to	242	244		|O
nevirapine	245	255		|O
is	256	258		|O
regularly	259	268		|O
carried	269	276		|O
out	277	280		|O
because	281	288		|O
of	289	291		|O
the	292	295		|O
cost	296	300		|O
and	301	304		|O
side	305	309		|O
effects	310	317		|O
of	318	320		|O
efavirenz	321	330		|O
.	330	331		|O
Pharmacokinetic	332	347		|O
studies	348	355		|O
suggested	356	365		|O
that	366	370		|O
nevirapine	371	381		|O
should	382	388		|O
be	389	391		|O
initiated	392	401		|O
at	402	404		|O
full	405	409		|O
dose	410	414		|O
when	415	419		|O
used	420	424		|O
as	425	427		|O
a	428	429		|O
substitute	430	440		|O
for	441	444		|O
efavirenz	445	454		|O
.	454	455		|O
OBJECTIVES	456	466		|O
:	466	467		|O
The	468	471		|O
aim	472	475		|O
of	476	478		|O
this	479	483		|O
study	484	489		|O
was	490	493		|O
to	494	496		|O
measure	497	504		|O
the	505	508		|O
cumulative	509	519		|O
incidence	520	529		|O
of	530	532		|O
adverse	533	540		|O
events	541	547		|O
(	548	549		|O
AEs	549	552		|O
)	552	553		|O
related	554	561		|O
to	562	564		|O
nevirapine	565	575		|O
in	576	578		|O
patients	579	587		|O
switched	588	596		|O
from	597	601		|O
efavirenz	602	611		|O
to	612	614		|O
immediate	615	624		|O
full	625	629		|O
-	629	630		|O
dose	630	634		|O
nevirapine	635	645		|O
(	646	647		|O
FDN	647	650		|O
)	650	651		|O
.	651	652		|O
METHODS	653	660		|O
:	660	661		|O
In	662	664		|O
2001	665	669		|O
an	670	672		|O
antiretroviral	673	687		|O
treatment	688	697		|O
programme	698	707		|O
was	708	711		|O
initiated	712	721		|O
with	722	726		|O
the	727	730		|O
first	731	736		|O
-	736	737		|O
line	737	741		|O
regimen	742	749		|O
stavudine	750	759		|O
,	759	760		|O
lamivudine	761	771		|O
and	772	775		|O
efavirenz	776	785		|O
.	785	786		|O
In	787	789		|O
2003	790	794		|O
,	794	795		|O
the	796	799		|O
fixed	800	805		|O
-	805	806		|O
dose	806	810		|O
combination	811	822		|O
of	823	825		|O
stavudine	826	835		|O
,	835	836		|O
lamivudine	837	847		|O
and	848	851		|O
nevirapine	852	862		|O
was	863	866		|O
recommended	867	878		|O
.	878	879		|O
Thus	880	884		|O
,	884	885		|O
first	886	891		|O
-	891	892		|O
line	892	896		|O
therapy	897	904		|O
was	905	908		|O
changed	909	916		|O
and	917	920		|O
FDN	921	924		|O
was	925	928		|O
initiated	929	938		|O
when	939	943		|O
patients	944	952		|O
were	953	957		|O
switched	958	966		|O
from	967	971		|O
efavirenz	972	981		|O
to	982	984		|O
nevirapine	985	995		|O
.	995	996		|O
RESULTS	997	1004		|O
:	1004	1005		|O
Between	1006	1013		|O
April	1014	1019		|O
and	1020	1023		|O
December	1024	1032		|O
2004	1033	1037		|O
,	1037	1038		|O
394	1039	1042		|O
patients	1043	1051		|O
were	1052	1056		|O
switched	1057	1065		|O
from	1066	1070		|O
efavirenz	1071	1080		|O
to	1081	1083		|O
FDN	1084	1087		|O
.	1087	1088		|O
The	1089	1092		|O
cumulative	1093	1103		|O
incidence	1104	1113		|O
of	1114	1116		|O
AEs	1117	1120		|O
related	1121	1128		|O
to	1129	1131		|O
nevirapine	1132	1142		|O
was	1143	1146		|O
13.2%	1147	1152		|O
[	1153	1154		|O
95%	1154	1157		|O
confidence	1158	1168		|O
interval	1169	1177		|O
(	1178	1179		|O
CI	1179	1181		|O
)	1181	1182		|O
10.2-16.7	1183	1192		|O
]	1192	1193		|O
and	1194	1197		|O
that	1198	1202		|O
of	1203	1205		|O
severe	1206	1212		|O
AEs	1213	1216		|O
was	1217	1220		|O
8.9%	1221	1225		|O
(	1226	1227		|O
95%	1227	1230		|O
CI	1231	1233		|O
6.5-11.9	1234	1242		|O
)	1242	1243		|O
.	1243	1244		|O
In	1245	1247		|O
women	1248	1253		|O
the	1254	1257		|O
incidence	1258	1267		|O
of	1268	1270		|O
AEs	1271	1274		|O
was	1275	1278		|O
17.6%	1279	1284		|O
(	1285	1286		|O
95%	1286	1289		|O
CI	1290	1292		|O
12.1-24.3	1293	1302		|O
)	1302	1303		|O
and	1304	1307		|O
that	1308	1312		|O
of	1313	1315		|O
severe	1316	1322		|O
AEs	1323	1326		|O
was	1327	1330		|O
12.2%	1331	1336		|O
(	1337	1338		|O
95%	1338	1341		|O
CI	1342	1344		|O
7.7-18.2	1345	1353		|O
)	1353	1354		|O
.	1354	1355		|O
CONCLUSIONS	1356	1367		|O
:	1367	1368		|O
Our	1369	1372		|O
results	1373	1380		|O
indicate	1381	1389		|O
that	1390	1394		|O
an	1395	1397		|O
FDN	1398	1401		|O
switch	1402	1408		|O
from	1409	1413		|O
efavirenz	1414	1423		|O
does	1424	1428		|O
not	1429	1432		|O
appear	1433	1439		|O
to	1440	1442		|O
result	1443	1449		|O
in	1450	1452		|O
more	1453	1457		|O
AEs	1458	1461		|O
than	1462	1466		|O
when	1467	1471		|O
nevirapine	1472	1482		|O
is	1483	1485		|O
initiated	1486	1495		|O
with	1496	1500		|O
escalating	1501	1511		|O
doses	1512	1517		|O
.	1517	1518		|O
These	1519	1524		|O
data	1525	1529		|O
are	1530	1533		|O
particularly	1534	1546		|O
relevant	1547	1555		|O
in	1556	1558		|O
resource	1559	1567		|O
-	1567	1568		|O
limited	1568	1575		|O
settings	1576	1584		|O
.	1584	1585		|O

### 18702618
Dronedarone	0	11		|O
:	11	12		|O
a	13	14		|O
new	15	18		|O
treatment	19	28		|O
for	29	32		|O
atrial	33	39	atrial fibrillation	|B-DISEASE
fibrillation	40	52		|I-DISEASE
.	52	53		|O
Dronedarone	55	66		|O
.	66	67		|O
Dronedarone	68	79		|O
is	80	82		|O
a	83	84		|O
benzofuran	85	95		|O
derivative	96	106		|O
pharmacologically	107	124		|O
related	125	132		|O
to	133	135		|O
amiodarone	136	146		|O
but	147	150		|O
without	151	158		|O
the	159	162		|O
iodine	163	169		|O
moiety	170	176		|O
.	176	177		|O
It	178	180		|O
is	181	183		|O
designed	184	192		|O
for	193	196		|O
the	197	200		|O
treatment	201	210		|O
of	211	213		|O
atrial	214	220	atrial fibrillation	|B-DISEASE
fibrillation	221	233		|I-DISEASE
and	234	237		|O
atrial	238	244	atrial flutter	|B-DISEASE
flutter	245	252		|I-DISEASE
.	252	253		|O
Historically	254	266		|O
,	266	267		|O
amiodarone	268	278		|O
has	279	282		|O
proved	283	289		|O
most	290	294		|O
effective	295	304		|O
in	305	307		|O
maintaining	308	319		|O
sinus	320	325		|O
rhythm	326	332		|O
and	333	336		|O
has	337	340		|O
been	341	345		|O
used	346	350		|O
safely	351	357		|O
in	358	360		|O
patients	361	369		|O
with	370	374		|O
advanced	375	383		|O
heart	384	389	heart failure	|B-DISEASE
failure	390	397		|I-DISEASE
.	397	398		|O
However	399	406		|O
,	406	407		|O
its	408	411		|O
use	412	415		|O
has	416	419		|O
been	420	424		|O
limited	425	432		|O
by	433	435		|O
cumulative	436	446		|O
and	447	450		|O
often	451	456		|O
irreversible	457	469	irreversible organ toxicity	|B-ADVERSE
organ	470	475		|I-ADVERSE
toxicity	476	484		|I-ADVERSE
,	484	485		|O
especially	486	496		|O
in	497	499		|O
younger	500	507		|O
patients	508	516		|O
.	516	517		|O
Dronedarone	518	529		|O
was	530	533		|O
developed	534	543		|O
in	544	546		|O
an	547	549		|O
effort	550	556		|O
to	557	559		|O
provide	560	567		|O
equivalent	568	578		|O
efficacy	579	587		|O
and	588	591		|O
safety	592	598		|O
with	599	603		|O
less	604	608		|O
toxicity	609	617		|O
.	617	618		|O
Dronedarone	619	630		|O
has	631	634		|O
proved	635	641		|O
efficacious	642	653		|O
without	654	661		|O
toxic	662	667		|O
or	668	670		|O
proarrhythmic	671	684		|O
effects	685	692		|O
and	693	696		|O
has	697	700		|O
minimal	701	708		|O
side	709	713		|O
effects	714	721		|O
,	721	722		|O
but	723	726		|O
remaining	727	736		|O
concerns	737	745		|O
exist	746	751		|O
regarding	752	761		|O
its	762	765		|O
use	766	769		|O
in	770	772		|O
patients	773	781		|O
with	782	786		|O
advanced	787	795		|O
heart	796	801	heart failure	|B-DISEASE
failure	802	809		|I-DISEASE
.	809	810		|O

### 18614615
Do	0	2		|O
doctors	3	10		|O
discuss	11	18		|O
fertility	19	28		|O
issues	29	35		|O
before	36	42		|O
they	43	47		|O
treat	48	53		|O
young	54	59		|O
patients	60	68		|O
with	69	73		|O
cancer	74	80	cancer	|B-DISEASE
?	80	81		|O
BACKGROUND	83	93		|O
:	93	94		|O
Many	95	99		|O
children	100	108		|O
treated	109	116		|O
for	117	120		|O
cancer	121	127	cancer	|B-DISEASE
are	128	131		|O
at	132	134		|O
risk	135	139		|O
of	140	142		|O
infertility	143	154	infertility	|B-ADVERSE
,	154	155		|O
but	156	159		|O
for	160	163		|O
girls	164	169		|O
and	170	173		|O
prepubertal	174	185		|O
boys	186	190		|O
,	190	191		|O
all	192	195		|O
fertility	196	205		|O
preservation	206	218		|O
techniques	219	229		|O
remain	230	236		|O
experimental	237	249		|O
.	249	250		|O
We	251	253		|O
have	254	258		|O
assessed	259	267		|O
UK	268	270		|O
practice	271	279		|O
relating	280	288		|O
to	289	291		|O
information	292	303		|O
provision	304	313		|O
about	314	319		|O
the	320	323		|O
effects	324	331		|O
of	332	334		|O
cancer	335	341	cancer	|B-DISEASE
treatment	342	351		|O
on	352	354		|O
fertility	355	364		|O
and	365	368		|O
options	369	376		|O
for	377	380		|O
fertility	381	390		|O
preservation	391	403		|O
.	403	404		|O
METHODS	405	412		|O
:	412	413		|O
Paediatric	414	424		|O
oncologists	425	436		|O
prospectively	437	450		|O
completed	451	460		|O
a	461	462		|O
data	463	467		|O
form	468	472		|O
for	473	476		|O
each	477	481		|O
new	482	485		|O
patient	486	493		|O
registered	494	504		|O
over	505	509		|O
a	510	511		|O
12	512	514		|O
month	515	520		|O
period	521	527		|O
.	527	528		|O
RESULTS	529	536		|O
:	536	537		|O
Data	538	542		|O
were	543	547		|O
available	548	557		|O
on	558	560		|O
1030	561	565		|O
patients	566	574		|O
(	575	576		|O
68%	576	579		|O
of	580	582		|O
total	583	588		|O
registered	589	599		|O
)	599	600		|O
.	600	601		|O
The	602	605		|O
effect	606	612		|O
of	613	615		|O
cancer	616	622	cancer	|B-DISEASE
treatment	623	632		|O
on	633	635		|O
fertility	636	645		|O
was	646	649		|O
discussed	650	659		|O
with	660	664		|O
63%	665	668		|O
of	669	671		|O
patients	672	680		|O
.	680	681		|O
Of	682	684		|O
these	685	690		|O
,	690	691		|O
61%	692	695		|O
were	696	700		|O
judged	701	707		|O
to	708	710		|O
be	711	713		|O
at	714	716		|O
high	717	721		|O
or	722	724		|O
medium	725	731		|O
risk	732	736		|O
of	737	739		|O
fertility	740	749		|O
problems	750	758		|O
.	758	759		|O
Discussions	760	771		|O
took	772	776		|O
place	777	782		|O
more	783	787		|O
commonly	788	796		|O
with	797	801		|O
boys	802	806		|O
than	807	811		|O
girls	812	817		|O
;	817	818		|O
the	819	822		|O
commonest	823	832		|O
reason	833	839		|O
for	840	843		|O
discussion	844	854		|O
not	855	858		|O
occurring	859	868		|O
was	869	872		|O
young	873	878		|O
age	879	882		|O
.	882	883		|O
The	884	887		|O
majority	888	896		|O
(	897	898		|O
83%	898	901		|O
)	901	902		|O
of	903	905		|O
post	906	910		|O
-	910	911		|O
pubertal	911	919		|O
boys	920	924		|O
assessed	925	933		|O
as	934	936		|O
high	937	941		|O
/	941	942		|O
medium	942	948		|O
risk	949	953		|O
of	954	956		|O
infertility	957	968	infertility	|B-ADVERSE
were	969	973		|O
referred	974	982		|O
for	983	986		|O
semen	987	992		|O
cryopreservation	993	1009		|O
.	1009	1010		|O
This	1011	1015		|O
rate	1016	1020		|O
fell	1021	1025		|O
to	1026	1028		|O
39%	1029	1032		|O
of	1033	1035		|O
those	1036	1041		|O
in	1042	1044		|O
early	1045	1050		|O
puberty	1051	1058		|O
.	1058	1059		|O
Only	1060	1064		|O
1%	1065	1067		|O
(	1068	1069		|O
n	1069	1070		|O
=	1070	1071		|O
4	1071	1072		|O
)	1072	1073		|O
of	1074	1076		|O
girls	1077	1082		|O
were	1083	1087		|O
referred	1088	1096		|O
to	1097	1099		|O
an	1100	1102		|O
assisted	1103	1111		|O
conception	1112	1122		|O
unit	1123	1127		|O
.	1127	1128		|O
CONCLUSIONS	1129	1140		|O
:	1140	1141		|O
These	1142	1147		|O
data	1148	1152		|O
indicate	1153	1161		|O
a	1162	1163		|O
high	1164	1168		|O
awareness	1169	1178		|O
of	1179	1181		|O
the	1182	1185		|O
potential	1186	1195		|O
adverse	1196	1203		|O
effects	1204	1211		|O
of	1212	1214		|O
therapy	1215	1222		|O
on	1223	1225		|O
fertility	1226	1235		|O
among	1236	1241		|O
UK	1242	1244		|O
paediatric	1245	1255		|O
oncologists	1256	1267		|O
.	1267	1268		|O
High	1269	1273		|O
referral	1274	1282		|O
rates	1283	1288		|O
for	1289	1292		|O
older	1293	1298		|O
boys	1299	1303		|O
indicate	1304	1312		|O
that	1313	1317		|O
current	1318	1325		|O
guidelines	1326	1336		|O
are	1337	1340		|O
followed	1341	1349		|O
,	1349	1350		|O
but	1351	1354		|O
there	1355	1360		|O
is	1361	1363		|O
a	1364	1365		|O
need	1366	1370		|O
for	1371	1374		|O
fertility	1375	1384		|O
preservation	1385	1397		|O
techniques	1398	1408		|O
for	1409	1412		|O
girls	1413	1418		|O
and	1419	1422		|O
younger	1423	1430		|O
boys	1431	1435		|O
.	1435	1436		|O

### 18599893
Risk	0	4		|O
of	5	7		|O
thrombogenicity	8	23	thrombogenicity	|B-ADVERSE
among	24	29		|O
nonionic	30	38		|O
radiocontrast	39	52		|O
agents	53	59		|O
.	59	60		|O
Several	62	69		|O
contrast	70	78		|O
agents	79	85		|O
have	86	90		|O
been	91	95		|O
approved	96	104		|O
in	105	107		|O
the	108	111		|O
United	112	118		|O
States	119	125		|O
for	126	129		|O
radiographic	130	142		|O
imaging	143	150		|O
purposes	151	159		|O
.	159	160		|O
Most	161	165		|O
of	166	168		|O
the	169	172		|O
older	173	178		|O
ionic	179	184		|O
,	184	185		|O
high	186	190		|O
-	190	191		|O
osmolar	191	198		|O
contrast	199	207		|O
agents	208	214		|O
are	215	218		|O
no	219	221		|O
longer	222	228		|O
used	229	233		|O
because	234	241		|O
of	242	244		|O
their	245	250		|O
side	251	255		|O
effect	256	262		|O
profile	263	270		|O
.	270	271		|O
Therefore	272	281		|O
,	281	282		|O
newer	283	288		|O
nonionic	289	297		|O
,	297	298		|O
low	299	302		|O
or	303	305		|O
iso	306	309		|O
-	309	310		|O
osmolar	310	317		|O
contrast	318	326		|O
agents	327	333		|O
have	334	338		|O
been	339	343		|O
widely	344	350		|O
accepted	351	359		|O
as	360	362		|O
an	363	365		|O
alternative	366	377		|O
due	378	381		|O
to	382	384		|O
their	385	390		|O
improved	391	399		|O
tolerability	400	412		|O
and	413	416		|O
safety	417	423		|O
.	423	424		|O
We	425	427		|O
investigated	428	440		|O
the	441	444		|O
thrombogenicity	445	460	thrombogenicity	|B-ADVERSE
of	461	463		|O
the	464	467		|O
6	468	469		|O
different	470	479		|O
nonionic	480	488		|O
radiocontrast	489	502		|O
media	503	508		|O
in	509	511		|O
terms	512	517		|O
of	518	520		|O
their	521	526		|O
platelet	527	535		|O
reactivity	536	546		|O
and	547	550		|O
noted	551	556		|O
some	557	561		|O
minor	562	567		|O
differences	568	579		|O
among	580	585		|O
them	586	590		|O
.	590	591		|O
In	592	594		|O
the	595	598		|O
50%	599	602		|O
contrast	603	611		|O
concentration	612	625		|O
group	626	631		|O
,	631	632		|O
all	633	636		|O
of	637	639		|O
the	640	643		|O
nonionic	644	652		|O
contrast	653	661		|O
agents	662	668		|O
inhibited	669	678		|O
aggregation	679	690		|O
,	690	691		|O
whereas	692	699		|O
in	700	702		|O
the	703	706		|O
10%	707	710		|O
contrast	711	719		|O
concentration	720	733		|O
group	734	739		|O
,	739	740		|O
all	741	744		|O
agents	745	751		|O
showed	752	758		|O
similar	759	766		|O
aggregation	767	778		|O
curves	779	785		|O
in	786	788		|O
comparison	789	799		|O
to	800	802		|O
the	803	806		|O
normal	807	813		|O
control	814	821		|O
.	821	822		|O
At	823	825		|O
50%	826	829		|O
contrast	830	838		|O
concentration	839	852		|O
,	852	853		|O
the	854	857		|O
inhibitory	858	868		|O
effect	869	875		|O
of	876	878		|O
aggregation	879	890		|O
appeared	891	899		|O
to	900	902		|O
be	903	905		|O
related	906	913		|O
to	914	916		|O
the	917	920		|O
inhibition	921	931		|O
of	932	934		|O
calcium	935	942		|O
mobilization	943	955		|O
,	955	956		|O
which	957	962		|O
may	963	966		|O
be	967	969		|O
one	970	973		|O
of	974	976		|O
the	977	980		|O
mechanistic	981	992		|O
effects	993	1000		|O
.	1000	1001		|O

### 18558361
Natural	0	7		|O
anti	8	12		|O
-	12	13		|O
Siglec	13	19		|O
autoantibodies	20	34		|O
mediate	35	42		|O
potential	43	52		|O
immunoregulatory	53	69		|O
mechanisms	70	80		|O
:	80	81		|O
implications	82	94		|O
for	95	98		|O
the	99	102		|O
clinical	103	111		|O
use	112	115		|O
of	116	118		|O
intravenous	119	130		|O
immunoglobulins	131	146		|O
(	147	148		|O
IVIg	148	152		|O
)	152	153		|O
.	153	154		|O
Human	156	161		|O
intravenous	162	173		|O
immunoglobulins	174	189		|O
(	190	191		|O
IVIg	191	195		|O
)	195	196		|O
contain	197	204		|O
natural	205	212		|O
autoantibodies	213	227		|O
against	228	235		|O
the	236	239		|O
inhibitory	240	250		|O
lectin	251	257		|O
-	257	258		|O
receptors	258	267		|O
Siglec	268	274		|O
-	274	275		|O
8	275	276		|O
and	277	280		|O
Siglec	281	287		|O
-	287	288		|O
9	288	289		|O
.	289	290		|O
These	291	296		|O
two	297	300		|O
members	301	308		|O
of	309	311		|O
the	312	315		|O
Siglec	316	322		|O
family	323	329		|O
are	330	333		|O
known	334	339		|O
to	340	342		|O
mediate	343	350		|O
both	351	355		|O
inhibitory	356	366		|O
and	367	370		|O
death	371	376		|O
signals	377	384		|O
.	384	385		|O
Here	386	390		|O
,	390	391		|O
we	392	394		|O
discuss	395	402		|O
recent	403	409		|O
findings	410	418		|O
regarding	419	428		|O
the	429	432		|O
cytotoxic	433	442	cytotoxic effects	|B-ADVERSE
effects	443	450		|I-ADVERSE
of	451	453		|O
natural	454	461		|O
anti	462	466		|O
-	466	467		|O
Siglec	467	473		|O
autoantibodies	474	488		|O
on	489	491		|O
both	492	496		|O
neutrophils	497	508		|O
and	509	512		|O
eosinophils	513	524		|O
,	524	525		|O
and	526	529		|O
present	530	537		|O
the	538	541		|O
concept	542	549		|O
of	550	552		|O
a	553	554		|O
novel	555	560		|O
regulatory	561	571		|O
mechanism	572	581		|O
exhibiting	582	592		|O
anti	593	597		|O
-	597	598		|O
inflammatory	598	610		|O
properties	611	621		|O
.	621	622		|O
Consequently	623	635		|O
,	635	636		|O
IVIg	637	641		|O
may	642	645		|O
amplify	646	653		|O
this	654	658		|O
regulatory	659	669		|O
pathway	670	677		|O
by	678	680		|O
increasing	681	691		|O
the	692	695		|O
concentration	696	709		|O
of	710	712		|O
natural	713	720		|O
anti	721	725		|O
-	725	726		|O
Siglec	726	732		|O
autoantibodies	733	747		|O
in	748	750		|O
blood	751	756		|O
and	757	760		|O
tissues	761	768		|O
.	768	769		|O

### 18824249
Orally	0	6		|O
administered	7	19		|O
apple	20	25		|O
procyanidins	26	38		|O
protect	39	46		|O
against	47	54		|O
experimental	55	67		|O
inflammatory	68	80	inflammatory bowel disease	|B-DISEASE
bowel	81	86		|I-DISEASE
disease	87	94		|I-DISEASE
in	95	97		|O
mice	98	102		|O
.	102	103		|O
Apple	105	110		|O
procyanidins	111	123		|O
(	124	125		|O
ACT	125	128		|O
)	128	129		|O
is	130	132		|O
a	133	134		|O
natural	135	142		|O
biologically	143	155		|O
active	156	162		|O
compound	163	171		|O
extracted	172	181		|O
from	182	186		|O
apple	187	192		|O
.	192	193		|O
Our	194	197		|O
recent	198	204		|O
studies	205	212		|O
have	213	217		|O
shown	218	223		|O
that	224	228		|O
ACT	229	232		|O
ameliorates	233	244		|O
the	245	248		|O
symptoms	249	257		|O
of	258	260		|O
atopic	261	267	atopic dermatitis	|B-DISEASE
dermatitis	268	278		|I-DISEASE
and	279	282		|O
inhibits	283	291		|O
food	292	296		|O
-	296	297		|O
allergen	297	305		|O
-	305	306		|O
induced	306	313		|O
oral	314	318		|O
sensitization	319	332		|O
.	332	333		|O
The	334	337		|O
aim	338	341		|O
of	342	344		|O
this	345	349		|O
study	350	355		|O
was	356	359		|O
to	360	362		|O
investigate	363	374		|O
the	375	378		|O
potential	379	388		|O
protective	389	399		|O
effect	400	406		|O
and	407	410		|O
mechanism	411	420		|O
of	421	423		|O
action	424	430		|O
of	431	433		|O
ACT	434	437		|O
in	438	440		|O
a	441	442		|O
murine	443	449		|O
model	450	455		|O
of	456	458		|O
inflammatory	459	471	inflammatory bowel disease	|B-DISEASE
bowel	472	477		|I-DISEASE
disease	478	485		|I-DISEASE
.	485	486		|O
We	487	489		|O
investigated	490	502		|O
the	503	506		|O
preventive	507	517		|O
effects	518	525		|O
of	526	528		|O
ACT	529	532		|O
in	533	535		|O
experimental	536	548		|O
models	549	555		|O
of	556	558		|O
colitis	559	566	colitis	|B-ADVERSE
induced	567	574		|O
by	575	577		|O
dextran	578	585		|O
sulfate	586	593		|O
sodium	594	600		|O
(	601	602		|O
DSS	602	605		|O
)	605	606		|O
or	607	609		|O
oxazolone	610	619		|O
.	619	620		|O
Oral	621	625		|O
administration	626	640		|O
of	641	643		|O
ACT	644	647		|O
before	648	654		|O
DSS	655	658		|O
treatment	659	668		|O
attenuated	669	679		|O
the	680	683		|O
DSS	684	687		|O
-	687	688		|O
induced	688	695		|O
mortality	696	705		|O
rate	706	710		|O
and	711	714		|O
decreased	715	724		|O
body	725	729		|O
weight	730	736		|O
loss	737	741		|O
.	741	742		|O
ACT	743	746		|O
also	747	751		|O
prevented	752	761		|O
the	762	765		|O
body	766	770		|O
weight	771	777		|O
loss	778	782		|O
associated	783	793		|O
with	794	798		|O
oxazolone	799	808		|O
-	808	809		|O
induced	809	816		|O
colitis	817	824	colitis	|B-ADVERSE
.	824	825		|O
Next	826	830		|O
we	831	833		|O
examined	834	842		|O
the	843	846		|O
effect	847	853		|O
of	854	856		|O
ACT	857	860		|O
on	861	863		|O
intraepithelial	864	879		|O
lymphocytes	880	891		|O
(	892	893		|O
IEL	893	896		|O
)	896	897		|O
,	897	898		|O
which	899	904		|O
is	905	907		|O
a	908	909		|O
major	910	915		|O
T	916	917		|O
cell	918	922		|O
population	923	933		|O
in	934	936		|O
the	937	940		|O
intestine	941	950		|O
.	950	951		|O
Oral	952	956		|O
administration	957	971		|O
of	972	974		|O
ACT	975	978		|O
increased	979	988		|O
the	989	992		|O
proportions	993	1004		|O
of	1005	1007		|O
TCRgammadelta	1008	1021		|O
and	1022	1025		|O
TCRalphabeta	1026	1038		|O
-	1038	1039		|O
CD8alphaalpha	1039	1052		|O
T	1053	1054		|O
cells	1055	1060		|O
in	1061	1063		|O
IEL	1064	1067		|O
and	1068	1071		|O
suppressed	1072	1082		|O
interferon	1083	1093		|O
gamma	1094	1099		|O
synthesis	1100	1109		|O
in	1110	1112		|O
stimulated	1113	1123		|O
IEL	1124	1127		|O
.	1127	1128		|O
In	1129	1131		|O
addition	1132	1140		|O
,	1140	1141		|O
ACT	1142	1145		|O
inhibited	1146	1155		|O
phorbol	1156	1163		|O
12	1164	1166		|O
-	1166	1167		|O
myristate	1167	1176		|O
13	1177	1179		|O
-	1179	1180		|O
acetate	1180	1187		|O
-	1187	1188		|O
induced	1188	1195		|O
secretion	1196	1205		|O
of	1206	1208		|O
interleukin	1209	1220		|O
8	1221	1222		|O
(	1223	1224		|O
IL	1224	1226		|O
-	1226	1227		|O
8	1227	1228		|O
)	1228	1229		|O
in	1230	1232		|O
intestinal	1233	1243		|O
epithelial	1244	1254		|O
cells	1255	1260		|O
.	1260	1261		|O
The	1262	1265		|O
combined	1266	1274		|O
anti	1275	1279		|O
-	1279	1280		|O
inflammatory	1280	1292		|O
and	1293	1296		|O
immunomodulatory	1297	1313		|O
effects	1314	1321		|O
of	1322	1324		|O
ACT	1325	1328		|O
on	1329	1331		|O
intestinal	1332	1342		|O
epithelial	1343	1353		|O
cells	1354	1359		|O
and	1360	1363		|O
IEL	1364	1367		|O
suggest	1368	1375		|O
that	1376	1380		|O
it	1381	1383		|O
may	1384	1387		|O
be	1388	1390		|O
an	1391	1393		|O
effective	1394	1403		|O
oral	1404	1408		|O
preventive	1409	1419		|O
agent	1420	1425		|O
for	1426	1429		|O
inflammatory	1430	1442	inflammatory bowel diseases	|B-DISEASE
bowel	1443	1448		|I-DISEASE
diseases	1449	1457		|I-DISEASE
.	1457	1458		|O

### 18771055
Mitochondrial	0	13		|O
RNA	14	17		|O
and	18	21		|O
DNA	22	25		|O
alterations	26	37		|O
in	38	40		|O
HIV	41	44	HIV lipoatrophy	|B-DISEASE
lipoatrophy	45	56		|I-DISEASE
are	57	60		|O
linked	61	67		|O
to	68	70		|O
antiretroviral	71	85		|O
therapy	86	93		|O
and	94	97		|O
not	98	101		|O
to	102	104		|O
HIV	105	108	HIV infection	|B-DISEASE
infection	109	118		|I-DISEASE
.	118	119		|O
BACKGROUND	121	131		|O
:	131	132		|O
The	133	136		|O
aim	137	140		|O
of	141	143		|O
this	144	148		|O
study	149	154		|O
was	155	158		|O
to	159	161		|O
assess	162	168		|O
the	169	172		|O
effect	173	179		|O
of	180	182		|O
antiretroviral	183	197		|O
therapy	198	205		|O
(	206	207		|O
ART	207	210		|O
)	210	211		|O
versus	212	218		|O
HIV	219	222		|O
on	223	225		|O
mitochondria	226	238		|O
in	239	241		|O
fat	242	245		|O
.	245	246		|O
METHODS	247	254		|O
:	254	255		|O
Subcutaneous	256	268		|O
fat	269	272		|O
was	273	276		|O
collected	277	286		|O
from	287	291		|O
45	292	294		|O
HIV	295	298		|O
-	298	299		|O
infected	299	307		|O
patients	308	316		|O
on	317	319		|O
ART	320	323		|O
with	324	328		|O
lipoatrophy	329	340	lipoatrophy	|B-DISEASE
,	340	341		|O
11	342	344		|O
HIV	345	348		|O
-	348	349		|O
infected	349	357		|O
ART	358	361		|O
-	361	362		|O
naive	362	367		|O
patients	368	376		|O
and	377	380		|O
nine	381	385		|O
healthy	386	393		|O
controls	394	402		|O
.	402	403		|O
Three	404	409		|O
mitochondrial	410	423		|O
transcripts	424	435		|O
:	435	436		|O
NADH	437	441		|O
dehydrogenase	442	455		|O
subunit	456	463		|O
1	464	465		|O
(	466	467		|O
ND1	467	470		|O
)	470	471		|O
,	471	472		|O
cytochrome	473	483		|O
B	484	485		|O
(	486	487		|O
CYTB	487	491		|O
)	491	492		|O
and	493	496		|O
NADH	497	501		|O
dehydrogenase	502	515		|O
subunit	516	523		|O
6	524	525		|O
(	526	527		|O
ND6	527	530		|O
)	530	531		|O
genes	532	537		|O
were	538	542		|O
quantitated	543	554		|O
using	555	560		|O
TaqMan	561	567		|O
probes	568	574		|O
and	575	578		|O
normalized	579	589		|O
to	590	592		|O
nuclear	593	600		|O
-	600	601		|O
encoded	601	608		|O
ribosomal	609	618		|O
L13	619	622		|O
.	622	623		|O
RESULTS	624	631		|O
:	631	632		|O
ND1	633	636		|O
/	636	637		|O
L13	637	640		|O
and	641	644		|O
CYTB	645	649		|O
/	649	650		|O
L13	650	653		|O
were	654	658		|O
lower	659	664		|O
in	665	667		|O
HIV	668	671		|O
-	671	672		|O
positive	672	680		|O
patients	681	689		|O
on	690	692		|O
ART	693	696		|O
with	697	701		|O
lipoatrophy	702	713	lipoatrophy	|B-DISEASE
versus	714	720		|O
ART	721	724		|O
-	724	725		|O
naive	725	730		|O
patients	731	739		|O
(	740	741		|O
3.4	741	744		|O
versus	745	751		|O
7.2	752	755		|O
[	756	757		|O
P	757	758		|O
=	758	759		|O
0.017	759	764		|O
]	764	765		|O
and	766	769		|O
2.5	770	773		|O
versus	774	780		|O
4.6	781	784		|O
[	785	786		|O
P	786	787		|O
=	787	788		|O
0.006	788	793		|O
]	793	794		|O
,	794	795		|O
respectively	796	808		|O
)	808	809		|O
.	809	810		|O
No	811	813		|O
difference	814	824		|O
was	825	828		|O
found	829	834		|O
between	835	842		|O
ART	843	846		|O
-	846	847		|O
naive	847	852		|O
patients	853	861		|O
and	862	865		|O
controls	866	874		|O
(	875	876		|O
P	876	877		|O
>	877	878		|O
0.70	878	882		|O
)	882	883		|O
.	883	884		|O
ND6	885	888		|O
/	888	889		|O
L13	889	892		|O
was	893	896		|O
similar	897	904		|O
between	905	912		|O
all	913	916		|O
groups	917	923		|O
.	923	924		|O
Dual	925	929		|O
-	929	930		|O
energy	930	936		|O
X	937	938		|O
-	938	939		|O
ray	939	942		|O
absorptiometry	943	957		|O
-	957	958		|O
measured	958	966		|O
limb	967	971		|O
fat	972	975		|O
and	976	979		|O
mitochondrial	980	993		|O
DNA	994	997		|O
in	998	1000		|O
fat	1001	1004		|O
were	1005	1009		|O
also	1010	1014		|O
lower	1015	1020		|O
in	1021	1023		|O
HIV	1024	1027		|O
-	1027	1028		|O
positive	1028	1036		|O
patients	1037	1045		|O
on	1046	1048		|O
ART	1049	1052		|O
with	1053	1057		|O
lipoatrophy	1058	1069	lipoatrophy	|B-DISEASE
versus	1070	1076		|O
HIV	1077	1080		|O
-	1080	1081		|O
infected	1081	1089		|O
,	1089	1090		|O
ART	1091	1094		|O
-	1094	1095		|O
naive	1095	1100		|O
patients	1101	1109		|O
(	1110	1111		|O
4,382	1111	1116		|O
versus	1117	1123		|O
7,662	1124	1129		|O
g	1130	1131		|O
[	1132	1133		|O
P	1133	1134		|O
=	1134	1135		|O
0.02	1135	1139		|O
]	1139	1140		|O
and	1141	1144		|O
726	1145	1148		|O
versus	1149	1155		|O
1,372	1156	1161		|O
copies	1162	1168		|O
/	1168	1169		|O
cell	1169	1173		|O
[	1174	1175		|O
P	1175	1176		|O
=	1176	1177		|O
0.03	1177	1181		|O
]	1181	1182		|O
,	1182	1183		|O
respectively	1184	1196		|O
)	1196	1197		|O
,	1197	1198		|O
but	1199	1202		|O
no	1203	1205		|O
difference	1206	1216		|O
was	1217	1220		|O
found	1221	1226		|O
between	1227	1234		|O
ART	1235	1238		|O
-	1238	1239		|O
naive	1239	1244		|O
and	1245	1248		|O
controls	1249	1257		|O
.	1257	1258		|O
In	1259	1261		|O
a	1262	1263		|O
multiple	1264	1272		|O
regression	1273	1283		|O
analysis	1284	1292		|O
,	1292	1293		|O
limb	1294	1298		|O
fat	1299	1302		|O
correlated	1303	1313		|O
with	1314	1318		|O
all	1319	1322		|O
three	1323	1328		|O
mitochrondrial	1329	1343		|O
RNA	1344	1347		|O
,	1347	1348		|O
whereas	1349	1356		|O
mitochondrial	1357	1370		|O
DNA	1371	1374		|O
did	1375	1378		|O
not	1379	1382		|O
correlate	1383	1392		|O
with	1393	1397		|O
mitochondrial	1398	1411		|O
RNA	1412	1415		|O
or	1416	1418		|O
limb	1419	1423		|O
fat	1424	1427		|O
.	1427	1428		|O
CONCLUSIONS	1429	1440		|O
:	1440	1441		|O
In	1442	1444		|O
contrast	1445	1453		|O
to	1454	1456		|O
ART	1457	1460		|O
-	1460	1461		|O
naive	1461	1466		|O
patients	1467	1475		|O
,	1475	1476		|O
HIV	1477	1480		|O
-	1480	1481		|O
positive	1481	1489		|O
patients	1490	1498		|O
on	1499	1501		|O
ART	1502	1505		|O
with	1506	1510		|O
lipoatrophy	1511	1522	lipoatrophy	|B-DISEASE
had	1523	1526		|O
significant	1527	1538		|O
depletion	1539	1548		|O
in	1549	1551		|O
mitochondrial	1552	1565		|O
DNA	1566	1569		|O
in	1570	1572		|O
fat	1573	1576		|O
and	1577	1580		|O
mitochondrial	1581	1594		|O
RNAs	1595	1599		|O
.	1599	1600		|O
This	1601	1605		|O
suggests	1606	1614		|O
that	1615	1619		|O
mitochondrial	1620	1633	mitochondrial toxicity	|B-ADVERSE
toxicity	1634	1642		|I-ADVERSE
in	1643	1645		|O
lipoatrophy	1646	1657	lipoatrophy	|B-DISEASE
could	1658	1663		|O
be	1664	1666		|O
driven	1667	1673		|O
by	1674	1676		|O
ART	1677	1680		|O
and	1681	1684		|O
not	1685	1688		|O
by	1689	1691		|O
HIV	1692	1695		|O
itself	1696	1702		|O
.	1702	1703		|O
In	1704	1706		|O
addition	1707	1715		|O
,	1715	1716		|O
mitochondrial	1717	1730		|O
RNA	1731	1734		|O
abnormalities	1735	1748		|O
,	1748	1749		|O
and	1750	1753		|O
not	1754	1757		|O
mitochondrial	1758	1771		|O
DNA	1772	1775		|O
depletion	1776	1785		|O
,	1785	1786		|O
could	1787	1792		|O
be	1793	1795		|O
a	1796	1797		|O
key	1798	1801		|O
driving	1802	1809		|O
force	1810	1815		|O
behind	1816	1822		|O
lipoatrophy	1823	1834	lipoatrophy	|B-DISEASE
.	1834	1835		|O

### 18954923
Environmental	0	13		|O
ozone	14	19		|O
exposure	20	28		|O
and	29	32		|O
oxidative	33	42		|O
DNA	43	46		|O
damage	47	53		|O
in	54	56		|O
adult	57	62		|O
residents	63	72		|O
of	73	75		|O
Florence	76	84		|O
,	84	85		|O
Italy	86	91		|O
.	91	92		|O
In	94	96		|O
71	97	99		|O
adults	100	106		|O
residing	107	115		|O
in	116	118		|O
Florence	119	127		|O
,	127	128		|O
Italy	129	134		|O
,	134	135		|O
enrolled	136	144		|O
in	145	147		|O
a	148	149		|O
prospective	150	161		|O
study	162	167		|O
,	167	168		|O
we	169	171		|O
investigated	172	184		|O
the	185	188		|O
correlation	189	200		|O
between	201	208		|O
individual	209	219		|O
levels	220	226		|O
of	227	229		|O
oxidative	230	239		|O
DNA	240	243		|O
damage	244	250		|O
detected	251	259		|O
by	260	262		|O
the	263	266		|O
Comet	267	272		|O
assay	273	278		|O
in	279	281		|O
circulating	282	293		|O
lymphocytes	294	305		|O
,	305	306		|O
and	307	310		|O
a	311	312		|O
specific	313	321		|O
ozone	322	327		|O
exposure	328	336		|O
score	337	342		|O
calculated	343	353		|O
in	354	356		|O
10	357	359		|O
different	360	369		|O
time	370	374		|O
-	374	375		|O
windows	375	382		|O
(	383	384		|O
0-5	384	387		|O
to	388	390		|O
0-90	391	395		|O
days	396	400		|O
)	400	401		|O
before	402	408		|O
blood	409	414		|O
drawing	415	422		|O
,	422	423		|O
based	424	429		|O
on	430	432		|O
daily	433	438		|O
measurements	439	451		|O
provided	452	460		|O
by	461	463		|O
the	464	467		|O
local	468	473		|O
environmental	474	487		|O
monitoring	488	498		|O
system	499	505		|O
.	505	506		|O
Overall	507	514		|O
,	514	515		|O
statistically	516	529		|O
significant	530	541		|O
positive	542	550		|O
correlations	551	563		|O
between	564	571		|O
average	572	579		|O
ozone	580	585		|O
concentrations	586	600		|O
and	601	604		|O
DNA	605	608		|O
damage	609	615		|O
emerged	616	623		|O
in	624	626		|O
almost	627	633		|O
all	634	637		|O
time	638	642		|O
-	642	643		|O
windows	643	650		|O
considered	651	661		|O
;	661	662		|O
correlations	663	675		|O
were	676	680		|O
more	681	685		|O
evident	686	693		|O
among	694	699		|O
males	700	705		|O
,	705	706		|O
non	707	710		|O
-	710	711		|O
smokers	711	718		|O
,	718	719		|O
and	720	723		|O
traffic	724	731		|O
-	731	732		|O
exposed	732	739		|O
workers	740	747		|O
.	747	748		|O
Multivariate	749	761		|O
regression	762	772		|O
analyses	773	781		|O
taking	782	788		|O
into	789	793		|O
account	794	801		|O
selected	802	810		|O
individual	811	821		|O
characteristics	822	837		|O
,	837	838		|O
showed	839	845		|O
an	846	848		|O
independent	849	860		|O
effect	861	867		|O
on	868	870		|O
DNA	871	874		|O
damage	875	881		|O
of	882	884		|O
average	885	892		|O
ozone	893	898		|O
concentrations	899	913		|O
in	914	916		|O
the	917	920		|O
last	921	925		|O
60-90	926	931		|O
days	932	936		|O
before	937	943		|O
blood	944	949		|O
drawing	950	957		|O
.	957	958		|O
Local	959	964		|O
residents	965	974		|O
showed	975	981		|O
a	982	983		|O
divergent	984	993		|O
pattern	994	1001		|O
with	1002	1006		|O
correlations	1007	1019		|O
restricted	1020	1030		|O
to	1031	1033		|O
shorter	1034	1041		|O
time	1042	1046		|O
-	1046	1047		|O
windows	1047	1054		|O
.	1054	1055		|O
Our	1056	1059		|O
results	1060	1067		|O
suggest	1068	1075		|O
that	1076	1080		|O
ozone	1081	1086		|O
concentrations	1087	1101		|O
at	1102	1104		|O
ground	1105	1111		|O
levels	1112	1118		|O
modulate	1119	1127		|O
oxidative	1128	1137		|O
DNA	1138	1141		|O
damage	1142	1148		|O
in	1149	1151		|O
circulating	1152	1163		|O
lymphocytes	1164	1175		|O
of	1176	1178		|O
residents	1179	1188		|O
of	1189	1191		|O
polluted	1192	1200		|O
areas	1201	1206		|O
.	1206	1207		|O

### 18581078
Methods	0	7		|O
to	8	10		|O
evaluate	11	19		|O
the	20	23		|O
pharmacology	24	36		|O
of	37	39		|O
oral	40	44		|O
antiplatelet	45	57		|O
drugs	58	63		|O
.	63	64		|O
Principally	66	77		|O
,	77	78		|O
there	79	84		|O
are	85	88		|O
two	89	92		|O
reasons	93	100		|O
why	101	104		|O
the	105	108		|O
pharmacological	109	124		|O
response	125	133		|O
to	134	136		|O
antiplatelet	137	149		|O
drugs	150	155		|O
should	156	162		|O
be	163	165		|O
measured	166	174		|O
:	174	175		|O
on	176	178		|O
the	179	182		|O
one	183	186		|O
hand	187	191		|O
,	191	192		|O
an	193	195		|O
insufficient	196	208		|O
inhibition	209	219		|O
of	220	222		|O
platelet	223	231		|O
function	232	240		|O
may	241	244		|O
result	245	251		|O
in	252	254		|O
atherothrombotic	255	271	atherothrombotic complications	|B-DISEASE
complications	272	285		|I-DISEASE
;	285	286		|O
on	287	289		|O
the	290	293		|O
other	294	299		|O
hand	300	304		|O
,	304	305		|O
an	306	308		|O
excessive	309	318		|O
inhibition	319	329		|O
of	330	332		|O
platelet	333	341		|O
function	342	350		|O
may	351	354		|O
lead	355	359		|O
to	360	362		|O
bleeding	363	371	bleeding complications	|B-DISEASE
complications	372	385		|I-DISEASE
.	385	386		|O
The	387	390		|O
clinical	391	399		|O
importance	400	410		|O
to	411	413		|O
measure	414	421		|O
the	422	425		|O
effects	426	433		|O
of	434	436		|O
antiplatelet	437	449		|O
drugs	450	455		|O
is	456	458		|O
demonstrated	459	471		|O
by	472	474		|O
increasingly	475	487		|O
growing	488	495		|O
evidence	496	504		|O
for	505	508		|O
an	509	511		|O
association	512	523		|O
of	524	526		|O
resistance	527	537		|O
to	538	540		|O
antiplatelet	541	553		|O
drugs	554	559		|O
with	560	564		|O
thromboembolic	565	579	thromboembolic events	|B-DISEASE
events	580	586		|I-DISEASE
.	586	587		|O
It	588	590		|O
is	591	593		|O
often	594	599		|O
claimed	600	607		|O
that	608	612		|O
there	613	618		|O
is	619	621		|O
no	622	624		|O
generally	625	634		|O
accepted	635	643		|O
definition	644	654		|O
of	655	657		|O
"	658	659		|O
resistance	659	669		|O
"	669	670		|O
and	671	674		|O
,	674	675		|O
instead	676	683		|O
,	683	684		|O
there	685	690		|O
is	691	693		|O
an	694	696		|O
ongoing	697	704		|O
semantic	705	713		|O
discussion	714	724		|O
about	725	730		|O
the	731	734		|O
correct	735	742		|O
term	743	747		|O
to	748	750		|O
be	751	753		|O
used	754	758		|O
to	759	761		|O
describe	762	770		|O
this	771	775		|O
phenomenon	776	786		|O
.	786	787		|O
From	788	792		|O
the	793	796		|O
pharmacological	797	812		|O
point	813	818		|O
of	819	821		|O
view	822	826		|O
,	826	827		|O
there	828	833		|O
is	834	836		|O
only	837	841		|O
one	842	845		|O
acceptable	846	856		|O
definition	857	867		|O
of	868	870		|O
"	871	872		|O
resistance	872	882		|O
"	882	883		|O
to	884	886		|O
antiplatelet	887	899		|O
drugs	900	905		|O
:	905	906		|O
the	907	910		|O
term	911	915		|O
"	916	917		|O
resistance	917	927		|O
"	927	928		|O
should	929	935		|O
be	936	938		|O
used	939	943		|O
when	944	948		|O
a	949	950		|O
drug	951	955		|O
is	956	958		|O
unable	959	965		|O
to	966	968		|O
hit	969	972		|O
its	973	976		|O
pharmacological	977	992		|O
target	993	999		|O
.	999	1000		|O
Thus	1001	1005		|O
,	1005	1006		|O
laboratory	1007	1017		|O
methods	1018	1025		|O
used	1026	1030		|O
to	1031	1033		|O
evaluate	1034	1042		|O
the	1043	1046		|O
effects	1047	1054		|O
of	1055	1057		|O
antiplatelet	1058	1070		|O
drugs	1071	1076		|O
should	1077	1083		|O
be	1084	1086		|O
designed	1087	1095		|O
to	1096	1098		|O
measure	1099	1106		|O
the	1107	1110		|O
direct	1111	1117		|O
pharmacodynamic	1118	1133		|O
effect	1134	1140		|O
of	1141	1143		|O
a	1144	1145		|O
drug	1146	1150		|O
,	1150	1151		|O
rather	1152	1158		|O
than	1159	1163		|O
the	1164	1167		|O
consequences	1168	1180		|O
for	1181	1184		|O
global	1185	1191		|O
platelet	1192	1200		|O
function	1201	1209		|O
.	1209	1210		|O
Based	1211	1216		|O
on	1217	1219		|O
physiological	1220	1233		|O
/	1233	1234		|O
pathophysiological	1234	1252		|O
,	1252	1253		|O
pharmacological	1254	1269		|O
,	1269	1270		|O
and	1271	1274		|O
practical	1275	1284		|O
considerations	1285	1299		|O
,	1299	1300		|O
the	1301	1304		|O
authors	1305	1312		|O
propose	1313	1320		|O
the	1321	1324		|O
following	1325	1334		|O
assays	1335	1341		|O
to	1342	1344		|O
be	1345	1347		|O
used	1348	1352		|O
to	1353	1355		|O
measure	1356	1363		|O
the	1364	1367		|O
effects	1368	1375		|O
of	1376	1378		|O
oral	1379	1383		|O
antiplatelet	1384	1396		|O
drugs	1397	1402		|O
:	1402	1403		|O
for	1404	1407		|O
the	1408	1411		|O
detection	1412	1421		|O
of	1422	1424		|O
aspirin	1425	1432		|O
actions	1433	1440		|O
,	1440	1441		|O
thromboxane	1442	1453		|O
or	1454	1456		|O
arachidonic	1457	1468		|O
acid	1469	1473		|O
-	1473	1474		|O
induced	1474	1481		|O
responses	1482	1491		|O
(	1492	1493		|O
light	1493	1498		|O
aggregometry	1499	1511		|O
,	1511	1512		|O
whole	1513	1518		|O
-	1518	1519		|O
blood	1519	1524		|O
aggregometry	1525	1537		|O
)	1537	1538		|O
should	1539	1545		|O
be	1546	1548		|O
measured	1549	1557		|O
;	1557	1558		|O
for	1559	1562		|O
the	1563	1566		|O
detection	1567	1576		|O
of	1577	1579		|O
clopidogrel	1580	1591		|O
actions	1592	1599		|O
,	1599	1600		|O
VASP	1601	1605		|O
(	1606	1607		|O
vasodilator	1607	1618		|O
-	1618	1619		|O
stimulated	1619	1629		|O
phosphoprotein	1630	1644		|O
)	1644	1645		|O
phosphorylation	1646	1661		|O
(	1662	1663		|O
flow	1663	1667		|O
cytometry	1668	1677		|O
)	1677	1678		|O
or	1679	1681		|O
ADP	1682	1685		|O
-	1685	1686		|O
(	1686	1687		|O
adenosine	1687	1696		|O
diphosphate	1697	1708		|O
-	1708	1709		|O
)	1709	1710		|O
induced	1710	1717		|O
responses	1718	1727		|O
(	1728	1729		|O
light	1729	1734		|O
aggregometry	1735	1747		|O
,	1747	1748		|O
whole	1749	1754		|O
-	1754	1755		|O
blood	1755	1760		|O
aggregometry	1761	1773		|O
,	1773	1774		|O
possibly	1775	1783		|O
also	1784	1788		|O
flow	1789	1793		|O
cytometry	1794	1803		|O
)	1803	1804		|O
should	1805	1811		|O
be	1812	1814		|O
measured	1815	1823		|O
.	1823	1824		|O

### 18604442
Comparison	0	10		|O
of	11	13		|O
three	14	19		|O
different	20	29		|O
chemotherapy	30	42		|O
regimens	43	51		|O
containing	52	62		|O
epirubicin	63	73		|O
in	74	76		|O
hormone	77	84	hormone-refractory prostate cancer	|B-DISEASE
-	84	85		|I-DISEASE
refractory	85	95		|I-DISEASE
prostate	96	104		|I-DISEASE
cancer	105	111		|I-DISEASE
patients	112	120		|O
.	120	121		|O
We	123	125		|O
compared	126	134		|O
three	135	140		|O
different	141	150		|O
chemotherapy	151	163		|O
regimens	164	172		|O
containing	173	183		|O
epirubicin	184	194		|O
in	195	197		|O
hormone	198	205	hormone-refractory prostate cancer	|B-DISEASE
-	205	206		|I-DISEASE
refractory	206	216		|I-DISEASE
prostate	217	225		|I-DISEASE
cancer	226	232		|I-DISEASE
(	233	234		|O
HRPC	234	238	HRPC	|B-DISEASE
)	238	239		|O
patients	240	248		|O
.	248	249		|O
Sixty	250	255		|O
-	255	256		|O
nine	256	260		|O
patients	261	269		|O
with	270	274		|O
HRPC	275	279		|O
were	280	284		|O
randomized	285	295		|O
into	296	300		|O
three	301	306		|O
groups	307	313		|O
.	313	314		|O
The	315	318		|O
first	319	324		|O
group	325	330		|O
(	331	332		|O
22	332	334		|O
patients	335	343		|O
)	343	344		|O
received	345	353		|O
30	354	356		|O
mg	357	359		|O
/	359	360		|O
m2	360	362		|O
/	362	363		|O
week	363	367		|O
i	368	369		|O
.	369	370		|O
v	370	371		|O
.	371	372		|O
epirubicin	373	383		|O
for	384	387		|O
8	388	389		|O
weeks	390	395		|O
.	395	396		|O
The	397	400		|O
second	401	407		|O
group	408	413		|O
(	414	415		|O
24	415	417		|O
patients	418	426		|O
)	426	427		|O
received	428	436		|O
30	437	439		|O
mg	440	442		|O
/	442	443		|O
m2	443	445		|O
/	445	446		|O
week	446	450		|O
i	451	452		|O
.	452	453		|O
v	453	454		|O
.	454	455		|O
epirubicin	456	466		|O
for	467	470		|O
8	471	472		|O
weeks	473	478		|O
followed	479	487		|O
by	488	490		|O
monthly	491	498		|O
maintenance	499	510		|O
therapy	511	518		|O
for	519	522		|O
4-6	523	526		|O
months	527	533		|O
.	533	534		|O
The	535	538		|O
third	539	544		|O
group	545	550		|O
(	551	552		|O
23	552	554		|O
patients	555	563		|O
)	563	564		|O
received	565	573		|O
oral	574	578		|O
estramustine	579	591		|O
phosphate	592	601		|O
(	602	603		|O
EMP	603	606		|O
)	606	607		|O
at	608	610		|O
a	611	612		|O
dose	613	617		|O
of	618	620		|O
840	621	624		|O
mg	625	627		|O
/	627	628		|O
day	628	631		|O
together	632	640		|O
with	641	645		|O
weekly	646	652		|O
and	653	656		|O
monthly	657	664		|O
maintenance	665	676		|O
epirubicin	677	687		|O
.	687	688		|O
The	689	692		|O
response	693	701		|O
rates	702	707		|O
,	707	708		|O
mean	709	713		|O
survival	714	722		|O
times	723	728		|O
,	728	729		|O
and	730	733		|O
toxicity	734	742		|O
were	743	747		|O
determined	748	758		|O
.	758	759		|O
Within	760	766		|O
the	767	770		|O
first	771	776		|O
3	777	778		|O
months	779	785		|O
,	785	786		|O
pain	787	791	pain	|B-DISEASE
and	792	795		|O
performance	796	807		|O
scores	808	814		|O
were	815	819		|O
improved	820	828		|O
by	829	831		|O
at	832	834		|O
least	835	840		|O
one	841	844		|O
degree	845	851		|O
in	852	854		|O
all	855	858		|O
the	859	862		|O
groups	863	869		|O
.	869	870		|O
One	871	874		|O
patient	875	882		|O
in	883	885		|O
group	886	891		|O
two	892	895		|O
and	896	899		|O
three	900	905		|O
patients	906	914		|O
in	915	917		|O
group	918	923		|O
three	924	929		|O
had	930	933		|O
complete	934	942		|O
response	943	951		|O
.	951	952		|O
Partial	953	960		|O
response	961	969		|O
rates	970	975		|O
were	976	980		|O
23%	981	984		|O
in	985	987		|O
group	988	993		|O
1	994	995		|O
,	995	996		|O
25%	997	1000		|O
in	1001	1003		|O
group	1004	1009		|O
2	1010	1011		|O
,	1011	1012		|O
and	1013	1016		|O
17%	1017	1020		|O
in	1021	1023		|O
group	1024	1029		|O
3	1030	1031		|O
.	1031	1032		|O
Stable	1033	1039		|O
disease	1040	1047		|O
rates	1048	1053		|O
were	1054	1058		|O
41%	1059	1062		|O
in	1063	1065		|O
group	1066	1071		|O
1	1072	1073		|O
,	1073	1074		|O
33%	1075	1078		|O
in	1079	1081		|O
group	1082	1087		|O
2	1088	1089		|O
,	1089	1090		|O
and	1091	1094		|O
26%	1095	1098		|O
in	1099	1101		|O
group	1102	1107		|O
3	1108	1109		|O
.	1109	1110		|O
The	1111	1114		|O
progression	1115	1126		|O
rates	1127	1132		|O
within	1133	1139		|O
the	1140	1143		|O
first	1144	1149		|O
3	1150	1151		|O
months	1152	1158		|O
were	1159	1163		|O
36%	1164	1167		|O
in	1168	1170		|O
group	1171	1176		|O
1	1177	1178		|O
,	1178	1179		|O
38%	1180	1183		|O
in	1184	1186		|O
group	1187	1192		|O
2	1193	1194		|O
,	1194	1195		|O
and	1196	1199		|O
44%	1200	1203		|O
in	1204	1206		|O
group	1207	1212		|O
3	1213	1214		|O
.	1214	1215		|O
None	1216	1220		|O
of	1221	1223		|O
the	1224	1227		|O
patients	1228	1236		|O
developed	1237	1246		|O
complications	1247	1260		|O
that	1261	1265		|O
were	1266	1270		|O
significant	1271	1282		|O
enough	1283	1289		|O
to	1290	1292		|O
terminate	1293	1302		|O
the	1303	1306		|O
treatment	1307	1316		|O
.	1316	1317		|O
Two	1318	1321		|O
patients	1322	1330		|O
in	1331	1333		|O
group	1334	1339		|O
3	1340	1341		|O
died	1342	1346		|O
of	1347	1349		|O
cardiotoxicity	1350	1364	cardiotoxicity	|B-ADVERSE
.	1364	1365		|O
The	1366	1369		|O
mean	1370	1374		|O
survival	1375	1383		|O
times	1384	1389		|O
were	1390	1394		|O
10.1	1395	1399		|O
,	1399	1400		|O
15.8	1401	1405		|O
,	1405	1406		|O
and	1407	1410		|O
16.1	1411	1415		|O
months	1416	1422		|O
in	1423	1425		|O
groups	1426	1432		|O
1	1433	1434		|O
,	1434	1435		|O
2	1436	1437		|O
,	1437	1438		|O
and	1439	1442		|O
3	1443	1444		|O
,	1444	1445		|O
respectively	1446	1458		|O
.	1458	1459		|O
It	1460	1462		|O
was	1463	1466		|O
determined	1467	1477		|O
that	1478	1482		|O
weekly	1483	1489		|O
and	1490	1493		|O
maintenance	1494	1505		|O
epirubicin	1506	1516		|O
treatment	1517	1526		|O
protocol	1527	1535		|O
,	1535	1536		|O
and	1537	1540		|O
estramustine	1541	1553		|O
treatment	1554	1563		|O
protocol	1564	1572		|O
in	1573	1575		|O
addition	1576	1584		|O
to	1585	1587		|O
this	1588	1592		|O
treatment	1593	1602		|O
,	1602	1603		|O
was	1604	1607		|O
only	1608	1612		|O
meaningfully	1613	1625		|O
more	1626	1630		|O
effective	1631	1640		|O
against	1641	1648		|O
weekly	1649	1655		|O
epirubicin	1656	1666		|O
treatment	1667	1676		|O
in	1677	1679		|O
the	1680	1683		|O
statistical	1684	1695		|O
sense	1696	1701		|O
(	1702	1703		|O
0.01	1703	1707		|O
<	1708	1709		|O
p	1710	1711		|O
<	1712	1713		|O
0.05	1714	1718		|O
)	1718	1719		|O
.	1719	1720		|O
However	1721	1728		|O
,	1728	1729		|O
due	1730	1733		|O
to	1734	1736		|O
the	1737	1740		|O
complications	1741	1754		|O
of	1755	1757		|O
EMP	1758	1761		|O
,	1761	1762		|O
which	1763	1768		|O
influence	1769	1778		|O
the	1779	1782		|O
quality	1783	1790		|O
of	1791	1793		|O
life	1794	1798		|O
,	1798	1799		|O
we	1800	1802		|O
believe	1803	1810		|O
that	1811	1815		|O
this	1816	1820		|O
was	1821	1824		|O
usable	1825	1831		|O
only	1832	1836		|O
when	1837	1841		|O
measures	1842	1850		|O
were	1851	1855		|O
adopted	1856	1863		|O
against	1864	1871		|O
these	1872	1877		|O
effects	1878	1885		|O
.	1885	1886		|O

### 18580952
Prognostic	0	10		|O
role	11	15		|O
of	16	18		|O
glutathione	19	30		|O
S	31	32		|O
-	32	33		|O
transferase	33	44		|O
polymorphisms	45	58		|O
in	59	61		|O
acute	62	67	acute myeloid leukemia	|B-DISEASE
myeloid	68	75		|I-DISEASE
leukemia	76	84		|I-DISEASE
.	84	85		|O
Glutathione	87	98		|O
S	99	100		|O
-	100	101		|O
transferases	101	113		|O
(	114	115		|O
GSTs	115	119		|O
)	119	120		|O
are	121	124		|O
phase	125	130		|O
II	131	133		|O
detoxification	134	148		|O
enzymes	149	156		|O
involved	157	165		|O
in	166	168		|O
the	169	172		|O
metabolism	173	183		|O
of	184	186		|O
carcinogens	187	198		|O
and	199	202		|O
anticancer	203	213		|O
drugs	214	219		|O
,	219	220		|O
known	221	226		|O
also	227	231		|O
to	232	234		|O
interact	235	243		|O
with	244	248		|O
kinase	249	255		|O
complexes	256	265		|O
during	266	272		|O
oxidative	273	282		|O
or	283	285		|O
chemical	286	294		|O
stress	295	301		|O
-	301	302		|O
induced	302	309		|O
apoptosis	310	319		|O
.	319	320		|O
We	321	323		|O
were	324	328		|O
interested	329	339		|O
whether	340	347		|O
their	348	353		|O
polymorphic	354	365		|O
variants	366	374		|O
may	375	378		|O
account	379	386		|O
for	387	390		|O
differences	391	402		|O
in	403	405		|O
outcome	406	413		|O
of	414	416		|O
patients	417	425		|O
with	426	430		|O
acute	431	436	acute myeloid leukemia	|B-DISEASE
myeloid	437	444		|I-DISEASE
leukemia	445	453		|I-DISEASE
(	454	455		|O
AML	455	458	AML	|B-DISEASE
)	458	459		|O
following	460	469		|O
chemotherapy	470	482		|O
.	482	483		|O
We	484	486		|O
studied	487	494		|O
the	495	498		|O
prognostic	499	509		|O
role	510	514		|O
of	515	517		|O
polymorphisms	518	531		|O
in	532	534		|O
three	535	540		|O
GST	541	544		|O
genes	545	550		|O
(	551	552		|O
GSTP1	552	557		|O
/	557	558		|O
M1	558	560		|O
/	560	561		|O
T1	561	563		|O
)	563	564		|O
in	565	567		|O
a	568	569		|O
large	570	575		|O
patient	576	583		|O
cohort	584	590		|O
of	591	593		|O
the	594	597		|O
German	598	604		|O
Austrian	605	613		|O
Acute	614	619	Acute Myeloid Leukemia	|B-DISEASE
Myeloid	620	627		|I-DISEASE
Leukemia	628	636		|I-DISEASE
Study	637	642		|O
Group	643	648		|O
,	648	649		|O
treated	650	657		|O
according	658	667		|O
to	668	670		|O
prospective	671	682		|O
multicenter	683	694		|O
clinical	695	703		|O
trials	704	710		|O
(	711	712		|O
AML	712	715	AML	|B-DISEASE
HD98A	716	721		|O
:	721	722		|O
254	723	726		|O
patients	727	735		|O
;	735	736		|O
AML	737	740	AML	|B-DISEASE
HD98	741	745		|O
-	745	746		|O
B	746	747		|O
:	747	748		|O
100	749	752		|O
patients	753	761		|O
)	761	762		|O
,	762	763		|O
with	764	768		|O
a	769	770		|O
median	771	777		|O
follow	778	784		|O
-	784	785		|O
up	785	787		|O
of	788	790		|O
46	791	793		|O
months	794	800		|O
.	800	801		|O
Looking	802	809		|O
at	810	812		|O
short	813	818		|O
-	818	819		|O
term	819	823		|O
adverse	824	831		|O
drug	832	836		|O
reactions	837	846		|O
,	846	847		|O
homozygous	848	858		|O
carriers	859	867		|O
of	868	870		|O
the	871	874		|O
GSTP1	875	880		|O
*	880	881		|O
105	881	884		|O
Val	885	888		|O
allele	889	895		|O
had	896	899		|O
a	900	901		|O
faster	902	908		|O
neutrophil	909	919		|O
and	920	923		|O
platelet	924	932		|O
recovery	933	941		|O
(	942	943		|O
P	943	944		|O
=	944	945		|O
0.002	945	950		|O
and	951	954		|O
0.02	955	959		|O
,	959	960		|O
respectively	961	973		|O
)	973	974		|O
and	975	978		|O
a	979	980		|O
reduced	981	988		|O
need	989	993		|O
of	994	996		|O
red	997	1000		|O
cell	1001	1005		|O
and	1006	1009		|O
platelet	1010	1018		|O
transfusions	1019	1031		|O
(	1032	1033		|O
P	1033	1034		|O
=	1034	1035		|O
0.01	1035	1039		|O
and	1040	1043		|O
0.03	1044	1048		|O
,	1048	1049		|O
respectively	1050	1062		|O
)	1062	1063		|O
.	1063	1064		|O
Response	1065	1073		|O
to	1074	1076		|O
induction	1077	1086		|O
chemotherapy	1087	1099		|O
did	1100	1103		|O
not	1104	1107		|O
vary	1108	1112		|O
according	1113	1122		|O
to	1123	1125		|O
GST	1126	1129		|O
polymorphisms	1130	1143		|O
.	1143	1144		|O
Multivariable	1145	1158		|O
Cox	1159	1162		|O
regression	1163	1173		|O
models	1174	1180		|O
revealed	1181	1189		|O
a	1190	1191		|O
significant	1192	1203		|O
better	1204	1210		|O
relapse	1211	1218		|O
-	1218	1219		|O
free	1219	1223		|O
(	1224	1225		|O
RFS	1225	1228		|O
)	1228	1229		|O
and	1230	1233		|O
overall	1234	1241		|O
survival	1242	1250		|O
for	1251	1254		|O
the	1255	1258		|O
GSTP1	1259	1264		|O
(	1264	1265		|O
*	1265	1266		|O
)	1266	1267		|O
105	1267	1270		|O
Val	1271	1274		|O
(	1275	1276		|O
P	1276	1277		|O
=	1277	1278		|O
0.003	1278	1283		|O
and	1284	1287		|O
0.03	1288	1292		|O
,	1292	1293		|O
respectively	1294	1306		|O
)	1306	1307		|O
,	1307	1308		|O
whereas	1309	1316		|O
GSTT1	1317	1322		|O
and	1323	1326		|O
GSTM1	1327	1332		|O
genotypes	1333	1342		|O
had	1343	1346		|O
no	1347	1349		|O
significant	1350	1361		|O
impact	1362	1368		|O
.	1368	1369		|O
The	1370	1373		|O
favorable	1374	1383		|O
impact	1384	1390		|O
of	1391	1393		|O
GSTP1	1394	1399		|O
(	1399	1400		|O
*	1400	1401		|O
)	1401	1402		|O
105	1402	1405		|O
Val	1406	1409		|O
on	1410	1412		|O
RFS	1413	1416		|O
seems	1417	1422		|O
to	1423	1425		|O
be	1426	1428		|O
restricted	1429	1439		|O
to	1440	1442		|O
the	1443	1446		|O
subgroup	1447	1455		|O
of	1456	1458		|O
patients	1459	1467		|O
exhibiting	1468	1478		|O
a	1479	1480		|O
normal	1481	1487		|O
karyotype	1488	1497		|O
.	1497	1498		|O

### 18621066
Increased	0	9		|O
damage	10	16		|O
of	17	19		|O
exon	20	24		|O
5	25	26		|O
of	27	29		|O
p53	30	33		|O
gene	34	38		|O
in	39	41		|O
workers	42	49		|O
from	50	54		|O
an	55	57		|O
arsenic	58	65		|O
plant	66	71		|O
.	71	72		|O
Mutagenesis	74	85		|O
is	86	88		|O
a	89	90		|O
multistage	91	101		|O
process	102	109		|O
.	109	110		|O
Substitution	111	123		|O
mutations	124	133		|O
can	134	137		|O
be	138	140		|O
induced	141	148		|O
by	149	151		|O
base	152	156		|O
modified	157	165		|O
through	166	173		|O
alteration	174	184		|O
of	185	187		|O
pairing	188	195		|O
property	196	204		|O
.	204	205		|O
Mutations	206	215		|O
of	216	218		|O
exon	219	223		|O
5	224	225		|O
and	226	229		|O
8	230	231		|O
of	232	234		|O
p53	235	238		|O
gene	239	243		|O
have	244	248		|O
been	249	253		|O
found	254	259		|O
in	260	262		|O
most	263	267		|O
arsenicosis	268	279		|O
patients	280	288		|O
with	289	293		|O
precarcinomas	294	307	precarcinomas	|B-DISEASE
and	308	311		|O
carcinomas	312	322	carcinomas	|B-DISEASE
,	322	323		|O
but	324	327		|O
never	328	333		|O
in	334	336		|O
arsenicosis	337	348		|O
individuals	349	360		|O
without	361	368		|O
precarcinomas	369	382	precarcinomas	|B-DISEASE
and	383	386		|O
carcinomas	387	397	carcinomas	|B-DISEASE
.	397	398		|O
This	399	403		|O
study	404	409		|O
investigates	410	422		|O
whether	423	430		|O
base	431	435		|O
modification	436	448		|O
exists	449	455		|O
in	456	458		|O
exon	459	463		|O
5	464	465		|O
and	466	469		|O
8	470	471		|O
of	472	474		|O
p53	475	478		|O
gene	479	483		|O
,	483	484		|O
and	485	488		|O
explores	489	497		|O
the	498	501		|O
dose	502	506		|O
-	506	507		|O
effect	507	513		|O
relationship	514	526		|O
between	527	534		|O
damage	535	541		|O
of	542	544		|O
exon	545	549		|O
5	550	551		|O
of	552	554		|O
p53	555	558		|O
gene	559	563		|O
and	564	567		|O
urinary	568	575		|O
arsenic	576	583		|O
.	583	584		|O
Concentrations	585	599		|O
of	600	602		|O
urinary	603	610		|O
8	611	612		|O
-	612	613		|O
hydroxydeoxyguanine	613	632		|O
(	633	634		|O
8	634	635		|O
-	635	636		|O
OHdG	636	640		|O
)	640	641		|O
are	642	645		|O
analyzed	646	654		|O
to	655	657		|O
identify	658	666		|O
the	667	670		|O
occurrence	671	681		|O
of	682	684		|O
DNA	685	688		|O
damage	689	695		|O
.	695	696		|O
The	697	700		|O
real	701	705		|O
-	705	706		|O
time	706	710		|O
PCR	711	714		|O
developed	715	724		|O
by	725	727		|O
Sikorsky	728	736		|O
et	737	739		|O
al.	740	743		|O
is	744	746		|O
applied	747	754		|O
to	755	757		|O
detect	758	764		|O
base	765	769		|O
modification	770	782		|O
in	783	785		|O
exon	786	790		|O
5	791	792		|O
and	793	796		|O
8	797	798		|O
of	799	801		|O
p53	802	805		|O
gene	806	810		|O
for	811	814		|O
apparently	815	825		|O
healthy	826	833		|O
participants	834	846		|O
.	846	847		|O
Our	848	851		|O
results	852	859		|O
show	860	864		|O
that	865	869		|O
the	870	873		|O
mean	874	878		|O
total	879	884		|O
arsenic	885	892		|O
concentrations	893	907		|O
of	908	910		|O
two	911	914		|O
exposed	915	922		|O
groups	923	929		|O
from	930	934		|O
an	935	937		|O
arsenic	938	945		|O
plant	946	951		|O
are	952	955		|O
significantly	956	969		|O
elevated	970	978		|O
compared	979	987		|O
with	988	992		|O
the	993	996		|O
control	997	1004		|O
group	1005	1010		|O
,	1010	1011		|O
and	1012	1015		|O
the	1016	1019		|O
damage	1020	1026		|O
level	1027	1032		|O
of	1033	1035		|O
exon	1036	1040		|O
5	1041	1042		|O
of	1043	1045		|O
the	1046	1049		|O
high	1050	1054		|O
-	1054	1055		|O
exposed	1055	1062		|O
group	1063	1068		|O
is	1069	1071		|O
significantly	1072	1085		|O
higher	1086	1092		|O
than	1093	1097		|O
that	1098	1102		|O
of	1103	1105		|O
the	1106	1109		|O
control	1110	1117		|O
group	1118	1123		|O
,	1123	1124		|O
but	1125	1128		|O
which	1129	1134		|O
does	1135	1139		|O
not	1140	1143		|O
happen	1144	1150		|O
in	1151	1153		|O
exon	1154	1158		|O
8	1159	1160		|O
.	1160	1161		|O
The	1162	1165		|O
closely	1166	1173		|O
correlation	1174	1185		|O
between	1186	1193		|O
the	1194	1197		|O
damage	1198	1204		|O
index	1205	1210		|O
of	1211	1213		|O
exon	1214	1218		|O
5	1219	1220		|O
and	1221	1224		|O
urinary	1225	1232		|O
organic	1233	1240		|O
arsenic	1241	1248		|O
concentration	1249	1262		|O
are	1263	1266		|O
found	1267	1272		|O
.	1272	1273		|O
Concentration	1274	1287		|O
of	1288	1290		|O
8	1291	1292		|O
-	1292	1293		|O
OHdG	1293	1297		|O
of	1298	1300		|O
the	1301	1304		|O
high	1305	1309		|O
-	1309	1310		|O
exposed	1310	1317		|O
group	1318	1323		|O
is	1324	1326		|O
significantly	1327	1340		|O
higher	1341	1347		|O
than	1348	1352		|O
that	1353	1357		|O
of	1358	1360		|O
the	1361	1364		|O
control	1365	1372		|O
group	1373	1378		|O
.	1378	1379		|O
These	1380	1385		|O
results	1386	1393		|O
imply	1394	1399		|O
that	1400	1404		|O
base	1405	1409		|O
modification	1410	1422		|O
in	1423	1425		|O
exon	1426	1430		|O
5	1431	1432		|O
of	1433	1435		|O
p53	1436	1439		|O
gene	1440	1444		|O
can	1445	1448		|O
be	1449	1451		|O
induced	1452	1459		|O
by	1460	1462		|O
arsenic	1463	1470		|O
.	1470	1471		|O
In	1472	1474		|O
addition	1475	1483		|O
,	1483	1484		|O
our	1485	1488		|O
study	1489	1494		|O
suggests	1495	1503		|O
that	1504	1508		|O
the	1509	1512		|O
damage	1513	1519		|O
level	1520	1525		|O
of	1526	1528		|O
exon	1529	1533		|O
5	1534	1535		|O
is	1536	1538		|O
a	1539	1540		|O
useful	1541	1547		|O
biomarker	1548	1557		|O
to	1558	1560		|O
assess	1561	1567		|O
adverse	1568	1575		|O
health	1576	1582		|O
effect	1583	1589		|O
levels	1590	1596		|O
caused	1597	1603		|O
by	1604	1606		|O
chronic	1607	1614		|O
exposure	1615	1623		|O
to	1624	1626		|O
arsenic	1627	1634		|O
.	1634	1635		|O

### 18721846
Genotoxic	0	9	Genotoxic damage	|B-ADVERSE
damage	10	16		|I-ADVERSE
in	17	19		|O
pathology	20	29		|O
anatomy	30	37		|O
laboratory	38	48		|O
workers	49	56		|O
exposed	57	64		|O
to	65	67		|O
formaldehyde	68	80		|O
.	80	81		|O
Formaldehyde	83	95		|O
(	96	97		|O
FA	97	99		|O
)	99	100		|O
is	101	103		|O
a	104	105		|O
chemical	106	114		|O
traditionally	115	128		|O
used	129	133		|O
in	134	136		|O
pathology	137	146		|O
and	147	150		|O
anatomy	151	158		|O
laboratories	159	171		|O
as	172	174		|O
a	175	176		|O
tissue	177	183		|O
preservative	184	196		|O
.	196	197		|O
Several	198	205		|O
epidemiological	206	221		|O
studies	222	229		|O
of	230	232		|O
occupational	233	245		|O
exposure	246	254		|O
to	255	257		|O
FA	258	260		|O
have	261	265		|O
indicated	266	275		|O
an	276	278		|O
increased	279	288		|O
risk	289	293		|O
of	294	296		|O
nasopharyngeal	297	311	nasopharyngeal cancers	|B-ADVERSE
cancers	312	319		|I-ADVERSE
in	320	322		|O
industrial	323	333		|O
workers	334	341		|O
,	341	342		|O
embalmers	343	352		|O
and	353	356		|O
pathology	357	366		|O
anatomists	367	377		|O
.	377	378		|O
There	379	384		|O
is	385	387		|O
also	388	392		|O
a	393	394		|O
clear	395	400		|O
evidence	401	409		|O
of	410	412		|O
nasal	413	418	nasal squamous cell carcinomas	|B-ADVERSE
squamous	419	427		|I-ADVERSE
cell	428	432		|I-ADVERSE
carcinomas	433	443		|I-ADVERSE
from	444	448		|O
inhalation	449	459		|O
studies	460	467		|O
in	468	470		|O
the	471	474		|O
rat	475	478		|O
.	478	479		|O
The	480	483		|O
postulated	484	494		|O
mode	495	499		|O
of	500	502		|O
action	503	509		|O
for	510	513		|O
nasal	514	519		|O
tumours	520	527		|O
in	528	530		|O
rats	531	535		|O
was	536	539		|O
considered	540	550		|O
biologically	551	563		|O
plausible	564	573		|O
and	574	577		|O
considered	578	588		|O
likely	589	595		|O
to	596	598		|O
be	599	601		|O
relevant	602	610		|O
to	611	613		|O
humans	614	620		|O
.	620	621		|O
Based	622	627		|O
on	628	630		|O
the	631	634		|O
available	635	644		|O
data	645	649		|O
IARC	650	654		|O
,	654	655		|O
the	656	659		|O
International	660	673		|O
Agency	674	680		|O
for	681	684		|O
Research	685	693		|O
on	694	696		|O
Cancer	697	703	Cancer	|B-DISEASE
,	703	704		|O
has	705	708		|O
recently	709	717		|O
classified	718	728		|O
FA	729	731		|O
as	732	734		|O
a	735	736		|O
human	737	742		|O
carcinogen	743	753		|O
.	753	754		|O
Although	755	763		|O
the	764	767		|O
in	768	770		|O
vitro	771	776		|O
genotoxic	777	786		|O
as	787	789		|O
well	790	794		|O
as	795	797		|O
the	798	801		|O
in	802	804		|O
vivo	805	809		|O
carcinogenic	810	822		|O
potentials	823	833		|O
of	834	836		|O
FA	837	839		|O
are	840	843		|O
well	844	848		|O
documented	849	859		|O
in	860	862		|O
mammalian	863	872		|O
cells	873	878		|O
and	879	882		|O
in	883	885		|O
rodents	886	893		|O
,	893	894		|O
evidence	895	903		|O
for	904	907		|O
genotoxic	908	917	genotoxic effects	|B-ADVERSE
effects	918	925		|I-ADVERSE
and	926	929		|O
carcinogenic	930	942		|O
properties	943	953		|O
in	954	956		|O
humans	957	963		|O
is	964	966		|O
insufficient	967	979		|O
and	980	983		|O
conflicting	984	995		|O
thus	996	1000		|O
remains	1001	1008		|O
to	1009	1011		|O
be	1012	1014		|O
more	1015	1019		|O
documented	1020	1030		|O
.	1030	1031		|O
To	1032	1034		|O
evaluate	1035	1043		|O
the	1044	1047		|O
genetic	1048	1055		|O
effects	1056	1063		|O
of	1064	1066		|O
long	1067	1071		|O
-	1071	1072		|O
term	1072	1076		|O
occupational	1077	1089		|O
exposure	1090	1098		|O
to	1099	1101		|O
FA	1102	1104		|O
a	1105	1106		|O
group	1107	1112		|O
of	1113	1115		|O
30	1116	1118		|O
Pathological	1119	1131		|O
Anatomy	1132	1139		|O
laboratory	1140	1150		|O
workers	1151	1158		|O
was	1159	1162		|O
tested	1163	1169		|O
for	1170	1173		|O
a	1174	1175		|O
variety	1176	1183		|O
of	1184	1186		|O
biological	1187	1197		|O
endpoints	1198	1207		|O
,	1207	1208		|O
cytogenetic	1209	1220		|O
tests	1221	1226		|O
(	1227	1228		|O
micronuclei	1228	1239		|O
,	1239	1240		|O
MN	1241	1243		|O
;	1243	1244		|O
sister	1245	1251		|O
chromatid	1252	1261		|O
exchange	1262	1270		|O
,	1270	1271		|O
SCE	1272	1275		|O
)	1275	1276		|O
and	1277	1280		|O
comet	1281	1286		|O
assay	1287	1292		|O
.	1292	1293		|O
The	1294	1297		|O
level	1298	1303		|O
of	1304	1306		|O
exposure	1307	1315		|O
to	1316	1318		|O
FA	1319	1321		|O
was	1322	1325		|O
evaluated	1326	1335		|O
near	1336	1340		|O
the	1341	1344		|O
breathing	1345	1354		|O
zone	1355	1359		|O
of	1360	1362		|O
workers	1363	1370		|O
,	1370	1371		|O
time	1372	1376		|O
weighted	1377	1385		|O
average	1386	1393		|O
of	1394	1396		|O
exposure	1397	1405		|O
was	1406	1409		|O
calculated	1410	1420		|O
for	1421	1424		|O
each	1425	1429		|O
subject	1430	1437		|O
.	1437	1438		|O
The	1439	1442		|O
association	1443	1454		|O
between	1455	1462		|O
the	1463	1466		|O
biomarkers	1467	1477		|O
and	1478	1481		|O
polymorphic	1482	1493		|O
genes	1494	1499		|O
of	1500	1502		|O
xenobiotic	1503	1513		|O
metabolising	1514	1526		|O
and	1527	1530		|O
DNA	1531	1534		|O
repair	1535	1541		|O
enzymes	1542	1549		|O
was	1550	1553		|O
also	1554	1558		|O
assessed	1559	1567		|O
.	1567	1568		|O
The	1569	1572		|O
mean	1573	1577		|O
level	1578	1583		|O
of	1584	1586		|O
exposure	1587	1595		|O
was	1596	1599		|O
0.44	1600	1604		|O
+	1604	1605		|O
/	1605	1606		|O
-	1606	1607		|O
0.08	1607	1611		|O
ppm	1611	1614		|O
(	1615	1616		|O
0.04-1.58	1616	1625		|O
ppm	1625	1628		|O
)	1628	1629		|O
.	1629	1630		|O
MN	1631	1633		|O
frequency	1634	1643		|O
was	1644	1647		|O
significantly	1648	1661		|O
higher	1662	1668		|O
(	1669	1670		|O
p	1670	1671		|O
=	1671	1672		|O
0.003	1672	1677		|O
)	1677	1678		|O
in	1679	1681		|O
the	1682	1685		|O
exposed	1686	1693		|O
subjects	1694	1702		|O
(	1703	1704		|O
5.47	1704	1708		|O
+	1708	1709		|O
/	1709	1710		|O
-	1710	1711		|O
0.76	1711	1715		|O
)	1715	1716		|O
when	1717	1721		|O
compared	1722	1730		|O
with	1731	1735		|O
controls	1736	1744		|O
(	1745	1746		|O
3.27	1746	1750		|O
+	1750	1751		|O
/	1751	1752		|O
-	1752	1753		|O
0.69	1753	1757		|O
)	1757	1758		|O
.	1758	1759		|O
SCE	1760	1763		|O
mean	1764	1768		|O
value	1769	1774		|O
was	1775	1778		|O
significantly	1779	1792		|O
higher	1793	1799		|O
(	1800	1801		|O
p	1801	1802		|O
<	1802	1803		|O
0.05	1803	1807		|O
)	1807	1808		|O
among	1809	1814		|O
the	1815	1818		|O
exposed	1819	1826		|O
group	1827	1832		|O
(	1833	1834		|O
6.13	1834	1838		|O
+	1838	1839		|O
/	1839	1840		|O
-	1840	1841		|O
0.29	1841	1845		|O
)	1845	1846		|O
compared	1847	1855		|O
with	1856	1860		|O
control	1861	1868		|O
group	1869	1874		|O
(	1875	1876		|O
4.49	1876	1880		|O
+	1880	1881		|O
/	1881	1882		|O
-	1882	1883		|O
0.16	1883	1887		|O
)	1887	1888		|O
.	1888	1889		|O
Comet	1890	1895		|O
assay	1896	1901		|O
data	1902	1906		|O
showed	1907	1913		|O
a	1914	1915		|O
significant	1916	1927		|O
increase	1928	1936		|O
(	1937	1938		|O
p	1938	1939		|O
<	1939	1940		|O
0.05	1940	1944		|O
)	1944	1945		|O
of	1946	1948		|O
TL	1949	1951		|O
in	1952	1954		|O
FA	1955	1957		|O
-	1957	1958		|O
exposed	1958	1965		|O
workers	1966	1973		|O
(	1974	1975		|O
60.00	1975	1980		|O
+	1980	1981		|O
/	1981	1982		|O
-	1982	1983		|O
2.31	1983	1987		|O
)	1987	1988		|O
with	1989	1993		|O
respect	1994	2001		|O
to	2002	2004		|O
the	2005	2008		|O
control	2009	2016		|O
group	2017	2022		|O
(	2023	2024		|O
41.85	2024	2029		|O
+	2029	2030		|O
/	2030	2031		|O
-	2031	2032		|O
1.97	2032	2036		|O
)	2036	2037		|O
.	2037	2038		|O
A	2039	2040		|O
positive	2041	2049		|O
correlation	2050	2061		|O
was	2062	2065		|O
found	2066	2071		|O
between	2072	2079		|O
FA	2080	2082		|O
exposure	2083	2091		|O
levels	2092	2098		|O
and	2099	2102		|O
MN	2103	2105		|O
frequency	2106	2115		|O
(	2116	2117		|O
r	2117	2118		|O
=	2118	2119		|O
0.384	2119	2124		|O
,	2124	2125		|O
p	2126	2127		|O
=	2127	2128		|O
0.001	2128	2133		|O
)	2133	2134		|O
and	2135	2138		|O
TL	2139	2141		|O
(	2142	2143		|O
r	2143	2144		|O
=	2144	2145		|O
0.333	2145	2150		|O
,	2150	2151		|O
p	2152	2153		|O
=	2153	2154		|O
0.005	2154	2159		|O
)	2159	2160		|O
.	2160	2161		|O
Regarding	2162	2171		|O
the	2172	2175		|O
genetic	2176	2183		|O
polymorphisms	2184	2197		|O
studied	2198	2205		|O
,	2205	2206		|O
no	2207	2209		|O
significant	2210	2221		|O
effect	2222	2228		|O
was	2229	2232		|O
found	2233	2238		|O
on	2239	2241		|O
the	2242	2245		|O
genotoxic	2246	2255		|O
endpoints	2256	2265		|O
.	2265	2266		|O
The	2267	2270		|O
results	2271	2278		|O
of	2279	2281		|O
the	2282	2285		|O
present	2286	2293		|O
biomonitoring	2294	2307		|O
study	2308	2313		|O
emphasize	2314	2323		|O
the	2324	2327		|O
need	2328	2332		|O
to	2333	2335		|O
develop	2336	2343		|O
safety	2344	2350		|O
programs	2351	2359		|O
.	2359	2360		|O

### 18677425
A	0	1		|O
novel	2	7		|O
panel	8	13		|O
of	14	16		|O
mouse	17	22		|O
models	23	29		|O
to	30	32		|O
evaluate	33	41		|O
the	42	45		|O
role	46	50		|O
of	51	53		|O
human	54	59		|O
pregnane	60	68		|O
X	69	70		|O
receptor	71	79		|O
and	80	83		|O
constitutive	84	96		|O
androstane	97	107		|O
receptor	108	116		|O
in	117	119		|O
drug	120	124		|O
response	125	133		|O
.	133	134		|O
The	136	139		|O
pregnane	140	148		|O
X	149	150		|O
receptor	151	159		|O
(	160	161		|O
PXR	161	164		|O
)	164	165		|O
and	166	169		|O
the	170	173		|O
constitutive	174	186		|O
androstane	187	197		|O
receptor	198	206		|O
(	207	208		|O
CAR	208	211		|O
)	211	212		|O
are	213	216		|O
closely	217	224		|O
related	225	232		|O
orphan	233	239		|O
nuclear	240	247		|O
hormone	248	255		|O
receptors	256	265		|O
that	266	270		|O
play	271	275		|O
a	276	277		|O
critical	278	286		|O
role	287	291		|O
as	292	294		|O
xenobiotic	295	305		|O
sensors	306	313		|O
in	314	316		|O
mammals	317	324		|O
.	324	325		|O
Both	326	330		|O
receptors	331	340		|O
regulate	341	349		|O
the	350	353		|O
expression	354	364		|O
of	365	367		|O
genes	368	373		|O
involved	374	382		|O
in	383	385		|O
the	386	389		|O
biotransformation	390	407		|O
of	408	410		|O
chemicals	411	420		|O
in	421	423		|O
a	424	425		|O
ligand	426	432		|O
-	432	433		|O
dependent	433	442		|O
manner	443	449		|O
.	449	450		|O
As	451	453		|O
the	454	457		|O
ligand	458	464		|O
specificity	465	476		|O
of	477	479		|O
PXR	480	483		|O
and	484	487		|O
CAR	488	491		|O
have	492	496		|O
diverged	497	505		|O
between	506	513		|O
species	514	521		|O
,	521	522		|O
the	523	526		|O
prediction	527	537		|O
of	538	540		|O
in	541	543		|O
vivo	544	548		|O
PXR	549	552		|O
and	553	556		|O
CAR	557	560		|O
interactions	561	573		|O
with	574	578		|O
a	579	580		|O
drug	581	585		|O
are	586	589		|O
difficult	590	599		|O
to	600	602		|O
extrapolate	603	614		|O
from	615	619		|O
animals	620	627		|O
to	628	630		|O
humans	631	637		|O
.	637	638		|O
We	639	641		|O
report	642	648		|O
the	649	652		|O
development	653	664		|O
of	665	667		|O
what	668	672		|O
we	673	675		|O
believe	676	683		|O
are	684	687		|O
novel	688	693		|O
PXR	694	697		|O
-	697	698		|O
and	699	702		|O
CAR	703	706		|O
-	706	707		|O
humanized	707	716		|O
mice	717	721		|O
,	721	722		|O
generated	723	732		|O
using	733	738		|O
a	739	740		|O
knockin	741	748		|O
strategy	749	757		|O
,	757	758		|O
and	759	762		|O
Pxr	763	766		|O
-	766	767		|O
and	768	771		|O
Car	772	775		|O
-	775	776		|O
KO	776	778		|O
mice	779	783		|O
as	784	786		|O
well	787	791		|O
as	792	794		|O
a	795	796		|O
panel	797	802		|O
of	803	805		|O
mice	806	810		|O
including	811	820		|O
all	821	824		|O
possible	825	833		|O
combinations	834	846		|O
of	847	849		|O
these	850	855		|O
genetic	856	863		|O
alterations	864	875		|O
.	875	876		|O
The	877	880		|O
expression	881	891		|O
of	892	894		|O
human	895	900		|O
CAR	901	904		|O
and	905	908		|O
PXR	909	912		|O
was	913	916		|O
in	917	919		|O
the	920	923		|O
predicted	924	933		|O
tissues	934	941		|O
at	942	944		|O
physiological	945	958		|O
levels	959	965		|O
,	965	966		|O
and	967	970		|O
splice	971	977		|O
variants	978	986		|O
of	987	989		|O
both	990	994		|O
human	995	1000		|O
receptors	1001	1010		|O
were	1011	1015		|O
expressed	1016	1025		|O
.	1025	1026		|O
The	1027	1030		|O
panel	1031	1036		|O
of	1037	1039		|O
mice	1040	1044		|O
will	1045	1049		|O
allow	1050	1055		|O
the	1056	1059		|O
dissection	1060	1070		|O
of	1071	1073		|O
the	1074	1077		|O
crosstalk	1078	1087		|O
between	1088	1095		|O
PXR	1096	1099		|O
and	1100	1103		|O
CAR	1104	1107		|O
in	1108	1110		|O
the	1111	1114		|O
response	1115	1123		|O
to	1124	1126		|O
different	1127	1136		|O
drugs	1137	1142		|O
.	1142	1143		|O
To	1144	1146		|O
demonstrate	1147	1158		|O
the	1159	1162		|O
utility	1163	1170		|O
of	1171	1173		|O
this	1174	1178		|O
panel	1179	1184		|O
of	1185	1187		|O
mice	1188	1192		|O
,	1192	1193		|O
we	1194	1196		|O
used	1197	1201		|O
the	1202	1205		|O
mice	1206	1210		|O
to	1211	1213		|O
show	1214	1218		|O
that	1219	1223		|O
the	1224	1227		|O
in	1228	1230		|O
vivo	1231	1235		|O
induction	1236	1245		|O
of	1246	1248		|O
Cyp3a11	1249	1256		|O
and	1257	1260		|O
Cyp2b10	1261	1268		|O
by	1269	1271		|O
phenobarbital	1272	1285		|O
was	1286	1289		|O
only	1290	1294		|O
mediated	1295	1303		|O
by	1304	1306		|O
CAR	1307	1310		|O
,	1310	1311		|O
although	1312	1320		|O
this	1321	1325		|O
compound	1326	1334		|O
is	1335	1337		|O
described	1338	1347		|O
as	1348	1350		|O
a	1351	1352		|O
PXR	1353	1356		|O
and	1357	1360		|O
CAR	1361	1364		|O
activator	1365	1374		|O
in	1375	1377		|O
vitro	1378	1383		|O
.	1383	1384		|O
This	1385	1389		|O
panel	1390	1395		|O
of	1396	1398		|O
mouse	1399	1404		|O
models	1405	1411		|O
is	1412	1414		|O
a	1415	1416		|O
useful	1417	1423		|O
tool	1424	1428		|O
to	1429	1431		|O
evaluate	1432	1440		|O
the	1441	1444		|O
roles	1445	1450		|O
of	1451	1453		|O
CAR	1454	1457		|O
and	1458	1461		|O
PXR	1462	1465		|O
in	1466	1468		|O
drug	1469	1473		|O
bioavailability	1474	1489		|O
,	1489	1490		|O
toxicity	1491	1499		|O
,	1499	1500		|O
and	1501	1504		|O
efficacy	1505	1513		|O
in	1514	1516		|O
humans	1517	1523		|O
.	1523	1524		|O

### 18605226
Paraquat	0	8		|O
and	9	12		|O
maneb	13	18		|O
induced	19	26		|O
neurotoxicity	27	40	neurotoxicity	|B-ADVERSE
.	40	41		|O
Parkinson	43	52	Parkinson's disease	|B-DISEASE
's	52	54		|I-DISEASE
disease	55	62		|I-DISEASE
is	63	65		|O
a	66	67		|O
progressive	68	79		|O
neurological	80	92	neurological disorder	|B-DISEASE
disorder	93	101		|I-DISEASE
associated	102	112		|O
with	113	117		|O
selective	118	127		|O
degeneration	128	140		|O
of	141	143		|O
nigrostriatal	144	157		|O
dopaminergic	158	170		|O
neurons	171	178		|O
.	178	179		|O
It	180	182		|O
is	183	185		|O
the	186	189		|O
most	190	194		|O
common	195	201		|O
of	202	204		|O
the	205	208		|O
neurodegenerative	209	226	neurodegenerative movement disorders	|B-DISEASE
movement	227	235		|I-DISEASE
disorders	236	245		|I-DISEASE
,	245	246		|O
affecting	247	256		|O
approximately	257	270		|O
1%	271	273		|O
of	274	276		|O
the	277	280		|O
population	281	291		|O
over	292	296		|O
age	297	300		|O
65	301	303		|O
.	303	304		|O
Though	305	311		|O
the	312	315		|O
exact	316	321		|O
cause	322	327		|O
of	328	330		|O
the	331	334		|O
neurodegeneration	335	352	neurodegeneration	|B-DISEASE
is	353	355		|O
unknown	356	363		|O
,	363	364		|O
it	365	367		|O
has	368	371		|O
been	372	376		|O
shown	377	382		|O
that	383	387		|O
environmental	388	401		|O
factors	402	409		|O
can	410	413		|O
contribute	414	424		|O
to	425	427		|O
the	428	431		|O
onset	432	437		|O
of	438	440		|O
Parkinson	441	450	Parkinson's disease	|B-DISEASE
's	450	452		|I-DISEASE
disease	453	460		|I-DISEASE
.	460	461		|O
Parkinsonian	462	474	Parkinsonian symptoms	|B-DISEASE
symptoms	475	483		|I-DISEASE
are	484	487		|O
seen	488	492		|O
following	493	502		|O
exposure	503	511		|O
to	512	514		|O
the	515	518		|O
herbicide	519	528		|O
paraquat	529	537		|O
,	537	538		|O
and	539	542		|O
the	543	546		|O
fungicide	547	556		|O
maneb	557	562		|O
.	562	563		|O
Furthermore	564	575		|O
,	575	576		|O
evidence	577	585		|O
clearly	586	593		|O
shows	594	599		|O
that	600	604		|O
neurodegeneration	605	622	neurodegeneration	|B-DISEASE
develops	623	631		|O
in	632	634		|O
environments	635	647		|O
where	648	653		|O
workers	654	661		|O
are	662	665		|O
co	666	668		|O
-	668	669		|O
exposed	669	676		|O
to	677	679		|O
paraquat	680	688		|O
and	689	692		|O
maneb	693	698		|O
.	698	699		|O
These	700	705		|O
neurotoxins	706	717		|O
cause	718	723		|O
a	724	725		|O
pesticide	726	735		|O
-	735	736		|O
induced	736	743		|O
loss	744	748		|O
of	749	751		|O
dopaminergic	752	764		|O
neurons	765	772		|O
,	772	773		|O
inducing	774	782		|O
a	783	784		|O
Parkinsonian	785	797		|O
phenotype	798	807		|O
.	807	808		|O
The	809	812		|O
specific	813	821		|O
mechanisms	822	832		|O
by	833	835		|O
which	836	841		|O
these	842	847		|O
environmental	848	861		|O
neurotoxins	862	873		|O
affect	874	880		|O
the	881	884		|O
nigral	885	891		|O
dopaminergic	892	904		|O
neurons	905	912		|O
are	913	916		|O
unknown	917	924		|O
.	924	925		|O
This	926	930		|O
gap	931	934		|O
in	935	937		|O
mechanistic	938	949		|O
understanding	950	963		|O
raises	964	970		|O
a	971	972		|O
need	973	977		|O
for	978	981		|O
further	982	989		|O
examination	990	1001		|O
of	1002	1004		|O
their	1005	1010		|O
cytotoxic	1011	1020	cytotoxic effects	|B-ADVERSE
effects	1021	1028		|I-ADVERSE
.	1028	1029		|O
Despite	1030	1037		|O
advances	1038	1046		|O
in	1047	1049		|O
pharmacotherapy	1050	1065		|O
that	1066	1070		|O
have	1071	1075		|O
improved	1076	1084		|O
quality	1085	1092		|O
of	1093	1095		|O
life	1096	1100		|O
,	1100	1101		|O
the	1102	1105		|O
mortality	1106	1115		|O
rate	1116	1120		|O
among	1121	1126		|O
Parkinson	1127	1136	Parkinson's disease	|B-DISEASE
's	1136	1138		|I-DISEASE
disease	1139	1146		|I-DISEASE
sufferers	1147	1156		|O
remains	1157	1164		|O
largely	1165	1172		|O
unchanged	1173	1182		|O
.	1182	1183		|O
There	1184	1189		|O
is	1190	1192		|O
need	1193	1197		|O
for	1198	1201		|O
a	1202	1203		|O
proactive	1204	1213		|O
treatment	1214	1223		|O
strategy	1224	1232		|O
that	1233	1237		|O
could	1238	1243		|O
provide	1244	1251		|O
neuroprotection	1252	1267		|O
or	1268	1270		|O
neurorestoration	1271	1287		|O
.	1287	1288		|O
Since	1289	1294		|O
evidence	1295	1303		|O
has	1304	1307		|O
shown	1308	1313		|O
that	1314	1318		|O
environmental	1319	1332		|O
neurotoxins	1333	1344		|O
play	1345	1349		|O
an	1350	1352		|O
important	1353	1362		|O
role	1363	1367		|O
in	1368	1370		|O
nigral	1371	1377		|O
degeneration	1378	1390		|O
,	1390	1391		|O
there	1392	1397		|O
is	1398	1400		|O
obviously	1401	1410		|O
a	1411	1412		|O
need	1413	1417		|O
to	1418	1420		|O
take	1421	1425		|O
a	1426	1427		|O
closer	1428	1434		|O
look	1435	1439		|O
at	1440	1442		|O
such	1443	1447		|O
toxins	1448	1454		|O
since	1455	1460		|O
a	1461	1462		|O
greater	1463	1470		|O
understanding	1471	1484		|O
could	1485	1490		|O
aid	1491	1494		|O
in	1495	1497		|O
development	1498	1509		|O
of	1510	1512		|O
novel	1513	1518		|O
pharmacological	1519	1534		|O
agents	1535	1541		|O
with	1542	1546		|O
anti	1547	1551		|O
-	1551	1552		|O
parkinson	1552	1561		|O
and	1562	1565		|O
neuroprotective	1566	1581		|O
effects	1582	1589		|O
.	1589	1590		|O
In	1591	1593		|O
this	1594	1598		|O
review	1599	1605		|O
,	1605	1606		|O
we	1607	1609		|O
intend	1610	1616		|O
to	1617	1619		|O
examine	1620	1627		|O
the	1628	1631		|O
role	1632	1636		|O
of	1637	1639		|O
environmental	1640	1653		|O
toxins	1654	1660		|O
,	1660	1661		|O
namely	1662	1668		|O
paraquat	1669	1677		|O
and	1678	1681		|O
maneb	1682	1687		|O
,	1687	1688		|O
in	1689	1691		|O
the	1692	1695		|O
neurotoxicity	1696	1709	neurotoxicity	|B-ADVERSE
that	1710	1714		|O
leads	1715	1720		|O
to	1721	1723		|O
dopamine	1724	1732		|O
depletion	1733	1742		|O
.	1742	1743		|O

### 18691879
Carboplatin	0	11		|O
and	12	15		|O
paclitaxel	16	26		|O
versus	27	33		|O
cisplatin	34	43		|O
,	43	44		|O
paclitaxel	45	55		|O
and	56	59		|O
doxorubicin	60	71		|O
for	72	75		|O
first	76	81		|O
-	81	82		|O
line	82	86		|O
chemotherapy	87	99		|O
of	100	102		|O
advanced	103	111		|O
ovarian	112	119	ovarian cancer	|B-DISEASE
cancer	120	126		|I-DISEASE
:	126	127		|O
a	128	129		|O
Hellenic	130	138		|O
Cooperative	139	150		|O
Oncology	151	159		|O
Group	160	165		|O
(	166	167		|O
HeCOG	167	172		|O
)	172	173		|O
study	174	179		|O
.	179	180		|O
INTRODUCTION	182	194		|O
:	194	195		|O
The	196	199		|O
combination	200	211		|O
of	212	214		|O
Carboplatin	215	226		|O
and	227	230		|O
Paclitaxel	231	241		|O
is	242	244		|O
considered	245	255		|O
the	256	259		|O
standard	260	268		|O
of	269	271		|O
care	272	276		|O
as	277	279		|O
initial	280	287		|O
chemotherapy	288	300		|O
for	301	304		|O
Advanced	305	313		|O
Ovarian	314	321	Ovarian Cancer	|B-DISEASE
Cancer	322	328		|I-DISEASE
(	329	330		|O
AOC	330	333	AOC	|B-DISEASE
)	333	334		|O
.	334	335		|O
We	336	338		|O
compared	339	347		|O
this	348	352		|O
regimen	353	360		|O
with	361	365		|O
the	366	369		|O
combination	370	381		|O
of	382	384		|O
Cisplatin	385	394		|O
,	394	395		|O
Paclitaxel	396	406		|O
and	407	410		|O
Doxorubicin	411	422		|O
.	422	423		|O
PATIENTS	424	432		|O
AND	433	436		|O
METHODS	437	444		|O
:	444	445		|O
Patients	446	454		|O
with	455	459		|O
AOC	460	463	AOC	|B-DISEASE
were	464	468		|O
randomised	469	479		|O
to	480	482		|O
either	483	489		|O
six	490	493		|O
courses	494	501		|O
of	502	504		|O
Paclitaxel	505	515		|O
175mg	516	521		|O
/	521	522		|O
m	522	523		|O
(	523	524		|O
2	524	525		|O
)	525	526		|O
plus	527	531		|O
Carboplatin	532	543		|O
7AUC	544	548		|O
or	549	551		|O
Paclitaxel	552	562		|O
at	563	565		|O
the	566	569		|O
same	570	574		|O
dose	575	579		|O
plus	580	584		|O
Cisplatin	585	594		|O
75mg	595	599		|O
/	599	600		|O
m	600	601		|O
(	601	602		|O
2	602	603		|O
)	603	604		|O
plus	605	609		|O
Doxorubicin	610	621		|O
40mg	622	626		|O
/	626	627		|O
m	627	628		|O
(	628	629		|O
2	629	630		|O
)	630	631		|O
.	631	632		|O
RESULTS	633	640		|O
:	640	641		|O
Analysis	642	650		|O
was	651	654		|O
performed	655	664		|O
on	665	667		|O
451	668	671		|O
patients	672	680		|O
.	680	681		|O
The	682	685		|O
treatment	686	695		|O
groups	696	702		|O
were	703	707		|O
well	708	712		|O
balanced	713	721		|O
with	722	726		|O
regard	727	733		|O
to	734	736		|O
patient	737	744		|O
and	745	748		|O
disease	749	756		|O
characteristics	757	772		|O
.	772	773		|O
Performance	774	785		|O
status	786	792		|O
(	793	794		|O
PS	794	796		|O
)	796	797		|O
was	798	801		|O
better	802	808		|O
in	809	811		|O
the	812	815		|O
anthracycline	816	829		|O
arm	830	833		|O
.	833	834		|O
In	835	837		|O
terms	838	843		|O
of	844	846		|O
severe	847	853		|O
toxicity	854	862		|O
,	862	863		|O
the	864	867		|O
only	868	872		|O
significant	873	884		|O
difference	885	895		|O
between	896	903		|O
the	904	907		|O
two	908	911		|O
groups	912	918		|O
was	919	922		|O
the	923	926		|O
development	927	938		|O
of	939	941		|O
febrile	942	949	febrile neutropaenia	|B-ADVERSE
neutropaenia	950	962		|I-ADVERSE
in	963	965		|O
the	966	969		|O
anthracycline	970	983		|O
arm	984	987		|O
.	987	988		|O
Overall	989	996		|O
response	997	1005		|O
rate	1006	1010		|O
was	1011	1014		|O
similar	1015	1022		|O
in	1023	1025		|O
both	1026	1030		|O
groups	1031	1037		|O
.	1037	1038		|O
With	1039	1043		|O
a	1044	1045		|O
median	1046	1052		|O
follow	1053	1059		|O
-	1059	1060		|O
up	1060	1062		|O
of	1063	1065		|O
57.5	1066	1070		|O
months	1071	1077		|O
,	1077	1078		|O
a	1079	1080		|O
marginal	1081	1089		|O
significance	1090	1102		|O
towards	1103	1110		|O
improved	1111	1119		|O
Progression	1120	1131		|O
-	1131	1132		|O
Free	1132	1136		|O
Survival	1137	1145		|O
(	1146	1147		|O
PFS	1147	1150		|O
)	1150	1151		|O
was	1152	1155		|O
noted	1156	1161		|O
in	1162	1164		|O
favour	1165	1171		|O
of	1172	1174		|O
the	1175	1178		|O
anthracycline	1179	1192		|O
arm	1193	1196		|O
,	1196	1197		|O
whilst	1198	1204		|O
there	1205	1210		|O
was	1211	1214		|O
no	1215	1217		|O
difference	1218	1228		|O
in	1229	1231		|O
overall	1232	1239		|O
survival	1240	1248		|O
.	1248	1249		|O
In	1250	1252		|O
multivariate	1253	1265		|O
analysis	1266	1274		|O
the	1275	1278		|O
hazard	1279	1285		|O
of	1286	1288		|O
disease	1289	1296		|O
progression	1297	1308		|O
at	1309	1311		|O
any	1312	1315		|O
time	1316	1320		|O
was	1321	1324		|O
significantly	1325	1338		|O
decreased	1339	1348		|O
by	1349	1351		|O
25.5%	1352	1357		|O
for	1358	1361		|O
patients	1362	1370		|O
of	1371	1373		|O
the	1374	1377		|O
anthracycline	1378	1391		|O
arm	1392	1395		|O
.	1395	1396		|O
CONCLUSION	1397	1407		|O
:	1407	1408		|O
The	1409	1412		|O
combination	1413	1424		|O
of	1425	1427		|O
Cisplatin	1428	1437		|O
,	1437	1438		|O
Paclitaxel	1439	1449		|O
and	1450	1453		|O
Doxorubicin	1454	1465		|O
demonstrates	1466	1478		|O
a	1479	1480		|O
marginal	1481	1489		|O
PFS	1490	1493		|O
improvement	1494	1505		|O
,	1505	1506		|O
but	1507	1510		|O
no	1511	1513		|O
additional	1514	1524		|O
survival	1525	1533		|O
benefit	1534	1541		|O
when	1542	1546		|O
compared	1547	1555		|O
with	1556	1560		|O
the	1561	1564		|O
standard	1565	1573		|O
Carboplatin	1574	1585		|O
/	1585	1586		|O
Paclitaxel	1586	1596		|O
regimen	1597	1604		|O
.	1604	1605		|O

### 18710788
Use	0	3		|O
of	4	6		|O
flow	7	11		|O
cytometry	12	21		|O
in	22	24		|O
an	25	27		|O
apoptosis	28	37		|O
assay	38	43		|O
to	44	46		|O
determine	47	56		|O
pH	57	59		|O
and	60	63		|O
temperature	64	75		|O
stability	76	85		|O
of	86	88		|O
shiga	89	94		|O
-	94	95		|O
like	95	99		|O
toxin	100	105		|O
1	106	107		|O
.	107	108		|O
Shiga	110	115		|O
toxins	116	122		|O
and	123	126		|O
Shiga	127	132		|O
-	132	133		|O
like	133	137		|O
toxins	138	144		|O
(	145	146		|O
Stx	146	149		|O
)	149	150		|O
are	151	154		|O
a	155	156		|O
relatively	157	167		|O
large	168	173		|O
group	174	179		|O
of	180	182		|O
cytotoxins	183	193		|O
produced	194	202		|O
by	203	205		|O
certain	206	213		|O
serotypes	214	223		|O
of	224	226		|O
Shigella	227	235		|O
and	236	239		|O
E	240	241		|O
.	241	242		|O
coli	243	247		|O
(	248	249		|O
STEC	249	253		|O
)	253	254		|O
.	254	255		|O
These	256	261		|O
toxins	262	268		|O
are	269	272		|O
responsible	273	284		|O
for	285	288		|O
diarrhea	289	297	diarrhea	|B-ADVERSE
,	297	298		|O
hemorrhagic	299	310	hemorrhagic colitis	|B-ADVERSE
colitis	311	318		|I-ADVERSE
and	319	322		|O
may	323	326		|O
induce	327	333		|O
hemolytic	334	343	hemolytic uremic syndrome	|B-ADVERSE
uremic	344	350		|I-ADVERSE
syndrome	351	359		|I-ADVERSE
(	360	361		|O
HUS	361	364	HUS	|B-ADVERSE
)	364	365		|O
with	366	370		|O
serious	371	378		|O
consequences	379	391		|O
in	392	394		|O
young	395	400		|O
children	401	409		|O
.	409	410		|O
The	411	414		|O
toxins	415	421		|O
are	422	425		|O
proteins	426	434		|O
made	435	439		|O
up	440	442		|O
of	443	445		|O
5	446	447		|O
small	448	453		|O
B	454	455		|O
subunits	456	464		|O
responsible	465	476		|O
for	477	480		|O
binding	481	488		|O
to	489	491		|O
an	492	494		|O
outer	495	500		|O
membrane	501	509		|O
ligand	510	516		|O
on	517	519		|O
host	520	524		|O
cells	525	530		|O
and	531	534		|O
surround	535	543		|O
the	544	547		|O
larger	548	554		|O
,	554	555		|O
biologically	556	568		|O
active	569	575		|O
A	576	577		|O
subunit	578	585		|O
.	585	586		|O
For	587	590		|O
Shiga	591	596		|O
-	596	597		|O
like	597	601		|O
toxin	602	607		|O
1	608	609		|O
(	610	611		|O
Stx1	611	615		|O
)	615	616		|O
,	616	617		|O
the	618	621		|O
cellular	622	630		|O
receptor	631	639		|O
is	640	642		|O
the	643	646		|O
carbohydrate	647	659		|O
globotriose	660	671		|O
.	671	672		|O
Stx1was	673	680		|O
purified	681	689		|O
from	690	694		|O
STEC	695	699		|O
.	699	700		|O
We	701	703		|O
utilized	704	712		|O
induction	713	722		|O
of	723	725		|O
apoptosis	726	735		|O
in	736	738		|O
the	739	742		|O
human	743	748		|O
monocyte	749	757		|O
cell	758	762		|O
line	763	767		|O
THP	768	771		|O
-	771	772		|O
1	772	773		|O
,	773	774		|O
as	775	777		|O
a	778	779		|O
biological	780	790		|O
endpoint	791	799		|O
to	800	802		|O
test	803	807		|O
the	808	811		|O
stability	812	821		|O
of	822	824		|O
Stx1	825	829		|O
activity	830	838		|O
added	839	844		|O
to	845	847		|O
fruit	848	853		|O
punch	854	859		|O
at	860	862		|O
different	863	872		|O
pH	873	875		|O
(	876	877		|O
2-9	877	880		|O
)	880	881		|O
and	882	885		|O
temperatures	886	898		|O
(	899	900		|O
4	900	901		|O
and	902	905		|O
20	906	908		|O
degrees	909	916		|O
C	917	918		|O
)	918	919		|O
.	919	920		|O
A	921	922		|O
flow	923	927		|O
cytometric	928	938		|O
method	939	945		|O
was	946	949		|O
used	950	954		|O
to	955	957		|O
test	958	962		|O
for	963	966		|O
early	967	972		|O
and	973	976		|O
late	977	981		|O
apoptotic	982	991		|O
events	992	998		|O
based	999	1004		|O
on	1005	1007		|O
binding	1008	1015		|O
of	1016	1018		|O
R	1019	1020		|O
-	1020	1021		|O
phycoerytherin	1021	1035		|O
-	1035	1036		|O
labeled	1036	1043		|O
annexin	1044	1051		|O
V	1052	1053		|O
to	1054	1056		|O
exposed	1057	1064		|O
membrane	1065	1073		|O
phosphatidyl	1074	1086		|O
serine	1087	1093		|O
.	1093	1094		|O
Membrane	1095	1103		|O
permeability	1104	1116		|O
to	1117	1119		|O
7	1120	1121		|O
-	1121	1122		|O
Amino	1122	1127		|O
-	1127	1128		|O
actinomycin	1128	1139		|O
corresponds	1140	1151		|O
with	1152	1156		|O
late	1157	1161		|O
apoptosis	1162	1171		|O
or	1172	1174		|O
necrosis	1175	1183		|O
.	1183	1184		|O
The	1185	1188		|O
combination	1189	1200		|O
of	1201	1203		|O
acid	1204	1208		|O
pH	1209	1211		|O
and	1212	1215		|O
higher	1216	1222		|O
storage	1223	1230		|O
temperature	1231	1242		|O
resulted	1243	1251		|O
in	1252	1254		|O
greatest	1255	1263		|O
degree	1264	1270		|O
of	1271	1273		|O
toxin	1274	1279		|O
inactivation	1280	1292		|O
.	1292	1293		|O
This	1294	1298		|O
approach	1299	1307		|O
provides	1308	1316		|O
a	1317	1318		|O
rapid	1319	1324		|O
and	1325	1328		|O
high	1329	1333		|O
throughput	1334	1344		|O
method	1345	1351		|O
to	1352	1354		|O
determine	1355	1364		|O
the	1365	1368		|O
functional	1369	1379		|O
activity	1380	1388		|O
of	1389	1391		|O
Stx1	1392	1396		|O
,	1396	1397		|O
and	1398	1401		|O
related	1402	1409		|O
toxins	1410	1416		|O
in	1417	1419		|O
a	1420	1421		|O
food	1422	1426		|O
matrix	1427	1433		|O
.	1433	1434		|O

### 18652557
Immunocompromised	0	17		|O
hosts	18	23		|O
:	23	24		|O
perspectives	25	37		|O
in	38	40		|O
the	41	44		|O
treatment	45	54		|O
and	55	58		|O
prophylaxis	59	70		|O
of	71	73		|O
cytomegalovirus	74	89	cytomegalovirus disease	|B-DISEASE
disease	90	97		|I-DISEASE
in	98	100		|O
solid	101	106		|O
-	106	107		|O
organ	107	112		|O
transplant	113	123		|O
recipients	124	134		|O
.	134	135		|O
Cytomegalovirus	137	152	Cytomegalovirus (CMV) infection	|B-DISEASE
(	153	154		|I-DISEASE
CMV	154	157		|I-DISEASE
)	157	158		|I-DISEASE
infection	159	168		|I-DISEASE
is	169	171		|O
an	172	174		|O
important	175	184		|O
complication	185	197		|O
of	198	200		|O
solid	201	206		|O
-	206	207		|O
organ	207	212		|O
transplantation	213	228		|O
.	228	229		|O
The	230	233		|O
availability	234	246		|O
of	247	249		|O
potent	250	256		|O
antiviral	257	266		|O
therapies	267	276		|O
has	277	280		|O
decreased	281	290		|O
the	291	294		|O
incidence	295	304		|O
of	305	307		|O
CMV	308	311	CMV disease	|B-DISEASE
disease	312	319		|I-DISEASE
among	320	325		|O
solid	326	331		|O
-	331	332		|O
organ	332	337		|O
transplant	338	348		|O
recipients	349	359		|O
but	360	363		|O
has	364	367		|O
also	368	372		|O
led	373	376		|O
to	377	379		|O
challenges	380	390		|O
,	390	391		|O
including	392	401		|O
ganciclovir	402	413		|O
resistance	414	424		|O
,	424	425		|O
late	426	430		|O
-	430	431		|O
onset	431	436		|O
CMV	437	440	CMV disease	|B-DISEASE
disease	441	448		|I-DISEASE
,	448	449		|O
and	450	453		|O
uncertainty	454	465		|O
about	466	471		|O
the	472	475		|O
optimal	476	483		|O
duration	484	492		|O
of	493	495		|O
prophylaxis	496	507		|O
or	508	510		|O
therapy	511	518		|O
for	519	522		|O
CMV	523	526	CMV disease	|B-DISEASE
disease	527	534		|I-DISEASE
.	534	535		|O
Specific	536	544		|O
therapies	545	554		|O
and	555	558		|O
management	559	569		|O
of	570	572		|O
CMV	573	576	CMV	|B-DISEASE
resistance	577	587		|O
will	588	592		|O
be	593	595		|O
addressed	596	605		|O
here	606	610		|O
.	610	611		|O
The	612	615		|O
best	616	620		|O
approach	621	629		|O
for	630	633		|O
CMV	634	637	CMV disease	|B-DISEASE
disease	638	645		|I-DISEASE
in	646	648		|O
solid	649	654		|O
-	654	655		|O
organ	655	660		|O
transplant	661	671		|O
recipients	672	682		|O
is	683	685		|O
prevention	686	696		|O
,	696	697		|O
but	698	701		|O
which	702	707		|O
strategy	708	716		|O
-	716	717		|O
-	717	718		|O
prophylaxis	718	729		|O
or	730	732		|O
preemptive	733	743		|O
therapy	744	751		|O
-	751	752		|O
-	752	753		|O
is	753	755		|O
optimal	756	763		|O
remains	764	771		|O
debatable	772	781		|O
.	781	782		|O
Ganciclovir	783	794		|O
and	795	798		|O
valganciclovir	799	813		|O
remain	814	820		|O
the	821	824		|O
best	825	829		|O
options	830	837		|O
for	838	841		|O
prevention	842	852		|O
and	853	856		|O
treatment	857	866		|O
of	867	869		|O
CMV	870	873	CMV disease	|B-DISEASE
disease	874	881		|I-DISEASE
in	882	884		|O
solid	885	890		|O
-	890	891		|O
organ	891	896		|O
transplant	897	907		|O
recipients	908	918		|O
,	918	919		|O
but	920	923		|O
they	924	928		|O
are	929	932		|O
costly	933	939		|O
and	940	943		|O
associated	944	954		|O
with	955	959		|O
toxicity	960	968		|O
.	968	969		|O
Foscarnet	970	979		|O
and	980	983		|O
cidofovir	984	993		|O
,	993	994		|O
indicated	995	1004		|O
for	1005	1008		|O
the	1009	1012		|O
treatment	1013	1022		|O
of	1023	1025		|O
patients	1026	1034		|O
who	1035	1038		|O
fail	1039	1043		|O
to	1044	1046		|O
respond	1047	1054		|O
to	1055	1057		|O
ganciclovir	1058	1069		|O
,	1069	1070		|O
are	1071	1074		|O
less	1075	1079		|O
attractive	1080	1090		|O
alternatives	1091	1103		|O
because	1104	1111		|O
of	1112	1114		|O
renal	1115	1120	renal toxicity	|B-ADVERSE
toxicity	1121	1129		|I-ADVERSE
.	1129	1130		|O
Therefore	1131	1140		|O
,	1140	1141		|O
new	1142	1145		|O
therapeutic	1146	1157		|O
agents	1158	1164		|O
for	1165	1168		|O
CMV	1169	1172	CMV	|B-DISEASE
and	1173	1176		|O
an	1177	1179		|O
immunogenic	1180	1191		|O
,	1191	1192		|O
safe	1193	1197		|O
CMV	1198	1201	CMV	|B-DISEASE
vaccine	1202	1209		|O
are	1210	1213		|O
critically	1214	1224		|O
needed	1225	1231		|O
.	1231	1232		|O

### 18956268
Hepatocyte	0	10		|O
growth	11	17		|O
factor	18	24		|O
and	25	28		|O
granulocyte	29	40		|O
colony	41	47		|O
-	47	48		|O
stimulating	48	59		|O
factor	60	66		|O
form	67	71		|O
a	72	73		|O
combined	74	82		|O
neovasculogenic	83	98		|O
therapy	99	106		|O
for	107	110		|O
ischemic	111	119	ischemic cardiomyopathy	|B-DISEASE
cardiomyopathy	120	134		|I-DISEASE
.	134	135		|O
BACKGROUND	137	147		|O
:	147	148		|O
Myocardial	149	159	Myocardial infarction	|B-DISEASE
infarction	160	170		|I-DISEASE
(	171	172		|O
MI	172	174	MI	|B-DISEASE
)	174	175		|O
is	176	178		|O
a	179	180		|O
significant	181	192		|O
cause	193	198		|O
of	199	201		|O
heart	202	207	heart failure	|B-DISEASE
failure	208	215		|I-DISEASE
.	215	216		|O
Current	217	224		|O
therapies	225	234		|O
are	235	238		|O
limited	239	246		|O
and	247	250		|O
,	250	251		|O
therefore	252	261		|O
,	261	262		|O
the	263	266		|O
development	267	278		|O
of	279	281		|O
novel	282	287		|O
revascularization	288	305		|O
methods	306	313		|O
is	314	316		|O
potentially	317	328		|O
important	329	338		|O
.	338	339		|O
We	340	342		|O
investigated	343	355		|O
whether	356	363		|O
hepatocyte	364	374		|O
growth	375	381		|O
factor	382	388		|O
(	389	390		|O
HGF	390	393		|O
)	393	394		|O
,	394	395		|O
expressed	396	405		|O
by	406	408		|O
genetically	409	420		|O
modified	421	429		|O
mesenchymal	430	441		|O
stromal	442	449		|O
cells	450	455		|O
(	456	457		|O
MSC	457	460		|O
)	460	461		|O
,	461	462		|O
in	463	465		|O
combination	466	477		|O
with	478	482		|O
granulocyte	483	494		|O
colony	495	501		|O
-	501	502		|O
stimulating	502	513		|O
factor	514	520		|O
(	521	522		|O
G	522	523		|O
-	523	524		|O
CSF	524	527		|O
)	527	528		|O
,	528	529		|O
exhibited	530	539		|O
a	540	541		|O
synergistic	542	553		|O
therapeutic	554	565		|O
benefit	566	573		|O
,	573	574		|O
as	575	577		|O
measured	578	586		|O
8	587	588		|O
weeks	589	594		|O
after	595	600		|O
MI	601	603	MI	|B-DISEASE
induction	604	613		|O
in	614	616		|O
a	617	618		|O
rat	619	622		|O
model	623	628		|O
.	628	629		|O
METHODS	630	637		|O
:	637	638		|O
Four	639	643		|O
weeks	644	649		|O
after	650	655		|O
MI	656	658	MI	|B-DISEASE
,	658	659		|O
rats	660	664		|O
were	665	669		|O
randomly	670	678		|O
divided	679	686		|O
into	687	691		|O
a	692	693		|O
control	694	701		|O
group	702	707		|O
(	708	709		|O
n	709	710		|O
=	710	711		|O
11	711	713		|O
)	713	714		|O
,	714	715		|O
HGF	716	719		|O
group	720	725		|O
(	726	727		|O
Adenovirus	727	737		|O
vector	738	744		|O
carrying	745	753		|O
human	754	759		|O
HGF	760	763		|O
(	764	765		|O
Ad	765	767		|O
-	767	768		|O
HGF	768	771		|O
)	771	772		|O
-	772	773		|O
transfected	773	784		|O
MSC	785	788		|O
transplanted	789	801		|O
into	802	806		|O
the	807	810		|O
infarct	811	818	infarct	|B-DISEASE
zone	819	823		|O
;	823	824		|O
n	825	826		|O
=	826	827		|O
11	827	829		|O
)	829	830		|O
,	830	831		|O
G	832	833		|O
-	833	834		|O
CSF	834	837		|O
group	838	843		|O
(	844	845		|O
intraperitoneal	845	860		|O
injection	861	870		|O
with	871	875		|O
G	876	877		|O
-	877	878		|O
CSF	878	881		|O
;	881	882		|O
n	883	884		|O
=	884	885		|O
11	885	887		|O
)	887	888		|O
,	888	889		|O
and	890	893		|O
HGF	894	897		|O
+	898	899		|O
G	900	901		|O
-	901	902		|O
CSF	902	905		|O
group	906	911		|O
(	912	913		|O
Ad	913	915		|O
-	915	916		|O
HGF	916	919		|O
-	919	920		|O
transfected	920	931		|O
MSC	932	935		|O
transplanted	936	948		|O
into	949	953		|O
the	954	957		|O
infarct	958	965	infarct	|B-DISEASE
zone	966	970		|O
and	971	974		|O
intraperitoneal	975	990		|O
injection	991	1000		|O
with	1001	1005		|O
G	1006	1007		|O
-	1007	1008		|O
CSF	1008	1011		|O
;	1011	1012		|O
n	1013	1014		|O
=	1014	1015		|O
11	1015	1017		|O
)	1017	1018		|O
.	1018	1019		|O
Four	1020	1024		|O
weeks	1025	1030		|O
later	1031	1036		|O
,	1036	1037		|O
hearts	1038	1044		|O
were	1045	1049		|O
analyzed	1050	1058		|O
for	1059	1062		|O
endothelial	1063	1074		|O
cell	1075	1079		|O
density	1080	1087		|O
and	1088	1091		|O
angiogenesis	1092	1104		|O
,	1104	1105		|O
ventricular	1106	1117		|O
geometry	1118	1126		|O
,	1126	1127		|O
myocardial	1128	1138		|O
function	1139	1147		|O
and	1148	1151		|O
levels	1152	1158		|O
of	1159	1161		|O
VCAM	1162	1166		|O
-	1166	1167		|O
1	1167	1168		|O
and	1169	1172		|O
MMP	1173	1176		|O
-	1176	1177		|O
9	1177	1178		|O
protein	1179	1186		|O
.	1186	1187		|O
RESULTS	1188	1195		|O
:	1195	1196		|O
The	1197	1200		|O
HGF	1201	1204		|O
+	1205	1206		|O
G	1207	1208		|O
-	1208	1209		|O
CSF	1209	1212		|O
group	1213	1218		|O
exhibited	1219	1228		|O
improved	1229	1237		|O
left	1238	1242		|O
ventricular	1243	1254		|O
systolic	1255	1263		|O
and	1264	1267		|O
diastolic	1268	1277		|O
function	1278	1286		|O
and	1287	1290		|O
experienced	1291	1302		|O
less	1303	1307		|O
adverse	1308	1315		|O
ventricular	1316	1327		|O
remodeling	1328	1338		|O
,	1338	1339		|O
as	1340	1342		|O
manifested	1343	1353		|O
by	1354	1356		|O
decreased	1357	1366		|O
left	1367	1371		|O
ventricular	1372	1383		|O
dilatation	1384	1394		|O
and	1395	1398		|O
increased	1399	1408		|O
border	1409	1415		|O
zone	1416	1420		|O
wall	1421	1425		|O
thickness	1426	1435		|O
.	1435	1436		|O
Angiogenesis	1437	1449		|O
was	1450	1453		|O
significantly	1454	1467		|O
enhanced	1468	1476		|O
in	1477	1479		|O
HGF	1480	1483		|O
+	1484	1485		|O
G	1486	1487		|O
-	1487	1488		|O
CSF	1488	1491		|O
rats	1492	1496		|O
by	1497	1499		|O
inducing	1500	1508		|O
the	1509	1512		|O
proliferation	1513	1526		|O
of	1527	1529		|O
endothelial	1530	1541		|O
cells	1542	1547		|O
.	1547	1548		|O
Furthermore	1549	1560		|O
,	1560	1561		|O
HGF	1562	1565		|O
induced	1566	1573		|O
expression	1574	1584		|O
of	1585	1587		|O
VCAM	1588	1592		|O
-	1592	1593		|O
1	1593	1594		|O
,	1594	1595		|O
and	1596	1599		|O
HGF	1600	1603		|O
treatment	1604	1613		|O
together	1614	1622		|O
with	1623	1627		|O
G	1628	1629		|O
-	1629	1630		|O
CSF	1630	1633		|O
synergistically	1634	1649		|O
stimulated	1650	1660		|O
MMP	1661	1664		|O
-	1664	1665		|O
9	1665	1666		|O
expression	1667	1677		|O
in	1678	1680		|O
ischemic	1681	1689		|O
hearts	1690	1696		|O
.	1696	1697		|O
DISCUSSION	1698	1708		|O
:	1708	1709		|O
The	1710	1713		|O
combination	1714	1725		|O
of	1726	1728		|O
G	1729	1730		|O
-	1730	1731		|O
CSF	1731	1734		|O
and	1735	1738		|O
HGF	1739	1742		|O
exhibited	1743	1752		|O
a	1753	1754		|O
significant	1755	1766		|O
synergistic	1767	1778		|O
effect	1779	1785		|O
and	1786	1789		|O
enhanced	1790	1798		|O
myocardial	1799	1809		|O
endothelial	1810	1821		|O
density	1822	1829		|O
,	1829	1830		|O
angiogenesis	1831	1843		|O
,	1843	1844		|O
geometric	1845	1854		|O
preservation	1855	1867		|O
and	1868	1871		|O
heart	1872	1877		|O
function	1878	1886		|O
in	1887	1889		|O
an	1890	1892		|O
ischemic	1893	1901	ischemic cardiomyopathy	|B-DISEASE
cardiomyopathy	1902	1916		|I-DISEASE
model	1917	1922		|O
.	1922	1923		|O

### 18756647
Sildenafil	0	10		|O
citrate	11	18		|O
and	19	22		|O
Torsade	23	30	Torsade de pointes	|B-DISEASE
de	31	33		|I-DISEASE
pointes	34	41		|I-DISEASE
.	41	42		|O
Sildenafil	44	54		|O
citrate	55	62		|O
is	63	65		|O
a	66	67		|O
drug	68	72		|O
used	73	77		|O
in	78	80		|O
the	81	84		|O
treatment	85	94		|O
of	95	97		|O
erectile	98	106	erectile dysfunction	|B-DISEASE
dysfunction	107	118		|I-DISEASE
.	118	119		|O
It	120	122		|O
is	123	125		|O
an	126	128		|O
inhibitor	129	138		|O
of	139	141		|O
the	142	145		|O
enzyme	146	152		|O
phosphordiesterase	153	171		|O
-	171	172		|O
5	172	173		|O
;	173	174		|O
it	175	177		|O
slows	178	183		|O
down	184	188		|O
the	189	192		|O
breakdown	193	202		|O
of	203	205		|O
c	206	207		|O
-	207	208		|O
GMP	208	211		|O
and	212	215		|O
nitrous	216	223		|O
oxide	224	229		|O
.	229	230		|O
The	231	234		|O
cardiac	235	242		|O
effects	243	250		|O
associated	251	261		|O
with	262	266		|O
Sildenafil	267	277		|O
citrate	278	285		|O
have	286	290		|O
been	291	295		|O
extensively	296	307		|O
studied	308	315		|O
in	316	318		|O
medical	319	326		|O
literature	327	337		|O
,	337	338		|O
especially	339	349		|O
its	350	353		|O
potent	354	360		|O
vasodilatory	361	373		|O
effect	374	380		|O
when	381	385		|O
combined	386	394		|O
with	395	399		|O
nitrate	400	407		|O
-	407	408		|O
based	408	413		|O
medications	414	425		|O
,	425	426		|O
producing	427	436		|O
intractable	437	448		|O
hypotension	449	460	hypotension	|B-DISEASE
,	460	461		|O
but	462	465		|O
a	466	467		|O
lesser	468	474		|O
known	475	480		|O
and	481	484		|O
potentially	485	496		|O
lethal	497	503		|O
side	504	508		|O
effect	509	515		|O
is	516	518		|O
prolonged	519	528		|O
cardiac	529	536		|O
repolarization	537	551		|O
when	552	556		|O
used	557	561		|O
at	562	564		|O
dosage	565	571		|O
greater	572	579		|O
than	580	584		|O
recommended	585	596		|O
,	596	597		|O
leading	598	605		|O
to	606	608		|O
QT	609	611		|O
prolongation	612	624		|O
that	625	629		|O
could	630	635		|O
theoretically	636	649		|O
lead	650	654		|O
to	655	657		|O
dangerous	658	667		|O
cardiac	668	675		|O
dysrrhythmias	676	689		|O
and	690	693		|O
sudden	694	700	sudden death	|B-DISEASE
death	701	706		|I-DISEASE
in	707	709		|O
men	710	713		|O
with	714	718		|O
coronary	719	727	coronary artery disease	|B-DISEASE
artery	728	734		|I-DISEASE
disease	735	742		|I-DISEASE
.	742	743		|O
The	744	747		|O
authors	748	755		|O
present	756	763		|O
the	764	767		|O
case	768	772		|O
of	773	775		|O
a	776	777		|O
49	778	780		|O
-	780	781		|O
year	781	785		|O
-	785	786		|O
old	786	789		|O
hypertensive	790	802	hypertensive	|B-DISEASE
Hispanic	803	811		|O
man	812	815		|O
who	816	819		|O
arrived	820	827		|O
to	828	830		|O
our	831	834		|O
emergency	835	844		|O
department	845	855		|O
with	856	860		|O
the	861	864		|O
chief	865	870		|O
complaint	871	880		|O
of	881	883		|O
acute	884	889		|O
epigastric	890	900	epigastric pain	|B-DISEASE
pain	901	905		|I-DISEASE
for	906	909		|O
3	910	911		|O
hours	912	917		|O
of	918	920		|O
evolution	921	930		|O
after	931	936		|O
ingestion	937	946		|O
of	947	949		|O
Sildenafil	950	960		|O
citrate	961	968		|O
50	969	971		|O
milligrams	972	982		|O
(	983	984		|O
mg	984	986		|O
)	986	987		|O
.	987	988		|O
The	989	992		|O
patient	993	1000		|O
was	1001	1004		|O
found	1005	1010		|O
to	1011	1013		|O
have	1014	1018		|O
an	1019	1021		|O
acute	1022	1027		|O
ST	1028	1030		|O
elevation	1031	1040		|O
inferior	1041	1049	inferior myocardial infarction	|B-DISEASE
myocardial	1050	1060		|I-DISEASE
infarction	1061	1071		|I-DISEASE
(	1072	1073		|O
STEMI	1073	1078	STEMI	|B-DISEASE
)	1078	1079		|O
.	1079	1080		|O
Shortly	1081	1088		|O
after	1089	1094		|O
diagnosis	1095	1104		|O
the	1105	1108		|O
patient	1109	1116		|O
developed	1117	1126		|O
a	1127	1128		|O
polymorphic	1129	1140	polymorphic ventricular tachycardia	|B-DISEASE
ventricular	1141	1152		|I-DISEASE
tachycardia	1153	1164		|I-DISEASE
(	1165	1166		|O
Torsade	1166	1173	Torsade de pointes	|B-DISEASE
de	1174	1176		|I-DISEASE
pointes	1177	1184		|I-DISEASE
)	1184	1185		|O
before	1186	1192		|O
thrombolytic	1193	1205		|O
administration	1206	1220		|O
.	1220	1221		|O
We	1222	1224		|O
present	1225	1232		|O
this	1233	1237		|O
case	1238	1242		|O
followed	1243	1251		|O
by	1252	1254		|O
a	1255	1256		|O
brief	1257	1262		|O
discussion	1263	1273		|O
,	1273	1274		|O
to	1275	1277		|O
heighten	1278	1286		|O
awareness	1287	1296		|O
of	1297	1299		|O
the	1300	1303		|O
possible	1304	1312		|O
association	1313	1324		|O
of	1325	1327		|O
acute	1328	1333		|O
inferior	1334	1342		|O
STEMI	1343	1348	STEMI	|B-DISEASE
and	1349	1352		|O
the	1353	1356		|O
development	1357	1368		|O
of	1369	1371		|O
Torsade	1372	1379	Torsade de Pointes	|B-DISEASE
de	1380	1382		|I-DISEASE
Pointes	1383	1390		|I-DISEASE
after	1391	1396		|O
the	1397	1400		|O
use	1401	1404		|O
of	1405	1407		|O
Sildenafil	1408	1418		|O
citrate	1419	1426		|O
.	1426	1427		|O

### 18758144
Descriptive	0	11		|O
study	12	17		|O
on	18	20		|O
the	21	24		|O
circumstances	25	38		|O
concerning	39	49		|O
confirmation	50	62		|O
of	63	65		|O
contraindications	66	83		|O
and	84	87		|O
careful	88	95		|O
administration	96	110		|O
upon	111	115		|O
purchasing	116	126		|O
over	127	131		|O
-	131	132		|O
the	132	135		|O
-	135	136		|O
counter	136	143		|O
cold	144	148	cold	|B-DISEASE
medication	149	159		|O
and	160	163		|O
manifestation	164	177		|O
of	178	180		|O
after	181	186		|O
-	186	187		|O
use	187	190		|O
urinary	191	198	urinary disorders	|B-DISEASE
disorders	199	208		|I-DISEASE
.	208	209		|O
Over	211	215		|O
-	215	216		|O
the	216	219		|O
-	219	220		|O
counter	220	227		|O
medications	228	239		|O
are	240	243		|O
primarily	244	253		|O
for	254	257		|O
self	258	262		|O
-	262	263		|O
medication	263	273		|O
,	273	274		|O
where	275	280		|O
the	281	284		|O
seller	285	291		|O
,	291	292		|O
such	293	297		|O
as	298	300		|O
a	301	302		|O
pharmacist	303	313		|O
,	313	314		|O
provides	315	323		|O
the	324	327		|O
necessary	328	337		|O
information	338	349		|O
and	350	353		|O
the	354	357		|O
consumer	358	366		|O
uses	367	371		|O
the	372	375		|O
medication	376	386		|O
at	387	389		|O
his	390	393		|O
or	394	396		|O
her	397	400		|O
own	401	404		|O
discretion	405	415		|O
based	416	421		|O
on	422	424		|O
the	425	428		|O
information	429	440		|O
provided	441	449		|O
.	449	450		|O
A	451	452		|O
Web	453	456		|O
survey	457	463		|O
was	464	467		|O
conducted	468	477		|O
from	478	482		|O
February	483	491		|O
8	492	493		|O
to	494	496		|O
13	497	499		|O
,	499	500		|O
2006	501	505		|O
,	505	506		|O
involving	507	516		|O
500	517	520		|O
men	521	524		|O
and	525	528		|O
women	529	534		|O
,	534	535		|O
ranging	536	543		|O
in	544	546		|O
age	547	550		|O
from	551	555		|O
50	556	558		|O
to	559	561		|O
69	562	564		|O
years	565	570		|O
,	570	571		|O
who	572	575		|O
had	576	579		|O
purchased	580	589		|O
over	590	594		|O
-	594	595		|O
the	595	598		|O
-	598	599		|O
counter	599	606		|O
medications	607	618		|O
for	619	622		|O
the	623	626		|O
common	627	633	common cold	|B-DISEASE
cold	634	638		|I-DISEASE
within	639	645		|O
the	646	649		|O
past	650	654		|O
3	655	656		|O
years	657	662		|O
.	662	663		|O
Upon	664	668		|O
consultation	669	681		|O
with	682	686		|O
and	687	690		|O
purchase	691	699		|O
of	700	702		|O
a	703	704		|O
cold	705	709	cold	|B-DISEASE
medication	710	720		|O
from	721	725		|O
a	726	727		|O
pharmacist	728	738		|O
,	738	739		|O
84.2%	740	745		|O
of	746	748		|O
respondents	749	760		|O
reported	761	769		|O
"	770	771		|O
being	771	776		|O
asked	777	782		|O
my	783	785		|O
symptoms	786	794		|O
,	794	795		|O
"	795	796		|O
and	797	800		|O
less	801	805		|O
frequently	806	816		|O
(	817	818		|O
12.3-21.3%	818	828		|O
)	828	829		|O
being	830	835		|O
asked	836	841		|O
about	842	847		|O
contraindications	848	865		|O
/	865	866		|O
careful	866	873		|O
administration	874	888		|O
.	888	889		|O
Most	890	894		|O
respondents	895	906		|O
(	907	908		|O
60.8%	908	913		|O
)	913	914		|O
when	915	919		|O
asked	920	925		|O
whether	926	933		|O
they	934	938		|O
confirmed	939	948		|O
"	949	950		|O
contraindications	950	967		|O
/	967	968		|O
careful	968	975		|O
administration	976	990		|O
"	990	991		|O
responded	992	1001		|O
negatively	1002	1012		|O
,	1012	1013		|O
stating	1014	1021		|O
they	1022	1026		|O
"	1027	1028		|O
occasionally	1028	1040		|O
do	1041	1043		|O
not	1044	1047		|O
confirm	1048	1055		|O
"	1055	1056		|O
or	1057	1059		|O
"	1060	1061		|O
do	1061	1063		|O
not	1064	1067		|O
confirm	1068	1075		|O
.	1075	1076		|O
"	1076	1077		|O
In	1078	1080		|O
addition	1081	1089		|O
,	1089	1090		|O
among	1091	1096		|O
men	1097	1100		|O
aged	1101	1105		|O
50-69	1106	1111		|O
years	1112	1117		|O
,	1117	1118		|O
it	1119	1121		|O
became	1122	1128		|O
clear	1129	1134		|O
that	1135	1139		|O
6.0%	1140	1144		|O
had	1145	1148		|O
experienced	1149	1160		|O
aggravation	1161	1172		|O
of	1173	1175		|O
prostatic	1176	1185	prostatic hypertrophy	|B-ADVERSE
hypertrophy	1186	1197		|I-ADVERSE
symptoms	1198	1206		|O
after	1207	1212		|O
taking	1213	1219		|O
a	1220	1221		|O
cold	1222	1226	cold	|B-DISEASE
medication	1227	1237		|O
.	1237	1238		|O
It	1239	1241		|O
is	1242	1244		|O
assumed	1245	1252		|O
that	1253	1257		|O
symptoms	1258	1266		|O
are	1267	1270		|O
usually	1271	1278		|O
confirmed	1279	1288		|O
upon	1289	1293		|O
the	1294	1297		|O
sale	1298	1302		|O
of	1303	1305		|O
over	1306	1310		|O
-	1310	1311		|O
the	1311	1314		|O
-	1314	1315		|O
counter	1315	1322		|O
medications	1323	1334		|O
,	1334	1335		|O
but	1336	1339		|O
the	1340	1343		|O
rate	1344	1348		|O
of	1349	1351		|O
confirming	1352	1362		|O
whether	1363	1370		|O
the	1371	1374		|O
consumer	1375	1383		|O
may	1384	1387		|O
need	1388	1392		|O
to	1393	1395		|O
consider	1396	1404		|O
contraindications	1405	1422		|O
/	1422	1423		|O
careful	1423	1430		|O
administration	1431	1445		|O
is	1446	1448		|O
low	1449	1452		|O
.	1452	1453		|O
Urinary	1454	1461	Urinary retention	|B-ADVERSE
retention	1462	1471		|I-ADVERSE
is	1472	1474		|O
a	1475	1476		|O
preventable	1477	1488		|O
side	1489	1493		|O
effect	1494	1500		|O
because	1501	1508		|O
the	1509	1512		|O
confirmation	1513	1525		|O
prior	1526	1531		|O
to	1532	1534		|O
taking	1535	1541		|O
the	1542	1545		|O
medication	1546	1556		|O
can	1557	1560		|O
be	1561	1563		|O
made	1564	1568		|O
.	1568	1569		|O
Accordingly	1570	1581		|O
,	1581	1582		|O
some	1583	1587		|O
of	1588	1590		|O
those	1591	1596		|O
side	1597	1601		|O
effects	1602	1609		|O
can	1610	1613		|O
be	1614	1616		|O
avoided	1617	1624		|O
by	1625	1627		|O
ensuring	1628	1636		|O
the	1637	1640		|O
environment	1641	1652		|O
for	1653	1656		|O
confirming	1657	1667		|O
whether	1668	1675		|O
the	1676	1679		|O
individual	1680	1690		|O
corresponds	1691	1702		|O
to	1703	1705		|O
"	1706	1707		|O
contraindications	1707	1724		|O
/	1724	1725		|O
careful	1725	1732		|O
administration	1733	1747		|O
"	1747	1748		|O
before	1749	1755		|O
taking	1756	1762		|O
the	1763	1766		|O
medication	1767	1777		|O
.	1777	1778		|O

### 18591791
Amiodarone	0	10		|O
increases	11	20		|O
the	21	24		|O
accumulation	25	37		|O
of	38	40		|O
DEA	41	44		|O
in	45	47		|O
a	48	49		|O
human	50	55		|O
alveolar	56	64		|O
epithelium	65	75		|O
-	75	76		|O
derived	76	83		|O
cell	84	88		|O
line	89	93		|O
.	93	94		|O
Amiodarone	96	106		|O
(	107	108		|O
AMD	108	111		|O
)	111	112		|O
-	112	113		|O
induced	113	120		|O
pulmonary	121	130	pulmonary toxicity	|B-ADVERSE
toxicity	131	139		|I-ADVERSE
(	140	141		|O
AIPT	141	145	AIPT	|B-ADVERSE
)	145	146		|O
is	147	149		|O
the	150	153		|O
most	154	158		|O
life	159	163		|O
-	163	164		|O
threatening	164	175		|O
side	176	180		|O
-	180	181		|O
effect	181	187		|O
of	188	190		|O
AMD	191	194		|O
treatment	195	204		|O
.	204	205		|O
N	206	207		|O
-	207	208		|O
Monodesethylamiodarone	208	230		|O
(	231	232		|O
DEA	232	235		|O
)	235	236		|O
,	236	237		|O
an	238	240		|O
active	241	247		|O
metabolite	248	258		|O
of	259	261		|O
AMD	262	265		|O
,	265	266		|O
also	267	271		|O
exhibits	272	280		|O
cytotoxicity	281	293		|O
and	294	297		|O
tends	298	303		|O
to	304	306		|O
accumulate	307	317		|O
in	318	320		|O
the	321	324		|O
lung	325	329		|O
more	330	334		|O
intensively	335	346		|O
than	347	351		|O
AMD	352	355		|O
.	355	356		|O
In	357	359		|O
this	360	364		|O
study	365	370		|O
,	370	371		|O
we	372	374		|O
characterized	375	388		|O
the	389	392		|O
mechanism	393	402		|O
of	403	405		|O
DEA	406	409		|O
accumulation	410	422		|O
using	423	428		|O
A549	429	433		|O
cells	434	439		|O
as	440	442		|O
a	443	444		|O
model	445	450		|O
of	451	453		|O
the	454	457		|O
alveolar	458	466		|O
epithelium	467	477		|O
.	477	478		|O
Typical	479	486		|O
ATP	487	490		|O
-	490	491		|O
depletion	491	500		|O
compounds	501	510		|O
caused	511	517		|O
an	518	520		|O
approximately	521	534		|O
30%	535	538		|O
increase	539	547		|O
in	548	550		|O
the	551	554		|O
accumulation	555	567		|O
of	568	570		|O
DEA	571	574		|O
in	575	577		|O
A549	578	582		|O
cells	583	588		|O
,	588	589		|O
although	590	598		|O
these	599	604		|O
effects	605	612		|O
were	613	617		|O
less	618	622		|O
than	623	627		|O
those	628	633		|O
in	634	636		|O
Caco	637	641		|O
-	641	642		|O
2	642	643		|O
cells	644	649		|O
.	649	650		|O
Triiodothyronine	651	667		|O
(	668	669		|O
T	669	670		|O
(	670	671		|O
3	671	672		|O
)	672	673		|O
)	673	674		|O
,	674	675		|O
which	676	681		|O
exhibited	682	691		|O
an	692	694		|O
inhibitory	695	705		|O
effect	706	712		|O
on	713	715		|O
DEA	716	719		|O
efflux	720	726		|O
in	727	729		|O
Caco	730	734		|O
-	734	735		|O
2	735	736		|O
cells	737	742		|O
,	742	743		|O
did	744	747		|O
not	748	751		|O
affect	752	758		|O
the	759	762		|O
accumulation	763	775		|O
of	776	778		|O
DEA	779	782		|O
in	783	785		|O
A549	786	790		|O
cells	791	796		|O
.	796	797		|O
On	798	800		|O
the	801	804		|O
other	805	810		|O
hand	811	815		|O
,	815	816		|O
100	817	820		|O
microM	821	827		|O
AMD	828	831		|O
caused	832	838		|O
an	839	841		|O
approximately	842	855		|O
200%	856	860		|O
increase	861	869		|O
in	870	872		|O
DEA	873	876		|O
content	877	884		|O
in	885	887		|O
A549	888	892		|O
cells	893	898		|O
,	898	899		|O
although	900	908		|O
AMD	909	912		|O
accumulation	913	925		|O
was	926	929		|O
not	930	933		|O
affected	934	942		|O
by	943	945		|O
100	946	949		|O
microM	950	956		|O
DEA	957	960		|O
.	960	961		|O
Since	962	967		|O
the	968	971		|O
reducing	972	980		|O
effect	981	987		|O
of	988	990		|O
AMD	991	994		|O
on	995	997		|O
cellular	998	1006		|O
ATP	1007	1010		|O
levels	1011	1017		|O
and	1018	1021		|O
that	1022	1026		|O
of	1027	1029		|O
FCCP	1030	1034		|O
were	1035	1039		|O
similar	1040	1047		|O
,	1047	1048		|O
the	1049	1052		|O
mechanism	1053	1062		|O
by	1063	1065		|O
which	1066	1071		|O
DEA	1072	1075		|O
accumulation	1076	1088		|O
is	1089	1091		|O
increased	1092	1101		|O
by	1102	1104		|O
AMD	1105	1108		|O
might	1109	1114		|O
be	1115	1117		|O
different	1118	1127		|O
from	1128	1132		|O
the	1133	1136		|O
ATP	1137	1140		|O
-	1140	1141		|O
dependent	1141	1150		|O
DEA	1151	1154		|O
efflux	1155	1161		|O
mechanism	1162	1171		|O
.	1171	1172		|O
The	1173	1176		|O
decrease	1177	1185		|O
in	1186	1188		|O
cell	1189	1193		|O
viability	1194	1203		|O
by	1204	1206		|O
DEA	1207	1210		|O
in	1211	1213		|O
the	1214	1217		|O
presence	1218	1226		|O
of	1227	1229		|O
AMD	1230	1233		|O
(	1234	1235		|O
IC	1235	1237		|O
(	1237	1238		|O
50	1238	1240		|O
)	1240	1241		|O
value	1242	1247		|O
of	1248	1250		|O
DEA	1251	1254		|O
for	1255	1258		|O
A549	1259	1263		|O
cell	1264	1268		|O
viability	1269	1278		|O
:	1278	1279		|O
25.4	1280	1284		|O
+	1284	1285		|O
/	1285	1286		|O
-	1286	1287		|O
2.4	1287	1290		|O
microM	1291	1297		|O
)	1297	1298		|O
was	1299	1302		|O
more	1303	1307		|O
pronounced	1308	1318		|O
than	1319	1323		|O
that	1324	1328		|O
by	1329	1331		|O
DEA	1332	1335		|O
alone	1336	1341		|O
(	1342	1343		|O
IC	1343	1345		|O
(	1345	1346		|O
50	1346	1348		|O
)	1348	1349		|O
value	1350	1355		|O
:	1355	1356		|O
11.5	1357	1361		|O
+	1361	1362		|O
/	1362	1363		|O
-	1363	1364		|O
3.0	1364	1367		|O
microM	1368	1374		|O
)	1374	1375		|O
.	1375	1376		|O
This	1377	1381		|O
further	1382	1389		|O
DEA	1390	1393		|O
accumulation	1394	1406		|O
by	1407	1409		|O
AMD	1410	1413		|O
might	1414	1419		|O
be	1420	1422		|O
a	1423	1424		|O
factor	1425	1431		|O
responsible	1432	1443		|O
for	1444	1447		|O
the	1448	1451		|O
greater	1452	1459		|O
accumulation	1460	1472		|O
of	1473	1475		|O
DEA	1476	1479		|O
than	1480	1484		|O
that	1485	1489		|O
of	1490	1492		|O
AMD	1493	1496		|O
in	1497	1499		|O
the	1500	1503		|O
lung	1504	1508		|O
in	1509	1511		|O
long	1512	1516		|O
-	1516	1517		|O
term	1517	1521		|O
AMD	1522	1525		|O
-	1525	1526		|O
treated	1526	1533		|O
patients	1534	1542		|O
.	1542	1543		|O

### 18929080
Sexual	0	6	Sexual dysfunction	|B-DISEASE
dysfunction	7	18		|I-DISEASE
in	19	21		|O
women	22	27		|O
with	28	32		|O
epilepsy	33	41	epilepsy	|B-DISEASE
:	41	42		|O
role	43	47		|O
of	48	50		|O
antiepileptic	51	64		|O
drugs	65	70		|O
and	71	74		|O
psychotropic	75	87		|O
medications	88	99		|O
.	99	100		|O
Sexual	102	108	Sexual dysfunction	|B-DISEASE
dysfunction	109	120		|I-DISEASE
is	121	123		|O
a	124	125		|O
frequently	126	136		|O
encountered	137	148		|O
comorbid	149	157		|O
disorder	158	166		|O
in	167	169		|O
patients	170	178		|O
with	179	183		|O
neurological	184	196		|O
and	197	200		|O
psychiatric	201	212	psychiatric disorders	|B-DISEASE
disorders	213	222		|I-DISEASE
.	222	223		|O
Importantly	224	235		|O
,	235	236		|O
sexual	237	243	sexual dysfunction	|B-ADVERSE
dysfunction	244	255		|I-ADVERSE
can	256	259		|O
also	260	264		|O
occur	265	270		|O
as	271	273		|O
a	274	275		|O
treatment	276	285		|O
emergent	286	294		|O
adverse	295	302		|O
effect	303	309		|O
of	310	312		|O
a	313	314		|O
number	315	321		|O
of	322	324		|O
commonly	325	333		|O
used	334	338		|O
psychotropic	339	351		|O
and	352	355		|O
antiepileptic	356	369		|O
medications	370	381		|O
,	381	382		|O
and	383	386		|O
can	387	390		|O
include	391	398		|O
decreased	399	408	decreased libido	|B-ADVERSE
libido	409	415		|I-ADVERSE
,	415	416		|O
erectile	417	425	erectile dysfunction	|B-ADVERSE
dysfunction	426	437		|I-ADVERSE
,	437	438		|O
disordered	439	449	disordered arousal	|B-ADVERSE
arousal	450	457		|I-ADVERSE
,	457	458		|O
delayed	459	466	delayed orgasm	|B-ADVERSE
orgasm	467	473		|I-ADVERSE
,	473	474		|O
and	475	478		|O
anorgasmia	479	489	anorgasmia	|B-ADVERSE
.	489	490		|O
These	491	496		|O
effects	497	504		|O
can	505	508		|O
occur	509	514		|O
in	515	517		|O
both	518	522		|O
men	523	526		|O
and	527	530		|O
women	531	536		|O
,	536	537		|O
and	538	541		|O
can	542	545		|O
be	546	548		|O
seen	549	553		|O
across	554	560		|O
age	561	564		|O
groups	565	571		|O
.	571	572		|O
Understanding	573	586		|O
the	587	590		|O
neurobiology	591	603		|O
of	604	606		|O
normal	607	613		|O
sexual	614	620		|O
response	621	629		|O
,	629	630		|O
as	631	633		|O
well	634	638		|O
as	639	641		|O
the	642	645		|O
pharmacologic	646	659		|O
mechanisms	660	670		|O
of	671	673		|O
these	674	679		|O
commonly	680	688		|O
used	689	693		|O
medications	694	705		|O
can	706	709		|O
enable	710	716		|O
the	717	720		|O
clinician	721	730		|O
to	731	733		|O
predict	734	741		|O
how	742	745		|O
medication	746	756		|O
use	757	760		|O
may	761	764		|O
impact	765	771		|O
different	772	781		|O
phases	782	788		|O
of	789	791		|O
sexual	792	798		|O
response	799	807		|O
.	807	808		|O
Discussion	809	819		|O
of	820	822		|O
the	823	826		|O
current	827	834		|O
treatment	835	844		|O
strategies	845	855		|O
for	856	859		|O
female	860	866	female sexual dysfunction	|B-DISEASE
sexual	867	873		|I-DISEASE
dysfunction	874	885		|I-DISEASE
is	886	888		|O
also	889	893		|O
elucidated	894	904		|O
in	905	907		|O
this	908	912		|O
chapter	913	920		|O
.	920	921		|O

### 18826299
Conjugated	0	10		|O
chitosan	11	19		|O
as	20	22		|O
a	23	24		|O
novel	25	30		|O
platform	31	39		|O
for	40	43		|O
oral	44	48		|O
delivery	49	57		|O
of	58	60		|O
paclitaxel	61	71		|O
.	71	72		|O
A	74	75		|O
new	76	79		|O
platform	80	88		|O
for	89	92		|O
oral	93	97		|O
delivery	98	106		|O
of	107	109		|O
paclitaxel	110	120		|O
(	121	122		|O
PTX	122	125		|O
)	125	126		|O
was	127	130		|O
developed	131	140		|O
through	141	148		|O
chemical	149	157		|O
conjugation	158	169		|O
of	170	172		|O
PTX	173	176		|O
to	177	179		|O
a	180	181		|O
low	182	185		|O
molecular	186	195		|O
weight	196	202		|O
chitosan	203	211		|O
(	212	213		|O
LMWC	213	217		|O
)	217	218		|O
.	218	219		|O
The	220	223		|O
LMWC	224	228		|O
-	228	229		|O
PTX	229	232		|O
conjugate	233	242		|O
contained	243	252		|O
approximately	253	266		|O
12	267	269		|O
wt	270	272		|O
%	273	274		|O
PTX	275	278		|O
and	279	282		|O
showed	283	289		|O
greatly	290	297		|O
enhanced	298	306		|O
water	307	312		|O
solubility	313	323		|O
(	324	325		|O
>	325	326		|O
1	326	327		|O
mg	328	330		|O
/	330	331		|O
mL	331	333		|O
)	333	334		|O
as	335	337		|O
compared	338	346		|O
to	347	349		|O
native	350	356		|O
PTX	357	360		|O
.	360	361		|O
The	362	365		|O
conjugate	366	375		|O
showed	376	382		|O
comparable	383	393		|O
IC	394	396		|O
50	397	399		|O
values	400	406		|O
to	407	409		|O
that	410	414		|O
of	415	417		|O
the	418	421		|O
parent	422	428		|O
PTX	429	432		|O
against	433	440		|O
human	441	446		|O
cancer	447	453		|O
cell	454	458		|O
lines	459	464		|O
.	464	465		|O
The	466	469		|O
pharmacokinetic	470	485		|O
data	486	490		|O
revealed	491	499		|O
approximately	500	513		|O
42%	514	517		|O
of	518	520		|O
bioavailability	521	536		|O
after	537	542		|O
oral	543	547		|O
administration	548	562		|O
of	563	565		|O
5	566	567		|O
mg	568	570		|O
PTX	571	574		|O
/	574	575		|O
kg	575	577		|O
of	578	580		|O
the	581	584		|O
conjugate	585	594		|O
.	594	595		|O
When	596	600		|O
the	601	604		|O
conjugate	605	614		|O
(	615	616		|O
10	616	618		|O
mg	619	621		|O
/	621	622		|O
kg	622	624		|O
based	625	630		|O
on	631	633		|O
PTX	634	637		|O
content	638	645		|O
)	645	646		|O
was	647	650		|O
administered	651	663		|O
orally	664	670		|O
to	671	673		|O
mice	674	678		|O
bearing	679	686		|O
xenograft	687	696		|O
or	697	699		|O
allograft	700	709		|O
tumors	710	716	tumors	|B-DISEASE
,	716	717		|O
the	718	721		|O
conjugate	722	731		|O
-	731	732		|O
treated	732	739		|O
group	740	745		|O
showed	746	752		|O
significant	753	764		|O
inhibition	765	775		|O
of	776	778		|O
tumor	779	784	tumor	|B-DISEASE
growth	785	791		|O
,	791	792		|O
which	793	798		|O
was	799	802		|O
comparable	803	813		|O
to	814	816		|O
that	817	821		|O
seen	822	826		|O
with	827	831		|O
PTX	832	835		|O
of	836	838		|O
the	839	842		|O
clinically	843	853		|O
available	854	863		|O
injected	864	872		|O
form	873	877		|O
,	877	878		|O
formulated	879	889		|O
in	890	892		|O
cremophor	893	902		|O
EL	903	905		|O
/	905	906		|O
ethanol	906	913		|O
(	914	915		|O
iv	915	917		|O
)	917	918		|O
but	919	922		|O
with	923	927		|O
much	928	932		|O
lower	933	938		|O
toxicity	939	947		|O
.	947	948		|O
Tracking	949	957		|O
I	958	959		|O
(	960	961		|O
125	961	964		|O
)	964	965		|O
-	965	966		|O
labeled	966	973		|O
conjugate	974	983		|O
showed	984	990		|O
that	991	995		|O
LMWC	996	1000		|O
-	1000	1001		|O
PTX	1001	1004		|O
was	1005	1008		|O
likely	1009	1015		|O
to	1016	1018		|O
be	1019	1021		|O
absorbed	1022	1030		|O
mainly	1031	1037		|O
from	1038	1042		|O
the	1043	1046		|O
ileum	1047	1052		|O
and	1053	1056		|O
reach	1057	1062		|O
the	1063	1066		|O
blood	1067	1072		|O
as	1073	1075		|O
the	1076	1079		|O
intact	1080	1086		|O
conjugate	1087	1096		|O
.	1096	1097		|O

### 18712998
Polyanhydrides	0	14		|O
as	15	17		|O
localized	18	27		|O
drug	28	32		|O
delivery	33	41		|O
carrier	42	49		|O
:	49	50		|O
an	51	53		|O
update	54	60		|O
.	60	61		|O
BACKGROUND	63	73		|O
:	73	74		|O
There	75	80		|O
is	81	83		|O
a	84	85		|O
continuing	86	96		|O
thrust	97	103		|O
to	104	106		|O
increase	107	115		|O
the	116	119		|O
efficacy	120	128		|O
and	129	132		|O
reduce	133	139		|O
the	140	143		|O
toxicity	144	152		|O
of	153	155		|O
existing	156	164		|O
and	165	168		|O
new	169	172		|O
drug	173	177		|O
molecules	178	187		|O
for	188	191		|O
their	192	197		|O
better	198	204		|O
usage	205	210		|O
to	211	213		|O
treat	214	219		|O
disease	220	227		|O
.	227	228		|O
Localized	229	238		|O
drug	239	243		|O
delivery	244	252		|O
has	253	256		|O
been	257	261		|O
explored	262	270		|O
in	271	273		|O
the	274	277		|O
same	278	282		|O
way	283	286		|O
,	286	287		|O
which	288	293		|O
can	294	297		|O
provide	298	305		|O
a	306	307		|O
platform	308	316		|O
to	317	319		|O
target	320	326		|O
local	327	332		|O
diseased	333	341		|O
tissues	342	349		|O
and	350	353		|O
can	354	357		|O
reduce	358	364		|O
the	365	368		|O
burden	369	375		|O
on	376	378		|O
the	379	382		|O
body	383	387		|O
by	388	390		|O
reducing	391	399		|O
the	400	403		|O
dose	404	408		|O
size	409	413		|O
and	414	417		|O
hence	418	423		|O
the	424	427		|O
dose	428	432	dose-related toxicity	|B-ADVERSE
-	432	433		|I-ADVERSE
related	433	440		|I-ADVERSE
toxicity	441	449		|I-ADVERSE
of	450	452		|O
the	453	456		|O
molecules	457	466		|O
.	466	467		|O
Various	468	475		|O
polymers	476	484		|O
have	485	489		|O
evolved	490	497		|O
for	498	501		|O
the	502	505		|O
purpose	506	513		|O
of	514	516		|O
localized	517	526		|O
drug	527	531		|O
delivery	532	540		|O
,	540	541		|O
however	542	549		|O
,	549	550		|O
polyanhydrides	551	565		|O
are	566	569		|O
considered	570	580		|O
the	581	584		|O
best	585	589		|O
,	589	590		|O
supported	591	600		|O
by	601	603		|O
products	604	612		|O
in	613	615		|O
the	616	619		|O
clinical	620	628		|O
phases	629	635		|O
.	635	636		|O
OBJECTIVE	637	646		|O
:	646	647		|O
To	648	650		|O
demonstrate	651	662		|O
the	663	666		|O
advantages	667	677		|O
of	678	680		|O
localized	681	690		|O
delivery	691	699		|O
using	700	705		|O
basic	706	711		|O
concepts	712	720		|O
and	721	724		|O
describing	725	735		|O
polyanhydride	736	749		|O
carrier	750	757		|O
with	758	762		|O
products	763	771		|O
such	772	776		|O
as	777	779		|O
Gliadel	780	787		|O
and	788	791		|O
Septacin	792	800		|O
.	800	801		|O
METHODS	802	809		|O
:	809	810		|O
The	811	814		|O
rationale	815	824		|O
behind	825	831		|O
localized	832	841		|O
drug	842	846		|O
delivery	847	855		|O
and	856	859		|O
the	860	863		|O
carrier	864	871		|O
for	872	875		|O
the	876	879		|O
same	880	884		|O
are	885	888		|O
dealt	889	894		|O
with	895	899		|O
.	899	900		|O
Polyanhydrides	901	915		|O
discussed	916	925		|O
in	926	928		|O
detail	929	935		|O
are	936	939		|O
those	940	945		|O
from	946	950		|O
subclasses	951	961		|O
that	962	966		|O
have	967	971		|O
been	972	976		|O
given	977	982		|O
less	983	987		|O
emphasis	988	996		|O
previously	997	1007		|O
and	1008	1011		|O
have	1012	1016		|O
been	1017	1021		|O
developed	1022	1031		|O
or	1032	1034		|O
investigated	1035	1047		|O
in	1048	1050		|O
the	1051	1054		|O
last	1055	1059		|O
5	1060	1061		|O
years	1062	1067		|O
.	1067	1068		|O
RESULTS	1069	1076		|O
/	1076	1077		|O
CONCLUSION	1077	1087		|O
:	1087	1088		|O
From	1089	1093		|O
the	1094	1097		|O
recent	1098	1104		|O
update	1105	1111		|O
on	1112	1114		|O
polyanhydrides	1115	1129		|O
,	1129	1130		|O
it	1131	1133		|O
can	1134	1137		|O
be	1138	1140		|O
concluded	1141	1150		|O
that	1151	1155		|O
these	1156	1161		|O
polymers	1162	1170		|O
have	1171	1175		|O
great	1176	1181		|O
potential	1182	1191		|O
as	1192	1194		|O
localized	1195	1204		|O
drug	1205	1209		|O
delivery	1210	1218		|O
carriers	1219	1227		|O
due	1228	1231		|O
to	1232	1234		|O
the	1235	1238		|O
versatility	1239	1250		|O
of	1251	1253		|O
their	1254	1259		|O
properties	1260	1270		|O
.	1270	1271		|O
However	1272	1279		|O
,	1279	1280		|O
the	1281	1284		|O
quest	1285	1290		|O
to	1291	1293		|O
stabilize	1294	1303		|O
the	1304	1307		|O
system	1308	1314		|O
in	1315	1317		|O
order	1318	1323		|O
to	1324	1326		|O
achieve	1327	1334		|O
a	1335	1336		|O
long	1337	1341		|O
shelf	1342	1347		|O
life	1348	1352		|O
remains	1353	1360		|O
ongoing	1361	1368		|O
.	1368	1369		|O

### 18760610
Antimicrobial	0	13		|O
and	14	17		|O
cytotoxic	18	27		|O
arylazoenamines	28	43		|O
.	43	44		|O
Part	45	49		|O
III	50	53		|O
:	53	54		|O
antiviral	55	64		|O
activity	65	73		|O
of	74	76		|O
selected	77	85		|O
classes	86	93		|O
of	94	96		|O
arylazoenamines	97	112		|O
.	112	113		|O
Eighty	115	121		|O
-	121	122		|O
five	122	126		|O
arylazoenamines	127	142		|O
,	142	143		|O
characterized	144	157		|O
by	158	160		|O
different	161	170		|O
types	171	176		|O
of	177	179		|O
aryl	180	184		|O
and	185	188		|O
basic	189	194		|O
moieties	195	203		|O
,	203	204		|O
have	205	209		|O
been	210	214		|O
synthesized	215	226		|O
and	227	230		|O
evaluated	231	240		|O
in	241	243		|O
cell	244	248		|O
-	248	249		|O
based	249	254		|O
assays	255	261		|O
for	262	265		|O
cytotoxicity	266	278		|O
and	279	282		|O
antiviral	283	292		|O
activity	293	301		|O
against	302	309		|O
a	310	311		|O
panel	312	317		|O
of	318	320		|O
ten	321	324		|O
RNA	325	328		|O
and	329	332		|O
DNA	333	336		|O
viruses	337	344		|O
.	344	345		|O
The	346	349		|O
most	350	354		|O
commonly	355	363		|O
affected	364	372		|O
viruses	373	380		|O
were	381	385		|O
,	385	386		|O
in	387	389		|O
decreasing	390	400		|O
order	401	406		|O
,	406	407		|O
CVB	408	411		|O
-	411	412		|O
2	412	413		|O
,	413	414		|O
RSV	415	418		|O
,	418	419		|O
BVDV	420	424		|O
,	424	425		|O
YFV	426	429		|O
,	429	430		|O
and	431	434		|O
Sb	435	437		|O
-	437	438		|O
1	438	439		|O
;	439	440		|O
the	441	444		|O
remaining	445	454		|O
viruses	455	462		|O
were	463	467		|O
either	468	474		|O
not	475	478		|O
affected	479	487		|O
(	488	489		|O
HIV	489	492		|O
-	492	493		|O
1	493	494		|O
,	494	495		|O
VSV	496	499		|O
,	499	500		|O
and	501	504		|O
VV	505	507		|O
)	507	508		|O
or	509	511		|O
susceptible	512	523		|O
only	524	528		|O
to	529	531		|O
a	532	533		|O
very	534	538		|O
few	539	542		|O
compounds	543	552		|O
(	553	554		|O
Reo	554	557		|O
-	557	558		|O
1	558	559		|O
and	560	563		|O
HSV	564	567		|O
-	567	568		|O
1	568	569		|O
)	569	570		|O
.	570	571		|O
Thirty	572	578		|O
-	578	579		|O
five	579	583		|O
compounds	584	593		|O
exhibited	594	603		|O
high	604	608		|O
activity	609	617		|O
,	617	618		|O
with	619	623		|O
EC	624	626		|O
(	626	627		|O
50	627	629		|O
)	629	630		|O
in	631	633		|O
the	634	637		|O
range	638	643		|O
0.8-10	644	650		|O
microM	651	657		|O
,	657	658		|O
and	659	662		|O
other	663	668		|O
28	669	671		|O
compounds	672	681		|O
had	682	685		|O
EC	686	688		|O
(	688	689		|O
50	689	691		|O
)	691	692		|O
between	693	700		|O
11	701	703		|O
and	704	707		|O
30	708	710		|O
microM	711	717		|O
,	717	718		|O
thus	719	723		|O
indicating	724	734		|O
that	735	739		|O
the	740	743		|O
arylazoenamine	744	758		|O
molecular	759	768		|O
pattern	769	776		|O
is	777	779		|O
an	780	782		|O
interesting	783	794		|O
novel	795	800		|O
pharmacophore	801	814		|O
for	815	818		|O
antiviral	819	828		|O
agents	829	835		|O
against	836	843		|O
ssRNA	844	849		|O
viruses	850	857		|O
.	857	858		|O
Moreover	859	867		|O
,	867	868		|O
some	869	873		|O
compounds	874	883		|O
(	884	885		|O
as	885	887		|O
28	888	890		|O
,	890	891		|O
32	892	894		|O
,	894	895		|O
42	896	898		|O
,	898	899		|O
and	900	903		|O
53	904	906		|O
)	906	907		|O
appear	908	914		|O
of	915	917		|O
high	918	922		|O
interest	923	931		|O
,	931	932		|O
being	933	938		|O
devoid	939	945		|O
of	946	948		|O
toxicity	949	957		|O
on	958	960		|O
the	961	964		|O
human	965	970		|O
MT	971	973		|O
-	973	974		|O
4	974	975		|O
cells	976	981		|O
(	982	983		|O
CC	983	985		|O
(	985	986		|O
50	986	988		|O
)	988	989		|O
>	989	990		|O
100	990	993		|O
microM	994	1000		|O
)	1000	1001		|O
.	1001	1002		|O
A	1003	1004		|O
ligand	1005	1011		|O
-	1011	1012		|O
based	1012	1017		|O
computational	1018	1031		|O
approach	1032	1040		|O
was	1041	1044		|O
employed	1045	1053		|O
to	1054	1056		|O
identify	1057	1065		|O
highly	1066	1072		|O
predictive	1073	1083		|O
pharmacophore	1084	1097		|O
models	1098	1104		|O
for	1105	1108		|O
the	1109	1112		|O
most	1113	1117		|O
frequently	1118	1128		|O
affected	1129	1137		|O
viruses	1138	1145		|O
CVB	1146	1149		|O
-	1149	1150		|O
2	1150	1151		|O
,	1151	1152		|O
RSV	1153	1156		|O
,	1156	1157		|O
and	1158	1161		|O
BVDV	1162	1166		|O
.	1166	1167		|O
These	1168	1173		|O
models	1174	1180		|O
should	1181	1187		|O
allow	1188	1193		|O
the	1194	1197		|O
design	1198	1204		|O
of	1205	1207		|O
second	1208	1214		|O
generation	1215	1225		|O
of	1226	1228		|O
more	1229	1233		|O
potent	1234	1240		|O
inhibitors	1241	1251		|O
of	1252	1254		|O
these	1255	1260		|O
human	1261	1266		|O
and	1267	1270		|O
veterinary	1271	1281		|O
pathogens	1282	1291		|O
.	1291	1292		|O

### 18806114
An	0	2		|O
approach	3	11		|O
to	12	14		|O
defining	15	23		|O
the	24	27		|O
upper	28	33		|O
safe	34	38		|O
limits	39	45		|O
of	46	48		|O
amino	49	54		|O
acid	55	59		|O
intake	60	66		|O
.	66	67		|O
The	69	72		|O
existing	73	81		|O
data	82	86		|O
on	87	89		|O
the	90	93		|O
safe	94	98		|O
upper	99	104		|O
limits	105	111		|O
of	112	114		|O
amino	115	120		|O
acid	121	125		|O
intake	126	132		|O
in	133	135		|O
humans	136	142		|O
is	143	145		|O
essentially	146	157		|O
observational	158	171		|O
;	171	172		|O
how	173	176		|O
much	177	181		|O
do	182	184		|O
individuals	185	196		|O
ingest	197	203		|O
and	204	207		|O
what	208	212		|O
side	213	217		|O
effects	218	225		|O
do	226	228		|O
they	229	233		|O
have	234	238		|O
?	238	239		|O
There	240	245		|O
are	246	249		|O
numerous	250	258		|O
studies	259	266		|O
in	267	269		|O
humans	270	276		|O
comparing	277	286		|O
the	287	290		|O
effects	291	298		|O
of	299	301		|O
high	302	306		|O
doses	307	312		|O
of	313	315		|O
amino	316	321		|O
acids	322	327		|O
given	328	333		|O
as	334	336		|O
protein	337	344		|O
bound	345	350		|O
vs.	351	354		|O
as	355	357		|O
free	358	362		|O
amino	363	368		|O
acids	369	374		|O
.	374	375		|O
These	376	381		|O
studies	382	389		|O
have	390	394		|O
shown	395	400		|O
that	401	405		|O
protein	406	413		|O
-	413	414		|O
bound	414	419		|O
amino	420	425		|O
acids	426	431		|O
have	432	436		|O
much	437	441		|O
less	442	446		|O
effect	447	453		|O
on	454	456		|O
plasma	457	463		|O
levels	464	470		|O
of	471	473		|O
the	474	477		|O
test	478	482		|O
amino	483	488		|O
acid	489	493		|O
,	493	494		|O
because	495	502		|O
protein	503	510		|O
intake	511	517		|O
stimulates	518	528		|O
protein	529	536		|O
synthesis	537	546		|O
as	547	549		|O
another	550	557		|O
sink	558	562		|O
for	563	566		|O
the	567	570		|O
increased	571	580		|O
amino	581	586		|O
acid	587	591		|O
intake	592	598		|O
.	598	599		|O
In	600	602		|O
practice	603	611		|O
,	611	612		|O
the	613	616		|O
highest	617	624		|O
amino	625	630		|O
acid	631	635		|O
intakes	636	643		|O
occur	644	649		|O
with	650	654		|O
free	655	659		|O
amino	660	665		|O
acid	666	670		|O
supplements	671	682		|O
that	683	687		|O
may	688	691		|O
be	692	694		|O
ingested	695	703		|O
by	704	706		|O
athletes	707	715		|O
who	716	719		|O
believe	720	727		|O
that	728	732		|O
the	733	736		|O
amino	737	742		|O
acids	743	748		|O
will	749	753		|O
benefit	754	761		|O
them	762	766		|O
in	767	769		|O
training	770	778		|O
and	779	782		|O
/	782	783		|O
or	783	785		|O
performance	786	797		|O
.	797	798		|O
Previously	799	809		|O
,	809	810		|O
in	811	813		|O
a	814	815		|O
piglet	816	822		|O
study	823	828		|O
,	828	829		|O
we	830	832		|O
were	833	837		|O
able	838	842		|O
to	843	845		|O
define	846	852		|O
the	853	856		|O
point	857	862		|O
at	863	865		|O
which	866	871		|O
maximal	872	879		|O
phenylalanine	880	893		|O
oxidation	894	903		|O
occurred	904	912		|O
,	912	913		|O
above	914	919		|O
which	920	925		|O
plasma	926	932		|O
phenylalanine	933	946		|O
concentration	947	960		|O
and	961	964		|O
body	965	969		|O
balance	970	977		|O
rose	978	982		|O
exponentially	983	996		|O
.	996	997		|O
We	998	1000		|O
regard	1001	1007		|O
this	1008	1012		|O
value	1013	1018		|O
of	1019	1021		|O
maximal	1022	1029		|O
disposal	1030	1038		|O
(	1039	1040		|O
oxidation	1040	1049		|O
)	1049	1050		|O
of	1051	1053		|O
an	1054	1056		|O
amino	1057	1062		|O
acid	1063	1067		|O
as	1068	1070		|O
one	1071	1074		|O
metabolic	1075	1084		|O
marker	1085	1091		|O
of	1092	1094		|O
the	1095	1098		|O
upper	1099	1104		|O
limit	1105	1110		|O
of	1111	1113		|O
intake	1114	1120		|O
.	1120	1121		|O
Recently	1122	1130		|O
,	1130	1131		|O
others	1132	1138		|O
have	1139	1143		|O
demonstrated	1144	1156		|O
a	1157	1158		|O
similar	1159	1166		|O
maximal	1167	1174		|O
oxidation	1175	1184		|O
rate	1185	1189		|O
for	1190	1193		|O
leucine	1194	1201		|O
in	1202	1204		|O
rats	1205	1209		|O
.	1209	1210		|O
Based	1211	1216		|O
on	1217	1219		|O
these	1220	1225		|O
experimental	1226	1238		|O
data	1239	1243		|O
and	1244	1247		|O
the	1248	1251		|O
paucity	1252	1259		|O
of	1260	1262		|O
published	1263	1272		|O
human	1273	1278		|O
data	1279	1283		|O
in	1284	1286		|O
controlled	1287	1297		|O
experiments	1298	1309		|O
,	1309	1310		|O
we	1311	1313		|O
think	1314	1319		|O
that	1320	1324		|O
a	1325	1326		|O
systematic	1327	1337		|O
approach	1338	1346		|O
needs	1347	1352		|O
to	1353	1355		|O
be	1356	1358		|O
undertaken	1359	1369		|O
to	1370	1372		|O
define	1373	1379		|O
the	1380	1383		|O
maximal	1384	1391		|O
oxidation	1392	1401		|O
rate	1402	1406		|O
for	1407	1410		|O
all	1411	1414		|O
dietary	1415	1422		|O
indispensable	1423	1436		|O
amino	1437	1442		|O
acids	1443	1448		|O
and	1449	1452		|O
other	1453	1458		|O
amino	1459	1464		|O
acids	1465	1470		|O
that	1471	1475		|O
may	1476	1479		|O
be	1480	1482		|O
ingested	1483	1491		|O
in	1492	1494		|O
excess	1495	1501		|O
by	1502	1504		|O
humans	1505	1511		|O
.	1511	1512		|O
We	1513	1515		|O
believe	1516	1523		|O
that	1524	1528		|O
this	1529	1533		|O
will	1534	1538		|O
provide	1539	1546		|O
a	1547	1548		|O
rational	1549	1557		|O
basis	1558	1563		|O
to	1564	1566		|O
begin	1567	1572		|O
to	1573	1575		|O
define	1576	1582		|O
the	1583	1586		|O
upper	1587	1592		|O
limits	1593	1599		|O
of	1600	1602		|O
tolerance	1603	1612		|O
for	1613	1616		|O
dietary	1617	1624		|O
amino	1625	1630		|O
acids	1631	1636		|O
.	1636	1637		|O
However	1638	1645		|O
,	1645	1646		|O
some	1647	1651		|O
amino	1652	1657		|O
acids	1658	1663		|O
,	1663	1664		|O
such	1665	1669		|O
as	1670	1672		|O
threonine	1673	1682		|O
and	1683	1686		|O
methionine	1687	1697		|O
,	1697	1698		|O
will	1699	1703		|O
be	1704	1706		|O
more	1707	1711		|O
difficult	1712	1721		|O
to	1722	1724		|O
study	1725	1730		|O
,	1730	1731		|O
because	1732	1739		|O
they	1740	1744		|O
have	1745	1749		|O
more	1750	1754		|O
than	1755	1759		|O
1	1760	1761		|O
route	1762	1767		|O
of	1768	1770		|O
disposal	1771	1779		|O
or	1780	1782		|O
very	1783	1787		|O
complex	1788	1795		|O
metabolic	1796	1805		|O
regulation	1806	1816		|O
,	1816	1817		|O
in	1818	1820		|O
which	1821	1826		|O
case	1827	1831		|O
defining	1832	1840		|O
their	1841	1846		|O
upper	1847	1852		|O
limits	1853	1859		|O
will	1860	1864		|O
be	1865	1867		|O
more	1868	1872		|O
multifaceted	1873	1885		|O
.	1885	1886		|O

### 18687998
Lentiviral	0	10		|O
short	11	16		|O
hairpin	17	24		|O
RNA	25	28		|O
screen	29	35		|O
of	36	38		|O
genes	39	44		|O
associated	45	55		|O
with	56	60		|O
multidrug	61	70		|O
resistance	71	81		|O
identifies	82	92		|O
PRP	93	96		|O
-	96	97		|O
4	97	98		|O
as	99	101		|O
a	102	103		|O
new	104	107		|O
regulator	108	117		|O
of	118	120		|O
chemoresistance	121	136		|O
in	137	139		|O
human	140	145		|O
ovarian	146	153	ovarian cancer	|B-DISEASE
cancer	154	160		|I-DISEASE
.	160	161		|O
Published	163	172		|O
reports	173	180		|O
implicate	181	190		|O
a	191	192		|O
variety	193	200		|O
of	201	203		|O
mechanisms	204	214		|O
that	215	219		|O
may	220	223		|O
contribute	224	234		|O
to	235	237		|O
drug	238	242		|O
resistance	243	253		|O
in	254	256		|O
ovarian	257	264	ovarian cancer	|B-DISEASE
cancer	265	271		|I-DISEASE
.	271	272		|O
The	273	276		|O
chief	277	282		|O
aim	283	286		|O
of	287	289		|O
this	290	294		|O
study	295	300		|O
is	301	303		|O
to	304	306		|O
understand	307	317		|O
the	318	321		|O
relationship	322	334		|O
between	335	342		|O
overexpression	343	357		|O
of	358	360		|O
drug	361	365		|O
resistance	366	376		|O
associated	377	387		|O
genes	388	393		|O
and	394	397		|O
multidrug	398	407		|O
resistance	408	418		|O
in	419	421		|O
ovarian	422	429	ovarian cancer	|B-DISEASE
cancer	430	436		|I-DISEASE
.	436	437		|O
Using	438	443		|O
lentiviral	444	454		|O
short	455	460		|O
hairpin	461	468		|O
RNA	469	472		|O
collections	473	484		|O
targeting	485	494		|O
132	495	498		|O
genes	499	504		|O
identified	505	515		|O
from	516	520		|O
transcriptional	521	536		|O
profiling	537	546		|O
of	547	549		|O
drug	550	554		|O
-	554	555		|O
resistant	555	564		|O
cancer	565	571		|O
cell	572	576		|O
lines	577	582		|O
,	582	583		|O
individual	584	594		|O
knockdown	595	604		|O
experiments	605	616		|O
were	617	621		|O
done	622	626		|O
in	627	629		|O
the	630	633		|O
presence	634	642		|O
of	643	645		|O
sublethal	646	655		|O
doses	656	661		|O
of	662	664		|O
paclitaxel	665	675		|O
.	675	676		|O
Specific	677	685		|O
genes	686	691		|O
whose	692	697		|O
knockdown	698	707		|O
was	708	711		|O
found	712	717		|O
to	718	720		|O
be	721	723		|O
associated	724	734		|O
with	735	739		|O
cellular	740	748	cellular toxicity	|B-ADVERSE
toxicity	749	757		|I-ADVERSE
included	758	766		|O
MDR1	767	771		|O
(	772	773		|O
ABCB1	773	778		|O
)	778	779		|O
,	779	780		|O
survivin	781	789		|O
,	789	790		|O
and	791	794		|O
pre	795	798		|O
-	798	799		|O
mRNA	799	803		|O
processing	804	814		|O
factor	815	821		|O
-	821	822		|O
4	822	823		|O
(	824	825		|O
PRP	825	828		|O
-	828	829		|O
4	829	830		|O
)	830	831		|O
.	831	832		|O
These	833	838		|O
genes	839	844		|O
,	844	845		|O
when	846	850		|O
repressed	851	860		|O
,	860	861		|O
can	862	865		|O
reverse	866	873		|O
paclitaxel	874	884		|O
resistance	885	895		|O
in	896	898		|O
the	899	902		|O
multidrug	903	912		|O
-	912	913		|O
resistant	913	922		|O
cell	923	927		|O
line	928	932		|O
SKOV	933	937		|O
-	937	938		|O
3	938	939		|O
(	939	940		|O
TR	940	942		|O
)	942	943		|O
and	944	947		|O
OVCAR8	948	954		|O
(	954	955		|O
TR	955	957		|O
)	957	958		|O
.	958	959		|O
Both	960	964		|O
MDR1	965	969		|O
and	970	973		|O
survivin	974	982		|O
have	983	987		|O
been	988	992		|O
reported	993	1001		|O
previously	1002	1012		|O
to	1013	1015		|O
play	1016	1020		|O
a	1021	1022		|O
role	1023	1027		|O
in	1028	1030		|O
multidrug	1031	1040		|O
resistance	1041	1051		|O
and	1052	1055		|O
chemotherapy	1056	1068		|O
-	1068	1069		|O
induced	1069	1076		|O
apoptosis	1077	1086		|O
;	1086	1087		|O
however	1088	1095		|O
,	1095	1096		|O
the	1097	1100		|O
effect	1101	1107		|O
of	1108	1110		|O
PRP	1111	1114		|O
-	1114	1115		|O
4	1115	1116		|O
expression	1117	1127		|O
on	1128	1130		|O
drug	1131	1135		|O
sensitivity	1136	1147		|O
is	1148	1150		|O
currently	1151	1160		|O
unrecognized	1161	1173		|O
.	1173	1174		|O
PRP	1175	1178		|O
-	1178	1179		|O
4	1179	1180		|O
belongs	1181	1188		|O
to	1189	1191		|O
the	1192	1195		|O
serine	1196	1202		|O
/	1202	1203		|O
threonine	1203	1212		|O
protein	1213	1220		|O
kinase	1221	1227		|O
family	1228	1234		|O
,	1234	1235		|O
plays	1236	1241		|O
a	1242	1243		|O
role	1244	1248		|O
in	1249	1251		|O
pre	1252	1255		|O
-	1255	1256		|O
mRNA	1256	1260		|O
splicing	1261	1269		|O
and	1270	1273		|O
cell	1274	1278		|O
mitosis	1279	1286		|O
,	1286	1287		|O
and	1288	1291		|O
interacts	1292	1301		|O
with	1302	1306		|O
CLK1	1307	1311		|O
.	1311	1312		|O
Northern	1313	1321		|O
analysis	1322	1330		|O
shows	1331	1336		|O
that	1337	1341		|O
PRP	1342	1345		|O
-	1345	1346		|O
4	1346	1347		|O
is	1348	1350		|O
overexpressed	1351	1364		|O
in	1365	1367		|O
several	1368	1375		|O
paclitaxel	1376	1386		|O
-	1386	1387		|O
resistant	1387	1396		|O
cell	1397	1401		|O
lines	1402	1407		|O
and	1408	1411		|O
confirms	1412	1420		|O
that	1421	1425		|O
PRP	1426	1429		|O
-	1429	1430		|O
4	1430	1431		|O
expression	1432	1442		|O
could	1443	1448		|O
be	1449	1451		|O
significantly	1452	1465		|O
repressed	1466	1475		|O
by	1476	1478		|O
PRP	1479	1482		|O
-	1482	1483		|O
4	1483	1484		|O
lentiviral	1485	1495		|O
short	1496	1501		|O
hairpin	1502	1509		|O
RNA	1510	1513		|O
.	1513	1514		|O
Both	1515	1519		|O
clonogenic	1520	1530		|O
and	1531	1534		|O
MTT	1535	1538		|O
assays	1539	1545		|O
confirm	1546	1553		|O
that	1554	1558		|O
transcriptional	1559	1574		|O
repression	1575	1585		|O
of	1586	1588		|O
PRP	1589	1592		|O
-	1592	1593		|O
4	1593	1594		|O
could	1595	1600		|O
reverse	1601	1608		|O
paclitaxel	1609	1619		|O
resistance	1620	1630		|O
5-10	1631	1635		|O
-	1635	1636		|O
fold	1636	1640		|O
in	1641	1643		|O
SKOV	1644	1648		|O
-	1648	1649		|O
3	1649	1650		|O
(	1650	1651		|O
TR	1651	1653		|O
)	1653	1654		|O
.	1654	1655		|O
Finally	1656	1663		|O
,	1663	1664		|O
overexpression	1665	1679		|O
of	1680	1682		|O
PRP	1683	1686		|O
-	1686	1687		|O
4	1687	1688		|O
in	1689	1691		|O
drug	1692	1696		|O
-	1696	1697		|O
sensitive	1697	1706		|O
cells	1707	1712		|O
could	1713	1718		|O
induce	1719	1725		|O
a	1726	1727		|O
modest	1728	1734		|O
level	1735	1740		|O
of	1741	1743		|O
drug	1744	1748		|O
resistance	1749	1759		|O
to	1760	1762		|O
paclitaxel	1763	1773		|O
,	1773	1774		|O
doxorubicin	1775	1786		|O
,	1786	1787		|O
and	1788	1791		|O
vincristine	1792	1803		|O
.	1803	1804		|O

### 18567054
Local	0	5		|O
tissue	6	12		|O
destruction	13	24		|O
and	25	28		|O
procoagulation	29	43		|O
properties	44	54		|O
of	55	57		|O
Echis	58	63		|O
carinatus	64	73		|O
venom	74	79		|O
:	79	80		|O
inhibition	81	91		|O
by	92	94		|O
Vitis	95	100		|O
vinifera	101	109		|O
seed	110	114		|O
methanol	115	123		|O
extract	124	131		|O
.	131	132		|O
Plant	134	139		|O
extracts	140	148		|O
are	149	152		|O
extensively	153	164		|O
used	165	169		|O
against	170	177		|O
snakebites	178	188		|O
in	189	191		|O
Indian	192	198		|O
folk	199	203		|O
medicine	204	212		|O
.	212	213		|O
In	214	216		|O
this	217	221		|O
study	222	227		|O
,	227	228		|O
one	229	232		|O
such	233	237		|O
traditionally	238	251		|O
used	252	256		|O
plant	257	262		|O
,	262	263		|O
Vitis	264	269		|O
vinifera	270	278		|O
L	279	280		|O
.	280	281		|O
(	282	283		|O
Vitaceae	283	291		|O
)	291	292		|O
seed	293	297		|O
methanol	298	306		|O
extract	307	314		|O
has	315	318		|O
been	319	323		|O
studied	324	331		|O
for	332	335		|O
its	336	339		|O
ability	340	347		|O
to	348	350		|O
neutralize	351	361		|O
Indian	362	368		|O
Echis	369	374		|O
carinatus	375	384		|O
(	385	386		|O
saw	386	389		|O
-	389	390		|O
scaled	390	396		|O
viper	397	402		|O
)	402	403		|O
venom	404	409		|O
.	409	410		|O
The	411	414		|O
extract	415	422		|O
effectively	423	434		|O
inhibited	435	444		|O
toxic	445	450		|O
effects	451	458		|O
,	458	459		|O
such	460	464		|O
as	465	467		|O
oedema	468	474	oedema	|B-ADVERSE
,	474	475		|O
haemorrhage	476	487	haemorrhage	|B-ADVERSE
,	487	488		|O
myonecrosis	489	500	myonecrosis	|B-ADVERSE
and	501	504		|O
coagulation	505	516	coagulation of citrated human plasma	|B-ADVERSE
of	517	519		|I-ADVERSE
citrated	520	528		|I-ADVERSE
human	529	534		|I-ADVERSE
plasma	535	541		|I-ADVERSE
.	541	542		|O
Further	543	550		|O
,	550	551		|O
the	552	555		|O
extract	556	563		|O
inhibited	564	573		|O
the	574	577		|O
caseinolytic	578	590		|O
,	590	591		|O
hyaluronolytic	592	606		|O
and	607	610		|O
fibrinogenolytic	611	627		|O
activities	628	638		|O
of	639	641		|O
the	642	645		|O
venom	646	651		|O
.	651	652		|O
The	653	656		|O
extract	657	664		|O
caused	665	671		|O
dose	672	676		|O
dependent	677	686		|O
inhibition	687	697		|O
of	698	700		|O
the	701	704		|O
toxic	705	710		|O
activities	711	721		|O
studied	722	729		|O
,	729	730		|O
suggesting	731	741		|O
venom	742	747		|O
inhibition	748	758		|O
.	758	759		|O
Thus	760	764		|O
,	764	765		|O
the	766	769		|O
anti	770	774		|O
-	774	775		|O
snake	775	780		|O
venom	781	786		|O
property	787	795		|O
of	796	798		|O
the	799	802		|O
extract	803	810		|O
appears	811	818		|O
to	819	821		|O
be	822	824		|O
highly	825	831		|O
promising	832	841		|O
for	842	845		|O
further	846	853		|O
investigation	854	867		|O
in	868	870		|O
order	871	876		|O
to	877	879		|O
achieve	880	887		|O
better	888	894		|O
neutralization	895	909		|O
of	910	912		|O
Indian	913	919		|O
E	920	921		|O
.	921	922		|O
carinatus	923	932		|O
venom	933	938	venom poisoning	|B-DISEASE
poisoning	939	948		|I-DISEASE
.	948	949		|O

### 18653608
An	0	2		|O
in	3	5		|O
vivo	6	10		|O
evaluation	11	21		|O
of	22	24		|O
Brilliant	25	34		|O
Blue	35	39		|O
G	40	41		|O
in	42	44		|O
animals	45	52		|O
and	53	56		|O
humans	57	63		|O
.	63	64		|O
BACKGROUND	66	76		|O
/	76	77		|O
AIMS	77	81		|O
:	81	82		|O
To	83	85		|O
evaluate	86	94		|O
the	95	98		|O
retinal	99	106	retinal toxicity	|B-ADVERSE
toxicity	107	115		|I-ADVERSE
of	116	118		|O
Brilliant	119	128		|O
Blue	129	133		|O
G	134	135		|O
(	136	137		|O
BBG	137	140		|O
)	140	141		|O
following	142	151		|O
intravitreal	152	164		|O
injection	165	174		|O
in	175	177		|O
rat	178	181		|O
eyes	182	186		|O
and	187	190		|O
examine	191	198		|O
the	199	202		|O
biocompatibility	203	219		|O
and	220	223		|O
the	224	227		|O
staining	228	236		|O
properties	237	247		|O
in	248	250		|O
humans	251	257		|O
.	257	258		|O
METHODS	259	266		|O
:	266	267		|O
BBG	268	271		|O
was	272	275		|O
injected	276	284		|O
into	285	289		|O
the	290	293		|O
11	294	296		|O
rat	297	300		|O
eyes	301	305		|O
to	306	308		|O
evaluate	309	317		|O
toxic	318	323		|O
effects	324	331		|O
with	332	336		|O
balanced	337	345		|O
salt	346	350		|O
solution	351	359		|O
(	360	361		|O
BSS	361	364		|O
)	364	365		|O
serving	366	373		|O
as	374	376		|O
control	377	384		|O
.	384	385		|O
Retinal	386	393	Retinal toxicity	|B-ADVERSE
toxicity	394	402		|I-ADVERSE
was	403	406		|O
assessed	407	415		|O
by	416	418		|O
retinal	419	426		|O
ganglion	427	435		|O
cell	436	440		|O
(	441	442		|O
RGC	442	445		|O
)	445	446		|O
counts	447	453		|O
and	454	457		|O
by	458	460		|O
light	461	466		|O
microscopy	467	477		|O
7	478	479		|O
days	480	484		|O
later	485	490		|O
.	490	491		|O
In	492	494		|O
addition	495	503		|O
,	503	504		|O
BBG	505	508		|O
was	509	512		|O
applied	513	520		|O
during	521	527		|O
vitrectomy	528	538		|O
for	539	542		|O
macular	543	550		|O
hole	551	555		|O
(	556	557		|O
MH	557	559		|O
)	559	560		|O
(	561	562		|O
n	562	563		|O
=	564	565		|O
15	566	568		|O
)	568	569		|O
or	570	572		|O
epiretinal	573	583		|O
membranes	584	593		|O
(	594	595		|O
ERM	595	598		|O
)	598	599		|O
(	600	601		|O
n	601	602		|O
=	603	604		|O
3	605	606		|O
)	606	607		|O
in	608	610		|O
a	611	612		|O
prospective	613	624		|O
,	624	625		|O
non	626	629		|O
-	629	630		|O
comparative	630	641		|O
consecutive	642	653		|O
series	654	660		|O
of	661	663		|O
patients	664	672		|O
.	672	673		|O
Before	674	680		|O
and	681	684		|O
after	685	690		|O
surgery	691	698		|O
,	698	699		|O
all	700	703		|O
patients	704	712		|O
underwent	713	722		|O
a	723	724		|O
complete	725	733		|O
clinical	734	742		|O
examination	743	754		|O
including	755	764		|O
measurement	765	776		|O
of	777	779		|O
best	780	784		|O
corrected	785	794		|O
visual	795	801		|O
acuity	802	808		|O
(	809	810		|O
VA	810	812		|O
)	812	813		|O
and	814	817		|O
intraocular	818	829		|O
pressure	830	838		|O
,	838	839		|O
perimetry	840	849		|O
,	849	850		|O
fundus	851	857		|O
photography	858	869		|O
and	870	873		|O
optical	874	881		|O
coherence	882	891		|O
tomography	892	902		|O
.	902	903		|O
Patients	904	912		|O
were	913	917		|O
seen	918	922		|O
1	923	924		|O
day	925	928		|O
before	929	935		|O
surgery	936	943		|O
and	944	947		|O
then	948	952		|O
in	953	955		|O
approximately	956	969		|O
four	970	974		|O
weeks	975	980		|O
intervals	981	990		|O
.	990	991		|O
RESULTS	992	999		|O
:	999	1000		|O
No	1001	1003		|O
significant	1004	1015		|O
reduction	1016	1025		|O
in	1026	1028		|O
RGC	1029	1032		|O
numbers	1033	1040		|O
and	1041	1044		|O
no	1045	1047		|O
morphological	1048	1061		|O
alterations	1062	1073		|O
were	1074	1078		|O
noted	1079	1084		|O
.	1084	1085		|O
A	1086	1087		|O
sufficient	1088	1098		|O
staining	1099	1107		|O
of	1108	1110		|O
the	1111	1114		|O
internal	1115	1123		|O
limiting	1124	1132		|O
membrane	1133	1141		|O
(	1142	1143		|O
ILM	1143	1146		|O
)	1146	1147		|O
was	1148	1151		|O
seen	1152	1156		|O
in	1157	1159		|O
patients	1160	1168		|O
with	1169	1173		|O
MH	1174	1176		|O
,	1176	1177		|O
while	1178	1183		|O
the	1184	1187		|O
staining	1188	1196		|O
pattern	1197	1204		|O
in	1205	1207		|O
ERM	1208	1211		|O
cases	1212	1217		|O
was	1218	1221		|O
patchy	1222	1228		|O
,	1228	1229		|O
indicating	1230	1240		|O
that	1241	1245		|O
parts	1246	1251		|O
of	1252	1254		|O
the	1255	1258		|O
ILM	1259	1262		|O
were	1263	1267		|O
peeled	1268	1274		|O
off	1275	1278		|O
along	1279	1284		|O
with	1285	1289		|O
the	1290	1293		|O
ERM	1294	1297		|O
in	1298	1300		|O
a	1301	1302		|O
variable	1303	1311		|O
extent	1312	1318		|O
.	1318	1319		|O
All	1320	1323		|O
MHs	1324	1327		|O
could	1328	1333		|O
be	1334	1336		|O
closed	1337	1343		|O
successfully	1344	1356		|O
.	1356	1357		|O
VA	1358	1360		|O
improved	1361	1369		|O
in	1370	1372		|O
10	1373	1375		|O
eyes	1376	1380		|O
(	1381	1382		|O
56%	1382	1385		|O
;	1385	1386		|O
8/15	1387	1391		|O
MH	1392	1394		|O
patients	1395	1403		|O
,	1403	1404		|O
2/3	1405	1408		|O
ERM	1409	1412		|O
patients	1413	1421		|O
)	1421	1422		|O
,	1422	1423		|O
was	1424	1427		|O
unchanged	1428	1437		|O
in	1438	1440		|O
four	1441	1445		|O
eyes	1446	1450		|O
(	1451	1452		|O
22%	1452	1455		|O
;	1455	1456		|O
all	1457	1460		|O
MH	1461	1463		|O
patients	1464	1472		|O
)	1472	1473		|O
and	1474	1477		|O
was	1478	1481		|O
reduced	1482	1489		|O
in	1490	1492		|O
four	1493	1497		|O
eyes	1498	1502		|O
(	1503	1504		|O
22%	1504	1507		|O
;	1507	1508		|O
3/15	1509	1513		|O
MH	1514	1516		|O
,	1516	1517		|O
1/3	1518	1521		|O
ERM	1522	1525		|O
)	1525	1526		|O
.	1526	1527		|O
No	1528	1530		|O
toxic	1531	1536		|O
effects	1537	1544		|O
attributable	1545	1557		|O
to	1558	1560		|O
the	1561	1564		|O
dye	1565	1568		|O
were	1569	1573		|O
noted	1574	1579		|O
during	1580	1586		|O
patient	1587	1594		|O
follow	1595	1601		|O
-	1601	1602		|O
up	1602	1604		|O
.	1604	1605		|O
The	1606	1609		|O
ultrastructure	1610	1624		|O
of	1625	1627		|O
tissue	1628	1634		|O
harvested	1635	1644		|O
during	1645	1651		|O
surgery	1652	1659		|O
was	1660	1663		|O
unremarkable	1664	1676		|O
.	1676	1677		|O
CONCLUSION	1678	1688		|O
:	1688	1689		|O
Brilliant	1690	1699		|O
Blue	1700	1704		|O
provides	1705	1713		|O
a	1714	1715		|O
sufficient	1716	1726		|O
and	1727	1730		|O
selective	1731	1740		|O
staining	1741	1749		|O
of	1750	1752		|O
the	1753	1756		|O
ILM	1757	1760		|O
.	1760	1761		|O
No	1762	1764		|O
retinal	1765	1772	retinal toxicity	|B-ADVERSE
toxicity	1773	1781		|I-ADVERSE
or	1782	1784		|O
adverse	1785	1792		|O
effects	1793	1800		|O
related	1801	1808		|O
to	1809	1811		|O
the	1812	1815		|O
dye	1816	1819		|O
were	1820	1824		|O
observed	1825	1833		|O
in	1834	1836		|O
animal	1837	1843		|O
and	1844	1847		|O
human	1848	1853		|O
studies	1854	1861		|O
.	1861	1862		|O
The	1863	1866		|O
long	1867	1871		|O
-	1871	1872		|O
term	1872	1876		|O
safety	1877	1883		|O
of	1884	1886		|O
this	1887	1891		|O
novel	1892	1897		|O
dye	1898	1901		|O
will	1902	1906		|O
have	1907	1911		|O
to	1912	1914		|O
be	1915	1917		|O
evaluated	1918	1927		|O
in	1928	1930		|O
larger	1931	1937		|O
patient	1938	1945		|O
series	1946	1952		|O
and	1953	1956		|O
a	1957	1958		|O
longer	1959	1965		|O
follow	1966	1972		|O
-	1972	1973		|O
up	1973	1975		|O
.	1975	1976		|O

### 18811200
Koshikamide	0	11		|O
B	12	13		|O
,	13	14		|O
a	15	16		|O
cytotoxic	17	26		|O
peptide	27	34		|O
lactone	35	42		|O
from	43	47		|O
a	48	49		|O
marine	50	56		|O
sponge	57	63		|O
Theonella	64	73		|O
sp	74	76		|O
.	76	77		|O
Koshikamide	79	90		|O
B	91	92		|O
(	93	94		|O
1	94	95		|O
)	95	96		|O
has	97	100		|O
been	101	105		|O
isolated	106	114		|O
from	115	119		|O
two	120	123		|O
separate	124	132		|O
collections	133	144		|O
of	145	147		|O
the	148	151		|O
marine	152	158		|O
sponge	159	165		|O
Theonella	166	175		|O
sp	176	178		|O
.	178	179		|O
as	180	182		|O
the	183	186		|O
major	187	192		|O
cytotoxic	193	202		|O
constituent	203	214		|O
.	214	215		|O
Koshikamide	216	227		|O
B	228	229		|O
is	230	232		|O
a	233	234		|O
17	235	237		|O
-	237	238		|O
residue	238	245		|O
peptide	246	253		|O
lactone	254	261		|O
composed	262	270		|O
of	271	273		|O
six	274	277		|O
proteinogenic	278	291		|O
amino	292	297		|O
acids	298	303		|O
,	303	304		|O
two	305	308		|O
D	309	310		|O
-	310	311		|O
isomers	311	318		|O
of	319	321		|O
proteinogenic	322	335		|O
amino	336	341		|O
acids	342	347		|O
,	347	348		|O
seven	349	354		|O
N	355	356		|O
-	356	357		|O
methylated	357	367		|O
amino	368	373		|O
acids	374	379		|O
,	379	380		|O
and	381	384		|O
two	385	388		|O
unusual	389	396		|O
amino	397	402		|O
acid	403	407		|O
residues	408	416		|O
.	416	417		|O
The	418	421		|O
unusual	422	429		|O
amino	430	435		|O
acids	436	441		|O
are	442	445		|O
N	446	447		|O
(	447	448		|O
delta	448	453		|O
)	453	454		|O
-	454	455		|O
carbamoylasparagine	455	474		|O
and	475	478		|O
2	479	480		|O
-	480	481		|O
(	481	482		|O
3	482	483		|O
-	483	484		|O
amino	484	489		|O
-	489	490		|O
2	490	491		|O
-	491	492		|O
hydroxy	492	499		|O
-	499	500		|O
5	500	501		|O
-	501	502		|O
oxopyrrolidin	502	515		|O
-	515	516		|O
2	516	517		|O
-	517	518		|O
yl	518	520		|O
)	520	521		|O
propionic	521	530		|O
acid	531	535		|O
(	536	537		|O
AHPP	537	541		|O
)	541	542		|O
;	542	543		|O
the	544	547		|O
former	548	554		|O
is	555	557		|O
first	558	563		|O
found	564	569		|O
as	570	572		|O
the	573	576		|O
constituent	577	588		|O
of	589	591		|O
peptides	592	600		|O
,	600	601		|O
whereas	602	609		|O
the	610	613		|O
latter	614	620		|O
is	621	623		|O
a	624	625		|O
new	626	629		|O
amino	630	635		|O
acid	636	640		|O
residue	641	648		|O
.	648	649		|O
The	650	653		|O
N	654	655		|O
-	655	656		|O
terminus	656	664		|O
of	665	667		|O
koshikamide	668	679		|O
B	680	681		|O
is	682	684		|O
blocked	685	692		|O
by	693	695		|O
a	696	697		|O
methoxyacetyl	698	711		|O
group	712	717		|O
.	717	718		|O
The	719	722		|O
structure	723	732		|O
of	733	735		|O
koshikamide	736	747		|O
B	748	749		|O
(	750	751		|O
1	751	752		|O
)	752	753		|O
has	754	757		|O
been	758	762		|O
determined	763	773		|O
by	774	776		|O
interpretation	777	791		|O
of	792	794		|O
spectral	795	803		|O
data	804	808		|O
and	809	812		|O
analysis	813	821		|O
of	822	824		|O
chemical	825	833		|O
degradation	834	845		|O
products	846	854		|O
.	854	855		|O
Koshikamide	856	867		|O
B	868	869		|O
(	870	871		|O
1	871	872		|O
)	872	873		|O
exhibits	874	882		|O
cytotoxicity	883	895	cytotoxicity	|B-ADVERSE
against	896	903		|O
P388	904	908		|O
murine	909	915		|O
leukemia	916	924		|O
cells	925	930		|O
and	931	934		|O
the	935	938		|O
human	939	944		|O
colon	945	950		|O
tumor	951	956		|O
(	957	958		|O
HCT	958	961		|O
-	961	962		|O
116	962	965		|O
)	965	966		|O
cell	967	971		|O
line	972	976		|O
with	977	981		|O
an	982	984		|O
IC50	985	989		|O
value	990	995		|O
of	996	998		|O
0.45	999	1003		|O
and	1004	1007		|O
7.5	1008	1011		|O
microg	1012	1018		|O
/	1018	1019		|O
mL	1019	1021		|O
,	1021	1022		|O
respectively	1023	1035		|O
.	1035	1036		|O

### 18775494
Minimization	0	12		|O
of	13	15		|O
calcineurin	16	27		|O
inhibitors	28	38		|O
to	39	41		|O
improve	42	49		|O
long	50	54		|O
-	54	55		|O
term	55	59		|O
outcomes	60	68		|O
in	69	71		|O
kidney	72	78		|O
transplantation	79	94		|O
.	94	95		|O
Long	97	101		|O
-	101	102		|O
term	102	106		|O
outcomes	107	115		|O
after	116	121		|O
kidney	122	128		|O
transplantation	129	144		|O
remain	145	151		|O
suboptimal	152	162		|O
,	162	163		|O
despite	164	171		|O
the	172	175		|O
great	176	181		|O
achievements	182	194		|O
observed	195	203		|O
in	204	206		|O
recent	207	213		|O
years	214	219		|O
with	220	224		|O
the	225	228		|O
use	229	232		|O
of	233	235		|O
modern	236	242		|O
immunosuppressive	243	260		|O
drugs	261	266		|O
.	266	267		|O
Currently	268	277		|O
,	277	278		|O
the	279	282		|O
calcineurin	283	294		|O
inhibitors	295	305		|O
(	306	307		|O
CNI	307	310		|O
)	310	311		|O
cyclosporine	312	324		|O
and	325	328		|O
tacrolimus	329	339		|O
remain	340	346		|O
the	347	350		|O
cornerstones	351	363		|O
of	364	366		|O
immunosuppressive	367	384		|O
regimens	385	393		|O
in	394	396		|O
many	397	401		|O
centers	402	409		|O
worldwide	410	419		|O
,	419	420		|O
regardless	421	431		|O
of	432	434		|O
their	435	440		|O
well	441	445		|O
described	446	455		|O
side	456	460		|O
-	460	461		|O
effects	461	468		|O
,	468	469		|O
including	470	479		|O
nephrotoxicity	480	494	nephrotoxicity	|B-ADVERSE
.	494	495		|O
In	496	498		|O
this	499	503		|O
article	504	511		|O
,	511	512		|O
we	513	515		|O
review	516	522		|O
recent	523	529		|O
CNI	530	533		|O
-	533	534		|O
minimization	534	546		|O
strategies	547	557		|O
in	558	560		|O
kidney	561	567		|O
transplantation	568	583		|O
,	583	584		|O
while	585	590		|O
emphasizing	591	602		|O
on	603	605		|O
the	606	609		|O
importance	610	620		|O
of	621	623		|O
long	624	628		|O
-	628	629		|O
term	629	633		|O
follow	634	640		|O
-	640	641		|O
up	641	643		|O
and	644	647		|O
patient	648	655		|O
monitoring	656	666		|O
.	666	667		|O
Finally	668	675		|O
,	675	676		|O
accumulating	677	689		|O
data	690	694		|O
indicate	695	703		|O
that	704	708		|O
low	709	712		|O
-	712	713		|O
dose	713	717		|O
CNI	718	721		|O
-	721	722		|O
based	722	727		|O
regimens	728	736		|O
would	737	742		|O
provide	743	750		|O
an	751	753		|O
interesting	754	765		|O
balance	766	773		|O
between	774	781		|O
efficacy	782	790		|O
and	791	794		|O
toxicity	795	803		|O
.	803	804		|O

### 18618001
Zebrafish	0	9		|O
whole	10	15		|O
-	15	16		|O
adult	16	21		|O
-	21	22		|O
organism	22	30		|O
chemogenomics	31	44		|O
for	45	48		|O
large	49	54		|O
-	54	55		|O
scale	55	60		|O
predictive	61	71		|O
and	72	75		|O
discovery	76	85		|O
chemical	86	94		|O
biology	95	102		|O
.	102	103		|O
The	105	108		|O
ability	109	116		|O
to	117	119		|O
perform	120	127		|O
large	128	133		|O
-	133	134		|O
scale	134	139		|O
,	139	140		|O
expression	141	151		|O
-	151	152		|O
based	152	157		|O
chemogenomics	158	171		|O
on	172	174		|O
whole	175	180		|O
adult	181	186		|O
organisms	187	196		|O
,	196	197		|O
as	198	200		|O
in	201	203		|O
invertebrate	204	216		|O
models	217	223		|O
(	224	225		|O
worm	225	229		|O
and	230	233		|O
fly	234	237		|O
)	237	238		|O
,	238	239		|O
is	240	242		|O
highly	243	249		|O
desirable	250	259		|O
for	260	263		|O
a	264	265		|O
vertebrate	266	276		|O
model	277	282		|O
but	283	286		|O
its	287	290		|O
feasibility	291	302		|O
and	303	306		|O
potential	307	316		|O
has	317	320		|O
not	321	324		|O
been	325	329		|O
demonstrated	330	342		|O
.	342	343		|O
We	344	346		|O
performed	347	356		|O
expression	357	367		|O
-	367	368		|O
based	368	373		|O
chemogenomics	374	387		|O
on	388	390		|O
the	391	394		|O
whole	395	400		|O
adult	401	406		|O
organism	407	415		|O
of	416	418		|O
a	419	420		|O
vertebrate	421	431		|O
model	432	437		|O
,	437	438		|O
the	439	442		|O
zebrafish	443	452		|O
,	452	453		|O
and	454	457		|O
demonstrated	458	470		|O
its	471	474		|O
potential	475	484		|O
for	485	488		|O
large	489	494		|O
-	494	495		|O
scale	495	500		|O
predictive	501	511		|O
and	512	515		|O
discovery	516	525		|O
chemical	526	534		|O
biology	535	542		|O
.	542	543		|O
Focusing	544	552		|O
on	553	555		|O
two	556	559		|O
classes	560	567		|O
of	568	570		|O
compounds	571	580		|O
with	581	585		|O
wide	586	590		|O
implications	591	603		|O
to	604	606		|O
human	607	612		|O
health	613	619		|O
,	619	620		|O
polycyclic	621	631		|O
(	632	633		|O
halogenated	633	644		|O
)	644	645		|O
aromatic	646	654		|O
hydrocarbons	655	667		|O
[	668	669		|O
P	669	670		|O
(	670	671		|O
H	671	672		|O
)	672	673		|O
AHs	673	676		|O
]	676	677		|O
and	678	681		|O
estrogenic	682	692		|O
compounds	693	702		|O
(	703	704		|O
ECs	704	707		|O
)	707	708		|O
,	708	709		|O
we	710	712		|O
generated	713	722		|O
robust	723	729		|O
prediction	730	740		|O
models	741	747		|O
that	748	752		|O
can	753	756		|O
discriminate	757	769		|O
compounds	770	779		|O
of	780	782		|O
the	783	786		|O
same	787	791		|O
class	792	797		|O
from	798	802		|O
those	803	808		|O
of	809	811		|O
different	812	821		|O
classes	822	829		|O
in	830	832		|O
two	833	836		|O
large	837	842		|O
independent	843	854		|O
experiments	855	866		|O
.	866	867		|O
The	868	871		|O
robust	872	878		|O
expression	879	889		|O
signatures	890	900		|O
led	901	904		|O
to	905	907		|O
the	908	911		|O
identification	912	926		|O
of	927	929		|O
biomarkers	930	940		|O
for	941	944		|O
potent	945	951		|O
aryl	952	956		|O
hydrocarbon	957	968		|O
receptor	969	977		|O
(	978	979		|O
AHR	979	982		|O
)	982	983		|O
and	984	987		|O
estrogen	988	996		|O
receptor	997	1005		|O
(	1006	1007		|O
ER	1007	1009		|O
)	1009	1010		|O
agonists	1011	1019		|O
,	1019	1020		|O
respectively	1021	1033		|O
,	1033	1034		|O
and	1035	1038		|O
were	1039	1043		|O
validated	1044	1053		|O
in	1054	1056		|O
multiple	1057	1065		|O
targeted	1066	1074		|O
tissues	1075	1082		|O
.	1082	1083		|O
Knowledge	1084	1093		|O
-	1093	1094		|O
based	1094	1099		|O
data	1100	1104		|O
mining	1105	1111		|O
of	1112	1114		|O
human	1115	1120		|O
homologs	1121	1129		|O
of	1130	1132		|O
zebrafish	1133	1142		|O
genes	1143	1148		|O
revealed	1149	1157		|O
highly	1158	1164		|O
conserved	1165	1174		|O
chemical	1175	1183		|O
-	1183	1184		|O
induced	1184	1191		|O
biological	1192	1202		|O
responses	1203	1212		|O
/	1212	1213		|O
effects	1213	1220		|O
,	1220	1221		|O
health	1222	1228		|O
risks	1229	1234		|O
,	1234	1235		|O
and	1236	1239		|O
novel	1240	1245		|O
biological	1246	1256		|O
insights	1257	1265		|O
associated	1266	1276		|O
with	1277	1281		|O
AHR	1282	1285		|O
and	1286	1289		|O
ER	1290	1292		|O
that	1293	1297		|O
could	1298	1303		|O
be	1304	1306		|O
inferred	1307	1315		|O
to	1316	1318		|O
humans	1319	1325		|O
.	1325	1326		|O
Thus	1327	1331		|O
,	1331	1332		|O
our	1333	1336		|O
study	1337	1342		|O
presents	1343	1351		|O
an	1352	1354		|O
effective	1355	1364		|O
,	1364	1365		|O
high	1366	1370		|O
-	1370	1371		|O
throughput	1371	1381		|O
strategy	1382	1390		|O
of	1391	1393		|O
capturing	1394	1403		|O
molecular	1404	1413		|O
snapshots	1414	1423		|O
of	1424	1426		|O
chemical	1427	1435		|O
-	1435	1436		|O
induced	1436	1443		|O
biological	1444	1454		|O
states	1455	1461		|O
of	1462	1464		|O
a	1465	1466		|O
whole	1467	1472		|O
adult	1473	1478		|O
vertebrate	1479	1489		|O
that	1490	1494		|O
provides	1495	1503		|O
information	1504	1515		|O
on	1516	1518		|O
biomarkers	1519	1529		|O
of	1530	1532		|O
effects	1533	1540		|O
,	1540	1541		|O
deregulated	1542	1553		|O
signaling	1554	1563		|O
pathways	1564	1572		|O
,	1572	1573		|O
and	1574	1577		|O
possible	1578	1586		|O
affected	1587	1595		|O
biological	1596	1606		|O
functions	1607	1616		|O
,	1616	1617		|O
perturbed	1618	1627		|O
physiological	1628	1641		|O
systems	1642	1649		|O
,	1649	1650		|O
and	1651	1654		|O
increased	1655	1664		|O
health	1665	1671		|O
risks	1672	1677		|O
.	1677	1678		|O
These	1679	1684		|O
findings	1685	1693		|O
place	1694	1699		|O
zebrafish	1700	1709		|O
in	1710	1712		|O
a	1713	1714		|O
strategic	1715	1724		|O
position	1725	1733		|O
to	1734	1736		|O
bridge	1737	1743		|O
the	1744	1747		|O
wide	1748	1752		|O
gap	1753	1756		|O
between	1757	1764		|O
cell	1765	1769		|O
-	1769	1770		|O
based	1770	1775		|O
and	1776	1779		|O
rodent	1780	1786		|O
models	1787	1793		|O
in	1794	1796		|O
chemogenomics	1797	1810		|O
research	1811	1819		|O
and	1820	1823		|O
applications	1824	1836		|O
,	1836	1837		|O
especially	1838	1848		|O
in	1849	1851		|O
preclinical	1852	1863		|O
drug	1864	1868		|O
discovery	1869	1878		|O
and	1879	1882		|O
toxicology	1883	1893		|O
.	1893	1894		|O

### 18845207
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
2	29	30		|O
-	30	31		|O
(	31	32		|O
1	32	33		|O
-	33	34		|O
methylpropyl	34	46		|O
)	46	47		|O
-	47	48		|O
1	48	49		|O
-	49	50		|O
vinylcyclohexyl	50	65		|O
acetate	66	73		|O
.	73	74		|O
A	76	77		|O
toxicologic	78	89		|O
and	90	93		|O
dermatologic	94	106		|O
review	107	113		|O
of	114	116		|O
2	117	118		|O
-	118	119		|O
(	119	120		|O
1	120	121		|O
-	121	122		|O
methylpropyl	122	134		|O
)	134	135		|O
-	135	136		|O
1	136	137		|O
-	137	138		|O
vinylcyclohexyl	138	153		|O
acetate	154	161		|O
when	162	166		|O
used	167	171		|O
as	172	174		|O
a	175	176		|O
fragrance	177	186		|O
ingredient	187	197		|O
is	198	200		|O
presented	201	210		|O
.	210	211		|O

### 18690968
QT	0	2		|O
prolongation	3	15		|O
and	16	19		|O
safety	20	26		|O
in	27	29		|O
the	30	33		|O
Indian	34	40		|O
population	41	51		|O
.	51	52		|O
The	54	57		|O
QT	58	60		|O
interval	61	69		|O
in	70	72		|O
electrocardiogram	73	90		|O
(	91	92		|O
ECG	92	95		|O
)	95	96		|O
reflects	97	105		|O
the	106	109		|O
total	110	115		|O
duration	116	124		|O
of	125	127		|O
ventricular	128	139		|O
myocardial	140	150		|O
depolarization	151	165		|O
and	166	169		|O
repolarization	170	184		|O
.	184	185		|O
It	186	188		|O
has	189	192		|O
been	193	197		|O
well	198	202		|O
recognized	203	213		|O
that	214	218		|O
many	219	223		|O
condition	224	233		|O
may	234	237		|O
cause	238	243		|O
QT	244	246		|O
interval	247	255		|O
prolongation	256	268		|O
.	268	269		|O
Unfortunately	270	283		|O
,	283	284		|O
numbers	285	292		|O
of	293	295		|O
cardiac	296	303		|O
and	304	307		|O
non	308	311		|O
-	311	312		|O
cardiac	312	319		|O
drug	320	324		|O
prolong	325	332		|O
the	333	336		|O
QT	337	339		|O
interval	340	348		|O
and	349	352		|O
cause	353	358		|O
a	359	360		|O
distinctive	361	372		|O
polymorphic	373	384	polymorphic ventricular tachycardia	|B-ADVERSE
ventricular	385	396		|I-ADVERSE
tachycardia	397	408		|I-ADVERSE
termed	409	415		|O
torsade	416	423	torsade de pointes	|B-ADVERSE
de	424	426		|I-ADVERSE
pointes	427	434		|I-ADVERSE
(	435	436		|O
TdP	436	439	TdP	|B-ADVERSE
)	439	440		|O
.	440	441		|O
TdP	442	445	TdP	|B-DISEASE
can	446	449		|O
degenerate	450	460		|O
into	461	465		|O
ventricular	466	477	ventricular fibrillation	|B-DISEASE
fibrillation	478	490		|I-DISEASE
,	490	491		|O
which	492	497		|O
leads	498	503		|O
to	504	506		|O
sudden	507	513	sudden cardiac death	|B-DISEASE
cardiac	514	521		|I-DISEASE
death	522	527		|I-DISEASE
.	527	528		|O
Recently	529	537		|O
various	538	545		|O
regulatory	546	556		|O
and	557	560		|O
clinical	561	569		|O
bodies	570	576		|O
of	577	579		|O
Europe	580	586		|O
,	586	587		|O
USA	588	591		|O
,	591	592		|O
Canada	593	599		|O
and	600	603		|O
Australia	604	613		|O
have	614	618		|O
made	619	623		|O
their	624	629		|O
focus	630	635		|O
on	636	638		|O
the	639	642		|O
drugs	643	648		|O
that	649	653		|O
induce	654	660		|O
prolongation	661	673		|O
of	674	676		|O
QT	677	679		|O
interval	680	688		|O
.	688	689		|O
Committee	690	699		|O
for	700	703		|O
Proprietary	704	715		|O
Medicinal	716	725		|O
Products	726	734		|O
(	735	736		|O
CPMP	736	740		|O
)	740	741		|O
of	742	744		|O
the	745	748		|O
European	749	757		|O
Agency	758	764		|O
issued	765	771		|O
a	772	773		|O
document	774	782		|O
entitled	783	791		|O
'	792	793		|O
Points	793	799		|O
to	800	802		|O
Consider	803	811		|O
:	811	812		|O
The	813	816		|O
assessment	817	827		|O
of	828	830		|O
the	831	834		|O
potential	835	844		|O
for	845	848		|O
QT	849	851		|O
interval	852	860		|O
prolongation	861	873		|O
by	874	876		|O
non	877	880		|O
-	880	881		|O
cardiovascular	881	895		|O
medicinal	896	905		|O
products	906	914		|O
'	914	915		|O
[	916	917		|O
1	917	918		|O
,	918	919		|O
2	920	921		|O
]	921	922		|O
.	922	923		|O
In	924	926		|O
addition	927	935		|O
,	935	936		|O
USFDA	937	942		|O
adopted	943	950		|O
the	951	954		|O
guideline	955	964		|O
'	965	966		|O
Clinical	966	974		|O
evaluation	975	985		|O
of	986	988		|O
QT	989	991		|O
/	991	992		|O
QTc	992	995		|O
interval	996	1004		|O
prolongation	1005	1017		|O
and	1018	1021		|O
proarrhythmic	1022	1035		|O
potential	1036	1045		|O
for	1046	1049		|O
non	1050	1053		|O
-	1053	1054		|O
anti	1054	1058		|O
arrhythmic	1059	1069		|O
drugs	1070	1075		|O
'	1075	1076		|O
[	1077	1078		|O
3	1078	1079		|O
]	1079	1080		|O
.	1080	1081		|O
These	1082	1087		|O
documents	1088	1097		|O
and	1098	1101		|O
guidelines	1102	1112		|O
are	1113	1116		|O
primarily	1117	1126		|O
concern	1127	1134		|O
with	1135	1139		|O
development	1140	1151		|O
of	1152	1154		|O
novel	1155	1160		|O
agents	1161	1167		|O
and	1168	1171		|O
the	1172	1175		|O
new	1176	1179		|O
use	1180	1183		|O
or	1184	1186		|O
new	1187	1190		|O
dose	1191	1195		|O
of	1196	1198		|O
already	1199	1206		|O
approved	1207	1215		|O
drugs	1216	1221		|O
.	1221	1222		|O
The	1223	1226		|O
scope	1227	1232		|O
of	1233	1235		|O
this	1236	1240		|O
guideline	1241	1250		|O
is	1251	1253		|O
to	1254	1256		|O
study	1257	1262		|O
the	1263	1266		|O
effect	1267	1273		|O
of	1274	1276		|O
drugs	1277	1282		|O
on	1283	1285		|O
QT	1286	1288		|O
prolongation	1289	1301		|O
and	1302	1305		|O
give	1306	1310		|O
idea	1311	1315		|O
of	1316	1318		|O
evaluation	1319	1329		|O
of	1330	1332		|O
drug	1333	1337		|O
's	1337	1339		|O
effects	1340	1347		|O
on	1348	1350		|O
QT	1351	1353		|O
prolongation	1354	1366		|O
.	1366	1367		|O
Today	1368	1373		|O
more	1374	1378		|O
than	1379	1383		|O
50	1384	1386		|O
available	1387	1396		|O
drugs	1397	1402		|O
(	1403	1404		|O
both	1404	1408		|O
old	1409	1412		|O
and	1413	1416		|O
new	1417	1420		|O
)	1420	1421		|O
have	1422	1426		|O
been	1427	1431		|O
identify	1432	1440		|O
,	1440	1441		|O
which	1442	1447		|O
prolong	1448	1455		|O
the	1456	1459		|O
QT	1460	1462		|O
interval	1463	1471		|O
[	1472	1473		|O
1	1473	1474		|O
]	1474	1475		|O
.	1475	1476		|O
Several	1477	1484		|O
drugs	1485	1490		|O
have	1491	1495		|O
been	1496	1500		|O
withdrawn	1501	1510		|O
from	1511	1515		|O
many	1516	1520		|O
countries	1521	1530		|O
on	1531	1533		|O
this	1534	1538		|O
basis	1539	1544		|O
but	1545	1548		|O
many	1549	1553		|O
of	1554	1556		|O
these	1557	1562		|O
drugs	1563	1568		|O
are	1569	1572		|O
still	1573	1578		|O
available	1579	1588		|O
in	1589	1591		|O
Indian	1592	1598		|O
market	1599	1605		|O
and	1606	1609		|O
potentially	1610	1621		|O
creating	1622	1630		|O
life	1631	1635		|O
-	1635	1636		|O
threatening	1636	1647		|O
arrhythmias	1648	1659	arrhythmias	|B-ADVERSE
.	1659	1660		|O
This	1661	1665		|O
article	1666	1673		|O
will	1674	1678		|O
focus	1679	1684		|O
on	1685	1687		|O
recommendation	1688	1702		|O
of	1703	1705		|O
study	1706	1711		|O
on	1712	1714		|O
the	1715	1718		|O
normal	1719	1725		|O
limits	1726	1732		|O
of	1733	1735		|O
QT	1736	1738		|O
interval	1739	1747		|O
in	1748	1750		|O
Indian	1751	1757		|O
population	1758	1768		|O
and	1769	1772		|O
preparation	1773	1784		|O
of	1785	1787		|O
the	1788	1791		|O
database	1792	1800		|O
,	1800	1801		|O
which	1802	1807		|O
can	1808	1811		|O
be	1812	1814		|O
helpful	1815	1822		|O
in	1823	1825		|O
withdrawal	1826	1836		|O
of	1837	1839		|O
drugs	1840	1845		|O
from	1846	1850		|O
the	1851	1854		|O
market	1855	1861		|O
that	1862	1866		|O
produces	1867	1875		|O
QT	1876	1878		|O
prolongation	1879	1891		|O
.	1891	1892		|O

### 18714077
Testosterone	0	12		|O
and	13	16		|O
the	17	20		|O
breast	21	27		|O
.	27	28		|O
Although	30	38		|O
women	39	44		|O
have	45	49		|O
been	50	54		|O
treated	55	62		|O
with	63	67		|O
testosterone	68	80		|O
(	81	82		|O
T	82	83		|O
)	83	84		|O
for	85	88		|O
female	89	95	female sexual dysfunction	|B-DISEASE
sexual	96	102		|I-DISEASE
dysfunction	103	114		|I-DISEASE
since	115	120		|O
the	121	124		|O
1950s	125	130		|O
,	130	131		|O
the	132	135		|O
role	136	140		|O
of	141	143		|O
T	144	145		|O
in	146	148		|O
normal	149	155		|O
female	156	162		|O
physiology	163	173		|O
is	174	176		|O
not	177	180		|O
yet	181	184		|O
fully	185	190		|O
defined	191	198		|O
.	198	199		|O
One	200	203		|O
of	204	206		|O
the	207	210		|O
major	211	216		|O
safety	217	223		|O
concerns	224	232		|O
of	233	235		|O
androgen	236	244		|O
therapy	245	252		|O
is	253	255		|O
whether	256	263		|O
androgens	264	273		|O
have	274	278		|O
a	279	280		|O
stimulatory	281	292		|O
effect	293	299		|O
on	300	302		|O
the	303	306		|O
breast	307	313		|O
that	314	318		|O
could	319	324		|O
lead	325	329		|O
to	330	332		|O
breast	333	339	breast carcinomas	|B-ADVERSE
carcinomas	340	350		|I-ADVERSE
.	350	351		|O
The	352	355		|O
proposed	356	364		|O
mechanisms	365	375		|O
for	376	379		|O
such	380	384		|O
stimulation	385	396		|O
include	397	404		|O
local	405	410		|O
estrogen	411	419		|O
production	420	430		|O
from	431	435		|O
the	436	439		|O
aromatase	440	449		|O
enzyme	450	456		|O
complex	457	464		|O
present	465	472		|O
in	473	475		|O
the	476	479		|O
breast	480	486		|O
tissue	487	493		|O
or	494	496		|O
by	497	499		|O
the	500	503		|O
direct	504	510		|O
stimulation	511	522		|O
of	523	525		|O
the	526	529		|O
androgen	530	538		|O
receptor	539	547		|O
.	547	548		|O
Predominant	549	560		|O
data	561	565		|O
from	566	570		|O
in	571	573		|O
vitro	574	579		|O
studies	580	587		|O
have	588	592		|O
shown	593	598		|O
that	599	603		|O
androgens	604	613		|O
actually	614	622		|O
have	623	627		|O
apoptotic	628	637		|O
and	638	641		|O
antiproliferative	642	659		|O
effects	660	667		|O
and	668	671		|O
not	672	675		|O
stimulatory	676	687		|O
effects	688	695		|O
.	695	696		|O
Animal	697	703		|O
models	704	710		|O
have	711	715		|O
shown	716	721		|O
similar	722	729		|O
results	730	737		|O
to	738	740		|O
in	741	743		|O
vitro	744	749		|O
studies	750	757		|O
,	757	758		|O
finding	759	766		|O
that	767	771		|O
androgens	772	781		|O
inhibit	782	789		|O
breast	790	796	breast cancer	|B-DISEASE
cancer	797	803		|I-DISEASE
growth	804	810		|O
.	810	811		|O
Prospective	812	823		|O
and	824	827		|O
retrospective	828	841		|O
epidemiological	842	857		|O
analyses	858	866		|O
have	867	871		|O
shown	872	877		|O
mixed	878	883		|O
outcomes	884	892		|O
,	892	893		|O
with	894	898		|O
no	899	901		|O
clear	902	907		|O
consensus	908	917		|O
regarding	918	927		|O
androgen	928	936		|O
use	937	940		|O
and	941	944		|O
breast	945	951	breast cancer	|B-ADVERSE
cancer	952	958		|I-ADVERSE
risk	959	963		|O
.	963	964		|O
Hyperandrogenism	965	981	Hyperandrogenism	|B-DISEASE
in	982	984		|O
patients	985	993		|O
with	994	998		|O
polycystic	999	1009	polycystic ovarian syndrome	|B-DISEASE
ovarian	1010	1017		|I-DISEASE
syndrome	1018	1026		|I-DISEASE
with	1027	1031		|O
elevated	1032	1040		|O
levels	1041	1047		|O
of	1048	1050		|O
endogenous	1051	1061		|O
T	1062	1063		|O
is	1064	1066		|O
not	1067	1070		|O
associated	1071	1081		|O
with	1082	1086		|O
an	1087	1089		|O
increased	1090	1099		|O
risk	1100	1104		|O
of	1105	1107		|O
breast	1108	1114	breast cancer	|B-ADVERSE
cancer	1115	1121		|I-ADVERSE
and	1122	1125		|O
may	1126	1129		|O
,	1129	1130		|O
in	1131	1133		|O
fact	1134	1138		|O
,	1138	1139		|O
be	1140	1142		|O
protective	1143	1153		|O
.	1153	1154		|O
Another	1155	1162		|O
human	1163	1168		|O
model	1169	1174		|O
with	1175	1179		|O
excess	1180	1186		|O
of	1187	1189		|O
T	1190	1191		|O
is	1192	1194		|O
female	1195	1201		|O
-	1201	1202		|O
to	1202	1204		|O
-	1204	1205		|O
male	1205	1209		|O
transgenderism	1210	1224		|O
,	1224	1225		|O
in	1226	1228		|O
which	1229	1234		|O
genotypic	1235	1244		|O
women	1245	1250		|O
are	1251	1254		|O
treated	1255	1262		|O
with	1263	1267		|O
large	1268	1273		|O
doses	1274	1279		|O
of	1280	1282		|O
exogenous	1283	1292		|O
T	1293	1294		|O
with	1295	1299		|O
no	1300	1302		|O
increased	1303	1312		|O
risk	1313	1317		|O
.	1317	1318		|O
High	1319	1323		|O
-	1323	1324		|O
dose	1324	1328		|O
androgen	1329	1337		|O
therapy	1338	1345		|O
also	1346	1350		|O
has	1351	1354		|O
been	1355	1359		|O
effective	1360	1369		|O
in	1370	1372		|O
treating	1373	1381		|O
patients	1382	1390		|O
with	1391	1395		|O
advanced	1396	1404		|O
breast	1405	1411	breast cancer	|B-DISEASE
cancer	1412	1418		|I-DISEASE
.	1418	1419		|O
Thus	1420	1424		|O
,	1424	1425		|O
the	1426	1429		|O
preponderance	1430	1443		|O
of	1444	1446		|O
data	1447	1451		|O
suggests	1452	1460		|O
that	1461	1465		|O
T	1466	1467		|O
use	1468	1471		|O
in	1472	1474		|O
females	1475	1482		|O
is	1483	1485		|O
not	1486	1489		|O
associated	1490	1500		|O
with	1501	1505		|O
an	1506	1508		|O
increased	1509	1518		|O
risk	1519	1523		|O
of	1524	1526		|O
breast	1527	1533	breast carcinoma	|B-DISEASE
carcinoma	1534	1543		|I-DISEASE
.	1543	1544		|O

### 18830260
Does	0	4		|O
chemotherapy	5	17		|O
modify	18	24		|O
the	25	28		|O
immune	29	35		|O
surveillance	36	48		|O
of	49	51		|O
hematological	52	65	hematological malignancies	|B-DISEASE
malignancies	66	78		|I-DISEASE
?	78	79		|O
Malignant	81	90	Malignant diseases	|B-DISEASE
diseases	91	99		|I-DISEASE
induce	100	106		|O
immune	107	113		|O
responses	114	123		|O
against	124	131		|O
them	132	136		|O
which	137	142		|O
have	143	147		|O
variable	148	156		|O
success	157	164		|O
in	165	167		|O
controlling	168	179		|O
progression	180	191		|O
of	192	194		|O
disease	195	202		|O
.	202	203		|O
A	204	205		|O
variety	206	213		|O
of	214	216		|O
congenital	217	227		|O
and	228	231		|O
acquired	232	240		|O
disorders	241	250		|O
provide	251	258		|O
evidence	259	267		|O
in	268	270		|O
support	271	278		|O
of	279	281		|O
T	282	283		|O
cell	284	288		|O
or	289	291		|O
NK	292	294		|O
cell	295	299		|O
immune	300	306		|O
surveillance	307	319		|O
mechanisms	320	330		|O
in	331	333		|O
human	334	339		|O
hematological	340	353	hematological malignancies	|B-DISEASE
malignancies	354	366		|I-DISEASE
.	366	367		|O
Furthermore	368	379		|O
,	379	380		|O
clinical	381	389		|O
experience	390	400		|O
with	401	405		|O
stem	406	410		|O
cell	411	415		|O
transplantation	416	431		|O
underlines	432	442		|O
the	443	446		|O
potential	447	456		|O
for	457	460		|O
both	461	465		|O
T	466	467		|O
and	468	471		|O
NK	472	474		|O
cell	475	479		|O
-	479	480		|O
mediated	480	488		|O
antileukemia	489	501		|O
effects	502	509		|O
.	509	510		|O
Animal	511	517		|O
models	518	524		|O
of	525	527		|O
tumor	528	533	tumor	|B-DISEASE
surveillance	534	546		|O
and	547	550		|O
viral	551	556		|O
-	556	557		|O
driven	557	563		|O
lymphoproliferative	564	583	lymphoproliferative diseases	|B-DISEASE
diseases	584	592		|I-DISEASE
in	593	595		|O
man	596	599		|O
emphasize	600	609		|O
the	610	613		|O
dynamic	614	621		|O
nature	622	628		|O
of	629	631		|O
the	632	635		|O
equilibrium	636	647		|O
between	648	655		|O
tumors	656	662		|O
and	663	666		|O
the	667	670		|O
immune	671	677		|O
system	678	684		|O
,	684	685		|O
which	686	691		|O
can	692	695		|O
lead	696	700		|O
to	701	703		|O
tumor	704	709	tumor	|B-DISEASE
escape	710	716		|O
in	717	719		|O
individuals	720	731		|O
with	732	736		|O
normal	737	743		|O
immune	744	750		|O
function	751	759		|O
.	759	760		|O
In	761	763		|O
hematological	764	777		|O
malignancies	778	790		|O
the	791	794		|O
implication	795	806		|O
of	807	809		|O
a	810	811		|O
dynamic	812	819		|O
immune	820	826		|O
surveillance	827	839		|O
model	840	845		|O
is	846	848		|O
that	849	853		|O
chemotherapy	854	866		|O
may	867	870		|O
disrupt	871	878		|O
potentially	879	890		|O
competent	891	900		|O
immune	901	907		|O
surveillance	908	920		|O
mechanisms	921	931		|O
leading	932	939		|O
to	940	942		|O
disease	943	950		|O
recurrence	951	961		|O
following	962	971		|O
successful	972	982		|O
tumor	983	988	tumor	|B-DISEASE
bulk	989	993		|O
reduction	994	1003		|O
by	1004	1006		|O
chemotherapy	1007	1019		|O
.	1019	1020		|O
This	1021	1025		|O
possibility	1026	1037		|O
deserves	1038	1046		|O
further	1047	1054		|O
investigation	1055	1068		|O
with	1069	1073		|O
a	1074	1075		|O
view	1076	1080		|O
to	1081	1083		|O
developing	1084	1094		|O
strategies	1095	1105		|O
to	1106	1108		|O
boost	1109	1114		|O
immune	1115	1121		|O
function	1122	1130		|O
following	1131	1140		|O
chemotherapy	1141	1153		|O
so	1154	1156		|O
as	1157	1159		|O
to	1160	1162		|O
combine	1163	1170		|O
the	1171	1174		|O
beneficial	1175	1185		|O
effect	1186	1192		|O
of	1193	1195		|O
chemotherapy	1196	1208		|O
with	1209	1213		|O
an	1214	1216		|O
immune	1217	1223		|O
response	1224	1232		|O
capable	1233	1240		|O
of	1241	1243		|O
sustaining	1244	1254		|O
remissions	1255	1265		|O
.	1265	1266		|O

### 18606968
Mechanisms	0	10		|O
of	11	13		|O
action	14	20		|O
of	21	23		|O
disease	24	31		|O
-	31	32		|O
modifying	32	41		|O
agents	42	48		|O
and	49	52		|O
brain	53	58		|O
volume	59	65		|O
changes	66	73		|O
in	74	76		|O
multiple	77	85	multiple sclerosis	|B-DISEASE
sclerosis	86	95		|I-DISEASE
.	95	96		|O
Disease	98	105		|O
-	105	106		|O
modifying	106	115		|O
agents	116	122		|O
(	123	124		|O
DMAs	124	128		|O
)	128	129		|O
,	129	130		|O
including	131	140		|O
interferon	141	151		|O
beta	152	156		|O
(	157	158		|O
IFNbeta	158	165		|O
)	165	166		|O
and	167	170		|O
glatiramer	171	181		|O
acetate	182	189		|O
(	190	191		|O
GA	191	193		|O
)	193	194		|O
,	194	195		|O
are	196	199		|O
the	200	203		|O
mainstays	204	213		|O
of	214	216		|O
long	217	221		|O
-	221	222		|O
term	222	226		|O
treatment	227	236		|O
of	237	239		|O
multiple	240	248	multiple sclerosis	|B-DISEASE
sclerosis	249	258		|I-DISEASE
(	259	260		|O
MS	260	262	MS	|B-DISEASE
)	262	263		|O
.	263	264		|O
Other	265	270		|O
potent	271	277		|O
anti	278	282		|O
-	282	283		|O
inflammatory	283	295		|O
agents	296	302		|O
like	303	307		|O
natalizumab	308	319		|O
and	320	323		|O
different	324	333		|O
types	334	339		|O
of	340	342		|O
chemotherapeutics	343	360		|O
are	361	364		|O
increasingly	365	377		|O
being	378	383		|O
used	384	388		|O
for	389	392		|O
treatment	393	402		|O
of	403	405		|O
MS	406	408	MS	|B-DISEASE
,	408	409		|O
particularly	410	422		|O
in	423	425		|O
patients	426	434		|O
with	435	439		|O
breakthrough	440	452		|O
disease	453	460		|O
activity	461	469		|O
.	469	470		|O
Brain	471	476		|O
volume	477	483		|O
(	484	485		|O
BV	485	487		|O
)	487	488		|O
loss	489	493		|O
occurs	494	500		|O
early	501	506		|O
in	507	509		|O
the	510	513		|O
disease	514	521		|O
process	522	529		|O
,	529	530		|O
accelerates	531	542		|O
over	543	547		|O
time	548	552		|O
,	552	553		|O
and	554	557		|O
may	558	561		|O
be	562	564		|O
only	565	569		|O
partially	570	579		|O
affected	580	588		|O
by	589	591		|O
DMA	592	595		|O
therapy	596	603		|O
.	603	604		|O
Low	605	608		|O
-	608	609		|O
dose	609	613		|O
,	613	614		|O
low	615	618		|O
frequency	619	628		|O
IFNbeta	629	636		|O
administered	637	649		|O
once	650	654		|O
weekly	655	661		|O
and	662	665		|O
GA	666	668		|O
appear	669	675		|O
to	676	678		|O
partially	679	688		|O
reduce	689	695		|O
BV	696	698		|O
decline	699	706		|O
over	707	711		|O
the	712	715		|O
second	716	722		|O
and	723	726		|O
third	727	732		|O
years	733	738		|O
of	739	741		|O
treatment	742	751		|O
.	751	752		|O
High	753	757		|O
dose	758	762		|O
,	762	763		|O
high	764	768		|O
frequency	769	778		|O
IFNbeta	779	786		|O
demonstrated	787	799		|O
no	800	802		|O
clear	803	808		|O
effect	809	815		|O
on	816	818		|O
BV	819	821		|O
loss	822	826		|O
during	827	833		|O
this	834	838		|O
time	839	843		|O
period	844	850		|O
.	850	851		|O
Current	852	859		|O
evidence	860	868		|O
suggests	869	877		|O
that	878	882		|O
changes	883	890		|O
in	891	893		|O
BV	894	896		|O
after	897	902		|O
immunoablation	903	917		|O
may	918	921		|O
not	922	925		|O
be	926	928		|O
due	929	932		|O
entirely	933	941		|O
to	942	944		|O
the	945	948		|O
resolution	949	959		|O
of	960	962		|O
edema	963	968	edema	|B-ADVERSE
but	969	972		|O
may	973	976		|O
be	977	979		|O
related	980	987		|O
to	988	990		|O
potential	991	1000		|O
chemotoxicity	1001	1014	chemotoxicity	|B-ADVERSE
of	1015	1017		|O
high	1018	1022		|O
dose	1023	1027		|O
cyclophosphamide	1028	1044		|O
.	1044	1045		|O
Natalizumab	1046	1057		|O
reduces	1058	1065		|O
the	1066	1069		|O
development	1070	1081		|O
of	1082	1084		|O
BV	1085	1087		|O
decline	1088	1095		|O
in	1096	1098		|O
the	1099	1102		|O
second	1103	1109		|O
and	1110	1113		|O
third	1114	1119		|O
years	1120	1125		|O
of	1126	1128		|O
treatment	1129	1138		|O
.	1138	1139		|O
IV	1140	1142		|O
immunoglobulin	1143	1157		|O
showed	1158	1164		|O
a	1165	1166		|O
positive	1167	1175		|O
effect	1176	1182		|O
on	1183	1185		|O
decelerating	1186	1198		|O
BV	1199	1201		|O
reduction	1202	1211		|O
in	1212	1214		|O
relapsing	1215	1224		|O
and	1225	1228		|O
advanced	1229	1237		|O
stages	1238	1244		|O
of	1245	1247		|O
MS	1248	1250	MS	|B-DISEASE
.	1250	1251		|O
These	1252	1257		|O
differences	1258	1269		|O
between	1270	1277		|O
DMAs	1278	1282		|O
may	1283	1286		|O
be	1287	1289		|O
explained	1290	1299		|O
by	1300	1302		|O
the	1303	1306		|O
extent	1307	1313		|O
of	1314	1316		|O
their	1317	1322		|O
therapeutic	1323	1334		|O
effects	1335	1342		|O
on	1343	1345		|O
inflammation	1346	1358	inflammation	|B-DISEASE
and	1359	1362		|O
on	1363	1365		|O
the	1366	1369		|O
balance	1370	1377		|O
between	1378	1385		|O
inhibition	1386	1396		|O
or	1397	1399		|O
promotion	1400	1409		|O
of	1410	1412		|O
remyelination	1413	1426		|O
and	1427	1430		|O
neuronal	1431	1439		|O
repair	1440	1446		|O
in	1447	1449		|O
the	1450	1453		|O
CNS	1454	1457		|O
.	1457	1458		|O
We	1459	1461		|O
described	1462	1471		|O
the	1472	1475		|O
mechanisms	1476	1486		|O
of	1487	1489		|O
action	1490	1496		|O
by	1497	1499		|O
which	1500	1505		|O
DMAs	1506	1510		|O
induce	1511	1517		|O
accelerated	1518	1529		|O
,	1529	1530		|O
non	1531	1534		|O
-	1534	1535		|O
tissue	1535	1541		|O
-	1541	1542		|O
related	1542	1549		|O
BV	1550	1552		|O
loss	1553	1557		|O
(	1558	1559		|O
pseudoatrophy	1559	1572	pseudoatrophy	|B-DISEASE
)	1572	1573		|O
in	1574	1576		|O
the	1577	1580		|O
short	1581	1586		|O
term	1587	1591		|O
but	1592	1595		|O
,	1595	1596		|O
in	1597	1599		|O
the	1600	1603		|O
long	1604	1608		|O
run	1609	1612		|O
,	1612	1613		|O
may	1614	1617		|O
still	1618	1623		|O
potentially	1624	1635		|O
lead	1636	1640		|O
to	1641	1643		|O
permanent	1644	1653		|O
BV	1654	1656		|O
decline	1657	1664		|O
.	1664	1665		|O
The	1666	1669		|O
effects	1670	1677		|O
of	1678	1680		|O
corticosteroid	1681	1695		|O
therapy	1696	1703		|O
on	1704	1706		|O
changes	1707	1714		|O
in	1715	1717		|O
BV	1718	1720		|O
in	1721	1723		|O
patients	1724	1732		|O
with	1733	1737		|O
MS	1738	1740	MS	|B-DISEASE
help	1741	1745		|O
clarify	1746	1753		|O
the	1754	1757		|O
mechanisms	1758	1768		|O
through	1769	1776		|O
which	1777	1782		|O
potent	1783	1789		|O
anti	1790	1794		|O
-	1794	1795		|O
inflammatory	1795	1807		|O
treatments	1808	1818		|O
may	1819	1822		|O
prevent	1823	1830		|O
,	1830	1831		|O
stabilize	1832	1841		|O
,	1841	1842		|O
or	1843	1845		|O
induce	1846	1852		|O
BV	1853	1855		|O
loss	1856	1860		|O
.	1860	1861		|O

### 18640100
Dioxin	0	6		|O
interferes	7	17		|O
in	18	20		|O
chromosomal	21	32		|O
positioning	33	44		|O
through	45	52		|O
the	53	56		|O
aryl	57	61		|O
hydrocarbon	62	73		|O
receptor	74	82		|O
.	82	83		|O
Each	85	89		|O
chromosome	90	100		|O
occupies	101	109		|O
its	110	113		|O
own	114	117		|O
-	117	118		|O
specific	118	126		|O
space	127	132		|O
called	133	139		|O
a	140	141		|O
't	142	144		|O
erritory	144	152		|O
'	152	153		|O
within	154	160		|O
the	161	164		|O
interphase	165	175		|O
nucleus	176	183		|O
,	183	184		|O
and	185	188		|O
the	189	192		|O
arrangement	193	204		|O
of	205	207		|O
chromosome	208	218		|O
territories	219	230		|O
(	231	232		|O
CTs	232	235		|O
)	235	236		|O
is	237	239		|O
important	240	249		|O
in	250	252		|O
epigenetic	253	263		|O
mechanisms	264	274		|O
.	274	275		|O
The	276	279		|O
molecular	280	289		|O
mechanism	290	299		|O
to	300	302		|O
determine	303	312		|O
the	313	316		|O
positioning	317	328		|O
of	329	331		|O
CTs	332	335		|O
,	335	336		|O
however	337	344		|O
,	344	345		|O
remains	346	353		|O
unknown	354	361		|O
.	361	362		|O
On	363	365		|O
the	366	369		|O
other	370	375		|O
hand	376	380		|O
,	380	381		|O
dioxin	382	388		|O
is	389	391		|O
known	392	397		|O
to	398	400		|O
be	401	403		|O
the	404	407		|O
typical	408	415		|O
environmental	416	429		|O
pollutant	430	439		|O
that	440	444		|O
affects	445	452		|O
a	453	454		|O
wide	455	459		|O
variety	460	467		|O
of	468	470		|O
biological	471	481		|O
events	482	488		|O
in	489	491		|O
many	492	496		|O
species	497	504		|O
.	504	505		|O
Here	506	510		|O
,	510	511		|O
we	512	514		|O
show	515	519		|O
that	520	524		|O
dioxin	525	531		|O
enlarges	532	540		|O
the	541	544		|O
minimum	545	552		|O
distance	553	561		|O
between	562	569		|O
chromosome	570	580		|O
12	581	583		|O
and	584	587		|O
chromosome	588	598		|O
16	599	601		|O
territories	602	613		|O
in	614	616		|O
human	617	622		|O
preadipocyte	623	635		|O
cells	636	641		|O
,	641	642		|O
and	643	646		|O
the	647	650		|O
alteration	651	661		|O
of	662	664		|O
chromosome	665	675		|O
positioning	676	687		|O
is	688	690		|O
canceled	691	699		|O
by	700	702		|O
an	703	705		|O
aryl	706	710		|O
hydrocarbon	711	722		|O
receptor	723	731		|O
(	732	733		|O
AhR	733	736		|O
)	736	737		|O
antagonist	738	748		|O
alpha	749	754		|O
-	754	755		|O
naphthoflavone	755	769		|O
.	769	770		|O
Thus	771	775		|O
,	775	776		|O
AhR	777	780		|O
may	781	784		|O
be	785	787		|O
a	788	789		|O
key	790	793		|O
molecule	794	802		|O
to	803	805		|O
regulate	806	814		|O
chromosome	815	825		|O
positioning	826	837		|O
.	837	838		|O
Our	839	842		|O
results	843	850		|O
suggest	851	858		|O
a	859	860		|O
novel	861	866		|O
effect	867	873		|O
of	874	876		|O
dioxin	877	883	dioxin toxicity	|B-ADVERSE
toxicity	884	892		|I-ADVERSE
,	892	893		|O
and	894	897		|O
demonstrate	898	909		|O
a	910	911		|O
clue	912	916		|O
to	917	919		|O
reveal	920	926		|O
the	927	930		|O
novel	931	936		|O
molecular	937	946		|O
mechanism	947	956		|O
for	957	960		|O
the	961	964		|O
arrangement	965	976		|O
of	977	979		|O
CTs	980	983		|O
.	983	984		|O

### 18929078
Contraception	0	13		|O
in	14	16		|O
women	17	22		|O
with	23	27		|O
epilepsy	28	36	epilepsy	|B-DISEASE
:	36	37		|O
pharmacokinetic	38	53		|O
interactions	54	66		|O
,	66	67		|O
contraceptive	68	81		|O
options	82	89		|O
,	89	90		|O
and	91	94		|O
management	95	105		|O
.	105	106		|O
Contraceptive	108	121		|O
counseling	122	132		|O
is	133	135		|O
a	136	137		|O
critical	138	146		|O
component	147	156		|O
of	157	159		|O
the	160	163		|O
management	164	174		|O
of	175	177		|O
the	178	181		|O
female	182	188		|O
patient	189	196		|O
with	197	201		|O
epilepsy	202	210	epilepsy	|B-DISEASE
because	211	218		|O
of	219	221		|O
the	222	225		|O
increased	226	235		|O
risk	236	240		|O
of	241	243		|O
pregnancy	244	253		|O
associated	254	264		|O
with	265	269		|O
epilepsy	270	278	epilepsy	|B-DISEASE
and	279	282		|O
the	283	286		|O
multitude	287	296		|O
of	297	299		|O
interactions	300	312		|O
between	313	320		|O
antiepileptic	321	334		|O
drugs	335	340		|O
(	341	342		|O
AEDs	342	346		|O
)	346	347		|O
and	348	351		|O
hormonal	352	360		|O
contraception	361	374		|O
.	374	375		|O
Steroid	376	383		|O
hormones	384	392		|O
and	393	396		|O
many	397	401		|O
of	402	404		|O
the	405	408		|O
AEDs	409	413		|O
are	414	417		|O
substrates	418	428		|O
for	429	432		|O
the	433	436		|O
cytochrome	437	447		|O
P450	448	452		|O
enzyme	453	459		|O
system	460	466		|O
,	466	467		|O
in	468	470		|O
particular	471	481		|O
,	481	482		|O
the	483	486		|O
3A4	487	490		|O
isoenzyme	491	500		|O
.	500	501		|O
As	502	504		|O
a	505	506		|O
result	507	513		|O
,	513	514		|O
concomitant	515	526		|O
use	527	530		|O
of	531	533		|O
hormonal	534	542		|O
contraceptives	543	557		|O
and	558	561		|O
AEDs	562	566		|O
may	567	570		|O
pose	571	575		|O
a	576	577		|O
risk	578	582		|O
for	583	586		|O
unexpected	587	597	unexpected pregnancy	|B-ADVERSE
pregnancy	598	607		|I-ADVERSE
,	607	608		|O
seizures	609	617	seizures	|B-ADVERSE
,	617	618		|O
and	619	622		|O
drug	623	627		|O
-	627	628		|O
related	628	635		|O
adverse	636	643		|O
effects	644	651		|O
.	651	652		|O
The	653	656		|O
risk	657	661		|O
of	662	664		|O
combined	665	673		|O
oral	674	678		|O
contraceptive	679	692		|O
(	693	694		|O
COC	694	697		|O
)	697	698		|O
failure	699	706		|O
is	707	709		|O
slightly	710	718		|O
increased	719	728		|O
in	729	731		|O
the	732	735		|O
presence	736	744		|O
of	745	747		|O
cytochrome	748	758		|O
P450	759	763		|O
3A4	764	767		|O
enzyme	768	774		|O
-	774	775		|O
inducing	775	783		|O
AEDs	784	788		|O
.	788	789		|O
Several	790	797		|O
AEDs	798	802		|O
induce	803	809		|O
the	810	813		|O
production	814	824		|O
of	825	827		|O
sex	828	831		|O
hormone	832	839		|O
binding	840	847		|O
globulin	848	856		|O
(	857	858		|O
SHBG	858	862		|O
)	862	863		|O
to	864	866		|O
which	867	872		|O
the	873	876		|O
progestins	877	887		|O
are	888	891		|O
tightly	892	899		|O
bound	900	905		|O
,	905	906		|O
resulting	907	916		|O
in	917	919		|O
lower	920	925		|O
concentrations	926	940		|O
of	941	943		|O
free	944	948		|O
progestin	949	958		|O
that	959	963		|O
may	964	967		|O
also	968	972		|O
lead	973	977		|O
to	978	980		|O
COC	981	984		|O
failure	985	992		|O
.	992	993		|O
There	994	999		|O
is	1000	1002		|O
no	1003	1005		|O
increase	1006	1014		|O
in	1015	1017		|O
the	1018	1021		|O
risk	1022	1026		|O
of	1027	1029		|O
COC	1030	1033		|O
failure	1034	1041		|O
in	1042	1044		|O
women	1045	1050		|O
taking	1051	1057		|O
nonenzyme	1058	1067		|O
-	1067	1068		|O
inducing	1068	1076		|O
AEDs	1077	1081		|O
.	1081	1082		|O
Oral	1083	1087		|O
contraceptives	1088	1102		|O
significantly	1103	1116		|O
increase	1117	1125		|O
the	1126	1129		|O
metabolism	1130	1140		|O
of	1141	1143		|O
lamotrigine	1144	1155		|O
,	1155	1156		|O
posing	1157	1163		|O
a	1164	1165		|O
risk	1166	1170		|O
of	1171	1173		|O
seizures	1174	1182	seizures	|B-ADVERSE
when	1183	1187		|O
hormonal	1188	1196		|O
agents	1197	1203		|O
are	1204	1207		|O
initiated	1208	1217		|O
and	1218	1221		|O
/	1221	1222		|O
or	1222	1224		|O
toxicity	1225	1233		|O
during	1234	1240		|O
pill	1241	1245		|O
-	1245	1246		|O
free	1246	1250		|O
weeks	1251	1256		|O
.	1256	1257		|O
There	1258	1263		|O
is	1264	1266		|O
no	1267	1269		|O
evidence	1270	1278		|O
that	1279	1283		|O
COCs	1284	1288		|O
increase	1289	1297		|O
seizures	1298	1306	seizures	|B-ADVERSE
in	1307	1309		|O
women	1310	1315		|O
with	1316	1320		|O
epilepsy	1321	1329	epilepsy	|B-DISEASE
.	1329	1330		|O
While	1331	1336		|O
higher	1337	1343		|O
dose	1344	1348		|O
COCs	1349	1353		|O
are	1354	1357		|O
one	1358	1361		|O
contraceptive	1362	1375		|O
option	1376	1382		|O
for	1383	1386		|O
women	1387	1392		|O
on	1393	1395		|O
enzyme	1396	1402		|O
-	1402	1403		|O
inducing	1403	1411		|O
AEDs	1412	1416		|O
,	1416	1417		|O
a	1418	1419		|O
variety	1420	1427		|O
of	1428	1430		|O
other	1431	1436		|O
options	1437	1444		|O
are	1445	1448		|O
available	1449	1458		|O
.	1458	1459		|O
Injectable	1460	1470		|O
contraception	1471	1484		|O
(	1485	1486		|O
depot	1486	1491		|O
medroxyprogesterone	1492	1511		|O
acetate	1512	1519		|O
)	1519	1520		|O
appears	1521	1528		|O
effective	1529	1538		|O
with	1539	1543		|O
AED	1544	1547		|O
use	1548	1551		|O
,	1551	1552		|O
but	1553	1556		|O
the	1557	1560		|O
potential	1561	1570		|O
for	1571	1574		|O
bone	1575	1579		|O
mineral	1580	1587		|O
density	1588	1595		|O
loss	1596	1600		|O
is	1601	1603		|O
a	1604	1605		|O
concern	1606	1613		|O
.	1613	1614		|O
Intrauterine	1615	1627		|O
devices	1628	1635		|O
(	1636	1637		|O
IUDs	1637	1641		|O
)	1641	1642		|O
and	1643	1646		|O
barrier	1647	1654		|O
methods	1655	1662		|O
do	1663	1665		|O
not	1666	1669		|O
rely	1670	1674		|O
on	1675	1677		|O
hormonal	1678	1686		|O
components	1687	1697		|O
for	1698	1701		|O
contraceptive	1702	1715		|O
efficacy	1716	1724		|O
,	1724	1725		|O
and	1726	1729		|O
are	1730	1733		|O
therefore	1734	1743		|O
appropriate	1744	1755		|O
to	1756	1758		|O
recommend	1759	1768		|O
for	1769	1772		|O
use	1773	1776		|O
in	1777	1779		|O
women	1780	1785		|O
using	1786	1791		|O
enzyme	1792	1798		|O
-	1798	1799		|O
inducing	1799	1807		|O
medications	1808	1819		|O
.	1819	1820		|O
This	1821	1825		|O
chapter	1826	1833		|O
reviews	1834	1841		|O
the	1842	1845		|O
evidence	1846	1854		|O
regarding	1855	1864		|O
the	1865	1868		|O
pharmacokinetic	1869	1884		|O
interaction	1885	1896		|O
between	1897	1904		|O
AEDs	1905	1909		|O
and	1910	1913		|O
oral	1914	1918		|O
contraceptive	1919	1932		|O
hormones	1933	1941		|O
,	1941	1942		|O
the	1943	1946		|O
known	1947	1952		|O
or	1953	1955		|O
potential	1956	1965		|O
interactions	1966	1978		|O
with	1979	1983		|O
alternative	1984	1995		|O
contraceptive	1996	2009		|O
methods	2010	2017		|O
,	2017	2018		|O
and	2019	2022		|O
provides	2023	2031		|O
practical	2032	2041		|O
advice	2042	2048		|O
for	2049	2052		|O
management	2053	2063		|O
of	2064	2066		|O
contraceptive	2067	2080		|O
needs	2081	2086		|O
in	2087	2089		|O
reproductive	2090	2102		|O
-	2102	2103		|O
age	2103	2106		|O
women	2107	2112		|O
.	2112	2113		|O

### 18554678
Styrene	0	7		|O
induces	8	15		|O
an	16	18		|O
inflammatory	19	31		|O
response	32	40		|O
in	41	43		|O
human	44	49		|O
lung	50	54		|O
epithelial	55	65		|O
cells	66	71		|O
via	72	75		|O
oxidative	76	85		|O
stress	86	92		|O
and	93	96		|O
NF	97	99		|O
-	99	100		|O
kappaB	100	106		|O
activation	107	117		|O
.	117	118		|O
Styrene	120	127		|O
is	128	130		|O
a	131	132		|O
volatile	133	141		|O
organic	142	149		|O
compound	150	158		|O
(	159	160		|O
VOC	160	163		|O
)	163	164		|O
that	165	169		|O
is	170	172		|O
widely	173	179		|O
used	180	184		|O
as	185	187		|O
a	188	189		|O
solvent	190	197		|O
in	198	200		|O
many	201	205		|O
industrial	206	216		|O
settings	217	225		|O
.	225	226		|O
Chronic	227	234		|O
exposure	235	243		|O
to	244	246		|O
styrene	247	254		|O
can	255	258		|O
result	259	265		|O
in	266	268		|O
irritation	269	279	irritation of the mucosa	|B-ADVERSE
of	280	282		|I-ADVERSE
the	283	286		|I-ADVERSE
mucosa	287	293		|I-ADVERSE
of	294	296		|O
the	297	300		|O
upper	301	306		|O
respiratory	307	318		|O
tract	319	324		|O
.	324	325		|O
Contact	326	333		|O
of	334	336		|O
styrene	337	344		|O
with	345	349		|O
epithelial	350	360		|O
cells	361	366		|O
stimulates	367	377		|O
the	378	381		|O
expression	382	392		|O
of	393	395		|O
a	396	397		|O
variety	398	405		|O
of	406	408		|O
inflammatory	409	421		|O
mediators	422	431		|O
,	431	432		|O
including	433	442		|O
the	443	446		|O
chemotactic	447	458		|O
cytokine	459	467		|O
monocyte	468	476		|O
chemoattractant	477	492		|O
protein	493	500		|O
-	500	501		|O
1	501	502		|O
(	503	504		|O
MCP	504	507		|O
-	507	508		|O
1	508	509		|O
)	509	510		|O
.	510	511		|O
To	512	514		|O
characterise	515	527		|O
the	528	531		|O
underlying	532	542		|O
mechanisms	543	553		|O
of	554	556		|O
the	557	560		|O
induction	561	570		|O
of	571	573		|O
inflammatory	574	586		|O
signals	587	594		|O
by	595	597		|O
styrene	598	605		|O
,	605	606		|O
we	607	609		|O
investigated	610	622		|O
the	623	626		|O
influence	627	636		|O
of	637	639		|O
this	640	644		|O
compound	645	653		|O
on	654	656		|O
the	657	660		|O
induction	661	670		|O
of	671	673		|O
oxidative	674	683		|O
stress	684	690		|O
and	691	694		|O
the	695	698		|O
activation	699	709		|O
of	710	712		|O
the	713	716		|O
nuclear	717	724		|O
factor	725	731		|O
-	731	732		|O
kappa	732	737		|O
B	738	739		|O
(	740	741		|O
NF	741	743		|O
-	743	744		|O
kappaB	744	750		|O
)	750	751		|O
signalling	752	762		|O
pathway	763	770		|O
in	771	773		|O
human	774	779		|O
lung	780	784		|O
epithelial	785	795		|O
cells	796	801		|O
(	802	803		|O
A549	803	807		|O
)	807	808		|O
.	808	809		|O
The	810	813		|O
results	814	821		|O
demonstrate	822	833		|O
that	834	838		|O
styrene	839	846		|O
-	846	847		|O
induced	847	854		|O
MCP	855	858		|O
-	858	859		|O
1	859	860		|O
expression	861	871		|O
,	871	872		|O
as	873	875		|O
well	876	880		|O
as	881	883		|O
the	884	887		|O
expression	888	898		|O
of	899	901		|O
the	902	905		|O
oxidative	906	915		|O
stress	916	922		|O
marker	923	929		|O
glutathione	930	941		|O
S	942	943		|O
-	943	944		|O
transferase	944	955		|O
(	956	957		|O
GST	957	960		|O
)	960	961		|O
,	961	962		|O
is	963	965		|O
associated	966	976		|O
with	977	981		|O
a	982	983		|O
concentration	984	997		|O
dependent	998	1007		|O
pattern	1008	1015		|O
of	1016	1018		|O
NF	1019	1021		|O
-	1021	1022		|O
kappaB	1022	1028		|O
activity	1029	1037		|O
.	1037	1038		|O
An	1039	1041		|O
inhibitor	1042	1051		|O
of	1052	1054		|O
NF	1055	1057		|O
-	1057	1058		|O
kappaB	1058	1064		|O
,	1064	1065		|O
IKK	1066	1069		|O
-	1069	1070		|O
NBD	1070	1073		|O
,	1073	1074		|O
and	1075	1078		|O
the	1079	1082		|O
anti	1083	1087		|O
-	1087	1088		|O
inflammatory	1088	1100		|O
antioxidant	1101	1112		|O
N	1113	1114		|O
-	1114	1115		|O
acetylcysteine	1115	1129		|O
(	1130	1131		|O
NAC	1131	1134		|O
)	1134	1135		|O
were	1136	1140		|O
both	1141	1145		|O
effective	1146	1155		|O
in	1156	1158		|O
suppressing	1159	1170		|O
styrene	1171	1178		|O
-	1178	1179		|O
induced	1179	1186		|O
MCP	1187	1190		|O
-	1190	1191		|O
1	1191	1192		|O
secretion	1193	1202		|O
.	1202	1203		|O
In	1204	1206		|O
addition	1207	1215		|O
,	1215	1216		|O
NAC	1217	1220		|O
was	1221	1224		|O
capable	1225	1232		|O
of	1233	1235		|O
inhibiting	1236	1246		|O
the	1247	1250		|O
upregulation	1251	1263		|O
of	1264	1266		|O
GST	1267	1270		|O
expression	1271	1281		|O
.	1281	1282		|O
Our	1283	1286		|O
findings	1287	1295		|O
suggest	1296	1303		|O
that	1304	1308		|O
the	1309	1312		|O
activation	1313	1323		|O
of	1324	1326		|O
the	1327	1330		|O
NF	1331	1333		|O
-	1333	1334		|O
kappaB	1334	1340		|O
signalling	1341	1351		|O
pathway	1352	1359		|O
by	1360	1362		|O
styrene	1363	1370		|O
is	1371	1373		|O
mediated	1374	1382		|O
via	1383	1386		|O
a	1387	1388		|O
redox	1389	1394		|O
-	1394	1395		|O
sensitive	1395	1404		|O
mechanism	1405	1414		|O
.	1414	1415		|O

### 18712494
Mutual	0	6		|O
stimulation	7	18		|O
of	19	21		|O
beta	22	26		|O
-	26	27		|O
amyloid	27	34		|O
fibrillogenesis	35	50		|O
by	51	53		|O
clioquinol	54	64		|O
and	65	68		|O
divalent	69	77		|O
metals	78	84		|O
.	84	85		|O
As	87	89		|O
reported	90	98		|O
by	99	101		|O
some	102	106		|O
authors	107	114		|O
,	114	115		|O
clioquinol	116	126		|O
(	127	128		|O
CQ	128	130		|O
)	130	131		|O
,	131	132		|O
a	133	134		|O
8	135	136		|O
-	136	137		|O
hydroxyquinoline	137	153		|O
derivative	154	164		|O
,	164	165		|O
has	166	169		|O
produced	170	178		|O
very	179	183		|O
encouraging	184	195		|O
results	196	203		|O
in	204	206		|O
the	207	210		|O
treatment	211	220		|O
of	221	223		|O
Alzheimer	224	233	Alzheimer's disease	|B-DISEASE
's	233	235		|I-DISEASE
disease	236	243		|I-DISEASE
(	244	245		|O
AD	245	247	AD	|B-DISEASE
)	247	248		|O
.	248	249		|O
Its	250	253		|O
biological	254	264		|O
effects	265	272		|O
are	273	276		|O
most	277	281		|O
likely	282	288		|O
ascribed	289	297		|O
to	298	300		|O
complexation	301	313		|O
of	314	316		|O
specific	317	325		|O
metal	326	331		|O
ions	332	336		|O
,	336	337		|O
such	338	342		|O
as	343	345		|O
copper	346	352		|O
(	353	354		|O
II	354	356		|O
)	356	357		|O
and	358	361		|O
zinc	362	366		|O
(	367	368		|O
II	368	370		|O
)	370	371		|O
,	371	372		|O
critically	373	383		|O
associated	384	394		|O
with	395	399		|O
beta	400	404		|O
-	404	405		|O
amyloid	405	412		|O
(	413	414		|O
A	414	415		|O
beta	416	420		|O
)	420	421		|O
aggregation	422	433		|O
/	433	434		|O
fibrillogenesis	434	449		|O
and	450	453		|O
degeneration	454	466		|O
processes	467	476		|O
in	477	479		|O
the	480	483		|O
brain	484	489		|O
.	489	490		|O
The	491	494		|O
present	495	502		|O
study	503	508		|O
was	509	512		|O
aimed	513	518		|O
at	519	521		|O
assessing	522	531		|O
the	532	535		|O
in	536	538		|O
vitro	539	544		|O
effects	545	552		|O
of	553	555		|O
CQ	556	558		|O
on	559	561		|O
the	562	565		|O
aggregation	566	577		|O
/	577	578		|O
fibrillogenesis	578	593		|O
properties	594	604		|O
of	605	607		|O
human	608	613		|O
A	614	615		|O
beta	616	620		|O
either	621	627		|O
alone	628	633		|O
or	634	636		|O
complexed	637	646		|O
with	647	651		|O
Cu	652	654		|O
(	654	655		|O
2+	655	657		|O
)	657	658		|O
and	659	662		|O
Zn	663	665		|O
(	665	666		|O
2+	666	668		|O
)	668	669		|O
.	669	670		|O
Surprisingly	671	683		|O
,	683	684		|O
our	685	688		|O
data	689	693		|O
indicated	694	703		|O
that	704	708		|O
CQ	709	711		|O
promoted	712	720		|O
rather	721	727		|O
than	728	732		|O
inhibited	733	742		|O
the	743	746		|O
formation	747	756		|O
of	757	759		|O
A	760	761		|O
beta	762	766		|O
fibrillar	767	776		|O
aggregates	777	787		|O
when	788	792		|O
added	793	798		|O
metal	799	804		|O
ions	805	809		|O
were	810	814		|O
present	815	822		|O
.	822	823		|O
To	824	826		|O
understand	827	837		|O
whether	838	845		|O
the	846	849		|O
latter	850	856		|O
effects	857	864		|O
were	865	869		|O
related	870	877		|O
to	878	880		|O
the	881	884		|O
peptide	885	892		|O
amino	893	898		|O
acid	899	903		|O
sequence	904	912		|O
,	912	913		|O
we	914	916		|O
also	917	921		|O
investigated	922	934		|O
the	935	938		|O
aggregational	939	952		|O
profile	953	960		|O
of	961	963		|O
rat	964	967		|O
A	968	969		|O
beta	970	974		|O
,	974	975		|O
which	976	981		|O
differs	982	989		|O
from	990	994		|O
the	995	998		|O
human	999	1004		|O
homologous	1005	1015		|O
for	1016	1019		|O
three	1020	1025		|O
amino	1026	1031		|O
acidic	1032	1038		|O
substitutions	1039	1052		|O
.	1052	1053		|O
Such	1054	1058		|O
a	1059	1060		|O
sequence	1061	1069		|O
alteration	1070	1080		|O
drastically	1081	1092		|O
reduced	1093	1100		|O
the	1101	1104		|O
tendency	1105	1113		|O
of	1114	1116		|O
the	1117	1120		|O
peptide	1121	1128		|O
to	1129	1131		|O
undergo	1132	1139		|O
spontaneous	1140	1151		|O
aggregation	1152	1163		|O
/	1163	1164		|O
fibrillization	1164	1178		|O
.	1178	1179		|O
In	1180	1182		|O
the	1183	1186		|O
presence	1187	1195		|O
of	1196	1198		|O
CQ	1199	1201		|O
and	1202	1205		|O
metals	1206	1212		|O
,	1212	1213		|O
however	1214	1221		|O
,	1221	1222		|O
also	1223	1227		|O
rat	1228	1231		|O
A	1232	1233		|O
beta	1234	1238		|O
showed	1239	1245		|O
a	1246	1247		|O
strong	1248	1254		|O
propensity	1255	1265		|O
to	1266	1268		|O
generate	1269	1277		|O
fibrillar	1278	1287		|O
aggregates	1288	1298		|O
.	1298	1299		|O
In	1300	1302		|O
agreement	1303	1312		|O
with	1313	1317		|O
the	1318	1321		|O
pro	1322	1325		|O
-	1325	1326		|O
aggregation	1326	1337		|O
effects	1338	1345		|O
observed	1346	1354		|O
in	1355	1357		|O
solution	1358	1366		|O
,	1366	1367		|O
studies	1368	1375		|O
with	1376	1380		|O
neuroblastoma	1381	1394		|O
cells	1395	1400		|O
demonstrated	1401	1413		|O
an	1414	1416		|O
impairment	1417	1427		|O
of	1428	1430		|O
cell	1431	1435		|O
functioning	1436	1447		|O
only	1448	1452		|O
in	1453	1455		|O
the	1456	1459		|O
presence	1460	1468		|O
of	1469	1471		|O
CQ	1472	1474		|O
+	1475	1476		|O
A	1477	1478		|O
beta	1479	1483		|O
-	1483	1484		|O
metals	1484	1490		|O
.	1490	1491		|O
Based	1492	1497		|O
on	1498	1500		|O
the	1501	1504		|O
present	1505	1512		|O
findings	1513	1521		|O
,	1521	1522		|O
the	1523	1526		|O
literature	1527	1537		|O
data	1538	1542		|O
on	1543	1545		|O
the	1546	1549		|O
potential	1550	1559		|O
effectiveness	1560	1573		|O
of	1574	1576		|O
CQ	1577	1579		|O
-	1579	1580		|O
based	1580	1585		|O
chelation	1586	1595		|O
therapy	1596	1603		|O
in	1604	1606		|O
AD	1607	1609	AD	|B-DISEASE
should	1610	1616		|O
be	1617	1619		|O
re	1620	1622		|O
-	1622	1623		|O
interpreted	1623	1634		|O
.	1634	1635		|O

### 18754195
Effect	0	6		|O
of	7	9		|O
an	10	12		|O
ibuprofen	13	22		|O
-	22	23		|O
releasing	23	32		|O
foam	33	37		|O
dressing	38	46		|O
on	47	49		|O
wound	50	55	wound pain	|B-DISEASE
pain	56	60		|I-DISEASE
:	60	61		|O
a	62	63		|O
real	64	68		|O
-	68	69		|O
life	69	73		|O
RCT	74	77		|O
.	77	78		|O
OBJECTIVE	80	89		|O
:	89	90		|O
To	91	93		|O
compare	94	101		|O
an	102	104		|O
ibuprofen	105	114		|O
-	114	115		|O
releasing	115	124		|O
foam	125	129		|O
dressing	130	138		|O
(	139	140		|O
Biatain	140	147		|O
Ibu	148	151		|O
,	151	152		|O
ColoplastA	153	163		|O
/	163	164		|O
S	164	165		|O
)	165	166		|O
with	167	171		|O
local	172	177		|O
best	178	182		|O
practice	183	191		|O
in	192	194		|O
the	195	198		|O
treatment	199	208		|O
of	209	211		|O
painful	212	219	painful exuding wounds	|B-DISEASE
exuding	220	227		|I-DISEASE
wounds	228	234		|I-DISEASE
.	234	235		|O
METHOD	236	242		|O
:	242	243		|O
In	244	246		|O
this	247	251		|O
large	252	257		|O
-	257	258		|O
scale	258	263		|O
randomised	264	274		|O
comparative	275	286		|O
study	287	292		|O
,	292	293		|O
853	294	297		|O
patients	298	306		|O
were	307	311		|O
randomised	312	322		|O
to	323	325		|O
either	326	332		|O
ibuprofen	333	342		|O
-	342	343		|O
releasing	343	352		|O
foam	353	357		|O
(	358	359		|O
test	359	363		|O
)	363	364		|O
dressing	365	373		|O
(	374	375		|O
n	375	376		|O
=	376	377		|O
467	377	380		|O
)	380	381		|O
or	382	384		|O
local	385	390		|O
best	391	395		|O
practice	396	404		|O
(	405	406		|O
n	406	407		|O
=	407	408		|O
386	408	411		|O
)	411	412		|O
.	412	413		|O
Primary	414	421		|O
endpoint	422	430		|O
was	431	434		|O
wound	435	440	wound pain	|B-DISEASE
pain	441	445		|I-DISEASE
relief	446	452		|O
from	453	457		|O
day	458	461		|O
1-7	462	465		|O
,	465	466		|O
assessed	467	475		|O
by	476	478		|O
the	479	482		|O
patients	483	491		|O
twice	492	497		|O
daily	498	503		|O
using	504	509		|O
a	510	511		|O
five	512	516		|O
-	516	517		|O
point	517	522		|O
verbal	523	529		|O
rating	530	536		|O
scale	537	542		|O
.	542	543		|O
Secondary	544	553		|O
endpoints	554	563		|O
were	564	568		|O
reduction	569	578		|O
in	579	581		|O
pain	582	586	pain	|B-DISEASE
intensity	587	596		|O
from	597	601		|O
day	602	605		|O
0-7	606	609		|O
(	610	611		|O
assessed	611	619		|O
using	620	625		|O
an	626	628		|O
11	629	631		|O
-	631	632		|O
point	632	637		|O
numeric	638	645		|O
box	646	649		|O
scale	650	655		|O
)	655	656		|O
,	656	657		|O
quality	658	665		|O
of	666	668		|O
life	669	673		|O
(	674	675		|O
assessed	675	683		|O
using	684	689		|O
the	690	693		|O
WHO	694	697		|O
-	697	698		|O
5	698	699		|O
well	700	704		|O
-	704	705		|O
being	705	710		|O
index	711	716		|O
and	717	720		|O
effect	721	727		|O
on	728	730		|O
health	731	737		|O
-	737	738		|O
related	738	745		|O
activities	746	756		|O
of	757	759		|O
daily	760	765		|O
living	766	772		|O
)	772	773		|O
and	774	777		|O
the	778	781		|O
incidence	782	791		|O
of	792	794		|O
adverse	795	802		|O
events	803	809		|O
.	809	810		|O
RESULTS	811	818		|O
:	818	819		|O
After	820	825		|O
seven	826	831		|O
days	832	836		|O
significantly	837	850		|O
more	851	855		|O
patients	856	864		|O
in	865	867		|O
the	868	871		|O
experimental	872	884		|O
group	885	890		|O
experienced	891	902		|O
relief	903	909		|O
from	910	914		|O
temporary	915	924		|O
and	925	928		|O
persistent	929	939		|O
pain	940	944	pain	|B-DISEASE
and	945	948		|O
a	949	950		|O
reduction	951	960		|O
in	961	963		|O
pain	964	968	pain	|B-DISEASE
intensity	969	978		|O
,	978	979		|O
when	979	983		|O
compared	984	992		|O
with	993	997		|O
patients	998	1006		|O
in	1007	1009		|O
the	1010	1013		|O
local	1014	1019		|O
best	1020	1024		|O
practice	1025	1033		|O
group	1034	1039		|O
(	1040	1041		|O
p	1041	1042		|O
<	1042	1043		|O
0.0001	1043	1049		|O
)	1049	1050		|O
.	1050	1051		|O
They	1052	1056		|O
also	1057	1061		|O
experienced	1062	1073		|O
a	1074	1075		|O
greater	1076	1083		|O
improvement	1084	1095		|O
in	1096	1098		|O
quality	1099	1106		|O
of	1107	1109		|O
life	1110	1114		|O
.	1114	1115		|O
The	1116	1119		|O
number	1120	1126		|O
of	1127	1129		|O
adverse	1130	1137		|O
events	1138	1144		|O
in	1145	1147		|O
both	1148	1152		|O
groups	1153	1159		|O
was	1160	1163		|O
low	1164	1167		|O
.	1167	1168		|O
CONCLUSION	1169	1179		|O
:	1179	1180		|O
The	1181	1184		|O
test	1185	1189		|O
dressing	1190	1198		|O
provided	1199	1207		|O
an	1208	1210		|O
appropriate	1211	1222		|O
wound	1223	1228	wound	|B-DISEASE
healing	1229	1236		|O
environment	1237	1248		|O
,	1248	1249		|O
relieved	1250	1258		|O
temporary	1259	1268		|O
and	1269	1272		|O
persistent	1273	1283		|O
wound	1284	1289	wound pain	|B-DISEASE
pain	1290	1294		|I-DISEASE
,	1294	1295		|O
and	1296	1299		|O
decreased	1300	1309		|O
pain	1310	1314	pain	|B-DISEASE
intensity	1315	1324		|O
.	1324	1325		|O
It	1326	1328		|O
was	1329	1332		|O
also	1333	1337		|O
associated	1338	1348		|O
with	1349	1353		|O
an	1354	1356		|O
improvement	1357	1368		|O
in	1369	1371		|O
quality	1372	1379		|O
of	1380	1382		|O
life	1383	1387		|O
.	1387	1388		|O

### 18663448
A	0	1		|O
multiple	2	10		|O
-	10	11		|O
center	11	17		|O
phase	18	23		|O
II	24	26		|O
study	27	32		|O
of	33	35		|O
biweekly	36	44		|O
oxaliplatin	45	56		|O
and	57	60		|O
tegafur	61	68		|O
-	68	69		|O
uracil	69	75		|O
/	75	76		|O
leucovorin	76	86		|O
for	87	90		|O
chemonaive	91	101		|O
patients	102	110		|O
with	111	115		|O
advanced	116	124		|O
gastric	125	132	gastric cancer	|B-DISEASE
cancer	133	139		|I-DISEASE
.	139	140		|O
PURPOSE	142	149		|O
:	149	150		|O
The	151	154		|O
current	155	162		|O
study	163	168		|O
assessed	169	177		|O
the	178	181		|O
efficacy	182	190		|O
and	191	194		|O
safety	195	201		|O
of	202	204		|O
biweekly	205	213		|O
oxaliplatin	214	225		|O
combining	226	235		|O
oral	236	240		|O
tegafur	241	248		|O
-	248	249		|O
uracil	249	255		|O
/	255	256		|O
leucovorin	256	266		|O
in	267	269		|O
treating	270	278		|O
chemonaive	279	289		|O
patients	290	298		|O
with	299	303		|O
advanced	304	312		|O
gastric	313	320	gastric cancer	|B-DISEASE
cancer	321	327		|I-DISEASE
.	327	328		|O
METHODS	329	336		|O
:	336	337		|O
Eligible	338	346		|O
patients	347	355		|O
were	356	360		|O
18-75	361	366		|O
years	367	372		|O
old	373	376		|O
,	376	377		|O
had	378	381		|O
stage	382	387		|O
IV	388	390		|O
disease	391	398		|O
or	399	401		|O
post	402	406		|O
-	406	407		|O
surgery	407	414		|O
recurrence	415	425		|O
,	425	426		|O
no	427	429		|O
prior	430	435		|O
palliative	436	446		|O
chemotherapy	447	459		|O
,	459	460		|O
and	461	464		|O
an	465	467		|O
ECOG	468	472		|O
performance	473	484		|O
status	485	491		|O
of	492	494		|O
0-2	495	498		|O
.	498	499		|O
Patients	500	508		|O
in	509	511		|O
the	512	515		|O
current	516	523		|O
study	524	529		|O
received	530	538		|O
2	539	540		|O
-	540	541		|O
h	541	542		|O
i	543	544		|O
.	544	545		|O
v	545	546		|O
.	546	547		|O
infusion	548	556		|O
of	557	559		|O
oxaliplatin	560	571		|O
at	572	574		|O
a	575	576		|O
dose	577	581		|O
of	582	584		|O
100	585	588		|O
mg	589	591		|O
/	591	592		|O
m	592	593		|O
(	593	594		|O
2	594	595		|O
)	595	596		|O
after	597	602		|O
diluting	603	611		|O
in	612	614		|O
500	615	618		|O
mL	619	621		|O
5%	622	624		|O
dextrose	625	633		|O
/	633	634		|O
water	634	639		|O
(	640	641		|O
dexan	641	646		|O
premedication	647	660		|O
)	660	661		|O
,	661	662		|O
and	663	666		|O
5	667	668		|O
-	668	669		|O
HT3	669	672		|O
antagonist	673	683		|O
biweekly	684	692		|O
.	692	693		|O
Oral	694	698		|O
tegafur	699	706		|O
-	706	707		|O
uracil	707	713		|O
and	714	717		|O
leucovorin	718	728		|O
was	729	732		|O
given	733	738		|O
at	739	741		|O
a	742	743		|O
dose	744	748		|O
of	749	751		|O
300	752	755		|O
mg	756	758		|O
/	758	759		|O
m	759	760		|O
(	760	761		|O
2	761	762		|O
)	762	763		|O
/	763	764		|O
day	764	767		|O
and	768	771		|O
60	772	774		|O
mg	775	777		|O
/	777	778		|O
day	778	781		|O
three	782	787		|O
times	788	793		|O
daily	794	799		|O
from	800	804		|O
day	805	808		|O
1	809	810		|O
to	811	813		|O
21	814	816		|O
,	816	817		|O
respectively	818	830		|O
,	830	831		|O
followed	832	840		|O
by	841	843		|O
a	844	845		|O
1	846	847		|O
-	847	848		|O
week	848	852		|O
rest	853	857		|O
.	857	858		|O
Response	859	867		|O
assessment	868	878		|O
was	879	882		|O
based	883	888		|O
on	889	891		|O
the	892	895		|O
RECIST	896	902		|O
criteria	903	911		|O
and	912	915		|O
was	916	919		|O
performed	920	929		|O
every	930	935		|O
two	936	939		|O
courses	940	947		|O
.	947	948		|O
Toxicity	949	957		|O
was	958	961		|O
assessed	962	970		|O
according	971	980		|O
to	981	983		|O
NCI	984	987		|O
common	988	994		|O
toxicity	995	1003		|O
criteria	1004	1012		|O
version	1013	1020		|O
2	1021	1022		|O
.	1022	1023		|O
RESULTS	1024	1031		|O
:	1031	1032		|O
From	1033	1037		|O
October	1038	1045		|O
2003	1046	1050		|O
to	1051	1053		|O
April	1054	1059		|O
2006	1060	1064		|O
,	1064	1065		|O
57	1066	1068		|O
patients	1069	1077		|O
were	1078	1082		|O
evaluated	1083	1092		|O
(	1093	1094		|O
55	1094	1096		|O
eligible	1097	1105		|O
)	1105	1106		|O
with	1107	1111		|O
a	1112	1113		|O
median	1114	1120		|O
age	1121	1124		|O
of	1125	1127		|O
61	1128	1130		|O
years	1131	1136		|O
(	1137	1138		|O
range	1138	1143		|O
31-75	1144	1149		|O
)	1149	1150		|O
.	1150	1151		|O
According	1152	1161		|O
to	1162	1164		|O
the	1165	1168		|O
assessment	1169	1179		|O
of	1180	1182		|O
response	1183	1191		|O
in	1192	1194		|O
48	1195	1197		|O
evaluable	1198	1207		|O
patients	1208	1216		|O
,	1216	1217		|O
partial	1218	1225		|O
response	1226	1234		|O
rate	1235	1239		|O
was	1240	1243		|O
24/48	1244	1249		|O
(	1250	1251		|O
50.0%	1251	1256		|O
)	1256	1257		|O
(	1258	1259		|O
95%	1259	1262		|O
CI	1263	1265		|O
:	1265	1266		|O
35.23-64.73%	1267	1279		|O
)	1279	1280		|O
and	1281	1284		|O
stable	1285	1291		|O
disease	1292	1299		|O
was	1300	1303		|O
observed	1304	1312		|O
in	1313	1315		|O
11	1316	1318		|O
patients	1319	1327		|O
(	1328	1329		|O
22.92%	1329	1335		|O
)	1335	1336		|O
,	1336	1337		|O
and	1338	1341		|O
diseased	1342	1350		|O
progressed	1351	1361		|O
in	1362	1364		|O
13	1365	1367		|O
patients	1368	1376		|O
(	1377	1378		|O
27.08%	1378	1384		|O
)	1384	1385		|O
.	1385	1386		|O
Mean	1387	1391		|O
number	1392	1398		|O
of	1399	1401		|O
oxaliplatin	1402	1413		|O
cycles	1414	1420		|O
was	1421	1424		|O
3	1425	1426		|O
(	1427	1428		|O
0.5-6.5	1428	1435		|O
)	1435	1436		|O
.	1436	1437		|O
Median	1438	1444		|O
time	1445	1449		|O
to	1450	1452		|O
progression	1453	1464		|O
was	1465	1468		|O
177	1469	1472		|O
days	1473	1477		|O
.	1477	1478		|O
Median	1479	1485		|O
overall	1486	1493		|O
survival	1494	1502		|O
was	1503	1506		|O
318	1507	1510		|O
days	1511	1515		|O
.	1515	1516		|O
Major	1517	1522		|O
-	1522	1523		|O
grade	1523	1528		|O
(	1529	1530		|O
III	1530	1533		|O
/	1533	1534		|O
IV	1534	1536		|O
)	1536	1537		|O
toxicities	1538	1548		|O
were	1549	1553		|O
diarrhea	1554	1562	diarrhea	|B-ADVERSE
25.5%	1563	1568		|O
,	1568	1569		|O
vomiting	1570	1578	vomiting	|B-ADVERSE
16.5%	1579	1584		|O
,	1584	1585		|O
anemia	1586	1592	anemia	|B-ADVERSE
10.9%	1593	1598		|O
,	1598	1599		|O
numbness	1600	1608	numbness	|B-ADVERSE
12.7%	1609	1614		|O
,	1614	1615		|O
thrombocytopenia	1616	1632	thrombocytopenia	|B-ADVERSE
7.3%	1633	1637		|O
,	1637	1638		|O
neutropenia	1639	1650	neutropenia	|B-ADVERSE
3.6%	1651	1655		|O
and	1656	1659		|O
leucopenia	1660	1670	leucopenia	|B-ADVERSE
1.8%	1671	1675		|O
.	1675	1676		|O
CONCLUSIONS	1677	1688		|O
:	1688	1689		|O
Biweekly	1690	1698		|O
,	1698	1699		|O
oxaliplatin	1700	1711		|O
combining	1712	1721		|O
oral	1722	1726		|O
tegafur	1727	1734		|O
-	1734	1735		|O
uracil	1735	1741		|O
/	1741	1742		|O
leucovorin	1742	1752		|O
in	1753	1755		|O
treating	1756	1764		|O
patients	1765	1773		|O
with	1774	1778		|O
advanced	1779	1787		|O
gastric	1788	1795	gastric cancer	|B-DISEASE
cancer	1796	1802		|I-DISEASE
showed	1803	1809		|O
acceptable	1810	1820		|O
activity	1821	1829		|O
and	1830	1833		|O
manageable	1834	1844		|O
toxicity	1845	1853		|O
.	1853	1854		|O

### 18589448
Insulin	0	7		|O
glargine	8	16		|O
versus	17	23		|O
intermediate	24	36		|O
-	36	37		|O
acting	37	43		|O
insulin	44	51		|O
as	52	54		|O
the	55	58		|O
basal	59	64		|O
component	65	74		|O
of	75	77		|O
multiple	78	86		|O
daily	87	92		|O
injection	93	102		|O
regimens	103	111		|O
for	112	115		|O
adolescents	116	127		|O
with	128	132		|O
type	133	137	type 1 diabetes mellitus	|B-DISEASE
1	138	139		|I-DISEASE
diabetes	140	148		|I-DISEASE
mellitus	149	157		|I-DISEASE
.	157	158		|O
OBJECTIVES	160	170		|O
:	170	171		|O
To	172	174		|O
compare	175	182		|O
long	183	187		|O
-	187	188		|O
acting	188	194		|O
insulin	195	202		|O
glargine	203	211		|O
(	212	213		|O
Lantus	213	219		|O
)	219	220		|O
with	221	225		|O
intermediate	226	238		|O
-	238	239		|O
acting	239	245		|O
insulin	246	253		|O
(	254	255		|O
neutral	255	262		|O
protamine	263	272		|O
Hagedorn	273	281		|O
[	282	283		|O
NPH	283	286		|O
]	286	287		|O
/	287	288		|O
Lente	288	293		|O
)	293	294		|O
when	295	299		|O
used	300	304		|O
as	305	307		|O
the	308	311		|O
basal	312	317		|O
component	318	327		|O
of	328	330		|O
a	331	332		|O
multiple	333	341		|O
daily	342	347		|O
injection	348	357		|O
(	358	359		|O
MDI	359	362		|O
)	362	363		|O
regimen	364	371		|O
with	372	376		|O
prandial	377	385		|O
insulin	386	393		|O
lispro	394	400		|O
(	401	402		|O
Humalog	402	409		|O
)	409	410		|O
in	411	413		|O
adolescents	414	425		|O
with	426	430		|O
type	431	435	type 1 diabetes mellitus	|B-DISEASE
1	436	437		|I-DISEASE
diabetes	438	446		|I-DISEASE
mellitus	447	455		|I-DISEASE
(	456	457		|O
T1DM	457	461	T1DM	|B-DISEASE
)	461	462		|O
.	462	463		|O
STUDY	464	469		|O
DESIGN	470	476		|O
:	476	477		|O
This	478	482		|O
was	483	486		|O
an	487	489		|O
active	490	496		|O
-	496	497		|O
controlled	497	507		|O
,	507	508		|O
randomized	509	519		|O
,	519	520		|O
open	521	525		|O
-	525	526		|O
label	526	531		|O
,	531	532		|O
sex	533	536		|O
-	536	537		|O
stratified	537	547		|O
,	547	548		|O
2	549	550		|O
-	550	551		|O
arm	551	554		|O
,	554	555		|O
parallel	556	564		|O
-	564	565		|O
group	565	570		|O
comparison	571	581		|O
of	582	584		|O
once	585	589		|O
-	589	590		|O
daily	590	595		|O
insulin	596	603		|O
glargine	604	612		|O
with	613	617		|O
twice	618	623		|O
-	623	624		|O
daily	624	629		|O
NPH	630	633		|O
/	633	634		|O
Lente	634	639		|O
in	640	642		|O
an	643	645		|O
MDI	646	649		|O
regimen	650	657		|O
.	657	658		|O
Changes	659	666		|O
in	667	669		|O
glycated	670	678		|O
hemoglobin	679	689		|O
A1C	690	693		|O
(	694	695		|O
A1C	695	698		|O
)	698	699		|O
,	699	700		|O
occurrence	701	711		|O
of	712	714		|O
hypoglycemia	715	727	hypoglycemia	|B-ADVERSE
,	727	728		|O
and	729	732		|O
adverse	733	740		|O
events	741	747		|O
were	748	752		|O
assessed	753	761		|O
in	762	764		|O
175	765	768		|O
patients	769	777		|O
(	778	779		|O
age	779	782		|O
9	783	784		|O
to	785	787		|O
17	788	790		|O
years	791	796		|O
)	796	797		|O
with	798	802		|O
T1DM	803	807		|O
.	807	808		|O
RESULTS	809	816		|O
:	816	817		|O
The	818	821		|O
overall	822	829		|O
mean	830	834		|O
change	835	841		|O
in	842	844		|O
A1C	845	848		|O
from	849	853		|O
baseline	854	862		|O
to	863	865		|O
week	866	870		|O
24	871	873		|O
was	874	877		|O
similar	878	885		|O
in	886	888		|O
the	889	892		|O
2	893	894		|O
groups	895	901		|O
:	901	902		|O
insulin	903	910		|O
glargine	911	919		|O
(	920	921		|O
n	921	922		|O
=	923	924		|O
76	925	927		|O
)	927	928		|O
,	928	929		|O
-	930	931		|O
0.25%	931	936		|O
+	937	938		|O
/	938	939		|O
-	939	940		|O
0.14%	941	946		|O
;	946	947		|O
NPH	948	951		|O
/	951	952		|O
Lente	952	957		|O
(	958	959		|O
n	959	960		|O
=	961	962		|O
81	963	965		|O
)	965	966		|O
,	966	967		|O
0.05%	968	973		|O
+	974	975		|O
/	975	976		|O
-	976	977		|O
0.13%	978	983		|O
(	984	985		|O
P	985	986		|O
=	987	988		|O
.1725	989	994		|O
)	994	995		|O
.	995	996		|O
However	997	1004		|O
,	1004	1005		|O
an	1006	1008		|O
analysis	1009	1017		|O
of	1018	1020		|O
covariance	1021	1031		|O
,	1031	1032		|O
adjusting	1033	1042		|O
for	1043	1046		|O
baseline	1047	1055		|O
A1C	1056	1059		|O
,	1059	1060		|O
revealed	1061	1069		|O
a	1070	1071		|O
strong	1072	1078		|O
study	1079	1084		|O
arm	1085	1088		|O
effect	1089	1095		|O
on	1096	1098		|O
the	1099	1102		|O
slopes	1103	1109		|O
of	1110	1112		|O
the	1113	1116		|O
regression	1117	1127		|O
lines	1128	1133		|O
,	1133	1134		|O
indicating	1135	1145		|O
that	1146	1150		|O
the	1151	1154		|O
reduction	1155	1164		|O
in	1165	1167		|O
A1C	1168	1171		|O
was	1172	1175		|O
significantly	1176	1189		|O
greater	1190	1197		|O
with	1198	1202		|O
insulin	1203	1210		|O
glargine	1211	1219		|O
in	1220	1222		|O
those	1223	1228		|O
patients	1229	1237		|O
with	1238	1242		|O
higher	1243	1249		|O
baseline	1250	1258		|O
A1C	1259	1262		|O
values	1263	1269		|O
.	1269	1270		|O
The	1271	1274		|O
rate	1275	1279		|O
of	1280	1282		|O
confirmed	1283	1292		|O
glucose	1293	1300		|O
values	1301	1307		|O
<	1308	1309		|O
70	1309	1311		|O
mg	1312	1314		|O
/	1314	1315		|O
dL	1315	1317		|O
was	1318	1321		|O
higher	1322	1328		|O
in	1329	1331		|O
the	1332	1335		|O
patients	1336	1344		|O
receiving	1345	1354		|O
insulin	1355	1362		|O
glargine	1363	1371		|O
(	1372	1373		|O
P	1373	1374		|O
=	1375	1376		|O
.0298	1377	1382		|O
)	1382	1383		|O
.	1383	1384		|O
No	1385	1387		|O
differences	1388	1399		|O
in	1400	1402		|O
the	1403	1406		|O
rate	1407	1411		|O
of	1412	1414		|O
severe	1415	1421		|O
hypoglycemia	1422	1434	hypoglycemia	|B-ADVERSE
(	1435	1436		|O
P	1436	1437		|O
=	1438	1439		|O
.1814	1440	1445		|O
)	1445	1446		|O
or	1447	1449		|O
the	1450	1453		|O
occurrence	1454	1464		|O
of	1465	1467		|O
glucose	1468	1475		|O
levels	1476	1482		|O
<	1483	1484		|O
50	1484	1486		|O
mg	1487	1489		|O
/	1489	1490		|O
dL	1490	1492		|O
(	1493	1494		|O
P	1494	1495		|O
=	1496	1497		|O
.82	1498	1501		|O
)	1501	1502		|O
or	1503	1505		|O
<	1506	1507		|O
36	1507	1509		|O
mg	1510	1512		|O
/	1512	1513		|O
dL	1513	1515		|O
(	1516	1517		|O
P	1517	1518		|O
=	1519	1520		|O
.32	1521	1524		|O
)	1524	1525		|O
were	1526	1530		|O
found	1531	1536		|O
between	1537	1544		|O
the	1545	1548		|O
2	1549	1550		|O
groups	1551	1557		|O
.	1557	1558		|O
CONCLUSIONS	1559	1570		|O
:	1570	1571		|O
Insulin	1572	1579		|O
glargine	1580	1588		|O
is	1589	1591		|O
well	1592	1596		|O
tolerated	1597	1606		|O
in	1607	1609		|O
MDI	1610	1613		|O
regimens	1614	1622		|O
for	1623	1626		|O
pediatric	1627	1636		|O
patients	1637	1645		|O
with	1646	1650		|O
T1DM	1651	1655	T1DM	|B-DISEASE
and	1656	1659		|O
may	1660	1663		|O
be	1664	1666		|O
more	1667	1671		|O
efficacious	1672	1683		|O
than	1684	1688		|O
NPH	1689	1692		|O
/	1692	1693		|O
Lente	1693	1698		|O
in	1699	1701		|O
those	1702	1707		|O
with	1708	1712		|O
elevated	1713	1721		|O
A1C	1722	1725		|O
.	1725	1726		|O

### 18604181
Novel	0	5		|O
therapies	6	15		|O
in	16	18		|O
lupus	19	24		|O
-	25	26		|O
focus	27	32		|O
on	33	35		|O
nephritis	36	45	nephritis	|B-DISEASE
.	45	46		|O
Lupus	48	53	Lupus nephritis	|B-DISEASE
nephritis	54	63		|I-DISEASE
(	64	65		|O
LN	65	67	LN	|B-DISEASE
)	67	68		|O
is	69	71		|O
one	72	75		|O
of	76	78		|O
the	79	82		|O
major	83	88		|O
complications	89	102		|O
of	103	105		|O
Systemic	106	114	Systemic Lupus Erythematosus	|B-DISEASE
Lupus	115	120		|I-DISEASE
Erythematosus	121	134		|I-DISEASE
(	135	136		|O
SLE	136	139	SLE	|B-DISEASE
)	139	140		|O
and	141	144		|O
its	145	148		|O
treatment	149	158		|O
remains	159	166		|O
a	167	168		|O
challenge	169	178		|O
.	178	179		|O
Although	180	188		|O
the	189	192		|O
classical	193	202		|O
and	203	206		|O
widely	207	213		|O
used	214	218		|O
immunosuppressive	219	236		|O
agents	237	243		|O
have	244	248		|O
accounted	249	258		|O
for	259	262		|O
a	263	264		|O
significant	265	276		|O
improvement	277	288		|O
in	289	291		|O
the	292	295		|O
survival	296	304		|O
and	305	308		|O
decreased	309	318		|O
the	319	322		|O
progression	323	334		|O
to	335	337		|O
end	338	341		|O
-	341	342		|O
stage	342	347		|O
renal	348	353	renal failure	|B-DISEASE
failure	354	361		|I-DISEASE
they	362	366		|O
lack	367	371		|O
selectivity	372	383		|O
for	384	387		|O
the	388	391		|O
underlying	392	402		|O
immune	403	409		|O
dysregulation	410	423		|O
.	423	424		|O
In	425	427		|O
addition	428	436		|O
the	437	440		|O
toxicity	441	449		|O
related	450	457		|O
to	458	460		|O
their	461	466		|O
use	467	470		|O
and	471	474		|O
the	475	478		|O
relapses	479	487		|O
after	488	493		|O
treatment	494	503		|O
are	504	507		|O
of	508	510		|O
major	511	516		|O
concern	517	524		|O
not	525	528		|O
least	529	534		|O
because	535	542		|O
of	543	545		|O
the	546	549		|O
adverse	550	557		|O
effect	558	564		|O
on	565	567		|O
the	568	571		|O
prognosis	572	581		|O
of	582	584		|O
the	585	588		|O
patients	589	597		|O
with	598	602		|O
SLE	603	606	SLE	|B-DISEASE
who	607	610		|O
have	611	615		|O
kidney	616	622		|O
involvement	623	634		|O
.	634	635		|O
The	636	639		|O
development	640	651		|O
of	652	654		|O
more	655	659		|O
specific	660	668		|O
pharmacological	669	684		|O
agents	685	691		|O
for	692	695		|O
patients	696	704		|O
with	705	709		|O
SLE	710	713	SLE	|B-DISEASE
is	714	716		|O
still	717	722		|O
a	723	724		|O
major	725	730		|O
research	731	739		|O
goal	740	744		|O
.	744	745		|O
Ideally	746	753		|O
these	754	759		|O
agents	760	766		|O
should	767	773		|O
provide	774	781		|O
a	782	783		|O
better	784	790		|O
long	791	795		|O
-	795	796		|O
term	796	800		|O
prognosis	801	810		|O
for	811	814		|O
SLE	815	818	SLE	|B-DISEASE
patients	819	827		|O
and	828	831		|O
be	832	834		|O
less	835	839		|O
toxic	840	845		|O
.	845	846		|O
In	847	849		|O
this	850	854		|O
review	855	861		|O
we	862	864		|O
summarise	865	874		|O
the	875	878		|O
mechanism	879	888		|O
of	889	891		|O
action	892	898		|O
and	899	902		|O
the	903	906		|O
results	907	914		|O
obtained	915	923		|O
with	924	928		|O
a	929	930		|O
variety	931	938		|O
of	939	941		|O
drugs	942	947		|O
that	948	952		|O
have	953	957		|O
recently	958	966		|O
been	967	971		|O
utilized	972	980		|O
in	981	983		|O
the	984	987		|O
treatment	988	997		|O
of	998	1000		|O
patients	1001	1009		|O
with	1010	1014		|O
lupus	1015	1020		|O
especially	1021	1031		|O
those	1032	1037		|O
with	1038	1042		|O
nephritis	1043	1052	nephritis	|B-DISEASE
.	1052	1053		|O
We	1054	1056		|O
discuss	1057	1064		|O
the	1065	1068		|O
clinical	1069	1077		|O
usefulness	1078	1088		|O
of	1089	1091		|O
B	1092	1093		|O
-	1093	1094		|O
-	1095	1096		|O
cell	1096	1100		|O
depletion	1101	1110		|O
principally	1111	1122		|O
anti	1123	1127		|O
-	1127	1128		|O
CD20	1128	1132		|O
antibodies	1133	1143		|O
blockage	1144	1152		|O
of	1153	1155		|O
co	1156	1158		|O
-	1158	1159		|O
stimulatory	1159	1170		|O
pathways	1171	1179		|O
(	1180	1181		|O
anti	1181	1185		|O
-	1185	1186		|O
CD40	1186	1190		|O
ligand	1191	1197		|O
antibody	1198	1206		|O
CTLA4Ig	1207	1214		|O
)	1214	1215		|O
the	1216	1219		|O
induction	1220	1229		|O
of	1230	1232		|O
immune	1233	1239		|O
tolerance	1240	1249		|O
(	1250	1251		|O
LJP	1251	1254		|O
394	1255	1258		|O
peptide	1259	1266		|O
specific	1267	1275		|O
vaccination	1276	1287		|O
)	1287	1288		|O
and	1289	1292		|O
therapy	1293	1300		|O
targeting	1301	1310		|O
cytokines	1311	1320		|O
(	1321	1322		|O
anti	1322	1326		|O
-	1326	1327		|O
IL10	1327	1331		|O
antibody	1332	1340		|O
BLyS	1341	1345		|O
blockage	1346	1354		|O
)	1354	1355		|O
and	1356	1359		|O
the	1360	1363		|O
complement	1364	1374		|O
system	1375	1381		|O
(	1382	1383		|O
anti	1383	1387		|O
-	1387	1388		|O
C5	1388	1390		|O
antibody	1391	1399		|O
)	1399	1400		|O
.	1400	1401		|O
Immunoablative	1402	1416		|O
doses	1417	1422		|O
of	1423	1425		|O
Cyclophosphamide	1426	1442		|O
(	1443	1444		|O
CyC	1444	1447		|O
)	1447	1448		|O
with	1449	1453		|O
or	1454	1456		|O
without	1457	1464		|O
Haematopoietic	1465	1479		|O
Stem	1480	1484		|O
Cell	1485	1489		|O
Transplantation	1490	1505		|O
(	1506	1507		|O
HSCT	1507	1511		|O
)	1511	1512		|O
and	1513	1516		|O
the	1517	1520		|O
possibilities	1521	1534		|O
of	1535	1537		|O
gene	1538	1542		|O
therapy	1543	1550		|O
are	1551	1554		|O
also	1555	1559		|O
reviewed	1560	1568		|O
.	1568	1569		|O
The	1570	1573		|O
use	1574	1577		|O
of	1578	1580		|O
intravenous	1581	1592		|O
immunoglobulin	1593	1607		|O
(	1608	1609		|O
IVIg	1609	1613		|O
)	1613	1614		|O
and	1615	1618		|O
plasmapheresis	1619	1633		|O
are	1634	1637		|O
not	1638	1641		|O
discussed	1642	1651		|O
because	1652	1659		|O
these	1660	1665		|O
treatments	1666	1676		|O
have	1677	1681		|O
been	1682	1686		|O
used	1687	1691		|O
in	1692	1694		|O
clinical	1695	1703		|O
practice	1704	1712		|O
for	1713	1716		|O
several	1717	1724		|O
years	1725	1730		|O
.	1730	1731		|O

### 18637031
A	0	1		|O
systematic	2	12		|O
review	13	19		|O
of	20	22		|O
phase	23	28		|O
II	29	31		|O
trials	32	38		|O
of	39	41		|O
thalidomide	42	53		|O
/	53	54		|O
dexamethasone	54	67		|O
combination	68	79		|O
therapy	80	87		|O
in	88	90		|O
patients	91	99		|O
with	100	104		|O
relapsed	105	113		|O
or	114	116		|O
refractory	117	127	refractory multiple myeloma	|B-DISEASE
multiple	128	136		|I-DISEASE
myeloma	137	144		|I-DISEASE
.	144	145		|O
Thalidomide	147	158		|O
monotherapy	159	170		|O
in	171	173		|O
relapsed	174	182	relapsed/refractory multiple myeloma	|B-DISEASE
/	182	183		|I-DISEASE
refractory	183	193		|I-DISEASE
multiple	194	202		|I-DISEASE
myeloma	203	210		|I-DISEASE
(	211	212		|O
MM	212	214	MM	|B-DISEASE
)	214	215		|O
has	216	219		|O
a	220	221		|O
response	222	230		|O
rate	231	235		|O
of	236	238		|O
30%	239	242		|O
.	242	243		|O
The	244	247		|O
combination	248	259		|O
of	260	262		|O
thalidomide	263	274		|O
with	275	279		|O
dexamethasone	280	293		|O
(	294	295		|O
Thal	295	299		|O
/	299	300		|O
Dex	300	303		|O
)	303	304		|O
is	305	307		|O
expected	308	316		|O
to	317	319		|O
improve	320	327		|O
responses	328	337		|O
,	337	338		|O
but	339	342		|O
it	343	345		|O
is	346	348		|O
unknown	349	356		|O
if	357	359		|O
the	360	363		|O
combination	364	375		|O
increases	376	385		|O
the	386	389		|O
rate	390	394		|O
of	395	397		|O
adverse	398	405		|O
events	406	412		|O
.	412	413		|O
Here	414	418		|O
,	418	419		|O
we	420	422		|O
conducted	423	432		|O
a	433	434		|O
systematic	435	445		|O
review	446	452		|O
of	453	455		|O
studies	456	463		|O
evaluating	464	474		|O
Thal	475	479		|O
/	479	480		|O
Dex	480	483		|O
in	484	486		|O
relapsed	487	495	relapsed/refractory MM	|B-DISEASE
/	495	496		|I-DISEASE
refractory	496	506		|I-DISEASE
MM	507	509		|I-DISEASE
.	509	510		|O
Twelve	511	517		|O
studies	518	525		|O
were	526	530		|O
included	531	539		|O
,	539	540		|O
comprising	541	551		|O
451	552	555		|O
patients	556	564		|O
.	564	565		|O
The	566	569		|O
response	570	578		|O
rate	579	583		|O
(	584	585		|O
CR	585	587		|O
and	588	591		|O
PR	592	594		|O
)	594	595		|O
was	596	599		|O
46%	600	603		|O
(	604	605		|O
95%	605	608		|O
CI	609	611		|O
42-51%	612	618		|O
)	618	619		|O
.	619	620		|O
Therapy	621	628	Therapy-related toxicity	|B-ADVERSE
-	628	629		|I-ADVERSE
related	629	636		|I-ADVERSE
toxicity	637	645		|I-ADVERSE
was	646	649		|O
comparable	650	660		|O
to	661	663		|O
thalidomide	664	675		|O
monotherapy	676	687		|O
and	688	691		|O
included	692	700		|O
somnolence	701	711	somnolence	|B-ADVERSE
(	712	713		|O
26%	713	716		|O
,	716	717		|O
95%	718	721		|O
CI	722	724		|O
22-31%	725	731		|O
)	731	732		|O
,	732	733		|O
constipation	734	746	constipation	|B-ADVERSE
(	747	748		|O
37%	748	751		|O
,	751	752		|O
95%	753	756		|O
CI	757	759		|O
32-42%	760	766		|O
)	766	767		|O
and	768	771		|O
peripheral	772	782	peripheral neuropathy	|B-ADVERSE
neuropathy	783	793		|I-ADVERSE
(	794	795		|O
27%	795	798		|O
,	798	799		|O
95%	800	803		|O
CI	804	806		|O
23-32%	807	813		|O
)	813	814		|O
.	814	815		|O
Only	816	820		|O
venous	821	827	venous thromboembolism	|B-ADVERSE
thromboembolism	828	843		|I-ADVERSE
appeared	844	852		|O
to	853	855		|O
occur	856	861		|O
more	862	866		|O
often	867	872		|O
with	873	877		|O
Thal	878	882		|O
/	882	883		|O
Dex	883	886		|O
(	887	888		|O
5%	888	890		|O
,	890	891		|O
95%	892	895		|O
CI	896	898		|O
3-8%	899	903		|O
)	903	904		|O
.	904	905		|O
Thus	906	910		|O
,	910	911		|O
using	912	917		|O
Thal	918	922		|O
/	922	923		|O
Dex	923	926		|O
results	927	934		|O
in	935	937		|O
an	938	940		|O
improved	941	949		|O
response	950	958		|O
rate	959	963		|O
in	964	966		|O
relapsed	967	975	relapsed/refractory MM	|B-DISEASE
/	975	976		|I-DISEASE
refractory	976	986		|I-DISEASE
MM	987	989		|I-DISEASE
,	989	990		|O
with	991	995		|O
a	996	997		|O
toxicity	998	1006		|O
rate	1007	1011		|O
comparable	1012	1022		|O
to	1023	1025		|O
thalidomide	1026	1037		|O
monotherapy	1038	1049		|O
.	1049	1050		|O

### 18719942
Bendamustine	0	12		|O
,	12	13		|O
but	14	17		|O
not	18	21		|O
fludarabine	22	33		|O
,	33	34		|O
exhibits	35	43		|O
a	44	45		|O
low	46	49		|O
stem	50	54	stem cell toxicity	|B-ADVERSE
cell	55	59		|I-ADVERSE
toxicity	60	68		|I-ADVERSE
in	69	71		|O
vitro	72	77		|O
.	77	78		|O
PURPOSE	80	87		|O
:	87	88		|O
We	89	91		|O
investigated	92	104		|O
the	105	108		|O
in	109	111		|O
vitro	112	117		|O
toxicity	118	126		|O
of	127	129		|O
bendamustine	130	142		|O
and	143	146		|O
fludarabine	147	158		|O
to	159	161		|O
hematopoietic	162	175		|O
progenitors	176	187		|O
and	188	191		|O
stem	192	196		|O
cells	197	202		|O
from	203	207		|O
healthy	208	215		|O
donors	216	222		|O
.	222	223		|O
METHODS	224	231		|O
:	231	232		|O
Clonogenic	233	243		|O
agar	244	248		|O
colony	249	255		|O
assays	256	262		|O
,	262	263		|O
non	264	267		|O
-	267	268		|O
clonogenic	268	278		|O
long	279	283		|O
-	283	284		|O
term	284	288		|O
liquid	289	295		|O
cultures	296	304		|O
(	305	306		|O
LTC	306	309		|O
)	309	310		|O
and	311	314		|O
apoptosis	315	324		|O
assays	325	331		|O
were	332	336		|O
used	337	341		|O
to	342	344		|O
assess	345	351		|O
the	352	355		|O
cytotoxicity	356	368	cytotoxicity	|B-ADVERSE
of	369	371		|O
both	372	376		|O
the	377	380		|O
agents	381	387		|O
.	387	388		|O
RESULTS	389	396		|O
:	396	397		|O
Total	398	403		|O
colony	404	410		|O
-	410	411		|O
forming	411	418		|O
units	419	424		|O
(	425	426		|O
CFU	426	429		|O
)	429	430		|O
were	431	435		|O
more	436	440		|O
sensitive	441	450		|O
to	451	453		|O
fludarabine	454	465		|O
than	466	470		|O
to	471	473		|O
bendamustine	474	486		|O
in	487	489		|O
agar	490	494		|O
colony	495	501		|O
assays	502	508		|O
(	509	510		|O
IC	510	512		|O
(	512	513		|O
50	513	515		|O
)	515	516		|O
0.7	517	520		|O
microM	521	527		|O
/	527	528		|O
L	528	529		|O
and	530	533		|O
8.5	534	537		|O
microM	538	544		|O
/	544	545		|O
L	545	546		|O
,	546	547		|O
respectively	548	560		|O
)	560	561		|O
.	561	562		|O
Using	563	568		|O
the	569	572		|O
Bliss	573	578		|O
independence	579	591		|O
model	592	597		|O
and	598	601		|O
combining	602	611		|O
the	612	615		|O
two	616	619		|O
agents	620	626		|O
yielded	627	634		|O
additive	635	643		|O
inhibition	644	654		|O
of	655	657		|O
progenitors	658	669		|O
.	669	670		|O
Non	671	674		|O
-	674	675		|O
clonogenic	675	685		|O
assays	686	692		|O
,	692	693		|O
including	694	703		|O
LTC	704	707		|O
and	708	711		|O
an	712	714		|O
apoptosis	715	724		|O
assay	725	730		|O
detecting	731	740		|O
activated	741	750		|O
caspases	751	759		|O
showed	760	766		|O
that	767	771		|O
stem	772	776		|O
cells	777	782		|O
are	783	786		|O
characterized	787	800		|O
by	801	803		|O
low	804	807		|O
sensitivity	808	819		|O
to	820	822		|O
bendamustine	823	835		|O
.	835	836		|O
In	837	839		|O
contrast	840	848		|O
,	848	849		|O
fludarabine	850	861		|O
strongly	862	870		|O
inhibited	871	880		|O
the	881	884		|O
viability	885	894		|O
and	895	898		|O
growth	899	905		|O
of	906	908		|O
stem	909	913		|O
cells	914	919		|O
in	920	922		|O
LTC	923	926		|O
.	926	927		|O
CONCLUSIONS	928	939		|O
:	939	940		|O
Our	941	944		|O
data	945	949		|O
show	950	954		|O
that	955	959		|O
bendamustine	960	972		|O
is	973	975		|O
characterized	976	989		|O
by	990	992		|O
lower	993	998		|O
in	999	1001		|O
vitro	1002	1007		|O
toxicity	1008	1016		|O
to	1017	1019		|O
hematopoietic	1020	1033		|O
progenitors	1034	1045		|O
and	1046	1049		|O
stem	1050	1054		|O
cells	1055	1060		|O
than	1061	1065		|O
fludarabine	1066	1077		|O
and	1078	1081		|O
might	1082	1087		|O
thus	1088	1092		|O
be	1093	1095		|O
preferable	1096	1106		|O
in	1107	1109		|O
regimens	1110	1118		|O
prior	1119	1124		|O
to	1125	1127		|O
stem	1128	1132		|O
cells	1133	1138		|O
apheresis	1139	1148		|O
.	1148	1149		|O

### 18548134
Lisdexamfetamine	0	16		|O
dimesylate	17	27		|O
for	28	31		|O
childhood	32	41		|O
ADHD	42	46	ADHD	|B-DISEASE
.	46	47		|O
Stimulants	49	59		|O
are	60	63		|O
extremely	64	73		|O
effective	74	83		|O
and	84	87		|O
safe	88	92		|O
and	93	96		|O
have	97	101		|O
been	102	106		|O
the	107	110		|O
mainstay	111	119		|O
for	120	123		|O
the	124	127		|O
pharmacological	128	143		|O
treatment	144	153		|O
of	154	156		|O
attention	157	166	attention deficit hyperactivity disorder	|B-DISEASE
deficit	167	174		|I-DISEASE
hyperactivity	175	188		|I-DISEASE
disorder	189	197		|I-DISEASE
(	198	199		|O
ADHD	199	203	ADHD	|B-DISEASE
)	203	204		|O
for	205	208		|O
many	209	213		|O
years	214	219		|O
.	219	220		|O
However	221	228		|O
,	228	229		|O
there	230	235		|O
have	236	240		|O
been	241	245		|O
some	246	250		|O
concerns	251	259		|O
regarding	260	269		|O
their	270	275		|O
abuse	276	281		|O
,	281	282		|O
especially	283	293		|O
by	294	296		|O
teenagers	297	306		|O
and	307	310		|O
young	311	316		|O
adults	317	323		|O
.	323	324		|O
Lisdexamfetamine	325	341		|O
was	342	345		|O
recently	346	354		|O
approved	355	363		|O
for	364	367		|O
the	368	371		|O
treatment	372	381		|O
of	382	384		|O
ADHD	385	389	ADHD	|B-DISEASE
in	390	392		|O
6-12	393	397		|O
-	397	398		|O
year	398	402		|O
-	402	403		|O
olds	403	407		|O
and	408	411		|O
provides	412	420		|O
a	421	422		|O
novel	423	428		|O
approach	429	437		|O
to	438	440		|O
the	441	444		|O
treatment	445	454		|O
of	455	457		|O
ADHD	458	462	ADHD	|B-DISEASE
.	462	463		|O
Lisdexamfetamine	464	480		|O
is	481	483		|O
a	484	485		|O
prodrug	486	493		|O
comprised	494	503		|O
of	504	506		|O
dextroamphetamine	507	524		|O
covalently	525	535		|O
attached	536	544		|O
to	545	547		|O
an	548	550		|O
essential	551	560		|O
amino	561	566		|O
acid	567	571		|O
,	571	572		|O
L	573	574		|O
-	574	575		|O
lysine	575	581		|O
.	581	582		|O
Following	583	592		|O
oral	593	597		|O
administration	598	612		|O
,	612	613		|O
the	614	617		|O
amide	618	623		|O
linkage	624	631		|O
between	632	639		|O
the	640	643		|O
two	644	647		|O
molecules	648	657		|O
is	658	660		|O
enzymatically	661	674		|O
hydrolyzed	675	685		|O
in	686	688		|O
the	689	692		|O
gastrointestinal	693	709		|O
tract	710	715		|O
,	715	716		|O
thus	717	721		|O
releasing	722	731		|O
active	732	738		|O
dextroamphetamine	739	756		|O
,	756	757		|O
which	758	763		|O
mediates	764	772		|O
the	773	776		|O
therapeutic	777	788		|O
effect	789	795		|O
in	796	798		|O
a	799	800		|O
fashion	801	808		|O
similar	809	816		|O
to	817	819		|O
other	820	825		|O
stimulants	826	836		|O
.	836	837		|O
The	838	841		|O
parent	842	848		|O
drug	849	853		|O
does	854	858		|O
not	859	862		|O
bind	863	867		|O
to	868	870		|O
sites	871	876		|O
responsible	877	888		|O
for	889	892		|O
the	893	896		|O
reuptake	897	905		|O
of	906	908		|O
norepinephrine	909	923		|O
and	924	927		|O
dopamine	928	936		|O
in	937	939		|O
vitro	940	945		|O
.	945	946		|O
Lisdexamfetamine	947	963		|O
does	964	968		|O
not	969	972		|O
produce	973	980		|O
high	981	985		|O
dextroamphetamine	986	1003		|O
levels	1004	1010		|O
when	1011	1015		|O
injected	1016	1024		|O
or	1025	1027		|O
snorted	1028	1035		|O
,	1035	1036		|O
and	1037	1040		|O
thus	1041	1045		|O
may	1046	1049		|O
have	1050	1054		|O
lower	1055	1060		|O
abuse	1061	1066		|O
potential	1067	1076		|O
compared	1077	1085		|O
to	1086	1088		|O
conventional	1089	1101		|O
stimulants	1102	1112		|O
.	1112	1113		|O
Lisdexamfetamine	1114	1130		|O
appears	1131	1138		|O
to	1139	1141		|O
have	1142	1146		|O
efficacy	1147	1155		|O
and	1156	1159		|O
tolerability	1160	1172		|O
comparable	1173	1183		|O
to	1184	1186		|O
other	1187	1192		|O
extended	1193	1201		|O
-	1201	1202		|O
release	1202	1209		|O
stimulant	1210	1219		|O
formulations	1220	1232		|O
used	1233	1237		|O
to	1238	1240		|O
treat	1241	1246		|O
ADHD	1247	1251	ADHD	|B-DISEASE
,	1251	1252		|O
but	1253	1256		|O
reduced	1257	1264		|O
potential	1265	1274		|O
for	1275	1278		|O
abuse	1279	1284		|O
-	1284	1285		|O
related	1285	1292		|O
liking	1293	1299		|O
effects	1300	1307		|O
.	1307	1308		|O
Compared	1309	1317		|O
to	1318	1320		|O
equivalent	1321	1331		|O
amounts	1332	1339		|O
of	1340	1342		|O
immediate	1343	1352		|O
-	1352	1353		|O
release	1353	1360		|O
dextroamphetamine	1361	1378		|O
.	1378	1379		|O

### 18710264
Copper	0	6		|O
oxide	7	12		|O
nanoparticles	13	26		|O
are	27	30		|O
highly	31	37		|O
toxic	38	43		|O
:	43	44		|O
a	45	46		|O
comparison	47	57		|O
between	58	65		|O
metal	66	71		|O
oxide	72	77		|O
nanoparticles	78	91		|O
and	92	95		|O
carbon	96	102		|O
nanotubes	103	112		|O
.	112	113		|O
Since	115	120		|O
the	121	124		|O
manufacture	125	136		|O
and	137	140		|O
use	141	144		|O
of	145	147		|O
nanoparticles	148	161		|O
are	162	165		|O
increasing	166	176		|O
,	176	177		|O
humans	178	184		|O
are	185	188		|O
more	189	193		|O
likely	194	200		|O
to	201	203		|O
be	204	206		|O
exposed	207	214		|O
occupationally	215	229		|O
or	230	232		|O
via	233	236		|O
consumer	237	245		|O
products	246	254		|O
and	255	258		|O
the	259	262		|O
environment	263	274		|O
.	274	275		|O
However	276	283		|O
,	283	284		|O
so	285	287		|O
far	288	291		|O
toxicity	292	300		|O
data	301	305		|O
for	306	309		|O
most	310	314		|O
manufactured	315	327		|O
nanoparticles	328	341		|O
are	342	345		|O
limited	346	353		|O
.	353	354		|O
The	355	358		|O
aim	359	362		|O
of	363	365		|O
this	366	370		|O
study	371	376		|O
was	377	380		|O
to	381	383		|O
investigate	384	395		|O
and	396	399		|O
compare	400	407		|O
different	408	417		|O
nanoparticles	418	431		|O
and	432	435		|O
nanotubes	436	445		|O
regarding	446	455		|O
cytotoxicity	456	468		|O
and	469	472		|O
ability	473	480		|O
to	481	483		|O
cause	484	489		|O
DNA	490	493		|O
damage	494	500		|O
and	501	504		|O
oxidative	505	514		|O
stress	515	521		|O
.	521	522		|O
The	523	526		|O
study	527	532		|O
was	533	536		|O
focused	537	544		|O
on	545	547		|O
different	548	557		|O
metal	558	563		|O
oxide	564	569		|O
particles	570	579		|O
(	580	581		|O
CuO	581	584		|O
,	584	585		|O
TiO2	586	590		|O
,	590	591		|O
ZnO	592	595		|O
,	595	596		|O
CuZnFe2O4	597	606		|O
,	606	607		|O
Fe3O4	608	613		|O
,	613	614		|O
Fe2O3	615	620		|O
)	620	621		|O
,	621	622		|O
and	623	626		|O
the	627	630		|O
toxicity	631	639		|O
was	640	643		|O
compared	644	652		|O
to	653	655		|O
that	656	660		|O
of	661	663		|O
carbon	664	670		|O
nanoparticles	671	684		|O
and	685	688		|O
multiwalled	689	700		|O
carbon	701	707		|O
nanotubes	708	717		|O
(	718	719		|O
MWCNT	719	724		|O
)	724	725		|O
.	725	726		|O
The	727	730		|O
human	731	736		|O
lung	737	741		|O
epithelial	742	752		|O
cell	753	757		|O
line	758	762		|O
A549	763	767		|O
was	768	771		|O
exposed	772	779		|O
to	780	782		|O
the	783	786		|O
particles	787	796		|O
,	796	797		|O
and	798	801		|O
cytotoxicity	802	814	cytotoxicity	|B-ADVERSE
was	815	818		|O
analyzed	819	827		|O
using	828	833		|O
trypan	834	840		|O
blue	841	845		|O
staining	846	854		|O
.	854	855		|O
DNA	856	859		|O
damage	860	866		|O
and	867	870		|O
oxidative	871	880		|O
lesions	881	888		|O
were	889	893		|O
determined	894	904		|O
using	905	910		|O
the	911	914		|O
comet	915	920		|O
assay	921	926		|O
,	926	927		|O
and	928	931		|O
intracellular	932	945		|O
production	946	956		|O
of	957	959		|O
reactive	960	968		|O
oxygen	969	975		|O
species	976	983		|O
(	984	985		|O
ROS	985	988		|O
)	988	989		|O
was	990	993		|O
measured	994	1002		|O
using	1003	1008		|O
the	1009	1012		|O
oxidation	1013	1022		|O
-	1022	1023		|O
sensitive	1023	1032		|O
fluoroprobe	1033	1044		|O
2'	1045	1047		|O
,	1047	1048		|O
7'	1048	1050		|O
-	1050	1051		|O
dichlorofluorescin	1051	1069		|O
diacetate	1070	1079		|O
(	1080	1081		|O
DCFH	1081	1085		|O
-	1085	1086		|O
DA	1086	1088		|O
)	1088	1089		|O
.	1089	1090		|O
The	1091	1094		|O
results	1095	1102		|O
showed	1103	1109		|O
that	1110	1114		|O
there	1115	1120		|O
was	1121	1124		|O
a	1125	1126		|O
high	1127	1131		|O
variation	1132	1141		|O
among	1142	1147		|O
different	1148	1157		|O
nanoparticles	1158	1171		|O
concerning	1172	1182		|O
their	1183	1188		|O
ability	1189	1196		|O
to	1197	1199		|O
cause	1200	1205		|O
toxic	1206	1211		|O
effects	1212	1219		|O
.	1219	1220		|O
CuO	1221	1224		|O
nanoparticles	1225	1238		|O
were	1239	1243		|O
most	1244	1248		|O
potent	1249	1255		|O
regarding	1256	1265		|O
cytotoxicity	1266	1278	cytotoxicity	|B-ADVERSE
and	1279	1282		|O
DNA	1283	1286		|O
damage	1287	1293		|O
.	1293	1294		|O
The	1295	1298		|O
toxicity	1299	1307		|O
was	1308	1311		|O
likely	1312	1318		|O
not	1319	1322		|O
explained	1323	1332		|O
by	1333	1335		|O
Cu	1336	1338		|O
ions	1339	1343		|O
released	1344	1352		|O
to	1353	1355		|O
the	1356	1359		|O
cell	1360	1364		|O
medium	1365	1371		|O
.	1371	1372		|O
These	1373	1378		|O
particles	1379	1388		|O
also	1389	1393		|O
caused	1394	1400		|O
oxidative	1401	1410		|O
lesions	1411	1418		|O
and	1419	1422		|O
were	1423	1427		|O
the	1428	1431		|O
only	1432	1436		|O
particles	1437	1446		|O
that	1447	1451		|O
induced	1452	1459		|O
an	1460	1462		|O
almost	1463	1469		|O
significant	1470	1481		|O
increase	1482	1490		|O
(	1491	1492		|O
p	1492	1493		|O
=	1494	1495		|O
0.058	1496	1501		|O
)	1501	1502		|O
in	1503	1505		|O
intracellular	1506	1519		|O
ROS	1520	1523		|O
.	1523	1524		|O
ZnO	1525	1528		|O
showed	1529	1535		|O
effects	1536	1543		|O
on	1544	1546		|O
cell	1547	1551		|O
viability	1552	1561		|O
as	1562	1564		|O
well	1565	1569		|O
as	1570	1572		|O
DNA	1573	1576		|O
damage	1577	1583		|O
,	1583	1584		|O
whereas	1585	1592		|O
the	1593	1596		|O
TiO2	1597	1601		|O
particles	1602	1611		|O
(	1612	1613		|O
a	1613	1614		|O
mix	1615	1618		|O
of	1619	1621		|O
rutile	1622	1628		|O
and	1629	1632		|O
anatase	1633	1640		|O
)	1640	1641		|O
only	1642	1646		|O
caused	1647	1653		|O
DNA	1654	1657		|O
damage	1658	1664		|O
.	1664	1665		|O
For	1666	1669		|O
iron	1670	1674		|O
oxide	1675	1680		|O
particles	1681	1690		|O
(	1691	1692		|O
Fe3O4	1692	1697		|O
,	1697	1698		|O
Fe2O3	1699	1704		|O
)	1704	1705		|O
,	1705	1706		|O
no	1707	1709		|O
or	1710	1712		|O
low	1713	1716		|O
toxicity	1717	1725		|O
was	1726	1729		|O
observed	1730	1738		|O
,	1738	1739		|O
but	1740	1743		|O
CuZnFe2O4	1744	1753		|O
particles	1754	1763		|O
were	1764	1768		|O
rather	1769	1775		|O
potent	1776	1782		|O
in	1783	1785		|O
inducing	1786	1794		|O
DNA	1795	1798		|O
lesions	1799	1806		|O
.	1806	1807		|O
Finally	1808	1815		|O
,	1815	1816		|O
the	1817	1820		|O
carbon	1821	1827		|O
nanotubes	1828	1837		|O
showed	1838	1844		|O
cytotoxic	1845	1854	cytotoxic effects	|B-ADVERSE
effects	1855	1862		|I-ADVERSE
and	1863	1866		|O
caused	1867	1873		|O
DNA	1874	1877		|O
damage	1878	1884		|O
in	1885	1887		|O
the	1888	1891		|O
lowest	1892	1898		|O
dose	1899	1903		|O
tested	1904	1910		|O
.	1910	1911		|O
The	1912	1915		|O
effects	1916	1923		|O
were	1924	1928		|O
not	1929	1932		|O
explained	1933	1942		|O
by	1943	1945		|O
soluble	1946	1953		|O
metal	1954	1959		|O
impurities	1960	1970		|O
.	1970	1971		|O
In	1972	1974		|O
conclusion	1975	1985		|O
,	1985	1986		|O
this	1987	1991		|O
study	1992	1997		|O
highlights	1998	2008		|O
the	2009	2012		|O
in	2013	2015		|O
vitro	2016	2021		|O
toxicity	2022	2030		|O
of	2031	2033		|O
CuO	2034	2037		|O
nanoparticles	2038	2051		|O
.	2051	2052		|O

### 18676353
Down	0	4		|O
-	4	5		|O
regulation	5	15		|O
of	16	18		|O
asymmetric	19	29		|O
arginine	30	38		|O
methylation	39	50		|O
during	51	57		|O
replicative	58	69		|O
and	70	73		|O
H2O2	74	78		|O
-	78	79		|O
induced	79	86		|O
premature	87	96		|O
senescence	97	107		|O
in	108	110		|O
WI	111	113		|O
-	113	114		|O
38	114	116		|O
human	117	122		|O
diploid	123	130		|O
fibroblasts	131	142		|O
.	142	143		|O
Protein	145	152		|O
arginine	153	161		|O
methylation	162	173		|O
is	174	176		|O
one	177	180		|O
of	181	183		|O
the	184	187		|O
post	188	192		|O
-	192	193		|O
translational	193	206		|O
modifications	207	220		|O
which	221	226		|O
yield	227	232		|O
monomethyl	233	243		|O
and	244	247		|O
dimethyl	248	256		|O
(	257	258		|O
asymmetric	258	268		|O
or	269	271		|O
symmetric	272	281		|O
)	281	282		|O
arginines	283	292		|O
in	293	295		|O
proteins	296	304		|O
.	304	305		|O
In	306	308		|O
the	309	312		|O
present	313	320		|O
study	321	326		|O
,	326	327		|O
we	328	330		|O
investigated	331	343		|O
the	344	347		|O
status	348	354		|O
of	355	357		|O
protein	358	365		|O
arginine	366	374		|O
methylation	375	386		|O
during	387	393		|O
human	394	399		|O
diploid	400	407		|O
fibroblast	408	418		|O
senescence	419	429		|O
.	429	430		|O
When	431	435		|O
the	436	439		|O
expression	440	450		|O
of	451	453		|O
protein	454	461		|O
arginine	462	470		|O
methyltransferases	471	489		|O
(	490	491		|O
PRMTs	491	496		|O
)	496	497		|O
,	497	498		|O
namely	499	505		|O
PRMT1	506	511		|O
,	511	512		|O
PRMT4	513	518		|O
,	518	519		|O
PRMT5	520	525		|O
and	526	529		|O
PRMT6	530	535		|O
was	536	539		|O
examined	540	548		|O
,	548	549		|O
a	550	551		|O
significant	552	563		|O
reduction	564	573		|O
was	574	577		|O
found	578	583		|O
in	584	586		|O
replicatively	587	600		|O
senescent	601	610		|O
cells	611	616		|O
as	617	619		|O
well	620	624		|O
as	625	627		|O
their	628	633		|O
catalytic	634	643		|O
activities	644	654		|O
against	655	662		|O
histone	663	670		|O
mixtures	671	679		|O
compared	680	688		|O
with	689	693		|O
the	694	697		|O
young	698	703		|O
cells	704	709		|O
.	709	710		|O
Furthermore	711	722		|O
,	722	723		|O
when	724	728		|O
the	729	732		|O
endogenous	733	743		|O
level	744	749		|O
of	750	752		|O
arginine	753	761		|O
-	761	762		|O
dimethylated	762	774		|O
proteins	775	783		|O
was	784	787		|O
determined	788	798		|O
,	798	799		|O
asymmetric	800	810		|O
modification	811	823		|O
(	824	825		|O
the	825	828		|O
product	829	836		|O
of	837	839		|O
type	840	844		|O
I	845	846		|O
PRMTs	847	852		|O
including	853	862		|O
PRMT1	863	868		|O
,	868	869		|O
PRMT4	870	875		|O
and	876	879		|O
PRMT6	880	885		|O
)	885	886		|O
was	887	890		|O
markedly	891	899		|O
down	900	904		|O
-	904	905		|O
regulated	905	914		|O
.	914	915		|O
In	916	918		|O
contrast	919	927		|O
,	927	928		|O
both	929	933		|O
up	934	936		|O
-	936	937		|O
and	938	941		|O
down	942	946		|O
-	946	947		|O
regulations	947	958		|O
of	959	961		|O
symmetrically	962	975		|O
arginine	976	984		|O
-	984	985		|O
methylated	985	995		|O
proteins	996	1004		|O
(	1005	1006		|O
the	1006	1009		|O
product	1010	1017		|O
of	1018	1020		|O
type	1021	1025		|O
II	1026	1028		|O
PRMTs	1029	1034		|O
including	1035	1044		|O
PRMT5	1045	1050		|O
)	1050	1051		|O
during	1052	1058		|O
replicative	1059	1070		|O
senescence	1071	1081		|O
were	1082	1086		|O
found	1087	1092		|O
.	1092	1093		|O
Furthermore	1094	1105		|O
,	1105	1106		|O
when	1107	1111		|O
young	1112	1117		|O
fibroblasts	1118	1129		|O
were	1130	1134		|O
induced	1135	1142		|O
to	1143	1145		|O
premature	1146	1155		|O
senescence	1156	1166		|O
by	1167	1169		|O
sub	1170	1173		|O
-	1173	1174		|O
cytotoxic	1174	1183		|O
H2O2	1184	1188		|O
treatment	1189	1198		|O
,	1198	1199		|O
results	1200	1207		|O
similar	1208	1215		|O
to	1216	1218		|O
replicative	1219	1230		|O
senescence	1231	1241		|O
were	1242	1246		|O
obtained	1247	1255		|O
.	1255	1256		|O
Finally	1257	1264		|O
,	1264	1265		|O
we	1266	1268		|O
found	1269	1274		|O
that	1275	1279		|O
SV40	1280	1284		|O
-	1284	1285		|O
mediated	1285	1293		|O
immortalized	1294	1306		|O
WI	1307	1309		|O
-	1309	1310		|O
38	1310	1312		|O
and	1313	1316		|O
HeLa	1317	1321		|O
cell	1322	1326		|O
lines	1327	1332		|O
maintained	1333	1343		|O
a	1344	1345		|O
higher	1346	1352		|O
level	1353	1358		|O
of	1359	1361		|O
asymmetrically	1362	1376		|O
modified	1377	1385		|O
proteins	1386	1394		|O
as	1395	1397		|O
well	1398	1402		|O
as	1403	1405		|O
type	1406	1410		|O
I	1411	1412		|O
PRMTs	1413	1418		|O
than	1419	1423		|O
young	1424	1429		|O
fibroblasts	1430	1441		|O
.	1441	1442		|O
These	1443	1448		|O
results	1449	1456		|O
suggest	1457	1464		|O
that	1465	1469		|O
the	1470	1473		|O
maintenance	1474	1485		|O
of	1486	1488		|O
asymmetric	1489	1499		|O
modification	1500	1512		|O
in	1513	1515		|O
the	1516	1519		|O
expressed	1520	1529		|O
target	1530	1536		|O
proteins	1537	1545		|O
of	1546	1548		|O
type	1549	1553		|O
I	1554	1555		|O
PRMTs	1556	1561		|O
might	1562	1567		|O
be	1568	1570		|O
critical	1571	1579		|O
for	1580	1583		|O
cellular	1584	1592		|O
proliferation	1593	1606		|O
.	1606	1607		|O

### 18841306
Anti	0	4		|O
-	4	5		|O
inflammatory	5	17		|O
activity	18	26		|O
of	27	29		|O
Crinum	30	36		|O
asiaticum	37	46		|O
Linne	47	52		|O
var	53	56		|O
.	56	57		|O
japonicum	58	67		|O
extract	68	75		|O
and	76	79		|O
its	80	83		|O
application	84	95		|O
as	96	98		|O
a	99	100		|O
cosmeceutical	101	114		|O
ingredient	115	125		|O
.	125	126		|O
Crinum	128	134		|O
asiaticum	135	144		|O
Linne	145	150		|O
var	151	154		|O
.	154	155		|O
japonicum	156	165		|O
has	166	169		|O
long	170	174		|O
been	175	179		|O
used	180	184		|O
as	185	187		|O
a	188	189		|O
rheumatic	190	199		|O
remedy	200	206		|O
,	206	207		|O
as	208	210		|O
an	211	213		|O
anti	214	218		|O
-	218	219		|O
pyretic	219	226		|O
and	227	230		|O
as	231	233		|O
an	234	236		|O
anti	237	241		|O
-	241	242		|O
ulcer	242	247		|O
treatment	248	257		|O
,	257	258		|O
and	259	262		|O
for	263	266		|O
the	267	270		|O
alleviation	271	282		|O
of	283	285		|O
local	286	291	local pain	|B-DISEASE
pain	292	296		|I-DISEASE
and	297	300		|O
fever	301	306	fever	|B-DISEASE
in	307	309		|O
Korea	310	315		|O
and	316	319		|O
Malaysia	320	328		|O
.	328	329		|O
In	330	332		|O
order	333	338		|O
to	339	341		|O
investigate	342	353		|O
the	354	357		|O
possibility	358	369		|O
of	370	372		|O
Crinum	373	379		|O
asiaticum	380	389		|O
Linne	390	395		|O
var	396	399		|O
.	399	400		|O
japonicum	401	410		|O
extract	411	418		|O
as	419	421		|O
a	422	423		|O
cosmetic	424	432		|O
ingredient	433	443		|O
,	443	444		|O
we	445	447		|O
measured	448	456		|O
its	457	460		|O
anti	461	465		|O
-	465	466		|O
inflammatory	466	478		|O
effect	479	485		|O
by	486	488		|O
its	489	492		|O
inhibition	493	503		|O
of	504	506		|O
iNOS	507	511		|O
(	512	513		|O
inducible	513	522		|O
nitric	523	529		|O
oxide	530	535		|O
synthase	536	544		|O
)	544	545		|O
and	546	549		|O
the	550	553		|O
release	554	561		|O
of	562	564		|O
PGE2	565	569		|O
,	569	570		|O
IL	571	573		|O
-	573	574		|O
6	574	575		|O
,	575	576		|O
and	577	580		|O
IL	581	583		|O
-	583	584		|O
8	584	585		|O
.	585	586		|O
We	587	589		|O
also	590	594		|O
measured	595	603		|O
its	604	607		|O
anti	608	612		|O
-	612	613		|O
allergic	613	621		|O
effect	622	628		|O
by	629	631		|O
its	632	635		|O
inhibition	636	646		|O
of	647	649		|O
beta	650	654		|O
-	654	655		|O
hexosamidase	655	667		|O
release	668	675		|O
.	675	676		|O
An	677	679		|O
HPLC	680	684		|O
experiment	685	695		|O
after	696	701		|O
extraction	702	712		|O
with	713	717		|O
95%	718	721		|O
EtOH	722	726		|O
at	727	729		|O
pH	730	732		|O
3.5	733	736		|O
showed	737	743		|O
that	744	748		|O
Crinum	749	755		|O
asiaticum	756	765		|O
Linne	766	771		|O
var	772	775		|O
.	775	776		|O
japonicum	777	786		|O
was	787	790		|O
mainly	791	797		|O
composed	798	806		|O
of	807	809		|O
lycorine	810	818		|O
(	819	820		|O
up	820	822		|O
to	823	825		|O
1%	826	828		|O
)	828	829		|O
,	829	830		|O
a	831	832		|O
well	833	837		|O
-	837	838		|O
known	838	843		|O
immunosuppressor	844	860		|O
.	860	861		|O
The	862	865		|O
content	866	873		|O
of	874	876		|O
lycorine	877	885		|O
varied	886	892		|O
,	892	893		|O
depending	894	903		|O
on	904	906		|O
the	907	910		|O
type	911	915		|O
of	916	918		|O
plant	919	924		|O
tissue	925	931		|O
analyzed	932	940		|O
and	941	944		|O
the	945	948		|O
extraction	949	959		|O
method	960	966		|O
.	966	967		|O
In	968	970		|O
an	971	973		|O
anti	974	978		|O
-	978	979		|O
inflammatory	979	991		|O
assay	992	997		|O
for	998	1001		|O
inhibition	1002	1012		|O
of	1013	1015		|O
nitric	1016	1022		|O
oxide	1023	1028		|O
formation	1029	1038		|O
on	1039	1041		|O
lipopolysaccharide	1042	1060		|O
(	1061	1062		|O
LPS	1062	1065		|O
)	1065	1066		|O
-	1066	1067		|O
activated	1067	1076		|O
mouse	1077	1082		|O
macrophage	1083	1093		|O
RAW	1094	1097		|O
264.7	1098	1103		|O
cells	1104	1109		|O
,	1109	1110		|O
the	1111	1114		|O
ethanol	1115	1122		|O
extract	1123	1130		|O
of	1131	1133		|O
Crinum	1134	1140		|O
asiaticum	1141	1150		|O
showed	1151	1157		|O
an	1158	1160		|O
inhibitory	1161	1171		|O
activity	1172	1180		|O
of	1181	1183		|O
NO	1184	1186		|O
production	1187	1197		|O
in	1198	1200		|O
a	1201	1202		|O
dose	1203	1207		|O
-	1207	1208		|O
dependent	1208	1217		|O
manner	1218	1224		|O
(	1225	1226		|O
IC50	1226	1230		|O
=	1231	1232		|O
58.5	1233	1237		|O
microg	1238	1244		|O
/	1244	1245		|O
ml	1245	1247		|O
)	1247	1248		|O
.	1248	1249		|O
Additional	1250	1260		|O
study	1261	1266		|O
by	1267	1269		|O
RT	1270	1272		|O
-	1272	1273		|O
PCR	1273	1276		|O
demonstrated	1277	1289		|O
that	1290	1294		|O
the	1295	1298		|O
extract	1299	1306		|O
of	1307	1309		|O
Crinum	1310	1316		|O
asiaticum	1317	1326		|O
significantly	1327	1340		|O
suppressed	1341	1351		|O
the	1352	1355		|O
expression	1356	1366		|O
of	1367	1369		|O
the	1370	1373		|O
iNOS	1374	1378		|O
gene	1379	1383		|O
.	1383	1384		|O
Moreover	1385	1393		|O
,	1393	1394		|O
the	1395	1398		|O
extract	1399	1406		|O
of	1407	1409		|O
Crinum	1410	1416		|O
asiaticum	1417	1426		|O
did	1427	1430		|O
not	1431	1434		|O
show	1435	1439		|O
any	1440	1443		|O
cytotoxicity	1444	1456	cytotoxicity	|B-ADVERSE
,	1456	1457		|O
but	1458	1461		|O
did	1462	1465		|O
show	1466	1470		|O
a	1471	1472		|O
cell	1473	1477		|O
proliferation	1478	1491		|O
effect	1492	1498		|O
against	1499	1506		|O
LPS	1507	1510		|O
(	1511	1512		|O
a	1512	1513		|O
10	1514	1516		|O
approximately	1517	1530		|O
60%	1531	1534		|O
increase	1535	1543		|O
in	1544	1546		|O
cell	1547	1551		|O
viability	1552	1561		|O
)	1561	1562		|O
.	1562	1563		|O
In	1564	1566		|O
an	1567	1569		|O
assay	1570	1575		|O
to	1576	1578		|O
determine	1579	1588		|O
inhibition	1589	1599		|O
of	1600	1602		|O
the	1603	1606		|O
H2O2	1607	1611		|O
-	1611	1612		|O
activated	1612	1621		|O
release	1622	1629		|O
of	1630	1632		|O
PGE2	1633	1637		|O
,	1637	1638		|O
IL	1639	1641		|O
-	1641	1642		|O
6	1642	1643		|O
,	1643	1644		|O
and	1645	1648		|O
IL	1649	1651		|O
-	1651	1652		|O
8	1652	1653		|O
in	1654	1656		|O
human	1657	1662		|O
normal	1663	1669		|O
fibroblast	1670	1680		|O
cell	1681	1685		|O
lines	1686	1691		|O
,	1691	1692		|O
the	1693	1696		|O
release	1697	1704		|O
of	1705	1707		|O
PGE2	1708	1712		|O
and	1713	1716		|O
IL	1717	1719		|O
-	1719	1720		|O
6	1720	1721		|O
was	1722	1725		|O
almost	1726	1732		|O
completely	1733	1743		|O
inhibited	1744	1753		|O
above	1754	1759		|O
concentrations	1760	1774		|O
of	1775	1777		|O
0.05%	1778	1783		|O
and	1784	1787		|O
1%	1788	1790		|O
,	1790	1791		|O
respectively	1792	1804		|O
.	1804	1805		|O
Moreover	1806	1814		|O
,	1814	1815		|O
the	1816	1819		|O
release	1820	1827		|O
of	1828	1830		|O
IL	1831	1833		|O
-	1833	1834		|O
8	1834	1835		|O
was	1836	1839		|O
completely	1840	1850		|O
inhibited	1851	1860		|O
over	1861	1865		|O
the	1866	1869		|O
entire	1870	1876		|O
range	1877	1882		|O
of	1883	1885		|O
concentration	1886	1899		|O
(	1900	1901		|O
>	1901	1902		|O
0.0025%	1902	1909		|O
)	1909	1910		|O
.	1910	1911		|O
In	1912	1914		|O
order	1915	1920		|O
to	1921	1923		|O
investigate	1924	1935		|O
the	1936	1939		|O
skin	1940	1944		|O
-	1944	1945		|O
sensitizing	1945	1956		|O
potentials	1957	1967		|O
of	1968	1970		|O
the	1971	1974		|O
extract	1975	1982		|O
of	1983	1985		|O
Crinum	1986	1992		|O
asiaticum	1993	2002		|O
,	2002	2003		|O
a	2004	2005		|O
human	2006	2011		|O
clinical	2012	2020		|O
test	2021	2025		|O
was	2026	2029		|O
performed	2030	2039		|O
after	2040	2045		|O
repeated	2046	2054		|O
epicutaneous	2055	2067		|O
48	2068	2070		|O
-	2070	2071		|O
h	2071	2072		|O
applications	2073	2085		|O
under	2086	2091		|O
an	2092	2094		|O
occlusive	2095	2104		|O
patch	2105	2110		|O
(	2111	2112		|O
RIPT	2112	2116		|O
)	2116	2117		|O
.	2117	2118		|O
The	2119	2122		|O
repeated	2123	2131		|O
and	2132	2135		|O
single	2136	2142		|O
cutaneous	2143	2152		|O
applications	2153	2165		|O
of	2166	2168		|O
Crinum	2169	2175		|O
asiaticum	2176	2185		|O
Linne	2186	2191		|O
var	2192	2195		|O
.	2195	2196		|O
japonicum	2197	2206		|O
extract	2207	2214		|O
under	2215	2220		|O
the	2221	2224		|O
occlusive	2225	2234		|O
patch	2235	2240		|O
did	2241	2244		|O
not	2245	2248		|O
provoke	2249	2256		|O
any	2257	2260		|O
cumulative	2261	2271		|O
irritation	2272	2282		|O
and	2283	2286		|O
sensitization	2287	2300		|O
reactions	2301	2310		|O
.	2310	2311		|O
The	2312	2315		|O
result	2316	2322		|O
showed	2323	2329		|O
that	2330	2334		|O
the	2335	2338		|O
extract	2339	2346		|O
of	2347	2349		|O
Crinum	2350	2356		|O
asiaticum	2357	2366		|O
Linne	2367	2372		|O
var	2373	2376		|O
.	2376	2377		|O
japonicum	2378	2387		|O
has	2388	2391		|O
a	2392	2393		|O
sufficient	2394	2404		|O
anti	2405	2409		|O
-	2409	2410		|O
inflammatory	2410	2422		|O
effect	2423	2429		|O
.	2429	2430		|O
Therefore	2431	2440		|O
,	2440	2441		|O
Crinum	2442	2448		|O
asiaticum	2449	2458		|O
Linne	2459	2464		|O
var	2465	2468		|O
.	2468	2469		|O
japonicum	2470	2479		|O
extract	2480	2487		|O
may	2488	2491		|O
be	2492	2494		|O
useful	2495	2501		|O
for	2502	2505		|O
development	2506	2517		|O
as	2518	2520		|O
an	2521	2523		|O
ingredient	2524	2534		|O
in	2535	2537		|O
cosmetic	2538	2546		|O
products	2547	2555		|O
.	2555	2556		|O

### 18653899
Acute	0	5	Acute interstitial nephritis	|B-ADVERSE
interstitial	6	18		|I-ADVERSE
nephritis	19	28		|I-ADVERSE
due	29	32		|O
to	33	35		|O
deferasirox	36	47		|O
:	47	48		|O
a	49	50		|O
case	51	55		|O
report	56	62		|O
.	62	63		|O
Deferasirox	65	76		|O
is	77	79		|O
a	80	81		|O
new	82	85		|O
oral	86	90		|O
iron	91	95		|O
chelator	96	104		|O
used	105	109		|O
to	110	112		|O
treat	113	118		|O
transfusional	119	132	transfusional iron overload	|B-DISEASE
iron	133	137		|I-DISEASE
overload	138	146		|I-DISEASE
.	146	147		|O
Pre	148	151		|O
-	151	152		|O
marketing	152	161		|O
clinical	162	170		|O
trials	171	177		|O
revealed	178	186		|O
little	187	193		|O
organ	194	199	organ-specific toxicity	|B-ADVERSE
-	199	200		|I-ADVERSE
specific	200	208		|I-ADVERSE
toxicity	209	217		|I-ADVERSE
.	217	218		|O
Increases	219	228		|O
in	229	231		|O
serum	232	237		|O
creatinine	238	248		|O
were	249	253		|O
noted	254	259		|O
in	260	262		|O
one	263	266		|O
-	266	267		|O
third	267	272		|O
of	273	275		|O
patients	276	284		|O
but	285	288		|O
were	289	293		|O
mild	294	298		|O
and	299	302		|O
non	303	306		|O
-	306	307		|O
progressive	307	318		|O
.	318	319		|O
We	320	322		|O
describe	323	331		|O
a	332	333		|O
62	334	336		|O
-	336	337		|O
year	337	341		|O
-	341	342		|O
old	342	345		|O
man	346	349		|O
with	350	354		|O
myelodysplastic	355	370	myelodysplastic syndrome	|B-DISEASE
syndrome	371	379		|I-DISEASE
who	380	383		|O
developed	384	393		|O
a	394	395		|O
progressive	396	407	progressive decline in renal function	|B-ADVERSE
decline	408	415		|I-ADVERSE
in	416	418		|I-ADVERSE
renal	419	424		|I-ADVERSE
function	425	433		|I-ADVERSE
after	434	439		|O
starting	440	448		|O
deferasirox	449	460		|O
.	460	461		|O
A	462	463		|O
kidney	464	470		|O
biopsy	471	477		|O
showed	478	484		|O
acute	485	490	acute interstitial nephritis	|B-ADVERSE
interstitial	491	503		|I-ADVERSE
nephritis	504	513		|I-ADVERSE
with	514	518		|O
increased	519	528		|O
eosinophils	529	540	eosinophils	|B-ADVERSE
,	540	541		|O
suggesting	542	552		|O
drug	553	557	drug hypersensitivity	|B-ADVERSE
hypersensitivity	558	574		|I-ADVERSE
.	574	575		|O
Deferasirox	576	587		|O
was	588	591		|O
discontinued	592	604		|O
and	605	608		|O
renal	609	614		|O
function	615	623		|O
returned	624	632		|O
to	633	635		|O
baseline	636	644		|O
.	644	645		|O
This	646	650		|O
is	651	653		|O
the	654	657		|O
first	658	663		|O
pathological	664	676		|O
description	677	688		|O
of	689	691		|O
deferasirox	692	703		|O
-	703	704		|O
related	704	711		|O
acute	712	717	acute kidney injury	|B-ADVERSE
kidney	718	724		|I-ADVERSE
injury	725	731		|I-ADVERSE
in	732	734		|O
humans	735	741		|O
,	741	742		|O
which	743	748		|O
differs	749	756		|O
from	757	761		|O
tubular	762	769		|O
vacuolization	770	783		|O
observed	784	792		|O
in	793	795		|O
animals	796	803		|O
.	803	804		|O

### 18787912
Gluten	0	6	Gluten ataxia	|B-DISEASE
ataxia	7	13		|I-DISEASE
.	13	14		|O
Gluten	16	22	Gluten ataxia	|B-DISEASE
ataxia	23	29		|I-DISEASE
is	30	32		|O
an	33	35		|O
immune	36	42		|O
-	42	43		|O
mediated	43	51		|O
disease	52	59		|O
triggered	60	69		|O
by	70	72		|O
the	73	76		|O
ingestion	77	86		|O
of	87	89		|O
gluten	90	96		|O
in	97	99		|O
genetically	100	111		|O
susceptible	112	123		|O
individuals	124	135		|O
.	135	136		|O
It	137	139		|O
should	140	146		|O
be	147	149		|O
considered	150	160		|O
in	161	163		|O
the	164	167		|O
differential	168	180		|O
diagnosis	181	190		|O
of	191	193		|O
all	194	197		|O
patients	198	206		|O
with	207	211		|O
idiopathic	212	222	idiopathic sporadic ataxia	|B-DISEASE
sporadic	223	231		|I-DISEASE
ataxia	232	238		|I-DISEASE
.	238	239		|O
Early	240	245		|O
diagnosis	246	255		|O
and	256	259		|O
treatment	260	269		|O
with	270	274		|O
a	275	276		|O
gluten	277	283		|O
free	284	288		|O
diet	289	293		|O
can	294	297		|O
improve	298	305		|O
ataxia	306	312	ataxia	|B-DISEASE
and	313	316		|O
prevent	317	324		|O
its	325	328		|O
progression	329	340		|O
.	340	341		|O
Readily	342	349		|O
available	350	359		|O
and	360	363		|O
sensitive	364	373		|O
markers	374	381		|O
of	382	384		|O
gluten	385	391	gluten ataxia	|B-DISEASE
ataxia	392	398		|I-DISEASE
include	399	406		|O
antigliadin	407	418		|O
antibodies	419	429		|O
.	429	430		|O
IgA	431	434		|O
deposits	435	443		|O
against	444	451		|O
TG2	452	455		|O
in	456	458		|O
the	459	462		|O
small	463	468		|O
bowel	469	474		|O
and	475	478		|O
at	479	481		|O
extraintestinal	482	497		|O
sites	498	503		|O
are	504	507		|O
proving	508	515		|O
to	516	518		|O
be	519	521		|O
additional	522	532		|O
reliable	533	541		|O
and	542	545		|O
perhaps	546	553		|O
more	554	558		|O
specific	559	567		|O
markers	568	575		|O
of	576	578		|O
the	579	582		|O
whole	583	588		|O
spectrum	589	597		|O
of	598	600		|O
gluten	601	607		|O
sensitivity	608	619		|O
.	619	620		|O
They	621	625		|O
may	626	629		|O
also	630	634		|O
hold	635	639		|O
the	640	643		|O
key	644	647		|O
to	648	650		|O
its	651	654		|O
pathogenesis	655	667		|O
.	667	668		|O

### 18769484
Effect	0	6		|O
of	7	9		|O
the	10	13		|O
frequency	14	23		|O
of	24	26		|O
self	27	31		|O
-	31	32		|O
monitoring	32	42		|O
blood	43	48		|O
glucose	49	56		|O
in	57	59		|O
patients	60	68		|O
with	69	73		|O
type	74	78	type 2 diabetes	|B-DISEASE
2	79	80		|I-DISEASE
diabetes	81	89		|I-DISEASE
treated	90	97		|O
with	98	102		|O
oral	103	107		|O
antidiabetic	108	120		|O
drugs	121	126		|O
-	126	127		|O
a	127	128		|O
multi	129	134		|O
-	134	135		|O
centre	135	141		|O
,	141	142		|O
randomized	143	153		|O
controlled	154	164		|O
trial	165	170		|O
.	170	171		|O
OBJECTIVE	173	182		|O
:	182	183		|O
Recommendations	184	199		|O
on	200	202		|O
the	203	206		|O
frequency	207	216		|O
of	217	219		|O
self	220	224		|O
-	224	225		|O
monitoring	225	235		|O
of	236	238		|O
blood	239	244		|O
glucose	245	252		|O
(	253	254		|O
SMBG	254	258		|O
)	258	259		|O
vary	260	264		|O
widely	265	271		|O
among	272	277		|O
physicians	278	288		|O
treating	289	297		|O
patients	298	306		|O
with	307	311		|O
type	312	316	type 2 diabetes	|B-DISEASE
2	317	318		|I-DISEASE
diabetes	319	327		|I-DISEASE
(	328	329		|O
T2D	329	332	T2D	|B-DISEASE
)	332	333		|O
.	333	334		|O
Aim	335	338		|O
of	339	341		|O
this	342	346		|O
study	347	352		|O
was	353	356		|O
to	357	359		|O
investigate	360	371		|O
two	372	375		|O
testing	376	383		|O
regimen	384	391		|O
of	392	394		|O
SMBG	395	399		|O
in	400	402		|O
patients	403	411		|O
with	412	416		|O
stable	417	423		|O
metabolic	424	433		|O
control	434	441		|O
.	441	442		|O
RESEARCH	443	451		|O
DESIGN	452	458		|O
AND	459	462		|O
METHODS	463	470		|O
:	470	471		|O
Patients	472	480		|O
with	481	485		|O
T2D	486	489	T2D	|B-DISEASE
treated	490	497		|O
with	498	502		|O
oral	503	507		|O
antidiabetic	508	520		|O
drugs	521	526		|O
were	527	531		|O
randomized	532	542		|O
to	543	545		|O
two	546	549		|O
groups	550	556		|O
:	556	557		|O
either	558	564		|O
one	565	568		|O
SMBG	569	573		|O
(	574	575		|O
low	575	578		|O
)	578	579		|O
or	580	582		|O
four	583	587		|O
SMBG	588	592		|O
(	593	594		|O
high	594	598		|O
)	598	599		|O
per	600	603		|O
week	604	608		|O
.	608	609		|O
Subjects	610	618		|O
were	619	623		|O
followed	624	632		|O
up	633	635		|O
after	636	641		|O
3	642	643		|O
,	643	644		|O
6	645	646		|O
and	647	650		|O
12	651	653		|O
months	654	660		|O
.	660	661		|O
Primary	662	669		|O
outcome	670	677		|O
parameter	678	687		|O
was	688	691		|O
the	692	695		|O
change	696	702		|O
in	703	705		|O
HbA1c	706	711		|O
between	712	719		|O
baseline	720	728		|O
and	729	732		|O
6	733	734		|O
months	735	741		|O
.	741	742		|O
Primary	743	750		|O
outcome	751	758		|O
criterion	759	768		|O
was	769	772		|O
tested	773	779		|O
by	780	782		|O
a	783	784		|O
one	785	788		|O
-	788	789		|O
sided	789	794		|O
t	795	796		|O
-	796	797		|O
test	798	802		|O
for	803	806		|O
non	807	810		|O
-	810	811		|O
inferiority	812	823		|O
.	823	824		|O
Secondary	825	834		|O
outcome	835	842		|O
parameters	843	853		|O
were	854	858		|O
safety	859	865		|O
,	865	866		|O
compliance	867	877		|O
and	878	881		|O
HbA1c	882	887		|O
at	888	890		|O
3	891	892		|O
and	893	896		|O
12	897	899		|O
months	900	906		|O
.	906	907		|O
RESULTS	908	915		|O
:	915	916		|O
There	917	922		|O
were	923	927		|O
no	928	930		|O
differences	931	942		|O
in	943	945		|O
the	946	949		|O
202	950	953		|O
subjects	954	962		|O
for	963	966		|O
demographic	967	978		|O
and	979	982		|O
sociodemographic	983	999		|O
parameters	1000	1010		|O
and	1011	1014		|O
drug	1015	1019		|O
treatment	1020	1029		|O
.	1029	1030		|O
HbA	1031	1034		|O
(	1034	1035		|O
1	1035	1036		|O
)	1036	1037		|O
c	1037	1038		|O
(	1039	1040		|O
%	1040	1041		|O
)	1041	1042		|O
at	1043	1045		|O
baseline	1046	1054		|O
was	1055	1058		|O
similar	1059	1066		|O
in	1067	1069		|O
both	1070	1074		|O
groups	1075	1081		|O
(	1082	1083		|O
7.2	1083	1086		|O
+	1086	1087		|O
/	1087	1088		|O
-	1088	1089		|O
1.4	1089	1092		|O
vs.	1093	1096		|O
7.2	1097	1100		|O
+	1100	1101		|O
/	1101	1102		|O
-	1102	1103		|O
1.0	1103	1106		|O
)	1106	1107		|O
.	1107	1108		|O
Non	1109	1112		|O
-	1112	1113		|O
inferiority	1114	1125		|O
was	1126	1129		|O
demonstrated	1130	1142		|O
for	1143	1146		|O
the	1147	1150		|O
low	1151	1154		|O
group	1155	1160		|O
(	1161	1162		|O
p	1162	1163		|O
=	1164	1165		|O
0.0022	1166	1172		|O
)	1172	1173		|O
with	1174	1178		|O
a	1179	1180		|O
difference	1181	1191		|O
from	1192	1196		|O
baseline	1197	1205		|O
to	1206	1208		|O
6	1209	1210		|O
months	1211	1217		|O
of	1218	1220		|O
0.24	1221	1225		|O
in	1226	1228		|O
the	1229	1232		|O
low	1233	1236		|O
and	1237	1240		|O
of	1241	1243		|O
0.16	1244	1248		|O
in	1249	1251		|O
the	1252	1255		|O
high	1256	1260		|O
group	1261	1266		|O
.	1266	1267		|O
Compliance	1268	1278		|O
with	1279	1283		|O
the	1284	1287		|O
testing	1288	1295		|O
regimen	1296	1303		|O
was	1304	1307		|O
82-90%	1308	1314		|O
in	1315	1317		|O
both	1318	1322		|O
groups	1323	1329		|O
.	1329	1330		|O
There	1331	1336		|O
were	1337	1341		|O
no	1342	1344		|O
statistical	1345	1356		|O
significant	1357	1368		|O
differences	1369	1380		|O
for	1381	1384		|O
compliance	1385	1395		|O
,	1395	1396		|O
HbA	1397	1400		|O
(	1400	1401		|O
1	1401	1402		|O
)	1402	1403		|O
c	1403	1404		|O
at	1405	1407		|O
3	1408	1409		|O
and	1410	1413		|O
12	1414	1416		|O
months	1417	1423		|O
and	1424	1427		|O
serious	1428	1435		|O
adverse	1436	1443		|O
events	1444	1450		|O
(	1451	1452		|O
SAE	1452	1455		|O
)	1455	1456		|O
.	1456	1457		|O
CONCLUSION	1458	1468		|O
:	1468	1469		|O
One	1470	1473		|O
SMBG	1474	1478		|O
per	1479	1482		|O
week	1483	1487		|O
is	1488	1490		|O
as	1491	1493		|O
sufficient	1494	1504		|O
and	1505	1508		|O
safe	1509	1513		|O
as	1514	1516		|O
four	1517	1521		|O
SMBG	1522	1526		|O
per	1527	1530		|O
week	1531	1535		|O
to	1536	1538		|O
maintain	1539	1547		|O
HbA	1548	1551		|O
(	1551	1552		|O
1	1552	1553		|O
)	1553	1554		|O
c	1554	1555		|O
in	1556	1558		|O
non	1559	1562		|O
-	1562	1563		|O
insulin	1563	1570		|O
treated	1571	1578		|O
T2D	1579	1582	T2D	|B-DISEASE
close	1583	1588		|O
to	1589	1591		|O
metabolic	1592	1601		|O
target	1602	1608		|O
.	1608	1609		|O
The	1610	1613		|O
results	1614	1621		|O
of	1622	1624		|O
this	1625	1629		|O
study	1630	1635		|O
are	1636	1639		|O
in	1640	1642		|O
contrast	1643	1651		|O
to	1652	1654		|O
current	1655	1662		|O
international	1663	1676		|O
consensus	1677	1686		|O
guidelines	1687	1697		|O
.	1697	1698		|O
TRIAL	1699	1704		|O
REGISTRATION	1705	1717		|O
:	1717	1718		|O
Controlled	1719	1729		|O
-	1729	1730		|O
Trials	1730	1736		|O
.	1736	1737		|O
com	1737	1740		|O
ISRCTN79164268	1741	1755		|O
.	1755	1756		|O

### 18949461
Studies	0	7		|O
of	8	10		|O
pharmacokinetic	11	26		|O
and	27	30		|O
pharmacodynamic	31	46		|O
properties	47	57		|O
of	58	60		|O
isoallopregnanolone	61	80		|O
in	81	83		|O
healthy	84	91		|O
women	92	97		|O
.	97	98		|O
RATIONALE	100	109		|O
:	109	110		|O
The	111	114		|O
pharmacokinetics	115	131		|O
and	132	135		|O
behavioral	136	146		|O
effects	147	154		|O
of	155	157		|O
isoallopregnanolone	158	177		|O
(	178	179		|O
3beta	179	184		|O
-	184	185		|O
hydoxy	185	191		|O
-	191	192		|O
5alpha	192	198		|O
-	198	199		|O
pregnan	199	206		|O
-	206	207		|O
20	207	209		|O
-	209	210		|O
one	210	213		|O
)	213	214		|O
in	215	217		|O
women	218	223		|O
are	224	227		|O
not	228	231		|O
known	232	237		|O
.	237	238		|O
OBJECTIVES	239	249		|O
:	249	250		|O
Allopregnanolone	251	267		|O
(	268	269		|O
3alpha	269	275		|O
-	275	276		|O
hydoxy	276	282		|O
-	282	283		|O
5alpha	283	289		|O
-	289	290		|O
pregnan	290	297		|O
-	297	298		|O
20	298	300		|O
-	300	301		|O
one	301	304		|O
)	304	305		|O
is	306	308		|O
a	309	310		|O
well	311	315		|O
-	315	316		|O
known	316	321		|O
neurosteroid	322	334		|O
,	334	335		|O
acting	336	342		|O
via	343	346		|O
the	347	350		|O
GABA	351	355		|O
(	355	356		|O
A	356	357		|O
)	357	358		|O
receptor	359	367		|O
in	368	370		|O
the	371	374		|O
human	375	380		|O
brain	381	386		|O
.	386	387		|O
The	388	391		|O
naturally	392	401		|O
occurring	402	411		|O
progesterone	412	424		|O
metabolite	425	435		|O
isoallopregnanolone	436	455		|O
is	456	458		|O
the	459	462		|O
3beta	463	468		|O
-	468	469		|O
stereoisomer	469	481		|O
of	482	484		|O
allopregnanolone	485	501		|O
.	501	502		|O
Prior	503	508		|O
studies	509	516		|O
have	517	521		|O
concluded	522	531		|O
that	532	536		|O
isoallopregnanolone	537	556		|O
has	557	560		|O
no	561	563		|O
effect	564	570		|O
on	571	573		|O
the	574	577		|O
GABA	578	582		|O
(	582	583		|O
A	583	584		|O
)	584	585		|O
receptor	586	594		|O
.	594	595		|O
However	596	603		|O
,	603	604		|O
an	605	607		|O
antagonistic	608	620		|O
effect	621	627		|O
of	628	630		|O
isoallopregnanolone	631	650		|O
to	651	653		|O
allopregnanolone	654	670		|O
on	671	673		|O
the	674	677		|O
GABA	678	682		|O
(	682	683		|O
A	683	684		|O
)	684	685		|O
receptor	686	694		|O
has	695	698		|O
been	699	703		|O
shown	704	709		|O
in	710	712		|O
animal	713	719		|O
and	720	723		|O
in	724	726		|O
vitro	727	732		|O
studies	733	740		|O
.	740	741		|O
The	742	745		|O
purpose	746	753		|O
of	754	756		|O
this	757	761		|O
study	762	767		|O
was	768	771		|O
to	772	774		|O
evaluate	775	783		|O
the	784	787		|O
pharmacokinetics	788	804		|O
and	805	808		|O
behavioral	809	819		|O
effects	820	827		|O
of	828	830		|O
isoallopregnanolone	831	850		|O
in	851	853		|O
humans	854	860		|O
.	860	861		|O
MATERIALS	862	871		|O
AND	872	875		|O
METHODS	876	883		|O
:	883	884		|O
Six	885	888		|O
healthy	889	896		|O
women	897	902		|O
were	903	907		|O
given	908	913		|O
three	914	919		|O
increasing	920	930		|O
doses	931	936		|O
of	937	939		|O
isoallopregnanolone	940	959		|O
intravenously	960	973		|O
in	974	976		|O
the	977	980		|O
follicular	981	991		|O
phase	992	997		|O
.	997	998		|O
Repeated	999	1007		|O
blood	1008	1013		|O
samples	1014	1021		|O
for	1022	1025		|O
analyses	1026	1034		|O
of	1035	1037		|O
isoallopregnanolone	1038	1057		|O
and	1058	1061		|O
allopregnanolone	1062	1078		|O
concentrations	1079	1093		|O
were	1094	1098		|O
drawn	1099	1104		|O
.	1104	1105		|O
Saccadic	1106	1114		|O
eye	1115	1118		|O
movement	1119	1127		|O
variables	1128	1137		|O
,	1137	1138		|O
self	1139	1143		|O
-	1143	1144		|O
rated	1144	1149		|O
sedation	1150	1158		|O
,	1158	1159		|O
and	1160	1163		|O
mood	1164	1168		|O
rating	1169	1175		|O
scales	1176	1182		|O
were	1183	1187		|O
used	1188	1192		|O
during	1193	1199		|O
the	1200	1203		|O
test	1204	1208		|O
day	1209	1212		|O
.	1212	1213		|O
A	1214	1215		|O
Likert	1216	1222		|O
scale	1223	1228		|O
for	1229	1232		|O
prospective	1233	1244		|O
symptoms	1245	1253		|O
was	1254	1257		|O
used	1258	1262		|O
to	1263	1265		|O
measure	1266	1273		|O
daily	1274	1279		|O
fluctuations	1280	1292		|O
during	1293	1299		|O
the	1300	1303		|O
ongoing	1304	1311		|O
menstrual	1312	1321		|O
cycle	1322	1327		|O
.	1327	1328		|O
RESULTS	1329	1336		|O
:	1336	1337		|O
Exogenously	1338	1349		|O
administered	1350	1362		|O
isoallopregnanolone	1363	1382		|O
produced	1383	1391		|O
a	1392	1393		|O
dose	1394	1398		|O
-	1398	1399		|O
dependent	1399	1408		|O
increase	1409	1417		|O
in	1418	1420		|O
the	1421	1424		|O
serum	1425	1430		|O
concentration	1431	1444		|O
of	1445	1447		|O
isoallopregnanolone	1448	1467		|O
.	1467	1468		|O
In	1469	1471		|O
parallel	1472	1480		|O
,	1480	1481		|O
there	1482	1487		|O
was	1488	1491		|O
also	1492	1496		|O
a	1497	1498		|O
rise	1499	1503		|O
in	1504	1506		|O
the	1507	1510		|O
allopregnanolone	1511	1527		|O
concentration	1528	1541		|O
.	1541	1542		|O
There	1543	1548		|O
was	1549	1552		|O
a	1553	1554		|O
decrease	1555	1563		|O
in	1564	1566		|O
saccadic	1567	1575		|O
eye	1576	1579		|O
movement	1580	1588		|O
variables	1589	1598		|O
,	1598	1599		|O
but	1600	1603		|O
no	1604	1606		|O
effect	1607	1613		|O
was	1614	1617		|O
found	1618	1623		|O
on	1624	1626		|O
self	1627	1631		|O
-	1631	1632		|O
rated	1632	1637		|O
sedation	1638	1646		|O
or	1647	1649		|O
mood	1650	1654		|O
and	1655	1658		|O
no	1659	1661		|O
changes	1662	1669		|O
were	1670	1674		|O
seen	1675	1679		|O
in	1680	1682		|O
prospective	1683	1694		|O
symptoms	1695	1703		|O
during	1704	1710		|O
the	1711	1714		|O
menstrual	1715	1724		|O
cycle	1725	1730		|O
.	1730	1731		|O
CONCLUSIONS	1732	1743		|O
:	1743	1744		|O
After	1745	1750		|O
administration	1751	1765		|O
of	1766	1768		|O
isoallopregnanolone	1769	1788		|O
at	1789	1791		|O
a	1792	1793		|O
cumulative	1794	1804		|O
dose	1805	1809		|O
of	1810	1812		|O
0.20	1813	1817		|O
mg	1818	1820		|O
/	1820	1821		|O
kg	1821	1823		|O
,	1823	1824		|O
no	1825	1827		|O
adverse	1828	1835		|O
effects	1836	1843		|O
were	1844	1848		|O
observed	1849	1857		|O
.	1857	1858		|O
There	1859	1864		|O
is	1865	1867		|O
a	1868	1869		|O
metabolism	1870	1880		|O
of	1881	1883		|O
isoallopregnanolone	1884	1903		|O
to	1904	1906		|O
allopregnanolone	1907	1923		|O
,	1923	1924		|O
most	1925	1929		|O
likely	1930	1936		|O
explaining	1937	1947		|O
the	1948	1951		|O
effects	1952	1959		|O
on	1960	1962		|O
the	1963	1966		|O
saccadic	1967	1975		|O
eye	1976	1979		|O
movements	1980	1989		|O
.	1989	1990		|O

### 18640204
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
l	29	30		|O
-	30	31		|O
borneol	31	38		|O
.	38	39		|O
A	41	42		|O
toxicologic	43	54		|O
and	55	58		|O
dermatologic	59	71		|O
review	72	78		|O
of	79	81		|O
l	82	83		|O
-	83	84		|O
borneol	84	91		|O
when	92	96		|O
used	97	101		|O
as	102	104		|O
a	105	106		|O
fragrance	107	116		|O
ingredient	117	127		|O
is	128	130		|O
presented	131	140		|O
.	140	141		|O

### 18636399
In	0	2		|O
vitro	3	8		|O
evaluation	9	19		|O
of	20	22		|O
the	23	26		|O
chemoprotective	27	42		|O
action	43	49		|O
mechanisms	50	60		|O
of	61	63		|O
leontopodic	64	75		|O
acid	76	80		|O
against	81	88		|O
aflatoxin	89	98		|O
B1	99	101		|O
and	102	105		|O
deoxynivalenol	106	120		|O
-	120	121		|O
induced	121	128		|O
cell	129	133		|O
damage	134	140		|O
.	140	141		|O
Several	143	150		|O
in	151	153		|O
vitro	154	159		|O
studies	160	167		|O
showed	168	174		|O
that	175	179		|O
free	180	184		|O
radical	185	192		|O
scavengers	193	203		|O
possess	204	211		|O
chemopreventive	212	227		|O
properties	228	238		|O
against	239	246		|O
mycotoxin	247	256		|O
-	256	257		|O
induced	257	264		|O
cell	265	269		|O
damage	270	276		|O
which	277	282		|O
are	283	286		|O
at	287	289		|O
least	290	295		|O
partially	296	305		|O
associated	306	316		|O
with	317	321		|O
the	322	325		|O
induction	326	335		|O
of	336	338		|O
phase	339	344		|O
II	345	347		|O
detoxifying	348	359		|O
enzymes	360	367		|O
and	368	371		|O
antioxidant	372	383		|O
enzymes	384	391		|O
like	392	396		|O
glutathione	397	408		|O
S	409	410		|O
-	410	411		|O
transferase	411	422		|O
(	423	424		|O
GST	424	427		|O
)	427	428		|O
and	429	432		|O
glutathione	433	444		|O
peroxidase	445	455		|O
(	456	457		|O
GPx	457	460		|O
)	460	461		|O
.	461	462		|O
The	463	466		|O
aim	467	470		|O
of	471	473		|O
this	474	478		|O
project	479	486		|O
was	487	490		|O
to	491	493		|O
study	494	499		|O
the	500	503		|O
chemopreventive	504	519		|O
effects	520	527		|O
of	528	530		|O
leontopodic	531	542		|O
acid	543	547		|O
(	548	549		|O
LA	549	551		|O
)	551	552		|O
,	552	553		|O
a	554	555		|O
potent	556	562		|O
natural	563	570		|O
occurring	571	580		|O
free	581	585		|O
radical	586	593		|O
scavenger	594	603		|O
isolated	604	612		|O
from	613	617		|O
the	618	621		|O
aerial	622	628		|O
parts	629	634		|O
of	635	637		|O
Leontopodium	638	650		|O
alpinum	651	658		|O
.	658	659		|O
Different	660	669		|O
mycotoxins	670	680		|O
were	681	685		|O
evaluated	686	695		|O
in	696	698		|O
two	699	702		|O
different	703	712		|O
cell	713	717		|O
lines	718	723		|O
on	724	726		|O
the	727	730		|O
basis	731	736		|O
of	737	739		|O
their	740	745		|O
specific	746	754		|O
toxicity	755	763		|O
:	763	764		|O
aflatoxin	765	774		|O
B1	775	777		|O
(	778	779		|O
AFB1	779	783		|O
)	783	784		|O
on	785	787		|O
HepG2	788	793		|O
cells	794	799		|O
and	800	803		|O
deoxynivalenol	804	818		|O
(	819	820		|O
DON	820	823		|O
)	823	824		|O
on	825	827		|O
U937	828	832		|O
cells	833	838		|O
.	838	839		|O
Cell	840	844		|O
viability	845	854		|O
and	855	858		|O
reactive	859	867		|O
oxygen	868	874		|O
species	875	882		|O
concentration	883	896		|O
were	897	901		|O
determined	902	912		|O
,	912	913		|O
and	914	917		|O
the	918	921		|O
effects	922	929		|O
of	930	932		|O
pre	933	936		|O
-	936	937		|O
treatment	937	946		|O
with	947	951		|O
LA	952	954		|O
on	955	957		|O
these	958	963		|O
parameters	964	974		|O
were	975	979		|O
investigated	980	992		|O
together	993	1001		|O
with	1002	1006		|O
the	1007	1010		|O
GST	1011	1014		|O
and	1015	1018		|O
GPx	1019	1022		|O
activity	1023	1031		|O
as	1032	1034		|O
well	1035	1039		|O
as	1040	1042		|O
the	1043	1046		|O
concentration	1047	1060		|O
of	1061	1063		|O
reduced	1064	1071		|O
glutathione	1072	1083		|O
.	1083	1084		|O
The	1085	1088		|O
results	1089	1096		|O
show	1097	1101		|O
that	1102	1106		|O
LA	1107	1109		|O
protects	1110	1118		|O
U937	1119	1123		|O
cells	1124	1129		|O
from	1130	1134		|O
DON	1135	1138		|O
-	1138	1139		|O
induced	1139	1146		|O
cell	1147	1151		|O
damage	1152	1158		|O
but	1159	1162		|O
not	1163	1166		|O
HepG2	1167	1172		|O
cells	1173	1178		|O
from	1179	1183		|O
AFB1	1184	1188		|O
.	1188	1189		|O
Moreover	1190	1198		|O
LA	1199	1201		|O
is	1202	1204		|O
able	1205	1209		|O
to	1210	1212		|O
enhance	1213	1220		|O
GPx	1221	1224		|O
activity	1225	1233		|O
in	1234	1236		|O
U937	1237	1241		|O
,	1241	1242		|O
but	1243	1246		|O
not	1247	1250		|O
GST	1251	1254		|O
activity	1255	1263		|O
in	1264	1266		|O
HepG2	1267	1272		|O
.	1272	1273		|O
We	1274	1276		|O
hypothesize	1277	1288		|O
that	1289	1293		|O
the	1294	1297		|O
increase	1298	1306		|O
in	1307	1309		|O
detoxifying	1310	1321		|O
enzymes	1322	1329		|O
is	1330	1332		|O
probably	1333	1341		|O
the	1342	1345		|O
main	1346	1350		|O
mechanism	1351	1360		|O
of	1361	1363		|O
antioxidant	1364	1375		|O
mediated	1376	1384		|O
chemoprevention	1385	1400		|O
.	1400	1401		|O

### 18671470
Sibutramine	0	11		|O
:	11	12		|O
current	13	20		|O
status	21	27		|O
as	28	30		|O
an	31	33		|O
anti	34	38		|O
-	38	39		|O
obesity	39	46		|O
drug	47	51		|O
and	52	55		|O
its	56	59		|O
future	60	66		|O
perspectives	67	79		|O
.	79	80		|O
BACKGROUND	82	92		|O
:	92	93		|O
Obesity	94	101	Obesity	|B-DISEASE
has	102	105		|O
become	106	112		|O
a	113	114		|O
global	115	121		|O
epidemic	122	130		|O
with	131	135		|O
recent	136	142		|O
estimates	143	152		|O
of	153	155		|O
>	156	157		|O
400	158	161		|O
million	162	169		|O
obese	170	175		|O
adults	176	182		|O
.	182	183		|O
Despite	184	191		|O
this	192	196		|O
,	196	197		|O
there	198	203		|O
are	204	207		|O
few	208	211		|O
safe	212	216		|O
and	217	220		|O
effective	221	230		|O
pharmacological	231	246		|O
interventions	247	260		|O
for	261	264		|O
obesity	265	272	obesity	|B-DISEASE
.	272	273		|O
Sibutramine	274	285		|O
is	286	288		|O
a	289	290		|O
weight	291	297		|O
loss	298	302		|O
agent	303	308		|O
,	308	309		|O
for	310	313		|O
use	314	317		|O
as	318	320		|O
an	321	323		|O
adjuvant	324	332		|O
to	333	335		|O
a	336	337		|O
comprehensive	338	351		|O
program	352	359		|O
of	360	362		|O
calorie	363	370		|O
restriction	371	382		|O
,	382	383		|O
exercise	384	392		|O
and	393	396		|O
behavioral	397	407		|O
therapy	408	415		|O
.	415	416		|O
OBJECTIVE	417	426		|O
:	426	427		|O
The	428	431		|O
goal	432	436		|O
of	437	439		|O
this	440	444		|O
article	445	452		|O
is	453	455		|O
to	456	458		|O
review	459	465		|O
the	466	469		|O
available	470	479		|O
literature	480	490		|O
of	491	493		|O
pharmacological	494	509		|O
interventions	510	523		|O
for	524	527		|O
obesity	528	535	obesity	|B-DISEASE
and	536	539		|O
specifically	540	552		|O
to	553	555		|O
examine	556	563		|O
data	564	568		|O
with	569	573		|O
sibutramine	574	585		|O
for	586	589		|O
the	590	593		|O
short	594	599		|O
term	600	604		|O
on	605	607		|O
safety	608	614		|O
and	615	618		|O
efficacy	619	627		|O
for	628	631		|O
weight	632	638		|O
loss	639	643		|O
.	643	644		|O
METHODS	645	652		|O
:	652	653		|O
The	654	657		|O
literature	658	668		|O
on	669	671		|O
sibutramine	672	683		|O
was	684	687		|O
reviewed	688	696		|O
after	697	702		|O
a	703	704		|O
PubMed	705	711		|O
and	712	715		|O
Medline	716	723		|O
search	724	730		|O
in	731	733		|O
March	734	739		|O
2008	740	744		|O
.	744	745		|O
All	746	749		|O
randomized	750	760		|O
clinical	761	769		|O
trails	770	776		|O
were	777	781		|O
reviewed	782	790		|O
.	790	791		|O
RESULTS	792	799		|O
/	799	800		|O
CONCLUSIONS	800	811		|O
:	811	812		|O
Sibutramine	813	824		|O
appears	825	832		|O
to	833	835		|O
be	836	838		|O
safe	839	843		|O
and	844	847		|O
effective	848	857		|O
in	858	860		|O
producing	861	870		|O
clinically	871	881		|O
significant	882	893		|O
weight	894	900		|O
loss	901	905		|O
for	906	909		|O
up	910	912		|O
to	913	915		|O
1	916	917		|O
year	918	922		|O
.	922	923		|O
Longer	924	930		|O
prospective	931	942		|O
clinical	943	951		|O
studies	952	959		|O
with	960	964		|O
sibutramine	965	976		|O
are	977	980		|O
needed	981	987		|O
to	988	990		|O
evaluate	991	999		|O
its	1000	1003		|O
safety	1004	1010		|O
(	1011	1012		|O
effect	1012	1018		|O
on	1019	1021		|O
blood	1022	1027		|O
pressure	1028	1036		|O
)	1036	1037		|O
and	1038	1041		|O
ability	1042	1049		|O
to	1050	1052		|O
maintain	1053	1061		|O
weight	1062	1068		|O
loss	1069	1073		|O
,	1073	1074		|O
improve	1075	1082		|O
metabolic	1083	1092		|O
profiles	1093	1101		|O
and	1102	1105		|O
reduce	1106	1112		|O
the	1113	1116		|O
risk	1117	1121		|O
of	1122	1124		|O
cardiovascular	1125	1139	cardiovascular diseases	|B-DISEASE
diseases	1140	1148		|I-DISEASE
.	1148	1149		|O

### 18626250
Bisphosphonate	0	14		|O
-	14	15		|O
induced	15	22		|O
necrosis	23	31	necrosis of the jaws	|B-ADVERSE
of	32	34		|I-ADVERSE
the	35	38		|I-ADVERSE
jaws	39	43		|I-ADVERSE
:	43	44		|O
a	45	46		|O
reconstructive	47	61		|O
nightmare	62	71		|O
.	71	72		|O
PURPOSE	74	81		|O
OF	82	84		|O
REVIEW	85	91		|O
:	91	92		|O
Bisphosphonates	93	108		|O
are	109	112		|O
used	113	117		|O
for	118	121		|O
the	122	125		|O
management	126	136		|O
of	137	139		|O
metastatic	140	150	metastatic bone disease	|B-DISEASE
bone	151	155		|I-DISEASE
disease	156	163		|I-DISEASE
,	163	164		|O
prevention	165	175		|O
and	176	179		|O
treatment	180	189		|O
of	190	192		|O
osteoporosis	193	205	osteoporosis	|B-DISEASE
and	206	209		|O
Paget	210	215	Paget's disease	|B-DISEASE
's	215	217		|I-DISEASE
disease	218	225		|I-DISEASE
of	226	228		|O
bone	229	233		|O
.	233	234		|O
An	235	237		|O
increasing	238	248		|O
number	249	255		|O
of	256	258		|O
reports	259	266		|O
have	267	271		|O
associated	272	282		|O
the	283	286		|O
use	287	290		|O
of	291	293		|O
bisphosphonates	294	309		|O
with	310	314		|O
the	315	318		|O
occurrence	319	329		|O
of	330	332		|O
osteoradionecrosis	333	351	osteoradionecrosis of the jaw	|B-ADVERSE
of	352	354		|I-ADVERSE
the	355	358		|I-ADVERSE
jaw	359	362		|I-ADVERSE
.	362	363		|O
The	364	367		|O
purpose	368	375		|O
of	376	378		|O
this	379	383		|O
review	384	390		|O
is	391	393		|O
to	394	396		|O
summarize	397	406		|O
the	407	410		|O
recent	411	417		|O
literature	418	428		|O
in	429	431		|O
this	432	436		|O
area	437	441		|O
,	441	442		|O
specifically	443	455		|O
focusing	456	464		|O
on	465	467		|O
its	468	471		|O
management	472	482		|O
.	482	483		|O
RECENT	484	490		|O
FINDINGS	491	499		|O
:	499	500		|O
Osteoradionecrosis	501	519	Osteoradionecrosis of the jaw	|B-ADVERSE
of	520	522		|I-ADVERSE
the	523	526		|I-ADVERSE
jaw	527	530		|I-ADVERSE
mostly	531	537		|O
results	538	545		|O
from	546	550		|O
the	551	554		|O
use	555	558		|O
of	559	561		|O
intravenous	562	573		|O
bisphosphonates	574	589		|O
for	590	593		|O
metastatic	594	604	metastatic bone disease	|B-DISEASE
bone	605	609		|I-DISEASE
disease	610	617		|I-DISEASE
and	618	621		|O
multiple	622	630	multiple myeloma	|B-DISEASE
myeloma	631	638		|I-DISEASE
;	638	639		|O
cases	640	645		|O
from	646	650		|O
oral	651	655		|O
treatment	656	665		|O
for	666	669		|O
osteoporosis	670	682	osteoporosis	|B-DISEASE
and	683	686		|O
Paget	687	692	Paget's disease	|B-DISEASE
's	692	694		|I-DISEASE
disease	695	702		|I-DISEASE
have	703	707		|O
also	708	712		|O
been	713	717		|O
reported	718	726		|O
.	726	727		|O
It	728	730		|O
mostly	731	737		|O
affects	738	745		|O
the	746	749		|O
posterior	750	759		|O
maxilla	760	767		|O
,	767	768		|O
followed	769	777		|O
by	778	780		|O
the	781	784		|O
posterior	785	794		|O
mandible	795	803		|O
.	803	804		|O
In	805	807		|O
more	808	812		|O
than	813	817		|O
half	818	822		|O
of	823	825		|O
the	826	829		|O
affected	830	838		|O
patients	839	847		|O
,	847	848		|O
there	849	854		|O
has	855	858		|O
been	859	863		|O
preceding	864	873		|O
dental	874	880	dental trauma	|B-DISEASE
trauma	881	887		|I-DISEASE
or	888	890		|O
procedure	891	900		|O
.	900	901		|O
Many	902	906		|O
treatment	907	916		|O
modalities	917	927		|O
have	928	932		|O
been	933	937		|O
attempted	938	947		|O
in	948	950		|O
order	951	956		|O
to	957	959		|O
limit	960	965		|O
disease	966	973		|O
progression	974	985		|O
.	985	986		|O
Conservative	987	999		|O
management	1000	1010		|O
with	1011	1015		|O
antibiotic	1016	1026		|O
therapy	1027	1034		|O
and	1035	1038		|O
mouthwashes	1039	1050		|O
seems	1051	1056		|O
to	1057	1059		|O
be	1060	1062		|O
most	1063	1067		|O
beneficial	1068	1078		|O
.	1078	1079		|O
Surgery	1080	1087		|O
should	1088	1094		|O
be	1095	1097		|O
reserved	1098	1106		|O
for	1107	1110		|O
refractory	1111	1121		|O
and	1122	1125		|O
symptomatic	1126	1137		|O
cases	1138	1143		|O
.	1143	1144		|O
SUMMARY	1145	1152		|O
:	1152	1153		|O
It	1154	1156		|O
is	1157	1159		|O
important	1160	1169		|O
for	1170	1173		|O
the	1174	1177		|O
reconstructive	1178	1192		|O
head	1193	1197		|O
and	1198	1201		|O
neck	1202	1206		|O
surgeon	1207	1214		|O
to	1215	1217		|O
recognize	1218	1227		|O
the	1228	1231		|O
clinical	1232	1240		|O
presentation	1241	1253		|O
of	1254	1256		|O
bisphosphonate	1257	1271		|O
-	1271	1272		|O
induced	1272	1279		|O
osteoradionecrosis	1280	1298	osteoradionecrosis of the jaw	|B-ADVERSE
of	1299	1301		|I-ADVERSE
the	1302	1305		|I-ADVERSE
jaw	1306	1309		|I-ADVERSE
and	1310	1313		|O
the	1314	1317		|O
role	1318	1322		|O
of	1323	1325		|O
conservative	1326	1338		|O
management	1339	1349		|O
in	1350	1352		|O
consistently	1353	1365		|O
achieving	1366	1375		|O
good	1376	1380		|O
results	1381	1388		|O
.	1388	1389		|O

### 18812562
Pharmacokinetic	0	15		|O
interaction	16	27		|O
between	28	35		|O
everolimus	36	46		|O
and	47	50		|O
antifungal	51	61		|O
triazoles	62	71		|O
in	72	74		|O
a	75	76		|O
liver	77	82		|O
transplant	83	93		|O
patient	94	101		|O
.	101	102		|O
OBJECTIVE	104	113		|O
:	113	114		|O
To	115	117		|O
describe	118	126		|O
the	127	130		|O
management	131	141		|O
of	142	144		|O
a	145	146		|O
pharmacokinetic	147	162		|O
interaction	163	174		|O
between	175	182		|O
azole	183	188		|O
antifungals	189	200		|O
(	201	202		|O
fluconazole	202	213		|O
and	214	217		|O
voriconazole	218	230		|O
)	230	231		|O
and	232	235		|O
everolimus	236	246		|O
in	247	249		|O
a	250	251		|O
patient	252	259		|O
who	260	263		|O
underwent	264	273		|O
an	274	276		|O
orthotopic	277	287		|O
liver	288	293		|O
transplant	294	304		|O
.	304	305		|O
CASE	306	310		|O
SUMMARY	311	318		|O
:	318	319		|O
A	320	321		|O
65	322	324		|O
-	324	325		|O
year	325	329		|O
-	329	330		|O
old	330	333		|O
male	334	338		|O
who	339	342		|O
received	343	351		|O
an	352	354		|O
orthotopic	355	365		|O
liver	366	371		|O
transplant	372	382		|O
experienced	383	394		|O
an	395	397		|O
iatrogenic	398	408	iatrogenic retroperitoneal duodenal perforation	|B-ADVERSE
retroperitoneal	409	424		|I-ADVERSE
duodenal	425	433		|I-ADVERSE
perforation	434	445		|I-ADVERSE
on	446	448		|O
postoperative	449	462		|O
day	463	466		|O
55	467	469		|O
.	469	470		|O
His	471	474		|O
condition	475	484		|O
was	485	488		|O
subsequently	489	501		|O
complicated	502	513		|O
by	514	516		|O
severe	517	523		|O
sepsis	524	530	sepsis	|B-ADVERSE
and	531	534		|O
acute	535	540	acute renal failure	|B-ADVERSE
renal	541	546		|I-ADVERSE
failure	547	554		|I-ADVERSE
.	554	555		|O
Intravenous	556	567		|O
fluconazole	568	579		|O
400	580	583		|O
mg	584	586		|O
,	586	587		|O
followed	588	596		|O
by	597	599		|O
100	600	603		|O
mg	604	606		|O
every	607	612		|O
24	613	615		|O
hours	616	621		|O
according	622	631		|O
to	632	634		|O
impaired	635	643	impaired renal function	|B-ADVERSE
renal	644	649		|I-ADVERSE
function	650	658		|I-ADVERSE
,	658	659		|O
was	660	663		|O
immediately	664	675		|O
started	676	683		|O
;	683	684		|O
to	685	687		|O
avoid	688	693		|O
further	694	701		|O
nephrotoxicity	702	716	nephrotoxicity	|B-ADVERSE
,	716	717		|O
immunosuppressant	718	735		|O
therapy	736	743		|O
was	744	747		|O
switched	748	756		|O
from	757	761		|O
cyclosporine	762	774		|O
plus	775	779		|O
mycophenolate	780	793		|O
mofetil	794	801		|O
to	802	804		|O
oral	805	809		|O
everolimus	810	820		|O
0.75	821	825		|O
mg	826	828		|O
every	829	834		|O
12	835	837		|O
hours	838	843		|O
.	843	844		|O
Satisfactory	845	857		|O
steady	858	864		|O
-	864	865		|O
state	865	870		|O
minimum	871	878		|O
concentration	879	892		|O
(	893	894		|O
C	894	895		|O
(	895	896		|O
min	896	899		|O
)	899	900		|O
)	900	901		|O
of	902	904		|O
everolimus	905	915		|O
was	916	919		|O
achieved	920	928		|O
(	929	930		|O
approximately	930	943		|O
5	944	945		|O
ng	946	948		|O
/	948	949		|O
mL	949	951		|O
)	951	952		|O
.	952	953		|O
On	954	956		|O
day	957	960		|O
72	961	963		|O
posttransplant	964	978		|O
,	978	979		|O
because	980	987		|O
of	988	990		|O
invasive	991	999	invasive aspergillosis	|B-ADVERSE
aspergillosis	1000	1013		|I-ADVERSE
,	1013	1014		|O
antifungal	1015	1025		|O
therapy	1026	1033		|O
was	1034	1037		|O
switched	1038	1046		|O
to	1047	1049		|O
intravenous	1050	1061		|O
voriconazole	1062	1074		|O
400	1075	1078		|O
mg	1079	1081		|O
every	1082	1087		|O
12	1088	1090		|O
hours	1091	1096		|O
on	1097	1099		|O
the	1100	1103		|O
first	1104	1109		|O
day	1110	1113		|O
,	1113	1114		|O
followed	1115	1123		|O
by	1124	1126		|O
200	1127	1130		|O
mg	1131	1133		|O
every	1134	1139		|O
12	1140	1142		|O
hours	1143	1148		|O
;	1148	1149		|O
to	1150	1152		|O
prevent	1153	1160		|O
drug	1161	1165	drug toxicity	|B-ADVERSE
toxicity	1166	1174		|I-ADVERSE
,	1174	1175		|O
the	1176	1179		|O
everolimus	1180	1190		|O
dosage	1191	1197		|O
was	1198	1201		|O
promptly	1202	1210		|O
lowered	1211	1218		|O
to	1219	1221		|O
0.25	1222	1226		|O
mg	1227	1229		|O
every	1230	1235		|O
24	1236	1238		|O
hours	1239	1244		|O
.	1244	1245		|O
At	1246	1248		|O
that	1249	1253		|O
time	1254	1258		|O
,	1258	1259		|O
the	1260	1263		|O
everolimus	1264	1274		|O
C	1275	1276		|O
(	1276	1277		|O
min	1277	1280		|O
)	1280	1281		|O
averaged	1282	1290		|O
approximately	1291	1304		|O
3	1305	1306		|O
ng	1307	1309		|O
/	1309	1310		|O
mL	1310	1312		|O
.	1312	1313		|O
The	1314	1317		|O
concentration	1318	1331		|O
/	1331	1332		|O
dose	1332	1336		|O
ratio	1337	1342		|O
of	1343	1345		|O
everolimus	1346	1356		|O
(	1357	1358		|O
ie	1358	1360		|O
,	1360	1361		|O
C	1362	1363		|O
(	1363	1364		|O
min	1364	1367		|O
)	1367	1368		|O
reached	1369	1376		|O
at	1377	1379		|O
steady	1380	1386		|O
-	1386	1387		|O
state	1387	1392		|O
for	1393	1396		|O
each	1397	1401		|O
milligram	1402	1411		|O
per	1412	1415		|O
kilogram	1416	1424		|O
of	1425	1427		|O
drug	1428	1432		|O
administered	1433	1445		|O
)	1445	1446		|O
was	1447	1450		|O
markedly	1451	1459		|O
lower	1460	1465		|O
during	1466	1472		|O
fluconazole	1473	1484		|O
versus	1485	1491		|O
voriconazole	1492	1504		|O
cotreatment	1505	1516		|O
(	1517	1518		|O
mean	1518	1522		|O
+	1523	1524		|O
/	1524	1525		|O
-	1525	1526		|O
SD	1527	1529		|O
,	1529	1530		|O
3.49	1531	1535		|O
+	1536	1537		|O
/	1537	1538		|O
-	1538	1539		|O
0.29	1540	1544		|O
vs	1545	1547		|O
11.05	1548	1553		|O
+	1554	1555		|O
/	1555	1556		|O
-	1556	1557		|O
0.81	1558	1562		|O
ng	1563	1565		|O
/	1565	1566		|O
mL	1566	1568		|O
per	1569	1572		|O
mg	1573	1575		|O
/	1575	1576		|O
kg	1576	1578		|O
/	1578	1579		|O
daily	1579	1584		|O
;	1584	1585		|O
p	1586	1587		|O
<	1588	1589		|O
0.001	1590	1595		|O
)	1595	1596		|O
.	1596	1597		|O
Despite	1598	1605		|O
intensive	1606	1615		|O
care	1616	1620		|O
,	1620	1621		|O
the	1622	1625		|O
patient	1626	1633		|O
's	1633	1635		|O
condition	1636	1645		|O
continued	1646	1655		|O
to	1656	1658		|O
deteriorate	1659	1670		|O
and	1671	1674		|O
he	1675	1677		|O
died	1678	1682		|O
on	1683	1685		|O
day	1686	1689		|O
84	1690	1692		|O
posttransplant	1693	1707		|O
.	1707	1708		|O
DISCUSSION	1709	1719		|O
:	1719	1720		|O
Both	1721	1725		|O
azole	1726	1731		|O
antifungals	1732	1743		|O
were	1744	1748		|O
considered	1749	1759		|O
probable	1760	1768		|O
causative	1769	1778		|O
agents	1779	1785		|O
of	1786	1788		|O
an	1789	1791		|O
interaction	1792	1803		|O
with	1804	1808		|O
everolimus	1809	1819		|O
according	1820	1829		|O
to	1830	1832		|O
the	1833	1836		|O
Drug	1837	1841		|O
Interaction	1842	1853		|O
Probability	1854	1865		|O
Scale	1866	1871		|O
.	1871	1872		|O
The	1873	1876		|O
interaction	1877	1888		|O
is	1889	1891		|O
due	1892	1895		|O
to	1896	1898		|O
the	1899	1902		|O
inhibition	1903	1913		|O
of	1914	1916		|O
CYP3A4	1917	1923		|O
-	1923	1924		|O
mediated	1924	1932		|O
everolimus	1933	1943		|O
clearance	1944	1953		|O
.	1953	1954		|O
Of	1955	1957		|O
note	1958	1962		|O
,	1962	1963		|O
prompt	1964	1970		|O
reduction	1971	1980		|O
of	1981	1983		|O
the	1984	1987		|O
everolimus	1988	1998		|O
dosage	1999	2005		|O
since	2006	2011		|O
the	2012	2015		|O
first	2016	2021		|O
azole	2022	2027		|O
coadministration	2028	2044		|O
,	2044	2045		|O
coupled	2046	2053		|O
with	2054	2058		|O
intensive	2059	2068		|O
therapeutic	2069	2080		|O
drug	2081	2085		|O
monitoring	2086	2096		|O
,	2096	2097		|O
represented	2098	2109		|O
a	2110	2111		|O
useful	2112	2118		|O
strategy	2119	2127		|O
to	2128	2130		|O
prevent	2131	2138		|O
drug	2139	2143		|O
overexposure	2144	2156		|O
.	2156	2157		|O
CONCLUSIONS	2158	2169		|O
:	2169	2170		|O
Our	2171	2174		|O
data	2175	2179		|O
suggest	2180	2187		|O
that	2188	2192		|O
during	2193	2199		|O
everolimus	2200	2210		|O
-	2210	2211		|O
azole	2211	2216		|O
cotreatment	2217	2228		|O
,	2228	2229		|O
a	2230	2231		|O
dose	2232	2236		|O
reduction	2237	2246		|O
of	2247	2249		|O
everolimus	2250	2260		|O
is	2261	2263		|O
needed	2264	2270		|O
to	2271	2273		|O
avoid	2274	2279		|O
overexposure	2280	2292		|O
.	2292	2293		|O
According	2294	2303		|O
to	2304	2306		|O
the	2307	2310		|O
different	2311	2320		|O
inhibitory	2321	2331		|O
potency	2332	2339		|O
of	2340	2342		|O
CYP3A4	2343	2349		|O
activity	2350	2358		|O
,	2358	2359		|O
the	2360	2363		|O
reduction	2364	2373		|O
should	2374	2380		|O
be	2381	2383		|O
lower	2384	2389		|O
during	2390	2396		|O
fluconazole	2397	2408		|O
than	2409	2413		|O
during	2414	2420		|O
voriconazole	2421	2433		|O
cotreatment	2434	2445		|O
.	2445	2446		|O

### 18537576
An	0	2		|O
update	3	9		|O
on	10	12		|O
clinical	13	21		|O
drug	22	26		|O
interactions	27	39		|O
with	40	44		|O
the	45	48		|O
herbal	49	55		|O
antidepressant	56	70		|O
St	71	73		|O
.	73	74		|O
John	75	79		|O
's	79	81		|O
wort	82	86		|O
.	86	87		|O
St	89	91		|O
.	91	92		|O
John	93	97		|O
's	97	99		|O
wort	100	104		|O
(	105	106		|O
Hypericum	106	115		|O
perforatum	116	126		|O
,	126	127		|O
SJW	128	131		|O
)	131	132		|O
is	133	135		|O
one	136	139		|O
of	140	142		|O
the	143	146		|O
most	147	151		|O
commonly	152	160		|O
used	161	165		|O
herbal	166	172		|O
antidepressants	173	188		|O
for	189	192		|O
the	193	196		|O
treatment	197	206		|O
of	207	209		|O
minor	210	215		|O
to	216	218		|O
moderate	219	227		|O
depression	228	238	depression	|B-DISEASE
.	238	239		|O
Limited	240	247		|O
clinical	248	256		|O
trials	257	263		|O
suggest	264	271		|O
that	272	276		|O
hypericum	277	286		|O
and	287	290		|O
standard	291	299		|O
antidepressants	300	315		|O
have	316	320		|O
similar	321	328		|O
beneficial	329	339		|O
effects	340	347		|O
,	347	348		|O
but	349	352		|O
current	353	360		|O
evidence	361	369		|O
regarding	370	379		|O
the	380	383		|O
antidepression	384	398		|O
effects	399	406		|O
of	407	409		|O
SJW	410	413		|O
extracts	414	422		|O
is	423	425		|O
inconsistent	426	438		|O
.	438	439		|O
A	440	441		|O
major	442	447		|O
safety	448	454		|O
concern	455	462		|O
about	463	468		|O
SJW	469	472		|O
is	473	475		|O
its	476	479		|O
ability	480	487		|O
to	488	490		|O
alter	491	496		|O
the	497	500		|O
pharmacokinetics	501	517		|O
and	518	521		|O
/	521	522		|O
or	522	524		|O
clinical	525	533		|O
response	534	542		|O
of	543	545		|O
a	546	547		|O
variety	548	555		|O
of	556	558		|O
clinically	559	569		|O
important	570	579		|O
drugs	580	585		|O
.	585	586		|O
This	587	591		|O
review	592	598		|O
highlights	599	609		|O
and	610	613		|O
updates	614	621		|O
the	622	625		|O
knowledge	626	635		|O
regarding	636	645		|O
drug	646	650		|O
interactions	651	663		|O
with	664	668		|O
SJW	669	672		|O
by	673	675		|O
a	676	677		|O
systematic	678	688		|O
review	689	695		|O
of	696	698		|O
all	699	702		|O
the	703	706		|O
available	707	716		|O
evidence	717	725		|O
,	725	726		|O
including	727	736		|O
worldwide	737	746		|O
published	747	756		|O
literature	757	767		|O
and	768	771		|O
spontaneous	772	783		|O
case	784	788		|O
reports	789	796		|O
.	796	797		|O
A	798	799		|O
number	800	806		|O
of	807	809		|O
clinically	810	820		|O
significant	821	832		|O
interactions	833	845		|O
of	846	848		|O
SJW	849	852		|O
have	853	857		|O
been	858	862		|O
identified	863	873		|O
with	874	878		|O
conventional	879	891		|O
drugs	892	897		|O
.	897	898		|O
These	899	904		|O
interactions	905	917		|O
often	918	923		|O
result	924	930		|O
in	931	933		|O
a	934	935		|O
decrease	936	944		|O
in	945	947		|O
the	948	951		|O
concentration	952	965		|O
or	966	968		|O
effect	969	975		|O
of	976	978		|O
the	979	982		|O
combined	983	991		|O
drug	992	996		|O
,	996	997		|O
most	998	1002		|O
probably	1003	1011		|O
due	1012	1015		|O
to	1016	1018		|O
the	1019	1022		|O
induction	1023	1032		|O
of	1033	1035		|O
cytochrome	1036	1046		|O
P450s	1047	1052		|O
(	1053	1054		|O
CYPs	1054	1058		|O
)	1058	1059		|O
and	1060	1063		|O
the	1064	1067		|O
key	1068	1071		|O
drug	1072	1076		|O
transporter	1077	1088		|O
P	1089	1090		|O
-	1090	1091		|O
glycoprotein	1091	1103		|O
(	1104	1105		|O
P	1105	1106		|O
-	1106	1107		|O
gp	1107	1109		|O
)	1109	1110		|O
by	1111	1113		|O
the	1114	1117		|O
major	1118	1123		|O
active	1124	1130		|O
constituents	1131	1143		|O
in	1144	1146		|O
SJW	1147	1150		|O
.	1150	1151		|O
SJW	1152	1155		|O
is	1156	1158		|O
a	1159	1160		|O
potent	1161	1167		|O
inducer	1168	1175		|O
of	1176	1178		|O
human	1179	1184		|O
CYP3A4	1185	1191		|O
and	1192	1195		|O
P	1196	1197		|O
-	1197	1198		|O
gp	1198	1200		|O
in	1201	1203		|O
vitro	1204	1209		|O
and	1210	1213		|O
in	1214	1216		|O
vivo	1217	1221		|O
.	1221	1222		|O
In	1223	1225		|O
addition	1226	1234		|O
,	1234	1235		|O
pharmacodynamic	1236	1251		|O
interactions	1252	1264		|O
of	1265	1267		|O
SJW	1268	1271		|O
with	1272	1276		|O
some	1277	1281		|O
drugs	1282	1287		|O
(	1288	1289		|O
e.g.	1289	1293		|O
selective	1294	1303		|O
serotonin	1304	1313		|O
re	1314	1316		|O
-	1316	1317		|O
uptake	1317	1323		|O
inhibitors	1324	1334		|O
)	1334	1335		|O
have	1336	1340		|O
been	1341	1345		|O
identified	1346	1356		|O
,	1356	1357		|O
which	1358	1363		|O
are	1364	1367		|O
associated	1368	1378		|O
with	1379	1383		|O
an	1384	1386		|O
increased	1387	1396		|O
risk	1397	1401		|O
of	1402	1404		|O
adverse	1405	1412		|O
reactions	1413	1422		|O
.	1422	1423		|O
Since	1424	1429		|O
potential	1430	1439		|O
interactions	1440	1452		|O
of	1453	1455		|O
SJW	1456	1459		|O
with	1460	1464		|O
conventional	1465	1477		|O
drugs	1478	1483		|O
is	1484	1486		|O
a	1487	1488		|O
major	1489	1494		|O
safety	1495	1501		|O
concern	1502	1509		|O
,	1509	1510		|O
it	1511	1513		|O
is	1514	1516		|O
important	1517	1526		|O
to	1527	1529		|O
minimize	1530	1538		|O
and	1539	1542		|O
avoid	1543	1548		|O
these	1549	1554		|O
interactions	1555	1567		|O
by	1568	1570		|O
taking	1571	1577		|O
appropriate	1578	1589		|O
approaches	1590	1600		|O
.	1600	1601		|O
These	1602	1607		|O
include	1608	1615		|O
systematic	1616	1626		|O
research	1627	1635		|O
to	1636	1638		|O
identify	1639	1647		|O
SJW	1648	1651		|O
-	1651	1652		|O
drug	1652	1656		|O
interaction	1657	1668		|O
;	1668	1669		|O
close	1670	1675		|O
therapeutic	1676	1687		|O
drug	1688	1692		|O
monitoring	1693	1703		|O
when	1704	1708		|O
SJW	1709	1712		|O
is	1713	1715		|O
combined	1716	1724		|O
with	1725	1729		|O
conventional	1730	1742		|O
drugs	1743	1748		|O
with	1749	1753		|O
a	1754	1755		|O
narrow	1756	1762		|O
therapeutic	1763	1774		|O
window	1775	1781		|O
;	1781	1782		|O
proper	1783	1789		|O
dose	1790	1794		|O
and	1795	1798		|O
regimen	1799	1806		|O
adjustment	1807	1817		|O
;	1817	1818		|O
patient	1819	1826		|O
education	1827	1836		|O
and	1837	1840		|O
communication	1841	1854		|O
between	1855	1862		|O
the	1863	1866		|O
patient	1867	1874		|O
and	1875	1878		|O
physician	1879	1888		|O
;	1888	1889		|O
design	1890	1896		|O
of	1897	1899		|O
new	1900	1903		|O
preparations	1904	1916		|O
of	1917	1919		|O
SJW	1920	1923		|O
without	1924	1931		|O
inducing	1932	1940		|O
ability	1941	1948		|O
of	1949	1951		|O
CYP3A4	1952	1958		|O
and	1959	1962		|O
P	1963	1964		|O
-	1964	1965		|O
gp	1965	1967		|O
while	1968	1973		|O
retaining	1974	1983		|O
its	1984	1987		|O
bioactivity	1988	1999		|O
;	1999	2000		|O
and	2001	2004		|O
appropriate	2005	2016		|O
regulation	2017	2027		|O
in	2028	2030		|O
herbal	2031	2037		|O
safety	2038	2044		|O
and	2045	2048		|O
efficacy	2049	2057		|O
.	2057	2058		|O
Further	2059	2066		|O
clinical	2067	2075		|O
and	2076	2079		|O
mechanistic	2080	2091		|O
studies	2092	2099		|O
are	2100	2103		|O
warranted	2104	2113		|O
to	2114	2116		|O
explore	2117	2124		|O
the	2125	2128		|O
interaction	2129	2140		|O
of	2141	2143		|O
SJW	2144	2147		|O
with	2148	2152		|O
other	2153	2158		|O
important	2159	2168		|O
drugs	2169	2174		|O
and	2175	2178		|O
clinical	2179	2187		|O
significance	2188	2200		|O
.	2200	2201		|O

### 18813359
Squalene	0	8		|O
selectively	9	20		|O
protects	21	29		|O
mouse	30	35		|O
bone	36	40		|O
marrow	41	47		|O
progenitors	48	59		|O
against	60	67		|O
cisplatin	68	77		|O
and	78	81		|O
carboplatin	82	93		|O
-	93	94		|O
induced	94	101		|O
cytotoxicity	102	114	cytotoxicity	|B-ADVERSE
in	115	117		|O
vivo	118	122		|O
without	123	130		|O
protecting	131	141		|O
tumor	142	147	tumor	|B-DISEASE
growth	148	154		|O
.	154	155		|O
Squalene	157	165		|O
,	165	166		|O
an	167	169		|O
isoprenoid	170	180		|O
antioxidant	181	192		|O
is	193	195		|O
a	196	197		|O
potential	198	207		|O
cytoprotective	208	222		|O
agent	223	228		|O
against	229	236		|O
chemotherapy	237	249		|O
-	249	250		|O
induced	250	257		|O
toxicity	258	266		|O
.	266	267		|O
We	268	270		|O
have	271	275		|O
previously	276	286		|O
published	287	296		|O
that	297	301		|O
squalene	302	310		|O
protects	311	319		|O
light	320	325		|O
-	325	326		|O
density	326	333		|O
bone	334	338		|O
marrow	339	345		|O
cells	346	351		|O
against	352	359		|O
cis	360	363		|O
-	363	364		|O
diamminedichloroplatinum	364	388		|O
(	388	389		|O
II	390	392		|O
)	392	393		|O
(	394	395		|O
cisplatin	395	404		|O
)	404	405		|O
-	405	406		|O
induced	406	413		|O
toxicity	414	422		|O
without	423	430		|O
protecting	431	441		|O
tumor	442	447		|O
cells	448	453		|O
in	454	456		|O
vitro	457	462		|O
.	462	463		|O
Here	464	468		|O
,	468	469		|O
we	470	472		|O
developed	473	482		|O
an	483	485		|O
in	486	488		|O
vivo	489	493		|O
mouse	494	499		|O
model	500	505		|O
of	506	508		|O
cisplatin	509	518		|O
and	519	522		|O
cis	523	526		|O
-	526	527		|O
diammine	527	535		|O
(	536	537		|O
cyclobutane	537	548		|O
-	548	549		|O
1,1	549	552		|O
-	552	553		|O
dicarboxylato	553	566		|O
)	566	567		|O
platinum	568	576		|O
(	576	577		|O
II	577	579		|O
)	579	580		|O
(	581	582		|O
carboplatin	582	593		|O
)	593	594		|O
-	594	595		|O
induced	595	602		|O
toxicity	603	611		|O
to	612	614		|O
further	615	622		|O
investigate	623	634		|O
squalene	635	643		|O
-	643	644		|O
mediated	644	652		|O
LD	653	655		|O
-	655	656		|O
BM	656	658		|O
cytoprotection	659	673		|O
including	674	683		|O
the	684	687		|O
molecular	688	697		|O
mechanism	698	707		|O
behind	708	714		|O
selective	715	724		|O
cytoprotection	725	739		|O
.	739	740		|O
We	741	743		|O
found	744	749		|O
that	750	754		|O
squalene	755	763		|O
significantly	764	777		|O
reduced	778	785		|O
the	786	789		|O
body	790	794		|O
weight	795	801		|O
loss	802	806		|O
of	807	809		|O
cisplatin	810	819		|O
and	820	823		|O
carboplatin	824	835		|O
-	835	836		|O
treated	836	843		|O
mice	844	848		|O
.	848	849		|O
Light	850	855		|O
-	855	856		|O
density	856	863		|O
bone	864	868		|O
marrow	869	875		|O
cells	876	881		|O
from	882	886		|O
squalene	887	895		|O
-	895	896		|O
treated	896	903		|O
mice	904	908		|O
exhibited	909	918		|O
improved	919	927		|O
formation	928	937		|O
of	938	940		|O
hematopoietic	941	954		|O
colonies	955	963		|O
(	964	965		|O
colony	965	971		|O
-	971	972		|O
forming	972	979		|O
unit	980	984		|O
-	984	985		|O
granulocyte	985	996		|O
macrophage	997	1007		|O
)	1007	1008		|O
.	1008	1009		|O
Furthermore	1010	1021		|O
,	1021	1022		|O
squalene	1023	1031		|O
also	1032	1036		|O
protected	1037	1046		|O
mesenchymal	1047	1058		|O
stem	1059	1063		|O
cell	1064	1068		|O
colonies	1069	1077		|O
(	1078	1079		|O
colony	1079	1085		|O
-	1085	1086		|O
forming	1086	1093		|O
unit	1094	1098		|O
-	1098	1099		|O
fibroblast	1099	1109		|O
)	1109	1110		|O
from	1111	1115		|O
cisplatin	1116	1125		|O
and	1126	1129		|O
carboplatin	1130	1141		|O
-	1141	1142		|O
induced	1142	1149		|O
toxicity	1150	1158		|O
.	1158	1159		|O
Squalene	1160	1168		|O
-	1168	1169		|O
induced	1169	1176		|O
protection	1177	1187		|O
was	1188	1191		|O
associated	1192	1202		|O
with	1203	1207		|O
decreased	1208	1217		|O
reactive	1218	1226		|O
oxygen	1227	1233		|O
species	1234	1241		|O
and	1242	1245		|O
increased	1246	1255		|O
levels	1256	1262		|O
of	1263	1265		|O
glutathione	1266	1277		|O
and	1278	1281		|O
glutathione	1282	1293		|O
peroxidase	1294	1304		|O
/	1304	1305		|O
glutathione	1305	1316		|O
-	1316	1317		|O
S	1317	1318		|O
-	1318	1319		|O
transferase	1319	1330		|O
.	1330	1331		|O
Importantly	1332	1343		|O
,	1343	1344		|O
squalene	1345	1353		|O
did	1354	1357		|O
not	1358	1361		|O
protect	1362	1369		|O
neuroblastoma	1370	1383	neuroblastoma	|B-DISEASE
,	1383	1384		|O
small	1385	1390	small cell carcinoma	|B-DISEASE
cell	1391	1395		|I-DISEASE
carcinoma	1396	1405		|I-DISEASE
,	1405	1406		|O
or	1407	1409		|O
medulloblastoma	1410	1425	medulloblastoma	|B-DISEASE
xenografts	1426	1436		|O
against	1437	1444		|O
cisplatin	1445	1454		|O
-	1454	1455		|O
induced	1455	1462		|O
toxicity	1463	1471		|O
.	1471	1472		|O
These	1473	1478		|O
results	1479	1486		|O
suggest	1487	1494		|O
that	1495	1499		|O
squalene	1500	1508		|O
is	1509	1511		|O
a	1512	1513		|O
potential	1514	1523		|O
candidate	1524	1533		|O
for	1534	1537		|O
future	1538	1544		|O
development	1545	1556		|O
as	1557	1559		|O
a	1560	1561		|O
cytoprotective	1562	1576		|O
agent	1577	1582		|O
against	1583	1590		|O
chemotherapeutic	1591	1607	chemotherapeutic toxicity	|B-ADVERSE
toxicity	1608	1616		|I-ADVERSE
.	1616	1617		|O

### 18648813
Phase	0	5		|O
II	6	8		|O
study	9	14		|O
of	15	17		|O
9	18	19		|O
-	19	20		|O
aminocamptothecin	20	37		|O
in	38	40		|O
previously	41	51		|O
treated	52	59		|O
lymphomas	60	69	lymphomas	|B-DISEASE
:	69	70		|O
results	71	78		|O
of	79	81		|O
Cancer	82	88	Cancer	|B-DISEASE
and	89	92		|O
Leukemia	93	101	Leukemia	|B-DISEASE
Group	102	107		|O
B	108	109		|O
9551	110	114		|O
.	114	115		|O
PURPOSE	117	124		|O
:	124	125		|O
To	126	128		|O
evaluate	129	137		|O
the	138	141		|O
efficacy	142	150		|O
and	151	154		|O
toxicity	155	163		|O
of	164	166		|O
the	167	170		|O
topoisomerase	171	184		|O
I	185	186		|O
inhibitor	187	196		|O
,	196	197		|O
9	198	199		|O
-	199	200		|O
aminocamptothecin	200	217		|O
(	218	219		|O
9	219	220		|O
-	220	221		|O
AC	221	223		|O
)	223	224		|O
,	224	225		|O
in	226	228		|O
patients	229	237		|O
with	238	242		|O
relapsed	243	251	relapsed lymphoma	|B-DISEASE
lymphoma	252	260		|I-DISEASE
and	261	264		|O
to	265	267		|O
correlate	268	277		|O
9	278	279		|O
-	279	280		|O
AC	280	282		|O
plasma	283	289		|O
concentrations	290	304		|O
with	305	309		|O
response	310	318		|O
and	319	322		|O
toxicity	323	331		|O
.	331	332		|O
METHODS	333	340		|O
:	340	341		|O
Eligible	342	350		|O
patients	351	359		|O
had	360	363		|O
relapsed	364	372	relapsed Hodgkin lymphoma	|B-DISEASE
Hodgkin	373	380		|I-DISEASE
lymphoma	381	389		|I-DISEASE
(	390	391		|O
HL	391	393	HL	|B-DISEASE
)	393	394		|O
treated	395	402		|O
with	403	407		|O
one	408	411		|O
or	412	414		|O
two	415	418		|O
prior	419	424		|O
regimens	425	433		|O
,	433	434		|O
low	435	438		|O
grade	439	444		|O
non	445	448	non-Hodgkin's lymphoma	|B-DISEASE
-	448	449		|I-DISEASE
Hodgkin	449	456		|I-DISEASE
's	456	458		|I-DISEASE
lymphoma	459	467		|I-DISEASE
(	468	469		|O
NHL	469	472	NHL	|B-DISEASE
)	472	473		|O
treated	474	481		|O
with	482	486		|O
one	487	490		|O
or	491	493		|O
two	494	497		|O
prior	498	503		|O
regimens	504	512		|O
,	512	513		|O
or	514	516		|O
aggressive	517	527		|O
NHL	528	531	NHL	|B-DISEASE
treated	532	539		|O
with	540	544		|O
one	545	548		|O
prior	549	554		|O
regimen	555	562		|O
.	562	563		|O
The	564	567		|O
first	568	573		|O
nine	574	578		|O
patients	579	587		|O
received	588	596		|O
9	597	598		|O
-	598	599		|O
AC	599	601		|O
dimethylacetamide	602	619		|O
0.85	620	624		|O
mg	625	627		|O
/	627	628		|O
m	628	629		|O
(	629	630		|O
2	630	631		|O
)	631	632		|O
per	633	636		|O
day	637	640		|O
intravenously	641	654		|O
over	655	659		|O
72	660	662		|O
h	663	664		|O
every	665	670		|O
2	671	672		|O
weeks	673	678		|O
and	679	682		|O
the	683	686		|O
remaining	687	696		|O
27	697	699		|O
patients	700	708		|O
received	709	717		|O
9	718	719		|O
-	719	720		|O
AC	720	722		|O
/	722	723		|O
colloidal	723	732		|O
dispersion	733	743		|O
1.1	744	747		|O
mg	748	750		|O
/	750	751		|O
m	751	752		|O
(	752	753		|O
2	753	754		|O
)	754	755		|O
per	756	759		|O
day	760	763		|O
.	763	764		|O
Patients	765	773		|O
received	774	782		|O
a	783	784		|O
minimum	785	792		|O
of	793	795		|O
three	796	801		|O
cycles	802	808		|O
unless	809	815		|O
progression	816	827		|O
or	828	830		|O
intolerable	831	842		|O
toxicity	843	851		|O
occurred	852	860		|O
.	860	861		|O
Responding	862	872		|O
patients	873	881		|O
received	882	890		|O
two	891	894		|O
cycles	895	901		|O
past	902	906		|O
best	907	911		|O
response	912	920		|O
with	921	925		|O
a	926	927		|O
minimum	928	935		|O
of	936	938		|O
six	939	942		|O
cycles	943	949		|O
.	949	950		|O
RESULTS	951	958		|O
:	958	959		|O
CALGB	960	965		|O
9551	966	970		|O
accrued	971	978		|O
37	979	981		|O
patients	982	990		|O
from	991	995		|O
April	996	1001		|O
1996	1002	1006		|O
through	1007	1014		|O
October	1015	1022		|O
2000	1023	1027		|O
;	1027	1028		|O
one	1029	1032		|O
patient	1033	1040		|O
with	1041	1045		|O
HD	1046	1048	HD	|B-DISEASE
,	1048	1049		|O
18	1050	1052		|O
patients	1053	1061		|O
with	1062	1066		|O
indolent	1067	1075		|O
lymphoma	1076	1084	lymphoma	|B-DISEASE
,	1084	1085		|O
and	1086	1089		|O
17	1090	1092		|O
patients	1093	1101		|O
with	1102	1106		|O
aggressive	1107	1117		|O
lymphoma	1118	1126	lymphoma	|B-DISEASE
.	1126	1127		|O
The	1128	1131		|O
overall	1132	1139		|O
response	1140	1148		|O
rate	1149	1153		|O
was	1154	1157		|O
17%	1158	1161		|O
,	1161	1162		|O
with	1163	1167		|O
response	1168	1176		|O
rates	1177	1182		|O
of	1183	1185		|O
11%	1186	1189		|O
(	1190	1191		|O
2	1191	1192		|O
partial	1193	1200		|O
responses	1201	1210		|O
)	1210	1211		|O
in	1212	1214		|O
patients	1215	1223		|O
with	1224	1228		|O
indolent	1229	1237		|O
histologies	1238	1249		|O
and	1250	1253		|O
23%	1254	1257		|O
(	1258	1259		|O
1	1259	1260		|O
complete	1261	1269		|O
response	1270	1278		|O
,	1278	1279		|O
3	1280	1281		|O
partial	1282	1289		|O
responses	1290	1299		|O
)	1299	1300		|O
in	1301	1303		|O
patients	1304	1312		|O
with	1313	1317		|O
aggressive	1318	1328		|O
histologies	1329	1340		|O
.	1340	1341		|O
The	1342	1345		|O
patient	1346	1353		|O
with	1354	1358		|O
HD	1359	1361	HD	|B-DISEASE
did	1362	1365		|O
not	1366	1369		|O
respond	1370	1377		|O
.	1377	1378		|O
Response	1379	1387		|O
rates	1388	1393		|O
were	1394	1398		|O
similar	1399	1406		|O
for	1407	1410		|O
both	1411	1415		|O
drug	1416	1420		|O
formulations	1421	1433		|O
.	1433	1434		|O
The	1435	1438		|O
median	1439	1445		|O
remission	1446	1455		|O
duration	1456	1464		|O
for	1465	1468		|O
the	1469	1472		|O
six	1473	1476		|O
responders	1477	1487		|O
was	1488	1491		|O
6.5	1492	1495		|O
months	1496	1502		|O
,	1502	1503		|O
with	1504	1508		|O
one	1509	1512		|O
remission	1513	1522		|O
lasting	1523	1530		|O
longer	1531	1537		|O
than	1538	1542		|O
12	1543	1545		|O
months	1546	1552		|O
.	1552	1553		|O
Significant	1554	1565		|O
grade	1566	1571		|O
3	1572	1573		|O
and	1574	1577		|O
4	1578	1579		|O
toxicities	1580	1590		|O
included	1591	1599		|O
neutropenia	1600	1611	neutropenia	|B-ADVERSE
(	1612	1613		|O
66%	1613	1616		|O
)	1616	1617		|O
,	1617	1618		|O
anemia	1619	1625	anemia	|B-ADVERSE
(	1626	1627		|O
31%	1627	1630		|O
)	1630	1631		|O
,	1631	1632		|O
and	1633	1636		|O
thrombocytopenia	1637	1653	thrombocytopenia	|B-ADVERSE
(	1654	1655		|O
36%	1655	1658		|O
)	1658	1659		|O
,	1659	1660		|O
with	1661	1665		|O
20%	1666	1669		|O
of	1670	1672		|O
patients	1673	1681		|O
experiencing	1682	1694		|O
grade	1695	1700		|O
3	1701	1702		|O
or	1703	1705		|O
4	1706	1707		|O
infection	1708	1717	infection	|B-ADVERSE
.	1717	1718		|O
No	1719	1721		|O
treatment	1722	1731		|O
related	1732	1739		|O
deaths	1740	1746		|O
occurred	1747	1755		|O
.	1755	1756		|O
Steady	1757	1763		|O
state	1764	1769		|O
serum	1770	1775		|O
concentrations	1776	1790		|O
did	1791	1794		|O
not	1795	1798		|O
correlate	1799	1808		|O
with	1809	1813		|O
patient	1814	1821		|O
response	1822	1830		|O
or	1831	1833		|O
toxicity	1834	1842		|O
.	1842	1843		|O
CONCLUSION	1844	1854		|O
:	1854	1855		|O
Single	1856	1862		|O
agent	1863	1868		|O
9	1869	1870		|O
-	1870	1871		|O
AC	1871	1873		|O
has	1874	1877		|O
modest	1878	1884		|O
activity	1885	1893		|O
in	1894	1896		|O
aggressive	1897	1907		|O
non	1908	1911	non-Hodgkin's lymphomas	|B-DISEASE
-	1911	1912		|I-DISEASE
Hodgkin	1912	1919		|I-DISEASE
's	1919	1921		|I-DISEASE
lymphomas	1922	1931		|I-DISEASE
.	1931	1932		|O

### 18578119
Safe	0	4		|O
use	5	8		|O
of	9	11		|O
rectal	12	18		|O
suppositories	19	32		|O
and	33	36		|O
enemas	37	43		|O
with	44	48		|O
adult	49	54		|O
patients	55	63		|O
.	63	64		|O
Medications	66	77		|O
that	78	82		|O
are	83	86		|O
given	87	92		|O
via	93	96		|O
the	97	100		|O
rectal	101	107		|O
route	108	113		|O
are	114	117		|O
prescribed	118	128		|O
for	129	132		|O
a	133	134		|O
variety	135	142		|O
of	143	145		|O
reasons	146	153		|O
and	154	157		|O
have	158	162		|O
either	163	169		|O
a	170	171		|O
local	172	177		|O
or	178	180		|O
systemic	181	189		|O
effect	190	196		|O
.	196	197		|O
The	198	201		|O
administration	202	216		|O
of	217	219		|O
suppositories	220	233		|O
and	234	237		|O
enemas	238	244		|O
is	245	247		|O
an	248	250		|O
intimate	251	259		|O
procedure	260	269		|O
which	270	275		|O
has	276	279		|O
the	280	283		|O
potential	284	293		|O
to	294	296		|O
cause	297	302		|O
embarrassment	303	316	embarrassment	|B-ADVERSE
and	317	320		|O
discomfort	321	331	discomfort	|B-ADVERSE
for	332	335		|O
the	336	339		|O
patient	340	347		|O
.	347	348		|O
This	349	353		|O
article	354	361		|O
outlines	362	370		|O
the	371	374		|O
reasons	375	382		|O
for	383	386		|O
the	387	390		|O
use	391	394		|O
of	395	397		|O
rectal	398	404		|O
medications	405	416		|O
and	417	420		|O
recommends	421	431		|O
a	432	433		|O
procedure	434	443		|O
to	444	446		|O
be	447	449		|O
followed	450	458		|O
when	459	463		|O
giving	464	470		|O
them	471	475		|O
.	475	476		|O

### 18707820
Weekly	0	6		|O
carboplatin	7	18		|O
reduces	19	26		|O
toxicity	27	35		|O
during	36	42		|O
synchronous	43	54		|O
chemoradiotherapy	55	72		|O
for	73	76		|O
Merkel	77	83	Merkel cell carcinoma of skin	|B-DISEASE
cell	84	88		|I-DISEASE
carcinoma	89	98		|I-DISEASE
of	99	101		|I-DISEASE
skin	102	106		|I-DISEASE
.	106	107		|O
PURPOSE	109	116		|O
:	116	117		|O
The	118	121		|O
toxicity	122	130		|O
of	131	133		|O
radiotherapy	134	146		|O
(	147	148		|O
RT	148	150		|O
)	150	151		|O
combined	152	160		|O
with	161	165		|O
weekly	166	172		|O
carboplatin	173	184		|O
and	185	188		|O
adjuvant	189	197		|O
carboplatin	198	209		|O
and	210	213		|O
etoposide	214	223		|O
was	224	227		|O
prospectively	228	241		|O
assessed	242	250		|O
in	251	253		|O
a	254	255		|O
group	256	261		|O
of	262	264		|O
patients	265	273		|O
with	274	278		|O
high	279	283		|O
-	283	284		|O
risk	284	288		|O
Stage	289	294		|O
I	295	296		|O
and	297	300		|O
II	301	303		|O
Merkel	304	310	Merkel cell carcinoma of the skin	|B-DISEASE
cell	311	315		|I-DISEASE
carcinoma	316	325		|I-DISEASE
of	326	328		|I-DISEASE
the	329	332		|I-DISEASE
skin	333	337		|I-DISEASE
.	337	338		|O
This	339	343		|O
regimen	344	351		|O
was	352	355		|O
compared	356	364		|O
with	365	369		|O
the	370	373		|O
Trans	374	379		|O
-	379	380		|O
Tasman	380	386		|O
Radiation	387	396		|O
Oncology	397	405		|O
Group	406	411		|O
96	412	414		|O
:	414	415		|O
07	415	417		|O
study	418	423		|O
,	423	424		|O
which	425	430		|O
used	431	435		|O
identical	436	445		|O
eligibility	446	457		|O
criteria	458	466		|O
but	467	470		|O
carboplatin	471	482		|O
and	483	486		|O
etoposide	487	496		|O
every	497	502		|O
3	503	504		|O
weeks	505	510		|O
during	511	517		|O
RT	518	520		|O
.	520	521		|O
PATIENTS	522	530		|O
AND	531	534		|O
METHODS	535	542		|O
:	542	543		|O
Patients	544	552		|O
were	553	557		|O
eligible	558	566		|O
if	567	569		|O
they	570	574		|O
had	575	578		|O
disease	579	586		|O
localized	587	596		|O
to	597	599		|O
the	600	603		|O
primary	604	611		|O
site	612	616		|O
and	617	620		|O
lymph	621	626		|O
nodes	627	632		|O
,	632	633		|O
with	634	638		|O
high	639	643		|O
-	643	644		|O
risk	644	648		|O
features	649	657		|O
.	657	658		|O
RT	659	661		|O
was	662	665		|O
delivered	666	675		|O
to	676	678		|O
the	679	682		|O
primary	683	690		|O
site	691	695		|O
and	696	699		|O
lymph	700	705		|O
nodes	706	711		|O
to	712	714		|O
a	715	716		|O
dose	717	721		|O
of	722	724		|O
50	725	727		|O
Gy	728	730		|O
and	731	734		|O
weekly	735	741		|O
carboplatin	742	753		|O
(	754	755		|O
area	755	759		|O
under	760	765		|O
the	766	769		|O
curve	770	775		|O
of	776	778		|O
2	779	780		|O
)	780	781		|O
was	782	785		|O
given	786	791		|O
during	792	798		|O
RT	799	801		|O
.	801	802		|O
This	803	807		|O
was	808	811		|O
followed	812	820		|O
by	821	823		|O
three	824	829		|O
cycles	830	836		|O
of	837	839		|O
carboplatin	840	851		|O
and	852	855		|O
etoposide	856	865		|O
.	865	866		|O
A	867	868		|O
total	869	874		|O
of	875	877		|O
18	878	880		|O
patients	881	889		|O
were	890	894		|O
entered	895	902		|O
into	903	907		|O
the	908	911		|O
study	912	917		|O
,	917	918		|O
and	919	922		|O
their	923	928		|O
data	929	933		|O
were	934	938		|O
compared	939	947		|O
with	948	952		|O
the	953	956		|O
data	957	961		|O
from	962	966		|O
53	967	969		|O
patients	970	978		|O
entered	979	986		|O
into	987	991		|O
the	992	995		|O
Trans	996	1001		|O
-	1001	1002		|O
Tasman	1002	1008		|O
Radiation	1009	1018		|O
Oncology	1019	1027		|O
Group	1028	1033		|O
96	1034	1036		|O
:	1036	1037		|O
07	1037	1039		|O
study	1040	1045		|O
.	1045	1046		|O
RESULTS	1047	1054		|O
:	1054	1055		|O
Involved	1056	1064		|O
lymph	1065	1070		|O
nodes	1071	1076		|O
(	1077	1078		|O
Stage	1078	1083		|O
II	1084	1086		|O
)	1086	1087		|O
were	1088	1092		|O
present	1093	1100		|O
in	1101	1103		|O
14	1104	1106		|O
patients	1107	1115		|O
(	1116	1117		|O
77%	1117	1120		|O
)	1120	1121		|O
.	1121	1122		|O
Treatment	1123	1132		|O
was	1133	1136		|O
completed	1137	1146		|O
as	1147	1149		|O
planned	1150	1157		|O
in	1158	1160		|O
16	1161	1163		|O
patients	1164	1172		|O
.	1172	1173		|O
The	1174	1177		|O
weekly	1178	1184		|O
carboplatin	1185	1196		|O
dose	1197	1201		|O
was	1202	1205		|O
delivered	1206	1215		|O
in	1216	1218		|O
17	1219	1221		|O
patients	1222	1230		|O
,	1230	1231		|O
and	1232	1235		|O
15	1236	1238		|O
were	1239	1243		|O
able	1244	1248		|O
to	1249	1251		|O
complete	1252	1260		|O
all	1261	1264		|O
three	1265	1270		|O
cycles	1271	1277		|O
of	1278	1280		|O
adjuvant	1281	1289		|O
carboplatin	1290	1301		|O
and	1302	1305		|O
etoposide	1306	1315		|O
.	1315	1316		|O
Grade	1317	1322		|O
3	1323	1324		|O
and	1325	1328		|O
4	1329	1330		|O
neutrophil	1331	1341	neutrophil toxicity	|B-ADVERSE
toxicity	1342	1350		|I-ADVERSE
occurred	1351	1359		|O
in	1360	1362		|O
7	1363	1364		|O
patients	1365	1373		|O
,	1373	1374		|O
but	1375	1378		|O
no	1379	1381		|O
cases	1382	1387		|O
of	1388	1390		|O
febrile	1391	1398	febrile neutropenia	|B-ADVERSE
neutropenia	1399	1410		|I-ADVERSE
developed	1411	1420		|O
.	1420	1421		|O
Compared	1422	1430		|O
with	1431	1435		|O
the	1436	1439		|O
Trans	1440	1445		|O
-	1445	1446		|O
Tasman	1446	1452		|O
Radiation	1453	1462		|O
Oncology	1463	1471		|O
Group	1472	1477		|O
96	1478	1480		|O
:	1480	1481		|O
07	1481	1483		|O
protocol	1484	1492		|O
(	1493	1494		|O
19	1494	1496		|O
of	1497	1499		|O
53	1500	1502		|O
cases	1503	1508		|O
of	1509	1511		|O
febrile	1512	1519	febrile neutropenia	|B-ADVERSE
neutropenia	1520	1531		|I-ADVERSE
)	1531	1532		|O
,	1532	1533		|O
the	1534	1537		|O
reduction	1538	1547		|O
in	1548	1550		|O
the	1551	1554		|O
febrile	1555	1562	febrile neutropenia	|B-ADVERSE
neutropenia	1563	1574		|I-ADVERSE
rate	1575	1579		|O
(	1580	1581		|O
p	1581	1582		|O
=	1583	1584		|O
0.003	1585	1590		|O
)	1590	1591		|O
and	1592	1595		|O
decrease	1596	1604		|O
in	1605	1607		|O
Grade	1608	1613		|O
3	1614	1615		|O
skin	1616	1620	skin toxicity	|B-ADVERSE
toxicity	1621	1629		|I-ADVERSE
(	1630	1631		|O
p	1631	1632		|O
=	1633	1634		|O
0.006	1635	1640		|O
)	1640	1641		|O
were	1642	1646		|O
highly	1647	1653		|O
statistically	1654	1667		|O
significant	1668	1679		|O
.	1679	1680		|O
CONCLUSION	1681	1691		|O
:	1691	1692		|O
The	1693	1696		|O
results	1697	1704		|O
of	1705	1707		|O
our	1708	1711		|O
study	1712	1717		|O
have	1718	1722		|O
shown	1723	1728		|O
that	1729	1733		|O
weekly	1734	1740		|O
carboplatin	1741	1752		|O
at	1753	1755		|O
this	1756	1760		|O
dosage	1761	1767		|O
is	1768	1770		|O
a	1771	1772		|O
safe	1773	1777		|O
way	1778	1781		|O
to	1782	1784		|O
deliver	1785	1792		|O
synchronous	1793	1804		|O
chemotherapy	1805	1817		|O
during	1818	1824		|O
RT	1825	1827		|O
for	1828	1831		|O
MCC	1832	1835		|O
and	1836	1839		|O
results	1840	1847		|O
in	1848	1850		|O
a	1851	1852		|O
marked	1853	1859		|O
reduction	1860	1869		|O
of	1870	1872		|O
febrile	1873	1880	febrile neutropenia	|B-ADVERSE
neutropenia	1881	1892		|I-ADVERSE
and	1893	1896		|O
Grade	1897	1902		|O
3	1903	1904		|O
skin	1905	1909	skin toxicity	|B-ADVERSE
toxicity	1910	1918		|I-ADVERSE
compared	1919	1927		|O
with	1928	1932		|O
the	1933	1936		|O
three	1937	1942		|O
weekly	1943	1949		|O
regimen	1950	1957		|O
.	1957	1958		|O

### 18620828
Considerations	0	14		|O
on	15	17		|O
the	18	21		|O
physiopathological	22	40		|O
mechanism	41	50		|O
of	51	53		|O
inner	54	59	inner ear damage	|B-ADVERSE
ear	60	63		|I-ADVERSE
damage	64	70		|I-ADVERSE
induced	71	78		|O
by	79	81		|O
intravenous	82	93		|O
cocaine	94	101		|O
abuse	102	107		|O
:	107	108		|O
cues	109	113		|O
from	114	118		|O
a	119	120		|O
case	121	125		|O
report	126	132		|O
.	132	133		|O
OBJECTIVE	135	144		|O
:	144	145		|O
Aim	146	149		|O
of	150	152		|O
the	153	156		|O
following	157	166		|O
paper	167	172		|O
is	173	175		|O
to	176	178		|O
discuss	179	186		|O
about	187	192		|O
the	193	196		|O
possible	197	205		|O
etiopathogenetic	206	222		|O
mechanisms	223	233		|O
of	234	236		|O
inner	237	242	inner ear damage	|B-ADVERSE
ear	243	246		|I-ADVERSE
damage	247	253		|I-ADVERSE
induced	254	261		|O
by	262	264		|O
cocaine	265	272		|O
abuse	273	278		|O
.	278	279		|O
Unfortunately	280	293		|O
the	294	297		|O
data	298	302		|O
concerning	303	313		|O
this	314	318		|O
topic	319	324		|O
are	325	328		|O
very	329	333		|O
limited	334	341		|O
;	341	342		|O
the	343	346		|O
authors	347	354		|O
are	355	358		|O
then	359	363		|O
presenting	364	374		|O
a	375	376		|O
literature	377	387		|O
review	388	394		|O
,	394	395		|O
also	396	400		|O
discussing	401	411		|O
the	412	415		|O
clinical	416	424		|O
presentation	425	437		|O
and	438	441		|O
the	442	445		|O
possible	446	454		|O
therapeutical	455	468		|O
approach	469	477		|O
of	478	480		|O
a	481	482		|O
clinical	483	491		|O
case	492	496		|O
of	497	499		|O
bilateral	500	509	bilateral sudden sensorineural hearing loss	|B-ADVERSE
sudden	510	516		|I-ADVERSE
sensorineural	517	530		|I-ADVERSE
hearing	531	538		|I-ADVERSE
loss	539	543		|I-ADVERSE
following	544	553		|O
i	554	555		|O
.	555	556		|O
v	556	557		|O
.	557	558		|O
injection	559	568		|O
of	569	571		|O
cocaine	572	579		|O
.	579	580		|O
PATIENTS	581	589		|O
:	589	590		|O
Case	591	595		|O
report	596	602		|O
.	602	603		|O
INTERVENTION	604	616		|O
:	616	617		|O
A	618	619		|O
strictly	620	628		|O
audiological	629	641		|O
evaluation	642	652		|O
has	653	656		|O
been	657	661		|O
performed	662	671		|O
,	671	672		|O
in	673	675		|O
order	676	681		|O
to	682	684		|O
identify	685	693		|O
the	694	697		|O
cochlear	698	706		|O
lesion	707	713		|O
site	714	718		|O
(	718	719		|O
s	719	720		|O
)	720	721		|O
and	722	725		|O
to	726	728		|O
provide	729	736		|O
the	737	740		|O
best	741	745		|O
medical	746	753		|O
treatment	754	763		|O
.	763	764		|O
CONCLUSIONS	765	776		|O
:	776	777		|O
To	778	780		|O
our	781	784		|O
knowledge	785	794		|O
,	794	795		|O
this	796	800		|O
is	801	803		|O
the	804	807		|O
first	808	813		|O
report	814	820		|O
of	821	823		|O
acute	824	829	acute cocaine intoxication	|B-ADVERSE
cocaine	830	837		|I-ADVERSE
intoxication	838	850		|I-ADVERSE
with	851	855		|O
sudden	856	862		|O
bilateral	863	872	bilateral hearing loss	|B-ADVERSE
hearing	873	880		|I-ADVERSE
loss	881	885		|I-ADVERSE
.	885	886		|O
Further	887	894		|O
studies	895	902		|O
are	903	906		|O
required	907	915		|O
in	916	918		|O
order	919	924		|O
to	925	927		|O
understand	928	938		|O
the	939	942		|O
effects	943	950		|O
of	951	953		|O
these	954	959		|O
substances	960	970		|O
on	971	973		|O
the	974	977		|O
inner	978	983		|O
ear	984	987		|O
cells	988	993		|O
and	994	997		|O
metabolism	998	1008		|O
.	1008	1009		|O

### 18821490
Lithium	0	7		|O
overdose	8	16		|O
with	17	21		|O
electrocardiogram	22	39		|O
changes	40	47		|O
suggesting	48	58		|O
ischemia	59	67	ischemia	|B-ADVERSE
.	67	68		|O
BACKGROUND	70	80		|O
:	80	81		|O
Lithium	82	89	Lithium toxicity	|B-ADVERSE
toxicity	90	98		|I-ADVERSE
is	99	101		|O
associated	102	112		|O
with	113	117		|O
electrocardiogram	118	135		|O
(	136	137		|O
ECG	137	140		|O
)	140	141		|O
changes	142	149		|O
,	149	150		|O
but	151	154		|O
changes	155	162		|O
suggestive	163	173		|O
of	174	176		|O
an	177	179		|O
ST	180	182	ST segment elevation myocardial infarction	|B-DISEASE
segment	183	190		|I-DISEASE
elevation	191	200		|I-DISEASE
myocardial	201	211		|I-DISEASE
infarction	212	222		|I-DISEASE
have	223	227		|O
not	228	231		|O
been	232	236		|O
reported	237	245		|O
.	245	246		|O
CASE	247	251		|O
REPORT	252	258		|O
:	258	259		|O
A	260	261		|O
46	262	264		|O
-	264	265		|O
year	265	269		|O
-	269	270		|O
old	270	273		|O
incarcerated	274	286		|O
man	287	290		|O
suffering	291	300		|O
from	301	305		|O
diabetes	306	314	diabetes	|B-DISEASE
,	314	315		|O
hypertension	316	328	hypertension	|B-DISEASE
,	328	329		|O
and	330	333		|O
schizoaffective	334	349		|O
/	349	350		|O
bipolar	350	357	bipolar disorder	|B-DISEASE
disorder	358	366		|I-DISEASE
was	367	370		|O
treated	371	378		|O
with	379	383		|O
lithium	384	391		|O
1,200	392	397		|O
mg	398	400		|O
twice	401	406		|O
daily	407	412		|O
.	412	413		|O
Two	414	417		|O
days	418	422		|O
prior	423	428		|O
to	429	431		|O
presentation	432	444		|O
the	445	448		|O
patient	449	456		|O
became	457	463		|O
confused	464	472		|O
,	472	473		|O
ataxic	474	480		|O
,	480	481		|O
and	482	485		|O
anorexic	486	494		|O
in	495	497		|O
jail	498	502		|O
.	502	503		|O
Lithium	504	511		|O
level	512	517		|O
was	518	521		|O
4.69	522	526		|O
mmol	527	531		|O
/	531	532		|O
L	532	533		|O
.	533	534		|O
He	535	537		|O
was	538	541		|O
transferred	542	553		|O
to	554	556		|O
the	557	560		|O
emergency	561	570		|O
department	571	581		|O
.	581	582		|O
On	583	585		|O
arrival	586	593		|O
,	593	594		|O
vital	595	600		|O
signs	601	606		|O
were	607	611		|O
normal	612	618		|O
.	618	619		|O
The	620	623		|O
ECG	624	627		|O
showed	628	634		|O
a	635	636		|O
normal	637	643		|O
sinus	644	649		|O
rhythm	650	656		|O
.	656	657		|O
ST	658	660		|O
segments	661	669		|O
were	670	674		|O
elevated	675	683		|O
in	684	686		|O
the	687	690		|O
anterior	691	699		|O
leads	700	705		|O
with	706	710		|O
downward	711	719		|O
concavity	720	729		|O
.	729	730		|O
T	731	732		|O
waves	733	738		|O
were	739	743		|O
biphasic	744	752		|O
.	752	753		|O
Since	754	759		|O
these	760	765		|O
changes	766	773		|O
suggested	774	783		|O
cardiac	784	791	cardiac ischemia	|B-DISEASE
ischemia	792	800		|I-DISEASE
and	801	804		|O
the	805	808		|O
patient	809	816		|O
was	817	820		|O
unable	821	827		|O
to	828	830		|O
respond	831	838		|O
to	839	841		|O
questions	842	851		|O
about	852	857		|O
chest	858	863	chest pain	|B-DISEASE
pain	864	868		|I-DISEASE
,	868	869		|O
cardiac	870	877		|O
enzymes	878	885		|O
and	886	889		|O
an	890	892		|O
emergent	893	901		|O
echocardiogram	902	916		|O
were	917	921		|O
done	922	926		|O
.	926	927		|O
Troponin	928	936		|O
I	937	938		|O
was	939	942		|O
less	943	947		|O
than	948	952		|O
0.1	953	956		|O
microg	957	963		|O
/	963	964		|O
L	964	965		|O
.	965	966		|O
Echocardiogram	967	981		|O
was	982	985		|O
normal	986	992		|O
,	992	993		|O
without	994	1001		|O
wall	1002	1006		|O
motion	1007	1013		|O
abnormalities	1014	1027		|O
.	1027	1028		|O
Treatment	1029	1038		|O
was	1039	1042		|O
with	1043	1047		|O
hemodialysis	1048	1060		|O
and	1061	1064		|O
whole	1065	1070		|O
-	1070	1071		|O
bowel	1071	1076		|O
irrigation	1077	1087		|O
.	1087	1088		|O
Postdialysis	1089	1101		|O
lithium	1102	1109		|O
level	1110	1115		|O
was	1116	1119		|O
1.30	1120	1124		|O
mmol	1125	1129		|O
/	1129	1130		|O
L	1130	1131		|O
.	1131	1132		|O
Over	1133	1137		|O
the	1138	1141		|O
next	1142	1146		|O
several	1147	1154		|O
days	1155	1159		|O
,	1159	1160		|O
electrocardiogram	1161	1178		|O
normalized	1179	1189		|O
.	1189	1190		|O
His	1191	1194		|O
speech	1195	1201		|O
gradually	1202	1211		|O
became	1212	1218		|O
coherent	1219	1227		|O
.	1227	1228		|O
After	1229	1234		|O
a	1235	1236		|O
1	1237	1238		|O
-	1238	1239		|O
week	1239	1243		|O
hospitalization	1244	1259		|O
,	1259	1260		|O
he	1261	1263		|O
returned	1264	1272		|O
to	1273	1275		|O
jail	1276	1280		|O
.	1280	1281		|O
CONCLUSION	1282	1292		|O
:	1292	1293		|O
Lithium	1294	1301	Lithium intoxication	|B-ADVERSE
intoxication	1302	1314		|I-ADVERSE
can	1315	1318		|O
cause	1319	1324		|O
transient	1325	1334		|O
ST	1335	1337		|O
segment	1338	1345		|O
elevations	1346	1356		|O
suggesting	1357	1367		|O
an	1368	1370		|O
acute	1371	1376	acute myocardial infarction	|B-ADVERSE
myocardial	1377	1387		|I-ADVERSE
infarction	1388	1398		|I-ADVERSE
.	1398	1399		|O
In	1400	1402		|O
the	1403	1406		|O
absence	1407	1414		|O
of	1415	1417		|O
a	1418	1419		|O
clear	1420	1425		|O
history	1426	1433		|O
,	1433	1434		|O
echocardiogram	1435	1449		|O
and	1450	1453		|O
cardiac	1454	1461		|O
enzymes	1462	1469		|O
can	1470	1473		|O
be	1474	1476		|O
used	1477	1481		|O
to	1482	1484		|O
rule	1485	1489		|O
out	1490	1493		|O
a	1494	1495		|O
myocardial	1496	1506	myocardial infarction	|B-DISEASE
infarction	1507	1517		|I-DISEASE
.	1517	1518		|O

### 18777478
Adverse	0	7		|O
effects	8	15		|O
of	16	18		|O
antiepileptic	19	32		|O
drugs	33	38		|O
.	38	39		|O
Adverse	41	48		|O
effects	49	56		|O
of	57	59		|O
antiepileptic	60	73		|O
drugs	74	79		|O
(	80	81		|O
AEDs	81	85		|O
)	85	86		|O
are	87	90		|O
considered	91	101		|O
by	102	104		|O
patients	105	113		|O
to	114	116		|O
be	117	119		|O
at	120	122		|O
least	123	128		|O
as	129	131		|O
important	132	141		|O
as	142	144		|O
repetitive	145	155	repetitive seizures	|B-DISEASE
seizures	156	164		|I-DISEASE
in	165	167		|O
terms	168	173		|O
of	174	176		|O
quality	177	184		|O
of	185	187		|O
life	188	192		|O
.	192	193		|O
AED	194	197	AED toxicity	|B-ADVERSE
toxicity	198	206		|I-ADVERSE
is	207	209		|O
frequent	210	218		|O
and	219	222		|O
contributes	223	234		|O
to	235	237		|O
a	238	239		|O
high	240	244		|O
proportion	245	255		|O
of	256	258		|O
treatment	259	268		|O
failures	269	277		|O
.	277	278		|O
Despite	279	286		|O
its	287	290		|O
high	291	295		|O
prevalence	296	306		|O
and	307	310		|O
clinical	311	319		|O
relevance	320	329		|O
,	329	330		|O
screening	331	340		|O
for	341	344		|O
adverse	345	352		|O
reactions	353	362		|O
to	363	365		|O
AEDs	366	370		|O
is	371	373		|O
not	374	377		|O
systematically	378	392		|O
included	393	401		|O
in	402	404		|O
everyday	405	413		|O
clinical	414	422		|O
practice	423	431		|O
;	431	432		|O
therefore	433	442		|O
it	443	445		|O
is	446	448		|O
very	449	453		|O
likely	454	460		|O
that	461	465		|O
it	466	468		|O
remains	469	476		|O
underestimated	477	491		|O
.	491	492		|O
Because	493	500		|O
there	501	506		|O
is	507	509		|O
little	510	516		|O
difference	517	527		|O
among	528	533		|O
AEDs	534	538		|O
in	539	541		|O
terms	542	547		|O
of	548	550		|O
efficacy	551	559		|O
,	559	560		|O
drug	561	565		|O
selection	566	575		|O
is	576	578		|O
often	579	584		|O
based	585	590		|O
on	591	593		|O
the	594	597		|O
adverse	598	605		|O
effects	606	613		|O
profile	614	621		|O
.	621	622		|O
AED	623	626	AED toxicity	|B-ADVERSE
toxicity	627	635		|I-ADVERSE
is	636	638		|O
classified	639	649		|O
according	650	659		|O
to	660	662		|O
different	663	672		|O
parameters	673	683		|O
,	683	684		|O
such	685	689		|O
as	690	692		|O
severity	693	701		|O
,	701	702		|O
time	703	707		|O
of	708	710		|O
occurrence	711	721		|O
,	721	722		|O
organ	723	728		|O
system	729	735		|O
involvement	736	747		|O
,	747	748		|O
and	749	752		|O
mechanisms	753	763		|O
of	764	766		|O
action	767	773		|O
.	773	774		|O
Although	775	783		|O
most	784	788		|O
toxic	789	794		|O
reactions	795	804		|O
to	805	807		|O
drugs	808	813		|O
can	814	817		|O
be	818	820		|O
predicted	821	830		|O
from	831	835		|O
cumulative	836	846		|O
experience	847	857		|O
,	857	858		|O
prevention	859	869		|O
is	870	872		|O
not	873	876		|O
always	877	883		|O
possible	884	892		|O
,	892	893		|O
since	894	899		|O
multiple	900	908		|O
mechanisms	909	919		|O
and	920	923		|O
individual	924	934		|O
susceptibility	935	949		|O
to	950	952		|O
each	953	957		|O
drug	958	962		|O
participate	963	974		|O
in	975	977		|O
the	978	981		|O
final	982	987		|O
outcome	988	995		|O
.	995	996		|O
However	997	1004		|O
,	1004	1005		|O
adverse	1006	1013		|O
effects	1014	1021		|O
can	1022	1025		|O
be	1026	1028		|O
reduced	1029	1036		|O
and	1037	1040		|O
appropriate	1041	1052		|O
action	1053	1059		|O
can	1060	1063		|O
be	1064	1066		|O
taken	1067	1072		|O
in	1073	1075		|O
time	1076	1080		|O
by	1081	1083		|O
means	1084	1089		|O
of	1090	1092		|O
a	1093	1094		|O
high	1095	1099		|O
degree	1100	1106		|O
of	1107	1109		|O
suspicion	1110	1119		|O
,	1119	1120		|O
knowledge	1121	1130		|O
of	1131	1133		|O
risk	1134	1138		|O
factors	1139	1146		|O
,	1146	1147		|O
and	1148	1151		|O
close	1152	1157		|O
follow	1158	1164		|O
-	1164	1165		|O
up	1165	1167		|O
.	1167	1168		|O
This	1169	1173		|O
article	1174	1181		|O
highlights	1182	1192		|O
factors	1193	1200		|O
to	1201	1203		|O
consider	1204	1212		|O
for	1213	1216		|O
detecting	1217	1226		|O
and	1227	1230		|O
managing	1231	1239		|O
AED	1240	1243		|O
adverse	1244	1251		|O
effects	1252	1259		|O
.	1259	1260		|O

### 18818457
Influence	0	9		|O
of	10	12		|O
nonsteroidal	13	25		|O
anti	26	30		|O
-	30	31		|O
inflammatory	31	43		|O
drugs	44	49		|O
on	50	52		|O
osseointegration	53	69		|O
.	69	70		|O
This	72	76		|O
paper	77	82		|O
reviews	83	90		|O
contemporary	91	103		|O
literature	104	114		|O
concerning	115	125		|O
the	126	129		|O
possible	130	138		|O
influence	139	148		|O
of	149	151		|O
nonsteroidal	152	164		|O
anti	165	169		|O
-	169	170		|O
inflammatory	170	182		|O
drugs	183	188		|O
(	189	190		|O
NSAIDs	190	196		|O
)	196	197		|O
on	198	200		|O
osseointegration	201	217		|O
.	217	218		|O
In	219	221		|O
vitro	222	227		|O
studies	228	235		|O
concerning	236	246		|O
the	247	250		|O
effect	251	257		|O
of	258	260		|O
NSAIDs	261	267		|O
on	268	270		|O
growth	271	277		|O
factors	278	285		|O
and	286	289		|O
bone	290	294		|O
-	294	295		|O
generating	295	305		|O
cells	306	311		|O
are	312	315		|O
the	316	319		|O
primary	320	327		|O
source	328	334		|O
of	335	337		|O
data	338	342		|O
pertaining	343	353		|O
to	354	356		|O
this	357	361		|O
issue	362	367		|O
because	368	375		|O
relatively	376	386		|O
few	387	390		|O
in	391	393		|O
vivo	394	398		|O
studies	399	406		|O
have	407	411		|O
been	412	416		|O
conducted	417	426		|O
.	426	427		|O
It	428	430		|O
is	431	433		|O
concluded	434	443		|O
that	444	448		|O
prescribing	449	460		|O
NSAIDs	461	467		|O
during	468	474		|O
the	475	478		|O
early	479	484		|O
postoperative	485	498		|O
period	499	505		|O
is	506	508		|O
likely	509	515		|O
not	516	519		|O
without	520	527		|O
negative	528	536		|O
effect	537	543		|O
,	543	544		|O
although	545	553		|O
any	554	557		|O
negative	558	566		|O
influence	567	576		|O
appears	577	584		|O
to	585	587		|O
be	588	590		|O
temporary	591	600		|O
and	601	604		|O
does	605	609		|O
not	610	613		|O
affect	614	620		|O
the	621	624		|O
final	625	630		|O
outcome	631	638		|O
of	639	641		|O
osseointegration	642	658		|O
.	658	659		|O

### 18582143
Drug	0	4		|O
-	4	5		|O
induced	5	12		|O
urinary	13	20	urinary incontinence	|B-ADVERSE
incontinence	21	33		|I-ADVERSE
.	33	34		|O
Physiological	36	49		|O
urinary	50	57		|O
continence	58	68		|O
depends	69	76		|O
on	77	79		|O
many	80	84		|O
factors	85	92		|O
that	93	97		|O
are	98	101		|O
potentially	102	113		|O
vulnerable	114	124		|O
to	125	127		|O
adverse	128	135		|O
drug	136	140		|O
effects	141	148		|O
,	148	149		|O
which	150	155		|O
may	156	159		|O
lead	160	164		|O
to	165	167		|O
incontinence	168	180	incontinence	|B-ADVERSE
.	180	181		|O
In	182	184		|O
principle	185	194		|O
,	194	195		|O
drugs	196	201		|O
could	202	207		|O
cause	208	213		|O
incontinence	214	226	incontinence	|B-ADVERSE
by	227	229		|O
lowering	230	238		|O
bladder	239	246		|O
outlet	247	253		|O
resistance	254	264		|O
and	265	268		|O
/	268	269		|O
or	269	271		|O
by	272	274		|O
increasing	275	285		|O
intravesical	286	298		|O
pressure	299	307		|O
,	307	308		|O
which	309	314		|O
disrupts	315	323		|O
the	324	327		|O
normal	328	334		|O
pressure	335	343		|O
relationship	344	356		|O
between	357	364		|O
the	365	368		|O
bladder	369	376		|O
and	377	380		|O
urethra	381	388		|O
and	389	392		|O
leads	393	398		|O
to	399	401		|O
urinary	402	409		|O
leakage	410	417		|O
;	417	418		|O
other	419	424		|O
possibilities	425	438		|O
include	439	446		|O
disturbances	447	459		|O
of	460	462		|O
central	463	470		|O
nervous	471	478		|O
control	479	486		|O
of	487	489		|O
voiding	490	497		|O
or	498	500		|O
an	501	503		|O
overproduction	504	518		|O
of	519	521		|O
urine	522	527		|O
.	527	528		|O
While	529	534		|O
many	535	539		|O
drug	540	544		|O
groups	545	551		|O
could	552	557		|O
theoretically	558	571		|O
induce	572	578		|O
urinary	579	586	urinary incontinence	|B-ADVERSE
incontinence	587	599		|I-ADVERSE
based	600	605		|O
upon	606	610		|O
pathophysiological	611	629		|O
considerations	630	644		|O
,	644	645		|O
evidence	646	654		|O
demonstrating	655	668		|O
a	669	670		|O
cause	671	676		|O
-	676	677		|O
effect	677	683		|O
relationship	684	696		|O
between	697	704		|O
drug	705	709		|O
usage	710	715		|O
and	716	719		|O
incontinence	720	732	incontinence	|B-ADVERSE
is	733	735		|O
sparse	736	742		|O
.	742	743		|O
Drug	744	748		|O
classes	749	756		|O
in	757	759		|O
which	760	765		|O
induction	766	775		|O
of	776	778		|O
incontinence	779	791	incontinence	|B-ADVERSE
has	792	795		|O
been	796	800		|O
proposed	801	809		|O
include	810	817		|O
alpha	818	823		|O
(	823	824		|O
1	824	825		|O
)	825	826		|O
-	826	827		|O
adrenoceptor	827	839		|O
antagonists	840	851		|O
,	851	852		|O
antipsychotics	853	867		|O
,	867	868		|O
benzodiazepines	869	884		|O
,	884	885		|O
antidepressants	886	901		|O
and	902	905		|O
hormone	906	913		|O
replacement	914	925		|O
therapy	926	933		|O
in	934	936		|O
postmenopausal	937	951		|O
women	952	957		|O
.	957	958		|O
However	959	966		|O
,	966	967		|O
other	968	973		|O
drug	974	978		|O
classes	979	986		|O
are	987	990		|O
not	991	994		|O
innocent	995	1003		|O
in	1004	1006		|O
terms	1007	1012		|O
of	1013	1015		|O
causing	1016	1023		|O
urinary	1024	1031	urinary incontinence	|B-ADVERSE
incontinence	1032	1044		|I-ADVERSE
and	1045	1048		|O
physicians	1049	1059		|O
are	1060	1063		|O
well	1064	1068		|O
advised	1069	1076		|O
to	1077	1079		|O
closely	1080	1087		|O
monitor	1088	1095		|O
patients	1096	1104		|O
for	1105	1108		|O
the	1109	1112		|O
occurrence	1113	1123		|O
of	1124	1126		|O
incontinence	1127	1139	incontinence	|B-ADVERSE
after	1140	1145		|O
new	1146	1149		|O
prescriptions	1150	1163		|O
and	1164	1167		|O
/	1167	1168		|O
or	1168	1170		|O
major	1171	1176		|O
dosage	1177	1183		|O
changes	1184	1191		|O
.	1191	1192		|O

### 18693965
The	0	3		|O
effect	4	10		|O
of	11	13		|O
implementing	14	26		|O
computerized	27	39		|O
provider	40	48		|O
order	49	54		|O
entry	55	60		|O
on	61	63		|O
medication	64	74		|O
prescribing	75	86		|O
errors	87	93		|O
in	94	96		|O
an	97	99		|O
emergency	100	109		|O
department	110	120		|O
.	120	121		|O
Medication	123	133		|O
errors	134	140		|O
are	141	144		|O
a	145	146		|O
major	147	152		|O
concern	153	160		|O
in	161	163		|O
the	164	167		|O
Emergency	168	177		|O
Department	178	188		|O
(	189	190		|O
ED	190	192		|O
)	192	193		|O
.	193	194		|O
We	195	197		|O
examined	198	206		|O
medication	207	217		|O
prescribing	218	229		|O
errors	230	236		|O
among	237	242		|O
consecutive	243	254		|O
adult	255	260		|O
ED	261	263		|O
patients	264	272		|O
during	273	279		|O
two	280	283		|O
10	284	286		|O
-	286	287		|O
day	287	290		|O
periods	291	298		|O
before	299	305		|O
and	306	309		|O
during	310	316		|O
one	317	320		|O
9	321	322		|O
-	322	323		|O
day	323	326		|O
period	327	333		|O
after	334	339		|O
implementing	340	352		|O
computerized	353	365		|O
provider	366	374		|O
order	375	380		|O
entry	381	386		|O
in	387	389		|O
an	390	392		|O
adult	393	398		|O
ED	399	401		|O
.	401	402		|O
2,073	403	408		|O
patients	409	417		|O
had	418	421		|O
5,950	422	427		|O
,	427	428		|O
orders	429	435		|O
.	435	436		|O
Before	437	443		|O
(	444	445		|O
after	445	450		|O
)	450	451		|O
implementation	452	466		|O
there	467	472		|O
were	473	477		|O
3.7	478	481		|O
(	482	483		|O
2.8	483	486		|O
)	486	487		|O
potential	488	497		|O
adverse	498	505		|O
drug	506	510		|O
events	511	517		|O
,	517	518		|O
222.0	519	524		|O
(	525	526		|O
21.0	526	530		|O
)	530	531		|O
medication	532	542		|O
prescribing	543	554		|O
errors	555	561		|O
,	561	562		|O
and	563	566		|O
5.1	567	570		|O
(	571	572		|O
0	572	573		|O
)	573	574		|O
rule	575	579		|O
violations	580	590		|O
per	591	594		|O
100	595	598		|O
orders	599	605		|O
.	605	606		|O

### 18635226
A	0	1		|O
phase	2	7		|O
II	8	10		|O
trial	11	16		|O
of	17	19		|O
gemcitabine	20	31		|O
plus	32	36		|O
capecitabine	37	49		|O
for	50	53		|O
metastatic	54	64	metastatic renal cell cancer	|B-DISEASE
renal	65	70		|I-DISEASE
cell	71	75		|I-DISEASE
cancer	76	82		|I-DISEASE
previously	83	93		|O
treated	94	101		|O
with	102	106		|O
immunotherapy	107	120		|O
and	121	124		|O
targeted	125	133		|O
agents	134	140		|O
.	140	141		|O
PURPOSE	143	150		|O
:	150	151		|O
We	152	154		|O
assessed	155	163		|O
the	164	167		|O
clinical	168	176		|O
activity	177	185		|O
and	186	189		|O
safety	190	196		|O
of	197	199		|O
gemcitabine	200	211		|O
plus	212	216		|O
capecitabine	217	229		|O
in	230	232		|O
patients	233	241		|O
with	242	246		|O
metastatic	247	257	metastatic renal cell cancer	|B-DISEASE
renal	258	263		|I-DISEASE
cell	264	268		|I-DISEASE
cancer	269	275		|I-DISEASE
previously	276	286		|O
treated	287	294		|O
with	295	299		|O
immunotherapy	300	313		|O
.	313	314		|O
MATERIALS	315	324		|O
AND	325	328		|O
METHODS	329	336		|O
:	336	337		|O
In	338	340		|O
this	341	345		|O
phase	346	351		|O
II	352	354		|O
trial	355	360		|O
patients	361	369		|O
received	370	378		|O
1,000	379	384		|O
mg	385	387		|O
/	387	388		|O
m	388	389		|O
(	389	390		|O
2	390	391		|O
)	391	392		|O
gemcitabine	393	404		|O
intravenously	405	418		|O
on	419	421		|O
days	422	426		|O
1	427	428		|O
,	428	429		|O
8	430	431		|O
and	432	435		|O
15	436	438		|O
,	438	439		|O
plus	440	444		|O
830	445	448		|O
mg	449	451		|O
/	451	452		|O
m	452	453		|O
(	453	454		|O
2	454	455		|O
)	455	456		|O
capecitabine	457	469		|O
orally	470	476		|O
twice	477	482		|O
daily	483	488		|O
on	489	491		|O
days	492	496		|O
1	497	498		|O
to	499	501		|O
21	502	504		|O
of	505	507		|O
28	508	510		|O
-	510	511		|O
day	511	514		|O
cycles	515	521		|O
.	521	522		|O
The	523	526		|O
primary	527	534		|O
end	535	538		|O
point	539	544		|O
was	545	548		|O
progression	549	560		|O
-	560	561		|O
free	561	565		|O
survival	566	574		|O
time	575	579		|O
.	579	580		|O
Secondary	581	590		|O
end	591	594		|O
points	595	601		|O
included	602	610		|O
overall	611	618		|O
survival	619	627		|O
time	628	632		|O
,	632	633		|O
objective	634	643		|O
response	644	652		|O
rate	653	657		|O
and	658	661		|O
toxicity	662	670		|O
.	670	671		|O
RESULTS	672	679		|O
:	679	680		|O
Of	681	683		|O
84	684	686		|O
patients	687	695		|O
enrolled	696	704		|O
83	705	707		|O
were	708	712		|O
evaluable	713	722		|O
for	723	726		|O
response	727	735		|O
and	736	739		|O
toxicity	740	748		|O
.	748	749		|O
A	750	751		|O
total	752	757		|O
of	758	760		|O
65	761	763		|O
patients	764	772		|O
had	773	776		|O
intermediate	777	789		|O
or	790	792		|O
poor	793	797		|O
risk	798	802		|O
prognosis	803	812		|O
.	812	813		|O
Median	814	820		|O
progression	821	832		|O
-	832	833		|O
free	833	837		|O
survival	838	846		|O
and	847	850		|O
overall	851	858		|O
survival	859	867		|O
were	868	872		|O
4.6	873	876		|O
(	877	878		|O
95%	878	881		|O
CI	882	884		|O
3.7-7.3	885	892		|O
)	892	893		|O
and	894	897		|O
17.9	898	902		|O
months	903	909		|O
(	910	911		|O
95%	911	914		|O
CI	915	917		|O
13.2-23.6	918	927		|O
)	927	928		|O
,	928	929		|O
respectively	930	942		|O
.	942	943		|O
There	944	949		|O
were	950	954		|O
6	955	956		|O
partial	957	964		|O
responses	965	974		|O
and	975	978		|O
1	979	980		|O
complete	981	989		|O
response	990	998		|O
(	999	1000		|O
objective	1000	1009		|O
response	1010	1018		|O
rate	1019	1023		|O
8.4%	1024	1028		|O
[	1029	1030		|O
95%	1030	1033		|O
CI	1034	1036		|O
3.5-16.6	1037	1045		|O
]	1045	1046		|O
)	1046	1047		|O
.	1047	1048		|O
Two	1049	1052		|O
patients	1053	1061		|O
remain	1062	1068		|O
in	1069	1071		|O
unmaintained	1072	1084		|O
remission	1085	1094		|O
close	1095	1100		|O
to	1101	1103		|O
3	1104	1105		|O
years	1106	1111		|O
from	1112	1116		|O
the	1117	1120		|O
initiation	1121	1131		|O
of	1132	1134		|O
gemcitabine	1135	1146		|O
plus	1147	1151		|O
capecitabine	1152	1164		|O
treatment	1165	1174		|O
.	1174	1175		|O
On	1176	1178		|O
multivariate	1179	1191		|O
analysis	1192	1200		|O
more	1201	1205		|O
than	1206	1210		|O
3	1211	1212		|O
disease	1213	1220		|O
sites	1221	1226		|O
were	1227	1231		|O
significantly	1232	1245		|O
associated	1246	1256		|O
with	1257	1261		|O
shorter	1262	1269		|O
progression	1270	1281		|O
-	1281	1282		|O
free	1282	1286		|O
survival	1287	1295		|O
and	1296	1299		|O
patients	1300	1308		|O
with	1309	1313		|O
thrombocytosis	1314	1328	thrombocytosis	|B-DISEASE
,	1328	1329		|O
more	1330	1334		|O
than	1335	1339		|O
3	1340	1341		|O
disease	1342	1349		|O
sites	1350	1355		|O
or	1356	1358		|O
anemia	1359	1365	anemia	|B-DISEASE
had	1366	1369		|O
a	1370	1371		|O
significantly	1372	1385		|O
increased	1386	1395		|O
risk	1396	1400		|O
of	1401	1403		|O
death	1404	1409		|O
.	1409	1410		|O
Adverse	1411	1418		|O
events	1419	1425		|O
occurring	1426	1435		|O
at	1436	1438		|O
least	1439	1444		|O
once	1445	1449		|O
in	1450	1452		|O
more	1453	1457		|O
than	1458	1462		|O
5%	1463	1465		|O
of	1466	1468		|O
patients	1469	1477		|O
included	1478	1486		|O
grade	1487	1492		|O
3	1493	1494		|O
or	1495	1497		|O
greater	1498	1505		|O
neutropenia	1506	1517	neutropenia	|B-ADVERSE
(	1518	1519		|O
83%	1519	1522		|O
)	1522	1523		|O
,	1523	1524		|O
grade	1525	1530		|O
2	1531	1532		|O
or	1533	1535		|O
greater	1536	1543		|O
hand	1544	1548	hand-foot syndrome	|B-ADVERSE
-	1548	1549		|I-ADVERSE
foot	1549	1553		|I-ADVERSE
syndrome	1554	1562		|I-ADVERSE
(	1563	1564		|O
13%	1564	1567		|O
)	1567	1568		|O
,	1568	1569		|O
grade	1570	1575		|O
3	1576	1577		|O
or	1578	1580		|O
greater	1581	1588		|O
thrombocytopenia	1589	1605	thrombocytopenia	|B-ADVERSE
(	1606	1607		|O
12%	1607	1610		|O
)	1610	1611		|O
,	1611	1612		|O
grade	1613	1618		|O
3	1619	1620		|O
or	1621	1623		|O
greater	1624	1631		|O
thromboembolic	1632	1646	thromboembolic events	|B-ADVERSE
events	1647	1653		|I-ADVERSE
(	1654	1655		|O
8%	1655	1657		|O
)	1657	1658		|O
,	1658	1659		|O
grade	1660	1665		|O
3	1666	1667		|O
or	1668	1670		|O
greater	1671	1678		|O
fatigue	1679	1686	fatigue	|B-ADVERSE
(	1687	1688		|O
8%	1688	1690		|O
)	1690	1691		|O
and	1692	1695		|O
grade	1696	1701		|O
2	1702	1703		|O
or	1704	1706		|O
greater	1707	1714		|O
mucositis	1715	1724	mucositis	|B-ADVERSE
(	1725	1726		|O
6%	1726	1728		|O
)	1728	1729		|O
.	1729	1730		|O
CONCLUSIONS	1731	1742		|O
:	1742	1743		|O
At	1744	1746		|O
the	1747	1750		|O
doses	1751	1756		|O
and	1757	1760		|O
schedule	1761	1769		|O
tested	1770	1776		|O
gemcitabine	1777	1788		|O
plus	1789	1793		|O
capecitabine	1794	1806		|O
demonstrated	1807	1819		|O
modest	1820	1826		|O
clinical	1827	1835		|O
activity	1836	1844		|O
in	1845	1847		|O
metastatic	1848	1858	metastatic renal cell cancer	|B-DISEASE
renal	1859	1864		|I-DISEASE
cell	1865	1869		|I-DISEASE
cancer	1870	1876		|I-DISEASE
after	1877	1882		|O
cytokine	1883	1891		|O
failure	1892	1899		|O
and	1900	1903		|O
produced	1904	1912		|O
significant	1913	1924		|O
neutropenia	1925	1936	neutropenia	|B-ADVERSE
.	1936	1937		|O
A	1938	1939		|O
modified	1940	1948		|O
gemcitabine	1949	1960		|O
plus	1961	1965		|O
capecitabine	1966	1978		|O
regimen	1979	1986		|O
may	1987	1990		|O
be	1991	1993		|O
evaluated	1994	2003		|O
in	2004	2006		|O
patients	2007	2015		|O
with	2016	2020		|O
metastatic	2021	2031	metastatic renal cell cancer	|B-DISEASE
renal	2032	2037		|I-DISEASE
cell	2038	2042		|I-DISEASE
cancer	2043	2049		|I-DISEASE
after	2050	2055		|O
failure	2056	2063		|O
of	2064	2066		|O
approved	2067	2075		|O
targeted	2076	2084		|O
therapies	2085	2094		|O
.	2094	2095		|O

### 18799925
Pulmonary	0	9	Pulmonary toxicity	|B-ADVERSE
toxicity	10	18		|I-ADVERSE
associated	19	29		|O
with	30	34		|O
vinorelbine	35	46		|O
-	46	47		|O
based	47	52		|O
chemotherapy	53	65		|O
in	66	68		|O
breast	69	75	breast cancer	|B-DISEASE
cancer	76	82		|I-DISEASE
.	82	83		|O
A	85	86		|O
41	87	89		|O
-	89	90		|O
year	90	94		|O
-	94	95		|O
old	95	98		|O
woman	99	104		|O
had	105	108		|O
undergone	109	118		|O
a	119	120		|O
left	121	125		|O
mastectomy	126	136		|O
breast	137	143	breast cancer	|B-DISEASE
cancer	144	150		|I-DISEASE
three	151	156		|O
years	157	162		|O
prior	163	168		|O
to	169	171		|O
presentation	172	184		|O
.	184	185		|O
No	186	188		|O
for	189	192		|O
at	193	195		|O
six	196	199		|O
months	200	206		|O
she	207	210		|O
had	211	214		|O
recurrence	215	225		|O
,	225	226		|O
this	227	231		|O
time	232	236		|O
in	237	239		|O
the	240	243		|O
right	244	249		|O
breast	250	256		|O
and	257	260		|O
skin	261	265		|O
.	265	266		|O
Despite	267	274		|O
first	275	280		|O
-	280	281		|O
and	281	284		|O
second	285	291		|O
-	291	292		|O
line	292	296		|O
chemotherapy	297	309		|O
,	309	310		|O
the	311	314		|O
mass	315	319		|O
showed	320	326		|O
progression	327	338		|O
of	339	341		|O
the	342	345		|O
disease	346	353		|O
.	353	354		|O
Thereafter	355	365		|O
,	365	366		|O
a	367	368		|O
weekly	369	375		|O
treatment	376	385		|O
of	386	388		|O
vinorelbine	389	400		|O
and	401	404		|O
trastuzumab	405	416		|O
was	417	420		|O
started	421	428		|O
,	428	429		|O
but	430	433		|O
one	434	437		|O
month	438	443		|O
later	444	449		|O
,	449	450		|O
she	451	454		|O
developed	455	464		|O
a	465	466		|O
slight	467	473		|O
fever	474	479	fever	|B-ADVERSE
and	480	483		|O
dry	484	487	dry cough	|B-ADVERSE
cough	488	493		|I-ADVERSE
.	493	494		|O
A	495	496		|O
chest	497	502		|O
CT	503	505		|O
scan	506	510		|O
revealed	511	519		|O
an	520	522		|O
infiltration	523	535		|O
shadow	536	542		|O
showing	543	550		|O
non	551	554		|O
-	554	555		|O
specific	555	563		|O
interstitial	564	576		|O
pattern	577	584		|O
in	585	587		|O
the	588	591		|O
right	592	597		|O
lung	598	602		|O
.	602	603		|O
A	604	605		|O
bronchoscopic	606	619		|O
examination	620	631		|O
showed	632	638		|O
lymphocyte	639	649		|O
dominance	650	659		|O
in	660	662		|O
bronchial	663	672		|O
lavage	673	679		|O
fluid	680	685		|O
,	685	686		|O
and	687	690		|O
lymphocyte	691	701		|O
infiltration	702	714		|O
into	715	719		|O
the	720	723		|O
interstium	724	734		|O
with	735	739		|O
fibrosis	740	748	fibrosis	|B-DISEASE
in	749	751		|O
the	752	755		|O
tissue	756	762		|O
specimens	763	772		|O
was	773	776		|O
found	777	782		|O
by	783	785		|O
transbronchial	786	800		|O
lung	801	805		|O
biopsy	806	812		|O
.	812	813		|O
After	814	819		|O
discontinuing	820	833		|O
the	834	837		|O
above	838	843		|O
vinorelbine	844	855		|O
therapy	856	863		|O
,	863	864		|O
the	865	868		|O
patient	869	876		|O
's	876	878		|O
condition	879	888		|O
improved	889	897		|O
.	897	898		|O
We	899	901		|O
therefore	902	911		|O
diagnosed	912	921		|O
this	922	926		|O
as	927	929		|O
a	930	931		|O
case	932	936		|O
of	937	939		|O
vinorelbine	940	951		|O
-	951	952		|O
and	952	955		|O
trastuzumab	956	967		|O
-	967	968		|O
induced	968	975		|O
interstitial	976	988	interstitial pneumonia	|B-ADVERSE
pneumonia	989	998		|I-ADVERSE
.	998	999		|O

### 18555982
Comparison	0	10		|O
of	11	13		|O
oxime	14	19		|O
reactivation	20	32		|O
and	33	36		|O
aging	37	42		|O
of	43	45		|O
nerve	46	51		|O
agent	52	57		|O
-	57	58		|O
inhibited	58	67		|O
monkey	68	74		|O
and	75	78		|O
human	79	84		|O
acetylcholinesterases	85	106		|O
.	106	107		|O
Non	109	112		|O
-	112	113		|O
human	113	118		|O
primates	119	127		|O
are	128	131		|O
valuable	132	140		|O
animal	141	147		|O
models	148	154		|O
that	155	159		|O
are	160	163		|O
used	164	168		|O
for	169	172		|O
the	173	176		|O
evaluation	177	187		|O
of	188	190		|O
nerve	191	196	nerve agent toxicity	|B-ADVERSE
agent	197	202		|I-ADVERSE
toxicity	203	211		|I-ADVERSE
as	212	214		|O
well	215	219		|O
as	220	222		|O
antidotes	223	232		|O
and	233	236		|O
results	237	244		|O
from	245	249		|O
animal	250	256		|O
experiments	257	268		|O
are	269	272		|O
extrapolated	273	285		|O
to	286	288		|O
humans	289	295		|O
.	295	296		|O
It	297	299		|O
has	300	303		|O
been	304	308		|O
demonstrated	309	321		|O
that	322	326		|O
the	327	330		|O
efficacy	331	339		|O
of	340	342		|O
an	343	345		|O
oxime	346	351		|O
primarily	352	361		|O
depends	362	369		|O
on	370	372		|O
its	373	376		|O
ability	377	384		|O
to	385	387		|O
reactivate	388	398		|O
nerve	399	404		|O
agent	405	410		|O
-	410	411		|O
inhibited	411	420		|O
acetylcholinesterase	421	441		|O
(	442	443		|O
AChE	443	447		|O
)	447	448		|O
.	448	449		|O
If	450	452		|O
the	453	456		|O
in	457	459		|O
vitro	460	465		|O
oxime	466	471		|O
reactivation	472	484		|O
of	485	487		|O
nerve	488	493		|O
agent	494	499		|O
-	499	500		|O
inhibited	500	509		|O
animal	510	516		|O
AChE	517	521		|O
is	522	524		|O
similar	525	532		|O
to	533	535		|O
that	536	540		|O
of	541	543		|O
human	544	549		|O
AChE	550	554		|O
,	554	555		|O
it	556	558		|O
is	559	561		|O
likely	562	568		|O
that	569	573		|O
the	574	577		|O
results	578	585		|O
of	586	588		|O
an	589	591		|O
in	592	594		|O
vivo	595	599		|O
animal	600	606		|O
study	607	612		|O
will	613	617		|O
reliably	618	626		|O
extrapolate	627	638		|O
to	639	641		|O
humans	642	648		|O
.	648	649		|O
Therefore	650	659		|O
,	659	660		|O
the	661	664		|O
goal	665	669		|O
of	670	672		|O
this	673	677		|O
study	678	683		|O
was	684	687		|O
to	688	690		|O
compare	691	698		|O
the	699	702		|O
aging	703	708		|O
and	709	712		|O
reactivation	713	725		|O
of	726	728		|O
human	729	734		|O
and	735	738		|O
different	739	748		|O
monkey	749	755		|O
(	756	757		|O
Rhesus	757	763		|O
,	763	764		|O
Cynomolgus	765	775		|O
,	775	776		|O
and	777	780		|O
African	781	788		|O
Green	789	794		|O
)	794	795		|O
AChEs	796	801		|O
inhibited	802	811		|O
by	812	814		|O
GF	815	817		|O
,	817	818		|O
GD	819	821		|O
,	821	822		|O
and	823	826		|O
VR	827	829		|O
.	829	830		|O
The	831	834		|O
oximes	835	841		|O
examined	842	850		|O
include	851	858		|O
the	859	862		|O
traditional	863	874		|O
oxime	875	880		|O
2	881	882		|O
-	882	883		|O
PAM	883	886		|O
,	886	887		|O
two	888	891		|O
H	892	893		|O
-	893	894		|O
oximes	894	900		|O
HI	901	903		|O
-	903	904		|O
6	904	905		|O
and	906	909		|O
HLo	910	913		|O
-	913	914		|O
7	914	915		|O
,	915	916		|O
and	917	920		|O
the	921	924		|O
new	925	928		|O
candidate	929	938		|O
oxime	939	944		|O
MMB4	945	949		|O
.	949	950		|O
Results	951	958		|O
indicate	959	967		|O
that	968	972		|O
oxime	973	978		|O
reactivation	979	991		|O
of	992	994		|O
all	995	998		|O
three	999	1004		|O
monkey	1005	1011		|O
AChEs	1012	1017		|O
was	1018	1021		|O
very	1022	1026		|O
similar	1027	1034		|O
to	1035	1037		|O
human	1038	1043		|O
AChE	1044	1048		|O
.	1048	1049		|O
The	1050	1053		|O
maximum	1054	1061		|O
difference	1062	1072		|O
in	1073	1075		|O
the	1076	1079		|O
second	1080	1086		|O
-	1086	1087		|O
order	1087	1092		|O
reactivation	1093	1105		|O
rate	1106	1110		|O
constant	1111	1119		|O
between	1120	1127		|O
human	1128	1133		|O
and	1134	1137		|O
three	1138	1143		|O
monkey	1144	1150		|O
AChEs	1151	1156		|O
or	1157	1159		|O
between	1160	1167		|O
AChEs	1168	1173		|O
from	1174	1178		|O
different	1179	1188		|O
monkey	1189	1195		|O
species	1196	1203		|O
was	1204	1207		|O
5	1208	1209		|O
-	1209	1210		|O
fold	1210	1214		|O
.	1214	1215		|O
Aging	1216	1221		|O
rate	1222	1226		|O
constants	1227	1236		|O
of	1237	1239		|O
GF	1240	1242		|O
-	1242	1243		|O
,	1243	1244		|O
GD	1245	1247		|O
-	1247	1248		|O
,	1248	1249		|O
and	1250	1253		|O
VR	1254	1256		|O
-	1256	1257		|O
inhibited	1257	1266		|O
monkey	1267	1273		|O
AChEs	1274	1279		|O
were	1280	1284		|O
very	1285	1289		|O
similar	1290	1297		|O
to	1298	1300		|O
human	1301	1306		|O
AChE	1307	1311		|O
except	1312	1318		|O
for	1319	1322		|O
GF	1323	1325		|O
-	1325	1326		|O
inhibited	1326	1335		|O
monkey	1336	1342		|O
AChEs	1343	1348		|O
,	1348	1349		|O
which	1350	1355		|O
aged	1356	1360		|O
2-3	1361	1364		|O
times	1365	1370		|O
faster	1371	1377		|O
than	1378	1382		|O
the	1383	1386		|O
human	1387	1392		|O
enzyme	1393	1399		|O
.	1399	1400		|O
The	1401	1404		|O
results	1405	1412		|O
of	1413	1415		|O
this	1416	1420		|O
study	1421	1426		|O
suggest	1427	1434		|O
that	1435	1439		|O
all	1440	1443		|O
three	1444	1449		|O
monkey	1450	1456		|O
species	1457	1464		|O
are	1465	1468		|O
suitable	1469	1477		|O
animal	1478	1484		|O
models	1485	1491		|O
for	1492	1495		|O
nerve	1496	1501		|O
agent	1502	1507		|O
antidote	1508	1516		|O
evaluation	1517	1527		|O
since	1528	1533		|O
monkey	1534	1540		|O
AChEs	1541	1546		|O
possess	1547	1554		|O
similar	1555	1562		|O
biochemical	1563	1574		|O
/	1574	1575		|O
pharmacological	1575	1590		|O
properties	1591	1601		|O
to	1602	1604		|O
human	1605	1610		|O
AChE	1611	1615		|O
.	1615	1616		|O

### 18633740
The	0	3		|O
impact	4	10		|O
of	11	13		|O
olanzapine	14	24		|O
on	25	27		|O
tardive	28	35	tardive dyskinetic symptoms	|B-DISEASE
dyskinetic	36	46		|I-DISEASE
symptoms	47	55		|I-DISEASE
in	56	58		|O
a	59	60		|O
state	61	66		|O
hospital	67	75		|O
population	76	86		|O
.	86	87		|O
BACKGROUND	89	99		|O
:	99	100		|O
Tardive	101	108	Tardive dyskinesia	|B-ADVERSE
dyskinesia	109	119		|I-ADVERSE
is	120	122		|O
a	123	124		|O
serious	125	132		|O
adverse	133	140		|O
event	141	146		|O
,	146	147		|O
which	148	153		|O
is	154	156		|O
associated	157	167		|O
mainly	168	174		|O
with	175	179		|O
the	180	183		|O
use	184	187		|O
of	188	190		|O
the	191	194		|O
first	195	200		|O
-	200	201		|O
generation	201	211		|O
antipsychotic	212	225		|O
agents	226	232		|O
.	232	233		|O
Convergent	234	244		|O
data	245	249		|O
from	250	254		|O
clinical	255	263		|O
trials	264	270		|O
suggest	271	278		|O
that	279	283		|O
second	284	290		|O
-	290	291		|O
generation	291	301		|O
antipsychotic	302	315		|O
agents	316	322		|O
are	323	326		|O
less	327	331		|O
likely	332	338		|O
to	339	341		|O
cause	342	347		|O
tardive	348	355	tardive dyskinesia	|B-ADVERSE
dyskinesia	356	366		|I-ADVERSE
.	366	367		|O
However	368	375		|O
,	375	376		|O
the	377	380		|O
data	381	385		|O
with	386	390		|O
regard	391	397		|O
to	398	400		|O
the	401	404		|O
effect	405	411		|O
of	412	414		|O
switching	415	424		|O
from	425	429		|O
first	430	435		|O
-	435	436		|O
to	437	439		|O
second	440	446		|O
-	446	447		|O
generation	447	457		|O
antipsychotic	458	471		|O
agents	472	478		|O
on	479	481		|O
pre	482	485		|O
-	485	486		|O
existing	486	494		|O
dyskinetic	495	505		|O
symptoms	506	514		|O
during	515	521		|O
routine	522	529		|O
clinical	530	538		|O
care	539	543		|O
is	544	546		|O
sparse	547	553		|O
.	553	554		|O
METHODS	555	562		|O
:	562	563		|O
Sixty	564	569		|O
-	569	570		|O
three	570	575		|O
patients	576	584		|O
with	585	589		|O
DSM	590	593	DSM-IV schizophrenia	|B-DISEASE
-	593	594		|I-DISEASE
IV	594	596		|I-DISEASE
schizophrenia	597	610		|I-DISEASE
or	611	613		|O
schizoaffective	614	629	schizoaffective disorder	|B-DISEASE
disorder	630	638		|I-DISEASE
(	639	640		|O
n	640	641		|O
=	642	643		|O
61	644	646		|O
)	646	647		|O
or	648	650		|O
bipolar	651	658	bipolar I disorder	|B-DISEASE
I	659	660		|I-DISEASE
disorder	661	669		|I-DISEASE
(	670	671		|O
n	671	672		|O
=	673	674		|O
2	675	676		|O
)	676	677		|O
consecutively	678	691		|O
admitted	692	700		|O
to	701	703		|O
a	704	705		|O
state	706	711		|O
hospital	712	720		|O
,	720	721		|O
who	722	725		|O
were	726	730		|O
treated	731	738		|O
either	739	745		|O
with	746	750		|O
olanzapine	751	761		|O
(	762	763		|O
n	763	764		|O
=	765	766		|O
35	767	769		|O
)	769	770		|O
or	771	773		|O
conventional	774	786		|O
antipsychotic	787	800		|O
agents	801	807		|O
(	808	809		|O
n	809	810		|O
=	811	812		|O
28	813	815		|O
)	815	816		|O
by	817	819		|O
physician	820	829		|O
choice	830	836		|O
,	836	837		|O
were	838	842		|O
enrolled	843	851		|O
in	852	854		|O
the	855	858		|O
study	859	864		|O
.	864	865		|O
The	866	869		|O
severity	870	878		|O
and	879	882		|O
frequency	883	892		|O
of	893	895		|O
tardive	896	903	tardive dyskinetic symptoms	|B-ADVERSE
dyskinetic	904	914		|I-ADVERSE
symptoms	915	923		|I-ADVERSE
using	924	929		|O
the	930	933		|O
Abnormal	934	942	Abnormal Involuntary Movement	|B-DISEASE
Involuntary	943	954		|I-DISEASE
Movement	955	963		|I-DISEASE
Scale	964	969		|O
were	970	974		|O
assessed	975	983		|O
in	984	986		|O
the	987	990		|O
two	991	994		|O
medication	995	1005		|O
groups	1006	1012		|O
at	1013	1015		|O
baseline	1016	1024		|O
,	1024	1025		|O
8	1026	1027		|O
weeks	1028	1033		|O
,	1033	1034		|O
and	1035	1038		|O
6	1039	1040		|O
months	1041	1047		|O
.	1047	1048		|O
RESULTS	1049	1056		|O
:	1056	1057		|O
There	1058	1063		|O
were	1064	1068		|O
statistically	1069	1082		|O
significant	1083	1094		|O
reductions	1095	1105		|O
in	1106	1108		|O
the	1109	1112		|O
prevalence	1113	1123		|O
and	1124	1127		|O
severity	1128	1136		|O
of	1137	1139		|O
dyskinetic	1140	1150	dyskinetic symptoms	|B-ADVERSE
symptoms	1151	1159		|I-ADVERSE
at	1160	1162		|O
8	1163	1164		|O
weeks	1165	1170		|O
and	1171	1174		|O
6	1175	1176		|O
months	1177	1183		|O
for	1184	1187		|O
the	1188	1191		|O
group	1192	1197		|O
treated	1198	1205		|O
with	1206	1210		|O
olanzapine	1211	1221		|O
but	1222	1225		|O
not	1226	1229		|O
for	1230	1233		|O
those	1234	1239		|O
treated	1240	1247		|O
with	1248	1252		|O
conventional	1253	1265		|O
agents	1266	1272		|O
.	1272	1273		|O
CONCLUSIONS	1274	1285		|O
:	1285	1286		|O
These	1287	1292		|O
preliminary	1293	1304		|O
data	1305	1309		|O
suggest	1310	1317		|O
that	1318	1322		|O
olanzapine	1323	1333		|O
may	1334	1337		|O
be	1338	1340		|O
a	1341	1342		|O
treatment	1343	1352		|O
option	1353	1359		|O
for	1360	1363		|O
subjects	1364	1372		|O
with	1373	1377		|O
tardive	1378	1385	tardive dyskinesia	|B-ADVERSE
dyskinesia	1386	1396		|I-ADVERSE
.	1396	1397		|O
However	1398	1405		|O
,	1405	1406		|O
the	1407	1410		|O
question	1411	1419		|O
whether	1420	1427		|O
olanzapine	1428	1438		|O
treats	1439	1445		|O
,	1445	1446		|O
ameliorates	1447	1458		|O
,	1458	1459		|O
or	1460	1462		|O
masks	1463	1468		|O
preexisting	1469	1480		|O
tardive	1481	1488	tardive dyskinesia	|B-ADVERSE
dyskinesia	1489	1499		|I-ADVERSE
was	1500	1503		|O
difficult	1504	1513		|O
to	1514	1516		|O
answer	1517	1523		|O
,	1523	1524		|O
as	1525	1527		|O
no	1528	1530		|O
dosage	1531	1537		|O
reduction	1538	1547		|O
or	1548	1550		|O
withdrawal	1551	1561		|O
was	1562	1565		|O
undertaken	1566	1576		|O
.	1576	1577		|O

### 18584977
Risk	0	4		|O
assessment	5	15		|O
of	16	18		|O
dietary	19	26		|O
exposures	27	36		|O
to	37	39		|O
compounds	40	49		|O
that	50	54		|O
are	55	58		|O
genotoxic	59	68		|O
and	69	72		|O
carcinogenic	73	85		|O
-	85	86		|O
-	86	87		|O
an	87	89		|O
overview	90	98		|O
.	98	99		|O
The	101	104		|O
process	105	112		|O
of	113	115		|O
risk	116	120		|O
assessment	121	131		|O
of	132	134		|O
dietary	135	142		|O
exposures	143	152		|O
to	153	155		|O
genotoxic	156	165		|O
carcinogens	166	177		|O
is	178	180		|O
summarised	181	191		|O
.	191	192		|O
Exposures	193	202		|O
to	203	205		|O
six	206	209		|O
genotoxic	210	219		|O
carcinogens	220	231		|O
in	232	234		|O
food	235	239		|O
(	240	241		|O
acrylamide	241	251		|O
,	251	252		|O
aflatoxin	253	262		|O
B1	263	265		|O
,	265	266		|O
benzo	267	272		|O
(	272	273		|O
a	273	274		|O
)	274	275		|O
pyrene	275	281		|O
,	281	282		|O
dimethylnitrosamine	283	302		|O
,	302	303		|O
ethyl	304	309		|O
carbamate	310	319		|O
,	319	320		|O
PhIP	321	325		|O
)	325	326		|O
have	327	331		|O
been	332	336		|O
used	337	341		|O
to	342	344		|O
illustrate	345	355		|O
the	356	359		|O
process	360	367		|O
.	367	368		|O
The	369	372		|O
margin	373	379		|O
of	380	382		|O
exposure	383	391		|O
(	392	393		|O
MOE	393	396		|O
)	396	397		|O
approach	398	406		|O
is	407	409		|O
seen	410	414		|O
as	415	417		|O
a	418	419		|O
useful	420	426		|O
method	427	433		|O
to	434	436		|O
be	437	439		|O
used	440	444		|O
in	445	447		|O
the	448	451		|O
risk	452	456		|O
characterisation	457	473		|O
step	474	478		|O
of	479	481		|O
assessing	482	491		|O
exposures	492	501		|O
to	502	504		|O
genotoxic	505	514		|O
carcinogens	515	526		|O
.	526	527		|O
This	528	532		|O
approach	533	541		|O
combines	542	550		|O
information	551	562		|O
on	563	565		|O
animal	566	572		|O
potency	573	580		|O
and	581	584		|O
human	585	590		|O
exposure	591	599		|O
,	599	600		|O
and	601	604		|O
can	605	608		|O
be	609	611		|O
used	612	616		|O
to	617	619		|O
indicate	620	628		|O
levels	629	635		|O
of	636	638		|O
concern	639	646		|O
and	647	650		|O
also	651	655		|O
the	656	659		|O
ranking	660	667		|O
between	668	675		|O
various	676	683		|O
exposures	684	693		|O
to	694	696		|O
such	697	701		|O
agents	702	708		|O
.	708	709		|O
Both	710	714		|O
the	715	718		|O
T25	719	722		|O
and	723	726		|O
the	727	730		|O
BMDL10	731	737		|O
methods	738	745		|O
may	746	749		|O
be	750	752		|O
used	753	757		|O
as	758	760		|O
a	761	762		|O
reference	763	772		|O
point	773	778		|O
.	778	779		|O
Should	780	786		|O
a	787	788		|O
specific	789	797		|O
MOE	798	801		|O
value	802	807		|O
be	808	810		|O
developed	811	820		|O
as	821	823		|O
a	824	825		|O
cut	826	829		|O
-	829	830		|O
off	830	833		|O
between	834	841		|O
levels	842	848		|O
of	849	851		|O
concern	852	859		|O
and	860	863		|O
levels	864	870		|O
of	871	873		|O
low	874	877		|O
concern	878	885		|O
,	885	886		|O
the	887	890		|O
value	891	896		|O
using	897	902		|O
T25	903	906		|O
data	907	911		|O
is	912	914		|O
proposed	915	923		|O
to	924	926		|O
be	927	929		|O
2.5	930	933		|O
-	933	934		|O
times	934	939		|O
higher	940	946		|O
than	947	951		|O
using	952	957		|O
BMDL10	958	964		|O
data	965	969		|O
.	969	970		|O
Linear	971	977		|O
low	978	981		|O
-	981	982		|O
dose	982	986		|O
extrapolation	987	1000		|O
using	1001	1006		|O
either	1007	1013		|O
T25	1014	1017		|O
or	1018	1020		|O
BMDL10	1021	1027		|O
,	1027	1028		|O
may	1029	1032		|O
also	1033	1037		|O
be	1038	1040		|O
applied	1041	1048		|O
.	1048	1049		|O
However	1050	1057		|O
,	1057	1058		|O
it	1059	1061		|O
should	1062	1068		|O
be	1069	1071		|O
understood	1072	1082		|O
that	1083	1087		|O
this	1088	1092		|O
approach	1093	1101		|O
should	1102	1108		|O
not	1109	1112		|O
be	1113	1115		|O
interpreted	1116	1127		|O
as	1128	1130		|O
giving	1131	1137		|O
a	1138	1139		|O
precise	1140	1147		|O
estimate	1148	1156		|O
of	1157	1159		|O
human	1160	1165		|O
risk	1166	1170		|O
.	1170	1171		|O
For	1172	1175		|O
exposures	1176	1185		|O
to	1186	1188		|O
mutagens	1189	1197		|O
in	1198	1200		|O
food	1201	1205		|O
lacking	1206	1213		|O
carcinogenicity	1214	1229	carcinogenicity	|B-ADVERSE
data	1230	1234		|O
,	1234	1235		|O
it	1236	1238		|O
is	1239	1241		|O
proposed	1242	1250		|O
to	1251	1253		|O
apply	1254	1259		|O
the	1260	1263		|O
MOE	1264	1267		|O
approach	1268	1276		|O
to	1277	1279		|O
the	1280	1283		|O
lowest	1284	1290		|O
effective	1291	1300		|O
dose	1301	1305		|O
(	1306	1307		|O
LED	1307	1310		|O
)	1310	1311		|O
for	1312	1315		|O
in	1316	1318		|O
vivo	1319	1323		|O
genotoxicity	1324	1336	genotoxicity	|B-ADVERSE
.	1336	1337		|O

### 18855271
The	0	3		|O
effect	4	10		|O
of	11	13		|O
trandolapril	14	26		|O
and	27	30		|O
its	31	34		|O
fixed	35	40		|O
-	40	41		|O
dose	41	45		|O
combination	46	57		|O
with	58	62		|O
verapamil	63	72		|O
on	73	75		|O
circulating	76	87		|O
adhesion	88	96		|O
molecules	97	106		|O
levels	107	113		|O
in	114	116		|O
hypertensive	117	129		|O
patients	130	138		|O
with	139	143		|O
type	144	148	type 2 diabetes	|B-DISEASE
2	149	150		|I-DISEASE
diabetes	151	159		|I-DISEASE
.	159	160		|O
BACKGROUND	162	172		|O
AND	173	176		|O
AIM	177	180		|O
:	180	181		|O
Endothelial	182	193	Endothelial dysfunction	|B-DISEASE
dysfunction	194	205		|I-DISEASE
in	206	208		|O
hypertensive	209	221		|O
type	222	226		|O
-	226	227		|O
2	227	228		|O
diabetic	229	237		|O
patients	238	246		|O
is	247	249		|O
associated	250	260		|O
with	261	265		|O
increased	266	275		|O
levels	276	282		|O
of	283	285		|O
circulating	286	297		|O
soluble	298	305		|O
adhesion	306	314		|O
molecules	315	324		|O
(	325	326		|O
SAM	326	329		|O
)	329	330		|O
.	330	331		|O
SAM	332	335		|O
participate	336	347		|O
in	348	350		|O
the	351	354		|O
development	355	366		|O
of	367	369		|O
diabetic	370	378	diabetic macroangiopathy	|B-DISEASE
macroangiopathy	379	394		|I-DISEASE
and	395	398		|O
microangiopathy	399	414	microangiopathy	|B-DISEASE
.	414	415		|O
The	416	419		|O
aim	420	423		|O
of	424	426		|O
this	427	431		|O
study	432	437		|O
was	438	441		|O
to	442	444		|O
compare	445	452		|O
the	453	456		|O
effect	457	463		|O
of	464	466		|O
trandolapril	467	479		|O
(	480	481		|O
T	481	482		|O
)	482	483		|O
and	484	487		|O
its	488	491		|O
fixed	492	497		|O
-	497	498		|O
dose	498	502		|O
combination	503	514		|O
with	515	519		|O
verapamil	520	529		|O
(	530	531		|O
FDTV	531	535		|O
)	535	536		|O
on	537	539		|O
SAM	540	543		|O
levels	544	550		|O
in	551	553		|O
hypertensive	554	566		|O
type	567	571		|O
-	571	572		|O
2	572	573		|O
diabetic	574	582		|O
patients	583	591		|O
.	591	592		|O
METHODS	593	600		|O
:	600	601		|O
Forty	602	607		|O
type	608	612		|O
-	612	613		|O
2	613	614		|O
diabetic	615	623		|O
patients	624	632		|O
with	633	637		|O
never	638	643		|O
-	643	644		|O
treated	644	651		|O
hypertension	652	664	hypertension	|B-DISEASE
were	665	669		|O
randomly	670	678		|O
assigned	679	687		|O
to	688	690		|O
two	691	694		|O
groups	695	701		|O
.	701	702		|O
One	703	706		|O
group	707	712		|O
(	713	714		|O
FDTV	714	718		|O
)	718	719		|O
received	720	728		|O
2/180	729	734		|O
mg	735	737		|O
once	738	742		|O
a	743	744		|O
day	745	748		|O
;	748	749		|O
the	750	753		|O
other	754	759		|O
group	760	765		|O
received	766	774		|O
T	775	776		|O
2	777	778		|O
mg	779	781		|O
once	782	786		|O
a	787	788		|O
day	789	792		|O
.	792	793		|O
Study	794	799		|O
drugs	800	805		|O
were	806	810		|O
administered	811	823		|O
for	824	827		|O
three	828	833		|O
months	834	840		|O
in	841	843		|O
both	844	848		|O
groups	849	855		|O
.	855	856		|O
VCAM	857	861		|O
-	861	862		|O
1	862	863		|O
,	863	864		|O
ICAM	865	869		|O
,	869	870		|O
and	871	874		|O
E	875	876		|O
-	876	877		|O
selectin	877	885		|O
were	886	890		|O
measured	891	899		|O
by	900	902		|O
ELISA	903	908		|O
at	909	911		|O
the	912	915		|O
beginning	916	925		|O
and	926	929		|O
end	930	933		|O
of	934	936		|O
the	937	940		|O
study	941	946		|O
.	946	947		|O
Patients	948	956		|O
were	957	961		|O
evaluated	962	971		|O
monthly	972	979		|O
for	980	983		|O
blood	984	989		|O
pressure	990	998		|O
,	998	999		|O
fasting	1000	1007		|O
serum	1008	1013		|O
glucose	1014	1021		|O
,	1021	1022		|O
and	1023	1026		|O
adverse	1027	1034		|O
events	1035	1041		|O
.	1041	1042		|O
Statistical	1043	1054		|O
analysis	1055	1063		|O
was	1064	1067		|O
performed	1068	1077		|O
with	1078	1082		|O
ANOVA	1083	1088		|O
.	1088	1089		|O
RESULTS	1090	1097		|O
:	1097	1098		|O
Both	1099	1103		|O
therapeutics	1104	1116		|O
regimens	1117	1125		|O
reduced	1126	1133		|O
significantly	1134	1147		|O
the	1148	1151		|O
levels	1152	1158		|O
of	1159	1161		|O
the	1162	1165		|O
SAM	1166	1169		|O
tested	1170	1176		|O
.	1176	1177		|O
When	1178	1182		|O
both	1183	1187		|O
groups	1188	1194		|O
were	1195	1199		|O
compared	1200	1208		|O
,	1208	1209		|O
we	1210	1212		|O
did	1213	1216		|O
not	1217	1220		|O
find	1221	1225		|O
a	1226	1227		|O
significant	1228	1239		|O
difference	1240	1250		|O
in	1251	1253		|O
ICAM	1254	1258		|O
and	1259	1262		|O
E	1263	1264		|O
-	1264	1265		|O
selectin	1265	1273		|O
reduction	1274	1283		|O
.	1283	1284		|O
However	1285	1292		|O
,	1292	1293		|O
VCAM	1294	1298		|O
-	1298	1299		|O
1	1299	1300		|O
presented	1301	1310		|O
a	1311	1312		|O
significantly	1313	1326		|O
greater	1327	1334		|O
reduction	1335	1344		|O
(	1345	1346		|O
p	1346	1347		|O
=	1348	1349		|O
0.022	1350	1355		|O
)	1355	1356		|O
in	1357	1359		|O
the	1360	1363		|O
trandolapril	1364	1376		|O
-	1376	1377		|O
verapamil	1377	1386		|O
group	1387	1392		|O
.	1392	1393		|O
No	1394	1396		|O
patient	1397	1404		|O
suffered	1405	1413		|O
adverse	1414	1421		|O
events	1422	1428		|O
.	1428	1429		|O
CONCLUSION	1430	1440		|O
:	1440	1441		|O
Our	1442	1445		|O
results	1446	1453		|O
show	1454	1458		|O
that	1459	1463		|O
FDTV	1464	1468		|O
produces	1469	1477		|O
a	1478	1479		|O
greater	1480	1487		|O
reduction	1488	1497		|O
of	1498	1500		|O
VCAM	1501	1505		|O
-	1505	1506		|O
1	1506	1507		|O
circulating	1508	1519		|O
levels	1520	1526		|O
than	1527	1531		|O
trandolapril	1532	1544		|O
alone	1545	1550		|O
.	1550	1551		|O
This	1552	1556		|O
may	1557	1560		|O
explain	1561	1568		|O
some	1569	1573		|O
of	1574	1576		|O
the	1577	1580		|O
beneficial	1581	1591		|O
effects	1592	1599		|O
of	1600	1602		|O
this	1603	1607		|O
fixed	1608	1613		|O
dosed	1614	1619		|O
combination	1620	1631		|O
that	1632	1636		|O
are	1637	1640		|O
non	1641	1644		|O
-	1644	1645		|O
related	1645	1652		|O
to	1653	1655		|O
its	1656	1659		|O
antihypertensive	1660	1676		|O
effects	1677	1684		|O
.	1684	1685		|O

### 18781664
Incidence	0	9		|O
and	10	13		|O
predictors	14	24		|O
of	25	27		|O
activation	28	38	activation syndrome	|B-DISEASE
syndrome	39	47		|I-DISEASE
induced	48	55		|O
by	56	58		|O
antidepressants	59	74		|O
.	74	75		|O
BACKGROUND	77	87		|O
:	87	88		|O
Activation	89	99	Activation syndrome	|B-DISEASE
syndrome	100	108		|I-DISEASE
is	109	111		|O
a	112	113		|O
side	114	118		|O
effect	119	125		|O
of	126	128		|O
antidepressants	129	144		|O
that	145	149		|O
is	150	152		|O
thought	153	160		|O
to	161	163		|O
carry	164	169		|O
a	170	171		|O
potentially	172	183		|O
increased	184	193		|O
risk	194	198		|O
of	199	201		|O
suicide	202	209	suicide	|B-DISEASE
.	209	210		|O
However	211	218		|O
,	218	219		|O
the	220	223		|O
incidence	224	233		|O
of	234	236		|O
activation	237	247	activation syndrome	|B-DISEASE
syndrome	248	256		|I-DISEASE
has	257	260		|O
not	261	264		|O
been	265	269		|O
fully	270	275		|O
investigated	276	288		|O
and	289	292		|O
little	293	299		|O
has	300	303		|O
been	304	308		|O
reported	309	317		|O
on	318	320		|O
its	321	324		|O
predictors	325	335		|O
.	335	336		|O
The	337	340		|O
aim	341	344		|O
of	345	347		|O
this	348	352		|O
study	353	358		|O
was	359	362		|O
to	363	365		|O
survey	366	372		|O
the	373	376		|O
incidence	377	386		|O
of	387	389		|O
activation	390	400	activation syndrome	|B-DISEASE
syndrome	401	409		|I-DISEASE
and	410	413		|O
clarify	414	421		|O
its	422	425		|O
predictors	426	436		|O
in	437	439		|O
a	440	441		|O
natural	442	449		|O
clinical	450	458		|O
setting	459	466		|O
.	466	467		|O
METHODS	468	475		|O
:	475	476		|O
Among	477	482		|O
2,521	483	488		|O
new	489	492		|O
outpatients	493	504		|O
visiting	505	513		|O
between	514	521		|O
August	522	528		|O
2003	529	533		|O
and	534	537		|O
March	538	543		|O
2005	544	548		|O
,	548	549		|O
we	550	552		|O
retrospectively	553	568		|O
surveyed	569	577		|O
the	578	581		|O
case	582	586		|O
records	587	594		|O
of	595	597		|O
729	598	601		|O
patients	602	610		|O
who	611	614		|O
had	615	618		|O
not	619	622		|O
taken	623	628		|O
any	629	632		|O
antidepressants	633	648		|O
during	649	655		|O
the	656	659		|O
1	660	661		|O
month	662	667		|O
before	668	674		|O
presentation	675	687		|O
and	688	691		|O
were	692	696		|O
prescribed	697	707		|O
antidepressants	708	723		|O
for	724	727		|O
3	728	729		|O
months	730	736		|O
after	737	742		|O
the	743	746		|O
initial	747	754		|O
visit	755	760		|O
.	760	761		|O
Patients	762	770		|O
were	771	775		|O
classified	776	786		|O
as	787	789		|O
developing	790	800		|O
activation	801	811	activation syndrome	|B-DISEASE
syndrome	812	820		|I-DISEASE
if	821	823		|O
they	824	828		|O
experienced	829	840		|O
any	841	844		|O
symptom	845	852		|O
of	853	855		|O
anxiety	856	863	anxiety	|B-DISEASE
,	863	864		|O
agitation	865	874	agitation	|B-DISEASE
,	874	875		|O
panic	876	881	panic attacks	|B-DISEASE
attacks	882	889		|I-DISEASE
,	889	890		|O
insomnia	891	899	insomnia	|B-DISEASE
,	899	900		|O
irritability	901	913	irritability	|B-DISEASE
,	913	914		|O
hostility	915	924	hostility	|B-DISEASE
,	924	925		|O
aggressiveness	926	940	aggressiveness	|B-DISEASE
,	940	941		|O
impulsivity	942	953		|O
,	953	954		|O
akathisia	955	964	akathisia	|B-DISEASE
,	964	965		|O
hypomania	966	975	hypomania	|B-DISEASE
,	975	976		|O
and	977	980		|O
mania	981	986	mania	|B-DISEASE
during	987	993		|O
the	994	997		|O
first	998	1003		|O
3	1004	1005		|O
months	1006	1012		|O
.	1012	1013		|O
RESULTS	1014	1021		|O
:	1021	1022		|O
Of	1023	1025		|O
the	1026	1029		|O
729	1030	1033		|O
patients	1034	1042		|O
,	1042	1043		|O
31	1044	1046		|O
(	1047	1048		|O
4.3%	1048	1052		|O
)	1052	1053		|O
developed	1054	1063		|O
activation	1064	1074	activation syndrome	|B-DISEASE
syndrome	1075	1083		|I-DISEASE
.	1083	1084		|O
The	1085	1088		|O
incidence	1089	1098		|O
was	1099	1102		|O
not	1103	1106		|O
significantly	1107	1120		|O
related	1121	1128		|O
to	1129	1131		|O
gender	1132	1138		|O
,	1138	1139		|O
age	1140	1143		|O
,	1143	1144		|O
class	1145	1150		|O
of	1151	1153		|O
antidepressant	1154	1168		|O
,	1168	1169		|O
combined	1170	1178		|O
use	1179	1182		|O
of	1183	1185		|O
benzodiazepine	1186	1200		|O
,	1200	1201		|O
or	1202	1204		|O
DSM	1205	1208		|O
-	1208	1209		|O
IV	1209	1211		|O
-	1211	1212		|O
TR	1212	1214		|O
diagnosis	1215	1224		|O
except	1225	1231		|O
for	1232	1235		|O
personality	1236	1247	personality disorder	|B-DISEASE
disorder	1248	1256		|I-DISEASE
.	1256	1257		|O
Diagnosis	1258	1267		|O
of	1268	1270		|O
personality	1271	1282	personality disorder	|B-DISEASE
disorder	1283	1291		|I-DISEASE
was	1292	1295		|O
significantly	1296	1309		|O
associated	1310	1320		|O
with	1321	1325		|O
the	1326	1329		|O
induction	1330	1339		|O
of	1340	1342		|O
activation	1343	1353	activation syndrome	|B-DISEASE
syndrome	1354	1362		|I-DISEASE
(	1363	1364		|O
odds	1364	1368		|O
ratio	1369	1374		|O
=	1374	1375		|O
4.20	1375	1379		|O
,	1379	1380		|O
P	1381	1382		|O
=	1382	1383		|O
0.002	1383	1388		|O
)	1388	1389		|O
.	1389	1390		|O
CONCLUSIONS	1391	1402		|O
:	1402	1403		|O
This	1404	1408		|O
study	1409	1414		|O
suggests	1415	1423		|O
that	1424	1428		|O
diagnosis	1429	1438		|O
of	1439	1441		|O
personality	1442	1453	personality disorder	|B-DISEASE
disorder	1454	1462		|I-DISEASE
may	1463	1466		|O
be	1467	1469		|O
a	1470	1471		|O
clinical	1472	1480		|O
predictor	1481	1490		|O
of	1491	1493		|O
activation	1494	1504	activation syndrome	|B-DISEASE
syndrome	1505	1513		|I-DISEASE
.	1513	1514		|O

### 18580955
Pharmacokinetic	0	15		|O
,	15	16		|O
pharmacodynamic	17	32		|O
and	33	36		|O
intracellular	37	50		|O
effects	51	58		|O
of	59	61		|O
PEG	62	65		|O
-	65	66		|O
asparaginase	66	78		|O
in	79	81		|O
newly	82	87		|O
diagnosed	88	97		|O
childhood	98	107		|O
acute	108	113	acute lymphoblastic leukemia	|B-DISEASE
lymphoblastic	114	127		|I-DISEASE
leukemia	128	136		|I-DISEASE
:	136	137		|O
results	138	145		|O
from	146	150		|O
a	151	152		|O
single	153	159		|O
agent	160	165		|O
window	166	172		|O
study	173	178		|O
.	178	179		|O
L	181	182		|O
-	182	183		|O
asparaginase	183	195		|O
is	196	198		|O
an	199	201		|O
effective	202	211		|O
drug	212	216		|O
for	217	220		|O
treatment	221	230		|O
of	231	233		|O
children	234	242		|O
with	243	247		|O
acute	248	253	acute lymphoblastic leukemia	|B-DISEASE
lymphoblastic	254	267		|I-DISEASE
leukemia	268	276		|I-DISEASE
(	277	278		|O
ALL	278	281	ALL	|B-DISEASE
)	281	282		|O
.	282	283		|O
The	284	287		|O
effectiveness	288	301		|O
is	302	304		|O
thought	305	312		|O
to	313	315		|O
result	316	322		|O
from	323	327		|O
depletion	328	337		|O
of	338	340		|O
asparagine	341	351		|O
in	352	354		|O
serum	355	360		|O
and	361	364		|O
cells	365	370		|O
.	370	371		|O
We	372	374		|O
investigated	375	387		|O
the	388	391		|O
clinical	392	400		|O
response	401	409		|O
in	410	412		|O
vivo	413	417		|O
of	418	420		|O
1000	421	425		|O
IU	426	428		|O
/	428	429		|O
m	429	430		|O
(	430	431		|O
2	431	432		|O
)	432	433		|O
pegylated	434	443		|O
(	444	445		|O
PEG	445	448		|O
)	448	449		|O
-	449	450		|O
asparaginase	450	462		|O
and	463	466		|O
its	467	470		|O
pharmacokinetic	471	486		|O
,	486	487		|O
pharmacodynamic	488	503		|O
and	504	507		|O
intracellular	508	521		|O
effects	522	529		|O
in	530	532		|O
children	533	541		|O
with	542	546		|O
newly	547	552		|O
diagnosed	553	562		|O
ALL	563	566	ALL	|B-DISEASE
before	567	573		|O
start	574	579		|O
of	580	582		|O
combination	583	594		|O
chemotherapy	595	607		|O
.	607	608		|O
The	609	612		|O
in	613	615		|O
vivo	616	620		|O
window	621	627		|O
response	628	636		|O
was	637	640		|O
significantly	641	654		|O
related	655	662		|O
to	663	665		|O
immunophenotype	666	681		|O
and	682	685		|O
genotype	686	694		|O
:	694	695		|O
26/38	696	701		|O
common	702	708		|O
/	708	709		|O
pre	709	712		|O
B	713	714		|O
-	714	715		|O
ALL	715	718		|O
cases	719	724		|O
,	724	725		|O
especially	726	736		|O
those	737	742		|O
with	743	747		|O
hyperdiploidy	748	761		|O
and	762	765		|O
TELAML1	766	773		|O
rearrangement	774	787		|O
,	787	788		|O
demonstrated	789	801		|O
a	802	803		|O
good	804	808		|O
clinical	809	817		|O
response	818	826		|O
compared	827	835		|O
to	836	838		|O
8/17	839	843		|O
T	844	845		|O
-	845	846		|O
ALL	846	849		|O
(	850	851		|O
P	851	852		|O
=	852	853		|O
0.01	853	857		|O
)	857	858		|O
and	859	862		|O
BCRABL	863	869		|O
-	869	870		|O
positive	870	878		|O
ALL	879	882	ALL	|B-DISEASE
(	883	884		|O
P	884	885		|O
=	885	886		|O
0.04	886	890		|O
)	890	891		|O
.	891	892		|O
A	893	894		|O
poor	895	899		|O
in	900	902		|O
vivo	903	907		|O
clinical	908	916		|O
window	917	923		|O
response	924	932		|O
was	933	936		|O
related	937	944		|O
to	945	947		|O
in	948	950		|O
vitro	951	956		|O
resistance	957	967		|O
to	968	970		|O
L	971	972		|O
-	972	973		|O
asparaginase	973	985		|O
(	986	987		|O
P	987	988		|O
=	988	989		|O
0.02	989	993		|O
)	993	994		|O
and	995	998		|O
both	999	1003		|O
were	1004	1008		|O
prognostic	1009	1019		|O
factors	1020	1027		|O
for	1028	1031		|O
long	1032	1036		|O
-	1036	1037		|O
term	1037	1041		|O
event	1042	1047		|O
-	1047	1048		|O
free	1048	1052		|O
survival	1053	1061		|O
(	1062	1063		|O
hazard	1063	1069		|O
ratio	1070	1075		|O
6.4	1076	1079		|O
,	1079	1080		|O
P	1081	1082		|O
=	1082	1083		|O
0.004	1083	1088		|O
;	1088	1089		|O
hazard	1090	1096		|O
ratio	1097	1102		|O
3.7	1103	1106		|O
,	1106	1107		|O
P	1108	1109		|O
=	1109	1110		|O
0.01	1110	1114		|O
)	1114	1115		|O
.	1115	1116		|O
After	1117	1122		|O
administration	1123	1137		|O
of	1138	1140		|O
one	1141	1144		|O
in	1145	1147		|O
vivo	1148	1152		|O
dose	1153	1157		|O
of	1158	1160		|O
PEG	1161	1164		|O
-	1164	1165		|O
asparaginase	1165	1177		|O
no	1178	1180		|O
changes	1181	1188		|O
in	1189	1191		|O
apoptotic	1192	1201		|O
parameters	1202	1212		|O
or	1213	1215		|O
in	1216	1218		|O
intracellular	1219	1232		|O
levels	1233	1239		|O
of	1240	1242		|O
twenty	1243	1249		|O
amino	1250	1255		|O
acids	1256	1261		|O
in	1262	1264		|O
leukemic	1265	1273		|O
cells	1274	1279		|O
could	1280	1285		|O
be	1286	1288		|O
measured	1289	1297		|O
,	1297	1298		|O
in	1299	1301		|O
contradiction	1302	1315		|O
to	1316	1318		|O
the	1319	1322		|O
changes	1323	1330		|O
found	1331	1336		|O
after	1337	1342		|O
in	1343	1345		|O
vitro	1346	1351		|O
exposure	1352	1360		|O
.	1360	1361		|O
This	1362	1366		|O
may	1367	1370		|O
be	1371	1373		|O
explained	1374	1383		|O
by	1384	1386		|O
the	1387	1390		|O
rapid	1391	1396		|O
removal	1397	1404		|O
of	1405	1407		|O
apoptotic	1408	1417		|O
cells	1418	1423		|O
from	1424	1428		|O
the	1429	1432		|O
circulation	1433	1444		|O
in	1445	1447		|O
vivo	1448	1452		|O
.	1452	1453		|O
One	1454	1457		|O
additional	1458	1468		|O
dose	1469	1473		|O
of	1474	1476		|O
PEG	1477	1480		|O
-	1480	1481		|O
asparaginase	1481	1493		|O
upfront	1494	1501		|O
ALL	1502	1505	ALL	|B-DISEASE
treatment	1506	1515		|O
did	1516	1519		|O
not	1520	1523		|O
lead	1524	1528		|O
to	1529	1531		|O
other	1532	1537		|O
severe	1538	1544		|O
toxicities	1545	1555		|O
.	1555	1556		|O

### 18785684
The	0	3		|O
assessment	4	14		|O
of	15	17		|O
genotoxic	18	27	genotoxic effects	|B-ADVERSE
effects	28	35		|I-ADVERSE
of	36	38		|O
wastewater	39	49		|O
from	50	54		|O
a	55	56		|O
fertilizer	57	67		|O
factory	68	75		|O
.	75	76		|O
In	78	80		|O
this	81	85		|O
study	86	91		|O
we	92	94		|O
investigated	95	107		|O
cytotoxic	108	117		|O
,	117	118		|O
mutagenic	119	128		|O
and	129	132		|O
genotoxic	133	142	genotoxic effects	|B-ADVERSE
effects	143	150		|I-ADVERSE
of	151	153		|O
different	154	163		|O
concentrations	164	178		|O
of	179	181		|O
wastewater	182	192		|O
from	193	197		|O
the	198	201		|O
phosphoric	202	212		|O
gypsum	213	219		|O
depot	220	225		|O
near	226	230		|O
the	231	234		|O
factory	235	242		|O
for	243	246		|O
fertilizing	247	258		|O
agents	259	265		|O
'	266	267		|O
INA	267	270		|O
Petrokemija	271	282		|O
'	282	283		|O
(	284	285		|O
Kutina	285	291		|O
,	291	292		|O
Croatia	293	300		|O
)	300	301		|O
.	301	302		|O
The	303	306		|O
Ames	307	311		|O
test	312	316		|O
was	317	320		|O
performed	321	330		|O
on	331	333		|O
Salmonella	334	344		|O
typhimurium	345	356		|O
TA98	357	361		|O
and	362	365		|O
TA100	366	371		|O
strains	372	379		|O
,	379	380		|O
in	381	383		|O
the	384	387		|O
presence	388	396		|O
of	397	399		|O
S9	400	402		|O
mix	403	406		|O
,	406	407		|O
glutathione	408	419		|O
and	420	423		|O
buffer	424	430		|O
,	430	431		|O
respectively	432	444		|O
.	444	445		|O
Cytotoxicity	446	458	Cytotoxicity	|B-ADVERSE
was	459	462		|O
studied	463	470		|O
on	471	473		|O
human	474	479		|O
laryngeal	480	489		|O
carcinoma	490	499		|O
cells	500	505		|O
(	506	507		|O
HEp2	507	511		|O
)	511	512		|O
and	513	516		|O
human	517	522		|O
cervical	523	531		|O
cells	532	537		|O
(	538	539		|O
HeLa	539	543		|O
)	543	544		|O
.	544	545		|O
The	546	549		|O
level	550	555		|O
of	556	558		|O
lipid	559	564		|O
peroxidation	565	577		|O
in	578	580		|O
these	581	586		|O
two	587	590		|O
cell	591	595		|O
lines	596	601		|O
was	602	605		|O
evaluated	606	615		|O
in	616	618		|O
parallel	619	627		|O
.	627	628		|O
To	629	631		|O
establish	632	641		|O
the	642	645		|O
levels	646	652		|O
of	653	655		|O
primary	656	663		|O
DNA	664	667		|O
damage	668	674		|O
,	674	675		|O
the	676	679		|O
alkaline	680	688		|O
comet	689	694		|O
assay	695	700		|O
was	701	704		|O
performed	705	714		|O
on	715	717		|O
treated	718	725		|O
human	726	731		|O
peripheral	732	742		|O
blood	743	748		|O
leukocytes	749	759		|O
.	759	760		|O
No	761	763		|O
mutagenic	764	773		|O
effects	774	781		|O
of	782	784		|O
phosphoric	785	795		|O
gypsum	796	802		|O
on	803	805		|O
Salmonella	806	816		|O
typhimurium	817	828		|O
strains	829	836		|O
in	837	839		|O
the	840	843		|O
presence	844	852		|O
of	853	855		|O
S9	856	858		|O
mix	859	862		|O
,	862	863		|O
GSH	864	867		|O
or	868	870		|O
PBS	871	874		|O
were	875	879		|O
observed	880	888		|O
.	888	889		|O
However	890	897		|O
,	897	898		|O
strong	899	905		|O
cytotoxic	906	915	cytotoxic effect	|B-ADVERSE
effect	916	922		|I-ADVERSE
was	923	926		|O
observed	927	935		|O
on	936	938		|O
both	939	943		|O
human	944	949		|O
cell	950	954		|O
lines	955	960		|O
when	961	965		|O
they	966	970		|O
were	971	975		|O
treated	976	983		|O
with	984	988		|O
different	989	998		|O
concentrations	999	1013		|O
of	1014	1016		|O
wastewater	1017	1027		|O
.	1027	1028		|O
Lipid	1029	1034		|O
peroxidation	1035	1047		|O
was	1048	1051		|O
induced	1052	1059		|O
and	1060	1063		|O
increased	1064	1073		|O
by	1074	1076		|O
prolonged	1077	1086		|O
time	1087	1091		|O
of	1092	1094		|O
incubation	1095	1105		|O
,	1105	1106		|O
highlighting	1107	1119		|O
that	1120	1124		|O
the	1125	1128		|O
damage	1129	1135		|O
was	1136	1139		|O
not	1140	1143		|O
repaired	1144	1152		|O
,	1152	1153		|O
but	1154	1157		|O
increased	1158	1167		|O
with	1168	1172		|O
the	1173	1176		|O
time	1177	1181		|O
of	1182	1184		|O
incubation	1185	1195		|O
.	1195	1196		|O
The	1197	1200		|O
results	1201	1208		|O
of	1209	1211		|O
the	1212	1215		|O
alkaline	1216	1224		|O
comet	1225	1230		|O
assay	1231	1236		|O
indicate	1237	1245		|O
significant	1246	1257		|O
DNA	1258	1261		|O
damaging	1262	1270		|O
potential	1271	1280		|O
of	1281	1283		|O
wastewater	1284	1294		|O
for	1295	1298		|O
human	1299	1304		|O
leukocytes	1305	1315		|O
.	1315	1316		|O
Since	1317	1322		|O
phosphoric	1323	1333		|O
gypsum	1334	1340		|O
transport	1341	1350		|O
water	1351	1356		|O
in	1357	1359		|O
its	1360	1363		|O
present	1364	1371		|O
composition	1372	1383		|O
and	1384	1387		|O
acidity	1388	1395		|O
is	1396	1398		|O
highly	1399	1405		|O
toxic	1406	1411		|O
and	1412	1415		|O
acts	1416	1420		|O
as	1421	1423		|O
prooxidant	1424	1434		|O
,	1434	1435		|O
causing	1436	1443		|O
free	1444	1448		|O
radicals	1449	1457		|O
formation	1458	1467		|O
and	1468	1471		|O
DNA	1472	1475		|O
damage	1476	1482		|O
,	1482	1483		|O
urgent	1484	1490		|O
neutralization	1491	1505		|O
/	1505	1506		|O
purification	1506	1518		|O
of	1519	1521		|O
the	1522	1525		|O
wastewater	1526	1536		|O
to	1537	1539		|O
a	1540	1541		|O
level	1542	1547		|O
acceptable	1548	1558		|O
for	1559	1562		|O
disposal	1563	1571		|O
into	1572	1576		|O
the	1577	1580		|O
environment	1581	1592		|O
is	1593	1595		|O
mandatory	1596	1605		|O
.	1605	1606		|O

### 18637887
Population	0	10		|O
pharmacokinetic	11	26		|O
and	27	30		|O
pharmacodynamic	31	46		|O
analysis	47	55		|O
to	56	58		|O
support	59	66		|O
treatment	67	76		|O
optimization	77	89		|O
of	90	92		|O
combination	93	104		|O
chemotherapy	105	117		|O
with	118	122		|O
indisulam	123	132		|O
and	133	136		|O
carboplatin	137	148		|O
.	148	149		|O
AIMS	151	155		|O
:	155	156		|O
Indisulam	157	166		|O
and	167	170		|O
carboplatin	171	182		|O
have	183	187		|O
shown	188	193		|O
synergistic	194	205		|O
activity	206	214		|O
in	215	217		|O
preclinical	218	229		|O
studies	230	237		|O
.	237	238		|O
In	239	241		|O
a	242	243		|O
dose	244	248		|O
escalation	249	259		|O
study	260	265		|O
of	266	268		|O
the	269	272		|O
combination	273	284		|O
,	284	285		|O
a	286	287		|O
treatment	288	297		|O
delay	298	303		|O
was	304	307		|O
frequently	308	318		|O
required	319	327		|O
in	328	330		|O
a	331	332		|O
3	333	334		|O
-	334	335		|O
weekly	335	341		|O
regimen	342	349		|O
to	350	352		|O
allow	353	358		|O
recovery	359	367		|O
from	368	372		|O
myelosuppression	373	389	myelosuppression	|B-ADVERSE
from	390	394		|O
previous	395	403		|O
cycles	404	410		|O
.	410	411		|O
A	412	413		|O
4	414	415		|O
-	415	416		|O
weekly	416	422		|O
regimen	423	430		|O
was	431	434		|O
better	435	441		|O
tolerated	442	451		|O
,	451	452		|O
but	453	456		|O
had	457	460		|O
a	461	462		|O
decreased	463	472		|O
dose	473	477		|O
-	477	478		|O
intensity	478	487		|O
which	488	493		|O
may	494	497		|O
compromise	498	508		|O
efficacy	509	517		|O
.	517	518		|O
The	519	522		|O
aims	523	527		|O
of	528	530		|O
this	531	535		|O
study	536	541		|O
were	542	546		|O
(	547	548		|O
i	548	549		|O
)	549	550		|O
to	551	553		|O
develop	554	561		|O
a	562	563		|O
pharmacokinetic	564	579		|O
-	579	580		|O
pharmacodynamic	580	595		|O
(	596	597		|O
PK	597	599		|O
-	599	600		|O
PD	600	602		|O
)	602	603		|O
model	604	609		|O
to	610	612		|O
describe	613	621		|O
the	622	625		|O
myelosuppressive	626	642	myelosuppressive effect	|B-ADVERSE
effect	643	649		|I-ADVERSE
of	650	652		|O
the	653	656		|O
combination	657	668		|O
,	668	669		|O
and	670	673		|O
(	674	675		|O
ii	675	677		|O
)	677	678		|O
to	679	681		|O
use	682	685		|O
this	686	690		|O
model	691	696		|O
to	697	699		|O
select	700	706		|O
a	707	708		|O
dosing	709	715		|O
regimen	716	723		|O
for	724	727		|O
Phase	728	733		|O
II	734	736		|O
evaluation	737	747		|O
.	747	748		|O
METHODS	749	756		|O
:	756	757		|O
Sixteen	758	765		|O
patients	766	774		|O
were	775	779		|O
treated	780	787		|O
at	788	790		|O
four	791	795		|O
different	796	805		|O
dose	806	810		|O
levels	811	817		|O
of	818	820		|O
indisulam	821	830		|O
(	831	832		|O
1	832	833		|O
-	833	834		|O
h	834	835		|O
infusion	836	844		|O
on	845	847		|O
day	848	851		|O
1	852	853		|O
)	853	854		|O
and	855	858		|O
carboplatin	859	870		|O
(	871	872		|O
30	872	874		|O
-	874	875		|O
min	875	878		|O
infusion	879	887		|O
on	888	890		|O
day	891	894		|O
2	895	896		|O
)	896	897		|O
.	897	898		|O
Pharmacokinetic	899	914		|O
data	915	919		|O
were	920	924		|O
analysed	925	933		|O
with	934	938		|O
nonlinear	939	948		|O
mixed	949	954		|O
effects	955	962		|O
modelling	963	972		|O
.	972	973		|O
A	974	975		|O
semiphysiological	976	993		|O
model	994	999		|O
describing	1000	1010		|O
chemotherapy	1011	1023		|O
-	1023	1024		|O
induced	1024	1031		|O
myelosuppression	1032	1048	myelosuppression	|B-ADVERSE
characterized	1049	1062		|O
the	1063	1066		|O
relationship	1067	1079		|O
between	1080	1087		|O
the	1088	1091		|O
pharmacokinetics	1092	1108		|O
and	1109	1112		|O
the	1113	1116		|O
haematological	1117	1131	haematological toxicity	|B-ADVERSE
toxicity	1132	1140		|I-ADVERSE
of	1141	1143		|O
indisulam	1144	1153		|O
and	1154	1157		|O
carboplatin	1158	1169		|O
.	1169	1170		|O
A	1171	1172		|O
simulation	1173	1183		|O
study	1184	1189		|O
was	1190	1193		|O
performed	1194	1203		|O
to	1204	1206		|O
evaluate	1207	1215		|O
the	1216	1219		|O
tolerability	1220	1232		|O
and	1233	1236		|O
dose	1237	1241		|O
-	1241	1242		|O
intensity	1242	1251		|O
for	1252	1255		|O
3	1256	1257		|O
-	1257	1258		|O
weekly	1258	1264		|O
and	1265	1268		|O
4	1269	1270		|O
-	1270	1271		|O
weekly	1271	1277		|O
treatment	1278	1287		|O
regimens	1288	1296		|O
.	1296	1297		|O
RESULTS	1298	1305		|O
:	1305	1306		|O
The	1307	1310		|O
PK	1311	1313		|O
-	1313	1314		|O
PD	1314	1316		|O
model	1317	1322		|O
described	1323	1332		|O
the	1333	1336		|O
pharmacokinetics	1337	1353		|O
and	1354	1357		|O
the	1358	1361		|O
myelosuppressive	1362	1378	myelosuppressive effect	|B-ADVERSE
effect	1379	1385		|I-ADVERSE
of	1386	1388		|O
indisulam	1389	1398		|O
and	1399	1402		|O
carboplatin	1403	1414		|O
.	1414	1415		|O
The	1416	1419		|O
risk	1420	1424		|O
of	1425	1427		|O
a	1428	1429		|O
treatment	1430	1439		|O
delay	1440	1445		|O
at	1446	1448		|O
cycle	1449	1454		|O
2	1455	1456		|O
due	1457	1460		|O
to	1461	1463		|O
myelosuppression	1464	1480	myelosuppression	|B-ADVERSE
was	1481	1484		|O
unacceptably	1485	1497		|O
high	1498	1502		|O
(	1503	1504		|O
34-65%	1504	1510		|O
)	1510	1511		|O
in	1512	1514		|O
a	1515	1516		|O
3	1517	1518		|O
-	1518	1519		|O
weekly	1519	1525		|O
regimen	1526	1533		|O
for	1534	1537		|O
various	1538	1545		|O
dose	1546	1550		|O
levels	1551	1557		|O
(	1558	1559		|O
350-600	1559	1566		|O
mg	1567	1569		|O
m	1570	1571		|O
(	1571	1572		|O
-	1572	1573		|O
2	1573	1574		|O
)	1574	1575		|O
indisulam	1576	1585		|O
in	1586	1588		|O
combination	1589	1600		|O
with	1601	1605		|O
carboplatin	1606	1617		|O
to	1618	1620		|O
achieve	1621	1628		|O
an	1629	1631		|O
AUC	1632	1635		|O
of	1636	1638		|O
4-6	1639	1642		|O
mg	1643	1645		|O
min	1646	1649		|O
(	1649	1650		|O
-	1650	1651		|O
1	1651	1652		|O
)	1652	1653		|O
ml	1654	1656		|O
(	1656	1657		|O
-	1657	1658		|O
1	1658	1659		|O
)	1659	1660		|O
)	1660	1661		|O
.	1661	1662		|O
This	1663	1667		|O
risk	1668	1672		|O
was	1673	1676		|O
acceptable	1677	1687		|O
for	1688	1691		|O
a	1692	1693		|O
4	1694	1695		|O
-	1695	1696		|O
weekly	1696	1702		|O
regimen	1703	1710		|O
(	1711	1712		|O
9-24%	1712	1717		|O
)	1717	1718		|O
,	1718	1719		|O
which	1720	1725		|O
is	1726	1728		|O
in	1729	1731		|O
line	1732	1736		|O
with	1737	1741		|O
the	1742	1745		|O
clinical	1746	1754		|O
study	1755	1760		|O
results	1761	1768		|O
.	1768	1769		|O
CONCLUSIONS	1770	1781		|O
:	1781	1782		|O
This	1783	1787		|O
PK	1788	1790		|O
-	1790	1791		|O
PD	1791	1793		|O
study	1794	1799		|O
supports	1800	1808		|O
the	1809	1812		|O
selection	1813	1822		|O
of	1823	1825		|O
indisulam	1826	1835		|O
500	1836	1839		|O
mg	1840	1842		|O
m	1843	1844		|O
(	1844	1845		|O
-	1845	1846		|O
2	1846	1847		|O
)	1847	1848		|O
and	1849	1852		|O
a	1853	1854		|O
dose	1855	1859		|O
of	1860	1862		|O
carboplatin	1863	1874		|O
to	1875	1877		|O
achieve	1878	1885		|O
an	1886	1888		|O
AUC	1889	1892		|O
of	1893	1895		|O
6	1896	1897		|O
mg	1898	1900		|O
min	1901	1904		|O
(	1904	1905		|O
-	1905	1906		|O
1	1906	1907		|O
)	1907	1908		|O
ml	1909	1911		|O
(	1911	1912		|O
-	1912	1913		|O
1	1913	1914		|O
)	1914	1915		|O
in	1916	1918		|O
a	1919	1920		|O
4	1921	1922		|O
-	1922	1923		|O
weekly	1923	1929		|O
regimen	1930	1937		|O
as	1938	1940		|O
the	1941	1944		|O
recommended	1945	1956		|O
dose	1957	1961		|O
for	1962	1965		|O
future	1966	1972		|O
studies	1973	1980		|O
.	1980	1981		|O

### 18800883
Inhaled	0	7		|O
sodium	8	14		|O
pyruvate	15	23		|O
improved	24	32		|O
FEV1	33	37		|O
and	38	41		|O
decreased	42	51		|O
expired	52	59		|O
breath	60	66		|O
levels	67	73		|O
of	74	76		|O
nitric	77	83		|O
oxide	84	89		|O
in	90	92		|O
patients	93	101		|O
with	102	106		|O
chronic	107	114	chronic obstructive pulmonary disease	|B-DISEASE
obstructive	115	126		|I-DISEASE
pulmonary	127	136		|I-DISEASE
disease	137	144		|I-DISEASE
.	144	145		|O
Exogenously	147	158		|O
administered	159	171		|O
sodium	172	178		|O
pyruvate	179	187		|O
has	188	191		|O
a	192	193		|O
variety	194	201		|O
of	202	204		|O
biological	205	215		|O
effects	216	223		|O
including	224	233		|O
antioxidant	234	245		|O
/	245	246		|O
anti	246	250		|O
-	250	251		|O
inflammatory	251	263		|O
effects	264	271		|O
.	271	272		|O
Chronic	273	280	Chronic obstructive pulmonary disease	|B-DISEASE
obstructive	281	292		|I-DISEASE
pulmonary	293	302		|I-DISEASE
disease	303	310		|I-DISEASE
(	311	312		|O
COPD	312	316	COPD	|B-DISEASE
)	316	317		|O
is	318	320		|O
an	321	323		|O
inflammatory	324	336		|O
disease	337	344		|O
of	345	347		|O
the	348	351		|O
airways	352	359		|O
mediated	360	368		|O
in	369	371		|O
part	372	376		|O
by	377	379		|O
reactive	380	388		|O
oxygen	389	395		|O
species	396	403		|O
(	404	405		|O
ROS	405	408		|O
)	408	409		|O
and	410	413		|O
reactive	414	422		|O
nitrogen	423	431		|O
species	432	439		|O
(	440	441		|O
RNS	441	444		|O
)	444	445		|O
.	445	446		|O
The	447	450		|O
current	451	458		|O
therapies	459	468		|O
for	469	472		|O
COPD	473	477	COPD	|B-DISEASE
have	478	482		|O
limited	483	490		|O
efficacy	491	499		|O
.	499	500		|O
This	501	505		|O
study	506	511		|O
was	512	515		|O
designed	516	524		|O
to	525	527		|O
test	528	532		|O
the	533	536		|O
safety	537	543		|O
and	544	547		|O
therapeutic	548	559		|O
efficacy	560	568		|O
of	569	571		|O
inhaled	572	579		|O
pyruvate	580	588		|O
in	589	591		|O
COPD	592	596	COPD	|B-DISEASE
patients	597	605		|O
.	605	606		|O
Subjects	607	615		|O
were	616	620		|O
randomized	621	631		|O
to	632	634		|O
receive	635	642		|O
either	643	649		|O
sodium	650	656		|O
pyruvate	657	665		|O
or	666	668		|O
placebo	669	676		|O
three	677	682		|O
times	683	688		|O
per	689	692		|O
day	693	696		|O
over	697	701		|O
a	702	703		|O
6	704	705		|O
-	705	706		|O
week	706	710		|O
period	711	717		|O
.	717	718		|O
Long	719	723		|O
-	723	724		|O
term	724	728		|O
efficacy	729	737		|O
was	738	741		|O
evaluated	742	751		|O
by	752	754		|O
spirometry	755	765		|O
and	766	769		|O
expired	770	777		|O
breath	778	784		|O
nitric	785	791		|O
oxide	792	797		|O
(	798	799		|O
NO	799	801		|O
)	801	802		|O
levels	803	809		|O
taken	810	815		|O
at	816	818		|O
baseline	819	827		|O
,	827	828		|O
3	829	830		|O
days	831	835		|O
,	835	836		|O
1	837	838		|O
week	839	843		|O
,	843	844		|O
2	845	846		|O
weeks	847	852		|O
,	852	853		|O
4	854	855		|O
weeks	856	861		|O
,	861	862		|O
and	863	866		|O
6	867	868		|O
weeks	869	874		|O
.	874	875		|O
In	876	878		|O
addition	879	887		|O
,	887	888		|O
acute	889	894		|O
assessments	895	906		|O
(	907	908		|O
1	908	909		|O
h	910	911		|O
pre	912	915		|O
-	915	916		|O
and	917	920		|O
1	921	922		|O
h	923	924		|O
postinhalation	925	939		|O
of	940	942		|O
compound	943	951		|O
)	951	952		|O
were	953	957		|O
made	958	962		|O
at	963	965		|O
day	966	969		|O
0	970	971		|O
and	972	975		|O
at	976	978		|O
4	979	980		|O
weeks	981	986		|O
.	986	987		|O
Subjects	988	996		|O
receiving	997	1006		|O
inhaled	1007	1014		|O
pyruvate	1015	1023		|O
showed	1024	1030		|O
significant	1031	1042		|O
(	1043	1044		|O
p	1044	1045		|O
<	1046	1047		|O
0.02	1048	1052		|O
)	1052	1053		|O
improvement	1054	1065		|O
of	1066	1068		|O
approximately	1069	1082		|O
11%	1083	1086		|O
in	1087	1089		|O
forced	1090	1096		|O
expiratory	1097	1107		|O
volume	1108	1114		|O
in	1115	1117		|O
1	1118	1119		|O
sec	1120	1123		|O
(	1124	1125		|O
FEV	1125	1128		|O
(	1128	1129		|O
1	1129	1130		|O
)	1130	1131		|O
)	1131	1132		|O
at	1133	1135		|O
6	1136	1137		|O
weeks	1138	1143		|O
,	1143	1144		|O
whereas	1145	1152		|O
subjects	1153	1161		|O
receiving	1162	1171		|O
placebo	1172	1179		|O
did	1180	1183		|O
not	1184	1187		|O
.	1187	1188		|O
The	1189	1192		|O
inhalation	1193	1203		|O
of	1204	1206		|O
pyruvate	1207	1215		|O
or	1216	1218		|O
placebo	1219	1226		|O
had	1227	1230		|O
no	1231	1233		|O
significant	1234	1245		|O
effect	1246	1252		|O
on	1253	1255		|O
expired	1256	1263		|O
breath	1264	1270		|O
NO	1271	1273		|O
levels	1274	1280		|O
at	1281	1283		|O
any	1284	1287		|O
of	1288	1290		|O
the	1291	1294		|O
long	1295	1299		|O
-	1299	1300		|O
term	1300	1304		|O
outcome	1305	1312		|O
time	1313	1317		|O
points	1318	1324		|O
;	1324	1325		|O
measurements	1326	1338		|O
were	1339	1343		|O
made	1344	1348		|O
12	1349	1351		|O
h	1352	1353		|O
after	1354	1359		|O
the	1360	1363		|O
last	1364	1368		|O
inhalation	1369	1379		|O
of	1380	1382		|O
the	1383	1386		|O
compound	1387	1395		|O
.	1395	1396		|O
In	1397	1399		|O
contrast	1400	1408		|O
,	1408	1409		|O
acute	1410	1415		|O
assessments	1416	1427		|O
(	1428	1429		|O
1	1429	1430		|O
h	1431	1432		|O
pre	1433	1436		|O
-	1436	1437		|O
and	1437	1440		|O
1	1441	1442		|O
h	1443	1444		|O
postinhalation	1445	1459		|O
of	1460	1462		|O
compound	1463	1471		|O
)	1471	1472		|O
of	1473	1475		|O
expired	1476	1483		|O
breath	1484	1490		|O
NO	1491	1493		|O
made	1494	1498		|O
at	1499	1501		|O
4	1502	1503		|O
weeks	1504	1509		|O
demonstrated	1510	1522		|O
that	1523	1527		|O
inhalation	1528	1538		|O
of	1539	1541		|O
pyruvate	1542	1550		|O
resulted	1551	1559		|O
in	1560	1562		|O
a	1563	1564		|O
significant	1565	1576		|O
(	1577	1578		|O
p	1578	1579		|O
<	1580	1581		|O
/	1581	1582		|O
=	1582	1583		|O
0.01	1584	1588		|O
)	1588	1589		|O
decrease	1590	1598		|O
(	1599	1600		|O
-	1600	1601		|O
22.7	1601	1605		|O
+	1606	1607		|O
/	1607	1608		|O
-	1608	1609		|O
6%	1610	1612		|O
)	1612	1613		|O
in	1614	1616		|O
expired	1617	1624		|O
breath	1625	1631		|O
NO	1632	1634		|O
compared	1635	1643		|O
to	1644	1646		|O
placebo	1647	1654		|O
(	1655	1656		|O
5.0	1656	1659		|O
+	1660	1661		|O
/	1661	1662		|O
-	1662	1663		|O
7%	1664	1666		|O
)	1666	1667		|O
.	1667	1668		|O
Inhalation	1669	1679		|O
of	1680	1682		|O
pyruvate	1683	1691		|O
was	1692	1695		|O
well	1696	1700		|O
tolerated	1701	1710		|O
and	1711	1714		|O
was	1715	1718		|O
associated	1719	1729		|O
with	1730	1734		|O
improvement	1735	1746		|O
in	1747	1749		|O
FEV	1750	1753		|O
(	1753	1754		|O
1	1754	1755		|O
)	1755	1756		|O
and	1757	1760		|O
expired	1761	1768		|O
breath	1769	1775		|O
NO	1776	1778		|O
,	1778	1779		|O
and	1780	1783		|O
was	1784	1787		|O
considered	1788	1798		|O
clinically	1799	1809		|O
important	1810	1819		|O
in	1820	1822		|O
COPD	1823	1827	COPD	|B-DISEASE
.	1827	1828		|O
These	1829	1834		|O
beneficial	1835	1845		|O
effects	1846	1853		|O
of	1854	1856		|O
inhaled	1857	1864		|O
pyruvate	1865	1873		|O
in	1874	1876		|O
COPD	1877	1881	COPD	|B-DISEASE
may	1882	1885		|O
be	1886	1888		|O
optimized	1889	1898		|O
with	1899	1903		|O
adjustments	1904	1915		|O
in	1916	1918		|O
both	1919	1923		|O
dose	1924	1928		|O
and	1929	1932		|O
length	1933	1939		|O
of	1940	1942		|O
treatment	1943	1952		|O
.	1952	1953		|O

### 18726058
Adverse	0	7		|O
effects	8	15		|O
of	16	18		|O
topical	19	26		|O
papaverine	27	37		|O
on	38	40		|O
auditory	41	49		|O
nerve	50	55		|O
function	56	64		|O
.	64	65		|O
BACKGROUND	67	77		|O
:	77	78		|O
Papaverine	79	89		|O
hydrochloride	90	103		|O
is	104	106		|O
a	107	108		|O
direct	109	115		|O
-	115	116		|O
acting	116	122		|O
vasodilator	123	134		|O
used	135	139		|O
to	140	142		|O
manage	143	149		|O
vasospasm	150	159	vasospasm	|B-DISEASE
during	160	166		|O
various	167	174		|O
neurosurgical	175	188		|O
operations	189	199		|O
.	199	200		|O
Transient	201	210		|O
cranial	211	218		|O
nerve	219	224		|O
dysfunction	225	236		|O
has	237	240		|O
been	241	245		|O
described	246	255		|O
in	256	258		|O
a	259	260		|O
few	261	264		|O
cases	265	270		|O
with	271	275		|O
topical	276	283		|O
papaverine	284	294		|O
.	294	295		|O
This	296	300		|O
study	301	306		|O
supports	307	315		|O
previous	316	324		|O
reports	325	332		|O
and	333	336		|O
provides	337	345		|O
neurophysiological	346	364		|O
evidence	365	373		|O
of	374	376		|O
an	377	379		|O
adverse	380	387		|O
effect	388	394		|O
on	395	397		|O
the	398	401		|O
auditory	402	410		|O
nerve	411	416		|O
.	416	417		|O
METHODS	418	425		|O
:	425	426		|O
We	427	429		|O
conducted	430	439		|O
a	440	441		|O
retrospective	442	455		|O
review	456	462		|O
of	463	465		|O
70	466	468		|O
consecutive	469	480		|O
microvascular	481	494		|O
decompression	495	508		|O
operations	509	519		|O
and	520	523		|O
studied	524	531		|O
those	532	537		|O
patients	538	546		|O
who	547	550		|O
received	551	559		|O
topical	560	567		|O
papaverine	568	578		|O
for	579	582		|O
vasospasm	583	592	vasospasm	|B-DISEASE
.	592	593		|O
Topical	594	601		|O
papaverine	602	612		|O
was	613	616		|O
used	617	621		|O
as	622	624		|O
a	625	626		|O
direct	627	633		|O
therapeutic	634	645		|O
action	646	652		|O
to	653	655		|O
manage	656	662		|O
vasospasm	663	672	vasospasm	|B-DISEASE
in	673	675		|O
a	676	677		|O
total	678	683		|O
of	684	686		|O
11	687	689		|O
patients	690	698		|O
.	698	699		|O
The	700	703		|O
timing	704	710		|O
of	711	713		|O
papaverine	714	724		|O
application	725	736		|O
and	737	740		|O
ongoing	741	748		|O
operative	749	758		|O
events	759	765		|O
was	766	769		|O
reviewed	770	778		|O
relative	779	787		|O
to	788	790		|O
changes	791	798		|O
in	799	801		|O
neurophysiological	802	820		|O
recordings	821	831		|O
.	831	832		|O
Brainstem	833	842		|O
auditory	843	851		|O
evoked	852	858		|O
potentials	859	869		|O
(	870	871		|O
BAEPs	871	876		|O
)	876	877		|O
were	878	882		|O
routinely	883	892		|O
used	893	897		|O
to	898	900		|O
monitor	901	908		|O
cochlear	909	917		|O
nerve	918	923		|O
function	924	932		|O
during	933	939		|O
these	940	945		|O
operations	946	956		|O
.	956	957		|O
FINDINGS	958	966		|O
:	966	967		|O
A	968	969		|O
temporal	970	978		|O
relationship	979	991		|O
was	992	995		|O
found	996	1001		|O
between	1002	1009		|O
topical	1010	1017		|O
papaverine	1018	1028		|O
and	1029	1032		|O
BAEP	1033	1037		|O
changes	1038	1045		|O
leading	1046	1053		|O
to	1054	1056		|O
complete	1057	1065		|O
waveform	1066	1074		|O
loss	1075	1079		|O
.	1079	1080		|O
The	1081	1084		|O
average	1085	1092		|O
temporal	1093	1101		|O
delay	1102	1107		|O
between	1108	1115		|O
papaverine	1116	1126		|O
and	1127	1130		|O
the	1131	1134		|O
onset	1135	1140		|O
of	1141	1143		|O
an	1144	1146		|O
adverse	1147	1154		|O
BAEP	1155	1159		|O
change	1160	1166		|O
was	1167	1170		|O
5	1171	1172		|O
min	1173	1176		|O
.	1176	1177		|O
In	1178	1180		|O
10	1181	1183		|O
of	1184	1186		|O
11	1187	1189		|O
patients	1190	1198		|O
,	1198	1199		|O
BAEP	1200	1204		|O
waves	1205	1210		|O
II	1211	1213		|O
/	1213	1214		|O
III	1214	1217		|O
-	1217	1218		|O
V	1218	1219		|O
completely	1220	1230		|O
disappeared	1231	1242		|O
within	1243	1249		|O
2	1250	1251		|O
to	1252	1254		|O
25	1255	1257		|O
min	1258	1261		|O
after	1262	1267		|O
papaverine	1268	1278		|O
.	1278	1279		|O
Eight	1280	1285		|O
of	1286	1288		|O
these	1289	1294		|O
10	1295	1297		|O
patients	1298	1306		|O
had	1307	1310		|O
complete	1311	1319		|O
loss	1320	1324		|O
of	1325	1327		|O
BAEP	1328	1332		|O
waveforms	1333	1342		|O
within	1343	1349		|O
10	1350	1352		|O
min	1353	1356		|O
.	1356	1357		|O
One	1358	1361		|O
patient	1362	1369		|O
showed	1370	1376		|O
no	1377	1379		|O
recovery	1380	1388		|O
of	1389	1391		|O
later	1392	1397		|O
waves	1398	1403		|O
and	1404	1407		|O
a	1408	1409		|O
delayed	1410	1417		|O
profound	1418	1426		|O
sensorineural	1427	1440	sensorineural hearing loss	|B-DISEASE
hearing	1441	1448		|I-DISEASE
loss	1449	1453		|I-DISEASE
.	1453	1454		|O
The	1455	1458		|O
average	1459	1466		|O
recovery	1467	1475		|O
time	1476	1480		|O
of	1481	1483		|O
BAEP	1484	1488		|O
waveforms	1489	1498		|O
to	1499	1501		|O
pre	1502	1505		|O
-	1505	1506		|O
papaverine	1506	1516		|O
baseline	1517	1525		|O
values	1526	1532		|O
was	1533	1536		|O
39	1537	1539		|O
min	1540	1543		|O
.	1543	1544		|O
CONCLUSIONS	1545	1556		|O
:	1556	1557		|O
Topical	1558	1565		|O
papaverine	1566	1576		|O
for	1577	1580		|O
the	1581	1584		|O
treatment	1585	1594		|O
of	1595	1597		|O
vasospasm	1598	1607	vasospasm	|B-DISEASE
was	1608	1611		|O
associated	1612	1622		|O
with	1623	1627		|O
the	1628	1631		|O
onset	1632	1637		|O
of	1638	1640		|O
a	1641	1642		|O
transient	1643	1652		|O
disturbance	1653	1664		|O
in	1665	1667		|O
neurophysiological	1668	1686		|O
function	1687	1695		|O
of	1696	1698		|O
the	1699	1702		|O
ascending	1703	1712		|O
auditory	1713	1721		|O
brainstem	1722	1731		|O
pathway	1732	1739		|O
.	1739	1740		|O
The	1741	1744		|O
complete	1745	1753		|O
disappearance	1754	1767		|O
of	1768	1770		|O
BAEP	1771	1775		|O
waveforms	1776	1785		|O
with	1786	1790		|O
a	1791	1792		|O
consistent	1793	1803		|O
temporal	1804	1812		|O
delay	1813	1818		|O
suggests	1819	1827		|O
a	1828	1829		|O
possible	1830	1838		|O
adverse	1839	1846		|O
effect	1847	1853		|O
on	1854	1856		|O
the	1857	1860		|O
proximal	1861	1869		|O
eighth	1870	1876		|O
nerve	1877	1882		|O
.	1882	1883		|O
Recommendations	1884	1899		|O
to	1900	1902		|O
avoid	1903	1908		|O
potential	1909	1918		|O
cranial	1919	1926		|O
nerve	1927	1932		|O
deficits	1933	1941		|O
from	1942	1946		|O
papaverine	1947	1957		|O
are	1958	1961		|O
provided	1962	1970		|O
.	1970	1971		|O

### 18801421
Neonatal	0	8		|O
nicotine	9	17		|O
exposure	18	26		|O
impairs	27	34		|O
development	35	46		|O
of	47	49		|O
auditory	50	58		|O
temporal	59	67		|O
processing	68	78		|O
.	78	79		|O
Accurate	81	89		|O
temporal	90	98		|O
processing	99	109		|O
of	110	112		|O
sound	113	118		|O
is	119	121		|O
essential	122	131		|O
for	132	135		|O
detecting	136	145		|O
word	146	150		|O
structures	151	161		|O
in	162	164		|O
speech	165	171		|O
.	171	172		|O
Maternal	173	181		|O
smoking	182	189		|O
affects	190	197		|O
speech	198	204		|O
processing	205	215		|O
in	216	218		|O
newborns	219	227		|O
and	228	231		|O
may	232	235		|O
influence	236	245		|O
child	246	251		|O
language	252	260		|O
development	261	272		|O
;	272	273		|O
however	274	281		|O
,	281	282		|O
it	283	285		|O
is	286	288		|O
unclear	289	296		|O
how	297	300		|O
neonatal	301	309		|O
exposure	310	318		|O
to	319	321		|O
nicotine	322	330		|O
,	330	331		|O
present	332	339		|O
in	340	342		|O
cigarettes	343	353		|O
,	353	354		|O
affects	355	362		|O
the	363	366		|O
normal	367	373		|O
development	374	385		|O
of	386	388		|O
temporal	389	397		|O
processing	398	408		|O
.	408	409		|O
The	410	413		|O
present	414	421		|O
study	422	427		|O
used	428	432		|O
the	433	436		|O
gap	437	440		|O
-	440	441		|O
induced	441	448		|O
prepulse	449	457		|O
inhibition	458	468		|O
(	469	470		|O
gap	470	473		|O
-	473	474		|O
PPI	474	477		|O
)	477	478		|O
of	479	481		|O
the	482	485		|O
acoustic	486	494		|O
startle	495	502		|O
response	503	511		|O
to	512	514		|O
investigate	515	526		|O
the	527	530		|O
effects	531	538		|O
of	539	541		|O
neonatal	542	550		|O
nicotine	551	559		|O
exposure	560	568		|O
on	569	571		|O
the	572	575		|O
normal	576	582		|O
development	583	594		|O
of	595	597		|O
gap	598	601		|O
detection	602	611		|O
,	611	612		|O
a	613	614		|O
behavioral	615	625		|O
testing	626	633		|O
procedure	634	643		|O
of	644	646		|O
auditory	647	655		|O
temporal	656	664		|O
resolution	665	675		|O
.	675	676		|O
Neonatal	677	685		|O
rats	686	690		|O
were	691	695		|O
injected	696	704		|O
twice	705	710		|O
per	711	714		|O
day	715	718		|O
with	719	723		|O
saline	724	730		|O
(	731	732		|O
control	732	739		|O
)	739	740		|O
,	740	741		|O
1mg	742	745		|O
/	745	746		|O
kg	746	748		|O
nicotine	749	757		|O
(	758	759		|O
N	759	760		|O
-	760	761		|O
1	761	762		|O
mg	763	765		|O
)	765	766		|O
or	767	769		|O
5	770	771		|O
mg	772	774		|O
/	774	775		|O
kg	775	777		|O
nicotine	778	786		|O
(	787	788		|O
N	788	789		|O
-	789	790		|O
5	790	791		|O
mg	792	794		|O
)	794	795		|O
from	796	800		|O
postnatal	801	810		|O
day	811	814		|O
8-12	815	819		|O
(	820	821		|O
P8	821	823		|O
-	823	824		|O
P12	824	827		|O
)	827	828		|O
.	828	829		|O
During	830	836		|O
the	837	840		|O
first	841	846		|O
month	847	852		|O
after	853	858		|O
birth	859	864		|O
,	864	865		|O
rats	866	870		|O
showed	871	877		|O
poor	878	882		|O
gap	883	886		|O
-	886	887		|O
PPI	887	890		|O
in	891	893		|O
all	894	897		|O
three	898	903		|O
groups	904	910		|O
.	910	911		|O
At	912	914		|O
P45	915	918		|O
and	919	922		|O
P60	923	926		|O
,	926	927		|O
gap	928	931		|O
-	931	932		|O
PPI	932	935		|O
in	936	938		|O
control	939	946		|O
rats	947	951		|O
improved	952	960		|O
significantly	961	974		|O
,	974	975		|O
whereas	976	983		|O
rats	984	988		|O
exposed	989	996		|O
to	997	999		|O
nicotine	1000	1008		|O
exhibited	1009	1018		|O
less	1019	1023		|O
improvement	1024	1035		|O
.	1035	1036		|O
At	1037	1039		|O
P60	1040	1043		|O
,	1043	1044		|O
the	1045	1048		|O
gap	1049	1052		|O
-	1052	1053		|O
detection	1053	1062		|O
threshold	1063	1072		|O
in	1073	1075		|O
the	1076	1079		|O
N	1080	1081		|O
-	1081	1082		|O
5	1082	1083		|O
mg	1084	1086		|O
group	1087	1092		|O
was	1093	1096		|O
significantly	1097	1110		|O
higher	1111	1117		|O
than	1118	1122		|O
in	1123	1125		|O
the	1126	1129		|O
control	1130	1137		|O
group	1138	1143		|O
,	1143	1144		|O
suggesting	1145	1155		|O
that	1156	1160		|O
neonatal	1161	1169		|O
nicotine	1170	1178		|O
exposure	1179	1187		|O
affects	1188	1195		|O
the	1196	1199		|O
normal	1200	1206		|O
development	1207	1218		|O
of	1219	1221		|O
gap	1222	1225		|O
-	1225	1226		|O
detection	1226	1235		|O
acuity	1236	1242		|O
.	1242	1243		|O
Additionally	1244	1256		|O
,	1256	1257		|O
1h	1258	1260		|O
after	1261	1266		|O
receiving	1267	1276		|O
an	1277	1279		|O
acute	1280	1285		|O
nicotine	1286	1294		|O
injection	1295	1304		|O
(	1305	1306		|O
1	1306	1307		|O
mg	1308	1310		|O
/	1310	1311		|O
kg	1311	1313		|O
)	1313	1314		|O
,	1314	1315		|O
gap	1316	1319		|O
-	1319	1320		|O
PPI	1320	1323		|O
recorded	1324	1332		|O
in	1333	1335		|O
adult	1336	1341		|O
rats	1342	1346		|O
from	1347	1351		|O
the	1352	1355		|O
N	1356	1357		|O
-	1357	1358		|O
5	1358	1359		|O
mg	1360	1362		|O
group	1363	1368		|O
showed	1369	1375		|O
a	1376	1377		|O
temporary	1378	1387		|O
significant	1388	1399		|O
improvement	1400	1411		|O
.	1411	1412		|O
These	1413	1418		|O
results	1419	1426		|O
suggest	1427	1434		|O
that	1435	1439		|O
neonatal	1440	1448		|O
nicotine	1449	1457		|O
exposure	1458	1466		|O
reduces	1467	1474		|O
gap	1475	1478		|O
-	1478	1479		|O
PPI	1479	1482		|O
implying	1483	1491		|O
an	1492	1494		|O
impairment	1495	1505		|O
of	1506	1508		|O
the	1509	1512		|O
normal	1513	1519		|O
development	1520	1531		|O
of	1532	1534		|O
auditory	1535	1543		|O
temporal	1544	1552		|O
processing	1553	1563		|O
by	1564	1566		|O
inducing	1567	1575		|O
changes	1576	1583		|O
in	1584	1586		|O
cholinergic	1587	1598		|O
systems	1599	1606		|O
.	1606	1607		|O

### 18615622
Triplet	0	7		|O
combination	8	19		|O
of	20	22		|O
gemcitabine	23	34		|O
,	34	35		|O
paclitaxel	36	46		|O
,	46	47		|O
and	48	51		|O
carboplatin	52	63		|O
followed	64	72		|O
by	73	75		|O
maintenance	76	87		|O
5	88	89		|O
-	89	90		|O
fluorouracil	90	102		|O
and	103	106		|O
folinic	107	114		|O
acid	115	119		|O
in	120	122		|O
patients	123	131		|O
with	132	136		|O
metastatic	137	147	metastatic nasopharyngeal carcinoma	|B-DISEASE
nasopharyngeal	148	162		|I-DISEASE
carcinoma	163	172		|I-DISEASE
.	172	173		|O
BACKGROUND	175	185		|O
:	185	186		|O
Nasopharyngeal	187	201	Nasopharyngeal carcinoma	|B-DISEASE
carcinoma	202	211		|I-DISEASE
(	212	213		|O
NPC	213	216	NPC	|B-DISEASE
)	216	217		|O
is	218	220		|O
a	221	222		|O
disease	223	230		|O
that	231	235		|O
is	236	238		|O
highly	239	245		|O
responsive	246	256		|O
to	257	259		|O
various	260	267		|O
chemotherapeutic	268	284		|O
agents	285	291		|O
.	291	292		|O
In	293	295		|O
the	296	299		|O
metastatic	300	310		|O
setting	311	318		|O
,	318	319		|O
2	320	321		|O
-	321	322		|O
drug	322	326		|O
combination	327	338		|O
chemotherapy	339	351		|O
generally	352	361		|O
provides	362	370		|O
a	371	372		|O
response	373	381		|O
rate	382	386		|O
of	387	389		|O
55%	390	393		|O
to	394	396		|O
75%	397	400		|O
,	400	401		|O
and	402	405		|O
median	406	412		|O
survival	413	421		|O
of	422	424		|O
10	425	427		|O
to	428	430		|O
12	431	433		|O
months	434	440		|O
.	440	441		|O
The	442	445		|O
objective	446	455		|O
of	456	458		|O
the	459	462		|O
current	463	470		|O
study	471	476		|O
was	477	480		|O
to	481	483		|O
assess	484	490		|O
the	491	494		|O
efficacy	495	503		|O
of	504	506		|O
a	507	508		|O
3	509	510		|O
-	510	511		|O
drug	511	515		|O
combination	516	527		|O
followed	528	536		|O
by	537	539		|O
maintenance	540	551		|O
treatment	552	561		|O
in	562	564		|O
patients	565	573		|O
with	574	578		|O
metastatic	579	589	metastatic NPC	|B-DISEASE
NPC	590	593		|I-DISEASE
.	593	594		|O
METHODS	595	602		|O
:	602	603		|O
Patients	604	612		|O
with	613	617		|O
metastatic	618	628	metastatic NPC	|B-DISEASE
NPC	629	632		|I-DISEASE
were	633	637		|O
treated	638	645		|O
with	646	650		|O
a	651	652		|O
combination	653	664		|O
of	665	667		|O
gemcitabine	668	679		|O
at	680	682		|O
a	683	684		|O
dose	685	689		|O
of	690	692		|O
1,000	693	698		|O
mg	699	701		|O
/	701	702		|O
m	702	703		|O
(	703	704		|O
2	704	705		|O
)	705	706		|O
,	706	707		|O
paclitaxel	708	718		|O
at	719	721		|O
a	722	723		|O
dose	724	728		|O
of	729	731		|O
70	732	734		|O
mg	735	737		|O
/	737	738		|O
m	738	739		|O
(	739	740		|O
2	740	741		|O
)	741	742		|O
,	742	743		|O
and	744	747		|O
carboplatin	748	759		|O
at	760	762		|O
an	763	765		|O
area	766	770		|O
under	771	776		|O
the	777	780		|O
concentration	781	794		|O
-	794	795		|O
time	795	799		|O
-	799	800		|O
curve	800	805		|O
(	806	807		|O
AUC	807	810		|O
)	810	811		|O
of	812	814		|O
2.5	815	818		|O
on	819	821		|O
Days	822	826		|O
1	827	828		|O
and	829	832		|O
8	833	834		|O
every	835	840		|O
21	841	843		|O
days	844	848		|O
.	848	849		|O
Patients	850	858		|O
who	859	862		|O
achieved	863	871		|O
partial	872	879		|O
or	880	882		|O
complete	883	891		|O
response	892	900		|O
continued	901	910		|O
to	911	913		|O
receive	914	921		|O
weekly	922	928		|O
5	929	930		|O
-	930	931		|O
fluorouracil	931	943		|O
at	944	946		|O
a	947	948		|O
dose	949	953		|O
of	954	956		|O
450	957	960		|O
mg	961	963		|O
/	963	964		|O
m	964	965		|O
(	965	966		|O
2	966	967		|O
)	967	968		|O
and	969	972		|O
leucovorin	973	983		|O
at	984	986		|O
a	987	988		|O
dose	989	993		|O
of	994	996		|O
30	997	999		|O
mg	1000	1002		|O
/	1002	1003		|O
m	1003	1004		|O
(	1004	1005		|O
2	1005	1006		|O
)	1006	1007		|O
for	1008	1011		|O
48	1012	1014		|O
weeks	1015	1020		|O
.	1020	1021		|O
RESULTS	1022	1029		|O
:	1029	1030		|O
Twenty	1031	1037		|O
-	1037	1038		|O
eight	1038	1043		|O
patients	1044	1052		|O
were	1053	1057		|O
recruited	1058	1067		|O
.	1067	1068		|O
Twenty	1069	1075		|O
-	1075	1076		|O
two	1076	1079		|O
(	1080	1081		|O
79%	1081	1084		|O
)	1084	1085		|O
patients	1086	1094		|O
had	1095	1098		|O
>	1099	1100		|O
or	1100	1102		|O
=	1102	1103		|O
2	1103	1104		|O
sites	1105	1110		|O
of	1111	1113		|O
disease	1114	1121		|O
.	1121	1122		|O
Toxicities	1123	1133		|O
were	1134	1138		|O
mainly	1139	1145		|O
from	1146	1150		|O
bone	1151	1155	bone marrow suppression	|B-ADVERSE
marrow	1156	1162		|I-ADVERSE
suppression	1163	1174		|I-ADVERSE
,	1174	1175		|O
with	1176	1180		|O
79%	1181	1184		|O
grade	1185	1190		|O
3/4	1191	1194		|O
neutropenia	1195	1206	neutropenia	|B-ADVERSE
,	1206	1207		|O
32%	1208	1211		|O
grade	1212	1217		|O
3/4	1218	1221		|O
anemia	1222	1228	anemia	|B-ADVERSE
,	1228	1229		|O
and	1230	1233		|O
29%	1234	1237		|O
grade	1238	1243		|O
3/4	1244	1247		|O
thrombocytopenia	1248	1264	thrombocytopenia	|B-ADVERSE
(	1265	1266		|O
according	1266	1275		|O
to	1276	1278		|O
the	1279	1282		|O
National	1283	1291		|O
Cancer	1292	1298	Cancer	|B-DISEASE
Institute	1299	1308		|O
Common	1309	1315		|O
Toxicity	1316	1324		|O
Criteria	1325	1333		|O
)	1333	1334		|O
.	1334	1335		|O
The	1336	1339		|O
overall	1340	1347		|O
response	1348	1356		|O
rate	1357	1361		|O
to	1362	1364		|O
the	1365	1368		|O
3	1369	1370		|O
-	1370	1371		|O
drug	1371	1375		|O
regimen	1376	1383		|O
was	1384	1387		|O
86%	1388	1391		|O
,	1391	1392		|O
with	1393	1397		|O
a	1398	1399		|O
complete	1400	1408		|O
response	1409	1417		|O
rate	1418	1422		|O
of	1423	1425		|O
11%	1426	1429		|O
.	1429	1430		|O
The	1431	1434		|O
median	1435	1441		|O
duration	1442	1450		|O
of	1451	1453		|O
response	1454	1462		|O
was	1463	1466		|O
8	1467	1468		|O
months	1469	1475		|O
and	1476	1479		|O
the	1480	1483		|O
median	1484	1490		|O
overall	1491	1498		|O
survival	1499	1507		|O
was	1508	1511		|O
22	1512	1514		|O
months	1515	1521		|O
.	1521	1522		|O
CONCLUSIONS	1523	1534		|O
:	1534	1535		|O
This	1536	1540		|O
regimen	1541	1548		|O
of	1549	1551		|O
a	1552	1553		|O
3	1554	1555		|O
-	1555	1556		|O
drug	1556	1560		|O
combination	1561	1572		|O
followed	1573	1581		|O
by	1582	1584		|O
maintenance	1585	1596		|O
is	1597	1599		|O
feasible	1600	1608		|O
and	1609	1612		|O
has	1613	1616		|O
demonstrated	1617	1629		|O
an	1630	1632		|O
encouraging	1633	1644		|O
response	1645	1653		|O
rate	1654	1658		|O
and	1659	1662		|O
overall	1663	1670		|O
survival	1671	1679		|O
.	1679	1680		|O

### 18785644
Multicenter	0	11		|O
prospective	12	23		|O
trial	24	29		|O
evaluating	30	40		|O
the	41	44		|O
tolerability	45	57		|O
of	58	60		|O
imatinib	61	69		|O
for	70	73		|O
Japanese	74	82		|O
patients	83	91		|O
with	92	96		|O
chronic	97	104	chronic myelogenous leukemia	|B-DISEASE
myelogenous	105	116		|I-DISEASE
leukemia	117	125		|I-DISEASE
in	126	128		|O
the	129	132		|O
chronic	133	140		|O
phase	141	146		|O
:	146	147		|O
does	148	152		|O
body	153	157		|O
weight	158	164		|O
matter	165	171		|O
?	171	172		|O
Imatinib	174	182		|O
at	183	185		|O
a	186	187		|O
daily	188	193		|O
dose	194	198		|O
of	199	201		|O
400	202	205		|O
mg	206	208		|O
is	209	211		|O
the	212	215		|O
standard	216	224		|O
treatment	225	234		|O
for	235	238		|O
chronic	239	246	chronic myelogenous leukemia	|B-DISEASE
myelogenous	247	258		|I-DISEASE
leukemia	259	267		|I-DISEASE
in	268	270		|O
the	271	274		|O
chronic	275	282		|O
phase	283	288		|O
.	288	289		|O
However	290	297		|O
,	297	298		|O
the	299	302		|O
feasibility	303	314		|O
of	315	317		|O
this	318	322		|O
dose	323	327		|O
for	328	331		|O
small	332	337		|O
Japanese	338	346		|O
adults	347	353		|O
has	354	357		|O
not	358	361		|O
been	362	366		|O
clarified	367	376		|O
.	376	377		|O
We	378	380		|O
prospectively	381	394		|O
investigated	395	407		|O
the	408	411		|O
toxicity	412	420		|O
and	421	424		|O
efficacy	425	433		|O
of	434	436		|O
this	437	441		|O
dose	442	446		|O
in	447	449		|O
adult	450	455		|O
Japanese	456	464		|O
patients	465	473		|O
.	473	474		|O
Among	475	480		|O
the	481	484		|O
89	485	487		|O
evaluable	488	497		|O
patients	498	506		|O
with	507	511		|O
a	512	513		|O
median	514	520		|O
body	521	525		|O
weight	526	532		|O
of	533	535		|O
62.8	536	540		|O
kg	541	543		|O
,	543	544		|O
imatinib	545	553		|O
therapy	554	561		|O
was	562	565		|O
held	566	570		|O
in	571	573		|O
40	574	576		|O
subjects	577	585		|O
(	586	587		|O
45%	587	590		|O
)	590	591		|O
,	591	592		|O
due	593	596		|O
to	597	599		|O
Grade	600	605		|O
3-4	606	609		|O
toxicities	610	620		|O
in	621	623		|O
30	624	626		|O
patients	627	635		|O
(	636	637		|O
75%	637	640		|O
)	640	641		|O
and	642	645		|O
Grade	646	651		|O
2	652	653		|O
toxicities	654	664		|O
at	665	667		|O
the	668	671		|O
discretion	672	682		|O
of	683	685		|O
the	686	689		|O
attending	690	699		|O
physician	700	709		|O
in	710	712		|O
10	713	715		|O
patients	716	724		|O
(	725	726		|O
25%	726	729		|O
)	729	730		|O
.	730	731		|O
However	732	739		|O
,	739	740		|O
treatment	741	750		|O
was	751	754		|O
resumed	755	762		|O
and	763	766		|O
the	767	770		|O
dose	771	775		|O
was	776	779		|O
gradually	780	789		|O
increased	790	799		|O
until	800	805		|O
62	806	808		|O
of	809	811		|O
the	812	815		|O
89	816	818		|O
patients	819	827		|O
tolerated	828	837		|O
a	838	839		|O
maintenance	840	851		|O
dose	852	856		|O
of	857	859		|O
400	860	863		|O
mg	864	866		|O
.	866	867		|O
Older	868	873		|O
age	874	877		|O
and	878	881		|O
lower	882	887		|O
body	888	892		|O
weight	893	899		|O
were	900	904		|O
significant	905	916		|O
independent	917	928		|O
risk	929	933		|O
factors	934	941		|O
for	942	945		|O
discontinuation	946	961		|O
of	962	964		|O
imatinib	965	973		|O
.	973	974		|O
After	975	980		|O
a	981	982		|O
median	983	989		|O
follow	990	996		|O
-	996	997		|O
up	997	999		|O
period	1000	1006		|O
of	1007	1009		|O
31	1010	1012		|O
months	1013	1019		|O
,	1019	1020		|O
84	1021	1023		|O
patients	1024	1032		|O
were	1033	1037		|O
alive	1038	1043		|O
without	1044	1051		|O
progression	1052	1063		|O
.	1063	1064		|O
The	1065	1068		|O
complete	1069	1077		|O
cytogenetic	1078	1089		|O
response	1090	1098		|O
rate	1099	1103		|O
was	1104	1107		|O
60	1108	1110		|O
and	1111	1114		|O
90%	1115	1118		|O
at	1119	1121		|O
6	1122	1123		|O
months	1124	1130		|O
and	1131	1134		|O
1	1135	1136		|O
year	1137	1141		|O
after	1142	1147		|O
starting	1148	1156		|O
imatinib	1157	1165		|O
,	1165	1166		|O
respectively	1167	1179		|O
.	1179	1180		|O
Older	1181	1186		|O
patients	1187	1195		|O
and	1196	1199		|O
those	1200	1205		|O
with	1206	1210		|O
a	1211	1212		|O
lower	1213	1218		|O
body	1219	1223		|O
weight	1224	1230		|O
were	1231	1235		|O
less	1236	1240		|O
likely	1241	1247		|O
to	1248	1250		|O
achieve	1251	1258		|O
a	1259	1260		|O
complete	1261	1269		|O
cytogenetic	1270	1281		|O
response	1282	1290		|O
.	1290	1291		|O
These	1292	1297		|O
findings	1298	1306		|O
suggest	1307	1314		|O
that	1315	1319		|O
the	1320	1323		|O
body	1324	1328		|O
weight	1329	1335		|O
has	1336	1339		|O
a	1340	1341		|O
significant	1342	1353		|O
influence	1354	1363		|O
on	1364	1366		|O
the	1367	1370		|O
toxicity	1371	1379		|O
and	1380	1383		|O
efficacy	1384	1392		|O
of	1393	1395		|O
imatinib	1396	1404		|O
in	1405	1407		|O
patients	1408	1416		|O
with	1417	1421		|O
a	1422	1423		|O
small	1424	1429		|O
body	1430	1434		|O
size	1435	1439		|O
,	1439	1440		|O
although	1441	1449		|O
dose	1450	1454		|O
reduction	1455	1464		|O
in	1465	1467		|O
proportion	1468	1478		|O
to	1479	1481		|O
weight	1482	1488		|O
may	1489	1492		|O
result	1493	1499		|O
in	1500	1502		|O
an	1503	1505		|O
inadequate	1506	1516		|O
response	1517	1525		|O
to	1526	1528		|O
imatinib	1529	1537		|O
.	1537	1538		|O

### 18589276
Magnetic	0	8		|O
resonance	9	18		|O
imaging	19	26		|O
appearance	27	37		|O
of	38	40		|O
the	41	44		|O
shoulder	45	53		|O
after	54	59		|O
subacromial	60	71		|O
injection	72	81		|O
with	82	86		|O
corticosteroids	87	102		|O
can	103	106		|O
mimic	107	112		|O
a	113	114		|O
rotator	115	122	rotator cuff tear	|B-DISEASE
cuff	123	127		|I-DISEASE
tear	128	132		|I-DISEASE
.	132	133		|O
Subacromial	135	146		|O
injections	147	157		|O
have	158	162		|O
been	163	167		|O
used	168	172		|O
to	173	175		|O
treat	176	181		|O
rotator	182	189	rotator cuff problems	|B-DISEASE
cuff	190	194		|I-DISEASE
problems	195	203		|I-DISEASE
.	203	204		|O
Previous	205	213		|O
studies	214	221		|O
have	222	226		|O
noted	227	232		|O
the	233	236		|O
difficulty	237	247		|O
in	248	250		|O
performing	251	261		|O
accurate	262	270		|O
injections	271	281		|O
into	282	286		|O
this	287	291		|O
area	292	296		|O
.	296	297		|O
In	298	300		|O
addition	301	309		|O
,	309	310		|O
one	311	314		|O
must	315	319		|O
also	320	324		|O
question	325	333		|O
the	334	337		|O
effects	338	345		|O
that	346	350		|O
misplaced	351	360		|O
corticosteroids	361	376		|O
could	377	382		|O
have	383	387		|O
on	388	390		|O
the	391	394		|O
surrounding	395	406		|O
tissues	407	414		|O
.	414	415		|O
In	416	418		|O
this	419	423		|O
case	424	428		|O
,	428	429		|O
a	430	431		|O
51	432	434		|O
-	434	435		|O
year	435	439		|O
-	439	440		|O
old	440	443		|O
woman	444	449		|O
presented	450	459		|O
with	460	464		|O
several	465	472		|O
weeks	473	478		|O
of	479	481		|O
left	482	486		|O
shoulder	487	495	shoulder pain	|B-DISEASE
pain	496	500		|I-DISEASE
and	501	504		|O
was	505	508		|O
diagnosed	509	518		|O
with	519	523		|O
rotator	524	531	rotator cuff tendonitis	|B-DISEASE
cuff	532	536		|I-DISEASE
tendonitis	537	547		|I-DISEASE
.	547	548		|O
After	549	554		|O
a	555	556		|O
subacromial	557	568		|O
injection	569	578		|O
with	579	583		|O
betamethasone	584	597		|O
and	598	601		|O
lidocaine	602	611		|O
,	611	612		|O
the	613	616		|O
patient	617	624		|O
noted	625	630		|O
3	631	632		|O
weeks	633	638		|O
of	639	641		|O
near	642	646		|O
complete	647	655		|O
pain	656	660	pain	|B-DISEASE
relief	661	667		|O
,	667	668		|O
followed	669	677		|O
by	678	680		|O
a	681	682		|O
return	683	689		|O
of	690	692		|O
her	693	696		|O
symptoms	697	705		|O
.	705	706		|O
A	707	708		|O
magnetic	709	717		|O
resonance	718	727		|O
imaging	728	735		|O
scan	736	740		|O
obtained	741	749		|O
7	750	751		|O
weeks	752	757		|O
after	758	763		|O
the	764	767		|O
injection	768	777		|O
showed	778	784		|O
a	785	786		|O
full	787	791		|O
-	791	792		|O
thickness	792	801		|O
tear	802	806		|O
of	807	809		|O
the	810	813		|O
supraspinatus	814	827		|O
tendon	828	834		|O
.	834	835		|O
Five	836	840		|O
weeks	841	846		|O
later	847	852		|O
,	852	853		|O
the	854	857		|O
patient	858	865		|O
underwent	866	875		|O
arthroscopic	876	888		|O
evaluation	889	899		|O
of	900	902		|O
the	903	906		|O
shoulder	907	915		|O
and	916	919		|O
subacromial	920	931		|O
decompression	932	945		|O
.	945	946		|O
The	947	950		|O
rotator	951	958		|O
cuff	959	963		|O
tendons	964	971		|O
were	972	976		|O
noted	977	982		|O
to	983	985		|O
be	986	988		|O
intact	989	995		|O
and	996	999		|O
normal	1000	1006		|O
in	1007	1009		|O
appearance	1010	1020		|O
.	1020	1021		|O
The	1022	1025		|O
patient	1026	1033		|O
eventually	1034	1044		|O
had	1045	1048		|O
full	1049	1053		|O
resolution	1054	1064		|O
of	1065	1067		|O
her	1068	1071		|O
symptoms	1072	1080		|O
.	1080	1081		|O
Six	1082	1085		|O
months	1086	1092		|O
postoperatively	1093	1108		|O
,	1108	1109		|O
she	1110	1113		|O
underwent	1114	1123		|O
a	1124	1125		|O
new	1126	1129		|O
scan	1130	1134		|O
that	1135	1139		|O
showed	1140	1146		|O
a	1147	1148		|O
normal	1149	1155		|O
supraspinatus	1156	1169		|O
tendon	1170	1176		|O
.	1176	1177		|O
Apparently	1178	1188		|O
,	1188	1189		|O
the	1190	1193		|O
subacromial	1194	1205		|O
injection	1206	1215		|O
penetrated	1216	1226		|O
the	1227	1230		|O
anterior	1231	1239		|O
half	1240	1244		|O
of	1245	1247		|O
the	1248	1251		|O
supraspinatus	1252	1265		|O
tendon	1266	1272		|O
,	1272	1273		|O
causing	1274	1281		|O
a	1282	1283		|O
transient	1284	1293		|O
effect	1294	1300		|O
and	1301	1304		|O
signal	1305	1311		|O
change	1312	1318		|O
.	1318	1319		|O
One	1320	1323		|O
should	1324	1330		|O
use	1331	1334		|O
caution	1335	1342		|O
in	1343	1345		|O
the	1346	1349		|O
interpretation	1350	1364		|O
of	1365	1367		|O
magnetic	1368	1376		|O
resonance	1377	1386		|O
imaging	1387	1394		|O
scans	1395	1400		|O
of	1401	1403		|O
the	1404	1407		|O
shoulder	1408	1416		|O
soon	1417	1421		|O
after	1422	1427		|O
the	1428	1431		|O
injection	1432	1441		|O
of	1442	1444		|O
corticosteroids	1445	1460		|O
.	1460	1461		|O

### 18783831
Evaluation	0	10		|O
of	11	13		|O
cytotoxic	14	23		|O
properties	24	34		|O
of	35	37		|O
organometallic	38	52		|O
ferrocifens	53	64		|O
on	65	67		|O
melanocytes	68	79		|O
,	79	80		|O
primary	81	88		|O
and	89	92		|O
metastatic	93	103		|O
melanoma	104	112		|O
cell	113	117		|O
lines	118	123		|O
.	123	124		|O
Malignant	126	135	Malignant melanoma	|B-DISEASE
melanoma	136	144		|I-DISEASE
is	145	147		|O
one	148	151		|O
of	152	154		|O
the	155	158		|O
most	159	163		|O
severe	164	170		|O
forms	171	176		|O
of	177	179		|O
skin	180	184	skin cancer	|B-DISEASE
cancer	185	191		|I-DISEASE
,	191	192		|O
and	193	196		|O
chemotherapeutic	197	213		|O
agents	214	220		|O
currently	221	230		|O
in	231	233		|O
use	234	237		|O
are	238	241		|O
poorly	242	248		|O
effective	249	258		|O
in	259	261		|O
curing	262	268		|O
the	269	272		|O
disease	273	280		|O
.	280	281		|O
Here	282	286		|O
we	287	289		|O
describe	290	298		|O
the	299	302		|O
properties	303	313		|O
of	314	316		|O
two	317	320		|O
organometallic	321	335		|O
ferrocenyl	336	346		|O
derivatives	347	358		|O
,	358	359		|O
ferrocifen	360	370		|O
(	371	372		|O
Fc	372	374		|O
-	374	375		|O
OH	375	377		|O
-	377	378		|O
Tam	378	381		|O
)	381	382		|O
and	383	386		|O
ferrociphenol	387	400		|O
(	401	402		|O
Fc	402	404		|O
-	404	405		|O
diOH	405	409		|O
)	409	410		|O
that	411	415		|O
show	416	420		|O
a	421	422		|O
specific	423	431		|O
antiproliferative	432	449		|O
effect	450	456		|O
on	457	459		|O
melanoma	460	468		|O
cells	469	474		|O
.	474	475		|O
After	476	481		|O
a	482	483		|O
short	484	489		|O
incubation	490	500		|O
period	501	507		|O
,	507	508		|O
Fc	509	511		|O
-	511	512		|O
OH	512	514		|O
-	514	515		|O
Tam	515	518		|O
is	519	521		|O
highly	522	528		|O
cytotoxic	529	538		|O
on	539	541		|O
melanoma	542	550		|O
cells	551	556		|O
but	557	560		|O
less	561	565		|O
toxic	566	571		|O
on	572	574		|O
melanocytes	575	586		|O
.	586	587		|O
Fc	588	590		|O
-	590	591		|O
diOH	591	595		|O
is	596	598		|O
slightly	599	607		|O
toxic	608	613		|O
at	614	616		|O
a	617	618		|O
high	619	623		|O
concentration	624	637		|O
but	638	641		|O
no	642	644		|O
discrepancy	645	656		|O
is	657	659		|O
observed	660	668		|O
between	669	676		|O
malignant	677	686		|O
and	687	690		|O
normal	691	697		|O
cells	698	703		|O
.	703	704		|O
After	705	710		|O
a	711	712		|O
long	713	717		|O
incubation	718	728		|O
time	729	733		|O
the	734	737		|O
latter	738	744		|O
is	745	747		|O
highly	748	754		|O
toxic	755	760		|O
for	761	764		|O
malignant	765	774		|O
cells	775	780		|O
but	781	784		|O
not	785	788		|O
for	789	792		|O
normal	793	799		|O
cells	800	805		|O
while	806	811		|O
the	812	815		|O
former	816	822		|O
was	823	826		|O
very	827	831		|O
highly	832	838		|O
toxic	839	844		|O
for	845	848		|O
primary	849	856		|O
malignant	857	866		|O
cells	867	872		|O
and	873	876		|O
significantly	877	890		|O
less	891	895		|O
toxic	896	901		|O
for	902	905		|O
normal	906	912		|O
cells	913	918		|O
.	918	919		|O
We	920	922		|O
also	923	927		|O
found	928	933		|O
that	934	938		|O
oxidative	939	948		|O
stress	949	955		|O
is	956	958		|O
not	959	962		|O
implicated	963	973		|O
in	974	976		|O
the	977	980		|O
mechanism	981	990		|O
of	991	993		|O
cytotoxicity	994	1006	cytotoxicity	|B-ADVERSE
,	1006	1007		|O
since	1008	1013		|O
both	1014	1018		|O
derivatives	1019	1030		|O
neither	1031	1038		|O
induce	1039	1045		|O
reactive	1046	1054		|O
oxygen	1055	1061		|O
species	1062	1069		|O
(	1070	1071		|O
ROS	1071	1074		|O
)	1074	1075		|O
level	1076	1081		|O
in	1082	1084		|O
melanocytes	1085	1096		|O
nor	1097	1100		|O
in	1101	1103		|O
melanoma	1104	1112		|O
cells	1113	1118		|O
.	1118	1119		|O
Finally	1120	1127		|O
,	1127	1128		|O
investigation	1129	1142		|O
on	1143	1145		|O
hair	1146	1150		|O
follicle	1151	1159		|O
growth	1160	1166		|O
revealed	1167	1175		|O
that	1176	1180		|O
the	1181	1184		|O
two	1185	1188		|O
organometallic	1189	1203		|O
derivatives	1204	1215		|O
induced	1216	1223		|O
an	1224	1226		|O
irreversible	1227	1239		|O
ejection	1240	1248		|O
of	1249	1251		|O
the	1252	1255		|O
hair	1256	1260		|O
shaft	1261	1266		|O
,	1266	1267		|O
thus	1268	1272		|O
predicting	1273	1283		|O
a	1284	1285		|O
potential	1286	1295		|O
hair	1296	1300	hair loss	|B-ADVERSE
loss	1301	1305		|I-ADVERSE
side	1306	1310		|O
effect	1311	1317		|O
if	1318	1320		|O
used	1321	1325		|O
as	1326	1328		|O
a	1329	1330		|O
chemotherapeutic	1331	1347		|O
treatment	1348	1357		|O
.	1357	1358		|O

### 18547491
Effect	0	6		|O
of	7	9		|O
Efalizumab	10	20		|O
on	21	23		|O
neutrophil	24	34		|O
and	35	38		|O
monocyte	39	47		|O
functions	48	57		|O
in	58	60		|O
patients	61	69		|O
with	70	74		|O
psoriasis	75	84	psoriasis	|B-DISEASE
.	84	85		|O
We	87	89		|O
evaluated	90	99		|O
the	100	103		|O
effect	104	110		|O
of	111	113		|O
efalizumab	114	124		|O
on	125	127		|O
neutrophil	128	138		|O
and	139	142		|O
monocyte	143	151		|O
functions	152	161		|O
.	161	162		|O
The	163	166		|O
in	167	169		|O
vitro	170	175		|O
pre	176	179		|O
-	179	180		|O
incubation	180	190		|O
with	191	195		|O
efalizumab	196	206		|O
concentrations	207	221		|O
similar	222	229		|O
to	230	232		|O
those	233	238		|O
reached	239	246		|O
during	247	253		|O
in	254	256		|O
vivo	257	261		|O
therapy	262	269		|O
almost	270	276		|O
completely	277	287		|O
saturated	288	297		|O
CD11a	298	303		|O
binding	304	311		|O
sites	312	317		|O
without	318	325		|O
affecting	326	335		|O
the	336	339		|O
membrane	340	348		|O
expression	349	359		|O
of	360	362		|O
CD11b	363	368		|O
,	368	369		|O
CD128a	370	376		|O
or	377	379		|O
CD128b	380	386		|O
.	386	387		|O
There	388	393		|O
was	394	397		|O
a	398	399		|O
significant	400	411		|O
reduction	412	421		|O
in	422	424		|O
the	425	428		|O
chemotactic	429	440		|O
activity	441	449		|O
of	450	452		|O
the	453	456		|O
pre	457	460		|O
-	460	461		|O
treated	461	468		|O
cells	469	474		|O
toward	475	481		|O
three	482	487		|O
different	488	497		|O
chemo	498	503		|O
-	503	504		|O
attractants	504	515		|O
,	515	516		|O
whereas	517	524		|O
their	525	530		|O
phagocytic	531	541		|O
capacity	542	550		|O
and	551	554		|O
production	555	565		|O
of	566	568		|O
oxygen	569	575		|O
radicals	576	584		|O
remained	585	593		|O
unchanged	594	603		|O
.	603	604		|O
One	605	608		|O
month	609	614		|O
after	615	620		|O
the	621	624		|O
administration	625	639		|O
of	640	642		|O
efalizumab	643	653		|O
to	654	656		|O
five	657	661		|O
patients	662	670		|O
with	671	675		|O
psoriasis	676	685	psoriasis	|B-DISEASE
(	686	687		|O
T1	687	689		|O
)	689	690		|O
circulating	691	702		|O
neutrophil	703	713		|O
counts	714	720		|O
increased	721	730		|O
by	731	733		|O
34%	734	737		|O
from	738	742		|O
pre	743	746		|O
-	746	747		|O
therapy	747	754		|O
(	755	756		|O
T0	756	758		|O
)	758	759		|O
with	760	764		|O
no	765	767		|O
change	768	774		|O
in	775	777		|O
the	778	781		|O
number	782	788		|O
of	789	791		|O
monocytes	792	801		|O
.	801	802		|O
In	803	805		|O
the	806	809		|O
same	810	814		|O
patients	815	823		|O
the	824	827		|O
CD11a	828	833		|O
binding	834	841		|O
sites	842	847		|O
on	848	850		|O
phagocytes	851	861		|O
were	862	866		|O
>	867	868		|O
90%	868	871		|O
saturated	872	881		|O
,	881	882		|O
and	883	886		|O
there	887	892		|O
was	893	896		|O
also	897	901		|O
a	902	903		|O
significant	904	915		|O
down	916	920		|O
-	920	921		|O
modulation	921	931		|O
on	932	934		|O
neutrophils	935	946		|O
(	947	948		|O
44%	948	951		|O
of	952	954		|O
T0	955	957		|O
)	957	958		|O
and	959	962		|O
monocytes	963	972		|O
(	973	974		|O
63%	974	977		|O
of	978	980		|O
T0	981	983		|O
)	983	984		|O
.	984	985		|O
In	986	988		|O
line	989	993		|O
with	994	998		|O
in	999	1001		|O
vitro	1002	1007		|O
results	1008	1015		|O
,	1015	1016		|O
efalizumab	1017	1027		|O
treatment	1028	1037		|O
caused	1038	1044		|O
a	1045	1046		|O
significant	1047	1058		|O
deficiency	1059	1069		|O
in	1070	1072		|O
the	1073	1076		|O
chemotactic	1077	1088		|O
properties	1089	1099		|O
of	1100	1102		|O
neutrophils	1103	1114		|O
and	1115	1118		|O
monocytes	1119	1128		|O
,	1128	1129		|O
but	1130	1133		|O
no	1134	1136		|O
changes	1137	1144		|O
in	1145	1147		|O
phagocytosis	1148	1160		|O
,	1160	1161		|O
oxidative	1162	1171		|O
burst	1172	1177		|O
,	1177	1178		|O
production	1179	1189		|O
of	1190	1192		|O
pro	1193	1196		|O
-	1196	1197		|O
inflammatory	1197	1209		|O
cytokines	1210	1219		|O
or	1220	1222		|O
the	1223	1226		|O
membrane	1227	1235		|O
expression	1236	1246		|O
of	1247	1249		|O
CD11b	1250	1255		|O
,	1255	1256		|O
CD128a	1257	1263		|O
and	1264	1267		|O
CD128b	1268	1274		|O
.	1274	1275		|O
Our	1276	1279		|O
findings	1280	1288		|O
suggest	1289	1296		|O
that	1297	1301		|O
neutrophils	1302	1313		|O
and	1314	1317		|O
monocytes	1318	1327		|O
may	1328	1331		|O
be	1332	1334		|O
among	1335	1340		|O
the	1341	1344		|O
targets	1345	1352		|O
of	1353	1355		|O
efalizumab	1356	1366		|O
activity	1367	1375		|O
in	1376	1378		|O
patients	1379	1387		|O
with	1388	1392		|O
psoriasis	1393	1402	psoriasis	|B-DISEASE
.	1402	1403		|O

### 18684796
Improving	0	9		|O
the	10	13		|O
applicability	14	27		|O
of	28	30		|O
(	31	32		|O
Q	32	33		|O
)	33	34		|O
SARs	34	38		|O
for	39	42		|O
percutaneous	43	55		|O
penetration	56	67		|O
in	68	70		|O
regulatory	71	81		|O
risk	82	86		|O
assessment	87	97		|O
.	97	98		|O
The	100	103		|O
new	104	107		|O
regulatory	108	118		|O
framework	119	128		|O
REACH	129	134		|O
(	135	136		|O
Registration	136	148		|O
,	148	149		|O
Evaluation	150	160		|O
,	160	161		|O
and	162	165		|O
Authorisation	166	179		|O
of	180	182		|O
Chemicals	183	192		|O
)	192	193		|O
foresees	194	202		|O
the	203	206		|O
use	207	210		|O
of	211	213		|O
non	214	217		|O
-	217	218		|O
testing	218	225		|O
approaches	226	236		|O
,	236	237		|O
such	238	242		|O
as	243	245		|O
read	246	250		|O
-	250	251		|O
across	251	257		|O
,	257	258		|O
chemical	259	267		|O
categories	268	278		|O
,	278	279		|O
structure	280	289		|O
-	289	290		|O
activity	290	298		|O
relationships	299	312		|O
(	313	314		|O
SARs	314	318		|O
)	318	319		|O
and	320	323		|O
quantitative	324	336		|O
structure	337	346		|O
-	346	347		|O
activity	347	355		|O
relationships	356	369		|O
(	370	371		|O
QSARs	371	376		|O
)	376	377		|O
.	377	378		|O
Although	379	387		|O
information	388	399		|O
on	400	402		|O
skin	403	407		|O
absorption	408	418		|O
data	419	423		|O
are	424	427		|O
not	428	431		|O
a	432	433		|O
formal	434	440		|O
requirement	441	452		|O
under	453	458		|O
REACH	459	464		|O
,	464	465		|O
data	466	470		|O
on	471	473		|O
dermal	474	480		|O
absorption	481	491		|O
are	492	495		|O
an	496	498		|O
integral	499	507		|O
part	508	512		|O
of	513	515		|O
risk	516	520		|O
assessment	521	531		|O
of	532	534		|O
substances	535	545		|O
/	545	546		|O
products	546	554		|O
to	555	557		|O
which	558	563		|O
man	564	567		|O
is	568	570		|O
predominantly	571	584		|O
exposed	585	592		|O
via	593	596		|O
the	597	600		|O
dermal	601	607		|O
route	608	613		|O
.	613	614		|O
In	615	617		|O
this	618	622		|O
study	623	628		|O
,	628	629		|O
we	630	632		|O
assess	633	639		|O
the	640	643		|O
present	644	651		|O
applicability	652	665		|O
of	666	668		|O
publicly	669	677		|O
available	678	687		|O
QSARs	688	693		|O
on	694	696		|O
skin	697	701		|O
absorption	702	712		|O
for	713	716		|O
risk	717	721		|O
assessment	722	732		|O
purposes	733	741		|O
.	741	742		|O
We	743	745		|O
explicitly	746	756		|O
did	757	760		|O
not	761	764		|O
aim	765	768		|O
to	769	771		|O
give	772	776		|O
scientific	777	787		|O
judgments	788	797		|O
on	798	800		|O
individual	801	811		|O
QSARs	812	817		|O
.	817	818		|O
A	819	820		|O
total	821	826		|O
of	827	829		|O
33	830	832		|O
QSARs	833	838		|O
selected	839	847		|O
from	848	852		|O
the	853	856		|O
public	857	863		|O
domain	864	870		|O
were	871	875		|O
evaluated	876	885		|O
using	886	891		|O
the	892	895		|O
OECD	896	900		|O
(	901	902		|O
Organisation	902	914		|O
for	915	918		|O
Economic	919	927		|O
Co	928	930		|O
-	930	931		|O
operation	931	940		|O
and	941	944		|O
Development	945	956		|O
)	956	957		|O
Principles	958	968		|O
for	969	972		|O
the	973	976		|O
Validation	977	987		|O
of	988	990		|O
(	991	992		|O
Q	992	993		|O
)	993	994		|O
SAR	994	997		|O
Models	998	1004		|O
.	1004	1005		|O
Additionally	1006	1018		|O
,	1018	1019		|O
several	1020	1027		|O
pragmatic	1028	1037		|O
criteria	1038	1046		|O
were	1047	1051		|O
formulated	1052	1062		|O
to	1063	1065		|O
select	1066	1072		|O
QSARs	1073	1078		|O
that	1079	1083		|O
are	1084	1087		|O
most	1088	1092		|O
suitable	1093	1101		|O
for	1102	1105		|O
their	1106	1111		|O
use	1112	1115		|O
in	1116	1118		|O
regulatory	1119	1129		|O
risk	1130	1134		|O
assessment	1135	1145		|O
.	1145	1146		|O
Based	1147	1152		|O
on	1153	1155		|O
these	1156	1161		|O
criteria	1162	1170		|O
,	1170	1171		|O
four	1172	1176		|O
QSARs	1177	1182		|O
were	1183	1187		|O
selected	1188	1196		|O
.	1196	1197		|O
The	1198	1201		|O
predictivity	1202	1214		|O
of	1215	1217		|O
these	1218	1223		|O
QSARs	1224	1229		|O
was	1230	1233		|O
evaluated	1234	1243		|O
by	1244	1246		|O
comparing	1247	1256		|O
their	1257	1262		|O
outcomes	1263	1271		|O
with	1272	1276		|O
experimentally	1277	1291		|O
derived	1292	1299		|O
skin	1300	1304		|O
absorption	1305	1315		|O
data	1316	1320		|O
(	1321	1322		|O
for	1322	1325		|O
62	1326	1328		|O
compounds	1329	1338		|O
)	1338	1339		|O
.	1339	1340		|O
The	1341	1344		|O
predictivity	1345	1357		|O
was	1358	1361		|O
low	1362	1365		|O
for	1366	1369		|O
three	1370	1375		|O
of	1376	1378		|O
four	1379	1383		|O
QSARs	1384	1389		|O
,	1389	1390		|O
whereas	1391	1398		|O
one	1399	1402		|O
model	1403	1408		|O
gave	1409	1413		|O
reasonable	1414	1424		|O
predictions	1425	1436		|O
.	1436	1437		|O
Several	1438	1445		|O
suggestions	1446	1457		|O
are	1458	1461		|O
made	1462	1466		|O
to	1467	1469		|O
increase	1470	1478		|O
the	1479	1482		|O
applicability	1483	1496		|O
of	1497	1499		|O
QSARs	1500	1505		|O
for	1506	1509		|O
skin	1510	1514		|O
absorption	1515	1525		|O
for	1526	1529		|O
risk	1530	1534		|O
assessment	1535	1545		|O
purposes	1546	1554		|O
.	1554	1555		|O

### 18665938
Comparative	0	11		|O
study	12	17		|O
of	18	20		|O
Helicobacter	21	33		|O
pylori	34	40		|O
eradication	41	52		|O
rates	53	58		|O
of	59	61		|O
twice	62	67		|O
-	67	68		|O
versus	68	74		|O
four	75	79		|O
-	79	80		|O
times	80	85		|O
-	85	86		|O
daily	86	91		|O
amoxicillin	92	103		|O
administered	104	116		|O
with	117	121		|O
proton	122	128		|O
pump	129	133		|O
inhibitor	134	143		|O
and	144	147		|O
clarithromycin	148	162		|O
:	162	163		|O
a	164	165		|O
randomized	166	176		|O
study	177	182		|O
.	182	183		|O
BACKGROUND	185	195		|O
:	195	196		|O
Proton	197	203		|O
pump	204	208		|O
inhibitor	209	218		|O
(	219	220		|O
PPI	220	223		|O
)	223	224		|O
-	224	225		|O
containing	225	235		|O
triple	236	242		|O
therapy	243	250		|O
with	251	255		|O
clarithromycin	256	270		|O
and	271	274		|O
amoxicillin	275	286		|O
is	287	289		|O
now	290	293		|O
a	294	295		|O
standard	296	304		|O
regimen	305	312		|O
for	313	316		|O
Helicobacter	317	329		|O
pylori	330	336		|O
eradication	337	348		|O
in	349	351		|O
Korea	352	357		|O
.	357	358		|O
Amoxicillin	359	370		|O
has	371	374		|O
time	375	379		|O
-	379	380		|O
dependent	380	389		|O
bactericidal	390	402		|O
activity	403	411		|O
against	412	419		|O
H	420	421		|O
.	421	422		|O
pylori	423	429		|O
;	429	430		|O
we	431	433		|O
therefore	434	443		|O
assumed	444	451		|O
a	452	453		|O
dosing	454	460		|O
schedule	461	469		|O
of	470	472		|O
amoxicillin	473	484		|O
would	485	490		|O
affect	491	497		|O
the	498	501		|O
eradication	502	513		|O
rate	514	518		|O
of	519	521		|O
H	522	523		|O
.	523	524		|O
pylori	525	531		|O
.	531	532		|O
The	533	536		|O
purpose	537	544		|O
of	545	547		|O
this	548	552		|O
study	553	558		|O
was	559	562		|O
to	563	565		|O
evaluate	566	574		|O
and	575	578		|O
compare	579	586		|O
the	587	590		|O
efficacy	591	599		|O
of	600	602		|O
different	603	612		|O
amoxicillin	613	624		|O
dosing	625	631		|O
schedules	632	641		|O
for	642	645		|O
the	646	649		|O
eradication	650	661		|O
of	662	664		|O
H	665	666		|O
.	666	667		|O
pylori	668	674		|O
.	674	675		|O
MATERIALS	676	685		|O
AND	686	689		|O
METHODS	690	697		|O
:	697	698		|O
One	699	702		|O
hundred	703	710		|O
and	711	714		|O
eighty	715	721		|O
-	721	722		|O
six	722	725		|O
patients	726	734		|O
with	735	739		|O
H	740	741	H. pylori infection	|B-DISEASE
.	741	742		|I-DISEASE
pylori	743	749		|I-DISEASE
infection	750	759		|I-DISEASE
were	760	764		|O
eligible	765	773		|O
for	774	777		|O
this	778	782		|O
study	783	788		|O
.	788	789		|O
Patients	790	798		|O
were	799	803		|O
randomly	804	812		|O
assigned	813	821		|O
to	822	824		|O
one	825	828		|O
of	829	831		|O
two	832	835		|O
regimens	836	844		|O
:	844	845		|O
amoxicillin	846	857		|O
1000	858	862		|O
mg	863	865		|O
with	866	870		|O
clarithromycin	871	885		|O
500	886	889		|O
mg	890	892		|O
and	893	896		|O
omeprazole	897	907		|O
20	908	910		|O
mg	911	913		|O
twice	914	919		|O
daily	920	925		|O
for	926	929		|O
2	930	931		|O
weeks	932	937		|O
(	938	939		|O
BID	939	942		|O
group	943	948		|O
,	948	949		|O
n	950	951		|O
=	952	953		|O
93	954	956		|O
)	956	957		|O
,	957	958		|O
or	959	961		|O
amoxicillin	962	973		|O
500	974	977		|O
mg	978	980		|O
four	981	985		|O
times	986	991		|O
daily	992	997		|O
with	998	1002		|O
clarithromycin	1003	1017		|O
500	1018	1021		|O
mg	1022	1024		|O
and	1025	1028		|O
omeprazole	1029	1039		|O
20	1040	1042		|O
mg	1043	1045		|O
twice	1046	1051		|O
daily	1052	1057		|O
for	1058	1061		|O
2	1062	1063		|O
weeks	1064	1069		|O
(	1070	1071		|O
QID	1071	1074		|O
group	1075	1080		|O
,	1080	1081		|O
n	1082	1083		|O
=	1084	1085		|O
93	1086	1088		|O
)	1088	1089		|O
.	1089	1090		|O
The	1091	1094		|O
success	1095	1102		|O
of	1103	1105		|O
H	1106	1107		|O
.	1107	1108		|O
pylori	1109	1115		|O
eradication	1116	1127		|O
was	1128	1131		|O
evaluated	1132	1141		|O
4-5	1142	1145		|O
weeks	1146	1151		|O
after	1152	1157		|O
completing	1158	1168		|O
treatment	1169	1178		|O
.	1178	1179		|O
RESULTS	1180	1187		|O
:	1187	1188		|O
Overall	1189	1196		|O
eradication	1197	1208		|O
rate	1209	1213		|O
was	1214	1217		|O
90.3%	1218	1223		|O
,	1223	1224		|O
and	1225	1228		|O
eradication	1229	1240		|O
rates	1241	1246		|O
were	1247	1251		|O
91.4%	1252	1257		|O
in	1258	1260		|O
the	1261	1264		|O
BID	1265	1268		|O
group	1269	1274		|O
and	1275	1278		|O
89.2%	1279	1284		|O
in	1285	1287		|O
the	1288	1291		|O
QID	1292	1295		|O
group	1296	1301		|O
(	1302	1303		|O
p	1303	1304		|O
=	1305	1306		|O
0.62	1307	1311		|O
)	1311	1312		|O
.	1312	1313		|O
Compliances	1314	1325		|O
was	1326	1329		|O
95.7%	1330	1335		|O
in	1336	1338		|O
the	1339	1342		|O
BID	1343	1346		|O
group	1347	1352		|O
and	1353	1356		|O
93.5%	1357	1362		|O
in	1363	1365		|O
the	1366	1369		|O
QID	1370	1373		|O
group	1374	1379		|O
(	1380	1381		|O
p	1381	1382		|O
=	1383	1384		|O
0.516	1385	1390		|O
)	1390	1391		|O
;	1391	1392		|O
this	1393	1397		|O
was	1398	1401		|O
the	1402	1405		|O
only	1406	1410		|O
factor	1411	1417		|O
that	1418	1422		|O
significantly	1423	1436		|O
affected	1437	1445		|O
H	1446	1447		|O
.	1447	1448		|O
pylori	1449	1455		|O
eradication	1456	1467		|O
in	1468	1470		|O
this	1471	1475		|O
study	1476	1481		|O
.	1481	1482		|O
Side	1483	1487		|O
effects	1488	1495		|O
in	1496	1498		|O
both	1499	1503		|O
groups	1504	1510		|O
were	1511	1515		|O
generally	1516	1525		|O
mild	1526	1530		|O
.	1530	1531		|O
CONCLUSIONS	1532	1543		|O
:	1543	1544		|O
Amoxicillin	1545	1556		|O
regimens	1557	1565		|O
with	1566	1570		|O
PPI	1571	1574		|O
and	1575	1578		|O
clarithromycin	1579	1593		|O
are	1594	1597		|O
found	1598	1603		|O
to	1604	1606		|O
be	1607	1609		|O
equally	1610	1617		|O
effective	1618	1627		|O
and	1628	1631		|O
safe	1632	1636		|O
in	1637	1639		|O
both	1640	1644		|O
the	1645	1648		|O
BID	1649	1652		|O
and	1653	1656		|O
QID	1657	1660		|O
groups	1661	1667		|O
for	1668	1671		|O
H	1672	1673		|O
.	1673	1674		|O
pylori	1675	1681		|O
eradication	1682	1693		|O
.	1693	1694		|O
Therefore	1695	1704		|O
,	1704	1705		|O
considering	1706	1717		|O
patient	1718	1725		|O
's	1725	1727		|O
comfort	1728	1735		|O
,	1735	1736		|O
we	1737	1739		|O
recommend	1740	1749		|O
a	1750	1751		|O
twice	1752	1757		|O
daily	1758	1763		|O
amoxicillin	1764	1775		|O
regimen	1776	1783		|O
.	1783	1784		|O

### 18550175
Moxifloxacin	0	12		|O
for	13	16		|O
the	17	20		|O
treatment	21	30		|O
of	31	33		|O
HIV	34	37	HIV-associated tuberculosis	|B-DISEASE
-	37	38		|I-DISEASE
associated	38	48		|I-DISEASE
tuberculosis	49	61		|I-DISEASE
in	62	64		|O
patients	65	73		|O
with	74	78		|O
contraindications	79	96		|O
or	97	99		|O
intolerance	100	111		|O
to	112	114		|O
rifamycins	115	125		|O
.	125	126		|O
Administration	128	142		|O
of	143	145		|O
rifampicin	146	156		|O
or	157	159		|O
rifabutin	160	169		|O
in	170	172		|O
the	173	176		|O
treatment	177	186		|O
of	187	189		|O
HIV	190	193	HIV-associated tuberculosis	|B-DISEASE
-	193	194		|I-DISEASE
associated	194	204		|I-DISEASE
tuberculosis	205	217		|I-DISEASE
(	218	219		|O
TB	219	221	TB	|B-DISEASE
)	221	222		|O
is	223	225		|O
made	226	230		|O
rather	231	237		|O
complex	238	245		|O
by	246	248		|O
the	249	252		|O
risk	253	257		|O
of	258	260		|O
drug	261	265		|O
-	265	266		|O
drug	266	270		|O
interactions	271	283		|O
with	284	288		|O
most	289	293		|O
antiretrovirals	294	309		|O
and	310	313		|O
/	313	314		|O
or	314	316		|O
for	317	320		|O
reasons	321	328		|O
of	329	331		|O
toxicity	332	340		|O
.	340	341		|O
While	342	347		|O
in	348	350		|O
selecting	351	360		|O
the	361	364		|O
appropriate	365	376		|O
concomitant	377	388		|O
regimens	389	397		|O
the	398	401		|O
priority	402	410		|O
usually	411	418		|O
goes	419	423		|O
to	424	426		|O
rifamycins	427	437		|O
with	438	442		|O
exclusion	443	452		|O
of	453	455		|O
interacting	456	467		|O
antiretrovirals	468	483		|O
,	483	484		|O
in	485	487		|O
some	488	492		|O
circumstances	493	506		|O
the	507	510		|O
former	511	517		|O
cannot	518	524		|O
be	525	527		|O
used	528	532		|O
and	533	536		|O
anti	537	541		|O
-	541	542		|O
TB	542	544		|O
rifamycin	545	554		|O
-	554	555		|O
free	555	559		|O
regimens	560	568		|O
must	569	573		|O
be	574	576		|O
administered	577	589		|O
.	589	590		|O
We	591	593		|O
describe	594	602		|O
here	603	607		|O
the	608	611		|O
clinical	612	620		|O
course	621	627		|O
of	628	630		|O
two	631	634		|O
patients	635	643		|O
with	644	648		|O
HIV	649	652	HIV-associated TB	|B-DISEASE
-	652	653		|I-DISEASE
associated	653	663		|I-DISEASE
TB	664	666		|I-DISEASE
in	667	669		|O
whom	670	674		|O
the	675	678		|O
last	679	683		|O
generation	684	694		|O
fluorquinolone	695	709		|O
moxifloxacin	710	722		|O
(	723	724		|O
found	724	729		|O
to	730	732		|O
exert	733	738		|O
significant	739	750		|O
activity	751	759		|O
against	760	767		|O
Mycobacterium	768	781		|O
tuberculosis	782	794		|O
)	794	795		|O
successfully	796	808		|O
replaced	809	817		|O
rifamycins	818	828		|O
.	828	829		|O

### 18569383
Gene	0	4		|O
expression	5	15		|O
changes	16	23		|O
after	24	29		|O
exposure	30	38		|O
to	39	41		|O
six	42	45		|O
-	45	46		|O
mix	46	49		|O
in	50	52		|O
a	53	54		|O
mouse	55	60		|O
model	61	66		|O
.	66	67		|O
The	69	72		|O
exposure	73	81		|O
of	82	84		|O
Libby	85	90		|O
MT	91	93		|O
residents	94	103		|O
to	104	106		|O
amphibole	107	116		|O
-	116	117		|O
contaminated	117	129		|O
vermiculite	130	141		|O
is	142	144		|O
well	145	149		|O
known	150	155		|O
.	155	156		|O
To	157	159		|O
explore	160	167		|O
the	168	171		|O
gene	172	176		|O
-	176	177		|O
environment	177	188		|O
interactions	189	201		|O
in	202	204		|O
the	205	208		|O
development	209	220		|O
of	221	223		|O
asbestos	224	232		|O
-	232	233		|O
related	233	240		|O
diseases	241	249		|O
(	250	251		|O
ARD	251	254		|O
)	254	255		|O
,	255	256		|O
a	257	258		|O
mouse	259	264		|O
model	265	270		|O
of	271	273		|O
asbestos	274	282		|O
exposure	283	291		|O
using	292	297		|O
Six	298	301		|O
-	301	302		|O
mix	302	305		|O
(	306	307		|O
a	307	308		|O
combination	309	320		|O
of	321	323		|O
amphibole	324	333		|O
fibers	334	340		|O
gathered	341	349		|O
from	350	354		|O
six	355	358		|O
sites	359	364		|O
at	365	367		|O
the	368	371		|O
Libby	372	377		|O
vermiculite	378	389		|O
mine	390	394		|O
)	394	395		|O
,	395	396		|O
crocidolite	397	408		|O
asbestos	409	417		|O
,	417	418		|O
or	419	421		|O
saline	422	428		|O
as	429	431		|O
a	432	433		|O
negative	434	442		|O
control	443	450		|O
was	451	454		|O
used	455	459		|O
to	460	462		|O
determine	463	472		|O
both	473	477		|O
gene	478	482		|O
expression	483	493		|O
responses	494	503		|O
by	504	506		|O
using	507	512		|O
mouse	513	518		|O
10,000	519	525		|O
oligonucleotide	526	541		|O
array	542	547		|O
and	548	551		|O
to	552	554		|O
visualize	555	564		|O
these	565	570		|O
changes	571	578		|O
histologically	579	593		|O
.	593	594		|O
Mice	595	599		|O
were	600	604		|O
sacrificed	605	615		|O
and	616	619		|O
whole	620	625		|O
lungs	626	631		|O
harvested	632	641		|O
for	642	645		|O
histology	646	655		|O
and	656	659		|O
microarray	660	670		|O
analysis	671	679		|O
six	680	683		|O
months	684	690		|O
following	691	700		|O
exposure	701	709		|O
via	710	713		|O
intratracheal	714	727		|O
instillation	728	740		|O
.	740	741		|O
Using	742	747		|O
an	748	750		|O
arbitrary	751	760		|O
cutoff	761	767		|O
of	768	770		|O
1.25	771	775		|O
-	775	776		|O
fold	776	780		|O
change	781	787		|O
,	787	788		|O
genes	789	794		|O
whose	795	800		|O
RNA	801	804		|O
expression	805	815		|O
levels	816	822		|O
were	823	827		|O
specifically	828	840		|O
altered	841	848		|O
in	849	851		|O
response	852	860		|O
to	861	863		|O
the	864	867		|O
different	868	877		|O
amphibole	878	887		|O
exposures	888	897		|O
were	898	902		|O
grouped	903	910		|O
into	911	915		|O
categories	916	926		|O
by	927	929		|O
a	930	931		|O
gene	932	936		|O
ontology	937	945		|O
analysis	946	954		|O
program	955	962		|O
,	962	963		|O
GoMiner	964	971		|O
.	971	972		|O
Our	973	976		|O
hypothesis	977	987		|O
was	988	991		|O
that	992	996		|O
assessment	997	1007		|O
of	1008	1010		|O
asbestos	1011	1019		|O
-	1019	1020		|O
responsive	1020	1030		|O
genes	1031	1036		|O
would	1037	1042		|O
provide	1043	1050		|O
a	1051	1052		|O
better	1053	1059		|O
understanding	1060	1073		|O
of	1074	1076		|O
response	1077	1085		|O
mechanisms	1086	1096		|O
.	1096	1097		|O
These	1098	1103		|O
experiments	1104	1115		|O
have	1116	1120		|O
provided	1121	1129		|O
new	1130	1133		|O
candidates	1134	1144		|O
for	1145	1148		|O
genes	1149	1154		|O
involved	1155	1163		|O
in	1164	1166		|O
the	1167	1170		|O
asbestos	1171	1179		|O
response	1180	1188		|O
pathways	1189	1197		|O
.	1197	1198		|O

### 18546202
Detailing	0	9		|O
the	10	13		|O
role	14	18		|O
of	19	21		|O
Bax	22	25		|O
translocation	26	39		|O
,	39	40		|O
cytochrome	41	51		|O
c	52	53		|O
release	54	61		|O
,	61	62		|O
and	63	66		|O
perinuclear	67	78		|O
clustering	79	89		|O
of	90	92		|O
the	93	96		|O
mitochondria	97	109		|O
in	110	112		|O
the	113	116		|O
killing	117	124		|O
of	125	127		|O
HeLa	128	132		|O
cells	133	138		|O
by	139	141		|O
TNF	142	145		|O
.	145	146		|O
Induction	148	157		|O
of	158	160		|O
cell	161	165		|O
death	166	171		|O
in	172	174		|O
HeLa	175	179		|O
cells	180	185		|O
with	186	190		|O
TNF	191	194		|O
and	195	198		|O
cycloheximide	199	212		|O
(	213	214		|O
CHX	214	217		|O
)	217	218		|O
required	219	227		|O
an	228	230		|O
adequate	231	239		|O
ATP	240	243		|O
supply	244	250		|O
and	251	254		|O
was	255	258		|O
accompanied	259	270		|O
by	271	273		|O
decrease	274	282		|O
in	283	285		|O
intracellular	286	299		|O
pH	300	302		|O
,	302	303		|O
translocation	304	317		|O
of	318	320		|O
Bax	321	324		|O
,	324	325		|O
perinuclear	326	337		|O
clustering	338	348		|O
of	349	351		|O
the	352	355		|O
mitochondria	356	368		|O
,	368	369		|O
and	370	373		|O
cytochrome	374	384		|O
c	385	386		|O
release	387	394		|O
.	394	395		|O
The	396	399		|O
chloride	400	408		|O
channel	409	416		|O
inhibitor	417	426		|O
furosemide	427	437		|O
prevented	438	447		|O
the	448	451		|O
intracellular	452	465		|O
acidification	466	479		|O
,	479	480		|O
the	481	484		|O
translocation	485	498		|O
of	499	501		|O
Bax	502	505		|O
and	506	509		|O
the	510	513		|O
cell	514	518		|O
death	519	524		|O
.	524	525		|O
Cyclosporin	526	537		|O
A	538	539		|O
(	540	541		|O
CyA	541	544		|O
)	544	545		|O
or	546	548		|O
bongkrekic	549	559		|O
acid	560	564		|O
(	565	566		|O
BK	566	568		|O
)	568	569		|O
inhibited	570	579		|O
the	580	583		|O
induction	584	593		|O
of	594	596		|O
the	597	600		|O
MPT	601	604		|O
,	604	605		|O
the	606	609		|O
release	610	617		|O
of	618	620		|O
cytochrome	621	631		|O
c	632	633		|O
and	634	637		|O
the	638	641		|O
cell	642	646		|O
death	647	652		|O
without	653	660		|O
affecting	661	670		|O
the	671	674		|O
perinuclear	675	686		|O
clustering	687	697		|O
of	698	700		|O
the	701	704		|O
mitochondria	705	717		|O
or	718	720		|O
the	721	724		|O
translocation	725	738		|O
of	739	741		|O
Bax	742	745		|O
.	745	746		|O
Energy	747	753		|O
depletion	754	763		|O
with	764	768		|O
the	769	772		|O
ATP	773	776		|O
synthase	777	785		|O
inhibitor	786	795		|O
oligomycin	796	806		|O
or	807	809		|O
the	810	813		|O
uncoupler	814	823		|O
FCCP	824	828		|O
in	829	831		|O
the	832	835		|O
presence	836	844		|O
of	845	847		|O
2	848	849		|O
-	849	850		|O
deoxy	850	855		|O
-	855	856		|O
glucose	856	863		|O
prevented	864	873		|O
the	874	877		|O
perinuclear	878	889		|O
clustering	890	900		|O
of	901	903		|O
the	904	907		|O
mitochondria	908	920		|O
and	921	924		|O
the	925	928		|O
cell	929	933		|O
killing	934	941		|O
.	941	942		|O
However	943	950		|O
,	950	951		|O
mitochondrial	952	965		|O
translocation	966	979		|O
of	980	982		|O
Bax	983	986		|O
was	987	990		|O
still	991	996		|O
observed	997	1005		|O
.	1005	1006		|O
By	1007	1009		|O
contrast	1010	1018		|O
,	1018	1019		|O
cytochrome	1020	1030		|O
c	1031	1032		|O
was	1033	1036		|O
released	1037	1045		|O
in	1046	1048		|O
the	1049	1052		|O
oligomycin	1053	1063		|O
-	1063	1064		|O
treated	1064	1071		|O
cells	1072	1077		|O
but	1078	1081		|O
not	1082	1085		|O
in	1086	1088		|O
the	1089	1092		|O
same	1093	1097		|O
cells	1098	1103		|O
treated	1104	1111		|O
with	1112	1116		|O
FCCP	1117	1121		|O
.	1121	1122		|O
The	1123	1126		|O
data	1127	1131		|O
demonstrate	1132	1143		|O
that	1144	1148		|O
apoptosis	1149	1158		|O
in	1159	1161		|O
HeLa	1162	1166		|O
cells	1167	1172		|O
is	1173	1175		|O
ATP	1176	1179		|O
dependent	1180	1189		|O
and	1190	1193		|O
requires	1194	1202		|O
the	1203	1206		|O
translocation	1207	1220		|O
of	1221	1223		|O
Bax	1224	1227		|O
.	1227	1228		|O
The	1229	1232		|O
movement	1233	1241		|O
of	1242	1244		|O
Bax	1245	1248		|O
to	1249	1251		|O
the	1252	1255		|O
mitochondria	1256	1268		|O
occurs	1269	1275		|O
before	1276	1282		|O
and	1283	1286		|O
during	1287	1293		|O
the	1294	1297		|O
perinuclear	1298	1309		|O
clustering	1310	1320		|O
of	1321	1323		|O
these	1324	1329		|O
organelles	1330	1340		|O
and	1341	1344		|O
does	1345	1349		|O
not	1350	1353		|O
require	1354	1361		|O
the	1362	1365		|O
presence	1366	1374		|O
of	1375	1377		|O
ATP	1378	1381		|O
.	1381	1382		|O
The	1383	1386		|O
release	1387	1394		|O
of	1395	1397		|O
cytochrome	1398	1408		|O
c	1409	1410		|O
depends	1411	1418		|O
on	1419	1421		|O
the	1422	1425		|O
induction	1426	1435		|O
of	1436	1438		|O
the	1439	1442		|O
mitochondrial	1443	1456		|O
permeability	1457	1469		|O
transition	1470	1480		|O
but	1481	1484		|O
not	1485	1488		|O
ATP	1489	1492		|O
content	1493	1500		|O
.	1500	1501		|O

### 18663869
Management	0	10		|O
of	11	13		|O
bisphosphonate	14	28		|O
-	28	29		|O
induced	29	36		|O
osteonecrosis	37	50	osteonecrosis of the jaw	|B-ADVERSE
of	51	53		|I-ADVERSE
the	54	57		|I-ADVERSE
jaw	58	61		|I-ADVERSE
.	61	62		|O
In	64	66		|O
conclusion	67	77		|O
,	77	78		|O
careful	79	86		|O
treatment	87	96		|O
planning	97	105		|O
minimizes	106	115		|O
BIONJ	116	121		|O
risk	122	126		|O
in	127	129		|O
patients	130	138		|O
with	139	143		|O
bisphosphonate	144	158		|O
exposure	159	167		|O
.	167	168		|O
The	169	172		|O
drug	173	177		|O
type	178	182		|O
,	182	183		|O
dose	184	188		|O
,	188	189		|O
potency	190	197		|O
,	197	198		|O
and	199	202		|O
duration	203	211		|O
are	212	215		|O
important	216	225		|O
factors	226	233		|O
in	234	236		|O
determining	237	248		|O
the	249	252		|O
cumulative	253	263		|O
effect	264	270		|O
on	271	273		|O
bone	274	278		|O
remodeling	279	289		|O
and	290	293		|O
resultant	294	303		|O
risk	304	308		|O
of	309	311		|O
BIONJ	312	317		|O
.	317	318		|O
Dentists	319	327		|O
and	328	331		|O
physicians	332	342		|O
should	343	349		|O
work	350	354		|O
closely	355	362		|O
to	363	365		|O
balance	366	373		|O
the	374	377		|O
risks	378	383		|O
of	384	386		|O
the	387	390		|O
oral	391	395		|O
and	396	399		|O
systemic	400	408		|O
conditions	409	419		|O
surrounding	420	431		|O
bisphosphonate	432	446		|O
use	447	450		|O
.	450	451		|O
A	452	453		|O
critical	454	462		|O
assessment	463	473		|O
of	474	476		|O
current	477	484		|O
literature	485	495		|O
is	496	498		|O
necessary	499	508		|O
to	509	511		|O
best	512	516		|O
serve	517	522		|O
our	523	526		|O
patients	527	535		|O
.	535	536		|O

### 18662289
Pharmacogenomic	0	15		|O
studies	16	23		|O
of	24	26		|O
the	27	30		|O
anticancer	31	41		|O
and	42	45		|O
immunosuppressive	46	63		|O
thiopurines	64	75		|O
mercaptopurine	76	90		|O
and	91	94		|O
azathioprine	95	107		|O
.	107	108		|O
AIMS	110	114		|O
:	114	115		|O
To	116	118		|O
examine	119	126		|O
the	127	130		|O
allelic	131	138		|O
variation	139	148		|O
of	149	151		|O
three	152	157		|O
enzymes	158	165		|O
involved	166	174		|O
in	175	177		|O
6	178	179		|O
-	179	180		|O
mercaptopurine	180	194		|O
/	194	195		|O
azathioprine	195	207		|O
(	208	209		|O
6	209	210		|O
-	210	211		|O
MP	211	213		|O
/	213	214		|O
AZA	214	217		|O
)	217	218		|O
metabolism	219	229		|O
and	230	233		|O
evaluate	234	242		|O
the	243	246		|O
influence	247	256		|O
of	257	259		|O
these	260	265		|O
polymorphisms	266	279		|O
on	280	282		|O
toxicity	283	291		|O
,	291	292		|O
haematological	293	307		|O
parameters	308	318		|O
and	319	322		|O
metabolite	323	333		|O
levels	334	340		|O
in	341	343		|O
patients	344	352		|O
with	353	357		|O
acute	358	363	acute lymphoblastic leukaemia	|B-DISEASE
lymphoblastic	364	377		|I-DISEASE
leukaemia	378	387		|I-DISEASE
(	388	389		|O
ALL	389	392	ALL	|B-DISEASE
)	392	393		|O
or	394	396		|O
inflammatory	397	409	inflammatory bowel disease	|B-DISEASE
bowel	410	415		|I-DISEASE
disease	416	423		|I-DISEASE
(	424	425		|O
IBD	425	428	IBD	|B-DISEASE
)	428	429		|O
.	429	430		|O
METHODS	431	438		|O
:	438	439		|O
Clinical	440	448		|O
data	449	453		|O
and	454	457		|O
blood	458	463		|O
samples	464	471		|O
were	472	476		|O
collected	477	486		|O
from	487	491		|O
19	492	494		|O
ALL	495	498	ALL	|B-DISEASE
paediatric	499	509		|O
patients	510	518		|O
and	519	522		|O
35	523	525		|O
IBD	526	529	IBD	|B-DISEASE
patients	530	538		|O
who	539	542		|O
were	543	547		|O
receiving	548	557		|O
6	558	559		|O
-	559	560		|O
MP	560	562		|O
/	562	563		|O
AZA	563	566		|O
therapy	567	574		|O
.	574	575		|O
All	576	579		|O
patients	580	588		|O
were	589	593		|O
screened	594	602		|O
for	603	606		|O
seven	607	612		|O
genetic	613	620		|O
polymorphisms	621	634		|O
in	635	637		|O
three	638	643		|O
enzymes	644	651		|O
involved	652	660		|O
in	661	663		|O
mercaptopurine	664	678		|O
metabolism	679	689		|O
[	690	691		|O
xanthine	691	699		|O
oxidase	700	707		|O
,	707	708		|O
inosine	709	716		|O
triphosphatase	717	731		|O
(	732	733		|O
C94	733	736		|O
-	736	737		|O
-	737	738		|O
>	738	739		|O
A	739	740		|O
and	741	744		|O
IVS2+	745	750		|O
21A	750	753		|O
-	753	754		|O
-	754	755		|O
>	755	756		|O
C	756	757		|O
)	757	758		|O
and	759	762		|O
thiopurine	763	773		|O
methyltransferase	774	791		|O
]	791	792		|O
.	792	793		|O
Erythrocyte	794	805		|O
and	806	809		|O
plasma	810	816		|O
metabolite	817	827		|O
concentrations	828	842		|O
were	843	847		|O
also	848	852		|O
determined	853	863		|O
.	863	864		|O
The	865	868		|O
associations	869	881		|O
between	882	889		|O
the	890	893		|O
various	894	901		|O
genotypes	902	911		|O
and	912	915		|O
myelotoxicity	916	929	myelotoxicity	|B-ADVERSE
,	929	930		|O
haematological	931	945		|O
parameters	946	956		|O
and	957	960		|O
metabolite	961	971		|O
concentrations	972	986		|O
were	987	991		|O
determined	992	1002		|O
.	1002	1003		|O
RESULTS	1004	1011		|O
:	1011	1012		|O
Thiopurine	1013	1023		|O
methyltransferase	1024	1041		|O
variant	1042	1049		|O
alleles	1050	1057		|O
were	1058	1062		|O
associated	1063	1073		|O
with	1074	1078		|O
a	1079	1080		|O
preferential	1081	1093		|O
metabolism	1094	1104		|O
away	1105	1109		|O
from	1110	1114		|O
6	1115	1116		|O
-	1116	1117		|O
methylmercaptopurine	1117	1137		|O
nucleotides	1138	1149		|O
(	1150	1151		|O
P	1151	1152		|O
=	1153	1154		|O
0.008	1155	1160		|O
in	1161	1163		|O
ALL	1164	1167	ALL	|B-DISEASE
patients	1168	1176		|O
,	1176	1177		|O
P	1178	1179		|O
=	1180	1181		|O
0.038	1182	1187		|O
in	1188	1190		|O
IBD	1191	1194	IBD	|B-DISEASE
patients	1195	1203		|O
)	1203	1204		|O
favouring	1205	1214		|O
6	1215	1216		|O
-	1216	1217		|O
thioguanine	1217	1228		|O
nucleotides	1229	1240		|O
(	1241	1242		|O
6	1242	1243		|O
-	1243	1244		|O
TGNs	1244	1248		|O
)	1248	1249		|O
(	1250	1251		|O
P	1251	1252		|O
=	1253	1254		|O
0.021	1255	1260		|O
in	1261	1263		|O
ALL	1264	1267	ALL	|B-DISEASE
patients	1268	1276		|O
)	1276	1277		|O
.	1277	1278		|O
Interestingly	1279	1292		|O
,	1292	1293		|O
carriers	1294	1302		|O
of	1303	1305		|O
inosine	1306	1313		|O
triphosphatase	1314	1328		|O
IVS2+	1329	1334		|O
21A	1334	1337		|O
-	1337	1338		|O
-	1338	1339		|O
>	1339	1340		|O
C	1340	1341		|O
variants	1342	1350		|O
among	1351	1356		|O
ALL	1357	1360	ALL	|B-DISEASE
and	1361	1364		|O
IBD	1365	1368	IBD	|B-DISEASE
patients	1369	1377		|O
had	1378	1381		|O
significantly	1382	1395		|O
higher	1396	1402		|O
concentrations	1403	1417		|O
of	1418	1420		|O
the	1421	1424		|O
active	1425	1431		|O
cytotoxic	1432	1441		|O
metabolites	1442	1453		|O
,	1453	1454		|O
6	1455	1456		|O
-	1456	1457		|O
TGNs	1457	1461		|O
(	1462	1463		|O
P	1463	1464		|O
=	1465	1466		|O
0.008	1467	1472		|O
in	1473	1475		|O
ALL	1476	1479	ALL	|B-DISEASE
patients	1480	1488		|O
,	1488	1489		|O
P	1490	1491		|O
=	1492	1493		|O
0.047	1494	1499		|O
in	1500	1502		|O
IBD	1503	1506	IBD	|B-DISEASE
patients	1507	1515		|O
)	1515	1516		|O
.	1516	1517		|O
The	1518	1521		|O
study	1522	1527		|O
confirmed	1528	1537		|O
the	1538	1541		|O
association	1542	1553		|O
of	1554	1556		|O
thiopurine	1557	1567		|O
methyltransferase	1568	1585		|O
heterozygosity	1586	1600		|O
with	1601	1605		|O
leucopenia	1606	1616	leucopenia	|B-ADVERSE
and	1617	1620		|O
neutropenia	1621	1632	neutropenia	|B-ADVERSE
in	1633	1635		|O
ALL	1636	1639	ALL	|B-DISEASE
patients	1640	1648		|O
and	1649	1652		|O
reported	1653	1661		|O
a	1662	1663		|O
significant	1664	1675		|O
association	1676	1687		|O
between	1688	1695		|O
inosine	1696	1703		|O
triphosphatase	1704	1718		|O
IVS2+	1719	1724		|O
21A	1724	1727		|O
-	1727	1728		|O
-	1728	1729		|O
>	1729	1730		|O
C	1730	1731		|O
variants	1732	1740		|O
with	1741	1745		|O
thrombocytopenia	1746	1762	thrombocytopenia	|B-ADVERSE
(	1763	1764		|O
P	1764	1765		|O
=	1766	1767		|O
0.012	1768	1773		|O
)	1773	1774		|O
.	1774	1775		|O
CONCLUSIONS	1776	1787		|O
;	1787	1788		|O
Pharmacogenetic	1789	1804		|O
polymorphisms	1805	1818		|O
in	1819	1821		|O
the	1822	1825		|O
6	1826	1827		|O
-	1827	1828		|O
MP	1828	1830		|O
pathway	1831	1838		|O
may	1839	1842		|O
help	1843	1847		|O
identify	1848	1856		|O
patients	1857	1865		|O
at	1866	1868		|O
risk	1869	1873		|O
for	1874	1877		|O
associated	1878	1888		|O
toxicities	1889	1899		|O
and	1900	1903		|O
may	1904	1907		|O
serve	1908	1913		|O
as	1914	1916		|O
a	1917	1918		|O
guide	1919	1924		|O
for	1925	1928		|O
dose	1929	1933		|O
individualization	1934	1951		|O
.	1951	1952		|O

### 18929871
Parkinsonism	0	12	Parkinsonism	|B-ADVERSE
during	13	19		|O
cyclosporine	20	32		|O
treatment	33	42		|O
in	43	45		|O
liver	46	51		|O
transplantation	52	67		|O
:	67	68		|O
an	69	71		|O
unusual	72	79		|O
case	80	84		|O
report	85	91		|O
.	91	92		|O
OBJECTIVES	94	104		|O
:	104	105		|O
Cyclosporine	106	118		|O
(	119	120		|O
CyA	120	123		|O
)	123	124		|O
has	125	128		|O
been	129	133		|O
associated	134	144		|O
with	145	149		|O
various	150	157		|O
neurological	158	170		|O
reactions	171	180		|O
but	181	184		|O
parkinsonism	185	197	parkinsonism	|B-ADVERSE
is	198	200		|O
not	201	204		|O
generally	205	214		|O
recognized	215	225		|O
as	226	228		|O
a	229	230		|O
nervous	231	238		|O
system	239	245		|O
side	246	250		|O
effect	251	257		|O
.	257	258		|O
We	259	261		|O
describe	262	270		|O
herein	271	277		|O
a	278	279		|O
rare	280	284		|O
case	285	289		|O
,	289	290		|O
in	291	293		|O
that	294	298		|O
the	299	302		|O
patient	303	310		|O
developed	311	320		|O
parkinsonism	321	333	parkinsonism	|B-ADVERSE
with	334	338		|O
rest	339	343	rest tremor	|B-ADVERSE
tremor	344	350		|I-ADVERSE
after	351	356		|O
receiving	357	366		|O
CyA	367	370		|O
following	371	380		|O
orthotopic	381	391		|O
liver	392	397		|O
transplantation	398	413		|O
(	414	415		|O
OLT	415	418		|O
)	418	419		|O
.	419	420		|O
METHODS	421	428		|O
:	428	429		|O
The	430	433		|O
patient	434	441		|O
was	442	445		|O
a	446	447		|O
42	448	450		|O
-	450	451		|O
year	451	455		|O
-	455	456		|O
old	456	459		|O
man	460	463		|O
who	464	467		|O
had	468	471		|O
liver	472	477	liver cirrhosis	|B-DISEASE
cirrhosis	478	487		|I-DISEASE
with	488	492		|O
hepatitis	493	502	hepatitis C	|B-DISEASE
C	503	504		|I-DISEASE
.	504	505		|O
We	506	508		|O
performed	509	518		|O
OLT	519	522		|O
because	523	530		|O
of	531	533		|O
liver	534	539	liver failure	|B-DISEASE
failure	540	547		|I-DISEASE
and	548	551		|O
started	552	559		|O
immunosuppressive	560	577		|O
therapy	578	585		|O
with	586	590		|O
CyA	591	594		|O
+	595	596		|O
methylprednisolone	597	615		|O
+	616	617		|O
CD25	618	622		|O
antibody	623	631		|O
.	631	632		|O
Ten	633	636		|O
days	637	641		|O
after	642	647		|O
OLT	648	651		|O
,	651	652		|O
he	653	655		|O
developed	656	665		|O
parkinsonism	666	678	parkinsonism	|B-ADVERSE
with	679	683		|O
a	684	685		|O
rest	686	690	rest tremor	|B-ADVERSE
tremor	691	697		|I-ADVERSE
.	697	698		|O
The	699	702		|O
patient	703	710		|O
did	711	714		|O
not	715	718		|O
have	719	723		|O
a	724	725		|O
pre	726	729		|O
-	729	730		|O
existent	730	738		|O
neurological	738	750	 neurological disorder	|B-DISEASE
disorder	752	760		|I-DISEASE
,	760	761		|O
and	762	765		|O
had	766	769		|O
not	770	773		|O
received	774	782		|O
significant	783	794		|O
amounts	795	802		|O
of	803	805		|O
dopamine	806	814		|O
-	814	815		|O
blocking	815	823		|O
drugs	824	829		|O
.	829	830		|O
RESULTS	831	838		|O
:	838	839		|O
We	840	842		|O
administered	843	855		|O
levodopa	856	864		|O
with	865	869		|O
marked	870	876		|O
improvement	877	888		|O
.	888	889		|O
Three	890	895		|O
days	896	900		|O
after	901	906		|O
that	907	911		|O
event	912	917		|O
,	917	918		|O
the	919	922		|O
neurologist	923	934		|O
suggested	935	944		|O
the	945	948		|O
possibility	949	960		|O
of	961	963		|O
drug	964	968		|O
-	968	969		|O
induced	969	976		|O
parkinsonism	977	989	parkinsonism	|B-ADVERSE
.	989	990		|O
We	991	993		|O
converted	994	1003		|O
the	1004	1007		|O
immunosuppressive	1008	1025		|O
drug	1026	1030		|O
from	1031	1035		|O
CyA	1036	1039		|O
to	1040	1042		|O
tacrolimus	1043	1053		|O
.	1053	1054		|O
After	1055	1060		|O
that	1061	1065		|O
,	1065	1066		|O
the	1067	1070		|O
symptom	1071	1078		|O
disappeared	1079	1090		|O
.	1090	1091		|O
At	1092	1094		|O
75	1095	1097		|O
days	1098	1102		|O
after	1103	1108		|O
OLT	1109	1112		|O
,	1112	1113		|O
he	1114	1116		|O
was	1117	1120		|O
discharged	1121	1131		|O
with	1132	1136		|O
no	1137	1139		|O
neurological	1140	1152		|O
medication	1153	1163		|O
and	1164	1167		|O
now	1168	1171		|O
he	1172	1174		|O
is	1175	1177		|O
completely	1178	1188		|O
recovered	1189	1198		|O
.	1198	1199		|O
CONCLUSION	1200	1210		|O
:	1210	1211		|O
We	1212	1214		|O
think	1215	1220		|O
that	1221	1225		|O
parkinsonism	1226	1238	parkinsonism	|B-ADVERSE
may	1239	1242		|O
be	1243	1245		|O
an	1246	1248		|O
occasional	1249	1259		|O
consequence	1260	1271		|O
of	1272	1274		|O
CyA	1275	1278		|O
because	1279	1286		|O
of	1287	1289		|O
its	1290	1293		|O
relation	1294	1302		|O
to	1303	1305		|O
withdrawal	1306	1316		|O
of	1317	1319		|O
the	1320	1323		|O
drug	1324	1328		|O
and	1329	1332		|O
the	1333	1336		|O
lack	1337	1341		|O
of	1342	1344		|O
another	1345	1352		|O
evident	1353	1360		|O
cause	1361	1366		|O
.	1366	1367		|O

### 18608208
Statin	0	6		|O
-	6	7		|O
induced	7	14		|O
inhibition	15	25		|O
of	26	28		|O
MCF	29	32		|O
-	32	33		|O
7	33	34		|O
breast	35	41		|O
cancer	42	48		|O
cell	49	53		|O
proliferation	54	67		|O
is	68	70		|O
related	71	78		|O
to	79	81		|O
cell	82	86		|O
cycle	87	92		|O
arrest	93	99		|O
and	100	103		|O
apoptotic	104	113		|O
and	114	117		|O
necrotic	118	126		|O
cell	127	131		|O
death	132	137		|O
mediated	138	146		|O
by	147	149		|O
an	150	152		|O
enhanced	153	161		|O
oxidative	162	171		|O
stress	172	178		|O
.	178	179		|O
Statins	181	188		|O
have	189	193		|O
antiproliferative	194	211		|O
and	212	215		|O
anti	216	220		|O
-	220	221		|O
tumoral	221	228		|O
effects	229	236		|O
in	237	239		|O
MCF	240	243		|O
-	243	244		|O
7	244	245		|O
cells	246	251		|O
.	251	252		|O
We	253	255		|O
determined	256	266		|O
the	267	270		|O
effect	271	277		|O
of	278	280		|O
statins	281	288		|O
upon	289	293		|O
MCF	294	297		|O
-	297	298		|O
7	298	299		|O
cell	300	304		|O
cycle	305	310		|O
,	310	311		|O
toxicity	312	320		|O
,	320	321		|O
cell	322	326		|O
death	327	332		|O
,	332	333		|O
reactive	334	342		|O
oxygen	343	349		|O
species	350	357		|O
(	358	359		|O
ROS	359	362		|O
)	362	363		|O
production	364	374		|O
and	375	378		|O
mitochondrial	379	392		|O
membrane	393	401		|O
potential	402	411		|O
.	411	412		|O
Fluvastatin	413	424		|O
,	424	425		|O
simvastatin	426	437		|O
and	438	441		|O
atorvastatin	442	454		|O
inhibited	455	464		|O
cell	465	469		|O
proliferation	470	483		|O
.	483	484		|O
Antiproliferation	485	502		|O
was	503	506		|O
associated	507	517		|O
with	518	522		|O
a	523	524		|O
decrease	525	533		|O
in	534	536		|O
the	537	540		|O
DNA	541	544		|O
synthesis	545	554		|O
and	555	558		|O
a	559	560		|O
cell	561	565		|O
cycle	566	571		|O
arrest	572	578		|O
in	579	581		|O
the	582	585		|O
G1	586	588		|O
and	589	592		|O
G2	593	595		|O
/	595	596		|O
M	596	597		|O
phases	598	604		|O
.	604	605		|O
A	606	607		|O
loss	608	612		|O
in	613	615		|O
the	616	619		|O
mitochondrial	620	633		|O
membrane	634	642		|O
potential	643	652		|O
was	653	656		|O
observed	657	665		|O
with	666	670		|O
fluvastatin	671	682		|O
.	682	683		|O
Statins	684	691		|O
induced	692	699		|O
increase	700	708		|O
in	709	711		|O
ROS	712	715		|O
production	716	726		|O
that	727	731		|O
was	732	735		|O
associated	736	746		|O
with	747	751		|O
cell	752	756		|O
death	757	762		|O
,	762	763		|O
which	764	769		|O
was	770	773		|O
abrogated	774	783		|O
by	784	786		|O
the	787	790		|O
antioxidant	791	802		|O
NAC	803	806		|O
.	806	807		|O
Our	808	811		|O
results	812	819		|O
suggest	820	827		|O
that	828	832		|O
the	833	836		|O
cytotoxic	837	846		|O
effect	847	853		|O
observed	854	862		|O
is	863	865		|O
mediated	866	874		|O
by	875	877		|O
an	878	880		|O
oxidative	881	890		|O
stress	891	897		|O
.	897	898		|O

### 18627515
Interactive	0	11		|O
transport	12	21		|O
,	21	22		|O
subcellular	23	34		|O
relocation	35	45		|O
and	46	49		|O
enhanced	50	58		|O
phototoxicity	59	72	phototoxicity	|B-ADVERSE
of	73	75		|O
hypericin	76	85		|O
encapsulated	86	98		|O
in	99	101		|O
guanidinylated	102	116		|O
liposomes	117	126		|O
via	127	130		|O
molecular	131	140		|O
recognition	141	152		|O
.	152	153		|O
Hypericin	155	164		|O
(	165	166		|O
HYP	166	169		|O
)	169	170		|O
,	170	171		|O
a	172	173		|O
photocytotoxic	174	188		|O
phenanthroperylenquinone	189	213		|O
was	214	217		|O
encapsulated	218	230		|O
in	231	233		|O
liposomes	234	243		|O
outfitted	244	253		|O
with	254	258		|O
guanidinium	259	270		|O
-	270	271		|O
bearing	271	278		|O
lipids	279	285		|O
to	286	288		|O
ensure	289	295		|O
efficient	296	305		|O
cell	306	310		|O
binding	311	318		|O
through	319	326		|O
molecular	327	336		|O
recognition	337	348		|O
with	349	353		|O
anionic	354	361		|O
groups	362	368		|O
resident	369	377		|O
on	378	380		|O
the	381	384		|O
plasma	385	391		|O
membrane	392	400		|O
.	400	401		|O
The	402	405		|O
uptake	406	412		|O
of	413	415		|O
HYP	416	419		|O
encapsulated	420	432		|O
in	433	435		|O
these	436	441		|O
liposomes	442	451		|O
by	452	454		|O
DU145	455	460		|O
human	461	466		|O
prostate	467	475		|O
cancer	476	482		|O
cells	483	488		|O
,	488	489		|O
was	490	493		|O
studied	494	501		|O
employing	502	511		|O
fluorescence	512	524		|O
,	524	525		|O
versus	526	532		|O
nonguadinylated	533	548		|O
liposomes	549	558		|O
and	559	562		|O
free	563	567		|O
HYP	568	571		|O
.	571	572		|O
The	573	576		|O
subcellular	577	588		|O
localization	589	601		|O
was	602	605		|O
in	606	608		|O
all	609	612		|O
cases	613	618		|O
studied	619	626		|O
by	627	629		|O
confocal	630	638		|O
microscopy	639	649		|O
employing	650	659		|O
specific	660	668		|O
subcellular	669	680		|O
organelle	681	690		|O
probes	691	697		|O
.	697	698		|O
The	699	702		|O
photocytotoxicity	703	720		|O
of	721	723		|O
HYP	724	727		|O
was	728	731		|O
assessed	732	740		|O
,	740	741		|O
24	742	744		|O
h	745	746		|O
following	747	756		|O
irradiation	757	768		|O
with	769	773		|O
15	774	776		|O
mWcm	777	781		|O
(	781	782		|O
-	782	783		|O
2	783	784		|O
)	784	785		|O
light	786	791		|O
through	792	799		|O
a	800	801		|O
GG	802	804		|O
495	805	808		|O
Schott	809	815		|O
filter	816	822		|O
,	822	823		|O
by	824	826		|O
a	827	828		|O
standard	829	837		|O
tetrazolium	838	849		|O
to	850	852		|O
formazan	853	861		|O
assay	862	867		|O
(	868	869		|O
XTT	869	872		|O
)	872	873		|O
.	873	874		|O
HYP	875	878		|O
uptake	879	885		|O
by	886	888		|O
DU145	889	894		|O
cells	895	900		|O
was	901	904		|O
found	905	910		|O
to	911	913		|O
be	914	916		|O
profoundly	917	927		|O
enhanced	928	936		|O
by	937	939		|O
using	940	945		|O
guanidinylated	946	960		|O
liposomes	961	970		|O
.	970	971		|O
Also	972	976		|O
the	977	980		|O
distance	981	989		|O
of	990	992		|O
the	993	996		|O
guanidinium	997	1008		|O
group	1009	1014		|O
from	1015	1019		|O
the	1020	1023		|O
liposomal	1024	1033		|O
surface	1034	1041		|O
was	1042	1045		|O
found	1046	1051		|O
to	1052	1054		|O
significantly	1055	1068		|O
affect	1069	1075		|O
HYP	1076	1079		|O
loading	1080	1087		|O
,	1087	1088		|O
subcellular	1089	1100		|O
localization	1101	1113		|O
and	1114	1117		|O
phototoxicity	1118	1131	phototoxicity	|B-DISEASE
.	1131	1132		|O
The	1133	1136		|O
two	1137	1140		|O
different	1141	1150		|O
modes	1151	1156		|O
of	1157	1159		|O
liposome	1160	1168		|O
cell	1169	1173		|O
internalization	1174	1189		|O
observed	1190	1198		|O
,	1198	1199		|O
i.e.	1200	1204		|O
plasma	1205	1211		|O
membrane	1212	1220		|O
fusion	1221	1227		|O
and	1228	1231		|O
endocytosis	1232	1243		|O
,	1243	1244		|O
were	1245	1249		|O
found	1250	1255		|O
to	1256	1258		|O
greatly	1259	1266		|O
affect	1267	1273		|O
the	1274	1277		|O
phototoxicity	1278	1291	phototoxicity	|B-DISEASE
of	1292	1294		|O
HYP	1295	1298		|O
.	1298	1299		|O
Molecular	1300	1309		|O
recognition	1310	1321		|O
was	1322	1325		|O
overall	1326	1333		|O
appraised	1334	1343		|O
as	1344	1346		|O
a	1347	1348		|O
promising	1349	1358		|O
,	1358	1359		|O
novel	1360	1365		|O
route	1366	1371		|O
for	1372	1375		|O
photodynamic	1376	1388		|O
therapy	1389	1396		|O
,	1396	1397		|O
profoundly	1398	1408		|O
enhancing	1409	1418		|O
its	1419	1422		|O
efficacy	1423	1431		|O
.	1431	1432		|O
HYP	1433	1436		|O
encapsulated	1437	1449		|O
in	1450	1452		|O
liposomes	1453	1462		|O
-	1462	1463		|O
bearing	1463	1470		|O
guanidinium	1471	1482		|O
groups	1483	1489		|O
was	1490	1493		|O
more	1494	1498		|O
efficiently	1499	1510		|O
taken	1511	1516		|O
up	1517	1519		|O
by	1520	1522		|O
cells	1523	1528		|O
,	1528	1529		|O
leading	1530	1537		|O
to	1538	1540		|O
enhanced	1541	1549		|O
phototoxicity	1550	1563	phototoxicity	|B-DISEASE
,	1563	1564		|O
in	1565	1567		|O
contrast	1568	1576		|O
to	1577	1579		|O
HYP	1580	1583		|O
encapsulated	1584	1596		|O
in	1597	1599		|O
their	1600	1605		|O
nonguanidinylated	1606	1623		|O
counterparts	1624	1636		|O
.	1636	1637		|O

### 18955203
Cutaneous	0	9		|O
adverse	10	17		|O
effects	18	25		|O
of	26	28		|O
biological	29	39		|O
therapies	40	49		|O
for	50	53		|O
psoriasis	54	63	psoriasis	|B-DISEASE
.	63	64		|O
Psoriasis	66	75	Psoriasis	|B-DISEASE
is	76	78		|O
a	79	80		|O
common	81	87		|O
immune	88	94	immune-mediated disease	|B-DISEASE
-	94	95		|I-DISEASE
mediated	95	103		|I-DISEASE
disease	104	111		|I-DISEASE
that	112	116		|O
affects	117	124		|O
approximately	125	138		|O
2%	139	141		|O
of	142	144		|O
the	145	148		|O
world	149	154		|O
's	154	156		|O
population	157	167		|O
.	167	168		|O
Most	169	173		|O
patients	174	182		|O
require	183	190		|O
lifelong	191	199		|O
treatment	200	209		|O
and	210	213		|O
many	214	218		|O
of	219	221		|O
the	222	225		|O
current	226	233		|O
systemic	234	242		|O
therapies	243	252		|O
are	253	256		|O
complicated	257	268		|O
by	269	271		|O
significant	272	283		|O
toxicities	284	294		|O
or	295	297		|O
inconvenience	298	311		|O
when	312	316		|O
administered	317	329		|O
long	330	334		|O
-	334	335		|O
term	335	339		|O
.	339	340		|O
New	341	344		|O
biological	345	355		|O
psoriasis	356	365	psoriasis	|B-DISEASE
therapies	366	375		|O
have	376	380		|O
been	381	385		|O
developed	386	395		|O
,	395	396		|O
which	397	402		|O
are	403	406		|O
thought	407	414		|O
to	415	417		|O
act	418	421		|O
through	422	429		|O
targeted	430	438		|O
molecular	439	448		|O
pathways	449	457		|O
,	457	458		|O
so	459	461		|O
as	462	464		|O
to	465	467		|O
administer	468	478		|O
them	479	483		|O
continuously	484	496		|O
without	497	504		|O
causing	505	512		|O
any	513	516		|O
relevant	517	525		|O
toxicity	526	534		|O
.	534	535		|O
Nevertheless	536	548		|O
,	548	549		|O
acute	550	555		|O
and	556	559		|O
chronic	560	567		|O
dermatological	568	582		|O
adverse	583	590		|O
effects	591	598		|O
are	599	602		|O
frequently	603	613		|O
observed	614	622		|O
,	622	623		|O
but	624	627		|O
knowledge	628	637		|O
about	638	643		|O
them	644	648		|O
is	649	651		|O
limited	652	659		|O
and	660	663		|O
the	664	667		|O
potential	668	677		|O
pathogenic	678	688		|O
mechanisms	689	699		|O
have	700	704		|O
not	705	708		|O
yet	709	712		|O
been	713	717		|O
identified	718	728		|O
.	728	729		|O
We	730	732		|O
present	733	740		|O
7	741	742		|O
patients	743	751		|O
from	752	756		|O
our	757	760		|O
dermatological	761	775		|O
department	776	786		|O
who	787	790		|O
presented	791	800		|O
different	801	810		|O
cutaneous	811	820		|O
adverse	821	828		|O
effects	829	836		|O
(	837	838		|O
2	838	839		|O
erythrodermias	840	854	erythrodermias	|B-ADVERSE
,	854	855		|O
1	856	857		|O
palmoplantar	858	870	palmoplantar pustulosis	|B-ADVERSE
pustulosis	871	881		|I-ADVERSE
,	881	882		|O
1	883	884		|O
flexural	885	893	flexural psoriasis	|B-ADVERSE
psoriasis	894	903		|I-ADVERSE
,	903	904		|O
1	905	906		|O
eczema	907	913	eczema	|B-ADVERSE
,	913	914		|O
1	915	916		|O
neutrophilic	917	929	neutrophilic dermatosis	|B-ADVERSE
dermatosis	930	940		|I-ADVERSE
and	941	944		|O
1	945	946		|O
papular	947	954	papular eruption	|B-ADVERSE
eruption	955	963		|I-ADVERSE
)	963	964		|O
during	965	971		|O
treatment	972	981		|O
with	982	986		|O
biological	987	997		|O
drugs	998	1003		|O
(	1004	1005		|O
4	1005	1006		|O
patients	1007	1015		|O
with	1016	1020		|O
efaluzimab	1021	1031		|O
,	1031	1032		|O
2	1033	1034		|O
patients	1035	1043		|O
with	1044	1048		|O
infliximab	1049	1059		|O
and	1060	1063		|O
1	1064	1065		|O
patient	1066	1073		|O
with	1074	1078		|O
etanercept	1079	1089		|O
)	1089	1090		|O
.	1090	1091		|O
The	1092	1095		|O
use	1096	1099		|O
of	1100	1102		|O
biological	1103	1113		|O
agents	1114	1120		|O
is	1121	1123		|O
expanding	1124	1133		|O
worldwide	1134	1143		|O
as	1144	1146		|O
new	1147	1150		|O
alternative	1151	1162		|O
treatments	1163	1173		|O
for	1174	1177		|O
psoriasis	1178	1187	psoriasis	|B-DISEASE
and	1188	1191		|O
other	1192	1197		|O
chronic	1198	1205	chronic inflammatory diseases	|B-DISEASE
inflammatory	1206	1218		|I-DISEASE
diseases	1219	1227		|I-DISEASE
.	1227	1228		|O
The	1229	1232		|O
increased	1233	1242		|O
use	1243	1246		|O
of	1247	1249		|O
these	1250	1255		|O
treatments	1256	1266		|O
has	1267	1270		|O
allowed	1271	1278		|O
identification	1279	1293		|O
of	1294	1296		|O
their	1297	1302		|O
acute	1303	1308		|O
and	1309	1312		|O
chronic	1313	1320		|O
systemic	1321	1329		|O
adverse	1330	1337		|O
events	1338	1344		|O
.	1344	1345		|O
Nevertheless	1346	1358		|O
,	1358	1359		|O
the	1360	1363		|O
dermatological	1364	1378		|O
adverse	1379	1386		|O
events	1387	1393		|O
of	1394	1396		|O
these	1397	1402		|O
biological	1403	1413		|O
drugs	1414	1419		|O
are	1420	1423		|O
less	1424	1428		|O
well	1429	1433		|O
known	1434	1439		|O
due	1440	1443		|O
to	1444	1446		|O
few	1447	1450		|O
reports	1451	1458		|O
about	1459	1464		|O
them	1465	1469		|O
and	1470	1473		|O
lack	1474	1478		|O
of	1479	1481		|O
information	1482	1493		|O
about	1494	1499		|O
their	1500	1505		|O
pathogenic	1506	1516		|O
mechanisms	1517	1527		|O
.	1527	1528		|O
Exact	1529	1534		|O
diagnosis	1535	1544		|O
of	1545	1547		|O
these	1548	1553		|O
cutaneous	1554	1563		|O
eruptions	1564	1573		|O
is	1574	1576		|O
very	1577	1581		|O
important	1582	1591		|O
in	1592	1594		|O
order	1595	1600		|O
to	1601	1603		|O
decide	1604	1610		|O
the	1611	1614		|O
need	1615	1619		|O
for	1620	1623		|O
discontinuation	1624	1639		|O
of	1640	1642		|O
the	1643	1646		|O
biological	1647	1657		|O
treatment	1658	1667		|O
.	1667	1668		|O

### 18776655
Structure	0	9		|O
-	9	10		|O
activity	10	18		|O
relationships	19	32		|O
of	33	35		|O
stemphones	36	46		|O
,	46	47		|O
potentiators	48	60		|O
of	61	63		|O
imipenem	64	72		|O
activity	73	81		|O
against	82	89		|O
methicillin	90	101		|O
-	101	102		|O
resistant	102	111		|O
Staphylococcus	112	126		|O
aureus	127	133		|O
.	133	134		|O
From	136	140		|O
a	141	142		|O
further	143	150		|O
purification	151	163		|O
study	164	169		|O
,	169	170		|O
four	171	175		|O
new	176	179		|O
stemphones	180	190		|O
D	191	192		|O
to	193	195		|O
G	196	197		|O
were	198	202		|O
isolated	203	211		|O
along	212	217		|O
with	218	222		|O
previously	223	233		|O
reported	234	242		|O
stemphones	243	253		|O
B	254	255		|O
and	256	259		|O
C	260	261		|O
from	262	266		|O
the	267	270		|O
culture	271	278		|O
broth	279	284		|O
of	285	287		|O
Aspergillus	288	299		|O
sp	300	302		|O
.	302	303		|O
FKI	304	307		|O
-	307	308		|O
2136	308	312		|O
.	312	313		|O
Twenty	314	320		|O
-	320	321		|O
one	321	324		|O
derivatives	325	336		|O
were	337	341		|O
semisynthetically	342	359		|O
prepared	360	368		|O
from	369	373		|O
stemphones	374	384		|O
C	385	386		|O
,	386	387		|O
E	388	389		|O
and	390	393		|O
G	394	395		|O
.	395	396		|O
Potentiation	397	409		|O
of	410	412		|O
imipenem	413	421		|O
activity	422	430		|O
against	431	438		|O
methicillin	439	450		|O
-	450	451		|O
resistant	451	460		|O
Staphylococcus	461	475		|O
aureus	476	482		|O
(	483	484		|O
MRSA	484	488		|O
)	488	489		|O
by	490	492		|O
all	493	496		|O
the	497	500		|O
stemphones	501	511		|O
including	512	521		|O
natural	522	529		|O
and	530	533		|O
semisynthetic	534	547		|O
ones	548	552		|O
was	553	556		|O
compared	557	565		|O
to	566	568		|O
study	569	574		|O
the	575	578		|O
structure	579	588		|O
-	588	589		|O
activity	589	597		|O
relationships	598	611		|O
.	611	612		|O
Derivatives	613	624		|O
with	625	629		|O
a	630	631		|O
free	632	636		|O
hydroxy	637	644		|O
or	645	647		|O
an	648	650		|O
O	651	652		|O
-	652	653		|O
acyl	653	657		|O
residue	658	665		|O
having	666	672		|O
a	673	674		|O
C2	675	677		|O
to	678	680		|O
C5	681	683		|O
carbon	684	690		|O
length	691	697		|O
at	698	700		|O
C	701	702		|O
-	702	703		|O
4	703	704		|O
held	705	709		|O
the	710	713		|O
potentiating	714	726		|O
activity	727	735		|O
,	735	736		|O
but	737	740		|O
those	741	746		|O
with	747	751		|O
a	752	753		|O
longer	754	760		|O
acyl	761	765		|O
residue	766	773		|O
lost	774	778		|O
the	779	782		|O
activity	783	791		|O
.	791	792		|O
The	793	796		|O
presence	797	805		|O
of	806	808		|O
an	809	811		|O
oxo	812	815		|O
or	816	818		|O
a	819	820		|O
free	821	825		|O
hydroxy	826	833		|O
residue	834	841		|O
at	842	844		|O
C	845	846		|O
-	846	847		|O
10	847	849		|O
is	850	852		|O
important	853	862		|O
for	863	866		|O
the	867	870		|O
potentiating	871	883		|O
activity	884	892		|O
because	893	900		|O
introduction	901	913		|O
of	914	916		|O
an	917	919		|O
alkyl	920	925		|O
or	926	928		|O
acyl	929	933		|O
residue	934	941		|O
at	942	944		|O
this	945	949		|O
position	950	958		|O
resulted	959	967		|O
in	968	970		|O
a	971	972		|O
loss	973	977		|O
of	978	980		|O
activity	981	989		|O
.	989	990		|O
Among	991	996		|O
them	997	1001		|O
,	1001	1002		|O
stemphone	1003	1012		|O
E	1013	1014		|O
exhibited	1015	1024		|O
the	1025	1028		|O
most	1029	1033		|O
potent	1034	1040		|O
potentiation	1041	1053		|O
of	1054	1056		|O
imipenem	1057	1065		|O
activity	1066	1074		|O
against	1075	1082		|O
MRSA	1083	1087		|O
and	1088	1091		|O
the	1092	1095		|O
lowest	1096	1102		|O
cytotoxic	1103	1112	cytotoxic activity	|B-ADVERSE
activity	1113	1121		|I-ADVERSE
against	1122	1129		|O
Jurkat	1130	1136		|O
cells	1137	1142		|O
.	1142	1143		|O

### 18562131
Genetic	0	7		|O
variation	8	17		|O
in	18	20		|O
the	21	24		|O
serotonin	25	34		|O
pathway	35	42		|O
and	43	46		|O
smoking	47	54		|O
cessation	55	64		|O
with	65	69		|O
nicotine	70	78		|O
replacement	79	90		|O
therapy	91	98		|O
:	98	99		|O
new	100	103		|O
data	104	108		|O
from	109	113		|O
the	114	117		|O
Patch	118	123		|O
in	124	126		|O
Practice	127	135		|O
trial	136	141		|O
and	142	145		|O
pooled	146	152		|O
analyses	153	161		|O
.	161	162		|O
The	164	167		|O
serotonin	168	177		|O
pathway	178	185		|O
has	186	189		|O
been	190	194		|O
implicated	195	205		|O
in	206	208		|O
nicotine	209	217	nicotine dependence	|B-DISEASE
dependence	218	228		|I-DISEASE
and	229	232		|O
may	233	236		|O
influence	237	246		|O
smoking	247	254		|O
cessation	255	264		|O
.	264	265		|O
Therefore	266	275		|O
,	275	276		|O
792	277	280		|O
cigarette	281	290		|O
smokers	291	298		|O
from	299	303		|O
the	304	307		|O
Patch	308	313		|O
in	314	316		|O
Practice	317	325		|O
trial	326	331		|O
were	332	336		|O
genotyped	337	346		|O
for	347	350		|O
the	351	354		|O
tryptophan	355	365		|O
hydroxylase	366	377		|O
(	378	379		|O
TPH1	379	383		|O
A779C	384	389		|O
)	389	390		|O
,	390	391		|O
serotonin	392	401		|O
transporter	402	413		|O
(	414	415		|O
SLC6A45	415	422		|O
-	422	423		|O
HTTLPR	423	429		|O
)	429	430		|O
,	430	431		|O
and	432	435		|O
5	436	437		|O
-	437	438		|O
HT1A	438	442		|O
(	443	444		|O
HTR1A	444	449		|O
C	450	451		|O
-	451	452		|O
1019G	452	457		|O
)	457	458		|O
polymorphisms	459	472		|O
.	472	473		|O
Cox	474	477		|O
regression	478	488		|O
analysis	489	497		|O
did	498	501		|O
not	502	505		|O
demonstrate	506	517		|O
significant	518	529		|O
effects	530	537		|O
of	538	540		|O
any	541	544		|O
of	545	547		|O
the	548	551		|O
three	552	557		|O
genotypes	558	567		|O
on	568	570		|O
relapse	571	578		|O
to	579	581		|O
smoking	582	589		|O
:	589	590		|O
TPH1	591	595		|O
(	596	597		|O
Reference	597	606		|O
AA	607	609		|O
;	609	610		|O
AC	611	613		|O
:	613	614		|O
hazard	615	621		|O
ratio	622	627		|O
(	628	629		|O
HR	629	631		|O
)	631	632		|O
0.99	633	637		|O
,	637	638		|O
95%	639	642		|O
confidence	643	653		|O
interval	654	662		|O
(	663	664		|O
CI	664	666		|O
)	666	667		|O
0.78	668	672		|O
,	672	673		|O
1.24	674	678		|O
,	678	679		|O
p	680	681		|O
=	681	682		|O
0.90	682	686		|O
;	686	687		|O
CC	688	690		|O
:	690	691		|O
HR	692	694		|O
0.93	695	699		|O
,	699	700		|O
95%	701	704		|O
CI	705	707		|O
0.73	708	712		|O
,	712	713		|O
1.18	714	718		|O
,	718	719		|O
p	720	721		|O
=	721	722		|O
0.55	722	726		|O
)	726	727		|O
;	727	728		|O
5	729	730		|O
-	730	731		|O
HTTLPR	731	737		|O
(	738	739		|O
Reference	739	748		|O
LL	749	751		|O
;	751	752		|O
SL	753	755		|O
:	755	756		|O
HR	757	759		|O
1.01	760	764		|O
,	764	765		|O
95%	766	769		|O
CI	770	772		|O
0.85	773	777		|O
,	777	778		|O
1.20	779	783		|O
,	783	784		|O
p	785	786		|O
=	786	787		|O
0.90	787	791		|O
;	791	792		|O
SS	793	795		|O
:	795	796		|O
HR	797	799		|O
1.13	800	804		|O
,	804	805		|O
95%	806	809		|O
CI	810	812		|O
0.91	813	817		|O
,	817	818		|O
1.39	819	823		|O
,	823	824		|O
p	825	826		|O
=	826	827		|O
0.27	827	831		|O
)	831	832		|O
;	832	833		|O
HTR1A	834	839		|O
(	840	841		|O
Reference	841	850		|O
CC	851	853		|O
;	853	854		|O
CG	855	857		|O
:	857	858		|O
HR	859	861		|O
1.04	862	866		|O
,	866	867		|O
95%	868	871		|O
CI	872	874		|O
0.86	875	879		|O
,	879	880		|O
1.25	881	885		|O
,	885	886		|O
p	887	888		|O
=	888	889		|O
0.70	889	893		|O
;	893	894		|O
GG	895	897		|O
:	897	898		|O
HR	899	901		|O
1.01	902	906		|O
,	906	907		|O
95%	908	911		|O
CI	912	914		|O
0.82	915	919		|O
,	919	920		|O
1.24	921	925		|O
,	925	926		|O
p	927	928		|O
=	928	929		|O
0.93	929	933		|O
)	933	934		|O
.	934	935		|O
Moreover	936	944		|O
,	944	945		|O
pooled	946	952		|O
analyses	953	961		|O
of	962	964		|O
data	965	969		|O
from	970	974		|O
all	975	978		|O
three	979	984		|O
extant	985	991		|O
pharmacogenetic	992	1007		|O
NRT	1008	1011		|O
trials	1012	1018		|O
(	1019	1020		|O
N	1020	1021		|O
=	1021	1022		|O
1398	1022	1026		|O
)	1026	1027		|O
found	1028	1033		|O
no	1034	1036		|O
significant	1037	1048		|O
effect	1049	1055		|O
of	1056	1058		|O
5	1059	1060		|O
-	1060	1061		|O
HTTLPR	1061	1067		|O
genotype	1068	1076		|O
on	1077	1079		|O
continuous	1080	1090		|O
abstinence	1091	1101		|O
at	1102	1104		|O
12	1105	1107		|O
-	1107	1108		|O
week	1108	1112		|O
(	1113	1114		|O
Reference	1114	1123		|O
LL	1124	1126		|O
;	1126	1127		|O
SL	1128	1130		|O
:	1130	1131		|O
odds	1132	1136		|O
ratio	1137	1142		|O
(	1143	1144		|O
OR	1144	1146		|O
)	1146	1147		|O
=	1147	1148		|O
1.25	1148	1152		|O
,	1152	1153		|O
95%	1154	1157		|O
CI	1158	1160		|O
0.89	1161	1165		|O
,	1165	1166		|O
1.74	1167	1171		|O
,	1171	1172		|O
p	1173	1174		|O
=	1174	1175		|O
0.19	1175	1179		|O
;	1179	1180		|O
SS	1181	1183		|O
:	1183	1184		|O
OR	1185	1187		|O
=	1187	1188		|O
1.31	1188	1192		|O
,	1192	1193		|O
95%	1194	1197		|O
CI	1198	1200		|O
0.86	1201	1205		|O
,	1205	1206		|O
1.98	1207	1211		|O
,	1211	1212		|O
p	1213	1214		|O
=	1214	1215		|O
0.21	1215	1219		|O
)	1219	1220		|O
or	1221	1223		|O
26	1224	1226		|O
-	1226	1227		|O
week	1227	1231		|O
follow	1232	1238		|O
-	1238	1239		|O
up	1239	1241		|O
(	1242	1243		|O
Reference	1243	1252		|O
LL	1253	1255		|O
;	1255	1256		|O
SL	1257	1259		|O
:	1259	1260		|O
OR	1261	1263		|O
=	1263	1264		|O
0.93	1264	1268		|O
,	1268	1269		|O
95%	1270	1273		|O
CI	1274	1276		|O
0.64	1277	1281		|O
,	1281	1282		|O
1.33	1283	1287		|O
,	1287	1288		|O
p	1289	1290		|O
=	1290	1291		|O
0.68	1291	1295		|O
;	1295	1296		|O
SS	1297	1299		|O
:	1299	1300		|O
OR	1301	1303		|O
=	1303	1304		|O
1.00	1304	1308		|O
,	1308	1309		|O
95%	1310	1313		|O
CI	1314	1316		|O
0.63	1317	1321		|O
,	1321	1322		|O
1.58	1323	1327		|O
,	1327	1328		|O
p	1329	1330		|O
=	1330	1331		|O
1.00	1331	1335		|O
)	1335	1336		|O
.	1336	1337		|O
These	1338	1343		|O
data	1344	1348		|O
do	1349	1351		|O
not	1352	1355		|O
support	1356	1363		|O
a	1364	1365		|O
statistically	1366	1379		|O
or	1380	1382		|O
clinically	1383	1393		|O
significant	1394	1405		|O
moderating	1406	1416		|O
effect	1417	1423		|O
of	1424	1426		|O
these	1427	1432		|O
specific	1433	1441		|O
5	1442	1443		|O
-	1443	1444		|O
HT	1444	1446		|O
pathway	1447	1454		|O
genetic	1455	1462		|O
variants	1463	1471		|O
on	1472	1474		|O
smoking	1475	1482		|O
cessation	1483	1492		|O
.	1492	1493		|O
However	1494	1501		|O
,	1501	1502		|O
the	1503	1506		|O
possibility	1507	1518		|O
remains	1519	1526		|O
that	1527	1531		|O
other	1532	1537		|O
variants	1538	1546		|O
in	1547	1549		|O
these	1550	1555		|O
or	1556	1558		|O
other	1559	1564		|O
5	1565	1566		|O
-	1566	1567		|O
HT	1567	1569		|O
genes	1570	1575		|O
may	1576	1579		|O
influence	1580	1589		|O
NRT	1590	1593		|O
efficacy	1594	1602		|O
for	1603	1606		|O
smoking	1607	1614		|O
cessation	1615	1624		|O
in	1625	1627		|O
treatment	1628	1637		|O
seeking	1638	1645		|O
smokers	1646	1653		|O
.	1653	1654		|O

### 18667824
Serum	0	5		|O
lactate	6	13		|O
dehydrogenase	14	27		|O
is	28	30		|O
a	31	32		|O
novel	33	38		|O
marker	39	45		|O
for	46	49		|O
the	50	53		|O
evaluation	54	64		|O
of	65	67		|O
disease	68	75		|O
severity	76	84		|O
in	85	87		|O
the	88	91		|O
early	92	97		|O
stage	98	103		|O
of	104	106		|O
toxic	107	112	toxic epidermal necrolysis	|B-DISEASE
epidermal	113	122		|I-DISEASE
necrolysis	123	133		|I-DISEASE
.	133	134		|O
OBJECTIVE	136	145		|O
:	145	146		|O
To	147	149		|O
evaluate	150	158		|O
serum	159	164		|O
lactate	165	172		|O
dehydrogenase	173	186		|O
(	187	188		|O
LDH	188	191		|O
)	191	192		|O
and	193	196		|O
its	197	200		|O
correlation	201	212		|O
with	213	217		|O
skin	218	222		|O
manifestations	223	237		|O
in	238	240		|O
patients	241	249		|O
with	250	254		|O
Stevens	255	262	Stevens-Johnson syndrome	|B-DISEASE
-	262	263		|I-DISEASE
Johnson	263	270		|I-DISEASE
syndrome	271	279		|I-DISEASE
(	280	281		|O
SJS	281	284	SJS	|B-DISEASE
)	284	285		|O
and	286	289		|O
toxic	290	295	toxic epidermal necrolysis	|B-DISEASE
epidermal	296	305		|I-DISEASE
necrolysis	306	316		|I-DISEASE
(	317	318		|O
TEN	318	321	TEN	|B-DISEASE
)	321	322		|O
.	322	323		|O
METHODS	324	331		|O
:	331	332		|O
Serum	333	338		|O
LDH	339	342		|O
levels	343	349		|O
were	350	354		|O
measured	355	363		|O
in	364	366		|O
33	367	369		|O
patients	370	378		|O
(	379	380		|O
17	380	382		|O
SJS	383	386	SJS	|B-DISEASE
and	387	390		|O
16	391	393		|O
TEN	394	397	TEN	|B-DISEASE
)	397	398		|O
,	398	399		|O
from	400	404		|O
initial	405	412		|O
hospital	413	421		|O
admission	422	431		|O
to	432	434		|O
remission	435	444		|O
stage	445	450		|O
.	450	451		|O
RESULTS	452	459		|O
:	459	460		|O
The	461	464		|O
mean	465	469		|O
LDH	470	473		|O
level	474	479		|O
was	480	483		|O
920.82	484	490		|O
+	491	492		|O
/	492	493		|O
-	493	494		|O
655.50	495	501		|O
U	502	503		|O
/	503	504		|O
l	504	505		|O
in	506	508		|O
TEN	509	512	TEN	|B-DISEASE
and	513	516		|O
595.35	517	523		|O
+	524	525		|O
/	525	526		|O
-	526	527		|O
182.03	528	534		|O
U	535	536		|O
/	536	537		|O
l	537	538		|O
in	539	541		|O
SJS	542	545	SJS	|B-DISEASE
(	546	547		|O
normal	547	553		|O
range	554	559		|O
:	559	560		|O
218-472	561	568		|O
)	568	569		|O
.	569	570		|O
We	571	573		|O
arbitrarily	574	585		|O
divided	586	593		|O
these	594	599		|O
patients	600	608		|O
into	609	613		|O
2	614	615		|O
groups	616	622		|O
,	622	623		|O
the	624	627		|O
first	628	633		|O
were	634	638		|O
admitted	639	647		|O
within	648	654		|O
3	655	656		|O
days	657	661		|O
of	662	664		|O
onset	665	670		|O
(	671	672		|O
early	672	677		|O
stage	678	683		|O
)	683	684		|O
and	685	688		|O
the	689	692		|O
second	693	699		|O
after	700	705		|O
4	706	707		|O
days	708	712		|O
of	713	715		|O
onset	716	721		|O
(	722	723		|O
late	723	727		|O
stage	728	733		|O
)	733	734		|O
.	734	735		|O
The	736	739		|O
ratio	740	745		|O
of	746	748		|O
early	749	754		|O
-	754	755		|O
to	756	758		|O
late	759	763		|O
-	763	764		|O
stage	764	769		|O
patients	770	778		|O
was	779	782		|O
7	783	784		|O
:	784	785		|O
9	785	786		|O
in	787	789		|O
TEN	790	793	TEN	|B-DISEASE
and	794	797		|O
7	798	799		|O
:	799	800		|O
10	800	802		|O
in	803	805		|O
SJS	806	809		|O
.	809	810		|O
The	811	814		|O
mean	815	819		|O
LDH	820	823		|O
level	824	829		|O
for	830	833		|O
7	834	835		|O
TEN	836	839	TEN	|B-DISEASE
patients	840	848		|O
in	849	851		|O
the	852	855		|O
early	856	861		|O
stage	862	867		|O
was	868	871		|O
1,319.14	872	880		|O
+	881	882		|O
/	882	883		|O
-	883	884		|O
843.10	885	891		|O
U	892	893		|O
/	893	894		|O
l	894	895		|O
,	895	896		|O
which	897	902		|O
was	903	906		|O
significantly	907	920		|O
higher	921	927		|O
than	928	932		|O
that	933	937		|O
of	938	940		|O
the	941	944		|O
SJS	945	948	SJS	|B-DISEASE
group	949	954		|O
(	955	956		|O
686.71	956	962		|O
+	963	964		|O
/	964	965		|O
-	965	966		|O
171.81	967	973		|O
U	974	975		|O
/	975	976		|O
l	976	977		|O
;	977	978		|O
p	979	980		|O
=	981	982		|O
0.024	983	988		|O
)	988	989		|O
.	989	990		|O
In	991	993		|O
the	994	997		|O
late	998	1002		|O
-	1002	1003		|O
stage	1003	1008		|O
patients	1009	1017		|O
,	1017	1018		|O
the	1019	1022		|O
mean	1023	1027		|O
levels	1028	1034		|O
of	1035	1037		|O
TEN	1038	1041	TEN	|B-DISEASE
and	1042	1045		|O
SJS	1046	1049	SJS	|B-DISEASE
patients	1050	1058		|O
were	1059	1063		|O
611.0	1064	1069		|O
+	1070	1071		|O
/	1071	1072		|O
-	1072	1073		|O
160.33	1074	1080		|O
and	1081	1084		|O
531.4	1085	1090		|O
+	1091	1092		|O
/	1092	1093		|O
-	1093	1094		|O
167.89	1095	1101		|O
U	1102	1103		|O
/	1103	1104		|O
l	1104	1105		|O
,	1105	1106		|O
respectively	1107	1119		|O
;	1119	1120		|O
these	1121	1126		|O
differences	1127	1138		|O
between	1139	1146		|O
TEN	1147	1150	TEN	|B-DISEASE
and	1151	1154		|O
SJS	1155	1158	SJS	|B-DISEASE
were	1159	1163		|O
not	1164	1167		|O
significant	1168	1179		|O
.	1179	1180		|O
CONCLUSION	1181	1191		|O
:	1191	1192		|O
Serum	1193	1198		|O
LDH	1199	1202		|O
levels	1203	1209		|O
can	1210	1213		|O
be	1214	1216		|O
used	1217	1221		|O
as	1222	1224		|O
a	1225	1226		|O
marker	1227	1233		|O
of	1234	1236		|O
disease	1237	1244		|O
severity	1245	1253		|O
in	1254	1256		|O
the	1257	1260		|O
early	1261	1266		|O
stage	1267	1272		|O
of	1273	1275		|O
TEN	1276	1279	TEN	|B-DISEASE
.	1279	1280		|O

### 18641920
A	0	1		|O
phase	2	7		|O
I	8	9		|O
trial	10	15		|O
of	16	18		|O
PTK787	19	25		|O
/	25	26		|O
ZK222584	26	34		|O
in	35	37		|O
combination	38	49		|O
with	50	54		|O
pemetrexed	55	65		|O
and	66	69		|O
cisplatin	70	79		|O
in	80	82		|O
patients	83	91		|O
with	92	96		|O
advanced	97	105		|O
solid	106	111	solid tumors	|B-DISEASE
tumors	112	118		|I-DISEASE
.	118	119		|O
Angiogenesis	121	133		|O
is	134	136		|O
recognized	137	147		|O
as	148	150		|O
an	151	153		|O
important	154	163		|O
biological	164	174		|O
process	175	182		|O
that	183	187		|O
allows	188	194		|O
growth	195	201		|O
of	202	204		|O
a	205	206		|O
tumor	207	212	tumor	|B-DISEASE
beyond	213	219		|O
an	220	222		|O
initial	223	230		|O
small	231	236		|O
size	237	241		|O
.	241	242		|O
PTK787	243	249		|O
/	249	250		|O
ZK222584	250	258		|O
,	258	259		|O
a	260	261		|O
potent	262	268		|O
orally	269	275		|O
active	276	282		|O
angiogenesis	283	295		|O
inhibitor	296	305		|O
capable	306	313		|O
of	314	316		|O
inhibiting	317	327		|O
all	328	331		|O
known	332	337		|O
isoforms	338	346		|O
of	347	349		|O
Vascular	350	358		|O
Endothelial	359	370		|O
Growth	371	377		|O
Factor	378	384		|O
(	385	386		|O
VEGF	386	390		|O
)	390	391		|O
receptor	392	400		|O
,	400	401		|O
belongs	402	409		|O
to	410	412		|O
the	413	416		|O
class	417	422		|O
of	423	425		|O
aminophthalazines	426	443		|O
.	443	444		|O
This	445	449		|O
study	450	455		|O
investigated	456	468		|O
a	469	470		|O
combination	471	482		|O
of	483	485		|O
chemotherapy	486	498		|O
(	499	500		|O
Cisplatin	500	509		|O
and	510	513		|O
Pemetrexed	514	524		|O
)	524	525		|O
with	526	530		|O
PTK787	531	537		|O
/	537	538		|O
ZK222584	538	546		|O
.	546	547		|O
Eight	548	553		|O
patients	554	562		|O
were	563	567		|O
enrolled	568	576		|O
but	577	580		|O
PTK787	581	587		|O
/	587	588		|O
ZK222584	588	596		|O
dose	597	601		|O
could	602	607		|O
not	608	611		|O
be	612	614		|O
escalated	615	624		|O
as	625	627		|O
planned	628	635		|O
because	636	643		|O
of	644	646		|O
dose	647	651	dose limiting toxicities	|B-ADVERSE
limiting	652	660		|I-ADVERSE
toxicities	661	671		|I-ADVERSE
(	672	673		|O
DLTs	673	677	DLTs	|B-ADVERSE
)	677	678		|O
observed	679	687		|O
on	688	690		|O
the	691	694		|O
first	695	700		|O
dose	701	705		|O
level	706	711		|O
.	711	712		|O
Limited	713	720		|O
pharmacokinetic	721	736		|O
profiling	737	746		|O
of	747	749		|O
PTK787	750	756		|O
/	756	757		|O
ZK222584	757	765		|O
revealed	766	774		|O
no	775	777		|O
evidence	778	786		|O
of	787	789		|O
drug	790	794		|O
-	794	795		|O
drug	795	799		|O
interactions	800	812		|O
.	812	813		|O
No	814	816		|O
responses	817	826		|O
were	827	831		|O
seen	832	836		|O
for	837	840		|O
this	841	845		|O
combination	846	857		|O
.	857	858		|O
This	859	863		|O
study	864	869		|O
was	870	873		|O
closed	874	880		|O
secondary	881	890		|O
to	891	893		|O
toxicity	894	902		|O
and	903	906		|O
lack	907	911		|O
of	912	914		|O
efficacy	915	923		|O
of	924	926		|O
the	927	930		|O
designed	931	939		|O
regimen	940	947		|O
.	947	948		|O

### 18804218
Bayesian	0	8		|O
adaptive	9	17		|O
non	18	21		|O
-	21	22		|O
inferiority	22	33		|O
with	34	38		|O
safety	39	45		|O
assessment	46	56		|O
:	56	57		|O
retrospective	58	71		|O
case	72	76		|O
study	77	82		|O
to	83	85		|O
highlight	86	95		|O
potential	96	105		|O
benefits	106	114		|O
and	115	118		|O
limitations	119	130		|O
of	131	133		|O
the	134	137		|O
approach	138	146		|O
.	146	147		|O
Adaptive	149	157		|O
trial	158	163		|O
design	164	170		|O
applied	171	178		|O
to	179	181		|O
randomized	182	192		|O
clinical	193	201		|O
trials	202	208		|O
of	209	211		|O
psychiatric	212	223		|O
medicines	224	233		|O
offers	234	240		|O
the	241	244		|O
potential	245	254		|O
to	255	257		|O
make	258	262		|O
clinical	263	271		|O
trials	272	278		|O
more	279	283		|O
efficient	284	293		|O
.	293	294		|O
In	295	297		|O
the	298	301		|O
current	302	309		|O
analysis	310	318		|O
,	318	319		|O
we	320	322		|O
retrospectively	323	338		|O
applied	339	346		|O
Bayesian	347	355		|O
adaptive	356	364		|O
allocation	365	375		|O
methods	376	383		|O
to	384	386		|O
a	387	388		|O
case	389	393		|O
study	394	399		|O
in	400	402		|O
agitated	403	411		|O
patients	412	420		|O
with	421	425		|O
schizophrenia	426	439	schizophrenia	|B-DISEASE
and	440	443		|O
related	444	451		|O
diseases	452	460		|O
.	460	461		|O
The	462	465		|O
original	466	474		|O
study	475	480		|O
used	481	485		|O
a	486	487		|O
randomized	488	498		|O
,	498	499		|O
double	500	506		|O
-	506	507		|O
blind	507	512		|O
,	512	513		|O
parallel	514	522		|O
design	523	529		|O
.	529	530		|O
The	531	534		|O
objective	535	544		|O
of	545	547		|O
this	548	552		|O
analysis	553	561		|O
was	562	565		|O
to	566	568		|O
demonstrate	569	580		|O
the	581	584		|O
potential	585	594		|O
benefits	595	603		|O
of	604	606		|O
Bayesian	607	615		|O
adaptive	616	624		|O
designs	625	632		|O
by	633	635		|O
shortening	636	646		|O
the	647	650		|O
study	651	656		|O
duration	657	665		|O
and	666	669		|O
therefore	670	679		|O
limiting	680	688		|O
patient	689	696		|O
exposure	697	705		|O
to	706	708		|O
ineffective	709	720		|O
placebo	721	728		|O
or	729	731		|O
an	732	734		|O
active	735	741		|O
comparator	742	752		|O
with	753	757		|O
a	758	759		|O
known	760	765		|O
side	766	770		|O
effect	771	777		|O
.	777	778		|O
Bayesian	779	787		|O
methods	788	795		|O
allowed	796	803		|O
us	804	806		|O
to	807	809		|O
fully	810	815		|O
leverage	816	824		|O
historical	825	835		|O
data	836	840		|O
along	841	846		|O
with	847	851		|O
data	852	856		|O
observed	857	865		|O
as	866	868		|O
the	869	872		|O
study	873	878		|O
was	879	882		|O
ongoing	883	890		|O
to	891	893		|O
calculate	894	903		|O
predictive	904	914		|O
probabilities	915	928		|O
of	929	931		|O
patient	932	939		|O
response	940	948		|O
to	949	951		|O
treatment	952	961		|O
without	962	969		|O
experiencing	970	982		|O
a	983	984		|O
specified	985	994		|O
side	995	999		|O
effect	1000	1006		|O
.	1006	1007		|O
Using	1008	1013		|O
the	1014	1017		|O
Bayesian	1018	1026		|O
adaptive	1027	1035		|O
approach	1036	1044		|O
would	1045	1050		|O
have	1051	1055		|O
required	1056	1064		|O
less	1065	1069		|O
than	1070	1074		|O
half	1075	1079		|O
the	1080	1083		|O
number	1084	1090		|O
of	1091	1093		|O
patients	1094	1102		|O
as	1103	1105		|O
the	1106	1109		|O
original	1110	1118		|O
study	1119	1124		|O
to	1125	1127		|O
draw	1128	1132		|O
the	1133	1136		|O
same	1137	1141		|O
conclusion	1142	1152		|O
.	1152	1153		|O
Sample	1154	1160		|O
size	1161	1165		|O
was	1166	1169		|O
reduced	1170	1177		|O
from	1178	1182		|O
311	1183	1186		|O
to	1187	1189		|O
156	1190	1193		|O
patients	1194	1202		|O
,	1202	1203		|O
thereby	1204	1211		|O
decreasing	1212	1222		|O
the	1223	1226		|O
number	1227	1233		|O
of	1234	1236		|O
patients	1237	1245		|O
exposed	1246	1253		|O
to	1254	1256		|O
placebo	1257	1264		|O
from	1265	1269		|O
54	1270	1272		|O
to	1273	1275		|O
30	1276	1278		|O
and	1279	1282		|O
the	1283	1286		|O
number	1287	1293		|O
exposed	1294	1301		|O
to	1302	1304		|O
the	1305	1308		|O
active	1309	1315		|O
control	1316	1323		|O
with	1324	1328		|O
a	1329	1330		|O
known	1331	1336		|O
side	1337	1341		|O
effect	1342	1348		|O
from	1349	1353		|O
126	1354	1357		|O
to	1358	1360		|O
60	1361	1363		|O
.	1363	1364		|O

### 18838379
Up	0	2		|O
-	2	3		|O
regulation	3	13		|O
and	14	17		|O
cytoprotective	18	32		|O
role	33	37		|O
of	38	40		|O
epithelial	41	51		|O
multidrug	52	61		|O
resistance	62	72		|O
-	72	73		|O
associated	73	83		|O
protein	84	91		|O
1	92	93		|O
in	94	96		|O
inflammatory	97	109	inflammatory bowel disease	|B-DISEASE
bowel	110	115		|I-DISEASE
disease	116	123		|I-DISEASE
.	123	124		|O
MRP1	126	130		|O
(	131	132		|O
multidrug	132	141		|O
resistance	142	152		|O
-	152	153		|O
associated	153	163		|O
protein	164	171		|O
1	172	173		|O
)	173	174		|O
is	175	177		|O
well	178	182		|O
known	183	188		|O
for	189	192		|O
its	193	196		|O
role	197	201		|O
in	202	204		|O
providing	205	214		|O
multidrug	215	224		|O
resistance	225	235		|O
to	236	238		|O
cancer	239	245		|O
cells	246	251		|O
.	251	252		|O
In	253	255		|O
addition	256	264		|O
,	264	265		|O
MRP1	266	270		|O
has	271	274		|O
been	275	279		|O
associated	280	290		|O
with	291	295		|O
both	296	300		|O
pro	301	304		|O
-	304	305		|O
and	306	309		|O
anti	310	314		|O
-	314	315		|O
inflammatory	315	327		|O
functions	328	337		|O
in	338	340		|O
nonmalignant	341	353		|O
cells	354	359		|O
.	359	360		|O
The	361	364		|O
pro	365	368		|O
-	368	369		|O
inflammatory	369	381		|O
function	382	390		|O
is	391	393		|O
evident	394	401		|O
from	402	406		|O
the	407	410		|O
fact	411	415		|O
that	416	420		|O
MRP1	421	425		|O
is	426	428		|O
a	429	430		|O
high	431	435		|O
affinity	436	444		|O
transporter	445	456		|O
for	457	460		|O
cysteinyl	461	470		|O
-	470	471		|O
leukotriene	471	482		|O
C4	483	485		|O
(	486	487		|O
LTC4	487	491		|O
)	491	492		|O
,	492	493		|O
a	494	495		|O
lipid	496	501		|O
mediator	502	510		|O
of	511	513		|O
inflammation	514	526	inflammation	|B-DISEASE
.	526	527		|O
It	528	530		|O
remains	531	538		|O
unexplained	539	550		|O
,	550	551		|O
however	552	559		|O
,	559	560		|O
why	561	564		|O
the	565	568		|O
absence	569	576		|O
of	577	579		|O
Mrp1	580	584		|O
leads	585	590		|O
to	591	593		|O
increased	594	603		|O
intestinal	604	614		|O
epithelial	615	625		|O
damage	626	632		|O
in	633	635		|O
mice	636	640		|O
treated	641	648		|O
with	649	653		|O
dextran	654	661		|O
-	661	662		|O
sodium	662	668		|O
sulfate	669	676		|O
,	676	677		|O
a	678	679		|O
model	680	685		|O
for	686	689		|O
inflammatory	690	702	inflammatory bowel disease	|B-DISEASE
bowel	703	708		|I-DISEASE
disease	709	716		|I-DISEASE
(	717	718		|O
IBD	718	721	IBD	|B-DISEASE
)	721	722		|O
.	722	723		|O
We	724	726		|O
found	727	732		|O
that	733	737		|O
MRP1	738	742		|O
expression	743	753		|O
is	754	756		|O
induced	757	764		|O
in	765	767		|O
the	768	771		|O
inflamed	772	780		|O
intestine	781	790		|O
of	791	793		|O
IBD	794	797	IBD	|B-DISEASE
patients	798	806		|O
,	806	807		|O
e.g.	808	812		|O
Crohn	813	818	Crohn disease	|B-DISEASE
disease	819	826		|I-DISEASE
and	827	830		|O
ulcerative	831	841	ulcerative colitis	|B-DISEASE
colitis	842	849		|I-DISEASE
.	849	850		|O
Increased	851	860		|O
MRP1	861	865		|O
expression	866	876		|O
was	877	880		|O
detected	881	889		|O
at	890	892		|O
the	893	896		|O
basolateral	897	908		|O
membrane	909	917		|O
of	918	920		|O
intestinal	921	931		|O
epithelial	932	942		|O
cells	943	948		|O
.	948	949		|O
To	950	952		|O
study	953	958		|O
a	959	960		|O
putative	961	969		|O
role	970	974		|O
for	975	978		|O
MRP1	979	983		|O
in	984	986		|O
protecting	987	997		|O
epithelial	998	1008		|O
cells	1009	1014		|O
against	1015	1022		|O
inflammatory	1023	1035		|O
cues	1036	1040		|O
,	1040	1041		|O
we	1042	1044		|O
manipulated	1045	1056		|O
MRP1	1057	1061		|O
levels	1062	1068		|O
in	1069	1071		|O
human	1072	1077		|O
epithelial	1078	1088		|O
DLD	1089	1092		|O
-	1092	1093		|O
1	1093	1094		|O
cells	1095	1100		|O
and	1101	1104		|O
exposed	1105	1112		|O
these	1113	1118		|O
cells	1119	1124		|O
to	1125	1127		|O
cytokines	1128	1137		|O
and	1138	1141		|O
anti	1142	1146		|O
-	1146	1147		|O
Fas	1147	1150		|O
.	1150	1151		|O
Inhibition	1152	1162		|O
of	1163	1165		|O
MRP1	1166	1170		|O
(	1171	1172		|O
by	1172	1174		|O
MK571	1175	1180		|O
or	1181	1183		|O
RNA	1184	1187		|O
interference	1188	1200		|O
)	1200	1201		|O
resulted	1202	1210		|O
in	1211	1213		|O
increased	1214	1223		|O
cytokine	1224	1232		|O
-	1232	1233		|O
and	1234	1237		|O
anti	1238	1242		|O
-	1242	1243		|O
Fas	1243	1246		|O
-	1246	1247		|O
induced	1247	1254		|O
apoptosis	1255	1264		|O
of	1265	1267		|O
DLD	1268	1271		|O
-	1271	1272		|O
1	1272	1273		|O
cells	1274	1279		|O
.	1279	1280		|O
Opposite	1281	1289		|O
effects	1290	1297		|O
,	1297	1298		|O
e.g.	1299	1303		|O
protection	1304	1314		|O
of	1315	1317		|O
DLD	1318	1321		|O
-	1321	1322		|O
1	1322	1323		|O
cells	1324	1329		|O
against	1330	1337		|O
cytokine	1338	1346		|O
-	1346	1347		|O
and	1348	1351		|O
anti	1352	1356		|O
-	1356	1357		|O
Fas	1357	1360		|O
-	1360	1361		|O
induced	1361	1368		|O
apoptosis	1369	1378		|O
,	1378	1379		|O
were	1380	1384		|O
observed	1385	1393		|O
after	1394	1399		|O
recombinant	1400	1411		|O
MRP1	1412	1416		|O
overexpression	1417	1431		|O
.	1431	1432		|O
Inhibition	1433	1443		|O
of	1444	1446		|O
LTC4	1447	1451		|O
synthesis	1452	1461		|O
reduced	1462	1469		|O
anti	1470	1474		|O
-	1474	1475		|O
Fas	1475	1478		|O
-	1478	1479		|O
induced	1479	1486		|O
apoptosis	1487	1496		|O
when	1497	1501		|O
MRP1	1502	1506		|O
function	1507	1515		|O
was	1516	1519		|O
blocked	1520	1527		|O
,	1527	1528		|O
suggesting	1529	1539		|O
that	1540	1544		|O
LTC4	1545	1549		|O
is	1550	1552		|O
the	1553	1556		|O
pro	1557	1560		|O
-	1560	1561		|O
apoptotic	1561	1570		|O
compound	1571	1579		|O
exported	1580	1588		|O
by	1589	1591		|O
epithelial	1592	1602		|O
MRP1	1603	1607		|O
during	1608	1614		|O
inflammation	1615	1627	inflammation	|B-DISEASE
.	1627	1628		|O
These	1629	1634		|O
data	1635	1639		|O
show	1640	1644		|O
that	1645	1649		|O
MRP1	1650	1654		|O
protects	1655	1663		|O
intestinal	1664	1674		|O
epithelial	1675	1685		|O
cells	1686	1691		|O
against	1692	1699		|O
inflammation	1700	1712		|O
-	1712	1713		|O
induced	1713	1720		|O
apoptotic	1721	1730		|O
cell	1731	1735		|O
death	1736	1741		|O
and	1742	1745		|O
provides	1746	1754		|O
a	1755	1756		|O
functional	1757	1767		|O
role	1768	1772		|O
for	1773	1776		|O
MRP1	1777	1781		|O
in	1782	1784		|O
the	1785	1788		|O
inflamed	1789	1797		|O
intestinal	1798	1808		|O
epithelium	1809	1819		|O
of	1820	1822		|O
IBD	1823	1826	IBD	|B-DISEASE
patients	1827	1835		|O
.	1835	1836		|O

### 18760140
Angiotensin	0	11		|O
inhibition	12	22		|O
in	23	25		|O
renovascular	26	38	renovascular disease	|B-DISEASE
disease	39	46		|I-DISEASE
:	46	47		|O
a	48	49		|O
population	50	60		|O
-	60	61		|O
based	61	66		|O
cohort	67	73		|O
study	74	79		|O
.	79	80		|O
BACKGROUND	82	92		|O
:	92	93		|O
Angiotensin	94	105		|O
-	105	106		|O
converting	106	116		|O
enzyme	117	123		|O
inhibitors	124	134		|O
and	135	138		|O
angiotensin	139	150		|O
receptor	151	159		|O
blockers	160	168		|O
effectively	169	180		|O
reduce	181	187		|O
blood	188	193		|O
pressure	194	202		|O
in	203	205		|O
patients	206	214		|O
with	215	219		|O
renovascular	220	232	renovascular disease	|B-DISEASE
disease	233	240		|I-DISEASE
(	241	242		|O
RVD	242	245	RVD	|B-DISEASE
)	245	246		|O
;	246	247		|O
yet	248	251		|O
,	251	252		|O
randomized	253	263		|O
cardiovascular	264	278		|O
prevention	279	289		|O
trials	290	296		|O
of	297	299		|O
these	300	305		|O
drugs	306	311		|O
typically	312	321		|O
exclude	322	329		|O
individuals	330	341		|O
with	342	346		|O
this	347	351		|O
condition	352	361		|O
.	361	362		|O
PATIENTS	363	371		|O
AND	372	375		|O
METHODS	376	383		|O
:	383	384		|O
We	385	387		|O
studied	388	395		|O
the	396	399		|O
association	400	411		|O
of	412	414		|O
renin	415	420		|O
-	420	421		|O
angiotensin	421	432		|O
system	433	439		|O
inhibition	440	450		|O
with	451	455		|O
prognosis	456	465		|O
in	466	468		|O
a	469	470		|O
population	471	481		|O
-	481	482		|O
based	482	487		|O
cohort	488	494		|O
comprising	495	505		|O
3,570	506	511		|O
patients	512	520		|O
with	521	525		|O
RVD	526	529	RVD	|B-DISEASE
in	530	532		|O
Ontario	533	540		|O
,	540	541		|O
Canada	542	548		|O
;	548	549		|O
slightly	550	558		|O
more	559	563		|O
than	564	568		|O
half	569	573		|O
(	574	575		|O
n	575	576		|O
=	577	578		|O
1,857	579	584		|O
,	584	585		|O
53%	586	589		|O
)	589	590		|O
were	591	595		|O
prescribed	596	606		|O
angiotensin	607	618		|O
inhibitors	619	629		|O
.	629	630		|O
The	631	634		|O
primary	635	642		|O
outcome	643	650		|O
was	651	654		|O
the	655	658		|O
composite	659	668		|O
of	669	671		|O
death	672	677		|O
,	677	678		|O
myocardial	679	689	myocardial infarction	|B-ADVERSE
infarction	690	700		|I-ADVERSE
,	700	701		|O
or	702	704		|O
stroke	705	711	stroke	|B-ADVERSE
.	711	712		|O
Secondary	713	722		|O
outcomes	723	731		|O
included	732	740		|O
individual	741	751		|O
cardiovascular	752	766		|O
and	767	770		|O
renal	771	776		|O
events	777	783		|O
.	783	784		|O
RESULTS	785	792		|O
:	792	793		|O
Patients	794	802		|O
receiving	803	812		|O
angiotensin	813	824		|O
inhibitors	825	835		|O
had	836	839		|O
a	840	841		|O
significantly	842	855		|O
lower	856	861		|O
risk	862	866		|O
for	867	870		|O
the	871	874		|O
primary	875	882		|O
outcome	883	890		|O
during	891	897		|O
follow	898	904		|O
-	904	905		|O
up	905	907		|O
(	908	909		|O
10.0	909	913		|O
vs	914	916		|O
13.0	917	921		|O
events	922	928		|O
per	929	932		|O
100	933	936		|O
patient	937	944		|O
-	944	945		|O
years	945	950		|O
at	951	953		|O
risk	954	958		|O
,	958	959		|O
multivariable	960	973		|O
adjusted	974	982		|O
hazard	983	989		|O
ratio	990	995		|O
[	996	997		|O
HR	997	999		|O
]	999	1000		|O
0.70	1001	1005		|O
,	1005	1006		|O
95%	1007	1010		|O
CI	1011	1013		|O
0.59-0.82	1014	1023		|O
)	1023	1024		|O
.	1024	1025		|O
In	1026	1028		|O
addition	1029	1037		|O
,	1037	1038		|O
hospitalization	1039	1054		|O
for	1055	1058		|O
congestive	1059	1069	congestive heart failure	|B-ADVERSE
heart	1070	1075		|I-ADVERSE
failure	1076	1083		|I-ADVERSE
(	1084	1085		|O
HR	1085	1087		|O
0.69	1088	1092		|O
,	1092	1093		|O
95%	1094	1097		|O
CI	1098	1100		|O
0.53-0.90	1101	1110		|O
)	1110	1111		|O
,	1111	1112		|O
chronic	1113	1120		|O
dialysis	1121	1129		|O
initiation	1130	1140		|O
(	1141	1142		|O
HR	1142	1144		|O
0.62	1145	1149		|O
,	1149	1150		|O
95%	1151	1154		|O
CI	1155	1157		|O
0.42-0.92	1158	1167		|O
)	1167	1168		|O
,	1168	1169		|O
and	1170	1173		|O
mortality	1174	1183		|O
(	1184	1185		|O
HR	1185	1187		|O
0.56	1188	1192		|O
,	1192	1193		|O
95%	1194	1197		|O
CI	1198	1200		|O
0.47-0.68	1201	1210		|O
)	1210	1211		|O
was	1212	1215		|O
lower	1216	1221		|O
in	1222	1224		|O
treated	1225	1232		|O
patients	1233	1241		|O
.	1241	1242		|O
Conversely	1243	1253		|O
,	1253	1254		|O
patients	1255	1263		|O
receiving	1264	1273		|O
angiotensin	1274	1285		|O
inhibitors	1286	1296		|O
were	1297	1301		|O
significantly	1302	1315		|O
more	1316	1320		|O
likely	1321	1327		|O
to	1328	1330		|O
be	1331	1333		|O
hospitalized	1334	1346		|O
for	1347	1350		|O
acute	1351	1356	acute renal failure	|B-ADVERSE
renal	1357	1362		|I-ADVERSE
failure	1363	1370		|I-ADVERSE
during	1371	1377		|O
follow	1378	1384		|O
-	1384	1385		|O
up	1385	1387		|O
(	1388	1389		|O
HR	1389	1391		|O
1.87	1392	1396		|O
,	1396	1397		|O
95%	1398	1401		|O
CI	1402	1404		|O
1.05-3.33	1405	1414		|O
;	1414	1415		|O
1.2	1416	1419		|O
vs	1420	1422		|O
0.6	1423	1426		|O
events	1427	1433		|O
per	1434	1437		|O
100	1438	1441		|O
patient	1442	1449		|O
-	1449	1450		|O
years	1450	1455		|O
at	1456	1458		|O
risk	1459	1463		|O
)	1463	1464		|O
.	1464	1465		|O
CONCLUSIONS	1466	1477		|O
:	1477	1478		|O
These	1479	1484		|O
data	1485	1489		|O
emphasize	1490	1499		|O
the	1500	1503		|O
high	1504	1508		|O
vascular	1509	1517		|O
risk	1518	1522		|O
of	1523	1525		|O
RVD	1526	1529	RVD	|B-ADVERSE
and	1530	1533		|O
suggest	1534	1541		|O
that	1542	1546		|O
angiotensin	1547	1558		|O
inhibitors	1559	1569		|O
may	1570	1573		|O
improve	1574	1581		|O
prognosis	1582	1591		|O
in	1592	1594		|O
this	1595	1599		|O
setting	1600	1607		|O
at	1608	1610		|O
the	1611	1614		|O
expense	1615	1622		|O
of	1623	1625		|O
acute	1626	1631	acute renal toxicity	|B-ADVERSE
renal	1632	1637		|I-ADVERSE
toxicity	1638	1646		|I-ADVERSE
.	1646	1647		|O
If	1648	1650		|O
the	1651	1654		|O
latter	1655	1661		|O
are	1662	1665		|O
selected	1666	1674		|O
in	1675	1677		|O
the	1678	1681		|O
management	1682	1692		|O
of	1693	1695		|O
RVD	1696	1699	RVD	|B-DISEASE
,	1699	1700		|O
renal	1701	1706		|O
function	1707	1715		|O
parameters	1716	1726		|O
should	1727	1733		|O
be	1734	1736		|O
assiduously	1737	1748		|O
followed	1749	1757		|O
.	1757	1758		|O

### 18721197
Inhibition	0	10		|O
of	11	13		|O
atopic	14	20	atopic dermatitis-like skin lesions	|B-DISEASE
dermatitis	21	31		|I-DISEASE
-	31	32		|I-DISEASE
like	32	36		|I-DISEASE
skin	37	41		|I-DISEASE
lesions	42	49		|I-DISEASE
by	50	52		|O
topical	53	60		|O
application	61	72		|O
of	73	75		|O
a	76	77		|O
novel	78	83		|O
ceramide	84	92		|O
derivative	93	103		|O
,	103	104		|O
K6PC	105	109		|O
-	109	110		|O
9p	110	112		|O
,	112	113		|O
in	114	116		|O
NC	117	119		|O
/	119	120		|O
Nga	120	123		|O
mice	124	128		|O
.	128	129		|O
Atopic	131	137	Atopic dermatitis	|B-DISEASE
dermatitis	138	148		|I-DISEASE
(	149	150		|O
AD	150	152	AD	|B-DISEASE
)	152	153		|O
is	154	156		|O
a	157	158		|O
chronic	159	166	chronic inflammatory skin disease	|B-DISEASE
inflammatory	167	179		|I-DISEASE
skin	180	184		|I-DISEASE
disease	185	192		|I-DISEASE
that	193	197		|O
commonly	198	206		|O
begins	207	213		|O
in	214	216		|O
childhood	217	226		|O
.	226	227		|O
K6PC	228	232		|O
-	232	233		|O
9p	233	235		|O
(	236	237		|O
N	237	238		|O
-	238	239		|O
(	239	240		|O
Ethyl	240	245		|O
dihydrogenphosphate	246	265		|O
)	265	266		|O
-	266	267		|O
2	267	268		|O
-	268	269		|O
hexyl	269	274		|O
-	274	275		|O
3	275	276		|O
-	276	277		|O
oxo	277	280		|O
-	280	281		|O
decanamide	281	291		|O
)	291	292		|O
is	293	295		|O
a	296	297		|O
synthetic	298	307		|O
ceramide	308	316		|O
derivative	317	327		|O
of	328	330		|O
PC	331	333		|O
-	333	334		|O
9S	334	336		|O
(	337	338		|O
N	338	339		|O
-	339	340		|O
Ethanol	340	347		|O
-	347	348		|O
2	348	349		|O
-	349	350		|O
mirystyl	350	358		|O
-	358	359		|O
3	359	360		|O
-	360	361		|O
oxo	361	364		|O
-	364	365		|O
staramide	365	374		|O
)	374	375		|O
,	375	376		|O
which	377	382		|O
was	383	386		|O
known	387	392		|O
to	393	395		|O
be	396	398		|O
effective	399	408		|O
in	409	411		|O
atopic	412	418		|O
patients	419	427		|O
.	427	428		|O
In	429	431		|O
this	432	436		|O
study	437	442		|O
,	442	443		|O
we	444	446		|O
examined	447	455		|O
the	456	459		|O
effect	460	466		|O
of	467	469		|O
topical	470	477		|O
application	478	489		|O
of	490	492		|O
K6PC	493	497		|O
-	497	498		|O
9p	498	500		|O
on	501	503		|O
skin	504	508	skin inflammation	|B-DISEASE
inflammation	509	521		|I-DISEASE
and	522	525		|O
AD	526	528	AD-like skin lesions	|B-DISEASE
-	528	529		|I-DISEASE
like	529	533		|I-DISEASE
skin	534	538		|I-DISEASE
lesions	539	546		|I-DISEASE
in	547	549		|O
mouse	550	555		|O
models	556	562		|O
.	562	563		|O
K6PC	564	568		|O
-	568	569		|O
9p	569	571		|O
dose	572	576		|O
-	576	577		|O
dependently	577	588		|O
inhibited	589	598		|O
phorbol	599	606		|O
ester	607	612		|O
-	612	613		|O
induced	613	620		|O
increase	621	629		|O
in	630	632		|O
ear	633	636		|O
thickness	637	646		|O
in	647	649		|O
BALB	650	654		|O
/	654	655		|O
c	655	656		|O
mice	657	661		|O
.	661	662		|O
Moreover	663	671		|O
,	671	672		|O
topical	673	680		|O
application	681	692		|O
of	693	695		|O
K6PC	696	700		|O
-	700	701		|O
9p	701	703		|O
suppressed	704	714		|O
dust	715	719		|O
mite	720	724		|O
extract	725	732		|O
-	732	733		|O
induced	733	740		|O
AD	741	743	AD-like skin lesions	|B-DISEASE
-	743	744		|I-DISEASE
like	744	748		|I-DISEASE
skin	749	753		|I-DISEASE
lesions	754	761		|I-DISEASE
in	762	764		|O
NC	765	767		|O
/	767	768		|O
Nga	768	771		|O
mice	772	776		|O
.	776	777		|O
Histopathological	778	795		|O
analysis	796	804		|O
revealed	805	813		|O
that	814	818		|O
both	819	823		|O
ear	824	827	ear swelling	|B-DISEASE
swelling	828	836		|I-DISEASE
and	837	840		|O
leucocyte	841	850		|O
infiltration	851	863		|O
were	864	868		|O
suppressed	869	879		|O
by	880	882		|O
K6PC	883	887		|O
-	887	888		|O
9p	888	890		|O
treatment	891	900		|O
.	900	901		|O
K6PC	902	906		|O
-	906	907		|O
9p	907	909		|O
also	910	914		|O
suppressed	915	925		|O
IL	926	928		|O
-	928	929		|O
4	929	930		|O
and	931	934		|O
TNF	935	938		|O
-	938	939		|O
alpha	939	944		|O
expression	945	955		|O
in	956	958		|O
the	959	962		|O
ears	963	967		|O
and	968	971		|O
mast	972	976		|O
cell	977	981		|O
infiltration	982	994		|O
into	995	999		|O
the	1000	1003		|O
ears	1004	1008		|O
in	1009	1011		|O
NC	1012	1014		|O
/	1014	1015		|O
Nga	1015	1018		|O
mice	1019	1023		|O
.	1023	1024		|O
Further	1025	1032		|O
study	1033	1038		|O
demonstrated	1039	1051		|O
that	1052	1056		|O
K6PC	1057	1061		|O
-	1061	1062		|O
9p	1062	1064		|O
inhibited	1065	1074		|O
ConA	1075	1079		|O
-	1079	1080		|O
induced	1080	1087		|O
IL	1088	1090		|O
-	1090	1091		|O
4	1091	1092		|O
secretion	1093	1102		|O
and	1103	1106		|O
LPS	1107	1110		|O
-	1110	1111		|O
induced	1111	1118		|O
macrophage	1119	1129		|O
activation	1130	1140		|O
.	1140	1141		|O
Taken	1142	1147		|O
together	1148	1156		|O
,	1156	1157		|O
our	1158	1161		|O
results	1162	1169		|O
showed	1170	1176		|O
that	1177	1181		|O
topical	1182	1189		|O
application	1190	1201		|O
of	1202	1204		|O
K6PC	1205	1209		|O
-	1209	1210		|O
9p	1210	1212		|O
exerts	1213	1219		|O
beneficial	1220	1230		|O
effects	1231	1238		|O
in	1239	1241		|O
animal	1242	1248		|O
model	1249	1254		|O
of	1255	1257		|O
skin	1258	1262	skin inflammation	|B-DISEASE
inflammation	1263	1275		|I-DISEASE
and	1276	1279		|O
AD	1280	1282	AD	|B-DISEASE
,	1282	1283		|O
suggesting	1284	1294		|O
that	1295	1299		|O
K6PC	1300	1304		|O
-	1304	1305		|O
9p	1305	1307		|O
might	1308	1313		|O
be	1314	1316		|O
a	1317	1318		|O
promising	1319	1328		|O
topical	1329	1336		|O
agent	1337	1342		|O
for	1343	1346		|O
the	1347	1350		|O
treatment	1351	1360		|O
of	1361	1363		|O
inflammatory	1364	1376	inflammatory skin diseases	|B-DISEASE
skin	1377	1381		|I-DISEASE
diseases	1382	1390		|I-DISEASE
.	1390	1391		|O

### 18937544
Distinct	0	8		|O
regulatory	9	19		|O
profiles	20	28		|O
of	29	31		|O
interleukins	32	44		|O
and	45	48		|O
chemokines	49	59		|O
in	60	62		|O
response	63	71		|O
to	72	74		|O
cigarette	75	84		|O
smoke	85	90		|O
condensate	91	101		|O
in	102	104		|O
normal	105	111		|O
human	112	117		|O
bronchial	118	127		|O
epithelial	128	138		|O
(	139	140		|O
NHBE	140	144		|O
)	144	145		|O
cells	146	151		|O
.	151	152		|O
Bronchial	154	163		|O
epithelium	164	174		|O
is	175	177		|O
frequently	178	188		|O
exposed	189	196		|O
to	197	199		|O
air	200	203		|O
pollutants	204	214		|O
,	214	215		|O
and	216	219		|O
it	220	222		|O
is	223	225		|O
hypothesized	226	238		|O
that	239	243		|O
these	244	249		|O
cells	250	255		|O
elicit	256	262		|O
inflammatory	263	275		|O
responses	276	285		|O
as	286	288		|O
early	289	294		|O
elements	295	303		|O
in	304	306		|O
pulmonary	307	316		|O
defense	317	324		|O
.	324	325		|O
Our	326	329		|O
purpose	330	337		|O
was	338	341		|O
to	342	344		|O
evaluate	345	353		|O
changes	354	361		|O
in	362	364		|O
messenger	365	374		|O
RNA	375	378		|O
levels	379	385		|O
of	386	388		|O
84	389	391		|O
genes	392	397		|O
representing	398	410		|O
cytokines	411	420		|O
and	421	424		|O
receptors	425	434		|O
over	435	439		|O
a	440	441		|O
repetitive	442	452		|O
-	452	453		|O
exposure	453	461		|O
time	462	466		|O
course	467	473		|O
to	474	476		|O
further	477	484		|O
define	485	491		|O
the	492	495		|O
inflammatory	496	508		|O
responses	509	518		|O
associated	519	529		|O
with	530	534		|O
mainstream	535	545		|O
cigarette	546	555		|O
smoke	556	561		|O
(	562	563		|O
MSS	563	566		|O
)	566	567		|O
exposure	568	576		|O
in	577	579		|O
an	580	582		|O
in	583	585		|O
vitro	586	591		|O
lung	592	596		|O
model	597	602		|O
.	602	603		|O
Normal	604	610		|O
human	611	616		|O
bronchial	617	626		|O
epithelial	627	637		|O
cells	638	643		|O
were	644	648		|O
treated	649	656		|O
with	657	661		|O
mainstream	662	672		|O
cigarette	673	682		|O
smoke	683	688		|O
condensate	689	699		|O
(	700	701		|O
CSC	701	704		|O
)	704	705		|O
prepared	706	714		|O
from	715	719		|O
Kentucky	720	728		|O
2R4F	729	733		|O
cigarettes	734	744		|O
(	745	746		|O
60	746	748		|O
microg	749	755		|O
total	756	761		|O
particulate	762	773		|O
matter	774	780		|O
/	780	781		|O
mL	781	783		|O
media	784	789		|O
,	789	790		|O
0.2%	791	795		|O
dimethylsulfoxide	796	813		|O
)	813	814		|O
,	814	815		|O
and	816	819		|O
examined	820	828		|O
by	829	831		|O
quantitative	832	844		|O
real	845	849		|O
-	849	850		|O
time	850	854		|O
polymerase	855	865		|O
chain	866	871		|O
reaction	872	880		|O
.	880	881		|O
Applications	882	894		|O
of	895	897		|O
CSC	898	901		|O
were	902	906		|O
designed	907	915		|O
in	916	918		|O
seven	919	924		|O
groups	925	931		|O
to	932	934		|O
test	935	939		|O
immediate	940	949		|O
,	949	950		|O
early	951	956		|O
,	956	957		|O
intermediate	958	970		|O
,	970	971		|O
and	972	975		|O
late	976	980		|O
responses	981	990		|O
evaluated	991	1000		|O
at	1001	1003		|O
the	1004	1007		|O
end	1008	1011		|O
of	1012	1014		|O
alternating	1015	1026		|O
exposure	1027	1035		|O
/	1035	1036		|O
recovery	1036	1044		|O
periods	1045	1052		|O
.	1052	1053		|O
Three	1054	1059		|O
predominant	1060	1071		|O
gene	1072	1076		|O
expression	1077	1087		|O
responses	1088	1097		|O
were	1098	1102		|O
observed	1103	1111		|O
:	1111	1112		|O
adaptive	1113	1121		|O
(	1122	1123		|O
return	1123	1129		|O
to	1130	1132		|O
baseline	1133	1141		|O
)	1141	1142		|O
,	1142	1143		|O
sustained	1144	1153		|O
(	1154	1155		|O
maintained	1155	1165		|O
expression	1166	1176		|O
during	1177	1183		|O
treatment	1184	1193		|O
)	1193	1194		|O
,	1194	1195		|O
and	1196	1199		|O
chronic	1200	1207		|O
(	1208	1209		|O
maintained	1209	1219		|O
expression	1220	1230		|O
posttreatment	1231	1244		|O
)	1244	1245		|O
.	1245	1246		|O
Overall	1247	1254		|O
,	1254	1255		|O
25	1256	1258		|O
genes	1259	1264		|O
exhibited	1265	1274		|O
statistically	1275	1288		|O
significant	1289	1300		|O
changes	1301	1308		|O
:	1308	1309		|O
14	1310	1312		|O
genes	1313	1318		|O
exclusively	1319	1330		|O
elevated	1331	1339		|O
,	1339	1340		|O
10	1341	1343		|O
genes	1344	1349		|O
exclusively	1350	1361		|O
depressed	1362	1371		|O
,	1371	1372		|O
and	1373	1376		|O
1	1377	1378		|O
,	1378	1379		|O
interleukin	1380	1391		|O
-	1391	1392		|O
8	1392	1393		|O
(	1394	1395		|O
IL8	1395	1398		|O
)	1398	1399		|O
,	1399	1400		|O
exhibiting	1401	1411		|O
both	1412	1416		|O
up	1417	1419		|O
-	1419	1420		|O
and	1421	1424		|O
downregulation	1425	1439		|O
in	1440	1442		|O
the	1443	1446		|O
seven	1447	1452		|O
groups	1453	1459		|O
.	1459	1460		|O
The	1461	1464		|O
most	1465	1469		|O
responsive	1470	1480		|O
genes	1481	1486		|O
were	1487	1491		|O
osteopontin	1492	1503		|O
(	1504	1505		|O
34	1505	1507		|O
-	1507	1508		|O
fold	1508	1512		|O
upregulation	1513	1525		|O
)	1525	1526		|O
and	1527	1530		|O
CXCL14	1531	1537		|O
(	1538	1539		|O
23	1539	1541		|O
-	1541	1542		|O
fold	1542	1546		|O
downregulation	1547	1561		|O
)	1561	1562		|O
.	1562	1563		|O
Our	1564	1567		|O
observations	1568	1580		|O
suggest	1581	1588		|O
that	1589	1593		|O
specific	1594	1602		|O
genes	1603	1608		|O
involved	1609	1617		|O
in	1618	1620		|O
inflammatory	1621	1633		|O
pathways	1634	1642		|O
respond	1643	1650		|O
to	1651	1653		|O
CSC	1654	1657		|O
in	1658	1660		|O
chronic	1661	1668		|O
,	1668	1669		|O
sustained	1670	1679		|O
,	1679	1680		|O
or	1681	1683		|O
adaptive	1684	1692		|O
patterns	1693	1701		|O
with	1702	1706		|O
the	1707	1710		|O
chronic	1711	1718		|O
pattern	1719	1726		|O
as	1727	1729		|O
the	1730	1733		|O
predominant	1734	1745		|O
behavior	1746	1754		|O
.	1754	1755		|O

### 18666379
Tirapazamine	0	12		|O
:	12	13		|O
from	14	18		|O
bench	19	24		|O
to	25	27		|O
clinical	28	36		|O
trials	37	43		|O
.	43	44		|O
Tumour	46	52	Tumour hypoxia	|B-DISEASE
hypoxia	53	60		|I-DISEASE
continues	61	70		|O
to	71	73		|O
remain	74	80		|O
one	81	84		|O
of	85	87		|O
the	88	91		|O
greatest	92	100		|O
challenges	101	111		|O
in	112	114		|O
the	115	118		|O
treatment	119	128		|O
of	129	131		|O
solid	132	137	solid tumours	|B-DISEASE
tumours	138	145		|I-DISEASE
.	145	146		|O
An	147	149		|O
important	150	159		|O
avenue	160	166		|O
to	167	169		|O
follow	170	176		|O
with	177	181		|O
both	182	186		|O
radiotherapy	187	199		|O
and	200	203		|O
chemotherapy	204	216		|O
is	217	219		|O
the	220	223		|O
development	224	235		|O
of	236	238		|O
hypoxic	239	246		|O
cytotoxins	247	257		|O
such	258	262		|O
as	263	265		|O
tirapazamine	266	278		|O
.	278	279		|O
The	280	283		|O
present	284	291		|O
review	292	298		|O
covers	299	305		|O
the	306	309		|O
history	310	317		|O
of	318	320		|O
tirapazamine	321	333		|O
from	334	338		|O
preclinical	339	350		|O
models	351	357		|O
to	358	360		|O
clinical	361	369		|O
trials	370	376		|O
.	376	377		|O
The	378	381		|O
biochemistry	382	394		|O
as	395	397		|O
well	398	402		|O
as	403	405		|O
the	406	409		|O
pharmacokinetics	410	426		|O
of	427	429		|O
this	430	434		|O
bioreductive	435	447		|O
agent	448	453		|O
are	454	457		|O
presented	458	467		|O
.	467	468		|O
Laboratory	469	479		|O
data	480	484		|O
demonstrating	485	498		|O
the	499	502		|O
enhanced	503	511		|O
effect	512	518		|O
of	519	521		|O
radiation	522	531		|O
and	532	535		|O
cisplatin	536	545		|O
when	546	550		|O
combined	551	559		|O
with	560	564		|O
tirapazamine	565	577		|O
are	578	581		|O
also	582	586		|O
discussed	587	596		|O
.	596	597		|O
There	598	603		|O
is	604	606		|O
considerable	607	619		|O
evidence	620	628		|O
supporting	629	639		|O
the	640	643		|O
potentiation	644	656		|O
of	657	659		|O
anti	660	664		|O
-	664	665		|O
tumour	665	671		|O
effect	672	678		|O
of	679	681		|O
cisplatin	682	691		|O
by	692	694		|O
tirapazamine	695	707		|O
.	707	708		|O
Several	709	716		|O
clinical	717	725		|O
trials	726	732		|O
for	733	736		|O
various	737	744		|O
tumour	745	751	tumour	|B-DISEASE
sites	752	757		|O
have	758	762		|O
been	763	767		|O
testing	768	775		|O
the	776	779		|O
synergistic	780	791		|O
effect	792	798		|O
of	799	801		|O
cisplatin	802	811		|O
-	811	812		|O
tirapazamine	812	824		|O
with	825	829		|O
and	830	833		|O
without	834	841		|O
radiotherapy	842	854		|O
.	854	855		|O
These	856	861		|O
are	862	865		|O
also	866	870		|O
reviewed	871	879		|O
in	880	882		|O
the	883	886		|O
present	887	894		|O
paper	895	900		|O
.	900	901		|O
The	902	905		|O
current	906	913		|O
literature	914	924		|O
data	925	929		|O
on	930	932		|O
tirapazamine	933	945		|O
leaves	946	952		|O
unanswered	953	963		|O
questions	964	973		|O
about	974	979		|O
its	980	983		|O
action	984	990		|O
and	991	994		|O
toxicity	995	1003		|O
.	1003	1004		|O
While	1005	1010		|O
the	1011	1014		|O
current	1015	1022		|O
number	1023	1029		|O
of	1030	1032		|O
phase	1033	1038		|O
III	1039	1042		|O
trials	1043	1049		|O
limits	1050	1056		|O
comprehensive	1057	1070		|O
conclusions	1071	1082		|O
about	1083	1088		|O
the	1089	1092		|O
administration	1093	1107		|O
of	1108	1110		|O
this	1111	1115		|O
drug	1116	1120		|O
,	1120	1121		|O
there	1122	1127		|O
is	1128	1130		|O
a	1131	1132		|O
unanimous	1133	1142		|O
indication	1143	1153		|O
that	1154	1158		|O
further	1159	1166		|O
clinical	1167	1175		|O
studies	1176	1183		|O
are	1184	1187		|O
warranted	1188	1197		|O
.	1197	1198		|O

### 18662739
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
myrtenol	29	37		|O
.	37	38		|O
A	40	41		|O
toxicologic	42	53		|O
and	54	57		|O
dermatologic	58	70		|O
review	71	77		|O
of	78	80		|O
myrtenol	81	89		|O
when	90	94		|O
used	95	99		|O
as	100	102		|O
a	103	104		|O
fragrance	105	114		|O
ingredient	115	125		|O
is	126	128		|O
presented	129	138		|O
.	138	139		|O

### 18930840
Medaka	0	6		|O
(	7	8		|O
Oryzias	8	15		|O
latipes	16	23		|O
)	23	24		|O
as	25	27		|O
a	28	29		|O
sentinel	30	38		|O
species	39	46		|O
for	47	50		|O
aquatic	51	58		|O
animals	59	66		|O
:	66	67		|O
Medaka	68	74		|O
cells	75	80		|O
exhibit	81	88		|O
a	89	90		|O
similar	91	98		|O
genotoxic	99	108		|O
response	109	117		|O
as	118	120		|O
North	121	126		|O
Atlantic	127	135		|O
right	136	141		|O
whale	142	147		|O
cells	148	153		|O
.	153	154		|O
Hexavalent	156	166		|O
chromium	167	175		|O
(	176	177		|O
Cr	177	179		|O
(	179	180		|O
VI	180	182		|O
)	182	183		|O
)	183	184		|O
is	185	187		|O
emerging	188	196		|O
as	197	199		|O
a	200	201		|O
major	202	207		|O
concern	208	215		|O
for	216	219		|O
aquatic	220	227		|O
environments	228	240		|O
,	240	241		|O
particularly	242	254		|O
marine	255	261		|O
environments	262	274		|O
.	274	275		|O
Medaka	276	282		|O
(	283	284		|O
Oryzias	284	291		|O
latipes	292	299		|O
)	299	300		|O
has	301	304		|O
been	305	309		|O
used	310	314		|O
as	315	317		|O
a	318	319		|O
model	320	325		|O
species	326	333		|O
for	334	337		|O
human	338	343		|O
and	344	347		|O
aquatic	348	355		|O
health	356	362		|O
,	362	363		|O
including	364	373		|O
the	374	377		|O
marine	378	384		|O
environment	385	396		|O
,	396	397		|O
though	398	404		|O
few	405	408		|O
studies	409	416		|O
have	417	421		|O
directly	422	430		|O
compared	431	439		|O
toxicological	440	453		|O
responses	454	463		|O
in	464	466		|O
medaka	467	473		|O
to	474	476		|O
humans	477	483		|O
or	484	486		|O
other	487	492		|O
aquatic	493	500		|O
species	501	508		|O
.	508	509		|O
We	510	512		|O
used	513	517		|O
a	518	519		|O
medaka	520	526		|O
fin	527	530		|O
cell	531	535		|O
line	536	540		|O
to	541	543		|O
compare	544	551		|O
the	552	555		|O
genotoxic	556	565		|O
response	566	574		|O
of	575	577		|O
medaka	578	584		|O
to	585	587		|O
Cr	588	590		|O
(	590	591		|O
VI	591	593		|O
)	593	594		|O
to	595	597		|O
the	598	601		|O
response	602	610		|O
observed	611	619		|O
in	620	622		|O
North	623	628		|O
Atlantic	629	637		|O
right	638	643		|O
whale	644	649		|O
cells	650	655		|O
to	656	658		|O
see	659	662		|O
if	663	665		|O
responses	666	675		|O
in	676	678		|O
medaka	679	685		|O
were	686	690		|O
similar	691	698		|O
to	699	701		|O
those	702	707		|O
of	708	710		|O
other	711	716		|O
aquatic	717	724		|O
species	725	732		|O
,	732	733		|O
particularly	734	746		|O
aquatic	747	754		|O
mammals	755	762		|O
.	762	763		|O
We	764	766		|O
used	767	771		|O
the	772	775		|O
production	776	786		|O
of	787	789		|O
chromosomal	790	801		|O
aberrations	802	813		|O
as	814	816		|O
a	817	818		|O
measure	819	826		|O
of	827	829		|O
genotoxicity	830	842	genotoxicity	|B-ADVERSE
.	842	843		|O
We	844	846		|O
found	847	852		|O
that	853	857		|O
in	858	860		|O
medaka	861	867		|O
cells	868	873		|O
,	873	874		|O
concentrations	875	889		|O
of	890	892		|O
1	893	894		|O
,	894	895		|O
5	896	897		|O
and	898	901		|O
10	902	904		|O
microM	905	911		|O
sodium	912	918		|O
chromate	919	927		|O
damaged	928	935		|O
17	936	938		|O
,	938	939		|O
32	940	942		|O
and	943	946		|O
43%	947	950		|O
of	951	953		|O
metaphases	954	964		|O
,	964	965		|O
respectively	966	978		|O
and	979	982		|O
these	983	988		|O
same	989	993		|O
concentrations	994	1008		|O
1	1009	1010		|O
,	1010	1011		|O
2.5	1012	1015		|O
,	1015	1016		|O
5	1017	1018		|O
and	1019	1022		|O
10	1023	1025		|O
microM	1026	1032		|O
sodium	1033	1039		|O
chromate	1040	1048		|O
damaged	1049	1056		|O
14	1057	1059		|O
,	1059	1060		|O
24	1061	1063		|O
and	1064	1067		|O
49%	1068	1071		|O
of	1072	1074		|O
metaphases	1075	1085		|O
,	1085	1086		|O
respectively	1087	1099		|O
,	1099	1100		|O
in	1101	1103		|O
North	1104	1109		|O
Atlantic	1110	1118		|O
right	1119	1124		|O
whale	1125	1130		|O
lung	1131	1135		|O
cells	1136	1141		|O
and	1142	1145		|O
11	1146	1148		|O
,	1148	1149		|O
32	1150	1152		|O
and	1153	1156		|O
41%	1157	1160		|O
of	1161	1163		|O
metaphases	1164	1174		|O
,	1174	1175		|O
respectively	1176	1188		|O
,	1188	1189		|O
in	1190	1192		|O
North	1193	1198		|O
Atlantic	1199	1207		|O
right	1208	1213		|O
whale	1214	1219		|O
testes	1220	1226		|O
cells	1227	1232		|O
.	1232	1233		|O
These	1234	1239		|O
data	1240	1244		|O
show	1245	1249		|O
that	1250	1254		|O
genotoxic	1255	1264		|O
responses	1265	1274		|O
in	1275	1277		|O
medaka	1278	1284		|O
are	1285	1288		|O
comparable	1289	1299		|O
to	1300	1302		|O
those	1303	1308		|O
seen	1309	1313		|O
in	1314	1316		|O
North	1317	1322		|O
Atlantic	1323	1331		|O
right	1332	1337		|O
whale	1338	1343		|O
cells	1344	1349		|O
,	1349	1350		|O
consistent	1351	1361		|O
with	1362	1366		|O
the	1367	1370		|O
hypothesis	1371	1381		|O
that	1382	1386		|O
medaka	1387	1393		|O
are	1394	1397		|O
a	1398	1399		|O
useful	1400	1406		|O
model	1407	1412		|O
for	1413	1416		|O
other	1417	1422		|O
aquatic	1423	1430		|O
species	1431	1438		|O
.	1438	1439		|O

### 18564982
No	0	2		|O
occurrence	3	13		|O
of	14	16		|O
Pneumocystis	17	29	Pneumocystis jiroveci (carinii) pneumonia	|B-DISEASE
jiroveci	30	38		|I-DISEASE
(	39	40		|I-DISEASE
carinii	40	47		|I-DISEASE
)	47	48		|I-DISEASE
pneumonia	49	58		|I-DISEASE
in	59	61		|O
120	62	65		|O
adults	66	72		|O
undergoing	73	83		|O
myeloablative	84	97		|O
unrelated	98	107		|O
cord	108	112		|O
blood	113	118		|O
transplantation	119	134		|O
.	134	135		|O
The	137	140		|O
incidence	141	150		|O
of	151	153		|O
pneumonia	154	163	pneumonia	|B-DISEASE
caused	164	170		|O
by	171	173		|O
Pneumocystis	174	186		|O
carinii	187	194		|O
(	195	196		|O
PCP	196	199	PCP	|B-DISEASE
)	199	200		|O
(	201	202		|O
organism	202	210		|O
now	211	214		|O
renamed	215	222		|O
Pneumocystis	223	235		|O
jiroveci	236	244		|O
)	244	245		|O
during	246	252		|O
the	253	256		|O
early	257	262		|O
period	263	269		|O
after	270	275		|O
cord	276	280		|O
blood	281	286		|O
transplantation	287	302		|O
(	303	304		|O
CBT	304	307		|O
)	307	308		|O
was	309	312		|O
studied	313	320		|O
in	321	323		|O
120	324	327		|O
adults	328	334		|O
.	334	335		|O
Initially	336	345		|O
89	346	348		|O
patients	349	357		|O
(	358	359		|O
74%	359	362		|O
)	362	363		|O
received	364	372		|O
oral	373	377		|O
administration	378	392		|O
of	393	395		|O
2	396	397		|O
single	398	404		|O
-	404	405		|O
strength	405	413		|O
trimethoprim	414	426		|O
-	426	427		|O
sulfamethoxazole	427	443		|O
(	444	445		|O
TMP	445	448		|O
-	448	449		|O
SMZ	449	452		|O
)	452	453		|O
tablets	454	461		|O
twice	462	467		|O
daily	468	473		|O
from	474	478		|O
day	479	482		|O
-	483	484		|O
21	484	486		|O
.	486	487		|O
In	488	490		|O
45	491	493		|O
of	494	496		|O
89	497	499		|O
patients	500	508		|O
(	509	510		|O
51%	510	513		|O
)	513	514		|O
,	514	515		|O
TMP	516	519		|O
-	519	520		|O
SMZ	520	523		|O
administration	524	538		|O
for	539	542		|O
a	543	544		|O
scheduled	545	554		|O
duration	555	563		|O
was	564	567		|O
completed	568	577		|O
.	577	578		|O
In	579	581		|O
the	582	585		|O
remaining	586	595		|O
44	596	598		|O
patients	599	607		|O
(	608	609		|O
49%	609	612		|O
)	612	613		|O
,	613	614		|O
however	615	622		|O
,	622	623		|O
TMP	624	627		|O
-	627	628		|O
SMZ	628	631		|O
administration	632	646		|O
was	647	650		|O
discontinued	651	663		|O
prior	664	669		|O
to	670	672		|O
day	673	676		|O
-	677	678		|O
3	678	679		|O
because	680	687		|O
of	688	690		|O
toxicity	691	699		|O
.	699	700		|O
Among	701	706		|O
these	707	712		|O
patients	713	721		|O
,	721	722		|O
42	723	725		|O
subsequently	726	738		|O
received	739	747		|O
aerosolized	748	759		|O
pentamidine	760	771		|O
(	772	773		|O
AP	773	775		|O
)	775	776		|O
on	777	779		|O
a	780	781		|O
median	782	788		|O
of	789	791		|O
day	792	795		|O
-	796	797		|O
13	797	799		|O
(	800	801		|O
range	801	806		|O
,	806	807		|O
-	808	809		|O
20	809	811		|O
to	812	814		|O
-	815	816		|O
6	816	817		|O
)	817	818		|O
.	818	819		|O
Thirty	820	826		|O
-	826	827		|O
one	827	830		|O
patients	831	839		|O
(	840	841		|O
26%	841	844		|O
)	844	845		|O
received	846	854		|O
AP	855	857		|O
without	858	865		|O
TMP	866	869		|O
-	869	870		|O
SMZ	870	873		|O
administration	874	888		|O
on	889	891		|O
a	892	893		|O
median	894	900		|O
of	901	903		|O
day	904	907		|O
-	908	909		|O
14	909	911		|O
(	912	913		|O
range	913	918		|O
,	918	919		|O
-	920	921		|O
21	921	923		|O
to	924	926		|O
-	927	928		|O
9	928	929		|O
)	929	930		|O
.	930	931		|O
None	932	936		|O
of	937	939		|O
the	940	943		|O
120	944	947		|O
patients	948	956		|O
were	957	961		|O
diagnosed	962	971		|O
with	972	976		|O
PCP	977	980	PCP	|B-DISEASE
within	981	987		|O
100	988	991		|O
days	992	996		|O
or	997	999		|O
2	1000	1001		|O
years	1002	1007		|O
after	1008	1013		|O
CBT	1014	1017		|O
;	1017	1018		|O
however	1019	1026		|O
,	1026	1027		|O
one	1028	1031		|O
patient	1032	1039		|O
who	1040	1043		|O
received	1044	1052		|O
AP	1053	1055		|O
before	1056	1062		|O
CBT	1063	1066		|O
but	1067	1070		|O
no	1071	1073		|O
prophylaxis	1074	1085		|O
after	1086	1091		|O
CBT	1092	1095		|O
developed	1096	1105		|O
cerebral	1106	1114	cerebral toxoplasmosis	|B-ADVERSE
toxoplasmosis	1115	1128		|I-ADVERSE
on	1129	1131		|O
day	1132	1135		|O
+	1136	1137		|O
91	1137	1139		|O
.	1139	1140		|O
Pre	1141	1144		|O
-	1144	1145		|O
transplant	1145	1155		|O
prophylaxis	1156	1167		|O
against	1168	1175		|O
PCP	1176	1179	PCP	|B-DISEASE
did	1180	1183		|O
not	1184	1187		|O
significantly	1188	1201		|O
affect	1202	1208		|O
transplantation	1209	1224		|O
-	1224	1225		|O
related	1225	1232		|O
mortality	1233	1242		|O
or	1243	1245		|O
disease	1246	1253		|O
-	1253	1254		|O
free	1254	1258		|O
survival	1259	1267		|O
at	1268	1270		|O
2	1271	1272		|O
years	1273	1278		|O
after	1279	1284		|O
CBT	1285	1288		|O
.	1288	1289		|O
The	1290	1293		|O
results	1294	1301		|O
suggest	1302	1309		|O
that	1310	1314		|O
PCP	1315	1318	PCP	|B-DISEASE
during	1319	1325		|O
the	1326	1329		|O
early	1330	1335		|O
period	1336	1342		|O
after	1343	1348		|O
CBT	1349	1352		|O
can	1353	1356		|O
be	1357	1359		|O
effectively	1360	1371		|O
prevented	1372	1381		|O
by	1382	1384		|O
any	1385	1388		|O
pre	1389	1392		|O
-	1392	1393		|O
transplant	1393	1403		|O
prophylactic	1404	1416		|O
method	1417	1423		|O
.	1423	1424		|O

### 18937598
Individualized	0	14		|O
medicine	15	23		|O
for	24	27		|O
renal	28	33	renal cell carcinoma	|B-DISEASE
cell	34	38		|I-DISEASE
carcinoma	39	48		|I-DISEASE
:	48	49		|O
establishment	50	63		|O
of	64	66		|O
primary	67	74		|O
cell	75	79		|O
line	80	84		|O
culture	85	92		|O
from	93	97		|O
surgical	98	106		|O
specimens	107	116		|O
.	116	117		|O
BACKGROUND	119	129		|O
:	129	130		|O
The	131	134		|O
lack	135	139		|O
of	140	142		|O
effective	143	152		|O
"	153	154		|O
in	154	156		|O
vivo	157	161		|O
"	161	162		|O
and	163	166		|O
"	167	168		|O
in	168	170		|O
vitro	171	176		|O
"	176	177		|O
models	178	184		|O
to	185	187		|O
predict	188	195		|O
success	196	203		|O
of	204	206		|O
pharmacological	207	222		|O
therapy	223	230		|O
for	231	234		|O
patients	235	243		|O
with	244	248		|O
renal	249	254	renal cell carcinoma	|B-DISEASE
cell	255	259		|I-DISEASE
carcinoma	260	269		|I-DISEASE
,	269	270		|O
as	271	273		|O
well	274	278		|O
as	279	281		|O
,	281	282		|O
the	283	286		|O
variety	287	294		|O
of	295	297		|O
cancer	298	304		|O
cell	305	309		|O
types	310	315		|O
demands	316	323		|O
the	324	327		|O
development	328	339		|O
of	340	342		|O
better	343	349		|O
experimental	350	362		|O
models	363	369		|O
to	370	372		|O
understand	373	383		|O
the	384	387		|O
pathophysiology	388	403		|O
of	404	406		|O
the	407	410		|O
disease	411	418		|O
and	419	422		|O
evaluate	423	431		|O
drug	432	436		|O
sensitivity	437	448		|O
in	449	451		|O
vitro	452	457		|O
.	457	458		|O
PURPOSE	459	466		|O
:	466	467		|O
To	468	470		|O
develop	471	478		|O
primary	479	486		|O
renal	487	492		|O
cancer	493	499		|O
cell	500	504		|O
culture	505	512		|O
irrespective	513	525		|O
of	526	528		|O
tumor	529	534	tumor	|B-DISEASE
grade	535	540		|O
and	541	544		|O
tumor	545	550	tumor	|B-DISEASE
type	551	555		|O
,	555	556		|O
harvested	557	566		|O
from	567	571		|O
the	572	575		|O
patient	576	583		|O
's	583	585		|O
pathological	586	598		|O
specimen	599	607		|O
immediately	608	619		|O
after	620	625		|O
the	626	629		|O
laparoscopic	630	642		|O
radical	643	650		|O
nephrectomy	651	662		|O
to	663	665		|O
study	666	671		|O
potential	672	681		|O
"	682	683		|O
in	683	685		|O
vivo	686	690		|O
"	690	691		|O
pharmacological	692	707		|O
sensitivity	708	719		|O
.	719	720		|O
MATERIALS	721	730		|O
AND	731	734		|O
METHODS	735	742		|O
:	742	743		|O
A	744	745		|O
total	746	751		|O
of	752	754		|O
24	755	757		|O
patients	758	766		|O
(	767	768		|O
17	768	770		|O
males	771	776		|O
and	777	780		|O
7	781	782		|O
females	783	790		|O
)	790	791		|O
.	791	792		|O
Mean	793	797		|O
age	798	801		|O
of	802	804		|O
63.1	805	809		|O
+	809	810		|O
/	810	811		|O
-	811	812		|O
3.1	812	815		|O
y	816	817		|O
.	817	818		|O
o	818	819		|O
.	819	820		|O
The	821	824		|O
mean	825	829		|O
size	830	834		|O
of	835	837		|O
the	838	841		|O
renal	842	847		|O
masses	848	854		|O
was	855	858		|O
7.56	859	863		|O
+	863	864		|O
/	864	865		|O
-	865	866		|O
3.1	866	869		|O
cm	870	872		|O
.	872	873		|O
Normal	874	880		|O
and	881	884		|O
pathological	885	897		|O
renal	898	903		|O
tissue	904	910		|O
was	911	914		|O
collected	915	924		|O
immediately	925	936		|O
after	937	942		|O
the	943	946		|O
specimen	947	955		|O
was	956	959		|O
extracted	960	969		|O
and	970	973		|O
submitted	974	983		|O
to	984	986		|O
enzymatic	987	996		|O
digestion	997	1006		|O
for	1007	1010		|O
16-24	1011	1016		|O
hours	1017	1022		|O
.	1022	1023		|O
Clear	1024	1029		|O
cell	1030	1034		|O
carcinoma	1035	1044		|O
cells	1045	1050		|O
were	1051	1055		|O
selected	1056	1064		|O
through	1065	1072		|O
multiple	1073	1081		|O
passages	1082	1090		|O
in	1091	1093		|O
DMEM	1094	1098		|O
medium	1099	1105		|O
supplemented	1106	1118		|O
with	1119	1123		|O
glucose	1124	1131		|O
and	1132	1135		|O
antibiotics	1136	1147		|O
.	1147	1148		|O
RESULTS	1149	1156		|O
:	1156	1157		|O
Establishment	1158	1171		|O
of	1172	1174		|O
cell	1175	1179		|O
line	1180	1184		|O
culture	1185	1192		|O
from	1193	1197		|O
all	1198	1201		|O
the	1202	1205		|O
patients	1206	1214		|O
'	1214	1215		|O
specimens	1216	1225		|O
irrespective	1226	1238		|O
of	1239	1241		|O
tumor	1242	1247	tumor	|B-DISEASE
grade	1248	1253		|O
and	1254	1257		|O
tumor	1258	1263	tumor	|B-DISEASE
type	1264	1268		|O
was	1269	1272		|O
achieved	1273	1281		|O
successfully	1282	1294		|O
.	1294	1295		|O
In	1296	1298		|O
addition	1299	1307		|O
to	1308	1310		|O
the	1311	1314		|O
tumor	1315	1320		|O
cell	1321	1325		|O
line	1326	1330		|O
culture	1331	1338		|O
,	1338	1339		|O
normal	1340	1346		|O
parenchyma	1347	1357		|O
tissue	1358	1364		|O
yielded	1365	1372		|O
primary	1373	1380		|O
cell	1381	1385		|O
lines	1386	1391		|O
to	1392	1394		|O
allow	1395	1400		|O
testing	1401	1408		|O
the	1409	1412		|O
response	1413	1421		|O
of	1422	1424		|O
tumor	1425	1430	tumor	|B-DISEASE
types	1431	1436		|O
to	1437	1439		|O
various	1440	1447		|O
pharmacological	1448	1463		|O
therapeutic	1464	1475		|O
agents	1476	1482		|O
and	1483	1486		|O
toxicity	1487	1495		|O
of	1496	1498		|O
such	1499	1503		|O
treatments	1504	1514		|O
to	1515	1517		|O
healthy	1518	1525		|O
tissue	1526	1532		|O
.	1532	1533		|O
From	1534	1538		|O
the	1539	1542		|O
initial	1543	1550		|O
collection	1551	1561		|O
of	1562	1564		|O
the	1565	1568		|O
specimens	1569	1578		|O
obtained	1579	1587		|O
after	1588	1593		|O
the	1594	1597		|O
removal	1598	1605		|O
of	1606	1608		|O
the	1609	1612		|O
kidney	1613	1619		|O
to	1620	1622		|O
the	1623	1626		|O
development	1627	1638		|O
of	1639	1641		|O
cell	1642	1646		|O
lines	1647	1652		|O
took	1653	1657		|O
occurred	1658	1666		|O
in	1667	1669		|O
average	1670	1677		|O
32	1678	1680		|O
+	1680	1681		|O
6	1681	1682		|O
hrs	1683	1686		|O
.	1686	1687		|O
The	1688	1691		|O
cells	1692	1697		|O
in	1698	1700		|O
culture	1701	1708		|O
showed	1709	1715		|O
characteristics	1716	1731		|O
of	1732	1734		|O
epithelial	1735	1745		|O
cells	1746	1751		|O
;	1751	1752		|O
like	1753	1757		|O
expression	1758	1768		|O
on	1769	1771		|O
cytokeratin	1772	1783		|O
and	1784	1787		|O
were	1788	1792		|O
maintained	1793	1803		|O
in	1804	1806		|O
culture	1807	1814		|O
for	1815	1818		|O
more	1819	1823		|O
than	1824	1828		|O
20	1829	1831		|O
passages	1832	1840		|O
.	1840	1841		|O
CONCLUSION	1842	1852		|O
:	1852	1853		|O
The	1854	1857		|O
development	1858	1869		|O
of	1870	1872		|O
renal	1873	1878		|O
cancer	1879	1885		|O
cell	1886	1890		|O
cultures	1891	1899		|O
in	1900	1902		|O
vitro	1903	1908		|O
is	1909	1911		|O
labor	1912	1917		|O
intense	1918	1925		|O
but	1926	1929		|O
may	1930	1933		|O
yield	1934	1939		|O
a	1940	1941		|O
more	1942	1946		|O
realistic	1947	1956		|O
model	1957	1962		|O
to	1963	1965		|O
tailor	1966	1972		|O
pharmacological	1973	1988		|O
therapies	1989	1998		|O
and	1999	2002		|O
predict	2003	2010		|O
therapeutic	2011	2022		|O
success	2023	2030		|O
prior	2031	2036		|O
to	2037	2039		|O
"	2040	2041		|O
in	2041	2043		|O
vivo	2044	2048		|O
"	2048	2049		|O
application	2050	2061		|O
-	2061	2062		|O
a	2062	2063		|O
step	2064	2068		|O
in	2069	2071		|O
the	2072	2075		|O
direction	2076	2085		|O
of	2086	2088		|O
individualized	2089	2103		|O
medicine	2104	2112		|O
for	2113	2116		|O
RCC	2117	2120		|O
.	2120	2121		|O

### 18822681
Gemcitabine	0	11		|O
and	12	15		|O
cisplatin	16	25		|O
treatment	26	35		|O
of	36	38		|O
advanced	39	47		|O
-	47	48		|O
stage	48	53		|O
non	54	57	non-small-cell lung cancer	|B-DISEASE
-	57	58		|I-DISEASE
small	58	63		|I-DISEASE
-	63	64		|I-DISEASE
cell	64	68		|I-DISEASE
lung	69	73		|I-DISEASE
cancer	74	80		|I-DISEASE
in	81	83		|O
patients	84	92		|O
given	93	98		|O
cisplatin	99	108		|O
on	109	111		|O
day	112	115		|O
8	116	117		|O
.	117	118		|O
AIMS	120	124		|O
AND	125	128		|O
BACKGROUND	129	139		|O
:	139	140		|O
Gemcitabine	141	152		|O
and	153	156		|O
cisplatin	157	166		|O
treatment	167	176		|O
were	177	181		|O
administered	182	194		|O
to	195	197		|O
patients	198	206		|O
with	207	211		|O
advanced	212	220		|O
-	220	221		|O
stage	221	226		|O
,	226	227		|O
non	228	231	non-small-cell lung cancer	|B-DISEASE
-	231	232		|I-DISEASE
small	232	237		|I-DISEASE
-	237	238		|I-DISEASE
cell	238	242		|I-DISEASE
lung	243	247		|I-DISEASE
cancer	248	254		|I-DISEASE
.	254	255		|O
During	256	262		|O
phase	263	268		|O
II	269	271		|O
studies	272	279		|O
,	279	280		|O
the	281	284		|O
treatment	285	294		|O
is	295	297		|O
performed	298	307		|O
using	308	313		|O
a	314	315		|O
28	316	318		|O
-	318	319		|O
day	319	322		|O
cycle	323	328		|O
,	328	329		|O
with	330	334		|O
gemcitabine	335	346		|O
administered	347	359		|O
on	360	362		|O
days	363	367		|O
1	368	369		|O
,	369	370		|O
8	371	372		|O
,	372	373		|O
and	374	377		|O
15	378	380		|O
.	380	381		|O
Although	382	390		|O
it	391	393		|O
is	394	396		|O
advised	397	404		|O
that	405	409		|O
cisplatin	410	419		|O
not	420	423		|O
be	424	426		|O
administered	427	439		|O
on	440	442		|O
the	443	446		|O
first	447	452		|O
day	453	456		|O
,	456	457		|O
gemcitabine	458	469		|O
and	470	473		|O
cisplatin	474	483		|O
treatment	484	493		|O
is	494	496		|O
usually	497	504		|O
performed	505	514		|O
using	515	520		|O
a	521	522		|O
21	523	525		|O
-	525	526		|O
day	526	529		|O
cycle	530	535		|O
,	535	536		|O
with	537	541		|O
gemcitabine	542	553		|O
administered	554	566		|O
on	567	569		|O
days	570	574		|O
1	575	576		|O
and	577	580		|O
8	581	582		|O
,	582	583		|O
and	584	587		|O
cisplatin	588	597		|O
is	598	600		|O
given	601	606		|O
on	607	609		|O
the	610	613		|O
first	614	619		|O
day	620	623		|O
in	624	626		|O
most	627	631		|O
phase	632	637		|O
III	638	641		|O
studies	642	649		|O
.	649	650		|O
In	651	653		|O
contrast	654	662		|O
with	663	667		|O
previous	668	676		|O
phase	677	682		|O
III	683	686		|O
studies	687	694		|O
,	694	695		|O
cisplatin	696	705		|O
was	706	709		|O
administered	710	722		|O
on	723	725		|O
day	726	729		|O
8	730	731		|O
in	732	734		|O
our	735	738		|O
study	739	744		|O
.	744	745		|O
Dose	746	750		|O
density	751	758		|O
,	758	759		|O
drug	760	764	drug toxicity	|B-ADVERSE
toxicity	765	773		|I-ADVERSE
,	773	774		|O
and	775	778		|O
efficacy	779	787		|O
were	788	792		|O
analyzed	793	801		|O
.	801	802		|O
METHODS	803	810		|O
AND	811	814		|O
STUDY	815	820		|O
DESIGN	821	827		|O
:	827	828		|O
Chemonaive	829	839		|O
patients	840	848		|O
with	849	853		|O
stage	854	859		|O
IIIB	860	864		|O
or	865	867		|O
stage	868	873		|O
IV	874	876		|O
nonsmall	877	885	nonsmall-cell lung cancer	|B-DISEASE
-	885	886		|I-DISEASE
cell	886	890		|I-DISEASE
lung	891	895		|I-DISEASE
cancer	896	902		|I-DISEASE
received	903	911		|O
gemcitabine	912	923		|O
(	924	925		|O
1250	925	929		|O
mg	930	932		|O
/	932	933		|O
m2	933	935		|O
)	935	936		|O
on	937	939		|O
days	940	944		|O
1	945	946		|O
and	947	950		|O
8	951	952		|O
plus	953	957		|O
cisplatin	958	967		|O
(	968	969		|O
75	969	971		|O
mg	972	974		|O
/	974	975		|O
m2	975	977		|O
)	977	978		|O
on	979	981		|O
day	982	985		|O
8	986	987		|O
every	988	993		|O
3	994	995		|O
weeks	996	1001		|O
(	1002	1003		|O
1	1003	1004		|O
cycle	1005	1010		|O
contained	1011	1020		|O
2	1021	1022		|O
applications	1023	1035		|O
)	1035	1036		|O
.	1036	1037		|O
RESULTS	1038	1045		|O
:	1045	1046		|O
Sixty	1047	1052		|O
-	1052	1053		|O
seven	1053	1058		|O
patients	1059	1067		|O
received	1068	1076		|O
a	1077	1078		|O
total	1079	1084		|O
of	1085	1087		|O
293	1088	1091		|O
applications	1092	1104		|O
.	1104	1105		|O
Dose	1106	1110		|O
densities	1111	1120		|O
were	1121	1125		|O
92.3%	1126	1131		|O
for	1132	1135		|O
gemcitabine	1136	1147		|O
and	1148	1151		|O
93.9%	1152	1157		|O
for	1158	1161		|O
cisplatin	1162	1171		|O
.	1171	1172		|O
The	1173	1176		|O
types	1177	1182		|O
and	1183	1186		|O
rates	1187	1192		|O
of	1193	1195		|O
grade	1196	1201		|O
3	1202	1203		|O
and	1204	1207		|O
grade	1208	1213		|O
4	1214	1215		|O
hematologic	1216	1227		|O
toxicities	1228	1238		|O
were	1239	1243		|O
anemia	1244	1250	anemia	|B-ADVERSE
(	1251	1252		|O
6%	1252	1254		|O
)	1254	1255		|O
,	1255	1256		|O
granulocytopenia	1257	1273	granulocytopenia	|B-ADVERSE
(	1274	1275		|O
46%	1275	1278		|O
)	1278	1279		|O
,	1279	1280		|O
and	1281	1284		|O
thrombocytopenia	1285	1301	thrombocytopenia	|B-ADVERSE
(	1302	1303		|O
6%	1303	1305		|O
)	1305	1306		|O
.	1306	1307		|O
Complete	1308	1316		|O
remission	1317	1326		|O
was	1327	1330		|O
seen	1331	1335		|O
in	1336	1338		|O
2	1339	1340		|O
patients	1341	1349		|O
(	1350	1351		|O
3%	1351	1353		|O
)	1353	1354		|O
;	1354	1355		|O
partial	1356	1363		|O
remission	1364	1373		|O
was	1374	1377		|O
40%	1378	1381		|O
,	1381	1382		|O
stable	1383	1389		|O
disease	1390	1397		|O
was	1398	1401		|O
39%	1402	1405		|O
,	1405	1406		|O
and	1407	1410		|O
progression	1411	1422		|O
of	1423	1425		|O
disease	1426	1433		|O
,	1433	1434		|O
10%	1435	1438		|O
.	1438	1439		|O
The	1440	1443		|O
median	1444	1450		|O
overall	1451	1458		|O
survival	1459	1467		|O
time	1468	1472		|O
was	1473	1476		|O
13	1477	1479		|O
months	1480	1486		|O
.	1486	1487		|O
The	1488	1491		|O
median	1492	1498		|O
progression	1499	1510		|O
-	1510	1511		|O
free	1511	1515		|O
survival	1516	1524		|O
time	1525	1529		|O
was	1530	1533		|O
9.5	1534	1537		|O
months	1538	1544		|O
.	1544	1545		|O
One	1546	1549		|O
-	1549	1550		|O
year	1550	1554		|O
survival	1555	1563		|O
rate	1564	1568		|O
was	1569	1572		|O
54%	1573	1576		|O
and	1577	1580		|O
2	1581	1582		|O
-	1582	1583		|O
year	1583	1587		|O
survival	1588	1596		|O
,	1596	1597		|O
10.4%	1598	1603		|O
.	1603	1604		|O
CONCLUSIONS	1605	1616		|O
:	1616	1617		|O
In	1618	1620		|O
this	1621	1625		|O
21	1626	1628		|O
-	1628	1629		|O
day	1629	1632		|O
treatment	1633	1642		|O
regimen	1643	1650		|O
,	1650	1651		|O
overall	1652	1659		|O
survival	1660	1668		|O
was	1669	1672		|O
longer	1673	1679		|O
than	1680	1684		|O
1	1685	1686		|O
year	1687	1691		|O
and	1692	1695		|O
the	1696	1699		|O
1	1700	1701		|O
-	1701	1702		|O
year	1702	1706		|O
survival	1707	1715		|O
rate	1716	1720		|O
was	1721	1724		|O
more	1725	1729		|O
than	1730	1734		|O
50%	1735	1738		|O
.	1738	1739		|O
Both	1740	1744		|O
the	1745	1748		|O
severity	1749	1757		|O
and	1758	1761		|O
rate	1762	1766		|O
of	1767	1769		|O
observed	1770	1778		|O
thrombocytopenia	1779	1795	thrombocytopenia	|B-ADVERSE
in	1796	1798		|O
the	1799	1802		|O
study	1803	1808		|O
were	1809	1813		|O
very	1814	1818		|O
low	1819	1822		|O
.	1822	1823		|O
Other	1824	1829		|O
adverse	1830	1837		|O
effects	1838	1845		|O
in	1846	1848		|O
the	1849	1852		|O
current	1853	1860		|O
study	1861	1866		|O
were	1867	1871		|O
comparable	1872	1882		|O
to	1883	1885		|O
those	1886	1891		|O
reported	1892	1900		|O
in	1901	1903		|O
the	1904	1907		|O
literature	1908	1918		|O
.	1918	1919		|O

### 18952555
Prolonged	0	9		|O
dose	10	14		|O
-	14	15		|O
dense	15	20		|O
epirubicin	21	31		|O
and	32	35		|O
cyclophosphamide	36	52		|O
followed	53	61		|O
by	62	64		|O
paclitaxel	65	75		|O
in	76	78		|O
breast	79	85	breast cancer	|B-DISEASE
cancer	86	92		|I-DISEASE
is	93	95		|O
feasible	96	104		|O
.	104	105		|O
PURPOSE	107	114		|O
:	114	115		|O
We	116	118		|O
conducted	119	128		|O
a	129	130		|O
pilot	131	136		|O
study	137	142		|O
of	143	145		|O
dose	146	150		|O
-	150	151		|O
dense	151	156		|O
epirubicin	157	167		|O
/	167	168		|O
cyclophosphamide	168	184		|O
(	185	186		|O
EC	186	188		|O
)	188	189		|O
x	190	191		|O
6	192	193		|O
-	194	195		|O
-	195	196		|O
>	196	197		|O
paclitaxel	198	208		|O
(	209	210		|O
P	210	211		|O
)	211	212		|O
x	213	214		|O
6	215	216		|O
with	217	221		|O
pegfilgrastim	222	235		|O
.	235	236		|O
A	237	238		|O
previous	239	247		|O
dose	248	252		|O
-	252	253		|O
dense	253	258		|O
trial	259	264		|O
of	265	267		|O
FEC	268	271		|O
(	272	273		|O
5	273	274		|O
-	274	275		|O
fluorouracil	275	287		|O
[	288	289		|O
5	289	290		|O
-	290	291		|O
FU	291	293		|O
]	293	294		|O
/	294	295		|O
EC	295	297		|O
)	297	298		|O
x	299	300		|O
6	301	302		|O
with	303	307		|O
filgrastim	308	318		|O
-	319	320		|O
-	320	321		|O
>	321	322		|O
by	323	325		|O
weekly	326	332		|O
paclitaxel	333	343		|O
alternating	344	355		|O
with	356	360		|O
docetaxel	361	370		|O
x	371	372		|O
18	373	375		|O
was	376	379		|O
not	380	383		|O
feasible	384	392		|O
because	393	400		|O
of	401	403		|O
pneumonitis	404	415	pneumonitis	|B-DISEASE
(	416	417		|O
with	417	421		|O
dose	422	426		|O
-	426	427		|O
dense	427	432		|O
FEC	433	436		|O
)	436	437		|O
and	438	441		|O
pericardial	442	453	pericardial/pleural effusion	|B-DISEASE
/	453	454		|I-DISEASE
pleural	454	461		|I-DISEASE
effusion	462	470		|I-DISEASE
(	471	472		|O
taxane	472	478		|O
phase	479	484		|O
)	484	485		|O
.	485	486		|O
Dose	487	491		|O
-	491	492		|O
dense	492	497		|O
EC	498	500		|O
(	501	502		|O
without	502	509		|O
the	510	513		|O
5	514	515		|O
-	515	516		|O
FU	516	518		|O
)	518	519		|O
is	520	522		|O
not	523	526		|O
associated	527	537		|O
with	538	542		|O
pneumonitis	543	554	pneumonitis	|B-DISEASE
,	554	555		|O
and	556	559		|O
dose	560	564		|O
-	564	565		|O
dense	565	570		|O
paclitaxel	571	581		|O
(	582	583		|O
alone	583	588		|O
)	588	589		|O
is	590	592		|O
feasible	593	601		|O
.	601	602		|O
Primary	603	610		|O
objective	611	620		|O
was	621	624		|O
feasibility	625	636		|O
.	636	637		|O
PATIENTS	638	646		|O
AND	647	650		|O
METHODS	651	658		|O
:	658	659		|O
Patients	660	668		|O
with	669	673		|O
resectable	674	684		|O
breast	685	691	breast cancer	|B-DISEASE
cancer	692	698		|I-DISEASE
were	699	703		|O
enrolled	704	712		|O
,	712	713		|O
regardless	714	724		|O
of	725	727		|O
surgery	728	735		|O
status	736	742		|O
,	742	743		|O
tumor	744	749		|O
size	750	754		|O
,	754	755		|O
or	756	758		|O
nodal	759	764		|O
status	765	771		|O
.	771	772		|O
Treatment	773	782		|O
regimen	783	790		|O
consisted	791	800		|O
of	801	803		|O
every	804	809		|O
-	809	810		|O
2	810	811		|O
-	811	812		|O
week	812	816		|O
EC	817	819		|O
(	820	821		|O
100/600	821	828		|O
mg	829	831		|O
/	831	832		|O
m2	832	834		|O
)	834	835		|O
x	836	837		|O
6	838	839		|O
-	840	841		|O
-	841	842		|O
>	842	843		|O
by	844	846		|O
2	847	848		|O
-	848	849		|O
weekly	849	855		|O
P	856	857		|O
(	858	859		|O
175	859	862		|O
mg	863	865		|O
/	865	866		|O
m2	866	868		|O
)	868	869		|O
x	870	871		|O
6	872	873		|O
with	874	878		|O
pegfilgrastim	879	892		|O
6	893	894		|O
mg	895	897		|O
on	898	900		|O
day	901	904		|O
2	905	906		|O
.	906	907		|O
RESULTS	908	915		|O
:	915	916		|O
Between	917	924		|O
November	925	933		|O
2004	934	938		|O
and	939	942		|O
May	943	946		|O
2005	947	951		|O
,	951	952		|O
38	953	955		|O
patients	956	964		|O
were	965	969		|O
enrolled	970	978		|O
.	978	979		|O
The	980	983		|O
median	984	990		|O
age	991	994		|O
was	995	998		|O
47	999	1001		|O
years	1002	1007		|O
(	1008	1009		|O
range	1009	1014		|O
,	1014	1015		|O
30-72	1016	1021		|O
years	1022	1027		|O
)	1027	1028		|O
;	1028	1029		|O
33	1030	1032		|O
of	1033	1035		|O
38	1036	1038		|O
(	1039	1040		|O
87%	1040	1043		|O
)	1043	1044		|O
were	1045	1049		|O
treated	1050	1057		|O
in	1058	1060		|O
the	1061	1064		|O
adjuvant	1065	1073		|O
setting	1074	1081		|O
and	1082	1085		|O
27	1086	1088		|O
of	1089	1091		|O
33	1092	1094		|O
(	1095	1096		|O
81%	1096	1099		|O
)	1099	1100		|O
had	1101	1104		|O
involved	1105	1113		|O
nodes	1114	1119		|O
(	1120	1121		|O
range	1121	1126		|O
,	1126	1127		|O
1-46	1128	1132		|O
)	1132	1133		|O
;	1133	1134		|O
5	1135	1136		|O
of	1137	1139		|O
38	1140	1142		|O
(	1143	1144		|O
13%	1144	1147		|O
)	1147	1148		|O
were	1149	1153		|O
treated	1154	1161		|O
pre	1162	1165		|O
-	1165	1166		|O
operatively	1166	1177		|O
;	1177	1178		|O
33	1179	1181		|O
of	1182	1184		|O
38	1185	1187		|O
(	1188	1189		|O
87%	1189	1192		|O
)	1192	1193		|O
completed	1194	1203		|O
all	1204	1207		|O
chemotherapy	1208	1220		|O
as	1221	1223		|O
planned	1224	1231		|O
;	1231	1232		|O
the	1233	1236		|O
remaining	1237	1246		|O
patients	1247	1255		|O
(	1256	1257		|O
13%	1257	1260		|O
)	1260	1261		|O
had	1262	1265		|O
treatment	1266	1275		|O
modifications	1276	1289		|O
for	1290	1293		|O
toxicity	1294	1302		|O
.	1302	1303		|O
Febrile	1304	1311	Febrile neutropenia	|B-ADVERSE
neutropenia	1312	1323		|I-ADVERSE
occurred	1324	1332		|O
in	1333	1335		|O
6	1336	1337		|O
of	1338	1340		|O
38	1341	1343		|O
patients	1344	1352		|O
(	1353	1354		|O
16	1354	1356		|O
%	1357	1358		|O
)	1358	1359		|O
and	1360	1363		|O
only	1364	1368		|O
during	1369	1375		|O
EC	1376	1378		|O
.	1378	1379		|O
There	1380	1385		|O
were	1386	1390		|O
12	1391	1393		|O
hospitalizations	1394	1410		|O
in	1411	1413		|O
9	1414	1415		|O
of	1416	1418		|O
38	1419	1421		|O
patients	1422	1430		|O
(	1431	1432		|O
24%	1432	1435		|O
)	1435	1436		|O
enrolled	1437	1445		|O
.	1445	1446		|O
CONCLUSION	1447	1457		|O
:	1457	1458		|O
Dose	1459	1463		|O
-	1463	1464		|O
dense	1464	1469		|O
every	1470	1475		|O
-	1475	1476		|O
2	1476	1477		|O
-	1477	1478		|O
week	1478	1482		|O
EC	1483	1485		|O
x	1486	1487		|O
6	1488	1489		|O
-	1490	1491		|O
-	1491	1492		|O
>	1492	1493		|O
P	1494	1495		|O
x	1496	1497		|O
6	1498	1499		|O
with	1500	1504		|O
pegfilgrastim	1505	1518		|O
is	1519	1521		|O
feasible	1522	1530		|O
based	1531	1536		|O
on	1537	1539		|O
our	1540	1543		|O
prospective	1544	1555		|O
definition	1556	1566		|O
.	1566	1567		|O

### 18630502
A	0	1		|O
comparison	2	12		|O
of	13	15		|O
two	16	19		|O
orally	20	26		|O
bioavailable	27	39		|O
anti	40	44		|O
-	44	45		|O
cancer	45	51		|O
agents	52	58		|O
,	58	59		|O
IRC	60	63		|O
-	63	64		|O
110160	64	70		|O
and	71	74		|O
STX140	75	81		|O
.	81	82		|O
This	84	88		|O
study	89	94		|O
characterises	95	108		|O
two	109	112		|O
recently	113	121		|O
developed	122	131		|O
anticancer	132	142		|O
agents	143	149		|O
in	150	152		|O
vitro	153	158		|O
and	159	162		|O
in	163	165		|O
vivo	166	170		|O
,	170	171		|O
2	172	173		|O
-	173	174		|O
methoxyoestra	174	187		|O
-	187	188		|O
1,3,5	188	193		|O
(	193	194		|O
10	194	196		|O
)	196	197		|O
,	197	198		|O
16	199	201		|O
-	201	202		|O
tetraene	202	210		|O
-	210	211		|O
3	211	212		|O
-	212	213		|O
carboxamide	213	224		|O
(	225	226		|O
IRC	226	229		|O
-	229	230		|O
110160	230	236		|O
)	236	237		|O
and	238	241		|O
STX140	242	248		|O
.	248	249		|O
MATERIALS	250	259		|O
AND	260	263		|O
METHODS	264	271		|O
:	271	272		|O
Hormone	273	280		|O
-	280	281		|O
dependent	281	290		|O
(	291	292		|O
MCF	292	295		|O
-	295	296		|O
7	296	297		|O
)	297	298		|O
,	298	299		|O
hormone	300	307		|O
-	307	308		|O
independent	308	319		|O
(	320	321		|O
MDA	321	324		|O
-	324	325		|O
MB	325	327		|O
-	327	328		|O
231	328	331		|O
)	331	332		|O
and	333	336		|O
P	337	338		|O
-	338	339		|O
glycoprotein	339	351		|O
overexpressing	352	366		|O
(	367	368		|O
MCF	368	371		|O
-	371	372		|O
7Dox	372	376		|O
)	376	377		|O
cells	378	383		|O
were	384	388		|O
used	389	393		|O
for	394	397		|O
proliferation	398	411		|O
experiments	412	423		|O
.	423	424		|O
For	425	428		|O
the	429	432		|O
tumour	433	439		|O
efficacy	440	448		|O
studies	449	456		|O
,	456	457		|O
female	458	464		|O
nude	465	469		|O
mice	470	474		|O
were	475	479		|O
inoculated	480	490		|O
with	491	495		|O
MDA	496	499		|O
-	499	500		|O
MB	500	502		|O
-	502	503		|O
231	503	506		|O
cells	507	512		|O
.	512	513		|O
RESULTS	514	521		|O
:	521	522		|O
IRC	523	526		|O
-	526	527		|O
110160	527	533		|O
is	534	536		|O
a	537	538		|O
potent	539	545		|O
inhibitor	546	555		|O
of	556	558		|O
both	559	563		|O
MCF	564	567		|O
-	567	568		|O
7	568	569		|O
and	570	573		|O
MDA	574	577		|O
-	577	578		|O
MB	578	580		|O
-	580	581		|O
231	581	584		|O
cell	585	589		|O
proliferation	590	603		|O
.	603	604		|O
Furthermore	605	616		|O
,	616	617		|O
the	618	621		|O
potency	622	629		|O
of	630	632		|O
IRC	633	636		|O
-	636	637		|O
110160	637	643		|O
was	644	647		|O
unaffected	648	658		|O
by	659	661		|O
the	662	665		|O
over	666	670		|O
-	670	671		|O
expression	671	681		|O
of	682	684		|O
the	685	688		|O
P	689	690		|O
-	690	691		|O
glycoprotein	691	703		|O
drug	704	708		|O
efflux	709	715		|O
pump	716	720		|O
.	720	721		|O
IRC	722	725		|O
-	725	726		|O
110160	726	732		|O
and	733	736		|O
2	737	738		|O
-	738	739		|O
methoxyoestradiol	739	756		|O
-	756	757		|O
3,17	757	761		|O
-	761	762		|O
O	762	763		|O
,	763	764		|O
O	764	765		|O
-	765	766		|O
bis	766	769		|O
-	769	770		|O
sulfamate	770	779		|O
(	780	781		|O
STX140	781	787		|O
)	787	788		|O
induced	789	796		|O
apoptosis	797	806		|O
in	807	809		|O
a	810	811		|O
similar	812	819		|O
timeframe	820	829		|O
in	830	832		|O
the	833	836		|O
MDA	837	840		|O
-	840	841		|O
MB	841	843		|O
-	843	844		|O
231	844	847		|O
cell	848	852		|O
line	853	857		|O
,	857	858		|O
but	859	862		|O
only	863	867		|O
STX140	868	874		|O
caused	875	881		|O
G2	882	884		|O
/	884	885		|O
M	885	886		|O
arrest	887	893		|O
in	894	896		|O
these	897	902		|O
cells	903	908		|O
.	908	909		|O
In	910	912		|O
the	913	916		|O
MDA	917	920		|O
-	920	921		|O
MB	921	923		|O
-	923	924		|O
231	924	927		|O
xenograft	928	937		|O
model	938	943		|O
300	944	947		|O
mg	948	950		|O
/	950	951		|O
kg	951	953		|O
p	954	955		|O
.	955	956		|O
o	956	957		|O
.	957	958		|O
(	959	960		|O
daily	960	965		|O
)	965	966		|O
of	967	969		|O
IRC	970	973		|O
-	973	974		|O
110160	974	980		|O
and	981	984		|O
20	985	987		|O
mg	988	990		|O
/	990	991		|O
kg	991	993		|O
p	994	995		|O
.	995	996		|O
o	996	997		|O
.	997	998		|O
STX140	999	1005		|O
(	1006	1007		|O
daily	1007	1012		|O
)	1012	1013		|O
both	1014	1018		|O
completely	1019	1029		|O
inhibited	1030	1039		|O
tumour	1040	1046	tumour	|B-DISEASE
growth	1047	1053		|O
;	1053	1054		|O
however	1055	1062		|O
some	1063	1067		|O
toxicity	1068	1076		|O
was	1077	1080		|O
observed	1081	1089		|O
with	1090	1094		|O
IRC	1095	1098		|O
-	1098	1099		|O
110160	1099	1105		|O
.	1105	1106		|O
After	1107	1112		|O
28	1113	1115		|O
days	1116	1120		|O
of	1121	1123		|O
daily	1124	1129		|O
dosing	1130	1136		|O
STX140	1137	1143		|O
(	1144	1145		|O
20	1145	1147		|O
mg	1148	1150		|O
/	1150	1151		|O
kg	1151	1153		|O
p	1154	1155		|O
.	1155	1156		|O
o	1156	1157		|O
.	1157	1158		|O
)	1158	1159		|O
had	1160	1163		|O
minimal	1164	1171		|O
effect	1172	1178		|O
on	1179	1181		|O
the	1182	1185		|O
white	1186	1191		|O
blood	1192	1197		|O
population	1198	1208		|O
of	1209	1211		|O
mice	1212	1216		|O
with	1217	1221		|O
tumours	1222	1229	tumours	|B-DISEASE
.	1229	1230		|O
The	1231	1234		|O
masking	1235	1242		|O
of	1243	1245		|O
STX140	1246	1252		|O
from	1253	1257		|O
white	1258	1263		|O
blood	1264	1269		|O
cells	1270	1275		|O
may	1276	1279		|O
be	1280	1282		|O
due	1283	1286		|O
to	1287	1289		|O
its	1290	1293		|O
interaction	1294	1305		|O
with	1306	1310		|O
carbonic	1311	1319		|O
anhydrase	1320	1329		|O
II	1330	1332		|O
(	1333	1334		|O
CAII	1334	1338		|O
)	1338	1339		|O
in	1340	1342		|O
the	1343	1346		|O
red	1347	1350		|O
blood	1351	1356		|O
cells	1357	1362		|O
.	1362	1363		|O
In	1364	1366		|O
contrast	1367	1375		|O
to	1376	1378		|O
STX140	1379	1385		|O
,	1385	1386		|O
IRC	1387	1390		|O
-	1390	1391		|O
110160	1391	1397		|O
does	1398	1402		|O
not	1403	1406		|O
inhibit	1407	1414		|O
CAII	1415	1419		|O
.	1419	1420		|O
These	1421	1426		|O
studies	1427	1434		|O
highlight	1435	1444		|O
the	1445	1448		|O
activity	1449	1457		|O
of	1458	1460		|O
two	1461	1464		|O
orally	1465	1471		|O
bioavailable	1472	1484		|O
anti	1485	1489		|O
-	1489	1490		|O
cancer	1490	1496		|O
agents	1497	1503		|O
one	1504	1507		|O
of	1508	1510		|O
which	1511	1516		|O
,	1516	1517		|O
STX140	1518	1524		|O
,	1524	1525		|O
may	1526	1529		|O
offer	1530	1535		|O
a	1536	1537		|O
significant	1538	1549		|O
clinical	1550	1558		|O
advantage	1559	1568		|O
over	1569	1573		|O
existing	1574	1582		|O
drugs	1583	1588		|O
as	1589	1591		|O
a	1592	1593		|O
common	1594	1600		|O
dose	1601	1605		|O
limiting	1606	1614		|O
factor	1615	1621		|O
,	1621	1622		|O
haemotoxicity	1623	1636	haemotoxicity	|B-ADVERSE
,	1636	1637		|O
may	1638	1641		|O
be	1642	1644		|O
minimised	1645	1654		|O
.	1654	1655		|O

### 18620949
Adjuvant	0	8		|O
therapy	9	16		|O
with	17	21		|O
pegylated	22	31		|O
interferon	32	42		|O
alfa	43	47		|O
-	47	48		|O
2b	48	50		|O
versus	51	57		|O
observation	58	69		|O
alone	70	75		|O
in	76	78		|O
resected	79	87		|O
stage	88	93		|O
III	94	97		|O
melanoma	98	106	melanoma	|B-DISEASE
:	106	107		|O
final	108	113		|O
results	114	121		|O
of	122	124		|O
EORTC	125	130		|O
18991	131	136		|O
,	136	137		|O
a	138	139		|O
randomised	140	150		|O
phase	151	156		|O
III	157	160		|O
trial	161	166		|O
.	166	167		|O
BACKGROUND	169	179		|O
:	179	180		|O
Any	181	184		|O
benefit	185	192		|O
of	193	195		|O
adjuvant	196	204		|O
interferon	205	215		|O
alfa	216	220		|O
-	220	221		|O
2b	221	223		|O
for	224	227		|O
melanoma	228	236	melanoma	|B-DISEASE
could	237	242		|O
depend	243	249		|O
on	250	252		|O
dose	253	257		|O
and	258	261		|O
duration	262	270		|O
of	271	273		|O
treatment	274	283		|O
.	283	284		|O
Our	285	288		|O
aim	289	292		|O
was	293	296		|O
to	297	299		|O
determine	300	309		|O
whether	310	317		|O
pegylated	318	327		|O
interferon	328	338		|O
alfa	339	343		|O
-	343	344		|O
2b	344	346		|O
can	347	350		|O
facilitate	351	361		|O
prolonged	362	371		|O
exposure	372	380		|O
while	381	386		|O
maintaining	387	398		|O
tolerability	399	411		|O
.	411	412		|O
METHODS	413	420		|O
:	420	421		|O
1256	422	426		|O
patients	427	435		|O
with	436	440		|O
resected	441	449		|O
stage	450	455		|O
III	456	459		|O
melanoma	460	468	melanoma	|B-DISEASE
were	469	473		|O
randomly	474	482		|O
assigned	483	491		|O
to	492	494		|O
observation	495	506		|O
(	507	508		|O
n	508	509		|O
=	509	510		|O
629	510	513		|O
)	513	514		|O
or	515	517		|O
pegylated	518	527		|O
interferon	528	538		|O
alfa	539	543		|O
-	543	544		|O
2b	544	546		|O
(	547	548		|O
n	548	549		|O
=	549	550		|O
627	550	553		|O
)	553	554		|O
6	555	556		|O
mug	557	560		|O
/	560	561		|O
kg	561	563		|O
per	564	567		|O
week	568	572		|O
for	573	576		|O
8	577	578		|O
weeks	579	584		|O
(	585	586		|O
induction	586	595		|O
)	595	596		|O
then	597	601		|O
3	602	603		|O
mug	604	607		|O
/	607	608		|O
kg	608	610		|O
per	611	614		|O
week	615	619		|O
(	620	621		|O
maintenance	621	632		|O
)	632	633		|O
for	634	637		|O
an	638	640		|O
intended	641	649		|O
duration	650	658		|O
of	659	661		|O
5	662	663		|O
years	664	669		|O
.	669	670		|O
Randomisation	671	684		|O
was	685	688		|O
stratified	689	699		|O
for	700	703		|O
microscopic	704	715		|O
(	716	717		|O
N1	717	719		|O
)	719	720		|O
versus	721	727		|O
macroscopic	728	739		|O
(	740	741		|O
N2	741	743		|O
)	743	744		|O
nodal	745	750		|O
involvement	751	762		|O
,	762	763		|O
number	764	770		|O
of	771	773		|O
positive	774	782		|O
nodes	783	788		|O
,	788	789		|O
ulceration	790	800		|O
and	801	804		|O
tumour	805	811		|O
thickness	812	821		|O
,	821	822		|O
sex	823	826		|O
,	826	827		|O
and	828	831		|O
centre	832	838		|O
.	838	839		|O
Randomisation	840	853		|O
was	854	857		|O
done	858	862		|O
with	863	867		|O
a	868	869		|O
minimisation	870	882		|O
technique	883	892		|O
.	892	893		|O
The	894	897		|O
primary	898	905		|O
endpoint	906	914		|O
was	915	918		|O
recurrence	919	929		|O
-	929	930		|O
free	930	934		|O
survival	935	943		|O
.	943	944		|O
Analyses	945	953		|O
were	954	958		|O
done	959	963		|O
by	964	966		|O
intention	967	976		|O
to	977	979		|O
treat	980	985		|O
.	985	986		|O
This	987	991		|O
study	992	997		|O
is	998	1000		|O
registered	1001	1011		|O
with	1012	1016		|O
ClinicalTrials	1017	1031		|O
.	1031	1032		|O
gov	1032	1035		|O
,	1035	1036		|O
number	1037	1043		|O
NCT00006249	1044	1055		|O
.	1055	1056		|O
FINDINGS	1057	1065		|O
:	1065	1066		|O
All	1067	1070		|O
randomised	1071	1081		|O
patients	1082	1090		|O
were	1091	1095		|O
included	1096	1104		|O
in	1105	1107		|O
the	1108	1111		|O
primary	1112	1119		|O
efficacy	1120	1128		|O
analysis	1129	1137		|O
.	1137	1138		|O
608	1139	1142		|O
patients	1143	1151		|O
in	1152	1154		|O
the	1155	1158		|O
interferon	1159	1169		|O
group	1170	1175		|O
and	1176	1179		|O
613	1180	1183		|O
patients	1184	1192		|O
in	1193	1195		|O
the	1196	1199		|O
observation	1200	1211		|O
group	1212	1217		|O
were	1218	1222		|O
included	1223	1231		|O
in	1232	1234		|O
safety	1235	1241		|O
analyses	1242	1250		|O
.	1250	1251		|O
The	1252	1255		|O
median	1256	1262		|O
length	1263	1269		|O
of	1270	1272		|O
treatment	1273	1282		|O
with	1283	1287		|O
pegylated	1288	1297		|O
interferon	1298	1308		|O
alfa	1309	1313		|O
-	1313	1314		|O
2b	1314	1316		|O
was	1317	1320		|O
12	1321	1323		|O
(	1324	1325		|O
IQR	1325	1328		|O
3.8-33.4	1329	1337		|O
)	1337	1338		|O
months	1339	1345		|O
.	1345	1346		|O
At	1347	1349		|O
3.8	1350	1353		|O
(	1354	1355		|O
3.2-4.2	1355	1362		|O
)	1362	1363		|O
years	1364	1369		|O
median	1370	1376		|O
follow	1377	1383		|O
-	1383	1384		|O
up	1384	1386		|O
,	1386	1387		|O
328	1388	1391		|O
recurrence	1392	1402		|O
events	1403	1409		|O
had	1410	1413		|O
occurred	1414	1422		|O
in	1423	1425		|O
the	1426	1429		|O
interferon	1430	1440		|O
group	1441	1446		|O
compared	1447	1455		|O
with	1456	1460		|O
368	1461	1464		|O
in	1465	1467		|O
the	1468	1471		|O
observation	1472	1483		|O
group	1484	1489		|O
(	1490	1491		|O
hazard	1491	1497		|O
ratio	1498	1503		|O
0.82	1504	1508		|O
,	1508	1509		|O
95%	1510	1513		|O
CI	1514	1516		|O
0.71-0.96	1517	1526		|O
;	1526	1527		|O
p	1528	1529		|O
=	1529	1530		|O
0.01	1530	1534		|O
)	1534	1535		|O
;	1535	1536		|O
the	1537	1540		|O
4	1541	1542		|O
-	1542	1543		|O
year	1543	1547		|O
rate	1548	1552		|O
of	1553	1555		|O
recurrence	1556	1566		|O
-	1566	1567		|O
free	1567	1571		|O
survival	1572	1580		|O
was	1581	1584		|O
45.6%	1585	1590		|O
(	1591	1592		|O
SE	1592	1594		|O
2.2	1595	1598		|O
)	1598	1599		|O
in	1600	1602		|O
the	1603	1606		|O
interferon	1607	1617		|O
group	1618	1623		|O
and	1624	1627		|O
38.9%	1628	1633		|O
(	1634	1635		|O
2.2	1635	1638		|O
)	1638	1639		|O
in	1640	1642		|O
the	1643	1646		|O
observation	1647	1658		|O
group	1659	1664		|O
.	1664	1665		|O
There	1666	1671		|O
was	1672	1675		|O
no	1676	1678		|O
difference	1679	1689		|O
in	1690	1692		|O
overall	1693	1700		|O
survival	1701	1709		|O
between	1710	1717		|O
the	1718	1721		|O
groups	1722	1728		|O
.	1728	1729		|O
Grade	1730	1735		|O
3	1736	1737		|O
adverse	1738	1745		|O
events	1746	1752		|O
occurred	1753	1761		|O
in	1762	1764		|O
246	1765	1768		|O
(	1769	1770		|O
40%	1770	1773		|O
)	1773	1774		|O
patients	1775	1783		|O
in	1784	1786		|O
the	1787	1790		|O
interferon	1791	1801		|O
group	1802	1807		|O
and	1808	1811		|O
60	1812	1814		|O
(	1815	1816		|O
10%	1816	1819		|O
)	1819	1820		|O
in	1821	1823		|O
the	1824	1827		|O
observation	1828	1839		|O
group	1840	1845		|O
;	1845	1846		|O
grade	1847	1852		|O
4	1853	1854		|O
adverse	1855	1862		|O
events	1863	1869		|O
occurred	1870	1878		|O
in	1879	1881		|O
32	1882	1884		|O
(	1885	1886		|O
5%	1886	1888		|O
)	1888	1889		|O
patients	1890	1898		|O
in	1899	1901		|O
the	1902	1905		|O
interferon	1906	1916		|O
group	1917	1922		|O
and	1923	1926		|O
14	1927	1929		|O
(	1930	1931		|O
2%	1931	1933		|O
)	1933	1934		|O
in	1935	1937		|O
the	1938	1941		|O
observation	1942	1953		|O
group	1954	1959		|O
.	1959	1960		|O
In	1961	1963		|O
the	1964	1967		|O
interferon	1968	1978		|O
group	1979	1984		|O
,	1984	1985		|O
the	1986	1989		|O
most	1990	1994		|O
common	1995	2001		|O
grade	2002	2007		|O
3	2008	2009		|O
or	2010	2012		|O
4	2013	2014		|O
adverse	2015	2022		|O
events	2023	2029		|O
were	2030	2034		|O
fatigue	2035	2042	fatigue	|B-ADVERSE
(	2043	2044		|O
97	2044	2046		|O
patients	2047	2055		|O
,	2055	2056		|O
16%	2057	2060		|O
)	2060	2061		|O
,	2061	2062		|O
hepatotoxicity	2063	2077	hepatotoxicity	|B-ADVERSE
(	2078	2079		|O
66	2079	2081		|O
,	2081	2082		|O
11%	2083	2086		|O
)	2086	2087		|O
,	2087	2088		|O
and	2089	2092		|O
depression	2093	2103	depression	|B-ADVERSE
(	2104	2105		|O
39	2105	2107		|O
,	2107	2108		|O
6%	2109	2111		|O
)	2111	2112		|O
.	2112	2113		|O
Treatment	2114	2123		|O
with	2124	2128		|O
pegylated	2129	2138		|O
interferon	2139	2149		|O
alfa	2150	2154		|O
-	2154	2155		|O
2b	2155	2157		|O
was	2158	2161		|O
discontinued	2162	2174		|O
because	2175	2182		|O
of	2183	2185		|O
toxicity	2186	2194		|O
in	2195	2197		|O
191	2198	2201		|O
(	2202	2203		|O
31%	2203	2206		|O
)	2206	2207		|O
patients	2208	2216		|O
.	2216	2217		|O
INTERPRETATION	2218	2232		|O
:	2232	2233		|O
Adjuvant	2234	2242		|O
pegylated	2243	2252		|O
interferon	2253	2263		|O
alfa	2264	2268		|O
-	2268	2269		|O
2b	2269	2271		|O
for	2272	2275		|O
stage	2276	2281		|O
III	2282	2285		|O
melanoma	2286	2294	melanoma	|B-DISEASE
has	2295	2298		|O
a	2299	2300		|O
significant	2301	2312		|O
,	2312	2313		|O
sustained	2314	2323		|O
effect	2324	2330		|O
on	2331	2333		|O
recurrence	2334	2344		|O
-	2344	2345		|O
free	2345	2349		|O
survival	2350	2358		|O
.	2358	2359		|O

### 18950559
LDL	0	3		|O
reduction	4	13		|O
:	13	14		|O
how	15	18		|O
low	19	22		|O
should	23	29		|O
we	30	32		|O
go	33	35		|O
and	36	39		|O
is	40	42		|O
it	43	45		|O
safe	46	50		|O
?	50	51		|O
High	53	57		|O
-	57	58		|O
dose	58	62		|O
statin	63	69		|O
therapy	70	77		|O
or	78	80		|O
combination	81	92		|O
statin	93	99		|O
treatment	100	109		|O
is	110	112		|O
necessary	113	122		|O
for	123	126		|O
most	127	131		|O
patients	132	140		|O
to	141	143		|O
achieve	144	151		|O
aggressive	152	162		|O
low	163	166		|O
-	166	167		|O
density	167	174		|O
lipoprotein	175	186		|O
cholesterol	187	198		|O
goals	199	204		|O
.	204	205		|O
Adding	206	212		|O
ezetimibe	213	222		|O
or	223	225		|O
bile	226	230		|O
acid	231	235		|O
sequestrants	236	248		|O
appears	249	256		|O
unlikely	257	265		|O
to	266	268		|O
increase	269	277		|O
the	278	281		|O
risk	282	286		|O
of	287	289		|O
myopathy	290	298	myopathy	|B-ADVERSE
.	298	299		|O
Although	300	308		|O
the	309	312		|O
combination	313	324		|O
of	325	327		|O
niacin	328	334		|O
or	335	337		|O
fenofibrate	338	349		|O
with	350	354		|O
moderate	355	363		|O
-	363	364		|O
dose	364	368		|O
statins	369	376		|O
appears	377	384		|O
to	385	387		|O
be	388	390		|O
reasonably	391	401		|O
safe	402	406		|O
,	406	407		|O
the	408	411		|O
safety	412	418		|O
of	419	421		|O
combination	422	433		|O
with	434	438		|O
high	439	443		|O
-	443	444		|O
dose	444	448		|O
statins	449	456		|O
has	457	460		|O
yet	461	464		|O
to	465	467		|O
be	468	470		|O
determined	471	481		|O
.	481	482		|O
To	483	485		|O
enhance	486	493		|O
patient	494	501		|O
outcomes	502	510		|O
,	510	511		|O
attention	512	521		|O
must	522	526		|O
be	527	529		|O
paid	530	534		|O
to	535	537		|O
characteristics	538	553		|O
that	554	558		|O
predict	559	566		|O
muscle	567	573		|O
and	574	577		|O
hepatic	578	585		|O
statin	586	592		|O
toxicity	593	601		|O
when	602	606		|O
considering	607	618		|O
using	619	624		|O
high	625	629		|O
-	629	630		|O
dose	630	634		|O
statin	635	641		|O
or	642	644		|O
combination	645	656		|O
statin	657	663		|O
therapy	664	671		|O
.	671	672		|O

### 18635701
Pharmacological	0	15		|O
interventions	16	29		|O
for	30	33		|O
the	34	37		|O
prevention	38	48		|O
of	49	51		|O
relapse	52	59		|O
in	60	62		|O
bipolar	63	70	bipolar disorder	|B-DISEASE
disorder	71	79		|I-DISEASE
:	79	80		|O
a	81	82		|O
systematic	83	93		|O
review	94	100		|O
of	101	103		|O
controlled	104	114		|O
trials	115	121		|O
.	121	122		|O
We	124	126		|O
conducted	127	136		|O
a	137	138		|O
systematic	139	149		|O
review	150	156		|O
and	157	160		|O
meta	161	165		|O
-	165	166		|O
analysis	166	174		|O
of	175	177		|O
randomised	178	188		|O
and	189	192		|O
quasi	193	198		|O
-	198	199		|O
randomised	199	209		|O
controlled	210	220		|O
trials	221	227		|O
evaluating	228	238		|O
all	239	242		|O
clinically	243	253		|O
relevant	254	262		|O
pharmacological	263	278		|O
interventions	279	292		|O
for	293	296		|O
the	297	300		|O
prevention	301	311		|O
of	312	314		|O
relapse	315	322		|O
in	323	325		|O
people	326	332		|O
with	333	337		|O
bipolar	338	345	bipolar disorder	|B-DISEASE
disorder	346	354		|I-DISEASE
.	354	355		|O
Thirty	356	362		|O
-	362	363		|O
four	363	367		|O
trials	368	374		|O
were	375	379		|O
included	380	388		|O
in	389	391		|O
the	392	395		|O
review	396	402		|O
.	402	403		|O
Direct	404	410		|O
comparisons	411	422		|O
with	423	427		|O
placebo	428	435		|O
and	436	439		|O
with	440	444		|O
lithium	445	452		|O
were	453	457		|O
available	458	467		|O
for	468	471		|O
most	472	476		|O
drugs	477	482		|O
.	482	483		|O
In	484	486		|O
addition	487	495		|O
,	495	496		|O
there	497	502		|O
were	503	507		|O
direct	508	514		|O
comparisons	515	526		|O
of	527	529		|O
valproate	530	539		|O
vs.	540	543		|O
olanzapine	544	554		|O
,	554	555		|O
imipramine	556	566		|O
vs.	567	570		|O
lithium	571	578		|O
plus	579	583		|O
imipramine	584	594		|O
,	594	595		|O
olanzapine	596	606		|O
plus	607	611		|O
mood	612	616		|O
stabilisers	617	628		|O
vs.	629	632		|O
mood	633	637		|O
stabilisers	638	649		|O
and	650	653		|O
perphenazine	654	666		|O
plus	667	671		|O
mood	672	676		|O
stabilisers	677	688		|O
vs.	689	692		|O
mood	693	697		|O
stabilisers	698	709		|O
.	709	710		|O
Methodological	711	725		|O
quality	726	733		|O
varied	734	740		|O
across	741	747		|O
studies	748	755		|O
and	756	759		|O
the	760	763		|O
strength	764	772		|O
of	773	775		|O
evidence	776	784		|O
was	785	788		|O
not	789	792		|O
equal	793	798		|O
for	799	802		|O
all	803	806		|O
treatments	807	817		|O
or	818	820		|O
for	821	824		|O
all	825	828		|O
comparisons	829	840		|O
.	840	841		|O
There	842	847		|O
is	848	850		|O
evidence	851	859		|O
from	860	864		|O
placebo	865	872		|O
-	872	873		|O
controlled	873	883		|O
trials	884	890		|O
for	891	894		|O
the	895	898		|O
efficacy	899	907		|O
of	908	910		|O
lithium	911	918		|O
,	918	919		|O
valproate	920	929		|O
and	930	933		|O
lamotrigine	934	945		|O
as	946	948		|O
maintenance	949	960		|O
therapy	961	968		|O
for	969	972		|O
the	973	976		|O
prevention	977	987		|O
of	988	990		|O
relapse	991	998		|O
in	999	1001		|O
bipolar	1002	1009	bipolar disorder	|B-DISEASE
disorder	1010	1018		|I-DISEASE
.	1018	1019		|O
Three	1020	1025		|O
drugs	1026	1031		|O
have	1032	1036		|O
a	1037	1038		|O
significant	1039	1050		|O
effect	1051	1057		|O
in	1058	1060		|O
the	1061	1064		|O
prevention	1065	1075		|O
of	1076	1078		|O
manic	1079	1084	manic relapses	|B-DISEASE
relapses	1085	1093		|I-DISEASE
(	1094	1095		|O
lithium	1095	1102		|O
,	1102	1103		|O
olanzapine	1104	1114		|O
and	1115	1118		|O
aripiprazole	1119	1131		|O
)	1131	1132		|O
and	1133	1136		|O
three	1137	1142		|O
in	1143	1145		|O
the	1146	1149		|O
prevention	1150	1160		|O
of	1161	1163		|O
depressive	1164	1174	depressive symptoms	|B-DISEASE
symptoms	1175	1183		|I-DISEASE
(	1184	1185		|O
valproate	1185	1194		|O
,	1194	1195		|O
lamotrigine	1196	1207		|O
and	1208	1211		|O
imipramine	1212	1222		|O
)	1222	1223		|O
.	1223	1224		|O
Imipramine	1225	1235		|O
is	1236	1238		|O
little	1239	1245		|O
used	1246	1250		|O
in	1251	1253		|O
practice	1254	1262		|O
,	1262	1263		|O
because	1264	1271		|O
of	1272	1274		|O
concern	1275	1282		|O
about	1283	1288		|O
adverse	1289	1296		|O
effects	1297	1304		|O
.	1304	1305		|O
The	1306	1309		|O
significant	1310	1321		|O
effects	1322	1329		|O
of	1330	1332		|O
olanzapine	1333	1343		|O
and	1344	1347		|O
aripiprazole	1348	1360		|O
were	1361	1365		|O
demonstrated	1366	1378		|O
in	1379	1381		|O
selected	1382	1390		|O
responsive	1391	1401		|O
bipolar	1402	1409		|O
I	1410	1411		|O
patients	1412	1420		|O
only	1421	1425		|O
.	1425	1426		|O
Despite	1427	1434		|O
widespread	1435	1445		|O
use	1446	1449		|O
in	1450	1452		|O
clinical	1453	1461		|O
practice	1462	1470		|O
,	1470	1471		|O
there	1472	1477		|O
is	1478	1480		|O
little	1481	1487		|O
evidence	1488	1496		|O
to	1497	1499		|O
support	1500	1507		|O
the	1508	1511		|O
efficacy	1512	1520		|O
of	1521	1523		|O
combination	1524	1535		|O
therapy	1536	1543		|O
.	1543	1544		|O

### 18826264
Cellular	0	8		|O
delivery	9	17		|O
and	18	21		|O
biological	22	32		|O
activity	33	41		|O
of	42	44		|O
antisense	45	54		|O
oligonucleotides	55	71		|O
conjugated	72	82		|O
to	83	85		|O
a	86	87		|O
targeted	88	96		|O
protein	97	104		|O
carrier	105	112		|O
.	112	113		|O
Targeted	115	123		|O
delivery	124	132		|O
can	133	136		|O
potentially	137	148		|O
improve	149	156		|O
the	157	160		|O
pharmacological	161	176		|O
effects	177	184		|O
of	185	187		|O
antisense	188	197		|O
and	198	201		|O
siRNA	202	207		|O
oligonucleotides	208	224		|O
.	224	225		|O
Here	226	230		|O
,	230	231		|O
we	232	234		|O
describe	235	243		|O
a	244	245		|O
novel	246	251		|O
bioconjugation	252	266		|O
approach	267	275		|O
to	276	278		|O
the	279	282		|O
delivery	283	291		|O
of	292	294		|O
splice	295	301		|O
-	301	302		|O
shifting	302	310		|O
antisense	311	320		|O
oligonucleotides	321	337		|O
(	338	339		|O
SSOs	339	343		|O
)	343	344		|O
.	344	345		|O
The	346	349		|O
SSOs	350	354		|O
are	355	358		|O
linked	359	365		|O
to	366	368		|O
albumin	369	376		|O
via	377	380		|O
reversible	381	391		|O
S	392	393		|O
-	393	394		|O
S	394	395		|O
bonds	396	401		|O
.	401	402		|O
The	403	406		|O
albumin	407	414		|O
is	415	417		|O
also	418	422		|O
conjugated	423	433		|O
with	434	438		|O
poly	439	443		|O
(	443	444		|O
ethylene	444	452		|O
glycol	453	459		|O
)	459	460		|O
(	461	462		|O
PEG	462	465		|O
)	465	466		|O
chains	467	473		|O
that	474	478		|O
terminate	479	488		|O
in	489	491		|O
an	492	494		|O
RGD	495	498		|O
ligand	499	505		|O
that	506	510		|O
selectively	511	522		|O
binds	523	528		|O
the	529	532		|O
alphavbeta3	533	544		|O
integrin	545	553		|O
.	553	554		|O
As	555	557		|O
a	558	559		|O
test	560	564		|O
system	565	571		|O
,	571	572		|O
we	573	575		|O
utilized	576	584		|O
human	585	590		|O
melanoma	591	599		|O
cells	600	605		|O
that	606	610		|O
express	611	618		|O
the	619	622		|O
alphavbeta3	623	634		|O
integrin	635	643		|O
and	644	647		|O
that	648	652		|O
also	653	657		|O
contain	658	665		|O
a	666	667		|O
luciferase	668	678		|O
reporter	679	687		|O
gene	688	692		|O
that	693	697		|O
can	698	701		|O
be	702	704		|O
induced	705	712		|O
by	713	715		|O
delivery	716	724		|O
of	725	727		|O
SSOs	728	732		|O
to	733	735		|O
the	736	739		|O
cell	740	744		|O
nucleus	745	752		|O
.	752	753		|O
The	754	757		|O
RGD	758	761		|O
-	761	762		|O
PEG	762	765		|O
-	765	766		|O
SSO	766	769		|O
-	769	770		|O
albumin	770	777		|O
conjugates	778	788		|O
were	789	793		|O
endocytosed	794	805		|O
by	806	808		|O
the	809	812		|O
cells	813	818		|O
in	819	821		|O
an	822	824		|O
RGD	825	828		|O
-	828	829		|O
dependent	829	838		|O
manner	839	845		|O
;	845	846		|O
using	847	852		|O
confocal	853	861		|O
fluorescence	862	874		|O
microscopy	875	885		|O
,	885	886		|O
evidence	887	895		|O
was	896	899		|O
obtained	900	908		|O
that	909	913		|O
the	914	917		|O
SSOs	918	922		|O
accumulate	923	933		|O
in	934	936		|O
the	937	940		|O
nucleus	941	948		|O
.	948	949		|O
The	950	953		|O
conjugates	954	964		|O
were	965	969		|O
able	970	974		|O
to	975	977		|O
robustly	978	986		|O
induce	987	993		|O
luciferase	994	1004		|O
expression	1005	1015		|O
at	1016	1018		|O
concentrations	1019	1033		|O
in	1034	1036		|O
the	1037	1040		|O
25-200	1041	1047		|O
nM	1048	1050		|O
range	1051	1056		|O
.	1056	1057		|O
At	1058	1060		|O
these	1061	1066		|O
levels	1067	1073		|O
,	1073	1074		|O
little	1075	1081		|O
short	1082	1087		|O
-	1087	1088		|O
term	1088	1092		|O
or	1093	1095		|O
long	1096	1100		|O
-	1100	1101		|O
term	1101	1105		|O
toxicity	1106	1114		|O
was	1115	1118		|O
observed	1119	1127		|O
.	1127	1128		|O
Thus	1129	1133		|O
,	1133	1134		|O
the	1135	1138		|O
RGD	1139	1142		|O
-	1142	1143		|O
PEG	1143	1146		|O
-	1146	1147		|O
albumin	1147	1154		|O
conjugates	1155	1165		|O
may	1166	1169		|O
provide	1170	1177		|O
an	1178	1180		|O
effective	1181	1190		|O
tool	1191	1195		|O
for	1196	1199		|O
targeted	1200	1208		|O
delivery	1209	1217		|O
of	1218	1220		|O
oligonucleotides	1221	1237		|O
to	1238	1240		|O
certain	1241	1248		|O
cells	1249	1254		|O
and	1255	1258		|O
tissues	1259	1266		|O
.	1266	1267		|O

### 18446180
Treatment	0	9		|O
of	10	12		|O
patent	13	19	patent ductus arteriosus	|B-DISEASE
ductus	20	26		|I-DISEASE
arteriosus	27	37		|I-DISEASE
:	37	38		|O
indomethacin	39	51		|O
or	52	54		|O
ibuprofen	55	64		|O
?	64	65		|O
Persistent	67	77		|O
patent	78	84	patent ductus arteriosus	|B-DISEASE
ductus	85	91		|I-DISEASE
arteriosus	92	102		|I-DISEASE
(	103	104		|O
PDA	104	107	PDA	|B-DISEASE
)	107	108		|O
in	109	111		|O
preterm	112	119		|O
infants	120	127		|O
can	128	131		|O
result	132	138		|O
in	139	141		|O
serious	142	149		|O
hemodynamic	150	161		|O
changes	162	169		|O
causing	170	177		|O
respiratory	178	189		|O
,	189	190		|O
gastrointestinal	191	207		|O
and	208	211		|O
renal	212	217		|O
morbidities	218	229		|O
if	230	232		|O
not	233	236		|O
treated	237	244		|O
within	245	251		|O
the	252	255		|O
first	256	261		|O
week	262	266		|O
of	267	269		|O
life	270	274		|O
.	274	275		|O
The	276	279		|O
treatment	280	289		|O
options	290	297		|O
available	298	307		|O
are	308	311		|O
a	312	313		|O
conservative	314	326		|O
approach	327	335		|O
,	335	336		|O
pharmacological	337	352		|O
treatment	353	362		|O
with	363	367		|O
cyclo	368	373		|O
-	373	374		|O
oxygenase	374	383		|O
(	384	385		|O
COX	385	388		|O
)	388	389		|O
inhibitors	390	400		|O
and	401	404		|O
surgical	405	413		|O
ligation	414	422		|O
.	422	423		|O
The	424	427		|O
COX	428	431		|O
inhibitors	432	442		|O
approved	443	451		|O
for	452	455		|O
use	456	459		|O
in	460	462		|O
the	463	466		|O
United	467	473		|O
States	474	480		|O
are	481	484		|O
indomethacin	485	497		|O
and	498	501		|O
ibuprofen	502	511		|O
lysine	512	518		|O
.	518	519		|O
Both	520	524		|O
of	525	527		|O
these	528	533		|O
drugs	534	539		|O
are	540	543		|O
equally	544	551		|O
effective	552	561		|O
in	562	564		|O
closing	565	572		|O
the	573	576		|O
PDA	577	580	PDA	|B-DISEASE
.	580	581		|O
Subtle	582	588		|O
differences	589	600		|O
exist	601	606		|O
between	607	614		|O
these	615	620		|O
two	621	624		|O
preparations	625	637		|O
.	637	638		|O
Indomethacin	639	651		|O
has	652	655		|O
a	656	657		|O
protective	658	668		|O
effect	669	675		|O
on	676	678		|O
the	679	682		|O
incidence	683	692		|O
of	693	695		|O
intraventricular	696	712	intraventricular hemorrhage	|B-DISEASE
hemorrhage	713	723		|I-DISEASE
(	724	725		|O
IVH	725	728	IVH	|B-DISEASE
)	728	729		|O
but	730	733		|O
reduces	734	741		|O
the	742	745		|O
blood	746	751		|O
flow	752	756		|O
to	757	759		|O
the	760	763		|O
kidneys	764	771		|O
and	772	775		|O
the	776	779		|O
brain	780	785		|O
.	785	786		|O
Ibuprofen	787	796		|O
is	797	799		|O
less	800	804		|O
toxic	805	810		|O
but	811	814		|O
has	815	818		|O
no	819	821		|O
effect	822	828		|O
on	829	831		|O
IVH	832	835	IVH	|B-DISEASE
.	835	836		|O
Efficacy	837	845		|O
of	846	848		|O
pharmacological	849	864		|O
treatment	865	874		|O
is	875	877		|O
influenced	878	888		|O
by	889	891		|O
timing	892	898		|O
of	899	901		|O
initiation	902	912		|O
of	913	915		|O
therapy	916	923		|O
.	923	924		|O
Surgical	925	933		|O
treatment	934	943		|O
is	944	946		|O
the	947	950		|O
only	951	955		|O
option	956	962		|O
when	963	967		|O
pharmacological	968	983		|O
treatment	984	993		|O
fails	994	999		|O
to	1000	1002		|O
close	1003	1008		|O
the	1009	1012		|O
PDA	1013	1016	PDA	|B-DISEASE
in	1017	1019		|O
symptomatic	1020	1031		|O
infants	1032	1039		|O
.	1039	1040		|O
Long	1041	1045		|O
-	1045	1046		|O
term	1046	1050		|O
neurological	1051	1063		|O
and	1064	1067		|O
respiratory	1068	1079		|O
morbidities	1080	1091		|O
are	1092	1095		|O
associated	1096	1106		|O
with	1107	1111		|O
surgical	1112	1120		|O
ligation	1121	1129		|O
.	1129	1130		|O
This	1131	1135		|O
paper	1136	1141		|O
reviews	1142	1149		|O
these	1150	1155		|O
medical	1156	1163		|O
considerations	1164	1178		|O
in	1179	1181		|O
the	1182	1185		|O
treatment	1186	1195		|O
options	1196	1203		|O
for	1204	1207		|O
PDA	1208	1211	PDA	|B-DISEASE
in	1212	1214		|O
premature	1215	1224		|O
infants	1225	1232		|O
.	1232	1233		|O

### 18805577
Toward	0	6		|O
experimental	7	19		|O
assessment	20	30		|O
of	31	33		|O
receptor	34	42		|O
occupancy	43	52		|O
:	52	53		|O
TGN1412	54	61		|O
revisited	62	71		|O
.	71	72		|O
In	74	76		|O
March	77	82		|O
2006	83	87		|O
,	87	88		|O
6	89	90		|O
healthy	91	98		|O
volunteers	99	109		|O
experienced	110	121		|O
serious	122	129		|O
adverse	130	137		|O
reactions	138	147		|O
during	148	154		|O
a	155	156		|O
first	157	162		|O
-	162	163		|O
in	163	165		|O
-	165	166		|O
human	166	171		|O
clinical	172	180		|O
trial	181	186		|O
of	187	189		|O
the	190	193		|O
superagonistic	194	208		|O
anti	209	213		|O
-	213	214		|O
CD28	214	218		|O
mAb	219	222		|O
TGN1412	223	230		|O
.	230	231		|O
A	232	233		|O
first	234	239		|O
investigation	240	253		|O
excluded	254	262		|O
contaminations	263	277		|O
of	278	280		|O
the	281	284		|O
drug	285	289		|O
product	290	297		|O
or	298	300		|O
protocol	301	309		|O
irregularities	310	324		|O
as	325	327		|O
the	328	331		|O
root	332	336		|O
cause	337	342		|O
.	342	343		|O
Later	344	349		|O
,	349	350		|O
an	351	353		|O
expert	354	360		|O
scientific	361	371		|O
group	372	377		|O
convened	378	386		|O
in	387	389		|O
the	390	393		|O
United	394	400		|O
Kingdom	401	408		|O
to	409	411		|O
develop	412	419		|O
recommendations	420	435		|O
pertinent	436	445		|O
to	446	448		|O
minimizing	449	459		|O
risks	460	465		|O
of	466	468		|O
first	469	474		|O
-	474	475		|O
in	475	477		|O
-	477	478		|O
human	478	483		|O
clinical	484	492		|O
trials	493	499		|O
.	499	500		|O
The	501	504		|O
expert	505	511		|O
scientific	512	522		|O
group	523	528		|O
concluded	529	538		|O
from	539	543		|O
in	544	546		|O
silico	547	553		|O
calculations	554	566		|O
that	567	571		|O
at	572	574		|O
the	575	578		|O
initial	579	586		|O
dose	587	591		|O
of	592	594		|O
0.1	595	598		|O
mg	599	601		|O
/	601	602		|O
kg	602	604		|O
,	604	605		|O
which	606	611		|O
was	612	615		|O
adjusted	616	624		|O
on	625	627		|O
the	628	631		|O
basis	632	637		|O
of	638	640		|O
the	641	644		|O
no	645	647		|O
observed	648	656		|O
adverse	657	664		|O
effect	665	671		|O
level	672	677		|O
,	677	678		|O
approximately	679	692		|O
86.2%	693	698		|O
to	699	701		|O
90.9%	702	707		|O
CD28	708	712		|O
receptor	713	721		|O
occupancy	722	731		|O
was	732	735		|O
obtained	736	744		|O
.	744	745		|O
Here	746	750		|O
we	751	753		|O
developed	754	763		|O
a	764	765		|O
flow	766	770		|O
cytometric	771	781		|O
method	782	788		|O
that	789	793		|O
revealed	794	802		|O
receptor	803	811		|O
occupancy	812	821		|O
of	822	824		|O
approximately	825	838		|O
45%	839	842		|O
to	843	845		|O
80%	846	849		|O
under	850	855		|O
the	856	859		|O
above	860	865		|O
conditions	866	876		|O
.	876	877		|O
Thus	878	882		|O
we	883	885		|O
present	886	893		|O
a	894	895		|O
method	896	902		|O
to	903	905		|O
experimentally	906	920		|O
determine	921	930		|O
receptor	931	939		|O
occupancy	940	949		|O
that	950	954		|O
can	955	958		|O
be	959	961		|O
taken	962	967		|O
as	968	970		|O
one	971	974		|O
parameter	975	984		|O
to	985	987		|O
define	988	994		|O
the	995	998		|O
minimal	999	1006		|O
anticipated	1007	1018		|O
biological	1019	1029		|O
effect	1030	1036		|O
level	1037	1042		|O
as	1043	1045		|O
the	1046	1049		|O
basis	1050	1055		|O
for	1056	1059		|O
calculating	1060	1071		|O
safer	1072	1077		|O
starting	1078	1086		|O
doses	1087	1092		|O
for	1093	1096		|O
first	1097	1102		|O
-	1102	1103		|O
in	1103	1105		|O
-	1105	1106		|O
human	1106	1111		|O
clinical	1112	1120		|O
trials	1121	1127		|O
for	1128	1131		|O
products	1132	1140		|O
in	1141	1143		|O
which	1144	1149		|O
a	1150	1151		|O
potential	1152	1161		|O
risk	1162	1166		|O
has	1167	1170		|O
been	1171	1175		|O
identified	1176	1186		|O
.	1186	1187		|O
Additional	1188	1198		|O
measures	1199	1207		|O
are	1208	1211		|O
being	1212	1217		|O
discussed	1218	1227		|O
that	1228	1232		|O
will	1233	1237		|O
help	1238	1242		|O
to	1243	1245		|O
significantly	1246	1259		|O
improve	1260	1267		|O
safety	1268	1274		|O
of	1275	1277		|O
first	1278	1283		|O
-	1283	1284		|O
in	1284	1286		|O
-	1286	1287		|O
human	1287	1292		|O
clinical	1293	1301		|O
trials	1302	1308		|O
.	1308	1309		|O

### 18789000
Blueberry	0	9		|O
opposes	10	17		|O
beta	18	22		|O
-	22	23		|O
amyloid	23	30		|O
peptide	31	38		|O
-	38	39		|O
induced	39	46		|O
microglial	47	57		|O
activation	58	68		|O
via	69	72		|O
inhibition	73	83		|O
of	84	86		|O
p44/42	87	93		|O
mitogen	94	101		|O
-	101	102		|O
activation	102	112		|O
protein	113	120		|O
kinase	121	127		|O
.	127	128		|O
Alzheimer	130	139	Alzheimer's Disease	|B-DISEASE
's	139	141		|I-DISEASE
Disease	142	149		|I-DISEASE
(	150	151		|O
AD	151	153	AD	|B-DISEASE
)	153	154		|O
is	155	157		|O
the	158	161		|O
most	162	166		|O
common	167	173		|O
age	174	177		|O
-	177	178		|O
related	178	185		|O
dementia	186	194	dementia	|B-DISEASE
,	194	195		|O
with	196	200		|O
a	201	202		|O
current	203	210		|O
prevalence	211	221		|O
in	222	224		|O
excess	225	231		|O
of	232	234		|O
five	235	239		|O
million	240	247		|O
individuals	248	259		|O
in	260	262		|O
the	263	266		|O
United	267	273		|O
States	274	280		|O
.	280	281		|O
The	282	285		|O
aggregation	286	297		|O
of	298	300		|O
amyloid	301	308		|O
-	308	309		|O
beta	309	313		|O
(	314	315		|O
A	315	316		|O
beta	317	321		|O
)	321	322		|O
into	323	327		|O
fibrillar	328	337		|O
amyloid	338	345		|O
plaques	346	353		|O
is	354	356		|O
a	357	358		|O
key	359	362		|O
pathological	363	375		|O
event	376	381		|O
in	382	384		|O
the	385	388		|O
development	389	400		|O
of	401	403		|O
the	404	407		|O
disease	408	415		|O
.	415	416		|O
Microglial	417	427		|O
proinflammatory	428	443		|O
activation	444	454		|O
is	455	457		|O
widely	458	464		|O
known	465	470		|O
to	471	473		|O
cause	474	479		|O
neuronal	480	488		|O
and	489	492		|O
synaptic	493	501		|O
damage	502	508		|O
that	509	513		|O
correlates	514	524		|O
with	525	529		|O
cognitive	530	539	cognitive impairment	|B-DISEASE
impairment	540	550		|I-DISEASE
in	551	553		|O
AD	554	556	AD	|B-DISEASE
.	556	557		|O
However	558	565		|O
,	565	566		|O
current	567	574		|O
pharmacological	575	590		|O
attempts	591	599		|O
at	600	602		|O
reducing	603	611		|O
neuroinflammation	612	629		|O
mediated	630	638		|O
via	639	642		|O
microglial	643	653		|O
activation	654	664		|O
have	665	669		|O
been	670	674		|O
largely	675	682		|O
negative	683	691		|O
in	692	694		|O
terms	695	700		|O
of	701	703		|O
slowing	704	711		|O
AD	712	714	AD	|B-DISEASE
progression	715	726		|O
.	726	727		|O
Previously	728	738		|O
,	738	739		|O
we	740	742		|O
have	743	747		|O
shown	748	753		|O
that	754	758		|O
microglia	759	768		|O
express	769	776		|O
proinflammatory	777	792		|O
cytokines	793	802		|O
and	803	806		|O
a	807	808		|O
reduced	809	816		|O
capacity	817	825		|O
to	826	828		|O
phagocytose	829	840		|O
A	841	842		|O
beta	843	847		|O
in	848	850		|O
the	851	854		|O
context	855	862		|O
of	863	865		|O
CD40	866	870		|O
,	870	871		|O
A	872	873		|O
beta	874	878		|O
peptides	879	887		|O
and	888	891		|O
/	891	892		|O
or	892	894		|O
lipopolysaccharide	895	913		|O
(	914	915		|O
LPS	915	918		|O
)	918	919		|O
stimulation	920	931		|O
,	931	932		|O
a	933	934		|O
phenomenon	935	945		|O
that	946	950		|O
can	951	954		|O
be	955	957		|O
opposed	958	965		|O
by	966	968		|O
attenuation	969	980		|O
of	981	983		|O
p44/42	984	990		|O
mitogen	991	998		|O
-	998	999		|O
activated	999	1008		|O
protein	1009	1016		|O
kinase	1017	1023		|O
(	1024	1025		|O
MAPK	1025	1029		|O
)	1029	1030		|O
signaling	1031	1040		|O
.	1040	1041		|O
Other	1042	1047		|O
groups	1048	1054		|O
have	1055	1059		|O
found	1060	1065		|O
that	1066	1070		|O
blueberry	1071	1080		|O
(	1081	1082		|O
BB	1082	1084		|O
)	1084	1085		|O
extract	1086	1093		|O
both	1094	1098		|O
inhibits	1099	1107		|O
phosphorylation	1108	1123		|O
of	1124	1126		|O
this	1127	1131		|O
MAPK	1132	1136		|O
module	1137	1143		|O
and	1144	1147		|O
also	1148	1152		|O
improves	1153	1161		|O
cognitive	1162	1171		|O
deficits	1172	1180		|O
in	1181	1183		|O
AD	1184	1186	AD	|B-DISEASE
model	1187	1192		|O
mice	1193	1197		|O
.	1197	1198		|O
Given	1199	1204		|O
these	1205	1210		|O
considerations	1211	1225		|O
and	1226	1229		|O
the	1230	1233		|O
lack	1234	1238		|O
of	1239	1241		|O
reduced	1242	1249		|O
A	1250	1251		|O
beta	1252	1256		|O
quantities	1257	1267		|O
in	1268	1270		|O
behaviorally	1271	1283		|O
improved	1284	1292		|O
BB	1293	1295		|O
-	1295	1296		|O
fed	1296	1299		|O
mice	1300	1304		|O
,	1304	1305		|O
we	1306	1308		|O
wished	1309	1315		|O
to	1316	1318		|O
determine	1319	1328		|O
whether	1329	1336		|O
BB	1337	1339		|O
supplementation	1340	1355		|O
would	1356	1361		|O
alter	1362	1367		|O
the	1368	1371		|O
microglial	1372	1382		|O
proinflammatory	1383	1398		|O
activation	1399	1409		|O
state	1410	1415		|O
in	1416	1418		|O
response	1419	1427		|O
to	1428	1430		|O
A	1431	1432		|O
beta	1433	1437		|O
.	1437	1438		|O
We	1439	1441		|O
found	1442	1447		|O
that	1448	1452		|O
BB	1453	1455		|O
significantly	1456	1469		|O
enhances	1470	1478		|O
microglial	1479	1489		|O
clearance	1490	1499		|O
of	1500	1502		|O
A	1503	1504		|O
beta	1505	1509		|O
,	1509	1510		|O
inhibits	1511	1519		|O
aggregation	1520	1531		|O
of	1532	1534		|O
A	1535	1536		|O
beta	1537	1541		|O
(	1541	1542		|O
1-42	1542	1546		|O
)	1546	1547		|O
,	1547	1548		|O
and	1549	1552		|O
suppresses	1553	1563		|O
microglial	1564	1574		|O
activation	1575	1585		|O
,	1585	1586		|O
all	1587	1590		|O
via	1591	1594		|O
suppression	1595	1606		|O
of	1607	1609		|O
the	1610	1613		|O
p44/42	1614	1620		|O
MAPK	1621	1625		|O
module	1626	1632		|O
.	1632	1633		|O
Thus	1634	1638		|O
,	1638	1639		|O
these	1640	1645		|O
data	1646	1650		|O
may	1651	1654		|O
explain	1655	1662		|O
the	1663	1666		|O
previously	1667	1677		|O
observed	1678	1686		|O
behavioral	1687	1697		|O
recovery	1698	1706		|O
in	1707	1709		|O
PSAPP	1710	1715		|O
mice	1716	1720		|O
and	1721	1724		|O
suggest	1725	1732		|O
a	1733	1734		|O
means	1735	1740		|O
by	1741	1743		|O
which	1744	1749		|O
dietary	1750	1757		|O
supplementation	1758	1773		|O
could	1774	1779		|O
mitigate	1780	1788		|O
an	1789	1791		|O
undesirable	1792	1803		|O
microglial	1804	1814		|O
response	1815	1823		|O
toward	1824	1830		|O
fibrillar	1831	1840		|O
A	1841	1842		|O
beta	1843	1847		|O
.	1847	1848		|O

### 18704634
Concurrent	0	10		|O
chemoradiation	11	25		|O
for	26	29		|O
locally	30	37		|O
advanced	38	46		|O
squamous	47	55	squamous cell carcinoma of the vagina	|B-DISEASE
cell	56	60		|I-DISEASE
carcinoma	61	70		|I-DISEASE
of	71	73		|I-DISEASE
the	74	77		|I-DISEASE
vagina	78	84		|I-DISEASE
:	84	85		|O
case	86	90		|O
series	91	97		|O
and	98	101		|O
literature	102	112		|O
review	113	119		|O
.	119	120		|O
BACKGROUND	122	132		|O
:	132	133		|O
We	134	136		|O
reviewed	137	145		|O
our	146	149		|O
experience	150	160		|O
with	161	165		|O
patients	166	174		|O
with	175	179		|O
primary	180	187		|O
squamous	188	196	squamous cell carcinoma of the vagina	|B-DISEASE
cell	197	201		|I-DISEASE
carcinoma	202	211		|I-DISEASE
of	212	214		|I-DISEASE
the	215	218		|I-DISEASE
vagina	219	225		|I-DISEASE
who	226	229		|O
received	230	238		|O
concurrent	239	249		|O
chemoradiation	250	264		|O
therapy	265	272		|O
(	273	274		|O
CCRT	274	278		|O
)	278	279		|O
.	279	280		|O
METHODS	281	288		|O
:	288	289		|O
We	290	292		|O
retrospectively	293	308		|O
analyzed	309	317		|O
six	318	321		|O
patients	322	330		|O
(	331	332		|O
median	332	338		|O
age	339	342		|O
,	342	343		|O
60	344	346		|O
years	347	352		|O
)	352	353		|O
with	354	358		|O
squamous	359	367	squamous cell carcinoma of the vagina	|B-DISEASE
cell	368	372		|I-DISEASE
carcinoma	373	382		|I-DISEASE
of	383	385		|I-DISEASE
the	386	389		|I-DISEASE
vagina	390	396		|I-DISEASE
who	397	400		|O
underwent	401	410		|O
CCRT	411	415		|O
between	416	423		|O
2002	424	428		|O
and	429	432		|O
2005	433	437		|O
at	438	440		|O
the	441	444		|O
University	445	455		|O
of	456	458		|O
the	459	462		|O
Ryukyus	463	470		|O
Hospital	471	479		|O
.	479	480		|O
Two	481	484		|O
patients	485	493		|O
were	494	498		|O
in	499	501		|O
International	502	515		|O
Federation	516	526		|O
of	527	529		|O
Obstetricians	530	543		|O
and	544	547		|O
Gynecologists	548	561		|O
(	562	563		|O
FIGO	563	567		|O
)	567	568		|O
stage	569	574		|O
II	575	577		|O
,	577	578		|O
one	579	582		|O
in	583	585		|O
stage	586	591		|O
III	592	595		|O
,	595	596		|O
and	597	600		|O
three	601	606		|O
in	607	609		|O
stage	610	615		|O
IVA	616	619		|O
.	619	620		|O
All	621	624		|O
patients	625	633		|O
had	634	637		|O
an	638	640		|O
Eastern	641	648		|O
Cooperative	649	660		|O
Oncology	661	669		|O
Group	670	675		|O
(	676	677		|O
ECOG	677	681		|O
)	681	682		|O
performance	683	694		|O
status	695	701		|O
of	702	704		|O
2	705	706		|O
or	707	709		|O
less	710	714		|O
.	714	715		|O
Tumor	716	721		|O
size	722	726		|O
ranged	727	733		|O
from	734	738		|O
3.2	739	742		|O
to	743	745		|O
7.7	746	749		|O
cm	750	752		|O
.	752	753		|O
All	754	757		|O
patients	758	766		|O
were	767	771		|O
treated	772	779		|O
with	780	784		|O
true	785	789		|O
pelvic	790	796		|O
external	797	805		|O
-	805	806		|O
beam	806	810		|O
radiotherapy	811	823		|O
(	824	825		|O
EBRT	825	829		|O
)	829	830		|O
at	831	833		|O
50	834	836		|O
Gy	837	839		|O
.	839	840		|O
Then	841	845		|O
two	846	849		|O
of	850	852		|O
the	853	856		|O
six	857	860		|O
patients	861	869		|O
underwent	870	879		|O
intracavitary	880	893		|O
vaginal	894	901		|O
brachy	902	908		|O
-	908	909		|O
therapy	909	916		|O
.	916	917		|O
The	918	921		|O
remaining	922	931		|O
four	932	936		|O
patients	937	945		|O
received	946	954		|O
boost	955	960		|O
EBRT	961	965		|O
with	966	970		|O
shrinking	971	980		|O
fields	981	987		|O
.	987	988		|O
Total	989	994		|O
radiation	995	1004		|O
dose	1005	1009		|O
to	1010	1012		|O
the	1013	1016		|O
vaginal	1017	1024	vaginal tumor	|B-DISEASE
tumor	1025	1030		|I-DISEASE
ranged	1031	1037		|O
from	1038	1042		|O
60	1043	1045		|O
to	1046	1048		|O
66	1049	1051		|O
Gy	1052	1054		|O
.	1054	1055		|O
All	1056	1059		|O
patients	1060	1068		|O
received	1069	1077		|O
two	1078	1081		|O
or	1082	1084		|O
three	1085	1090		|O
concomitant	1091	1102		|O
cycles	1103	1109		|O
of	1110	1112		|O
cisplatin	1113	1122		|O
during	1123	1129		|O
EBRT	1130	1134		|O
.	1134	1135		|O
RESULTS	1136	1143		|O
:	1143	1144		|O
All	1145	1148		|O
six	1149	1152		|O
patients	1153	1161		|O
completed	1162	1171		|O
their	1172	1177		|O
scheduled	1178	1187		|O
CCRT	1188	1192		|O
,	1192	1193		|O
and	1194	1197		|O
achieved	1198	1206		|O
a	1207	1208		|O
clinical	1209	1217		|O
complete	1218	1226		|O
response	1227	1235		|O
.	1235	1236		|O
One	1237	1240		|O
stage	1241	1246		|O
II	1247	1249		|O
patient	1250	1257		|O
died	1258	1262		|O
of	1263	1265		|O
disease	1266	1273		|O
24	1274	1276		|O
months	1277	1283		|O
after	1284	1289		|O
treatment	1290	1299		|O
,	1299	1300		|O
and	1301	1304		|O
the	1305	1308		|O
stage	1309	1314		|O
III	1315	1318		|O
patient	1319	1326		|O
had	1327	1330		|O
local	1331	1336		|O
failure	1337	1344		|O
at	1345	1347		|O
12	1348	1350		|O
months	1351	1357		|O
.	1357	1358		|O
The	1359	1362		|O
remaining	1363	1372		|O
four	1373	1377		|O
patients	1378	1386		|O
were	1387	1391		|O
free	1392	1396		|O
of	1397	1399		|O
their	1400	1405		|O
disease	1406	1413		|O
at	1414	1416		|O
18	1417	1419		|O
,	1419	1420		|O
23	1421	1423		|O
,	1423	1424		|O
33	1425	1427		|O
,	1427	1428		|O
and	1429	1432		|O
55	1433	1435		|O
months	1436	1442		|O
,	1442	1443		|O
respectively	1444	1456		|O
.	1456	1457		|O
One	1458	1461		|O
patient	1462	1469		|O
with	1470	1474		|O
stage	1475	1480		|O
IVA	1481	1484		|O
developed	1485	1494		|O
a	1495	1496		|O
vesicovaginal	1497	1510	vesicovaginal fistula	|B-ADVERSE
fistula	1511	1518		|I-ADVERSE
during	1519	1525		|O
CCRT	1526	1530		|O
.	1530	1531		|O
Nevertheless	1532	1544		|O
,	1544	1545		|O
CCRT	1546	1550		|O
was	1551	1554		|O
well	1555	1559		|O
tolerated	1560	1569		|O
by	1570	1572		|O
all	1573	1576		|O
six	1577	1580		|O
patients	1581	1589		|O
,	1589	1590		|O
and	1591	1594		|O
no	1595	1597		|O
grade	1598	1603		|O
3	1604	1605		|O
or	1606	1608		|O
4	1609	1610		|O
late	1611	1615		|O
toxicity	1616	1624		|O
was	1625	1628		|O
observed	1629	1637		|O
,	1637	1638		|O
as	1639	1641		|O
evaluated	1642	1651		|O
by	1652	1654		|O
the	1655	1658		|O
Radiation	1659	1668		|O
Therapy	1669	1676		|O
Oncology	1677	1685		|O
Group	1686	1691		|O
(	1692	1693		|O
RTOG	1693	1697		|O
)	1697	1698		|O
scoring	1699	1706		|O
system	1707	1713		|O
.	1713	1714		|O
CONCLUSION	1715	1725		|O
:	1725	1726		|O
CCRT	1727	1731		|O
is	1732	1734		|O
effective	1735	1744		|O
for	1745	1748		|O
primary	1749	1756		|O
squamous	1757	1765	squamous cell carcinoma of the vagina	|B-DISEASE
cell	1766	1770		|I-DISEASE
carcinoma	1771	1780		|I-DISEASE
of	1781	1783		|I-DISEASE
the	1784	1787		|I-DISEASE
vagina	1788	1794		|I-DISEASE
and	1795	1798		|O
should	1799	1805		|O
be	1806	1808		|O
considered	1809	1819		|O
for	1820	1823		|O
treatment	1824	1833		|O
in	1834	1836		|O
patients	1837	1845		|O
with	1846	1850		|O
high	1851	1855		|O
-	1855	1856		|O
risk	1856	1860		|O
disease	1861	1868		|O
having	1869	1875		|O
good	1876	1880		|O
performance	1881	1892		|O
status	1893	1899		|O
.	1899	1900		|O

### 18637601
Methemoglobin	0	13		|O
levels	14	20		|O
during	21	27		|O
epidural	28	36		|O
anesthesia	37	47		|O
for	48	51		|O
renal	52	57		|O
transplantation	58	73		|O
-	73	74		|O
-	74	75		|O
comparison	75	85		|O
of	86	88		|O
prilocaine	89	99		|O
with	100	104		|O
bupivacaine	105	116		|O
.	116	117		|O
BACKGROUND	119	129		|O
AND	130	133		|O
OBJECTIVE	134	143		|O
:	143	144		|O
One	145	148		|O
goal	149	153		|O
of	154	156		|O
anesthesia	157	167		|O
for	168	171		|O
renal	172	177		|O
transplantation	178	193		|O
is	194	196		|O
to	197	199		|O
avoid	200	205		|O
an	206	208		|O
excess	209	215		|O
load	216	220		|O
to	221	223		|O
be	224	226		|O
imposed	227	234		|O
on	235	237		|O
the	238	241		|O
newly	242	247		|O
functioning	248	259		|O
kidney	260	266		|O
,	266	267		|O
by	268	270		|O
using	271	276		|O
appropriate	277	288		|O
agents	289	295		|O
and	296	299		|O
dosages	300	307		|O
in	308	310		|O
the	311	314		|O
perioperative	315	328		|O
management	329	339		|O
.	339	340		|O
The	341	344		|O
purpose	345	352		|O
of	353	355		|O
this	356	360		|O
study	361	366		|O
was	367	370		|O
to	371	373		|O
investigate	374	385		|O
the	386	389		|O
effect	390	396		|O
of	397	399		|O
prilocaine	400	410		|O
on	411	413		|O
serum	414	419		|O
methemoglobin	420	433		|O
levels	434	440		|O
when	441	445		|O
used	446	450		|O
as	451	453		|O
the	454	457		|O
local	458	463		|O
anesthetic	464	474		|O
in	475	477		|O
epidural	478	486		|O
anesthesia	487	497		|O
for	498	501		|O
renal	502	507		|O
transplantation	508	523		|O
,	523	524		|O
and	525	528		|O
to	529	531		|O
compare	532	539		|O
its	540	543		|O
effects	544	551		|O
with	552	556		|O
that	557	561		|O
of	562	564		|O
bupivacaine	565	576		|O
,	576	577		|O
which	578	583		|O
is	584	586		|O
the	587	590		|O
standard	591	599		|O
local	600	605		|O
anesthetic	606	616		|O
used	617	621		|O
.	621	622		|O
METHODS	623	630		|O
:	630	631		|O
26	632	634		|O
adult	635	640		|O
renal	641	646		|O
recipients	647	657		|O
were	658	662		|O
randomized	663	673		|O
into	674	678		|O
2	679	680		|O
equal	681	686		|O
groups	687	693		|O
according	694	703		|O
to	704	706		|O
the	707	710		|O
local	711	716		|O
anesthetic	717	727		|O
used	728	732		|O
for	733	736		|O
epidural	737	745		|O
anesthesia	746	756		|O
during	757	763		|O
the	764	767		|O
operation	768	777		|O
.	777	778		|O
Patients	779	787		|O
in	788	790		|O
group	791	796		|O
P	797	798		|O
(	799	800		|O
n	800	801		|O
=	802	803		|O
13	804	806		|O
)	806	807		|O
were	808	812		|O
given	813	818		|O
prilocaine	819	829		|O
and	830	833		|O
those	834	839		|O
in	840	842		|O
group	843	848		|O
B	849	850		|O
(	851	852		|O
control	852	859		|O
,	859	860		|O
n	861	862		|O
=	863	864		|O
13	865	867		|O
)	867	868		|O
received	869	877		|O
bupivacaine	878	889		|O
.	889	890		|O
The	891	894		|O
methemoglobin	895	908		|O
measurement	909	920		|O
intervals	921	930		|O
were	931	935		|O
at	936	938		|O
:	938	939		|O
baseline	940	948		|O
before	949	955		|O
administration	956	970		|O
of	971	973		|O
local	974	979		|O
anesthetic	980	990		|O
,	990	991		|O
and	992	995		|O
then	996	1000		|O
at	1001	1003		|O
2	1004	1005		|O
hours	1006	1011		|O
,	1011	1012		|O
5	1013	1014		|O
hours	1015	1020		|O
,	1020	1021		|O
and	1022	1025		|O
12	1026	1028		|O
hours	1029	1034		|O
of	1035	1037		|O
local	1038	1043		|O
anesthetic	1044	1054		|O
administration	1055	1069		|O
.	1069	1070		|O
RESULTS	1071	1078		|O
:	1078	1079		|O
Methemoglobin	1080	1093		|O
levels	1094	1100		|O
in	1101	1103		|O
the	1104	1107		|O
prilocaine	1108	1118		|O
group	1119	1124		|O
were	1125	1129		|O
above	1130	1135		|O
the	1136	1139		|O
normal	1140	1146		|O
range	1147	1152		|O
in	1153	1155		|O
all	1156	1159		|O
measurements	1160	1172		|O
other	1173	1178		|O
than	1179	1183		|O
baseline	1184	1192		|O
.	1192	1193		|O
In	1194	1196		|O
the	1197	1200		|O
bupivacaine	1201	1212		|O
group	1213	1218		|O
,	1218	1219		|O
methemoglobin	1220	1233		|O
levels	1234	1240		|O
increased	1241	1250		|O
only	1251	1255		|O
at	1256	1258		|O
5	1259	1260		|O
hours	1261	1266		|O
of	1267	1269		|O
local	1270	1275		|O
anesthetic	1276	1286		|O
administration	1287	1301		|O
.	1301	1302		|O
However	1303	1310		|O
,	1310	1311		|O
methemoglobin	1312	1325		|O
concentrations	1326	1340		|O
and	1341	1344		|O
hemoglobin	1345	1355		|O
levels	1356	1362		|O
were	1363	1367		|O
comparable	1368	1378		|O
between	1379	1386		|O
the	1387	1390		|O
two	1391	1394		|O
groups	1395	1401		|O
at	1402	1404		|O
all	1405	1408		|O
time	1409	1413		|O
intervals	1414	1423		|O
,	1423	1424		|O
and	1425	1428		|O
none	1429	1433		|O
of	1434	1436		|O
the	1437	1440		|O
patients	1441	1449		|O
demonstrated	1450	1462		|O
clinical	1463	1471		|O
symptoms	1472	1480		|O
.	1480	1481		|O
CONCLUSION	1482	1492		|O
:	1492	1493		|O
The	1494	1497		|O
use	1498	1501		|O
of	1502	1504		|O
prilocaine	1505	1515		|O
in	1516	1518		|O
epidural	1519	1527		|O
anesthesia	1528	1538		|O
for	1539	1542		|O
renal	1543	1548		|O
transplantation	1549	1564		|O
surgery	1565	1572		|O
resulted	1573	1581		|O
in	1582	1584		|O
an	1585	1587		|O
increase	1588	1596		|O
in	1597	1599		|O
methemoglobin	1600	1613		|O
levels	1614	1620		|O
,	1620	1621		|O
which	1622	1627		|O
did	1628	1631		|O
not	1632	1635		|O
cause	1636	1641		|O
any	1642	1645		|O
clinical	1646	1654		|O
symptoms	1655	1663		|O
and	1664	1667		|O
was	1668	1671		|O
similar	1672	1679		|O
to	1680	1682		|O
those	1683	1688		|O
of	1689	1691		|O
bupivacaine	1692	1703		|O
at	1704	1706		|O
all	1707	1710		|O
time	1711	1715		|O
measurements	1716	1728		|O
.	1728	1729		|O

### 18935781
HIV	0	3		|O
drug	4	8		|O
resistance	9	19		|O
tendencies	20	30		|O
in	31	33		|O
Latvia	34	40		|O
.	40	41		|O
The	43	46		|O
treatment	47	56		|O
of	57	59		|O
HIV	60	63	HIV infection	|B-DISEASE
infection	64	73		|I-DISEASE
in	74	76		|O
Latvia	77	83		|O
by	84	86		|O
using	87	92		|O
highly	93	99		|O
active	100	106		|O
antiretroviral	107	121		|O
therapy	122	129		|O
(	130	131		|O
HAART	131	136		|O
)	136	137		|O
was	138	141		|O
started	142	149		|O
in	150	152		|O
1996	153	157		|O
.	157	158		|O
The	159	162		|O
prevalence	163	173		|O
and	174	177		|O
tendencies	178	188		|O
of	189	191		|O
HIV	192	195		|O
drug	196	200		|O
resistance	201	211		|O
among	212	217		|O
treated	218	225		|O
and	226	229		|O
treatment	230	239		|O
-	239	240		|O
naive	240	245		|O
patients	246	254		|O
in	255	257		|O
Latvia	258	264		|O
in	265	267		|O
the	268	271		|O
years	272	277		|O
2006-2007	278	287		|O
were	288	292		|O
evaluated	293	302		|O
in	303	305		|O
this	306	310		|O
study	311	316		|O
.	316	317		|O
Data	318	322		|O
of	323	325		|O
HIV	326	329		|O
genotyping	330	340		|O
,	340	341		|O
performed	342	351		|O
in	352	354		|O
132	355	358		|O
HIV	359	362		|O
-	362	363		|O
1	363	364		|O
infected	365	373		|O
during	374	380		|O
years	381	386		|O
2006-2007	387	396		|O
by	397	399		|O
TRUGENE	400	407		|O
HIV	408	411		|O
-	411	412		|O
1	412	413		|O
genotyping	414	424		|O
assay	425	430		|O
(	431	432		|O
BayerHealthCare	432	447		|O
-	447	448		|O
diagnostics	448	459		|O
)	459	460		|O
are	461	464		|O
included	465	473		|O
in	474	476		|O
the	477	480		|O
study	481	486		|O
.	486	487		|O
Analysis	488	496		|O
of	497	499		|O
data	500	504		|O
showed	505	511		|O
that	512	516		|O
in	517	519		|O
the	520	523		|O
group	524	529		|O
of	530	532		|O
treatment	533	542		|O
-	542	543		|O
naive	543	548		|O
individuals	549	560		|O
majority	561	569		|O
carried	570	577		|O
wild	578	582		|O
type	583	587		|O
virus	588	593		|O
.	593	594		|O
Prevalence	595	605		|O
of	606	608		|O
resistance	609	619		|O
-	619	620		|O
associated	620	630		|O
mutations	631	640		|O
(	641	642		|O
RAMs	642	646		|O
)	646	647		|O
in	648	650		|O
the	651	654		|O
treatment	655	664		|O
-	664	665		|O
naive	665	670		|O
group	671	676		|O
according	677	686		|O
to	687	689		|O
IAS	690	693		|O
list	694	698		|O
was	699	702		|O
28%	703	706		|O
.	706	707		|O
In	708	710		|O
most	711	715		|O
cases	716	721		|O
it	722	724		|O
was	725	728		|O
NRTI	729	733		|O
mutation	734	742		|O
A62V	743	747		|O
that	748	752		|O
is	753	755		|O
associated	756	766		|O
with	767	771		|O
multinucleoside	772	787		|O
resistance	788	798		|O
caused	799	805		|O
by	806	808		|O
Q151M	809	814		|O
,	814	815		|O
its	816	819		|O
effect	820	826		|O
in	827	829		|O
the	830	833		|O
absence	834	841		|O
of	842	844		|O
Q151M	845	850		|O
is	851	853		|O
not	854	857		|O
known	858	863		|O
.	863	864		|O
By	865	867		|O
many	868	872		|O
authors	873	880		|O
A62V	881	885		|O
is	886	888		|O
supposed	889	897		|O
to	898	900		|O
be	901	903		|O
a	904	905		|O
result	906	912		|O
of	913	915		|O
polymorphism	916	928		|O
in	929	931		|O
RT	932	934		|O
gene	935	939		|O
and	940	943		|O
is	944	946		|O
excluded	947	955		|O
from	956	960		|O
the	961	964		|O
list	965	969		|O
of	970	972		|O
resistance	973	983		|O
mutations	984	993		|O
.	993	994		|O
High	995	999		|O
prevalence	1000	1010		|O
of	1011	1013		|O
A62V	1014	1018		|O
is	1019	1021		|O
typical	1022	1029		|O
for	1030	1033		|O
HIV	1034	1037		|O
-	1037	1038		|O
1	1038	1039		|O
subtype	1040	1047		|O
A	1048	1049		|O
.	1049	1050		|O
As	1051	1053		|O
majority	1054	1062		|O
of	1063	1065		|O
treatment	1066	1075		|O
-	1075	1076		|O
naive	1076	1081		|O
cases	1082	1087		|O
(	1088	1089		|O
89%	1089	1092		|O
)	1092	1093		|O
in	1094	1096		|O
this	1097	1101		|O
study	1102	1107		|O
were	1108	1112		|O
with	1113	1117		|O
HIV	1118	1121		|O
-	1121	1122		|O
1	1122	1123		|O
subtypes	1124	1132		|O
A	1133	1134		|O
or	1135	1137		|O
AE	1138	1140		|O
,	1140	1141		|O
we	1142	1144		|O
excluded	1145	1153		|O
A62V	1154	1158		|O
mutation	1159	1167		|O
and	1168	1171		|O
estimated	1172	1181		|O
RAMs	1182	1186		|O
prevalence	1187	1197		|O
in	1198	1200		|O
group	1201	1206		|O
of	1207	1209		|O
treatment	1210	1219		|O
-	1219	1220		|O
naive	1220	1225		|O
HIV	1226	1229		|O
-	1229	1230		|O
infected	1230	1238		|O
individuals	1239	1250		|O
as	1251	1253		|O
7%	1254	1256		|O
.	1256	1257		|O
Minor	1258	1263		|O
PI	1264	1266		|O
mutations	1267	1276		|O
were	1277	1281		|O
not	1282	1285		|O
included	1286	1294		|O
in	1295	1297		|O
analyses	1298	1306		|O
.	1306	1307		|O
In	1308	1310		|O
Europe	1311	1317		|O
published	1318	1327		|O
rates	1328	1333		|O
generally	1334	1343		|O
very	1344	1348		|O
between	1349	1356		|O
5%	1357	1359		|O
and	1360	1363		|O
15%	1364	1367		|O
.	1367	1368		|O
In	1369	1371		|O
the	1372	1375		|O
group	1376	1381		|O
of	1382	1384		|O
treatment	1385	1394		|O
-	1394	1395		|O
experienced	1395	1406		|O
HIV	1407	1410		|O
infected	1411	1419		|O
people	1420	1426		|O
25/75	1427	1432		|O
were	1433	1437		|O
with	1438	1442		|O
HIV	1443	1446		|O
-	1446	1447		|O
1	1447	1448		|O
subtype	1449	1456		|O
B	1457	1458		|O
,	1458	1459		|O
the	1460	1463		|O
rest	1464	1468		|O
part	1469	1473		|O
-	1473	1474		|O
-	1474	1475		|O
with	1475	1479		|O
non	1480	1483		|O
-	1483	1484		|O
B	1484	1485		|O
subtypes	1486	1494		|O
:	1494	1495		|O
A	1496	1497		|O
/	1497	1498		|O
AE	1498	1500		|O
(	1501	1502		|O
35/75	1502	1507		|O
)	1507	1508		|O
,	1508	1509		|O
CRF	1510	1513		|O
-	1513	1514		|O
01AE	1514	1518		|O
(	1519	1520		|O
7/75	1520	1524		|O
)	1524	1525		|O
,	1525	1526		|O
B	1527	1528		|O
/	1528	1529		|O
AE	1529	1531		|O
(	1532	1533		|O
4/75	1533	1537		|O
)	1537	1538		|O
and	1539	1542		|O
others	1543	1549		|O
.	1549	1550		|O
In	1551	1553		|O
treatment	1554	1563		|O
-	1563	1564		|O
experienced	1564	1575		|O
patients	1576	1584		|O
RAMs	1585	1589		|O
prevalence	1590	1600		|O
was	1601	1604		|O
estimated	1605	1614		|O
as	1615	1617		|O
58.6%	1618	1623		|O
.	1623	1624		|O
Most	1625	1629		|O
frequently	1630	1640		|O
RAMs	1641	1645		|O
were	1646	1650		|O
found	1651	1656		|O
for	1657	1660		|O
nucleoside	1661	1671		|O
reverse	1672	1679		|O
transcriptase	1680	1693		|O
inhibitors	1694	1704		|O
(	1705	1706		|O
NRTI	1706	1710		|O
)	1710	1711		|O
(	1712	1713		|O
49.3%	1713	1718		|O
)	1718	1719		|O
followed	1720	1728		|O
by	1729	1731		|O
non	1732	1735		|O
-	1735	1736		|O
nucleoside	1736	1746		|O
reverse	1747	1754		|O
transcriptase	1755	1768		|O
inhibitors	1769	1779		|O
(	1780	1781		|O
NNRTI	1781	1786		|O
)	1786	1787		|O
(	1788	1789		|O
22.6%	1789	1794		|O
)	1794	1795		|O
and	1796	1799		|O
protease	1800	1808		|O
inhibitors	1809	1819		|O
(	1820	1821		|O
PI	1821	1823		|O
)	1823	1824		|O
(	1825	1826		|O
16%	1826	1829		|O
)	1829	1830		|O
.	1830	1831		|O
In	1832	1834		|O
the	1835	1838		|O
group	1839	1844		|O
of	1845	1847		|O
NRTI	1848	1852		|O
mutations	1853	1862		|O
M184V	1863	1868		|O
(	1869	1870		|O
26/75	1870	1875		|O
;	1875	1876		|O
34.6%	1877	1882		|O
)	1882	1883		|O
,	1883	1884		|O
A62V	1885	1889		|O
(	1890	1891		|O
12/75	1891	1896		|O
;	1896	1897		|O
16.0%	1898	1903		|O
)	1903	1904		|O
and	1905	1908		|O
T215Y	1909	1914		|O
(	1915	1916		|O
8/75	1916	1920		|O
;	1920	1921		|O
10.6%	1922	1927		|O
)	1927	1928		|O
,	1928	1929		|O
in	1930	1932		|O
NNRTI	1933	1938		|O
mutations	1939	1948		|O
K103N	1949	1954		|O
(	1955	1956		|O
10/75	1956	1961		|O
;	1961	1962		|O
13.3%	1963	1968		|O
)	1968	1969		|O
,	1969	1970		|O
G190S	1971	1976		|O
(	1977	1978		|O
6/75	1978	1982		|O
;	1982	1983		|O
8.0%	1984	1988		|O
)	1988	1989		|O
,	1989	1990		|O
in	1991	1993		|O
PI	1994	1996		|O
group	1997	2002		|O
mutations	2003	2012		|O
L90M	2013	2017		|O
(	2018	2019		|O
6/75	2019	2023		|O
;	2023	2024		|O
8.0%	2025	2029		|O
)	2029	2030		|O
and	2031	2034		|O
M461	2035	2039		|O
/	2039	2040		|O
L	2040	2041		|O
(	2042	2043		|O
6/75	2043	2047		|O
;	2047	2048		|O
8.0%	2049	2053		|O
)	2053	2054		|O
occurred	2055	2063		|O
most	2064	2068		|O
frequently	2069	2079		|O
.	2079	2080		|O
The	2081	2084		|O
following	2085	2094		|O
drug	2095	2099		|O
susceptibility	2100	2114		|O
was	2115	2118		|O
predicted	2119	2128		|O
according	2129	2138		|O
to	2139	2141		|O
the	2142	2145		|O
Trugen	2146	2152		|O
expert	2153	2159		|O
interpretations	2160	2175		|O
:	2175	2176		|O
in	2177	2179		|O
33/75	2180	2185		|O
(	2186	2187		|O
44%	2187	2190		|O
)	2190	2191		|O
patients	2192	2200		|O
no	2201	2203		|O
evidence	2204	2212		|O
of	2213	2215		|O
resistance	2216	2226		|O
,	2226	2227		|O
in	2228	2230		|O
21/75	2231	2236		|O
(	2237	2238		|O
28%	2238	2241		|O
)	2241	2242		|O
patients	2243	2251		|O
resistance	2252	2262		|O
to	2263	2265		|O
1	2266	2267		|O
drug	2268	2272		|O
class	2273	2278		|O
(	2279	2280		|O
NRTI	2280	2284		|O
-	2284	2285		|O
-	2285	2286		|O
16/75	2286	2291		|O
,	2291	2292		|O
NNRTI	2293	2298		|O
-	2298	2299		|O
-	2299	2300		|O
4/75	2300	2304		|O
,	2304	2305		|O
PI	2306	2308		|O
-	2308	2309		|O
-	2309	2310		|O
1/75	2310	2314		|O
)	2314	2315		|O
,	2315	2316		|O
in	2317	2319		|O
17	2320	2322		|O
patients	2323	2331		|O
(	2332	2333		|O
22.6%	2333	2338		|O
)	2338	2339		|O
resistance	2340	2350		|O
to	2351	2353		|O
2	2354	2355		|O
drug	2356	2360		|O
classes	2361	2368		|O
(	2369	2370		|O
NRTI+	2370	2375		|O
NNRTI	2375	2380		|O
-	2380	2381		|O
-	2381	2382		|O
9/75	2382	2386		|O
,	2386	2387		|O
NRTI+	2388	2393		|O
PI	2393	2395		|O
-	2395	2396		|O
-	2396	2397		|O
7/75	2397	2401		|O
,	2401	2402		|O
NNRTI+	2403	2409		|O
PI	2409	2411		|O
-	2411	2412		|O
-	2412	2413		|O
1/75	2413	2417		|O
)	2417	2418		|O
and	2419	2422		|O
in	2423	2425		|O
3/75	2426	2430		|O
(	2431	2432		|O
4%	2432	2434		|O
)	2434	2435		|O
patients	2436	2444		|O
resistance	2445	2455		|O
to	2456	2458		|O
all	2459	2462		|O
3	2463	2464		|O
classes	2465	2472		|O
of	2473	2475		|O
drugs	2476	2481		|O
(	2482	2483		|O
NRTI+	2483	2488		|O
NNRTI+	2488	2494		|O
PI	2494	2496		|O
)	2496	2497		|O
.	2497	2498		|O
We	2499	2501		|O
conclude	2502	2510		|O
,	2510	2511		|O
that	2512	2516		|O
prevalence	2517	2527		|O
of	2528	2530		|O
RAMs	2531	2535		|O
in	2536	2538		|O
treatment	2539	2548		|O
-	2548	2549		|O
naive	2549	2554		|O
HIV	2555	2558		|O
infected	2559	2567		|O
persons	2568	2575		|O
in	2576	2578		|O
Latvia	2579	2585		|O
is	2586	2588		|O
comparable	2589	2599		|O
with	2600	2604		|O
prevalence	2605	2615		|O
in	2616	2618		|O
Europe	2619	2625		|O
.	2625	2626		|O
The	2627	2630		|O
origin	2631	2637		|O
of	2638	2640		|O
predominated	2641	2653		|O
mutation	2654	2662		|O
A62V	2663	2667		|O
associated	2668	2678		|O
with	2679	2683		|O
NRTI	2684	2688		|O
at	2689	2691		|O
present	2692	2699		|O
is	2700	2702		|O
not	2703	2706		|O
clear	2707	2712		|O
.	2712	2713		|O
In	2714	2716		|O
more	2717	2721		|O
than	2722	2726		|O
half	2727	2731		|O
of	2732	2734		|O
treated	2735	2742		|O
HIV	2743	2746		|O
infected	2747	2755		|O
patients	2756	2764		|O
HIV	2765	2768		|O
resistance	2769	2779		|O
to	2780	2782		|O
at	2783	2785		|O
least	2786	2791		|O
one	2792	2795		|O
HAART	2796	2801		|O
class	2802	2807		|O
was	2808	2811		|O
predicted	2812	2821		|O
.	2821	2822		|O

### 18622878
Ibuprofen	0	9		|O
slow	10	14		|O
-	14	15		|O
release	15	22		|O
foam	23	27		|O
dressing	28	36		|O
reduces	37	44		|O
wound	45	50	wound pain	|B-DISEASE
pain	51	55		|I-DISEASE
in	56	58		|O
painful	59	66		|O
exuding	67	74		|O
wounds	75	81		|O
:	81	82		|O
preliminary	83	94		|O
findings	95	103		|O
from	104	108		|O
an	109	111		|O
international	112	125		|O
real	126	130		|O
-	130	131		|O
life	131	135		|O
study	136	141		|O
.	141	142		|O
BACKGROUND	144	154		|O
:	154	155		|O
Wound	156	161	Wound pain	|B-DISEASE
pain	162	166		|I-DISEASE
is	167	169		|O
a	170	171		|O
serious	172	179		|O
problem	180	187		|O
for	188	191		|O
people	192	198		|O
with	199	203		|O
chronic	204	211	chronic wounds	|B-DISEASE
wounds	212	218		|I-DISEASE
.	218	219		|O
The	220	223		|O
aim	224	227		|O
of	228	230		|O
this	231	235		|O
real	236	240		|O
-	240	241		|O
life	241	245		|O
study	246	251		|O
was	252	255		|O
to	256	258		|O
compare	259	266		|O
the	267	270		|O
effect	271	277		|O
of	278	280		|O
a	281	282		|O
foam	283	287		|O
dressing	288	296		|O
that	297	301		|O
releases	302	310		|O
ibuprofen	311	320		|O
(	321	322		|O
Biatain	322	329		|O
Ibu	330	333		|O
)	333	334		|O
with	335	339		|O
local	340	345		|O
best	346	350		|O
practice	351	359		|O
on	360	362		|O
the	363	366		|O
treatment	367	376		|O
of	377	379		|O
painful	380	387	painful exuding wounds	|B-DISEASE
exuding	388	395		|I-DISEASE
wounds	396	402		|I-DISEASE
.	402	403		|O
METHODS	404	411		|O
:	411	412		|O
A	413	414		|O
total	415	420		|O
of	421	423		|O
185	424	427		|O
patients	428	436		|O
with	437	441		|O
painful	442	449	painful exuding wounds	|B-DISEASE
exuding	450	457		|I-DISEASE
wounds	458	464		|I-DISEASE
were	465	469		|O
randomized	470	480		|O
to	481	483		|O
either	484	490		|O
ibuprofen	491	500		|O
foam	501	505		|O
treatment	506	515		|O
(	516	517		|O
n	517	518		|O
=	519	520		|O
98	521	523		|O
)	523	524		|O
or	525	527		|O
local	528	533		|O
best	534	538		|O
practice	539	547		|O
(	548	549		|O
n	549	550		|O
=	551	552		|O
87	553	555		|O
)	555	556		|O
.	556	557		|O
The	558	561		|O
primary	562	569		|O
endpoint	570	578		|O
was	579	582		|O
pain	583	587	pain	|B-DISEASE
relief	588	594		|O
over	595	599		|O
7	600	601		|O
days	602	606		|O
of	607	609		|O
treatment	610	619		|O
,	619	620		|O
assessed	621	629		|O
daily	630	635		|O
using	636	641		|O
a	642	643		|O
5	644	645		|O
-	645	646		|O
point	646	651		|O
verbal	652	658		|O
rating	659	665		|O
scale	666	671		|O
(	672	673		|O
no	673	675		|O
relief	676	682		|O
,	682	683		|O
slight	684	690		|O
relief	691	697		|O
,	697	698		|O
moderate	699	707		|O
relief	708	714		|O
,	714	715		|O
lots	716	720		|O
of	721	723		|O
relief	724	730		|O
,	730	731		|O
and	732	735		|O
complete	736	744		|O
relief	745	751		|O
)	751	752		|O
.	752	753		|O
Secondary	754	763		|O
endpoints	764	773		|O
included	774	782		|O
a	783	784		|O
total	785	790		|O
reduction	791	800		|O
in	801	803		|O
pain	804	808	pain	|B-DISEASE
intensity	809	818		|O
for	819	822		|O
the	823	826		|O
whole	827	832		|O
study	833	838		|O
period	839	845		|O
(	846	847		|O
using	847	852		|O
an	853	855		|O
11	856	858		|O
-	858	859		|O
point	859	864		|O
Numeric	865	872		|O
Box	873	876		|O
Scale	877	882		|O
:	882	883		|O
0	884	885		|O
=	886	887		|O
no	888	890		|O
pain	891	895	pain	|B-DISEASE
to	896	898		|O
10	899	901		|O
=	902	903		|O
worst	904	909		|O
possible	910	918		|O
pain	919	923	pain	|B-DISEASE
)	923	924		|O
and	925	928		|O
incidence	929	938		|O
of	939	941		|O
adverse	942	949		|O
events	950	956		|O
(	957	958		|O
AEs	958	961		|O
)	961	962		|O
.	962	963		|O
RESULTS	964	971		|O
:	971	972		|O
More	973	977		|O
patients	978	986		|O
in	987	989		|O
the	990	993		|O
ibuprofen	994	1003		|O
foam	1004	1008		|O
treatment	1009	1018		|O
group	1019	1024		|O
reported	1025	1033		|O
wound	1034	1039	wound pain	|B-DISEASE
pain	1040	1044		|I-DISEASE
relief	1045	1051		|O
and	1052	1055		|O
lower	1056	1061		|O
wound	1062	1067	wound pain	|B-DISEASE
pain	1068	1072		|I-DISEASE
intensity	1073	1082		|O
values	1083	1089		|O
after	1090	1095		|O
7	1096	1097		|O
days	1098	1102		|O
(	1103	1104		|O
p	1104	1105		|O
<	1106	1107		|O
0.0001	1108	1114		|O
for	1115	1118		|O
both	1119	1123		|O
variables	1124	1133		|O
)	1133	1134		|O
.	1134	1135		|O
Within	1136	1142		|O
the	1143	1146		|O
four	1147	1151		|O
most	1152	1156		|O
common	1157	1163		|O
ulcer	1164	1169	ulcer aetiolgies	|B-DISEASE
aetiolgies	1170	1180		|I-DISEASE
,	1180	1181		|O
patients	1182	1190		|O
reported	1191	1199		|O
significantly	1200	1213		|O
more	1214	1218		|O
effective	1219	1228		|O
pain	1229	1233	pain	|B-DISEASE
relief	1234	1240		|O
with	1241	1245		|O
ibuprofen	1246	1255		|O
foam	1256	1260		|O
treatment	1261	1270		|O
(	1271	1272		|O
venous	1272	1278		|O
:	1278	1279		|O
p	1280	1281		|O
=	1282	1283		|O
0.009	1284	1289		|O
,	1289	1290		|O
mixed	1291	1296		|O
arterial	1297	1305		|O
venous	1306	1312		|O
:	1312	1313		|O
p	1314	1315		|O
<	1316	1317		|O
0.0001	1318	1324		|O
,	1324	1325		|O
arterial	1326	1334		|O
:	1334	1335		|O
p	1336	1337		|O
=	1338	1339		|O
0.0009	1340	1346		|O
,	1346	1347		|O
and	1348	1351		|O
vasculitis	1352	1362	vasculitis	|B-DISEASE
:	1362	1363		|O
p	1364	1365		|O
=	1366	1367		|O
0.009	1368	1373		|O
)	1373	1374		|O
.	1374	1375		|O
In	1376	1378		|O
all	1379	1382		|O
groups	1383	1389		|O
,	1389	1390		|O
patients	1391	1399		|O
from	1400	1404		|O
the	1405	1408		|O
ibuprofen	1409	1418		|O
foam	1419	1423		|O
group	1424	1429		|O
reported	1430	1438		|O
lower	1439	1444		|O
pain	1445	1449	pain	|B-DISEASE
intensities	1450	1461		|O
.	1461	1462		|O
The	1463	1466		|O
results	1467	1474		|O
were	1475	1479		|O
significant	1480	1491		|O
for	1492	1495		|O
patients	1496	1504		|O
with	1505	1509		|O
venous	1510	1516		|O
(	1517	1518		|O
p	1518	1519		|O
<	1520	1521		|O
0.002	1522	1527		|O
)	1527	1528		|O
and	1529	1532		|O
arterial	1533	1541		|O
(	1542	1543		|O
p	1543	1544		|O
<	1545	1546		|O
0.0001	1547	1553		|O
)	1553	1554		|O
leg	1555	1558	leg ulcers	|B-DISEASE
ulcers	1559	1565		|I-DISEASE
.	1565	1566		|O
Two	1567	1570		|O
AEs	1571	1574		|O
were	1575	1579		|O
reported	1580	1588		|O
.	1588	1589		|O
CONCLUSIONS	1590	1601		|O
:	1601	1602		|O
The	1603	1606		|O
ibuprofen	1607	1616		|O
foam	1617	1621		|O
represents	1622	1632		|O
an	1633	1635		|O
effective	1636	1645		|O
and	1646	1649		|O
safe	1650	1654		|O
alternative	1655	1666		|O
to	1667	1669		|O
local	1670	1675		|O
best	1676	1680		|O
practice	1681	1689		|O
in	1690	1692		|O
the	1693	1696		|O
management	1697	1707		|O
of	1708	1710		|O
painful	1711	1718	painful exuding wounds	|B-DISEASE
exuding	1719	1726		|I-DISEASE
wounds	1727	1733		|I-DISEASE
.	1733	1734		|O

### 18628067
Histone	0	7		|O
deacetylase	8	19		|O
inhibitors	20	30		|O
:	30	31		|O
mechanism	32	41		|O
of	42	44		|O
action	45	51		|O
and	52	55		|O
therapeutic	56	67		|O
use	68	71		|O
in	72	74		|O
cancer	75	81	cancer	|B-DISEASE
.	81	82		|O
Histone	84	91		|O
deacetylases	92	104		|O
(	105	106		|O
HDACs	106	111		|O
)	111	112		|O
remove	113	119		|O
the	120	123		|O
acetyl	124	130		|O
groups	131	137		|O
of	138	140		|O
lysine	141	147		|O
residues	148	156		|O
of	157	159		|O
histone	160	167		|O
tails	168	173		|O
leading	174	181		|O
to	182	184		|O
chromatin	185	194		|O
compaction	195	205		|O
and	206	209		|O
transcriptional	210	225		|O
repression	226	236		|O
.	236	237		|O
In	238	240		|O
addition	241	249		|O
,	249	250		|O
HDACs	251	256		|O
can	257	260		|O
also	261	265		|O
influence	266	275		|O
transcription	276	289		|O
-	289	290		|O
independent	290	301		|O
events	302	308		|O
such	309	313		|O
as	314	316		|O
mitosis	317	324		|O
or	325	327		|O
deoxyribonucleic	328	344		|O
acid	345	349		|O
(	350	351		|O
DNA	351	354		|O
)	354	355		|O
repair	356	362		|O
and	363	366		|O
deacetylate	367	378		|O
nonhistone	379	389		|O
proteins	390	398		|O
involved	399	407		|O
in	408	410		|O
cell	411	415		|O
proliferation	416	429		|O
and	430	433		|O
death	434	439		|O
,	439	440		|O
altering	441	449		|O
their	450	455		|O
function	456	464		|O
.	464	465		|O
Histone	466	473		|O
deacetylase	474	485		|O
inhibitors	486	496		|O
(	497	498		|O
HDACi	498	503		|O
)	503	504		|O
constitute	505	515		|O
a	516	517		|O
promising	518	527		|O
treatment	528	537		|O
for	538	541		|O
cancer	542	548	cancer	|B-DISEASE
therapy	549	556		|O
due	557	560		|O
to	561	563		|O
their	564	569		|O
low	570	573		|O
toxicity	574	582		|O
.	582	583		|O
HDACi	584	589		|O
have	590	594		|O
been	595	599		|O
shown	600	605		|O
to	606	608		|O
induce	609	615		|O
differentiation	616	631		|O
,	631	632		|O
cell	633	637		|O
-	637	638		|O
cycle	638	643		|O
arrest	644	650		|O
,	650	651		|O
and	652	655		|O
apoptosis	656	665		|O
and	666	669		|O
to	670	672		|O
inhibit	673	680		|O
migration	681	690		|O
,	690	691		|O
invasion	692	700		|O
,	700	701		|O
and	702	705		|O
angiogenesis	706	718		|O
in	719	721		|O
many	722	726		|O
cancer	727	733		|O
cell	734	738		|O
lines	739	744		|O
.	744	745		|O
In	746	748		|O
addition	749	757		|O
,	757	758		|O
these	759	764		|O
compounds	765	774		|O
inhibit	775	782		|O
tumor	783	788		|O
growth	789	795		|O
in	796	798		|O
animal	799	805		|O
models	806	812		|O
and	813	816		|O
show	817	821		|O
antitumor	822	831		|O
activity	832	840		|O
in	841	843		|O
patients	844	852		|O
.	852	853		|O
HDACi	854	859		|O
alone	860	865		|O
and	866	869		|O
in	870	872		|O
combination	873	884		|O
with	885	889		|O
a	890	891		|O
variety	892	899		|O
of	900	902		|O
anticancer	903	913		|O
drugs	914	919		|O
are	920	923		|O
being	924	929		|O
tested	930	936		|O
in	937	939		|O
clinical	940	948		|O
trials	949	955		|O
,	955	956		|O
showing	957	964		|O
significant	965	976		|O
anticancer	977	987		|O
activity	988	996		|O
both	997	1001		|O
in	1002	1004		|O
hematological	1005	1018		|O
and	1019	1022		|O
solid	1023	1028		|O
tumors	1029	1035		|O
.	1035	1036		|O
SAHA	1037	1041		|O
(	1042	1043		|O
vorinostat	1043	1053		|O
,	1053	1054		|O
Zolinza	1055	1062		|O
)	1062	1063		|O
was	1064	1067		|O
the	1068	1071		|O
first	1072	1077		|O
HDACi	1078	1083		|O
approved	1084	1092		|O
by	1093	1095		|O
the	1096	1099		|O
US	1100	1102		|O
Food	1103	1107		|O
and	1108	1111		|O
Drug	1112	1116		|O
Administration	1117	1131		|O
to	1132	1134		|O
enter	1135	1140		|O
the	1141	1144		|O
clinical	1145	1153		|O
oncology	1154	1162		|O
market	1163	1169		|O
for	1170	1173		|O
treating	1174	1182		|O
cutaneous	1183	1192	cutaneous T-cell lymphoma	|B-DISEASE
T	1193	1194		|I-DISEASE
-	1194	1195		|I-DISEASE
cell	1195	1199		|I-DISEASE
lymphoma	1200	1208		|I-DISEASE
(	1209	1210		|O
CTCL	1210	1214	CTCL	|B-DISEASE
)	1214	1215		|O
and	1216	1219		|O
is	1220	1222		|O
being	1223	1228		|O
tested	1229	1235		|O
for	1236	1239		|O
other	1240	1245		|O
malignancies	1246	1258	malignancies	|B-DISEASE
.	1258	1259		|O

### 18726697
CNS	0	3		|O
delivery	4	12		|O
via	13	16		|O
adsorptive	17	27		|O
transcytosis	28	40		|O
.	40	41		|O
Adsorptive	43	53		|O
-	53	54		|O
mediated	54	62		|O
transcytosis	63	75		|O
(	76	77		|O
AMT	77	80		|O
)	80	81		|O
provides	82	90		|O
a	91	92		|O
means	93	98		|O
for	99	102		|O
brain	103	108		|O
delivery	109	117		|O
of	118	120		|O
medicines	121	130		|O
across	131	137		|O
the	138	141		|O
blood	142	147		|O
-	147	148		|O
brain	148	153		|O
barrier	154	161		|O
(	162	163		|O
BBB	163	166		|O
)	166	167		|O
.	167	168		|O
The	169	172		|O
BBB	173	176		|O
is	177	179		|O
readily	180	187		|O
equipped	188	196		|O
for	197	200		|O
the	201	204		|O
AMT	205	208		|O
process	209	216		|O
:	216	217		|O
it	218	220		|O
provides	221	229		|O
both	230	234		|O
the	235	238		|O
potential	239	248		|O
for	249	252		|O
binding	253	260		|O
and	261	264		|O
uptake	265	271		|O
of	272	274		|O
cationic	275	283		|O
molecules	284	293		|O
to	294	296		|O
the	297	300		|O
luminal	301	308		|O
surface	309	316		|O
of	317	319		|O
endothelial	320	331		|O
cells	332	337		|O
,	337	338		|O
and	339	342		|O
then	343	347		|O
for	348	351		|O
exocytosis	352	362		|O
at	363	365		|O
the	366	369		|O
abluminal	370	379		|O
surface	380	387		|O
.	387	388		|O
The	389	392		|O
transcytotic	393	405		|O
pathways	406	414		|O
present	415	422		|O
at	423	425		|O
the	426	429		|O
BBB	430	433		|O
and	434	437		|O
its	438	441		|O
morphological	442	455		|O
and	456	459		|O
enzymatic	460	469		|O
properties	470	480		|O
provide	481	488		|O
the	489	492		|O
means	493	498		|O
for	499	502		|O
movement	503	511		|O
of	512	514		|O
the	515	518		|O
molecules	519	528		|O
through	529	536		|O
the	537	540		|O
endothelial	541	552		|O
cytoplasm	553	562		|O
.	562	563		|O
AMT	564	567		|O
-	567	568		|O
based	568	573		|O
drug	574	578		|O
delivery	579	587		|O
to	588	590		|O
the	591	594		|O
brain	595	600		|O
was	601	604		|O
performed	605	614		|O
using	615	620		|O
cationic	621	629		|O
proteins	630	638		|O
and	639	642		|O
cell	643	647		|O
-	647	648		|O
penetrating	648	659		|O
peptides	660	668		|O
(	669	670		|O
CPPs	670	674		|O
)	674	675		|O
.	675	676		|O
Protein	677	684		|O
cationization	685	698		|O
using	699	704		|O
either	705	711		|O
synthetic	712	721		|O
or	722	724		|O
natural	725	732		|O
polyamines	733	743		|O
is	744	746		|O
discussed	747	756		|O
and	757	760		|O
some	761	765		|O
examples	766	774		|O
of	775	777		|O
diamine	778	785		|O
/	785	786		|O
polyamine	786	795		|O
modified	796	804		|O
proteins	805	813		|O
that	814	818		|O
cross	819	824		|O
BBB	825	828		|O
are	829	832		|O
described	833	842		|O
.	842	843		|O
Two	844	847		|O
main	848	852		|O
families	853	861		|O
of	862	864		|O
CPPs	865	869		|O
belonging	870	879		|O
to	880	882		|O
the	883	886		|O
Tat	887	890		|O
-	890	891		|O
derived	891	898		|O
peptides	899	907		|O
and	908	911		|O
Syn	912	915		|O
-	915	916		|O
B	916	917		|O
vectors	918	925		|O
have	926	930		|O
been	931	935		|O
extensively	936	947		|O
used	948	952		|O
in	953	955		|O
CPP	956	959		|O
vector	960	966		|O
-	966	967		|O
mediated	967	975		|O
strategies	976	986		|O
allowing	987	995		|O
delivery	996	1004		|O
of	1005	1007		|O
a	1008	1009		|O
large	1010	1015		|O
variety	1016	1023		|O
of	1024	1026		|O
small	1027	1032		|O
molecules	1033	1042		|O
as	1043	1045		|O
well	1046	1050		|O
as	1051	1053		|O
proteins	1054	1062		|O
across	1063	1069		|O
cell	1070	1074		|O
membranes	1075	1084		|O
in	1085	1087		|O
vitro	1088	1093		|O
and	1094	1097		|O
the	1098	1101		|O
BBB	1102	1105		|O
in	1106	1108		|O
vivo	1109	1113		|O
.	1113	1114		|O
CPP	1115	1118		|O
strategy	1119	1127		|O
suffers	1128	1135		|O
from	1136	1140		|O
several	1141	1148		|O
limitations	1149	1160		|O
such	1161	1165		|O
as	1166	1168		|O
toxicity	1169	1177		|O
and	1178	1181		|O
immunogenicity	1182	1196	immunogenicity	|B-ADVERSE
-	1196	1197		|O
-	1197	1198		|O
like	1198	1202		|O
the	1203	1206		|O
cationization	1207	1220		|O
strategy	1221	1229		|O
-	1229	1230		|O
-	1230	1231		|O
as	1231	1233		|O
well	1234	1238		|O
as	1239	1241		|O
the	1242	1245		|O
instability	1246	1257		|O
of	1258	1260		|O
peptide	1261	1268		|O
vectors	1269	1276		|O
in	1277	1279		|O
biological	1280	1290		|O
media	1291	1296		|O
.	1296	1297		|O
The	1298	1301		|O
review	1302	1308		|O
concludes	1309	1318		|O
by	1319	1321		|O
stressing	1322	1331		|O
the	1332	1335		|O
need	1336	1340		|O
to	1341	1343		|O
improve	1344	1351		|O
the	1352	1355		|O
understanding	1356	1369		|O
of	1370	1372		|O
AMT	1373	1376		|O
mechanisms	1377	1387		|O
at	1388	1390		|O
BBB	1391	1394		|O
and	1395	1398		|O
the	1399	1402		|O
effectiveness	1403	1416		|O
of	1417	1419		|O
cationized	1420	1430		|O
proteins	1431	1439		|O
and	1440	1443		|O
CPP	1444	1447		|O
-	1447	1448		|O
vectorized	1448	1458		|O
proteins	1459	1467		|O
as	1468	1470		|O
neurotherapeutics	1471	1488		|O
.	1488	1489		|O

### 18594138
Simvastatin	0	11		|O
-	11	12		|O
induced	12	19		|O
rhabdomyolysis	20	34	rhabdomyolysis	|B-ADVERSE
and	35	38		|O
acute	39	44	acute renal injury	|B-ADVERSE
renal	45	50		|I-ADVERSE
injury	51	57		|I-ADVERSE
.	57	58		|O
Simvastatin	60	71		|O
is	72	74		|O
one	75	78		|O
of	79	81		|O
the	82	85		|O
most	86	90		|O
commonly	91	99		|O
prescribed	100	110		|O
CoA	111	114		|O
reductase	115	124		|O
inhibitors	125	135		|O
.	135	136		|O
The	137	140		|O
safety	141	147		|O
profile	148	155		|O
of	156	158		|O
this	159	163		|O
drug	164	168		|O
has	169	172		|O
been	173	177		|O
widely	178	184		|O
discussed	185	194		|O
in	195	197		|O
the	198	201		|O
medical	202	209		|O
and	210	213		|O
consumer	214	222		|O
advocacy	223	231		|O
communities	232	243		|O
.	243	244		|O
Like	245	249		|O
other	250	255		|O
statins	256	263		|O
,	263	264		|O
simvastatin	265	276		|O
can	277	280		|O
cause	281	286		|O
a	287	288		|O
serious	289	296		|O
and	297	300		|O
potentially	301	312		|O
life	313	317		|O
-	317	318		|O
threatening	318	329		|O
complication	330	342		|O
:	342	343		|O
rhabdomyolysis	344	358	rhabdomyolysis	|B-ADVERSE
.	358	359		|O
We	360	362		|O
describe	363	371		|O
a	372	373		|O
case	374	378		|O
of	379	381		|O
simvastatin	382	393		|O
-	393	394		|O
induced	394	401		|O
rhabdomyolysis	402	416	rhabdomyolysis	|B-ADVERSE
complicated	417	428		|O
by	429	431		|O
acute	432	437	acute renal failure	|B-ADVERSE
renal	438	443		|I-ADVERSE
failure	444	451		|I-ADVERSE
requiring	452	461		|O
urgent	462	468		|O
hemodialysis	469	481		|O
.	481	482		|O
The	483	486		|O
relative	487	495		|O
safety	496	502		|O
of	503	505		|O
simvastatin	506	517		|O
compared	518	526		|O
to	527	529		|O
other	530	535		|O
HMG	536	539		|O
-	539	540		|O
CoA	540	543		|O
reductase	544	553		|O
inhibitors	554	564		|O
and	565	568		|O
the	569	572		|O
conditions	573	583		|O
that	584	588		|O
can	589	592		|O
potentiate	593	603		|O
its	604	607		|O
toxicity	608	616		|O
are	617	620		|O
discussed	621	630		|O
.	630	631		|O
The	632	635		|O
clinical	636	644		|O
features	645	653		|O
of	654	656		|O
rhabdomyolysis	657	671	rhabdomyolysis	|B-ADVERSE
,	671	672		|O
and	673	676		|O
subsequent	677	687		|O
acute	688	693	acute renal failure	|B-ADVERSE
renal	694	699		|I-ADVERSE
failure	700	707		|I-ADVERSE
,	707	708		|O
and	709	712		|O
their	713	718		|O
treatment	719	728		|O
modalities	729	739		|O
are	740	743		|O
presented	744	753		|O
.	753	754		|O

### 18752977
The	0	3		|O
reduction	4	13		|O
in	14	16		|O
visceral	17	25		|O
fat	26	29		|O
mass	30	34		|O
in	35	37		|O
response	38	46		|O
to	47	49		|O
growth	50	56		|O
hormone	57	64		|O
is	65	67		|O
more	68	72		|O
marked	73	79		|O
in	80	82		|O
men	83	86		|O
than	87	91		|O
in	92	94		|O
oestrogen	95	104		|O
-	104	105		|O
deficient	105	114		|O
women	115	120		|O
.	120	121		|O
CONTEXT	123	130		|O
:	130	131		|O
Women	132	137		|O
with	138	142		|O
severe	143	149		|O
growth	150	156	growth hormone (GH) deficiency	|B-DISEASE
hormone	157	164		|I-DISEASE
(	165	166		|I-DISEASE
GH	166	168		|I-DISEASE
)	168	169		|I-DISEASE
deficiency	170	180		|I-DISEASE
have	181	185		|O
a	186	187		|O
less	188	192		|O
marked	193	199		|O
response	200	208		|O
to	209	211		|O
GH	212	214		|O
replacement	215	226		|O
than	227	231		|O
men	232	235		|O
.	235	236		|O
This	237	241		|O
has	242	245		|O
mostly	246	252		|O
been	253	257		|O
attributed	258	268		|O
to	269	271		|O
the	272	275		|O
attenuating	276	287		|O
effects	288	295		|O
of	296	298		|O
oestrogen	299	308		|O
replacement	309	320		|O
therapy	321	328		|O
.	328	329		|O
OBJECTIVE	330	339		|O
:	339	340		|O
To	341	343		|O
study	344	349		|O
gender	350	356		|O
related	357	364		|O
differences	365	376		|O
in	377	379		|O
the	380	383		|O
response	384	392		|O
to	393	395		|O
GH	396	398		|O
treatment	399	408		|O
in	409	411		|O
men	412	415		|O
and	416	419		|O
postmenopausal	420	434		|O
women	435	440		|O
.	440	441		|O
METHODS	442	449		|O
:	449	450		|O
Fifteen	451	458		|O
men	459	462		|O
and	463	466		|O
15	467	469		|O
age	470	473		|O
-	473	474		|O
and	475	478		|O
BMI	479	482		|O
-	482	483		|O
matched	483	490		|O
women	491	496		|O
with	497	501		|O
abdominal	502	511	abdominal obesity	|B-DISEASE
obesity	512	519		|I-DISEASE
(	520	521		|O
mean	521	525		|O
age	526	529		|O
:	529	530		|O
58	531	533		|O
;	533	534		|O
range	535	540		|O
51-64	541	546		|O
years	547	552		|O
)	552	553		|O
were	554	558		|O
treated	559	566		|O
for	567	570		|O
one	571	574		|O
year	575	579		|O
with	580	584		|O
similar	585	592		|O
doses	593	598		|O
(	599	600		|O
0.47	600	604		|O
vs.	605	608		|O
0.51	609	613		|O
mg	614	616		|O
/	616	617		|O
day	617	620		|O
)	620	621		|O
of	622	624		|O
GH	625	627		|O
.	627	628		|O
All	629	632		|O
women	633	638		|O
were	639	643		|O
postmenopausal	644	658		|O
not	659	662		|O
receiving	663	672		|O
oestrogen	673	682		|O
treatment	683	692		|O
.	692	693		|O
Insulin	694	701		|O
sensitivity	702	713		|O
was	714	717		|O
assessed	718	726		|O
using	727	732		|O
a	733	734		|O
hyperinsulinemic	735	751		|O
euglycemic	752	762		|O
clamp	763	768		|O
and	769	772		|O
body	773	777		|O
composition	778	789		|O
by	790	792		|O
computed	793	801		|O
tomography	802	812		|O
(	813	814		|O
CT	814	816		|O
)	816	817		|O
scans	818	823		|O
and	824	827		|O
from	828	832		|O
total	833	838		|O
body	839	843		|O
potassium	844	853		|O
,	853	854		|O
K	855	856		|O
(	856	857		|O
40	857	859		|O
)	859	860		|O
.	860	861		|O
RESULTS	862	869		|O
:	869	870		|O
Men	871	874		|O
and	875	878		|O
women	879	884		|O
were	885	889		|O
comparable	890	900		|O
at	901	903		|O
baseline	904	912		|O
in	913	915		|O
terms	916	921		|O
of	922	924		|O
waist	925	930		|O
circumference	931	944		|O
,	944	945		|O
IGF	946	949		|O
-	949	950		|O
1	950	951		|O
and	952	955		|O
lipid	956	961		|O
levels	962	968		|O
.	968	969		|O
After	970	975		|O
one	976	979		|O
year	980	984		|O
of	985	987		|O
GH	988	990		|O
treatment	991	1000		|O
,	1000	1001		|O
there	1002	1007		|O
was	1008	1011		|O
a	1012	1013		|O
18%	1014	1017		|O
reduction	1018	1027		|O
in	1028	1030		|O
visceral	1031	1039		|O
adipose	1040	1047		|O
tissue	1048	1054		|O
(	1055	1056		|O
VAT	1056	1059		|O
)	1059	1060		|O
in	1061	1063		|O
men	1064	1067		|O
and	1068	1071		|O
a	1072	1073		|O
5%	1074	1076		|O
reduction	1077	1086		|O
in	1087	1089		|O
women	1090	1095		|O
(	1096	1097		|O
P	1097	1098		|O
=	1098	1099		|O
0.0001	1099	1105		|O
men	1106	1109		|O
vs.	1110	1113		|O
women	1114	1119		|O
)	1119	1120		|O
.	1120	1121		|O
Although	1122	1130		|O
the	1131	1134		|O
magnitude	1135	1144		|O
of	1145	1147		|O
the	1148	1151		|O
difference	1152	1162		|O
was	1163	1166		|O
small	1167	1172		|O
,	1172	1173		|O
men	1174	1177		|O
increased	1178	1187		|O
more	1188	1192		|O
in	1193	1195		|O
thigh	1196	1201		|O
muscle	1202	1208		|O
mass	1209	1213		|O
(	1214	1215		|O
P	1215	1216		|O
<	1216	1217		|O
0.0001	1217	1223		|O
vs.	1224	1227		|O
women	1228	1233		|O
)	1233	1234		|O
.	1234	1235		|O
A	1236	1237		|O
reduction	1238	1247		|O
in	1248	1250		|O
thigh	1251	1256		|O
intermuscular	1257	1270		|O
adipose	1271	1278		|O
tissue	1279	1285		|O
(	1286	1287		|O
IMAT	1287	1291		|O
)	1291	1292		|O
and	1293	1296		|O
diastolic	1297	1306		|O
blood	1307	1312		|O
pressure	1313	1321		|O
was	1322	1325		|O
seen	1326	1330		|O
only	1331	1335		|O
in	1336	1338		|O
men	1339	1342		|O
(	1343	1344		|O
both	1344	1348		|O
p	1349	1350		|O
<	1350	1351		|O
0.05	1351	1355		|O
vs.	1356	1359		|O
baseline	1360	1368		|O
)	1368	1369		|O
.	1369	1370		|O
A	1371	1372		|O
decrease	1373	1381		|O
in	1382	1384		|O
LDL	1385	1388		|O
cholesterol	1389	1400		|O
,	1400	1401		|O
and	1402	1405		|O
an	1406	1408		|O
increase	1409	1417		|O
in	1418	1420		|O
serum	1421	1426		|O
insulin	1427	1434		|O
,	1434	1435		|O
was	1436	1439		|O
observed	1440	1448		|O
only	1449	1453		|O
in	1454	1456		|O
women	1457	1462		|O
(	1463	1464		|O
both	1464	1468		|O
p	1469	1470		|O
<	1470	1471		|O
0.05	1471	1475		|O
vs.	1476	1479		|O
baseline	1480	1488		|O
)	1488	1489		|O
.	1489	1490		|O
CONCLUSION	1491	1501		|O
:	1501	1502		|O
Low	1503	1506		|O
dose	1507	1511		|O
GH	1512	1514		|O
treatment	1515	1524		|O
reduced	1525	1532		|O
VAT	1533	1536		|O
more	1537	1541		|O
markedly	1542	1550		|O
in	1551	1553		|O
men	1554	1557		|O
as	1558	1560		|O
compared	1561	1569		|O
with	1570	1574		|O
women	1575	1580		|O
.	1580	1581		|O
As	1582	1584		|O
all	1585	1588		|O
women	1589	1594		|O
were	1595	1599		|O
postmenopausal	1600	1614		|O
and	1615	1618		|O
oestrogen	1619	1628		|O
-	1628	1629		|O
deficient	1629	1638		|O
,	1638	1639		|O
this	1640	1644		|O
gender	1645	1651		|O
difference	1652	1662		|O
in	1663	1665		|O
responsiveness	1666	1680		|O
was	1681	1684		|O
not	1685	1688		|O
due	1689	1692		|O
to	1693	1695		|O
an	1696	1698		|O
antagonistic	1699	1711		|O
effect	1712	1718		|O
of	1719	1721		|O
oestrogen	1722	1731		|O
on	1732	1734		|O
peripheral	1735	1745		|O
GH	1746	1748		|O
action	1749	1755		|O
.	1755	1756		|O

### 18640214
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
tetrahydromuguol	29	45		|O
.	45	46		|O
A	48	49		|O
toxicologic	50	61		|O
and	62	65		|O
dermatologic	66	78		|O
review	79	85		|O
of	86	88		|O
tetrahydromuguol	89	105		|O
when	106	110		|O
used	111	115		|O
as	116	118		|O
a	119	120		|O
fragrance	121	130		|O
ingredient	131	141		|O
is	142	144		|O
presented	145	154		|O
.	154	155		|O

### 18778437
Predictors	0	10		|O
of	11	13		|O
subjective	14	24		|O
and	25	28		|O
objective	29	38		|O
quality	39	46		|O
of	47	49		|O
life	50	54		|O
in	55	57		|O
outpatients	58	69		|O
with	70	74		|O
schizophrenia	75	88	schizophrenia	|B-DISEASE
.	88	89		|O
AIM	91	94		|O
:	94	95		|O
In	96	98		|O
recent	99	105		|O
years	106	111		|O
,	111	112		|O
greater	113	120		|O
attention	121	130		|O
has	131	134		|O
been	135	139		|O
given	140	145		|O
to	146	148		|O
quality	149	156		|O
of	157	159		|O
life	160	164		|O
(	165	166		|O
QOL	166	169		|O
)	169	170		|O
in	171	173		|O
schizophrenia	174	187	schizophrenia	|B-DISEASE
and	188	191		|O
several	192	199		|O
studies	200	207		|O
reported	208	216		|O
that	217	221		|O
negative	222	230		|O
and	231	234		|O
depressive	235	245	depressive symptoms	|B-DISEASE
symptoms	246	254		|I-DISEASE
and	255	258		|O
cognitive	259	268	cognitive dysfunction	|B-DISEASE
dysfunction	269	280		|I-DISEASE
are	281	284		|O
related	285	292		|O
to	293	295		|O
patient	296	303		|O
QOL	304	307		|O
.	307	308		|O
But	309	312		|O
because	313	320		|O
a	321	322		|O
variety	323	330		|O
of	331	333		|O
QOL	334	337		|O
measures	338	346		|O
have	347	351		|O
been	352	356		|O
used	357	361		|O
in	362	364		|O
the	365	368		|O
previous	369	377		|O
studies	378	385		|O
,	385	386		|O
there	387	392		|O
seems	393	398		|O
to	399	401		|O
be	402	404		|O
no	405	407		|O
unanimous	408	417		|O
predictors	418	428		|O
for	429	432		|O
subjective	433	443		|O
and	444	447		|O
objective	448	457		|O
QOL	458	461		|O
.	461	462		|O
The	463	466		|O
purpose	467	474		|O
of	475	477		|O
the	478	481		|O
present	482	489		|O
study	490	495		|O
was	496	499		|O
to	500	502		|O
elucidate	503	512		|O
the	513	516		|O
relationship	517	529		|O
between	530	537		|O
clinical	538	546		|O
variables	547	556		|O
and	557	560		|O
subjective	561	571		|O
and	572	575		|O
objective	576	585		|O
QOL	586	589		|O
in	590	592		|O
outpatients	593	604		|O
with	605	609		|O
schizophrenia	610	623	schizophrenia	|B-DISEASE
,	623	624		|O
using	625	630		|O
schizophrenia	631	644	schizophrenia	|B-DISEASE
disease	645	652		|O
-	652	653		|O
specific	653	661		|O
QOL	662	665		|O
measures	666	674		|O
.	674	675		|O
Particular	676	686		|O
attention	687	696		|O
was	697	700		|O
paid	701	705		|O
to	706	708		|O
cognitive	709	718		|O
function	719	727		|O
as	728	730		|O
a	731	732		|O
predictor	733	742		|O
of	743	745		|O
QOL	746	749		|O
.	749	750		|O
METHODS	751	758		|O
:	758	759		|O
Schizophrenia	760	773	Schizophrenia symptoms	|B-DISEASE
symptoms	774	782		|I-DISEASE
of	783	785		|O
the	786	789		|O
Positive	790	798		|O
and	799	802		|O
Negative	803	811		|O
Syndrome	812	820		|O
Scale	821	826		|O
(	827	828		|O
PANSS	828	833		|O
)	833	834		|O
were	835	839		|O
divided	840	847		|O
into	848	852		|O
five	853	857		|O
factors	858	865		|O
:	865	866		|O
positive	867	875		|O
factor	876	882		|O
,	882	883		|O
negative	884	892		|O
factor	893	899		|O
,	899	900		|O
cognitive	901	910		|O
factor	911	917		|O
,	917	918		|O
emotional	919	928	emotional discomfort	|B-DISEASE
discomfort	929	939		|I-DISEASE
,	939	940		|O
and	941	944		|O
hostility	945	954		|O
.	954	955		|O
The	956	959		|O
study	960	965		|O
sample	966	972		|O
consisted	973	982		|O
of	983	985		|O
84	986	988		|O
schizophrenia	989	1002	schizophrenia	|B-DISEASE
outpatients	1003	1014		|O
.	1014	1015		|O
Subjective	1016	1026		|O
and	1027	1030		|O
objective	1031	1040		|O
QOL	1041	1044		|O
were	1045	1049		|O
assessed	1050	1058		|O
with	1059	1063		|O
Schizophrenia	1064	1077	Schizophrenia	|B-DISEASE
Quality	1078	1085		|O
of	1086	1088		|O
Life	1089	1093		|O
Scale	1094	1099		|O
(	1100	1101		|O
SQLS	1101	1105		|O
)	1105	1106		|O
and	1107	1110		|O
the	1111	1114		|O
Quality	1115	1122		|O
of	1123	1125		|O
Life	1126	1130		|O
Scale	1131	1136		|O
(	1137	1138		|O
QLS	1138	1141		|O
)	1141	1142		|O
,	1142	1143		|O
respectively	1144	1156		|O
.	1156	1157		|O
RESULTS	1158	1165		|O
:	1165	1166		|O
Subjective	1167	1177		|O
QOL	1178	1181		|O
correlated	1182	1192		|O
significantly	1193	1206		|O
with	1207	1211		|O
emotional	1212	1221	emotional discomfort	|B-DISEASE
discomfort	1222	1232		|I-DISEASE
,	1232	1233		|O
positive	1234	1242		|O
factor	1243	1249		|O
,	1249	1250		|O
negative	1251	1259		|O
factor	1260	1266		|O
,	1266	1267		|O
extrapyramidal	1268	1282	extrapyramidal symptoms	|B-DISEASE
symptoms	1283	1291		|I-DISEASE
and	1292	1295		|O
cognitive	1296	1305		|O
factor	1306	1312		|O
,	1312	1313		|O
while	1314	1319		|O
objective	1320	1329		|O
QOL	1330	1333		|O
correlated	1334	1344		|O
with	1345	1349		|O
negative	1350	1358		|O
factor	1359	1365		|O
,	1365	1366		|O
cognitive	1367	1376		|O
factor	1377	1383		|O
,	1383	1384		|O
emotional	1385	1394	emotional discomfort	|B-DISEASE
discomfort	1395	1405		|I-DISEASE
,	1405	1406		|O
extrapyramidal	1407	1421	extrapyramidal symptoms	|B-DISEASE
symptoms	1422	1430		|I-DISEASE
,	1430	1431		|O
and	1432	1435		|O
dose	1436	1440		|O
of	1441	1443		|O
antipsychotics	1444	1458		|O
.	1458	1459		|O
Total	1460	1465		|O
score	1466	1471		|O
and	1472	1475		|O
three	1476	1481		|O
of	1482	1484		|O
four	1485	1489		|O
subscales	1490	1499		|O
in	1500	1502		|O
the	1503	1506		|O
QLS	1507	1510		|O
correlated	1511	1521		|O
significantly	1522	1535		|O
with	1536	1540		|O
cognitive	1541	1550		|O
factor	1551	1557		|O
,	1557	1558		|O
while	1559	1564		|O
cognitive	1565	1574		|O
factor	1575	1581		|O
had	1582	1585		|O
a	1586	1587		|O
significant	1588	1599		|O
correlation	1600	1611		|O
with	1612	1616		|O
only	1617	1621		|O
one	1622	1625		|O
of	1626	1628		|O
three	1629	1634		|O
scales	1635	1641		|O
of	1642	1644		|O
SQLS	1645	1649		|O
.	1649	1650		|O
Stepwise	1651	1659		|O
regression	1660	1670		|O
showed	1671	1677		|O
that	1678	1682		|O
subjective	1683	1693		|O
QOL	1694	1697		|O
was	1698	1701		|O
significantly	1702	1715		|O
predicted	1716	1725		|O
by	1726	1728		|O
emotional	1729	1738	emotional discomfort	|B-DISEASE
discomfort	1739	1749		|I-DISEASE
and	1750	1753		|O
extrapyramidal	1754	1768	extrapyramidal symptoms	|B-DISEASE
symptoms	1769	1777		|I-DISEASE
,	1777	1778		|O
while	1779	1784		|O
negative	1785	1793		|O
factor	1794	1800		|O
was	1801	1804		|O
the	1805	1808		|O
most	1809	1813		|O
important	1814	1823		|O
predictor	1824	1833		|O
of	1834	1836		|O
objective	1837	1846		|O
QOL	1847	1850		|O
.	1850	1851		|O
CONCLUSION	1852	1862		|O
:	1862	1863		|O
Cognitive	1864	1873	Cognitive dysfunction	|B-DISEASE
dysfunction	1874	1885		|I-DISEASE
had	1886	1889		|O
a	1890	1891		|O
greater	1892	1899		|O
influence	1900	1909		|O
on	1910	1912		|O
objective	1913	1922		|O
QOL	1923	1926		|O
than	1927	1931		|O
subjective	1932	1942		|O
QOL	1943	1946		|O
.	1946	1947		|O
Treating	1948	1956		|O
depressive	1957	1967		|O
and	1968	1971		|O
negative	1972	1980		|O
symptoms	1981	1989		|O
and	1990	1993		|O
extrapyramidal	1994	2008	extrapyramidal symptoms	|B-DISEASE
symptoms	2009	2017		|I-DISEASE
might	2018	2023		|O
contribute	2024	2034		|O
to	2035	2037		|O
enhanced	2038	2046		|O
subjective	2047	2057		|O
and	2058	2061		|O
objective	2062	2071		|O
QOL	2072	2075		|O
.	2075	2076		|O

### 18720672
Chloroquine	0	11		|O
psychosis	12	21	psychosis	|B-ADVERSE
masquerading	22	34		|O
as	35	37		|O
PCP	38	41		|O
:	41	42		|O
a	43	44		|O
case	45	49		|O
report	50	56		|O
.	56	57		|O
Chloroquine	59	70		|O
and	71	74		|O
its	75	78		|O
derivatives	79	90		|O
have	91	95		|O
been	96	100		|O
drugs	101	106		|O
of	107	109		|O
choice	110	116		|O
in	117	119		|O
the	120	123		|O
prophylaxis	124	135		|O
and	136	139		|O
treatment	140	149		|O
of	150	152		|O
malaria	153	160	malaria	|B-DISEASE
for	161	164		|O
over	165	169		|O
50	170	172		|O
years	173	178		|O
.	178	179		|O
These	180	185		|O
drugs	186	191		|O
are	192	195		|O
also	196	200		|O
frequently	201	211		|O
used	212	216		|O
in	217	219		|O
the	220	223		|O
treatment	224	233		|O
of	234	236		|O
various	237	244		|O
rheumatologic	245	258	rheumatologic disorders	|B-DISEASE
disorders	259	268		|I-DISEASE
.	268	269		|O
Because	270	277		|O
many	278	282		|O
Americans	283	292		|O
now	293	296		|O
travel	297	303		|O
abroad	304	310		|O
and	311	314		|O
may	315	318		|O
require	319	326		|O
chloroquine	327	338		|O
prophylaxis	339	350		|O
,	350	351		|O
as	352	354		|O
well	355	359		|O
as	360	362		|O
the	363	366		|O
fact	367	371		|O
that	372	376		|O
such	377	381		|O
medications	382	393		|O
are	394	397		|O
readily	398	405		|O
available	406	415		|O
through	416	423		|O
Internet	424	432		|O
-	432	433		|O
based	433	438		|O
supply	439	445		|O
houses	446	452		|O
,	452	453		|O
clinicians	454	464		|O
should	465	471		|O
be	472	474		|O
aware	475	480		|O
of	481	483		|O
the	484	487		|O
potential	488	497		|O
toxicity	498	506		|O
associated	507	517		|O
with	518	522		|O
the	523	526		|O
use	527	530		|O
of	531	533		|O
these	534	539		|O
agents	540	546		|O
.	546	547		|O
We	548	550		|O
present	551	558		|O
the	559	562		|O
case	563	567		|O
of	568	570		|O
an	571	573		|O
adolescent	574	584		|O
female	585	591		|O
who	592	595		|O
presented	596	605		|O
with	606	610		|O
acute	611	616		|O
,	616	617		|O
chloroquine	618	629		|O
-	629	630		|O
induced	630	637		|O
toxic	638	643	toxic psychosis	|B-ADVERSE
psychosis	644	653		|I-ADVERSE
resembling	654	664		|O
that	665	669		|O
induced	670	677		|O
by	678	680		|O
phencyclidine	681	694		|O
(	695	696		|O
PCP	696	699		|O
)	699	700		|O
in	701	703		|O
clinical	704	712		|O
presentation	713	725		|O
and	726	729		|O
laboratory	730	740		|O
findings	741	749		|O
.	749	750		|O
In	751	753		|O
the	754	757		|O
acute	758	763		|O
setting	764	771		|O
,	771	772		|O
the	773	776		|O
differentiation	777	792		|O
between	793	800		|O
chloroquine	801	812		|O
toxic	813	818	toxic psychosis	|B-ADVERSE
psychosis	819	828		|I-ADVERSE
and	829	832		|O
PCP	833	836	PCP psychosis	|B-ADVERSE
psychosis	837	846		|I-ADVERSE
may	847	850		|O
be	851	853		|O
difficult	854	863		|O
.	863	864		|O
Therefore	865	874		|O
,	874	875		|O
the	876	879		|O
syndrome	880	888		|O
of	889	891		|O
chloroquine	892	903		|O
-	903	904		|O
induced	904	911		|O
psychosis	912	921	psychosis	|B-ADVERSE
is	922	924		|O
reviewed	925	933		|O
and	934	937		|O
its	938	941		|O
differentiation	942	957		|O
from	958	962		|O
PCP	963	966	PCP psychosis	|B-ADVERSE
psychosis	967	976		|I-ADVERSE
highlighted	977	988		|O
as	989	991		|O
it	992	994		|O
relates	995	1002		|O
to	1003	1005		|O
important	1006	1015		|O
aspects	1016	1023		|O
of	1024	1026		|O
this	1027	1031		|O
case	1032	1036		|O
.	1036	1037		|O

### 18690914
Headache	0	8	Headache	|B-ADVERSE
:	8	9		|O
one	10	13		|O
of	14	16		|O
the	17	20		|O
most	21	25		|O
common	26	32		|O
and	33	36		|O
troublesome	37	48		|O
adverse	49	56		|O
reactions	57	66		|O
to	67	69		|O
drugs	70	75		|O
.	75	76		|O
It	78	80		|O
is	81	83		|O
difficult	84	93		|O
to	94	96		|O
attribute	97	106		|O
the	107	110		|O
diagnosis	111	120		|O
of	121	123		|O
adverse	124	131		|O
drug	132	136		|O
reaction	137	145		|O
to	146	148		|O
a	149	150		|O
condition	151	160		|O
which	161	166		|O
is	167	169		|O
also	170	174		|O
a	175	176		|O
common	177	183		|O
symptom	184	191		|O
.	191	192		|O
The	193	196		|O
decision	197	205		|O
might	206	211		|O
be	212	214		|O
arduous	215	222		|O
in	223	225		|O
the	226	229		|O
case	230	234		|O
of	235	237		|O
headache	238	246	headache	|B-ADVERSE
,	246	247		|O
because	248	255		|O
this	256	260		|O
disorder	261	269		|O
is	270	272		|O
very	273	277		|O
frequent	278	286		|O
in	287	289		|O
the	290	293		|O
general	294	301		|O
population	302	312		|O
.	312	313		|O
The	314	317		|O
drugs	318	323		|O
that	324	328		|O
more	329	333		|O
frequently	334	344		|O
induce	345	351		|O
headache	352	360	headache	|B-ADVERSE
belong	361	367		|O
to	368	370		|O
a	371	372		|O
variety	373	380		|O
of	381	383		|O
therapeutic	384	395		|O
classes	396	403		|O
with	404	408		|O
different	409	418		|O
mechanisms	419	429		|O
of	430	432		|O
action	433	439		|O
and	440	443		|O
different	444	453		|O
toxicity	454	462		|O
.	462	463		|O
In	464	466		|O
the	467	470		|O
majority	471	479		|O
of	480	482		|O
cases	483	488		|O
the	489	492		|O
headache	493	501	headache	|B-ADVERSE
has	502	505		|O
not	506	509		|O
a	510	511		|O
typical	512	519		|O
feature	520	527		|O
,	527	528		|O
it	529	531		|O
is	532	534		|O
dose	535	539		|O
-	539	540		|O
dependent	540	549		|O
,	549	550		|O
and	551	554		|O
is	555	557		|O
associated	558	568		|O
to	569	571		|O
other	572	577		|O
symptoms	578	586		|O
of	587	589		|O
neurotoxicity	590	603	neurotoxicity	|B-ADVERSE
.	603	604		|O
Some	605	609		|O
drugs	610	615		|O
cause	616	621		|O
,	621	622		|O
instead	623	630		|O
,	630	631		|O
a	632	633		|O
specific	634	642		|O
headache	643	651	headache	|B-ADVERSE
:	651	652		|O
this	653	657		|O
is	658	660		|O
the	661	664		|O
case	665	669		|O
of	670	672		|O
NO	673	675		|O
donors	676	682		|O
,	682	683		|O
which	684	689		|O
are	690	693		|O
also	694	698		|O
used	699	703		|O
in	704	706		|O
experimental	707	719		|O
studies	720	727		|O
in	728	730		|O
order	731	736		|O
to	737	739		|O
induce	740	746		|O
headache	747	755	headache	|B-ADVERSE
.	755	756		|O
This	757	761		|O
review	762	768		|O
describes	769	778		|O
the	779	782		|O
classes	783	790		|O
of	791	793		|O
drugs	794	799		|O
which	800	805		|O
induce	806	812		|O
headache	813	821	headache	|B-ADVERSE
,	821	822		|O
analyzes	823	831		|O
the	832	835		|O
frequency	836	845		|O
of	846	848		|O
headache	849	857	headache	|B-ADVERSE
induction	858	867		|O
among	868	873		|O
the	874	877		|O
drugs	878	883		|O
of	884	886		|O
the	887	890		|O
same	891	895		|O
class	896	901		|O
,	901	902		|O
and	903	906		|O
discusses	907	916		|O
the	917	920		|O
possible	921	929		|O
mechanisms	930	940		|O
underlying	941	951		|O
headache	952	960	headache	|B-ADVERSE
induction	961	970		|O
.	970	971		|O
It	972	974		|O
is	975	977		|O
to	978	980		|O
be	981	983		|O
hoped	984	989		|O
that	990	994		|O
a	995	996		|O
better	997	1003		|O
awareness	1004	1013		|O
of	1014	1016		|O
this	1017	1021		|O
issue	1022	1027		|O
would	1028	1033		|O
help	1034	1038		|O
the	1039	1042		|O
physician	1043	1052		|O
to	1053	1055		|O
consider	1056	1064		|O
it	1065	1067		|O
in	1068	1070		|O
the	1071	1074		|O
differential	1075	1087		|O
diagnosis	1088	1097		|O
of	1098	1100		|O
a	1101	1102		|O
recent	1103	1109		|O
-	1109	1110		|O
onset	1110	1115		|O
or	1116	1118		|O
changed	1119	1126		|O
headache	1127	1135	headache	|B-ADVERSE
and	1136	1139		|O
to	1140	1142		|O
avoid	1143	1148		|O
prescription	1149	1161		|O
of	1162	1164		|O
drugs	1165	1170		|O
known	1171	1176		|O
to	1177	1179		|O
cause	1180	1185		|O
headache	1186	1194	headache	|B-ADVERSE
to	1195	1197		|O
patients	1198	1206		|O
already	1207	1214		|O
suffering	1215	1224		|O
from	1225	1229		|O
this	1230	1234		|O
disorder	1235	1243		|O
.	1243	1244		|O

### 18613449
Effects	0	7		|O
of	8	10		|O
mosapride	11	20		|O
citrate	21	28		|O
on	29	31		|O
patients	32	40		|O
after	41	46		|O
vagal	47	52		|O
nerve	53	58		|O
,	58	59		|O
lower	60	65		|O
esophageal	66	76		|O
sphincter	77	86		|O
,	86	87		|O
and	88	91		|O
pyloric	92	99		|O
sphincter	100	109		|O
-	109	110		|O
preserving	110	120		|O
nearly	121	127		|O
total	128	133		|O
gastrectomy	134	145		|O
reconstructed	146	159		|O
by	160	162		|O
jejunal	163	170		|O
J	171	172		|O
pouch	173	178		|O
interposition	179	192		|O
,	192	193		|O
and	194	197		|O
postoperative	198	211		|O
quality	212	219		|O
of	220	222		|O
life	223	227		|O
.	227	228		|O
BACKGROUND	230	240		|O
/	240	241		|O
AIMS	241	245		|O
:	245	246		|O
Vagal	247	252		|O
nerve	253	258		|O
and	259	262		|O
pylorus	263	270		|O
-	270	271		|O
preserving	271	281		|O
nearly	282	288		|O
total	289	294		|O
gastrectomy	295	306		|O
reconstructed	307	320		|O
by	321	323		|O
interposition	324	337		|O
of	338	340		|O
a	341	342		|O
jejunal	343	350		|O
J	351	352		|O
pouch	353	358		|O
(	359	360		|O
hereinafter	360	371		|O
called	372	378		|O
NTGP	379	383		|O
)	383	384		|O
is	385	387		|O
a	388	389		|O
function	390	398		|O
-	398	399		|O
preserving	399	409		|O
operation	410	419		|O
for	420	423		|O
early	424	429		|O
gastric	430	437	gastric cancer	|B-DISEASE
cancer	438	444		|I-DISEASE
.	444	445		|O
However	446	453		|O
,	453	454		|O
some	455	459		|O
patients	460	468		|O
after	469	474		|O
NTGP	475	479		|O
have	480	484		|O
suffered	485	493		|O
from	494	498		|O
postprandial	499	511		|O
food	512	516		|O
stasis	517	523		|O
in	524	526		|O
the	527	530		|O
substitute	531	541		|O
stomach	542	549		|O
,	549	550		|O
and	551	554		|O
postprandial	555	567		|O
stasis	568	574		|O
leads	575	580		|O
to	581	583		|O
abdominal	584	593	abdominal symptoms	|B-DISEASE
symptoms	594	602		|I-DISEASE
.	602	603		|O
To	604	606		|O
clarify	607	614		|O
the	615	618		|O
clinical	619	627		|O
effect	628	634		|O
of	635	637		|O
mosapride	638	647		|O
citrate	648	655		|O
(	656	657		|O
hereinafter	657	668		|O
called	669	675		|O
MS	676	678		|O
)	678	679		|O
for	680	683		|O
prevention	684	694		|O
of	695	697		|O
food	698	702		|O
stasis	703	709		|O
in	710	712		|O
the	713	716		|O
substitute	717	727		|O
stomach	728	735		|O
for	736	739		|O
patients	740	748		|O
after	749	754		|O
NTGP	755	759		|O
,	759	760		|O
we	761	763		|O
studied	764	771		|O
the	772	775		|O
clinical	776	784		|O
effects	785	792		|O
of	793	795		|O
MS	796	798		|O
before	799	805		|O
and	806	809		|O
after	810	815		|O
administration	816	830		|O
of	831	833		|O
MS	834	836		|O
.	836	837		|O
METHODOLOGY	838	849		|O
:	849	850		|O
In	851	853		|O
a	854	855		|O
total	856	861		|O
of	862	864		|O
24	865	867		|O
patients	868	876		|O
(	877	878		|O
18	878	880		|O
males	881	886		|O
,	886	887		|O
6	888	889		|O
females	890	897		|O
;	897	898		|O
aged	899	903		|O
44-70	904	909		|O
years	910	915		|O
,	915	916		|O
average	917	924		|O
58.1	925	929		|O
years	930	935		|O
)	935	936		|O
during	937	943		|O
5	944	945		|O
years	946	951		|O
after	952	957		|O
NTGP	958	962		|O
for	963	966		|O
early	967	972		|O
gastric	973	980	gastric cancer	|B-DISEASE
cancer	981	987		|I-DISEASE
(	988	989		|O
D1	989	991		|O
lymph	992	997		|O
node	998	1002		|O
dissection	1003	1013		|O
,	1013	1014		|O
curability	1015	1025		|O
A	1026	1027		|O
)	1027	1028		|O
,	1028	1029		|O
the	1030	1033		|O
relationship	1034	1046		|O
between	1047	1054		|O
their	1055	1060		|O
postoperative	1061	1074		|O
quality	1075	1082		|O
of	1083	1085		|O
life	1086	1090		|O
(	1091	1092		|O
QOL	1092	1095		|O
)	1095	1096		|O
and	1097	1100		|O
emptying	1101	1109		|O
function	1110	1118		|O
of	1119	1121		|O
the	1122	1125		|O
substitute	1126	1136		|O
stomach	1137	1144		|O
(	1145	1146		|O
hereinafter	1146	1157		|O
called	1158	1164		|O
EFS	1165	1168		|O
)	1168	1169		|O
was	1170	1173		|O
compared	1174	1182		|O
using	1183	1188		|O
a	1189	1190		|O
radioisotope	1191	1203		|O
method	1204	1210		|O
before	1211	1217		|O
MS	1218	1220		|O
therapy	1221	1228		|O
and	1229	1232		|O
after	1233	1238		|O
MS	1239	1241		|O
therapy	1242	1249		|O
at	1250	1252		|O
an	1253	1255		|O
oral	1256	1260		|O
dose	1261	1265		|O
of	1266	1268		|O
15mg	1269	1273		|O
/	1273	1274		|O
day	1274	1277		|O
for	1278	1281		|O
3	1282	1283		|O
months	1284	1290		|O
.	1290	1291		|O
RESULTS	1292	1299		|O
:	1299	1300		|O
The	1301	1304		|O
interviews	1305	1315		|O
showd	1316	1321		|O
that	1322	1326		|O
after	1327	1332		|O
MS	1333	1335		|O
therapy	1336	1343		|O
,	1343	1344		|O
patients	1345	1353		|O
had	1354	1357		|O
more	1358	1362		|O
evident	1363	1370		|O
appetite	1371	1379		|O
and	1380	1383		|O
ate	1384	1387		|O
more	1388	1392		|O
food	1393	1397		|O
with	1398	1402		|O
a	1403	1404		|O
slight	1405	1411		|O
increase	1412	1420		|O
in	1421	1423		|O
body	1424	1428		|O
weight	1429	1435		|O
(	1436	1437		|O
0.52	1437	1441		|O
Kg	1441	1443		|O
)	1443	1444		|O
compared	1445	1453		|O
with	1454	1458		|O
patients	1459	1467		|O
before	1468	1474		|O
MS	1475	1477		|O
therapy	1478	1485		|O
.	1485	1486		|O
Before	1487	1493		|O
and	1494	1497		|O
after	1498	1503		|O
MS	1504	1506		|O
therapy	1507	1514		|O
,	1514	1515		|O
patients	1516	1524		|O
had	1525	1528		|O
no	1529	1531		|O
early	1532	1537		|O
dumping	1538	1545		|O
symtoms	1546	1553		|O
,	1553	1554		|O
while	1555	1560		|O
patients	1561	1569		|O
after	1570	1575		|O
MS	1576	1578		|O
therapy	1579	1586		|O
clearly	1587	1594		|O
had	1595	1598		|O
fewer	1599	1604		|O
symptoms	1605	1613		|O
such	1614	1618		|O
as	1619	1621		|O
reflux	1622	1628	reflux esophagitis	|B-ADVERSE
esophagitis	1629	1640		|I-ADVERSE
,	1640	1641		|O
nausea	1642	1648	nausea	|B-ADVERSE
,	1648	1649		|O
and	1650	1653		|O
abdominal	1654	1663	abdominal pain	|B-ADVERSE
pain	1664	1668		|I-ADVERSE
compared	1669	1677		|O
with	1678	1682		|O
before	1683	1689		|O
MS	1690	1692		|O
therapy	1693	1700		|O
.	1700	1701		|O
After	1702	1707		|O
MS	1708	1710		|O
therapy	1711	1718		|O
,	1718	1719		|O
patients	1720	1728		|O
also	1729	1733		|O
had	1734	1737		|O
significantly	1738	1751		|O
decreased	1752	1761		|O
abdominal	1762	1771	abdominal fullness	|B-DISEASE
fullness	1772	1780		|I-DISEASE
compared	1781	1789		|O
with	1790	1794		|O
before	1795	1801		|O
MS	1802	1804		|O
therapy	1805	1812		|O
(	1813	1814		|O
p	1814	1815		|O
=	1816	1817		|O
0.0046	1818	1824		|O
)	1824	1825		|O
.	1825	1826		|O
Endoscopically	1827	1841		|O
,	1841	1842		|O
we	1843	1845		|O
found	1846	1851		|O
reflux	1852	1858	reflux esophagitis	|B-DISEASE
esophagitis	1859	1870		|I-DISEASE
in	1871	1873		|O
4	1874	1875		|O
patients	1876	1884		|O
before	1885	1891		|O
MS	1892	1894		|O
therapy	1895	1902		|O
but	1903	1906		|O
in	1907	1909		|O
no	1910	1912		|O
patients	1913	1921		|O
after	1922	1927		|O
MS	1928	1930		|O
therapy	1931	1938		|O
.	1938	1939		|O
All	1940	1943		|O
patients	1944	1952		|O
before	1953	1959		|O
MS	1960	1962		|O
therapy	1963	1970		|O
showed	1971	1977		|O
residual	1978	1986		|O
contents	1987	1995		|O
in	1996	1998		|O
the	1999	2002		|O
substitute	2003	2013		|O
stomach	2014	2021		|O
,	2021	2022		|O
but	2023	2026		|O
only	2027	2031		|O
10	2032	2034		|O
patients	2035	2043		|O
after	2044	2049		|O
MS	2050	2052		|O
therapy	2053	2060		|O
showed	2061	2067		|O
residual	2068	2076		|O
contents	2077	2085		|O
in	2086	2088		|O
the	2089	2092		|O
substitute	2093	2103		|O
stomach	2104	2111		|O
.	2111	2112		|O
There	2113	2118		|O
was	2119	2122		|O
a	2123	2124		|O
significant	2125	2136		|O
difference	2137	2147		|O
between	2148	2155		|O
before	2156	2162		|O
and	2163	2166		|O
after	2167	2172		|O
MS	2173	2175		|O
therapy	2176	2183		|O
(	2184	2185		|O
p	2185	2186		|O
=	2187	2188		|O
0.0016	2189	2195		|O
)	2195	2196		|O
.	2196	2197		|O
Regarding	2198	2207		|O
EFS	2208	2211		|O
,	2211	2212		|O
the	2213	2216		|O
time	2217	2221		|O
to	2222	2224		|O
50%	2225	2228		|O
residual	2229	2237		|O
rate	2238	2242		|O
before	2243	2249		|O
MS	2250	2252		|O
therapy	2253	2260		|O
(	2261	2262		|O
98.7	2262	2266		|O
+	2267	2268		|O
/	2268	2269		|O
-	2269	2270		|O
13.0	2271	2275		|O
min	2276	2279		|O
)	2279	2280		|O
was	2281	2284		|O
significantly	2285	2298		|O
slower	2299	2305		|O
than	2306	2310		|O
that	2311	2315		|O
after	2316	2321		|O
MS	2322	2324		|O
therapy	2325	2332		|O
(	2333	2334		|O
83.2	2334	2338		|O
+	2339	2340		|O
/	2340	2341		|O
-	2341	2342		|O
13.8	2343	2347		|O
min	2348	2351		|O
)	2351	2352		|O
(	2353	2354		|O
p	2354	2355		|O
=	2356	2357		|O
0.0134	2358	2364		|O
)	2364	2365		|O
.	2365	2366		|O
After	2367	2372		|O
MS	2373	2375		|O
therapy	2376	2383		|O
(	2384	2385		|O
37.0	2385	2389		|O
+	2390	2391		|O
/	2391	2392		|O
-	2392	2393		|O
4.9%	2394	2398		|O
)	2398	2399		|O
,	2399	2400		|O
the	2401	2404		|O
residual	2405	2413		|O
rates	2414	2419		|O
at	2420	2422		|O
120	2423	2426		|O
minutes	2427	2434		|O
were	2435	2439		|O
significantly	2440	2453		|O
decreased	2454	2463		|O
compared	2464	2472		|O
with	2473	2477		|O
patients	2478	2486		|O
before	2487	2493		|O
MS	2494	2496		|O
therapy	2497	2504		|O
(	2505	2506		|O
44.8	2506	2510		|O
+	2511	2512		|O
/	2512	2513		|O
-	2513	2514		|O
5.3%	2515	2519		|O
)	2519	2520		|O
(	2521	2522		|O
p	2522	2523		|O
=	2524	2525		|O
0.0028	2526	2532		|O
)	2532	2533		|O
.	2533	2534		|O
Patients	2535	2543		|O
after	2544	2549		|O
MS	2550	2552		|O
therapy	2553	2560		|O
clearly	2561	2568		|O
had	2569	2572		|O
improved	2573	2581		|O
stasis	2582	2588		|O
of	2589	2591		|O
substitute	2592	2602		|O
stomach	2603	2610		|O
compared	2611	2619		|O
with	2620	2624		|O
before	2625	2631		|O
MS	2632	2634		|O
therapy	2635	2642		|O
.	2642	2643		|O
CONCLUSIONS	2644	2655		|O
:	2655	2656		|O
It	2657	2659		|O
was	2660	2663		|O
considered	2664	2674		|O
that	2675	2679		|O
MS	2680	2682		|O
therapy	2683	2690		|O
subsequently	2691	2703		|O
improves	2704	2712		|O
abdominal	2713	2722	abdominal fullness	|B-DISEASE
fullness	2723	2731		|I-DISEASE
due	2732	2735		|O
to	2736	2738		|O
the	2739	2742		|O
postprandial	2743	2755		|O
food	2756	2760		|O
stasis	2761	2767		|O
in	2768	2770		|O
the	2771	2774		|O
substitute	2775	2785		|O
stomach	2786	2793		|O
,	2793	2794		|O
contributing	2795	2807		|O
to	2808	2810		|O
the	2811	2814		|O
improvement	2815	2826		|O
of	2827	2829		|O
QOL	2830	2833		|O
of	2834	2836		|O
patients	2837	2845		|O
after	2846	2851		|O
NTGP	2852	2856		|O
.	2856	2857		|O

### 18612868
Alert	0	5		|O
:	5	6		|O
inaccurate	7	17		|O
lithium	18	25		|O
assay	26	31		|O
results	32	39		|O
.	39	40		|O
OBJECTIVES	42	52		|O
:	52	53		|O
A	54	55		|O
patient	56	63		|O
who	64	67		|O
had	68	71		|O
experienced	72	83		|O
bipolar	84	91	bipolar disorder	|B-DISEASE
disorder	92	100		|I-DISEASE
for	101	104		|O
over	105	109		|O
20	110	112		|O
years	113	118		|O
and	119	122		|O
who	123	126		|O
had	127	130		|O
been	131	135		|O
euthymic	136	144		|O
for	145	148		|O
most	149	153		|O
of	154	156		|O
that	157	161		|O
period	162	168		|O
while	169	174		|O
highly	175	181		|O
compliant	182	191		|O
with	192	196		|O
lithium	197	204		|O
,	204	205		|O
had	206	209		|O
falsely	210	217		|O
low	218	221		|O
lithium	222	229		|O
levels	230	236		|O
reported	237	245		|O
over	246	250		|O
two	251	254		|O
periods	255	262		|O
,	262	263		|O
6	264	265		|O
years	266	271		|O
apart	272	277		|O
,	277	278		|O
and	279	282		|O
was	283	286		|O
actually	287	295		|O
lithium	296	303		|O
toxic	304	309		|O
on	310	312		|O
the	313	316		|O
most	317	321		|O
recent	322	328		|O
occasion	329	337		|O
.	337	338		|O
At	339	341		|O
that	342	346		|O
latter	347	353		|O
time	354	358		|O
the	359	362		|O
spuriously	363	373		|O
low	374	377		|O
lithium	378	385		|O
levels	386	392		|O
reported	393	401		|O
on	402	404		|O
the	405	408		|O
assay	409	414		|O
risked	415	421		|O
dispelling	422	432		|O
any	433	436		|O
clinical	437	445		|O
suspicion	446	455		|O
of	456	458		|O
lithium	459	466	lithium toxicity	|B-ADVERSE
toxicity	467	475		|I-ADVERSE
,	475	476		|O
although	477	485		|O
toxicity	486	494		|O
was	495	498		|O
later	499	504		|O
confirmed	505	514		|O
.	514	515		|O
METHOD	516	522		|O
:	522	523		|O
Case	524	528		|O
report	529	535		|O
.	535	536		|O
RESULTS	537	544		|O
:	544	545		|O
The	546	549		|O
latter	550	556		|O
incident	557	565		|O
identified	566	576		|O
a	577	578		|O
serious	579	586		|O
problem	587	594		|O
,	594	595		|O
whereby	596	603		|O
it	604	606		|O
is	607	609		|O
likely	610	616		|O
that	617	621		|O
the	622	625		|O
particular	626	636		|O
assay	637	642		|O
risks	643	648		|O
generating	649	659		|O
spuriously	660	670		|O
low	671	674		|O
values	675	681		|O
when	682	686		|O
high	687	691		|O
serum	692	697		|O
levels	698	704		|O
of	705	707		|O
lithium	708	715		|O
are	716	719		|O
present	720	727		|O
-	727	728		|O
-	728	729		|O
a	729	730		|O
so	731	733		|O
-	733	734		|O
called	734	740		|O
'	741	742		|O
hook	742	746		|O
phenomenon	747	757		|O
'	757	758		|O
that	759	763		|O
has	764	767		|O
been	768	772		|O
described	773	782		|O
for	783	786		|O
some	787	791		|O
quantitative	792	804		|O
immunoassays	805	817		|O
.	817	818		|O
CONCLUSIONS	819	830		|O
:	830	831		|O
It	832	834		|O
is	835	837		|O
in	838	840		|O
situations	841	851		|O
of	852	854		|O
high	855	859		|O
potential	860	869		|O
gravity	870	877		|O
-	877	878		|O
-	878	879		|O
when	879	883		|O
lithium	884	891	lithium toxicity	|B-ADVERSE
toxicity	892	900		|I-ADVERSE
is	901	903		|O
present	904	911		|O
-	911	912		|O
-	912	913		|O
that	913	917		|O
lithium	918	925		|O
quantification	926	940		|O
is	941	943		|O
most	944	948		|O
likely	949	955		|O
to	956	958		|O
be	959	961		|O
compromised	962	973		|O
and	974	977		|O
low	978	981		|O
values	982	988		|O
generated	989	998		|O
.	998	999		|O
Also	1000	1004		|O
of	1005	1007		|O
grave	1008	1013		|O
concern	1014	1021		|O
is	1022	1024		|O
the	1025	1028		|O
fact	1029	1033		|O
that	1034	1038		|O
there	1039	1044		|O
are	1045	1048		|O
no	1049	1051		|O
regulatory	1052	1062		|O
processes	1063	1072		|O
in	1073	1075		|O
place	1076	1081		|O
to	1082	1084		|O
communicate	1085	1096		|O
this	1097	1101		|O
problem	1102	1109		|O
to	1110	1112		|O
lithium	1113	1120		|O
prescribers	1121	1132		|O
.	1132	1133		|O

### 18937624
Clindamycin	0	11		|O
phosphate	12	21		|O
/	21	22		|O
tretinoin	22	31		|O
gel	32	35		|O
formulation	36	47		|O
in	48	50		|O
the	51	54		|O
treatment	55	64		|O
of	65	67		|O
acne	68	72	acne vulgaris	|B-DISEASE
vulgaris	73	81		|I-DISEASE
.	81	82		|O
Clindamycin	84	95		|O
phosphate	96	105		|O
1.2%	106	110		|O
together	111	119		|O
with	120	124		|O
tretinoin	125	134		|O
0.025%	135	141		|O
as	142	144		|O
a	145	146		|O
gel	147	150		|O
(	151	152		|O
CTG	152	155		|O
)	155	156		|O
is	157	159		|O
a	160	161		|O
topical	162	169		|O
formulation	170	181		|O
of	182	184		|O
a	185	186		|O
fixed	187	192		|O
and	193	196		|O
stable	197	203		|O
combination	204	215		|O
approved	216	224		|O
by	225	227		|O
the	228	231		|O
FDA	232	235		|O
for	236	239		|O
the	240	243		|O
treatment	244	253		|O
of	254	256		|O
acne	257	261	acne vulgaris	|B-DISEASE
vulgaris	262	270		|I-DISEASE
in	271	273		|O
patients	274	282		|O
12	283	285		|O
years	286	291		|O
of	292	294		|O
age	295	298		|O
or	299	301		|O
older	302	307		|O
.	307	308		|O
The	309	312		|O
main	313	317		|O
indication	318	328		|O
of	329	331		|O
CTG	332	335		|O
is	336	338		|O
the	339	342		|O
management	343	353		|O
of	354	356		|O
moderate	357	365		|O
comedonal	366	375		|O
and	376	379		|O
mild	380	384		|O
-	384	385		|O
to	385	387		|O
-	387	388		|O
moderate	388	396		|O
papulopustular	397	411	papulopustular acne	|B-DISEASE
acne	412	416		|I-DISEASE
,	416	417		|O
an	418	420		|O
acne	421	425	acne	|B-DISEASE
form	426	430		|O
which	431	436		|O
is	437	439		|O
present	440	447		|O
in	448	450		|O
more	451	455		|O
than	456	460		|O
50%	461	464		|O
of	465	467		|O
acne	468	472	acne	|B-DISEASE
patients	473	481		|O
.	481	482		|O
CTG	483	486		|O
can	487	490		|O
also	491	495		|O
be	496	498		|O
combined	499	507		|O
with	508	512		|O
systemic	513	521		|O
antiacne	522	530		|O
therapy	531	538		|O
,	538	539		|O
such	540	544		|O
as	545	547		|O
systemic	548	556		|O
isotretinoin	557	569		|O
,	569	570		|O
in	571	573		|O
nodulocystic	574	586	nodulocystic acne	|B-DISEASE
acne	587	591		|I-DISEASE
.	591	592		|O
The	593	596		|O
product	597	604		|O
combines	605	613		|O
the	614	617		|O
anti	618	622		|O
-	622	623		|O
inflammatory	623	635		|O
and	636	639		|O
antibacterial	640	653		|O
properties	654	664		|O
of	665	667		|O
clindamycin	668	679		|O
with	680	684		|O
the	685	688		|O
well	689	693		|O
proven	694	700		|O
and	701	704		|O
beneficial	705	715		|O
comedolytic	716	727		|O
and	728	731		|O
anticomedogenic	732	747		|O
effects	748	755		|O
of	756	758		|O
tretinoin	759	768		|O
(	769	770		|O
all	770	773		|O
-	773	774		|O
trans	774	779		|O
retinoic	780	788		|O
acid	789	793		|O
)	793	794		|O
.	794	795		|O
The	796	799		|O
addition	800	808		|O
of	809	811		|O
clindamycin	812	823		|O
to	824	826		|O
tretinoin	827	836		|O
enhances	837	845		|O
the	846	849		|O
comedolytic	850	861		|O
efficacy	862	870		|O
of	871	873		|O
tretinoin	874	883		|O
in	884	886		|O
moderate	887	895		|O
-	895	896		|O
to	896	898		|O
-	898	899		|O
severe	899	905		|O
acne	906	910	acne of the face	|B-DISEASE
of	911	913		|I-DISEASE
the	914	917		|I-DISEASE
face	918	922		|I-DISEASE
.	922	923		|O
The	924	927		|O
comedolytic	928	939		|O
activity	940	948		|O
of	949	951		|O
tretinoin	952	961		|O
and	962	965		|O
the	966	969		|O
anti	970	974		|O
-	974	975		|O
inflammatory	975	987		|O
efficacy	988	996		|O
of	997	999		|O
clindamycin	1000	1011		|O
accelerate	1012	1022		|O
resolution	1023	1033		|O
of	1034	1036		|O
all	1037	1040		|O
types	1041	1046		|O
of	1047	1049		|O
acne	1050	1054	acne lesions	|B-DISEASE
lesions	1055	1062		|I-DISEASE
without	1063	1070		|O
affecting	1071	1080		|O
the	1081	1084		|O
safety	1085	1091		|O
of	1092	1094		|O
both	1095	1099		|O
compounds	1100	1109		|O
.	1109	1110		|O
Discontinuation	1111	1126		|O
rates	1127	1132		|O
due	1133	1136		|O
to	1137	1139		|O
adverse	1140	1147		|O
events	1148	1154		|O
related	1155	1162		|O
to	1163	1165		|O
this	1166	1170		|O
formulation	1171	1182		|O
were	1183	1187		|O
found	1188	1193		|O
to	1194	1196		|O
be	1197	1199		|O
low	1200	1203		|O
(	1204	1205		|O
<	1205	1206		|O
/	1206	1207		|O
=	1207	1208		|O
1%	1209	1211		|O
)	1211	1212		|O
.	1212	1213		|O
Safety	1214	1220		|O
of	1221	1223		|O
CTG	1224	1227		|O
use	1228	1231		|O
in	1232	1234		|O
pregnancy	1235	1244		|O
has	1245	1248		|O
not	1249	1252		|O
been	1253	1257		|O
established	1258	1269		|O
.	1269	1270		|O
The	1271	1274		|O
combination	1275	1286		|O
formulation	1287	1298		|O
is	1299	1301		|O
mainly	1302	1308		|O
designed	1309	1317		|O
to	1318	1320		|O
enhance	1321	1328		|O
effectiveness	1329	1342		|O
and	1343	1346		|O
minimize	1347	1355		|O
irritation	1356	1366		|O
.	1366	1367		|O
The	1368	1371		|O
once	1372	1376		|O
daily	1377	1382		|O
use	1383	1386		|O
of	1387	1389		|O
CTG	1390	1393		|O
,	1393	1394		|O
its	1395	1398		|O
rapid	1399	1404		|O
and	1405	1408		|O
dual	1409	1413		|O
effect	1414	1420		|O
and	1421	1424		|O
good	1425	1429		|O
tolerability	1430	1442		|O
have	1443	1447		|O
a	1448	1449		|O
positive	1450	1458		|O
impact	1459	1465		|O
on	1466	1468		|O
the	1469	1472		|O
duration	1473	1481		|O
of	1482	1484		|O
disease	1485	1492		|O
,	1492	1493		|O
patients	1494	1502		|O
'	1502	1503		|O
compliance	1504	1514		|O
and	1515	1518		|O
overall	1519	1526		|O
costs	1527	1532		|O
of	1533	1535		|O
therapy	1536	1543		|O
.	1543	1544		|O

### 18547214
Maximum	0	7		|O
effect	8	14		|O
of	15	17		|O
triptans	18	26		|O
in	27	29		|O
migraine	30	38	migraine	|B-DISEASE
?	38	39		|O
A	40	41		|O
comment	42	49		|O
.	49	50		|O
The	52	55		|O
efficacy	56	64		|O
of	65	67		|O
triptans	68	76		|O
in	77	79		|O
the	80	83		|O
treatment	84	93		|O
of	94	96		|O
migraine	97	105	migraine	|B-DISEASE
was	106	109		|O
recently	110	118		|O
contested	119	128		|O
.	128	129		|O
How	130	133		|O
high	134	138		|O
is	139	141		|O
then	142	146		|O
the	147	150		|O
maximum	151	158		|O
effect	159	165		|O
of	166	168		|O
a	169	170		|O
triptan	171	178		|O
?	178	179		|O
After	180	185		|O
subcutaneous	186	198		|O
naratriptan	199	210		|O
10	211	213		|O
mg	214	216		|O
a	217	218		|O
88%	219	222		|O
pain	223	227		|O
-	227	228		|O
free	228	232		|O
response	233	241		|O
was	242	245		|O
observed	246	254		|O
.	254	255		|O
This	256	260		|O
result	261	267		|O
was	268	271		|O
obtained	272	280		|O
despite	281	288		|O
the	289	292		|O
fact	293	297		|O
that	298	302		|O
more	303	307		|O
half	308	312		|O
of	313	315		|O
the	316	319		|O
patients	320	328		|O
had	329	332		|O
a	333	334		|O
migraine	335	343	migraine	|B-DISEASE
duration	344	352		|O
of	353	355		|O
>	356	357		|O
4	358	359		|O
h	360	361		|O
.	361	362		|O
These	363	368		|O
results	369	376		|O
indicate	377	385		|O
that	386	390		|O
subcutaneous	391	403		|O
naratriptan	404	415		|O
in	416	418		|O
a	419	420		|O
high	421	425		|O
dose	426	430		|O
can	431	434		|O
overcome	435	443		|O
central	444	451		|O
sensitization	452	465		|O
that	466	470		|O
occurs	471	477		|O
in	478	480		|O
migraine	481	489	migraine	|B-DISEASE
attacks	490	497		|O
.	497	498		|O

### 18617665
Practical	0	9		|O
model	10	15		|O
-	15	16		|O
based	16	21		|O
dose	22	26		|O
finding	27	34		|O
in	35	37		|O
early	38	43		|O
-	43	44		|O
phase	44	49		|O
clinical	50	58		|O
trials	59	65		|O
:	65	66		|O
optimizing	67	77		|O
tissue	78	84		|O
plasminogen	85	96		|O
activator	97	106		|O
dose	107	111		|O
for	112	115		|O
treatment	116	125		|O
of	126	128		|O
ischemic	129	137	ischemic stroke	|B-DISEASE
stroke	138	144		|I-DISEASE
in	145	147		|O
children	148	156		|O
.	156	157		|O
BACKGROUND	159	169		|O
AND	170	173		|O
PURPOSE	174	181		|O
:	181	182		|O
A	183	184		|O
safe	185	189		|O
and	190	193		|O
effective	194	203		|O
tissue	204	210		|O
plasminogen	211	222		|O
activator	223	232		|O
(	233	234		|O
tPA	234	237		|O
)	237	238		|O
dose	239	243		|O
for	244	247		|O
childhood	248	257		|O
stroke	258	264	stroke	|B-DISEASE
has	265	268		|O
not	269	272		|O
been	273	277		|O
established	278	289		|O
.	289	290		|O
This	291	295		|O
article	296	303		|O
describes	304	313		|O
a	314	315		|O
Bayesian	316	324		|O
outcome	325	332		|O
-	332	333		|O
adaptive	333	341		|O
method	342	348		|O
for	349	352		|O
determining	353	364		|O
the	365	368		|O
best	369	373		|O
dose	374	378		|O
of	379	381		|O
an	382	384		|O
experimental	385	397		|O
agent	398	403		|O
and	404	407		|O
explains	408	416		|O
how	417	420		|O
this	421	425		|O
method	426	432		|O
was	433	436		|O
used	437	441		|O
to	442	444		|O
design	445	451		|O
a	452	453		|O
dose	454	458		|O
-	458	459		|O
finding	459	466		|O
trial	467	472		|O
for	473	476		|O
tPA	477	480		|O
in	481	483		|O
childhood	484	493		|O
.	493	494		|O
METHODS	495	502		|O
:	502	503		|O
The	504	507		|O
method	508	514		|O
assigns	515	522		|O
doses	523	528		|O
to	529	531		|O
successive	532	542		|O
cohorts	543	550		|O
of	551	553		|O
patients	554	562		|O
on	563	565		|O
the	566	569		|O
basis	570	575		|O
of	576	578		|O
each	579	583		|O
dose	584	588		|O
's	588	590		|O
desirability	591	603		|O
,	603	604		|O
quantified	605	615		|O
in	616	618		|O
terms	619	624		|O
of	625	627		|O
the	628	631		|O
tradeoff	632	640		|O
between	641	648		|O
efficacy	649	657		|O
and	658	661		|O
toxicity	662	670		|O
.	670	671		|O
The	672	675		|O
tradeoff	676	684		|O
function	685	693		|O
is	694	696		|O
constructed	697	708		|O
from	709	713		|O
several	714	721		|O
pairs	722	727		|O
of	728	730		|O
equally	731	738		|O
desirable	739	748		|O
(	749	750		|O
efficacy	750	758		|O
,	758	759		|O
toxicity	760	768		|O
)	768	769		|O
probabilities	770	783		|O
specified	784	793		|O
by	794	796		|O
the	797	800		|O
physicians	801	811		|O
planning	812	820		|O
the	821	824		|O
trial	825	830		|O
.	830	831		|O
Each	832	836		|O
cohort	837	843		|O
's	843	845		|O
dose	846	850		|O
is	851	853		|O
chosen	854	860		|O
adaptively	861	871		|O
,	871	872		|O
based	873	878		|O
on	879	881		|O
dose	882	886		|O
-	886	887		|O
outcome	887	894		|O
data	895	899		|O
from	900	904		|O
the	905	908		|O
patients	909	917		|O
treated	918	925		|O
previously	926	936		|O
in	937	939		|O
the	940	943		|O
trial	944	949		|O
,	949	950		|O
to	951	953		|O
optimize	954	962		|O
the	963	966		|O
efficacy	967	975		|O
-	975	976		|O
toxicity	976	984		|O
tradeoff	985	993		|O
.	993	994		|O
Application	995	1006		|O
of	1007	1009		|O
the	1010	1013		|O
method	1014	1020		|O
to	1021	1023		|O
design	1024	1030		|O
the	1031	1034		|O
tPA	1035	1038		|O
trial	1039	1044		|O
is	1045	1047		|O
described	1048	1057		|O
,	1057	1058		|O
including	1059	1068		|O
a	1069	1070		|O
computer	1071	1079		|O
simulation	1080	1090		|O
study	1091	1096		|O
to	1097	1099		|O
establish	1100	1109		|O
design	1110	1116		|O
properties	1117	1127		|O
.	1127	1128		|O
A	1129	1130		|O
hypothetical	1131	1143		|O
cohort	1144	1150		|O
-	1150	1151		|O
by	1151	1153		|O
-	1153	1154		|O
cohort	1154	1160		|O
example	1161	1168		|O
is	1169	1171		|O
given	1172	1177		|O
to	1178	1180		|O
illustrate	1181	1191		|O
how	1192	1195		|O
the	1196	1199		|O
method	1200	1206		|O
works	1207	1212		|O
during	1213	1219		|O
trial	1220	1225		|O
conduct	1226	1233		|O
.	1233	1234		|O
RESULTS	1235	1242		|O
:	1242	1243		|O
Because	1244	1251		|O
only	1252	1256		|O
a	1257	1258		|O
dose	1259	1263		|O
that	1264	1268		|O
is	1269	1271		|O
both	1272	1276		|O
safe	1277	1281		|O
and	1282	1285		|O
efficacious	1286	1297		|O
may	1298	1301		|O
be	1302	1304		|O
selected	1305	1313		|O
and	1314	1317		|O
the	1318	1321		|O
method	1322	1328		|O
combines	1329	1337		|O
phase	1338	1343		|O
I	1344	1345		|O
and	1346	1349		|O
phase	1350	1355		|O
II	1356	1358		|O
by	1359	1361		|O
integrating	1362	1373		|O
efficacy	1374	1382		|O
and	1383	1386		|O
toxicity	1387	1395		|O
to	1396	1398		|O
choose	1399	1405		|O
doses	1406	1411		|O
,	1411	1412		|O
it	1413	1415		|O
avoids	1416	1422		|O
the	1423	1426		|O
more	1427	1431		|O
time	1432	1436		|O
-	1436	1437		|O
consuming	1437	1446		|O
and	1447	1450		|O
expensive	1451	1460		|O
conventional	1461	1473		|O
approach	1474	1482		|O
of	1483	1485		|O
conducting	1486	1496		|O
a	1497	1498		|O
phase	1499	1504		|O
I	1505	1506		|O
trial	1507	1512		|O
based	1513	1518		|O
on	1519	1521		|O
toxicity	1522	1530		|O
alone	1531	1536		|O
followed	1537	1545		|O
by	1546	1548		|O
a	1549	1550		|O
phase	1551	1556		|O
II	1557	1559		|O
trial	1560	1565		|O
based	1566	1571		|O
on	1572	1574		|O
efficacy	1575	1583		|O
alone	1584	1589		|O
.	1589	1590		|O
This	1591	1595		|O
is	1596	1598		|O
especially	1599	1609		|O
useful	1610	1616		|O
in	1617	1619		|O
settings	1620	1628		|O
with	1629	1633		|O
low	1634	1637		|O
accrual	1638	1645		|O
rates	1646	1651		|O
,	1651	1652		|O
such	1653	1657		|O
as	1658	1660		|O
trials	1661	1667		|O
of	1668	1670		|O
tPA	1671	1674		|O
for	1675	1678		|O
pediatric	1679	1688		|O
acute	1689	1694	acute ischemic stroke	|B-DISEASE
ischemic	1695	1703		|I-DISEASE
stroke	1704	1710		|I-DISEASE
.	1710	1711		|O

### 18685414
Systemic	0	8		|O
therapy	9	16		|O
for	17	20		|O
unresectable	21	33		|O
and	34	37		|O
metastatic	38	48	metastatic transitional cell carcinoma of the urothelium	|B-DISEASE
transitional	49	61		|I-DISEASE
cell	62	66		|I-DISEASE
carcinoma	67	76		|I-DISEASE
of	77	79		|I-DISEASE
the	80	83		|I-DISEASE
urothelium	84	94		|I-DISEASE
:	94	95		|O
first	96	101		|O
-	101	102		|O
line	102	106		|O
and	107	110		|O
beyond	111	117		|O
.	117	118		|O
PURPOSE	120	127		|O
OF	128	130		|O
REVIEW	131	137		|O
:	137	138		|O
The	139	142		|O
review	143	149		|O
aims	150	154		|O
to	155	157		|O
provide	158	165		|O
an	166	168		|O
overview	169	177		|O
of	178	180		|O
recent	181	187		|O
advances	188	196		|O
and	197	200		|O
future	201	207		|O
research	208	216		|O
direction	217	226		|O
in	227	229		|O
the	230	233		|O
management	234	244		|O
of	245	247		|O
patients	248	256		|O
with	257	261		|O
advanced	262	270		|O
transitional	271	283	transitional cell carcinoma	|B-DISEASE
cell	284	288		|I-DISEASE
carcinoma	289	298		|I-DISEASE
.	298	299		|O
RECENT	300	306		|O
FINDINGS	307	315		|O
:	315	316		|O
Early	317	322		|O
data	323	327		|O
of	328	330		|O
the	331	334		|O
randomized	335	345		|O
phase	346	351		|O
III	352	355		|O
study	356	361		|O
comparing	362	371		|O
paclitaxel	372	382		|O
,	382	383		|O
cisplatin	384	393		|O
,	393	394		|O
and	395	398		|O
gemcitabine	399	410		|O
with	411	415		|O
gemcitabine	416	427		|O
plus	428	432		|O
cisplatin	433	442		|O
for	443	446		|O
advanced	447	455		|O
urothelial	456	466	urothelial cancer	|B-DISEASE
cancer	467	473		|I-DISEASE
detected	474	482		|O
no	483	485		|O
survival	486	494		|O
difference	495	505		|O
.	505	506		|O
A	507	508		|O
phase	509	514		|O
II	515	517		|O
study	518	523		|O
investigated	524	536		|O
the	537	540		|O
safety	541	547		|O
and	548	551		|O
efficacy	552	560		|O
of	561	563		|O
trastuzumab	564	575		|O
,	575	576		|O
carboplatin	577	588		|O
,	588	589		|O
gemcitabine	590	601		|O
,	601	602		|O
and	603	606		|O
paclitaxel	607	617		|O
in	618	620		|O
human	621	626		|O
epidermal	627	636		|O
growth	637	643		|O
factor	644	650		|O
receptor	651	659		|O
-	659	660		|O
2	660	661		|O
/	661	662		|O
neu	662	665		|O
-	665	666		|O
positive	666	674		|O
advanced	675	683		|O
urothelial	684	694	urothelial carcinoma	|B-DISEASE
carcinoma	695	704		|I-DISEASE
and	705	708		|O
reported	709	717		|O
promising	718	727		|O
results	728	735		|O
.	735	736		|O
Renal	737	742		|O
-	742	743		|O
sparing	743	750		|O
regimens	751	759		|O
are	760	763		|O
under	764	769		|O
active	770	776		|O
development	777	788		|O
.	788	789		|O
A	790	791		|O
nonrandomized	792	805		|O
comparison	806	816		|O
of	817	819		|O
the	820	823		|O
3	824	825		|O
-	825	826		|O
week	826	830		|O
with	831	835		|O
the	836	839		|O
4	840	841		|O
-	841	842		|O
week	842	846		|O
schedule	847	855		|O
for	856	859		|O
gemcitabine	860	871		|O
and	872	875		|O
cisplatin	876	885		|O
showed	886	892		|O
that	893	897		|O
the	898	901		|O
3	902	903		|O
-	903	904		|O
week	904	908		|O
schedule	909	917		|O
had	918	921		|O
less	922	926		|O
hematological	927	940	hematological toxicity	|B-ADVERSE
toxicity	941	949		|I-ADVERSE
and	950	953		|O
better	954	960		|O
dose	961	965		|O
intensity	966	975		|O
.	975	976		|O
Potential	977	986		|O
molecular	987	996		|O
markers	997	1004		|O
such	1005	1009		|O
as	1010	1012		|O
excision	1013	1021		|O
repair	1022	1028		|O
cross	1029	1034		|O
-	1034	1035		|O
complementation	1035	1050		|O
group	1051	1056		|O
1	1057	1058		|O
,	1058	1059		|O
emmprin	1060	1067		|O
,	1067	1068		|O
and	1069	1072		|O
survivin	1073	1081		|O
for	1082	1085		|O
survival	1086	1094		|O
and	1095	1098		|O
/	1098	1099		|O
or	1099	1101		|O
platinum	1102	1110		|O
resistance	1111	1121		|O
in	1122	1124		|O
patients	1125	1133		|O
with	1134	1138		|O
transitional	1139	1151	transitional cell carcinoma	|B-DISEASE
cell	1152	1156		|I-DISEASE
carcinoma	1157	1166		|I-DISEASE
showed	1167	1173		|O
promise	1174	1181		|O
.	1181	1182		|O
SUMMARY	1183	1190		|O
:	1190	1191		|O
Recent	1192	1198		|O
data	1199	1203		|O
do	1204	1206		|O
not	1207	1210		|O
support	1211	1218		|O
change	1219	1225		|O
in	1226	1228		|O
the	1229	1232		|O
current	1233	1240		|O
standard	1241	1249		|O
of	1250	1252		|O
care	1253	1257		|O
for	1258	1261		|O
advanced	1262	1270		|O
transitional	1271	1283	transitional cell carcinoma	|B-DISEASE
cell	1284	1288		|I-DISEASE
carcinoma	1289	1298		|I-DISEASE
.	1298	1299		|O
Clinical	1300	1308		|O
testing	1309	1316		|O
of	1317	1319		|O
emerging	1320	1328		|O
anticancer	1329	1339		|O
therapies	1340	1349		|O
using	1350	1355		|O
new	1356	1359		|O
agents	1360	1366		|O
,	1366	1367		|O
new	1368	1371		|O
combinations	1372	1384		|O
,	1384	1385		|O
and	1386	1389		|O
new	1390	1393		|O
approaches	1394	1404		|O
is	1405	1407		|O
under	1408	1413		|O
active	1414	1420		|O
investigation	1421	1434		|O
.	1434	1435		|O
Rational	1436	1444		|O
combination	1445	1456		|O
and	1457	1460		|O
new	1461	1464		|O
strategy	1465	1473		|O
in	1474	1476		|O
clinical	1477	1485		|O
trial	1486	1491		|O
design	1492	1498		|O
are	1499	1502		|O
critical	1503	1511		|O
for	1512	1515		|O
new	1516	1519		|O
drug	1520	1524		|O
development	1525	1536		|O
for	1537	1540		|O
transitional	1541	1553	transitional cell carcinoma	|B-DISEASE
cell	1554	1558		|I-DISEASE
carcinoma	1559	1568		|I-DISEASE
.	1568	1569		|O

### 18572379
Neuroprotection	0	15		|O
by	16	18		|O
Spirulina	19	28		|O
platensis	29	38		|O
protean	39	46		|O
extract	47	54		|O
and	55	58		|O
phycocyanin	59	70		|O
against	71	78		|O
iron	79	83		|O
-	83	84		|O
induced	84	91		|O
toxicity	92	100		|O
in	101	103		|O
SH	104	106		|O
-	106	107		|O
SY5Y	107	111		|O
neuroblastoma	112	125		|O
cells	126	131		|O
.	131	132		|O
We	134	136		|O
investigated	137	149		|O
the	150	153		|O
effect	154	160		|O
of	161	163		|O
Spirulina	164	173		|O
platensis	174	183		|O
protean	184	191		|O
extract	192	199		|O
and	200	203		|O
the	204	207		|O
biliprotein	208	219		|O
phycocyanin	220	231		|O
isolated	232	240		|O
from	241	245		|O
this	246	250		|O
microalga	251	260		|O
,	260	261		|O
on	262	264		|O
the	265	268		|O
activities	269	279		|O
of	280	282		|O
the	283	286		|O
antioxidant	287	298		|O
enzymes	299	306		|O
SOD	307	310		|O
,	310	311		|O
CAT	312	315		|O
,	315	316		|O
GPx	317	320		|O
,	320	321		|O
and	322	325		|O
GR	326	328		|O
,	328	329		|O
lipid	330	335		|O
peroxidation	336	348		|O
inhibitory	349	359		|O
activity	360	368		|O
and	369	372		|O
glutathione	373	384		|O
levels	385	391		|O
after	392	397		|O
the	398	401		|O
iron	402	406		|O
induced	407	414		|O
oxidative	415	424		|O
stress	425	431		|O
in	432	434		|O
SH	435	437		|O
-	437	438		|O
SY5Y	438	442		|O
neuroblastoma	443	456		|O
cells	457	462		|O
.	462	463		|O
Iron	464	468		|O
is	469	471		|O
one	472	475		|O
of	476	478		|O
the	479	482		|O
most	483	487		|O
important	488	497		|O
agents	498	504		|O
that	505	509		|O
produce	510	517		|O
oxidative	518	527		|O
stress	528	534		|O
and	535	538		|O
decline	539	546		|O
of	547	549		|O
neuronal	550	558		|O
functions	559	568		|O
.	568	569		|O
S	570	571		|O
.	571	572		|O
platensis	573	582		|O
protean	583	590		|O
extract	591	598		|O
and	599	602		|O
phycocyanin	603	614		|O
exert	615	620		|O
the	621	624		|O
antioxidant	625	636		|O
activity	637	645		|O
by	646	648		|O
protecting	649	659		|O
the	660	663		|O
activity	664	672		|O
of	673	675		|O
the	676	679		|O
cellular	680	688		|O
antioxidant	689	700		|O
enzymes	701	708		|O
total	709	714		|O
GPx	715	718		|O
,	718	719		|O
GPx	720	723		|O
-	723	724		|O
Se	724	726		|O
and	727	730		|O
GR	731	733		|O
and	734	737		|O
by	738	740		|O
increasing	741	751		|O
reduced	752	759		|O
glutathione	760	771		|O
in	772	774		|O
cells	775	780		|O
against	781	788		|O
oxidative	789	798		|O
stress	799	805		|O
induced	806	813		|O
by	814	816		|O
iron	817	821		|O
.	821	822		|O
These	823	828		|O
results	829	836		|O
suggested	837	846		|O
that	847	851		|O
S	852	853		|O
.	853	854		|O
platensis	855	864		|O
protean	865	872		|O
extract	873	880		|O
is	881	883		|O
a	884	885		|O
powerful	886	894		|O
antioxidant	895	906		|O
through	907	914		|O
a	915	916		|O
mechanism	917	926		|O
related	927	934		|O
to	935	937		|O
antioxidant	938	949		|O
activity	950	958		|O
,	958	959		|O
capable	960	967		|O
of	968	970		|O
interfering	971	982		|O
with	983	987		|O
radical	988	995		|O
-	995	996		|O
mediated	996	1004		|O
cell	1005	1009		|O
death	1010	1015		|O
.	1015	1016		|O
S	1017	1018		|O
.	1018	1019		|O
platensis	1020	1029		|O
may	1030	1033		|O
be	1034	1036		|O
useful	1037	1043		|O
in	1044	1046		|O
diseases	1047	1055		|O
known	1056	1061		|O
to	1062	1064		|O
be	1065	1067		|O
aggravated	1068	1078		|O
by	1079	1081		|O
reactive	1082	1090		|O
oxygen	1091	1097		|O
species	1098	1105		|O
and	1106	1109		|O
in	1110	1112		|O
the	1113	1116		|O
development	1117	1128		|O
of	1129	1131		|O
novel	1132	1137		|O
treatments	1138	1148		|O
for	1149	1152		|O
neurodegenerative	1153	1170	neurodegenerative disorders	|B-DISEASE
disorders	1171	1180		|I-DISEASE
as	1181	1183		|O
long	1184	1188		|O
as	1189	1191		|O
iron	1192	1196		|O
has	1197	1200		|O
been	1201	1205		|O
implicated	1206	1216		|O
in	1217	1219		|O
the	1220	1223		|O
neuropathology	1224	1238		|O
of	1239	1241		|O
several	1242	1249		|O
neurodegenerative	1250	1267	neurodegenerative disorders	|B-DISEASE
disorders	1268	1277		|I-DISEASE
such	1278	1282		|O
as	1283	1285		|O
Alzheimer	1286	1295		|O
's	1295	1297		|O
or	1298	1300		|O
Parkinson	1301	1310	Parkinson diseases	|B-DISEASE
diseases	1311	1319		|I-DISEASE
.	1319	1320		|O

### 18514630
Nutritional	0	11		|O
supplements	12	23		|O
with	24	28		|O
oral	29	33		|O
amino	34	39		|O
acid	40	44		|O
mixtures	45	53		|O
increases	54	63		|O
whole	64	69		|O
-	69	70		|O
body	70	74		|O
lean	75	79		|O
mass	80	84		|O
and	85	88		|O
insulin	89	96		|O
sensitivity	97	108		|O
in	109	111		|O
elderly	112	119		|O
subjects	120	128		|O
with	129	133		|O
sarcopenia	134	144	sarcopenia	|B-DISEASE
.	144	145		|O
Decreases	147	156		|O
in	157	159		|O
whole	160	165		|O
-	165	166		|O
body	166	170		|O
lean	171	175		|O
mass	176	180		|O
can	181	184		|O
cause	185	190		|O
sarcopenia	191	201	sarcopenia	|B-DISEASE
,	201	202		|O
a	203	204		|O
disease	205	212		|O
frequently	213	223		|O
found	224	229		|O
in	230	232		|O
the	233	236		|O
elderly	237	244		|O
.	244	245		|O
This	246	250		|O
condition	251	260		|O
is	261	263		|O
frequently	264	274		|O
associated	275	285		|O
with	286	290		|O
frailty	291	298	frailty	|B-DISEASE
and	299	302		|O
disability	303	313	disability in aging	|B-DISEASE
in	314	316		|I-DISEASE
aging	317	322		|I-DISEASE
as	323	325		|O
well	326	330		|O
as	331	333		|O
the	334	337		|O
onset	338	343		|O
and	344	347		|O
progression	348	359		|O
of	360	362		|O
several	363	370		|O
geriatric	371	380	geriatric syndromes	|B-DISEASE
syndromes	381	390		|I-DISEASE
.	390	391		|O
Sarcopenia	392	402	Sarcopenia	|B-DISEASE
therefore	403	412		|O
must	413	417		|O
be	418	420		|O
managed	421	428		|O
with	429	433		|O
multidimensional	434	450		|O
approaches	451	461		|O
that	462	466		|O
include	467	474		|O
physical	475	483		|O
training	484	492		|O
,	492	493		|O
nutritional	494	505		|O
support	506	513		|O
,	513	514		|O
and	515	518		|O
metabolic	519	528		|O
and	529	532		|O
anabolic	533	541		|O
treatment	542	551		|O
.	551	552		|O
The	553	556		|O
purpose	557	564		|O
of	565	567		|O
our	568	571		|O
study	572	577		|O
was	578	581		|O
to	582	584		|O
assess	585	591		|O
the	592	595		|O
effect	596	602		|O
of	603	605		|O
an	606	608		|O
orally	609	615		|O
administered	616	628		|O
special	629	636		|O
mixture	637	644		|O
of	645	647		|O
amino	648	653		|O
acids	654	659		|O
(	660	661		|O
AAs	661	664		|O
)	664	665		|O
in	666	668		|O
elderly	669	676		|O
subjects	677	685		|O
with	686	690		|O
reduced	691	698		|O
lean	699	703		|O
body	704	708		|O
mass	709	713		|O
and	714	717		|O
sarcopenia	718	728	sarcopenia	|B-DISEASE
.	728	729		|O
A	730	731		|O
randomized	732	742		|O
,	742	743		|O
open	744	748		|O
-	748	749		|O
label	749	754		|O
,	754	755		|O
crossover	756	765		|O
study	766	771		|O
was	772	775		|O
conducted	776	785		|O
in	786	788		|O
41	789	791		|O
elderly	792	799		|O
subjects	800	808		|O
(	809	810		|O
age	810	813		|O
range	814	819		|O
:	819	820		|O
66-84	821	826		|O
years	827	832		|O
)	832	833		|O
with	834	838		|O
sarcopenia	839	849	sarcopenia	|B-DISEASE
,	849	850		|O
assigned	851	859		|O
to	860	862		|O
2	863	864		|O
distinct	865	873		|O
treatments	874	884		|O
(	885	886		|O
AAs	886	889		|O
and	890	893		|O
placebo	894	901		|O
)	901	902		|O
.	902	903		|O
All	904	907		|O
subjects	908	916		|O
had	917	920		|O
normal	921	927		|O
body	928	932		|O
weight	933	939		|O
(	940	941		|O
body	941	945		|O
mass	946	950		|O
index	951	956		|O
within	957	963		|O
19-23	964	969		|O
)	969	970		|O
.	970	971		|O
The	972	975		|O
AA	976	978		|O
treatment	979	988		|O
consisted	989	998		|O
of	999	1001		|O
70.6	1002	1006		|O
kcal	1007	1011		|O
/	1011	1012		|O
day	1012	1015		|O
(	1016	1017		|O
1	1017	1018		|O
kcal	1019	1023		|O
=	1024	1025		|O
4.2	1026	1029		|O
kJ	1030	1032		|O
)	1032	1033		|O
of	1034	1036		|O
8	1037	1038		|O
g	1039	1040		|O
of	1041	1043		|O
essential	1044	1053		|O
AA	1054	1056		|O
snacks	1057	1063		|O
,	1063	1064		|O
given	1065	1070		|O
at	1071	1073		|O
10	1074	1076		|O
:	1076	1077		|O
00	1077	1079		|O
am	1080	1082		|O
and	1083	1086		|O
5	1087	1088		|O
:	1088	1089		|O
00	1089	1091		|O
pm	1092	1094		|O
.	1094	1095		|O
Lean	1096	1100		|O
mass	1101	1105		|O
was	1106	1109		|O
measured	1110	1118		|O
with	1119	1123		|O
dual	1124	1128		|O
-	1128	1129		|O
energy	1129	1135		|O
x	1136	1137		|O
-	1137	1138		|O
ray	1138	1141		|O
absorptiometry	1142	1156		|O
in	1157	1159		|O
leg	1160	1163		|O
,	1163	1164		|O
arm	1165	1168		|O
,	1168	1169		|O
and	1170	1173		|O
trunk	1174	1179		|O
tissues	1180	1187		|O
.	1187	1188		|O
Significant	1189	1200		|O
increases	1201	1210		|O
in	1211	1213		|O
whole	1214	1219		|O
-	1219	1220		|O
body	1220	1224		|O
lean	1225	1229		|O
mass	1230	1234		|O
in	1235	1237		|O
all	1238	1241		|O
areas	1242	1247		|O
were	1248	1252		|O
seen	1253	1257		|O
after	1258	1263		|O
6	1264	1265		|O
months	1266	1272		|O
and	1273	1276		|O
more	1277	1281		|O
consistently	1282	1294		|O
after	1295	1300		|O
18	1301	1303		|O
months	1304	1310		|O
of	1311	1313		|O
oral	1314	1318		|O
nutritional	1319	1330		|O
supplementation	1331	1346		|O
with	1347	1351		|O
AAs	1352	1355		|O
.	1355	1356		|O
Fasting	1357	1364		|O
blood	1365	1370		|O
glucose	1371	1378		|O
,	1378	1379		|O
serum	1380	1385		|O
insulin	1386	1393		|O
,	1393	1394		|O
and	1395	1398		|O
homeostatic	1399	1410		|O
model	1411	1416		|O
assessment	1417	1427		|O
of	1428	1430		|O
insulin	1431	1438	insulin resistance	|B-DISEASE
resistance	1439	1449		|I-DISEASE
(	1450	1451		|O
an	1451	1453		|O
index	1454	1459		|O
of	1460	1462		|O
insulin	1463	1470	insulin resistance	|B-DISEASE
resistance	1471	1481		|I-DISEASE
)	1481	1482		|O
significantly	1483	1496		|O
decreased	1497	1506		|O
during	1507	1513		|O
AA	1514	1516		|O
treatment	1517	1526		|O
.	1526	1527		|O
Furthermore	1528	1539		|O
,	1539	1540		|O
a	1541	1542		|O
significant	1543	1554		|O
reduction	1555	1564		|O
in	1565	1567		|O
serum	1568	1573		|O
tumor	1574	1579		|O
necrosis	1580	1588		|O
factor	1589	1595		|O
-	1595	1596		|O
alpha	1596	1601		|O
(	1602	1603		|O
TNF	1603	1606		|O
-	1606	1607		|O
alpha	1607	1612		|O
)	1612	1613		|O
and	1614	1617		|O
a	1618	1619		|O
significant	1620	1631		|O
increase	1632	1640		|O
in	1641	1643		|O
both	1644	1648		|O
insulin	1649	1656		|O
-	1656	1657		|O
like	1657	1661		|O
growth	1662	1668		|O
factor	1669	1675		|O
-	1675	1676		|O
1	1676	1677		|O
(	1678	1679		|O
IGF	1679	1682		|O
-	1682	1683		|O
1	1683	1684		|O
)	1684	1685		|O
serum	1686	1691		|O
concentrations	1692	1706		|O
and	1707	1710		|O
in	1711	1713		|O
the	1714	1717		|O
IGF	1718	1721		|O
-	1721	1722		|O
1	1722	1723		|O
/	1723	1724		|O
TNF	1724	1727		|O
-	1727	1728		|O
alpha	1728	1733		|O
ratio	1734	1739		|O
were	1740	1744		|O
also	1745	1749		|O
found	1750	1755		|O
.	1755	1756		|O
No	1757	1759		|O
significant	1760	1771		|O
adverse	1772	1779		|O
effects	1780	1787		|O
were	1788	1792		|O
observed	1793	1801		|O
during	1802	1808		|O
AA	1809	1811		|O
treatment	1812	1821		|O
.	1821	1822		|O
These	1823	1828		|O
preliminary	1829	1840		|O
data	1841	1845		|O
indicate	1846	1854		|O
that	1855	1859		|O
nutritional	1860	1871		|O
supplements	1872	1883		|O
with	1884	1888		|O
the	1889	1892		|O
oral	1893	1897		|O
AA	1898	1900		|O
mixture	1901	1908		|O
significantly	1909	1922		|O
increased	1923	1932		|O
whole	1933	1938		|O
-	1938	1939		|O
body	1939	1943		|O
lean	1944	1948		|O
mass	1949	1953		|O
in	1954	1956		|O
elderly	1957	1964		|O
subjects	1965	1973		|O
with	1974	1978		|O
sarcopenia	1979	1989	sarcopenia	|B-DISEASE
.	1989	1990		|O
The	1991	1994		|O
improvement	1995	2006		|O
in	2007	2009		|O
the	2010	2013		|O
amount	2014	2020		|O
of	2021	2023		|O
whole	2024	2029		|O
-	2029	2030		|O
body	2030	2034		|O
lean	2035	2039		|O
mass	2040	2044		|O
could	2045	2050		|O
be	2051	2053		|O
linked	2054	2060		|O
to	2061	2063		|O
increased	2064	2073		|O
insulin	2074	2081		|O
sensitivity	2082	2093		|O
and	2094	2097		|O
anabolic	2098	2106		|O
conditions	2107	2117		|O
related	2118	2125		|O
to	2126	2128		|O
IGF	2129	2132		|O
-	2132	2133		|O
1	2133	2134		|O
availability	2135	2147		|O
.	2147	2148		|O

### 18824097
Lipid	0	5		|O
nanoparticles	6	19		|O
for	20	23		|O
parenteral	24	34		|O
delivery	35	43		|O
of	44	46		|O
actives	47	54		|O
.	54	55		|O
The	57	60		|O
present	61	68		|O
review	69	75		|O
compiles	76	84		|O
the	85	88		|O
applications	89	101		|O
of	102	104		|O
lipid	105	110		|O
nanoparticles	111	124		|O
mainly	125	131		|O
solid	132	137		|O
lipid	138	143		|O
nanoparticles	144	157		|O
(	158	159		|O
SLN	159	162		|O
)	162	163		|O
,	163	164		|O
nanostructured	165	179		|O
lipid	180	185		|O
carriers	186	194		|O
(	195	196		|O
NLC	196	199		|O
)	199	200		|O
and	201	204		|O
lipid	205	210		|O
drug	211	215		|O
conjugates	216	226		|O
(	227	228		|O
LDC	228	231		|O
)	231	232		|O
in	233	235		|O
parenteral	236	246		|O
delivery	247	255		|O
of	256	258		|O
pharmaceutical	259	273		|O
actives	274	281		|O
.	281	282		|O
The	283	286		|O
attempts	287	295		|O
to	296	298		|O
incorporate	299	310		|O
anticancer	311	321		|O
agents	322	328		|O
,	328	329		|O
imaging	330	337		|O
agents	338	344		|O
,	344	345		|O
antiparasitics	346	360		|O
,	360	361		|O
antiarthritics	362	376		|O
,	376	377		|O
genes	378	383		|O
for	384	387		|O
transfection	388	400		|O
,	400	401		|O
agents	402	408		|O
for	409	412		|O
liver	413	418		|O
,	418	419		|O
cardiovascular	420	434		|O
and	435	438		|O
central	439	446		|O
nervous	447	454		|O
system	455	461		|O
targeting	462	471		|O
have	472	476		|O
been	477	481		|O
summarized	482	492		|O
.	492	493		|O
The	494	497		|O
utility	498	505		|O
of	506	508		|O
lipid	509	514		|O
nanoparticles	515	528		|O
as	529	531		|O
adjuvant	532	540		|O
has	541	544		|O
been	545	549		|O
discussed	550	559		|O
separately	560	570		|O
.	570	571		|O
A	572	573		|O
special	574	581		|O
focus	582	587		|O
of	588	590		|O
this	591	595		|O
review	596	602		|O
is	603	605		|O
on	606	608		|O
toxicity	609	617		|O
caused	618	624		|O
by	625	627		|O
these	628	633		|O
kinds	634	639		|O
of	640	642		|O
lipid	643	648		|O
nanoparticles	649	662		|O
with	663	667		|O
a	668	669		|O
glance	670	676		|O
on	677	679		|O
the	680	683		|O
fate	684	688		|O
of	689	691		|O
lipid	692	697		|O
nanoparticles	698	711		|O
after	712	717		|O
their	718	723		|O
parenteral	724	734		|O
delivery	735	743		|O
in	744	746		|O
vivo	747	751		|O
viz	752	755		|O
the	756	759		|O
protein	760	767		|O
adsorption	768	778		|O
patterns	779	787		|O
.	787	788		|O

### 18679045
Role	0	4		|O
of	5	7		|O
physical	8	16		|O
chemical	17	25		|O
properties	26	36		|O
in	37	39		|O
drug	40	44		|O
relay	45	50		|O
into	51	55		|O
skin	56	60		|O
compartments	61	73		|O
.	73	74		|O
The	76	79		|O
ability	80	87		|O
of	88	90		|O
a	91	92		|O
drug	93	97		|O
to	98	100		|O
reach	101	106		|O
the	107	110		|O
interstitial	111	123		|O
fluid	124	129		|O
is	130	132		|O
an	133	135		|O
important	136	145		|O
aspect	146	152		|O
of	153	155		|O
drug	156	160		|O
efficacy	161	169		|O
-	170	171		|O
as	172	174		|O
a	175	176		|O
possible	177	185		|O
indicator	186	195		|O
of	196	198		|O
skin	199	203		|O
and	204	207		|O
cell	208	212		|O
compartment	213	224		|O
concentration	225	238		|O
.	238	239		|O
This	240	244		|O
overview	245	253		|O
addresses	254	263		|O
the	264	267		|O
relationship	268	280		|O
of	281	283		|O
the	284	287		|O
physical	288	296		|O
properties	297	307		|O
of	308	310		|O
several	311	318		|O
antibiotics	319	330		|O
to	331	333		|O
their	334	339		|O
ability	340	347		|O
to	348	350		|O
enter	351	356		|O
the	357	360		|O
interstitial	361	373		|O
fluid	374	379		|O
utilizing	380	389		|O
a	390	391		|O
cantharidin	392	403		|O
blister	404	411		|O
model	412	417		|O
.	417	418		|O
By	419	421		|O
collecting	422	432		|O
pharmacokinetic	433	448		|O
data	449	453		|O
for	454	457		|O
12	458	460		|O
antibiotics	461	472		|O
administered	473	485		|O
orally	486	492		|O
and	493	496		|O
11	497	499		|O
intravenously	500	513		|O
,	513	514		|O
we	515	517		|O
compared	518	526		|O
the	527	530		|O
fraction	531	539		|O
of	540	542		|O
drug	543	547		|O
that	548	552		|O
reaches	553	560		|O
the	561	564		|O
interstitial	565	577		|O
fluid	578	583		|O
(	584	585		|O
AUC	585	588		|O
(	588	589		|O
blister	589	596		|O
)	596	597		|O
/	597	598		|O
AUC	598	601		|O
(	601	602		|O
serum	602	607		|O
)	607	608		|O
)	608	609		|O
to	610	612		|O
partition	613	622		|O
coefficients	623	635		|O
.	635	636		|O
Following	637	646		|O
data	647	651		|O
analysis	652	660		|O
,	660	661		|O
we	662	664		|O
found	665	670		|O
no	671	673		|O
correlation	674	685		|O
(	686	687		|O
p	687	688		|O
=	689	690		|O
0.98	691	695		|O
and	696	699		|O
0.09	700	704		|O
,	704	705		|O
respectively	706	718		|O
)	718	719		|O
between	720	727		|O
hydrophobicity	728	742		|O
and	743	746		|O
the	747	750		|O
ability	751	758		|O
to	759	761		|O
reach	762	767		|O
the	768	771		|O
interstitium	772	784		|O
.	784	785		|O
Both	786	790		|O
orally	791	797		|O
and	798	801		|O
intravenously	802	815		|O
administered	816	828		|O
antibiotics	829	840		|O
display	841	848		|O
a	849	850		|O
strong	851	857		|O
linear	858	864		|O
correlation	865	876		|O
(	877	878		|O
p	878	879		|O
<	880	881		|O
0.001	882	887		|O
and	888	891		|O
p	892	893		|O
=	894	895		|O
0.006	896	901		|O
,	901	902		|O
respectively	903	915		|O
)	915	916		|O
in	917	919		|O
the	920	923		|O
total	924	929		|O
concentration	930	943		|O
found	944	949		|O
in	950	952		|O
the	953	956		|O
serum	957	962		|O
and	963	966		|O
interstitial	967	979		|O
fluid	980	985		|O
indicating	986	996		|O
that	997	1001		|O
serum	1002	1007		|O
concentration	1008	1021		|O
may	1022	1025		|O
be	1026	1028		|O
an	1029	1031		|O
important	1032	1041		|O
factor	1042	1048		|O
in	1049	1051		|O
dictating	1052	1061		|O
interstitial	1062	1074		|O
fluid	1075	1080		|O
concentration	1081	1094		|O
.	1094	1095		|O
This	1096	1100		|O
correlation	1101	1112		|O
may	1113	1116		|O
prove	1117	1122		|O
useful	1123	1129		|O
in	1130	1132		|O
clinical	1133	1141		|O
application	1142	1153		|O
as	1154	1156		|O
a	1157	1158		|O
means	1159	1164		|O
of	1165	1167		|O
determining	1168	1179		|O
interstitial	1180	1192		|O
fluid	1193	1198		|O
concentration	1199	1212		|O
by	1213	1215		|O
measuring	1216	1225		|O
only	1226	1230		|O
serum	1231	1236		|O
levels	1237	1243		|O
.	1243	1244		|O

### 18591543
Low	0	3		|O
-	3	4		|O
dose	4	8		|O
interleukin	9	20		|O
-	20	21		|O
2	21	22		|O
immunotherapy	23	36		|O
does	37	41		|O
not	42	45		|O
improve	46	53		|O
outcome	54	61		|O
of	62	64		|O
patients	65	73		|O
age	74	77		|O
60	78	80		|O
years	81	86		|O
and	87	90		|O
older	91	96		|O
with	97	101		|O
acute	102	107	acute myeloid leukemia	|B-DISEASE
myeloid	108	115		|I-DISEASE
leukemia	116	124		|I-DISEASE
in	125	127		|O
first	128	133		|O
complete	134	142		|O
remission	143	152		|O
:	152	153		|O
Cancer	154	160	Cancer	|B-DISEASE
and	161	164		|O
Leukemia	165	173	Leukemia	|B-DISEASE
Group	174	179		|O
B	180	181		|O
Study	182	187		|O
9720	188	192		|O
.	192	193		|O
PURPOSE	195	202		|O
:	202	203		|O
Cancer	204	210	Cancer	|B-DISEASE
and	211	214		|O
Leukemia	215	223	Leukemia	|B-DISEASE
Group	224	229		|O
B	230	231		|O
(	232	233		|O
CALGB	233	238		|O
)	238	239		|O
9720	240	244		|O
evaluated	245	254		|O
subcutaneous	255	267		|O
low	268	271		|O
-	271	272		|O
dose	272	276		|O
recombinant	277	288		|O
interleukin	289	300		|O
-	300	301		|O
2	301	302		|O
(	303	304		|O
rIL	304	307		|O
-	307	308		|O
2	308	309		|O
)	309	310		|O
maintenance	311	322		|O
immunotherapy	323	336		|O
as	337	339		|O
a	340	341		|O
strategy	342	350		|O
for	351	354		|O
prolonging	355	365		|O
remission	366	375		|O
in	376	378		|O
older	379	384		|O
patients	385	393		|O
with	394	398		|O
acute	399	404	acute myeloid leukemia	|B-DISEASE
myeloid	405	412		|I-DISEASE
leukemia	413	421		|I-DISEASE
(	422	423		|O
AML	423	426	AML	|B-DISEASE
)	426	427		|O
.	427	428		|O
PATIENTS	429	437		|O
AND	438	441		|O
METHODS	442	449		|O
:	449	450		|O
AML	451	454	AML	|B-DISEASE
patients	455	463		|O
age	464	467		|O
60	468	470		|O
years	471	476		|O
and	477	480		|O
older	481	486		|O
in	487	489		|O
first	490	495		|O
complete	496	504		|O
remission	505	514		|O
after	515	520		|O
induction	521	530		|O
and	531	534		|O
consolidation	535	548		|O
chemotherapy	549	561		|O
were	562	566		|O
randomly	567	575		|O
assigned	576	584		|O
to	585	587		|O
no	588	590		|O
further	591	598		|O
therapy	599	606		|O
or	607	609		|O
a	610	611		|O
90	612	614		|O
-	614	615		|O
day	615	618		|O
regimen	619	626		|O
of	627	629		|O
14	630	632		|O
-	632	633		|O
day	633	636		|O
cycles	637	643		|O
of	644	646		|O
low	647	650		|O
-	650	651		|O
dose	651	655		|O
rIL	656	659		|O
-	659	660		|O
2	660	661		|O
,	661	662		|O
aimed	663	668		|O
at	669	671		|O
expanding	672	681		|O
natural	682	689		|O
killer	690	696		|O
(	697	698		|O
NK	698	700		|O
)	700	701		|O
cells	702	707		|O
,	707	708		|O
followed	709	717		|O
by	718	720		|O
3	721	722		|O
-	722	723		|O
day	723	726		|O
higher	727	733		|O
doses	734	739		|O
aimed	740	745		|O
at	746	748		|O
activating	749	759		|O
cytotoxicity	760	772		|O
of	773	775		|O
expanded	776	784		|O
NK	785	787		|O
cells	788	793		|O
to	794	796		|O
lyse	797	801		|O
residual	802	810		|O
AML	811	814		|O
cells	815	820		|O
.	820	821		|O
All	822	825		|O
randomly	826	834		|O
assigned	835	843		|O
patients	844	852		|O
were	853	857		|O
included	858	866		|O
in	867	869		|O
an	870	872		|O
intention	873	882		|O
-	882	883		|O
to	883	885		|O
-	885	886		|O
treat	886	891		|O
analysis	892	900		|O
.	900	901		|O
RESULTS	902	909		|O
:	909	910		|O
A	911	912		|O
total	913	918		|O
of	919	921		|O
163	922	925		|O
(	926	927		|O
64%	927	930		|O
)	930	931		|O
of	932	934		|O
254	935	938		|O
patients	939	947		|O
who	948	951		|O
completed	952	961		|O
induction	962	971		|O
and	972	975		|O
consolidation	976	989		|O
chemotherapy	990	1002		|O
on	1003	1005		|O
CALGB	1006	1011		|O
9720	1012	1016		|O
were	1017	1021		|O
randomly	1022	1030		|O
assigned	1031	1039		|O
to	1040	1042		|O
rIL	1043	1046		|O
-	1046	1047		|O
2	1047	1048		|O
(	1049	1050		|O
n	1050	1051		|O
=	1052	1053		|O
81	1054	1056		|O
)	1056	1057		|O
or	1058	1060		|O
no	1061	1063		|O
further	1064	1071		|O
therapy	1072	1079		|O
(	1080	1081		|O
n	1081	1082		|O
=	1083	1084		|O
82	1085	1087		|O
)	1087	1088		|O
;	1088	1089		|O
the	1090	1093		|O
most	1094	1098		|O
common	1099	1105		|O
reasons	1106	1113		|O
for	1114	1117		|O
lack	1118	1122		|O
of	1123	1125		|O
random	1126	1132		|O
assignment	1133	1143		|O
were	1144	1148		|O
patient	1149	1156		|O
refusal	1157	1164		|O
and	1165	1168		|O
relapse	1169	1176		|O
.	1176	1177		|O
Fifteen	1178	1185		|O
patients	1186	1194		|O
randomly	1195	1203		|O
assigned	1204	1212		|O
to	1213	1215		|O
rIL	1216	1219		|O
-	1219	1220		|O
2	1220	1221		|O
never	1222	1227		|O
initiated	1228	1237		|O
it	1238	1240		|O
because	1241	1248		|O
of	1249	1251		|O
refusal	1252	1259		|O
,	1259	1260		|O
intercurrent	1261	1273		|O
medical	1274	1281		|O
problems	1282	1290		|O
,	1290	1291		|O
or	1292	1294		|O
relapse	1295	1302		|O
,	1302	1303		|O
and	1304	1307		|O
24	1308	1310		|O
patients	1311	1319		|O
initiated	1320	1329		|O
rIL	1330	1333		|O
-	1333	1334		|O
2	1334	1335		|O
but	1336	1339		|O
stopped	1340	1347		|O
early	1348	1353		|O
because	1354	1361		|O
of	1362	1364		|O
toxicity	1365	1373		|O
or	1374	1376		|O
relapse	1377	1384		|O
.	1384	1385		|O
Grade	1386	1391		|O
4	1392	1393		|O
toxicities	1394	1404		|O
during	1405	1411		|O
rIL	1412	1415		|O
-	1415	1416		|O
2	1416	1417		|O
therapy	1418	1425		|O
included	1426	1434		|O
thrombocytopenia	1435	1451	thrombocytopenia	|B-ADVERSE
(	1452	1453		|O
65%	1453	1456		|O
)	1456	1457		|O
and	1458	1461		|O
neutropenia	1462	1473	neutropenia	|B-ADVERSE
(	1474	1475		|O
64%	1475	1478		|O
)	1478	1479		|O
,	1479	1480		|O
and	1481	1484		|O
grade	1485	1490		|O
3	1491	1492		|O
toxicities	1493	1503		|O
included	1504	1512		|O
anemia	1513	1519	anemia	|B-ADVERSE
(	1520	1521		|O
33%	1521	1524		|O
)	1524	1525		|O
,	1525	1526		|O
infection	1527	1536	infection	|B-ADVERSE
(	1537	1538		|O
24%	1538	1541		|O
)	1541	1542		|O
and	1543	1546		|O
malaise	1547	1554	malaise	|B-ADVERSE
/	1554	1555		|O
fatigue	1555	1562	fatigue	|B-ADVERSE
(	1563	1564		|O
14%	1564	1567		|O
)	1567	1568		|O
.	1568	1569		|O
Forty	1570	1575		|O
-	1575	1576		|O
two	1576	1579		|O
patients	1580	1588		|O
(	1589	1590		|O
52%	1590	1593		|O
)	1593	1594		|O
randomly	1595	1603		|O
assigned	1604	1612		|O
to	1613	1615		|O
rIL	1616	1619		|O
-	1619	1620		|O
2	1620	1621		|O
completed	1622	1631		|O
the	1632	1635		|O
full	1636	1640		|O
90	1641	1643		|O
-	1643	1644		|O
day	1644	1647		|O
course	1648	1654		|O
.	1654	1655		|O
Patients	1656	1664		|O
in	1665	1667		|O
both	1668	1672		|O
arms	1673	1677		|O
had	1678	1681		|O
similar	1682	1689		|O
distributions	1690	1703		|O
of	1704	1706		|O
both	1707	1711		|O
disease	1712	1719		|O
-	1719	1720		|O
free	1720	1724		|O
(	1725	1726		|O
combined	1726	1734		|O
median	1735	1741		|O
=	1742	1743		|O
6.1	1744	1747		|O
months	1748	1754		|O
;	1754	1755		|O
P	1756	1757		|O
=	1758	1759		|O
.47	1760	1763		|O
)	1763	1764		|O
and	1765	1768		|O
overall	1769	1776		|O
survival	1777	1785		|O
(	1786	1787		|O
combined	1787	1795		|O
median	1796	1802		|O
=	1803	1804		|O
14.7	1805	1809		|O
months	1810	1816		|O
;	1816	1817		|O
P	1818	1819		|O
=	1820	1821		|O
.61	1822	1825		|O
)	1825	1826		|O
after	1827	1832		|O
random	1833	1839		|O
assignment	1840	1850		|O
.	1850	1851		|O
Moreover	1852	1860		|O
,	1860	1861		|O
the	1862	1865		|O
42	1866	1868		|O
patients	1869	1877		|O
who	1878	1881		|O
completed	1882	1891		|O
all	1892	1895		|O
planned	1896	1903		|O
therapy	1904	1911		|O
did	1912	1915		|O
not	1916	1919		|O
show	1920	1924		|O
prolongation	1925	1937		|O
of	1938	1940		|O
disease	1941	1948		|O
-	1948	1949		|O
free	1949	1953		|O
or	1954	1956		|O
overall	1957	1964		|O
survival	1965	1973		|O
.	1973	1974		|O
CONCLUSION	1975	1985		|O
:	1985	1986		|O
Low	1987	1990		|O
-	1990	1991		|O
dose	1991	1995		|O
rIL	1996	1999		|O
-	1999	2000		|O
2	2000	2001		|O
maintenance	2002	2013		|O
immunotherapy	2014	2027		|O
is	2028	2030		|O
not	2031	2034		|O
a	2035	2036		|O
successful	2037	2047		|O
strategy	2048	2056		|O
in	2057	2059		|O
older	2060	2065		|O
AML	2066	2069	AML	|B-DISEASE
patients	2070	2078		|O
.	2078	2079		|O

### 18541635
Variable	0	8		|O
response	9	17		|O
to	18	20		|O
opioid	21	27		|O
treatment	28	37		|O
:	37	38		|O
any	39	42		|O
genetic	43	50		|O
predictors	51	61		|O
within	62	68		|O
sight	69	74		|O
?	74	75		|O
The	77	80		|O
aim	81	84		|O
of	85	87		|O
this	88	92		|O
literature	93	103		|O
review	104	110		|O
is	111	113		|O
to	114	116		|O
summarize	117	126		|O
and	127	130		|O
discuss	131	138		|O
the	139	142		|O
available	143	152		|O
evidence	153	161		|O
for	162	165		|O
a	166	167		|O
relationship	168	180		|O
between	181	188		|O
polymorphisms	189	202		|O
in	203	205		|O
human	206	211		|O
genes	212	217		|O
and	218	221		|O
variability	222	233		|O
in	234	236		|O
opioid	237	243		|O
analgesia	244	253		|O
and	254	257		|O
side	258	262		|O
effects	263	270		|O
among	271	276		|O
patients	277	285		|O
treated	286	293		|O
for	294	297		|O
moderate	298	306		|O
or	307	309		|O
severe	310	316		|O
pain	317	321	pain	|B-DISEASE
.	321	322		|O
The	323	326		|O
evidence	327	335		|O
supporting	336	346		|O
a	347	348		|O
role	349	353		|O
of	354	356		|O
certain	357	364		|O
alleles	365	372		|O
,	372	373		|O
genotypes	374	383		|O
or	384	386		|O
haplotypes	387	397		|O
in	398	400		|O
modulation	401	411		|O
of	412	414		|O
opioid	415	421		|O
analgesia	422	431		|O
is	432	434		|O
derived	435	442		|O
from	443	447		|O
a	448	449		|O
limited	450	457		|O
number	458	464		|O
of	465	467		|O
studies	468	475		|O
,	475	476		|O
a	477	478		|O
limited	479	486		|O
number	487	493		|O
of	494	496		|O
genes	497	502		|O
and	503	506		|O
a	507	508		|O
limited	509	516		|O
number	517	523		|O
of	524	526		|O
opioids	527	534		|O
.	534	535		|O
Although	536	544		|O
several	545	552		|O
interesting	553	564		|O
candidates	565	575		|O
have	576	580		|O
emerged	581	588		|O
as	589	591		|O
potentially	592	603		|O
relevant	604	612		|O
factors	613	620		|O
,	620	621		|O
only	622	626		|O
for	627	630		|O
one	631	634		|O
polymorphism	635	647		|O
,	647	648		|O
the	649	652		|O
prevalent	653	662		|O
118A	663	667		|O
>	667	668		|O
G	668	669		|O
of	670	672		|O
the	673	676		|O
micro	677	682		|O
-	682	683		|O
opioid	683	689		|O
receptor	690	698		|O
,	698	699		|O
the	700	703		|O
accumulated	704	715		|O
evidence	716	724		|O
is	725	727		|O
sufficient	728	738		|O
to	739	741		|O
suggest	742	749		|O
a	750	751		|O
clinically	752	762		|O
relevant	763	771		|O
effect	772	778		|O
for	779	782		|O
an	783	785		|O
opioid	786	792		|O
used	793	797		|O
for	798	801		|O
moderate	802	810		|O
or	811	813		|O
severe	814	820		|O
pain	821	825	pain	|B-DISEASE
.	825	826		|O
Still	827	832		|O
the	833	836		|O
data	837	841		|O
are	842	845		|O
valid	846	851		|O
only	852	856		|O
at	857	859		|O
the	860	863		|O
group	864	869		|O
level	870	875		|O
and	876	879		|O
cannot	880	886		|O
be	887	889		|O
used	890	894		|O
to	895	897		|O
predict	898	905		|O
treatment	906	915		|O
outcome	916	923		|O
in	924	926		|O
individual	927	937		|O
patients	938	946		|O
.	946	947		|O
Only	948	952		|O
a	953	954		|O
few	955	958		|O
of	959	961		|O
the	962	965		|O
symptoms	966	974		|O
often	975	980		|O
seen	981	985		|O
as	986	988		|O
opioid	989	995		|O
adverse	996	1003		|O
effects	1004	1011		|O
in	1012	1014		|O
palliative	1015	1025		|O
care	1026	1030		|O
,	1030	1031		|O
such	1032	1036		|O
as	1037	1039		|O
nausea	1040	1046	nausea	|B-ADVERSE
,	1046	1047		|O
vomiting	1048	1056	vomiting	|B-ADVERSE
,	1056	1057		|O
constipation	1058	1070	constipation	|B-ADVERSE
and	1071	1074		|O
sedation	1075	1083	sedation	|B-ADVERSE
,	1083	1084		|O
have	1085	1089		|O
been	1090	1094		|O
associated	1095	1105		|O
with	1106	1110		|O
genetic	1111	1118		|O
variants	1119	1127		|O
in	1128	1130		|O
various	1131	1138		|O
genes	1139	1144		|O
,	1144	1145		|O
but	1146	1149		|O
the	1150	1153		|O
results	1154	1161		|O
have	1162	1166		|O
been	1167	1171		|O
based	1172	1177		|O
on	1178	1180		|O
case	1181	1185		|O
reports	1186	1193		|O
,	1193	1194		|O
healthy	1195	1202		|O
volunteers	1203	1213		|O
or	1214	1216		|O
post	1217	1221		|O
-	1221	1222		|O
operative	1222	1231		|O
patients	1232	1240		|O
.	1240	1241		|O
So	1242	1244		|O
far	1245	1248		|O
,	1248	1249		|O
there	1250	1255		|O
is	1256	1258		|O
no	1259	1261		|O
clear	1262	1267		|O
evidence	1268	1276		|O
that	1277	1281		|O
genetic	1282	1289		|O
markers	1290	1297		|O
can	1298	1301		|O
be	1302	1304		|O
used	1305	1309		|O
to	1310	1312		|O
predict	1313	1320		|O
opioid	1321	1327		|O
efficacy	1328	1336		|O
or	1337	1339		|O
adverse	1340	1347		|O
effects	1348	1355		|O
in	1356	1358		|O
palliative	1359	1369		|O
care	1370	1374		|O
patients	1375	1383		|O
.	1383	1384		|O
This	1385	1389		|O
reflects	1390	1398		|O
the	1399	1402		|O
general	1403	1410		|O
lack	1411	1415		|O
of	1416	1418		|O
studies	1419	1426		|O
performed	1427	1436		|O
in	1437	1439		|O
the	1440	1443		|O
context	1444	1451		|O
of	1452	1454		|O
palliative	1455	1465		|O
care	1466	1470		|O
,	1470	1471		|O
the	1472	1475		|O
lack	1476	1480		|O
of	1481	1483		|O
sufficiently	1484	1496		|O
scaled	1497	1503		|O
studies	1504	1511		|O
and	1512	1515		|O
the	1516	1519		|O
lack	1520	1524		|O
of	1525	1527		|O
international	1528	1541		|O
standards	1542	1551		|O
for	1552	1555		|O
the	1556	1559		|O
assessment	1560	1570		|O
of	1571	1573		|O
subjective	1574	1584		|O
symptoms	1585	1593		|O
.	1593	1594		|O

### 18640215
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
geraniol	29	37		|O
.	37	38		|O
A	40	41		|O
toxicologic	42	53		|O
and	54	57		|O
dermatologic	58	70		|O
review	71	77		|O
of	78	80		|O
geraniol	81	89		|O
when	90	94		|O
used	95	99		|O
as	100	102		|O
a	103	104		|O
fragrance	105	114		|O
ingredient	115	125		|O
is	126	128		|O
presented	129	138		|O
.	138	139		|O

### 18697792
Inhibition	0	10		|O
of	11	13		|O
class	14	19		|O
I	20	21		|O
histone	22	29		|O
deacetylase	30	41		|O
with	42	46		|O
an	47	49		|O
apicidin	50	58		|O
derivative	59	69		|O
prevents	70	78		|O
cardiac	79	86	cardiac hypertrophy	|B-DISEASE
hypertrophy	87	98		|I-DISEASE
and	99	102		|O
failure	103	110		|O
.	110	111		|O
AIMS	113	117		|O
:	117	118		|O
Recent	119	125		|O
studies	126	133		|O
have	134	138		|O
demonstrated	139	151		|O
the	152	155		|O
importance	156	166		|O
of	167	169		|O
chromatin	170	179		|O
remodelling	180	191		|O
via	192	195		|O
histone	196	203		|O
acetylation	204	215		|O
/	215	216		|O
deacetylation	216	229		|O
for	230	233		|O
the	234	237		|O
control	238	245		|O
of	246	248		|O
cardiac	249	256		|O
gene	257	261		|O
expression	262	272		|O
.	272	273		|O
Specific	274	282		|O
histone	283	290		|O
deacetylases	291	303		|O
(	304	305		|O
HDACs	305	310		|O
)	310	311		|O
can	312	315		|O
,	315	316		|O
in	317	319		|O
fact	320	324		|O
,	324	325		|O
play	326	330		|O
a	331	332		|O
positive	333	341		|O
or	342	344		|O
negative	345	353		|O
role	354	358		|O
in	359	361		|O
determining	362	373		|O
cardiac	374	381		|O
myocyte	382	389		|O
(	390	391		|O
CM	391	393		|O
)	393	394		|O
size	395	399		|O
.	399	400		|O
Here	401	405		|O
,	405	406		|O
we	407	409		|O
report	410	416		|O
on	417	419		|O
the	420	423		|O
effect	424	430		|O
on	431	433		|O
hypertrophy	434	445	hypertrophy	|B-DISEASE
development	446	457		|O
of	458	460		|O
three	461	466		|O
inhibitors	467	477		|O
(	478	479		|O
HDACi	479	484		|O
)	484	485		|O
of	486	488		|O
class	489	494		|O
I	495	496		|O
HDACs	497	502		|O
.	502	503		|O
METHODS	504	511		|O
AND	512	515		|O
RESULTS	516	523		|O
:	523	524		|O
The	525	528		|O
compounds	529	538		|O
were	539	543		|O
first	544	549		|O
analysed	550	558		|O
in	559	561		|O
vitro	562	567		|O
by	568	570		|O
scoring	571	578		|O
hypertrophy	579	590	hypertrophy	|B-DISEASE
,	590	591		|O
expression	592	602		|O
of	603	605		|O
foetal	606	612		|O
genes	613	618		|O
,	618	619		|O
and	620	623		|O
apoptosis	624	633		|O
of	634	636		|O
neonatal	637	645		|O
rat	646	649		|O
CMs	650	653		|O
stimulated	654	664		|O
with	665	669		|O
phenylephrine	670	683		|O
,	683	684		|O
an	685	687		|O
alpha1	688	694		|O
-	694	695		|O
adrenergic	695	705		|O
agonist	706	713		|O
.	713	714		|O
This	715	719		|O
initial	720	727		|O
screening	728	737		|O
indicated	738	747		|O
that	748	752		|O
a	753	754		|O
truncated	755	764		|O
derivative	765	775		|O
of	776	778		|O
apicidin	779	787		|O
with	788	792		|O
class	793	798		|O
I	799	800		|O
HDAC	801	805		|O
specificity	806	817		|O
,	817	818		|O
denoted	819	826		|O
API	827	830		|O
-	830	831		|O
D	831	832		|O
,	832	833		|O
had	834	837		|O
the	838	841		|O
highest	842	849		|O
efficacy	850	858		|O
to	859	861		|O
toxicity	862	870		|O
ratio	871	876		|O
,	876	877		|O
and	878	881		|O
was	882	885		|O
thus	886	890		|O
selected	891	899		|O
for	900	903		|O
further	904	911		|O
analysis	912	920		|O
in	921	923		|O
vivo	924	928		|O
.	928	929		|O
Administration	930	944		|O
of	945	947		|O
this	948	952		|O
drug	953	957		|O
significantly	958	971		|O
decreased	972	981		|O
myocardial	982	992	myocardial hypertrophy	|B-DISEASE
hypertrophy	993	1004		|I-DISEASE
and	1005	1008		|O
foetal	1009	1015		|O
gene	1016	1020		|O
expression	1021	1031		|O
after	1032	1037		|O
1	1038	1039		|O
week	1040	1044		|O
of	1045	1047		|O
pressure	1048	1056		|O
overload	1057	1065		|O
induced	1066	1073		|O
by	1074	1076		|O
thoracic	1077	1085		|O
aortic	1086	1092		|O
constriction	1093	1105		|O
(	1106	1107		|O
TAC	1107	1110		|O
)	1110	1111		|O
in	1112	1114		|O
mice	1115	1119		|O
.	1119	1120		|O
After	1121	1126		|O
9	1127	1128		|O
weeks	1129	1134		|O
of	1135	1137		|O
TAC	1138	1141		|O
,	1141	1142		|O
when	1143	1147		|O
manifest	1148	1156		|O
heart	1157	1162	heart failure	|B-DISEASE
failure	1163	1170		|I-DISEASE
is	1171	1173		|O
encountered	1174	1185		|O
,	1185	1186		|O
mice	1187	1191		|O
treated	1192	1199		|O
with	1200	1204		|O
API	1205	1208		|O
-	1208	1209		|O
D	1209	1210		|O
presented	1211	1220		|O
with	1221	1225		|O
significantly	1226	1239		|O
improved	1240	1248		|O
echocardiographic	1249	1266		|O
and	1267	1270		|O
haemodynamic	1271	1283		|O
parameters	1284	1294		|O
of	1295	1297		|O
cardiac	1298	1305		|O
function	1306	1314		|O
when	1315	1319		|O
compared	1320	1328		|O
with	1329	1333		|O
untreated	1334	1343		|O
TAC	1344	1347		|O
-	1347	1348		|O
operated	1348	1356		|O
mice	1357	1361		|O
.	1361	1362		|O
CONCLUSION	1363	1373		|O
:	1373	1374		|O
The	1375	1378		|O
apicidin	1379	1387		|O
derivative	1388	1398		|O
,	1398	1399		|O
API	1400	1403		|O
-	1403	1404		|O
D	1404	1405		|O
,	1405	1406		|O
is	1407	1409		|O
capable	1410	1417		|O
of	1418	1420		|O
reducing	1421	1429		|O
hypertrophy	1430	1441	hypertrophy	|B-DISEASE
and	1442	1445		|O
,	1445	1446		|O
consequently	1447	1459		|O
,	1459	1460		|O
the	1461	1464		|O
transition	1465	1475		|O
to	1476	1478		|O
heart	1479	1484	heart failure	|B-DISEASE
failure	1485	1492		|I-DISEASE
in	1493	1495		|O
mice	1496	1500		|O
subjected	1501	1510		|O
to	1511	1513		|O
TAC	1514	1517		|O
.	1517	1518		|O
Treatment	1519	1528		|O
with	1529	1533		|O
this	1534	1538		|O
substance	1539	1548		|O
,	1548	1549		|O
therefore	1550	1559		|O
,	1559	1560		|O
holds	1561	1566		|O
promise	1567	1574		|O
as	1575	1577		|O
an	1578	1580		|O
important	1581	1590		|O
therapeutic	1591	1602		|O
option	1603	1609		|O
for	1610	1613		|O
heart	1614	1619	heart failure	|B-DISEASE
failure	1620	1627		|I-DISEASE
.	1627	1628		|O

### 18925770
Peptide	0	7		|O
-	7	8		|O
mediated	8	16		|O
cellular	17	25		|O
uptake	26	32		|O
of	33	35		|O
cryptophane	36	47		|O
.	47	48		|O
Cryptophane	50	61		|O
-	61	62		|O
A	62	63		|O
has	64	67		|O
generated	68	77		|O
considerable	78	90		|O
interest	91	99		|O
based	100	105		|O
on	106	108		|O
its	109	112		|O
high	113	117		|O
affinity	118	126		|O
for	127	130		|O
xenon	131	136		|O
and	137	140		|O
potential	141	150		|O
for	151	154		|O
creating	155	163		|O
biosensors	164	174		|O
for	175	178		|O
(	179	180		|O
129	180	183		|O
)	183	184		|O
Xe	184	186		|O
nuclear	187	194		|O
magnetic	195	203		|O
resonance	204	213		|O
(	214	215		|O
NMR	215	218		|O
)	218	219		|O
spectroscopy	220	232		|O
.	232	233		|O
Here	234	238		|O
,	238	239		|O
we	240	242		|O
report	243	249		|O
the	250	253		|O
cellular	254	262		|O
delivery	263	271		|O
of	272	274		|O
three	275	280		|O
peptide	281	288		|O
-	288	289		|O
functionalized	289	303		|O
cryptophane	304	315		|O
biosensors	316	326		|O
.	326	327		|O
Cryptophanes	328	340		|O
were	341	345		|O
delivered	346	355		|O
using	356	361		|O
two	362	365		|O
cationic	366	374		|O
cell	375	379		|O
penetrating	380	391		|O
peptides	392	400		|O
into	401	405		|O
several	406	413		|O
human	414	419		|O
cancer	420	426	cancer	|B-DISEASE
and	427	430		|O
normal	431	437		|O
cell	438	442		|O
lines	443	448		|O
.	448	449		|O
An	450	452		|O
RGD	453	456		|O
peptide	457	464		|O
targeting	465	474		|O
alpha	475	480		|O
(	480	481		|O
v	481	482		|O
)	482	483		|O
beta	483	487		|O
(	487	488		|O
3	488	489		|O
)	489	490		|O
integrin	491	499		|O
receptor	500	508		|O
was	509	512		|O
shown	513	518		|O
to	519	521		|O
increase	522	530		|O
specificity	531	542		|O
of	543	545		|O
cryptophane	546	557		|O
cell	558	562		|O
uptake	563	569		|O
.	569	570		|O
Labeling	571	579		|O
the	580	583		|O
peptides	584	592		|O
with	593	597		|O
Cy3	598	601		|O
made	602	606		|O
it	607	609		|O
possible	610	618		|O
to	619	621		|O
monitor	622	629		|O
cellular	630	638		|O
delivery	639	647		|O
using	648	653		|O
confocal	654	662		|O
laser	663	668		|O
scanning	669	677		|O
microscopy	678	688		|O
.	688	689		|O
The	690	693		|O
peptido	694	701		|O
-	701	702		|O
cryptophanes	702	714		|O
were	715	719		|O
determined	720	730		|O
to	731	733		|O
be	734	736		|O
relatively	737	747		|O
nontoxic	748	756		|O
by	757	759		|O
MTT	760	763		|O
assay	764	769		|O
at	770	772		|O
the	773	776		|O
micromolar	777	787		|O
cryptophane	788	799		|O
concentrations	800	814		|O
that	815	819		|O
are	820	823		|O
required	824	832		|O
for	833	836		|O
(	837	838		|O
129	838	841		|O
)	841	842		|O
Xe	842	844		|O
NMR	845	848		|O
biosensing	849	859		|O
experiments	860	871		|O
.	871	872		|O

### 18709447
Preparation	0	11		|O
of	12	14		|O
BMP	15	18		|O
-	18	19		|O
2	19	20		|O
containing	21	31		|O
bovine	32	38		|O
serum	39	44		|O
albumin	45	52		|O
(	53	54		|O
BSA	54	57		|O
)	57	58		|O
nanoparticles	59	72		|O
stabilized	73	83		|O
by	84	86		|O
polymer	87	94		|O
coating	95	102		|O
.	102	103		|O
PURPOSE	105	112		|O
:	112	113		|O
The	114	117		|O
purpose	118	125		|O
of	126	128		|O
this	129	133		|O
study	134	139		|O
was	140	143		|O
to	144	146		|O
investigate	147	158		|O
the	159	162		|O
preparation	163	174		|O
process	175	182		|O
of	183	185		|O
bone	186	190		|O
morphogenetic	191	204		|O
protein	205	212		|O
-	212	213		|O
2	213	214		|O
(	215	216		|O
BMP	216	219		|O
-	219	220		|O
2	220	221		|O
)	221	222		|O
containing	223	233		|O
bovine	234	240		|O
serum	241	246		|O
albumin	247	254		|O
(	255	256		|O
BSA	256	259		|O
)	259	260		|O
nanoparticles	261	274		|O
(	275	276		|O
NPs	276	279		|O
)	279	280		|O
,	280	281		|O
and	282	285		|O
to	286	288		|O
assess	289	295		|O
the	296	299		|O
bioactivity	300	311		|O
of	312	314		|O
BMP	315	318		|O
-	318	319		|O
2	319	320		|O
encapsulated	321	333		|O
in	334	336		|O
such	337	341		|O
NPs	342	345		|O
.	345	346		|O
METHODS	347	354		|O
:	354	355		|O
The	356	359		|O
NPs	360	363		|O
were	364	368		|O
prepared	369	377		|O
by	378	380		|O
a	381	382		|O
coacervation	383	395		|O
method	396	402		|O
,	402	403		|O
and	404	407		|O
the	408	411		|O
effects	412	419		|O
of	420	422		|O
process	423	430		|O
parameters	431	441		|O
on	442	444		|O
NP	445	447		|O
size	448	452		|O
and	453	456		|O
polydispersity	457	471		|O
were	472	476		|O
examined	477	485		|O
.	485	486		|O
Polymer	487	494		|O
coated	495	501		|O
NPs	502	505		|O
were	506	510		|O
characterized	511	524		|O
with	525	529		|O
respect	530	537		|O
to	538	540		|O
amount	541	547		|O
of	548	550		|O
adsorbed	551	559		|O
polymer	560	567		|O
,	567	568		|O
particle	569	577		|O
size	578	582		|O
and	583	586		|O
zeta	587	591		|O
potential	592	601		|O
.	601	602		|O
Using	603	608		|O
bone	609	613		|O
marrow	614	620		|O
stromal	621	628		|O
cells	629	634		|O
(	635	636		|O
BMSC	636	640		|O
)	640	641		|O
,	641	642		|O
biocompatibility	643	659		|O
of	660	662		|O
the	663	666		|O
NPs	667	670		|O
was	671	674		|O
investigated	675	687		|O
by	688	690		|O
the	691	694		|O
3	695	696		|O
-	696	697		|O
(	697	698		|O
4,5	698	701		|O
-	701	702		|O
dimethylthiazol	702	717		|O
-	717	718		|O
2	718	719		|O
-	719	720		|O
yl	720	722		|O
)	722	723		|O
-	723	724		|O
2,5	724	727		|O
-	727	728		|O
diphenyl	728	736		|O
-	736	737		|O
tetrazolium	737	748		|O
bromide	749	756		|O
(	757	758		|O
MTT	758	761		|O
)	761	762		|O
Assay	763	768		|O
,	768	769		|O
and	770	773		|O
bioactivity	774	785		|O
of	786	788		|O
the	789	792		|O
encapsulated	793	805		|O
BMP	806	809		|O
-	809	810		|O
2	810	811		|O
was	812	815		|O
investigated	816	828		|O
by	829	831		|O
alkaline	832	840		|O
phosphatase	841	852		|O
(	853	854		|O
ALP	854	857		|O
)	857	858		|O
induction	859	868		|O
and	869	872		|O
calcification	873	886		|O
.	886	887		|O
RESULTS	888	895		|O
:	895	896		|O
The	897	900		|O
size	901	905		|O
of	906	908		|O
NPs	909	912		|O
could	913	918		|O
be	919	921		|O
controlled	922	932		|O
in	933	935		|O
the	936	939		|O
50-400	940	946		|O
nm	947	949		|O
range	950	955		|O
by	956	958		|O
process	959	966		|O
parameters	967	977		|O
including	978	987		|O
BSA	988	991		|O
concentration	992	1005		|O
,	1005	1006		|O
non	1007	1010		|O
-	1010	1011		|O
solvent	1011	1018		|O
:	1018	1019		|O
solvent	1019	1026		|O
ratio	1027	1032		|O
and	1033	1036		|O
pH	1037	1039		|O
value	1040	1045		|O
.	1045	1046		|O
After	1047	1052		|O
coating	1053	1060		|O
with	1061	1065		|O
cationic	1066	1074		|O
polymers	1075	1083		|O
,	1083	1084		|O
the	1085	1088		|O
particle	1089	1097		|O
size	1098	1102		|O
and	1103	1106		|O
zeta	1107	1111		|O
potential	1112	1121		|O
were	1122	1126		|O
significantly	1127	1140		|O
increased	1141	1150		|O
.	1150	1151		|O
MTT	1152	1155		|O
assay	1156	1161		|O
indicated	1162	1171		|O
no	1172	1174		|O
toxicity	1175	1183		|O
of	1184	1186		|O
both	1187	1191		|O
the	1192	1195		|O
uncoated	1196	1204		|O
and	1205	1208		|O
coated	1209	1215		|O
NPs	1216	1219		|O
on	1220	1222		|O
BMSC	1223	1227		|O
.	1227	1228		|O
Based	1229	1234		|O
on	1235	1237		|O
ALP	1238	1241		|O
induction	1242	1251		|O
and	1252	1255		|O
calcification	1256	1269		|O
,	1269	1270		|O
full	1271	1275		|O
retention	1276	1285		|O
of	1286	1288		|O
BMP	1289	1292		|O
-	1292	1293		|O
2	1293	1294		|O
bioactivity	1295	1306		|O
was	1307	1310		|O
retained	1311	1319		|O
in	1320	1322		|O
the	1323	1326		|O
polymer	1327	1334		|O
-	1334	1335		|O
coated	1335	1341		|O
NPs	1342	1345		|O
.	1345	1346		|O
CONCLUSIONS	1347	1358		|O
:	1358	1359		|O
This	1360	1364		|O
study	1365	1370		|O
described	1371	1380		|O
a	1381	1382		|O
preparation	1383	1394		|O
procedure	1395	1404		|O
for	1405	1408		|O
BSA	1409	1412		|O
NPs	1413	1416		|O
with	1417	1421		|O
controllable	1422	1434		|O
particle	1435	1443		|O
size	1444	1448		|O
,	1448	1449		|O
and	1450	1453		|O
such	1454	1458		|O
polymer	1459	1466		|O
-	1466	1467		|O
coated	1467	1473		|O
BSA	1474	1477		|O
NPs	1478	1481		|O
are	1482	1485		|O
promising	1486	1495		|O
delivery	1496	1504		|O
agents	1505	1511		|O
for	1512	1515		|O
local	1516	1521		|O
and	1522	1525		|O
systemic	1526	1534		|O
administration	1535	1549		|O
of	1550	1552		|O
BMP	1553	1556		|O
-	1556	1557		|O
2	1557	1558		|O
in	1559	1561		|O
bone	1562	1566		|O
regeneration	1567	1579		|O
.	1579	1580		|O

### 18619980
Pre	0	3		|O
-	3	4		|O
clinical	4	12		|O
evidence	13	21		|O
for	22	25		|O
altered	26	33		|O
absorption	34	44		|O
and	45	48		|O
biliary	49	56		|O
excretion	57	66		|O
of	67	69		|O
irinotecan	70	80		|O
(	81	82		|O
CPT	82	85		|O
-	85	86		|O
11	86	88		|O
)	88	89		|O
in	90	92		|O
combination	93	104		|O
with	105	109		|O
quercetin	110	119		|O
:	119	120		|O
possible	121	129		|O
contribution	130	142		|O
of	143	145		|O
P	146	147		|O
-	147	148		|O
glycoprotein	148	160		|O
.	160	161		|O
P	163	164		|O
-	164	165		|O
glycoprotein	165	177		|O
(	178	179		|O
P	179	180		|O
-	180	181		|O
gp	181	183		|O
)	183	184		|O
is	185	187		|O
found	188	193		|O
to	194	196		|O
play	197	201		|O
a	202	203		|O
very	204	208		|O
significant	209	220		|O
role	221	225		|O
in	226	228		|O
intestinal	229	239		|O
and	240	243		|O
biliary	244	251		|O
transport	252	261		|O
of	262	264		|O
irinotecan	265	275		|O
and	276	279		|O
its	280	283		|O
active	284	290		|O
metabolite	291	301		|O
,	301	302		|O
SN	303	305		|O
-	305	306		|O
38	306	308		|O
.	308	309		|O
This	310	314		|O
makes	315	320		|O
P	321	322		|O
-	322	323		|O
gp	323	325		|O
inhibition	326	336		|O
a	337	338		|O
logical	339	346		|O
strategy	347	355		|O
for	356	359		|O
improving	360	369		|O
irinotecan	370	380		|O
's	380	382		|O
oral	383	387		|O
efficacy	388	396		|O
and	397	400		|O
reducing	401	409		|O
its	410	413		|O
toxicity	414	422		|O
.	422	423		|O
The	424	427		|O
objective	428	437		|O
of	438	440		|O
the	441	444		|O
present	445	452		|O
study	453	458		|O
was	459	462		|O
to	463	465		|O
identify	466	474		|O
the	475	478		|O
most	479	483		|O
suitable	484	492		|O
P	493	494		|O
-	494	495		|O
gp	495	497		|O
inhibitor	498	507		|O
,	507	508		|O
amongst	509	516		|O
various	517	524		|O
commonly	525	533		|O
used	534	538		|O
herbal	539	545		|O
components	546	556		|O
via	557	560		|O
in	561	563		|O
vitro	564	569		|O
screening	570	579		|O
;	579	580		|O
followed	581	589		|O
by	590	592		|O
determination	593	606		|O
of	607	609		|O
in	610	612		|O
vivo	613	617		|O
effects	618	625		|O
in	626	628		|O
rats	629	633		|O
.	633	634		|O
Caco	635	639		|O
-	639	640		|O
2	640	641		|O
cell	642	646		|O
monolayers	647	657		|O
were	658	662		|O
used	663	667		|O
to	668	670		|O
investigate	671	682		|O
the	683	686		|O
influence	687	696		|O
of	697	699		|O
various	700	707		|O
components	708	718		|O
(	719	720		|O
quercetin	720	729		|O
,	729	730		|O
hesperitin	731	741		|O
,	741	742		|O
piperine	743	751		|O
,	751	752		|O
curcumin	753	761		|O
and	762	765		|O
naringenin	766	776		|O
)	776	777		|O
on	778	780		|O
the	781	784		|O
transport	785	794		|O
of	795	797		|O
irinotecan	798	808		|O
.	808	809		|O
The	810	813		|O
secretory	814	823		|O
transport	824	833		|O
(	834	835		|O
basolateral	835	846		|O
-	846	847		|O
to	847	849		|O
-	849	850		|O
apical	850	856		|O
)	856	857		|O
was	858	861		|O
significantly	862	875		|O
decreased	876	885		|O
by	886	888		|O
all	889	892		|O
components	893	903		|O
(	904	905		|O
p	905	906		|O
<	906	907		|O
0.05	907	911		|O
)	911	912		|O
except	913	919		|O
piperine	920	928		|O
.	928	929		|O
In	930	932		|O
the	933	936		|O
apical	937	943		|O
-	943	944		|O
to	944	946		|O
-	946	947		|O
basolateral	947	958		|O
transport	959	968		|O
,	968	969		|O
quercetin	970	979		|O
showed	980	986		|O
the	987	990		|O
highest	991	998		|O
absorptive	999	1009		|O
permeability	1010	1022		|O
enhancement	1023	1034		|O
and	1035	1038		|O
P	1039	1040		|O
-	1040	1041		|O
gp	1041	1043		|O
interaction	1044	1055		|O
potential	1056	1065		|O
making	1066	1072		|O
it	1073	1075		|O
an	1076	1078		|O
appropriate	1079	1090		|O
candidate	1091	1100		|O
for	1101	1104		|O
further	1105	1112		|O
in	1113	1115		|O
vivo	1116	1120		|O
studies	1121	1128		|O
in	1129	1131		|O
female	1132	1138		|O
Wistar	1139	1145		|O
rats	1146	1150		|O
.	1150	1151		|O
Quercetin	1152	1161		|O
pre	1162	1165		|O
-	1165	1166		|O
treatment	1166	1175		|O
resulted	1176	1184		|O
in	1185	1187		|O
increased	1188	1197		|O
irinotecan	1198	1208		|O
C	1209	1210		|O
(	1210	1211		|O
max	1211	1214		|O
)	1214	1215		|O
and	1216	1219		|O
area	1220	1224		|O
under	1225	1230		|O
curve	1231	1236		|O
(	1237	1238		|O
AUC	1238	1241		|O
)	1241	1242		|O
with	1243	1247		|O
a	1248	1249		|O
concomitant	1250	1261		|O
decrease	1262	1270		|O
in	1271	1273		|O
t	1274	1275		|O
(	1275	1276		|O
max	1276	1279		|O
)	1279	1280		|O
,	1280	1281		|O
plasma	1282	1288		|O
clearance	1289	1298		|O
and	1299	1302		|O
volume	1303	1309		|O
of	1310	1312		|O
distribution	1313	1325		|O
(	1326	1327		|O
p	1327	1328		|O
<	1328	1329		|O
0.05	1329	1333		|O
)	1333	1334		|O
.	1334	1335		|O
The	1336	1339		|O
absolute	1340	1348		|O
bioavailability	1349	1364		|O
(	1365	1366		|O
F	1366	1367		|O
)	1367	1368		|O
of	1369	1371		|O
irinotecan	1372	1382		|O
control	1383	1390		|O
was	1391	1394		|O
33%	1395	1398		|O
,	1398	1399		|O
which	1400	1405		|O
was	1406	1409		|O
increased	1410	1419		|O
to	1420	1422		|O
43%	1423	1426		|O
(	1427	1428		|O
1.3	1428	1431		|O
fold	1432	1436		|O
)	1436	1437		|O
by	1438	1440		|O
quercetin	1441	1450		|O
administration	1451	1465		|O
.	1465	1466		|O
The	1467	1470		|O
amounts	1471	1478		|O
of	1479	1481		|O
irinotecan	1482	1492		|O
and	1493	1496		|O
SN	1497	1499		|O
-	1499	1500		|O
38	1500	1502		|O
eliminated	1503	1513		|O
in	1514	1516		|O
bile	1517	1521		|O
in	1522	1524		|O
control	1525	1532		|O
rats	1533	1537		|O
,	1537	1538		|O
is	1539	1541		|O
reduced	1542	1549		|O
to	1550	1552		|O
almost	1553	1559		|O
half	1560	1564		|O
when	1565	1569		|O
treated	1570	1577		|O
with	1578	1582		|O
quercetin	1583	1592		|O
.	1592	1593		|O
Our	1594	1597		|O
studies	1598	1605		|O
not	1606	1609		|O
only	1610	1614		|O
propose	1615	1622		|O
a	1623	1624		|O
safe	1625	1629		|O
approach	1630	1638		|O
for	1639	1642		|O
bioavailability	1643	1658		|O
enhancement	1659	1670		|O
and	1671	1674		|O
reducing	1675	1683		|O
toxicity	1684	1692		|O
of	1693	1695		|O
irinotecan	1696	1706		|O
by	1707	1709		|O
P	1710	1711		|O
-	1711	1712		|O
gp	1712	1714		|O
inhibition	1715	1725		|O
but	1726	1729		|O
in	1730	1732		|O
another	1733	1740		|O
way	1741	1744		|O
also	1745	1749		|O
reiterate	1750	1759		|O
the	1760	1763		|O
significance	1764	1776		|O
of	1777	1779		|O
elucidating	1780	1791		|O
herb	1792	1796		|O
-	1796	1797		|O
drug	1797	1801		|O
interactions	1802	1814		|O
for	1815	1818		|O
future	1819	1825		|O
insights	1826	1834		|O
.	1834	1835		|O

### 18801642
Right	0	5		|O
-	5	6		|O
sided	6	11		|O
vagus	12	17		|O
nerve	18	23		|O
stimulation	24	35		|O
in	36	38		|O
humans	39	45		|O
:	45	46		|O
an	47	49		|O
effective	50	59		|O
therapy	60	67		|O
?	67	68		|O
Vagus	70	75		|O
nerve	76	81		|O
stimulation	82	93		|O
(	94	95		|O
VNS	95	98		|O
)	98	99		|O
is	100	102		|O
an	103	105		|O
additive	106	114		|O
treatment	115	124		|O
option	125	131		|O
for	132	135		|O
refractory	136	146	refractory epilepsy	|B-DISEASE
epilepsy	147	155		|I-DISEASE
.	155	156		|O
The	157	160		|O
electrode	161	170		|O
is	171	173		|O
placed	174	180		|O
on	181	183		|O
the	184	187		|O
cervical	188	196		|O
trunk	197	202		|O
of	203	205		|O
the	206	209		|O
left	210	214		|O
vagus	215	220		|O
nerve	221	226		|O
.	226	227		|O
In	228	230		|O
patients	231	239		|O
who	240	243		|O
are	244	247		|O
not	248	251		|O
suitable	252	260		|O
for	261	264		|O
left	265	269		|O
-	269	270		|O
sided	270	275		|O
vagus	276	281		|O
nerve	282	287		|O
stimulation	288	299		|O
(	300	301		|O
L	301	302		|O
-	302	303		|O
VNS	303	306		|O
)	306	307		|O
right	308	313		|O
-	313	314		|O
sided	314	319		|O
vagus	320	325		|O
nerve	326	331		|O
stimulation	332	343		|O
(	344	345		|O
R	345	346		|O
-	346	347		|O
VNS	347	350		|O
)	350	351		|O
may	352	355		|O
be	356	358		|O
as	359	361		|O
effective	362	371		|O
.	371	372		|O
In	373	375		|O
animal	376	382		|O
models	383	389		|O
epilepsy	390	398	epilepsy	|B-DISEASE
is	399	401		|O
sufficiently	402	414		|O
suppressed	415	425		|O
by	426	428		|O
R	429	430		|O
-	430	431		|O
VNS	431	434		|O
.	434	435		|O
In	436	438		|O
a	439	440		|O
16	441	443		|O
years	444	449		|O
old	450	453		|O
boy	454	457		|O
suffering	458	467		|O
from	468	472		|O
medically	473	482		|O
refractory	483	493	refractory psychomotoric seizures	|B-DISEASE
psychomotoric	494	507		|I-DISEASE
seizures	508	516		|I-DISEASE
with	517	521		|O
secondary	522	531		|O
generalisation	532	546		|O
,	546	547		|O
L	548	549		|O
-	549	550		|O
VNS	550	553		|O
reduced	554	561		|O
the	562	565		|O
frequency	566	575		|O
of	576	578		|O
generalized	579	590		|O
seizures	591	599	seizures	|B-DISEASE
.	599	600		|O
A	601	602		|O
deep	603	607		|O
wound	608	613	wound infection	|B-DISEASE
infection	614	623		|I-DISEASE
required	624	632		|O
the	633	636		|O
removal	637	644		|O
of	645	647		|O
the	648	651		|O
system	652	658		|O
eight	659	664		|O
weeks	665	670		|O
later	671	676		|O
.	676	677		|O
Cicatrisation	678	691		|O
did	692	695		|O
not	696	699		|O
allow	700	705		|O
preparation	706	717		|O
of	718	720		|O
the	721	724		|O
left	725	729		|O
vagus	730	735		|O
nerve	736	741		|O
,	741	742		|O
therefore	743	752		|O
we	753	755		|O
implanted	756	765		|O
R	766	767		|O
-	767	768		|O
VNS	768	771		|O
with	772	776		|O
sufficient	777	787		|O
seizure	788	795	seizure	|B-DISEASE
suppression	796	807		|O
.	807	808		|O
However	809	816		|O
,	816	817		|O
compared	818	826		|O
to	827	829		|O
L	830	831		|O
-	831	832		|O
VNS	832	835		|O
,	835	836		|O
the	837	840		|O
effect	841	847		|O
occurred	848	856		|O
months	857	863		|O
later	864	869		|O
and	870	873		|O
cardiac	874	881	cardiac symptoms	|B-DISEASE
symptoms	882	890		|I-DISEASE
were	891	895		|O
induced	896	903		|O
by	904	906		|O
stimulation	907	918		|O
of	919	921		|O
the	922	925		|O
right	926	931		|O
vagus	932	937		|O
nerve	938	943		|O
.	943	944		|O
R	945	946		|O
-	946	947		|O
VNS	947	950		|O
seems	951	956		|O
to	957	959		|O
be	960	962		|O
an	963	965		|O
effective	966	975		|O
and	976	979		|O
alternative	980	991		|O
therapy	992	999		|O
in	1000	1002		|O
selected	1003	1011		|O
patients	1012	1020		|O
responding	1021	1031		|O
to	1032	1034		|O
L	1035	1036		|O
-	1036	1037		|O
VNS	1037	1040		|O
where	1041	1046		|O
a	1047	1048		|O
left	1049	1053		|O
-	1053	1054		|O
sided	1054	1059		|O
reimplantation	1060	1074		|O
is	1075	1077		|O
not	1078	1081		|O
possible	1082	1090		|O
.	1090	1091		|O
Placement	1092	1101		|O
and	1102	1105		|O
adjustment	1106	1116		|O
of	1117	1119		|O
the	1120	1123		|O
device	1124	1130		|O
should	1131	1137		|O
be	1138	1140		|O
performed	1141	1150		|O
under	1151	1156		|O
ECG	1157	1160		|O
control	1161	1168		|O
.	1168	1169		|O
Further	1170	1177		|O
studies	1178	1185		|O
are	1186	1189		|O
necessary	1190	1199		|O
to	1200	1202		|O
compare	1203	1210		|O
the	1211	1214		|O
efficacy	1215	1223		|O
of	1224	1226		|O
L	1227	1228		|O
-	1228	1229		|O
VNS	1229	1232		|O
and	1233	1236		|O
R	1237	1238		|O
-	1238	1239		|O
VNS	1239	1242		|O
.	1242	1243		|O

### 18590344
Safety	0	6		|O
and	7	10		|O
pharmacodynamics	11	27		|O
of	28	30		|O
lansoprazole	31	43		|O
in	44	46		|O
patients	47	55		|O
with	56	60		|O
gastroesophageal	61	77	gastroesophageal reflux disease	|B-DISEASE
reflux	78	84		|I-DISEASE
disease	85	92		|I-DISEASE
aged	93	97		|O
<	98	99		|O
1	99	100		|O
year	101	105		|O
.	105	106		|O
BACKGROUND	108	118		|O
:	118	119		|O
The	120	123		|O
use	124	127		|O
of	128	130		|O
proton	131	137		|O
pump	138	142		|O
inhibitors	143	153		|O
(	154	155		|O
PPIs	155	159		|O
)	159	160		|O
for	161	164		|O
the	165	168		|O
treatment	169	178		|O
of	179	181		|O
gastroesophageal	182	198	gastroesophageal reflux disease	|B-DISEASE
reflux	199	205		|I-DISEASE
disease	206	213		|I-DISEASE
(	214	215		|O
GERD	215	219	GERD	|B-DISEASE
)	219	220		|O
in	221	223		|O
pediatric	224	233		|O
patients	234	242		|O
<	243	244		|O
1	244	245		|O
year	246	250		|O
of	251	253		|O
age	254	257		|O
is	258	260		|O
increasing	261	271		|O
.	271	272		|O
However	273	280		|O
,	280	281		|O
few	282	285		|O
studies	286	293		|O
with	294	298		|O
PPIs	299	303		|O
have	304	308		|O
been	309	313		|O
reported	314	322		|O
in	323	325		|O
such	326	330		|O
patients	331	339		|O
.	339	340		|O
OBJECTIVES	341	351		|O
:	351	352		|O
To	353	355		|O
assess	356	362		|O
the	363	366		|O
effect	367	373		|O
of	374	376		|O
once	377	381		|O
-	381	382		|O
daily	382	387		|O
lansoprazole	388	400		|O
on	401	403		|O
safety	404	410		|O
and	411	414		|O
to	415	417		|O
characterize	418	430		|O
the	431	434		|O
pharmacodynamic	435	450		|O
profile	451	458		|O
of	459	461		|O
lansoprazole	462	474		|O
in	475	477		|O
a	478	479		|O
subset	480	486		|O
of	487	489		|O
subjects	490	498		|O
<	499	500		|O
1	500	501		|O
year	502	506		|O
of	507	509		|O
age	510	513		|O
.	513	514		|O
The	515	518		|O
effect	519	525		|O
of	526	528		|O
lansoprazole	529	541		|O
on	542	544		|O
predefined	545	555		|O
GERD	556	560	GERD-associated symptoms	|B-DISEASE
-	560	561		|I-DISEASE
associated	561	571		|I-DISEASE
symptoms	572	580		|I-DISEASE
was	581	584		|O
also	585	589		|O
assessed	590	598		|O
.	598	599		|O
METHODS	600	607		|O
:	607	608		|O
Two	609	612		|O
phase	613	618		|O
I	619	620		|O
,	620	621		|O
single	622	628		|O
-	628	629		|O
and	630	633		|O
repeated	634	642		|O
-	642	643		|O
dose	643	647		|O
,	647	648		|O
randomized	649	659		|O
,	659	660		|O
parallel	661	669		|O
-	669	670		|O
group	670	675		|O
,	675	676		|O
open	677	681		|O
-	681	682		|O
label	682	687		|O
,	687	688		|O
multicenter	689	700		|O
studies	701	708		|O
were	709	713		|O
performed	714	723		|O
.	723	724		|O
Both	725	729		|O
studies	730	737		|O
involved	738	746		|O
either	747	753		|O
a	754	755		|O
7	756	757		|O
-	757	758		|O
or	759	761		|O
14	762	764		|O
-	764	765		|O
day	765	768		|O
pre	769	772		|O
-	772	773		|O
treatment	773	782		|O
period	783	789		|O
,	789	790		|O
with	791	795		|O
a	796	797		|O
dose	798	802		|O
administration	803	817		|O
period	818	824		|O
of	825	827		|O
5	828	829		|O
days	830	834		|O
,	834	835		|O
and	836	839		|O
a	840	841		|O
follow	842	848		|O
-	848	849		|O
up	849	851		|O
period	852	858		|O
of	859	861		|O
30	862	864		|O
days	865	869		|O
for	870	873		|O
adverse	874	881		|O
events	882	888		|O
collection	889	899		|O
.	899	900		|O
A	901	902		|O
total	903	908		|O
of	909	911		|O
six	912	915		|O
investigative	916	929		|O
sites	930	935		|O
were	936	940		|O
involved	941	949		|O
:	949	950		|O
four	951	955		|O
university	956	966		|O
hospital	967	975		|O
/	975	976		|O
medical	976	983		|O
centers	984	991		|O
(	992	993		|O
three	993	998		|O
in	999	1001		|O
Poland	1002	1008		|O
,	1008	1009		|O
one	1010	1013		|O
in	1014	1016		|O
the	1017	1020		|O
US	1021	1023		|O
)	1023	1024		|O
,	1024	1025		|O
one	1026	1029		|O
large	1030	1035		|O
regional	1036	1044		|O
medical	1045	1052		|O
center	1053	1059		|O
(	1060	1061		|O
Poland	1061	1067		|O
)	1067	1068		|O
,	1068	1069		|O
and	1070	1073		|O
one	1074	1077		|O
private	1078	1085		|O
practice	1086	1094		|O
(	1095	1096		|O
US	1096	1098		|O
)	1098	1099		|O
.	1099	1100		|O
The	1101	1104		|O
studies	1105	1112		|O
involved	1113	1121		|O
24	1122	1124		|O
neonates	1125	1133		|O
(	1134	1135		|O
<	1135	1136		|O
or	1136	1138		|O
=	1138	1139		|O
28	1139	1141		|O
days	1142	1146		|O
of	1147	1149		|O
age	1150	1153		|O
)	1153	1154		|O
and	1155	1158		|O
24	1159	1161		|O
infants	1162	1169		|O
(	1170	1171		|O
>	1171	1172		|O
28	1172	1174		|O
days	1175	1179		|O
but	1180	1183		|O
<	1184	1185		|O
1	1185	1186		|O
year	1187	1191		|O
of	1192	1194		|O
age	1195	1198		|O
)	1198	1199		|O
with	1200	1204		|O
GERD	1205	1209		|O
-	1209	1210		|O
associated	1210	1220		|O
symptoms	1221	1229		|O
diagnosed	1230	1239		|O
by	1240	1242		|O
medical	1243	1250		|O
history	1251	1258		|O
and	1259	1262		|O
the	1263	1266		|O
clinical	1267	1275		|O
judgment	1276	1284		|O
of	1285	1287		|O
the	1288	1291		|O
treating	1292	1300		|O
physician	1301	1310		|O
.	1310	1311		|O
Eligible	1312	1320		|O
subjects	1321	1329		|O
were	1330	1334		|O
randomized	1335	1345		|O
to	1346	1348		|O
receive	1349	1356		|O
either	1357	1363		|O
lansoprazole	1364	1376		|O
0.5	1377	1380		|O
or	1381	1383		|O
1.0	1384	1387		|O
mg	1388	1390		|O
/	1390	1391		|O
kg	1391	1393		|O
/	1393	1394		|O
day	1394	1397		|O
(	1398	1399		|O
neonates	1399	1407		|O
)	1407	1408		|O
,	1408	1409		|O
or	1410	1412		|O
1.0	1413	1416		|O
or	1417	1419		|O
2.0	1420	1423		|O
mg	1424	1426		|O
/	1426	1427		|O
kg	1427	1429		|O
/	1429	1430		|O
day	1430	1433		|O
(	1434	1435		|O
infants	1435	1442		|O
)	1442	1443		|O
,	1443	1444		|O
for	1445	1448		|O
5	1449	1450		|O
days	1451	1455		|O
.	1455	1456		|O
Safety	1456	1462		|O
and	1463	1466		|O
pharmacodynamic	1467	1482		|O
parameters	1483	1493		|O
were	1494	1498		|O
the	1499	1502		|O
primary	1503	1510		|O
outcome	1511	1518		|O
measures	1519	1527		|O
.	1527	1528		|O
Safety	1529	1535		|O
and	1536	1539		|O
GERD	1540	1544	GERD symptoms	|B-DISEASE
symptoms	1545	1553		|I-DISEASE
were	1554	1558		|O
assessed	1559	1567		|O
in	1568	1570		|O
all	1571	1574		|O
participants	1575	1587		|O
.	1587	1588		|O
Intragastric	1589	1601		|O
/	1601	1602		|O
intraesophageal	1602	1617		|O
pH	1618	1620		|O
monitoring	1621	1631		|O
was	1632	1635		|O
performed	1636	1645		|O
in	1646	1648		|O
a	1649	1650		|O
subset	1651	1657		|O
of	1658	1660		|O
six	1661	1664		|O
neonates	1665	1673		|O
and	1674	1677		|O
six	1678	1681		|O
infants	1682	1689		|O
at	1690	1692		|O
baseline	1693	1701		|O
and	1702	1705		|O
on	1706	1708		|O
dose	1709	1713		|O
administration	1714	1728		|O
days	1729	1733		|O
1	1734	1735		|O
and	1736	1739		|O
5	1740	1741		|O
.	1741	1742		|O
RESULTS	1743	1750		|O
:	1750	1751		|O
Over	1752	1756		|O
5	1757	1758		|O
days	1759	1763		|O
of	1764	1766		|O
daily	1767	1772		|O
dose	1773	1777		|O
administration	1778	1792		|O
,	1792	1793		|O
lansoprazole	1794	1806		|O
was	1807	1810		|O
well	1811	1815		|O
tolerated	1816	1825		|O
in	1826	1828		|O
neonates	1829	1837		|O
and	1838	1841		|O
infants	1842	1849		|O
.	1849	1850		|O
Four	1851	1855		|O
neonates	1856	1864		|O
and	1865	1868		|O
one	1869	1872		|O
infant	1873	1879		|O
experienced	1880	1891		|O
mild	1892	1896		|O
to	1897	1899		|O
moderate	1900	1908		|O
treatment	1909	1918		|O
-	1918	1919		|O
related	1919	1926		|O
adverse	1927	1934		|O
events	1935	1941		|O
during	1942	1948		|O
the	1949	1952		|O
dose	1953	1957		|O
administration	1958	1972		|O
period	1973	1979		|O
.	1979	1980		|O
One	1981	1984		|O
neonate	1985	1992		|O
experienced	1993	2004		|O
a	2005	2006		|O
serious	2007	2014		|O
adverse	2015	2022		|O
event	2023	2028		|O
that	2029	2033		|O
was	2034	2037		|O
unrelated	2038	2047		|O
to	2048	2050		|O
treatment	2051	2060		|O
.	2060	2061		|O
Lansoprazole	2062	2074		|O
increased	2075	2084		|O
the	2085	2088		|O
percentage	2089	2099		|O
of	2100	2102		|O
time	2103	2107		|O
that	2108	2112		|O
intragastric	2113	2125		|O
pH	2126	2128		|O
was	2129	2132		|O
above	2133	2138		|O
3	2139	2140		|O
,	2140	2141		|O
4	2142	2143		|O
,	2143	2144		|O
5	2145	2146		|O
,	2146	2147		|O
and	2148	2151		|O
6	2152	2153		|O
over	2154	2158		|O
the	2159	2162		|O
24	2163	2165		|O
-	2165	2166		|O
hour	2166	2170		|O
post	2171	2175		|O
-	2175	2176		|O
dose	2176	2180		|O
period	2181	2187		|O
on	2188	2190		|O
days	2191	2195		|O
1	2196	2197		|O
and	2198	2201		|O
5	2202	2203		|O
when	2204	2208		|O
compared	2209	2217		|O
with	2218	2222		|O
baseline	2223	2231		|O
.	2231	2232		|O
Mean	2233	2237		|O
24	2238	2240		|O
-	2240	2241		|O
hour	2241	2245		|O
integrated	2246	2256		|O
gastric	2257	2264		|O
acidity	2265	2272		|O
decreased	2273	2282		|O
from	2283	2287		|O
baseline	2288	2296		|O
to	2297	2299		|O
day	2300	2303		|O
5	2304	2305		|O
in	2306	2308		|O
both	2309	2313		|O
populations	2314	2325		|O
.	2325	2326		|O
The	2327	2330		|O
daily	2331	2336		|O
number	2337	2343		|O
of	2344	2346		|O
episodes	2347	2355		|O
of	2356	2358		|O
regurgitation	2359	2372	regurgitation	|B-ADVERSE
/	2372	2373		|O
vomiting	2373	2381	vomiting	|B-ADVERSE
was	2382	2385		|O
lower	2386	2391		|O
than	2392	2396		|O
at	2397	2399		|O
baseline	2400	2408		|O
among	2409	2414		|O
neonates	2415	2423		|O
after	2424	2429		|O
5	2430	2431		|O
days	2432	2436		|O
of	2437	2439		|O
lansoprazole	2440	2452		|O
treatment	2453	2462		|O
;	2462	2463		|O
among	2464	2469		|O
infants	2470	2477		|O
,	2477	2478		|O
both	2479	2483		|O
the	2484	2487		|O
prevalence	2488	2498		|O
and	2499	2502		|O
the	2503	2506		|O
average	2507	2514		|O
daily	2515	2520		|O
number	2521	2527		|O
of	2528	2530		|O
episodes	2531	2539		|O
of	2540	2542		|O
several	2543	2550		|O
individual	2551	2561		|O
GERD	2562	2566	GERD-associated symptoms	|B-DISEASE
-	2566	2567		|I-DISEASE
associated	2567	2577		|I-DISEASE
symptoms	2578	2586		|I-DISEASE
were	2587	2591		|O
lower	2592	2597		|O
than	2598	2602		|O
at	2603	2605		|O
baseline	2606	2614		|O
.	2614	2615		|O
CONCLUSIONS	2616	2627		|O
:	2627	2628		|O
After	2629	2634		|O
5	2635	2636		|O
days	2637	2641		|O
of	2642	2644		|O
open	2645	2649		|O
-	2649	2650		|O
label	2650	2655		|O
administration	2656	2670		|O
,	2670	2671		|O
lansoprazole	2672	2684		|O
was	2685	2688		|O
well	2689	2693		|O
tolerated	2694	2703		|O
and	2704	2707		|O
increased	2708	2717		|O
intragastric	2718	2730		|O
pH	2731	2733		|O
in	2734	2736		|O
pediatric	2737	2746		|O
subjects	2747	2755		|O
<	2756	2757		|O
1	2757	2758		|O
year	2759	2763		|O
of	2764	2766		|O
age	2767	2770		|O
.	2770	2771		|O
A	2772	2773		|O
decrease	2774	2782		|O
in	2783	2785		|O
the	2786	2789		|O
frequency	2790	2799		|O
of	2800	2802		|O
GERD	2803	2807	GERD symptoms	|B-DISEASE
symptoms	2808	2816		|I-DISEASE
was	2817	2820		|O
also	2821	2825		|O
observed	2826	2834		|O
.	2834	2835		|O

### 18554256
Design	0	6		|O
of	7	9		|O
potent	10	16		|O
,	16	17		|O
non	18	21		|O
-	21	22		|O
toxic	22	27		|O
antimicrobial	28	41		|O
agents	42	48		|O
based	49	54		|O
upon	55	59		|O
the	60	63		|O
naturally	64	73		|O
occurring	74	83		|O
frog	84	88		|O
skin	89	93		|O
peptides	94	102		|O
,	102	103		|O
ascaphin	104	112		|O
-	112	113		|O
8	113	114		|O
and	115	118		|O
peptide	119	126		|O
XT	127	129		|O
-	129	130		|O
7	130	131		|O
.	131	132		|O
The	134	137		|O
frog	138	142		|O
skin	143	147		|O
peptides	148	156		|O
,	156	157		|O
ascaphin	158	166		|O
-	166	167		|O
8	167	168		|O
(	169	170		|O
GFKDLLKGAAKALVKTVLF	170	189		|O
.	189	190		|O
NH	190	192		|O
(	192	193		|O
2	193	194		|O
)	194	195		|O
)	195	196		|O
and	197	200		|O
XT	201	203		|O
-	203	204		|O
7	204	205		|O
(	206	207		|O
GLLGPLLKIAAKVGSNLL	207	225		|O
.	225	226		|O
NH	226	228		|O
(	228	229		|O
2	229	230		|O
)	230	231		|O
)	231	232		|O
,	232	233		|O
show	234	238		|O
broad	239	244		|O
-	244	245		|O
spectrum	245	253		|O
antimicrobial	254	267		|O
activity	268	276		|O
but	277	280		|O
their	281	286		|O
therapeutic	287	298		|O
potential	299	308		|O
is	309	311		|O
limited	312	319		|O
by	320	322		|O
toxicity	323	331		|O
against	332	339		|O
mammalian	340	349		|O
cells	350	355		|O
.	355	356		|O
Circular	357	365		|O
dichroism	366	375		|O
spectra	376	383		|O
demonstrate	384	395		|O
that	396	400		|O
the	401	404		|O
peptides	405	413		|O
adopt	414	419		|O
an	420	422		|O
amphipathic	423	434		|O
alpha	435	440		|O
-	440	441		|O
helical	441	448		|O
conformation	449	461		|O
in	462	464		|O
a	465	466		|O
membrane	467	475		|O
-	475	476		|O
mimetic	476	483		|O
solvent	484	491		|O
.	491	492		|O
This	493	497		|O
study	498	503		|O
has	504	507		|O
investigated	508	520		|O
the	521	524		|O
cytolytic	525	534		|O
properties	535	545		|O
of	546	548		|O
analogs	549	556		|O
containing	557	567		|O
selected	568	576		|O
amino	577	582		|O
acid	583	587		|O
substitutions	588	601		|O
that	602	606		|O
increase	607	615		|O
cationicity	616	627		|O
while	628	633		|O
maintaining	634	645		|O
amphipathicity	646	660		|O
.	660	661		|O
Substitutions	662	675		|O
at	676	678		|O
Ala	679	682		|O
(	682	683		|O
10	683	685		|O
)	685	686		|O
,	686	687		|O
Val	688	691		|O
(	691	692		|O
14	692	694		|O
)	694	695		|O
,	695	696		|O
and	697	700		|O
Leu	701	704		|O
(	704	705		|O
18	705	707		|O
)	707	708		|O
in	709	711		|O
ascaphin	712	720		|O
-	720	721		|O
8	721	722		|O
by	723	725		|O
either	726	732		|O
L	733	734		|O
-	734	735		|O
Lys	735	738		|O
or	739	741		|O
D	742	743		|O
-	743	744		|O
Lys	744	747		|O
produced	748	756		|O
peptides	757	765		|O
that	766	770		|O
retained	771	779		|O
antimicrobial	780	793		|O
activity	794	802		|O
against	803	810		|O
the	811	814		|O
bacteria	815	823		|O
Escherichia	824	835		|O
coli	836	840		|O
and	841	844		|O
Staphylococcus	845	859		|O
aureus	860	866		|O
and	867	870		|O
the	871	874		|O
opportunistic	875	888		|O
yeast	889	894		|O
pathogen	895	903		|O
,	903	904		|O
Candida	905	912		|O
albicans	913	921		|O
but	922	925		|O
showed	926	932		|O
appreciably	933	944		|O
reduced	945	952		|O
toxicities	953	963		|O
(	964	965		|O
>	965	966		|O
10	966	968		|O
-	968	969		|O
fold	969	973		|O
)	973	974		|O
against	975	982		|O
human	983	988		|O
erythrocytes	989	1001		|O
,	1001	1002		|O
HepG2	1003	1008		|O
hepatoma	1009	1017		|O
-	1017	1018		|O
derived	1018	1025		|O
cells	1026	1031		|O
,	1031	1032		|O
and	1033	1036		|O
L929	1037	1041		|O
fibroblasts	1042	1053		|O
.	1053	1054		|O
The	1055	1058		|O
improved	1059	1067		|O
therapeutic	1068	1079		|O
index	1080	1085		|O
of	1086	1088		|O
the	1089	1092		|O
L	1093	1094		|O
-	1094	1095		|O
Lys	1095	1098		|O
(	1098	1099		|O
18	1099	1101		|O
)	1101	1102		|O
and	1103	1106		|O
D	1107	1108		|O
-	1108	1109		|O
Lys	1109	1112		|O
(	1112	1113		|O
18	1113	1115		|O
)	1115	1116		|O
analogs	1117	1124		|O
correlated	1125	1135		|O
with	1136	1140		|O
a	1141	1142		|O
decrease	1143	1151		|O
in	1152	1154		|O
%	1155	1156		|O
helicity	1157	1165		|O
and	1166	1169		|O
in	1170	1172		|O
effective	1173	1182		|O
hydrophobicity	1183	1197		|O
.	1197	1198		|O
Substitution	1199	1211		|O
of	1212	1214		|O
Gly	1215	1218		|O
(	1218	1219		|O
4	1219	1220		|O
)	1220	1221		|O
by	1222	1224		|O
L	1225	1226		|O
-	1226	1227		|O
Lys	1227	1230		|O
in	1231	1233		|O
XT	1234	1236		|O
-	1236	1237		|O
7	1237	1238		|O
produced	1239	1247		|O
an	1248	1250		|O
analog	1251	1257		|O
with	1258	1262		|O
high	1263	1267		|O
potency	1268	1275		|O
against	1276	1283		|O
micro	1284	1289		|O
-	1289	1290		|O
organisms	1290	1299		|O
(	1300	1301		|O
MIC	1301	1304		|O
<	1305	1306		|O
or	1307	1309		|O
=	1310	1311		|O
25	1312	1314		|O
microM	1315	1321		|O
)	1321	1322		|O
but	1323	1326		|O
low	1327	1330		|O
cytolytic	1331	1340		|O
activity	1341	1349		|O
against	1350	1357		|O
erythrocytes	1358	1370		|O
(	1371	1372		|O
LD	1372	1374		|O
(	1374	1375		|O
50	1375	1377		|O
)	1377	1378		|O
>	1379	1380		|O
500	1381	1384		|O
microM	1385	1391		|O
)	1391	1392		|O
and	1393	1396		|O
this	1397	1401		|O
increase	1402	1410		|O
in	1411	1413		|O
therapeutic	1414	1425		|O
index	1426	1431		|O
also	1432	1436		|O
correlated	1437	1447		|O
with	1448	1452		|O
decreased	1453	1462		|O
helicity	1463	1471		|O
and	1472	1475		|O
hydrophobicity	1476	1490		|O
.	1490	1491		|O
Analogs	1492	1499		|O
of	1500	1502		|O
XT	1503	1505		|O
-	1505	1506		|O
7	1506	1507		|O
with	1508	1512		|O
increased	1513	1522		|O
cationicity	1523	1534		|O
,	1534	1535		|O
containing	1536	1546		|O
multiple	1547	1555		|O
substitutions	1556	1569		|O
by	1570	1572		|O
L	1573	1574		|O
-	1574	1575		|O
Lys	1575	1578		|O
,	1578	1579		|O
not	1580	1583		|O
only	1584	1588		|O
displayed	1589	1598		|O
increased	1599	1608		|O
antimicrobial	1609	1622		|O
potencies	1623	1632		|O
,	1632	1633		|O
particularly	1634	1646		|O
against	1647	1654		|O
Candida	1655	1662		|O
albicans	1663	1671		|O
(	1672	1673		|O
MIC	1673	1676		|O
<	1677	1678		|O
or	1679	1681		|O
=	1682	1683		|O
6	1684	1685		|O
microM	1686	1692		|O
)	1692	1693		|O
,	1693	1694		|O
but	1695	1698		|O
also	1699	1703		|O
increased	1704	1713		|O
hemolytic	1714	1723		|O
activities	1724	1734		|O
.	1734	1735		|O

### 18597941
Prostaglandin	0	13		|O
receptor	14	22		|O
EP2	23	26		|O
protects	27	35		|O
dopaminergic	36	48		|O
neurons	49	56		|O
against	57	64		|O
6	65	66		|O
-	66	67		|O
OHDA	67	71		|O
-	71	72		|O
mediated	72	80		|O
low	81	84		|O
oxidative	85	94		|O
stress	95	101		|O
.	101	102		|O
Dopaminergic	104	116		|O
neurons	117	124		|O
in	125	127		|O
the	128	131		|O
substantia	132	142		|O
nigra	143	148		|O
(	149	150		|O
SN	150	152		|O
)	152	153		|O
selectively	154	165		|O
die	166	169		|O
in	170	172		|O
Parkinson	173	182	Parkinson's disease	|B-DISEASE
's	182	184		|I-DISEASE
disease	185	192		|I-DISEASE
(	193	194		|O
PD	194	196	PD	|B-DISEASE
)	196	197		|O
,	197	198		|O
but	199	202		|O
it	203	205		|O
is	206	208		|O
unclear	209	216		|O
how	217	220		|O
and	221	224		|O
why	225	228		|O
this	229	233		|O
occurs	234	240		|O
.	240	241		|O
Recent	242	248		|O
findings	249	257		|O
implicate	258	267		|O
prostaglandin	268	281		|O
E	282	283		|O
(	283	284		|O
2	284	285		|O
)	285	286		|O
(	287	288		|O
PGE	288	291		|O
(	291	292		|O
2	292	293		|O
)	293	294		|O
)	294	295		|O
and	296	299		|O
two	300	303		|O
of	304	306		|O
its	307	310		|O
four	311	315		|O
receptors	316	325		|O
,	325	326		|O
namely	327	333		|O
EP1	334	337		|O
and	338	341		|O
EP2	342	345		|O
,	345	346		|O
as	347	349		|O
mediators	350	359		|O
of	360	362		|O
degenerative	363	375		|O
and	376	379		|O
protective	380	390		|O
events	391	397		|O
in	398	400		|O
situations	401	411		|O
of	412	414		|O
acute	415	420		|O
and	421	424		|O
chronic	425	432	chronic neuronal death	|B-DISEASE
neuronal	433	441		|I-DISEASE
death	442	447		|I-DISEASE
.	447	448		|O
EP1	449	452		|O
activation	453	463		|O
can	464	467		|O
exacerbate	468	478		|O
excitotoxic	479	490		|O
damage	491	497		|O
in	498	500		|O
stroke	501	507	stroke	|B-DISEASE
models	508	514		|O
and	515	518		|O
our	519	522		|O
recent	523	529		|O
study	530	535		|O
showed	536	542		|O
that	543	547		|O
EP1	548	551		|O
activation	552	562		|O
may	563	566		|O
explain	567	574		|O
the	575	578		|O
selective	579	588		|O
sensitivity	589	600		|O
of	601	603		|O
dopaminergic	604	616		|O
neurons	617	624		|O
to	625	627		|O
oxidative	628	637		|O
stress	638	644		|O
.	644	645		|O
Conversely	646	656		|O
,	656	657		|O
EP2	658	661		|O
activation	662	672		|O
may	673	676		|O
be	677	679		|O
neuroprotective	680	695		|O
,	695	696		|O
although	697	705		|O
toxic	706	711		|O
effects	712	719		|O
have	720	724		|O
also	725	729		|O
been	730	734		|O
demonstrated	735	747		|O
.	747	748		|O
Here	749	753		|O
we	754	756		|O
investigated	757	769		|O
if	770	772		|O
and	773	776		|O
how	777	780		|O
EP2	781	784		|O
activation	785	795		|O
might	796	801		|O
alter	802	807		|O
the	808	811		|O
survival	812	820		|O
of	821	823		|O
dopaminergic	824	836		|O
neurons	837	844		|O
following	845	854		|O
selective	855	864		|O
low	865	868		|O
-	868	869		|O
level	869	874		|O
oxidative	875	884		|O
injury	885	891		|O
evoked	892	898		|O
by	899	901		|O
the	902	905		|O
neurotoxin	906	916		|O
6	917	918		|O
-	918	919		|O
hydroxydopamine	919	934		|O
(	935	936		|O
6	936	937		|O
-	937	938		|O
OHDA	938	942		|O
)	942	943		|O
in	944	946		|O
primary	947	954		|O
neuronal	955	963		|O
cultures	964	972		|O
prepared	973	981		|O
from	982	986		|O
embryonic	987	996		|O
rat	997	1000		|O
midbrain	1001	1009		|O
.	1009	1010		|O
We	1011	1013		|O
found	1014	1019		|O
that	1020	1024		|O
cultured	1025	1033		|O
dopaminergic	1034	1046		|O
neurons	1047	1054		|O
displayed	1055	1064		|O
EP2	1065	1068		|O
receptors	1069	1078		|O
.	1078	1079		|O
Butaprost	1080	1089		|O
,	1089	1090		|O
a	1091	1092		|O
selective	1093	1102		|O
EP2	1103	1106		|O
agonist	1107	1114		|O
,	1114	1115		|O
significantly	1116	1129		|O
reduced	1130	1137		|O
6	1138	1139		|O
-	1139	1140		|O
OHDA	1140	1144		|O
neurotoxicity	1145	1158	neurotoxicity	|B-ADVERSE
.	1158	1159		|O
EP2	1160	1163		|O
receptors	1164	1173		|O
are	1174	1177		|O
coupled	1178	1185		|O
to	1186	1188		|O
stimulatory	1189	1200		|O
G	1201	1202		|O
-	1202	1203		|O
proteins	1203	1211		|O
(	1212	1213		|O
Gs	1213	1215		|O
)	1215	1216		|O
,	1216	1217		|O
which	1218	1223		|O
activate	1224	1232		|O
adenylate	1233	1242		|O
cyclase	1243	1250		|O
,	1250	1251		|O
increasing	1252	1262		|O
cAMP	1263	1267		|O
synthesis	1268	1277		|O
,	1277	1278		|O
which	1279	1284		|O
then	1285	1289		|O
activates	1290	1299		|O
protein	1300	1307		|O
kinase	1308	1314		|O
A	1315	1316		|O
(	1317	1318		|O
PKA	1318	1321		|O
)	1321	1322		|O
.	1322	1323		|O
Both	1324	1328		|O
dibutyryl	1329	1338		|O
cAMP	1339	1343		|O
and	1344	1347		|O
forskolin	1348	1357		|O
reduced	1358	1365		|O
dopaminergic	1366	1378		|O
cell	1379	1383		|O
loss	1384	1388		|O
after	1389	1394		|O
6	1395	1396		|O
-	1396	1397		|O
OHDA	1397	1401		|O
exposure	1402	1410		|O
.	1410	1411		|O
Conversely	1412	1422		|O
,	1422	1423		|O
KT5720	1424	1430		|O
and	1431	1434		|O
H	1435	1436		|O
-	1436	1437		|O
89	1437	1439		|O
,	1439	1440		|O
two	1441	1444		|O
structurally	1445	1457		|O
distinct	1458	1466		|O
high	1467	1471		|O
-	1471	1472		|O
affinity	1472	1480		|O
PKA	1481	1484		|O
inhibitors	1485	1495		|O
,	1495	1496		|O
abolished	1497	1506		|O
the	1507	1510		|O
protective	1511	1521		|O
effect	1522	1528		|O
of	1529	1531		|O
butaprost	1532	1541		|O
,	1541	1542		|O
implicating	1543	1554		|O
cAMP	1555	1559		|O
-	1559	1560		|O
dependent	1560	1569		|O
PKA	1570	1573		|O
activity	1574	1582		|O
in	1583	1585		|O
the	1586	1589		|O
neuroprotection	1590	1605		|O
by	1606	1608		|O
EP2	1609	1612		|O
activation	1613	1623		|O
.	1623	1624		|O
Finally	1625	1632		|O
,	1632	1633		|O
we	1634	1636		|O
show	1637	1641		|O
that	1642	1646		|O
melanized	1647	1656		|O
dopaminergic	1657	1669		|O
neurons	1670	1677		|O
in	1678	1680		|O
the	1681	1684		|O
human	1685	1690		|O
SN	1691	1693		|O
express	1694	1701		|O
EP2	1702	1705		|O
.	1705	1706		|O
This	1707	1711		|O
pathway	1712	1719		|O
warrants	1720	1728		|O
consideration	1729	1742		|O
as	1743	1745		|O
a	1746	1747		|O
neuroprotective	1748	1763		|O
strategy	1764	1772		|O
for	1773	1776		|O
PD	1777	1779	PD	|B-DISEASE
.	1779	1780		|O

### 18845202
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
1	29	30		|O
-	30	31		|O
ethynylcyclohexyl	31	48		|O
acetate	49	56		|O
.	56	57		|O
A	59	60		|O
toxicologic	61	72		|O
and	73	76		|O
dermatologic	77	89		|O
review	90	96		|O
of	97	99		|O
1	100	101		|O
-	101	102		|O
ethynylcyclohexyl	102	119		|O
acetate	120	127		|O
when	128	132		|O
used	133	137		|O
as	138	140		|O
a	141	142		|O
fragrance	143	152		|O
ingredient	153	163		|O
is	164	166		|O
presented	167	176		|O
.	176	177		|O

### 18822368
Protective	0	10		|O
effect	11	17		|O
of	18	20		|O
Pycnogenol	21	31		|O
in	32	34		|O
human	35	40		|O
neuroblastoma	41	54		|O
SH	55	57		|O
-	57	58		|O
SY5Y	58	62		|O
cells	63	68		|O
following	69	78		|O
acrolein	79	87		|O
-	87	88		|O
induced	88	95		|O
cytotoxicity	96	108	cytotoxicity	|B-ADVERSE
.	108	109		|O
Oxidative	111	120		|O
stress	121	127		|O
is	128	130		|O
one	131	134		|O
of	135	137		|O
the	138	141		|O
hypotheses	142	152		|O
involved	153	161		|O
in	162	164		|O
the	165	168		|O
etiology	169	177		|O
of	178	180		|O
Alzheimer	181	190	Alzheimer's disease	|B-DISEASE
's	190	192		|I-DISEASE
disease	193	200		|I-DISEASE
(	201	202		|O
AD	202	204	AD	|B-DISEASE
)	204	205		|O
.	205	206		|O
Considerable	207	219		|O
attention	220	229		|O
has	230	233		|O
been	234	238		|O
focused	239	246		|O
on	247	249		|O
increasing	250	260		|O
the	261	264		|O
intracellular	265	278		|O
glutathione	279	290		|O
(	291	292		|O
GSH	292	295		|O
)	295	296		|O
levels	297	303		|O
in	304	306		|O
many	307	311		|O
neurodegenerative	312	329	neurodegenerative diseases	|B-DISEASE
diseases	330	338		|I-DISEASE
,	338	339		|O
including	340	349		|O
AD	350	352	AD	|B-DISEASE
.	352	353		|O
Pycnogenol	354	364		|O
(	365	366		|O
PYC	366	369		|O
)	369	370		|O
has	371	374		|O
antioxidant	375	386		|O
properties	387	397		|O
and	398	401		|O
stabilizes	402	412		|O
intracellular	413	426		|O
antioxidant	427	438		|O
defense	439	446		|O
systems	447	454		|O
including	455	464		|O
glutathione	465	476		|O
levels	477	483		|O
.	483	484		|O
The	485	488		|O
present	489	496		|O
study	497	502		|O
investigated	503	515		|O
the	516	519		|O
protective	520	530		|O
effects	531	538		|O
of	539	541		|O
PYC	542	545		|O
on	546	548		|O
acrolein	549	557		|O
-	557	558		|O
induced	558	565		|O
oxidative	566	575	oxidative cell toxicity	|B-ADVERSE
cell	576	580		|I-ADVERSE
toxicity	581	589		|I-ADVERSE
in	590	592		|O
cultured	593	601		|O
SH	602	604		|O
-	604	605		|O
SY5Y	605	609		|O
neuroblastoma	610	623		|O
cells	624	629		|O
.	629	630		|O
Decreased	631	640		|O
cell	641	645		|O
survival	646	654		|O
in	655	657		|O
SH	658	660		|O
-	660	661		|O
SY5Y	661	665		|O
cultures	666	674		|O
treated	675	682		|O
with	683	687		|O
acrolein	688	696		|O
correlated	697	707		|O
with	708	712		|O
oxidative	713	722		|O
stress	723	729		|O
,	729	730		|O
increased	731	740		|O
NADPH	741	746		|O
oxidase	747	754		|O
activity	755	763		|O
,	763	764		|O
free	765	769		|O
radical	770	777		|O
production	778	788		|O
,	788	789		|O
protein	790	797		|O
oxidation	798	807		|O
/	807	808		|O
nitration	808	817		|O
(	818	819		|O
protein	819	826		|O
carbonyl	827	835		|O
,	835	836		|O
3	837	838		|O
-	838	839		|O
nitrotyrosine	839	852		|O
)	852	853		|O
,	853	854		|O
and	855	858		|O
lipid	859	864		|O
peroxidation	865	877		|O
(	878	879		|O
4	879	880		|O
-	880	881		|O
hydroxy	881	888		|O
-	888	889		|O
2	889	890		|O
-	890	891		|O
nonenal	891	898		|O
)	898	899		|O
.	899	900		|O
Pretreatment	901	913		|O
with	914	918		|O
PYC	919	922		|O
significantly	923	936		|O
attenuated	937	947		|O
acrolein	948	956		|O
-	956	957		|O
induced	957	964		|O
cytotoxicity	965	977	cytotoxicity	|B-ADVERSE
,	977	978		|O
protein	979	986		|O
damage	987	993		|O
,	993	994		|O
lipid	995	1000		|O
peroxidation	1001	1013		|O
,	1013	1014		|O
and	1015	1018		|O
cell	1019	1023		|O
death	1024	1029		|O
.	1029	1030		|O
A	1031	1032		|O
dose	1033	1037		|O
-	1037	1038		|O
response	1038	1046		|O
study	1047	1052		|O
suggested	1053	1062		|O
that	1063	1067		|O
PYC	1068	1071		|O
showed	1072	1078		|O
protective	1079	1089		|O
effects	1090	1097		|O
against	1098	1105		|O
acrolein	1106	1114	acrolein toxicity	|B-ADVERSE
toxicity	1115	1123		|I-ADVERSE
by	1124	1126		|O
modulating	1127	1137		|O
oxidative	1138	1147		|O
stress	1148	1154		|O
and	1155	1158		|O
increasing	1159	1169		|O
GSH	1170	1173		|O
.	1173	1174		|O
These	1175	1180		|O
findings	1181	1189		|O
provide	1190	1197		|O
support	1198	1205		|O
that	1206	1210		|O
PYC	1211	1214		|O
may	1215	1218		|O
provide	1219	1226		|O
a	1227	1228		|O
promising	1229	1238		|O
approach	1239	1247		|O
for	1248	1251		|O
the	1252	1255		|O
treatment	1256	1265		|O
of	1266	1268		|O
oxidative	1269	1278		|O
stress	1279	1285		|O
-	1285	1286		|O
related	1286	1293		|O
neurodegenerative	1294	1311	neurodegenerative diseases	|B-DISEASE
diseases	1312	1320		|I-DISEASE
such	1321	1325		|O
as	1326	1328		|O
AD	1329	1331	AD	|B-DISEASE
.	1331	1332		|O

### 18837771
Orally	0	6		|O
administrated	7	20		|O
Juzen	21	26		|O
-	26	27		|O
taiho	27	32		|O
-	32	33		|O
to	33	35		|O
/	35	36		|O
TJ	36	38		|O
-	38	39		|O
48	39	41		|O
ameliorates	42	53		|O
erythropoietin	54	68	erythropoietin (rHuEPO)-resistant anemia	|B-DISEASE
(	69	70		|I-DISEASE
rHuEPO	70	76		|I-DISEASE
)	76	77		|I-DISEASE
-	77	78		|I-DISEASE
resistant	78	87		|I-DISEASE
anemia	88	94		|I-DISEASE
in	95	97		|O
patients	98	106		|O
on	107	109		|O
hemodialysis	110	122		|O
.	122	123		|O
Maintenance	125	136		|O
of	137	139		|O
the	140	143		|O
red	144	147		|O
blood	148	153		|O
cell	154	158		|O
volume	159	165		|O
is	166	168		|O
a	169	170		|O
fundamental	171	182		|O
aspect	183	189		|O
of	190	192		|O
ensuring	193	201		|O
oxygen	202	208		|O
supply	209	215		|O
to	216	218		|O
the	219	222		|O
tissue	223	229		|O
.	229	230		|O
Recombinant	231	242		|O
human	243	248		|O
erythropoietin	249	263		|O
(	264	265		|O
rHuEPO	265	271		|O
)	271	272		|O
was	273	276		|O
approved	277	285		|O
for	286	289		|O
marketing	290	299		|O
in	300	302		|O
Japan	303	308		|O
in	309	311		|O
1990	312	316		|O
for	317	320		|O
the	321	324		|O
treatment	325	334		|O
of	335	337		|O
anemia	338	344	anemia	|B-DISEASE
in	345	347		|O
patients	348	356		|O
on	357	359		|O
dialysis	360	368		|O
.	368	369		|O
Recombinant	370	381		|O
human	382	387		|O
erythropoietin	388	402		|O
caused	403	409		|O
a	410	411		|O
significant	412	423		|O
increase	424	432		|O
in	433	435		|O
hemoglobin	436	446		|O
(	447	448		|O
Hb	448	450		|O
)	450	451		|O
levels	452	458		|O
in	459	461		|O
patients	462	470		|O
on	471	473		|O
dialysis	474	482		|O
.	482	483		|O
However	484	491		|O
,	491	492		|O
not	493	496		|O
all	497	500		|O
have	501	505		|O
a	506	507		|O
good	508	512		|O
response	513	521		|O
to	522	524		|O
rHuEPO	525	531		|O
therapy	532	539		|O
;	539	540		|O
the	541	544		|O
causes	545	551		|O
of	552	554		|O
rHuEPO	555	561		|O
failure	562	569		|O
include	570	577		|O
iron	578	582	iron deficiency	|B-ADVERSE
deficiency	583	593		|I-ADVERSE
,	593	594		|O
infection	595	604	infection	|B-ADVERSE
,	604	605		|O
uremia	606	612	uremia	|B-ADVERSE
,	612	613		|O
and	614	617		|O
interaction	618	629		|O
of	630	632		|O
some	633	637		|O
drugs	638	643		|O
.	643	644		|O
Juzen	645	650		|O
-	650	651		|O
taiho	651	656		|O
-	656	657		|O
to	657	659		|O
(	660	661		|O
TJ	661	663		|O
-	663	664		|O
48	664	666		|O
)	666	667		|O
,	667	668		|O
a	669	670		|O
mixture	671	678		|O
of	679	681		|O
extracts	682	690		|O
from	691	695		|O
10	696	698		|O
medicinal	699	708		|O
herbs	709	714		|O
,	714	715		|O
has	716	719		|O
been	720	724		|O
used	725	729		|O
traditionally	730	743		|O
to	744	746		|O
treat	747	752		|O
patients	753	761		|O
with	762	766		|O
anemia	767	773	anemia	|B-DISEASE
,	773	774		|O
anorexia	775	783	anorexia	|B-DISEASE
,	783	784		|O
or	785	787		|O
fatigue	788	795	fatigue	|B-DISEASE
.	795	796		|O
To	797	799		|O
clarify	800	807		|O
the	808	811		|O
effect	812	818		|O
of	819	821		|O
TJ	822	824		|O
-	824	825		|O
48	825	827		|O
on	828	830		|O
erythropoietin	831	845	erythropoietin-resistant anemia	|B-DISEASE
-	845	846		|I-DISEASE
resistant	846	855		|I-DISEASE
anemia	856	862		|I-DISEASE
,	862	863		|O
we	864	866		|O
studied	867	874		|O
the	875	878		|O
effect	879	885		|O
of	886	888		|O
TJ	889	891		|O
-	891	892		|O
48	892	894		|O
in	895	897		|O
patients	898	906		|O
on	907	909		|O
hemodialysis	910	922		|O
with	923	927		|O
erythropoietin	928	942	erythropoietin-resistant anemia	|B-DISEASE
-	942	943		|I-DISEASE
resistant	943	952		|I-DISEASE
anemia	953	959		|I-DISEASE
.	959	960		|O
We	961	963		|O
divided	964	971		|O
42	972	974		|O
end	975	978		|O
-	978	979		|O
stage	979	984		|O
renal	985	990	renal disease	|B-DISEASE
disease	991	998		|I-DISEASE
patients	999	1007		|O
on	1008	1010		|O
hemodialysis	1011	1023		|O
with	1024	1028		|O
erythropoietin	1029	1043	erythropoietin-resistant anemia	|B-DISEASE
-	1043	1044		|I-DISEASE
resistant	1044	1053		|I-DISEASE
anemia	1054	1060		|I-DISEASE
(	1061	1062		|O
Hb	1062	1064		|O
<	1064	1065		|O
10.0	1065	1069		|O
g	1070	1071		|O
/	1071	1072		|O
dL	1072	1074		|O
with	1075	1079		|O
rHuEPO	1080	1086		|O
9000	1087	1091		|O
U	1092	1093		|O
/	1093	1094		|O
wk	1094	1096		|O
or	1097	1099		|O
15	1100	1102		|O
U	1103	1104		|O
/	1104	1105		|O
kg	1105	1107		|O
/	1107	1108		|O
wk	1108	1110		|O
treatment	1111	1120		|O
)	1120	1121		|O
into	1122	1126		|O
2	1127	1128		|O
groups	1129	1135		|O
as	1136	1138		|O
follows	1139	1146		|O
:	1146	1147		|O
a	1148	1149		|O
TJ	1150	1152		|O
-	1152	1153		|O
48	1153	1155		|O
-	1155	1156		|O
treated	1156	1163		|O
group	1164	1169		|O
(	1170	1171		|O
TJ	1171	1173		|O
-	1173	1174		|O
48	1174	1176		|O
group	1177	1182		|O
,	1182	1183		|O
7.5	1184	1187		|O
g	1188	1189		|O
/	1189	1190		|O
d	1190	1191		|O
,	1191	1192		|O
n	1193	1194		|O
=	1194	1195		|O
22	1195	1197		|O
)	1197	1198		|O
and	1199	1202		|O
a	1203	1204		|O
TJ	1205	1207		|O
-	1207	1208		|O
48	1208	1210		|O
nontreated	1211	1221		|O
(	1222	1223		|O
control	1223	1230		|O
group	1231	1236		|O
,	1236	1237		|O
n	1238	1239		|O
=	1239	1240		|O
20	1240	1242		|O
)	1242	1243		|O
.	1243	1244		|O
At	1245	1247		|O
the	1248	1251		|O
beginning	1252	1261		|O
of	1262	1264		|O
this	1265	1269		|O
study	1270	1275		|O
,	1275	1276		|O
there	1277	1282		|O
was	1283	1286		|O
no	1287	1289		|O
significant	1290	1301		|O
difference	1302	1312		|O
between	1313	1320		|O
the	1321	1324		|O
groups	1325	1331		|O
in	1332	1334		|O
age	1335	1338		|O
,	1338	1339		|O
sex	1340	1343		|O
,	1343	1344		|O
serum	1345	1350		|O
creatinine	1351	1361		|O
,	1361	1362		|O
blood	1363	1368		|O
urea	1369	1373		|O
nitrogen	1374	1382		|O
,	1382	1383		|O
serum	1384	1389		|O
iron	1390	1394		|O
,	1394	1395		|O
and	1396	1399		|O
ferritin	1400	1408		|O
.	1408	1409		|O
After	1410	1415		|O
12	1416	1418		|O
weeks	1419	1424		|O
of	1425	1427		|O
treatment	1428	1437		|O
,	1437	1438		|O
the	1439	1442		|O
Hb	1443	1445		|O
level	1446	1451		|O
had	1452	1455		|O
significantly	1456	1469		|O
increased	1470	1479		|O
from	1480	1484		|O
8.4	1485	1488		|O
+	1489	1490		|O
/	1490	1491		|O
-	1491	1492		|O
1.1	1493	1496		|O
to	1497	1499		|O
9.5	1500	1503		|O
+	1504	1505		|O
/	1505	1506		|O
-	1506	1507		|O
1.3	1508	1511		|O
g	1512	1513		|O
/	1513	1514		|O
dL	1514	1516		|O
(	1517	1518		|O
P	1518	1519		|O
=	1519	1520		|O
0.0272	1520	1526		|O
)	1526	1527		|O
in	1528	1530		|O
the	1531	1534		|O
TJ	1535	1537		|O
-	1537	1538		|O
48	1538	1540		|O
group	1541	1546		|O
.	1546	1547		|O
C	1548	1549		|O
-	1549	1550		|O
reactive	1550	1558		|O
protein	1559	1566		|O
(	1567	1568		|O
CRP	1568	1571		|O
)	1571	1572		|O
had	1573	1576		|O
significantly	1577	1590		|O
decreased	1591	1600		|O
from	1601	1605		|O
1.4	1606	1609		|O
+	1610	1611		|O
/	1611	1612		|O
-	1612	1613		|O
1.7	1614	1617		|O
to	1618	1620		|O
0.6	1621	1624		|O
+	1625	1626		|O
/	1626	1627		|O
-	1627	1628		|O
0.8	1629	1632		|O
mg	1633	1635		|O
/	1635	1636		|O
dL	1636	1638		|O
(	1639	1640		|O
P	1640	1641		|O
=	1641	1642		|O
0.0438	1642	1648		|O
)	1648	1649		|O
.	1649	1650		|O
There	1651	1656		|O
was	1657	1660		|O
a	1661	1662		|O
significant	1663	1674		|O
negative	1675	1683		|O
correlation	1684	1695		|O
between	1696	1703		|O
Hb	1704	1706		|O
and	1707	1710		|O
CRP	1711	1714		|O
in	1715	1717		|O
the	1718	1721		|O
TJ	1722	1724		|O
-	1724	1725		|O
48	1725	1727		|O
group	1728	1733		|O
(	1734	1735		|O
r	1735	1736		|O
(	1736	1737		|O
2	1737	1738		|O
)	1738	1739		|O
=	1739	1740		|O
0.121	1740	1745		|O
,	1745	1746		|O
P	1747	1748		|O
=	1748	1749		|O
0.0066	1749	1755		|O
)	1755	1756		|O
.	1756	1757		|O
In	1758	1760		|O
contrast	1761	1769		|O
,	1769	1770		|O
in	1771	1773		|O
the	1774	1777		|O
control	1778	1785		|O
group	1786	1791		|O
,	1791	1792		|O
Hb	1793	1795		|O
and	1796	1799		|O
CRP	1800	1803		|O
showed	1804	1810		|O
no	1811	1813		|O
significant	1814	1825		|O
changes	1826	1833		|O
throughout	1834	1844		|O
this	1845	1849		|O
study	1850	1855		|O
.	1855	1856		|O
Nor	1857	1860		|O
was	1861	1864		|O
there	1865	1870		|O
a	1871	1872		|O
significant	1873	1884		|O
correlation	1885	1896		|O
between	1897	1904		|O
Hb	1905	1907		|O
and	1908	1911		|O
CRP	1912	1915		|O
in	1916	1918		|O
the	1919	1922		|O
control	1923	1930		|O
group	1931	1936		|O
.	1936	1937		|O
In	1938	1940		|O
conclusion	1941	1951		|O
,	1951	1952		|O
TJ	1953	1955		|O
-	1955	1956		|O
48	1956	1958		|O
was	1959	1962		|O
effective	1963	1972		|O
in	1973	1975		|O
improving	1976	1985		|O
erythropoietin	1986	2000	erythropoietin-resistant anemia	|B-DISEASE
-	2000	2001		|I-DISEASE
resistant	2001	2010		|I-DISEASE
anemia	2011	2017		|I-DISEASE
in	2018	2020		|O
end	2021	2024		|O
-	2024	2025		|O
stage	2025	2030		|O
renal	2031	2036	renal disease	|B-DISEASE
disease	2037	2044		|I-DISEASE
patients	2045	2053		|O
.	2053	2054		|O
This	2055	2059		|O
effect	2060	2066		|O
was	2067	2070		|O
,	2070	2071		|O
at	2072	2074		|O
least	2075	2080		|O
in	2081	2083		|O
part	2084	2088		|O
,	2088	2089		|O
due	2090	2093		|O
to	2094	2096		|O
the	2097	2100		|O
anti	2101	2105		|O
-	2105	2106		|O
inflammatory	2106	2118		|O
effect	2119	2125		|O
of	2126	2128		|O
TJ	2129	2131		|O
-	2131	2132		|O
48	2132	2134		|O
in	2135	2137		|O
patients	2138	2146		|O
on	2147	2149		|O
hemodialysis	2150	2162		|O
.	2162	2163		|O

### 18767405
Understanding	0	13		|O
the	14	17		|O
genetic	18	25		|O
causes	26	32		|O
of	33	35		|O
inter	36	41		|O
-	41	42		|O
patient	42	49		|O
variability	50	61		|O
.	61	62		|O
Clinical	63	71		|O
relevance	72	81		|O
with	82	86		|O
focus	87	92		|O
on	93	95		|O
cardiovascular	96	110		|O
drugs	111	116		|O
.	116	117		|O
There	119	124		|O
is	125	127		|O
a	128	129		|O
large	130	135		|O
inter	136	141		|O
-	141	142		|O
patient	142	149		|O
variability	150	161		|O
concerning	162	172		|O
the	173	176		|O
response	177	185		|O
to	186	188		|O
drug	189	193		|O
therapy	194	201		|O
and	202	205		|O
a	206	207		|O
great	208	213		|O
interest	214	222		|O
for	223	226		|O
determining	227	238		|O
the	239	242		|O
causes	243	249		|O
of	250	252		|O
this	253	257		|O
variability	258	269		|O
.	269	270		|O
This	271	275		|O
review	276	282		|O
takes	283	288		|O
into	289	293		|O
discussion	294	304		|O
some	305	309		|O
aspects	310	317		|O
of	318	320		|O
cardiovascular	321	335		|O
drugs	336	341		|O
metabolism	342	352		|O
and	353	356		|O
transport	357	366		|O
,	366	367		|O
pointing	368	376		|O
out	377	380		|O
the	381	384		|O
effects	385	392		|O
of	393	395		|O
genetic	396	403		|O
variation	404	413		|O
.	413	414		|O
Isoenyzmes	415	425		|O
belonging	426	435		|O
to	436	438		|O
the	439	442		|O
Cytochrome	443	453		|O
P450	454	458		|O
super	459	464		|O
family	465	471		|O
have	472	476		|O
an	477	479		|O
important	480	489		|O
role	490	494		|O
in	495	497		|O
cardiovascular	498	512		|O
drug	513	517		|O
metabolism	518	528		|O
,	528	529		|O
namely	530	536		|O
CYP	537	540		|O
1A2	541	544		|O
;	544	545		|O
CYP	546	549		|O
3A	550	552		|O
;	552	553		|O
CYP	554	557		|O
2C19	558	562		|O
;	562	563		|O
CYP2C9	564	570		|O
;	570	571		|O
CYP	572	575		|O
2D6	576	579		|O
,	579	580		|O
involved	581	589		|O
in	590	592		|O
the	593	596		|O
oxidative	597	606		|O
phase	607	612		|O
and	613	616		|O
also	617	621		|O
N	622	623		|O
-	623	624		|O
acetyltransferase	624	641		|O
2	642	643		|O
,	643	644		|O
involved	645	653		|O
in	654	656		|O
the	657	660		|O
conjungative	661	673		|O
phase	674	679		|O
of	680	682		|O
the	683	686		|O
metabolism	687	697		|O
.	697	698		|O
P	699	700		|O
-	700	701		|O
glycoprotein	701	713		|O
is	714	716		|O
implied	717	724		|O
in	725	727		|O
cardiovascular	728	742		|O
drug	743	747		|O
transport	748	757		|O
.	757	758		|O
Polymorphisms	759	772		|O
of	773	775		|O
those	776	781		|O
enzymes	782	789		|O
and	790	793		|O
transport	794	803		|O
protein	804	811		|O
result	812	818		|O
in	819	821		|O
different	822	831		|O
phenotypes	832	842		|O
,	842	843		|O
that	844	848		|O
is	849	851		|O
the	852	855		|O
case	856	860		|O
of	861	863		|O
CYP	864	867		|O
isoenyzmes	868	878		|O
with	879	883		|O
abolished	884	893		|O
,	893	894		|O
low	895	898		|O
or	899	901		|O
increased	902	911		|O
activity	912	920		|O
and	921	924		|O
in	925	927		|O
the	928	931		|O
case	932	936		|O
of	937	939		|O
N	940	941		|O
-	941	942		|O
acetyltransferase	942	959		|O
2	960	961		|O
,	961	962		|O
slow	963	967		|O
,	967	968		|O
intermediate	969	981		|O
and	982	985		|O
rapid	986	991		|O
acetylator	992	1002		|O
phenotypes	1003	1013		|O
.	1013	1014		|O
There	1015	1020		|O
is	1021	1023		|O
hope	1024	1028		|O
that	1029	1033		|O
,	1033	1034		|O
in	1035	1037		|O
the	1038	1041		|O
future	1042	1048		|O
,	1048	1049		|O
a	1050	1051		|O
more	1052	1056		|O
individualized	1057	1071		|O
treatment	1072	1081		|O
of	1082	1084		|O
a	1085	1086		|O
certain	1087	1094		|O
disease	1095	1102		|O
,	1102	1103		|O
with	1104	1108		|O
minimum	1109	1116		|O
adverse	1117	1124		|O
effects	1125	1132		|O
and	1133	1136		|O
a	1137	1138		|O
maximum	1139	1146		|O
therapeutic	1147	1158		|O
effect	1159	1165		|O
,	1165	1166		|O
will	1167	1171		|O
be	1172	1174		|O
available	1175	1184		|O
,	1184	1185		|O
by	1186	1188		|O
means	1189	1194		|O
of	1195	1197		|O
genetic	1198	1205		|O
testing	1206	1213		|O
.	1213	1214		|O

### 18607671
Utility	0	7		|O
of	8	10		|O
published	11	20		|O
guidelines	21	31		|O
on	32	34		|O
the	35	38		|O
use	39	42		|O
of	43	45		|O
nonsteroidal	46	58		|O
anti	59	63		|O
-	63	64		|O
inflammatory	64	76		|O
drugs	77	82		|O
in	83	85		|O
the	86	89		|O
elderly	90	97		|O
.	97	98		|O
Canadian	100	108		|O
Consensus	109	118		|O
guidelines	119	129		|O
regarding	130	139		|O
appropriate	140	151		|O
use	152	155		|O
of	156	158		|O
nonsteroidal	159	171		|O
anti	172	176		|O
-	176	177		|O
inflammatory	177	189		|O
drugs	190	195		|O
(	196	197		|O
NSAID	197	202		|O
)	202	203		|O
were	204	208		|O
recently	209	217		|O
published	218	227		|O
.	227	228		|O
This	229	233		|O
study	234	239		|O
was	240	243		|O
done	244	248		|O
to	249	251		|O
evaluate	252	260		|O
the	261	264		|O
application	265	276		|O
of	277	279		|O
these	280	285		|O
guidelines	286	296		|O
on	297	299		|O
NSAID	300	305		|O
practice	306	314		|O
patterns	315	323		|O
in	324	326		|O
frail	327	332		|O
elderly	333	340		|O
patients	341	349		|O
referred	350	358		|O
to	359	361		|O
a	362	363		|O
specialist	364	374		|O
Geriatric	375	384		|O
Assessment	385	395		|O
Clinic	396	402		|O
.	402	403		|O
A	404	405		|O
retrospective	406	419		|O
chart	420	425		|O
review	426	432		|O
was	433	436		|O
undertaken	437	447		|O
of	448	450		|O
referrals	451	460		|O
who	461	464		|O
were	465	469		|O
currently	470	479		|O
prescribed	480	490		|O
NSAIDs	491	497		|O
.	497	498		|O
Data	499	503		|O
were	504	508		|O
captured	509	517		|O
on	518	520		|O
age	521	524		|O
,	524	525		|O
sex	526	529		|O
,	529	530		|O
weight	531	537		|O
,	537	538		|O
diagnoses	539	548		|O
,	548	549		|O
medications	550	561		|O
and	562	565		|O
dosages	566	573		|O
,	573	574		|O
indication	575	585		|O
for	586	589		|O
NSAID	590	595		|O
treatment	596	605		|O
,	605	606		|O
lying	607	612		|O
BP	613	615		|O
(	616	617		|O
as	617	619		|O
assessed	620	628		|O
in	629	631		|O
the	632	635		|O
clinic	636	642		|O
)	642	643		|O
and	644	647		|O
recent	648	654		|O
serum	655	660		|O
creatinine	661	671		|O
result	672	678		|O
.	678	679		|O
Creatinine	680	690		|O
clearance	691	700		|O
was	701	704		|O
subsequently	705	717		|O
calculated	718	728		|O
use	729	732		|O
the	733	736		|O
Cockcroft	737	746		|O
-	746	747		|O
Gault	747	752		|O
equation	753	761		|O
.	761	762		|O
Complete	763	771		|O
data	772	776		|O
were	777	781		|O
available	782	791		|O
on	792	794		|O
107	795	798		|O
patients	799	807		|O
(	808	809		|O
68%	809	812		|O
women	813	818		|O
,	818	819		|O
average	820	827		|O
age	828	831		|O
80.6	832	836		|O
years	837	842		|O
)	842	843		|O
.	843	844		|O
Thirty	845	851		|O
percent	852	859		|O
were	860	864		|O
on	865	867		|O
a	868	869		|O
traditional	870	881		|O
NSAID	882	887		|O
,	887	888		|O
the	889	892		|O
remainder	893	902		|O
were	903	907		|O
on	908	910		|O
a	911	912		|O
Coxib	913	918		|O
.	918	919		|O
Concomitant	920	931		|O
aspirin	932	939		|O
was	940	943		|O
prescribed	944	954		|O
in	955	957		|O
37%	958	961		|O
.	961	962		|O
Cytoprotection	963	977		|O
was	978	981		|O
being	982	987		|O
used	988	992		|O
in	993	995		|O
38%	996	999		|O
and	1000	1003		|O
did	1004	1007		|O
not	1008	1011		|O
increase	1012	1020		|O
appreciably	1021	1032		|O
in	1033	1035		|O
patients	1036	1044		|O
with	1045	1049		|O
additional	1050	1060		|O
risk	1061	1065		|O
factors	1066	1073		|O
for	1074	1077		|O
GI	1078	1080	GI toxicity	|B-ADVERSE
toxicity	1081	1089		|I-ADVERSE
,	1089	1090		|O
i.e.	1091	1095		|O
,	1095	1096		|O
concomitant	1097	1108		|O
aspirin	1109	1116		|O
usage	1117	1122		|O
(	1123	1124		|O
35%	1124	1127		|O
)	1127	1128		|O
,	1128	1129		|O
and	1130	1133		|O
history	1134	1141		|O
of	1142	1144		|O
GI	1145	1147	GI toxicity	|B-ADVERSE
toxicity	1148	1156		|I-ADVERSE
(	1157	1158		|O
48%	1158	1161		|O
)	1161	1162		|O
.	1162	1163		|O
Sixty	1164	1169		|O
-	1169	1170		|O
seven	1170	1175		|O
were	1176	1180		|O
taking	1181	1187		|O
anti	1188	1192		|O
-	1192	1193		|O
hypertensive	1193	1205		|O
medications	1206	1217		|O
,	1217	1218		|O
although	1219	1227		|O
more	1228	1232		|O
than	1233	1237		|O
two	1238	1241		|O
thirds	1242	1248		|O
of	1249	1251		|O
these	1252	1257		|O
patients	1258	1266		|O
were	1267	1271		|O
uncontrolled	1272	1284		|O
.	1284	1285		|O
Newly	1286	1291		|O
diagnosed	1292	1301		|O
hypertension	1302	1314	hypertension	|B-ADVERSE
was	1315	1318		|O
present	1319	1326		|O
in	1327	1329		|O
19.6%	1330	1335		|O
.	1335	1336		|O
Calculated	1337	1347		|O
creatinine	1348	1358		|O
clearance	1359	1368		|O
revealed	1369	1377		|O
moderate	1378	1386		|O
to	1387	1389		|O
severe	1390	1396		|O
renal	1397	1402	renal impairment	|B-ADVERSE
impairment	1403	1413		|I-ADVERSE
in	1414	1416		|O
79%	1417	1420		|O
of	1421	1423		|O
subjects	1424	1432		|O
,	1432	1433		|O
although	1434	1442		|O
serum	1443	1448		|O
creatinine	1449	1459		|O
was	1460	1463		|O
only	1464	1468		|O
elevated	1469	1477		|O
in	1478	1480		|O
18%	1481	1484		|O
.	1484	1485		|O
In	1486	1488		|O
total	1489	1494		|O
,	1494	1495		|O
70%	1496	1499		|O
of	1500	1502		|O
subjects	1503	1511		|O
were	1512	1516		|O
found	1517	1522		|O
to	1523	1525		|O
have	1526	1530		|O
relative	1531	1539		|O
or	1540	1542		|O
absolute	1543	1551		|O
risk	1552	1556		|O
factors	1557	1564		|O
for	1565	1568		|O
NSAID	1569	1574		|O
therapy	1575	1582		|O
.	1582	1583		|O
Given	1584	1589		|O
the	1590	1593		|O
high	1594	1598		|O
prevalence	1599	1609		|O
of	1610	1612		|O
potential	1613	1622		|O
contraindications	1623	1640		|O
to	1641	1643		|O
anti	1644	1648		|O
-	1648	1649		|O
inflammatory	1649	1661		|O
drug	1662	1666		|O
usage	1667	1672		|O
in	1673	1675		|O
this	1676	1680		|O
study	1681	1686		|O
,	1686	1687		|O
we	1688	1690		|O
advocate	1691	1699		|O
the	1700	1703		|O
dissemination	1704	1717		|O
and	1718	1721		|O
application	1722	1733		|O
of	1734	1736		|O
these	1737	1742		|O
guidelines	1743	1753		|O
in	1754	1756		|O
geriatric	1757	1766		|O
patients	1767	1775		|O
in	1776	1778		|O
an	1779	1781		|O
attempt	1782	1789		|O
to	1790	1792		|O
reduce	1793	1799		|O
potential	1800	1809		|O
morbidity	1810	1819		|O
and	1820	1823		|O
mortality	1824	1833		|O
.	1833	1834		|O

### 18774732
The	0	3		|O
islet	4	9		|O
beta	10	14		|O
-	14	15		|O
cell	15	19		|O
:	19	20		|O
fuel	21	25		|O
responsive	26	36		|O
and	37	40		|O
vulnerable	41	51		|O
.	51	52		|O
The	54	57		|O
pancreatic	58	68		|O
beta	69	73		|O
-	73	74		|O
cell	74	78		|O
senses	79	85		|O
blood	86	91		|O
nutrient	92	100		|O
levels	101	107		|O
and	108	111		|O
is	112	114		|O
modulated	115	124		|O
by	125	127		|O
neurohormonal	128	141		|O
signals	142	149		|O
so	150	152		|O
that	153	157		|O
it	158	160		|O
secretes	161	169		|O
insulin	170	177		|O
according	178	187		|O
to	188	190		|O
the	191	194		|O
need	195	199		|O
of	200	202		|O
the	203	206		|O
organism	207	215		|O
.	215	216		|O
Nutrient	217	225		|O
sensing	226	233		|O
involves	234	242		|O
marked	243	249		|O
metabolic	250	259		|O
activation	260	270		|O
,	270	271		|O
resulting	272	281		|O
in	282	284		|O
the	285	288		|O
production	289	299		|O
of	300	302		|O
coupling	303	311		|O
signals	312	319		|O
that	320	324		|O
promote	325	332		|O
insulin	333	340		|O
biosynthesis	341	353		|O
and	354	357		|O
secretion	358	367		|O
.	367	368		|O
The	369	372		|O
beta	373	377		|O
-	377	378		|O
cell	378	382		|O
's	382	384		|O
high	385	389		|O
capacity	390	398		|O
for	399	402		|O
nutrient	403	411		|O
sensing	412	419		|O
,	419	420		|O
however	421	428		|O
,	428	429		|O
necessitates	430	442		|O
reduced	443	450		|O
protection	451	461		|O
to	462	464		|O
nutrient	465	473	nutrient toxicity	|B-ADVERSE
toxicity	474	482		|I-ADVERSE
.	482	483		|O
This	484	488		|O
potentially	489	500		|O
explains	501	509		|O
why	510	513		|O
in	514	516		|O
susceptible	517	528		|O
individuals	529	540		|O
,	540	541		|O
chronic	542	549		|O
fuel	550	554		|O
surfeit	555	562		|O
results	563	570		|O
in	571	573		|O
beta	574	578		|O
-	578	579		|O
cell	579	583		|O
failure	584	591		|O
and	592	595		|O
type	596	600	type 2 diabetes	|B-DISEASE
2	601	602		|I-DISEASE
diabetes	603	611		|I-DISEASE
.	611	612		|O
Here	613	617		|O
we	618	620		|O
discuss	621	628		|O
recent	629	635		|O
insights	636	644		|O
into	645	649		|O
first	650	655		|O
,	655	656		|O
the	657	660		|O
biochemical	661	672		|O
basis	673	678		|O
of	679	681		|O
beta	682	686		|O
-	686	687		|O
cell	687	691		|O
signaling	692	701		|O
in	702	704		|O
response	705	713		|O
to	714	716		|O
glucose	717	724		|O
,	724	725		|O
amino	726	731		|O
acids	732	737		|O
and	738	741		|O
fatty	742	747		|O
acids	748	753		|O
,	753	754		|O
and	755	758		|O
second	759	765		|O
,	765	766		|O
beta	767	771		|O
-	771	772		|O
cell	772	776		|O
nutrient	777	785		|O
detoxification	786	800		|O
.	800	801		|O
We	802	804		|O
emphasize	805	814		|O
the	815	818		|O
emerging	819	827		|O
role	828	832		|O
of	833	835		|O
glycerolipid	836	848		|O
/	848	849		|O
fatty	849	854		|O
acid	855	859		|O
cycling	860	867		|O
in	868	870		|O
these	871	876		|O
processes	877	886		|O
.	886	887		|O

### 18715837
Effect	0	6		|O
of	7	9		|O
cement	10	16		|O
dust	17	21		|O
exposure	22	30		|O
on	31	33		|O
phagocytic	34	44		|O
function	45	53		|O
of	54	56		|O
polymorphonuclear	57	74		|O
neutrophils	75	86		|O
in	87	89		|O
cement	90	96		|O
mill	97	101		|O
workers	102	109		|O
.	109	110		|O
OBJECTIVES	112	122		|O
:	122	123		|O
Exposure	124	132		|O
to	133	135		|O
cement	136	142		|O
dust	143	147		|O
can	148	151		|O
cause	152	157		|O
various	158	165		|O
occupational	166	178		|O
health	179	185		|O
problems	186	194		|O
due	195	198		|O
to	199	201		|O
its	202	205		|O
increasing	206	216		|O
incidence	217	226		|O
and	227	230		|O
long	231	235		|O
-	235	236		|O
term	236	240		|O
complications	241	254		|O
.	254	255		|O
However	256	263		|O
,	263	264		|O
the	265	268		|O
influence	269	278		|O
of	279	281		|O
cement	282	288		|O
dust	289	293		|O
on	294	296		|O
phagocytic	297	307		|O
function	308	316		|O
of	317	319		|O
polymorphonuclear	320	337		|O
neutrophils	338	349		|O
(	350	351		|O
PMNs	351	355		|O
)	355	356		|O
,	356	357		|O
has	358	361		|O
not	362	365		|O
as	366	368		|O
yet	369	372		|O
been	373	377		|O
investigated	378	390		|O
.	390	391		|O
Therefore	392	401		|O
,	401	402		|O
the	403	406		|O
aim	407	410		|O
of	411	413		|O
the	414	417		|O
study	418	423		|O
was	424	427		|O
to	428	430		|O
measure	431	438		|O
the	439	442		|O
phagocytic	443	453		|O
activity	454	462		|O
of	463	465		|O
PMNs	466	470		|O
by	471	473		|O
assessing	474	483		|O
chemilumiscence	484	499		|O
(	500	501		|O
CL	501	503		|O
)	503	504		|O
response	505	513		|O
in	514	516		|O
cement	517	523		|O
mill	524	528		|O
workers	529	536		|O
and	537	540		|O
controls	541	549		|O
.	549	550		|O
MATERIAL	551	559		|O
AND	560	563		|O
METHODS	564	571		|O
:	571	572		|O
In	573	575		|O
this	576	580		|O
study	581	586		|O
,	586	587		|O
50	588	590		|O
volunteer	591	600		|O
males	601	606		|O
,	606	607		|O
aged	608	612		|O
25-60	613	618		|O
years	619	624		|O
,	624	625		|O
apparently	626	636		|O
healthy	637	644		|O
and	645	648		|O
nonsmoking	649	659		|O
,	659	660		|O
were	661	665		|O
randomly	666	674		|O
selected	675	683		|O
from	684	688		|O
among	689	694		|O
cement	695	701		|O
mill	702	706		|O
workers	707	714		|O
.	714	715		|O
These	716	721		|O
workers	722	729		|O
were	730	734		|O
further	735	742		|O
classified	743	753		|O
into	754	758		|O
subgroups	759	768		|O
based	769	774		|O
on	775	777		|O
exposure	778	786		|O
duration	787	795		|O
of	796	798		|O
less	799	803		|O
than	804	808		|O
10	809	811		|O
,	811	812		|O
10-20	813	818		|O
,	818	819		|O
and	820	823		|O
more	824	828		|O
than	829	833		|O
20	834	836		|O
years	837	842		|O
.	842	843		|O
The	844	847		|O
controls	848	856		|O
were	857	861		|O
50	862	864		|O
healthy	865	872		|O
,	872	873		|O
nonsmoking	874	884		|O
,	884	885		|O
males	886	891		|O
who	892	895		|O
matched	896	903		|O
the	904	907		|O
study	908	913		|O
group	914	919		|O
with	920	924		|O
respect	925	932		|O
to	933	935		|O
age	936	939		|O
,	939	940		|O
height	941	947		|O
,	947	948		|O
weight	949	955		|O
,	955	956		|O
and	957	960		|O
socioeconomic	961	974		|O
status	975	981		|O
.	981	982		|O
The	983	986		|O
phagocytic	987	997		|O
function	998	1006		|O
of	1007	1009		|O
PMNs	1010	1014		|O
,	1014	1015		|O
stimulated	1016	1026		|O
with	1027	1031		|O
opsonized	1032	1041		|O
zymosan	1042	1049		|O
,	1049	1050		|O
was	1051	1054		|O
determined	1055	1065		|O
by	1066	1068		|O
measuring	1069	1078		|O
CL	1079	1081		|O
response	1082	1090		|O
.	1090	1091		|O
RESULTS	1092	1099		|O
:	1099	1100		|O
The	1101	1104		|O
findings	1105	1113		|O
show	1114	1118		|O
a	1119	1120		|O
significant	1121	1132		|O
decrease	1133	1141		|O
in	1142	1144		|O
phagocytic	1145	1155		|O
activity	1156	1164		|O
of	1165	1167		|O
PMNs	1168	1172		|O
[	1173	1174		|O
PMNs	1174	1178		|O
OPZ	1179	1182		|O
p	1183	1184		|O
<	1185	1186		|O
0.005	1187	1192		|O
]	1192	1193		|O
in	1194	1196		|O
cement	1197	1203		|O
mill	1204	1208		|O
workers	1209	1216		|O
compared	1217	1225		|O
to	1226	1228		|O
controls	1229	1237		|O
.	1237	1238		|O
CONCLUSION	1239	1249		|O
:	1249	1250		|O
It	1251	1253		|O
is	1254	1256		|O
concluded	1257	1266		|O
that	1267	1271		|O
exposure	1272	1280		|O
to	1281	1283		|O
cement	1284	1290		|O
dust	1291	1295		|O
can	1296	1299		|O
impair	1300	1306		|O
the	1307	1310		|O
phagocytic	1311	1321		|O
function	1322	1330		|O
of	1331	1333		|O
PMNs	1334	1338		|O
which	1339	1344		|O
is	1345	1347		|O
reflected	1348	1357		|O
in	1358	1360		|O
decreased	1361	1370		|O
chemiluminescence	1371	1388		|O
response	1389	1397		|O
.	1397	1398		|O

### 18702535
Application	0	11		|O
of	12	14		|O
stable	15	21		|O
isotope	22	29		|O
-	29	30		|O
labeled	30	37		|O
compounds	38	47		|O
in	48	50		|O
metabolism	51	61		|O
and	62	65		|O
in	66	68		|O
metabolism	69	79	metabolism-mediated toxicity	|B-ADVERSE
-	79	80		|I-ADVERSE
mediated	80	88		|I-ADVERSE
toxicity	89	97		|I-ADVERSE
studies	98	105		|O
.	105	106		|O
Stable	108	114		|O
isotope	115	122		|O
-	122	123		|O
labeled	123	130		|O
compounds	131	140		|O
have	141	145		|O
been	146	150		|O
synthesized	151	162		|O
and	163	166		|O
utilized	167	175		|O
by	176	178		|O
scientists	179	189		|O
from	190	194		|O
various	195	202		|O
areas	203	208		|O
of	209	211		|O
biomedical	212	222		|O
research	223	231		|O
during	232	238		|O
the	239	242		|O
last	243	247		|O
several	248	255		|O
decades	256	263		|O
.	263	264		|O
Compounds	265	274		|O
labeled	275	282		|O
with	283	287		|O
stable	288	294		|O
isotopes	295	303		|O
,	303	304		|O
such	305	309		|O
as	310	312		|O
deuterium	313	322		|O
and	323	326		|O
carbon	327	333		|O
-	333	334		|O
13	334	336		|O
,	336	337		|O
have	338	342		|O
been	343	347		|O
used	348	352		|O
effectively	353	364		|O
by	365	367		|O
drug	368	372		|O
metabolism	373	383		|O
scientists	384	394		|O
and	395	398		|O
toxicologists	399	412		|O
to	413	415		|O
gain	416	420		|O
better	421	427		|O
understanding	428	441		|O
of	442	444		|O
drugs	445	450		|O
'	450	451		|O
disposition	452	463		|O
and	464	467		|O
their	468	473		|O
potential	474	483		|O
role	484	488		|O
in	489	491		|O
target	492	498	target organ toxicities	|B-ADVERSE
organ	499	504		|I-ADVERSE
toxicities	505	515		|I-ADVERSE
.	515	516		|O
The	517	520		|O
combination	521	532		|O
of	533	535		|O
stable	536	542		|O
isotope	543	550		|O
-	550	551		|O
labeling	551	559		|O
techniques	560	570		|O
with	571	575		|O
mass	576	580		|O
spectrometry	581	593		|O
and	594	597		|O
nuclear	598	605		|O
magnetic	606	614		|O
resonance	615	624		|O
(	625	626		|O
NMR	626	629		|O
)	629	630		|O
spectroscopy	631	643		|O
,	643	644		|O
which	645	650		|O
allows	651	657		|O
rapid	658	663		|O
acquisition	664	675		|O
and	676	679		|O
interpretation	680	694		|O
of	695	697		|O
data	698	702		|O
,	702	703		|O
has	704	707		|O
promoted	708	716		|O
greater	717	724		|O
use	725	728		|O
of	729	731		|O
these	732	737		|O
stable	738	744		|O
isotope	745	752		|O
-	752	753		|O
labeled	753	760		|O
compounds	761	770		|O
in	771	773		|O
absorption	774	784		|O
,	784	785		|O
distribution	786	798		|O
,	798	799		|O
metabolism	800	810		|O
,	810	811		|O
and	812	815		|O
excretion	816	825		|O
(	826	827		|O
ADME	827	831		|O
)	831	832		|O
studies	833	840		|O
.	840	841		|O
Examples	842	850		|O
of	851	853		|O
the	854	857		|O
use	858	861		|O
of	862	864		|O
stable	865	871		|O
isotope	872	879		|O
-	879	880		|O
labeled	880	887		|O
compounds	888	897		|O
in	898	900		|O
elucidating	901	912		|O
structures	913	923		|O
of	924	926		|O
metabolites	927	938		|O
and	939	942		|O
delineating	943	954		|O
complex	955	962		|O
metabolic	963	972		|O
pathways	973	981		|O
are	982	985		|O
presented	986	995		|O
in	996	998		|O
this	999	1003		|O
review	1004	1010		|O
.	1010	1011		|O
The	1012	1015		|O
application	1016	1027		|O
of	1028	1030		|O
labeled	1031	1038		|O
compounds	1039	1048		|O
in	1049	1051		|O
mechanistic	1052	1063		|O
toxicity	1064	1072		|O
studies	1073	1080		|O
will	1081	1085		|O
be	1086	1088		|O
discussed	1089	1098		|O
by	1099	1101		|O
providing	1102	1111		|O
an	1112	1114		|O
example	1115	1122		|O
of	1123	1125		|O
how	1126	1129		|O
strategic	1130	1139		|O
placement	1140	1149		|O
of	1150	1152		|O
a	1153	1154		|O
deuterium	1155	1164		|O
atom	1165	1169		|O
in	1170	1172		|O
a	1173	1174		|O
drug	1175	1179		|O
molecule	1180	1188		|O
mitigated	1189	1198		|O
specific	1199	1207		|O
-	1207	1208		|O
specific	1208	1216		|O
renal	1217	1222	renal toxicity	|B-ADVERSE
toxicity	1223	1231		|I-ADVERSE
.	1231	1232		|O
Other	1233	1238		|O
examples	1239	1247		|O
from	1248	1252		|O
the	1253	1256		|O
literature	1257	1267		|O
demonstrating	1268	1281		|O
the	1282	1285		|O
application	1286	1297		|O
of	1298	1300		|O
stable	1301	1307		|O
isotope	1308	1315		|O
-	1315	1316		|O
labeled	1316	1323		|O
compounds	1324	1333		|O
in	1334	1336		|O
understanding	1337	1350		|O
metabolism	1351	1361	metabolism-mediated toxicities	|B-ADVERSE
-	1361	1362		|I-ADVERSE
mediated	1362	1370		|I-ADVERSE
toxicities	1371	1381		|I-ADVERSE
are	1382	1385		|O
presented	1386	1395		|O
.	1395	1396		|O
Furthermore	1397	1408		|O
,	1408	1409		|O
an	1410	1412		|O
example	1413	1420		|O
of	1421	1423		|O
how	1424	1427		|O
a	1428	1429		|O
stable	1430	1436		|O
isotope	1437	1444		|O
-	1444	1445		|O
labeled	1445	1452		|O
compound	1453	1461		|O
was	1462	1465		|O
utilized	1466	1474		|O
to	1475	1477		|O
better	1478	1484		|O
understand	1485	1495		|O
some	1496	1500		|O
of	1501	1503		|O
the	1504	1507		|O
gene	1508	1512		|O
changes	1513	1520		|O
in	1521	1523		|O
toxicogenomic	1524	1537		|O
studies	1538	1545		|O
is	1546	1548		|O
discussed	1549	1558		|O
.	1558	1559		|O
The	1560	1563		|O
interpretation	1564	1578		|O
of	1579	1581		|O
large	1582	1587		|O
sets	1588	1592		|O
of	1593	1595		|O
data	1596	1600		|O
produced	1601	1609		|O
from	1610	1614		|O
toxicogenomics	1615	1629		|O
studies	1630	1637		|O
can	1638	1641		|O
be	1642	1644		|O
a	1645	1646		|O
challenge	1647	1656		|O
.	1656	1657		|O
One	1658	1661		|O
approach	1662	1670		|O
that	1671	1675		|O
could	1676	1681		|O
be	1682	1684		|O
used	1685	1689		|O
to	1690	1692		|O
simplify	1693	1701		|O
interpretation	1702	1716		|O
of	1717	1719		|O
the	1720	1723		|O
data	1724	1728		|O
,	1728	1729		|O
especially	1730	1740		|O
from	1741	1745		|O
studies	1746	1753		|O
designed	1754	1762		|O
to	1763	1765		|O
link	1766	1770		|O
gene	1771	1775		|O
changes	1776	1783		|O
with	1784	1788		|O
the	1789	1792		|O
formation	1793	1802		|O
of	1803	1805		|O
reactive	1806	1814		|O
metabolites	1815	1826		|O
thought	1827	1834		|O
to	1835	1837		|O
be	1838	1840		|O
responsible	1841	1852		|O
for	1853	1856		|O
toxicities	1857	1867		|O
,	1867	1868		|O
is	1869	1871		|O
through	1872	1879		|O
the	1880	1883		|O
use	1884	1887		|O
of	1888	1890		|O
stable	1891	1897		|O
isotope	1898	1905		|O
-	1905	1906		|O
labeled	1906	1913		|O
compounds	1914	1923		|O
.	1923	1924		|O
This	1925	1929		|O
is	1930	1932		|O
a	1933	1934		|O
relatively	1935	1945		|O
unexplored	1946	1956		|O
territory	1957	1966		|O
and	1967	1970		|O
needs	1971	1976		|O
to	1977	1979		|O
be	1980	1982		|O
further	1983	1990		|O
investigated	1991	2003		|O
.	2003	2004		|O
The	2005	2008		|O
employment	2009	2019		|O
of	2020	2022		|O
analytical	2023	2033		|O
techniques	2034	2044		|O
,	2044	2045		|O
especially	2046	2056		|O
mass	2057	2061		|O
spectrometry	2062	2074		|O
and	2075	2078		|O
NMR	2079	2082		|O
,	2082	2083		|O
used	2084	2088		|O
in	2089	2091		|O
conjunction	2092	2103		|O
with	2104	2108		|O
stable	2109	2115		|O
isotope	2116	2123		|O
-	2123	2124		|O
labeled	2124	2131		|O
compounds	2132	2141		|O
to	2142	2144		|O
establish	2145	2154		|O
and	2155	2158		|O
understand	2159	2169		|O
mechanistic	2170	2181		|O
link	2182	2186		|O
between	2187	2194		|O
reactive	2195	2203		|O
metabolite	2204	2214		|O
formation	2215	2224		|O
,	2224	2225		|O
genomic	2226	2233		|O
,	2233	2234		|O
and	2235	2238		|O
proteomic	2239	2248		|O
changes	2249	2256		|O
and	2257	2260		|O
onset	2261	2266		|O
of	2267	2269		|O
toxicity	2270	2278		|O
is	2279	2281		|O
proposed	2282	2290		|O
.	2290	2291		|O
The	2292	2295		|O
use	2296	2299		|O
of	2300	2302		|O
stable	2303	2309		|O
isotope	2310	2317		|O
-	2317	2318		|O
labeled	2318	2325		|O
compounds	2326	2335		|O
in	2336	2338		|O
early	2339	2344		|O
human	2345	2350		|O
ADME	2351	2355		|O
studies	2356	2363		|O
as	2364	2366		|O
a	2367	2368		|O
way	2369	2372		|O
of	2373	2375		|O
identifying	2376	2387		|O
and	2388	2391		|O
possibly	2392	2400		|O
quantifying	2401	2412		|O
all	2413	2416		|O
drug	2417	2421		|O
-	2421	2422		|O
related	2422	2429		|O
components	2430	2440		|O
present	2441	2448		|O
in	2449	2451		|O
systemic	2452	2460		|O
circulation	2461	2472		|O
is	2473	2475		|O
suggested	2476	2485		|O
.	2485	2486		|O

### 18726085
Mitochondrial	0	13		|O
dysfunction	14	25		|O
and	26	29		|O
delayed	30	37		|O
hepatotoxicity	38	52	hepatotoxicity	|B-ADVERSE
:	52	53		|O
another	54	61		|O
lesson	62	68		|O
from	69	73		|O
troglitazone	74	86		|O
.	86	87		|O
AIMS	89	93		|O
/	93	94		|O
HYPOTHESIS	94	104		|O
:	104	105		|O
Troglitazone	106	118		|O
was	119	122		|O
approved	123	131		|O
for	132	135		|O
treatment	136	145		|O
of	146	148		|O
type	149	153	type 2 diabetes mellitus	|B-DISEASE
2	154	155		|I-DISEASE
diabetes	156	164		|I-DISEASE
mellitus	165	173		|I-DISEASE
,	173	174		|O
but	175	178		|O
by	179	181		|O
2000	182	186		|O
it	187	189		|O
had	190	193		|O
been	194	198		|O
removed	199	206		|O
from	207	211		|O
all	212	215		|O
world	216	221		|O
markets	222	229		|O
due	230	233		|O
to	234	236		|O
severe	237	243		|O
drug	244	248		|O
-	248	249		|O
induced	249	256		|O
liver	257	262	liver injury	|B-ADVERSE
injury	263	269		|I-ADVERSE
.	269	270		|O
Even	271	275		|O
today	276	281		|O
,	281	282		|O
we	283	285		|O
still	286	291		|O
do	292	294		|O
not	295	298		|O
know	299	303		|O
how	304	307		|O
many	308	312		|O
patients	313	321		|O
sustained	322	331		|O
a	332	333		|O
long	334	338		|O
-	338	339		|O
term	339	343		|O
liver	344	349	liver injury	|B-ADVERSE
injury	350	356		|I-ADVERSE
.	356	357		|O
No	358	360		|O
system	361	367		|O
is	368	370		|O
in	371	373		|O
place	374	379		|O
to	380	382		|O
acquire	383	390		|O
that	391	395		|O
knowledge	396	405		|O
.	405	406		|O
Regarding	407	416		|O
toxicity	417	425		|O
mechanisms	426	436		|O
,	436	437		|O
controversy	438	449		|O
persists	450	458		|O
as	459	461		|O
to	462	464		|O
which	465	470		|O
ones	471	475		|O
are	476	479		|O
class	480	485		|O
effects	486	493		|O
of	494	496		|O
thiazolidinediones	497	515		|O
(	516	517		|O
TZDs	517	521		|O
)	521	522		|O
and	523	526		|O
which	527	532		|O
are	533	536		|O
unique	537	543		|O
to	544	546		|O
troglitazone	547	559		|O
.	559	560		|O
This	561	565		|O
study	566	571		|O
aims	572	576		|O
to	577	579		|O
provide	580	587		|O
long	588	592		|O
-	592	593		|O
term	593	597		|O
outcome	598	605		|O
data	606	610		|O
and	611	614		|O
new	615	618		|O
insights	619	627		|O
on	628	630		|O
mechanisms	631	641		|O
of	642	644		|O
troglitazone	645	657		|O
-	657	658		|O
induced	658	665		|O
liver	666	671	liver injury	|B-ADVERSE
injury	672	678		|I-ADVERSE
.	678	679		|O
METHODS	680	687		|O
:	687	688		|O
This	689	693		|O
case	694	698		|O
series	699	705		|O
reports	706	713		|O
the	714	717		|O
liver	718	723		|O
injuries	724	732		|O
sustained	733	742		|O
by	743	745		|O
eleven	746	752		|O
type	753	757		|O
2	758	759		|O
diabetic	760	768		|O
patients	769	777		|O
treated	778	785		|O
with	786	790		|O
troglitazone	791	803		|O
between	804	811		|O
1997	812	816		|O
and	817	820		|O
2000	821	825		|O
.	825	826		|O
Exhaustive	827	837		|O
review	838	844		|O
of	845	847		|O
medical	848	855		|O
records	856	863		|O
was	864	867		|O
performed	868	877		|O
for	878	881		|O
all	882	885		|O
patients	886	894		|O
.	894	895		|O
Long	896	900		|O
-	900	901		|O
term	901	905		|O
outcomes	906	914		|O
were	915	919		|O
available	920	929		|O
for	930	933		|O
all	934	937		|O
the	938	941		|O
non	942	945		|O
-	945	946		|O
fatal	946	951		|O
cases	952	957		|O
.	957	958		|O
A	959	960		|O
comprehensive	961	974		|O
literature	975	985		|O
review	986	992		|O
was	993	996		|O
also	997	1001		|O
performed	1002	1011		|O
.	1011	1012		|O
RESULTS	1013	1020		|O
:	1020	1021		|O
Long	1022	1026		|O
-	1026	1027		|O
term	1027	1031		|O
liver	1032	1037	liver injury	|B-ADVERSE
injury	1038	1044		|I-ADVERSE
progressing	1045	1056		|O
to	1057	1059		|O
cirrhosis	1060	1069	cirrhosis	|B-ADVERSE
was	1070	1073		|O
identified	1074	1084		|O
in	1085	1087		|O
seven	1088	1093		|O
patients	1094	1102		|O
.	1102	1103		|O
All	1104	1107		|O
eleven	1108	1114		|O
cases	1115	1120		|O
had	1121	1124		|O
liver	1125	1130	liver injury	|B-ADVERSE
injury	1131	1137		|I-ADVERSE
patterns	1138	1146		|O
consistent	1147	1157		|O
with	1158	1162		|O
troglitazone	1163	1175		|O
toxicity	1176	1184		|O
.	1184	1185		|O
Analysis	1186	1194		|O
of	1195	1197		|O
these	1198	1203		|O
cases	1204	1209		|O
and	1210	1213		|O
of	1214	1216		|O
the	1217	1220		|O
experimental	1221	1233		|O
troglitazone	1234	1246		|O
toxicity	1247	1255		|O
data	1256	1260		|O
points	1261	1267		|O
to	1268	1270		|O
mitochondrial	1271	1284	mitochondrial toxicity	|B-ADVERSE
toxicity	1285	1293		|I-ADVERSE
as	1294	1296		|O
a	1297	1298		|O
central	1299	1306		|O
factor	1307	1313		|O
.	1313	1314		|O
The	1315	1318		|O
general	1319	1326		|O
clinical	1327	1335		|O
patterns	1336	1344		|O
of	1345	1347		|O
mitochondrial	1348	1361	mitochondrial hepatotoxic events	|B-ADVERSE
hepatotoxic	1362	1373		|I-ADVERSE
events	1374	1380		|I-ADVERSE
are	1381	1384		|O
reviewed	1385	1393		|O
,	1393	1394		|O
as	1395	1397		|O
are	1398	1401		|O
the	1402	1405		|O
implications	1406	1418		|O
for	1419	1422		|O
other	1423	1428		|O
members	1429	1436		|O
of	1437	1439		|O
the	1440	1443		|O
TZD	1444	1447		|O
family	1448	1454		|O
.	1454	1455		|O
CONCLUSIONS	1456	1467		|O
/	1467	1468		|O
INTERPRETATION	1468	1482		|O
:	1482	1483		|O
This	1484	1488		|O
analysis	1489	1497		|O
enables	1498	1505		|O
the	1506	1509		|O
liver	1510	1515	liver injury	|B-ADVERSE
injury	1516	1522		|I-ADVERSE
induced	1523	1530		|O
by	1531	1533		|O
troglitazone	1534	1546		|O
to	1547	1549		|O
be	1550	1552		|O
better	1553	1559		|O
understood	1560	1570		|O
.	1570	1571		|O
In	1572	1574		|O
future	1575	1581		|O
cases	1582	1587		|O
of	1588	1590		|O
delayed	1591	1598		|O
drug	1599	1603		|O
-	1603	1604		|O
induced	1604	1611		|O
liver	1612	1617	liver injury	|B-ADVERSE
injury	1618	1624		|I-ADVERSE
that	1625	1629		|O
progresses	1630	1640		|O
after	1641	1646		|O
discontinuation	1647	1662		|O
,	1662	1663		|O
the	1664	1667		|O
possibility	1668	1679		|O
of	1680	1682		|O
mitochondrial	1683	1696	mitochondrial toxicity	|B-ADVERSE
toxicity	1697	1705		|I-ADVERSE
should	1706	1712		|O
be	1713	1715		|O
considered	1716	1726		|O
.	1726	1727		|O
When	1728	1732		|O
appropriate	1733	1744		|O
,	1744	1745		|O
this	1746	1750		|O
can	1751	1754		|O
then	1755	1759		|O
be	1760	1762		|O
evaluated	1763	1772		|O
experimentally	1773	1787		|O
.	1787	1788		|O
Such	1789	1793		|O
proactive	1794	1803		|O
investigation	1804	1817		|O
may	1818	1821		|O
anticipate	1822	1832		|O
clinical	1833	1841		|O
risk	1842	1846		|O
before	1847	1853		|O
a	1854	1855		|O
large	1856	1861		|O
-	1861	1862		|O
scale	1862	1867		|O
therapeutic	1868	1879		|O
misadventure	1880	1892		|O
occurs	1893	1899		|O
.	1899	1900		|O
Drug	1901	1905		|O
-	1905	1906		|O
induced	1906	1913		|O
liver	1914	1919	liver injury	|B-ADVERSE
injury	1920	1926		|I-ADVERSE
due	1927	1930		|O
to	1931	1933		|O
mitochondrial	1934	1947		|O
hepatotoxins	1948	1960		|O
may	1961	1964		|O
be	1965	1967		|O
less	1968	1972		|O
unpredictable	1973	1986		|O
than	1987	1991		|O
has	1992	1995		|O
previously	1996	2006		|O
been	2007	2011		|O
surmised	2012	2020		|O
.	2020	2021		|O

### 18691649
Catalase	0	8		|O
ameliorates	9	20		|O
polychlorinated	21	36		|O
biphenyl	37	45		|O
-	45	46		|O
induced	46	53		|O
cytotoxicity	54	66	cytotoxicity	|B-ADVERSE
in	67	69		|O
nonmalignant	70	82		|O
human	83	88		|O
breast	89	95		|O
epithelial	96	106		|O
cells	107	112		|O
.	112	113		|O
Polychlorinated	115	130		|O
biphenyls	131	140		|O
(	141	142		|O
PCBs	142	146		|O
)	146	147		|O
are	148	151		|O
environmental	152	165		|O
chemical	166	174		|O
contaminants	175	187		|O
believed	188	196		|O
to	197	199		|O
adversely	200	209		|O
affect	210	216		|O
cellular	217	225		|O
processes	226	235		|O
.	235	236		|O
We	237	239		|O
investigated	240	252		|O
the	253	256		|O
hypothesis	257	267		|O
that	268	272		|O
PCB	273	276		|O
-	276	277		|O
induced	277	284		|O
changes	285	292		|O
in	293	295		|O
the	296	299		|O
levels	300	306		|O
of	307	309		|O
cellular	310	318		|O
reactive	319	327		|O
oxygen	328	334		|O
species	335	342		|O
(	343	344		|O
ROS	344	347		|O
)	347	348		|O
induce	349	355		|O
DNA	356	359		|O
damage	360	366		|O
resulting	367	376		|O
in	377	379		|O
cytotoxicity	380	392	cytotoxicity	|B-ADVERSE
.	392	393		|O
Exponentially	394	407		|O
growing	408	415		|O
cultures	416	424		|O
of	425	427		|O
human	428	433		|O
nonmalignant	434	446		|O
breast	447	453		|O
epithelial	454	464		|O
cells	465	470		|O
(	471	472		|O
MCF10A	472	478		|O
)	478	479		|O
were	480	484		|O
incubated	485	494		|O
with	495	499		|O
PCBs	500	504		|O
for	505	508		|O
3	509	510		|O
days	511	515		|O
and	516	519		|O
assayed	520	527		|O
for	528	531		|O
cell	532	536		|O
number	537	543		|O
,	543	544		|O
ROS	545	548		|O
levels	549	555		|O
,	555	556		|O
DNA	557	560		|O
damage	561	567		|O
,	567	568		|O
and	569	572		|O
cytotoxicity	573	585	cytotoxicity	|B-ADVERSE
.	585	586		|O
Exposure	587	595		|O
to	596	598		|O
2,2	599	602		|O
'	602	603		|O
,	603	604		|O
4,4	604	607		|O
'	607	608		|O
,	608	609		|O
5,5	609	612		|O
'	612	613		|O
-	613	614		|O
hexachlorobiphenyl	614	632		|O
(	633	634		|O
PCB153	634	640		|O
)	640	641		|O
or	642	644		|O
2	645	646		|O
-	646	647		|O
(	647	648		|O
4	648	649		|O
-	649	650		|O
chlorophenyl	650	662		|O
)	662	663		|O
benzo	663	668		|O
-	668	669		|O
1,4	669	672		|O
-	672	673		|O
quinone	673	680		|O
(	681	682		|O
4	682	683		|O
-	683	684		|O
Cl	684	686		|O
-	686	687		|O
BQ	687	689		|O
)	689	690		|O
,	690	691		|O
a	692	693		|O
metabolite	694	704		|O
of	705	707		|O
4	708	709		|O
-	709	710		|O
chlorobiphenyl	710	724		|O
(	725	726		|O
PCB3	726	730		|O
)	730	731		|O
,	731	732		|O
significantly	733	746		|O
decreased	747	756		|O
cell	757	761		|O
number	762	768		|O
and	769	772		|O
MTS	773	776		|O
reduction	777	786		|O
and	787	790		|O
increased	791	800		|O
the	801	804		|O
percentage	805	815		|O
of	816	818		|O
cells	819	824		|O
with	825	829		|O
sub	830	833		|O
-	833	834		|O
G1	834	836		|O
DNA	837	840		|O
content	841	848		|O
.	848	849		|O
Results	850	857		|O
from	858	862		|O
electron	863	871		|O
paramagnetic	872	884		|O
resonance	885	894		|O
(	895	896		|O
EPR	896	899		|O
)	899	900		|O
spectroscopy	901	913		|O
showed	914	920		|O
a	921	922		|O
4	923	924		|O
-	924	925		|O
fold	925	929		|O
increase	930	938		|O
in	939	941		|O
the	942	945		|O
steady	946	952		|O
-	952	953		|O
state	953	958		|O
levels	959	965		|O
of	966	968		|O
ROS	969	972		|O
,	972	973		|O
which	974	979		|O
was	980	983		|O
suppressed	984	994		|O
in	995	997		|O
cells	998	1003		|O
pretreated	1004	1014		|O
with	1015	1019		|O
catalase	1020	1028		|O
.	1028	1029		|O
EPR	1030	1033		|O
measurements	1034	1046		|O
in	1047	1049		|O
cells	1050	1055		|O
treated	1056	1063		|O
with	1064	1068		|O
4	1069	1070		|O
-	1070	1071		|O
Cl	1071	1073		|O
-	1073	1074		|O
BQ	1074	1076		|O
detected	1077	1085		|O
the	1086	1089		|O
presence	1090	1098		|O
of	1099	1101		|O
a	1102	1103		|O
semiquinone	1104	1115		|O
radical	1116	1123		|O
,	1123	1124		|O
suggesting	1125	1135		|O
that	1136	1140		|O
the	1141	1144		|O
increased	1145	1154		|O
levels	1155	1161		|O
of	1162	1164		|O
ROS	1165	1168		|O
could	1169	1174		|O
be	1175	1177		|O
due	1178	1181		|O
to	1182	1184		|O
the	1185	1188		|O
redox	1189	1194		|O
cycling	1195	1202		|O
of	1203	1205		|O
4	1206	1207		|O
-	1207	1208		|O
Cl	1208	1210		|O
-	1210	1211		|O
BQ	1211	1213		|O
.	1213	1214		|O
A	1215	1216		|O
dose	1217	1221		|O
-	1221	1222		|O
dependent	1222	1231		|O
increase	1232	1240		|O
in	1241	1243		|O
micronuclei	1244	1255		|O
frequency	1256	1265		|O
was	1266	1269		|O
observed	1270	1278		|O
in	1279	1281		|O
PCB	1282	1285		|O
-	1285	1286		|O
treated	1286	1293		|O
cells	1294	1299		|O
,	1299	1300		|O
consistent	1301	1311		|O
with	1312	1316		|O
an	1317	1319		|O
increase	1320	1328		|O
in	1329	1331		|O
histone	1332	1339		|O
2AX	1340	1343		|O
phosphorylation	1344	1359		|O
.	1359	1360		|O
Treatment	1361	1370		|O
of	1371	1373		|O
cells	1374	1379		|O
with	1380	1384		|O
catalase	1385	1393		|O
blunted	1394	1401		|O
the	1402	1405		|O
PCB	1406	1409		|O
-	1409	1410		|O
induced	1410	1417		|O
increase	1418	1426		|O
in	1427	1429		|O
micronuclei	1430	1441		|O
frequency	1442	1451		|O
and	1452	1455		|O
H2AX	1456	1460		|O
phosphorylation	1461	1476		|O
that	1477	1481		|O
was	1482	1485		|O
consistent	1486	1496		|O
with	1497	1501		|O
an	1502	1504		|O
increase	1505	1513		|O
in	1514	1516		|O
cell	1517	1521		|O
survival	1522	1530		|O
.	1530	1531		|O
Our	1532	1535		|O
results	1536	1543		|O
demonstrate	1544	1555		|O
a	1556	1557		|O
PCB	1558	1561		|O
-	1561	1562		|O
induced	1562	1569		|O
increase	1570	1578		|O
in	1579	1581		|O
cellular	1582	1590		|O
levels	1591	1597		|O
of	1598	1600		|O
ROS	1601	1604		|O
causing	1605	1612		|O
DNA	1613	1616		|O
damage	1617	1623		|O
,	1623	1624		|O
resulting	1625	1634		|O
in	1635	1637		|O
cell	1638	1642		|O
killing	1643	1650		|O
.	1650	1651		|O

### 18922041
Vitamin	0	7		|O
K	8	9		|O
supplementation	10	25		|O
in	26	28		|O
postmenopausal	29	43		|O
women	44	49		|O
with	50	54		|O
osteopenia	55	65	osteopenia	|B-DISEASE
(	66	67		|O
ECKO	67	71		|O
trial	72	77		|O
)	77	78		|O
:	78	79		|O
a	80	81		|O
randomized	82	92		|O
controlled	93	103		|O
trial	104	109		|O
.	109	110		|O
BACKGROUND	112	122		|O
:	122	123		|O
Vitamin	124	131		|O
K	132	133		|O
has	134	137		|O
been	138	142		|O
widely	143	149		|O
promoted	150	158		|O
as	159	161		|O
a	162	163		|O
supplement	164	174		|O
for	175	178		|O
decreasing	179	189		|O
bone	190	194	bone loss	|B-DISEASE
loss	195	199		|I-DISEASE
in	200	202		|O
postmenopausal	203	217		|O
women	218	223		|O
,	223	224		|O
but	225	228		|O
the	229	232		|O
long	233	237		|O
-	237	238		|O
term	238	242		|O
benefits	243	251		|O
and	252	255		|O
potential	256	265		|O
harms	266	271		|O
are	272	275		|O
unknown	276	283		|O
.	283	284		|O
This	285	289		|O
study	290	295		|O
was	296	299		|O
conducted	300	309		|O
to	310	312		|O
determine	313	322		|O
whether	323	330		|O
daily	331	336		|O
high	337	341		|O
-	341	342		|O
dose	342	346		|O
vitamin	347	354		|O
K1	355	357		|O
supplementation	358	373		|O
safely	374	380		|O
reduces	381	388		|O
bone	389	393	bone loss	|B-DISEASE
loss	394	398		|I-DISEASE
,	398	399		|O
bone	400	404		|O
turnover	405	413		|O
,	413	414		|O
and	415	418		|O
fractures	419	428		|O
.	428	429		|O
METHODS	430	437		|O
AND	438	441		|O
FINDINGS	442	450		|O
:	450	451		|O
This	452	456		|O
single	457	463		|O
-	463	464		|O
center	464	470		|O
study	471	476		|O
was	477	480		|O
designed	481	489		|O
as	490	492		|O
a	493	494		|O
2	495	496		|O
-	496	497		|O
y	497	498		|O
randomized	499	509		|O
,	509	510		|O
placebo	511	518		|O
-	518	519		|O
controlled	519	529		|O
,	529	530		|O
double	531	537		|O
-	537	538		|O
blind	538	543		|O
trial	544	549		|O
,	549	550		|O
extended	551	559		|O
for	560	563		|O
earlier	564	571		|O
participants	572	584		|O
for	585	588		|O
up	589	591		|O
to	592	594		|O
an	595	597		|O
additional	598	608		|O
2	609	610		|O
y	611	612		|O
because	613	620		|O
of	621	623		|O
interest	624	632		|O
in	633	635		|O
long	636	640		|O
-	640	641		|O
term	641	645		|O
safety	646	652		|O
and	653	656		|O
fractures	657	666		|O
.	666	667		|O
A	668	669		|O
total	670	675		|O
of	676	678		|O
440	679	682		|O
postmenopausal	683	697		|O
women	698	703		|O
with	704	708		|O
osteopenia	709	719	osteopenia	|B-DISEASE
were	720	724		|O
randomized	725	735		|O
to	736	738		|O
either	739	745		|O
5	746	747		|O
mg	748	750		|O
of	751	753		|O
vitamin	754	761		|O
K1	762	764		|O
or	765	767		|O
placebo	768	775		|O
daily	776	781		|O
.	781	782		|O
Primary	783	790		|O
outcomes	791	799		|O
were	800	804		|O
changes	805	812		|O
in	813	815		|O
BMD	816	819		|O
at	820	822		|O
the	823	826		|O
lumbar	827	833		|O
spine	834	839		|O
and	840	843		|O
total	844	849		|O
hip	850	853		|O
at	854	856		|O
2	857	858		|O
y	859	860		|O
.	860	861		|O
Secondary	862	871		|O
outcomes	872	880		|O
included	881	889		|O
changes	890	897		|O
in	898	900		|O
BMD	901	904		|O
at	905	907		|O
other	908	913		|O
sites	914	919		|O
and	920	923		|O
other	924	929		|O
time	930	934		|O
points	935	941		|O
,	941	942		|O
bone	943	947		|O
turnover	948	956		|O
markers	957	964		|O
,	964	965		|O
height	966	972		|O
,	972	973		|O
fractures	974	983		|O
,	983	984		|O
adverse	985	992		|O
effects	993	1000		|O
,	1000	1001		|O
and	1002	1005		|O
health	1006	1012		|O
-	1012	1013		|O
related	1013	1020		|O
quality	1021	1028		|O
of	1029	1031		|O
life	1032	1036		|O
.	1036	1037		|O
This	1038	1042		|O
study	1043	1048		|O
has	1049	1052		|O
a	1053	1054		|O
power	1055	1060		|O
of	1061	1063		|O
90%	1064	1067		|O
to	1068	1070		|O
detect	1071	1077		|O
3%	1078	1080		|O
differences	1081	1092		|O
in	1093	1095		|O
BMD	1096	1099		|O
between	1100	1107		|O
the	1108	1111		|O
two	1112	1115		|O
groups	1116	1122		|O
.	1122	1123		|O
The	1124	1127		|O
women	1128	1133		|O
in	1134	1136		|O
this	1137	1141		|O
study	1142	1147		|O
were	1148	1152		|O
vitamin	1153	1160		|O
D	1161	1162		|O
replete	1163	1170		|O
,	1170	1171		|O
with	1172	1176		|O
a	1177	1178		|O
mean	1179	1183		|O
serum	1184	1189		|O
25	1190	1192		|O
-	1192	1193		|O
hydroxyvitamin	1193	1207		|O
D	1208	1209		|O
level	1210	1215		|O
of	1216	1218		|O
77	1219	1221		|O
nmol	1222	1226		|O
/	1226	1227		|O
l	1227	1228		|O
at	1229	1231		|O
baseline	1232	1240		|O
.	1240	1241		|O
Over	1242	1246		|O
2	1247	1248		|O
y	1249	1250		|O
,	1250	1251		|O
BMD	1252	1255		|O
decreased	1256	1265		|O
by	1266	1268		|O
-	1269	1270		|O
1.28%	1270	1275		|O
and	1276	1279		|O
-	1280	1281		|O
1.22%	1281	1286		|O
(	1287	1288		|O
p	1288	1289		|O
=	1290	1291		|O
0.84	1292	1296		|O
)	1296	1297		|O
(	1298	1299		|O
difference	1299	1309		|O
of	1310	1312		|O
-	1313	1314		|O
0.06%	1314	1319		|O
;	1319	1320		|O
95%	1321	1324		|O
confidence	1325	1335		|O
interval	1336	1344		|O
[	1345	1346		|O
CI	1346	1348		|O
]	1348	1349		|O
-	1350	1351		|O
0.67%	1351	1356		|O
to	1357	1359		|O
0.54%	1360	1365		|O
)	1365	1366		|O
at	1367	1369		|O
the	1370	1373		|O
lumbar	1374	1380		|O
spine	1381	1386		|O
and	1387	1390		|O
-	1391	1392		|O
0.69%	1392	1397		|O
and	1398	1401		|O
-	1402	1403		|O
0.88%	1403	1408		|O
(	1409	1410		|O
p	1410	1411		|O
=	1412	1413		|O
0.51	1414	1418		|O
)	1418	1419		|O
(	1420	1421		|O
difference	1421	1431		|O
of	1432	1434		|O
0.19%	1435	1440		|O
;	1440	1441		|O
95%	1442	1445		|O
CI	1446	1448		|O
-	1449	1450		|O
0.37%	1450	1455		|O
to	1456	1458		|O
0.75%	1459	1464		|O
)	1464	1465		|O
at	1466	1468		|O
the	1469	1472		|O
total	1473	1478		|O
hip	1479	1482		|O
in	1483	1485		|O
the	1486	1489		|O
vitamin	1490	1497		|O
K	1498	1499		|O
and	1500	1503		|O
placebo	1504	1511		|O
groups	1512	1518		|O
,	1518	1519		|O
respectively	1520	1532		|O
.	1532	1533		|O
There	1534	1539		|O
were	1540	1544		|O
no	1545	1547		|O
significant	1548	1559		|O
differences	1560	1571		|O
in	1572	1574		|O
changes	1575	1582		|O
in	1583	1585		|O
BMD	1586	1589		|O
at	1590	1592		|O
any	1593	1596		|O
site	1597	1601		|O
between	1602	1609		|O
the	1610	1613		|O
two	1614	1617		|O
groups	1618	1624		|O
over	1625	1629		|O
the	1630	1633		|O
2	1634	1635		|O
-	1635	1636		|O
to	1637	1639		|O
4	1640	1641		|O
-	1641	1642		|O
y	1642	1643		|O
period	1644	1650		|O
.	1650	1651		|O
Daily	1652	1657		|O
vitamin	1658	1665		|O
K1	1666	1668		|O
supplementation	1669	1684		|O
increased	1685	1694		|O
serum	1695	1700		|O
vitamin	1701	1708		|O
K1	1709	1711		|O
levels	1712	1718		|O
by	1719	1721		|O
10	1722	1724		|O
-	1724	1725		|O
fold	1725	1729		|O
,	1729	1730		|O
and	1731	1734		|O
decreased	1735	1744		|O
the	1745	1748		|O
percentage	1749	1759		|O
of	1760	1762		|O
undercarboxylated	1763	1780		|O
osteocalcin	1781	1792		|O
and	1793	1796		|O
total	1797	1802		|O
osteocalcin	1803	1814		|O
levels	1815	1821		|O
(	1822	1823		|O
bone	1823	1827		|O
formation	1828	1837		|O
marker	1838	1844		|O
)	1844	1845		|O
.	1845	1846		|O
However	1847	1854		|O
,	1854	1855		|O
C	1856	1857		|O
-	1857	1858		|O
telopeptide	1858	1869		|O
levels	1870	1876		|O
(	1877	1878		|O
bone	1878	1882		|O
resorption	1883	1893		|O
marker	1894	1900		|O
)	1900	1901		|O
were	1902	1906		|O
not	1907	1910		|O
significantly	1911	1924		|O
different	1925	1934		|O
between	1935	1942		|O
the	1943	1946		|O
two	1947	1950		|O
groups	1951	1957		|O
.	1957	1958		|O
Fewer	1959	1964		|O
women	1965	1970		|O
in	1971	1973		|O
the	1974	1977		|O
vitamin	1978	1985		|O
K	1986	1987		|O
group	1988	1993		|O
had	1994	1997		|O
clinical	1998	2006		|O
fractures	2007	2016		|O
(	2017	2018		|O
nine	2018	2022		|O
versus	2023	2029		|O
20	2030	2032		|O
,	2032	2033		|O
p	2034	2035		|O
=	2036	2037		|O
0.04	2038	2042		|O
)	2042	2043		|O
and	2044	2047		|O
fewer	2048	2053		|O
had	2054	2057		|O
cancers	2058	2065		|O
(	2066	2067		|O
three	2067	2072		|O
versus	2073	2079		|O
12	2080	2082		|O
,	2082	2083		|O
p	2084	2085		|O
=	2086	2087		|O
0.02	2088	2092		|O
)	2092	2093		|O
.	2093	2094		|O
Vitamin	2095	2102		|O
K	2103	2104		|O
supplements	2105	2116		|O
were	2117	2121		|O
well	2122	2126		|O
-	2126	2127		|O
tolerated	2127	2136		|O
over	2137	2141		|O
the	2142	2145		|O
4	2146	2147		|O
-	2147	2148		|O
y	2148	2149		|O
period	2150	2156		|O
.	2156	2157		|O
There	2158	2163		|O
were	2164	2168		|O
no	2169	2171		|O
significant	2172	2183		|O
differences	2184	2195		|O
in	2196	2198		|O
adverse	2199	2206		|O
effects	2207	2214		|O
or	2215	2217		|O
health	2218	2224		|O
-	2224	2225		|O
related	2225	2232		|O
quality	2233	2240		|O
of	2241	2243		|O
life	2244	2248		|O
between	2249	2256		|O
the	2257	2260		|O
two	2261	2264		|O
groups	2265	2271		|O
.	2271	2272		|O
The	2273	2276		|O
study	2277	2282		|O
was	2283	2286		|O
not	2287	2290		|O
powered	2291	2298		|O
to	2299	2301		|O
examine	2302	2309		|O
fractures	2310	2319		|O
or	2320	2322		|O
cancers	2323	2330		|O
,	2330	2331		|O
and	2332	2335		|O
their	2336	2341		|O
numbers	2342	2349		|O
were	2350	2354		|O
small	2355	2360		|O
.	2360	2361		|O
CONCLUSIONS	2362	2373		|O
:	2373	2374		|O
Daily	2375	2380		|O
5	2381	2382		|O
mg	2383	2385		|O
of	2386	2388		|O
vitamin	2389	2396		|O
K1	2397	2399		|O
supplementation	2400	2415		|O
for	2416	2419		|O
2	2420	2421		|O
to	2422	2424		|O
4	2425	2426		|O
y	2427	2428		|O
does	2429	2433		|O
not	2434	2437		|O
protect	2438	2445		|O
against	2446	2453		|O
age	2454	2457		|O
-	2457	2458		|O
related	2458	2465		|O
decline	2466	2473		|O
in	2474	2476		|O
BMD	2477	2480		|O
,	2480	2481		|O
but	2482	2485		|O
may	2486	2489		|O
protect	2490	2497		|O
against	2498	2505		|O
fractures	2506	2515		|O
and	2516	2519		|O
cancers	2520	2527		|O
in	2528	2530		|O
postmenopausal	2531	2545		|O
women	2546	2551		|O
with	2552	2556		|O
osteopenia	2557	2567	osteopenia	|B-DISEASE
.	2567	2568		|O
More	2569	2573		|O
studies	2574	2581		|O
are	2582	2585		|O
needed	2586	2592		|O
to	2593	2595		|O
further	2596	2603		|O
examine	2604	2611		|O
the	2612	2615		|O
effect	2616	2622		|O
of	2623	2625		|O
vitamin	2626	2633		|O
K	2634	2635		|O
on	2636	2638		|O
fractures	2639	2648		|O
and	2649	2652		|O
cancers	2653	2660		|O
.	2660	2661		|O
Trial	2662	2667		|O
registration	2668	2680		|O
:	2680	2681		|O
ClinicalTrials	2682	2696		|O
.	2696	2697		|O
gov	2697	2700		|O
(	2701	2702		|O
#	2702	2703		|O
NCT00150969	2703	2714		|O
)	2714	2715		|O
and	2716	2719		|O
Current	2720	2727		|O
Controlled	2728	2738		|O
Trials	2739	2745		|O
(	2746	2747		|O
#	2747	2748		|O
ISRCTN61708241	2748	2762		|O
)	2762	2763		|O
.	2763	2764		|O

### 18722631
Tadalafil	0	9		|O
administered	10	22		|O
once	23	27		|O
daily	28	33		|O
for	34	37		|O
lower	38	43		|O
urinary	44	51	urinary tract symptoms	|B-DISEASE
tract	52	57		|I-DISEASE
symptoms	58	66		|I-DISEASE
secondary	67	76		|O
to	77	79		|O
benign	80	86	benign prostatic hyperplasia	|B-DISEASE
prostatic	87	96		|I-DISEASE
hyperplasia	97	108		|I-DISEASE
:	108	109		|O
a	110	111		|O
dose	112	116		|O
finding	117	124		|O
study	125	130		|O
.	130	131		|O
PURPOSE	133	140		|O
:	140	141		|O
Phosphodiesterase	142	159		|O
type	160	164		|O
5	165	166		|O
inhibitors	167	177		|O
are	178	181		|O
widely	182	188		|O
used	189	193		|O
to	194	196		|O
treat	197	202		|O
erectile	203	211	erectile dysfunction	|B-DISEASE
dysfunction	212	223		|I-DISEASE
.	223	224		|O
Preliminary	225	236		|O
data	237	241		|O
have	242	246		|O
suggested	247	256		|O
phosphodiesterase	257	274		|O
type	275	279		|O
5	280	281		|O
inhibitor	282	291		|O
efficacy	292	300		|O
in	301	303		|O
men	304	307		|O
with	308	312		|O
lower	313	318		|O
urinary	319	326	urinary tract symptoms	|B-DISEASE
tract	327	332		|I-DISEASE
symptoms	333	341		|I-DISEASE
associated	342	352		|O
with	353	357		|O
clinical	358	366		|O
benign	367	373	benign prostatic hyperplasia	|B-DISEASE
prostatic	374	383		|I-DISEASE
hyperplasia	384	395		|I-DISEASE
.	395	396		|O
MATERIALS	397	406		|O
AND	407	410		|O
METHODS	411	418		|O
:	418	419		|O
After	420	425		|O
a	426	427		|O
4	428	429		|O
-	429	430		|O
week	430	434		|O
placebo	435	442		|O
run	443	446		|O
-	446	447		|O
in	447	449		|O
period	450	456		|O
1,058	457	462		|O
men	463	466		|O
with	467	471		|O
benign	472	478	benign prostatic hyperplasia lower urinary tract symptoms	|B-DISEASE
prostatic	479	488		|I-DISEASE
hyperplasia	489	500		|I-DISEASE
lower	501	506		|I-DISEASE
urinary	507	514		|I-DISEASE
tract	515	520		|I-DISEASE
symptoms	521	529		|I-DISEASE
were	530	534		|O
randomly	535	543		|O
allocated	544	553		|O
to	554	556		|O
receive	557	564		|O
12	565	567		|O
-	567	568		|O
week	568	572		|O
,	572	573		|O
once	574	578		|O
daily	579	584		|O
treatment	585	594		|O
with	595	599		|O
placebo	600	607		|O
or	608	610		|O
tadalafil	611	620		|O
(	621	622		|O
2.5	622	625		|O
,	625	626		|O
5	627	628		|O
,	628	629		|O
10	630	632		|O
or	633	635		|O
20	636	638		|O
mg	639	641		|O
)	641	642		|O
.	642	643		|O
RESULTS	644	651		|O
:	651	652		|O
The	653	656		|O
International	657	670		|O
Prostate	671	679		|O
Symptom	680	687		|O
Score	688	693		|O
least	694	699		|O
squares	700	707		|O
mean	708	712		|O
change	713	719		|O
from	720	724		|O
baseline	725	733		|O
to	734	736		|O
end	737	740		|O
point	741	746		|O
was	747	750		|O
significantly	751	764		|O
improved	765	773		|O
for	774	777		|O
2.5	778	781		|O
(	782	783		|O
-	783	784		|O
3.9	784	787		|O
,	787	788		|O
p	789	790		|O
=	791	792		|O
0.015	793	798		|O
)	798	799		|O
,	799	800		|O
5	801	802		|O
(	803	804		|O
-	804	805		|O
4.9	805	808		|O
,	808	809		|O
p	810	811		|O
<	812	813		|O
0.001	813	818		|O
)	818	819		|O
,	819	820		|O
10	821	823		|O
(	824	825		|O
-	825	826		|O
5.2	826	829		|O
,	829	830		|O
p	831	832		|O
<	833	834		|O
0.001	834	839		|O
)	839	840		|O
and	841	844		|O
20	845	847		|O
mg	848	850		|O
(	851	852		|O
-	852	853		|O
5.2	853	856		|O
,	856	857		|O
p	858	859		|O
<	860	861		|O
0.001	861	866		|O
)	866	867		|O
tadalafil	868	877		|O
compared	878	886		|O
to	887	889		|O
placebo	890	897		|O
(	898	899		|O
-	899	900		|O
2.3	900	903		|O
)	903	904		|O
.	904	905		|O
International	906	919		|O
Prostate	920	928		|O
Symptom	929	936		|O
Score	937	942		|O
improvements	943	955		|O
at	956	958		|O
4	959	960		|O
,	960	961		|O
8	962	963		|O
and	964	967		|O
12	968	970		|O
weeks	971	976		|O
were	977	981		|O
significant	982	993		|O
for	994	997		|O
all	998	1001		|O
tadalafil	1002	1011		|O
doses	1012	1017		|O
and	1018	1021		|O
they	1022	1026		|O
demonstrated	1027	1039		|O
a	1040	1041		|O
dose	1042	1046		|O
-	1046	1047		|O
response	1047	1055		|O
relationship	1056	1068		|O
.	1068	1069		|O
Tadalafil	1070	1079		|O
(	1080	1081		|O
2.5	1081	1084		|O
mg	1085	1087		|O
)	1087	1088		|O
significantly	1089	1102		|O
improved	1103	1111		|O
the	1112	1115		|O
International	1116	1129		|O
Prostate	1130	1138		|O
Symptom	1139	1146		|O
Score	1147	1152		|O
obstructive	1153	1164		|O
subscore	1165	1173		|O
and	1174	1177		|O
the	1178	1181		|O
International	1182	1195		|O
Index	1196	1201		|O
of	1202	1204		|O
Erectile	1205	1213		|O
Function	1214	1222		|O
-	1222	1223		|O
Erectile	1223	1231		|O
Function	1232	1240		|O
domain	1241	1247		|O
,	1247	1248		|O
the	1249	1252		|O
latter	1253	1259		|O
in	1260	1262		|O
sexually	1263	1271		|O
active	1272	1278		|O
men	1279	1282		|O
with	1283	1287		|O
a	1288	1289		|O
history	1290	1297		|O
of	1298	1300		|O
erectile	1301	1309	erectile dysfunction	|B-DISEASE
dysfunction	1310	1321		|I-DISEASE
.	1321	1322		|O
Statistically	1323	1336		|O
significant	1337	1348		|O
improvements	1349	1361		|O
were	1362	1366		|O
noted	1367	1372		|O
for	1373	1376		|O
5	1377	1378		|O
,	1378	1379		|O
10	1380	1382		|O
and	1383	1386		|O
20	1387	1389		|O
mg	1390	1392		|O
tadalafil	1393	1402		|O
compared	1403	1411		|O
to	1412	1414		|O
placebo	1415	1422		|O
,	1422	1423		|O
as	1424	1426		|O
assessed	1427	1435		|O
by	1436	1438		|O
the	1439	1442		|O
International	1443	1456		|O
Prostate	1457	1465		|O
Symptom	1466	1473		|O
Score	1474	1479		|O
irritative	1480	1490		|O
and	1491	1494		|O
obstructive	1495	1506		|O
subscores	1507	1516		|O
,	1516	1517		|O
International	1518	1531		|O
Prostate	1532	1540		|O
Symptom	1541	1548		|O
Score	1549	1554		|O
Quality	1555	1562		|O
of	1563	1565		|O
Life	1566	1570		|O
,	1570	1571		|O
Benign	1572	1578	Benign Prostatic Hyperplasia	|B-DISEASE
Prostatic	1579	1588		|I-DISEASE
Hyperplasia	1589	1600		|I-DISEASE
Impact	1601	1607		|O
Index	1608	1613		|O
(	1614	1615		|O
nonsignificant	1615	1629		|O
for	1630	1633		|O
10	1634	1636		|O
mg	1637	1639		|O
)	1639	1640		|O
,	1640	1641		|O
Global	1642	1648		|O
Assessment	1649	1659		|O
Question	1660	1668		|O
and	1669	1672		|O
International	1673	1686		|O
Index	1687	1692		|O
of	1693	1695		|O
Erectile	1696	1704		|O
Function	1705	1713		|O
-	1713	1714		|O
Erectile	1714	1722		|O
Function	1723	1731		|O
domain	1732	1738		|O
.	1738	1739		|O
No	1740	1742		|O
statistically	1743	1756		|O
significant	1757	1768		|O
effect	1769	1775		|O
of	1776	1778		|O
treatment	1779	1788		|O
compared	1789	1797		|O
to	1798	1800		|O
placebo	1801	1808		|O
was	1809	1812		|O
noted	1813	1818		|O
for	1819	1822		|O
peak	1823	1827		|O
flow	1828	1832		|O
at	1833	1835		|O
any	1836	1839		|O
tadalafil	1840	1849		|O
dose	1850	1854		|O
.	1854	1855		|O
Treatment	1856	1865		|O
emergent	1866	1874		|O
adverse	1875	1882		|O
events	1883	1889		|O
were	1890	1894		|O
infrequent	1895	1905		|O
in	1906	1908		|O
all	1909	1912		|O
tadalafil	1913	1922		|O
groups	1923	1929		|O
.	1929	1930		|O
CONCLUSIONS	1931	1942		|O
:	1942	1943		|O
Once	1944	1948		|O
daily	1949	1954		|O
tadalafil	1955	1964		|O
demonstrated	1965	1977		|O
clinically	1978	1988		|O
meaningful	1989	1999		|O
and	2000	2003		|O
statistically	2004	2017		|O
significant	2018	2029		|O
efficacy	2030	2038		|O
and	2039	2042		|O
it	2043	2045		|O
was	2046	2049		|O
well	2050	2054		|O
tolerated	2055	2064		|O
in	2065	2067		|O
men	2068	2071		|O
with	2072	2076		|O
benign	2077	2083	benign prostatic hyperplasia lower urinary tract symptoms	|B-DISEASE
prostatic	2084	2093		|I-DISEASE
hyperplasia	2094	2105		|I-DISEASE
lower	2106	2111		|I-DISEASE
urinary	2112	2119		|I-DISEASE
tract	2120	2125		|I-DISEASE
symptoms	2126	2134		|I-DISEASE
.	2134	2135		|O
Of	2136	2138		|O
the	2139	2142		|O
doses	2143	2148		|O
studied	2149	2156		|O
5	2157	2158		|O
mg	2159	2161		|O
tadalafil	2162	2171		|O
appeared	2172	2180		|O
to	2181	2183		|O
provide	2184	2191		|O
a	2192	2193		|O
positive	2194	2202		|O
risk	2203	2207		|O
-	2207	2208		|O
benefit	2208	2215		|O
profile	2216	2223		|O
.	2223	2224		|O

### 18799936
A	0	1		|O
single	2	8		|O
dose	9	13		|O
of	14	16		|O
anti	17	21		|O
-	21	22		|O
D	22	23		|O
immunoglobulin	24	38		|O
raises	39	45		|O
platelet	46	54		|O
count	55	60		|O
as	61	63		|O
efficiently	64	75		|O
as	76	78		|O
intravenous	79	90		|O
immunoglobulin	91	105		|O
in	106	108		|O
newly	109	114		|O
diagnosed	115	124		|O
immune	125	131	immune thrombocytopenic purpura	|B-DISEASE
thrombocytopenic	132	148		|I-DISEASE
purpura	149	156		|I-DISEASE
in	157	159		|O
Korean	160	166		|O
children	167	175		|O
.	175	176		|O
OBJECTIVE	178	187		|O
:	187	188		|O
The	189	192		|O
aim	193	196		|O
of	197	199		|O
this	200	204		|O
study	205	210		|O
is	211	213		|O
to	214	216		|O
compare	217	224		|O
the	225	228		|O
efficacy	229	237		|O
and	238	241		|O
safety	242	248		|O
of	249	251		|O
a	252	253		|O
single	254	260		|O
dose	261	265		|O
of	266	268		|O
anti	269	273		|O
-	273	274		|O
D	274	275		|O
immunoglobulin	276	290		|O
(	291	292		|O
anti	292	296		|O
-	296	297		|O
D	297	298		|O
)	298	299		|O
at	300	302		|O
50	303	305		|O
mug	306	309		|O
/	309	310		|O
kg	310	312		|O
to	313	315		|O
intravenous	316	327		|O
immunoglobulin	328	342		|O
(	343	344		|O
IVIG	344	348		|O
)	348	349		|O
in	350	352		|O
Korean	353	359		|O
children	360	368		|O
with	369	373		|O
acute	374	379	acute immune thrombocytopenic purpura	|B-DISEASE
immune	380	386		|I-DISEASE
thrombocytopenic	387	403		|I-DISEASE
purpura	404	411		|I-DISEASE
(	412	413		|O
ITP	413	416	ITP	|B-DISEASE
)	416	417		|O
.	417	418		|O
METHODS	419	426		|O
:	426	427		|O
We	428	430		|O
performed	431	440		|O
this	441	445		|O
study	446	451		|O
prospectively	452	465		|O
by	466	468		|O
randomly	469	477		|O
administering	478	491		|O
2	492	493		|O
consecutive	494	505		|O
doses	506	511		|O
of	512	514		|O
IVIG	515	519		|O
at	520	522		|O
a	523	524		|O
dose	525	529		|O
of	530	532		|O
1.0	533	536		|O
g	537	538		|O
/	538	539		|O
kg	539	541		|O
/	541	542		|O
dor	542	545		|O
a	546	547		|O
single	548	554		|O
dose	555	559		|O
of	560	562		|O
anti	563	567		|O
-	567	568		|O
D	568	569		|O
at	570	572		|O
50	573	575		|O
microg	576	582		|O
/	582	583		|O
kg	583	585		|O
to	586	588		|O
children	589	597		|O
upon	598	602		|O
initial	603	610		|O
diagnosis	611	620		|O
of	621	623		|O
acute	624	629	acute ITP	|B-DISEASE
ITP	630	633		|I-DISEASE
.	633	634		|O
The	635	638		|O
platelet	639	647		|O
count	648	653		|O
and	654	657		|O
adverse	658	665		|O
events	666	672		|O
,	672	673		|O
including	674	683		|O
hemoglobin	684	694		|O
concentration	695	708		|O
,	708	709		|O
were	710	714		|O
then	715	719		|O
serially	720	728		|O
evaluated	729	738		|O
,	738	739		|O
and	740	743		|O
the	744	747		|O
responses	748	757		|O
were	758	762		|O
compared	763	771		|O
.	771	772		|O
RESULTS	773	780		|O
:	780	781		|O
The	782	785		|O
likelihood	786	796		|O
of	797	799		|O
having	800	806		|O
a	807	808		|O
platelet	809	817		|O
count	818	823		|O
greater	824	831		|O
than	832	836		|O
20x10	837	842		|O
/	842	843		|O
mm	843	845		|O
after	846	851		|O
3	852	853		|O
days	854	858		|O
of	859	861		|O
treatment	862	871		|O
in	872	874		|O
the	875	878		|O
IVIG	879	883		|O
and	884	887		|O
anti	888	892		|O
-	892	893		|O
D	893	894		|O
group	895	900		|O
was	901	904		|O
93%	905	908		|O
and	909	912		|O
92%	913	916		|O
,	916	917		|O
respectively	918	930		|O
.	930	931		|O
In	932	934		|O
addition	935	943		|O
,	943	944		|O
hemoglobin	945	955		|O
concentration	956	969		|O
in	970	972		|O
the	973	976		|O
anti	977	981		|O
-	981	982		|O
D	982	983		|O
group	984	989		|O
had	990	993		|O
declined	994	1002		|O
more	1003	1007		|O
than	1008	1012		|O
that	1013	1017		|O
of	1018	1020		|O
the	1021	1024		|O
IVIG	1025	1029		|O
group	1030	1035		|O
(	1036	1037		|O
1.49	1037	1041		|O
g	1042	1043		|O
/	1043	1044		|O
dL	1044	1046		|O
vs.	1047	1050		|O
0.80	1051	1055		|O
g	1056	1057		|O
/	1057	1058		|O
dL	1058	1060		|O
,	1060	1061		|O
P	1062	1063		|O
=	1063	1064		|O
0.014	1064	1069		|O
)	1069	1070		|O
3	1071	1072		|O
days	1073	1077		|O
after	1078	1083		|O
treatment	1084	1093		|O
.	1093	1094		|O
Fever	1095	1100	Fever	|B-ADVERSE
,	1100	1101		|O
chills	1102	1108	chills	|B-ADVERSE
,	1108	1109		|O
and	1110	1113		|O
headache	1114	1122	headache	|B-ADVERSE
occurred	1123	1131		|O
less	1132	1136		|O
frequently	1137	1147		|O
in	1148	1150		|O
the	1151	1154		|O
anti	1155	1159		|O
-	1159	1160		|O
D	1160	1161		|O
group	1162	1167		|O
than	1168	1172		|O
the	1173	1176		|O
IVIG	1177	1181		|O
group	1182	1187		|O
,	1187	1188		|O
however	1189	1196		|O
,	1196	1197		|O
this	1198	1202		|O
difference	1203	1213		|O
was	1214	1217		|O
not	1218	1221		|O
statistically	1222	1235		|O
significant	1236	1247		|O
(	1248	1249		|O
25%	1249	1252		|O
vs.	1253	1256		|O
45%	1257	1260		|O
,	1260	1261		|O
P	1262	1263		|O
=	1263	1264		|O
0.494	1264	1269		|O
)	1269	1270		|O
.	1270	1271		|O
CONCLUSIONS	1272	1283		|O
:	1283	1284		|O
A	1285	1286		|O
single	1287	1293		|O
dose	1294	1298		|O
of	1299	1301		|O
50	1302	1304		|O
microg	1305	1311		|O
/	1311	1312		|O
kg	1312	1314		|O
of	1315	1317		|O
anti	1318	1322		|O
-	1322	1323		|O
D	1323	1324		|O
raised	1325	1331		|O
platelet	1332	1340		|O
count	1341	1346		|O
as	1347	1349		|O
efficiently	1350	1361		|O
as	1362	1364		|O
IVIG	1365	1369		|O
in	1370	1372		|O
newly	1373	1378		|O
diagnosed	1379	1388		|O
cases	1389	1394		|O
of	1395	1397		|O
ITP	1398	1401	ITP	|B-DISEASE
in	1402	1404		|O
Korean	1405	1411		|O
children	1412	1420		|O
.	1420	1421		|O
Although	1422	1430		|O
50	1431	1433		|O
microg	1434	1440		|O
/	1440	1441		|O
kg	1441	1443		|O
of	1444	1446		|O
anti	1447	1451		|O
-	1451	1452		|O
D	1452	1453		|O
had	1454	1457		|O
a	1458	1459		|O
greater	1460	1467		|O
effect	1468	1474		|O
on	1475	1477		|O
the	1478	1481		|O
hemoglobin	1482	1492		|O
concentration	1493	1506		|O
than	1507	1511		|O
IVIG	1512	1516		|O
,	1516	1517		|O
the	1518	1521		|O
adverse	1522	1529		|O
effects	1530	1537		|O
were	1538	1542		|O
found	1543	1548		|O
to	1549	1551		|O
be	1552	1554		|O
acceptable	1555	1565		|O
,	1565	1566		|O
and	1567	1570		|O
no	1571	1573		|O
serious	1574	1581		|O
events	1582	1588		|O
were	1589	1593		|O
observed	1594	1602		|O
.	1602	1603		|O

### 18782632
Recurrent	0	9		|O
seizures	10	18	seizures	|B-DISEASE
in	19	21		|O
patients	22	30		|O
with	31	35		|O
dementia	36	44	dementia	|B-DISEASE
:	44	45		|O
frequency	46	55		|O
,	55	56		|O
seizure	57	64	seizure	|B-DISEASE
types	65	70		|O
,	70	71		|O
and	72	75		|O
treatment	76	85		|O
outcome	86	93		|O
.	93	94		|O
OBJECTIVE	96	105		|O
:	105	106		|O
Patients	107	115		|O
with	116	120		|O
a	121	122		|O
primary	123	130		|O
neurodegenerative	131	148	neurodegenerative disorder	|B-DISEASE
disorder	149	157		|I-DISEASE
associated	158	168		|O
with	169	173		|O
cognitive	174	183	cognitive impairment	|B-DISEASE
impairment	184	194		|I-DISEASE
are	195	198		|O
at	199	201		|O
increased	202	211		|O
risk	212	216		|O
for	217	220		|O
epilepsy	221	229	epilepsy	|B-DISEASE
.	229	230		|O
The	231	234		|O
goal	235	239		|O
of	240	242		|O
the	243	246		|O
present	247	254		|O
study	255	260		|O
was	261	264		|O
to	265	267		|O
characterize	268	280		|O
seizure	281	288	seizure	|B-DISEASE
type	289	293		|O
(	293	294		|O
s	294	295		|O
)	295	296		|O
,	296	297		|O
etiological	298	309		|O
diagnosis	310	319		|O
of	320	322		|O
dementia	323	331	dementia	|B-DISEASE
,	331	332		|O
electroencephalogram	333	353		|O
(	354	355		|O
EEG	355	358		|O
)	358	359		|O
and	360	363		|O
imaging	364	371		|O
findings	372	380		|O
,	380	381		|O
and	382	385		|O
response	386	394		|O
to	395	397		|O
antiepileptic	398	411		|O
drug	412	416		|O
(	417	418		|O
AED	418	421		|O
)	421	422		|O
therapy	423	430		|O
in	431	433		|O
these	434	439		|O
individuals	440	451		|O
.	451	452		|O
METHODS	453	460		|O
:	460	461		|O
A	462	463		|O
retrospective	464	477		|O
study	478	483		|O
was	484	487		|O
performed	488	497		|O
identifying	498	509		|O
patients	510	518		|O
in	519	521		|O
the	522	525		|O
Mayo	526	530		|O
Alzheimer	531	540	Alzheimer Disease	|B-DISEASE
Disease	541	548		|I-DISEASE
Patient	549	556		|O
Registry	557	565		|O
(	566	567		|O
ADPR	567	571		|O
)	571	572		|O
and	573	576		|O
Alzheimer	577	586	Alzheimer Disease	|B-DISEASE
Disease	587	594		|I-DISEASE
Research	595	603		|O
Center	604	610		|O
(	611	612		|O
ADRC	612	616		|O
)	616	617		|O
who	618	621		|O
were	622	626		|O
classified	627	637		|O
as	638	640		|O
having	641	647		|O
dementia	648	656	dementia	|B-DISEASE
and	657	660		|O
epilepsy	661	669	epilepsy	|B-DISEASE
from	670	674		|O
1986	675	679		|O
to	680	682		|O
2006	683	687		|O
.	687	688		|O
Multiple	689	697		|O
clinical	698	706		|O
parameters	707	717		|O
were	718	722		|O
extracted	723	732		|O
from	733	737		|O
patient	738	745		|O
charts	746	752		|O
and	753	756		|O
evaluated	757	766		|O
to	767	769		|O
characterize	770	782		|O
the	783	786		|O
primary	787	794		|O
neurodegenerative	795	812	neurodegenerative disorder	|B-DISEASE
disorder	813	821		|I-DISEASE
and	822	825		|O
seizure	826	833	seizure	|B-DISEASE
outcomes	834	842		|O
.	842	843		|O
RESULTS	844	851		|O
:	851	852		|O
Sixty	853	858		|O
-	858	859		|O
three	859	864		|O
of	865	867		|O
the	868	871		|O
1738	872	876		|O
ADPR	877	881		|O
and	882	885		|O
ADRC	886	890		|O
patients	891	899		|O
(	900	901		|O
3.6%	901	905		|O
)	905	906		|O
had	907	910		|O
epilepsy	911	919	epilepsy	|B-DISEASE
.	919	920		|O
Twenty	921	927		|O
-	927	928		|O
four	928	932		|O
of	933	935		|O
the	936	939		|O
63	940	942		|O
patients	943	951		|O
were	952	956		|O
excluded	957	965		|O
because	966	973		|O
of	974	976		|O
insufficient	977	989		|O
information	990	1001		|O
regarding	1002	1011		|O
their	1012	1017		|O
epilepsy	1018	1026	epilepsy	|B-DISEASE
.	1026	1027		|O
The	1028	1031		|O
remaining	1032	1041		|O
39	1042	1044		|O
patients	1045	1053		|O
were	1054	1058		|O
analyzed	1059	1067		|O
.	1067	1068		|O
Twenty	1069	1075		|O
-	1075	1076		|O
eight	1076	1081		|O
of	1082	1084		|O
the	1085	1088		|O
63	1089	1091		|O
patients	1092	1100		|O
(	1101	1102		|O
72%	1102	1105		|O
)	1105	1106		|O
experienced	1107	1118		|O
complex	1119	1126	complex partial seizures	|B-DISEASE
partial	1127	1134		|I-DISEASE
seizures	1135	1143		|I-DISEASE
.	1143	1144		|O
Head	1145	1149		|O
MRI	1150	1153		|O
was	1154	1157		|O
performed	1158	1167		|O
in	1168	1170		|O
35	1171	1173		|O
patients	1174	1182		|O
(	1183	1184		|O
90%	1184	1187		|O
)	1187	1188		|O
.	1188	1189		|O
Fourteen	1190	1198		|O
patients	1199	1207		|O
(	1208	1209		|O
36%	1209	1212		|O
)	1212	1213		|O
had	1214	1217		|O
MRI	1218	1221		|O
-	1221	1222		|O
identified	1222	1232		|O
structural	1233	1243		|O
lesions	1244	1251		|O
that	1252	1256		|O
included	1257	1265		|O
remote	1266	1272		|O
stroke	1273	1279	stroke	|B-DISEASE
and	1280	1283		|O
prior	1284	1289		|O
intracerebral	1290	1303	intracerebral hemorrhage	|B-DISEASE
hemorrhage	1304	1314		|I-DISEASE
.	1314	1315		|O
EEGs	1316	1320		|O
were	1321	1325		|O
obtained	1326	1334		|O
in	1335	1337		|O
29	1338	1340		|O
patients	1341	1349		|O
(	1350	1351		|O
74%	1351	1354		|O
)	1354	1355		|O
.	1355	1356		|O
Fifteen	1357	1364		|O
patients	1365	1373		|O
(	1374	1375		|O
38%	1375	1378		|O
)	1378	1379		|O
had	1380	1383		|O
epileptiform	1384	1396		|O
discharges	1397	1407		|O
.	1407	1408		|O
Overall	1409	1416		|O
,	1416	1417		|O
it	1418	1420		|O
was	1421	1424		|O
found	1425	1430		|O
that	1431	1435		|O
79%	1436	1439		|O
had	1440	1443		|O
an	1444	1446		|O
excellent	1447	1456		|O
response	1457	1465		|O
to	1466	1468		|O
AED	1469	1472		|O
therapy	1473	1480		|O
.	1480	1481		|O
Approximately	1482	1495		|O
one	1496	1499		|O
-	1499	1500		|O
third	1500	1505		|O
of	1506	1508		|O
the	1509	1512		|O
patients	1513	1521		|O
had	1522	1525		|O
dose	1526	1530	dose-related side effects	|B-ADVERSE
-	1530	1531		|I-ADVERSE
related	1531	1538		|I-ADVERSE
side	1539	1543		|I-ADVERSE
effects	1544	1551		|I-ADVERSE
from	1552	1556		|O
an	1557	1559		|O
AED	1560	1563		|O
.	1563	1564		|O
CONCLUSION	1565	1575		|O
:	1575	1576		|O
The	1577	1580		|O
present	1581	1588		|O
study	1589	1594		|O
indicated	1595	1604		|O
that	1605	1609		|O
most	1610	1614		|O
individuals	1615	1626		|O
with	1627	1631		|O
the	1632	1635		|O
comorbidity	1636	1647		|O
of	1648	1650		|O
epilepsy	1651	1659	epilepsy	|B-DISEASE
and	1660	1663		|O
dementia	1664	1672	dementia	|B-DISEASE
have	1673	1677		|O
complex	1678	1685	complex partial seizures	|B-DISEASE
partial	1686	1693		|I-DISEASE
seizures	1694	1702		|I-DISEASE
that	1703	1707		|O
may	1708	1711		|O
be	1712	1714		|O
adequately	1715	1725		|O
controlled	1726	1736		|O
on	1737	1739		|O
AED	1740	1743		|O
therapy	1744	1751		|O
.	1751	1752		|O
The	1753	1756		|O
long	1757	1761		|O
-	1761	1762		|O
term	1762	1766		|O
effect	1767	1773		|O
of	1774	1776		|O
seizure	1777	1784	seizure	|B-DISEASE
activity	1785	1793		|O
on	1794	1796		|O
the	1797	1800		|O
neurodegenerative	1801	1818	neurodegenerative disorder	|B-DISEASE
disorder	1819	1827		|I-DISEASE
is	1828	1830		|O
unknown	1831	1838		|O
.	1838	1839		|O

### 18640301
A	0	1		|O
phase	2	7		|O
II	8	10		|O
trial	11	16		|O
of	17	19		|O
tetrathiomolybdate	20	38		|O
after	39	44		|O
surgery	45	52		|O
for	53	56		|O
malignant	57	66	malignant mesothelioma	|B-DISEASE
mesothelioma	67	79		|I-DISEASE
:	79	80		|O
final	81	86		|O
results	87	94		|O
.	94	95		|O
BACKGROUND	97	107		|O
:	107	108		|O
Tetrathiomolybdate	109	127		|O
(	128	129		|O
TM	129	131		|O
)	131	132		|O
is	133	135		|O
an	136	138		|O
oral	139	143		|O
copper	144	150		|O
-	150	151		|O
depleting	151	160		|O
agent	161	166		|O
that	167	171		|O
has	172	175		|O
been	176	180		|O
shown	181	186		|O
to	187	189		|O
inhibit	190	197		|O
angiogenesis	198	210		|O
,	210	211		|O
and	212	215		|O
angiogenesis	216	228		|O
is	229	231		|O
a	232	233		|O
predictor	234	243		|O
of	244	246		|O
poor	247	251		|O
prognosis	252	261		|O
in	262	264		|O
malignant	265	274	malignant pleural mesothelioma	|B-DISEASE
pleural	275	282		|I-DISEASE
mesothelioma	283	295		|I-DISEASE
.	295	296		|O
We	297	299		|O
hypothesized	300	312		|O
that	313	317		|O
cytoreduction	318	331		|O
of	332	334		|O
malignant	335	344	malignant pleural mesothelioma	|B-DISEASE
pleural	345	352		|I-DISEASE
mesothelioma	353	365		|I-DISEASE
followed	366	374		|O
by	375	377		|O
TM	378	380		|O
will	381	385		|O
delay	386	391		|O
time	392	396		|O
to	397	399		|O
progression	400	411		|O
.	411	412		|O
METHODS	413	420		|O
:	420	421		|O
Between	422	429		|O
November	430	438		|O
2000	439	443		|O
and	444	447		|O
August	448	454		|O
2003	455	459		|O
,	459	460		|O
30	461	463		|O
patients	464	472		|O
with	473	477		|O
malignant	478	487	malignant pleural mesothelioma	|B-DISEASE
pleural	488	495		|I-DISEASE
mesothelioma	496	508		|I-DISEASE
received	509	517		|O
postoperative	518	531		|O
TM	532	534		|O
beginning	535	544		|O
4	545	546		|O
to	547	549		|O
6	550	551		|O
weeks	552	557		|O
after	558	563		|O
surgery	564	571		|O
at	572	574		|O
a	575	576		|O
dose	577	581		|O
adjusted	582	590		|O
to	591	593		|O
keep	594	598		|O
ceruloplasmin	599	612		|O
between	613	620		|O
5	621	622		|O
and	623	626		|O
15	627	629		|O
mg	630	632		|O
/	632	633		|O
dL	633	635		|O
)	635	636		|O
.	636	637		|O
Time	638	642		|O
to	643	645		|O
progression	646	657		|O
was	658	661		|O
compared	662	670		|O
with	671	675		|O
the	676	679		|O
55	680	682		|O
stage	683	688		|O
I	689	690		|O
and	691	694		|O
II	695	697		|O
patients	698	706		|O
and	707	710		|O
109	711	714		|O
stage	715	720		|O
III	721	724		|O
patients	725	733		|O
previously	734	744		|O
treated	745	752		|O
with	753	757		|O
cytoreduction	758	771		|O
by	772	774		|O
one	775	778		|O
of	779	781		|O
us	782	784		|O
(	785	786		|O
H	786	787		|O
.	787	788		|O
P	788	789		|O
.	789	790		|O
)	790	791		|O
.	791	792		|O
RESULTS	793	800		|O
:	800	801		|O
The	802	805		|O
30	806	808		|O
patients	809	817		|O
(	818	819		|O
25	819	821		|O
men	822	825		|O
,	825	826		|O
5	827	828		|O
women	829	834		|O
;	834	835		|O
13	836	838		|O
stage	839	844		|O
I	845	846		|O
and	847	850		|O
II	851	853		|O
,	853	854		|O
17	855	857		|O
stage	858	863		|O
III	864	867		|O
)	867	868		|O
,	868	869		|O
median	870	876		|O
age	877	880		|O
67	881	883		|O
years	884	889		|O
(	890	891		|O
range	891	896		|O
,	896	897		|O
49-81	898	903		|O
years	904	909		|O
)	909	910		|O
,	910	911		|O
remained	912	920		|O
on	921	923		|O
TM	924	926		|O
a	927	928		|O
median	929	935		|O
of	936	938		|O
14.9	939	943		|O
months	944	950		|O
(	951	952		|O
range	952	957		|O
,	957	958		|O
2	959	960		|O
to	961	963		|O
57	964	966		|O
months	967	973		|O
)	973	974		|O
.	974	975		|O
All	976	979		|O
patients	980	988		|O
reached	989	996		|O
target	997	1003		|O
ceruloplasmin	1004	1017		|O
levels	1018	1024		|O
at	1025	1027		|O
a	1028	1029		|O
mean	1030	1034		|O
of	1035	1037		|O
34	1038	1040		|O
+	1041	1042		|O
/	1042	1043		|O
-	1043	1044		|O
2	1045	1046		|O
days	1047	1051		|O
(	1052	1053		|O
95%	1053	1056		|O
confidence	1057	1067		|O
interval	1068	1076		|O
,	1076	1077		|O
30	1078	1080		|O
to	1081	1083		|O
39	1084	1086		|O
days	1087	1091		|O
)	1091	1092		|O
,	1092	1093		|O
and	1094	1097		|O
vascular	1098	1106		|O
endothelial	1107	1118		|O
growth	1119	1125		|O
factor	1126	1132		|O
levels	1133	1139		|O
at	1140	1142		|O
baseline	1143	1151		|O
(	1152	1153		|O
ceruloplasmin	1153	1166		|O
=	1167	1168		|O
45.2	1169	1173		|O
+	1174	1175		|O
/	1175	1176		|O
-	1176	1177		|O
2	1178	1179		|O
mg	1180	1182		|O
/	1182	1183		|O
dL	1183	1185		|O
)	1185	1186		|O
decreased	1187	1196		|O
from	1197	1201		|O
2,086	1202	1207		|O
+	1208	1209		|O
/	1209	1210		|O
-	1210	1211		|O
390	1212	1215		|O
pg	1216	1218		|O
/	1218	1219		|O
mL	1219	1221		|O
to	1222	1224		|O
1,250	1225	1230		|O
+	1231	1232		|O
/	1232	1233		|O
-	1233	1234		|O
712	1235	1238		|O
pg	1239	1241		|O
/	1241	1242		|O
mL	1242	1244		|O
(	1245	1246		|O
p	1246	1247		|O
<	1248	1249		|O
0.002	1250	1255		|O
)	1255	1256		|O
at	1257	1259		|O
target	1260	1266		|O
ceruloplasmin	1267	1280		|O
(	1281	1282		|O
13	1282	1284		|O
+	1285	1286		|O
/	1286	1287		|O
-	1287	1288		|O
2	1289	1290		|O
mg	1291	1293		|O
/	1293	1294		|O
dL	1294	1296		|O
;	1296	1297		|O
p	1298	1299		|O
<	1300	1301		|O
0.0001	1302	1308		|O
from	1309	1313		|O
baseline	1314	1322		|O
)	1322	1323		|O
.	1323	1324		|O
The	1325	1328		|O
time	1329	1333		|O
to	1334	1336		|O
progression	1337	1348		|O
for	1349	1352		|O
all	1353	1356		|O
stage	1357	1362		|O
I	1363	1364		|O
or	1365	1367		|O
II	1368	1370		|O
TM	1371	1373		|O
patients	1374	1382		|O
was	1383	1386		|O
20	1387	1389		|O
months	1390	1396		|O
whereas	1397	1404		|O
that	1405	1409		|O
of	1410	1412		|O
55	1413	1415		|O
stage	1416	1421		|O
I	1422	1423		|O
or	1424	1426		|O
II	1427	1429		|O
non	1430	1433		|O
-	1433	1434		|O
TM	1434	1436		|O
-	1436	1437		|O
treated	1437	1444		|O
patients	1445	1453		|O
was	1454	1457		|O
10	1458	1460		|O
months	1461	1467		|O
(	1468	1469		|O
p	1469	1470		|O
=	1471	1472		|O
0.046	1473	1478		|O
versus	1479	1485		|O
TM	1486	1488		|O
)	1488	1489		|O
.	1489	1490		|O
No	1491	1493		|O
differences	1494	1505		|O
in	1506	1508		|O
time	1509	1513		|O
to	1514	1516		|O
progression	1517	1528		|O
for	1529	1532		|O
the	1533	1536		|O
stage	1537	1542		|O
III	1543	1546		|O
TM	1547	1549		|O
patents	1550	1557		|O
from	1558	1562		|O
surgery	1563	1570		|O
were	1571	1575		|O
seen	1576	1580		|O
(	1581	1582		|O
7	1582	1583		|O
months	1584	1590		|O
)	1590	1591		|O
.	1591	1592		|O
CONCLUSIONS	1593	1604		|O
:	1604	1605		|O
Tetrathiomolybdate	1606	1624		|O
has	1625	1628		|O
antiangiogenic	1629	1643		|O
effects	1644	1651		|O
in	1652	1654		|O
malignant	1655	1664	malignant pleural mesothelioma	|B-DISEASE
pleural	1665	1672		|I-DISEASE
mesothelioma	1673	1685		|I-DISEASE
patients	1686	1694		|O
after	1695	1700		|O
resection	1701	1710		|O
of	1711	1713		|O
gross	1714	1719	gross disease	|B-DISEASE
disease	1720	1727		|I-DISEASE
,	1727	1728		|O
and	1729	1732		|O
exhibits	1733	1741		|O
minimal	1742	1749		|O
toxicity	1750	1758		|O
and	1759	1762		|O
comparable	1763	1773		|O
efficacy	1774	1782		|O
to	1783	1785		|O
previous	1786	1794		|O
multimodality	1795	1808		|O
trials	1809	1815		|O
.	1815	1816		|O
Tetrathiomolybdate	1817	1835		|O
should	1836	1842		|O
be	1843	1845		|O
evaluated	1846	1855		|O
for	1856	1859		|O
efficacy	1860	1868		|O
in	1869	1871		|O
combination	1872	1883		|O
with	1884	1888		|O
standard	1889	1897		|O
malignant	1898	1907	malignant pleural mesothelioma	|B-DISEASE
pleural	1908	1915		|I-DISEASE
mesothelioma	1916	1928		|I-DISEASE
regimens	1929	1937		|O
,	1937	1938		|O
as	1939	1941		|O
well	1942	1946		|O
as	1947	1949		|O
for	1950	1953		|O
postsurgical	1954	1966		|O
maintenance	1967	1978		|O
therapy	1979	1986		|O
.	1986	1987		|O

### 18790781
Pharmacokinetic	0	15		|O
-	15	16		|O
directed	16	24		|O
dosing	25	31		|O
of	32	34		|O
vandetanib	35	45		|O
and	46	49		|O
docetaxel	50	59		|O
in	60	62		|O
a	63	64		|O
mouse	65	70		|O
model	71	76		|O
of	77	79		|O
human	80	85		|O
squamous	86	94	squamous cell carcinoma	|B-DISEASE
cell	95	99		|I-DISEASE
carcinoma	100	109		|I-DISEASE
.	109	110		|O
Docetaxel	112	121		|O
,	121	122		|O
usually	123	130		|O
administered	131	143		|O
according	144	153		|O
to	154	156		|O
maximum	157	164		|O
tolerated	165	174		|O
dose	175	179		|O
(	180	181		|O
MTD	181	184		|O
)	184	185		|O
,	185	186		|O
can	187	190		|O
inhibit	191	198		|O
endothelial	199	210		|O
cell	211	215		|O
proliferation	216	229		|O
at	230	232		|O
low	233	236		|O
nanomolar	237	246		|O
concentrations	247	261		|O
.	261	262		|O
Docetaxel	263	272		|O
may	273	276		|O
exert	277	282		|O
antiangiogenic	283	297		|O
effects	298	305		|O
if	306	308		|O
dosed	309	314		|O
so	315	317		|O
plasma	318	324		|O
levels	325	331		|O
are	332	335		|O
maintained	336	346		|O
at	347	349		|O
low	350	353		|O
nanomolar	354	363		|O
concentrations	364	378		|O
over	379	383		|O
a	384	385		|O
prolonged	386	395		|O
time	396	400		|O
.	400	401		|O
We	402	404		|O
evaluated	405	414		|O
metronomic	415	425		|O
and	426	429		|O
MTD	430	433		|O
-	433	434		|O
based	434	439		|O
dosing	440	446		|O
of	447	449		|O
docetaxel	450	459		|O
with	460	464		|O
and	465	468		|O
without	469	476		|O
vandetanib	477	487		|O
,	487	488		|O
a	489	490		|O
vascular	491	499		|O
endothelial	500	511		|O
growth	512	518		|O
factor	519	525		|O
receptor	526	534		|O
-	534	535		|O
2	535	536		|O
and	537	540		|O
epidermal	541	550		|O
growth	551	557		|O
factor	558	564		|O
receptor	565	573		|O
tyrosine	574	582		|O
kinase	583	589		|O
inhibitor	590	599		|O
with	600	604		|O
antiangiogenic	605	619		|O
and	620	623		|O
antitumor	624	633		|O
activity	634	642		|O
,	642	643		|O
in	644	646		|O
a	647	648		|O
head	649	653		|O
and	654	657		|O
neck	658	662		|O
xenograft	663	672		|O
model	673	678		|O
.	678	679		|O
A	680	681		|O
murine	682	688		|O
physiologically	689	704		|O
based	705	710		|O
pharmacokinetic	711	726		|O
model	727	732		|O
was	733	736		|O
modified	737	745		|O
to	746	748		|O
predict	749	756		|O
docetaxel	757	766		|O
distribution	767	779		|O
following	780	789		|O
i	790	791		|O
.	791	792		|O
p	792	793		|O
.	793	794		|O
administration	795	809		|O
to	810	812		|O
design	813	819		|O
dosing	820	826		|O
regimens	827	835		|O
that	836	840		|O
target	841	847		|O
prespecified	848	860		|O
plasma	861	867		|O
concentrations	868	882		|O
,	882	883		|O
for	884	887		|O
antiendothelial	888	903		|O
effects	904	911		|O
(	912	913		|O
metronomic	913	923		|O
)	923	924		|O
,	924	925		|O
or	926	928		|O
exposure	929	937		|O
,	937	938		|O
to	939	941		|O
mimic	942	947		|O
30	948	950		|O
mg	951	953		|O
/	953	954		|O
m2	954	956		|O
(	957	958		|O
weekly	958	964		|O
/	964	965		|O
MTD	965	968		|O
)	968	969		|O
docetaxel	970	979		|O
in	980	982		|O
humans	983	989		|O
.	989	990		|O
Animals	991	998		|O
were	999	1003		|O
treated	1004	1011		|O
for	1012	1015		|O
28	1016	1018		|O
days	1019	1023		|O
with	1024	1028		|O
1	1029	1030		|O
mg	1031	1033		|O
/	1033	1034		|O
kg	1034	1036		|O
/	1036	1037		|O
d	1037	1038		|O
(	1039	1040		|O
DTX1	1040	1044		|O
)	1044	1045		|O
or	1046	1048		|O
6	1049	1050		|O
mg	1051	1053		|O
/	1053	1054		|O
kg	1054	1056		|O
q4d	1057	1060		|O
(	1061	1062		|O
DTX6	1062	1066		|O
)	1066	1067		|O
docetaxel	1068	1077		|O
with	1078	1082		|O
or	1083	1085		|O
without	1086	1093		|O
vandetanib	1094	1104		|O
(	1105	1106		|O
15	1106	1108		|O
mg	1109	1111		|O
/	1111	1112		|O
kg	1112	1114		|O
/	1114	1115		|O
d	1115	1116		|O
p	1117	1118		|O
.	1118	1119		|O
o	1119	1120		|O
.	1120	1121		|O
)	1121	1122		|O
in	1123	1125		|O
mice	1126	1130		|O
bearing	1131	1138		|O
UMSCC2	1139	1145		|O
tumor	1146	1151	tumor	|B-DISEASE
xenografts	1152	1162		|O
.	1162	1163		|O
The	1164	1167		|O
DTX1	1168	1172		|O
dosing	1173	1179		|O
scheme	1180	1186		|O
was	1187	1190		|O
adjusted	1191	1199		|O
to	1200	1202		|O
treatment	1203	1212		|O
for	1213	1216		|O
10	1217	1219		|O
days	1220	1224		|O
followed	1225	1233		|O
by	1234	1236		|O
9	1237	1238		|O
days	1239	1243		|O
off	1244	1247		|O
due	1248	1251		|O
to	1252	1254		|O
severe	1255	1261		|O
gastrointestinal	1262	1278	gastrointestinal toxicity	|B-ADVERSE
toxicity	1279	1287		|I-ADVERSE
.	1287	1288		|O
All	1289	1292		|O
treatment	1293	1302		|O
groups	1303	1309		|O
significantly	1310	1323		|O
reduced	1324	1331		|O
tumor	1332	1337	tumor	|B-DISEASE
volume	1338	1344		|O
,	1344	1345		|O
tumor	1346	1351	tumor	|B-DISEASE
proliferation	1352	1365		|O
(	1366	1367		|O
Ki	1367	1369		|O
-	1369	1370		|O
67	1370	1372		|O
)	1372	1373		|O
,	1373	1374		|O
and	1375	1378		|O
tumor	1379	1384		|O
endothelial	1385	1396		|O
cell	1397	1401		|O
proliferation	1402	1415		|O
(	1416	1417		|O
Ki	1417	1419		|O
-	1419	1420		|O
67	1420	1422		|O
/	1422	1423		|O
von	1423	1426		|O
Willebrand	1427	1437		|O
factor	1438	1444		|O
)	1444	1445		|O
compared	1446	1454		|O
with	1455	1459		|O
control	1460	1467		|O
.	1467	1468		|O
Addition	1469	1477		|O
of	1478	1480		|O
vandetanib	1481	1491		|O
to	1492	1494		|O
docetaxel	1495	1504		|O
treatment	1505	1514		|O
significantly	1515	1528		|O
enhanced	1529	1537		|O
tumor	1538	1543	tumor	|B-DISEASE
growth	1544	1550		|O
inhibition	1551	1561		|O
over	1562	1566		|O
single	1567	1573		|O
-	1573	1574		|O
agent	1574	1579		|O
therapy	1580	1587		|O
.	1587	1588		|O
A	1589	1590		|O
positive	1591	1599		|O
correlation	1600	1611		|O
of	1612	1614		|O
tumor	1615	1620		|O
endothelial	1621	1632		|O
cell	1633	1637		|O
proliferation	1638	1651		|O
with	1652	1656		|O
tumor	1657	1662	tumor	|B-DISEASE
growth	1663	1669		|O
rates	1670	1675		|O
demonstrates	1676	1688		|O
vandetanib	1689	1699		|O
and	1700	1703		|O
docetaxel	1704	1713		|O
antiangiogenic	1714	1728		|O
effects	1729	1736		|O
.	1736	1737		|O
Due	1738	1741		|O
to	1742	1744		|O
the	1745	1748		|O
morbidity	1749	1758		|O
observed	1759	1767		|O
with	1768	1772		|O
DTX1	1773	1777		|O
treatment	1778	1787		|O
,	1787	1788		|O
it	1789	1791		|O
is	1792	1794		|O
difficult	1795	1804		|O
to	1805	1807		|O
clearly	1808	1815		|O
ascertain	1816	1825		|O
if	1826	1828		|O
metronomic	1829	1839		|O
schedules	1840	1849		|O
will	1850	1854		|O
be	1855	1857		|O
effective	1858	1867		|O
for	1868	1871		|O
treatment	1872	1881		|O
.	1881	1882		|O
Docetaxel	1883	1892		|O
with	1893	1897		|O
vandetanib	1898	1908		|O
is	1909	1911		|O
effective	1912	1921		|O
in	1922	1924		|O
treating	1925	1933		|O
UMSCC2	1934	1940		|O
xenografts	1941	1951		|O
at	1952	1954		|O
concentrations	1955	1969		|O
relevant	1970	1978		|O
to	1979	1981		|O
exposures	1982	1991		|O
in	1992	1994		|O
humans	1995	2001		|O
.	2001	2002		|O

### 18793299
Prospective	0	11		|O
evaluation	12	22		|O
of	23	25		|O
sexual	26	32		|O
function	33	41		|O
in	42	44		|O
patients	45	53		|O
receiving	54	63		|O
cryosurgery	64	75		|O
as	76	78		|O
a	79	80		|O
primary	81	88		|O
radical	89	96		|O
treatment	97	106		|O
for	107	110		|O
localized	111	120		|O
prostate	121	129	prostate cancer	|B-DISEASE
cancer	130	136		|I-DISEASE
.	136	137		|O
OBJECTIVE	139	148		|O
:	148	149		|O
To	150	152		|O
evaluate	153	161		|O
prospectively	162	175		|O
the	176	179		|O
sexual	180	186		|O
function	187	195		|O
of	196	198		|O
patients	199	207		|O
undergoing	208	218		|O
cryosurgery	219	230		|O
as	231	233		|O
a	234	235		|O
primary	236	243		|O
radical	244	251		|O
treatment	252	261		|O
for	262	265		|O
localized	266	275		|O
prostate	276	284	prostate cancer	|B-DISEASE
cancer	285	291		|I-DISEASE
,	291	292		|O
as	293	295		|O
the	296	299		|O
development	300	311		|O
of	312	314		|O
17	315	317		|O
G	318	319		|O
cryotherapy	320	331		|O
probes	332	338		|O
has	339	342		|O
improved	343	351		|O
the	352	355		|O
delivery	356	364		|O
of	365	367		|O
this	368	372		|O
treatment	373	382		|O
,	382	383		|O
but	384	387		|O
one	388	391		|O
of	392	394		|O
the	395	398		|O
side	399	403		|O
-	403	404		|O
effects	404	411		|O
of	412	414		|O
cryosurgery	415	426		|O
is	427	429		|O
the	430	433		|O
development	434	445		|O
of	446	448		|O
erectile	449	457	erectile dysfunction	|B-ADVERSE
dysfunction	458	469		|I-ADVERSE
(	470	471		|O
ED	471	473	ED	|B-ADVERSE
)	473	474		|O
.	474	475		|O
PATIENTS	476	484		|O
AND	485	488		|O
METHODS	489	496		|O
:	496	497		|O
Between	498	505		|O
July	506	510		|O
2003	511	515		|O
and	516	519		|O
May	520	523		|O
2008	524	528		|O
,	528	529		|O
53	530	532		|O
patients	533	541		|O
were	542	546		|O
treated	547	554		|O
using	555	560		|O
an	561	563		|O
argon	564	569		|O
-	569	570		|O
based	570	575		|O
third	576	581		|O
-	581	582		|O
generation	582	592		|O
cryotherapy	593	604		|O
system	605	611		|O
(	612	613		|O
Oncura	613	619		|O
,	619	620		|O
Arlington	621	630		|O
Heights	631	638		|O
,	638	639		|O
IL	640	642		|O
,	642	643		|O
USA	644	647		|O
)	647	648		|O
.	648	649		|O
Prospective	650	661		|O
data	662	666		|O
were	667	671		|O
collected	672	681		|O
at	682	684		|O
6	685	686		|O
weeks	687	692		|O
,	692	693		|O
3	694	695		|O
months	696	702		|O
,	702	703		|O
then	704	708		|O
3	709	710		|O
-	710	711		|O
monthly	711	718		|O
up	719	721		|O
to	722	724		|O
1	725	726		|O
year	727	731		|O
and	732	735		|O
subsequently	736	748		|O
6	749	750		|O
-	750	751		|O
monthly	751	758		|O
.	758	759		|O
Patients	760	768		|O
were	769	773		|O
followed	774	782		|O
up	783	785		|O
for	786	789		|O
up	790	792		|O
to	793	795		|O
54	796	798		|O
months	799	805		|O
,	805	806		|O
with	807	811		|O
a	812	813		|O
median	814	820		|O
(	821	822		|O
mean	822	826		|O
)	826	827		|O
follow	828	834		|O
-	834	835		|O
up	835	837		|O
36	838	840		|O
(	841	842		|O
30.5	842	846		|O
)	846	847		|O
months	848	854		|O
.	854	855		|O
RESULTS	856	863		|O
:	863	864		|O
All	865	868		|O
53	869	871		|O
patients	872	880		|O
were	881	885		|O
followed	886	894		|O
after	895	900		|O
receiving	901	910		|O
cryosurgery	911	922		|O
as	923	925		|O
primary	926	933		|O
treatment	934	943		|O
for	944	947		|O
prostate	948	956	prostate cancer	|B-DISEASE
cancer	957	963		|I-DISEASE
;	963	964		|O
51	965	967		|O
(	968	969		|O
96.3%	969	974		|O
)	974	975		|O
had	976	979		|O
ED	980	982		|O
at	983	985		|O
6	986	987		|O
weeks	988	993		|O
while	994	999		|O
two	1000	1003		|O
(	1004	1005		|O
3.7%	1005	1009		|O
)	1009	1010		|O
were	1011	1015		|O
experiencing	1016	1028		|O
partial	1029	1036		|O
erections	1037	1046		|O
.	1046	1047		|O
By	1048	1050		|O
9	1051	1052		|O
months	1053	1059		|O
one	1060	1063		|O
(	1064	1065		|O
2.4%	1065	1069		|O
)	1069	1070		|O
of	1071	1073		|O
42	1074	1076		|O
patients	1077	1085		|O
was	1086	1089		|O
fully	1090	1095		|O
potent	1096	1102		|O
using	1103	1108		|O
phosphodiesterase	1109	1126		|O
type	1127	1131		|O
-	1131	1132		|O
5	1132	1133		|O
inhibitors	1134	1144		|O
,	1144	1145		|O
and	1146	1149		|O
six	1150	1153		|O
(	1154	1155		|O
14.3%	1155	1160		|O
)	1160	1161		|O
were	1162	1166		|O
experiencing	1167	1179		|O
partial	1180	1187		|O
erections	1188	1197		|O
.	1197	1198		|O
By	1199	1201		|O
18	1202	1204		|O
months	1205	1211		|O
eight	1212	1217		|O
(	1218	1219		|O
21%	1219	1222		|O
)	1222	1223		|O
of	1224	1226		|O
39	1227	1229		|O
patients	1230	1238		|O
followed	1239	1247		|O
up	1248	1250		|O
had	1251	1254		|O
regained	1255	1263		|O
full	1264	1268		|O
potency	1269	1276		|O
and	1277	1280		|O
by	1281	1283		|O
24	1284	1286		|O
months	1287	1293		|O
eight	1294	1299		|O
(	1300	1301		|O
24%	1301	1304		|O
)	1304	1305		|O
of	1306	1308		|O
33	1309	1311		|O
patients	1312	1320		|O
were	1321	1325		|O
fully	1326	1331		|O
potent	1332	1338		|O
and	1339	1342		|O
three	1343	1348		|O
(	1349	1350		|O
9%	1350	1352		|O
)	1352	1353		|O
experienced	1354	1365		|O
partial	1366	1373		|O
erections	1374	1383		|O
.	1383	1384		|O
CONCLUSION	1385	1395		|O
:	1395	1396		|O
While	1397	1402		|O
ED	1403	1405	ED	|B-ADVERSE
is	1406	1408		|O
a	1409	1410		|O
significant	1411	1422		|O
side	1423	1427		|O
-	1427	1428		|O
effect	1428	1434		|O
of	1435	1437		|O
cryotherapy	1438	1449		|O
,	1449	1450		|O
a	1451	1452		|O
considerable	1453	1465		|O
proportion	1466	1476		|O
of	1477	1479		|O
patients	1480	1488		|O
who	1489	1492		|O
have	1493	1497		|O
no	1498	1500		|O
ED	1501	1503	ED	|B-ADVERSE
before	1504	1510		|O
treatment	1511	1520		|O
(	1521	1522		|O
39%	1522	1525		|O
)	1525	1526		|O
recover	1527	1534		|O
full	1535	1539		|O
sexual	1540	1546		|O
function	1547	1555		|O
afterward	1556	1565		|O
.	1565	1566		|O
Focal	1567	1572		|O
nerve	1573	1578		|O
-	1578	1579		|O
sparing	1579	1586		|O
cryosurgery	1587	1598		|O
might	1599	1604		|O
be	1605	1607		|O
the	1608	1611		|O
way	1612	1615		|O
forward	1616	1623		|O
in	1624	1626		|O
an	1627	1629		|O
attempt	1630	1637		|O
to	1638	1640		|O
preserve	1641	1649		|O
erectile	1650	1658		|O
function	1659	1667		|O
in	1668	1670		|O
men	1671	1674		|O
who	1675	1678		|O
had	1679	1682		|O
no	1683	1685		|O
ED	1686	1688	ED	|B-DISEASE
before	1689	1695		|O
treatment	1696	1705		|O
.	1705	1706		|O
Erectile	1707	1715		|O
aids	1716	1720		|O
should	1721	1727		|O
be	1728	1730		|O
made	1731	1735		|O
available	1736	1745		|O
for	1746	1749		|O
those	1750	1755		|O
patients	1756	1764		|O
for	1765	1768		|O
whom	1769	1773		|O
sexual	1774	1780	sexual dysfunction	|B-DISEASE
dysfunction	1781	1792		|I-DISEASE
compromises	1793	1804		|O
the	1805	1808		|O
quality	1809	1816		|O
of	1817	1819		|O
their	1820	1825		|O
life	1826	1830		|O
and	1831	1834		|O
relationships	1835	1848		|O
.	1848	1849		|O

### 18558430
The	0	3		|O
role	4	8		|O
of	9	11		|O
placental	12	21		|O
breast	22	28		|O
cancer	29	35		|O
resistance	36	46		|O
protein	47	54		|O
in	55	57		|O
the	58	61		|O
efflux	62	68		|O
of	69	71		|O
glyburide	72	81		|O
across	82	88		|O
the	89	92		|O
human	93	98		|O
placenta	99	107		|O
.	107	108		|O
Gestational	110	121	Gestational diabetes mellitus	|B-DISEASE
diabetes	122	130		|I-DISEASE
mellitus	131	139		|I-DISEASE
is	140	142		|O
a	143	144		|O
common	145	151		|O
medical	152	159		|O
complication	160	172		|O
in	173	175		|O
pregnancy	176	185		|O
.	185	186		|O
Recent	187	193		|O
findings	194	202		|O
demonstrate	203	214		|O
that	215	219		|O
glyburide	220	229		|O
is	230	232		|O
effluxed	233	241		|O
against	242	249		|O
a	250	251		|O
concentration	252	265		|O
gradient	266	274		|O
from	275	279		|O
the	280	283		|O
fetal	284	289		|O
to	290	292		|O
the	293	296		|O
maternal	297	305		|O
circulation	306	317		|O
.	317	318		|O
However	319	326		|O
,	326	327		|O
the	328	331		|O
transport	332	341		|O
systems	342	349		|O
involved	350	358		|O
in	359	361		|O
the	362	365		|O
active	366	372		|O
efflux	373	379		|O
of	380	382		|O
glyburide	383	392		|O
in	393	395		|O
the	396	399		|O
human	400	405		|O
placenta	406	414		|O
have	415	419		|O
not	420	423		|O
yet	424	427		|O
been	428	432		|O
identified	433	443		|O
.	443	444		|O
The	445	448		|O
ATP	449	452		|O
-	452	453		|O
binding	453	460		|O
cassette	461	469		|O
transporter	470	481		|O
,	481	482		|O
breast	483	489		|O
cancer	490	496		|O
resistance	497	507		|O
protein	508	515		|O
(	516	517		|O
BCRP	517	521		|O
)	521	522		|O
,	522	523		|O
is	524	526		|O
highly	527	533		|O
expressed	534	543		|O
in	544	546		|O
placental	547	556		|O
syncytiotrophoblast	557	576		|O
suggesting	577	587		|O
it	588	590		|O
may	591	594		|O
play	595	599		|O
a	600	601		|O
role	602	606		|O
in	607	609		|O
protecting	610	620		|O
the	621	624		|O
fetus	625	630		|O
from	631	635		|O
drug	636	640	drug toxicity	|B-ADVERSE
toxicity	641	649		|I-ADVERSE
.	649	650		|O
The	651	654		|O
objective	655	664		|O
of	665	667		|O
the	668	671		|O
present	672	679		|O
study	680	685		|O
was	686	689		|O
to	690	692		|O
determine	693	702		|O
whether	703	710		|O
BCRP	711	715		|O
participates	716	728		|O
in	729	731		|O
the	732	735		|O
transport	736	745		|O
of	746	748		|O
glyburide	749	758		|O
across	759	765		|O
the	766	769		|O
human	770	775		|O
placenta	776	784		|O
.	784	785		|O
The	786	789		|O
placental	790	799		|O
transfer	800	808		|O
of	809	811		|O
glyburide	812	821		|O
in	822	824		|O
the	825	828		|O
presence	829	837		|O
of	838	840		|O
specific	841	849		|O
BCRP	850	854		|O
inhibitor	855	864		|O
,	864	865		|O
nicardipine	866	877		|O
,	877	878		|O
was	879	882		|O
investigated	883	895		|O
using	896	901		|O
the	902	905		|O
ex	906	908		|O
vivo	909	913		|O
dual	914	918		|O
perfusion	919	928		|O
system	929	935		|O
of	936	938		|O
isolated	939	947		|O
human	948	953		|O
placental	954	963		|O
lobules	964	971		|O
.	971	972		|O
In	973	975		|O
a	976	977		|O
closed	978	984		|O
experiment	985	995		|O
,	995	996		|O
glyburide	997	1006		|O
was	1007	1010		|O
added	1011	1016		|O
(	1017	1018		|O
200	1018	1021		|O
ng	1022	1024		|O
/	1024	1025		|O
mL	1025	1027		|O
)	1027	1028		|O
to	1029	1031		|O
the	1032	1035		|O
maternal	1036	1044		|O
and	1045	1048		|O
fetal	1049	1054		|O
circulations	1055	1067		|O
and	1068	1071		|O
the	1072	1075		|O
BCRP	1076	1080		|O
inhibitor	1081	1090		|O
(	1091	1092		|O
20	1092	1094		|O
microM	1095	1101		|O
)	1101	1102		|O
was	1103	1106		|O
added	1107	1112		|O
to	1113	1115		|O
the	1116	1119		|O
maternal	1120	1128		|O
circulation	1129	1140		|O
.	1140	1141		|O
Samples	1142	1149		|O
were	1150	1154		|O
taken	1155	1160		|O
during	1161	1167		|O
pre	1168	1171		|O
-	1171	1172		|O
control	1172	1179		|O
,	1179	1180		|O
experimental	1181	1193		|O
,	1193	1194		|O
and	1195	1198		|O
post	1199	1203		|O
-	1203	1204		|O
control	1204	1211		|O
periods	1212	1219		|O
for	1220	1223		|O
measurement	1224	1235		|O
of	1236	1238		|O
glyburide	1239	1248		|O
and	1249	1252		|O
markers	1253	1260		|O
of	1261	1263		|O
tissue	1264	1270		|O
viability	1271	1280		|O
.	1280	1281		|O
Results	1282	1289		|O
obtained	1290	1298		|O
from	1299	1303		|O
perfusions	1304	1314		|O
(	1315	1316		|O
n	1316	1317		|O
=	1317	1318		|O
4	1318	1319		|O
)	1319	1320		|O
in	1321	1323		|O
the	1324	1327		|O
presence	1328	1336		|O
of	1337	1339		|O
the	1340	1343		|O
BCRP	1344	1348		|O
inhibitor	1349	1358		|O
show	1359	1363		|O
a	1364	1365		|O
significant	1366	1377		|O
increase	1378	1386		|O
in	1387	1389		|O
the	1390	1393		|O
mean	1394	1398		|O
fetal	1399	1404		|O
-	1404	1405		|O
to	1405	1407		|O
-	1407	1408		|O
maternal	1408	1416		|O
concentration	1417	1430		|O
ratio	1431	1436		|O
of	1437	1439		|O
glyburide	1440	1449		|O
determined	1450	1460		|O
at	1461	1463		|O
180	1464	1467		|O
min	1468	1471		|O
,	1471	1472		|O
0.56	1473	1477		|O
+	1477	1478		|O
/	1478	1479		|O
-	1479	1480		|O
0.06	1480	1484		|O
,	1484	1485		|O
when	1486	1490		|O
compared	1491	1499		|O
to	1500	1502		|O
the	1503	1506		|O
mean	1507	1511		|O
ratio	1512	1517		|O
obtained	1518	1526		|O
in	1527	1529		|O
the	1530	1533		|O
absence	1534	1541		|O
of	1542	1544		|O
inhibitor	1545	1554		|O
,	1554	1555		|O
0.32	1556	1560		|O
+	1560	1561		|O
/	1561	1562		|O
-	1562	1563		|O
0.06	1563	1567		|O
(	1568	1569		|O
p	1569	1570		|O
=	1570	1571		|O
0.04	1571	1575		|O
)	1575	1576		|O
.	1576	1577		|O
These	1578	1583		|O
data	1584	1588		|O
indicate	1589	1597		|O
that	1598	1602		|O
nicardipine	1603	1614		|O
partially	1615	1624		|O
blocked	1625	1632		|O
the	1633	1636		|O
transfer	1637	1645		|O
of	1646	1648		|O
glyburide	1649	1658		|O
across	1659	1665		|O
the	1666	1669		|O
whole	1670	1675		|O
placenta	1676	1684		|O
through	1685	1692		|O
its	1693	1696		|O
inhibition	1697	1707		|O
of	1708	1710		|O
BCRP	1711	1715		|O
.	1715	1716		|O
This	1717	1721		|O
is	1722	1724		|O
the	1725	1728		|O
first	1729	1734		|O
ex	1735	1737		|O
vivo	1738	1742		|O
evidence	1743	1751		|O
that	1752	1756		|O
BCRP	1757	1761		|O
actively	1762	1770		|O
transports	1771	1781		|O
glyburide	1782	1791		|O
.	1791	1792		|O

### 18707752
Delayed	0	7		|O
initiation	8	18		|O
of	19	21		|O
breast	22	28		|O
development	29	40		|O
in	41	43		|O
girls	44	49		|O
with	50	54		|O
higher	55	61		|O
prenatal	62	70		|O
dioxin	71	77		|O
exposure	78	86		|O
;	86	87		|O
a	88	89		|O
longitudinal	90	102		|O
cohort	103	109		|O
study	110	115		|O
.	115	116		|O
OBJECTIVES	118	128		|O
:	128	129		|O
While	130	135		|O
many	136	140		|O
studies	141	148		|O
have	149	153		|O
assessed	154	162		|O
the	163	166		|O
health	167	173		|O
impacts	174	181		|O
of	182	184		|O
PCDD	185	189		|O
/	189	190		|O
Fs	190	192		|O
and	193	196		|O
PCBs	197	201		|O
on	202	204		|O
animals	205	212		|O
and	213	216		|O
humans	217	223		|O
,	223	224		|O
long	225	229		|O
-	229	230		|O
term	230	234		|O
consequences	235	247		|O
for	248	251		|O
especially	252	262		|O
adolescents	263	274		|O
,	274	275		|O
have	276	280		|O
not	281	284		|O
(	285	286		|O
yet	286	289		|O
)	289	290		|O
been	291	295		|O
well	296	300		|O
documented	301	311		|O
.	311	312		|O
This	313	317		|O
is	318	320		|O
certainly	321	330		|O
also	331	335		|O
true	336	340		|O
for	341	344		|O
the	345	348		|O
effects	349	356		|O
of	357	359		|O
PBDE	360	364		|O
exposure	365	373		|O
.	373	374		|O
As	375	377		|O
part	378	382		|O
of	383	385		|O
a	386	387		|O
longitudinal	388	400		|O
cohort	401	407		|O
study	408	413		|O
,	413	414		|O
now	415	418		|O
well	419	423		|O
into	424	428		|O
its	429	432		|O
second	433	439		|O
decade	440	446		|O
,	446	447		|O
effects	448	455		|O
of	456	458		|O
perinatal	459	468		|O
and	469	472		|O
current	473	480		|O
PCDD	481	485		|O
/	485	486		|O
F	486	487		|O
exposure	488	496		|O
,	496	497		|O
as	498	500		|O
well	501	505		|O
as	506	508		|O
current	509	516		|O
dl	517	519		|O
-	519	520		|O
PCB	520	523		|O
and	524	527		|O
PBDE	528	532		|O
exposures	533	542		|O
,	542	543		|O
on	544	546		|O
puberty	547	554		|O
,	554	555		|O
were	556	560		|O
assessed	561	569		|O
.	569	570		|O
STUDY	571	576		|O
DESIGN	577	583		|O
:	583	584		|O
Prenatal	585	593		|O
,	593	594		|O
lactational	595	606		|O
and	607	610		|O
current	611	618		|O
PCDD	619	623		|O
/	623	624		|O
F	624	625		|O
,	625	626		|O
dl	627	629		|O
-	629	630		|O
PCB	630	633		|O
and	634	637		|O
PBDE	638	642		|O
concentrations	643	657		|O
were	658	662		|O
determined	663	673		|O
using	674	679		|O
GC	680	682		|O
-	682	683		|O
MS	683	685		|O
.	685	686		|O
Pubertal	687	695		|O
development	696	707		|O
and	708	711		|O
growth	712	718		|O
were	719	723		|O
assessed	724	732		|O
by	733	735		|O
means	736	741		|O
of	742	744		|O
physical	745	753		|O
examination	754	765		|O
and	766	769		|O
the	770	773		|O
Tanner	774	780		|O
scale	781	786		|O
.	786	787		|O
33	788	790		|O
Children	791	799		|O
(	800	801		|O
born	801	805		|O
between	806	813		|O
1986	814	818		|O
and	819	822		|O
1991	823	827		|O
)	827	828		|O
consented	829	838		|O
to	839	841		|O
the	842	845		|O
current	846	853		|O
follow	854	860		|O
-	860	861		|O
up	861	863		|O
study	864	869		|O
.	869	870		|O
Outcomes	871	879		|O
were	880	884		|O
evaluated	885	894		|O
using	895	900		|O
linear	901	907		|O
regression	908	918		|O
or	919	921		|O
the	922	925		|O
non	926	929		|O
parametric	930	940		|O
Spearman	941	949		|O
's	949	951		|O
correlation	952	963		|O
coefficient	964	975		|O
.	975	976		|O
RESULTS	977	984		|O
:	984	985		|O
A	986	987		|O
delay	988	993		|O
in	994	996		|O
initiation	997	1007		|O
of	1008	1010		|O
breast	1011	1017		|O
development	1018	1029		|O
was	1030	1033		|O
found	1034	1039		|O
in	1040	1042		|O
girls	1043	1048		|O
(	1049	1050		|O
n	1050	1051		|O
=	1052	1053		|O
18	1054	1056		|O
)	1056	1057		|O
with	1058	1062		|O
higher	1063	1069		|O
prenatal	1070	1078		|O
(	1079	1080		|O
p	1080	1081		|O
=	1082	1083		|O
0.023	1084	1089		|O
)	1089	1090		|O
and	1091	1094		|O
lactational	1095	1106		|O
PCDD	1107	1111		|O
/	1111	1112		|O
F	1112	1113		|O
exposure	1114	1122		|O
(	1123	1124		|O
p	1124	1125		|O
=	1126	1127		|O
0.048	1128	1133		|O
)	1133	1134		|O
.	1134	1135		|O
The	1136	1139		|O
males	1140	1145		|O
revealed	1146	1154		|O
a	1155	1156		|O
negative	1157	1165		|O
trend	1166	1171		|O
with	1172	1176		|O
age	1177	1180		|O
at	1181	1183		|O
first	1184	1189		|O
ejaculation	1190	1201		|O
.	1201	1202		|O
For	1203	1206		|O
other	1207	1212		|O
endpoints	1213	1222		|O
on	1223	1225		|O
puberty	1226	1233		|O
and	1234	1237		|O
growth	1238	1244		|O
(	1245	1246		|O
pubic	1246	1251		|O
hair	1252	1256		|O
,	1256	1257		|O
axillary	1258	1266		|O
hair	1267	1271		|O
,	1271	1272		|O
genital	1273	1280		|O
stage	1281	1286		|O
,	1286	1287		|O
length	1288	1294		|O
,	1294	1295		|O
BMI	1296	1299		|O
,	1299	1300		|O
testicular	1301	1311		|O
volume	1312	1318		|O
,	1318	1319		|O
menarche	1320	1328		|O
)	1328	1329		|O
no	1330	1332		|O
significant	1333	1344		|O
relation	1345	1353		|O
was	1354	1357		|O
found	1358	1363		|O
with	1364	1368		|O
any	1369	1372		|O
of	1373	1375		|O
the	1376	1379		|O
measured	1380	1388		|O
compounds	1389	1398		|O
.	1398	1399		|O
DISCUSSION	1400	1410		|O
AND	1411	1414		|O
CONCLUSION	1415	1425		|O
:	1425	1426		|O
A	1427	1428		|O
relation	1429	1437		|O
between	1438	1445		|O
prenatal	1446	1454		|O
PCDD	1455	1459		|O
/	1459	1460		|O
F	1460	1461		|O
exposure	1462	1470		|O
and	1471	1474		|O
later	1475	1480		|O
initiation	1481	1491		|O
of	1492	1494		|O
breast	1495	1501		|O
development	1502	1513		|O
was	1514	1517		|O
seen	1518	1522		|O
.	1522	1523		|O
A	1524	1525		|O
Belgian	1526	1533		|O
study	1534	1539		|O
found	1540	1545		|O
a	1546	1547		|O
delay	1548	1553		|O
in	1554	1556		|O
breast	1557	1563		|O
development	1564	1575		|O
with	1576	1580		|O
higher	1581	1587		|O
current	1588	1595		|O
serum	1596	1601		|O
concentrations	1602	1616		|O
of	1617	1619		|O
dioxin	1620	1626		|O
-	1626	1627		|O
like	1627	1631		|O
compounds	1632	1641		|O
.	1641	1642		|O
The	1643	1646		|O
initiation	1647	1657		|O
of	1658	1660		|O
puberty	1661	1668		|O
is	1669	1671		|O
a	1672	1673		|O
complex	1674	1681		|O
process	1682	1689		|O
and	1690	1693		|O
it	1694	1696		|O
is	1697	1699		|O
yet	1700	1703		|O
not	1704	1707		|O
clear	1708	1713		|O
how	1714	1717		|O
dioxin	1718	1724		|O
-	1724	1725		|O
like	1725	1729		|O
compounds	1730	1739		|O
precisely	1740	1749		|O
affect	1750	1756		|O
this	1757	1761		|O
process	1762	1769		|O
prenatally	1770	1780		|O
.	1780	1781		|O
Further	1782	1789		|O
follow	1790	1796		|O
-	1796	1797		|O
up	1797	1799		|O
into	1800	1804		|O
adulthood	1805	1814		|O
is	1815	1817		|O
warranted	1818	1827		|O
,	1827	1828		|O
in	1829	1831		|O
order	1832	1837		|O
to	1838	1840		|O
detect	1841	1847		|O
the	1848	1851		|O
possibility	1852	1863		|O
of	1864	1866		|O
developing	1867	1877		|O
malignancies	1878	1890	malignancies	|B-DISEASE
and	1891	1894		|O
fertility	1895	1904		|O
problems	1905	1913		|O
.	1913	1914		|O

### 18568441
The	0	3		|O
efficacy	4	12		|O
of	13	15		|O
Femal	16	21		|O
in	22	24		|O
women	25	30		|O
with	31	35		|O
premenstrual	36	48	premenstrual syndrome	|B-DISEASE
syndrome	49	57		|I-DISEASE
:	57	58		|O
a	59	60		|O
randomised	61	71		|O
,	71	72		|O
double	73	79		|O
-	79	80		|O
blind	80	85		|O
,	85	86		|O
parallel	87	95		|O
-	95	96		|O
group	96	101		|O
,	101	102		|O
placebo	103	110		|O
-	110	111		|O
controlled	111	121		|O
,	121	122		|O
multicentre	123	134		|O
study	135	140		|O
.	140	141		|O
INTRODUCTION	143	155		|O
:	155	156		|O
A	157	158		|O
double	159	165		|O
-	165	166		|O
blind	166	171		|O
,	171	172		|O
placebo	173	180		|O
-	180	181		|O
controlled	181	191		|O
,	191	192		|O
randomised	193	203		|O
,	203	204		|O
parallel	205	213		|O
-	213	214		|O
group	214	219		|O
,	219	220		|O
multicentre	221	232		|O
study	233	238		|O
was	239	242		|O
conducted	243	252		|O
to	253	255		|O
evaluate	256	264		|O
the	265	268		|O
effect	269	275		|O
of	276	278		|O
a	279	280		|O
pollen	281	287		|O
-	287	288		|O
based	288	293		|O
herbal	294	300		|O
medicinal	301	310		|O
product	311	318		|O
,	318	319		|O
Femal	320	325		|O
(	326	327		|O
Sea	327	330		|O
-	330	331		|O
Band	331	335		|O
Ltd	336	339		|O
,	339	340		|O
Leicestershire	341	355		|O
,	355	356		|O
UK	357	359		|O
)	359	360		|O
,	360	361		|O
on	362	364		|O
premenstrual	365	377	premenstrual sleep disturbances	|B-DISEASE
sleep	378	383		|I-DISEASE
disturbances	384	396		|I-DISEASE
(	397	398		|O
PSD	398	401	PSD	|B-DISEASE
)	401	402		|O
in	403	405		|O
women	406	411		|O
with	412	416		|O
premenstrual	417	429	premenstrual syndrome	|B-DISEASE
syndrome	430	438		|I-DISEASE
(	439	440		|O
PMS	440	443	PMS	|B-DISEASE
)	443	444		|O
.	444	445		|O
METHODS	446	453		|O
:	453	454		|O
Femal	455	460		|O
,	460	461		|O
160	462	465		|O
mg	466	468		|O
twice	469	474		|O
-	474	475		|O
daily	475	480		|O
,	480	481		|O
was	482	485		|O
given	486	491		|O
for	492	495		|O
four	496	500		|O
menstrual	501	510		|O
cycles	511	517		|O
to	518	520		|O
50	521	523		|O
women	524	529		|O
,	529	530		|O
and	531	534		|O
placebo	535	542		|O
to	543	545		|O
51	546	548		|O
women	549	554		|O
.	554	555		|O
PSD	556	559	PSD	|B-DISEASE
were	560	564		|O
evaluated	565	574		|O
on	575	577		|O
a	578	579		|O
visual	580	586		|O
analogue	587	595		|O
scale	596	601		|O
prior	602	607		|O
to	608	610		|O
and	611	614		|O
after	615	620		|O
the	621	624		|O
four	625	629		|O
cycles	630	636		|O
.	636	637		|O
The	638	641		|O
effect	642	648		|O
on	649	651		|O
overall	652	659		|O
PMS	660	663	PMS symptoms	|B-DISEASE
symptoms	664	672		|I-DISEASE
was	673	676		|O
assessed	677	685		|O
with	686	690		|O
the	691	694		|O
Steiner	695	702		|O
premenstrual	703	715	premenstrual tension syndrome	|B-DISEASE
tension	716	723		|I-DISEASE
syndrome	724	732		|I-DISEASE
(	733	734		|O
PMTS	734	738	PMTS	|B-DISEASE
)	738	739		|O
self	740	744		|O
-	744	745		|O
rating	745	751		|O
questionnaire	752	765		|O
.	765	766		|O
The	767	770		|O
results	771	778		|O
were	779	783		|O
analysed	784	792		|O
statistically	793	806		|O
based	807	812		|O
on	813	815		|O
intention	816	825		|O
to	826	828		|O
treat	829	834		|O
.	834	835		|O
RESULTS	836	843		|O
:	843	844		|O
Femal	845	850		|O
treatment	851	860		|O
resulted	861	869		|O
in	870	872		|O
a	873	874		|O
significant	875	886		|O
reduction	887	896		|O
in	897	899		|O
PSD	900	903	PSD	|B-DISEASE
(	904	905		|O
P	905	906		|O
<	906	907		|O
0.05	907	911		|O
)	911	912		|O
whereas	913	920		|O
placebo	921	928		|O
had	929	932		|O
no	933	935		|O
significant	936	947		|O
effect	948	954		|O
(	955	956		|O
P	956	957		|O
>	957	958		|O
0.05	958	962		|O
)	962	963		|O
.	963	964		|O
In	965	967		|O
a	968	969		|O
subgroup	970	978		|O
analysis	979	987		|O
of	988	990		|O
women	991	996		|O
with	997	1001		|O
irritability	1002	1014	irritability	|B-DISEASE
as	1015	1017		|O
their	1018	1023		|O
main	1024	1028		|O
PMS	1029	1032	PMS symptom	|B-DISEASE
symptom	1033	1040		|I-DISEASE
cluster	1041	1048		|O
,	1048	1049		|O
the	1050	1053		|O
reduction	1054	1063		|O
of	1064	1066		|O
PSD	1067	1070	PSD	|B-DISEASE
was	1071	1074		|O
even	1075	1079		|O
more	1080	1084		|O
pronounced	1085	1095		|O
(	1096	1097		|O
P	1097	1098		|O
<	1098	1099		|O
0.001	1099	1104		|O
)	1104	1105		|O
.	1105	1106		|O
There	1107	1112		|O
was	1113	1116		|O
no	1117	1119		|O
significant	1120	1131		|O
difference	1132	1142		|O
in	1143	1145		|O
overall	1146	1153		|O
degree	1154	1160		|O
of	1161	1163		|O
PMS	1164	1167	PMS symptom	|B-DISEASE
symptom	1168	1175		|I-DISEASE
reduction	1176	1185		|O
between	1186	1193		|O
Femal	1194	1199		|O
and	1200	1203		|O
placebo	1204	1211		|O
when	1212	1216		|O
all	1217	1220		|O
participating	1221	1234		|O
women	1235	1240		|O
were	1241	1245		|O
evaluated	1246	1255		|O
(	1256	1257		|O
P	1257	1258		|O
>	1258	1259		|O
0.05	1259	1263		|O
)	1263	1264		|O
.	1264	1265		|O
However	1266	1273		|O
,	1273	1274		|O
in	1275	1277		|O
women	1278	1283		|O
with	1284	1288		|O
irritability	1289	1301	irritability	|B-DISEASE
as	1302	1304		|O
their	1305	1310		|O
main	1311	1315		|O
PMS	1316	1319	PMS symptom	|B-DISEASE
symptom	1320	1327		|I-DISEASE
cluster	1328	1335		|O
,	1335	1336		|O
Femal	1337	1342		|O
treatment	1343	1352		|O
resulted	1353	1361		|O
in	1362	1364		|O
a	1365	1366		|O
significant	1367	1378		|O
reduction	1379	1388		|O
of	1389	1391		|O
the	1392	1395		|O
Steiner	1396	1403		|O
score	1404	1409		|O
(	1410	1411		|O
P	1411	1412		|O
<	1412	1413		|O
0.05	1413	1417		|O
)	1417	1418		|O
.	1418	1419		|O
The	1420	1423		|O
frequency	1424	1433		|O
of	1434	1436		|O
adverse	1437	1444		|O
events	1445	1451		|O
was	1452	1455		|O
not	1456	1459		|O
significantly	1460	1473		|O
different	1474	1483		|O
in	1484	1486		|O
women	1487	1492		|O
on	1493	1495		|O
Femal	1496	1501		|O
compared	1502	1510		|O
to	1511	1513		|O
women	1514	1519		|O
on	1520	1522		|O
placebo	1523	1530		|O
(	1531	1532		|O
P	1532	1533		|O
>	1533	1534		|O
0.05	1534	1538		|O
)	1538	1539		|O
.	1539	1540		|O
No	1541	1543		|O
serious	1544	1551		|O
adverse	1552	1559		|O
events	1560	1566		|O
were	1567	1571		|O
recorded	1572	1580		|O
.	1580	1581		|O
CONCLUSION	1582	1592		|O
:	1592	1593		|O
Femal	1594	1599		|O
treatment	1600	1609		|O
reduced	1610	1617		|O
PSD	1618	1621	PSD	|B-DISEASE
to	1622	1624		|O
a	1625	1626		|O
significant	1627	1638		|O
degree	1639	1645		|O
,	1645	1646		|O
particularly	1647	1659		|O
in	1660	1662		|O
women	1663	1668		|O
with	1669	1673		|O
irritability	1674	1686	irritability	|B-DISEASE
as	1687	1689		|O
their	1690	1695		|O
main	1696	1700		|O
PMS	1701	1704	PMS symptom	|B-DISEASE
symptom	1705	1712		|I-DISEASE
.	1712	1713		|O
Femal	1714	1719		|O
treatment	1720	1729		|O
also	1730	1734		|O
reduced	1735	1742		|O
overall	1743	1750		|O
PMS	1751	1754	PMS symptoms	|B-DISEASE
symptoms	1755	1763		|I-DISEASE
in	1764	1766		|O
women	1767	1772		|O
with	1773	1777		|O
irritability	1778	1790	irritability	|B-DISEASE
(	1791	1792		|O
but	1792	1795		|O
not	1796	1799		|O
dysphoria	1800	1809	dysphoria	|B-DISEASE
)	1809	1810		|O
as	1811	1813		|O
their	1814	1819		|O
main	1820	1824		|O
PMS	1825	1828	PMS symptom	|B-DISEASE
symptom	1829	1836		|I-DISEASE
.	1836	1837		|O
The	1838	1841		|O
safety	1842	1848		|O
of	1849	1851		|O
Femal	1852	1857		|O
and	1858	1861		|O
its	1862	1865		|O
efficacy	1866	1874		|O
in	1875	1877		|O
PSD	1878	1881	PSD	|B-DISEASE
and	1882	1885		|O
other	1886	1891		|O
symptoms	1892	1900		|O
in	1901	1903		|O
women	1904	1909		|O
with	1910	1914		|O
irritability	1915	1927	irritability	|B-DISEASE
as	1928	1930		|O
the	1931	1934		|O
main	1935	1939		|O
symptom	1940	1947		|O
cluster	1948	1955		|O
makes	1956	1961		|O
this	1962	1966		|O
herbal	1967	1973		|O
medicinal	1974	1983		|O
product	1984	1991		|O
a	1992	1993		|O
promising	1994	2003		|O
addition	2004	2012		|O
to	2013	2015		|O
the	2016	2019		|O
therapeutic	2020	2031		|O
arsenal	2032	2039		|O
for	2040	2043		|O
women	2044	2049		|O
with	2050	2054		|O
PMS	2055	2058	PMS	|B-DISEASE
.	2058	2059		|O

### 18928414
Effectiveness	0	13		|O
and	14	17		|O
tolerability	18	30		|O
of	31	33		|O
open	34	38		|O
label	39	44		|O
olanzapine	45	55		|O
in	56	58		|O
children	59	67		|O
and	68	71		|O
adolescents	72	83		|O
with	84	88		|O
Tourette	89	97	Tourette syndrome	|B-DISEASE
syndrome	98	106		|I-DISEASE
.	106	107		|O
OBJECTIVES	109	119		|O
:	119	120		|O
The	121	124		|O
primary	125	132		|O
aim	133	136		|O
of	137	139		|O
the	140	143		|O
study	144	149		|O
was	150	153		|O
to	154	156		|O
evaluate	157	165		|O
the	166	169		|O
effectiveness	170	183		|O
and	184	187		|O
tolerability	188	200		|O
of	201	203		|O
open	204	208		|O
-	208	209		|O
label	209	214		|O
olanzapine	215	225		|O
on	226	228		|O
motor	229	234		|O
and	235	238		|O
vocal	239	244		|O
tics	245	249		|O
in	250	252		|O
children	253	261		|O
and	262	265		|O
adolescents	266	277		|O
with	278	282		|O
Tourette	283	291	Tourette syndrome	|B-DISEASE
syndrome	292	300		|I-DISEASE
(	301	302		|O
TS	302	304	TS	|B-DISEASE
)	304	305		|O
.	305	306		|O
Secondary	307	316		|O
aims	317	321		|O
included	322	330		|O
assessing	331	340		|O
the	341	344		|O
response	345	353		|O
of	354	356		|O
TS	357	359		|O
-	359	360		|O
associated	360	370		|O
disruptive	371	381	disruptive behaviors	|B-ADVERSE
behaviors	382	391		|I-ADVERSE
to	392	394		|O
olanzapine	395	405		|O
exposure	406	414		|O
.	414	415		|O
METHOD	416	422		|O
:	422	423		|O
Twelve	424	430		|O
children	431	439		|O
and	440	443		|O
adolescents	444	455		|O
(	456	457		|O
mean	457	461		|O
age	462	465		|O
11.3	466	470		|O
+	471	472		|O
/	472	473		|O
-	473	474		|O
2.4	475	478		|O
years	479	484		|O
,	484	485		|O
range	486	491		|O
7-14	492	496		|O
years	497	502		|O
)	502	503		|O
with	504	508		|O
Diagnostic	509	519		|O
and	520	523		|O
Statistical	524	535		|O
Manual	536	542		|O
of	543	545		|O
Mental	546	552	Mental Disorders	|B-DISEASE
Disorders	553	562		|I-DISEASE
,	562	563		|O
4th	564	567		|O
edition	568	575		|O
(	576	577		|O
DSM	577	580		|O
-	580	581		|O
IV	581	583		|O
)	583	584		|O
TS	585	587	TS	|B-DISEASE
were	588	592		|O
enrolled	593	601		|O
in	602	604		|O
a	605	606		|O
single	607	613		|O
-	613	614		|O
site	614	618		|O
,	618	619		|O
6	620	621		|O
-	621	622		|O
week	622	626		|O
,	626	627		|O
open	628	632		|O
-	632	633		|O
label	633	638		|O
,	638	639		|O
prospective	640	651		|O
,	651	652		|O
flexible	653	661		|O
-	661	662		|O
dose	662	666		|O
design	667	673		|O
in	674	676		|O
outpatients	677	688		|O
receiving	689	698		|O
monotherapy	699	710		|O
with	711	715		|O
olanzapine	716	726		|O
.	726	727		|O
Standardized	728	740		|O
ratings	741	748		|O
of	749	751		|O
tic	752	755	tic symptoms	|B-DISEASE
symptoms	756	764		|I-DISEASE
,	764	765		|O
disruptive	766	776	disruptive behaviors	|B-DISEASE
behaviors	777	786		|I-DISEASE
,	786	787		|O
and	788	791		|O
aggression	792	802	aggression	|B-DISEASE
were	803	807		|O
obtained	808	816		|O
,	816	817		|O
along	818	823		|O
with	824	828		|O
adverse	829	836		|O
events	837	843		|O
and	844	847		|O
safety	848	854		|O
data	855	859		|O
.	859	860		|O
RESULTS	861	868		|O
:	868	869		|O
Over	870	874		|O
the	875	878		|O
6	879	880		|O
-	880	881		|O
week	881	885		|O
trial	886	891		|O
,	891	892		|O
olanzapine	893	903		|O
administration	904	918		|O
was	919	922		|O
associated	923	933		|O
with	934	938		|O
a	939	940		|O
significant	941	952		|O
decrease	953	961		|O
in	962	964		|O
total	965	970		|O
tic	971	974	tic	|B-DISEASE
severity	975	983		|O
as	984	986		|O
measured	987	995		|O
by	996	998		|O
the	999	1002		|O
Yale	1003	1007		|O
Global	1008	1014		|O
Tic	1015	1018	Tic	|B-DISEASE
Severity	1019	1027		|O
Scale	1028	1033		|O
(	1034	1035		|O
30%	1035	1038		|O
reduction	1039	1048		|O
by	1049	1051		|O
week	1052	1056		|O
6	1057	1058		|O
;	1058	1059		|O
effect	1060	1066		|O
size	1067	1071		|O
0.49	1072	1076		|O
)	1076	1077		|O
.	1077	1078		|O
A	1079	1080		|O
significant	1081	1092		|O
majority	1093	1101		|O
of	1102	1104		|O
subjects	1105	1113		|O
were	1114	1118		|O
rated	1119	1124		|O
as	1125	1127		|O
"	1128	1129		|O
much	1129	1133		|O
improved	1134	1142		|O
"	1142	1143		|O
or	1144	1146		|O
"	1147	1148		|O
very	1148	1152		|O
much	1153	1157		|O
improved	1158	1166		|O
"	1166	1167		|O
on	1168	1170		|O
the	1171	1174		|O
Clinical	1175	1183		|O
Global	1184	1190		|O
Impressions	1191	1202		|O
-	1202	1203		|O
Improvement	1203	1214		|O
Scale	1215	1220		|O
(	1221	1222		|O
GCI	1222	1225		|O
-	1225	1226		|O
I	1226	1227		|O
)	1227	1228		|O
by	1229	1231		|O
both	1232	1236		|O
clinicians	1237	1247		|O
(	1248	1249		|O
67%	1249	1252		|O
;	1252	1253		|O
8/12	1254	1258		|O
)	1258	1259		|O
and	1260	1263		|O
parents	1264	1271		|O
(	1272	1273		|O
64%	1273	1276		|O
;	1276	1277		|O
7/11	1278	1282		|O
)	1282	1283		|O
.	1283	1284		|O
Attention	1285	1294	Attention-deficit/hyperactivity disorder	|B-DISEASE
-	1294	1295		|I-DISEASE
deficit	1295	1302		|I-DISEASE
/	1302	1303		|I-DISEASE
hyperactivity	1303	1316		|I-DISEASE
disorder	1317	1325		|I-DISEASE
(	1326	1327		|O
ADHD	1327	1331	ADHD	|B-DISEASE
)	1331	1332		|O
symptoms	1333	1341		|O
showed	1342	1348		|O
significant	1349	1360		|O
improvements	1361	1373		|O
from	1374	1378		|O
baseline	1379	1387		|O
for	1388	1391		|O
both	1392	1396		|O
inattention	1397	1408		|O
(	1409	1410		|O
33%	1410	1413		|O
decrease	1414	1422		|O
)	1422	1423		|O
and	1424	1427		|O
hyperactive	1428	1439		|O
/	1439	1440		|O
impulsivity	1440	1451		|O
(	1452	1453		|O
50%	1453	1456		|O
decrease	1457	1465		|O
)	1465	1466		|O
scores	1467	1473		|O
(	1474	1475		|O
effect	1475	1481		|O
sizes	1482	1487		|O
0.44	1488	1492		|O
and	1493	1496		|O
0.43	1497	1501		|O
,	1501	1502		|O
respectively	1503	1515		|O
)	1515	1516		|O
.	1516	1517		|O
Aggression	1518	1528	Aggression	|B-DISEASE
was	1529	1532		|O
also	1533	1537		|O
decreased	1538	1547		|O
as	1548	1550		|O
assessed	1551	1559		|O
by	1560	1562		|O
fewer	1563	1568		|O
numbers	1569	1576		|O
of	1577	1579		|O
aggressive	1580	1590		|O
episodes	1591	1599		|O
on	1600	1602		|O
the	1603	1606		|O
Overt	1607	1612		|O
Aggression	1613	1623	Aggression	|B-DISEASE
Scale	1624	1629		|O
(	1630	1631		|O
OAS	1631	1634		|O
)	1634	1635		|O
.	1635	1636		|O
Little	1637	1643		|O
change	1644	1650		|O
in	1651	1653		|O
anxiety	1654	1661	anxiety	|B-DISEASE
symptoms	1662	1670		|O
was	1671	1674		|O
noted	1675	1680		|O
.	1680	1681		|O
The	1682	1685		|O
most	1686	1690		|O
widely	1691	1697		|O
reported	1698	1706		|O
side	1707	1711		|O
effects	1712	1719		|O
were	1720	1724		|O
drowsiness	1725	1735	drowsiness	|B-ADVERSE
/	1735	1736		|O
sedation	1736	1744	sedation	|B-ADVERSE
and	1745	1748		|O
weight	1749	1755		|O
gain	1756	1760		|O
;	1760	1761		|O
adverse	1762	1769		|O
events	1770	1776		|O
were	1777	1781		|O
generally	1782	1791		|O
well	1792	1796		|O
tolerated	1797	1806		|O
.	1806	1807		|O
Mean	1808	1812		|O
weight	1813	1819		|O
gain	1820	1824		|O
of	1825	1827		|O
4.1	1828	1831		|O
+	1832	1833		|O
/	1833	1834		|O
-	1834	1835		|O
2.0	1836	1839		|O
kg	1840	1842		|O
was	1843	1846		|O
observed	1847	1855		|O
over	1856	1860		|O
the	1861	1864		|O
6	1865	1866		|O
-	1866	1867		|O
week	1867	1871		|O
trial	1872	1877		|O
,	1877	1878		|O
a	1879	1880		|O
mean	1881	1885		|O
percent	1886	1893		|O
change	1894	1900		|O
of	1901	1903		|O
8.4	1904	1907		|O
+	1908	1909		|O
/	1909	1910		|O
-	1910	1911		|O
4.4	1912	1915		|O
(	1916	1917		|O
p	1917	1918		|O
<	1919	1920		|O
0.001	1921	1926		|O
)	1926	1927		|O
.	1927	1928		|O
CONCLUSIONS	1929	1940		|O
:	1940	1941		|O
Additional	1942	1952		|O
studies	1953	1960		|O
of	1961	1963		|O
the	1964	1967		|O
benefits	1968	1976		|O
of	1977	1979		|O
olanzapine	1980	1990		|O
treatment	1991	2000		|O
for	2001	2004		|O
tic	2005	2008	tic	|B-DISEASE
control	2009	2016		|O
as	2017	2019		|O
well	2020	2024		|O
as	2025	2027		|O
the	2028	2031		|O
commonly	2032	2040		|O
associated	2041	2051		|O
co	2052	2054		|O
-	2054	2055		|O
morbid	2055	2061		|O
features	2062	2070		|O
of	2071	2073		|O
TS	2074	2076	TS	|B-DISEASE
are	2077	2080		|O
indicated	2081	2090		|O
,	2090	2091		|O
especially	2092	2102		|O
if	2103	2105		|O
approaches	2106	2116		|O
to	2117	2119		|O
predict	2120	2127		|O
or	2128	2130		|O
minimize	2131	2139		|O
weight	2140	2146		|O
gain	2147	2151		|O
can	2152	2155		|O
be	2156	2158		|O
determined	2159	2169		|O
.	2169	2170		|O

### 18571386
A	0	1		|O
novel	2	7		|O
polyherbal	8	18		|O
microbicide	19	30		|O
with	31	35		|O
inhibitory	36	46		|O
effect	47	53		|O
on	54	56		|O
bacterial	57	66		|O
,	66	67		|O
fungal	68	74		|O
and	75	78		|O
viral	79	84		|O
genital	85	92		|O
pathogens	93	102		|O
.	102	103		|O
A	105	106		|O
polyherbal	107	117		|O
cream	118	123		|O
(	124	125		|O
Basant	125	131		|O
)	131	132		|O
has	133	136		|O
been	137	141		|O
formulated	142	152		|O
using	153	158		|O
diferuloylmethane	159	176		|O
(	177	178		|O
curcumin	178	186		|O
)	186	187		|O
,	187	188		|O
purified	189	197		|O
extracts	198	206		|O
of	207	209		|O
Emblica	210	217		|O
officinalis	218	229		|O
(	230	231		|O
Amla	231	235		|O
)	235	236		|O
,	236	237		|O
purified	238	246		|O
saponins	247	255		|O
from	256	260		|O
Sapindus	261	269		|O
mukorossi	270	279		|O
,	279	280		|O
Aloe	281	285		|O
vera	286	290		|O
and	291	294		|O
rose	295	299		|O
water	300	305		|O
along	306	311		|O
with	312	316		|O
pharmacopoeially	317	333		|O
approved	334	342		|O
excipients	343	353		|O
and	354	357		|O
preservatives	358	371		|O
.	371	372		|O
Basant	373	379		|O
inhibits	380	388		|O
the	389	392		|O
growth	393	399		|O
of	400	402		|O
WHO	403	406		|O
strains	407	414		|O
and	415	418		|O
clinical	419	427		|O
isolates	428	436		|O
of	437	439		|O
Neisseria	440	449		|O
gonorrhoeae	450	461		|O
,	461	462		|O
including	463	472		|O
those	473	478		|O
resistant	479	488		|O
to	489	491		|O
penicillin	492	502		|O
,	502	503		|O
tetracycline	504	516		|O
,	516	517		|O
nalidixic	518	527		|O
acid	528	532		|O
and	533	536		|O
ciprofloxacin	537	550		|O
.	550	551		|O
It	552	554		|O
has	555	558		|O
pronounced	559	569		|O
inhibitory	570	580		|O
action	581	587		|O
against	588	595		|O
Candida	596	603		|O
glabrata	604	612		|O
,	612	613		|O
Candida	614	621		|O
albicans	622	630		|O
and	631	634		|O
Candida	635	642		|O
tropicalis	643	653		|O
isolated	654	662		|O
from	663	667		|O
women	668	673		|O
with	674	678		|O
vulvovaginal	679	691	vulvovaginal candidiasis	|B-DISEASE
candidiasis	692	703		|I-DISEASE
,	703	704		|O
including	705	714		|O
three	715	720		|O
isolates	721	729		|O
resistant	730	739		|O
to	740	742		|O
azole	743	748		|O
drugs	749	754		|O
and	755	758		|O
amphotericin	759	771		|O
B	772	773		|O
.	773	774		|O
Basant	775	781		|O
displayed	782	791		|O
a	792	793		|O
high	794	798		|O
virucidal	799	808		|O
action	809	815		|O
against	816	823		|O
human	824	829		|O
immunodeficiency	830	846		|O
virus	847	852		|O
HIV	853	856		|O
-	856	857		|O
1NL4	857	861		|O
.3	861	863		|O
in	864	866		|O
CEM	867	870		|O
-	870	871		|O
GFP	871	874		|O
reporter	875	883		|O
T	884	885		|O
and	886	889		|O
P4	890	892		|O
(	893	894		|O
Hela	894	898		|O
-	898	899		|O
CD4	899	902		|O
-	902	903		|O
LTR	903	906		|O
-	906	907		|O
betaGal	907	914		|O
)	914	915		|O
cell	916	920		|O
lines	921	926		|O
with	927	931		|O
a	932	933		|O
50%	934	937		|O
effective	938	947		|O
concentration	948	961		|O
(	962	963		|O
EC50	963	967		|O
)	967	968		|O
of	969	971		|O
1	972	973		|O
:	973	974		|O
20000	974	979		|O
dilution	980	988		|O
and	989	992		|O
nearly	993	999		|O
complete	1000	1008		|O
(	1009	1010		|O
98-99%	1010	1016		|O
)	1016	1017		|O
inhibition	1018	1028		|O
at	1029	1031		|O
1	1032	1033		|O
:	1033	1034		|O
1000	1034	1038		|O
dilution	1039	1047		|O
.	1047	1048		|O
It	1049	1051		|O
also	1052	1056		|O
prevented	1057	1066		|O
the	1067	1070		|O
entry	1071	1076		|O
of	1077	1079		|O
HIV	1080	1083		|O
-	1083	1084		|O
1	1084	1085		|O
(	1085	1086		|O
IIIB	1086	1090		|O
)	1090	1091		|O
virus	1092	1097		|O
into	1098	1102		|O
P4	1103	1105		|O
-	1105	1106		|O
CCR5	1106	1110		|O
cells	1111	1116		|O
(	1117	1118		|O
EC50	1118	1122		|O
approximately	1123	1136		|O
1	1137	1138		|O
:	1138	1139		|O
2492	1139	1143		|O
)	1143	1144		|O
.	1144	1145		|O
Two	1146	1149		|O
ingredients	1150	1161		|O
,	1161	1162		|O
Aloe	1163	1167		|O
and	1168	1171		|O
Amla	1172	1176		|O
,	1176	1177		|O
inhibited	1178	1187		|O
the	1188	1191		|O
transduction	1192	1204		|O
of	1205	1207		|O
human	1208	1213		|O
papillomavirus	1214	1228		|O
type	1229	1233		|O
16	1234	1236		|O
(	1237	1238		|O
HPV	1238	1241		|O
-	1241	1242		|O
16	1242	1244		|O
)	1244	1245		|O
pseudovirus	1246	1257		|O
in	1258	1260		|O
HeLa	1261	1265		|O
cells	1266	1271		|O
at	1272	1274		|O
concentrations	1275	1289		|O
far	1290	1293		|O
below	1294	1299		|O
those	1300	1305		|O
that	1306	1310		|O
are	1311	1314		|O
cytotoxic	1315	1324		|O
and	1325	1328		|O
those	1329	1334		|O
used	1335	1339		|O
in	1340	1342		|O
the	1343	1346		|O
formulation	1347	1358		|O
.	1358	1359		|O
Basant	1360	1366		|O
was	1367	1370		|O
found	1371	1376		|O
to	1377	1379		|O
be	1380	1382		|O
totally	1383	1390		|O
safe	1391	1395		|O
according	1396	1405		|O
to	1406	1408		|O
pre	1409	1412		|O
-	1412	1413		|O
clinical	1413	1421		|O
toxicology	1422	1432		|O
carried	1433	1440		|O
out	1441	1444		|O
on	1445	1447		|O
rabbit	1448	1454		|O
vagina	1455	1461		|O
after	1462	1467		|O
application	1468	1479		|O
for	1480	1483		|O
7	1484	1485		|O
consecutive	1486	1497		|O
days	1498	1502		|O
or	1503	1505		|O
twice	1506	1511		|O
daily	1512	1517		|O
for	1518	1521		|O
3	1522	1523		|O
weeks	1524	1529		|O
.	1529	1530		|O
Basant	1531	1537		|O
has	1538	1541		|O
the	1542	1545		|O
potential	1546	1555		|O
of	1556	1558		|O
regressing	1559	1569		|O
vulvovaginal	1570	1582	vulvovaginal candidiasis	|B-DISEASE
candidiasis	1583	1594		|I-DISEASE
and	1595	1598		|O
preventing	1599	1609		|O
N	1610	1611		|O
.	1611	1612		|O
gonorrhoeae	1613	1624		|O
,	1624	1625		|O
HIV	1626	1629		|O
and	1630	1633		|O
HPV	1634	1637	HPV infections	|B-DISEASE
infections	1638	1648		|I-DISEASE
.	1648	1649		|O

### 18803658
Astaxanthin	0	11		|O
,	11	12		|O
canthaxanthin	13	26		|O
and	27	30		|O
beta	31	35		|O
-	35	36		|O
carotene	36	44		|O
differently	45	56		|O
affect	57	63		|O
UVA	64	67		|O
-	67	68		|O
induced	68	75		|O
oxidative	76	85		|O
damage	86	92		|O
and	93	96		|O
expression	97	107		|O
of	108	110		|O
oxidative	111	120		|O
stress	121	127		|O
-	127	128		|O
responsive	128	138		|O
enzymes	139	146		|O
.	146	147		|O
Carotenoids	149	160		|O
are	161	164		|O
used	165	169		|O
for	170	173		|O
systemic	174	182		|O
photoprotection	183	198		|O
in	199	201		|O
humans	202	208		|O
.	208	209		|O
Regarding	210	219		|O
mechanisms	220	230		|O
underlying	231	241		|O
photoprotective	242	257		|O
effects	258	265		|O
of	266	268		|O
carotenoids	269	280		|O
,	280	281		|O
here	282	286		|O
we	287	289		|O
compared	290	298		|O
the	299	302		|O
modulation	303	313		|O
of	314	316		|O
UVA	317	320		|O
-	320	321		|O
related	321	328		|O
injury	329	335		|O
by	336	338		|O
carotenoids	339	350		|O
.	350	351		|O
Human	352	357		|O
dermal	358	364		|O
fibroblasts	365	376		|O
(	377	378		|O
HDF	378	381		|O
)	381	382		|O
were	383	387		|O
exposed	388	395		|O
to	396	398		|O
moderate	399	407		|O
doses	408	413		|O
of	414	416		|O
UVA	417	420		|O
,	420	421		|O
which	422	427		|O
stimulated	428	438		|O
apoptosis	439	448		|O
,	448	449		|O
increased	450	459		|O
levels	460	466		|O
of	467	469		|O
reactive	470	478		|O
oxygen	479	485		|O
species	486	493		|O
and	494	497		|O
thiobarbituric	498	512		|O
acid	513	517		|O
reactive	518	526		|O
substances	527	537		|O
,	537	538		|O
decreased	539	548		|O
antioxidant	549	560		|O
enzymes	561	568		|O
activities	569	579		|O
,	579	580		|O
promoted	581	589		|O
membrane	590	598		|O
perturbation	599	611		|O
,	611	612		|O
and	613	616		|O
induced	617	624		|O
the	625	628		|O
expression	629	639		|O
of	640	642		|O
heme	643	647		|O
oxygenase	648	657		|O
-	657	658		|O
1	658	659		|O
(	660	661		|O
HO	661	663		|O
-	663	664		|O
1	664	665		|O
)	665	666		|O
.	666	667		|O
The	668	671		|O
carotenoids	672	683		|O
astaxanthin	684	695		|O
(	696	697		|O
AX	697	699		|O
)	699	700		|O
,	700	701		|O
canthaxanthin	702	715		|O
(	716	717		|O
CX	717	719		|O
)	719	720		|O
and	721	724		|O
beta	725	729		|O
-	729	730		|O
carotene	730	738		|O
(	739	740		|O
betaC	740	745		|O
)	745	746		|O
were	747	751		|O
delivered	752	761		|O
to	762	764		|O
HDF	765	768		|O
24	769	771		|O
h	772	773		|O
before	774	780		|O
exposure	781	789		|O
to	790	792		|O
UVA	793	796		|O
.	796	797		|O
Astaxanthin	798	809		|O
exhibited	810	819		|O
a	820	821		|O
pronounced	822	832		|O
photoprotective	833	848		|O
effect	849	855		|O
and	856	859		|O
counteracted	860	872		|O
all	873	876		|O
of	877	879		|O
the	880	883		|O
above	884	889		|O
-	889	890		|O
mentioned	890	899		|O
UVA	900	903		|O
-	903	904		|O
induced	904	911		|O
alterations	912	923		|O
to	924	926		|O
a	927	928		|O
significant	929	940		|O
extent	941	947		|O
.	947	948		|O
beta	949	953		|O
-	953	954		|O
Carotene	954	962		|O
only	963	967		|O
partially	968	977		|O
prevented	978	987		|O
the	988	991		|O
UVA	992	995		|O
-	995	996		|O
induced	996	1003		|O
decline	1004	1011		|O
of	1012	1014		|O
catalase	1015	1023		|O
and	1024	1027		|O
superoxide	1028	1038		|O
dismutase	1039	1048		|O
activities	1049	1059		|O
,	1059	1060		|O
but	1061	1064		|O
it	1065	1067		|O
increased	1068	1077		|O
membrane	1078	1086		|O
damage	1087	1093		|O
and	1094	1097		|O
stimulated	1098	1108		|O
HO	1109	1111		|O
-	1111	1112		|O
1	1112	1113		|O
expression	1114	1124		|O
.	1124	1125		|O
Moreover	1126	1134		|O
,	1134	1135		|O
betaC	1136	1141		|O
dose	1142	1146		|O
-	1146	1147		|O
dependently	1147	1158		|O
induced	1159	1166		|O
caspase	1167	1174		|O
-	1174	1175		|O
3	1175	1176		|O
activity	1177	1185		|O
following	1186	1195		|O
UVA	1196	1199		|O
exposure	1200	1208		|O
.	1208	1209		|O
In	1210	1212		|O
contrast	1213	1221		|O
,	1221	1222		|O
CX	1223	1225		|O
had	1226	1229		|O
no	1230	1232		|O
effect	1233	1239		|O
on	1240	1242		|O
oxidative	1243	1252		|O
damage	1253	1259		|O
,	1259	1260		|O
except	1261	1267		|O
for	1268	1271		|O
HO	1272	1274		|O
-	1274	1275		|O
1	1275	1276		|O
expression	1277	1287		|O
,	1287	1288		|O
which	1289	1294		|O
was	1295	1298		|O
augmented	1299	1308		|O
.	1308	1309		|O
Uptake	1310	1316		|O
of	1317	1319		|O
AX	1320	1322		|O
by	1323	1325		|O
fibroblasts	1326	1337		|O
was	1338	1341		|O
higher	1342	1348		|O
than	1349	1353		|O
that	1354	1358		|O
of	1359	1361		|O
the	1362	1365		|O
other	1366	1371		|O
two	1372	1375		|O
carotenoids	1376	1387		|O
.	1387	1388		|O
The	1389	1392		|O
photostability	1393	1407		|O
of	1408	1410		|O
the	1411	1414		|O
three	1415	1420		|O
compounds	1421	1430		|O
in	1431	1433		|O
fibroblasts	1434	1445		|O
was	1446	1449		|O
AX	1450	1452		|O
>	1453	1454		|O
CX	1455	1457		|O
>	1458	1459		|O
>	1459	1460		|O
betaC	1461	1466		|O
.	1466	1467		|O
The	1468	1471		|O
data	1472	1476		|O
indicate	1477	1485		|O
that	1486	1490		|O
the	1491	1494		|O
oxo	1495	1498		|O
-	1498	1499		|O
carotenoid	1499	1509		|O
AX	1510	1512		|O
has	1513	1516		|O
a	1517	1518		|O
superior	1519	1527		|O
preventive	1528	1538		|O
effect	1539	1545		|O
towards	1546	1553		|O
photo	1554	1559		|O
-	1559	1560		|O
oxidative	1560	1569		|O
changes	1570	1577		|O
in	1578	1580		|O
cell	1581	1585		|O
culture	1586	1593		|O
.	1593	1594		|O

### 18640208
Fragrance	0	9		|O
Material	10	18		|O
Review	19	25		|O
on	26	28		|O
isopulegol	29	39		|O
.	39	40		|O
A	42	43		|O
toxicologic	44	55		|O
and	56	59		|O
dermatologic	60	72		|O
review	73	79		|O
of	80	82		|O
isopulegol	83	93		|O
when	94	98		|O
used	99	103		|O
as	104	106		|O
a	107	108		|O
fragrance	109	118		|O
ingredient	119	129		|O
is	130	132		|O
presented	133	142		|O
.	142	143		|O

### 18572632
The	0	3		|O
use	4	7		|O
of	8	10		|O
ultrasound	11	21		|O
and	22	25		|O
micelles	26	34		|O
in	35	37		|O
cancer	38	44	cancer	|B-DISEASE
treatment	45	54		|O
.	54	55		|O
The	57	60		|O
high	61	65		|O
toxicity	66	74		|O
of	75	77		|O
potent	78	84		|O
chemotherapeutic	85	101		|O
drugs	102	107		|O
like	108	112		|O
Doxorubicin	113	124		|O
(	125	126		|O
Dox	126	129		|O
)	129	130		|O
limits	131	137		|O
the	138	141		|O
therapeutic	142	153		|O
window	154	160		|O
in	161	163		|O
which	164	169		|O
they	170	174		|O
can	175	178		|O
be	179	181		|O
applied	182	189		|O
.	189	190		|O
This	191	195		|O
window	196	202		|O
can	203	206		|O
be	207	209		|O
expanded	210	218		|O
by	219	221		|O
controlling	222	233		|O
the	234	237		|O
drug	238	242		|O
delivery	243	251		|O
in	252	254		|O
both	255	259		|O
space	260	265		|O
and	266	269		|O
time	270	274		|O
such	275	279		|O
that	280	284		|O
non	285	288		|O
-	288	289		|O
targeted	289	297		|O
tissues	298	305		|O
are	306	309		|O
not	310	313		|O
adversely	314	323		|O
affected	324	332		|O
.	332	333		|O
Recent	334	340		|O
research	341	349		|O
has	350	353		|O
shown	354	359		|O
that	360	364		|O
ultrasound	365	375		|O
(	376	377		|O
US	377	379		|O
)	379	380		|O
can	381	384		|O
be	385	387		|O
used	388	392		|O
to	393	395		|O
control	396	403		|O
the	404	407		|O
release	408	415		|O
of	416	418		|O
Dox	419	422		|O
and	423	426		|O
other	427	432		|O
hydrophobic	433	444		|O
drugs	445	450		|O
from	451	455		|O
polymeric	456	465		|O
micelles	466	474		|O
in	475	477		|O
both	478	482		|O
time	483	487		|O
and	488	491		|O
space	492	497		|O
.	497	498		|O
It	499	501		|O
has	502	505		|O
also	506	510		|O
been	511	515		|O
shown	516	521		|O
using	522	527		|O
an	528	530		|O
in	531	533		|O
vivo	534	538		|O
rat	539	542		|O
tumor	543	548		|O
model	549	554		|O
that	555	559		|O
Dox	560	563		|O
activity	564	572		|O
can	573	576		|O
be	577	579		|O
enhanced	580	588		|O
by	589	591		|O
ultrasound	592	602		|O
in	603	605		|O
one	606	609		|O
region	610	616		|O
,	616	617		|O
while	618	623		|O
in	624	626		|O
an	627	629		|O
adjacent	630	638		|O
region	639	645		|O
there	646	651		|O
is	652	654		|O
little	655	661		|O
or	662	664		|O
no	665	667		|O
effect	668	674		|O
of	675	677		|O
the	678	681		|O
drug	682	686		|O
.	686	687		|O
In	688	690		|O
this	691	695		|O
article	696	703		|O
,	703	704		|O
we	705	707		|O
review	708	714		|O
the	715	718		|O
in	719	721		|O
vivo	722	726		|O
and	727	730		|O
in	731	733		|O
vitro	734	739		|O
research	740	748		|O
being	749	754		|O
conducted	755	764		|O
in	765	767		|O
the	768	771		|O
area	772	776		|O
of	777	779		|O
using	780	785		|O
ultrasound	786	796		|O
to	797	799		|O
enhance	800	807		|O
and	808	811		|O
target	812	818		|O
micellar	819	827		|O
drug	828	832		|O
delivery	833	841		|O
to	842	844		|O
cancerous	845	854		|O
tissues	855	862		|O
.	862	863		|O
Additionally	864	876		|O
,	876	877		|O
we	878	880		|O
summarize	881	890		|O
our	891	894		|O
previously	895	905		|O
published	906	915		|O
mathematical	916	928		|O
models	929	935		|O
that	936	940		|O
attempt	941	948		|O
to	949	951		|O
represent	952	961		|O
the	962	965		|O
release	966	973		|O
and	974	977		|O
re	978	980		|O
-	980	981		|O
encapsulation	981	994		|O
phenomena	995	1004		|O
of	1005	1007		|O
Dox	1008	1011		|O
from	1012	1016		|O
Pluronic	1017	1025		|O
P105	1026	1030		|O
micelles	1031	1039		|O
upon	1040	1044		|O
the	1045	1048		|O
application	1049	1060		|O
of	1061	1063		|O
ultrasound	1064	1074		|O
.	1074	1075		|O
The	1076	1079		|O
potential	1080	1089		|O
benefits	1090	1098		|O
of	1099	1101		|O
such	1102	1106		|O
controlled	1107	1117		|O
chemotherapy	1118	1130		|O
compels	1131	1138		|O
a	1139	1140		|O
thorough	1141	1149		|O
investigation	1150	1163		|O
of	1164	1166		|O
the	1167	1170		|O
role	1171	1175		|O
of	1176	1178		|O
ultrasound	1179	1189		|O
(	1190	1191		|O
US	1191	1193		|O
)	1193	1194		|O
and	1195	1198		|O
the	1199	1202		|O
mechanisms	1203	1213		|O
by	1214	1216		|O
which	1217	1222		|O
US	1223	1225		|O
accomplishes	1226	1238		|O
drug	1239	1243		|O
release	1244	1251		|O
and	1252	1255		|O
/	1255	1256		|O
or	1256	1258		|O
enhances	1259	1267		|O
drug	1268	1272		|O
potency	1273	1280		|O
.	1280	1281		|O
Therefore	1282	1291		|O
we	1292	1294		|O
will	1295	1299		|O
summarize	1300	1309		|O
our	1310	1313		|O
findings	1314	1322		|O
related	1323	1330		|O
to	1331	1333		|O
the	1334	1337		|O
mechanism	1338	1347		|O
involved	1348	1356		|O
in	1357	1359		|O
acoustically	1360	1372		|O
activated	1373	1382		|O
micellar	1383	1391		|O
drug	1392	1396		|O
delivery	1397	1405		|O
to	1406	1408		|O
tumors	1409	1415	tumors	|B-DISEASE
.	1415	1416		|O

### 18549344
Apaziquone	0	10		|O
for	11	14		|O
non	15	18	non-muscle invasive bladder cancer	|B-DISEASE
-	18	19		|I-DISEASE
muscle	19	25		|I-DISEASE
invasive	26	34		|I-DISEASE
bladder	35	42		|I-DISEASE
cancer	43	49		|I-DISEASE
:	49	50		|O
a	51	52		|O
critical	53	61		|O
review	62	68		|O
.	68	69		|O
OBJECTIVE	71	80		|O
:	80	81		|O
To	82	84		|O
describe	85	93		|O
clinical	94	102		|O
needs	103	108		|O
in	109	111		|O
non	112	115	non-muscle invasive bladder cancer	|B-DISEASE
-	115	116		|I-DISEASE
muscle	116	122		|I-DISEASE
invasive	123	131		|I-DISEASE
bladder	132	139		|I-DISEASE
cancer	140	146		|I-DISEASE
(	147	148		|O
NMIBC	148	153	NMIBC	|B-DISEASE
)	153	154		|O
and	155	158		|O
review	159	165		|O
the	166	169		|O
potential	170	179		|O
of	180	182		|O
apaziquone	183	193		|O
in	194	196		|O
this	197	201		|O
respect	202	209		|O
.	209	210		|O
METHODS	211	218		|O
:	218	219		|O
Epidemiology	220	232		|O
and	233	236		|O
clinical	237	245		|O
practice	246	254		|O
in	255	257		|O
NMIBC	258	263	NMIBC	|B-DISEASE
,	263	264		|O
as	265	267		|O
well	268	272		|O
as	273	275		|O
new	276	279		|O
drugs	280	285		|O
and	286	289		|O
strategies	290	300		|O
are	301	304		|O
reviewed	305	313		|O
.	313	314		|O
RESULTS	315	322		|O
:	322	323		|O
Bladder	324	331	Bladder cancer	|B-DISEASE
cancer	332	338		|I-DISEASE
is	339	341		|O
a	342	343		|O
heterogeneous	344	357		|O
and	358	361		|O
frequent	362	370		|O
disease	371	378		|O
.	378	379		|O
Clinical	380	388		|O
risk	389	393		|O
factors	394	401		|O
help	402	406		|O
in	407	409		|O
determining	410	421		|O
additional	422	432		|O
therapy	433	440		|O
after	441	446		|O
initial	447	454		|O
resection	455	464		|O
.	464	465		|O
However	466	473		|O
,	473	474		|O
current	475	482		|O
treatments	483	493		|O
have	494	498		|O
clear	499	504		|O
limitations	505	516		|O
with	517	521		|O
regard	522	528		|O
to	529	531		|O
efficacy	532	540		|O
and	541	544		|O
/	544	545		|O
or	545	547		|O
toxicity	548	556		|O
.	556	557		|O
New	558	561		|O
drugs	562	567		|O
and	568	571		|O
strategies	572	582		|O
have	583	587		|O
been	588	592		|O
tested	593	599		|O
recently	600	608		|O
and	609	612		|O
are	613	616		|O
in	617	619		|O
(	620	621		|O
pre	621	624		|O
)	624	625		|O
clinical	625	633		|O
use	634	637		|O
.	637	638		|O
Intravesical	639	651		|O
apaziquone	652	662		|O
(	663	664		|O
EOquin	664	670		|O
)	670	671		|O
is	672	674		|O
a	675	676		|O
new	677	680		|O
drug	681	685		|O
.	685	686		|O
It	687	689		|O
has	690	693		|O
theoretical	694	705		|O
advantages	706	716		|O
for	717	720		|O
intravesical	721	733		|O
use	734	737		|O
,	737	738		|O
has	739	742		|O
proven	743	749		|O
safety	750	756		|O
and	757	760		|O
is	761	763		|O
presently	764	773		|O
under	774	779		|O
further	780	787		|O
clinical	788	796		|O
evaluation	797	807		|O
.	807	808		|O
CONCLUSION	809	819		|O
:	819	820		|O
Apaziquone	821	831		|O
is	832	834		|O
a	835	836		|O
promising	837	846		|O
drug	847	851		|O
for	852	855		|O
intravesical	856	868		|O
use	869	872		|O
in	873	875		|O
patients	876	884		|O
with	885	889		|O
NMIBC	890	895	NMIBC	|B-DISEASE
.	895	896		|O

### 18830207
Limited	0	7		|O
place	8	13		|O
for	14	17		|O
plasma	18	24		|O
monitoring	25	35		|O
of	36	38		|O
new	39	42		|O
antiepileptic	43	56		|O
drugs	57	62		|O
in	63	65		|O
clinical	66	74		|O
practice	75	83		|O
.	83	84		|O
Therapeutic	86	97		|O
drug	98	102		|O
monitoring	103	113		|O
(	114	115		|O
TDM	115	118		|O
)	118	119		|O
has	120	123		|O
been	124	128		|O
recognized	129	139		|O
as	140	142		|O
a	143	144		|O
useful	145	151		|O
guide	152	157		|O
in	158	160		|O
the	161	164		|O
clinical	165	173		|O
management	174	184		|O
of	185	187		|O
patients	188	196		|O
with	197	201		|O
epilepsy	202	210	epilepsy	|B-DISEASE
,	210	211		|O
in	212	214		|O
particular	215	225		|O
those	226	231		|O
on	232	234		|O
therapy	235	242		|O
with	243	247		|O
traditional	248	259		|O
antiepileptic	260	273		|O
drugs	274	279		|O
(	280	281		|O
AEDs	281	285		|O
)	285	286		|O
.	286	287		|O
The	288	291		|O
demonstration	292	305		|O
of	306	308		|O
significant	309	320		|O
drug	321	325		|O
interactions	326	338		|O
and	339	342		|O
the	343	346		|O
introduction	347	359		|O
of	360	362		|O
the	363	366		|O
concept	367	374		|O
"	375	376		|O
therapeutic	376	387		|O
range	388	393		|O
"	393	394		|O
have	395	399		|O
also	400	404		|O
contributed	405	416		|O
to	417	419		|O
the	420	423		|O
view	424	428		|O
that	429	433		|O
monotherapy	434	445		|O
should	446	452		|O
be	453	455		|O
considered	456	466		|O
the	467	470		|O
"	471	472		|O
gold	472	476		|O
standard	477	485		|O
"	485	486		|O
in	487	489		|O
the	490	493		|O
treatment	494	503		|O
of	504	506		|O
epilepsy	507	515	epilepsy	|B-DISEASE
.	515	516		|O
Ten	517	520		|O
new	521	524		|O
AEDs	525	529		|O
have	530	534		|O
been	535	539		|O
approved	540	548		|O
and	549	552		|O
released	553	561		|O
to	562	564		|O
the	565	568		|O
market	569	575		|O
in	576	578		|O
the	579	582		|O
last	583	587		|O
fifteen	588	595		|O
years	596	601		|O
.	601	602		|O
The	603	606		|O
most	607	611		|O
obvious	612	619		|O
consequence	620	631		|O
has	632	635		|O
been	636	640		|O
an	641	643		|O
increased	644	653		|O
number	654	660		|O
of	661	663		|O
patients	664	672		|O
on	673	675		|O
polytherapy	676	687		|O
.	687	688		|O
In	689	691		|O
general	692	699		|O
,	699	700		|O
newer	701	706		|O
AEDs	707	711		|O
have	712	716		|O
better	717	723		|O
and	724	727		|O
more	728	732		|O
predictable	733	744		|O
pharmacokinetics	745	761		|O
than	762	766		|O
older	767	772		|O
AEDs	773	777		|O
and	778	781		|O
usually	782	789		|O
show	790	794		|O
lower	795	800		|O
risk	801	805		|O
of	806	808		|O
interactions	809	821		|O
leading	822	829		|O
to	830	832		|O
toxicity	833	841		|O
as	842	844		|O
well	845	849		|O
as	850	852		|O
large	853	858		|O
therapeutic	859	870		|O
indexes	871	878		|O
.	878	879		|O
This	880	884		|O
pragmatic	885	894		|O
review	895	901		|O
focuses	902	909		|O
on	910	912		|O
practical	913	922		|O
suggestions	923	934		|O
about	935	940		|O
the	941	944		|O
potential	945	954		|O
clinical	955	963		|O
usefulness	964	974		|O
of	975	977		|O
TDM	978	981		|O
of	982	984		|O
newer	985	990		|O
AEDs	991	995		|O
in	996	998		|O
relation	999	1007		|O
to	1008	1010		|O
their	1011	1016		|O
mechanism	1017	1026		|O
of	1027	1029		|O
action	1030	1036		|O
and	1037	1040		|O
pharmacokinetic	1041	1056		|O
characteristics	1057	1072		|O
and	1073	1076		|O
in	1077	1079		|O
response	1080	1088		|O
to	1089	1091		|O
patient	1092	1099		|O
-	1099	1100		|O
specific	1100	1108		|O
problems	1109	1117		|O
.	1117	1118		|O
Overall	1119	1126		|O
,	1126	1127		|O
the	1128	1131		|O
usefulness	1132	1142		|O
of	1143	1145		|O
TDM	1146	1149		|O
of	1150	1152		|O
newer	1153	1158		|O
AEDs	1159	1163		|O
seems	1164	1169		|O
to	1170	1172		|O
be	1173	1175		|O
limited	1176	1183		|O
and	1184	1187		|O
its	1188	1191		|O
indiscriminate	1192	1206		|O
use	1207	1210		|O
is	1211	1213		|O
not	1214	1217		|O
justified	1218	1227		|O
.	1227	1228		|O
However	1229	1236		|O
,	1236	1237		|O
in	1238	1240		|O
selected	1241	1249		|O
cases	1250	1255		|O
or	1256	1258		|O
in	1259	1261		|O
response	1262	1270		|O
to	1271	1273		|O
a	1274	1275		|O
specific	1276	1284		|O
clinical	1285	1293		|O
question	1294	1302		|O
,	1302	1303		|O
a	1304	1305		|O
wise	1306	1310		|O
use	1311	1314		|O
of	1315	1317		|O
TDM	1318	1321		|O
of	1322	1324		|O
some	1325	1329		|O
new	1330	1333		|O
AEDs	1334	1338		|O
could	1339	1344		|O
represent	1345	1354		|O
a	1355	1356		|O
useful	1357	1363		|O
tool	1364	1368		|O
in	1369	1371		|O
the	1372	1375		|O
management	1376	1386		|O
of	1387	1389		|O
epileptic	1390	1399		|O
patients	1400	1408		|O
.	1408	1409		|O
Exceptions	1410	1420		|O
are	1421	1424		|O
thus	1425	1429		|O
represented	1430	1441		|O
by	1442	1444		|O
special	1445	1452		|O
conditions	1453	1463		|O
such	1464	1468		|O
as	1469	1471		|O
renal	1472	1477	renal failure	|B-DISEASE
failure	1478	1485		|I-DISEASE
,	1485	1486		|O
dialysis	1487	1495		|O
,	1495	1496		|O
ascertainment	1497	1510		|O
of	1511	1513		|O
non	1514	1517		|O
-	1517	1518		|O
compliance	1518	1528		|O
,	1528	1529		|O
and	1530	1533		|O
pregnancy	1534	1543		|O
.	1543	1544		|O
For	1545	1548		|O
some	1549	1553		|O
new	1554	1557		|O
AEDs	1558	1562		|O
,	1562	1563		|O
TDM	1564	1567		|O
could	1568	1573		|O
be	1574	1576		|O
selectively	1577	1588		|O
and	1589	1592		|O
properly	1593	1601		|O
used	1602	1606		|O
in	1607	1609		|O
response	1610	1618		|O
to	1619	1621		|O
a	1622	1623		|O
single	1624	1630		|O
patient	1631	1638		|O
-	1638	1639		|O
specific	1639	1647		|O
pharmacokinetic	1648	1663		|O
or	1664	1666		|O
pharmacodynamic	1667	1682		|O
issue	1683	1688		|O
.	1688	1689		|O

### 18765960
The	0	3		|O
phenomenology	4	17		|O
of	18	20		|O
the	21	24		|O
psychotic	25	34		|O
break	35	40		|O
and	41	44		|O
Huxley	45	51		|O
's	51	53		|O
trip	54	58		|O
:	58	59		|O
substance	60	69		|O
use	70	73		|O
and	74	77		|O
the	78	81		|O
onset	82	87		|O
of	88	90		|O
psychosis	91	100	psychosis	|B-DISEASE
.	100	101		|O
BACKGROUND	103	113		|O
:	113	114		|O
While	115	120		|O
considerable	121	133		|O
research	134	142		|O
attention	143	152		|O
has	153	156		|O
been	157	161		|O
devoted	162	169		|O
to	170	172		|O
the	173	176		|O
causal	177	183		|O
relationship	184	196		|O
between	197	204		|O
substance	205	214		|O
use	215	218		|O
and	219	222		|O
psychosis	223	232	psychosis	|B-DISEASE
,	232	233		|O
the	234	237		|O
phenomenology	238	251		|O
of	252	254		|O
the	255	258		|O
association	259	270		|O
between	271	278		|O
the	279	282		|O
two	283	286		|O
has	287	290		|O
largely	291	298		|O
been	299	303		|O
ignored	304	311		|O
.	311	312		|O
This	313	317		|O
is	318	320		|O
a	321	322		|O
significant	323	334		|O
shortcoming	335	346		|O
,	346	347		|O
because	348	355		|O
it	356	358		|O
blinds	359	365		|O
researchers	366	377		|O
to	378	380		|O
the	381	384		|O
possibility	385	396		|O
that	397	401		|O
there	402	407		|O
may	408	411		|O
be	412	414		|O
elements	415	423		|O
of	424	426		|O
the	427	430		|O
subjective	431	441		|O
experience	442	452		|O
of	453	455		|O
substance	456	465		|O
use	466	469		|O
and	470	473		|O
psychosis	474	483	psychosis	|B-DISEASE
that	484	488		|O
contribute	489	499		|O
to	500	502		|O
their	503	508		|O
apparent	509	517		|O
relationship	518	530		|O
in	531	533		|O
empirical	534	543		|O
studies	544	551		|O
.	551	552		|O
SAMPLING	553	561		|O
AND	562	565		|O
METHODS	566	573		|O
:	573	574		|O
The	575	578		|O
current	579	586		|O
paper	587	592		|O
examines	593	601		|O
the	602	605		|O
phenomenology	606	619		|O
of	620	622		|O
the	623	626		|O
onset	627	632		|O
of	633	635		|O
psychosis	636	645	psychosis	|B-DISEASE
and	646	649		|O
the	650	653		|O
phenomenology	654	667		|O
of	668	670		|O
substance	671	680		|O
intoxication	681	693		|O
through	694	701		|O
consideration	702	715		|O
of	716	718		|O
two	719	722		|O
texts	723	728		|O
:	728	729		|O
Sass	730	734		|O
's	734	736		|O
account	737	744		|O
of	745	747		|O
the	748	751		|O
phenomenology	752	765		|O
of	766	768		|O
psychosis	769	778	psychosis	|B-DISEASE
onset	779	784		|O
and	785	788		|O
Huxley	789	795		|O
's	795	797		|O
account	798	805		|O
of	806	808		|O
the	809	812		|O
experience	813	823		|O
of	824	826		|O
hallucinogenic	827	841	hallucinogenic intoxication	|B-ADVERSE
intoxication	842	854		|I-ADVERSE
.	854	855		|O
Sass	856	860		|O
's	860	862		|O
account	863	870		|O
of	871	873		|O
psychosis	874	883	psychosis	|B-DISEASE
onset	884	889		|O
includes	890	898		|O
four	899	903		|O
components	904	914		|O
:	914	915		|O
Unreality	916	925		|O
,	925	926		|O
Fragmentation	927	940		|O
,	940	941		|O
Mere	942	946		|O
Being	947	952		|O
,	952	953		|O
and	954	957		|O
Apophany	958	966		|O
.	966	967		|O
RESULTS	968	975		|O
:	975	976		|O
The	977	980		|O
analysis	981	989		|O
reveals	990	997		|O
significant	998	1009		|O
parallels	1010	1019		|O
-	1020	1021		|O
and	1022	1025		|O
also	1026	1030		|O
some	1031	1035		|O
differences	1036	1047		|O
-	1048	1049		|O
between	1050	1057		|O
this	1058	1062		|O
account	1063	1070		|O
and	1071	1074		|O
the	1075	1078		|O
phenomenology	1079	1092		|O
of	1093	1095		|O
substance	1096	1105		|O
intoxication	1106	1118		|O
.	1118	1119		|O
CONCLUSIONS	1120	1131		|O
:	1131	1132		|O
We	1133	1135		|O
discuss	1136	1143		|O
the	1144	1147		|O
implications	1148	1160		|O
of	1161	1163		|O
this	1164	1168		|O
for	1169	1172		|O
the	1173	1176		|O
causal	1177	1183		|O
relationship	1184	1196		|O
between	1197	1204		|O
psychosis	1205	1214	psychosis	|B-DISEASE
and	1215	1218		|O
substance	1219	1228		|O
use	1229	1232		|O
and	1233	1236		|O
suggest	1237	1244		|O
several	1245	1252		|O
ways	1253	1257		|O
of	1258	1260		|O
understanding	1261	1274		|O
the	1275	1278		|O
overlapping	1279	1290		|O
phenomenologies	1291	1306		|O
.	1306	1307		|O
This	1308	1312		|O
includes	1313	1321		|O
the	1322	1325		|O
suggestion	1326	1336		|O
of	1337	1339		|O
a	1340	1341		|O
shared	1342	1348		|O
factor	1349	1355		|O
,	1355	1356		|O
perhaps	1357	1364		|O
best	1365	1369		|O
described	1370	1379		|O
as	1380	1382		|O
psychotic	1383	1392		|O
-	1392	1393		|O
like	1393	1397		|O
experience	1398	1408		|O
,	1408	1409		|O
which	1410	1415		|O
seems	1416	1421		|O
to	1422	1424		|O
involve	1425	1432		|O
a	1433	1434		|O
breakdown	1435	1444		|O
of	1445	1447		|O
the	1448	1451		|O
sign	1452	1456		|O
-	1456	1457		|O
referent	1457	1465		|O
relationship	1466	1478		|O
and	1479	1482		|O
relationship	1483	1495		|O
with	1496	1500		|O
the	1501	1504		|O
common	1505	1511		|O
-	1511	1512		|O
sense	1512	1517		|O
,	1517	1518		|O
practical	1519	1528		|O
world	1529	1534		|O
.	1534	1535		|O
However	1536	1543		|O
,	1543	1544		|O
in	1545	1547		|O
the	1548	1551		|O
onset	1552	1557		|O
of	1558	1560		|O
psychosis	1561	1570	psychosis	|B-DISEASE
,	1570	1571		|O
this	1572	1576		|O
breakdown	1577	1586		|O
is	1587	1589		|O
primarily	1590	1599		|O
experienced	1600	1611		|O
as	1612	1614		|O
a	1615	1616		|O
sense	1617	1622		|O
of	1623	1625		|O
alienation	1626	1636		|O
from	1637	1641		|O
self	1642	1646		|O
and	1647	1650		|O
world	1651	1656		|O
,	1656	1657		|O
whereas	1658	1665		|O
in	1666	1668		|O
the	1669	1672		|O
hallucinogenic	1673	1687		|O
state	1688	1693		|O
a	1694	1695		|O
sense	1696	1701		|O
of	1702	1704		|O
mystical	1705	1713		|O
union	1714	1719		|O
and	1720	1723		|O
revelation	1724	1734		|O
seems	1735	1740		|O
predominant	1741	1752		|O
.	1752	1753		|O
Further	1754	1761		|O
research	1762	1770		|O
may	1771	1774		|O
extend	1775	1781		|O
this	1782	1786		|O
analysis	1787	1795		|O
by	1796	1798		|O
looking	1799	1806		|O
at	1807	1809		|O
experiences	1810	1821		|O
with	1822	1826		|O
other	1827	1832		|O
drugs	1833	1838		|O
,	1838	1839		|O
particularly	1840	1852		|O
cannabis	1853	1861		|O
,	1861	1862		|O
and	1863	1866		|O
by	1867	1869		|O
examining	1870	1879		|O
the	1880	1883		|O
phenomenology	1884	1897		|O
of	1898	1900		|O
psychotic	1901	1910	psychotic disorder	|B-DISEASE
disorder	1911	1919		|I-DISEASE
beyond	1920	1926		|O
the	1927	1930		|O
first	1931	1936		|O
episode	1937	1944		|O
.	1944	1945		|O

### 18784429
High	0	4		|O
-	4	5		|O
dose	5	9		|O
methylprednisolone	10	28		|O
in	29	31		|O
a	32	33		|O
pregnant	34	42		|O
woman	43	48		|O
with	49	53		|O
Crohn	54	59	Crohn's disease	|B-DISEASE
's	59	61		|I-DISEASE
disease	62	69		|I-DISEASE
and	70	73		|O
adrenal	74	81	adrenal suppression	|B-DISEASE
suppression	82	93		|I-DISEASE
in	94	96		|O
her	97	100		|O
newborn	101	108		|O
.	108	109		|O
BACKGROUND	111	121		|O
:	121	122		|O
The	123	126		|O
synthetic	127	136		|O
corticosteroid	137	151		|O
methylprednisolone	152	170		|O
is	171	173		|O
used	174	178		|O
for	179	182		|O
the	183	186		|O
treatment	187	196		|O
of	197	199		|O
acute	200	205		|O
exacerbations	206	219		|O
of	220	222		|O
Crohn	223	228	Crohn's disease	|B-DISEASE
's	228	230		|I-DISEASE
disease	231	238		|I-DISEASE
,	238	239		|O
also	240	244		|O
in	245	247		|O
pregnancy	248	257		|O
.	257	258		|O
Its	259	262		|O
use	263	266		|O
is	267	269		|O
considered	270	280		|O
to	281	283		|O
be	284	286		|O
less	287	291		|O
harmful	292	299		|O
than	300	304		|O
the	305	308		|O
effect	309	315		|O
of	316	318		|O
active	319	325		|O
disease	326	333		|O
on	334	336		|O
the	337	340		|O
fetus	341	346		|O
.	346	347		|O
Adrenal	348	355	Adrenal suppression	|B-ADVERSE
suppression	356	367		|I-ADVERSE
in	368	370		|O
a	371	372		|O
fetus	373	378		|O
due	379	382		|O
to	383	385		|O
administration	386	400		|O
of	401	403		|O
methylprednisolone	404	422		|O
has	423	426		|O
hitherto	427	435		|O
been	436	440		|O
rarely	441	447		|O
published	448	457		|O
.	457	458		|O
OBJECTIVE	459	468		|O
:	468	469		|O
To	470	472		|O
present	473	480		|O
a	481	482		|O
case	483	487		|O
of	488	490		|O
neonatal	491	499	neonatal adrenal suppression	|B-ADVERSE
adrenal	500	507		|I-ADVERSE
suppression	508	519		|I-ADVERSE
due	520	523		|O
to	524	526		|O
the	527	530		|O
use	531	534		|O
of	535	537		|O
high	538	542		|O
-	542	543		|O
dose	543	547		|O
methylprednisolone	548	566		|O
in	567	569		|O
late	570	574		|O
pregnancy	575	584		|O
of	585	587		|O
a	588	589		|O
woman	590	595		|O
with	596	600		|O
Crohn	601	606	Crohn's disease	|B-DISEASE
's	606	608		|I-DISEASE
disease	609	616		|I-DISEASE
.	616	617		|O
METHODS	618	625		|O
AND	626	629		|O
RESULTS	630	637		|O
:	637	638		|O
Clinical	639	647		|O
signs	648	653		|O
of	654	656		|O
adrenal	657	664	adrenal suppression	|B-ADVERSE
suppression	665	676		|I-ADVERSE
were	677	681		|O
observed	682	690		|O
in	691	693		|O
the	694	697		|O
newborn	698	705		|O
3	706	707		|O
h	708	709		|O
after	710	715		|O
birth	716	721		|O
.	721	722		|O
After	723	728		|O
hydrocortisone	729	743		|O
supplementation	744	759		|O
and	760	763		|O
intensive	764	773		|O
therapy	774	781		|O
the	782	785		|O
baby	786	790		|O
recovered	791	800		|O
completely	801	811		|O
.	811	812		|O
CONCLUSIONS	813	824		|O
:	824	825		|O
Life	826	830		|O
-	830	831		|O
threatening	831	842		|O
adrenal	843	850	adrenal suppression	|B-ADVERSE
suppression	851	862		|I-ADVERSE
,	862	863		|O
requiring	864	873		|O
hydrocortisone	874	888		|O
supplementation	889	904		|O
and	905	908		|O
intensive	909	918		|O
therapy	919	926		|O
,	926	927		|O
was	928	931		|O
observed	932	940		|O
and	941	944		|O
successfully	945	957		|O
treated	958	965		|O
in	966	968		|O
a	969	970		|O
newborn	971	978		|O
,	978	979		|O
whose	980	985		|O
mother	986	992		|O
had	993	996		|O
received	997	1005		|O
high	1006	1010		|O
-	1010	1011		|O
dose	1011	1015		|O
methylprednisolone	1016	1034		|O
in	1035	1037		|O
late	1038	1042		|O
pregnancy	1043	1052		|O
.	1052	1053		|O

### 18700638
Variability	0	11		|O
in	12	14		|O
platelet	15	23		|O
response	24	32		|O
to	33	35		|O
a	36	37		|O
single	38	44		|O
daily	45	50		|O
dose	51	55		|O
of	56	58		|O
150	59	62		|O
mg	63	65		|O
enteric	66	73		|O
coated	74	80		|O
aspirin	81	88		|O
in	89	91		|O
a	92	93		|O
high	94	98		|O
risk	99	103		|O
population	104	114		|O
.	114	115		|O
PURPOSE	117	124		|O
:	124	125		|O
Previous	126	134		|O
studies	135	142		|O
have	143	147		|O
reported	148	156		|O
inadequate	157	167		|O
anti	168	172		|O
-	172	173		|O
platelet	173	181		|O
effect	182	188		|O
in	189	191		|O
0.4-35%	192	199		|O
of	200	202		|O
patients	203	211		|O
taking	212	218		|O
aspirin	219	226		|O
.	226	227		|O
Such	228	232		|O
studies	233	240		|O
have	241	245		|O
arbitrarily	246	257		|O
defined	258	265		|O
the	266	269		|O
terms	270	275		|O
"	276	277		|O
semi	277	281		|O
-	281	282		|O
responders	282	292		|O
"	292	293		|O
,	293	294		|O
"	295	296		|O
non	296	299		|O
-	299	300		|O
responders	300	310		|O
"	310	311		|O
or	312	314		|O
"	315	316		|O
resistant	316	325		|O
"	325	326		|O
to	327	329		|O
variable	330	338		|O
doses	339	344		|O
of	345	347		|O
aspirin	348	355		|O
on	356	358		|O
the	359	362		|O
basis	363	368		|O
of	369	371		|O
absolute	372	380		|O
values	381	387		|O
derived	388	395		|O
from	396	400		|O
different	401	410		|O
ex	411	413		|O
-	413	414		|O
vivo	414	418		|O
platelet	419	427		|O
aggregation	428	439		|O
(	440	441		|O
PA	441	443		|O
)	443	444		|O
methods	445	452		|O
.	452	453		|O
Our	454	457		|O
objective	458	467		|O
was	468	471		|O
to	472	474		|O
define	475	481		|O
response	482	490		|O
to	491	493		|O
150	494	497		|O
-	497	498		|O
mg	498	500		|O
dose	501	505		|O
of	506	508		|O
aspirin	509	516		|O
in	517	519		|O
terms	520	525		|O
of	526	528		|O
normally	529	537		|O
distributed	538	549		|O
values	550	556		|O
using	557	562		|O
an	563	565		|O
ex	566	568		|O
-	568	569		|O
vivo	569	573		|O
measure	574	581		|O
of	582	584		|O
PA	585	587		|O
in	588	590		|O
a	591	592		|O
population	593	603		|O
at	604	606		|O
high	607	611		|O
risk	612	616		|O
for	617	620		|O
vascular	621	629		|O
events	630	636		|O
.	636	637		|O
METHODS	638	645		|O
:	645	646		|O
We	647	649		|O
prospectively	650	663		|O
studied	664	671		|O
high	672	676		|O
risk	677	681		|O
patients	682	690		|O
with	691	695		|O
either	696	702		|O
established	703	714		|O
coronary	715	723	coronary artery disease	|B-DISEASE
artery	724	730		|I-DISEASE
disease	731	738		|I-DISEASE
(	739	740		|O
CAD	740	743	CAD	|B-DISEASE
)	743	744		|O
or	745	747		|O
stroke	748	754	stroke	|B-DISEASE
or	755	757		|O
transient	758	767	transient ischemic attack	|B-DISEASE
ischemic	768	776		|I-DISEASE
attack	777	783		|I-DISEASE
(	784	785		|O
TIA	785	788	TIA	|B-DISEASE
)	788	789		|O
or	790	792		|O
peripheral	793	803	peripheral vascular disease	|B-DISEASE
vascular	804	812		|I-DISEASE
disease	813	820		|I-DISEASE
or	821	823		|O
with	824	828		|O
multiple	829	837		|O
atherothrombotic	838	854		|O
risk	855	859		|O
factors	860	867		|O
like	868	872		|O
diabetes	873	881	diabetes	|B-DISEASE
plus	882	886		|O
one	887	890		|O
of	891	893		|O
the	894	897		|O
following	898	907		|O
-	907	908		|O
-	908	909		|O
hypertension	910	922	hypertension	|B-DISEASE
,	922	923		|O
increased	924	933		|O
total	934	939		|O
cholesterol	940	951		|O
,	951	952		|O
cigarette	953	962		|O
smoking	963	970		|O
,	970	971		|O
micro	972	977		|O
-	977	978		|O
albuminuria	978	989		|O
,	989	990		|O
low	991	994		|O
-	994	995		|O
high	995	999		|O
density	1000	1007		|O
lipoprotein	1008	1019		|O
(	1020	1021		|O
HDL	1021	1024		|O
)	1024	1025		|O
,	1025	1026		|O
family	1027	1033		|O
history	1034	1041		|O
of	1042	1044		|O
CAD	1045	1048	CAD	|B-DISEASE
and	1049	1052		|O
receiving	1053	1062		|O
single	1063	1069		|O
150	1070	1073		|O
mg	1074	1076		|O
dose	1077	1081		|O
of	1082	1084		|O
aspirin	1085	1092		|O
daily	1093	1098		|O
.	1098	1099		|O
PA	1100	1102		|O
was	1103	1106		|O
assessed	1107	1115		|O
by	1116	1118		|O
chronolog	1119	1128		|O
lumi	1129	1133		|O
-	1133	1134		|O
aggregometer	1134	1146		|O
(	1147	1148		|O
490-2	1148	1153		|O
D	1153	1154		|O
)	1154	1155		|O
using	1156	1161		|O
arachidonic	1162	1173		|O
acid	1174	1178		|O
(	1179	1180		|O
AA	1180	1182		|O
)	1182	1183		|O
reagent	1184	1191		|O
.	1191	1192		|O
RESULTS	1193	1200		|O
:	1200	1201		|O
130	1202	1205		|O
patients	1206	1214		|O
were	1215	1219		|O
studied	1220	1227		|O
.	1227	1228		|O
The	1229	1232		|O
response	1233	1241		|O
of	1242	1244		|O
subjects	1245	1253		|O
to	1254	1256		|O
aspirin	1257	1264		|O
followed	1265	1273		|O
a	1274	1275		|O
normal	1276	1282		|O
,	1282	1283		|O
bell	1284	1288		|O
shaped	1289	1295		|O
distribution	1296	1308		|O
curve	1309	1314		|O
with	1315	1319		|O
a	1320	1321		|O
mean	1322	1326		|O
and	1327	1330		|O
standard	1331	1339		|O
deviation	1340	1349		|O
(	1350	1351		|O
S	1351	1352		|O
.	1352	1353		|O
D	1353	1354		|O
.	1354	1355		|O
)	1355	1356		|O
of	1357	1359		|O
13.1	1360	1364		|O
+	1365	1366		|O
/	1366	1367		|O
-	1367	1368		|O
4.4%	1369	1373		|O
.	1373	1374		|O
3.1%	1375	1379		|O
patients	1380	1388		|O
had	1389	1392		|O
PA	1393	1395		|O
values	1396	1402		|O
more	1403	1407		|O
than	1408	1412		|O
2	1413	1414		|O
S	1415	1416		|O
.	1416	1417		|O
D	1417	1418		|O
.	1418	1419		|O
of	1420	1422		|O
the	1423	1426		|O
mean	1427	1431		|O
,	1431	1432		|O
hence	1433	1438		|O
termed	1439	1445		|O
as	1446	1448		|O
hypo	1449	1453		|O
-	1453	1454		|O
responders	1454	1464		|O
to	1465	1467		|O
aspirin	1468	1475		|O
while	1476	1481		|O
another	1482	1489		|O
3.1%	1490	1494		|O
patients	1495	1503		|O
had	1504	1507		|O
PA	1508	1510		|O
values	1511	1517		|O
less	1518	1522		|O
than	1523	1527		|O
2	1528	1529		|O
S	1530	1531		|O
.	1531	1532		|O
D	1532	1533		|O
.	1533	1534		|O
of	1535	1537		|O
the	1538	1541		|O
mean	1542	1546		|O
,	1546	1547		|O
hence	1548	1553		|O
termed	1554	1560		|O
as	1561	1563		|O
hyper	1564	1569		|O
-	1569	1570		|O
responders	1570	1580		|O
to	1581	1583		|O
aspirin	1584	1591		|O
.	1591	1592		|O
CONCLUSION	1593	1603		|O
:	1603	1604		|O
There	1605	1610		|O
is	1611	1613		|O
minimal	1614	1621		|O
inter	1622	1627		|O
-	1627	1628		|O
individual	1628	1638		|O
variability	1639	1650		|O
in	1651	1653		|O
the	1654	1657		|O
response	1658	1666		|O
to	1667	1669		|O
aspirin	1670	1677		|O
when	1678	1682		|O
tested	1683	1689		|O
with	1690	1694		|O
AA	1695	1697		|O
as	1698	1700		|O
the	1701	1704		|O
reagent	1705	1712		|O
.	1712	1713		|O
The	1714	1717		|O
response	1718	1726		|O
to	1727	1729		|O
aspirin	1730	1737		|O
follows	1738	1745		|O
a	1746	1747		|O
normal	1748	1754		|O
Gaussian	1755	1763		|O
distribution	1764	1776		|O
.	1776	1777		|O
The	1778	1781		|O
prevalence	1782	1792		|O
of	1793	1795		|O
hypo	1796	1800		|O
-	1800	1801		|O
responders	1801	1811		|O
to	1812	1814		|O
aspirin	1815	1822		|O
in	1823	1825		|O
high	1826	1830		|O
risk	1831	1835		|O
population	1836	1846		|O
is	1847	1849		|O
only	1850	1854		|O
3.1%	1855	1859		|O
.	1859	1860		|O
This	1861	1865		|O
is	1866	1868		|O
the	1869	1872		|O
first	1873	1878		|O
study	1879	1884		|O
to	1885	1887		|O
document	1888	1896		|O
"	1897	1898		|O
hypo	1898	1902		|O
"	1902	1903		|O
and	1904	1907		|O
"	1908	1909		|O
hyper	1909	1914		|O
-	1914	1915		|O
responders	1915	1925		|O
"	1925	1926		|O
to	1927	1929		|O
single	1930	1936		|O
daily	1937	1942		|O
dose	1943	1947		|O
of	1948	1950		|O
150	1951	1954		|O
mg	1955	1957		|O
aspirin	1958	1965		|O
.	1965	1966		|O
The	1967	1970		|O
clinical	1971	1979		|O
relevance	1980	1989		|O
of	1990	1992		|O
these	1993	1998		|O
findings	1999	2007		|O
remains	2008	2015		|O
to	2016	2018		|O
be	2019	2021		|O
determined	2022	2032		|O
.	2032	2033		|O

### 18551282
Allopregnanolone	0	16		|O
impairs	17	24		|O
episodic	25	33		|O
memory	34	40		|O
in	41	43		|O
healthy	44	51		|O
women	52	57		|O
.	57	58		|O
OBJECTIVE	60	69		|O
:	69	70		|O
Allopregnanolone	71	87		|O
is	88	90		|O
an	91	93		|O
endogenous	94	104		|O
neuroactive	105	116		|O
steroid	117	124		|O
that	125	129		|O
,	129	130		|O
through	131	138		|O
its	139	142		|O
binding	143	150		|O
to	151	153		|O
the	154	157		|O
gamma	158	163		|O
-	163	164		|O
aminobutyric	164	176		|O
acid	177	181		|O
(	182	183		|O
GABA	183	187		|O
)	187	188		|O
A	189	190		|O
receptor	191	199		|O
,	199	200		|O
has	201	204		|O
GABA	205	209		|O
-	209	210		|O
active	210	216		|O
properties	217	227		|O
.	227	228		|O
Animal	229	235		|O
studies	236	243		|O
indicate	244	252		|O
that	253	257		|O
allopregnanolone	258	274		|O
administration	275	289		|O
results	290	297		|O
in	298	300		|O
diminished	301	311	diminished learning	|B-ADVERSE
learning	312	320		|I-ADVERSE
and	321	324		|O
memory	325	331	memory impairment	|B-ADVERSE
impairment	332	342		|I-ADVERSE
.	342	343		|O
The	344	347		|O
aim	348	351		|O
of	352	354		|O
the	355	358		|O
current	359	366		|O
study	367	372		|O
was	373	376		|O
to	377	379		|O
investigate	380	391		|O
the	392	395		|O
effect	396	402		|O
of	403	405		|O
intravenously	406	419		|O
administered	420	432		|O
allopregnanolone	433	449		|O
on	450	452		|O
episodic	453	461		|O
memory	462	468		|O
,	468	469		|O
semantic	470	478		|O
memory	479	485		|O
,	485	486		|O
and	487	490		|O
working	491	498		|O
memory	499	505		|O
in	506	508		|O
healthy	509	516		|O
women	517	522		|O
.	522	523		|O
MATERIALS	524	533		|O
AND	534	537		|O
METHODS	538	545		|O
:	545	546		|O
Twenty	547	553		|O
-	553	554		|O
eight	554	559		|O
healthy	560	567		|O
women	568	573		|O
were	574	578		|O
included	579	587		|O
in	588	590		|O
the	591	594		|O
study	595	600		|O
.	600	601		|O
The	602	605		|O
participants	606	618		|O
were	619	623		|O
scheduled	624	633		|O
for	634	637		|O
the	638	641		|O
memory	642	648		|O
tests	649	654		|O
twice	655	660		|O
in	661	663		|O
the	664	667		|O
follicular	668	678		|O
phase	679	684		|O
.	684	685		|O
During	686	692		|O
the	693	696		|O
test	697	701		|O
sessions	702	710		|O
,	710	711		|O
an	712	714		|O
intravenous	715	726		|O
allopregnanolone	727	743		|O
and	744	747		|O
placebo	748	755		|O
infusion	756	764		|O
were	765	769		|O
administered	770	782		|O
in	783	785		|O
a	786	787		|O
double	788	794		|O
-	794	795		|O
blinded	795	802		|O
,	802	803		|O
randomized	804	814		|O
order	815	820		|O
at	821	823		|O
intervals	824	833		|O
of	834	836		|O
48	837	839		|O
h	840	841		|O
.	841	842		|O
Before	843	849		|O
and	850	853		|O
10	854	856		|O
min	857	860		|O
after	861	866		|O
the	867	870		|O
allopregnanolone	871	887		|O
/	887	888		|O
placebo	888	895		|O
injections	896	906		|O
,	906	907		|O
memory	908	914		|O
tasks	915	920		|O
were	921	925		|O
performed	926	935		|O
.	935	936		|O
RESULTS	937	944		|O
:	944	945		|O
The	946	949		|O
study	950	955		|O
demonstrated	956	968		|O
that	969	973		|O
allopregnanolone	974	990		|O
impaired	991	999		|O
episodic	1000	1008		|O
memory	1009	1015		|O
in	1016	1018		|O
healthy	1019	1026		|O
women	1027	1032		|O
.	1032	1033		|O
There	1034	1039		|O
was	1040	1043		|O
a	1044	1045		|O
significant	1046	1057		|O
difference	1058	1068		|O
between	1069	1076		|O
pre	1077	1080		|O
-	1080	1081		|O
and	1082	1085		|O
postallopregnanolone	1086	1106		|O
injection	1107	1116		|O
episodic	1117	1125		|O
memory	1126	1132		|O
scores	1133	1139		|O
(	1140	1141		|O
p	1141	1142		|O
<	1143	1144		|O
0.05	1145	1149		|O
)	1149	1150		|O
,	1150	1151		|O
whereas	1152	1159		|O
there	1160	1165		|O
was	1166	1169		|O
no	1170	1172		|O
change	1173	1179		|O
in	1180	1182		|O
episodic	1183	1191		|O
memory	1192	1198		|O
performance	1199	1210		|O
following	1211	1220		|O
the	1221	1224		|O
placebo	1225	1232		|O
injections	1233	1243		|O
.	1243	1244		|O
There	1245	1250		|O
was	1251	1254		|O
also	1255	1259		|O
a	1260	1261		|O
significant	1262	1273		|O
difference	1274	1284		|O
between	1285	1292		|O
allopregnanolone	1293	1309		|O
and	1310	1313		|O
placebo	1314	1321		|O
postinjection	1322	1335		|O
episodic	1336	1344		|O
memory	1345	1351		|O
scores	1352	1358		|O
(	1359	1360		|O
p	1360	1361		|O
<	1362	1363		|O
0.05	1364	1368		|O
)	1368	1369		|O
.	1369	1370		|O
There	1371	1376		|O
were	1377	1381		|O
no	1382	1384		|O
effects	1385	1392		|O
of	1393	1395		|O
allopregnanolone	1396	1412		|O
on	1413	1415		|O
the	1416	1419		|O
semantic	1420	1428		|O
memory	1429	1435		|O
task	1436	1440		|O
or	1441	1443		|O
working	1444	1451		|O
memory	1452	1458		|O
task	1459	1463		|O
.	1463	1464		|O
CONCLUSION	1465	1475		|O
:	1475	1476		|O
Intravenous	1477	1488		|O
allopregnanolone	1489	1505		|O
impairs	1506	1513		|O
episodic	1514	1522		|O
memory	1523	1529		|O
in	1530	1532		|O
healthy	1533	1540		|O
women	1541	1546		|O
,	1546	1547		|O
but	1548	1551		|O
there	1552	1557		|O
is	1558	1560		|O
a	1561	1562		|O
high	1563	1567		|O
degree	1568	1574		|O
of	1575	1577		|O
individual	1578	1588		|O
variability	1589	1600		|O
.	1600	1601		|O

### 18623382
Optimizing	0	10		|O
docetaxel	11	20		|O
chemotherapy	21	33		|O
in	34	36		|O
patients	37	45		|O
with	46	50		|O
cancer	51	57	cancer of the gastric and gastroesophageal junction	|B-DISEASE
of	58	60		|I-DISEASE
the	61	64		|I-DISEASE
gastric	65	72		|I-DISEASE
and	73	76		|I-DISEASE
gastroesophageal	77	93		|I-DISEASE
junction	94	102		|I-DISEASE
:	102	103		|O
evolution	104	113		|O
of	114	116		|O
the	117	120		|O
docetaxel	121	130		|O
,	130	131		|O
cisplatin	132	141		|O
,	141	142		|O
and	143	146		|O
5	147	148		|O
-	148	149		|O
fluorouracil	149	161		|O
regimen	162	169		|O
.	169	170		|O
Advanced	172	180		|O
gastroesophageal	181	197	gastroesophageal cancer	|B-DISEASE
cancer	198	204		|I-DISEASE
patients	205	213		|O
are	214	217		|O
often	218	223		|O
treated	224	231		|O
with	232	236		|O
systemic	237	245		|O
combination	246	257		|O
chemotherapy	258	270		|O
.	270	271		|O
The	272	275		|O
V	276	277		|O
-	277	278		|O
325	278	281		|O
study	282	287		|O
demonstrated	288	300		|O
that	301	305		|O
adding	306	312		|O
docetaxel	313	322		|O
(	323	324		|O
D	324	325		|O
)	325	326		|O
to	327	329		|O
a	330	331		|O
frequently	332	342		|O
used	343	347		|O
regimen	348	355		|O
of	356	358		|O
cisplatin	359	368		|O
and	369	372		|O
5	373	374		|O
-	374	375		|O
fluorouracil	375	387		|O
(	388	389		|O
CF	389	391		|O
)	391	392		|O
provided	393	401		|O
benefits	402	410		|O
with	411	415		|O
regard	416	422		|O
to	423	425		|O
overall	426	433		|O
survival	434	442		|O
,	442	443		|O
response	444	452		|O
rate	453	457		|O
,	457	458		|O
time	459	463		|O
-	463	464		|O
to	464	466		|O
-	466	467		|O
disease	467	474		|O
progression	475	486		|O
,	486	487		|O
clinical	488	496		|O
benefit	497	504		|O
,	504	505		|O
and	506	509		|O
health	510	516		|O
-	516	517		|O
related	517	524		|O
quality	525	532		|O
of	533	535		|O
life	536	540		|O
.	540	541		|O
Although	542	550		|O
the	551	554		|O
DCF	555	558		|O
regimen	559	566		|O
provides	567	575		|O
these	576	581		|O
advantages	582	592		|O
,	592	593		|O
it	594	596		|O
is	597	599		|O
accompanied	600	611		|O
by	612	614		|O
an	615	617		|O
increase	618	626		|O
in	627	629		|O
toxicity	630	638		|O
compared	639	647		|O
with	648	652		|O
the	653	656		|O
doublet	657	664		|O
regimen	665	672		|O
.	672	673		|O
The	674	677		|O
toxicity	678	686		|O
profile	687	694		|O
of	695	697		|O
DCF	698	701		|O
is	702	704		|O
acceptable	705	715		|O
only	716	720		|O
with	721	725		|O
appropriately	726	739		|O
selected	740	748		|O
patients	749	757		|O
and	758	761		|O
comprehensive	762	775		|O
toxicity	776	784		|O
management	785	795		|O
strategies	796	806		|O
.	806	807		|O
The	808	811		|O
objective	812	821		|O
of	822	824		|O
the	825	828		|O
current	829	836		|O
review	837	843		|O
was	844	847		|O
to	848	850		|O
identify	851	859		|O
trials	860	866		|O
that	867	871		|O
investigated	872	884		|O
modifications	885	898		|O
to	899	901		|O
the	902	905		|O
original	906	914		|O
DCF	915	918		|O
regimen	919	926		|O
to	927	929		|O
improve	930	937		|O
its	938	941		|O
toxicity	942	950		|O
profile	951	958		|O
and	959	962		|O
summarize	963	972		|O
response	973	981		|O
rate	982	986		|O
and	987	990		|O
toxicities	991	1001		|O
.	1001	1002		|O
An	1003	1005		|O
attempt	1006	1013		|O
was	1014	1017		|O
also	1018	1022		|O
made	1023	1027		|O
to	1028	1030		|O
summarize	1031	1040		|O
ongoing	1041	1048		|O
modifications	1049	1062		|O
of	1063	1065		|O
the	1066	1069		|O
DCF	1070	1073		|O
regimen	1074	1081		|O
.	1081	1082		|O
MEDLINE	1083	1090		|O
,	1090	1091		|O
major	1092	1097		|O
meeting	1098	1105		|O
proceedings	1106	1117		|O
,	1117	1118		|O
and	1119	1122		|O
the	1123	1126		|O
government	1127	1137		|O
clinical	1138	1146		|O
trials	1147	1153		|O
website	1154	1161		|O
were	1162	1166		|O
searched	1167	1175		|O
until	1176	1181		|O
2007	1182	1186		|O
.	1186	1187		|O
The	1188	1191		|O
modified	1192	1200		|O
DCF	1201	1204		|O
regimens	1205	1213		|O
appear	1214	1220		|O
to	1221	1223		|O
improve	1224	1231		|O
the	1232	1235		|O
toxicity	1236	1244		|O
profile	1245	1252		|O
when	1253	1257		|O
compared	1258	1266		|O
with	1267	1271		|O
the	1272	1275		|O
original	1276	1284		|O
DCF	1285	1288		|O
regimen	1289	1296		|O
.	1296	1297		|O
The	1298	1301		|O
docetaxel	1302	1311		|O
-	1311	1312		|O
based	1312	1317		|O
triplet	1318	1325		|O
combinations	1326	1338		|O
appear	1339	1345		|O
to	1346	1348		|O
have	1349	1353		|O
a	1354	1355		|O
higher	1356	1362		|O
response	1363	1371		|O
rate	1372	1376		|O
than	1377	1381		|O
the	1382	1385		|O
doublet	1386	1393		|O
combinations	1394	1406		|O
.	1406	1407		|O
Many	1408	1412		|O
institutions	1413	1425		|O
and	1426	1429		|O
cooperative	1430	1441		|O
groups	1442	1448		|O
continue	1449	1457		|O
to	1458	1460		|O
study	1461	1466		|O
docetaxel	1467	1476		|O
-	1476	1477		|O
based	1477	1482		|O
modifications	1483	1496		|O
of	1497	1499		|O
the	1500	1503		|O
DCF	1504	1507		|O
regimen	1508	1515		|O
to	1516	1518		|O
treat	1519	1524		|O
patients	1525	1533		|O
with	1534	1538		|O
gastroesophageal	1539	1555	gastroesophageal carcinoma	|B-DISEASE
carcinoma	1556	1565		|I-DISEASE
.	1565	1566		|O
However	1567	1574		|O
,	1574	1575		|O
although	1576	1584		|O
modified	1585	1593		|O
DCF	1594	1597		|O
reduces	1598	1605		|O
the	1606	1609		|O
frequency	1610	1619		|O
of	1620	1622		|O
severe	1623	1629		|O
toxicities	1630	1640		|O
previously	1641	1651		|O
reported	1652	1660		|O
with	1661	1665		|O
DCF	1666	1669		|O
,	1669	1670		|O
considerably	1671	1683		|O
more	1684	1688		|O
advances	1689	1697		|O
are	1698	1701		|O
needed	1702	1708		|O
to	1709	1711		|O
improve	1712	1719		|O
the	1720	1723		|O
safety	1724	1730		|O
,	1730	1731		|O
survival	1732	1740		|O
,	1740	1741		|O
and	1742	1745		|O
convenience	1746	1757		|O
of	1758	1760		|O
patients	1761	1769		|O
with	1770	1774		|O
advanced	1775	1783		|O
gastroesophageal	1784	1800	gastroesophageal cancer	|B-DISEASE
cancer	1801	1807		|I-DISEASE
.	1807	1808		|O

### 18710631
Multicenter	0	11		|O
clinical	12	20		|O
study	21	26		|O
on	27	29		|O
the	30	33		|O
efficacy	34	42		|O
and	43	46		|O
safety	47	53		|O
of	54	56		|O
inhalable	57	66		|O
insulin	67	74		|O
aerosol	75	82		|O
in	83	85		|O
the	86	89		|O
treatment	90	99		|O
of	100	102		|O
type	103	107	type 2 diabetes	|B-DISEASE
2	108	109		|I-DISEASE
diabetes	110	118		|I-DISEASE
.	118	119		|O
BACKGROUND	121	131		|O
:	131	132		|O
A	133	134		|O
new	135	138		|O
inhalable	139	148		|O
insulin	149	156		|O
aerosol	157	164		|O
(	165	166		|O
Inh	166	169		|O
-	169	170		|O
Ins	170	173		|O
)	173	174		|O
was	175	178		|O
developed	179	188		|O
in	189	191		|O
China	192	197		|O
.	197	198		|O
The	199	202		|O
aim	203	206		|O
of	207	209		|O
this	210	214		|O
multicenter	215	226		|O
clinical	227	235		|O
study	236	241		|O
was	242	245		|O
to	246	248		|O
evaluate	249	257		|O
the	258	261		|O
efficacy	262	270		|O
and	271	274		|O
safety	275	281		|O
of	282	284		|O
this	285	289		|O
new	290	293		|O
Inh	294	297		|O
-	297	298		|O
Ins	298	301		|O
as	302	304		|O
a	305	306		|O
treatment	307	316		|O
of	317	319		|O
type	320	324	type 2 diabetes	|B-DISEASE
2	325	326		|I-DISEASE
diabetes	327	335		|I-DISEASE
.	335	336		|O
Regular	337	344		|O
porcine	345	352		|O
insulin	353	360		|O
(	361	362		|O
RI	362	364		|O
)	364	365		|O
was	366	369		|O
used	370	374		|O
as	375	377		|O
a	378	379		|O
control	380	387		|O
.	387	388		|O
METHODS	389	396		|O
:	396	397		|O
This	398	402		|O
study	403	408		|O
is	409	411		|O
a	412	413		|O
prospective	414	425		|O
,	425	426		|O
randomized	427	437		|O
,	437	438		|O
open	439	443		|O
-	443	444		|O
label	444	449		|O
,	449	450		|O
parallel	451	459		|O
-	459	460		|O
group	460	465		|O
multicenter	466	477		|O
clinical	478	486		|O
trial	487	492		|O
in	493	495		|O
which	496	501		|O
253	502	505		|O
qualified	506	515		|O
patients	516	524		|O
with	525	529		|O
type	530	534	type 2 diabetes	|B-DISEASE
2	535	536		|I-DISEASE
diabetes	537	545		|I-DISEASE
received	546	554		|O
the	555	558		|O
insulin	559	566		|O
Glargine	567	575		|O
daily	576	581		|O
at	582	584		|O
bedtime	585	592		|O
plus	593	597		|O
either	598	604		|O
a	605	606		|O
pre	607	610		|O
-	610	611		|O
meal	611	615		|O
Inh	616	619		|O
-	619	620		|O
Ins	620	623		|O
or	624	626		|O
a	627	628		|O
pre	629	632		|O
-	632	633		|O
meal	633	637		|O
subcutaneous	638	650		|O
RI	651	653		|O
for	654	657		|O
12	658	660		|O
weeks	661	666		|O
.	666	667		|O
HbA1c	668	673		|O
,	673	674		|O
fasting	675	682		|O
plasma	683	689		|O
glucose	690	697		|O
(	698	699		|O
FPG	699	702		|O
)	702	703		|O
,	703	704		|O
the	705	708		|O
1	709	710		|O
-	710	711		|O
hour	711	715		|O
-	715	716		|O
postprandial	716	728		|O
blood	729	734		|O
glucose	735	742		|O
(	743	744		|O
1hPBG	744	749		|O
)	749	750		|O
and	751	754		|O
the	755	758		|O
2	759	760		|O
-	760	761		|O
hour	761	765		|O
-	765	766		|O
postprandial	766	778		|O
blood	779	784		|O
glucose	785	792		|O
(	793	794		|O
2hPBG	794	799		|O
)	799	800		|O
were	801	805		|O
measured	806	814		|O
.	814	815		|O
Events	816	822		|O
were	823	827		|O
monitored	828	837		|O
for	838	841		|O
adverse	842	849		|O
effects	850	857		|O
.	857	858		|O
RESULTS	859	866		|O
:	866	867		|O
After	868	873		|O
12	874	876		|O
weeks	877	882		|O
,	882	883		|O
the	884	887		|O
HbA1c	888	893		|O
decreased	894	903		|O
significantly	904	917		|O
from	918	922		|O
baseline	923	931		|O
in	932	934		|O
both	935	939		|O
treatment	940	949		|O
groups	950	956		|O
,	956	957		|O
with	958	962		|O
no	963	965		|O
significant	966	977		|O
difference	978	988		|O
between	989	996		|O
the	997	1000		|O
two	1001	1004		|O
regimens	1005	1013		|O
.	1013	1014		|O
In	1015	1017		|O
the	1018	1021		|O
Inh	1022	1025		|O
-	1025	1026		|O
Ins	1026	1029		|O
group	1030	1035		|O
,	1035	1036		|O
FPG	1037	1040		|O
,	1040	1041		|O
both	1042	1046		|O
1hPBG	1047	1052		|O
and	1053	1056		|O
2hPBG	1057	1062		|O
significantly	1063	1076		|O
declined	1077	1085		|O
from	1086	1090		|O
baseline	1091	1099		|O
after	1100	1105		|O
the	1106	1109		|O
8th	1110	1113		|O
-	1113	1114		|O
and	1115	1118		|O
12th	1119	1123		|O
-	1123	1124		|O
weeks	1124	1129		|O
of	1130	1132		|O
treatment	1133	1142		|O
.	1142	1143		|O
The	1144	1147		|O
reduced	1148	1155		|O
values	1156	1162		|O
of	1163	1165		|O
FPG	1166	1169		|O
or	1170	1172		|O
1hPBG	1173	1178		|O
between	1179	1186		|O
the	1187	1190		|O
two	1191	1194		|O
groups	1195	1201		|O
showed	1202	1208		|O
a	1209	1210		|O
more	1211	1215		|O
significant	1216	1227		|O
hypoglycemic	1228	1240		|O
effect	1241	1247		|O
with	1248	1252		|O
the	1253	1256		|O
Inh	1257	1260		|O
-	1260	1261		|O
Ins	1261	1264		|O
than	1265	1269		|O
the	1270	1273		|O
RI	1274	1276		|O
.	1276	1277		|O
After	1278	1283		|O
12	1284	1286		|O
weeks	1287	1292		|O
,	1292	1293		|O
the	1294	1297		|O
pulmonary	1298	1307		|O
carbon	1308	1314		|O
monoxide	1315	1323		|O
diffusing	1324	1333		|O
capacity	1334	1342		|O
(	1343	1344		|O
DLco	1344	1348		|O
)	1348	1349		|O
was	1350	1353		|O
significantly	1354	1367		|O
lower	1368	1373		|O
in	1374	1376		|O
Inh	1377	1380		|O
-	1380	1381		|O
Ins	1381	1384		|O
group	1385	1390		|O
than	1391	1395		|O
in	1396	1398		|O
the	1399	1402		|O
RI	1403	1405		|O
.	1405	1406		|O
The	1407	1410		|O
main	1411	1415		|O
side	1416	1420		|O
effects	1421	1428		|O
of	1429	1431		|O
Inh	1432	1435		|O
-	1435	1436		|O
Ins	1436	1439		|O
were	1440	1444		|O
coughing	1445	1453	coughing	|B-ADVERSE
,	1453	1454		|O
excessive	1455	1464	excessive sputum	|B-ADVERSE
sputum	1465	1471		|I-ADVERSE
,	1471	1472		|O
and	1473	1476		|O
hypoglycemia	1477	1489	hypoglycemia	|B-ADVERSE
.	1489	1490		|O
CONCLUSIONS	1491	1502		|O
:	1502	1503		|O
Inh	1504	1507		|O
-	1507	1508		|O
Ins	1508	1511		|O
was	1512	1515		|O
effective	1516	1525		|O
in	1526	1528		|O
decreasing	1529	1539		|O
HbA1c	1540	1545		|O
like	1546	1550		|O
the	1551	1554		|O
RI	1555	1557		|O
.	1557	1558		|O
It	1559	1561		|O
was	1562	1565		|O
better	1566	1572		|O
in	1573	1575		|O
lowering	1576	1584		|O
the	1585	1588		|O
FPG	1589	1592		|O
and	1593	1596		|O
the	1597	1600		|O
1hPBG	1601	1606		|O
than	1607	1611		|O
the	1612	1615		|O
RI	1616	1618		|O
.	1618	1619		|O
Its	1620	1623		|O
main	1624	1628		|O
side	1629	1633		|O
effects	1634	1641		|O
were	1642	1646		|O
coughing	1647	1655	coughing	|B-ADVERSE
,	1655	1656		|O
excessive	1657	1666	excessive sputum	|B-ADVERSE
sputum	1667	1673		|I-ADVERSE
,	1673	1674		|O
and	1675	1678		|O
hypoglycemia	1679	1691	hypoglycemia	|B-ADVERSE
.	1691	1692		|O
Also	1693	1697		|O
,	1697	1698		|O
Inh	1699	1702		|O
-	1702	1703		|O
Ins	1703	1706		|O
slightly	1707	1715		|O
impaired	1716	1724		|O
DLco	1725	1729		|O
.	1729	1730		|O

### 18619950
Inhibition	0	10		|O
of	11	13		|O
cell	14	18		|O
-	18	19		|O
cycle	19	24		|O
progression	25	36		|O
in	37	39		|O
human	40	45		|O
colorectal	46	56		|O
carcinoma	57	66		|O
Lovo	67	71		|O
cells	72	77		|O
by	78	80		|O
andrographolide	81	96		|O
.	96	97		|O
In	99	101		|O
recent	102	108		|O
years	109	114		|O
,	114	115		|O
attention	116	125		|O
has	126	129		|O
been	130	134		|O
focused	135	142		|O
on	143	145		|O
the	146	149		|O
anti	150	154		|O
-	154	155		|O
cancer	155	161		|O
properties	162	172		|O
of	173	175		|O
pure	176	180		|O
components	181	191		|O
,	191	192		|O
an	193	195		|O
important	196	205		|O
role	206	210		|O
in	211	213		|O
the	214	217		|O
prevention	218	228		|O
of	229	231		|O
disease	232	239		|O
.	239	240		|O
Andrographolide	241	256		|O
(	257	258		|O
Andro	258	263		|O
)	263	264		|O
,	264	265		|O
the	266	269		|O
major	270	275		|O
constituent	276	287		|O
of	288	290		|O
Andrographis	291	303		|O
paniculata	304	314		|O
(	315	316		|O
Burm	316	320		|O
.	320	321		|O
F	322	323		|O
.	323	324		|O
)	324	325		|O
Nees	326	330		|O
plant	331	336		|O
,	336	337		|O
is	338	340		|O
implicated	341	351		|O
towards	352	359		|O
its	360	363		|O
pharmacological	364	379		|O
activity	380	388		|O
.	388	389		|O
To	390	392		|O
investigate	393	404		|O
the	405	408		|O
mechanism	409	418		|O
basis	419	424		|O
for	425	428		|O
the	429	432		|O
anti	433	437		|O
-	437	438		|O
tumor	438	443		|O
properties	444	454		|O
of	455	457		|O
Andro	458	463		|O
,	463	464		|O
Andro	465	470		|O
was	471	474		|O
used	475	479		|O
to	480	482		|O
examine	483	490		|O
its	491	494		|O
effect	495	501		|O
on	502	504		|O
cell	505	509		|O
-	509	510		|O
cycle	510	515		|O
progression	516	527		|O
in	528	530		|O
human	531	536		|O
colorectal	537	547		|O
carcinoma	548	557		|O
Lovo	558	562		|O
cells	563	568		|O
.	568	569		|O
The	570	573		|O
data	574	578		|O
from	579	583		|O
cell	584	588		|O
growth	589	595		|O
experiment	596	606		|O
showed	607	613		|O
that	614	618		|O
Andro	619	624		|O
exhibited	625	634		|O
the	635	638		|O
anti	639	643		|O
-	643	644		|O
proliferation	644	657		|O
effect	658	664		|O
on	665	667		|O
Lovo	668	672		|O
cells	673	678		|O
in	679	681		|O
a	682	683		|O
time	684	688		|O
-	688	689		|O
and	690	693		|O
dose	694	698		|O
-	698	699		|O
dependent	699	708		|O
manner	709	715		|O
.	715	716		|O
This	717	721		|O
event	722	727		|O
was	728	731		|O
accompanied	732	743		|O
the	744	747		|O
arrest	748	754		|O
of	755	757		|O
the	758	761		|O
cells	762	767		|O
at	768	770		|O
the	771	774		|O
G1	775	777		|O
-	777	778		|O
S	778	779		|O
phase	780	785		|O
by	786	788		|O
Andro	789	794		|O
at	795	797		|O
the	798	801		|O
tested	802	808		|O
concentrations	809	823		|O
of	824	826		|O
0-30	827	831		|O
microM	832	838		|O
.	838	839		|O
Cellular	840	848		|O
uptake	849	855		|O
of	856	858		|O
Andro	859	864		|O
and	865	868		|O
Andro	869	874		|O
was	875	878		|O
confirmed	879	888		|O
by	889	891		|O
capillary	892	901		|O
electrophoresis	902	917		|O
analysis	918	926		|O
and	927	930		|O
the	931	934		|O
intracellular	935	948		|O
accumulation	949	961		|O
of	962	964		|O
Andro	965	970		|O
(	971	972		|O
0.61	972	976		|O
+	976	977		|O
/	977	978		|O
-	978	979		|O
0.07	979	983		|O
microM	984	990		|O
/	990	991		|O
mg	991	993		|O
protein	994	1001		|O
)	1001	1002		|O
was	1003	1006		|O
observed	1007	1015		|O
when	1016	1020		|O
treatment	1021	1030		|O
of	1031	1033		|O
Lovo	1034	1038		|O
cells	1039	1044		|O
with	1045	1049		|O
Andro	1050	1055		|O
for	1056	1059		|O
12h	1060	1063		|O
.	1063	1064		|O
In	1065	1067		|O
addition	1068	1076		|O
,	1076	1077		|O
an	1078	1080		|O
accumulation	1081	1093		|O
of	1094	1096		|O
the	1097	1100		|O
cells	1101	1106		|O
in	1107	1109		|O
G1	1110	1112		|O
phase	1113	1118		|O
(	1119	1120		|O
15%	1120	1123		|O
increase	1124	1132		|O
for	1133	1136		|O
10	1137	1139		|O
microM	1140	1146		|O
of	1147	1149		|O
Andro	1150	1155		|O
)	1155	1156		|O
was	1157	1160		|O
observed	1161	1169		|O
as	1170	1172		|O
well	1173	1177		|O
as	1178	1180		|O
by	1181	1183		|O
the	1184	1187		|O
association	1188	1199		|O
with	1200	1204		|O
a	1205	1206		|O
marked	1207	1213		|O
decrease	1214	1222		|O
in	1223	1225		|O
the	1226	1229		|O
protein	1230	1237		|O
expression	1238	1248		|O
of	1249	1251		|O
Cyclin	1252	1258		|O
A	1259	1260		|O
,	1260	1261		|O
Cyclin	1262	1268		|O
D1	1269	1271		|O
,	1271	1272		|O
Cdk2	1273	1277		|O
and	1278	1281		|O
Cdk4	1282	1286		|O
.	1286	1287		|O
Andro	1288	1293		|O
also	1294	1298		|O
inducted	1299	1307		|O
the	1308	1311		|O
content	1312	1319		|O
of	1320	1322		|O
Cdk	1323	1326		|O
inhibitor	1327	1336		|O
p21	1337	1340		|O
and	1341	1344		|O
p16	1345	1348		|O
,	1348	1349		|O
and	1350	1353		|O
the	1354	1357		|O
phosphorylation	1358	1373		|O
of	1374	1376		|O
p53	1377	1380		|O
.	1380	1381		|O
Further	1382	1389		|O
immunoprecipitation	1390	1409		|O
studies	1410	1417		|O
found	1418	1423		|O
that	1424	1428		|O
,	1428	1429		|O
in	1430	1432		|O
response	1433	1441		|O
to	1442	1444		|O
the	1445	1448		|O
treatment	1449	1458		|O
,	1458	1459		|O
the	1460	1463		|O
formation	1464	1473		|O
of	1474	1476		|O
Cyclin	1477	1483		|O
D1	1484	1486		|O
/	1486	1487		|O
Cdk4	1487	1491		|O
and	1492	1495		|O
Cyclin	1496	1502		|O
A	1503	1504		|O
/	1504	1505		|O
Cdk2	1505	1509		|O
complexes	1510	1519		|O
had	1520	1523		|O
declined	1524	1532		|O
,	1532	1533		|O
preventing	1534	1544		|O
the	1545	1548		|O
phosphorylation	1549	1564		|O
of	1565	1567		|O
Rb	1568	1570		|O
and	1571	1574		|O
the	1575	1578		|O
subsequent	1579	1589		|O
dissociation	1590	1602		|O
of	1603	1605		|O
Rb	1606	1608		|O
/	1608	1609		|O
E2F	1609	1612		|O
complex	1613	1620		|O
.	1620	1621		|O
These	1622	1627		|O
results	1628	1635		|O
suggested	1636	1645		|O
Andro	1646	1651		|O
can	1652	1655		|O
inhibit	1656	1663		|O
Lovo	1664	1668		|O
cell	1669	1673		|O
growth	1674	1680		|O
by	1681	1683		|O
G1	1684	1686		|O
-	1686	1687		|O
S	1687	1688		|O
phase	1689	1694		|O
arrest	1695	1701		|O
,	1701	1702		|O
and	1703	1706		|O
was	1707	1710		|O
exerted	1711	1718		|O
by	1719	1721		|O
inducing	1722	1730		|O
the	1731	1734		|O
expression	1735	1745		|O
of	1746	1748		|O
p53	1749	1752		|O
,	1752	1753		|O
p21	1754	1757		|O
and	1758	1761		|O
p16	1762	1765		|O
that	1766	1770		|O
,	1770	1771		|O
in	1772	1774		|O
turn	1775	1779		|O
,	1779	1780		|O
repressed	1781	1790		|O
the	1791	1794		|O
activity	1795	1803		|O
of	1804	1806		|O
Cyclin	1807	1813		|O
D1	1814	1816		|O
/	1816	1817		|O
Cdk4	1817	1821		|O
and	1822	1825		|O
/	1825	1826		|O
or	1826	1828		|O
Cyclin	1829	1835		|O
A	1836	1837		|O
/	1837	1838		|O
Cdk2	1838	1842		|O
,	1842	1843		|O
as	1844	1846		|O
well	1847	1851		|O
as	1852	1854		|O
Rb	1855	1857		|O
phosphorylation	1858	1873		|O
.	1873	1874		|O

### 18760317
INN	0	3		|O
-	3	4		|O
toxin	4	9		|O
,	9	10		|O
a	11	12		|O
highly	13	19		|O
lethal	20	26		|O
peptide	27	34		|O
from	35	39		|O
the	40	43		|O
venom	44	49		|O
of	50	52		|O
Indian	53	59		|O
cobra	60	65		|O
(	66	67		|O
Naja	67	71		|O
naja	72	76		|O
)	76	77		|O
venom	78	83		|O
-	83	84		|O
Isolation	84	93		|O
,	93	94		|O
characterization	95	111		|O
and	112	115		|O
pharmacological	116	131		|O
actions	132	139		|O
.	139	140		|O
A	142	143		|O
novel	144	149		|O
toxic	150	155		|O
polypeptide	156	167		|O
,	167	168		|O
INN	169	172		|O
-	172	173		|O
toxin	173	178		|O
,	178	179		|O
is	180	182		|O
purified	183	191		|O
from	192	196		|O
the	197	200		|O
venom	201	206		|O
of	207	209		|O
Naja	210	214		|O
naja	215	219		|O
using	220	225		|O
combination	226	237		|O
of	238	240		|O
gel	241	244		|O
-	244	245		|O
permeation	245	255		|O
and	256	259		|O
ion	260	263		|O
-	263	264		|O
exchange	264	272		|O
chromatography	273	287		|O
.	287	288		|O
It	289	291		|O
has	292	295		|O
a	296	297		|O
molecular	298	307		|O
mass	308	312		|O
of	313	315		|O
6951.6	316	322		|O
Da	322	324		|O
as	325	327		|O
determined	328	338		|O
by	339	341		|O
MALDI	342	347		|O
-	347	348		|O
TOF	348	351		|O
/	351	352		|O
MS	352	354		|O
and	355	358		|O
the	359	362		|O
N	363	364		|O
-	364	365		|O
terminal	365	373		|O
sequence	374	382		|O
of	383	385		|O
LKXNKLVPLF	386	396		|O
.	396	397		|O
It	398	400		|O
showed	401	407		|O
both	408	412		|O
neurotoxic	413	423		|O
as	424	426		|O
well	427	431		|O
as	432	434		|O
cytotoxic	435	444	cytotoxic activities	|B-ADVERSE
activities	445	455		|I-ADVERSE
.	455	456		|O
INN	457	460		|O
-	460	461		|O
toxin	461	466		|O
is	467	469		|O
lethal	470	476		|O
to	477	479		|O
mice	480	484		|O
with	485	489		|O
a	490	491		|O
LD	492	494		|O
(	494	495		|O
50	495	497		|O
)	497	498		|O
of	499	501		|O
1.2	502	505		|O
mg	505	507		|O
/	507	508		|O
kg	508	510		|O
body	511	515		|O
weight	516	522		|O
.	522	523		|O
IgY	524	527		|O
raised	528	534		|O
in	535	537		|O
chicks	538	544		|O
against	545	552		|O
basic	553	558		|O
peptide	559	566		|O
pool	567	571		|O
neutralized	572	583		|O
the	584	587		|O
toxicity	588	596		|O
of	597	599		|O
INN	600	603		|O
-	603	604		|O
toxin	604	609		|O
.	609	610		|O
INN	611	614		|O
-	614	615		|O
toxin	615	620		|O
did	621	624		|O
not	625	628		|O
inhibit	629	636		|O
cholinesterase	637	651		|O
activity	652	660		|O
.	660	661		|O
It	662	664		|O
is	665	667		|O
toxic	668	673		|O
to	674	676		|O
Ehrlich	677	684		|O
ascites	685	692		|O
tumor	693	698		|O
(	699	700		|O
EAT	700	703		|O
)	703	704		|O
cells	705	710		|O
,	710	711		|O
but	712	715		|O
it	716	718		|O
is	719	721		|O
not	722	725		|O
toxic	726	731		|O
to	732	734		|O
leukocyte	735	744		|O
culture	745	752		|O
.	752	753		|O
The	754	757		|O
toxin	758	763		|O
appears	764	771		|O
to	772	774		|O
be	775	777		|O
specific	778	786		|O
in	787	789		|O
its	790	793		|O
mode	794	798		|O
of	799	801		|O
action	802	808		|O
.	808	809		|O
Interaction	810	821		|O
of	822	824		|O
N	825	826		|O
-	826	827		|O
bromosuccinamide	827	843		|O
(	844	845		|O
NBS	845	848		|O
)	848	849		|O
with	850	854		|O
the	855	858		|O
peptide	859	866		|O
resulted	867	875		|O
in	876	878		|O
the	879	882		|O
modification	883	895		|O
of	896	898		|O
tryptophan	899	909		|O
residues	910	918		|O
and	919	922		|O
loss	923	927		|O
of	928	930		|O
lethal	931	937		|O
toxicity	938	946		|O
of	947	949		|O
INN	950	953		|O
-	953	954		|O
toxin	954	959		|O
.	959	960		|O

### 18591554
Doxorubicin	0	11		|O
,	11	12		|O
cardiac	13	20		|O
risk	21	25		|O
factors	26	33		|O
,	33	34		|O
and	35	38		|O
cardiac	39	46	cardiac toxicity	|B-ADVERSE
toxicity	47	55		|I-ADVERSE
in	56	58		|O
elderly	59	66		|O
patients	67	75		|O
with	76	80		|O
diffuse	81	88		|O
B	89	90	B-cell non-Hodgkin's lymphoma	|B-DISEASE
-	90	91		|I-DISEASE
cell	91	95		|I-DISEASE
non	96	99		|I-DISEASE
-	99	100		|I-DISEASE
Hodgkin	100	107		|I-DISEASE
's	107	109		|I-DISEASE
lymphoma	110	118		|I-DISEASE
.	118	119		|O
PURPOSE	121	128		|O
:	128	129		|O
Anthracycline	130	143		|O
-	143	144		|O
based	144	149		|O
chemotherapy	150	162		|O
,	162	163		|O
which	164	169		|O
improves	170	178		|O
survival	179	187		|O
for	188	191		|O
patients	192	200		|O
with	201	205		|O
non	206	209	non-Hodgkin's lymphoma	|B-DISEASE
-	209	210		|I-DISEASE
Hodgkin	210	217		|I-DISEASE
's	217	219		|I-DISEASE
lymphoma	220	228		|I-DISEASE
,	228	229		|O
is	230	232		|O
often	233	238		|O
withheld	239	247		|O
from	248	252		|O
elderly	253	260		|O
patients	261	269		|O
because	270	277		|O
of	278	280		|O
its	281	284		|O
cardiotoxicity	285	299	cardiotoxicity	|B-ADVERSE
.	299	300		|O
We	301	303		|O
studied	304	311		|O
the	312	315		|O
cardiac	316	323		|O
effects	324	331		|O
of	332	334		|O
doxorubicin	335	346		|O
in	347	349		|O
a	350	351		|O
population	352	362		|O
-	362	363		|O
based	363	368		|O
sample	369	375		|O
of	376	378		|O
older	379	384		|O
patients	385	393		|O
with	394	398		|O
diffuse	399	406	diffuse large B-cell lymphoma	|B-DISEASE
large	407	412		|I-DISEASE
B	413	414		|I-DISEASE
-	414	415		|I-DISEASE
cell	415	419		|I-DISEASE
lymphoma	420	428		|I-DISEASE
(	429	430		|O
DLBCL	430	435	DLBCL	|B-DISEASE
)	435	436		|O
.	436	437		|O
PATIENTS	438	446		|O
AND	447	450		|O
METHODS	451	458		|O
:	458	459		|O
Among	460	465		|O
patients	466	474		|O
age	475	478		|O
>	479	480		|O
or	481	483		|O
=	484	485		|O
65	486	488		|O
years	489	494		|O
diagnosed	495	504		|O
with	505	509		|O
DLBCL	510	515	DLBCL	|B-DISEASE
from	516	520		|O
1991	521	525		|O
to	526	528		|O
2002	529	533		|O
in	534	536		|O
the	537	540		|O
Surveillance	541	553		|O
,	553	554		|O
Epidemiology	555	567		|O
,	567	568		|O
and	569	572		|O
End	573	576		|O
Results	577	584		|O
-	584	585		|O
Medicare	585	593		|O
database	594	602		|O
,	602	603		|O
we	604	606		|O
developed	607	616		|O
logistic	617	625		|O
regression	626	636		|O
models	637	643		|O
of	644	646		|O
the	647	650		|O
associations	651	663		|O
of	664	666		|O
doxorubicin	667	678		|O
with	679	683		|O
demographic	684	695		|O
,	695	696		|O
clinical	697	705		|O
,	705	706		|O
and	707	710		|O
cardiac	711	718		|O
variables	719	728		|O
.	728	729		|O
We	730	732		|O
then	733	737		|O
developed	738	747		|O
Cox	748	751		|O
proportional	752	764		|O
hazards	765	772		|O
models	773	779		|O
of	780	782		|O
the	783	786		|O
association	787	798		|O
between	799	806		|O
doxorubicin	807	818		|O
and	819	822		|O
subsequent	823	833		|O
congestive	834	844	congestive heart failure	|B-ADVERSE
heart	845	850		|I-ADVERSE
failure	851	858		|I-ADVERSE
(	859	860		|O
CHF	860	863	CHF	|B-ADVERSE
)	863	864		|O
,	864	865		|O
taking	866	872		|O
predictors	873	883		|O
of	884	886		|O
CHF	887	890	CHF	|B-ADVERSE
into	891	895		|O
account	896	903		|O
.	903	904		|O
RESULTS	905	912		|O
:	912	913		|O
Of	914	916		|O
9,438	917	922		|O
patients	923	931		|O
with	932	936		|O
DLBCL	937	942	DLBCL	|B-DISEASE
,	942	943		|O
3,164	944	949		|O
(	950	951		|O
42%	951	954		|O
)	954	955		|O
received	956	964		|O
doxorubicin	965	976		|O
-	976	977		|O
based	977	982		|O
chemotherapy	983	995		|O
.	995	996		|O
Any	997	1000		|O
doxorubicin	1001	1012		|O
use	1013	1016		|O
was	1017	1020		|O
associated	1021	1031		|O
with	1032	1036		|O
a	1037	1038		|O
29%	1039	1042		|O
increase	1043	1051		|O
in	1052	1054		|O
risk	1055	1059		|O
of	1060	1062		|O
CHF	1063	1066	CHF	|B-ADVERSE
(	1067	1068		|O
95%	1068	1071		|O
CI	1072	1074		|O
,	1074	1075		|O
1.02	1076	1080		|O
to	1081	1083		|O
1.62	1084	1088		|O
)	1088	1089		|O
;	1089	1090		|O
CHF	1091	1094	CHF	|B-ADVERSE
risk	1095	1099		|O
increased	1100	1109		|O
with	1110	1114		|O
number	1115	1121		|O
of	1122	1124		|O
doxorubicin	1125	1136		|O
claims	1137	1143		|O
,	1143	1144		|O
increasing	1145	1155		|O
age	1156	1159		|O
,	1159	1160		|O
prior	1161	1166	prior heart disease	|B-ADVERSE
heart	1167	1172		|I-ADVERSE
disease	1173	1180		|I-ADVERSE
,	1180	1181		|O
comorbidities	1182	1195		|O
,	1195	1196		|O
diabetes	1197	1205	diabetes	|B-ADVERSE
,	1205	1206		|O
and	1207	1210		|O
hypertension	1211	1223	hypertension	|B-ADVERSE
;	1223	1224		|O
hypertension	1225	1237	hypertension	|B-ADVERSE
intensified	1238	1249		|O
the	1250	1253		|O
effect	1254	1260		|O
of	1261	1263		|O
doxorubicin	1264	1275		|O
on	1276	1278		|O
risk	1279	1283		|O
of	1284	1286		|O
CHF	1287	1290	CHF	|B-ADVERSE
(	1291	1292		|O
hazard	1292	1298		|O
ratio	1299	1304		|O
=	1305	1306		|O
1.8	1307	1310		|O
;	1310	1311		|O
P	1312	1313		|O
<	1314	1315		|O
.01	1316	1319		|O
)	1319	1320		|O
.	1320	1321		|O
In	1322	1324		|O
the	1325	1328		|O
8	1329	1330		|O
years	1331	1336		|O
after	1337	1342		|O
diagnosis	1343	1352		|O
,	1352	1353		|O
the	1354	1357		|O
adjusted	1358	1366		|O
CHF	1367	1370		|O
-	1370	1371		|O
free	1371	1375		|O
survival	1376	1384		|O
rate	1385	1389		|O
was	1390	1393		|O
74%	1394	1397		|O
in	1398	1400		|O
doxorubicin	1401	1412		|O
-	1412	1413		|O
treated	1413	1420		|O
patients	1421	1429		|O
versus	1430	1436		|O
79%	1437	1440		|O
in	1441	1443		|O
patients	1444	1452		|O
not	1453	1456		|O
treated	1457	1464		|O
with	1465	1469		|O
doxorubicin	1470	1481		|O
.	1481	1482		|O
CONCLUSION	1483	1493		|O
:	1493	1494		|O
Among	1495	1500		|O
patients	1501	1509		|O
receiving	1510	1519		|O
chemotherapy	1520	1532		|O
for	1533	1536		|O
DLBCL	1537	1542	DLBCL	|B-DISEASE
,	1542	1543		|O
those	1544	1549		|O
with	1550	1554		|O
prior	1555	1560	prior heart disease	|B-ADVERSE
heart	1561	1566		|I-ADVERSE
disease	1567	1574		|I-ADVERSE
were	1575	1579		|O
less	1580	1584		|O
likely	1585	1591		|O
than	1592	1596		|O
others	1597	1603		|O
to	1604	1606		|O
be	1607	1609		|O
treated	1610	1617		|O
with	1618	1622		|O
doxorubicin	1623	1634		|O
,	1634	1635		|O
and	1636	1639		|O
those	1640	1645		|O
who	1646	1649		|O
received	1650	1658		|O
doxorubicin	1659	1670		|O
were	1671	1675		|O
more	1676	1680		|O
likely	1681	1687		|O
than	1688	1692		|O
others	1693	1699		|O
to	1700	1702		|O
develop	1703	1710		|O
CHF	1711	1714	CHF	|B-ADVERSE
.	1714	1715		|O
Various	1716	1723		|O
cardiac	1724	1731		|O
risk	1732	1736		|O
factors	1737	1744		|O
increased	1745	1754		|O
CHF	1755	1758	CHF	|B-ADVERSE
risk	1759	1763		|O
,	1763	1764		|O
but	1765	1768		|O
only	1769	1773		|O
hypertension	1774	1786	hypertension	|B-ADVERSE
was	1787	1790		|O
synergistic	1791	1802		|O
with	1803	1807		|O
doxorubicin	1808	1819		|O
.	1819	1820		|O
Doxorubicin	1821	1832		|O
has	1833	1836		|O
dramatically	1837	1849		|O
improved	1850	1858		|O
survival	1859	1867		|O
of	1868	1870		|O
DLBCL	1871	1876	DLBCL	|B-DISEASE
patients	1877	1885		|O
;	1885	1886		|O
nonetheless	1887	1898		|O
,	1898	1899		|O
some	1900	1904		|O
subgroups	1905	1914		|O
may	1915	1918		|O
benefit	1919	1926		|O
from	1927	1931		|O
efforts	1932	1939		|O
to	1940	1942		|O
reduce	1943	1949		|O
doxorubicin	1950	1961		|O
-	1961	1962		|O
related	1962	1969		|O
CHF	1970	1973	CHF	|B-ADVERSE
risk	1974	1978		|O
.	1978	1979		|O

### 18690970
Safety	0	6		|O
of	7	9		|O
drug	10	14		|O
eluting	15	22		|O
stents	23	29		|O
:	29	30		|O
current	31	38		|O
concerns	39	47		|O
and	48	51		|O
controversies	52	65		|O
.	65	66		|O
Coronary	68	76		|O
artery	77	83		|O
stenting	84	92		|O
is	93	95		|O
currently	96	105		|O
the	106	109		|O
most	110	114		|O
frequently	115	125		|O
performed	126	135		|O
percutaneous	136	148		|O
coronary	149	157		|O
intervention	158	170		|O
for	171	174		|O
the	175	178		|O
treatment	179	188		|O
of	189	191		|O
coronary	192	200	coronary artery disease	|B-DISEASE
artery	201	207		|I-DISEASE
disease	208	215		|I-DISEASE
.	215	216		|O
Recently	217	225		|O
,	225	226		|O
drug	227	231		|O
-	231	232		|O
eluting	233	240		|O
stents	241	247		|O
,	247	248		|O
loaded	249	255		|O
with	256	260		|O
anti	261	265		|O
-	265	266		|O
inflammatory	266	278		|O
,	278	279		|O
anti	280	284		|O
-	284	285		|O
migratory	285	294		|O
,	294	295		|O
anti	296	300		|O
-	300	301		|O
proliferative	301	314		|O
or	315	317		|O
pro	318	321		|O
-	321	322		|O
healing	322	329		|O
drugs	330	335		|O
,	335	336		|O
have	337	341		|O
revolutionized	342	356		|O
the	357	360		|O
management	361	371		|O
of	372	374		|O
coronary	375	383	coronary artery disease	|B-DISEASE
artery	384	390		|I-DISEASE
disease	391	398		|I-DISEASE
by	399	401		|O
markedly	402	410		|O
reducing	411	419		|O
in	420	422		|O
-	422	423		|O
stent	423	428		|O
restenosis	429	439		|O
.	439	440		|O
Despite	441	448		|O
the	449	452		|O
excellent	453	462		|O
short	463	468		|O
-	468	469		|O
and	470	473		|O
mid	474	477		|O
-	477	478		|O
term	478	482		|O
results	483	490		|O
of	491	493		|O
randomized	494	504		|O
controlled	505	515		|O
trials	516	522		|O
observed	523	531		|O
with	532	536		|O
drug	537	541		|O
-	541	542		|O
eluting	542	549		|O
stents	550	556		|O
,	556	557		|O
there	558	563		|O
remain	564	570		|O
a	571	572		|O
number	573	579		|O
of	580	582		|O
unresolved	583	593		|O
issues	594	600		|O
and	601	604		|O
valid	605	610		|O
concerns	611	619		|O
about	620	625		|O
long	626	630		|O
-	630	631		|O
term	631	635		|O
safety	636	642		|O
and	643	646		|O
efficacy	647	655		|O
of	656	658		|O
this	659	663		|O
revolutionary	664	677		|O
technology	678	688		|O
.	688	689		|O
Important	690	699		|O
safety	700	706		|O
issues	707	713		|O
such	714	718		|O
as	719	721		|O
thrombosis	722	732	thrombosis	|B-ADVERSE
,	732	733		|O
late	734	738		|O
stent	739	744	stent malapposition	|B-ADVERSE
malapposition	745	758		|I-ADVERSE
,	758	759		|O
aneurysm	760	768	aneurysm	|B-ADVERSE
formation	769	778		|O
,	778	779		|O
edge	780	784	edge effect	|B-ADVERSE
effect	785	791		|I-ADVERSE
,	791	792		|O
late	793	797		|O
inflammation	798	810	inflammation	|B-ADVERSE
due	811	814		|O
to	815	817		|O
choice	818	824		|O
of	825	827		|O
polymer	828	835		|O
used	836	840		|O
to	841	843		|O
bind	844	848		|O
the	849	852		|O
drug	853	857		|O
,	857	858		|O
the	859	862		|O
release	863	870		|O
of	871	873		|O
toxins	874	880		|O
,	880	881		|O
and	882	885		|O
potential	886	895		|O
interactions	896	908		|O
with	909	913		|O
brachytherapy	914	927		|O
and	928	931		|O
drugs	932	937		|O
have	938	942		|O
not	943	946		|O
been	947	951		|O
completely	952	962		|O
addressed	963	972		|O
.	972	973		|O
This	974	978		|O
review	979	985		|O
article	986	993		|O
evaluates	994	1003		|O
current	1004	1011		|O
available	1012	1021		|O
scientific	1022	1032		|O
evidence	1033	1041		|O
on	1042	1044		|O
the	1045	1048		|O
various	1049	1056		|O
safety	1057	1063		|O
issues	1064	1070		|O
related	1071	1078		|O
to	1079	1081		|O
the	1082	1085		|O
use	1086	1089		|O
of	1090	1092		|O
drug	1093	1097		|O
-	1097	1098		|O
eluting	1098	1105		|O
stents	1106	1112		|O
.	1112	1113		|O

### 18597654
Pharmacogenetics	0	16		|O
of	17	19		|O
analgesics	20	30		|O
:	30	31		|O
toward	32	38		|O
the	39	42		|O
individualization	43	60		|O
of	61	63		|O
prescription	64	76		|O
.	76	77		|O
The	79	82		|O
use	83	86		|O
of	87	89		|O
analgesics	90	100		|O
is	101	103		|O
based	104	109		|O
on	110	112		|O
the	113	116		|O
empiric	117	124		|O
administration	125	139		|O
of	140	142		|O
a	143	144		|O
given	145	150		|O
drug	151	155		|O
with	156	160		|O
clinical	161	169		|O
monitoring	170	180		|O
for	181	184		|O
efficacy	185	193		|O
and	194	197		|O
toxicity	198	206		|O
.	206	207		|O
However	208	215		|O
,	215	216		|O
individual	217	227		|O
responses	228	237		|O
to	238	240		|O
drugs	241	246		|O
are	247	250		|O
influenced	251	261		|O
by	262	264		|O
a	265	266		|O
combination	267	278		|O
of	279	281		|O
pharmacokinetic	282	297		|O
and	298	301		|O
pharmacodynamic	302	317		|O
factors	318	325		|O
that	326	330		|O
can	331	334		|O
sometimes	335	344		|O
be	345	347		|O
regulated	348	357		|O
by	358	360		|O
genetic	361	368		|O
factors	369	376		|O
.	376	377		|O
Whereas	378	385		|O
polymorphic	386	397		|O
drug	398	402		|O
-	402	403		|O
metabolizing	403	415		|O
enzymes	416	423		|O
and	424	427		|O
drug	428	432		|O
transporters	433	445		|O
may	446	449		|O
affect	450	456		|O
the	457	460		|O
pharmacokinetics	461	477		|O
of	478	480		|O
drugs	481	486		|O
,	486	487		|O
polymorphic	488	499		|O
drug	500	504		|O
targets	505	512		|O
and	513	516		|O
disease	517	524		|O
-	524	525		|O
related	525	532		|O
pathways	533	541		|O
may	542	545		|O
influence	546	555		|O
the	556	559		|O
pharmacodynamic	560	575		|O
action	576	582		|O
of	583	585		|O
drugs	586	591		|O
.	591	592		|O
After	593	598		|O
a	599	600		|O
usual	601	606		|O
dose	607	611		|O
,	611	612		|O
variations	613	623		|O
in	624	626		|O
drug	627	631	drug toxicity	|B-ADVERSE
toxicity	632	640		|I-ADVERSE
and	641	644		|O
inefficacy	645	655		|O
can	656	659		|O
be	660	662		|O
observed	663	671		|O
depending	672	681		|O
on	682	684		|O
the	685	688		|O
polymorphism	689	701		|O
,	701	702		|O
the	703	706		|O
analgesic	707	716		|O
considered	717	727		|O
and	728	731		|O
the	732	735		|O
presence	736	744		|O
or	745	747		|O
absence	748	755		|O
of	756	758		|O
active	759	765		|O
metabolites	766	777		|O
.	777	778		|O
For	779	782		|O
opioids	783	790		|O
,	790	791		|O
the	792	795		|O
most	796	800		|O
studied	801	808		|O
being	809	814		|O
morphine	815	823		|O
,	823	824		|O
mutations	825	834		|O
in	835	837		|O
the	838	841		|O
ABCB1	842	847		|O
gene	848	852		|O
,	852	853		|O
coding	854	860		|O
for	861	864		|O
P	865	866		|O
-	866	867		|O
glycoprotein	867	879		|O
(	880	881		|O
P	881	882		|O
-	882	883		|O
gp	883	885		|O
)	885	886		|O
,	886	887		|O
and	888	891		|O
in	892	894		|O
the	895	898		|O
micro	899	904		|O
-	904	905		|O
opioid	905	911		|O
receptor	912	920		|O
reduce	921	927		|O
morphine	928	936		|O
potency	937	944		|O
.	944	945		|O
Cytochrome	946	956		|O
P450	957	961		|O
(	962	963		|O
CYP	963	966		|O
)	966	967		|O
2D6	968	971		|O
mutations	972	981		|O
influence	982	991		|O
the	992	995		|O
analgesic	996	1005		|O
effect	1006	1012		|O
of	1013	1015		|O
codeine	1016	1023		|O
and	1024	1027		|O
tramadol	1028	1036		|O
,	1036	1037		|O
and	1038	1041		|O
polymorphism	1042	1054		|O
of	1055	1057		|O
CYP2C9	1058	1064		|O
is	1065	1067		|O
potentially	1068	1079		|O
linked	1080	1086		|O
to	1087	1089		|O
an	1090	1092		|O
increase	1093	1101		|O
in	1102	1104		|O
nonsteroidal	1105	1117		|O
anti	1118	1122		|O
-	1122	1123		|O
inflammatory	1123	1135		|O
drug	1136	1140		|O
-	1140	1141		|O
induced	1141	1148		|O
adverse	1149	1156		|O
events	1157	1163		|O
.	1163	1164		|O
Furthermore	1165	1176		|O
,	1176	1177		|O
drug	1178	1182		|O
interactions	1183	1195		|O
can	1196	1199		|O
mimic	1200	1205		|O
genetic	1206	1213		|O
deficiency	1214	1224		|O
and	1225	1228		|O
contribute	1229	1239		|O
to	1240	1242		|O
the	1243	1246		|O
variability	1247	1258		|O
in	1259	1261		|O
response	1262	1270		|O
to	1271	1273		|O
analgesics	1274	1284		|O
.	1284	1285		|O
This	1286	1290		|O
review	1291	1297		|O
summarizes	1298	1308		|O
the	1309	1312		|O
available	1313	1322		|O
data	1323	1327		|O
on	1328	1330		|O
the	1331	1334		|O
pharmacokinetic	1335	1350		|O
and	1351	1354		|O
pharmacodynamic	1355	1370		|O
consequences	1371	1383		|O
of	1384	1386		|O
known	1387	1392		|O
polymorphisms	1393	1406		|O
of	1407	1409		|O
drug	1410	1414		|O
-	1414	1415		|O
metabolizing	1415	1427		|O
enzymes	1428	1435		|O
,	1435	1436		|O
drug	1437	1441		|O
transporters	1442	1454		|O
,	1454	1455		|O
drug	1456	1460		|O
targets	1461	1468		|O
and	1469	1472		|O
other	1473	1478		|O
nonopioid	1479	1488		|O
biological	1489	1499		|O
systems	1500	1507		|O
on	1508	1510		|O
central	1511	1518		|O
and	1519	1522		|O
peripheral	1523	1533		|O
analgesics	1534	1544		|O
.	1544	1545		|O

### 18666751
Chronopharmacology	0	18		|O
and	19	22		|O
antimicrobial	23	36		|O
therapeutics	37	49		|O
.	49	50		|O
Chronobiology	52	65		|O
studies	66	73		|O
the	74	77		|O
phenomenon	78	88		|O
of	89	91		|O
rhythmicity	92	103		|O
in	104	106		|O
living	107	113		|O
organisms	114	123		|O
.	123	124		|O
Circadian	125	134		|O
rhythms	135	142		|O
are	143	146		|O
genetically	147	158		|O
determined	159	169		|O
and	170	173		|O
are	174	177		|O
regulated	178	187		|O
by	188	190		|O
external	191	199		|O
synchronizers	200	213		|O
(	214	215		|O
i.e.	215	219		|O
light	220	225		|O
/	225	226		|O
day	226	229		|O
cycle	230	235		|O
)	235	236		|O
.	236	237		|O
Several	238	245		|O
biological	246	256		|O
processes	257	266		|O
involved	267	275		|O
in	276	278		|O
the	279	282		|O
pharmacokinetics	283	299		|O
and	300	303		|O
pharmacodynamics	304	320		|O
of	321	323		|O
drugs	324	329		|O
are	330	333		|O
subject	334	341		|O
to	342	344		|O
circadian	345	354		|O
variations	355	365		|O
.	365	366		|O
Chronopharmacology	367	385		|O
studies	386	393		|O
how	394	397		|O
biological	398	408		|O
rhythms	409	416		|O
impact	417	423		|O
on	424	426		|O
drug	427	431		|O
pharmacokinetic	432	447		|O
(	448	449		|O
chronokinetics	449	463		|O
)	463	464		|O
,	464	465		|O
pharmacodynamics	466	482		|O
(	483	484		|O
chronoesthesy	484	497		|O
)	497	498		|O
and	499	502		|O
toxicity	503	511		|O
and	512	515		|O
determines	516	526		|O
whether	527	534		|O
time	535	539		|O
of	540	542		|O
day	543	546		|O
administration	547	561		|O
modifies	562	570		|O
drug	571	575		|O
's	575	577		|O
pharmacological	578	593		|O
characteristics	594	609		|O
.	609	610		|O
Chronotherapy	611	624		|O
applies	625	632		|O
chronopharmacological	633	654		|O
studies	655	662		|O
to	663	665		|O
clinical	666	674		|O
treatments	675	685		|O
,	685	686		|O
determining	687	698		|O
the	699	702		|O
best	703	707		|O
biological	708	718		|O
time	719	723		|O
for	724	727		|O
its	728	731		|O
dosing	732	738		|O
,	738	739		|O
i.e.	740	744		|O
when	745	749		|O
beneficial	750	760		|O
effects	761	768		|O
are	769	772		|O
maximal	773	780		|O
and	781	784		|O
incidence	785	794		|O
and	795	798		|O
/	798	799		|O
or	799	801		|O
intensity	802	811		|O
of	812	814		|O
related	815	822		|O
side	823	827		|O
-	827	828		|O
effects	828	835		|O
and	836	839		|O
toxicity	840	848		|O
are	849	852		|O
minimal	853	860		|O
.	860	861		|O
Significant	862	873		|O
variations	874	884		|O
in	885	887		|O
the	888	891		|O
pharmacokinetics	892	908		|O
and	909	912		|O
toxicity	913	921		|O
of	922	924		|O
antibiotics	925	936		|O
(	937	938		|O
aminoglycosides	938	953		|O
,	953	954		|O
beta	955	959		|O
-	959	960		|O
lactams	960	967		|O
and	968	971		|O
fluoroquinolones	972	988		|O
)	988	989		|O
related	990	997		|O
to	998	1000		|O
administration	1001	1015		|O
time	1016	1020		|O
are	1021	1024		|O
well	1025	1029		|O
known	1030	1035		|O
.	1035	1036		|O
The	1037	1040		|O
aims	1041	1045		|O
of	1046	1048		|O
this	1049	1053		|O
review	1054	1060		|O
are	1061	1064		|O
to	1065	1067		|O
discuss	1068	1075		|O
,	1075	1076		|O
briefly	1077	1084		|O
,	1084	1085		|O
the	1086	1089		|O
currently	1090	1099		|O
accepted	1100	1108		|O
model	1109	1114		|O
of	1115	1117		|O
the	1118	1121		|O
circadian	1122	1131		|O
system	1132	1138		|O
that	1139	1143		|O
substantiates	1144	1157		|O
endogenous	1158	1168		|O
rhythmicity	1169	1180		|O
and	1181	1184		|O
to	1185	1187		|O
provide	1188	1195		|O
an	1196	1198		|O
update	1199	1205		|O
on	1206	1208		|O
the	1209	1212		|O
knowledge	1213	1222		|O
of	1223	1225		|O
circadian	1226	1235		|O
rhythms	1236	1243		|O
applied	1244	1251		|O
to	1252	1254		|O
drugs	1255	1260		|O
used	1261	1265		|O
as	1266	1268		|O
medicines	1269	1278		|O
,	1278	1279		|O
with	1280	1284		|O
a	1285	1286		|O
special	1287	1294		|O
mention	1295	1302		|O
to	1303	1305		|O
the	1306	1309		|O
possible	1310	1318		|O
impact	1319	1325		|O
on	1326	1328		|O
antimicrobial	1329	1342		|O
treatments	1343	1353		|O
.	1353	1354		|O
It	1355	1357		|O
is	1358	1360		|O
concluded	1361	1370		|O
that	1371	1375		|O
the	1376	1379		|O
dosing	1380	1386		|O
time	1387	1391		|O
of	1392	1394		|O
an	1395	1397		|O
antimicrobial	1398	1411		|O
agent	1412	1417		|O
might	1418	1423		|O
be	1424	1426		|O
clinically	1427	1437		|O
relevant	1438	1446		|O
in	1447	1449		|O
some	1450	1454		|O
treatments	1455	1465		|O
,	1465	1466		|O
thus	1467	1471		|O
,	1471	1472		|O
clinicians	1473	1483		|O
should	1484	1490		|O
be	1491	1493		|O
aware	1494	1499		|O
that	1500	1504		|O
the	1505	1508		|O
dosing	1509	1515		|O
time	1516	1520		|O
might	1521	1526		|O
affect	1527	1533		|O
the	1534	1537		|O
clinical	1538	1546		|O
response	1547	1555		|O
of	1556	1558		|O
a	1559	1560		|O
drug	1561	1565		|O
.	1565	1566		|O

### 18675764
Effect	0	6		|O
of	7	9		|O
darbepoetin	10	21		|O
alfa	22	26		|O
administered	27	39		|O
once	40	44		|O
monthly	45	52		|O
on	53	55		|O
maintaining	56	67		|O
hemoglobin	68	78		|O
levels	79	85		|O
in	86	88		|O
older	89	94		|O
patients	95	103		|O
with	104	108		|O
chronic	109	116	chronic kidney disease	|B-DISEASE
kidney	117	123		|I-DISEASE
disease	124	131		|I-DISEASE
.	131	132		|O
BACKGROUND	134	144		|O
:	144	145		|O
The	146	149		|O
anemia	150	156	anemia of chronic kidney disease	|B-DISEASE
of	157	159		|I-DISEASE
chronic	160	167		|I-DISEASE
kidney	168	174		|I-DISEASE
disease	175	182		|I-DISEASE
(	183	184		|O
CKD	184	187	CKD	|B-DISEASE
)	187	188		|O
is	189	191		|O
associated	192	202		|O
with	203	207		|O
increased	208	217		|O
hospitalizations	218	234		|O
,	234	235		|O
increased	236	245		|O
cardiovascular	246	260		|O
morbidity	261	270		|O
and	271	274		|O
mortality	275	284		|O
,	284	285		|O
and	286	289		|O
diminished	290	300		|O
quality	301	308		|O
of	309	311		|O
life	312	316		|O
in	317	319		|O
the	320	323		|O
elderly	324	331		|O
.	331	332		|O
Darbepoetin	333	344		|O
alfa	345	349		|O
is	350	352		|O
an	353	355		|O
erythropoiesis	356	370		|O
-	370	371		|O
stimulating	371	382		|O
agent	383	388		|O
that	389	393		|O
has	394	397		|O
been	398	402		|O
shown	403	408		|O
to	409	411		|O
be	412	414		|O
effective	415	424		|O
in	425	427		|O
treating	428	436		|O
anemia	437	443	anemia	|B-DISEASE
in	444	446		|O
patients	447	455		|O
with	456	460		|O
CKD	461	464	CKD	|B-DISEASE
(	465	466		|O
but	466	469		|O
not	470	473		|O
on	474	476		|O
dialysis	477	485		|O
)	485	486		|O
when	487	491		|O
administered	492	504		|O
using	505	510		|O
extended	511	519		|O
-	519	520		|O
dosing	520	526		|O
regimens	527	535		|O
.	535	536		|O
OBJECTIVE	537	546		|O
:	546	547		|O
The	548	551		|O
purpose	552	559		|O
of	560	562		|O
this	563	567		|O
post	568	572		|O
hoc	573	576		|O
analysis	577	585		|O
was	586	589		|O
to	590	592		|O
examine	593	600		|O
the	601	604		|O
efficacy	605	613		|O
and	614	617		|O
safety	618	624		|O
profile	625	632		|O
of	633	635		|O
once	636	640		|O
-	640	641		|O
monthly	641	648		|O
(	649	650		|O
QM	650	652		|O
)	652	653		|O
darbepoetin	654	665		|O
alfa	666	670		|O
in	671	673		|O
study	674	679		|O
patients	680	688		|O
stratified	689	699		|O
according	700	709		|O
to	710	712		|O
age	713	716		|O
(	717	718		|O
ie	718	720		|O
,	720	721		|O
<	722	723		|O
65	723	725		|O
,	725	726		|O
65-74	727	732		|O
,	732	733		|O
and	734	737		|O
>	738	739		|O
or	740	742		|O
=	743	744		|O
75	744	746		|O
years	747	752		|O
)	752	753		|O
.	753	754		|O
METHODS	755	762		|O
:	762	763		|O
Patients	764	772		|O
with	773	777		|O
CKD	778	781	CKD	|B-DISEASE
but	782	785		|O
not	786	789		|O
on	790	792		|O
dialysis	793	801		|O
,	801	802		|O
receiving	803	812		|O
darbepoetin	813	824		|O
alfa	825	829		|O
every	830	835		|O
other	836	841		|O
week	842	846		|O
(	847	848		|O
Q2W	848	851		|O
)	851	852		|O
,	852	853		|O
and	854	857		|O
with	858	862		|O
stable	863	869		|O
hemoglobin	870	880		|O
(	881	882		|O
Hb	882	884		|O
)	884	885		|O
levels	886	892		|O
between	893	900		|O
11	901	903		|O
and	904	907		|O
13	908	910		|O
g	911	912		|O
/	912	913		|O
dL	913	915		|O
,	915	916		|O
inclusive	917	926		|O
,	926	927		|O
were	928	932		|O
enrolled	933	941		|O
in	942	944		|O
this	945	949		|O
33	950	952		|O
-	952	953		|O
week	953	957		|O
,	957	958		|O
multicenter	959	970		|O
,	970	971		|O
open	972	976		|O
-	976	977		|O
label	977	982		|O
,	982	983		|O
single	984	990		|O
-	990	991		|O
arm	991	994		|O
study	995	1000		|O
.	1000	1001		|O
The	1002	1005		|O
study	1006	1011		|O
was	1012	1015		|O
carried	1016	1023		|O
out	1024	1027		|O
at	1028	1030		|O
36	1031	1033		|O
US	1034	1036		|O
centers	1037	1044		|O
and	1045	1048		|O
consisted	1049	1058		|O
of	1059	1061		|O
a	1062	1063		|O
24	1064	1066		|O
-	1066	1067		|O
week	1067	1071		|O
QM	1072	1074		|O
darbepoetin	1075	1086		|O
alfa	1087	1091		|O
dose	1092	1096		|O
-	1096	1097		|O
titration	1097	1106		|O
period	1107	1113		|O
followed	1114	1122		|O
by	1123	1125		|O
an	1126	1128		|O
8	1129	1130		|O
-	1130	1131		|O
week	1131	1135		|O
evaluation	1136	1146		|O
period	1147	1153		|O
.	1153	1154		|O
Hb	1155	1157		|O
levels	1158	1164		|O
were	1165	1169		|O
measured	1170	1178		|O
Q2W	1179	1182		|O
.	1182	1183		|O
Study	1184	1189		|O
results	1190	1197		|O
were	1198	1202		|O
stratified	1203	1213		|O
according	1214	1223		|O
to	1224	1226		|O
patient	1227	1234		|O
age	1235	1238		|O
(	1239	1240		|O
<	1240	1241		|O
65	1241	1243		|O
,	1243	1244		|O
65-74	1245	1250		|O
,	1250	1251		|O
and	1252	1255		|O
>	1256	1257		|O
or	1258	1260		|O
=	1261	1262		|O
75	1262	1264		|O
years	1265	1270		|O
)	1270	1271		|O
.	1271	1272		|O
RESULTS	1273	1280		|O
:	1280	1281		|O
A	1282	1283		|O
total	1284	1289		|O
of	1290	1292		|O
152	1293	1296		|O
patients	1297	1305		|O
(	1306	1307		|O
79	1307	1309		|O
women	1310	1315		|O
,	1315	1316		|O
73	1317	1319		|O
men	1320	1323		|O
)	1323	1324		|O
were	1325	1329		|O
enrolled	1330	1338		|O
;	1338	1339		|O
55	1340	1342		|O
patients	1343	1351		|O
(	1352	1353		|O
36%	1353	1356		|O
)	1356	1357		|O
were	1358	1362		|O
<	1363	1364		|O
65	1364	1366		|O
years	1367	1372		|O
of	1373	1375		|O
age	1376	1379		|O
,	1379	1380		|O
46	1381	1383		|O
(	1384	1385		|O
30%	1385	1388		|O
)	1388	1389		|O
were	1390	1394		|O
65	1395	1397		|O
to	1398	1400		|O
74	1401	1403		|O
years	1404	1409		|O
of	1410	1412		|O
age	1413	1416		|O
,	1416	1417		|O
and	1418	1421		|O
51	1422	1424		|O
(	1425	1426		|O
34%	1426	1429		|O
)	1429	1430		|O
were	1431	1435		|O
>	1436	1437		|O
or	1438	1440		|O
=	1441	1442		|O
75	1442	1444		|O
years	1445	1450		|O
of	1451	1453		|O
age	1454	1457		|O
.	1457	1458		|O
In	1459	1461		|O
patients	1462	1470		|O
who	1471	1474		|O
received	1475	1483		|O
>	1484	1485		|O
or	1486	1488		|O
=	1489	1490		|O
1	1490	1491		|O
dose	1492	1496		|O
of	1497	1499		|O
darbepoetin	1500	1511		|O
alfa	1512	1516		|O
,	1516	1517		|O
Hb	1518	1520		|O
levels	1521	1527		|O
>	1528	1529		|O
or	1530	1532		|O
=	1533	1534		|O
11	1534	1536		|O
g	1537	1538		|O
/	1538	1539		|O
dL	1539	1541		|O
were	1542	1546		|O
maintained	1547	1557		|O
in	1558	1560		|O
76%	1561	1564		|O
,	1564	1565		|O
80%	1566	1569		|O
,	1569	1570		|O
and	1571	1574		|O
71%	1575	1578		|O
of	1579	1581		|O
patients	1582	1590		|O
aged	1591	1595		|O
<	1596	1597		|O
65	1597	1599		|O
,	1599	1600		|O
65	1601	1603		|O
to	1604	1606		|O
74	1607	1609		|O
,	1609	1610		|O
and	1611	1614		|O
>	1615	1616		|O
or	1617	1619		|O
=	1620	1621		|O
75	1621	1623		|O
years	1624	1629		|O
,	1629	1630		|O
respectively	1631	1643		|O
.	1643	1644		|O
For	1645	1648		|O
patients	1649	1657		|O
who	1658	1661		|O
completed	1662	1671		|O
the	1672	1675		|O
study	1676	1681		|O
,	1681	1682		|O
the	1683	1686		|O
proportions	1687	1698		|O
who	1699	1702		|O
maintained	1703	1713		|O
Hb	1714	1716		|O
levels	1717	1723		|O
>	1724	1725		|O
or	1726	1728		|O
=	1729	1730		|O
11	1730	1732		|O
g	1733	1734		|O
/	1734	1735		|O
dL	1735	1737		|O
were	1738	1742		|O
83%	1743	1746		|O
,	1746	1747		|O
88%	1748	1751		|O
,	1751	1752		|O
and	1753	1756		|O
85%	1757	1760		|O
,	1760	1761		|O
respectively	1762	1774		|O
,	1774	1775		|O
for	1776	1779		|O
the	1780	1783		|O
3	1784	1785		|O
age	1786	1789		|O
groups	1790	1796		|O
.	1796	1797		|O
The	1798	1801		|O
safety	1802	1808		|O
profile	1809	1816		|O
of	1817	1819		|O
QM	1820	1822		|O
darbepoetin	1823	1834		|O
alfa	1835	1839		|O
in	1840	1842		|O
this	1843	1847		|O
study	1848	1853		|O
was	1854	1857		|O
consistent	1858	1868		|O
with	1869	1873		|O
that	1874	1878		|O
expected	1879	1887		|O
in	1888	1890		|O
patients	1891	1899		|O
with	1900	1904		|O
CKD	1905	1908	CKD	|B-DISEASE
not	1909	1912		|O
receiving	1913	1922		|O
dialysis	1923	1931		|O
.	1931	1932		|O
CONCLUSIONS	1933	1944		|O
:	1944	1945		|O
Darbepoetin	1946	1957		|O
alfa	1958	1962		|O
administered	1963	1975		|O
QM	1976	1978		|O
maintained	1979	1989		|O
Hb	1990	1992		|O
levels	1993	1999		|O
>	2000	2001		|O
or	2002	2004		|O
=	2005	2006		|O
11	2006	2008		|O
g	2009	2010		|O
/	2010	2011		|O
dL	2011	2013		|O
in	2014	2016		|O
patients	2017	2025		|O
with	2026	2030		|O
CKD	2031	2034	CKD	|B-DISEASE
(	2035	2036		|O
not	2036	2039		|O
on	2040	2042		|O
dialysis	2043	2051		|O
)	2051	2052		|O
aged	2053	2057		|O
<	2058	2059		|O
65	2059	2061		|O
,	2061	2062		|O
65	2063	2065		|O
to	2066	2068		|O
74	2069	2071		|O
,	2071	2072		|O
and	2073	2076		|O
>	2077	2078		|O
or	2079	2081		|O
=	2082	2083		|O
75	2083	2085		|O
years	2086	2091		|O
.	2091	2092		|O
This	2093	2097		|O
treatment	2098	2107		|O
regimen	2108	2115		|O
may	2116	2119		|O
help	2120	2124		|O
optimize	2125	2133		|O
anemia	2134	2140	anemia	|B-DISEASE
management	2141	2151		|O
for	2152	2155		|O
older	2156	2161		|O
community	2162	2171		|O
-	2171	2172		|O
dwelling	2172	2180		|O
and	2181	2184		|O
long	2185	2189		|O
-	2189	2190		|O
term	2190	2194		|O
care	2195	2199		|O
patients	2200	2208		|O
.	2208	2209		|O

### 18805435
Nicotine	0	8		|O
and	9	12		|O
4	13	14		|O
-	14	15		|O
(	15	16		|O
methylnitrosamino	16	33		|O
)	33	34		|O
-	34	35		|O
1	35	36		|O
-	36	37		|O
(	37	38		|O
3	38	39		|O
-	39	40		|O
pyridyl	40	47		|O
)	47	48		|O
-	48	49		|O
1	49	50		|O
-	50	51		|O
butanone	51	59		|O
induce	60	66		|O
cyclooxygenase	67	81		|O
-	81	82		|O
2	82	83		|O
activity	84	92		|O
in	93	95		|O
human	96	101		|O
gastric	102	109		|O
cancer	110	116		|O
cells	117	122		|O
:	122	123		|O
Involvement	124	135		|O
of	136	138		|O
nicotinic	139	148		|O
acetylcholine	149	162		|O
receptor	163	171		|O
(	172	173		|O
nAChR	173	178		|O
)	178	179		|O
and	180	183		|O
beta	184	188		|O
-	188	189		|O
adrenergic	189	199		|O
receptor	200	208		|O
signaling	209	218		|O
pathways	219	227		|O
.	227	228		|O
Induction	230	239		|O
of	240	242		|O
cyclooxygenase	243	257		|O
-	257	258		|O
2	258	259		|O
(	260	261		|O
COX	261	264		|O
-	264	265		|O
2	265	266		|O
)	266	267		|O
associates	268	278		|O
with	279	283		|O
cigarette	284	293		|O
smoke	294	299		|O
exposure	300	308		|O
in	309	311		|O
many	312	316		|O
malignancies	317	329		|O
.	329	330		|O
Nicotine	331	339		|O
and	340	343		|O
its	344	347		|O
derivative	348	358		|O
,	358	359		|O
4	360	361		|O
-	361	362		|O
(	362	363		|O
methylnitrosamino	363	380		|O
)	380	381		|O
-	381	382		|O
1	382	383		|O
-	383	384		|O
(	384	385		|O
3	385	386		|O
-	386	387		|O
pyridyl	387	394		|O
)	394	395		|O
-	395	396		|O
1	396	397		|O
-	397	398		|O
butanone	398	406		|O
(	407	408		|O
NNK	408	411		|O
)	411	412		|O
,	412	413		|O
are	414	417		|O
the	418	421		|O
two	422	425		|O
important	426	435		|O
components	436	446		|O
in	447	449		|O
cigarette	450	459		|O
smoke	460	465		|O
that	466	470		|O
contributes	471	482		|O
to	483	485		|O
cancer	486	492	cancer	|B-ADVERSE
development	493	504		|O
.	504	505		|O
However	506	513		|O
,	513	514		|O
the	515	518		|O
molecular	519	528		|O
mechanism	529	538		|O
(	538	539		|O
s	539	540		|O
)	540	541		|O
by	542	544		|O
which	545	550		|O
nicotine	551	559		|O
or	560	562		|O
NNK	563	566		|O
promotes	567	575		|O
gastric	576	583		|O
carcinogenesis	584	598		|O
remains	599	606		|O
largely	607	614		|O
unknown	615	622		|O
.	622	623		|O
We	624	626		|O
found	627	632		|O
that	633	637		|O
nicotine	638	646		|O
and	647	650		|O
NNK	651	654		|O
significantly	655	668		|O
enhanced	669	677		|O
cell	678	682		|O
proliferation	683	696		|O
in	697	699		|O
AGS	700	703		|O
cells	704	709		|O
that	710	714		|O
expressed	715	724		|O
both	725	729		|O
alpha7	730	736		|O
nicotinic	737	746		|O
acetylcholine	747	760		|O
receptor	761	769		|O
(	770	771		|O
alpha7	771	777		|O
nAChR	778	783		|O
)	783	784		|O
and	785	788		|O
beta	789	793		|O
-	793	794		|O
adrenergic	794	804		|O
receptors	805	814		|O
.	814	815		|O
Treatment	816	825		|O
of	826	828		|O
cells	829	834		|O
with	835	839		|O
alpha	840	845		|O
-	845	846		|O
bungarotoxin	846	858		|O
(	859	860		|O
alpha	860	865		|O
-	865	866		|O
BTX	866	869		|O
,	869	870		|O
alpha7nAChR	871	882		|O
antagonist	883	893		|O
)	893	894		|O
or	895	897		|O
propranolol	898	909		|O
(	910	911		|O
beta	911	915		|O
-	915	916		|O
adrenergic	916	926		|O
receptor	927	935		|O
antagonist	936	946		|O
)	946	947		|O
blocked	948	955		|O
NNK	956	959		|O
-	959	960		|O
induced	960	967		|O
COX	968	971		|O
-	971	972		|O
2	972	973		|O
/	973	974		|O
PGE	974	977		|O
(	977	978		|O
2	978	979		|O
)	979	980		|O
and	981	984		|O
cell	985	989		|O
proliferation	990	1003		|O
,	1003	1004		|O
while	1005	1010		|O
nicotine	1011	1019		|O
-	1019	1020		|O
mediated	1020	1028		|O
cell	1029	1033		|O
growth	1034	1040		|O
and	1041	1044		|O
COX	1045	1048		|O
-	1048	1049		|O
2	1049	1050		|O
/	1050	1051		|O
PGE	1051	1054		|O
(	1054	1055		|O
2	1055	1056		|O
)	1056	1057		|O
induction	1058	1067		|O
can	1068	1071		|O
only	1072	1076		|O
be	1077	1079		|O
suppressed	1080	1090		|O
by	1091	1093		|O
propranolol	1094	1105		|O
,	1105	1106		|O
but	1107	1110		|O
not	1111	1114		|O
alpha	1115	1120		|O
-	1120	1121		|O
BTX	1121	1124		|O
.	1124	1125		|O
Moreover	1126	1134		|O
,	1134	1135		|O
in	1136	1138		|O
contrast	1139	1147		|O
to	1148	1150		|O
the	1151	1154		|O
dependence	1155	1165		|O
of	1166	1168		|O
growth	1169	1175		|O
promoting	1176	1185		|O
effect	1186	1192		|O
of	1193	1195		|O
nicotine	1196	1204		|O
on	1205	1207		|O
Erk	1208	1211		|O
activation	1212	1222		|O
,	1222	1223		|O
inhibitor	1224	1233		|O
of	1234	1236		|O
p38	1237	1240		|O
mitogen	1241	1248		|O
-	1248	1249		|O
activated	1249	1258		|O
protein	1259	1266		|O
kinase	1267	1273		|O
(	1274	1275		|O
MAPK	1275	1279		|O
)	1279	1280		|O
repressed	1281	1290		|O
NNK	1291	1294		|O
-	1294	1295		|O
induced	1295	1302		|O
COX	1303	1306		|O
-	1306	1307		|O
2	1307	1308		|O
upregulation	1309	1321		|O
and	1322	1325		|O
resulted	1326	1334		|O
in	1335	1337		|O
suppression	1338	1349		|O
of	1350	1352		|O
cell	1353	1357		|O
growth	1358	1364		|O
.	1364	1365		|O
In	1366	1368		|O
addition	1369	1377		|O
,	1377	1378		|O
nicotine	1379	1387		|O
and	1388	1391		|O
NNK	1392	1395		|O
mediated	1396	1404		|O
COX	1405	1408		|O
-	1408	1409		|O
2	1409	1410		|O
induction	1411	1420		|O
via	1421	1424		|O
different	1425	1434		|O
receptors	1435	1444		|O
to	1445	1447		|O
modulate	1448	1456		|O
several	1457	1464		|O
G1	1465	1467		|O
/	1467	1468		|O
S	1468	1469		|O
transition	1470	1480		|O
regulatory	1481	1491		|O
proteins	1492	1500		|O
and	1501	1504		|O
promote	1505	1512		|O
gastric	1513	1520		|O
cancer	1521	1527		|O
cell	1528	1532		|O
growth	1533	1539		|O
.	1539	1540		|O
Selective	1541	1550		|O
COX	1551	1554		|O
-	1554	1555		|O
2	1555	1556		|O
inhibitor	1557	1566		|O
(	1567	1568		|O
SC	1568	1570		|O
-	1570	1571		|O
236	1571	1574		|O
)	1574	1575		|O
caused	1576	1582		|O
G1	1583	1585		|O
arrest	1586	1592		|O
and	1593	1596		|O
abrogated	1597	1606		|O
nicotine	1607	1615		|O
/	1615	1616		|O
NNK	1616	1619		|O
-	1619	1620		|O
induced	1620	1627		|O
cell	1628	1632		|O
proliferation	1633	1646		|O
.	1646	1647		|O
Aberrant	1648	1656		|O
expression	1657	1667		|O
of	1668	1670		|O
cyclin	1671	1677		|O
D1	1678	1680		|O
and	1681	1684		|O
other	1685	1690		|O
G1	1691	1693		|O
regulatory	1694	1704		|O
proteins	1705	1713		|O
are	1714	1717		|O
reversed	1718	1726		|O
by	1727	1729		|O
blockade	1730	1738		|O
of	1739	1741		|O
COX	1742	1745		|O
-	1745	1746		|O
2	1746	1747		|O
.	1747	1748		|O
These	1749	1754		|O
results	1755	1762		|O
pointed	1763	1770		|O
to	1771	1773		|O
the	1774	1777		|O
importance	1778	1788		|O
of	1789	1791		|O
adrenergic	1792	1802		|O
and	1803	1806		|O
nicotinic	1807	1816		|O
receptors	1817	1826		|O
in	1827	1829		|O
gastric	1830	1837	gastric tumor	|B-ADVERSE
tumor	1838	1843		|I-ADVERSE
growth	1844	1850		|O
through	1851	1858		|O
MAPK	1859	1863		|O
/	1863	1864		|O
COX	1864	1867		|O
-	1867	1868		|O
2	1868	1869		|O
activation	1870	1880		|O
,	1880	1881		|O
which	1882	1887		|O
may	1888	1891		|O
perhaps	1892	1899		|O
provide	1900	1907		|O
a	1908	1909		|O
chemoprevention	1910	1925		|O
strategy	1926	1934		|O
for	1935	1938		|O
cigarette	1939	1948		|O
smoke	1949	1954		|O
-	1954	1955		|O
related	1955	1962		|O
gastric	1963	1970	gastric carcinogenesis	|B-ADVERSE
carcinogenesis	1971	1985		|I-ADVERSE
.	1985	1986		|O

### 18762710
Role	0	4		|O
and	5	8		|O
relevance	9	18		|O
of	19	21		|O
PEPT2	22	27		|O
in	28	30		|O
drug	31	35		|O
disposition	36	47		|O
,	47	48		|O
dynamics	49	57		|O
,	57	58		|O
and	59	62		|O
toxicity	63	71		|O
.	71	72		|O
Pept2	74	79		|O
knockout	80	88		|O
mice	89	93		|O
are	94	97		|O
an	98	100		|O
important	101	110		|O
tool	111	115		|O
to	116	118		|O
evaluate	119	127		|O
the	128	131		|O
evolving	132	140		|O
role	141	145		|O
and	146	149		|O
relevance	150	159		|O
of	160	162		|O
this	163	167		|O
proton	168	174		|O
-	174	175		|O
coupled	175	182		|O
oligopeptide	183	195		|O
transporter	196	207		|O
beyond	208	214		|O
drug	215	219		|O
disposition	220	231		|O
,	231	232		|O
where	233	238		|O
the	239	242		|O
transporter	243	254		|O
also	255	259		|O
modulates	260	269		|O
the	270	273		|O
pharmacodynamic	274	289		|O
and	290	293		|O
toxicodynamic	294	307		|O
effects	308	315		|O
of	316	318		|O
drug	319	323		|O
substrates	324	334		|O
.	334	335		|O
Our	336	339		|O
in	340	342		|O
vivo	343	347		|O
studies	348	355		|O
with	356	360		|O
glycylsarcosine	361	376		|O
in	377	379		|O
Pept2	380	385		|O
knockout	386	394		|O
mice	395	399		|O
have	400	404		|O
established	405	416		|O
"	417	418		|O
proof	418	423		|O
of	424	426		|O
concept	427	434		|O
"	434	435		|O
that	436	440		|O
PEPT2	441	446		|O
can	447	450		|O
have	451	455		|O
a	456	457		|O
significant	458	469		|O
effect	470	476		|O
on	477	479		|O
dipeptide	480	489		|O
disposition	490	501		|O
.	501	502		|O
Subsequent	503	513		|O
studies	514	521		|O
with	522	526		|O
the	527	530		|O
aminocephalosporin	531	549		|O
antibiotic	550	560		|O
cefadroxil	561	571		|O
have	572	576		|O
shown	577	582		|O
relevance	583	592		|O
to	593	595		|O
pharmacology	596	608		|O
and	609	612		|O
infectious	613	623		|O
disease	624	631		|O
.	631	632		|O
Finally	633	640		|O
,	640	641		|O
studies	642	649		|O
with	650	654		|O
the	655	658		|O
endogenous	659	669		|O
peptidomimetic	670	684		|O
5	685	686		|O
-	686	687		|O
aminolevulinic	687	701		|O
acid	702	706		|O
have	707	711		|O
demonstrated	712	724		|O
relevance	725	734		|O
to	735	737		|O
toxicology	738	748		|O
in	749	751		|O
the	752	755		|O
framework	756	765		|O
of	766	768		|O
porphyria	769	778		|O
-	778	779		|O
and	780	783		|O
lead	784	788		|O
-	788	789		|O
induced	789	796		|O
neurotoxicity	797	810	neurotoxicity	|B-ADVERSE
.	810	811		|O
These	812	817		|O
studies	818	825		|O
have	826	830		|O
consistently	831	843		|O
demonstrated	844	856		|O
the	857	860		|O
dual	861	865		|O
action	866	872		|O
of	873	875		|O
PEPT2	876	881		|O
with	882	886		|O
respect	887	894		|O
to	895	897		|O
its	898	901		|O
apical	902	908		|O
localization	909	921		|O
in	922	924		|O
choroid	925	932		|O
plexus	933	939		|O
epithelium	940	950		|O
and	951	954		|O
kidney	955	961		|O
in	962	964		|O
:	964	965		|O
1	966	967		|O
)	967	968		|O
effluxing	969	978		|O
substrates	979	989		|O
from	990	994		|O
CSF	995	998		|O
into	999	1003		|O
choroid	1004	1011		|O
plexus	1012	1018		|O
,	1018	1019		|O
thereby	1020	1027		|O
affecting	1028	1037		|O
regional	1038	1046		|O
pharmacokinetics	1047	1063		|O
in	1064	1066		|O
brain	1067	1072		|O
;	1072	1073		|O
and	1074	1077		|O
2	1078	1079		|O
)	1079	1080		|O
reabsorbing	1081	1092		|O
substrates	1093	1103		|O
from	1104	1108		|O
renal	1109	1114		|O
tubular	1115	1122		|O
fluid	1123	1128		|O
into	1129	1133		|O
proximal	1134	1142		|O
tubules	1143	1150		|O
,	1150	1151		|O
thereby	1152	1159		|O
affecting	1160	1169		|O
systemic	1170	1178		|O
pharmacokinetics	1179	1195		|O
and	1196	1199		|O
exposure	1200	1208		|O
.	1208	1209		|O
Moreover	1210	1218		|O
,	1218	1219		|O
these	1220	1225		|O
studies	1226	1233		|O
have	1234	1238		|O
shown	1239	1244		|O
that	1245	1249		|O
the	1250	1253		|O
regional	1254	1262		|O
effect	1263	1269		|O
of	1270	1272		|O
PEPT2	1273	1278		|O
in	1279	1281		|O
limiting	1282	1290		|O
substrate	1291	1300		|O
concentrations	1301	1315		|O
in	1316	1318		|O
the	1319	1322		|O
CSF	1323	1326		|O
is	1327	1329		|O
more	1330	1334		|O
dramatic	1335	1343		|O
than	1344	1348		|O
its	1349	1352		|O
effect	1353	1359		|O
in	1360	1362		|O
increasing	1363	1373		|O
systemic	1374	1382		|O
exposure	1383	1391		|O
.	1391	1392		|O
In	1393	1395		|O
the	1396	1399		|O
case	1400	1404		|O
of	1405	1407		|O
5	1408	1409		|O
-	1409	1410		|O
aminolevulinic	1410	1424		|O
acid	1425	1429		|O
,	1429	1430		|O
such	1431	1435		|O
regional	1436	1444		|O
modulation	1445	1455		|O
of	1456	1458		|O
drug	1459	1463		|O
disposition	1464	1475		|O
translates	1476	1486		|O
directly	1487	1495		|O
into	1496	1500		|O
significant	1501	1512		|O
changes	1513	1520		|O
in	1521	1523		|O
neurotoxicity	1524	1537	neurotoxicity	|B-ADVERSE
.	1537	1538		|O

### 18802751
Protective	0	10		|O
effects	11	18		|O
of	19	21		|O
asiatic	22	29		|O
acid	30	34		|O
on	35	37		|O
rotenone	38	46		|O
-	46	47		|O
or	48	50		|O
H2O2	51	55		|O
-	55	56		|O
induced	56	63		|O
injury	64	70		|O
in	71	73		|O
SH	74	76		|O
-	76	77		|O
SY5Y	77	81		|O
cells	82	87		|O
.	87	88		|O
Parkinson	90	99	Parkinson's disease	|B-DISEASE
's	99	101		|I-DISEASE
disease	102	109		|I-DISEASE
(	110	111		|O
PD	111	113	PD	|B-DISEASE
)	113	114		|O
is	115	117		|O
a	118	119		|O
progressive	120	131	progressive neurodegenerative disorder	|B-DISEASE
neurodegenerative	132	149		|I-DISEASE
disorder	150	158		|I-DISEASE
with	159	163		|O
a	164	165		|O
prevalence	166	176		|O
of	177	179		|O
1-2%	180	184		|O
in	185	187		|O
people	188	194		|O
over	195	199		|O
the	200	203		|O
age	204	207		|O
of	208	210		|O
50	211	213		|O
.	213	214		|O
Mitochondrial	215	228		|O
dysfunction	229	240		|O
occurred	241	249		|O
in	250	252		|O
PD	253	255	PD	|B-DISEASE
patients	256	264		|O
showing	265	272		|O
a	273	274		|O
15-30%	275	281		|O
loss	282	286		|O
of	287	289		|O
activity	290	298		|O
in	299	301		|O
complex	302	309		|O
I	310	311		|O
.	311	312		|O
Asiatic	313	320		|O
acid	321	325		|O
(	326	327		|O
AA	327	329		|O
)	329	330		|O
,	330	331		|O
a	332	333		|O
triterpenoid	334	346		|O
,	346	347		|O
is	348	350		|O
an	351	353		|O
antioxidant	354	365		|O
and	366	369		|O
used	370	374		|O
for	375	378		|O
depression	379	389	depression	|B-DISEASE
treatment	390	399		|O
,	399	400		|O
but	401	404		|O
the	405	408		|O
effect	409	415		|O
of	416	418		|O
AA	419	421		|O
against	422	429		|O
PD	430	432	PD	|B-DISEASE
-	432	433		|O
like	433	437		|O
damage	438	444		|O
has	445	448		|O
never	449	454		|O
been	455	459		|O
reported	460	468		|O
.	468	469		|O
In	470	472		|O
the	473	476		|O
present	477	484		|O
study	485	490		|O
,	490	491		|O
we	492	494		|O
investigated	495	507		|O
the	508	511		|O
protective	512	522		|O
effects	523	530		|O
of	531	533		|O
AA	534	536		|O
against	537	544		|O
H	545	546		|O
(	546	547		|O
2	547	548		|O
)	548	549		|O
O	549	550		|O
(	550	551		|O
2	551	552		|O
)	552	553		|O
or	554	556		|O
rotenone	557	565		|O
-	565	566		|O
induced	566	573		|O
cellular	574	582	cellular injury	|B-ADVERSE
injury	583	589		|I-ADVERSE
and	590	593		|O
mitochondrial	594	607		|O
dysfunction	608	619		|O
in	620	622		|O
SH	623	625		|O
-	625	626		|O
SY5Y	626	630		|O
cells	631	636		|O
.	636	637		|O
Mitochondrial	638	651		|O
membrane	652	660		|O
potential	661	670		|O
(	671	672		|O
MMP	672	675		|O
)	675	676		|O
and	677	680		|O
the	681	684		|O
expression	685	695		|O
of	696	698		|O
voltage	699	706		|O
-	706	707		|O
dependent	707	716		|O
anion	717	722		|O
channel	723	730		|O
(	731	732		|O
VDAC	732	736		|O
)	736	737		|O
were	738	742		|O
detected	743	751		|O
with	752	756		|O
or	757	759		|O
without	760	767		|O
AA	768	770		|O
pretreatment	771	783		|O
following	784	793		|O
cellular	794	802	cellular injury	|B-ADVERSE
injury	803	809		|I-ADVERSE
to	810	812		|O
address	813	820		|O
the	821	824		|O
possible	825	833		|O
mechanisms	834	844		|O
of	845	847		|O
AA	848	850		|O
neuroprotection	851	866		|O
.	866	867		|O
The	868	871		|O
results	872	879		|O
showed	880	886		|O
that	887	891		|O
pre	892	895		|O
-	895	896		|O
treatment	896	905		|O
of	906	908		|O
AA	909	911		|O
(	912	913		|O
0.01-100	913	921		|O
nM	922	924		|O
)	924	925		|O
protected	926	935		|O
cells	936	941		|O
against	942	949		|O
the	950	953		|O
toxicity	954	962		|O
induced	963	970		|O
by	971	973		|O
rotenone	974	982		|O
or	983	985		|O
H	986	987		|O
(	987	988		|O
2	988	989		|O
)	989	990		|O
O	990	991		|O
(	991	992		|O
2	992	993		|O
)	993	994		|O
.	994	995		|O
In	996	998		|O
addition	999	1007		|O
,	1007	1008		|O
MMP	1009	1012		|O
dissipation	1013	1024		|O
occurred	1025	1033		|O
following	1034	1043		|O
the	1044	1047		|O
exposure	1048	1056		|O
of	1057	1059		|O
rotenone	1060	1068		|O
,	1068	1069		|O
which	1070	1075		|O
could	1076	1081		|O
be	1082	1084		|O
prevented	1085	1094		|O
by	1095	1097		|O
AA	1098	1100		|O
treatment	1101	1110		|O
.	1110	1111		|O
More	1112	1116		|O
interestingly	1117	1130		|O
,	1130	1131		|O
pre	1132	1135		|O
-	1135	1136		|O
administration	1136	1150		|O
of	1151	1153		|O
AA	1154	1156		|O
inhibited	1157	1166		|O
the	1167	1170		|O
elevation	1171	1180		|O
of	1181	1183		|O
VDAC	1184	1188		|O
mRNA	1189	1193		|O
and	1194	1197		|O
protein	1198	1205		|O
levels	1206	1212		|O
induced	1213	1220		|O
by	1221	1223		|O
rotenone	1224	1232		|O
(	1232	1233		|O
100	1233	1236		|O
nM	1237	1239		|O
)	1239	1240		|O
or	1241	1243		|O
H	1244	1245		|O
(	1245	1246		|O
2	1246	1247		|O
)	1247	1248		|O
O	1248	1249		|O
(	1249	1250		|O
2	1250	1251		|O
)	1251	1252		|O
(	1253	1254		|O
300	1254	1257		|O
microM	1258	1264		|O
)	1264	1265		|O
.	1265	1266		|O
These	1266	1271		|O
data	1272	1276		|O
indicate	1277	1285		|O
that	1286	1290		|O
AA	1291	1293		|O
could	1294	1299		|O
protect	1300	1307		|O
neuronal	1308	1316		|O
cells	1317	1322		|O
against	1323	1330		|O
mitochondrial	1331	1344		|O
dysfunctional	1345	1358		|O
injury	1359	1365		|O
and	1366	1369		|O
suggest	1370	1377		|O
that	1378	1382		|O
AA	1383	1385		|O
might	1386	1391		|O
be	1392	1394		|O
developed	1395	1404		|O
as	1405	1407		|O
an	1408	1410		|O
agent	1411	1416		|O
for	1417	1420		|O
PD	1421	1423		|O
prevention	1424	1434		|O
or	1435	1437		|O
therapy	1438	1445		|O
.	1445	1446		|O

### 18714577
Two	0	3		|O
rare	4	8		|O
cases	9	14		|O
of	15	17		|O
methotrexate	18	30		|O
-	30	31		|O
induced	31	38		|O
pneumonitis	39	50	pneumonitis	|B-ADVERSE
and	51	54		|O
pleurisy	55	63	pleurisy	|B-ADVERSE
in	64	66		|O
patients	67	75		|O
with	76	80		|O
gestational	81	92	gestational trophoblastic neoplasms	|B-DISEASE
trophoblastic	93	106		|I-DISEASE
neoplasms	107	116		|I-DISEASE
.	116	117		|O
BACKGROUND	119	129		|O
:	129	130		|O
Pneumonitis	131	142	Pneumonitis	|B-ADVERSE
is	143	145		|O
a	146	147		|O
serious	148	155		|O
and	156	159		|O
unpredictable	160	173		|O
side	174	178		|O
-	178	179		|O
effect	179	185		|O
of	186	188		|O
treatment	189	198		|O
with	199	203		|O
methotrexate	204	216		|O
(	217	218		|O
MTX	218	221		|O
)	221	222		|O
that	223	227		|O
may	228	231		|O
result	232	238		|O
in	239	241		|O
a	242	243		|O
life	244	248		|O
-	248	249		|O
threatening	249	260		|O
outcome	261	268		|O
.	268	269		|O
Pulmonary	270	279	Pulmonary toxicity	|B-ADVERSE
toxicity	280	288		|I-ADVERSE
of	289	291		|O
methotrexate	292	304		|O
in	305	307		|O
patients	308	316		|O
with	317	321		|O
a	322	323		|O
gestational	324	335	gestational trophoblastic neoplasm	|B-DISEASE
trophoblastic	336	349		|I-DISEASE
neoplasm	350	358		|I-DISEASE
(	359	360		|O
GTN	360	363	GTN	|B-DISEASE
)	363	364		|O
has	365	368		|O
rarely	369	375		|O
been	376	380		|O
reported	381	389		|O
before	390	396		|O
.	396	397		|O
CASE	398	402		|O
REPORTS	403	410		|O
:	410	411		|O
For	412	415		|O
the	416	419		|O
first	420	425		|O
time	426	430		|O
two	431	434		|O
cases	435	440		|O
of	441	443		|O
methotrexate	444	456		|O
-	456	457		|O
induced	457	464		|O
pneumonitis	465	476	pneumonitis	|B-ADVERSE
and	477	480		|O
pleurisy	481	489	pleurisy	|B-ADVERSE
in	490	492		|O
GTN	493	496	GTN	|B-DISEASE
patients	497	505		|O
of	506	508		|O
Chinese	509	516		|O
ethnicity	517	526		|O
are	527	530		|O
presented	531	540		|O
.	540	541		|O
Two	542	545		|O
patients	546	554		|O
were	555	559		|O
both	560	564		|O
categorized	565	576		|O
as	577	579		|O
the	580	583		|O
low	584	587		|O
-	587	588		|O
risk	588	592		|O
group	593	598		|O
,	598	599		|O
and	600	603		|O
underwent	604	613		|O
a	614	615		|O
single	616	622		|O
regimen	623	630		|O
therapy	631	638		|O
of	639	641		|O
methotrexate	642	654		|O
.	654	655		|O
Their	656	661		|O
symptoms	662	670		|O
,	670	671		|O
such	672	676		|O
as	677	679		|O
fever	680	685	fever	|B-ADVERSE
,	685	686		|O
chest	687	692	chest pain	|B-ADVERSE
pain	693	697		|I-ADVERSE
,	697	698		|O
acute	699	704	acute nonproductive cough	|B-ADVERSE
nonproductive	705	718		|I-ADVERSE
cough	719	724		|I-ADVERSE
,	724	725		|O
dyspnea	726	733	dyspnea	|B-ADVERSE
and	734	737		|O
hypoxemia	738	747	hypoxemia	|B-ADVERSE
did	748	751		|O
not	752	755		|O
respond	756	763		|O
to	764	766		|O
antibiotics	767	778		|O
immediately	779	790		|O
.	790	791		|O
Treatment	792	801		|O
with	802	806		|O
corticosteroids	807	822		|O
may	823	826		|O
be	827	829		|O
helpful	830	837		|O
.	837	838		|O
CONCLUSION	839	849		|O
:	849	850		|O
Awareness	851	860		|O
of	861	863		|O
pneumonitis	864	875	pneumonitis	|B-ADVERSE
and	876	879		|O
pleurisy	880	888	pleurisy	|B-ADVERSE
,	888	889		|O
potentially	890	901		|O
life	902	906		|O
-	906	907		|O
threatening	907	918		|O
complications	919	932		|O
of	933	935		|O
MTX	936	939		|O
,	939	940		|O
is	941	943		|O
very	944	948		|O
necessary	949	958		|O
and	959	962		|O
important	963	972		|O
to	973	975		|O
early	976	981		|O
recognition	982	993		|O
and	994	997		|O
treatment	998	1007		|O
.	1007	1008		|O

### 18705805
Effect	0	6		|O
of	7	9		|O
2	10	11		|O
-	11	12		|O
hydroxyethyl	12	24		|O
-	24	25		|O
methacrylate	25	37		|O
(	38	39		|O
HEMA	39	43		|O
)	43	44		|O
on	45	47		|O
the	48	51		|O
phagocytic	52	62		|O
and	63	66		|O
respiratory	67	78		|O
burst	79	84		|O
activity	85	93		|O
of	94	96		|O
human	97	102		|O
neutrophils	103	114		|O
and	115	118		|O
monocytes	119	128		|O
.	128	129		|O
Neutrophils	131	142		|O
and	143	146		|O
monocytes	147	156		|O
/	156	157		|O
macrophages	157	168		|O
(	169	170		|O
M	170	171		|O
?	171	172		|O
)	172	173		|O
,	173	174		|O
found	175	180		|O
in	181	183		|O
oral	184	188		|O
mucosa	189	195		|O
and	196	199		|O
gingival	200	208		|O
sulcus	209	215		|O
,	215	216		|O
phagocytose	217	228		|O
and	229	232		|O
kill	233	237		|O
bacteria	238	246		|O
using	247	252		|O
products	253	261		|O
produced	262	270		|O
during	271	277		|O
a	278	279		|O
respiratory	280	291		|O
burst	292	297		|O
.	297	298		|O
2	299	300		|O
-	300	301		|O
Hydroxyethyl	301	313		|O
-	313	314		|O
methacrylate	314	326		|O
(	327	328		|O
HEMA	328	332		|O
)	332	333		|O
is	334	336		|O
a	337	338		|O
major	339	344		|O
component	345	354		|O
released	355	363		|O
from	364	368		|O
resin	369	374		|O
glass	375	380		|O
ionomer	381	388		|O
and	389	392		|O
dental	393	399		|O
adhesives	400	409		|O
.	409	410		|O
Hence	411	416		|O
,	416	417		|O
in	418	420		|O
pulp	421	425		|O
and	426	429		|O
gingiva	430	437		|O
,	437	438		|O
phagocytes	439	449		|O
can	450	453		|O
come	454	458		|O
into	459	463		|O
contact	464	471		|O
with	472	476		|O
unpolymerized	477	490		|O
HEMA	491	495		|O
monomers	496	504		|O
.	504	505		|O
The	506	509		|O
aim	510	513		|O
of	514	516		|O
this	517	521		|O
study	522	527		|O
was	528	531		|O
to	532	534		|O
examine	535	542		|O
the	543	546		|O
effects	547	554		|O
of	555	557		|O
exposure	558	566		|O
to	567	569		|O
HEMA	570	574		|O
on	575	577		|O
neutrophil	578	588		|O
and	589	592		|O
monocyte	593	601		|O
bactericidal	602	614		|O
function	615	623		|O
.	623	624		|O
Blood	625	630		|O
collected	631	640		|O
from	641	645		|O
five	646	650		|O
female	651	657		|O
volunteers	658	668		|O
was	669	672		|O
exposed	673	680		|O
in	681	683		|O
vitro	684	689		|O
to	690	692		|O
HEMA	693	697		|O
for	698	701		|O
2	702	703		|O
h	704	705		|O
and	706	709		|O
then	710	714		|O
phagocytosis	715	727		|O
,	727	728		|O
respiratory	729	740		|O
burst	741	746		|O
,	746	747		|O
and	748	751		|O
cellular	752	760		|O
integrity	761	770		|O
were	771	775		|O
measured	776	784		|O
using	785	790		|O
flow	791	795		|O
cytometry	796	805		|O
.	805	806		|O
Respiratory	807	818		|O
burst	819	824		|O
was	825	828		|O
quantified	829	839		|O
by	840	842		|O
measuring	843	852		|O
fluorescent	853	864		|O
rhodamine	865	874		|O
123	875	878		|O
generated	879	888		|O
via	889	892		|O
oxidation	893	902		|O
of	903	905		|O
dihydrorhodamine	906	922		|O
123	923	926		|O
.	926	927		|O
Cellular	928	936		|O
membrane	937	945		|O
integrity	946	955		|O
was	956	959		|O
evaluated	960	969		|O
by	970	972		|O
staining	973	981		|O
with	982	986		|O
propidium	987	996		|O
iodide	997	1003		|O
.	1003	1004		|O
The	1005	1008		|O
respiratory	1009	1020		|O
burst	1021	1026		|O
activity	1027	1035		|O
of	1036	1038		|O
the	1039	1042		|O
neutrophils	1043	1054		|O
was	1055	1058		|O
significantly	1059	1072		|O
decreased	1073	1082		|O
by	1083	1085		|O
exposure	1086	1094		|O
to	1095	1097		|O
7.5	1098	1101		|O
and	1102	1105		|O
15	1106	1108		|O
mM	1109	1111		|O
HEMA	1112	1116		|O
.	1116	1117		|O
No	1118	1120		|O
significant	1121	1132		|O
effect	1133	1139		|O
of	1140	1142		|O
HEMA	1143	1147		|O
was	1148	1151		|O
seen	1152	1156		|O
on	1157	1159		|O
the	1160	1163		|O
number	1164	1170		|O
of	1171	1173		|O
granulocytes	1174	1186		|O
or	1187	1189		|O
monocytes	1190	1199		|O
capable	1200	1207		|O
of	1208	1210		|O
performing	1211	1221		|O
respiratory	1222	1233		|O
burst	1234	1239		|O
.	1239	1240		|O
Furthermore	1241	1252		|O
,	1252	1253		|O
there	1254	1259		|O
was	1260	1263		|O
no	1264	1266		|O
significant	1267	1278		|O
effect	1279	1285		|O
of	1286	1288		|O
HEMA	1289	1293		|O
on	1294	1296		|O
the	1297	1300		|O
phagocytic	1301	1311		|O
activity	1312	1320		|O
of	1321	1323		|O
the	1324	1327		|O
monocytes	1328	1337		|O
or	1338	1340		|O
the	1341	1344		|O
granulocytes	1345	1357		|O
.	1357	1358		|O
In	1359	1361		|O
conclusion	1362	1372		|O
,	1372	1373		|O
HEMA	1374	1378		|O
did	1379	1382		|O
not	1383	1386		|O
affect	1387	1393		|O
the	1394	1397		|O
phagocytosis	1398	1410		|O
activity	1411	1419		|O
of	1420	1422		|O
neutrophils	1423	1434		|O
;	1434	1435		|O
however	1436	1443		|O
,	1443	1444		|O
the	1445	1448		|O
ability	1449	1456		|O
of	1457	1459		|O
the	1460	1463		|O
cells	1464	1469		|O
to	1470	1472		|O
kill	1473	1477		|O
internalized	1478	1490		|O
prey	1491	1495		|O
was	1496	1499		|O
significantly	1500	1513		|O
reduced	1514	1521		|O
.	1521	1522		|O

### 18843733
Platinum	0	8		|O
versus	9	15		|O
non	16	19		|O
-	19	20		|O
platinum	20	28		|O
chemotherapy	29	41		|O
regimens	42	50		|O
for	51	54		|O
small	55	60	small cell lung cancer	|B-DISEASE
cell	61	65		|I-DISEASE
lung	66	70		|I-DISEASE
cancer	71	77		|I-DISEASE
.	77	78		|O
BACKGROUND	80	90		|O
:	90	91		|O
Small	92	97	Small cell lung cancer	|B-DISEASE
cell	98	102		|I-DISEASE
lung	103	107		|I-DISEASE
cancer	108	114		|I-DISEASE
(	115	116		|O
SCLC	116	120	SCLC	|B-DISEASE
)	120	121		|O
is	122	124		|O
a	125	126		|O
very	127	131		|O
fast	132	136		|O
growing	137	144		|O
form	145	149		|O
of	150	152		|O
cancer	153	159	cancer	|B-DISEASE
and	160	163		|O
is	164	166		|O
characterised	167	180		|O
by	181	183		|O
early	184	189		|O
metastasis	190	200	metastasis	|B-DISEASE
.	200	201		|O
As	202	204		|O
a	205	206		|O
result	207	213		|O
,	213	214		|O
chemotherapy	215	227		|O
is	228	230		|O
the	231	234		|O
mainstay	235	243		|O
of	244	246		|O
treatment	247	256		|O
.	256	257		|O
A	258	259		|O
number	260	266		|O
of	267	269		|O
different	270	279		|O
platinum	280	288		|O
-	288	289		|O
based	289	294		|O
chemotherapy	295	307		|O
regimens	308	316		|O
and	317	320		|O
non	321	324		|O
-	324	325		|O
platinum	325	333		|O
-	333	334		|O
based	334	339		|O
chemotherapy	340	352		|O
regimens	353	361		|O
have	362	366		|O
been	367	371		|O
used	372	376		|O
for	377	380		|O
the	381	384		|O
treatment	385	394		|O
of	395	397		|O
SCLC	398	402	SCLC	|B-DISEASE
,	402	403		|O
with	404	408		|O
varying	409	416		|O
results	417	424		|O
.	424	425		|O
This	426	430		|O
review	431	437		|O
was	438	441		|O
conducted	442	451		|O
to	452	454		|O
analyse	455	462		|O
the	463	466		|O
data	467	471		|O
from	472	476		|O
these	477	482		|O
trials	483	489		|O
in	490	492		|O
order	493	498		|O
to	499	501		|O
compare	502	509		|O
their	510	515		|O
effectiveness	516	529		|O
.	529	530		|O
OBJECTIVES	531	541		|O
:	541	542		|O
To	543	545		|O
determine	546	555		|O
the	556	559		|O
effectiveness	560	573		|O
of	574	576		|O
platinum	577	585		|O
chemotherapy	586	598		|O
regimens	599	607		|O
compared	608	616		|O
with	617	621		|O
non	622	625		|O
-	625	626		|O
platinum	626	634		|O
chemotherapy	635	647		|O
regimens	648	656		|O
in	657	659		|O
the	660	663		|O
treatment	664	673		|O
of	674	676		|O
SCLC	677	681	SCLC	|B-DISEASE
with	682	686		|O
respect	687	694		|O
to	695	697		|O
survival	698	706		|O
,	706	707		|O
tumour	708	714	tumour	|B-DISEASE
response	715	723		|O
,	723	724		|O
toxicity	725	733		|O
and	734	737		|O
quality	738	745		|O
of	746	748		|O
life	749	753		|O
.	753	754		|O
SEARCH	755	761		|O
STRATEGY	762	770		|O
:	770	771		|O
We	772	774		|O
searched	775	783		|O
the	784	787		|O
biomedical	788	798		|O
literature	799	809		|O
databases	810	819		|O
CENTRAL	820	827		|O
(	828	829		|O
The	829	832		|O
Cochrane	833	841		|O
Library	842	849		|O
2007	850	854		|O
,	854	855		|O
Issue	856	861		|O
2	862	863		|O
)	863	864		|O
,	864	865		|O
MEDLINE	866	873		|O
,	873	874		|O
EMBASE	875	881		|O
and	882	885		|O
CINAHL	886	892		|O
from	893	897		|O
1966	898	902		|O
to	903	905		|O
April	906	911		|O
2007	912	916		|O
.	916	917		|O
In	918	920		|O
addition	921	929		|O
,	929	930		|O
we	931	933		|O
handsearched	934	946		|O
reference	947	956		|O
lists	957	962		|O
from	963	967		|O
relevant	968	976		|O
resources	977	986		|O
.	986	987		|O
SELECTION	988	997		|O
CRITERIA	998	1006		|O
:	1006	1007		|O
All	1008	1011		|O
randomised	1012	1022		|O
controlled	1023	1033		|O
trials	1034	1040		|O
involving	1041	1050		|O
patients	1051	1059		|O
with	1060	1064		|O
pathologically	1065	1079		|O
confirmed	1080	1089		|O
(	1090	1091		|O
cytological	1091	1102		|O
or	1103	1105		|O
histological	1106	1118		|O
)	1118	1119		|O
SCLC	1120	1124	SCLC	|B-DISEASE
and	1125	1128		|O
the	1129	1132		|O
use	1133	1136		|O
of	1137	1139		|O
a	1140	1141		|O
platinum	1142	1150		|O
-	1150	1151		|O
based	1151	1156		|O
chemotherapy	1157	1169		|O
regimen	1170	1177		|O
in	1178	1180		|O
at	1181	1183		|O
least	1184	1189		|O
one	1190	1193		|O
treatment	1194	1203		|O
arm	1204	1207		|O
and	1208	1211		|O
a	1212	1213		|O
non	1214	1217		|O
-	1217	1218		|O
platinum	1218	1226		|O
-	1226	1227		|O
based	1227	1232		|O
chemotherapy	1233	1245		|O
regimen	1246	1253		|O
in	1254	1256		|O
a	1257	1258		|O
separate	1259	1267		|O
arm	1268	1271		|O
.	1271	1272		|O
DATA	1273	1277		|O
COLLECTION	1278	1288		|O
AND	1289	1292		|O
ANALYSIS	1293	1301		|O
:	1301	1302		|O
Two	1303	1306		|O
authors	1307	1314		|O
independently	1315	1328		|O
assessed	1329	1337		|O
search	1338	1344		|O
results	1345	1352		|O
.	1352	1353		|O
We	1354	1356		|O
assessed	1357	1365		|O
included	1366	1374		|O
studies	1375	1382		|O
for	1383	1386		|O
methodological	1387	1401		|O
quality	1402	1409		|O
and	1410	1413		|O
recorded	1414	1422		|O
the	1423	1426		|O
following	1427	1436		|O
outcome	1437	1444		|O
data	1445	1449		|O
:	1449	1450		|O
survival	1451	1459		|O
,	1459	1460		|O
tumour	1461	1467	tumour	|B-DISEASE
response	1468	1476		|O
,	1476	1477		|O
toxicity	1478	1486		|O
and	1487	1490		|O
quality	1491	1498		|O
of	1499	1501		|O
life	1502	1506		|O
.	1506	1507		|O
We	1508	1510		|O
combined	1511	1519		|O
the	1520	1523		|O
results	1524	1531		|O
of	1532	1534		|O
the	1535	1538		|O
survival	1539	1547		|O
,	1547	1548		|O
tumour	1549	1555	tumour	|B-DISEASE
response	1556	1564		|O
and	1565	1568		|O
toxicity	1569	1577		|O
data	1578	1582		|O
in	1583	1585		|O
a	1586	1587		|O
meta	1588	1592		|O
-	1592	1593		|O
analysis	1593	1601		|O
.	1601	1602		|O
MAIN	1603	1607		|O
RESULTS	1608	1615		|O
:	1615	1616		|O
A	1617	1618		|O
total	1619	1624		|O
of	1625	1627		|O
29	1628	1630		|O
trials	1631	1637		|O
involving	1638	1647		|O
5530	1648	1652		|O
patients	1653	1661		|O
were	1662	1666		|O
included	1667	1675		|O
in	1676	1678		|O
this	1679	1683		|O
systematic	1684	1694		|O
review	1695	1701		|O
.	1701	1702		|O
There	1703	1708		|O
was	1709	1712		|O
no	1713	1715		|O
statistically	1716	1729		|O
significant	1730	1741		|O
difference	1742	1752		|O
between	1753	1760		|O
treatment	1761	1770		|O
groups	1771	1777		|O
in	1778	1780		|O
terms	1781	1786		|O
of	1787	1789		|O
survival	1790	1798		|O
at	1799	1801		|O
6	1802	1803		|O
months	1804	1810		|O
,	1810	1811		|O
12	1812	1814		|O
months	1815	1821		|O
and	1822	1825		|O
24	1826	1828		|O
months	1829	1835		|O
.	1835	1836		|O
There	1837	1842		|O
was	1843	1846		|O
also	1847	1851		|O
no	1852	1854		|O
statistically	1855	1868		|O
significant	1869	1880		|O
difference	1881	1891		|O
in	1892	1894		|O
terms	1895	1900		|O
of	1901	1903		|O
overall	1904	1911		|O
tumour	1912	1918	tumour	|B-DISEASE
response	1919	1927		|O
.	1927	1928		|O
However	1929	1936		|O
,	1936	1937		|O
platinum	1938	1946		|O
-	1946	1947		|O
based	1947	1952		|O
treatment	1953	1962		|O
regimens	1963	1971		|O
did	1972	1975		|O
have	1976	1980		|O
a	1981	1982		|O
significantly	1983	1996		|O
higher	1997	2003		|O
rate	2004	2008		|O
of	2009	2011		|O
complete	2012	2020		|O
response	2021	2029		|O
.	2029	2030		|O
Platinum	2031	2039		|O
-	2039	2040		|O
based	2040	2045		|O
chemotherapy	2046	2058		|O
regimens	2059	2067		|O
had	2068	2071		|O
significantly	2072	2085		|O
higher	2086	2092		|O
rates	2093	2098		|O
of	2099	2101		|O
nausea	2102	2108	nausea	|B-ADVERSE
and	2109	2112		|O
vomiting	2113	2121	vomiting	|B-ADVERSE
,	2121	2122		|O
anaemia	2123	2130	anaemia	|B-ADVERSE
and	2131	2134		|O
thrombocytopenia	2135	2151	thrombocytopenia	|B-ADVERSE
toxicity	2152	2160		|O
.	2160	2161		|O
Three	2162	2167		|O
trials	2168	2174		|O
presented	2175	2184		|O
quality	2185	2192		|O
of	2193	2195		|O
life	2196	2200		|O
data	2201	2205		|O
but	2206	2209		|O
the	2210	2213		|O
data	2214	2218		|O
presented	2219	2228		|O
were	2229	2233		|O
not	2234	2237		|O
complete	2238	2246		|O
and	2247	2250		|O
therefore	2251	2260		|O
could	2261	2266		|O
not	2267	2270		|O
be	2271	2273		|O
combined	2274	2282		|O
in	2283	2285		|O
a	2286	2287		|O
meta	2288	2292		|O
-	2292	2293		|O
analysis	2293	2301		|O
.	2301	2302		|O
AUTHORS	2303	2310		|O
'	2310	2311		|O
CONCLUSIONS	2312	2323		|O
:	2323	2324		|O
Platinum	2325	2333		|O
-	2333	2334		|O
based	2334	2339		|O
chemotherapy	2340	2352		|O
regimens	2353	2361		|O
did	2362	2365		|O
not	2366	2369		|O
offer	2370	2375		|O
a	2376	2377		|O
statistically	2378	2391		|O
significant	2392	2403		|O
benefit	2404	2411		|O
in	2412	2414		|O
survival	2415	2423		|O
or	2424	2426		|O
overall	2427	2434		|O
tumour	2435	2441	tumour	|B-DISEASE
response	2442	2450		|O
compared	2451	2459		|O
with	2460	2464		|O
non	2465	2468		|O
-	2468	2469		|O
platinum	2469	2477		|O
-	2477	2478		|O
based	2478	2483		|O
regimens	2484	2492		|O
.	2492	2493		|O
However	2494	2501		|O
,	2501	2502		|O
platinum	2503	2511		|O
-	2511	2512		|O
based	2512	2517		|O
chemotherapy	2518	2530		|O
regimens	2531	2539		|O
did	2540	2543		|O
increase	2544	2552		|O
complete	2553	2561		|O
response	2562	2570		|O
rates	2571	2576		|O
,	2576	2577		|O
at	2578	2580		|O
the	2581	2584		|O
cost	2585	2589		|O
of	2590	2592		|O
higher	2593	2599		|O
adverse	2600	2607		|O
events	2608	2614		|O
including	2615	2624		|O
nausea	2625	2631	nausea	|B-ADVERSE
and	2632	2635		|O
vomiting	2636	2644	vomiting	|B-ADVERSE
,	2644	2645		|O
anaemia	2646	2653	anaemia	|B-ADVERSE
and	2654	2657		|O
thrombocytopenia	2658	2674	thrombocytopenia	|B-ADVERSE
toxicity	2675	2683		|O
.	2683	2684		|O
These	2685	2690		|O
data	2691	2695		|O
suggest	2696	2703		|O
non	2704	2707		|O
-	2707	2708		|O
platinum	2708	2716		|O
chemotherapy	2717	2729		|O
regimens	2730	2738		|O
have	2739	2743		|O
a	2744	2745		|O
more	2746	2750		|O
advantageous	2751	2763		|O
risk	2764	2768		|O
-	2768	2769		|O
benefit	2769	2776		|O
profile	2777	2784		|O
.	2784	2785		|O
This	2786	2790		|O
systematic	2791	2801		|O
review	2802	2808		|O
highlights	2809	2819		|O
the	2820	2823		|O
lack	2824	2828		|O
of	2829	2831		|O
quality	2832	2839		|O
of	2840	2842		|O
life	2843	2847		|O
data	2848	2852		|O
in	2853	2855		|O
trials	2856	2862		|O
involving	2863	2872		|O
chemotherapy	2873	2885		|O
treatment	2886	2895		|O
for	2896	2899		|O
SCLC	2900	2904	SCLC	|B-DISEASE
.	2904	2905		|O
With	2906	2910		|O
poor	2911	2915		|O
long	2916	2920		|O
-	2920	2921		|O
term	2921	2925		|O
survival	2926	2934		|O
associated	2935	2945		|O
with	2946	2950		|O
both	2951	2955		|O
treatment	2956	2965		|O
groups	2966	2972		|O
,	2972	2973		|O
the	2974	2977		|O
issue	2978	2983		|O
of	2984	2986		|O
the	2987	2990		|O
quality	2991	2998		|O
of	2999	3001		|O
the	3002	3005		|O
survival	3006	3014		|O
period	3015	3021		|O
takes	3022	3027		|O
on	3028	3030		|O
even	3031	3035		|O
more	3036	3040		|O
significance	3041	3053		|O
.	3053	3054		|O
It	3055	3057		|O
would	3058	3063		|O
be	3064	3066		|O
beneficial	3067	3077		|O
for	3078	3081		|O
future	3082	3088		|O
trials	3089	3095		|O
in	3096	3098		|O
this	3099	3103		|O
area	3104	3108		|O
to	3109	3111		|O
include	3112	3119		|O
a	3120	3121		|O
quality	3122	3129		|O
of	3130	3132		|O
life	3133	3137		|O
assessment	3138	3148		|O
.	3148	3149		|O

### 18711953
Choosing	0	8		|O
a	9	10		|O
skeletal	11	19		|O
muscle	20	26		|O
relaxant	27	35		|O
.	35	36		|O
Skeletal	38	46		|O
muscle	47	53		|O
relaxants	54	63		|O
are	64	67		|O
widely	68	74		|O
used	75	79		|O
in	80	82		|O
treating	83	91		|O
musculoskeletal	92	107		|O
conditions	108	118		|O
.	118	119		|O
However	120	127		|O
,	127	128		|O
evidence	129	137		|O
of	138	140		|O
their	141	146		|O
effectiveness	147	160		|O
consists	161	169		|O
mainly	170	176		|O
of	177	179		|O
studies	180	187		|O
with	188	192		|O
poor	193	197		|O
methodologic	198	210		|O
design	211	217		|O
.	217	218		|O
In	219	221		|O
addition	222	230		|O
,	230	231		|O
these	232	237		|O
drugs	238	243		|O
have	244	248		|O
not	249	252		|O
been	253	257		|O
proven	258	264		|O
to	265	267		|O
be	268	270		|O
superior	271	279		|O
to	280	282		|O
acetaminophen	283	296		|O
or	297	299		|O
nonsteroidal	300	312		|O
anti	313	317		|O
-	317	318		|O
inflammatory	318	330		|O
drugs	331	336		|O
for	337	340		|O
low	341	344	low back pain	|B-DISEASE
back	345	349		|I-DISEASE
pain	350	354		|I-DISEASE
.	354	355		|O
Systematic	356	366		|O
reviews	367	374		|O
and	375	378		|O
meta	379	383		|O
-	383	384		|O
analyses	384	392		|O
support	393	400		|O
using	401	406		|O
skeletal	407	415		|O
muscle	416	422		|O
relaxants	423	432		|O
for	433	436		|O
short	437	442		|O
-	442	443		|O
term	443	447		|O
relief	448	454		|O
of	455	457		|O
acute	458	463	acute low back pain	|B-DISEASE
low	464	467		|I-DISEASE
back	468	472		|I-DISEASE
pain	473	477		|I-DISEASE
when	478	482		|O
nonsteroidal	483	495		|O
anti	496	500		|O
-	500	501		|O
inflammatory	501	513		|O
drugs	514	519		|O
or	520	522		|O
acetaminophen	523	536		|O
are	537	540		|O
not	541	544		|O
effective	545	554		|O
or	555	557		|O
tolerated	558	567		|O
.	567	568		|O
Comparison	569	579		|O
studies	580	587		|O
have	588	592		|O
not	593	596		|O
shown	597	602		|O
one	603	606		|O
skeletal	607	615		|O
muscle	616	622		|O
relaxant	623	631		|O
to	632	634		|O
be	635	637		|O
superior	638	646		|O
to	647	649		|O
another	650	657		|O
.	657	658		|O
Cyclobenzaprine	659	674		|O
is	675	677		|O
the	678	681		|O
most	682	686		|O
heavily	687	694		|O
studied	695	702		|O
and	703	706		|O
has	707	710		|O
been	711	715		|O
shown	716	721		|O
to	722	724		|O
be	725	727		|O
effective	728	737		|O
for	738	741		|O
various	742	749		|O
musculoskeletal	750	765		|O
conditions	766	776		|O
.	776	777		|O
The	778	781		|O
sedative	782	790		|O
properties	791	801		|O
of	802	804		|O
tizanidine	805	815		|O
and	816	819		|O
cyclobenzaprine	820	835		|O
may	836	839		|O
benefit	840	847		|O
patients	848	856		|O
with	857	861		|O
insomnia	862	870	insomnia	|B-DISEASE
caused	871	877		|O
by	878	880		|O
severe	881	887		|O
muscle	888	894	muscle spasms	|B-DISEASE
spasms	895	901		|I-DISEASE
.	901	902		|O
Methocarbamol	903	916		|O
and	917	920		|O
metaxalone	921	931		|O
are	932	935		|O
less	936	940		|O
sedating	941	949		|O
,	949	950		|O
although	951	959		|O
effectiveness	960	973		|O
evidence	974	982		|O
is	983	985		|O
limited	986	993		|O
.	993	994		|O
Adverse	995	1002		|O
effects	1003	1010		|O
,	1010	1011		|O
particularly	1012	1024		|O
dizziness	1025	1034	dizziness	|B-DISEASE
and	1035	1038		|O
drowsiness	1039	1049	drowsiness	|B-DISEASE
,	1049	1050		|O
are	1051	1054		|O
consistently	1055	1067		|O
reported	1068	1076		|O
with	1077	1081		|O
all	1082	1085		|O
skeletal	1086	1094		|O
muscle	1095	1101		|O
relaxants	1102	1111		|O
.	1111	1112		|O
The	1113	1116		|O
potential	1117	1126		|O
adverse	1127	1134		|O
effects	1135	1142		|O
should	1143	1149		|O
be	1150	1152		|O
communicated	1153	1165		|O
clearly	1166	1173		|O
to	1174	1176		|O
the	1177	1180		|O
patient	1181	1188		|O
.	1188	1189		|O
Because	1190	1197		|O
of	1198	1200		|O
limited	1201	1208		|O
comparable	1209	1219		|O
effectiveness	1220	1233		|O
data	1234	1238		|O
,	1238	1239		|O
choice	1240	1246		|O
of	1247	1249		|O
agent	1250	1255		|O
should	1256	1262		|O
be	1263	1265		|O
based	1266	1271		|O
on	1272	1274		|O
side	1275	1279		|O
-	1279	1280		|O
effect	1280	1286		|O
profile	1287	1294		|O
,	1294	1295		|O
patient	1296	1303		|O
preference	1304	1314		|O
,	1314	1315		|O
abuse	1316	1321	abuse	|B-DISEASE
potential	1322	1331		|O
,	1331	1332		|O
and	1333	1336		|O
possible	1337	1345		|O
drug	1346	1350		|O
interactions	1351	1363		|O
.	1363	1364		|O

### 18725460
Phase	0	5		|O
II	6	8		|O
preradiation	9	21		|O
R115777	22	29		|O
(	30	31		|O
tipifarnib	31	41		|O
)	41	42		|O
in	43	45		|O
newly	46	51		|O
diagnosed	52	61		|O
GBM	62	65		|O
with	66	70		|O
residual	71	79		|O
enhancing	80	89		|O
disease	90	97		|O
.	97	98		|O
Glioblastoma	100	112	Glioblastoma multiforme	|B-DISEASE
multiforme	113	123		|I-DISEASE
(	124	125		|O
GBM	125	128	GBM	|B-DISEASE
)	128	129		|O
is	130	132		|O
a	133	134		|O
lethal	135	141		|O
primary	142	149		|O
malignant	150	159	malignant brain tumor	|B-DISEASE
brain	160	165		|I-DISEASE
tumor	166	171		|I-DISEASE
in	172	174		|O
adults	175	181		|O
.	181	182		|O
R115777	183	190		|O
(	191	192		|O
tipifarnib	192	202		|O
)	202	203		|O
is	204	206		|O
an	207	209		|O
oral	210	214		|O
agent	215	220		|O
with	221	225		|O
antiproliferative	226	243		|O
effects	244	251		|O
,	251	252		|O
being	253	258		|O
a	259	260		|O
potent	261	267		|O
and	268	271		|O
selective	272	281		|O
inhibitor	282	291		|O
of	292	294		|O
farnesyltransferase	295	314		|O
.	314	315		|O
This	316	320		|O
multicenter	321	332		|O
,	332	333		|O
open	334	338		|O
-	338	339		|O
label	339	344		|O
phase	345	350		|O
II	351	353		|O
study	354	359		|O
was	360	363		|O
designed	364	372		|O
to	373	375		|O
evaluate	376	384		|O
the	385	388		|O
efficacy	389	397		|O
and	398	401		|O
safety	402	408		|O
of	409	411		|O
R115777	412	419		|O
given	420	425		|O
after	426	431		|O
surgery	432	439		|O
and	440	443		|O
prior	444	449		|O
to	450	452		|O
radiation	453	462		|O
in	463	465		|O
patients	466	474		|O
with	475	479		|O
newly	480	485		|O
diagnosed	486	495		|O
and	496	499		|O
residual	500	508		|O
enhancing	509	518		|O
GBM	519	522	GBM	|B-DISEASE
.	522	523		|O
Following	524	533		|O
surgery	534	541		|O
,	541	542		|O
an	543	545		|O
MRI	546	549		|O
confirmed	550	559		|O
the	560	563		|O
presence	564	572		|O
of	573	575		|O
residual	576	584		|O
enhancing	585	594		|O
tumor	595	600		|O
.	600	601		|O
Patients	602	610		|O
on	611	613		|O
enzyme	614	620		|O
-	620	621		|O
inducing	621	629		|O
antiseizure	630	641		|O
drugs	642	647		|O
(	648	649		|O
EIASDs	649	655		|O
)	655	656		|O
received	657	665		|O
600	666	669		|O
mg	670	672		|O
twice	673	678		|O
per	679	682		|O
day	683	686		|O
,	686	687		|O
and	688	691		|O
those	692	697		|O
not	698	701		|O
on	702	704		|O
EIASDs	705	711		|O
received	712	720		|O
300	721	724		|O
mg	725	727		|O
twice	728	733		|O
per	734	737		|O
day	738	741		|O
.	741	742		|O
One	743	746		|O
to	747	749		|O
three	750	755		|O
monthly	756	763		|O
cycles	764	770		|O
of	771	773		|O
R115777	774	781		|O
were	782	786		|O
administered	787	799		|O
,	799	800		|O
and	801	804		|O
radiation	805	814		|O
was	815	818		|O
initiated	819	828		|O
with	829	833		|O
progression	834	845		|O
or	846	848		|O
after	849	854		|O
three	855	860		|O
cycles	861	867		|O
.	867	868		|O
A	869	870		|O
cycle	871	876		|O
consisted	877	886		|O
of	887	889		|O
3	890	891		|O
weeks	892	897		|O
of	898	900		|O
continuous	901	911		|O
R115777	912	919		|O
followed	920	928		|O
by	929	931		|O
a	932	933		|O
1	934	935		|O
-	935	936		|O
week	936	940		|O
rest	941	945		|O
.	945	946		|O
MRI	947	950		|O
was	951	954		|O
done	955	959		|O
monthly	960	967		|O
.	967	968		|O
The	969	972		|O
primary	973	980		|O
end	981	984		|O
point	985	990		|O
was	991	994		|O
overall	995	1002		|O
survival	1003	1011		|O
;	1011	1012		|O
secondary	1013	1022		|O
end	1023	1026		|O
points	1027	1033		|O
were	1034	1038		|O
tumor	1039	1044	tumor	|B-DISEASE
response	1045	1053		|O
rate	1054	1058		|O
and	1059	1062		|O
toxicity	1063	1071		|O
.	1071	1072		|O
A	1073	1074		|O
total	1075	1080		|O
of	1081	1083		|O
28	1084	1086		|O
confirmed	1087	1096		|O
GBM	1097	1100		|O
patients	1101	1109		|O
entered	1110	1117		|O
the	1118	1121		|O
study	1122	1127		|O
;	1127	1128		|O
15	1129	1131		|O
patients	1132	1140		|O
(	1141	1142		|O
54%	1142	1145		|O
)	1145	1146		|O
were	1147	1151		|O
on	1152	1154		|O
EIASDs	1155	1161		|O
.	1161	1162		|O
The	1163	1166		|O
overall	1167	1174		|O
median	1175	1181		|O
time	1182	1186		|O
of	1187	1189		|O
survival	1190	1198		|O
was	1199	1202		|O
7.7	1203	1206		|O
months	1207	1213		|O
.	1213	1214		|O
There	1215	1220		|O
were	1221	1225		|O
no	1226	1228		|O
tumor	1229	1234	tumor	|B-DISEASE
responses	1235	1244		|O
.	1244	1245		|O
Eight	1246	1251		|O
patients	1252	1260		|O
(	1261	1262		|O
29%	1262	1265		|O
)	1265	1266		|O
had	1267	1270		|O
stable	1271	1277		|O
disease	1278	1285		|O
as	1286	1288		|O
the	1289	1292		|O
best	1293	1297		|O
response	1298	1306		|O
.	1306	1307		|O
The	1308	1311		|O
study	1312	1317		|O
was	1318	1321		|O
stopped	1322	1329		|O
early	1330	1335		|O
due	1336	1339		|O
to	1340	1342		|O
progression	1343	1354		|O
of	1355	1357		|O
the	1358	1361		|O
disease	1362	1369		|O
in	1370	1372		|O
12	1373	1375		|O
patients	1376	1384		|O
(	1385	1386		|O
48%	1386	1389		|O
)	1389	1390		|O
.	1390	1391		|O
A	1392	1393		|O
total	1394	1399		|O
of	1400	1402		|O
24	1403	1405		|O
patients	1406	1414		|O
(	1415	1416		|O
85%	1416	1419		|O
)	1419	1420		|O
were	1421	1425		|O
off	1426	1429		|O
study	1430	1435		|O
before	1436	1442		|O
the	1443	1446		|O
planned	1447	1454		|O
treatment	1455	1464		|O
schedule	1465	1473		|O
for	1474	1477		|O
radiation	1478	1487		|O
therapy	1488	1495		|O
.	1495	1496		|O
R115777	1497	1504		|O
administered	1505	1517		|O
prior	1518	1523		|O
to	1524	1526		|O
radiation	1527	1536		|O
therapy	1537	1544		|O
in	1545	1547		|O
patients	1548	1556		|O
with	1557	1561		|O
newly	1562	1567		|O
diagnosed	1568	1577		|O
GBM	1578	1581	GBM	|B-DISEASE
and	1582	1585		|O
residual	1586	1594		|O
enhancing	1595	1604		|O
disease	1605	1612		|O
did	1613	1616		|O
not	1617	1620		|O
result	1621	1627		|O
in	1628	1630		|O
any	1631	1634		|O
measurable	1635	1645		|O
responses	1646	1655		|O
or	1656	1658		|O
improvement	1659	1670		|O
in	1671	1673		|O
survival	1674	1682		|O
.	1682	1683		|O
R115777	1684	1691		|O
administered	1692	1704		|O
prior	1705	1710		|O
to	1711	1713		|O
radiation	1714	1723		|O
therapy	1724	1731		|O
is	1732	1734		|O
not	1735	1738		|O
recommended	1739	1750		|O
for	1751	1754		|O
patients	1755	1763		|O
with	1764	1768		|O
newly	1769	1774		|O
diagnosed	1775	1784		|O
GBM	1785	1788	GBM	|B-DISEASE
.	1788	1789		|O

### 18821991
Inhibition	0	10		|O
of	11	13		|O
hydroxyapatite	14	28		|O
dissolution	29	40		|O
by	41	43		|O
whole	44	49		|O
casein	50	56		|O
:	56	57		|O
the	58	61		|O
effects	62	69		|O
of	70	72		|O
pH	73	75		|O
,	75	76		|O
protein	77	84		|O
concentration	85	98		|O
,	98	99		|O
calcium	100	107		|O
,	107	108		|O
and	109	112		|O
ionic	113	118		|O
strength	119	127		|O
.	127	128		|O
Formulating	130	141		|O
drinks	142	148		|O
with	149	153		|O
reduced	154	161		|O
erosive	162	169		|O
potential	170	179		|O
is	180	182		|O
one	183	186		|O
approach	187	195		|O
for	196	199		|O
reducing	200	208		|O
dental	209	215		|O
erosion	216	223		|O
.	223	224		|O
In	225	227		|O
this	228	232		|O
study	233	238		|O
,	238	239		|O
whole	240	245		|O
casein	246	252		|O
was	253	256		|O
added	257	262		|O
to	263	265		|O
citric	266	272		|O
acid	273	277		|O
solutions	278	287		|O
representative	288	302		|O
of	303	305		|O
soft	306	310		|O
drinks	311	317		|O
,	317	318		|O
and	319	322		|O
the	323	326		|O
hydroxyapatite	327	341		|O
dissolution	342	353		|O
rate	354	358		|O
was	359	362		|O
assessed	363	371		|O
.	371	372		|O
Adding	373	379		|O
0.02%	380	385		|O
(	386	387		|O
w	387	388		|O
/	388	389		|O
v	389	390		|O
)	390	391		|O
casein	392	398		|O
to	399	401		|O
acid	402	406		|O
solutions	407	416		|O
significantly	417	430		|O
reduced	431	438		|O
the	439	442		|O
hydroxyapatite	443	457		|O
dissolution	458	469		|O
rate	470	474		|O
by	475	477		|O
51	478	480		|O
+	481	482		|O
/	482	483		|O
-	483	484		|O
4%	485	487		|O
at	488	490		|O
pH	491	493		|O
values	494	500		|O
of	501	503		|O
2.80	504	508		|O
,	508	509		|O
3.00	510	514		|O
,	514	515		|O
3.20	516	520		|O
,	520	521		|O
3.40	522	526		|O
,	526	527		|O
and	528	531		|O
3.60	532	536		|O
,	536	537		|O
although	538	546		|O
the	547	550		|O
baseline	551	559		|O
dissolution	560	571		|O
rates	572	577		|O
of	578	580		|O
course	581	587		|O
varied	588	594		|O
as	595	597		|O
a	598	599		|O
function	600	608		|O
of	609	611		|O
pH	612	614		|O
.	614	615		|O
The	616	619		|O
protein	620	627		|O
concentration	628	641		|O
[	642	643		|O
0.002	643	648		|O
,	648	649		|O
0.02	650	654		|O
,	654	655		|O
and	656	659		|O
0.2%	660	664		|O
(	665	666		|O
w	666	667		|O
/	667	668		|O
v	668	669		|O
)	669	670		|O
casein	671	677		|O
]	677	678		|O
had	679	682		|O
no	683	685		|O
significant	686	697		|O
effect	698	704		|O
on	705	707		|O
dissolution	708	719		|O
inhibition	720	730		|O
.	730	731		|O
Adding	732	738		|O
both	739	743		|O
casein	744	750		|O
and	751	754		|O
calcium	755	762		|O
to	763	765		|O
citric	766	772		|O
acid	773	777		|O
resulted	778	786		|O
in	787	789		|O
a	790	791		|O
further	792	799		|O
reduction	800	809		|O
in	810	812		|O
the	813	816		|O
dissolution	817	828		|O
rate	829	833		|O
at	834	836		|O
low	837	840		|O
and	841	844		|O
intermediate	845	857		|O
calcium	858	865		|O
concentrations	866	880		|O
(	881	882		|O
5	882	883		|O
and	884	887		|O
10	888	890		|O
mM	891	893		|O
)	893	894		|O
but	895	898		|O
not	899	902		|O
at	903	905		|O
higher	906	912		|O
calcium	913	920		|O
concentrations	921	935		|O
(	936	937		|O
20	937	939		|O
and	940	943		|O
50	944	946		|O
mM	947	949		|O
)	949	950		|O
.	950	951		|O
Ionic	952	957		|O
strength	958	966		|O
had	967	970		|O
no	971	973		|O
significant	974	985		|O
impact	986	992		|O
on	993	995		|O
the	996	999		|O
efficacy	1000	1008		|O
of	1009	1011		|O
casein	1012	1018		|O
.	1018	1019		|O
Casein	1020	1026		|O
also	1027	1031		|O
significantly	1032	1045		|O
reduced	1046	1053		|O
the	1054	1057		|O
hydroxyapatite	1058	1072		|O
dissolution	1073	1084		|O
rate	1085	1089		|O
when	1090	1094		|O
the	1095	1098		|O
hydroxyapatite	1099	1113		|O
was	1114	1117		|O
coated	1118	1124		|O
with	1125	1129		|O
a	1130	1131		|O
salivary	1132	1140		|O
pellicle	1141	1149		|O
.	1149	1150		|O
The	1151	1154		|O
reduction	1155	1164		|O
in	1165	1167		|O
dissolution	1168	1179		|O
rate	1180	1184		|O
is	1185	1187		|O
ascribed	1188	1196		|O
to	1197	1199		|O
firmly	1200	1206		|O
adsorbed	1207	1215		|O
casein	1216	1222		|O
on	1223	1225		|O
the	1226	1229		|O
hydroxyapatite	1230	1244		|O
surface	1245	1252		|O
,	1252	1253		|O
which	1254	1259		|O
stabilizes	1260	1270		|O
the	1271	1274		|O
crystal	1275	1282		|O
surface	1283	1290		|O
and	1291	1294		|O
inhibits	1295	1303		|O
ion	1304	1307		|O
detachment	1308	1318		|O
.	1318	1319		|O

### 18640178
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
sclareol	29	37		|O
.	37	38		|O
A	40	41		|O
toxicologic	42	53		|O
and	54	57		|O
dermatologic	58	70		|O
review	71	77		|O
of	78	80		|O
sclareol	81	89		|O
when	90	94		|O
used	95	99		|O
as	100	102		|O
a	103	104		|O
fragrance	105	114		|O
ingredient	115	125		|O
is	126	128		|O
presented	129	138		|O
.	138	139		|O

### 18723826
Estimates	0	9		|O
of	10	12		|O
cancer	13	19	cancer	|B-ADVERSE
potency	20	27		|O
of	28	30		|O
2,3,4,7,8	31	40		|O
-	40	41		|O
pentachlorodibenzofuran	41	64		|O
using	65	70		|O
both	71	75		|O
nonlinear	76	85		|O
and	86	89		|O
linear	90	96		|O
approaches	97	107		|O
.	107	108		|O
Cancer	110	116	Cancer	|B-ADVERSE
potency	117	124		|O
estimates	125	134		|O
were	135	139		|O
derived	140	147		|O
for	148	151		|O
2,3,4,7,8	152	161		|O
-	161	162		|O
pentachlorodibenzofuran	162	185		|O
(	186	187		|O
4	187	188		|O
-	188	189		|O
PeCDF	189	194		|O
)	194	195		|O
using	196	201		|O
data	202	206		|O
collected	207	216		|O
from	217	221		|O
the	222	225		|O
recently	226	234		|O
published	235	244		|O
National	245	253		|O
Toxicology	254	264		|O
Program	265	272		|O
bioassay	273	281		|O
in	282	284		|O
female	285	291		|O
Sprague	292	299		|O
-	299	300		|O
Dawley	300	306		|O
rats	307	311		|O
.	311	312		|O
By	313	315		|O
using	316	321		|O
a	322	323		|O
toxicokinetic	324	337		|O
model	338	343		|O
for	344	347		|O
4	348	349		|O
-	349	350		|O
PeCDF	350	355		|O
,	355	356		|O
the	357	360		|O
dose	361	365		|O
-	365	366		|O
response	366	374		|O
relationship	375	387		|O
for	388	391		|O
combined	392	400		|O
liver	401	406	liver tumors	|B-ADVERSE
tumors	407	413		|I-ADVERSE
(	414	415		|O
hepatocellular	415	429	hepatocellular adenomas	|B-ADVERSE
adenomas	430	438		|I-ADVERSE
and	439	442		|O
cholangiocarcinomas	443	462	cholangiocarcinomas	|B-ADVERSE
)	462	463		|O
in	464	466		|O
rats	467	471		|O
was	472	475		|O
assessed	476	484		|O
in	485	487		|O
terms	488	493		|O
of	494	496		|O
lifetime	497	505		|O
average	506	513		|O
liver	514	519		|O
concentration	520	533		|O
and	534	537		|O
lifetime	538	546		|O
average	547	554		|O
adipose	555	562		|O
concentration	563	576		|O
with	577	581		|O
data	582	586		|O
from	587	591		|O
both	592	596		|O
the	597	600		|O
lifetime	601	609		|O
and	610	613		|O
the	614	617		|O
stop	618	622		|O
-	622	623		|O
exposure	623	631		|O
components	632	642		|O
of	643	645		|O
the	646	649		|O
bioassay	650	658		|O
.	658	659		|O
Benchmark	660	669		|O
dose	670	674		|O
modeling	675	683		|O
was	684	687		|O
performed	688	697		|O
to	698	700		|O
estimate	701	709		|O
tissue	710	716		|O
concentrations	717	731		|O
at	732	734		|O
two	735	738		|O
points	739	745		|O
of	746	748		|O
departure	749	758		|O
(	759	760		|O
EC	760	762		|O
(	762	763		|O
10	763	765		|O
)	765	766		|O
and	767	770		|O
EC	771	773		|O
(	773	774		|O
01	774	776		|O
)	776	777		|O
and	778	781		|O
their	782	787		|O
95%	788	791		|O
upper	792	797		|O
and	798	801		|O
lower	802	807		|O
confidence	808	818		|O
limits	819	825		|O
)	825	826		|O
.	826	827		|O
The	828	831		|O
same	832	836		|O
toxicokinetic	837	850		|O
model	851	856		|O
with	857	861		|O
human	862	867		|O
input	868	873		|O
values	874	880		|O
was	881	884		|O
then	885	889		|O
used	890	894		|O
to	895	897		|O
back	898	902		|O
-	902	903		|O
extrapolate	903	914		|O
human	915	920		|O
equivalent	921	931		|O
doses	932	937		|O
that	938	942		|O
corresponded	943	955		|O
to	956	958		|O
the	959	962		|O
internal	963	971		|O
tissue	972	978		|O
concentration	979	992		|O
measures	993	1001		|O
at	1002	1004		|O
the	1005	1008		|O
points	1009	1015		|O
of	1016	1018		|O
departure	1019	1028		|O
.	1028	1029		|O
Information	1030	1041		|O
regarding	1042	1051		|O
the	1052	1055		|O
cancer	1056	1062	cancer	|B-DISEASE
mode	1063	1067		|O
of	1068	1070		|O
action	1071	1077		|O
was	1078	1081		|O
used	1082	1086		|O
to	1087	1089		|O
support	1090	1097		|O
the	1098	1101		|O
development	1102	1113		|O
of	1114	1116		|O
several	1117	1124		|O
toxicity	1125	1133		|O
criterion	1134	1143		|O
values	1144	1150		|O
based	1151	1156		|O
on	1157	1159		|O
a	1160	1161		|O
nonlinear	1162	1171		|O
method	1172	1178		|O
,	1178	1179		|O
e.g.	1180	1184		|O
,	1184	1185		|O
reference	1186	1195		|O
dose	1196	1200		|O
or	1201	1203		|O
tolerable	1204	1213		|O
daily	1214	1219		|O
intake	1220	1226		|O
.	1226	1227		|O
Nonlinear	1228	1237		|O
estimates	1238	1247		|O
of	1248	1250		|O
toxicity	1251	1259		|O
criteria	1260	1268		|O
based	1269	1274		|O
on	1275	1277		|O
observed	1278	1286		|O
noncancer	1287	1296		|O
toxic	1297	1302		|O
events	1303	1309		|O
as	1310	1312		|O
possible	1313	1321		|O
precursors	1322	1332		|O
to	1333	1335		|O
tumor	1336	1341	tumor	|B-ADVERSE
formation	1342	1351		|O
were	1352	1356		|O
also	1357	1361		|O
derived	1362	1369		|O
and	1370	1373		|O
were	1374	1378		|O
similar	1379	1386		|O
in	1387	1389		|O
value	1390	1395		|O
to	1396	1398		|O
those	1399	1404		|O
based	1405	1410		|O
on	1411	1413		|O
combined	1414	1422		|O
liver	1423	1428	liver tumors	|B-ADVERSE
tumors	1429	1435		|I-ADVERSE
.	1435	1436		|O
For	1437	1440		|O
comparison	1441	1451		|O
purposes	1452	1460		|O
,	1460	1461		|O
linear	1462	1468		|O
estimates	1469	1478		|O
of	1479	1481		|O
cancer	1482	1488	cancer	|B-ADVERSE
potency	1489	1496		|O
were	1497	1501		|O
also	1502	1506		|O
derived	1507	1514		|O
.	1514	1515		|O

### 18728729
Effects	0	7		|O
of	8	10		|O
in	11	13		|O
vitro	14	19		|O
brevetoxin	20	30		|O
exposure	31	39		|O
on	40	42		|O
apoptosis	43	52		|O
and	53	56		|O
cellular	57	65		|O
metabolism	66	76		|O
in	77	79		|O
a	80	81		|O
leukemic	82	90		|O
T	91	92		|O
cell	93	97		|O
line	98	102		|O
(	103	104		|O
Jurkat	104	110		|O
)	110	111		|O
.	111	112		|O
Harmful	114	121		|O
algal	122	127		|O
blooms	128	134		|O
(	135	136		|O
HABs	136	140		|O
)	140	141		|O
of	142	144		|O
the	145	148		|O
toxic	149	154		|O
dinoflagellate	155	169		|O
,	169	170		|O
Karenia	171	178		|O
brevis	179	185		|O
,	185	186		|O
produce	187	194		|O
red	195	198		|O
tide	199	203		|O
toxins	204	210		|O
,	210	211		|O
or	212	214		|O
brevetoxins	215	226		|O
.	226	227		|O
Significant	228	239		|O
health	240	246		|O
effects	247	254		|O
associated	255	265		|O
with	266	270		|O
red	271	274		|O
tide	275	279		|O
toxin	280	285		|O
exposure	286	294		|O
have	295	299		|O
been	300	304		|O
reported	305	313		|O
in	314	316		|O
sea	317	320		|O
life	321	325		|O
and	326	329		|O
in	330	332		|O
humans	333	339		|O
,	339	340		|O
with	341	345		|O
brevetoxins	346	357		|O
documented	358	368		|O
within	369	375		|O
immune	376	382		|O
cells	383	388		|O
from	389	393		|O
many	394	398		|O
species	399	406		|O
.	406	407		|O
The	408	411		|O
objective	412	421		|O
of	422	424		|O
this	425	429		|O
research	430	438		|O
was	439	442		|O
to	443	445		|O
investigate	446	457		|O
potential	458	467		|O
immunotoxic	468	479		|O
effects	480	487		|O
of	488	490		|O
brevetoxins	491	502		|O
using	503	508		|O
a	509	510		|O
leukemic	511	519		|O
T	520	521		|O
cell	522	526		|O
line	527	531		|O
(	532	533		|O
Jurkat	533	539		|O
)	539	540		|O
as	541	543		|O
an	544	546		|O
in	547	549		|O
vitro	550	555		|O
model	556	561		|O
system	562	568		|O
.	568	569		|O
Viability	570	579		|O
,	579	580		|O
cell	581	585		|O
proliferation	586	599		|O
,	599	600		|O
and	601	604		|O
apoptosis	605	614		|O
assays	615	621		|O
were	622	626		|O
conducted	627	636		|O
using	637	642		|O
brevetoxin	643	653		|O
congeners	654	663		|O
PbTx	664	668		|O
-	668	669		|O
2	669	670		|O
,	670	671		|O
PbTx	672	676		|O
-	676	677		|O
3	677	678		|O
,	678	679		|O
and	680	683		|O
PbTx	684	688		|O
-	688	689		|O
6	689	690		|O
.	690	691		|O
The	692	695		|O
effects	696	703		|O
of	704	706		|O
in	707	709		|O
vitro	710	715		|O
brevetoxin	716	726		|O
exposure	727	735		|O
on	736	738		|O
cell	739	743		|O
viability	744	753		|O
and	754	757		|O
cellular	758	766		|O
metabolism	767	777		|O
or	778	780		|O
proliferation	781	794		|O
were	795	799		|O
determined	800	810		|O
using	811	816		|O
trypan	817	823		|O
blue	824	828		|O
and	829	832		|O
MTT	833	836		|O
(	837	838		|O
1	838	839		|O
-	839	840		|O
(	840	841		|O
4,5	841	844		|O
-	844	845		|O
dimethylthiazol	845	860		|O
-	860	861		|O
2	861	862		|O
-	862	863		|O
yl	863	865		|O
)	865	866		|O
-	866	867		|O
3,5	867	870		|O
-	870	871		|O
diphenylformazan	871	887		|O
)	887	888		|O
,	888	889		|O
respectively	890	902		|O
.	902	903		|O
Using	904	909		|O
MTT	910	913		|O
,	913	914		|O
cellular	915	923		|O
metabolic	924	933		|O
activity	934	942		|O
was	943	946		|O
decreased	947	956		|O
in	957	959		|O
Jurkat	960	966		|O
cells	967	972		|O
exposed	973	980		|O
to	981	983		|O
5	984	985		|O
-	986	987		|O
10	988	990		|O
microg	991	997		|O
/	997	998		|O
ml	998	1000		|O
PbTx	1001	1005		|O
-	1005	1006		|O
2	1006	1007		|O
or	1008	1010		|O
PbTx	1011	1015		|O
-	1015	1016		|O
6	1016	1017		|O
.	1017	1018		|O
After	1019	1024		|O
3	1025	1026		|O
h	1027	1028		|O
,	1028	1029		|O
no	1030	1032		|O
significant	1033	1044		|O
effects	1045	1052		|O
on	1053	1055		|O
cell	1056	1060		|O
viability	1061	1070		|O
were	1071	1075		|O
observed	1076	1084		|O
with	1085	1089		|O
any	1090	1093		|O
toxin	1094	1099		|O
congener	1100	1108		|O
in	1109	1111		|O
concentrations	1112	1126		|O
up	1127	1129		|O
to	1130	1132		|O
10	1133	1135		|O
microg	1136	1142		|O
/	1142	1143		|O
ml	1143	1145		|O
.	1145	1146		|O
Viability	1147	1156		|O
decreased	1157	1166		|O
dramatically	1167	1179		|O
after	1180	1185		|O
24	1186	1188		|O
h	1189	1190		|O
in	1191	1193		|O
cells	1194	1199		|O
treated	1200	1207		|O
with	1208	1212		|O
PbTx	1213	1217		|O
-	1217	1218		|O
2	1218	1219		|O
or	1220	1222		|O
-	1223	1224		|O
6	1224	1225		|O
.	1225	1226		|O
Apoptosis	1227	1236		|O
,	1236	1237		|O
as	1238	1240		|O
measured	1241	1249		|O
by	1250	1252		|O
caspase	1253	1260		|O
-	1260	1261		|O
3	1261	1262		|O
activity	1263	1271		|O
,	1271	1272		|O
was	1273	1276		|O
significantly	1277	1290		|O
increased	1291	1300		|O
in	1301	1303		|O
cells	1304	1309		|O
exposed	1310	1317		|O
to	1318	1320		|O
PbTx	1321	1325		|O
-	1325	1326		|O
2	1326	1327		|O
or	1328	1330		|O
PbTx	1331	1335		|O
-	1335	1336		|O
6	1336	1337		|O
.	1337	1338		|O
In	1339	1341		|O
summary	1342	1349		|O
,	1349	1350		|O
brevetoxin	1351	1361		|O
congeners	1362	1371		|O
varied	1372	1378		|O
in	1379	1381		|O
effects	1382	1389		|O
on	1390	1392		|O
Jurkat	1393	1399		|O
cells	1400	1405		|O
,	1405	1406		|O
with	1407	1411		|O
PbTx	1412	1416		|O
-	1416	1417		|O
2	1417	1418		|O
and	1419	1422		|O
PbTx	1423	1427		|O
-	1427	1428		|O
6	1428	1429		|O
eliciting	1430	1439		|O
greater	1440	1447		|O
cellular	1448	1456		|O
effects	1457	1464		|O
compared	1465	1473		|O
to	1474	1476		|O
PbTx	1477	1481		|O
-	1481	1482		|O
3	1482	1483		|O
.	1483	1484		|O

### 18623084
Impact	0	6		|O
of	7	9		|O
antioxidant	10	21		|O
supplementation	22	37		|O
on	38	40		|O
chemotherapeutic	41	57	chemotherapeutic toxicity	|B-ADVERSE
toxicity	58	66		|I-ADVERSE
:	66	67		|O
a	68	69		|O
systematic	70	80		|O
review	81	87		|O
of	88	90		|O
the	91	94		|O
evidence	95	103		|O
from	104	108		|O
randomized	109	119		|O
controlled	120	130		|O
trials	131	137		|O
.	137	138		|O
Much	140	144		|O
debate	145	151		|O
has	152	155		|O
focused	156	163		|O
on	164	166		|O
whether	167	174		|O
antioxidants	175	187		|O
interfere	188	197		|O
with	198	202		|O
the	203	206		|O
efficacy	207	215		|O
of	216	218		|O
cancer	219	225	cancer	|B-DISEASE
chemotherapy	226	238		|O
.	238	239		|O
The	240	243		|O
objective	244	253		|O
of	254	256		|O
this	257	261		|O
study	262	267		|O
is	268	270		|O
to	271	273		|O
systematically	274	288		|O
review	289	295		|O
the	296	299		|O
randomized	300	310		|O
,	310	311		|O
controlled	312	322		|O
clinical	323	331		|O
trial	332	337		|O
evidence	338	346		|O
evaluating	347	357		|O
the	358	361		|O
effects	362	369		|O
of	370	372		|O
concurrent	373	383		|O
use	384	387		|O
of	388	390		|O
antioxidants	391	403		|O
with	404	408		|O
chemotherapy	409	421		|O
on	422	424		|O
toxic	425	430		|O
side	431	435		|O
effects	436	443		|O
.	443	444		|O
We	445	447		|O
performed	448	457		|O
a	458	459		|O
search	460	466		|O
of	467	469		|O
literature	470	480		|O
from	481	485		|O
1966	486	490		|O
-	490	491		|O
October	491	498		|O
2007	499	503		|O
using	504	509		|O
MEDLINE	510	517		|O
,	517	518		|O
Cochrane	519	527		|O
,	527	528		|O
CinAhl	529	535		|O
,	535	536		|O
AMED	537	541		|O
,	541	542		|O
AltHealthWatch	543	557		|O
and	558	561		|O
EMBASE	562	568		|O
databases	569	578		|O
.	578	579		|O
Randomized	580	590		|O
,	590	591		|O
controlled	592	602		|O
clinical	603	611		|O
trials	612	618		|O
reporting	619	628		|O
antioxidant	629	640		|O
-	640	641		|O
based	641	646		|O
mitigation	647	657		|O
of	658	660		|O
chemotherapy	661	673	chemotherapy toxicity	|B-ADVERSE
toxicity	674	682		|I-ADVERSE
were	683	687		|O
included	688	696		|O
in	697	699		|O
the	700	703		|O
final	704	709		|O
tally	710	715		|O
.	715	716		|O
Searches	717	725		|O
were	726	730		|O
performed	731	740		|O
following	741	750		|O
a	751	752		|O
standardized	753	765		|O
protocol	766	774		|O
for	775	778		|O
systematic	779	789		|O
reviews	790	797		|O
.	797	798		|O
Only	799	803		|O
33	804	806		|O
of	807	809		|O
965	810	813		|O
articles	814	822		|O
considered	823	833		|O
,	833	834		|O
including	835	844		|O
2,446	845	850		|O
subjects	851	859		|O
,	859	860		|O
met	861	864		|O
the	865	868		|O
inclusion	869	878		|O
criteria	879	887		|O
.	887	888		|O
Antioxidants	889	901		|O
evaluated	902	911		|O
were	912	916		|O
:	916	917		|O
glutathione	918	929		|O
(	930	931		|O
11	931	933		|O
)	933	934		|O
,	934	935		|O
melatonin	936	945		|O
(	946	947		|O
7	947	948		|O
)	948	949		|O
,	949	950		|O
vitamin	951	958		|O
A	959	960		|O
(	961	962		|O
1	962	963		|O
)	963	964		|O
,	964	965		|O
an	966	968		|O
antioxidant	969	980		|O
mixture	981	988		|O
(	989	990		|O
2	990	991		|O
)	991	992		|O
,	992	993		|O
N	994	995		|O
-	995	996		|O
acetylcysteine	996	1010		|O
(	1011	1012		|O
2	1012	1013		|O
)	1013	1014		|O
,	1014	1015		|O
vitamin	1016	1023		|O
E	1024	1025		|O
(	1026	1027		|O
5	1027	1028		|O
)	1028	1029		|O
,	1029	1030		|O
selenium	1031	1039		|O
(	1040	1041		|O
2	1041	1042		|O
)	1042	1043		|O
,	1043	1044		|O
L	1045	1046		|O
-	1046	1047		|O
carnitine	1047	1056		|O
(	1057	1058		|O
1	1058	1059		|O
)	1059	1060		|O
,	1060	1061		|O
Co	1062	1064		|O
-	1064	1065		|O
Q10	1065	1068		|O
(	1069	1070		|O
1	1070	1071		|O
)	1071	1072		|O
and	1073	1076		|O
ellagic	1077	1084		|O
acid	1085	1089		|O
(	1090	1091		|O
1	1091	1092		|O
)	1092	1093		|O
.	1093	1094		|O
The	1095	1098		|O
majority	1099	1107		|O
(	1108	1109		|O
24	1109	1111		|O
)	1111	1112		|O
of	1113	1115		|O
the	1116	1119		|O
33	1120	1122		|O
studies	1123	1130		|O
included	1131	1139		|O
reported	1140	1148		|O
evidence	1149	1157		|O
of	1158	1160		|O
decreased	1161	1170		|O
toxicities	1171	1181		|O
from	1182	1186		|O
the	1187	1190		|O
concurrent	1191	1201		|O
use	1202	1205		|O
of	1206	1208		|O
antioxidants	1209	1221		|O
with	1222	1226		|O
chemotherapy	1227	1239		|O
.	1239	1240		|O
Nine	1241	1245		|O
studies	1246	1253		|O
reported	1254	1262		|O
no	1263	1265		|O
difference	1266	1276		|O
in	1277	1279		|O
toxicities	1280	1290		|O
between	1291	1298		|O
the	1299	1302		|O
2	1303	1304		|O
groups	1305	1311		|O
.	1311	1312		|O
Only	1313	1317		|O
1	1318	1319		|O
study	1320	1325		|O
(	1326	1327		|O
vitamin	1327	1334		|O
A	1335	1336		|O
)	1336	1337		|O
reported	1338	1346		|O
a	1347	1348		|O
significant	1349	1360		|O
increase	1361	1369		|O
in	1370	1372		|O
toxicity	1373	1381		|O
in	1382	1384		|O
the	1385	1388		|O
antioxidant	1389	1400		|O
group	1401	1406		|O
.	1406	1407		|O
Five	1408	1412		|O
studies	1413	1420		|O
reported	1421	1429		|O
the	1430	1433		|O
antioxidant	1434	1445		|O
group	1446	1451		|O
completed	1452	1461		|O
more	1462	1466		|O
full	1467	1471		|O
doses	1472	1477		|O
of	1478	1480		|O
chemotherapy	1481	1493		|O
or	1494	1496		|O
had	1497	1500		|O
less	1501	1505		|O
-	1505	1506		|O
dose	1506	1510		|O
reduction	1511	1520		|O
than	1521	1525		|O
control	1526	1533		|O
groups	1534	1540		|O
.	1540	1541		|O
Statistical	1542	1553		|O
power	1554	1559		|O
and	1560	1563		|O
poor	1564	1568		|O
study	1569	1574		|O
quality	1575	1582		|O
were	1583	1587		|O
concerns	1588	1596		|O
with	1597	1601		|O
some	1602	1606		|O
studies	1607	1614		|O
.	1614	1615		|O
This	1616	1620		|O
review	1621	1627		|O
provides	1628	1636		|O
the	1637	1640		|O
first	1641	1646		|O
systematically	1647	1661		|O
reviewed	1662	1670		|O
evidence	1671	1679		|O
that	1680	1684		|O
antioxidant	1685	1696		|O
supplementation	1697	1712		|O
during	1713	1719		|O
chemotherapy	1720	1732		|O
holds	1733	1738		|O
potential	1739	1748		|O
for	1749	1752		|O
reducing	1753	1761		|O
dose	1762	1766		|O
-	1766	1767		|O
limiting	1767	1775		|O
toxicities	1776	1786		|O
.	1786	1787		|O
However	1788	1795		|O
,	1795	1796		|O
well	1797	1801		|O
-	1801	1802		|O
designed	1802	1810		|O
studies	1811	1818		|O
evaluating	1819	1829		|O
larger	1830	1836		|O
populations	1837	1848		|O
of	1849	1851		|O
patients	1852	1860		|O
given	1861	1866		|O
specific	1867	1875		|O
antioxidants	1876	1888		|O
defined	1889	1896		|O
by	1897	1899		|O
dose	1900	1904		|O
and	1905	1908		|O
schedule	1909	1917		|O
relative	1918	1926		|O
to	1927	1929		|O
chemotherapy	1930	1942		|O
are	1943	1946		|O
warranted	1947	1956		|O
.	1956	1957		|O

### 18638709
The	0	3		|O
effect	4	10		|O
of	11	13		|O
QuYuHuaTanTongLuo	14	31		|O
Decoction	32	41		|O
on	42	44		|O
the	45	48		|O
non	49	52	non-alcoholic steatohepatitis	|B-DISEASE
-	52	53		|I-DISEASE
alcoholic	53	62		|I-DISEASE
steatohepatitis	63	78		|I-DISEASE
.	78	79		|O
Non	81	84	Non-alcoholic steatohepatitis	|B-DISEASE
-	84	85		|I-DISEASE
alcoholic	85	94		|I-DISEASE
steatohepatitis	95	110		|I-DISEASE
(	111	112		|O
NASH	112	116		|O
)	116	117		|O
is	118	120		|O
the	121	124		|O
most	125	129		|O
common	130	136		|O
cause	137	142		|O
of	143	145		|O
cryptogenic	146	157	cryptogenic cirrhosis	|B-DISEASE
cirrhosis	158	167		|I-DISEASE
,	167	168		|O
is	169	171		|O
becoming	172	180		|O
more	181	185		|O
prevalent	186	195		|O
in	196	198		|O
China	199	204		|O
.	204	205		|O
However	206	213		|O
,	213	214		|O
there	215	220		|O
is	221	223		|O
as	224	226		|O
yet	227	230		|O
no	231	233		|O
clearly	234	241		|O
established	242	253		|O
therapy	254	261		|O
for	262	265		|O
reversing	266	275		|O
fatty	276	281	fatty liver	|B-DISEASE
liver	282	287		|I-DISEASE
.	287	288		|O
Our	289	292		|O
aim	293	296		|O
is	297	299		|O
to	300	302		|O
explore	303	310		|O
the	311	314		|O
effect	315	321		|O
of	322	324		|O
traditional	325	336		|O
Chinese	337	344		|O
herbs	345	350		|O
QuYuHuaTanTongLuo	351	368		|O
Decoction	369	378		|O
(	379	380		|O
QYHTTLD	380	387		|O
)	387	388		|O
on	389	391		|O
non	392	395	non-alcoholic steatohepatitis	|B-DISEASE
-	395	396		|I-DISEASE
alcoholic	396	405		|I-DISEASE
steatohepatitis	406	421		|I-DISEASE
.	421	422		|O
Sixty	423	428		|O
-	428	429		|O
nine	429	433		|O
non	434	437	non-alcoholic steatohepatitis	|B-DISEASE
-	437	438		|I-DISEASE
alcoholic	438	447		|I-DISEASE
steatohepatitis	448	463		|I-DISEASE
patients	464	472		|O
were	473	477		|O
randomly	478	486		|O
divided	487	494		|O
into	495	499		|O
two	500	503		|O
groups	504	510		|O
.	510	511		|O
One	512	515		|O
group	516	521		|O
of	522	524		|O
35	525	527		|O
patients	528	536		|O
were	537	541		|O
treated	542	549		|O
by	550	552		|O
QYHTTLD	553	560		|O
,	560	561		|O
another	562	569		|O
group	570	575		|O
of	576	578		|O
34	579	581		|O
patients	582	590		|O
were	591	595		|O
treated	596	603		|O
by	604	606		|O
Ursodeoxycholic	607	622		|O
acid	623	627		|O
(	628	629		|O
UDCA	629	633		|O
)	633	634		|O
.	634	635		|O
The	636	639		|O
TNF	640	643		|O
-	643	644		|O
alpha	644	649		|O
,	649	650		|O
IL	651	653		|O
-	653	654		|O
8	654	655		|O
,	655	656		|O
MDA	657	660		|O
level	661	666		|O
,	666	667		|O
SOD	668	671		|O
activity	672	680		|O
and	681	684		|O
liver	685	690		|O
function	691	699		|O
,	699	700		|O
as	701	703		|O
well	704	708		|O
as	709	711		|O
B	712	713		|O
ultrasonic	714	724		|O
image	725	730		|O
were	731	735		|O
detected	736	744		|O
before	745	751		|O
and	752	755		|O
after	756	761		|O
being	762	767		|O
treated	768	775		|O
.	775	776		|O
The	777	780		|O
results	781	788		|O
showed	789	795		|O
:	795	796		|O
after	797	802		|O
6	803	804		|O
months	805	811		|O
treatment	812	821		|O
,	821	822		|O
MBI	823	826		|O
of	827	829		|O
the	830	833		|O
treatment	834	843		|O
group	844	849		|O
was	850	853		|O
obviously	854	863		|O
decreased	864	873		|O
(	874	875		|O
p	875	876		|O
<	876	877		|O
0.05	877	881		|O
)	881	882		|O
.	882	883		|O
The	884	887		|O
levels	888	894		|O
of	895	897		|O
TC	898	900		|O
,	900	901		|O
TG	902	904		|O
and	905	908		|O
LDL	909	912		|O
-	912	913		|O
C	913	914		|O
were	915	919		|O
significantly	920	933		|O
decreased	934	943		|O
whereas	944	951		|O
the	952	955		|O
level	956	961		|O
of	962	964		|O
HDL	965	968		|O
-	968	969		|O
C	969	970		|O
increased	971	980		|O
(	981	982		|O
p	982	983		|O
<	983	984		|O
0.01	984	988		|O
,	988	989		|O
p	990	991		|O
<	991	992		|O
0.05	992	996		|O
,	996	997		|O
p	998	999		|O
<	999	1000		|O
0.05	1000	1004		|O
,	1004	1005		|O
and	1006	1009		|O
p	1010	1011		|O
<	1011	1012		|O
0.05	1012	1016		|O
,	1016	1017		|O
respectively	1018	1030		|O
)	1030	1031		|O
in	1032	1034		|O
the	1035	1038		|O
treatment	1039	1048		|O
group	1049	1054		|O
,	1054	1055		|O
the	1056	1059		|O
levels	1060	1066		|O
of	1067	1069		|O
TC	1070	1072		|O
,	1072	1073		|O
TG	1074	1076		|O
,	1076	1077		|O
LDL	1078	1081		|O
-	1081	1082		|O
C	1082	1083		|O
and	1084	1087		|O
HDL	1088	1091		|O
-	1091	1092		|O
C	1092	1093		|O
had	1094	1097		|O
no	1098	1100		|O
significant	1101	1112		|O
difference	1113	1123		|O
in	1124	1126		|O
the	1127	1130		|O
control	1131	1138		|O
group	1139	1144		|O
(	1145	1146		|O
p	1146	1147		|O
>	1147	1148		|O
0.05	1148	1152		|O
)	1152	1153		|O
.	1153	1154		|O
The	1155	1158		|O
levels	1159	1165		|O
of	1166	1168		|O
TNF	1169	1172		|O
-	1172	1173		|O
alpha	1173	1178		|O
,	1178	1179		|O
IL	1180	1182		|O
-	1182	1183		|O
8	1183	1184		|O
and	1185	1188		|O
MDA	1189	1192		|O
were	1193	1197		|O
significantly	1198	1211		|O
decreased	1212	1221		|O
whereas	1222	1229		|O
SOD	1230	1233		|O
activity	1234	1242		|O
was	1243	1246		|O
significantly	1247	1260		|O
increased	1261	1270		|O
(	1271	1272		|O
p	1272	1273		|O
<	1273	1274		|O
0.01	1274	1278		|O
,	1278	1279		|O
p	1280	1281		|O
<	1281	1282		|O
0.05	1282	1286		|O
,	1286	1287		|O
p	1288	1289		|O
<	1289	1290		|O
0.01	1290	1294		|O
,	1294	1295		|O
and	1296	1299		|O
p	1300	1301		|O
<	1301	1302		|O
0.01	1302	1306		|O
,	1306	1307		|O
respectively	1308	1320		|O
)	1320	1321		|O
in	1322	1324		|O
the	1325	1328		|O
treatment	1329	1338		|O
group	1339	1344		|O
,	1344	1345		|O
the	1346	1349		|O
level	1350	1355		|O
of	1356	1358		|O
MDA	1359	1362		|O
was	1363	1366		|O
significantly	1367	1380		|O
decreased	1381	1390		|O
in	1391	1393		|O
the	1394	1397		|O
control	1398	1405		|O
group	1406	1411		|O
(	1412	1413		|O
p	1413	1414		|O
<	1414	1415		|O
0.05	1415	1419		|O
)	1419	1420		|O
.	1420	1421		|O
B	1422	1423		|O
ultrasonic	1424	1434		|O
images	1435	1441		|O
were	1442	1446		|O
ameliorated	1447	1458		|O
in	1459	1461		|O
different	1462	1471		|O
degree	1472	1478		|O
(	1479	1480		|O
p	1480	1481		|O
<	1481	1482		|O
0.01	1482	1486		|O
and	1487	1490		|O
p	1491	1492		|O
<	1492	1493		|O
0.01	1493	1497		|O
,	1497	1498		|O
respectively	1499	1511		|O
)	1511	1512		|O
.	1512	1513		|O
Both	1514	1518		|O
QYHTTLD	1519	1526		|O
and	1527	1530		|O
UDCA	1531	1535		|O
had	1536	1539		|O
the	1540	1543		|O
effect	1544	1550		|O
in	1551	1553		|O
improving	1554	1563		|O
the	1564	1567		|O
scores	1568	1574		|O
of	1575	1577		|O
symptoms	1578	1586		|O
and	1587	1590		|O
signs	1591	1596		|O
of	1597	1599		|O
patients	1600	1608		|O
,	1608	1609		|O
however	1610	1617		|O
,	1617	1618		|O
the	1619	1622		|O
difference	1623	1633		|O
value	1634	1639		|O
of	1640	1642		|O
the	1643	1646		|O
scores	1647	1653		|O
in	1654	1656		|O
treatment	1657	1666		|O
group	1667	1672		|O
were	1673	1677		|O
significantly	1678	1691		|O
higher	1692	1698		|O
than	1699	1703		|O
that	1704	1708		|O
in	1709	1711		|O
control	1712	1719		|O
group	1720	1725		|O
after	1726	1731		|O
being	1732	1737		|O
treated	1738	1745		|O
for	1746	1749		|O
6	1750	1751		|O
months	1752	1758		|O
(	1759	1760		|O
p	1760	1761		|O
<	1761	1762		|O
0.05	1762	1766		|O
)	1766	1767		|O
.	1767	1768		|O
Conclusion	1769	1779		|O
:	1779	1780		|O
QYHTTLD	1781	1788		|O
is	1789	1791		|O
effective	1792	1801		|O
for	1802	1805		|O
treating	1806	1814		|O
non	1815	1818	non-alcoholic steatohepatitis	|B-DISEASE
-	1818	1819		|I-DISEASE
alcoholic	1819	1828		|I-DISEASE
steatohepatitis	1829	1844		|I-DISEASE
,	1844	1845		|O
and	1846	1849		|O
its	1850	1853		|O
effect	1854	1860		|O
seems	1861	1866		|O
to	1867	1869		|O
relate	1870	1876		|O
with	1877	1881		|O
the	1882	1885		|O
ways	1886	1890		|O
of	1891	1893		|O
QYHTTL	1894	1900		|O
down	1901	1905		|O
-	1905	1906		|O
regulating	1906	1916		|O
inflammation	1917	1929	inflammation	|B-DISEASE
cytokine	1930	1938		|O
IL	1939	1941		|O
-	1941	1942		|O
8	1942	1943		|O
level	1944	1949		|O
and	1950	1953		|O
relieving	1954	1963		|O
lipid	1964	1969		|O
peroxidation	1970	1982		|O
of	1983	1985		|O
liver	1986	1991		|O
.	1991	1992		|O

### 18593597
A	0	1		|O
high	2	6		|O
throughput	7	17		|O
in	18	20		|O
vitro	21	26		|O
analytical	27	37		|O
approach	38	46		|O
to	47	49		|O
screen	50	56		|O
for	57	60		|O
oxidative	61	70		|O
stress	71	77		|O
potential	78	87		|O
exerted	88	95		|O
by	96	98		|O
nanomaterials	99	112		|O
using	113	118		|O
a	119	120		|O
biologically	121	133		|O
relevant	134	142		|O
matrix	143	149		|O
:	149	150		|O
human	151	156		|O
blood	157	162		|O
serum	163	168		|O
.	168	169		|O
Limited	171	178		|O
studies	179	186		|O
have	187	191		|O
shown	192	197		|O
that	198	202		|O
selected	203	211		|O
nanomaterials	212	225		|O
(	226	227		|O
NMs	227	230		|O
)	230	231		|O
impart	232	238		|O
various	239	246		|O
forms	247	252		|O
of	253	255		|O
toxicity	256	264		|O
in	265	267		|O
biological	268	278		|O
systems	279	286		|O
;	286	287		|O
however	288	295		|O
,	295	296		|O
a	297	298		|O
common	299	305		|O
metric	306	312		|O
to	313	315		|O
screen	316	322		|O
for	323	326		|O
potential	327	336		|O
toxicity	337	345		|O
is	346	348		|O
needed	349	355		|O
.	355	356		|O
This	357	361		|O
study	362	367		|O
optimized	368	377		|O
and	378	381		|O
utilized	382	390		|O
a	391	392		|O
'	393	394		|O
Ferric	394	400		|O
reducing	401	409		|O
ability	410	417		|O
of	418	420		|O
serum	421	426		|O
(	427	428		|O
FRAS	428	432		|O
)	432	433		|O
'	433	434		|O
assay	435	440		|O
as	441	443		|O
a	444	445		|O
screening	446	455		|O
tool	456	460		|O
to	461	463		|O
quantitate	464	474		|O
the	475	478		|O
degree	479	485		|O
of	486	488		|O
oxidative	489	498		|O
damage	499	505		|O
induced	506	513		|O
by	514	516		|O
NMs	517	520		|O
on	521	523		|O
human	524	529		|O
blood	530	535		|O
serum	536	541		|O
.	541	542		|O
Antioxidants	543	555		|O
in	556	558		|O
blood	559	564		|O
protect	565	572		|O
against	573	580		|O
oxidative	581	590		|O
damage	591	597		|O
caused	598	604		|O
by	605	607		|O
free	608	612		|O
radicals	613	621		|O
via	622	625		|O
chemical	626	634		|O
quenching	635	644		|O
and	645	648		|O
will	649	653		|O
decrease	654	662		|O
when	663	667		|O
exposed	668	675		|O
to	676	678		|O
oxidatively	679	690		|O
stressful	691	700		|O
materials	701	710		|O
.	710	711		|O
Using	712	717		|O
this	718	722		|O
approach	723	731		|O
,	731	732		|O
the	733	736		|O
antioxidant	737	748		|O
capacity	749	757		|O
of	758	760		|O
NM	761	763		|O
treated	764	771		|O
serum	772	777		|O
was	778	781		|O
significantly	782	795		|O
decreased	796	805		|O
by	806	808		|O
nano	809	813		|O
-	813	814		|O
silver	814	820		|O
,	820	821		|O
a	822	823		|O
series	824	830		|O
of	831	833		|O
nano	834	838		|O
-	838	839		|O
carbon	839	845		|O
blacks	846	852		|O
,	852	853		|O
fullerene	854	863		|O
soot	864	868		|O
,	868	869		|O
and	870	873		|O
nano	874	878		|O
-	878	879		|O
TiO	879	882		|O
(	882	883		|O
2	883	884		|O
)	884	885		|O
(	886	887		|O
anatase	887	894		|O
,	894	895		|O
p	896	897		|O
<	897	898		|O
0.05	898	902		|O
)	902	903		|O
,	903	904		|O
but	905	908		|O
not	909	912		|O
with	913	917		|O
nano	918	922		|O
-	922	923		|O
alumina	923	930		|O
,	930	931		|O
fullerite	932	941		|O
,	941	942		|O
purified	943	951		|O
fullerene	952	961		|O
,	961	962		|O
fine	963	967		|O
TiO	968	971		|O
(	971	972		|O
2	972	973		|O
)	973	974		|O
(	975	976		|O
rutile	976	982		|O
)	982	983		|O
and	984	987		|O
Min	988	991		|O
-	991	992		|O
U	992	993		|O
-	993	994		|O
Sil	994	997		|O
5	998	999		|O
.	999	1000		|O
Particle	1001	1009		|O
surface	1010	1017		|O
area	1018	1022		|O
and	1023	1026		|O
not	1027	1030		|O
biological	1031	1041		|O
particle	1042	1050		|O
size	1051	1055		|O
was	1056	1059		|O
highly	1060	1066		|O
associated	1067	1077		|O
with	1078	1082		|O
the	1083	1086		|O
degree	1087	1093		|O
of	1094	1096		|O
oxidative	1097	1106		|O
stress	1107	1113		|O
observed	1114	1122		|O
.	1122	1123		|O
This	1124	1128		|O
approach	1129	1137		|O
appears	1138	1145		|O
responsive	1146	1156		|O
to	1157	1159		|O
multiple	1160	1168		|O
determinants	1169	1181		|O
of	1182	1184		|O
oxidative	1185	1194		|O
damage	1195	1201		|O
,	1201	1202		|O
including	1203	1212		|O
particle	1213	1221		|O
chemistry	1222	1231		|O
,	1231	1232		|O
surface	1233	1240		|O
area	1241	1245		|O
and	1246	1249		|O
impurities	1250	1260		|O
,	1260	1261		|O
and	1262	1265		|O
may	1266	1269		|O
be	1270	1272		|O
a	1273	1274		|O
valid	1275	1280		|O
screening	1281	1290		|O
method	1291	1297		|O
to	1298	1300		|O
determine	1301	1310		|O
oxidative	1311	1320		|O
damage	1321	1327		|O
imparted	1328	1336		|O
by	1337	1339		|O
nanomaterials	1340	1353		|O
.	1353	1354		|O

### 18640219
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
ocimenol	29	37		|O
.	37	38		|O
A	40	41		|O
toxicologic	42	53		|O
and	54	57		|O
dermatologic	58	70		|O
review	71	77		|O
of	78	80		|O
ocimenol	81	89		|O
when	90	94		|O
used	95	99		|O
as	100	102		|O
a	103	104		|O
fragrance	105	114		|O
ingredient	115	125		|O
is	126	128		|O
presented	129	138		|O
.	138	139		|O

### 18829735
Early	0	5		|O
-	5	6		|O
onset	6	11		|O
pancytopenia	12	24	pancytopenia	|B-ADVERSE
and	25	28		|O
skin	29	33	skin ulcer	|B-ADVERSE
ulcer	34	39		|I-ADVERSE
following	40	49		|O
low	50	53		|O
-	53	54		|O
dose	54	58		|O
methotrexate	59	71		|O
therapy	72	79		|O
.	79	80		|O
Pancytopenia	82	94	Pancytopenia	|B-ADVERSE
is	95	97		|O
a	98	99		|O
rare	100	104		|O
but	105	108		|O
serious	109	116		|O
adverse	117	124		|O
effect	125	131		|O
of	132	134		|O
low	135	138		|O
-	138	139		|O
dose	139	143		|O
methotrexate	144	156		|O
(	157	158		|O
MTX	158	161		|O
)	161	162		|O
sodium	163	169		|O
therapy	170	177		|O
,	177	178		|O
and	179	182		|O
this	183	187		|O
case	188	192		|O
report	193	199		|O
describes	200	209		|O
a	210	211		|O
very	212	216		|O
early	217	222		|O
-	222	223		|O
onset	223	228		|O
of	229	231		|O
pancytopenia	232	244	pancytopenia	|B-ADVERSE
and	245	248		|O
cutaneous	249	258	cutaneous lesions	|B-ADVERSE
lesions	259	266		|I-ADVERSE
after	267	272		|O
three	273	278		|O
days	279	283		|O
of	284	286		|O
ingestion	287	296		|O
.	296	297		|O
A	298	299		|O
64	300	302		|O
-	302	303		|O
year	303	307		|O
-	307	308		|O
old	308	311		|O
man	312	315		|O
was	316	319		|O
presented	320	329		|O
to	330	332		|O
Emergency	333	342		|O
Department	343	353		|O
with	354	358		|O
weakness	359	367	weakness	|B-ADVERSE
,	367	368		|O
fever	369	374	fever	|B-ADVERSE
,	374	375		|O
poor	376	380	poor appetite	|B-ADVERSE
appetite	381	389		|I-ADVERSE
,	389	390		|O
nausea	391	397	nausea	|B-ADVERSE
,	397	398		|O
and	399	402		|O
vomiting	403	411	vomiting	|B-ADVERSE
after	412	417		|O
he	418	420		|O
had	421	424		|O
had	425	428		|O
accidentally	429	441		|O
ingested	442	450		|O
MTX	451	454		|O
tablets	455	462		|O
(	463	464		|O
2.5	464	467		|O
mg	468	470		|O
)	470	471		|O
twice	472	477		|O
a	478	479		|O
day	480	483		|O
for	484	487		|O
the	488	491		|O
last	492	496		|O
three	497	502		|O
days	503	507		|O
.	507	508		|O
On	509	511		|O
initial	512	519		|O
examination	520	531		|O
,	531	532		|O
several	533	540		|O
painful	541	548	painful lesions	|B-ADVERSE
lesions	549	556		|I-ADVERSE
in	557	559		|O
his	560	563		|O
oral	564	568		|O
mucosa	569	575		|O
and	576	579		|O
a	580	581		|O
cutaneous	582	591	cutaneous ulceration	|B-ADVERSE
ulceration	592	602		|I-ADVERSE
on	603	605		|O
his	606	609		|O
right	610	615		|O
foot	616	620		|O
were	621	625		|O
also	626	630		|O
observed	631	639		|O
.	639	640		|O
He	641	643		|O
had	644	647		|O
severe	648	654		|O
pancytopenia	655	667	pancytopenia	|B-ADVERSE
,	667	668		|O
poor	669	673		|O
kidney	674	680		|O
functions	681	690		|O
,	690	691		|O
and	692	695		|O
abnormal	696	704	abnormal coagulation	|B-ADVERSE
coagulation	705	716		|I-ADVERSE
parameters	717	727		|O
.	727	728		|O
The	729	732		|O
blood	733	738		|O
level	739	744		|O
of	745	747		|O
MTX	748	751		|O
was	752	755		|O
found	756	761		|O
to	762	764		|O
be	765	767		|O
within	768	774		|O
therapeutic	775	786		|O
range	787	792		|O
.	792	793		|O
He	794	796		|O
was	797	800		|O
treated	801	808		|O
with	809	813		|O
leucovorine	814	825		|O
,	825	826		|O
intravenous	827	838		|O
antibiotics	839	850		|O
,	850	851		|O
and	852	855		|O
appropriate	856	867		|O
blood	868	873		|O
transfusions	874	886		|O
;	886	887		|O
he	888	890		|O
was	891	894		|O
discharged	895	905		|O
from	906	910		|O
hospital	911	919		|O
without	920	927		|O
any	928	931		|O
sequela	932	939		|O
.	939	940		|O
Pancytopenia	941	953	Pancytopenia	|B-ADVERSE
associated	954	964		|O
with	965	969		|O
low	970	973		|O
-	973	974		|O
dose	974	978		|O
(	979	980		|O
cumulative	980	990		|O
dose	991	995		|O
of	996	998		|O
15	999	1001		|O
mg	1002	1004		|O
in	1005	1007		|O
3	1008	1009		|O
days	1010	1014		|O
)	1014	1015		|O
MTX	1016	1019		|O
therapy	1020	1027		|O
had	1028	1031		|O
not	1032	1035		|O
been	1036	1040		|O
reported	1041	1049		|O
previously	1050	1060		|O
.	1060	1061		|O
The	1062	1065		|O
Naranjo	1066	1073		|O
probability	1074	1085		|O
scale	1086	1091		|O
showed	1092	1098		|O
pancytopenia	1099	1111	pancytopenia	|B-ADVERSE
and	1112	1115		|O
skin	1116	1120	skin ulcer	|B-ADVERSE
ulcer	1121	1126		|I-ADVERSE
associated	1127	1137		|O
with	1138	1142		|O
low	1143	1146		|O
-	1146	1147		|O
dose	1147	1151		|O
MTX	1152	1155		|O
therapy	1156	1163		|O
as	1164	1166		|O
probable	1167	1175		|O
adverse	1176	1183		|O
reactions	1184	1193		|O
.	1193	1194		|O
Risk	1195	1199		|O
factors	1200	1207		|O
for	1208	1211		|O
pancytopenia	1212	1224	pancytopenia	|B-ADVERSE
such	1225	1229		|O
as	1230	1232		|O
renal	1233	1238	renal insufficiency	|B-ADVERSE
insufficiency	1239	1252		|I-ADVERSE
,	1252	1253		|O
hypoalbuminemia	1254	1269	hypoalbuminemia	|B-ADVERSE
,	1269	1270		|O
low	1271	1274		|O
folate	1275	1281		|O
levels	1282	1288		|O
,	1288	1289		|O
concomitant	1290	1301	concomitant infections	|B-ADVERSE
infections	1302	1312		|I-ADVERSE
,	1312	1313		|O
concomitant	1314	1325		|O
use	1326	1329		|O
of	1330	1332		|O
drugs	1333	1338		|O
,	1338	1339		|O
and	1340	1343		|O
folate	1344	1350		|O
supplementation	1351	1366		|O
were	1367	1371		|O
not	1372	1375		|O
identified	1376	1386		|O
in	1387	1389		|O
our	1390	1393		|O
patient	1394	1401		|O
.	1401	1402		|O
Although	1403	1411		|O
pancytopenia	1412	1424	pancytopenia	|B-ADVERSE
associated	1425	1435		|O
with	1436	1440		|O
low	1441	1444		|O
-	1444	1445		|O
dose	1445	1449		|O
MTX	1450	1453		|O
therapy	1454	1461		|O
is	1462	1464		|O
not	1465	1468		|O
expected	1469	1477		|O
as	1478	1480		|O
early	1481	1486		|O
as	1487	1489		|O
3	1490	1491		|O
days	1492	1496		|O
after	1497	1502		|O
initiation	1503	1513		|O
of	1514	1516		|O
the	1517	1520		|O
therapy	1521	1528		|O
,	1528	1529		|O
physicians	1530	1540		|O
should	1541	1547		|O
also	1548	1552		|O
be	1553	1555		|O
aware	1556	1561		|O
of	1562	1564		|O
this	1565	1569		|O
life	1570	1574		|O
threatening	1575	1586		|O
adverse	1587	1594		|O
effect	1595	1601		|O
during	1602	1608		|O
the	1609	1612		|O
very	1613	1617		|O
first	1618	1623		|O
days	1624	1628		|O
of	1629	1631		|O
MTX	1632	1635		|O
therapy	1636	1643		|O
for	1644	1647		|O
rheumatoid	1648	1658	rheumatoid arthritis	|B-DISEASE
arthritis	1659	1668		|I-DISEASE
patients	1669	1677		|O
.	1677	1678		|O

### 18791717
Multiple	0	8		|O
-	8	9		|O
pool	9	13		|O
cell	14	18		|O
lifespan	19	27		|O
models	28	34		|O
for	35	38		|O
neutropenia	39	50	neutropenia	|B-DISEASE
to	51	53		|O
assess	54	60		|O
the	61	64		|O
population	65	75		|O
pharmacodynamics	76	92		|O
of	93	95		|O
unbound	96	103		|O
paclitaxel	104	114		|O
from	115	119		|O
two	120	123		|O
formulations	124	136		|O
in	137	139		|O
cancer	140	146	cancer	|B-DISEASE
patients	147	155		|O
.	155	156		|O
PURPOSE	158	165		|O
:	165	166		|O
Our	167	170		|O
objective	171	180		|O
was	181	184		|O
to	185	187		|O
build	188	193		|O
a	194	195		|O
mechanism	196	205		|O
-	205	206		|O
based	206	211		|O
pharmacodynamic	212	227		|O
model	228	233		|O
for	234	237		|O
the	238	241		|O
time	242	246		|O
course	247	253		|O
of	254	256		|O
neutropenia	257	268	neutropenia	|B-DISEASE
in	269	271		|O
cancer	272	278	cancer	|B-DISEASE
patients	279	287		|O
following	288	297		|O
paclitaxel	298	308		|O
treatment	309	318		|O
with	319	323		|O
a	324	325		|O
tocopherol	326	336		|O
-	336	337		|O
based	337	342		|O
Cremophor	343	352		|O
-	352	353		|O
free	353	357		|O
formulation	358	369		|O
(	370	371		|O
Tocosol	371	378		|O
Paclitaxel	379	389		|O
)	389	390		|O
and	391	394		|O
Cremophor	395	404		|O
EL	405	407		|O
-	407	408		|O
formulated	408	418		|O
paclitaxel	419	429		|O
(	430	431		|O
Taxol	431	436		|O
)	436	437		|O
.	437	438		|O
METHODS	439	446		|O
:	446	447		|O
A	448	449		|O
randomized	450	460		|O
two	461	464		|O
-	464	465		|O
way	465	468		|O
crossover	469	478		|O
trial	479	484		|O
was	485	488		|O
performed	489	498		|O
with	499	503		|O
35	504	506		|O
adult	507	512		|O
patients	513	521		|O
who	522	525		|O
received	526	534		|O
175	535	538		|O
mg	539	541		|O
/	541	542		|O
m	542	543		|O
(	543	544		|O
2	544	545		|O
)	545	546		|O
paclitaxel	547	557		|O
as	558	560		|O
either	561	567		|O
15	568	570		|O
min	571	574		|O
(	575	576		|O
Tocosol	576	583		|O
Paclitaxel	584	594		|O
)	594	595		|O
or	596	598		|O
3	599	600		|O
h	601	602		|O
(	603	604		|O
Taxol	604	609		|O
)	609	610		|O
intravenous	611	622		|O
infusions	623	632		|O
.	632	633		|O
Paclitaxel	634	644		|O
concentrations	645	659		|O
were	660	664		|O
measured	665	673		|O
by	674	676		|O
LC	677	679		|O
-	679	680		|O
MS	680	682		|O
/	682	683		|O
MS	683	685		|O
.	685	686		|O
NONMEM	687	693		|O
VI	694	696		|O
was	697	700		|O
used	701	705		|O
for	706	709		|O
population	710	720		|O
pharmacodynamics	721	737		|O
.	737	738		|O
RESULTS	739	746		|O
:	746	747		|O
The	748	751		|O
cytotoxic	752	761	cytotoxic effect	|B-ADVERSE
effect	762	768		|I-ADVERSE
on	769	771		|O
neutrophils	772	783		|O
was	784	787		|O
described	788	797		|O
by	798	800		|O
four	801	805		|O
mechanism	806	815		|O
-	815	816		|O
based	816	821		|O
models	822	828		|O
predicated	829	839		|O
on	840	842		|O
known	843	848		|O
properties	849	859		|O
of	860	862		|O
paclitaxel	863	873		|O
that	874	878		|O
used	879	883		|O
unbound	884	891		|O
concentrations	892	906		|O
in	907	909		|O
the	910	913		|O
central	914	921		|O
,	921	922		|O
deep	923	927		|O
peripheral	928	938		|O
or	939	941		|O
an	942	944		|O
intracellular	945	958		|O
compartment	959	970		|O
as	971	973		|O
forcing	974	981		|O
functions	982	991		|O
.	991	992		|O
Tocosol	993	1000		|O
Paclitaxel	1001	1011		|O
was	1012	1015		|O
estimated	1016	1025		|O
to	1026	1028		|O
release	1029	1036		|O
9.8%	1037	1041		|O
of	1042	1044		|O
the	1045	1048		|O
dose	1049	1053		|O
directly	1054	1062		|O
into	1063	1067		|O
the	1068	1071		|O
deep	1072	1076		|O
peripheral	1077	1087		|O
compartment	1088	1099		|O
(	1100	1101		|O
DPC	1101	1104		|O
)	1104	1105		|O
.	1105	1106		|O
All	1107	1110		|O
models	1111	1117		|O
provided	1118	1126		|O
reasonable	1127	1137		|O
fitting	1138	1145		|O
of	1146	1148		|O
neutropenic	1149	1160		|O
effects	1161	1168		|O
.	1168	1169		|O
The	1170	1173		|O
model	1174	1179		|O
with	1180	1184		|O
the	1185	1188		|O
best	1189	1193		|O
predictive	1194	1204		|O
performance	1205	1216		|O
assumed	1217	1224		|O
that	1225	1229		|O
this	1230	1234		|O
dose	1235	1239		|O
fraction	1240	1248		|O
was	1249	1252		|O
released	1253	1261		|O
into	1262	1266		|O
22.5%	1267	1272		|O
of	1273	1275		|O
the	1276	1279		|O
DPC	1280	1283		|O
which	1284	1289		|O
included	1290	1298		|O
the	1299	1302		|O
site	1303	1307		|O
of	1308	1310		|O
toxicity	1311	1319		|O
.	1319	1320		|O
The	1321	1324		|O
second	1325	1331		|O
-	1331	1332		|O
order	1332	1337		|O
cytotoxic	1338	1347		|O
rate	1348	1352		|O
constant	1353	1361		|O
was	1362	1365		|O
0.00211	1366	1373		|O
mL	1374	1376		|O
/	1376	1377		|O
ng	1377	1379		|O
per	1380	1383		|O
hour	1384	1388		|O
(	1389	1390		|O
variability	1390	1401		|O
:	1401	1402		|O
52%	1403	1406		|O
CV	1407	1409		|O
)	1409	1410		|O
.	1410	1411		|O
The	1412	1415		|O
relative	1416	1424		|O
exposure	1425	1433		|O
at	1434	1436		|O
the	1437	1440		|O
site	1441	1445		|O
of	1446	1448		|O
toxicity	1449	1457		|O
was	1458	1461		|O
2.21	1462	1466		|O
+	1467	1468		|O
/	1468	1469		|O
-	1469	1470		|O
0.41	1471	1475		|O
times	1476	1481		|O
(	1482	1483		|O
average	1483	1490		|O
+	1491	1492		|O
/	1492	1493		|O
-	1493	1494		|O
SD	1495	1497		|O
)	1497	1498		|O
larger	1499	1505		|O
for	1506	1509		|O
Tocosol	1510	1517		|O
Paclitaxel	1518	1528		|O
compared	1529	1537		|O
to	1538	1540		|O
Taxol	1541	1546		|O
.	1546	1547		|O
Lifespan	1548	1556		|O
was	1557	1560		|O
11.0	1561	1565		|O
days	1566	1570		|O
for	1571	1574		|O
progenitor	1575	1585		|O
cells	1586	1591		|O
,	1591	1592		|O
1.95	1593	1597		|O
days	1598	1602		|O
for	1603	1606		|O
maturating	1607	1617		|O
cells	1618	1623		|O
,	1623	1624		|O
and	1625	1628		|O
4.38	1629	1633		|O
days	1634	1638		|O
for	1639	1642		|O
neutrophils	1643	1654		|O
.	1654	1655		|O
Total	1656	1661		|O
drug	1662	1666		|O
exposure	1667	1675		|O
in	1676	1678		|O
blood	1679	1684		|O
explained	1685	1694		|O
half	1695	1699		|O
of	1700	1702		|O
the	1703	1706		|O
variance	1707	1715		|O
in	1716	1718		|O
nadir	1719	1724		|O
to	1725	1727		|O
baseline	1728	1736		|O
neutrophil	1737	1747		|O
count	1748	1753		|O
ratio	1754	1759		|O
.	1759	1760		|O
CONCLUSIONS	1761	1772		|O
:	1772	1773		|O
The	1774	1777		|O
relative	1778	1786		|O
exposure	1787	1795		|O
of	1796	1798		|O
unbound	1799	1806		|O
paclitaxel	1807	1817		|O
at	1818	1820		|O
the	1821	1824		|O
site	1825	1829		|O
of	1830	1832		|O
toxicity	1833	1841		|O
was	1842	1845		|O
twice	1846	1851		|O
as	1852	1854		|O
large	1855	1860		|O
for	1861	1864		|O
Tocosol	1865	1872		|O
Paclitaxel	1873	1883		|O
compared	1884	1892		|O
to	1893	1895		|O
Taxol	1896	1901		|O
.	1901	1902		|O
The	1903	1906		|O
proposed	1907	1915		|O
mechanism	1916	1925		|O
-	1925	1926		|O
based	1926	1931		|O
models	1932	1938		|O
explained	1939	1948		|O
the	1949	1952		|O
extent	1953	1959		|O
and	1960	1963		|O
time	1964	1968		|O
course	1969	1975		|O
of	1976	1978		|O
neutropenia	1979	1990	neutropenia	|B-DISEASE
jointly	1991	1998		|O
for	1999	2002		|O
both	2003	2007		|O
formulations	2008	2020		|O
.	2020	2021		|O

### 18645333
Topical	0	7		|O
pyrethrin	8	17	pyrethrin toxicity	|B-ADVERSE
toxicity	18	26		|I-ADVERSE
leading	27	34		|O
to	35	37		|O
acute	38	43	acute-onset stuttering	|B-ADVERSE
-	43	44		|I-ADVERSE
onset	44	49		|I-ADVERSE
stuttering	50	60		|I-ADVERSE
in	61	63		|O
a	64	65		|O
toddler	66	73		|O
.	73	74		|O
Pyrethrin	76	85		|O
compounds	86	95		|O
can	96	99		|O
cause	100	105		|O
neurotoxicity	106	119	neurotoxicity	|B-ADVERSE
when	120	124		|O
used	125	129		|O
in	130	132		|O
an	133	135		|O
excessive	136	145		|O
dose	146	150		|O
.	150	151		|O
A	152	153		|O
case	154	158		|O
of	159	161		|O
stuttering	162	172	stuttering	|B-ADVERSE
and	173	176		|O
general	177	184		|O
clumsiness	185	195	clumsiness	|B-ADVERSE
in	196	198		|O
a	199	200		|O
toddler	201	208		|O
associated	209	219		|O
with	220	224		|O
topical	225	232		|O
pyrethrin	233	242		|O
use	243	246		|O
is	247	249		|O
described	250	259		|O
.	259	260		|O

### 18803262
Efficient	0	9		|O
telomerase	10	20		|O
inhibition	21	31		|O
in	32	34		|O
human	35	40		|O
non	41	44		|O
-	44	45		|O
small	45	50		|O
cell	51	55		|O
lung	56	60		|O
cancer	61	67		|O
cells	68	73		|O
by	74	76		|O
liposomal	77	86		|O
delivery	87	95		|O
of	96	98		|O
2'	99	101		|O
-	101	102		|O
O	102	103		|O
-	103	104		|O
methyl	104	110		|O
-	110	111		|O
RNA	111	114		|O
.	114	115		|O
The	117	120		|O
antisense	121	130		|O
oligonucleotide	131	146		|O
2'	147	149		|O
-	149	150		|O
O	150	151		|O
-	151	152		|O
methyl	152	158		|O
-	158	159		|O
RNA	159	162		|O
is	163	165		|O
a	166	167		|O
selective	168	177		|O
telomerase	178	188		|O
inhibitor	189	198		|O
targeting	199	208		|O
the	209	212		|O
telomerase	213	223		|O
RNA	224	227		|O
component	228	237		|O
and	238	241		|O
represents	242	252		|O
a	253	254		|O
potential	255	264		|O
candidate	265	274		|O
for	275	278		|O
anticancer	279	289		|O
therapy	290	297		|O
.	297	298		|O
The	299	302		|O
poor	303	307		|O
cellular	308	316		|O
uptake	317	323		|O
of	324	326		|O
2'	327	329		|O
-	329	330		|O
O	330	331		|O
-	331	332		|O
methyl	332	338		|O
-	338	339		|O
RNA	339	342		|O
is	343	345		|O
a	346	347		|O
limiting	348	356		|O
factor	357	363		|O
that	364	368		|O
may	369	372		|O
contribute	373	383		|O
to	384	386		|O
the	387	390		|O
lack	391	395		|O
of	396	398		|O
functional	399	409		|O
efficacy	410	418		|O
.	418	419		|O
To	420	422		|O
improve	423	430		|O
delivery	431	439		|O
of	440	442		|O
2'	443	445		|O
-	445	446		|O
O	446	447		|O
-	447	448		|O
methyl	448	454		|O
-	454	455		|O
RNA	455	458		|O
and	459	462		|O
consequently	463	475		|O
antitumoral	476	487		|O
efficiency	488	498		|O
in	499	501		|O
human	502	507		|O
lung	508	512		|O
cancer	513	519		|O
cells	520	525		|O
,	525	526		|O
we	527	529		|O
have	530	534		|O
investigated	535	547		|O
several	548	555		|O
transfection	556	568		|O
reagents	569	577		|O
.	577	578		|O
The	579	582		|O
transfection	583	595		|O
reagents	596	604		|O
DOTAP	605	610		|O
,	610	611		|O
MegaFectin	612	622		|O
60	623	625		|O
,	625	626		|O
SuperFect	627	636		|O
,	636	637		|O
FuGENE	638	644		|O
6	645	646		|O
and	647	650		|O
MATra	651	656		|O
-	656	657		|O
A	657	658		|O
were	659	663		|O
tested	664	670		|O
for	671	674		|O
intracellular	675	688		|O
delivery	689	697		|O
.	697	698		|O
A	699	700		|O
FAM	701	704		|O
-	704	705		|O
labeled	705	712		|O
2'	713	715		|O
-	715	716		|O
O	716	717		|O
-	717	718		|O
methyl	718	724		|O
-	724	725		|O
RNA	725	728		|O
was	729	732		|O
used	733	737		|O
to	738	740		|O
assess	741	747		|O
the	748	751		|O
intracellular	752	765		|O
distribution	766	778		|O
by	779	781		|O
confocal	782	790		|O
laser	791	796		|O
scanning	797	805		|O
microscopy	806	816		|O
in	817	819		|O
A549	820	824		|O
human	825	830		|O
non	831	834		|O
-	834	835		|O
small	835	840		|O
cell	841	845		|O
lung	846	850		|O
cancer	851	857		|O
cells	858	863		|O
.	863	864		|O
Telomerase	865	875		|O
activity	876	884		|O
was	885	888		|O
measured	889	897		|O
using	898	903		|O
the	904	907		|O
telomeric	908	917		|O
repeat	918	924		|O
amplification	925	938		|O
protocol	939	947		|O
.	947	948		|O
Cell	949	953		|O
viability	954	963		|O
after	964	969		|O
transfection	970	982		|O
was	983	986		|O
quantified	987	997		|O
by	998	1000		|O
the	1001	1004		|O
MTT	1005	1008		|O
assay	1009	1014		|O
.	1014	1015		|O
All	1016	1019		|O
transfection	1020	1032		|O
reagents	1033	1041		|O
enhanced	1042	1050		|O
2'	1051	1053		|O
-	1053	1054		|O
O	1054	1055		|O
-	1055	1056		|O
methyl	1056	1062		|O
-	1062	1063		|O
RNA	1063	1066		|O
uptake	1067	1073		|O
in	1074	1076		|O
A549	1077	1081		|O
cells	1082	1087		|O
but	1088	1091		|O
the	1092	1095		|O
cationic	1096	1104		|O
lipid	1105	1110		|O
reagents	1111	1119		|O
DOTAP	1120	1125		|O
and	1126	1129		|O
MegaFectin	1130	1140		|O
60	1141	1143		|O
were	1144	1148		|O
most	1149	1153		|O
efficient	1154	1163		|O
in	1164	1166		|O
the	1167	1170		|O
delivery	1171	1179		|O
of	1180	1182		|O
2'	1183	1185		|O
-	1185	1186		|O
O	1186	1187		|O
-	1187	1188		|O
methyl	1188	1194		|O
-	1194	1195		|O
RNA	1195	1198		|O
resulting	1199	1208		|O
in	1209	1211		|O
telomerase	1212	1222		|O
inhibition	1223	1233		|O
.	1233	1234		|O
Among	1235	1240		|O
both	1241	1245		|O
DOTAP	1246	1251		|O
exhibited	1252	1261		|O
the	1262	1265		|O
lowest	1266	1272		|O
cytotoxicity	1273	1285	cytotoxicity	|B-ADVERSE
.	1285	1286		|O
Our	1287	1290		|O
experiments	1291	1302		|O
show	1303	1307		|O
that	1308	1312		|O
DOTAP	1313	1318		|O
is	1319	1321		|O
the	1322	1325		|O
most	1326	1330		|O
suitable	1331	1339		|O
transfection	1340	1352		|O
reagent	1353	1360		|O
for	1361	1364		|O
the	1365	1368		|O
delivery	1369	1377		|O
of	1378	1380		|O
2'	1381	1383		|O
-	1383	1384		|O
O	1384	1385		|O
-	1385	1386		|O
methyl	1386	1392		|O
-	1392	1393		|O
RNA	1393	1396		|O
in	1397	1399		|O
human	1400	1405		|O
lung	1406	1410		|O
cancer	1411	1417		|O
cells	1418	1423		|O
according	1424	1433		|O
to	1434	1436		|O
its	1437	1440		|O
relatively	1441	1451		|O
low	1452	1455		|O
cytotoxicity	1456	1468	cytotoxicity	|B-ADVERSE
and	1469	1472		|O
its	1473	1476		|O
ability	1477	1484		|O
to	1485	1487		|O
promote	1488	1495		|O
efficient	1496	1505		|O
uptake	1506	1512		|O
leading	1513	1520		|O
to	1521	1523		|O
the	1524	1527		|O
inhibition	1528	1538		|O
of	1539	1541		|O
telomerase	1542	1552		|O
.	1552	1553		|O

### 18687352
How	0	3		|O
can	4	7		|O
biologically	8	20		|O
-	20	21		|O
based	21	26		|O
modeling	27	35		|O
of	36	38		|O
arsenic	39	46		|O
kinetics	47	55		|O
and	56	59		|O
dynamics	60	68		|O
inform	69	75		|O
the	76	79		|O
risk	80	84		|O
assessment	85	95		|O
process	96	103		|O
?	103	104		|O
-	105	106		|O
A	107	108		|O
workshop	109	117		|O
review	118	124		|O
.	124	125		|O
Quantitative	127	139		|O
biologically	140	152		|O
-	152	153		|O
based	153	158		|O
models	159	165		|O
describing	166	176		|O
key	177	180		|O
events	181	187		|O
in	188	190		|O
the	191	194		|O
continuum	195	204		|O
from	205	209		|O
arsenic	210	217		|O
exposure	218	226		|O
to	227	229		|O
the	230	233		|O
development	234	245		|O
of	246	248		|O
adverse	249	256		|O
health	257	263		|O
effects	264	271		|O
provide	272	279		|O
a	280	281		|O
framework	282	291		|O
to	292	294		|O
integrate	295	304		|O
information	305	316		|O
obtained	317	325		|O
across	326	332		|O
diverse	333	340		|O
research	341	349		|O
areas	350	355		|O
.	355	356		|O
For	357	360		|O
example	361	368		|O
,	368	369		|O
genetic	370	377		|O
polymorphisms	378	391		|O
in	392	394		|O
arsenic	395	402		|O
metabolizing	403	415		|O
enzymes	416	423		|O
can	424	427		|O
lead	428	432		|O
to	433	435		|O
differences	436	447		|O
in	448	450		|O
target	451	457		|O
tissue	458	464		|O
dosimetry	465	474		|O
for	475	478		|O
key	479	482		|O
metabolites	483	494		|O
causative	495	504		|O
in	505	507		|O
toxic	508	513		|O
and	514	517		|O
carcinogenic	518	530	carcinogenic response	|B-ADVERSE
response	531	539		|I-ADVERSE
.	539	540		|O
This	541	545		|O
type	546	550		|O
of	551	553		|O
variation	554	563		|O
can	564	567		|O
be	568	570		|O
quantitatively	571	585		|O
incorporated	586	598		|O
into	599	603		|O
pharmacokinetic	604	619		|O
(	620	621		|O
PK	621	623		|O
)	623	624		|O
models	625	631		|O
and	632	635		|O
used	636	640		|O
together	641	649		|O
with	650	654		|O
population	655	665		|O
-	665	666		|O
based	666	671		|O
modeling	672	680		|O
approaches	681	691		|O
to	692	694		|O
evaluate	695	703		|O
the	704	707		|O
impact	708	714		|O
of	715	717		|O
genetic	718	725		|O
variation	726	735		|O
in	736	738		|O
methylation	739	750		|O
capacity	751	759		|O
on	760	762		|O
dose	763	767		|O
of	768	770		|O
key	771	774		|O
metabolites	775	786		|O
to	787	789		|O
target	790	796		|O
tissue	797	803		|O
.	803	804		|O
The	805	808		|O
PK	809	811		|O
model	812	817		|O
is	818	820		|O
an	821	823		|O
essential	824	833		|O
bridge	834	840		|O
to	841	843		|O
the	844	847		|O
pharmacodynamic	848	863		|O
(	864	865		|O
PD	865	867		|O
)	867	868		|O
models	869	875		|O
.	875	876		|O
A	877	878		|O
particular	879	889		|O
benefit	890	897		|O
of	898	900		|O
PD	901	903		|O
modeling	904	912		|O
for	913	916		|O
arsenic	917	924		|O
is	925	927		|O
that	928	932		|O
alternative	933	944		|O
models	945	951		|O
can	952	955		|O
be	956	958		|O
constructed	959	970		|O
for	971	974		|O
multiple	975	983		|O
proposed	984	992		|O
modes	993	998		|O
of	999	1001		|O
action	1002	1008		|O
for	1009	1012		|O
arsenicals	1013	1023		|O
.	1023	1024		|O
Genomics	1025	1033		|O
data	1034	1038		|O
will	1039	1043		|O
prove	1044	1049		|O
useful	1050	1056		|O
for	1057	1060		|O
identifying	1061	1072		|O
the	1073	1076		|O
key	1077	1080		|O
pathways	1081	1089		|O
involved	1090	1098		|O
in	1099	1101		|O
particular	1102	1112		|O
responses	1113	1122		|O
and	1123	1126		|O
aid	1127	1130		|O
in	1131	1133		|O
determining	1134	1145		|O
other	1146	1151		|O
types	1152	1157		|O
of	1158	1160		|O
data	1161	1165		|O
needed	1166	1172		|O
for	1173	1176		|O
quantitative	1177	1189		|O
modeling	1190	1198		|O
.	1198	1199		|O
These	1200	1205		|O
models	1206	1212		|O
,	1212	1213		|O
when	1214	1218		|O
linked	1219	1225		|O
with	1226	1230		|O
PK	1231	1233		|O
models	1234	1240		|O
,	1240	1241		|O
can	1242	1245		|O
be	1246	1248		|O
used	1249	1253		|O
to	1254	1256		|O
better	1257	1263		|O
understand	1264	1274		|O
and	1275	1278		|O
explain	1279	1286		|O
dose	1287	1291		|O
-	1291	1292		|O
and	1293	1296		|O
time	1297	1301		|O
-	1301	1302		|O
response	1302	1310		|O
behaviors	1311	1320		|O
.	1320	1321		|O
This	1322	1326		|O
in	1327	1329		|O
turn	1330	1334		|O
assists	1335	1342		|O
in	1343	1345		|O
prioritizing	1346	1358		|O
modes	1359	1364		|O
of	1365	1367		|O
action	1368	1374		|O
with	1375	1379		|O
respect	1380	1387		|O
to	1388	1390		|O
their	1391	1396		|O
risk	1397	1401		|O
assessment	1402	1412		|O
relevance	1413	1422		|O
and	1423	1426		|O
future	1427	1433		|O
research	1434	1442		|O
.	1442	1443		|O
This	1444	1448		|O
type	1449	1453		|O
of	1454	1456		|O
integrated	1457	1467		|O
modeling	1468	1476		|O
approach	1477	1485		|O
can	1486	1489		|O
form	1490	1494		|O
the	1495	1498		|O
basis	1499	1504		|O
for	1505	1508		|O
a	1509	1510		|O
highly	1511	1517		|O
informative	1518	1529		|O
mode	1530	1534		|O
-	1534	1535		|O
of	1535	1537		|O
-	1537	1538		|O
action	1538	1544		|O
directed	1545	1553		|O
risk	1554	1558		|O
assessment	1559	1569		|O
for	1570	1573		|O
inorganic	1574	1583		|O
arsenic	1584	1591		|O
(	1592	1593		|O
iAs	1593	1596		|O
)	1596	1597		|O
.	1597	1598		|O
This	1599	1603		|O
paper	1604	1609		|O
will	1610	1614		|O
address	1615	1622		|O
both	1623	1627		|O
practical	1628	1637		|O
and	1638	1641		|O
theoretical	1642	1653		|O
aspects	1654	1661		|O
of	1662	1664		|O
integrating	1665	1676		|O
PK	1677	1679		|O
and	1680	1683		|O
PD	1684	1686		|O
data	1687	1691		|O
in	1692	1694		|O
a	1695	1696		|O
modeling	1697	1705		|O
framework	1706	1715		|O
,	1715	1716		|O
including	1717	1726		|O
practical	1727	1736		|O
barriers	1737	1745		|O
to	1746	1748		|O
its	1749	1752		|O
application	1753	1764		|O
.	1764	1765		|O

### 18801423
Effect	0	6		|O
of	7	9		|O
ABCG2	10	15		|O
on	16	18		|O
cytotoxicity	19	31	cytotoxicity	|B-ADVERSE
of	32	34		|O
platinum	35	43		|O
drugs	44	49		|O
:	49	50		|O
interference	51	63		|O
of	64	66		|O
EGFP	67	71		|O
.	71	72		|O
ATP	74	77		|O
-	77	78		|O
binding	78	85		|O
drug	86	90		|O
efflux	91	97		|O
transporters	98	110		|O
decrease	111	119		|O
intracellular	120	133		|O
concentrations	134	148		|O
of	149	151		|O
cytotoxic	152	161		|O
drugs	162	167		|O
,	167	168		|O
causing	169	176		|O
multidrug	177	186		|O
resistance	187	197		|O
in	198	200		|O
cancer	201	207	cancer	|B-DISEASE
.	207	208		|O
In	209	211		|O
this	212	216		|O
study	217	222		|O
,	222	223		|O
we	224	226		|O
examined	227	235		|O
possible	236	244		|O
interactions	245	257		|O
of	258	260		|O
ABCG2	261	266		|O
transporter	267	278		|O
with	279	283		|O
platinum	284	292		|O
cytotoxic	293	302		|O
drugs	303	308		|O
.	308	309		|O
We	310	312		|O
demonstrate	313	324		|O
here	325	329		|O
an	330	332		|O
interference	333	345		|O
of	346	348		|O
platinum	349	357		|O
drugs	358	363		|O
with	364	368		|O
enhanced	369	377		|O
green	378	383		|O
fluorescence	384	396		|O
protein	397	404		|O
(	405	406		|O
EGFP	406	410		|O
)	410	411		|O
in	412	414		|O
the	415	418		|O
cellular	419	427		|O
models	428	434		|O
,	434	435		|O
where	436	441		|O
EGFP	442	446		|O
was	447	450		|O
employed	451	459		|O
as	460	462		|O
a	463	464		|O
reporter	465	473		|O
gene	474	478		|O
.	478	479		|O
Cytotoxicity	480	492	Cytotoxicity	|B-ADVERSE
of	493	495		|O
cisplatin	496	505		|O
(	506	507		|O
CIP	507	510		|O
)	510	511		|O
,	511	512		|O
carboplatin	513	524		|O
(	525	526		|O
CAP	526	529		|O
)	529	530		|O
and	531	534		|O
oxaliplatin	535	546		|O
(	547	548		|O
OXP	548	551		|O
)	551	552		|O
was	553	556		|O
significantly	557	570		|O
lowered	571	578		|O
in	579	581		|O
MDCKII	582	588		|O
cells	589	594		|O
transfected	595	606		|O
with	607	611		|O
ABCG2	612	617		|O
transporter	618	629		|O
and	630	633		|O
EGFP	634	638		|O
reporter	639	647		|O
.	647	648		|O
The	649	652		|O
IC	653	655		|O
(	655	656		|O
50	656	658		|O
)	658	659		|O
values	660	666		|O
in	667	669		|O
MDCKII	670	676		|O
-	676	677		|O
ABCG2	677	682		|O
were	683	687		|O
25.7	688	692		|O
,	692	693		|O
164	694	697		|O
and	698	701		|O
165	702	705		|O
microM	706	712		|O
for	713	716		|O
CIP	717	720		|O
,	720	721		|O
CAP	722	725		|O
and	726	729		|O
OXP	730	733		|O
,	733	734		|O
respectively	735	747		|O
,	747	748		|O
whereas	749	756		|O
IC	757	759		|O
(	759	760		|O
50	760	762		|O
)	762	763		|O
for	764	767		|O
the	768	771		|O
same	772	776		|O
cytostatics	777	788		|O
in	789	791		|O
MDCKII	792	798		|O
cells	799	804		|O
were	805	809		|O
as	810	812		|O
follows	813	820		|O
:	820	821		|O
15.4	822	826		|O
,	826	827		|O
133	828	831		|O
and	832	835		|O
50.3	836	840		|O
microM	841	847		|O
.	847	848		|O
Addition	849	857		|O
of	858	860		|O
fumitremorgin	861	874		|O
C	875	876		|O
(	877	878		|O
FTC	878	881		|O
)	881	882		|O
,	882	883		|O
a	884	885		|O
potent	886	892		|O
ABCG2	893	898		|O
inhibitor	899	908		|O
,	908	909		|O
significantly	910	923		|O
suppressed	924	934		|O
the	935	938		|O
resistance	939	949		|O
of	950	952		|O
MDCKII	953	959		|O
-	959	960		|O
ABCG2	960	965		|O
to	966	968		|O
OXP	969	972		|O
,	972	973		|O
suggesting	974	984		|O
that	985	989		|O
OXP	990	993		|O
interacts	994	1003		|O
with	1004	1008		|O
ABCG2	1009	1014		|O
.	1014	1015		|O
However	1016	1023		|O
,	1023	1024		|O
FTC	1025	1028		|O
did	1029	1032		|O
not	1033	1036		|O
change	1037	1043		|O
the	1044	1047		|O
sensitivity	1048	1059		|O
of	1060	1062		|O
the	1063	1066		|O
cells	1067	1072		|O
to	1073	1075		|O
CIP	1076	1079		|O
and	1080	1083		|O
CAP	1084	1087		|O
.	1087	1088		|O
We	1089	1091		|O
assume	1092	1098		|O
that	1099	1103		|O
EGFP	1104	1108		|O
rather	1109	1115		|O
than	1116	1120		|O
ABCG2	1121	1126		|O
causes	1127	1133		|O
the	1134	1137		|O
diminished	1138	1148		|O
toxicity	1149	1157		|O
of	1158	1160		|O
the	1161	1164		|O
platinum	1165	1173		|O
cytostatics	1174	1185		|O
in	1186	1188		|O
the	1189	1192		|O
transfected	1193	1204		|O
cells	1205	1210		|O
.	1210	1211		|O
This	1212	1216		|O
hypothesis	1217	1227		|O
was	1228	1231		|O
confirmed	1232	1241		|O
in	1242	1244		|O
human	1245	1250		|O
Hep2	1251	1255		|O
cells	1256	1261		|O
expressing	1262	1272		|O
EGFP	1273	1277		|O
:	1277	1278		|O
using	1279	1284		|O
MTT	1285	1288		|O
test	1289	1293		|O
,	1293	1294		|O
IC	1295	1297		|O
(	1297	1298		|O
50	1298	1300		|O
)	1300	1301		|O
of	1302	1304		|O
30.0	1305	1309		|O
,	1309	1310		|O
247	1311	1314		|O
and	1315	1318		|O
27.9	1319	1323		|O
microM	1324	1330		|O
were	1331	1335		|O
obtained	1336	1344		|O
for	1345	1348		|O
CIP	1349	1352		|O
,	1352	1353		|O
CAP	1354	1357		|O
and	1358	1361		|O
OXP	1362	1365		|O
,	1365	1366		|O
respectively	1367	1379		|O
,	1379	1380		|O
while	1381	1386		|O
12.3	1387	1391		|O
,	1391	1392		|O
106	1393	1396		|O
and	1397	1400		|O
20.5	1401	1405		|O
microM	1406	1412		|O
were	1413	1417		|O
observed	1418	1426		|O
in	1427	1429		|O
the	1430	1433		|O
parent	1434	1440		|O
Hep2	1441	1445		|O
cells	1446	1451		|O
.	1451	1452		|O
Employing	1453	1462		|O
neutral	1463	1470		|O
red	1471	1474		|O
cytotoxicity	1475	1487	cytotoxicity	|B-ADVERSE
assay	1488	1493		|O
,	1493	1494		|O
similar	1495	1502		|O
data	1503	1507		|O
were	1508	1512		|O
obtained	1513	1521		|O
(	1522	1523		|O
IC	1523	1525		|O
(	1525	1526		|O
50	1526	1528		|O
)	1528	1529		|O
7.73	1530	1534		|O
,	1534	1535		|O
685	1536	1539		|O
and	1540	1543		|O
112	1544	1547		|O
microM	1548	1554		|O
for	1555	1558		|O
CIP	1559	1562		|O
,	1562	1563		|O
CAP	1564	1567		|O
,	1567	1568		|O
and	1569	1572		|O
OXP	1573	1576		|O
,	1576	1577		|O
respectively	1578	1590		|O
,	1590	1591		|O
in	1592	1594		|O
the	1595	1598		|O
Hep2	1599	1603		|O
-	1603	1604		|O
EGFP	1604	1608		|O
cells	1609	1614		|O
and	1615	1618		|O
1.65	1619	1623		|O
,	1623	1624		|O
79.4	1625	1629		|O
and	1630	1633		|O
24.5	1634	1638		|O
microM	1639	1645		|O
in	1646	1648		|O
the	1649	1652		|O
parent	1653	1659		|O
Hep2	1660	1664		|O
cells	1665	1670		|O
)	1670	1671		|O
.	1671	1672		|O
Caspase	1673	1680		|O
-	1680	1681		|O
3/7	1681	1684		|O
assay	1685	1690		|O
revealed	1691	1699		|O
lower	1700	1705		|O
susceptibility	1706	1720		|O
of	1721	1723		|O
EGFP	1724	1728		|O
expressing	1729	1739		|O
Hep2	1740	1744		|O
cells	1745	1750		|O
to	1751	1753		|O
apoptosis	1754	1763		|O
induced	1764	1771		|O
by	1772	1774		|O
CIP	1775	1778		|O
when	1779	1783		|O
compared	1784	1792		|O
to	1793	1795		|O
the	1796	1799		|O
parent	1800	1806		|O
cell	1807	1811		|O
line	1812	1816		|O
.	1816	1817		|O
We	1818	1820		|O
therefore	1821	1830		|O
conclude	1831	1839		|O
that	1840	1844		|O
EGFP	1845	1849		|O
in	1850	1852		|O
transfected	1853	1864		|O
cells	1865	1870		|O
interferes	1871	1881		|O
with	1882	1886		|O
cytotoxicity	1887	1899	cytotoxicity	|B-ADVERSE
of	1900	1902		|O
platinum	1903	1911		|O
drugs	1912	1917		|O
by	1918	1920		|O
hindering	1921	1930		|O
the	1931	1934		|O
drug	1935	1939		|O
induced	1940	1947		|O
apoptosis	1948	1957		|O
and	1958	1961		|O
could	1962	1967		|O
cause	1968	1973		|O
misinterpretation	1974	1991		|O
of	1992	1994		|O
results	1995	2002		|O
obtained	2003	2011		|O
in	2012	2014		|O
cytotoxicity	2015	2027	cytotoxicity	|B-ADVERSE
studies	2028	2035		|O
.	2035	2036		|O

### 18845211
Fragrance	0	9		|O
material	10	18		|O
review	19	25		|O
on	26	28		|O
tricyclodecanyl	29	44		|O
acetate	45	52		|O
.	52	53		|O
A	55	56		|O
toxicologic	57	68		|O
and	69	72		|O
dermatologic	73	85		|O
review	86	92		|O
of	93	95		|O
tricyclodecanyl	96	111		|O
acetate	112	119		|O
when	120	124		|O
used	125	129		|O
as	130	132		|O
a	133	134		|O
fragrance	135	144		|O
ingredient	145	155		|O
is	156	158		|O
presented	159	168		|O
.	168	169		|O

### 18591544
AIDS	0	4	AIDS-related malignancies	|B-DISEASE
-	4	5		|I-DISEASE
related	5	12		|I-DISEASE
malignancies	13	25		|I-DISEASE
:	25	26		|O
state	27	32		|O
of	33	35		|O
the	36	39		|O
art	40	43		|O
and	44	47		|O
therapeutic	48	59		|O
challenges	60	70		|O
.	70	71		|O
Despite	73	80		|O
the	81	84		|O
impact	85	91		|O
of	92	94		|O
combination	95	106		|O
antiretroviral	107	121		|O
therapy	122	129		|O
(	130	131		|O
cART	131	135		|O
)	135	136		|O
on	137	139		|O
HIV	140	143		|O
-	143	144		|O
related	144	151		|O
mortality	152	161		|O
,	161	162		|O
malignancy	163	173		|O
remains	174	181		|O
an	182	184		|O
important	185	194		|O
cause	195	200		|O
of	201	203		|O
death	204	209		|O
in	210	212		|O
the	213	216		|O
current	217	224		|O
era	225	228		|O
.	228	229		|O
Although	230	238		|O
the	239	242		|O
advent	243	249		|O
of	250	252		|O
cART	253	257		|O
has	258	261		|O
resulted	262	270		|O
in	271	273		|O
reductions	274	284		|O
in	285	287		|O
the	288	291		|O
incidence	292	301		|O
of	302	304		|O
Kaposi	305	311	Kaposi's sarcoma	|B-DISEASE
's	311	313		|I-DISEASE
sarcoma	314	321		|I-DISEASE
and	322	325		|O
non	326	329	non-Hodgkin's lymphoma	|B-DISEASE
-	329	330		|I-DISEASE
Hodgkin	330	337		|I-DISEASE
's	337	339		|I-DISEASE
lymphoma	340	348		|I-DISEASE
,	348	349		|O
non	350	353	non-AIDS-defining malignancies	|B-DISEASE
-	353	354		|I-DISEASE
AIDS	354	358		|I-DISEASE
-	358	359		|I-DISEASE
defining	359	367		|I-DISEASE
malignancies	368	380		|I-DISEASE
present	381	388		|O
an	389	391		|O
increased	392	401		|O
risk	402	406		|O
for	407	410		|O
HIV	411	414		|O
-	414	415		|O
infected	415	423		|O
patients	424	432		|O
,	432	433		|O
characterized	434	447		|O
by	448	450		|O
some	451	455		|O
common	456	462		|O
clinical	463	471		|O
features	472	480		|O
,	480	481		|O
generally	482	491		|O
with	492	496		|O
a	497	498		|O
more	499	503		|O
aggressive	504	514	aggressive behavior	|B-DISEASE
behavior	515	523		|I-DISEASE
and	524	527		|O
a	528	529		|O
more	530	534		|O
advanced	535	543		|O
disease	544	551		|O
at	552	554		|O
diagnosis	555	564		|O
,	564	565		|O
which	566	571		|O
is	572	574		|O
responsible	575	586		|O
for	587	590		|O
poorer	591	597		|O
patient	598	605		|O
outcomes	606	614		|O
.	614	615		|O
Specific	616	624		|O
therapeutic	625	636		|O
recommendations	637	652		|O
are	653	656		|O
lacking	657	664		|O
for	665	668		|O
these	669	674		|O
new	675	678		|O
nonopportunistic	679	695		|O
malignancies	696	708	malignancies	|B-DISEASE
,	708	709		|O
such	710	714		|O
as	715	717		|O
Hodgkin	718	725	Hodgkin's lymphoma	|B-DISEASE
's	725	727		|I-DISEASE
lymphoma	728	736		|I-DISEASE
,	736	737		|O
anal	738	742	anal cancer	|B-DISEASE
cancer	743	749		|I-DISEASE
,	749	750		|O
lung	751	755	lung cancer	|B-DISEASE
cancer	756	762		|I-DISEASE
,	762	763		|O
hepatocarcinoma	764	779	hepatocarcinoma	|B-DISEASE
,	779	780		|O
and	781	784		|O
many	785	789		|O
others	790	796		|O
.	796	797		|O
Antiretroviral	798	812		|O
agents	813	819		|O
have	820	824		|O
a	825	826		|O
propensity	827	837		|O
for	838	841		|O
causing	842	849		|O
drug	850	854		|O
interactions	855	867		|O
as	868	870		|O
a	871	872		|O
result	873	879		|O
of	880	882		|O
their	883	888		|O
ability	889	896		|O
to	897	899		|O
either	900	906		|O
inhibit	907	914		|O
or	915	917		|O
induce	918	924		|O
the	925	928		|O
cytochrome	929	939		|O
P450	940	944		|O
(	945	946		|O
CYP	946	949		|O
)	949	950		|O
enzyme	951	957		|O
system	958	964		|O
.	964	965		|O
Because	966	973		|O
many	974	978		|O
antineoplastic	979	993		|O
drugs	994	999		|O
are	1000	1003		|O
also	1004	1008		|O
metabolized	1009	1020		|O
by	1021	1023		|O
the	1024	1027		|O
CYP	1028	1031		|O
system	1032	1038		|O
,	1038	1039		|O
coadministration	1040	1056		|O
with	1057	1061		|O
cART	1062	1066		|O
could	1067	1072		|O
result	1073	1079		|O
in	1080	1082		|O
either	1083	1089		|O
drug	1090	1094		|O
accumulation	1095	1107		|O
with	1108	1112		|O
increased	1113	1122		|O
toxicity	1123	1131		|O
,	1131	1132		|O
or	1133	1135		|O
decreased	1136	1145		|O
efficacy	1146	1154		|O
of	1155	1157		|O
one	1158	1161		|O
or	1162	1164		|O
both	1165	1169		|O
classes	1170	1177		|O
of	1178	1180		|O
drugs	1181	1186		|O
.	1186	1187		|O
Further	1188	1195		|O
research	1196	1204		|O
delineating	1205	1216		|O
the	1217	1220		|O
combined	1221	1229		|O
safety	1230	1236		|O
and	1237	1240		|O
pharmacokinetics	1241	1257		|O
of	1258	1260		|O
antiretrovirals	1261	1276		|O
and	1277	1280		|O
antineoplastic	1281	1295		|O
therapy	1296	1303		|O
is	1304	1306		|O
necessary	1307	1316		|O
.	1316	1317		|O
Special	1318	1325		|O
considerations	1326	1340		|O
of	1341	1343		|O
these	1344	1349		|O
AIDS	1350	1354		|O
-	1354	1355		|O
related	1355	1362		|O
and	1363	1366		|O
non	1367	1370	non-AIDS-related malignancies	|B-DISEASE
-	1370	1371		|I-DISEASE
AIDS	1371	1375		|I-DISEASE
-	1375	1376		|I-DISEASE
related	1376	1383		|I-DISEASE
malignancies	1384	1396		|I-DISEASE
and	1397	1400		|O
their	1401	1406		|O
clinical	1407	1415		|O
and	1416	1419		|O
therapeutic	1420	1431		|O
aspects	1432	1439		|O
constitute	1440	1450		|O
the	1451	1454		|O
subject	1455	1462		|O
of	1463	1465		|O
this	1466	1470		|O
review	1471	1477		|O
.	1477	1478		|O

### 18614900
Should	0	6		|O
we	7	9		|O
abandon	10	17		|O
corticosteroids	18	33		|O
during	34	40		|O
septic	41	47	septic shock	|B-DISEASE
shock	48	53		|I-DISEASE
?	53	54		|O
No	55	57		|O
.	57	58		|O
PURPOSE	60	67		|O
OF	68	70		|O
REVIEW	71	77		|O
:	77	78		|O
With	79	83		|O
the	84	87		|O
publication	88	99		|O
of	100	102		|O
the	103	106		|O
results	107	114		|O
of	115	117		|O
the	118	121		|O
recent	122	128		|O
CORTICUS	129	137		|O
trial	138	143		|O
,	143	144		|O
stress	145	151		|O
(	152	153		|O
'	153	154		|O
low	154	157		|O
'	157	158		|O
)	158	159		|O
doses	160	165		|O
of	166	168		|O
corticosteroids	169	184		|O
for	185	188		|O
the	189	192		|O
treatment	193	202		|O
of	203	205		|O
vasopressor	206	217		|O
-	217	218		|O
dependent	218	227		|O
septic	228	234	septic shock	|B-DISEASE
shock	235	240		|I-DISEASE
in	241	243		|O
adults	244	250		|O
can	251	254		|O
still	255	260		|O
be	261	263		|O
considered	264	274		|O
controversial	275	288		|O
.	288	289		|O
The	290	293		|O
purpose	294	301		|O
of	302	304		|O
this	305	309		|O
narrative	310	319		|O
review	320	326		|O
is	327	329		|O
to	330	332		|O
elaborate	333	342		|O
the	343	346		|O
pros	347	351		|O
and	352	355		|O
cons	356	360		|O
of	361	363		|O
this	364	368		|O
treatment	369	378		|O
in	379	381		|O
clinical	382	390		|O
practice	391	399		|O
and	400	403		|O
to	404	406		|O
formulate	407	416		|O
clinical	417	425		|O
and	426	429		|O
research	430	438		|O
directions	439	449		|O
.	449	450		|O
RECENT	451	457		|O
FINDINGS	458	466		|O
:	466	467		|O
The	468	471		|O
recent	472	478		|O
CORTICUS	479	487		|O
study	488	493		|O
only	494	498		|O
shows	499	504		|O
a	505	506		|O
beneficial	507	517		|O
effect	518	524		|O
of	525	527		|O
stress	528	534		|O
doses	535	540		|O
of	541	543		|O
corticosteroids	544	559		|O
in	560	562		|O
the	563	566		|O
time	567	571		|O
interval	572	580		|O
to	581	583		|O
shock	584	589		|O
reversal	590	598		|O
and	599	602		|O
not	603	606		|O
on	607	609		|O
mortality	610	619		|O
,	619	620		|O
potentially	621	632		|O
explained	633	642		|O
by	643	645		|O
an	646	648		|O
increased	649	658		|O
risk	659	663		|O
for	664	667		|O
superinfection	668	682	superinfection	|B-ADVERSE
.	682	683		|O
The	684	687		|O
mortality	688	697		|O
in	698	700		|O
the	701	704		|O
placebo	705	712		|O
arm	713	716		|O
was	717	720		|O
relatively	721	731		|O
low	732	735		|O
and	736	739		|O
lower	740	745		|O
than	746	750		|O
in	751	753		|O
earlier	754	761		|O
randomized	762	772		|O
studies	773	780		|O
in	781	783		|O
which	784	789		|O
stress	790	796		|O
doses	797	802		|O
of	803	805		|O
corticosteroids	806	821		|O
had	822	825		|O
a	826	827		|O
favorable	828	837		|O
hemodynamic	838	849		|O
effect	850	856		|O
and	857	860		|O
conferred	861	870		|O
a	871	872		|O
survival	873	881		|O
benefit	882	889		|O
in	890	892		|O
septic	893	899	septic shock	|B-DISEASE
shock	900	905		|I-DISEASE
.	905	906		|O
SUMMARY	907	914		|O
:	914	915		|O
Treatment	916	925		|O
by	926	928		|O
stress	929	935		|O
doses	936	941		|O
of	942	944		|O
corticosteroids	945	960		|O
should	961	967		|O
not	968	971		|O
be	972	974		|O
abandoned	975	984		|O
during	985	991		|O
septic	992	998	septic shock	|B-DISEASE
shock	999	1004		|I-DISEASE
.	1004	1005		|O
Additional	1006	1016		|O
studies	1017	1024		|O
are	1025	1028		|O
needed	1029	1035		|O
,	1035	1036		|O
however	1037	1044		|O
,	1044	1045		|O
to	1046	1048		|O
better	1049	1055		|O
delineate	1056	1065		|O
the	1066	1069		|O
patient	1070	1077		|O
group	1078	1083		|O
with	1084	1088		|O
the	1089	1092		|O
highest	1093	1100		|O
likelihood	1101	1111		|O
to	1112	1114		|O
benefit	1115	1122		|O
from	1123	1127		|O
this	1128	1132		|O
therapy	1133	1140		|O
,	1140	1141		|O
as	1142	1144		|O
a	1145	1146		|O
function	1147	1155		|O
of	1156	1158		|O
severity	1159	1167		|O
of	1168	1170		|O
illness	1171	1178		|O
,	1178	1179		|O
response	1180	1188		|O
to	1189	1191		|O
adrenocorticotrophic	1192	1212		|O
hormone	1213	1220		|O
testing	1221	1228		|O
or	1229	1231		|O
both	1232	1236		|O
.	1236	1237		|O
For	1238	1241		|O
now	1242	1245		|O
,	1245	1246		|O
results	1247	1254		|O
of	1255	1257		|O
the	1258	1261		|O
CORTICUS	1262	1270		|O
study	1271	1276		|O
should	1277	1283		|O
not	1284	1287		|O
change	1288	1294		|O
current	1295	1302		|O
clinical	1303	1311		|O
practice	1312	1320		|O
of	1321	1323		|O
administering	1324	1337		|O
200-300	1338	1345		|O
mg	1346	1348		|O
of	1349	1351		|O
hydrocortisone	1352	1366		|O
daily	1367	1372		|O
(	1373	1374		|O
in	1374	1376		|O
divided	1377	1384		|O
doses	1385	1390		|O
)	1390	1391		|O
in	1392	1394		|O
case	1395	1399		|O
of	1400	1402		|O
fluid	1403	1408		|O
and	1409	1412		|O
vasopressor	1413	1424		|O
-	1424	1425		|O
insensitive	1425	1436		|O
septic	1437	1443	septic shock	|B-DISEASE
shock	1444	1449		|I-DISEASE
and	1450	1453		|O
rapid	1454	1459		|O
tapering	1460	1468		|O
of	1469	1471		|O
this	1472	1476		|O
treatment	1477	1486		|O
on	1487	1489		|O
the	1490	1493		|O
basis	1494	1499		|O
of	1500	1502		|O
a	1503	1504		|O
hemodynamic	1505	1516		|O
response	1517	1525		|O
.	1525	1526		|O

### 18673278
Eosinophil	0	10		|O
-	10	11		|O
derived	11	18		|O
neurotoxin	19	29		|O
/	30	31		|O
RNase	32	37		|O
2	38	39		|O
:	39	40		|O
connecting	41	51		|O
the	52	55		|O
past	56	60		|O
,	60	61		|O
the	62	65		|O
present	66	73		|O
and	74	77		|O
the	78	81		|O
future	82	88		|O
.	88	89		|O
The	91	94		|O
eosinophil	95	105		|O
-	105	106		|O
derived	106	113		|O
neurotoxin	114	124		|O
(	125	126		|O
EDN	126	129		|O
,	129	130		|O
also	131	135		|O
known	136	141		|O
as	142	144		|O
eosinophil	145	155		|O
protein	156	163		|O
-	163	164		|O
X	164	165		|O
)	165	166		|O
is	167	169		|O
best	170	174		|O
-	174	175		|O
known	175	180		|O
as	181	183		|O
one	184	187		|O
of	188	190		|O
the	191	194		|O
four	195	199		|O
major	200	205		|O
proteins	206	214		|O
found	215	220		|O
in	221	223		|O
the	224	227		|O
large	228	233		|O
specific	234	242		|O
granules	243	251		|O
of	252	254		|O
human	255	260		|O
eosinophilic	261	273		|O
leukocytes	274	284		|O
.	284	285		|O
Although	286	294		|O
it	295	297		|O
was	298	301		|O
named	302	307		|O
for	308	311		|O
its	312	315		|O
discovery	316	325		|O
and	326	329		|O
initial	330	337		|O
characterization	338	354		|O
as	355	357		|O
a	358	359		|O
neurotoxin	360	370		|O
,	370	371		|O
it	372	374		|O
is	375	377		|O
also	378	382		|O
expressed	383	392		|O
constitutively	393	407		|O
in	408	410		|O
human	411	416		|O
liver	417	422		|O
tissue	423	429		|O
and	430	433		|O
its	434	437		|O
expression	438	448		|O
can	449	452		|O
be	453	455		|O
induced	456	463		|O
in	464	466		|O
macrophages	467	478		|O
by	479	481		|O
proinflammatory	482	497		|O
stimuli	498	505		|O
.	505	506		|O
EDN	507	510		|O
and	511	514		|O
its	515	518		|O
divergent	519	528		|O
orthologs	529	538		|O
in	539	541		|O
rodents	542	549		|O
have	550	554		|O
ribonuclease	555	567		|O
activity	568	576		|O
,	576	577		|O
and	578	581		|O
are	582	585		|O
members	586	593		|O
of	594	596		|O
the	597	600		|O
extensive	601	610		|O
RNase	611	616		|O
A	617	618		|O
superfamily	619	630		|O
,	630	631		|O
although	632	640		|O
the	641	644		|O
relationship	645	657		|O
between	658	665		|O
the	666	669		|O
characterized	670	683		|O
physiologic	684	695		|O
functions	696	705		|O
and	706	709		|O
enzymatic	710	719		|O
activity	720	728		|O
remains	729	736		|O
poorly	737	743		|O
understood	744	754		|O
.	754	755		|O
Recent	756	762		|O
explorations	763	775		|O
into	776	780		|O
potential	781	790		|O
physiologic	791	802		|O
functions	803	812		|O
for	813	816		|O
EDN	817	820		|O
have	821	825		|O
provided	826	834		|O
us	835	837		|O
with	838	842		|O
some	843	847		|O
insights	848	856		|O
into	857	861		|O
its	862	865		|O
role	866	870		|O
in	871	873		|O
antiviral	874	883		|O
host	884	888		|O
defense	889	896		|O
,	896	897		|O
as	898	900		|O
a	901	902		|O
chemoattractant	903	918		|O
for	919	922		|O
human	923	928		|O
dendritic	929	938		|O
cells	939	944		|O
,	944	945		|O
and	946	949		|O
most	950	954		|O
recently	955	963		|O
,	963	964		|O
as	965	967		|O
an	968	970		|O
endogenous	971	981		|O
ligand	982	988		|O
for	989	992		|O
toll	993	997		|O
-	997	998		|O
like	998	1002		|O
receptor	1003	1011		|O
(	1012	1013		|O
TLR	1013	1016		|O
)	1016	1017		|O
2	1017	1018		|O
.	1018	1019		|O

### 18587135
Long	0	4		|O
-	4	5		|O
term	5	9		|O
clinical	10	18		|O
and	19	22		|O
surrogate	23	32		|O
marker	33	39		|O
effects	40	47		|O
of	48	50		|O
subcutaneous	51	63		|O
intermittent	64	76		|O
interleukin	77	88		|O
-	88	89		|O
2	89	90		|O
without	91	98		|O
antiretroviral	99	113		|O
therapy	114	121		|O
in	122	124		|O
HIV	125	128		|O
-	128	129		|O
infected	129	137		|O
patients	138	146		|O
.	146	147		|O
OBJECTIVES	149	159		|O
:	159	160		|O
Subcutaneous	161	173		|O
administration	174	188		|O
of	189	191		|O
interleukin	192	203		|O
-	203	204		|O
2	204	205		|O
(	206	207		|O
IL	207	209		|O
-	209	210		|O
2	210	211		|O
)	211	212		|O
has	213	216		|O
been	217	221		|O
shown	222	227		|O
to	228	230		|O
increase	231	239		|O
CD4	240	243		|O
counts	244	250		|O
in	251	253		|O
HIV	254	257		|O
-	257	258		|O
infected	258	266		|O
patients	267	275		|O
.	275	276		|O
It	277	279		|O
remains	280	287		|O
unclear	288	295		|O
whether	296	303		|O
this	304	308		|O
effect	309	315		|O
is	316	318		|O
associated	319	329		|O
with	330	334		|O
a	335	336		|O
clinical	337	345		|O
benefit	346	353		|O
.	353	354		|O
PATIENTS	355	363		|O
AND	364	367		|O
METHODS	368	375		|O
:	375	376		|O
We	377	379		|O
conducted	380	389		|O
a	390	391		|O
long	392	396		|O
-	396	397		|O
term	397	401		|O
follow	402	408		|O
-	408	409		|O
up	409	411		|O
in	412	414		|O
the	415	418		|O
cohort	419	425		|O
of	426	428		|O
the	429	432		|O
UK	433	435		|O
-	435	436		|O
Vanguard	436	444		|O
study	445	450		|O
in	451	453		|O
which	454	459		|O
three	460	465		|O
groups	466	472		|O
of	473	475		|O
12	476	478		|O
antiretroviral	479	493		|O
-	493	494		|O
naive	494	499		|O
subjects	500	508		|O
with	509	513		|O
CD4	514	517		|O
cell	518	522		|O
counts	523	529		|O
>	530	531		|O
350	531	534		|O
cells	535	540		|O
/	540	541		|O
mm	541	543		|O
(	543	544		|O
3	544	545		|O
)	545	546		|O
received	547	555		|O
no	556	558		|O
treatment	559	568		|O
or	569	571		|O
IL	572	574		|O
-	574	575		|O
2	575	576		|O
at	577	579		|O
either	580	586		|O
4.5	587	590		|O
or	591	593		|O
7.5	594	597		|O
MIU	598	601		|O
twice	602	607		|O
daily	608	613		|O
in	614	616		|O
5	617	618		|O
day	619	622		|O
cycles	623	629		|O
,	629	630		|O
respectively	631	643		|O
.	643	644		|O
RESULTS	645	652		|O
:	652	653		|O
Mean	654	658		|O
follow	659	665		|O
-	665	666		|O
up	666	668		|O
was	669	672		|O
376	673	676		|O
weeks	677	682		|O
.	682	683		|O
IL	684	686		|O
-	686	687		|O
2	687	688		|O
therapy	689	696		|O
was	697	700		|O
associated	701	711		|O
with	712	716		|O
a	717	718		|O
higher	719	725		|O
area	726	730		|O
under	731	736		|O
the	737	740		|O
curve	741	746		|O
of	747	749		|O
CD4	750	753		|O
cell	754	758		|O
count	759	764		|O
change	765	771		|O
from	772	776		|O
baseline	777	785		|O
at	786	788		|O
week	789	793		|O
48	794	796		|O
but	797	800		|O
not	801	804		|O
thereafter	805	815		|O
.	815	816		|O
HIV	817	820		|O
-	820	821		|O
RNA	821	824		|O
levels	825	831		|O
were	832	836		|O
unaffected	837	847		|O
.	847	848		|O
Highly	849	855		|O
active	856	862		|O
antiretroviral	863	877		|O
therapy	878	885		|O
(	886	887		|O
HAART	887	892		|O
)	892	893		|O
was	894	897		|O
initiated	898	907		|O
after	908	913		|O
a	914	915		|O
mean	916	920		|O
of	921	923		|O
172	924	927		|O
,	927	928		|O
175	929	932		|O
and	933	936		|O
152	937	940		|O
weeks	941	946		|O
in	947	949		|O
the	950	953		|O
control	954	961		|O
group	962	967		|O
,	967	968		|O
low	969	972		|O
-	972	973		|O
dose	973	977		|O
and	978	981		|O
high	982	986		|O
-	986	987		|O
dose	987	991		|O
IL	992	994		|O
-	994	995		|O
2	995	996		|O
treatment	997	1006		|O
group	1007	1012		|O
,	1012	1013		|O
respectively	1014	1026		|O
,	1026	1027		|O
a	1028	1029		|O
statistically	1030	1043		|O
non	1044	1047		|O
-	1047	1048		|O
significant	1048	1059		|O
difference	1060	1070		|O
.	1070	1071		|O
There	1072	1077		|O
was	1078	1081		|O
a	1082	1083		|O
tendency	1084	1092		|O
to	1093	1095		|O
start	1096	1101		|O
HAART	1102	1107		|O
soon	1108	1112		|O
after	1113	1118		|O
discontinuation	1119	1134		|O
of	1135	1137		|O
IL	1138	1140		|O
-	1140	1141		|O
2	1141	1142		|O
therapy	1143	1150		|O
which	1151	1156		|O
may	1157	1160		|O
have	1161	1165		|O
been	1166	1170		|O
triggered	1171	1180		|O
by	1181	1183		|O
the	1184	1187		|O
steep	1188	1193		|O
decay	1194	1199		|O
of	1200	1202		|O
CD4	1203	1206		|O
counts	1207	1213		|O
.	1213	1214		|O
There	1215	1220		|O
were	1221	1225		|O
two	1226	1229		|O
serious	1230	1237		|O
adverse	1238	1245		|O
events	1246	1252		|O
in	1253	1255		|O
the	1256	1259		|O
control	1260	1267		|O
group	1268	1273		|O
,	1273	1274		|O
seven	1275	1280		|O
in	1281	1283		|O
the	1284	1287		|O
low	1288	1291		|O
-	1291	1292		|O
dose	1292	1296		|O
IL	1297	1299		|O
-	1299	1300		|O
2	1300	1301		|O
group	1302	1307		|O
and	1308	1311		|O
eight	1312	1317		|O
in	1318	1320		|O
the	1321	1324		|O
high	1325	1329		|O
-	1329	1330		|O
dose	1330	1334		|O
IL	1335	1337		|O
-	1337	1338		|O
2	1338	1339		|O
group	1340	1345		|O
.	1345	1346		|O
No	1347	1349		|O
pattern	1350	1357		|O
of	1358	1360		|O
disease	1361	1368		|O
was	1369	1372		|O
detected	1373	1381		|O
,	1381	1382		|O
making	1383	1389		|O
an	1390	1392		|O
association	1393	1404		|O
with	1405	1409		|O
IL	1410	1412		|O
-	1412	1413		|O
2	1413	1414		|O
therapy	1415	1422		|O
unlikely	1423	1431		|O
.	1431	1432		|O
CONCLUSIONS	1433	1444		|O
:	1444	1445		|O
We	1446	1448		|O
could	1449	1454		|O
detect	1455	1461		|O
neither	1462	1469		|O
a	1470	1471		|O
benefit	1472	1479		|O
of	1480	1482		|O
IL	1483	1485		|O
-	1485	1486		|O
2	1486	1487		|O
therapy	1488	1495		|O
after	1496	1501		|O
week	1502	1506		|O
48	1507	1509		|O
nor	1510	1513		|O
delayed	1514	1521		|O
initiation	1522	1532		|O
of	1533	1535		|O
HAART	1536	1541		|O
.	1541	1542		|O
This	1543	1547		|O
is	1548	1550		|O
currently	1551	1560		|O
the	1561	1564		|O
longest	1565	1572		|O
follow	1573	1579		|O
-	1579	1580		|O
up	1580	1582		|O
data	1583	1587		|O
comparing	1588	1597		|O
IL	1598	1600		|O
-	1600	1601		|O
2	1601	1602		|O
therapy	1603	1610		|O
with	1611	1615		|O
no	1616	1618		|O
therapy	1619	1626		|O
in	1627	1629		|O
antiretroviral	1630	1644		|O
-	1644	1645		|O
naive	1645	1650		|O
HIV	1651	1654		|O
-	1654	1655		|O
infected	1655	1663		|O
patients	1664	1672		|O
and	1673	1676		|O
does	1677	1681		|O
not	1682	1685		|O
show	1686	1690		|O
a	1691	1692		|O
persistent	1693	1703		|O
benefit	1704	1711		|O
of	1712	1714		|O
the	1715	1718		|O
intervention	1719	1731		|O
.	1731	1732		|O

### 18922700
Optimal	0	7		|O
timing	8	14		|O
for	15	18		|O
adjuvant	19	27		|O
radiation	28	37		|O
therapy	38	45		|O
in	46	48		|O
breast	49	55	breast cancer	|B-DISEASE
cancer	56	62		|I-DISEASE
:	62	63		|O
a	64	65		|O
comprehensive	66	79		|O
review	80	86		|O
and	87	90		|O
perspectives	91	103		|O
.	103	104		|O
PURPOSE	106	113		|O
:	113	114		|O
The	115	118		|O
optimal	119	126		|O
sequence	127	135		|O
of	136	138		|O
modalities	139	149		|O
involved	150	158		|O
in	159	161		|O
breast	162	168	breast cancer	|B-DISEASE
cancer	169	175		|I-DISEASE
treatment	176	185		|O
with	186	190		|O
respect	191	198		|O
to	199	201		|O
radiotherapy	202	214		|O
and	215	218		|O
the	219	222		|O
maximum	223	230		|O
acceptable	231	241		|O
interval	242	250		|O
between	251	258		|O
radiotherapy	259	271		|O
and	272	275		|O
surgery	276	283		|O
need	284	288		|O
to	289	291		|O
be	292	294		|O
determined	295	305		|O
.	305	306		|O
DESIGN	307	313		|O
:	313	314		|O
This	315	319		|O
review	320	326		|O
attempts	327	335		|O
a	336	337		|O
critical	338	346		|O
reading	347	354		|O
of	355	357		|O
the	358	361		|O
literature	362	372		|O
.	372	373		|O
RESULTS	374	381		|O
:	381	382		|O
A	383	384		|O
delay	385	390		|O
of	391	393		|O
radiotherapy	394	406		|O
more	407	411		|O
than	412	416		|O
8-12	417	421		|O
weeks	422	427		|O
after	428	433		|O
surgery	434	441		|O
adversely	442	451		|O
affects	452	459		|O
local	460	465		|O
recurrence	466	476		|O
.	476	477		|O
Radiotherapy	478	490		|O
should	491	497		|O
be	498	500		|O
administered	501	513		|O
within	514	520		|O
7	521	522		|O
months	523	529		|O
after	530	535		|O
surgery	536	543		|O
,	543	544		|O
when	545	549		|O
chemotherapy	550	562		|O
is	563	565		|O
administered	566	578		|O
first	579	584		|O
.	584	585		|O
Several	586	593		|O
chemotherapy	594	606		|O
regimens	607	615		|O
can	616	619		|O
be	620	622		|O
safely	623	629		|O
administered	630	642		|O
concurrently	643	655		|O
with	656	660		|O
radiotherapy	661	673		|O
.	673	674		|O
The	675	678		|O
concurrent	679	689		|O
use	690	693		|O
of	694	696		|O
tamoxifen	697	706		|O
with	707	711		|O
chemotherapy	712	724		|O
should	725	731		|O
be	732	734		|O
avoided	735	742		|O
,	742	743		|O
but	744	747		|O
not	748	751		|O
with	752	756		|O
radiotherapy	757	769		|O
.	769	770		|O
Data	771	775		|O
is	776	778		|O
insufficient	779	791		|O
with	792	796		|O
regard	797	803		|O
to	804	806		|O
concurrent	807	817		|O
use	818	821		|O
of	822	824		|O
aromatase	825	834		|O
inhibitors	835	845		|O
with	846	850		|O
radiotherapy	851	863		|O
.	863	864		|O
The	865	868		|O
use	869	872		|O
of	873	875		|O
trastuzumab	876	887		|O
concomitantly	888	901		|O
with	902	906		|O
radiotherapy	907	919		|O
may	920	923		|O
enhance	924	931		|O
toxicities	932	942		|O
but	943	946		|O
may	947	950		|O
also	951	955		|O
improve	956	963		|O
its	964	967		|O
efficacy	968	976		|O
.	976	977		|O
CONCLUSIONS	978	989		|O
:	989	990		|O
Although	991	999		|O
the	1000	1003		|O
issue	1004	1009		|O
of	1010	1012		|O
radiotherapy	1013	1025		|O
delay	1026	1031		|O
and	1032	1035		|O
that	1036	1040		|O
of	1041	1043		|O
sequence	1044	1052		|O
with	1053	1057		|O
chemotherapy	1058	1070		|O
or	1071	1073		|O
tamoxifen	1074	1083		|O
are	1084	1087		|O
clarified	1088	1097		|O
,	1097	1098		|O
the	1099	1102		|O
sequence	1103	1111		|O
of	1112	1114		|O
radiotherapy	1115	1127		|O
with	1128	1132		|O
aromatase	1133	1142		|O
inhibitors	1143	1153		|O
and	1154	1157		|O
trastuzumab	1158	1169		|O
needs	1170	1175		|O
to	1176	1178		|O
be	1179	1181		|O
defined	1182	1189		|O
.	1189	1190		|O
Individual	1191	1201		|O
radiosensitivity	1202	1218		|O
may	1219	1222		|O
influence	1223	1232		|O
toxicity	1233	1241		|O
.	1241	1242		|O
New	1243	1246		|O
biologic	1247	1255		|O
markers	1256	1263		|O
have	1264	1268		|O
to	1269	1271		|O
be	1272	1274		|O
determined	1275	1285		|O
in	1286	1288		|O
the	1289	1292		|O
future	1293	1299		|O
for	1300	1303		|O
tailoring	1304	1313		|O
radiotherapy	1314	1326		|O
in	1327	1329		|O
breast	1330	1336	breast cancer	|B-DISEASE
cancer	1337	1343		|I-DISEASE
.	1343	1344		|O

### 18783727
Risk	0	4		|O
assessment	5	15		|O
of	16	18		|O
khat	19	23		|O
use	24	27		|O
in	28	30		|O
the	31	34		|O
Netherlands	35	46		|O
:	46	47		|O
a	48	49		|O
review	50	56		|O
based	57	62		|O
on	63	65		|O
adverse	66	73		|O
health	74	80		|O
effects	81	88		|O
,	88	89		|O
prevalence	90	100		|O
,	100	101		|O
criminal	102	110		|O
involvement	111	122		|O
and	123	126		|O
public	127	133		|O
order	134	139		|O
.	139	140		|O
In	142	144		|O
preparing	145	154		|O
a	155	156		|O
decision	157	165		|O
about	166	171		|O
the	172	175		|O
legal	176	181		|O
status	182	188		|O
of	189	191		|O
khat	192	196		|O
in	197	199		|O
the	200	203		|O
Netherlands	204	215		|O
,	215	216		|O
the	217	220		|O
Dutch	221	226		|O
Minister	227	235		|O
of	236	238		|O
Health	239	245		|O
requested	246	255		|O
CAM	256	259		|O
(	260	261		|O
Coordination	261	273		|O
point	274	279		|O
Assessment	280	290		|O
and	291	294		|O
Monitoring	295	305		|O
new	306	309		|O
drugs	310	315		|O
)	315	316		|O
to	317	319		|O
assess	320	326		|O
the	327	330		|O
overall	331	338		|O
risk	339	343		|O
of	344	346		|O
khat	347	351		|O
in	352	354		|O
the	355	358		|O
Netherlands	359	370		|O
.	370	371		|O
The	372	375		|O
present	376	383		|O
paper	384	389		|O
is	390	392		|O
a	393	394		|O
redraft	395	402		|O
of	403	405		|O
a	406	407		|O
report	408	414		|O
which	415	420		|O
formed	421	427		|O
the	428	431		|O
scientific	432	442		|O
basis	443	448		|O
of	449	451		|O
the	452	455		|O
risk	456	460		|O
evaluation	461	471		|O
procedure	472	481		|O
(	482	483		|O
October	483	490		|O
2007	491	495		|O
)	495	496		|O
.	496	497		|O
This	498	502		|O
report	503	509		|O
reviews	510	517		|O
the	518	521		|O
scientific	522	532		|O
data	533	537		|O
about	538	543		|O
khat	544	548		|O
available	549	558		|O
in	559	561		|O
the	562	565		|O
international	566	579		|O
literature	580	590		|O
.	590	591		|O
In	592	594		|O
addition	595	603		|O
,	603	604		|O
the	605	608		|O
report	609	615		|O
contains	616	624		|O
some	625	629		|O
information	630	641		|O
specific	642	650		|O
for	651	654		|O
the	655	658		|O
Netherlands	659	670		|O
(	671	672		|O
prevalence	672	682		|O
,	682	683		|O
availability	684	696		|O
of	697	699		|O
khat	700	704		|O
and	705	708		|O
public	709	715		|O
order	716	721		|O
aspects	722	729		|O
)	729	730		|O
.	730	731		|O
The	732	735		|O
main	736	740		|O
psychoactive	741	753		|O
compounds	754	763		|O
in	764	766		|O
khat	767	771		|O
leaves	772	778		|O
are	779	782		|O
cathine	783	790		|O
and	791	794		|O
cathinone	795	804		|O
,	804	805		|O
which	806	811		|O
are	812	815		|O
some	816	820		|O
2	821	822		|O
-	822	823		|O
to	824	826		|O
10	827	829		|O
-	829	830		|O
fold	830	834		|O
less	835	839		|O
active	840	846		|O
than	847	851		|O
amphetamine	852	863		|O
.	863	864		|O
Acute	865	870		|O
health	871	877		|O
problems	878	886		|O
are	887	890		|O
rarely	891	897		|O
seen	898	902		|O
,	902	903		|O
and	904	907		|O
are	908	911		|O
usually	912	919		|O
related	920	927		|O
with	928	932		|O
malnutrition	933	945		|O
,	945	946		|O
social	947	953		|O
and	954	957		|O
financial	958	967		|O
problems	968	976		|O
.	976	977		|O
Khat	978	982		|O
has	983	986		|O
a	987	988		|O
low	989	992		|O
addictive	993	1002		|O
potential	1003	1012		|O
.	1012	1013		|O
Chronic	1014	1021	Chronic toxicity	|B-ADVERSE
toxicity	1022	1030		|I-ADVERSE
of	1031	1033		|O
khat	1034	1038		|O
is	1039	1041		|O
modest	1042	1048		|O
when	1049	1053		|O
used	1054	1058		|O
in	1059	1061		|O
low	1062	1065		|O
amounts	1066	1073		|O
,	1073	1074		|O
whereas	1075	1082		|O
at	1083	1085		|O
high	1086	1090		|O
levels	1091	1097		|O
,	1097	1098		|O
khat	1099	1103		|O
use	1104	1107		|O
is	1108	1110		|O
associated	1111	1121		|O
with	1122	1126		|O
adverse	1127	1134		|O
effects	1135	1142		|O
,	1142	1143		|O
like	1144	1148		|O
hypertension	1149	1161	hypertension	|B-ADVERSE
,	1161	1162		|O
heart	1163	1168	heart rhythm disorders	|B-ADVERSE
rhythm	1169	1175		|I-ADVERSE
disorders	1176	1185		|I-ADVERSE
,	1185	1186		|O
insomnia	1187	1195	insomnia	|B-ADVERSE
and	1196	1199		|O
loss	1200	1204	loss of appetite	|B-ADVERSE
of	1205	1207		|I-ADVERSE
appetite	1208	1216		|I-ADVERSE
.	1216	1217		|O
In	1218	1220		|O
addition	1221	1229		|O
,	1229	1230		|O
khat	1231	1235		|O
users	1236	1241		|O
show	1242	1246		|O
a	1247	1248		|O
higher	1249	1255		|O
prevalence	1256	1266		|O
of	1267	1269		|O
cancers	1270	1277	cancers	|B-DISEASE
in	1278	1280		|O
the	1281	1284		|O
digestive	1285	1294		|O
tract	1295	1300		|O
.	1300	1301		|O
At	1302	1304		|O
population	1305	1315		|O
level	1316	1321		|O
,	1321	1322		|O
khat	1323	1327		|O
does	1328	1332		|O
not	1333	1336		|O
lead	1337	1341		|O
to	1342	1344		|O
specific	1345	1353		|O
health	1354	1360		|O
risks	1361	1366		|O
in	1367	1369		|O
the	1370	1373		|O
Netherlands	1374	1385		|O
,	1385	1386		|O
as	1387	1389		|O
its	1390	1393		|O
use	1394	1397		|O
is	1398	1400		|O
confined	1401	1409		|O
to	1410	1412		|O
East	1413	1417		|O
-	1417	1418		|O
African	1418	1425		|O
immigrants	1426	1436		|O
.	1436	1437		|O
A	1438	1439		|O
relationship	1440	1452		|O
between	1453	1460		|O
khat	1461	1465		|O
use	1466	1469		|O
and	1470	1473		|O
psychiatric	1474	1485		|O
disorders	1486	1495		|O
has	1496	1499		|O
been	1500	1504		|O
suggested	1505	1514		|O
,	1514	1515		|O
but	1516	1519		|O
the	1520	1523		|O
reports	1524	1531		|O
are	1532	1535		|O
contradictory	1536	1549		|O
,	1549	1550		|O
and	1551	1554		|O
such	1555	1559		|O
studies	1560	1567		|O
are	1568	1571		|O
presumably	1572	1582		|O
heavily	1583	1590		|O
confounded	1591	1601		|O
by	1602	1604		|O
posttraumatic	1605	1618		|O
and	1619	1622		|O
social	1623	1629		|O
stress	1630	1636		|O
.	1636	1637		|O
In	1638	1640		|O
the	1641	1644		|O
Netherlands	1645	1656		|O
(	1657	1658		|O
and	1658	1661		|O
other	1662	1667		|O
countries	1668	1677		|O
)	1677	1678		|O
,	1678	1679		|O
khat	1680	1684		|O
use	1685	1688		|O
occasionally	1689	1701		|O
leads	1702	1707		|O
to	1708	1710		|O
minor	1711	1716		|O
disturbance	1717	1728		|O
of	1729	1731		|O
civil	1732	1737		|O
order	1738	1743		|O
in	1744	1746		|O
the	1747	1750		|O
public	1751	1757		|O
domain	1758	1764		|O
(	1765	1766		|O
loud	1766	1770		|O
talking	1771	1778		|O
,	1778	1779		|O
spitting	1780	1788		|O
)	1788	1789		|O
,	1789	1790		|O
but	1791	1794		|O
is	1795	1797		|O
not	1798	1801		|O
related	1802	1809		|O
to	1810	1812		|O
criminal	1813	1821		|O
activities	1822	1832		|O
.	1832	1833		|O
Following	1834	1843		|O
the	1844	1847		|O
assessment	1848	1858		|O
,	1858	1859		|O
CAM	1860	1863		|O
estimated	1864	1873		|O
the	1874	1877		|O
overall	1878	1885		|O
risk	1886	1890		|O
potential	1891	1900		|O
of	1901	1903		|O
khat	1904	1908		|O
use	1909	1912		|O
in	1913	1915		|O
the	1916	1919		|O
Netherlands	1920	1931		|O
as	1932	1934		|O
very	1935	1939		|O
low	1940	1943		|O
.	1943	1944		|O
A	1945	1946		|O
similar	1947	1954		|O
conclusion	1955	1965		|O
may	1966	1969		|O
be	1970	1972		|O
drawn	1973	1978		|O
for	1979	1982		|O
countries	1983	1992		|O
with	1993	1997		|O
a	1998	1999		|O
comparable	2000	2010		|O
prevalence	2011	2021		|O
of	2022	2024		|O
khat	2025	2029		|O
use	2030	2033		|O
and	2034	2037		|O
khat	2038	2042		|O
related	2043	2050		|O
public	2051	2057		|O
order	2058	2063		|O
disturbance	2064	2075		|O
.	2075	2076		|O

### 18813917
Spatial	0	7		|O
and	8	11		|O
temporal	12	20		|O
aspects	21	28		|O
of	29	31		|O
muscle	32	38	muscle hyperalgesia	|B-ADVERSE
hyperalgesia	39	51		|I-ADVERSE
induced	52	59		|O
by	60	62		|O
nerve	63	68		|O
growth	69	75		|O
factor	76	82		|O
in	83	85		|O
humans	86	92		|O
.	92	93		|O
Intramuscular	95	108		|O
injection	109	118		|O
of	119	121		|O
nerve	122	127		|O
growth	128	134		|O
factor	135	141		|O
(	142	143		|O
NGF	143	146		|O
)	146	147		|O
has	148	151		|O
been	152	156		|O
shown	157	162		|O
to	163	165		|O
induce	166	172		|O
long	173	177		|O
-	177	178		|O
term	178	182		|O
sensitisation	183	196		|O
and	197	200		|O
time	201	205		|O
-	205	206		|O
dependent	206	215		|O
hyperalgesia	216	228	hyperalgesia	|B-ADVERSE
indicating	229	239		|O
potential	240	249		|O
involvement	250	261		|O
of	262	264		|O
both	265	269		|O
central	270	277		|O
and	278	281		|O
peripheral	282	292		|O
pain	293	297	pain	|B-ADVERSE
mechanisms	298	308		|O
.	308	309		|O
This	310	314		|O
double	315	321		|O
-	321	322		|O
blind	322	327		|O
placebo	328	335		|O
-	335	336		|O
controlled	336	346		|O
study	347	352		|O
was	353	356		|O
designed	357	365		|O
to	366	368		|O
describe	369	377		|O
the	378	381		|O
spatial	382	389		|O
distribution	390	402		|O
of	403	405		|O
muscle	406	412	muscle hyperalgesia	|B-ADVERSE
hyperalgesia	413	425		|I-ADVERSE
over	426	430		|O
time	431	435		|O
(	436	437		|O
immediately	437	448		|O
after	449	454		|O
,	454	455		|O
3	456	457		|O
h	458	459		|O
,	459	460		|O
1	461	462		|O
,	462	463		|O
4	464	465		|O
,	465	466		|O
7	467	468		|O
and	469	472		|O
21	473	475		|O
days	476	480		|O
)	480	481		|O
after	482	487		|O
injecting	488	497		|O
NGF	498	501		|O
(	502	503		|O
5	503	504		|O
mug	505	508		|O
)	508	509		|O
into	510	514		|O
the	515	518		|O
tibialis	519	527		|O
anterior	528	536		|O
(	537	538		|O
TA	538	540		|O
)	540	541		|O
muscle	542	548		|O
,	548	549		|O
to	550	552		|O
explore	553	560		|O
possibly	561	569		|O
involved	570	578		|O
central	579	586		|O
pain	587	591	pain	|B-ADVERSE
mechanisms	592	602		|O
and	603	606		|O
to	607	609		|O
investigate	610	621		|O
the	622	625		|O
effect	626	632		|O
of	633	635		|O
gender	636	642		|O
on	643	645		|O
development	646	657		|O
of	658	660		|O
hyperalgesia	661	673	hyperalgesia	|B-ADVERSE
.	673	674		|O
Totally	675	682		|O
20	683	685		|O
healthy	686	693		|O
volunteers	694	704		|O
(	705	706		|O
10	706	708		|O
men	709	712		|O
and	713	716		|O
10	717	719		|O
women	720	725		|O
)	725	726		|O
participated	727	739		|O
in	740	742		|O
the	743	746		|O
study	747	752		|O
.	752	753		|O
An	754	756		|O
isotonic	757	765		|O
saline	766	772		|O
injection	773	782		|O
into	783	787		|O
the	788	791		|O
contralateral	792	805		|O
TA	806	808		|O
muscle	809	815		|O
served	816	822		|O
as	823	825		|O
a	826	827		|O
control	828	835		|O
condition	836	845		|O
for	846	849		|O
the	850	853		|O
NGF	854	857		|O
injection	858	867		|O
.	867	868		|O
Pressure	869	877		|O
pain	878	882	pain	|B-DISEASE
thresholds	883	893		|O
(	894	895		|O
PPT	895	898		|O
)	898	899		|O
were	900	904		|O
used	905	909		|O
to	910	912		|O
test	913	917		|O
for	918	921		|O
muscle	922	928	muscle hyperalgesia	|B-DISEASE
hyperalgesia	929	941		|I-DISEASE
along	942	947		|O
the	948	951		|O
TA	952	954		|O
(	955	956		|O
seven	956	961		|O
sites	962	967		|O
)	967	968		|O
muscle	969	975		|O
at	976	978		|O
the	979	982		|O
extensor	983	991		|O
digitorum	992	1001		|O
longus	1002	1008		|O
and	1009	1012		|O
at	1013	1015		|O
the	1016	1019		|O
web	1020	1023		|O
between	1024	1031		|O
1st	1032	1035		|O
and	1036	1039		|O
2nd	1040	1043		|O
metatarsal	1044	1054		|O
(	1055	1056		|O
central	1056	1063		|O
involvement	1064	1075		|O
)	1075	1076		|O
.	1076	1077		|O
One	1078	1081		|O
day	1082	1085		|O
after	1086	1091		|O
the	1092	1095		|O
NGF	1096	1099		|O
/	1099	1100		|O
control	1100	1107		|O
injections	1108	1118		|O
,	1118	1119		|O
hypertonic	1120	1130		|O
saline	1131	1137		|O
(	1138	1139		|O
0.5	1139	1142		|O
ml	1143	1145		|O
,	1145	1146		|O
5.8%	1147	1151		|O
)	1151	1152		|O
was	1153	1156		|O
injected	1157	1165		|O
into	1166	1170		|O
the	1171	1174		|O
left	1175	1179		|O
and	1180	1183		|O
right	1184	1189		|O
TA	1190	1192		|O
to	1193	1195		|O
study	1196	1201		|O
the	1202	1205		|O
pain	1206	1210	pain	|B-DISEASE
response	1211	1219		|O
to	1220	1222		|O
chemical	1223	1231		|O
stimulation	1232	1243		|O
of	1244	1246		|O
the	1247	1250		|O
hyperalgesic	1251	1263		|O
muscle	1264	1270		|O
tissue	1271	1277		|O
.	1277	1278		|O
Scores	1279	1285		|O
on	1286	1288		|O
a	1289	1290		|O
modified	1291	1299		|O
Likert	1300	1306		|O
scale	1307	1312		|O
were	1313	1317		|O
used	1318	1322		|O
to	1323	1325		|O
assess	1326	1332		|O
soreness	1333	1341		|O
during	1342	1348		|O
muscle	1349	1355		|O
function	1356	1364		|O
.	1364	1365		|O
An	1366	1368		|O
area	1369	1373		|O
of	1374	1376		|O
hyperalgesia	1377	1389	hyperalgesia	|B-ADVERSE
was	1390	1393		|O
observed	1394	1402		|O
locally	1403	1410		|O
at	1411	1413		|O
the	1414	1417		|O
injected	1418	1426		|O
site	1427	1431		|O
3	1432	1433		|O
h	1434	1435		|O
after	1436	1441		|O
injection	1442	1451		|O
of	1452	1454		|O
NGF	1455	1458		|O
,	1458	1459		|O
which	1460	1465		|O
expanded	1466	1474		|O
both	1475	1479		|O
proximally	1480	1490		|O
and	1491	1494		|O
distally	1495	1503		|O
on	1504	1506		|O
day	1507	1510		|O
1	1511	1512		|O
;	1512	1513		|O
this	1514	1518		|O
effect	1519	1525		|O
subsided	1526	1534		|O
on	1535	1537		|O
day	1538	1541		|O
4	1542	1543		|O
.	1543	1544		|O
Decreased	1545	1554		|O
PPT	1555	1558		|O
was	1559	1562		|O
also	1563	1567		|O
found	1568	1573		|O
between	1574	1581		|O
1st	1582	1585		|O
and	1586	1589		|O
2nd	1590	1593		|O
metatarsal	1594	1604		|O
on	1605	1607		|O
day	1608	1611		|O
1	1612	1613		|O
.	1613	1614		|O
Hypertonic	1615	1625		|O
saline	1626	1632		|O
evoked	1633	1639		|O
more	1640	1644		|O
pain	1645	1649	pain	|B-ADVERSE
in	1650	1652		|O
men	1653	1656		|O
when	1657	1661		|O
injected	1662	1670		|O
in	1671	1673		|O
the	1674	1677		|O
NGF	1678	1681		|O
treated	1682	1689		|O
TA	1690	1692		|O
compared	1693	1701		|O
to	1702	1704		|O
the	1705	1708		|O
control	1709	1716		|O
leg	1717	1720		|O
.	1720	1721		|O
Injection	1722	1731		|O
of	1732	1734		|O
NGF	1735	1738		|O
increased	1739	1748		|O
muscle	1749	1755	muscle soreness	|B-ADVERSE
soreness	1756	1764		|I-ADVERSE
during	1765	1771		|O
muscle	1772	1778		|O
activity	1779	1787		|O
for	1788	1791		|O
7	1792	1793		|O
days	1794	1798		|O
.	1798	1799		|O
In	1800	1802		|O
this	1803	1807		|O
material	1808	1816		|O
there	1817	1822		|O
was	1823	1826		|O
no	1827	1829		|O
gender	1830	1836		|O
effect	1837	1843		|O
of	1844	1846		|O
NGF	1847	1850		|O
-	1850	1851		|O
induced	1851	1858		|O
muscle	1859	1865	muscle hyperalgesia	|B-ADVERSE
hyperalgesia	1866	1878		|I-ADVERSE
.	1878	1879		|O
The	1880	1883		|O
expansion	1884	1893		|O
of	1894	1896		|O
muscle	1897	1903	muscle hyperalgesia	|B-DISEASE
hyperalgesia	1904	1916		|I-DISEASE
to	1917	1919		|O
distant	1920	1927		|O
areas	1928	1933		|O
indicates	1934	1943		|O
that	1944	1948		|O
central	1949	1956		|O
mechanisms	1957	1967		|O
are	1968	1971		|O
involved	1972	1980		|O
.	1980	1981		|O

### 18672535
Pharmacokinetic	0	15		|O
interaction	16	27		|O
between	28	35		|O
ethinyl	36	43		|O
estradiol	44	53		|O
,	53	54		|O
norethindrone	55	68		|O
and	69	72		|O
darunavir	73	82		|O
with	83	87		|O
low	88	91		|O
-	91	92		|O
dose	92	96		|O
ritonavir	97	106		|O
in	107	109		|O
healthy	110	117		|O
women	118	123		|O
.	123	124		|O
BACKGROUND	126	136		|O
:	136	137		|O
An	138	140		|O
open	141	145		|O
-	145	146		|O
label	146	151		|O
,	151	152		|O
randomized	153	163		|O
,	163	164		|O
crossover	165	174		|O
study	175	180		|O
was	181	184		|O
performed	185	194		|O
to	195	197		|O
investigate	198	209		|O
the	210	213		|O
effect	214	220		|O
of	221	223		|O
multiple	224	232		|O
doses	233	238		|O
of	239	241		|O
darunavir	242	251		|O
co	252	254		|O
-	254	255		|O
administered	255	267		|O
with	268	272		|O
low	273	276		|O
-	276	277		|O
dose	277	281		|O
ritonavir	282	291		|O
(	292	293		|O
DRV	293	296		|O
/	296	297		|O
r	297	298		|O
)	298	299		|O
on	300	302		|O
the	303	306		|O
steady	307	313		|O
-	313	314		|O
state	314	319		|O
pharmacokinetics	320	336		|O
of	337	339		|O
the	340	343		|O
oral	344	348		|O
contraceptives	349	363		|O
ethinyl	364	371		|O
estradiol	372	381		|O
(	382	383		|O
EE	383	385		|O
)	385	386		|O
and	387	390		|O
norethindrone	391	404		|O
(	405	406		|O
NE	406	408		|O
)	408	409		|O
(	410	411		|O
commercial	411	421		|O
name	422	426		|O
of	427	429		|O
the	430	433		|O
combined	434	442		|O
drug	443	447		|O
Ortho	448	453		|O
-	453	454		|O
Novum	454	459		|O
1/35	460	464		|O
)	464	465		|O
in	466	468		|O
19	469	471		|O
HIV	472	475		|O
-	475	476		|O
negative	476	484		|O
healthy	485	492		|O
women	493	498		|O
.	498	499		|O
METHODS	500	507		|O
:	507	508		|O
In	509	511		|O
session	512	519		|O
1	520	521		|O
,	521	522		|O
participants	523	535		|O
received	536	544		|O
35	545	547		|O
microg	548	554		|O
EE	555	557		|O
and	558	561		|O
1.0	562	565		|O
mg	566	568		|O
NE	569	571		|O
from	572	576		|O
days	577	581		|O
1	582	583		|O
to	584	586		|O
21	587	589		|O
.	589	590		|O
In	591	593		|O
session	594	601		|O
2	602	603		|O
,	603	604		|O
participants	605	617		|O
received	618	626		|O
the	627	630		|O
same	631	635		|O
oral	636	640		|O
contraceptive	641	654		|O
treatment	655	664		|O
as	665	667		|O
in	668	670		|O
session	671	678		|O
1	679	680		|O
on	681	683		|O
days	684	688		|O
1	689	690		|O
to	691	693		|O
21	694	696		|O
plus	697	701		|O
DRV	702	705		|O
/	705	706		|O
r	706	707		|O
(	708	709		|O
600	709	712		|O
mg	713	715		|O
/	715	716		|O
100	716	719		|O
mg	720	722		|O
twice	723	728		|O
daily	729	734		|O
)	734	735		|O
on	736	738		|O
days	739	743		|O
1	744	745		|O
to	746	748		|O
14	749	751		|O
.	751	752		|O
Pharmacokinetic	753	768		|O
assessments	769	780		|O
were	781	785		|O
performed	786	795		|O
on	796	798		|O
day	799	802		|O
14	803	805		|O
for	806	809		|O
each	810	814		|O
session	815	822		|O
.	822	823		|O
RESULTS	824	831		|O
:	831	832		|O
Steady	833	839		|O
-	839	840		|O
state	840	845		|O
systemic	846	854		|O
exposure	855	863		|O
to	864	866		|O
EE	867	869		|O
and	870	873		|O
NE	874	876		|O
decreased	877	886		|O
when	887	891		|O
DRV	892	895		|O
/	895	896		|O
r	896	897		|O
was	898	901		|O
co	902	904		|O
-	904	905		|O
administered	905	917		|O
,	917	918		|O
based	919	924		|O
on	925	927		|O
the	928	931		|O
ratio	932	937		|O
of	938	940		|O
least	941	946		|O
square	947	953		|O
means	954	959		|O
of	960	962		|O
the	963	966		|O
minimum	967	974		|O
plasma	975	981		|O
concentration	982	995		|O
(	996	997		|O
Cmin	997	1001		|O
)	1001	1002		|O
,	1002	1003		|O
the	1004	1007		|O
maximum	1008	1015		|O
plasma	1016	1022		|O
concentration	1023	1036		|O
(	1037	1038		|O
Cmax	1038	1042		|O
)	1042	1043		|O
,	1043	1044		|O
and	1045	1048		|O
the	1049	1052		|O
area	1053	1057		|O
under	1058	1063		|O
the	1064	1067		|O
curve	1068	1073		|O
(	1074	1075		|O
AUC24h	1075	1081		|O
)	1081	1082		|O
of	1083	1085		|O
EE	1086	1088		|O
(	1089	1090		|O
which	1090	1095		|O
decreased	1096	1105		|O
by	1106	1108		|O
62%	1109	1112		|O
,	1112	1113		|O
32%	1114	1117		|O
and	1118	1121		|O
44%	1122	1125		|O
,	1125	1126		|O
respectively	1127	1139		|O
)	1139	1140		|O
and	1141	1144		|O
NE	1145	1147		|O
(	1148	1149		|O
which	1149	1154		|O
decreased	1155	1164		|O
by	1165	1167		|O
30%	1168	1171		|O
,	1171	1172		|O
10%	1173	1176		|O
and	1177	1180		|O
14%	1181	1184		|O
,	1184	1185		|O
respectively	1186	1198		|O
)	1198	1199		|O
compared	1200	1208		|O
with	1209	1213		|O
administration	1214	1228		|O
of	1229	1231		|O
EE	1232	1234		|O
and	1235	1238		|O
NE	1239	1241		|O
alone	1242	1247		|O
.	1247	1248		|O
Five	1249	1253		|O
participants	1254	1266		|O
discontinued	1267	1279		|O
the	1280	1283		|O
study	1284	1289		|O
due	1290	1293		|O
to	1294	1296		|O
grade	1297	1302		|O
2	1303	1304		|O
cutaneous	1305	1314		|O
events	1315	1321		|O
,	1321	1322		|O
as	1323	1325		|O
required	1326	1334		|O
per	1335	1338		|O
protocol	1339	1347		|O
,	1347	1348		|O
during	1349	1355		|O
treatment	1356	1365		|O
with	1366	1370		|O
EE	1371	1373		|O
and	1374	1377		|O
NE	1378	1380		|O
in	1381	1383		|O
combination	1384	1395		|O
with	1396	1400		|O
DRV	1401	1404		|O
/	1404	1405		|O
r	1405	1406		|O
.	1406	1407		|O
There	1408	1413		|O
were	1414	1418		|O
no	1419	1421		|O
clinically	1422	1432		|O
relevant	1433	1441		|O
findings	1442	1450		|O
for	1451	1454		|O
laboratory	1455	1465		|O
and	1466	1469		|O
cardiovascular	1470	1484		|O
parameters	1485	1495		|O
.	1495	1496		|O
CONCLUSIONS	1497	1508		|O
:	1508	1509		|O
The	1510	1513		|O
pharmacokinetic	1514	1529		|O
interaction	1530	1541		|O
observed	1542	1550		|O
here	1551	1555		|O
is	1556	1558		|O
considered	1559	1569		|O
to	1570	1572		|O
be	1573	1575		|O
clinically	1576	1586		|O
relevant	1587	1595		|O
as	1596	1598		|O
EE	1599	1601		|O
concentrations	1602	1616		|O
are	1617	1620		|O
considerably	1621	1633		|O
reduced	1634	1641		|O
when	1642	1646		|O
DRV	1647	1650		|O
/	1650	1651		|O
r	1651	1652		|O
is	1653	1655		|O
co	1656	1658		|O
-	1658	1659		|O
administered	1659	1671		|O
with	1672	1676		|O
EE	1677	1679		|O
and	1680	1683		|O
NE	1684	1686		|O
.	1686	1687		|O
Alternative	1688	1699		|O
or	1700	1702		|O
additional	1703	1713		|O
contraceptive	1714	1727		|O
measures	1728	1736		|O
should	1737	1743		|O
be	1744	1746		|O
used	1747	1751		|O
when	1752	1756		|O
oestrogen	1757	1766		|O
-	1766	1767		|O
based	1767	1772		|O
contraceptives	1773	1787		|O
are	1788	1791		|O
co	1792	1794		|O
-	1794	1795		|O
administered	1795	1807		|O
with	1808	1812		|O
DRV	1813	1816		|O
/	1816	1817		|O
r	1817	1818		|O
.	1818	1819		|O

### 18753192
Tacrolimus	0	10		|O
for	11	14		|O
the	15	18		|O
treatment	19	28		|O
of	29	31		|O
systemic	32	40	systemic lupus erythematosus	|B-DISEASE
lupus	41	46		|I-DISEASE
erythematosus	47	60		|I-DISEASE
with	61	65		|O
pure	66	70		|O
class	71	76		|O
V	77	78		|O
nephritis	79	88	nephritis	|B-DISEASE
.	88	89		|O
OBJECTIVES	91	101		|O
:	101	102		|O
The	103	106		|O
treatment	107	116		|O
of	117	119		|O
pure	120	124		|O
membranous	125	135		|O
(	136	137		|O
class	137	142		|O
V	143	144		|O
)	144	145		|O
lupus	146	151	lupus nephropathy	|B-DISEASE
nephropathy	152	163		|I-DISEASE
remains	164	171		|O
unsatisfactory	172	186		|O
.	186	187		|O
We	188	190		|O
studied	191	198		|O
the	199	202		|O
efficacy	203	211		|O
and	212	215		|O
safety	216	222		|O
of	223	225		|O
tacrolimus	226	236		|O
in	237	239		|O
the	240	243		|O
treatment	244	253		|O
of	254	256		|O
membranous	257	267	membranous nephritis	|B-DISEASE
nephritis	268	277		|I-DISEASE
secondary	278	287		|O
to	288	290		|O
SLE	291	294	SLE	|B-DISEASE
.	294	295		|O
METHODS	296	303		|O
:	303	304		|O
We	305	307		|O
recruited	308	317		|O
18	318	320		|O
consecutive	321	332		|O
SLE	333	336	SLE	|B-DISEASE
patients	337	345		|O
(	346	347		|O
tacrolimus	347	357		|O
group	358	363		|O
)	363	364		|O
with	365	369		|O
recently	370	378		|O
confirmed	379	388		|O
biopsy	389	395		|O
-	395	396		|O
proven	396	402		|O
class	403	408		|O
V	409	410		|O
lupus	411	416	lupus nephritis	|B-DISEASE
nephritis	417	426		|I-DISEASE
.	426	427		|O
They	428	432		|O
were	433	437		|O
treated	438	445		|O
with	446	450		|O
a	451	452		|O
tailing	453	460		|O
dose	461	465		|O
of	466	468		|O
oral	469	473		|O
prednisolone	474	486		|O
and	487	490		|O
tacrolimus	491	501		|O
0.1-0.2	502	509		|O
mg	510	512		|O
/	512	513		|O
kg	513	515		|O
/	515	516		|O
day	516	519		|O
for	520	523		|O
6	524	525		|O
months	526	532		|O
,	532	533		|O
followed	534	542		|O
by	543	545		|O
maintenance	546	557		|O
prednisolone	558	570		|O
and	571	574		|O
AZA	575	578		|O
.	578	579		|O
The	580	583		|O
rate	584	588		|O
of	589	591		|O
resolution	592	602		|O
of	603	605		|O
proteinuria	606	617	proteinuria	|B-DISEASE
and	618	621		|O
SLEDAI	622	628		|O
were	629	633		|O
compared	634	642		|O
with	643	647		|O
19	648	650		|O
historical	651	661		|O
controls	662	670		|O
treated	671	678		|O
with	679	683		|O
oral	684	688		|O
cyclophosphamide	689	705		|O
or	706	708		|O
AZA	709	712		|O
(	713	714		|O
control	714	721		|O
group	722	727		|O
)	727	728		|O
.	728	729		|O
All	730	733		|O
patients	734	742		|O
were	743	747		|O
followed	748	756		|O
for	757	760		|O
12	761	763		|O
months	764	770		|O
.	770	771		|O
RESULTS	772	779		|O
:	779	780		|O
Baseline	781	789		|O
clinical	790	798		|O
characteristics	799	814		|O
were	815	819		|O
comparable	820	830		|O
between	831	838		|O
the	839	842		|O
groups	843	849		|O
.	849	850		|O
For	851	854		|O
the	855	858		|O
tacrolimus	859	869		|O
group	870	875		|O
,	875	876		|O
the	877	880		|O
complete	881	889		|O
and	890	893		|O
partial	894	901		|O
remission	902	911		|O
rates	912	917		|O
were	918	922		|O
27.8	923	927		|O
and	928	931		|O
50.0%	932	937		|O
,	937	938		|O
respectively	939	951		|O
at	952	954		|O
12	955	957		|O
weeks	958	963		|O
;	963	964		|O
for	965	968		|O
the	969	972		|O
control	973	980		|O
group	981	986		|O
,	986	987		|O
they	988	992		|O
were	993	997		|O
15.8	998	1002		|O
and	1003	1006		|O
47.4%	1007	1012		|O
,	1012	1013		|O
respectively	1014	1026		|O
(	1027	1028		|O
overall	1028	1035		|O
chi	1036	1039		|O
-	1039	1040		|O
square	1040	1046		|O
test	1047	1051		|O
,	1051	1052		|O
P	1053	1054		|O
=	1055	1056		|O
0.5	1057	1060		|O
)	1060	1061		|O
.	1061	1062		|O
However	1063	1070		|O
,	1070	1071		|O
tacrolimus	1072	1082		|O
group	1083	1088		|O
had	1089	1092		|O
faster	1093	1099		|O
resolution	1100	1110		|O
of	1111	1113		|O
proteinuria	1114	1125	proteinuria	|B-DISEASE
than	1126	1130		|O
the	1131	1134		|O
control	1135	1142		|O
group	1143	1148		|O
by	1149	1151		|O
the	1152	1155		|O
general	1156	1163		|O
linear	1164	1170		|O
model	1171	1176		|O
with	1177	1181		|O
repeated	1182	1190		|O
measures	1191	1199		|O
(	1200	1201		|O
P	1201	1202		|O
=	1203	1204		|O
0.032	1205	1210		|O
)	1210	1211		|O
.	1211	1212		|O
At	1213	1215		|O
12	1216	1218		|O
weeks	1219	1224		|O
,	1224	1225		|O
proteinuria	1226	1237	proteinuria	|B-DISEASE
was	1238	1241		|O
reduced	1242	1249		|O
by	1250	1252		|O
76.2	1253	1257		|O
+	1258	1259		|O
/	1259	1260		|O
-	1260	1261		|O
17.0%	1262	1267		|O
for	1268	1271		|O
the	1272	1275		|O
tacrolimus	1276	1286		|O
group	1287	1292		|O
and	1293	1296		|O
47.1	1297	1301		|O
+	1302	1303		|O
/	1303	1304		|O
-	1304	1305		|O
51.1%	1306	1311		|O
for	1312	1315		|O
the	1316	1319		|O
control	1320	1327		|O
group	1328	1333		|O
(	1334	1335		|O
P	1335	1336		|O
=	1337	1338		|O
0.028	1339	1344		|O
)	1344	1345		|O
.	1345	1346		|O
Serial	1347	1353		|O
change	1354	1360		|O
in	1361	1363		|O
renal	1364	1369		|O
function	1370	1378		|O
and	1379	1382		|O
SLEDAI	1383	1389		|O
score	1390	1395		|O
did	1396	1399		|O
not	1400	1403		|O
differ	1404	1410		|O
between	1411	1418		|O
the	1419	1422		|O
groups	1423	1429		|O
.	1429	1430		|O
During	1431	1437		|O
the	1438	1441		|O
study	1442	1447		|O
period	1448	1454		|O
,	1454	1455		|O
four	1456	1460		|O
patients	1461	1469		|O
of	1470	1472		|O
the	1473	1476		|O
tacrolimus	1477	1487		|O
group	1488	1493		|O
,	1493	1494		|O
and	1495	1498		|O
11	1499	1501		|O
of	1502	1504		|O
the	1505	1508		|O
control	1509	1516		|O
group	1517	1522		|O
,	1522	1523		|O
developed	1524	1533		|O
lupus	1534	1539	lupus flare	|B-ADVERSE
flare	1540	1545		|I-ADVERSE
(	1546	1547		|O
P	1547	1548		|O
=	1549	1550		|O
0.027	1551	1556		|O
)	1556	1557		|O
.	1557	1558		|O
There	1559	1564		|O
was	1565	1568		|O
no	1569	1571		|O
serious	1572	1579		|O
adverse	1580	1587		|O
effect	1588	1594		|O
in	1595	1597		|O
the	1598	1601		|O
tacrolimus	1602	1612		|O
group	1613	1618		|O
.	1618	1619		|O
CONCLUSIONS	1620	1631		|O
:	1631	1632		|O
A	1633	1634		|O
6	1635	1636		|O
-	1636	1637		|O
month	1637	1642		|O
course	1643	1649		|O
of	1650	1652		|O
tacrolimus	1653	1663		|O
is	1664	1666		|O
a	1667	1668		|O
safe	1669	1673		|O
and	1674	1677		|O
effective	1678	1687		|O
treatment	1688	1697		|O
of	1698	1700		|O
pure	1701	1705		|O
class	1706	1711		|O
V	1712	1713		|O
(	1714	1715		|O
membranous	1715	1725		|O
)	1725	1726		|O
lupus	1727	1732	lupus nephritis	|B-DISEASE
nephritis	1733	1742		|I-DISEASE
.	1742	1743		|O
As	1744	1746		|O
compared	1747	1755		|O
with	1756	1760		|O
conventional	1761	1773		|O
cytotoxic	1774	1783		|O
treatment	1784	1793		|O
,	1793	1794		|O
tacrolimus	1795	1805		|O
possibly	1806	1814		|O
results	1815	1822		|O
in	1823	1825		|O
a	1826	1827		|O
faster	1828	1834		|O
resolution	1835	1845		|O
of	1846	1848		|O
proteinuria	1849	1860	proteinuria	|B-DISEASE
,	1860	1861		|O
and	1862	1865		|O
a	1866	1867		|O
lower	1868	1873		|O
risk	1874	1878		|O
of	1879	1881		|O
lupus	1882	1887	lupus flare	|B-ADVERSE
flare	1888	1893		|I-ADVERSE
within	1894	1900		|O
1	1901	1902		|O
yr	1903	1905		|O
.	1905	1906		|O
The	1907	1910		|O
long	1911	1915		|O
-	1915	1916		|O
term	1916	1920		|O
effect	1921	1927		|O
and	1928	1931		|O
optimal	1932	1939		|O
regimen	1940	1947		|O
of	1948	1950		|O
tacrolimus	1951	1961		|O
require	1962	1969		|O
further	1970	1977		|O
study	1978	1983		|O
.	1983	1984		|O

### 18651721
Antitumor	0	9		|O
properties	10	20		|O
of	21	23		|O
a	24	25		|O
sulfated	26	34		|O
polysaccharide	35	49		|O
from	50	54		|O
the	55	58		|O
red	59	62		|O
seaweed	63	70		|O
Champia	71	78		|O
feldmannii	79	89		|O
(	90	91		|O
Diaz	91	95		|O
-	95	96		|O
Pifferer	96	104		|O
)	104	105		|O
.	105	106		|O
In	108	110		|O
recent	111	117		|O
years	118	123		|O
,	123	124		|O
much	125	129		|O
attention	130	139		|O
has	140	143		|O
been	144	148		|O
focused	149	156		|O
on	157	159		|O
polysaccharides	160	175		|O
isolated	176	184		|O
from	185	189		|O
natural	190	197		|O
sources	198	205		|O
.	205	206		|O
The	207	210		|O
aim	211	214		|O
of	215	217		|O
this	218	222		|O
study	223	228		|O
was	229	232		|O
to	233	235		|O
investigate	236	247		|O
the	248	251		|O
in	252	254		|O
vitro	255	260		|O
and	261	264		|O
in	265	267		|O
vivo	268	272		|O
antitumor	273	282		|O
properties	283	293		|O
of	294	296		|O
a	297	298		|O
sulfated	299	307		|O
polysaccharide	308	322		|O
isolated	323	331		|O
from	332	336		|O
the	337	340		|O
seaweed	341	348		|O
C	349	350		|O
.	350	351		|O
feldmannii	352	362		|O
(	363	364		|O
Cf	364	366		|O
-	366	367		|O
PLS	367	370		|O
)	370	371		|O
.	371	372		|O
Hematological	373	386		|O
,	386	387		|O
biochemical	388	399		|O
and	400	403		|O
histopathological	404	421		|O
analyses	422	430		|O
were	431	435		|O
performed	436	445		|O
in	446	448		|O
order	449	454		|O
to	455	457		|O
evaluate	458	466		|O
the	467	470		|O
toxicological	471	484		|O
aspects	485	492		|O
related	493	500		|O
to	501	503		|O
Cf	504	506		|O
-	506	507		|O
PLS	507	510		|O
treatment	511	520		|O
.	520	521		|O
Its	522	525		|O
effects	526	533		|O
on	534	536		|O
the	537	540		|O
immunological	541	554		|O
system	555	561		|O
were	562	566		|O
also	567	571		|O
investigated	572	584		|O
.	584	585		|O
The	586	589		|O
Cf	590	592		|O
-	592	593		|O
PLS	593	596		|O
did	597	600		|O
not	601	604		|O
show	605	609		|O
any	610	613		|O
significant	614	625		|O
in	626	628		|O
vitro	629	634		|O
cytotoxicity	635	647	cytotoxicity	|B-ADVERSE
at	648	650		|O
the	651	654		|O
experimental	655	667		|O
exposure	668	676		|O
levels	677	683		|O
that	684	688		|O
were	689	693		|O
used	694	698		|O
,	698	699		|O
but	700	703		|O
showed	704	710		|O
in	711	713		|O
vivo	714	718		|O
antitumor	719	728		|O
effect	729	735		|O
.	735	736		|O
The	737	740		|O
inhibition	741	751		|O
rates	752	757		|O
of	758	760		|O
sarcoma	761	768	sarcoma	|B-DISEASE
180	769	772		|O
tumor	773	778	tumor	|B-DISEASE
development	779	790		|O
were	791	795		|O
48.62	796	801		|O
and	802	805		|O
48.16%	806	812		|O
at	813	815		|O
the	816	819		|O
doses	820	825		|O
of	826	828		|O
10	829	831		|O
and	832	835		|O
25	836	838		|O
mg	839	841		|O
kg	842	844		|O
(	844	845		|O
-	845	846		|O
1	846	847		|O
)	847	848		|O
,	848	849		|O
respectively	850	862		|O
.	862	863		|O
In	864	866		|O
addition	867	875		|O
,	875	876		|O
Cf	877	879		|O
-	879	880		|O
PLS	880	883		|O
was	884	887		|O
also	888	892		|O
able	893	897		|O
to	898	900		|O
increase	901	909		|O
the	910	913		|O
response	914	922		|O
elicited	923	931		|O
by	932	934		|O
5	935	936		|O
-	936	937		|O
fluorouracil	937	949		|O
(	950	951		|O
5	951	952		|O
-	952	953		|O
FU	953	955		|O
)	955	956		|O
from	957	961		|O
48.66	962	967		|O
to	968	970		|O
68.32%	971	977		|O
.	977	978		|O
The	979	982		|O
histopathological	983	1000		|O
analysis	1001	1009		|O
of	1010	1012		|O
liver	1013	1018		|O
and	1019	1022		|O
kidney	1023	1029		|O
showed	1030	1036		|O
that	1037	1041		|O
both	1042	1046		|O
organs	1047	1053		|O
were	1054	1058		|O
moderately	1059	1069		|O
affected	1070	1078		|O
by	1079	1081		|O
Cf	1082	1084		|O
-	1084	1085		|O
PLS	1085	1088		|O
-	1088	1089		|O
treatment	1089	1098		|O
.	1098	1099		|O
Neither	1100	1107		|O
enzymatic	1108	1117		|O
activity	1118	1126		|O
of	1127	1129		|O
alanine	1130	1137		|O
aminotransferase	1138	1154		|O
nor	1155	1158		|O
urea	1159	1163		|O
or	1164	1166		|O
creatinine	1167	1177		|O
levels	1178	1184		|O
were	1185	1189		|O
significantly	1190	1203		|O
altered	1204	1211		|O
.	1211	1212		|O
In	1213	1215		|O
hematological	1216	1229		|O
analysis	1230	1238		|O
,	1238	1239		|O
leucopeny	1240	1249	leucopeny	|B-ADVERSE
was	1250	1253		|O
observed	1254	1262		|O
after	1263	1268		|O
5	1269	1270		|O
-	1270	1271		|O
FU	1271	1273		|O
treatment	1274	1283		|O
,	1283	1284		|O
but	1285	1288		|O
this	1289	1293		|O
effect	1294	1300		|O
was	1301	1304		|O
prevented	1305	1314		|O
when	1315	1319		|O
the	1320	1323		|O
treatment	1324	1333		|O
was	1334	1337		|O
associated	1338	1348		|O
with	1349	1353		|O
the	1354	1357		|O
Cf	1358	1360		|O
-	1360	1361		|O
PLS	1361	1364		|O
.	1364	1365		|O
It	1366	1368		|O
was	1369	1372		|O
also	1373	1377		|O
demonstrated	1378	1390		|O
that	1391	1395		|O
Cf	1396	1398		|O
-	1398	1399		|O
PLS	1399	1402		|O
acts	1403	1407		|O
as	1408	1410		|O
an	1411	1413		|O
immunomodulatory	1414	1430		|O
agent	1431	1436		|O
,	1436	1437		|O
raising	1438	1445		|O
the	1446	1449		|O
production	1450	1460		|O
of	1461	1463		|O
specific	1464	1472		|O
antibodies	1473	1483		|O
,	1483	1484		|O
and	1485	1488		|O
increasing	1489	1499		|O
the	1500	1503		|O
production	1504	1514		|O
of	1515	1517		|O
OVA	1518	1521		|O
-	1521	1522		|O
specific	1522	1530		|O
antibodies	1531	1541		|O
.	1541	1542		|O
It	1543	1545		|O
also	1546	1550		|O
induced	1551	1558		|O
a	1559	1560		|O
discreet	1561	1569		|O
hyperplasia	1570	1581	hyperplasia of lymphoid folicules	|B-ADVERSE
of	1582	1584		|I-ADVERSE
lymphoid	1585	1593		|I-ADVERSE
folicules	1594	1603		|I-ADVERSE
of	1604	1606		|O
the	1607	1610		|O
white	1611	1616		|O
pulp	1617	1621		|O
in	1622	1624		|O
the	1625	1628		|O
spleen	1629	1635		|O
of	1636	1638		|O
treated	1639	1646		|O
mice	1647	1651		|O
.	1651	1652		|O
In	1653	1655		|O
conclusion	1656	1666		|O
,	1666	1667		|O
Cf	1668	1670		|O
-	1670	1671		|O
PLS	1671	1674		|O
has	1675	1678		|O
some	1679	1683		|O
interesting	1684	1695		|O
anticancer	1696	1706		|O
activity	1707	1715		|O
that	1716	1720		|O
could	1721	1726		|O
be	1727	1729		|O
associated	1730	1740		|O
with	1741	1745		|O
its	1746	1749		|O
immunostimulating	1750	1767		|O
properties	1768	1778		|O
.	1778	1779		|O

### 18804180
Particulate	0	11		|O
matter	12	18		|O
inhibits	19	27		|O
DNA	28	31		|O
repair	32	38		|O
and	39	42		|O
enhances	43	51		|O
mutagenesis	52	63		|O
.	63	64		|O
Exposure	66	74		|O
to	75	77		|O
ambient	78	85		|O
air	86	89		|O
pollution	90	99		|O
has	100	103		|O
been	104	108		|O
associated	109	119		|O
with	120	124		|O
adverse	125	132		|O
health	133	139		|O
effects	140	147		|O
including	148	157		|O
lung	158	162	lung cancer	|B-ADVERSE
cancer	163	169		|I-ADVERSE
.	169	170		|O
A	171	172		|O
recent	173	179		|O
epidemiology	180	192		|O
study	193	198		|O
has	199	202		|O
established	203	214		|O
that	215	219		|O
each	220	224		|O
10	225	227		|O
microg	228	234		|O
/	234	235		|O
m3	235	237		|O
elevation	238	247		|O
in	248	250		|O
long	251	255		|O
-	255	256		|O
term	256	260		|O
exposure	261	269		|O
to	270	272		|O
average	273	280		|O
PM2	281	284		|O
.5	284	286		|O
ambient	287	294		|O
concentration	295	308		|O
was	309	312		|O
associated	313	323		|O
with	324	328		|O
approximately	329	342		|O
8%	343	345		|O
of	346	348		|O
lung	349	353	lung cancer	|B-ADVERSE
cancer	354	360		|I-ADVERSE
mortality	361	370		|O
.	370	371		|O
The	372	375		|O
underlying	376	386		|O
mechanisms	387	397		|O
of	398	400		|O
how	401	404		|O
PM	405	407		|O
contributes	408	419		|O
to	420	422		|O
lung	423	427		|O
carcinogenesis	428	442		|O
,	442	443		|O
however	444	451		|O
,	451	452		|O
remain	453	459		|O
to	460	462		|O
be	463	465		|O
elucidated	466	476		|O
.	476	477		|O
We	478	480		|O
have	481	485		|O
recently	486	494		|O
found	495	500		|O
that	501	505		|O
transition	506	516		|O
metals	517	523		|O
such	524	528		|O
as	529	531		|O
nickel	532	538		|O
and	539	542		|O
chromium	543	551		|O
and	552	555		|O
oxidative	556	565		|O
stress	566	572		|O
induced	573	580		|O
lipid	581	586		|O
peroxidation	587	599		|O
metabolites	600	611		|O
such	612	616		|O
as	617	619		|O
aldehydes	620	629		|O
can	630	633		|O
greatly	634	641		|O
inhibit	642	649		|O
nucleotide	650	660		|O
excision	661	669		|O
repair	670	676		|O
(	677	678		|O
NER	678	681		|O
)	681	682		|O
and	683	686		|O
enhance	687	694		|O
carcinogen	695	705		|O
-	705	706		|O
induced	706	713		|O
mutations	714	723		|O
.	723	724		|O
Because	725	732		|O
PM	733	735		|O
is	736	738		|O
rich	739	743		|O
in	744	746		|O
metal	747	752		|O
and	753	756		|O
aldehyde	757	765		|O
content	766	773		|O
and	774	777		|O
can	778	781		|O
induce	782	788		|O
oxidative	789	798		|O
stress	799	805		|O
,	805	806		|O
we	807	809		|O
tested	810	816		|O
the	817	820		|O
effect	821	827		|O
of	828	830		|O
PM	831	833		|O
on	834	836		|O
DNA	837	840		|O
repair	841	847		|O
capacity	848	856		|O
in	857	859		|O
cultured	860	868		|O
human	869	874		|O
lung	875	879		|O
cells	880	885		|O
using	886	891		|O
in	892	894		|O
vitro	895	900		|O
DNA	901	904		|O
repair	905	911		|O
synthesis	912	921		|O
and	922	925		|O
host	926	930		|O
cell	931	935		|O
reactivation	936	948		|O
assays	949	955		|O
.	955	956		|O
We	957	959		|O
found	960	965		|O
that	966	970		|O
PM	971	973		|O
greatly	974	981		|O
inhibits	982	990		|O
NER	991	994		|O
for	995	998		|O
ultraviolet	999	1010		|O
(	1011	1012		|O
UV	1012	1014		|O
)	1014	1015		|O
light	1016	1021		|O
and	1022	1025		|O
benzo	1026	1031		|O
(	1031	1032		|O
a	1032	1033		|O
)	1033	1034		|O
pyrene	1034	1040		|O
diol	1041	1045		|O
epoxide	1046	1053		|O
(	1054	1055		|O
BPDE	1055	1059		|O
)	1059	1060		|O
induced	1061	1068		|O
DNA	1069	1072		|O
damage	1073	1079		|O
in	1080	1082		|O
human	1083	1088		|O
lung	1089	1093		|O
cells	1094	1099		|O
.	1099	1100		|O
We	1101	1103		|O
further	1104	1111		|O
demonstrated	1112	1124		|O
that	1125	1129		|O
PM	1130	1132		|O
exposure	1133	1141		|O
can	1142	1145		|O
significantly	1146	1159		|O
increase	1160	1168		|O
both	1169	1173		|O
spontaneous	1174	1185		|O
and	1186	1189		|O
UV	1190	1192		|O
-	1192	1193		|O
induced	1193	1200		|O
mutagenesis	1201	1212		|O
.	1212	1213		|O
These	1214	1219		|O
results	1220	1227		|O
together	1228	1236		|O
suggest	1237	1244		|O
that	1245	1249		|O
the	1250	1253		|O
carcinogenicity	1254	1269	carcinogenicity	|B-ADVERSE
of	1270	1272		|O
PM	1273	1275		|O
may	1276	1279		|O
act	1280	1283		|O
through	1284	1291		|O
its	1292	1295		|O
combined	1296	1304		|O
effect	1305	1311		|O
on	1312	1314		|O
suppression	1315	1326		|O
of	1327	1329		|O
DNA	1330	1333		|O
repair	1334	1340		|O
and	1341	1344		|O
enhancement	1345	1356		|O
of	1357	1359		|O
DNA	1360	1363		|O
replication	1364	1375		|O
errors	1376	1382		|O
.	1382	1383		|O

### 18821468
Novel	0	5		|O
therapeutic	6	17		|O
agents	18	24		|O
targeting	25	34		|O
the	35	38		|O
glucocorticoid	39	53		|O
receptor	54	62		|O
for	63	66		|O
inflammation	67	79	inflammation	|B-DISEASE
and	80	83		|O
cancer	84	90	cancer	|B-DISEASE
.	90	91		|O
Glucocorticoids	93	108		|O
,	108	109		|O
through	110	117		|O
their	118	123		|O
interaction	124	135		|O
with	136	140		|O
the	141	144		|O
ubiquitous	145	155		|O
glucocorticoid	156	170		|O
receptor	171	179		|O
(	180	181		|O
GR	181	183		|O
)	183	184		|O
,	184	185		|O
have	186	190		|O
extensive	191	200		|O
and	201	204		|O
disparate	205	214		|O
effects	215	222		|O
on	223	225		|O
different	226	235		|O
cells	236	241		|O
and	242	245		|O
tissues	246	253		|O
.	253	254		|O
They	255	259		|O
have	260	264		|O
long	265	269		|O
been	270	274		|O
used	275	279		|O
in	280	282		|O
the	283	286		|O
treatment	287	296		|O
of	297	299		|O
asthma	300	306	asthma	|B-DISEASE
,	306	307		|O
arthritis	308	317	arthritis	|B-DISEASE
and	318	321		|O
autoimmune	322	332	autoimmune diseases	|B-DISEASE
diseases	333	341		|I-DISEASE
based	342	347		|O
on	348	350		|O
their	351	356		|O
anti	357	361		|O
-	361	362		|O
inflammatory	362	374		|O
and	375	378		|O
immunosuppressive	379	396		|O
effects	397	404		|O
.	404	405		|O
For	406	409		|O
these	410	415		|O
reasons	416	423		|O
,	423	424		|O
as	425	427		|O
well	428	432		|O
as	433	435		|O
for	436	439		|O
their	440	445		|O
ability	446	453		|O
to	454	456		|O
induce	457	463		|O
massive	464	471		|O
apoptosis	472	481		|O
in	482	484		|O
hematological	485	498	hematological malignancies	|B-DISEASE
malignancies	499	511		|I-DISEASE
,	511	512		|O
they	513	517		|O
are	518	521		|O
also	522	526		|O
commonly	527	535		|O
used	536	540		|O
as	541	543		|O
cotreatment	544	555		|O
in	556	558		|O
cancers	559	566	cancers	|B-DISEASE
.	566	567		|O
Despite	568	575		|O
their	576	581		|O
wide	582	586		|O
usage	587	592		|O
,	592	593		|O
chronic	594	601		|O
glucocorticoid	602	616		|O
therapy	617	624		|O
has	625	628		|O
deleterious	629	640		|O
side	641	645		|O
effects	646	653		|O
,	653	654		|O
including	655	664		|O
weight	665	671		|O
gain	672	676		|O
,	676	677		|O
osteoporosis	678	690	osteoporosis	|B-ADVERSE
and	691	694		|O
diabetes	695	703	diabetes mellitus	|B-ADVERSE
mellitus	704	712		|I-ADVERSE
,	712	713		|O
and	714	717		|O
has	718	721		|O
been	722	726		|O
shown	727	732		|O
to	733	735		|O
diminish	736	744		|O
the	745	748		|O
tumor	749	754	tumor toxicity	|B-ADVERSE
toxicity	755	763		|I-ADVERSE
of	764	766		|O
chemotherapy	767	779		|O
,	779	780		|O
preventing	781	791		|O
the	792	795		|O
full	796	800		|O
potential	801	810		|O
of	811	813		|O
glucocorticoid	814	828		|O
treatment	829	838		|O
from	839	843		|O
being	844	849		|O
realized	850	858		|O
.	858	859		|O
Technological	860	873		|O
advances	874	882		|O
have	883	887		|O
contributed	888	899		|O
to	900	902		|O
a	903	904		|O
better	905	911		|O
understanding	912	925		|O
of	926	928		|O
the	929	932		|O
mechanism	933	942		|O
of	943	945		|O
glucocorticoid	946	960		|O
action	961	967		|O
,	967	968		|O
prompting	969	978		|O
the	979	982		|O
development	983	994		|O
of	995	997		|O
tailored	998	1006		|O
therapeutics	1007	1019		|O
targeting	1020	1029		|O
the	1030	1033		|O
desired	1034	1041		|O
outcomes	1042	1050		|O
of	1051	1053		|O
GR	1054	1056		|O
signaling	1057	1066		|O
.	1066	1067		|O
This	1068	1072		|O
review	1073	1079		|O
discusses	1080	1089		|O
recent	1090	1096		|O
advances	1097	1105		|O
in	1106	1108		|O
the	1109	1112		|O
development	1113	1124		|O
of	1125	1127		|O
novel	1128	1133		|O
therapeutic	1134	1145		|O
agents	1146	1152		|O
for	1153	1156		|O
inflammation	1157	1169	inflammation	|B-DISEASE
and	1170	1173		|O
cancer	1174	1180	cancer	|B-DISEASE
through	1181	1188		|O
targeting	1189	1198		|O
the	1199	1202		|O
GR	1203	1205		|O
.	1205	1206		|O

### 18809314
An	0	2		|O
EORTC	3	8		|O
phase	9	14		|O
I	15	16		|O
study	17	22		|O
of	23	25		|O
Bortezomib	26	36		|O
in	37	39		|O
combination	40	51		|O
with	52	56		|O
oxaliplatin	57	68		|O
,	68	69		|O
leucovorin	70	80		|O
and	81	84		|O
5	85	86		|O
-	86	87		|O
fluorouracil	87	99		|O
in	100	102		|O
patients	103	111		|O
with	112	116		|O
advanced	117	125		|O
colorectal	126	136	colorectal cancer	|B-DISEASE
cancer	137	143		|I-DISEASE
.	143	144		|O
The	146	149		|O
combination	150	161		|O
of	162	164		|O
oxaliplatin	165	176		|O
,	176	177		|O
leucovorin	178	188		|O
and	189	192		|O
5	193	194		|O
-	194	195		|O
fluorouracil	195	207		|O
(	208	209		|O
FOLFOX	209	215		|O
-	215	216		|O
4	216	217		|O
)	217	218		|O
is	219	221		|O
still	222	227		|O
a	228	229		|O
reference	230	239		|O
regimen	240	247		|O
in	248	250		|O
advanced	251	259		|O
colorectal	260	270	colorectal cancer	|B-DISEASE
cancer	271	277		|I-DISEASE
;	277	278		|O
however	279	286		|O
,	286	287		|O
the	288	291		|O
addition	292	300		|O
of	301	303		|O
new	304	307		|O
biologic	308	316		|O
compounds	317	326		|O
represents	327	337		|O
a	338	339		|O
significant	340	351		|O
way	352	355		|O
forward	356	363		|O
.	363	364		|O
Bortezomib	365	375		|O
is	376	378		|O
an	379	381		|O
inhibitor	382	391		|O
of	392	394		|O
proteasome	395	405		|O
,	405	406		|O
a	407	408		|O
multicatalytic	409	423		|O
enzyme	424	430		|O
complex	431	438		|O
that	439	443		|O
degrades	444	452		|O
several	453	460		|O
intracellular	461	474		|O
proteins	475	483		|O
.	483	484		|O
In	485	487		|O
this	488	492		|O
study	493	498		|O
,	498	499		|O
escalating	500	510		|O
doses	511	516		|O
of	517	519		|O
Bortezomib	520	530		|O
were	531	535		|O
administered	536	548		|O
along	549	554		|O
with	555	559		|O
the	560	563		|O
standard	564	572		|O
FOLFOX	573	579		|O
-	579	580		|O
4	580	581		|O
doses	582	587		|O
,	587	588		|O
in	589	591		|O
order	592	597		|O
to	598	600		|O
evaluate	601	609		|O
the	610	613		|O
dose	614	618	dose-limiting toxicity	|B-ADVERSE
-	618	619		|I-ADVERSE
limiting	619	627		|I-ADVERSE
toxicity	628	636		|I-ADVERSE
(	637	638		|O
DLT	638	641	DLT	|B-ADVERSE
)	641	642		|O
,	642	643		|O
toxicity	644	652		|O
profile	653	660		|O
and	661	664		|O
activity	665	673		|O
of	674	676		|O
the	677	680		|O
combination	681	692		|O
.	692	693		|O
Patients	694	702		|O
with	703	707		|O
advanced	708	716		|O
colorectal	717	727	colorectal cancer	|B-DISEASE
cancer	728	734		|I-DISEASE
,	734	735		|O
unpretreated	736	748		|O
for	749	752		|O
metastatic	753	763	metastatic disease	|B-DISEASE
disease	764	771		|I-DISEASE
,	771	772		|O
were	773	777		|O
enroled	778	785		|O
in	786	788		|O
the	789	792		|O
study	793	798		|O
.	798	799		|O
Bortezomib	800	810		|O
starting	811	819		|O
dose	820	824		|O
was	825	828		|O
1.3	829	832		|O
mg	832	834		|O
/	834	835		|O
m	835	836		|O
(	836	837		|O
2	837	838		|O
)	838	839		|O
,	839	840		|O
which	841	846		|O
was	847	850		|O
to	851	853		|O
be	854	856		|O
escalated	857	866		|O
in	867	869		|O
the	870	873		|O
subsequent	874	884		|O
steps	885	890		|O
according	891	900		|O
to	901	903		|O
the	904	907		|O
toxicities	908	918		|O
observed	919	927		|O
after	928	933		|O
first	934	939		|O
cycle	940	945		|O
.	945	946		|O
Exploratory	947	958		|O
pharmacogenetics	959	975		|O
research	976	984		|O
was	985	988		|O
conducted	989	998		|O
by	999	1001		|O
analysing	1002	1011		|O
the	1012	1015		|O
association	1016	1027		|O
between	1028	1035		|O
clinical	1036	1044		|O
outcomes	1045	1053		|O
and	1054	1057		|O
polymorphisms	1058	1071		|O
in	1072	1074		|O
candidate	1075	1084		|O
genes	1085	1090		|O
for	1091	1094		|O
response	1095	1103		|O
to	1104	1106		|O
each	1107	1111		|O
of	1112	1114		|O
the	1115	1118		|O
used	1119	1123		|O
drugs	1124	1129		|O
.	1129	1130		|O
Correlation	1131	1142		|O
between	1143	1150		|O
tumour	1151	1157		|O
marker	1158	1164		|O
changes	1165	1172		|O
and	1173	1176		|O
response	1177	1185		|O
was	1186	1189		|O
also	1190	1194		|O
investigated	1195	1207		|O
.	1207	1208		|O
One	1209	1212		|O
mg	1213	1215		|O
/	1215	1216		|O
m	1216	1217		|O
(	1217	1218		|O
2	1218	1219		|O
)	1219	1220		|O
(	1221	1222		|O
DL	1222	1224		|O
-	1224	1225		|O
1	1225	1226		|O
)	1226	1227		|O
was	1228	1231		|O
defined	1232	1239		|O
as	1240	1242		|O
being	1243	1248		|O
the	1249	1252		|O
maximum	1253	1260		|O
tolerated	1261	1270		|O
dose	1271	1275		|O
since	1276	1281		|O
only	1282	1286		|O
1	1287	1288		|O
DLT	1289	1292		|O
was	1293	1296		|O
observed	1297	1305		|O
in	1306	1308		|O
6	1309	1310		|O
patients	1311	1319		|O
.	1319	1320		|O
The	1321	1324		|O
main	1325	1329		|O
toxicities	1330	1340		|O
were	1341	1345		|O
haematologic	1346	1358		|O
,	1358	1359		|O
neuropathy	1360	1370	neuropathy	|B-ADVERSE
,	1370	1371		|O
diarrhoea	1372	1381	diarrhoea	|B-ADVERSE
and	1382	1385		|O
fatigue	1386	1393	fatigue	|B-ADVERSE
.	1393	1394		|O
Amongst	1395	1402		|O
13	1403	1405		|O
evaluable	1406	1415		|O
patients	1416	1424		|O
,	1424	1425		|O
five	1426	1430		|O
had	1431	1434		|O
a	1435	1436		|O
partial	1437	1444		|O
response	1445	1453		|O
,	1453	1454		|O
five	1455	1459		|O
had	1460	1463		|O
a	1464	1465		|O
stable	1466	1472		|O
disease	1473	1480		|O
and	1481	1484		|O
three	1485	1490		|O
patients	1491	1499		|O
progressed	1500	1510		|O
.	1510	1511		|O
Two	1512	1515		|O
patients	1516	1524		|O
are	1525	1528		|O
long	1529	1533		|O
-	1533	1534		|O
term	1534	1538		|O
survivors	1539	1548		|O
after	1549	1554		|O
a	1555	1556		|O
combined	1557	1565		|O
chemosurgical	1566	1579		|O
approach	1580	1588		|O
.	1588	1589		|O
Further	1590	1597		|O
trials	1598	1604		|O
of	1605	1607		|O
the	1608	1611		|O
current	1612	1619		|O
combination	1620	1631		|O
may	1632	1635		|O
be	1636	1638		|O
justified	1639	1648		|O
.	1648	1649		|O

### 18624435
Using	0	5		|O
dietary	6	13		|O
exposure	14	22		|O
and	23	26		|O
physiologically	27	42		|O
based	43	48		|O
pharmacokinetic	49	64		|O
/	64	65		|O
pharmacodynamic	65	80		|O
modeling	81	89		|O
in	90	92		|O
human	93	98		|O
risk	99	103		|O
extrapolations	104	118		|O
for	119	122		|O
acrylamide	123	133	acrylamide toxicity	|B-ADVERSE
toxicity	134	142		|I-ADVERSE
.	142	143		|O
The	145	148		|O
discovery	149	158		|O
of	159	161		|O
acrylamide	162	172		|O
(	173	174		|O
AA	174	176		|O
)	176	177		|O
in	178	180		|O
many	181	185		|O
common	186	192		|O
cooked	193	199		|O
starchy	200	207		|O
foods	208	213		|O
has	214	217		|O
presented	218	227		|O
significant	228	239		|O
challenges	240	250		|O
to	251	253		|O
toxicologists	254	267		|O
,	267	268		|O
food	269	273		|O
scientists	274	284		|O
,	284	285		|O
and	286	289		|O
national	290	298		|O
regulatory	299	309		|O
and	310	313		|O
public	314	320		|O
health	321	327		|O
organizations	328	341		|O
because	342	349		|O
of	350	352		|O
the	353	356		|O
potential	357	366		|O
for	367	370		|O
producing	371	380		|O
neurotoxicity	381	394	neurotoxicity	|B-ADVERSE
and	395	398		|O
cancer	399	405	cancer	|B-ADVERSE
.	405	406		|O
This	407	411		|O
paper	412	417		|O
reviews	418	425		|O
some	426	430		|O
of	431	433		|O
the	434	437		|O
underlying	438	448		|O
experimental	449	461		|O
bases	462	467		|O
for	468	471		|O
AA	472	474	AA toxicity	|B-ADVERSE
toxicity	475	483		|I-ADVERSE
and	484	487		|O
earlier	488	495		|O
risk	496	500		|O
assessments	501	512		|O
.	512	513		|O
Then	514	518		|O
,	518	519		|O
dietary	520	527		|O
exposure	528	536		|O
modeling	537	545		|O
is	546	548		|O
used	549	553		|O
to	554	556		|O
estimate	557	565		|O
probable	566	574		|O
AA	575	577		|O
intake	578	584		|O
in	585	587		|O
the	588	591		|O
U	592	593		|O
.	593	594		|O
S	594	595		|O
.	595	596		|O
population	597	607		|O
,	607	608		|O
and	609	612		|O
physiologically	613	628		|O
based	629	634		|O
pharmacokinetic	635	650		|O
/	650	651		|O
pharmacodynamic	651	666		|O
(	667	668		|O
PBPK	668	672		|O
/	672	673		|O
PD	673	675		|O
)	675	676		|O
modeling	677	685		|O
is	686	688		|O
used	689	693		|O
to	694	696		|O
integrate	697	706		|O
the	707	710		|O
findings	711	719		|O
of	720	722		|O
rodent	723	729		|O
neurotoxicity	730	743	neurotoxicity	|B-ADVERSE
and	744	747		|O
cancer	748	754	cancer	|B-ADVERSE
into	755	759		|O
estimates	760	769		|O
of	770	772		|O
risks	773	778		|O
from	779	783		|O
human	784	789		|O
AA	790	792		|O
exposure	793	801		|O
through	802	809		|O
the	810	813		|O
diet	814	818		|O
.	818	819		|O
The	820	823		|O
goal	824	828		|O
of	829	831		|O
these	832	837		|O
modeling	838	846		|O
techniques	847	857		|O
is	858	860		|O
to	861	863		|O
reduce	864	870		|O
the	871	874		|O
uncertainty	875	886		|O
inherent	887	895		|O
in	896	898		|O
extrapolating	899	912		|O
toxicological	913	926		|O
findings	927	935		|O
across	936	942		|O
species	943	950		|O
and	951	954		|O
dose	955	959		|O
by	960	962		|O
comparing	963	972		|O
common	973	979		|O
exposure	980	988		|O
biomarkers	989	999		|O
.	999	1000		|O
PBPK	1001	1005		|O
/	1005	1006		|O
PD	1006	1008		|O
modeling	1009	1017		|O
estimated	1018	1027		|O
population	1028	1038		|O
-	1038	1039		|O
based	1039	1044		|O
lifetime	1045	1053		|O
excess	1054	1060		|O
cancer	1061	1067	cancer	|B-ADVERSE
risks	1068	1073		|O
from	1074	1078		|O
average	1079	1086		|O
AA	1087	1089		|O
consumption	1090	1101		|O
in	1102	1104		|O
the	1105	1108		|O
diet	1109	1113		|O
in	1114	1116		|O
the	1117	1120		|O
range	1121	1126		|O
of	1127	1129		|O
1-4	1130	1133		|O
x	1134	1135		|O
10	1136	1138		|O
(	1139	1140		|O
-	1140	1141		|O
4	1141	1142		|O
)	1142	1143		|O
;	1143	1144		|O
however	1145	1152		|O
,	1152	1153		|O
modeling	1154	1162		|O
did	1163	1166		|O
not	1167	1170		|O
support	1171	1178		|O
a	1179	1180		|O
link	1181	1185		|O
between	1186	1193		|O
dietary	1194	1201		|O
AA	1202	1204		|O
exposure	1205	1213		|O
and	1214	1217		|O
human	1218	1223		|O
neurotoxicity	1224	1237	neurotoxicity	|B-ADVERSE
because	1238	1245		|O
marginal	1246	1254		|O
exposure	1255	1263		|O
ratios	1264	1270		|O
were	1271	1275		|O
50-300	1276	1282		|O
lower	1283	1288		|O
than	1289	1293		|O
in	1294	1296		|O
rodents	1297	1304		|O
.	1304	1305		|O
In	1306	1308		|O
addition	1309	1317		|O
,	1317	1318		|O
dietary	1319	1326		|O
exposure	1327	1335		|O
modeling	1336	1344		|O
suggests	1345	1353		|O
that	1354	1358		|O
because	1359	1366		|O
AA	1367	1369		|O
is	1370	1372		|O
found	1373	1378		|O
in	1379	1381		|O
so	1382	1384		|O
many	1385	1389		|O
common	1390	1396		|O
foods	1397	1402		|O
,	1402	1403		|O
even	1404	1408		|O
big	1409	1412		|O
changes	1413	1420		|O
in	1421	1423		|O
concentration	1424	1437		|O
for	1438	1441		|O
single	1442	1448		|O
foods	1449	1454		|O
or	1455	1457		|O
groups	1458	1464		|O
of	1465	1467		|O
foods	1468	1473		|O
would	1474	1479		|O
probably	1480	1488		|O
have	1489	1493		|O
a	1494	1495		|O
small	1496	1501		|O
impact	1502	1508		|O
on	1509	1511		|O
overall	1512	1519		|O
population	1520	1530		|O
-	1530	1531		|O
based	1531	1536		|O
intake	1537	1543		|O
and	1544	1547		|O
risk	1548	1552		|O
.	1552	1553		|O
These	1554	1559		|O
results	1560	1567		|O
suggest	1568	1575		|O
that	1576	1580		|O
a	1581	1582		|O
more	1583	1587		|O
holistic	1588	1596		|O
analysis	1597	1605		|O
of	1606	1608		|O
dietary	1609	1616	dietary cancer	|B-ADVERSE
cancer	1617	1623		|I-ADVERSE
risks	1624	1629		|O
may	1630	1633		|O
be	1634	1636		|O
appropriate	1637	1648		|O
,	1648	1649		|O
by	1650	1652		|O
which	1653	1658		|O
potential	1659	1668		|O
risks	1669	1674		|O
from	1675	1679		|O
AA	1680	1682		|O
should	1683	1689		|O
be	1690	1692		|O
considered	1693	1703		|O
in	1704	1706		|O
conjunction	1707	1718		|O
with	1719	1723		|O
other	1724	1729		|O
risks	1730	1735		|O
and	1736	1739		|O
benefits	1740	1748		|O
from	1749	1753		|O
foods	1754	1759		|O
.	1759	1760		|O

### 18601306
A	0	1		|O
randomized	2	12		|O
,	12	13		|O
double	14	20		|O
-	20	21		|O
blind	21	26		|O
,	26	27		|O
crossover	28	37		|O
study	38	43		|O
of	44	46		|O
once	47	51		|O
-	51	52		|O
daily	52	57		|O
dexmethylphenidate	58	76		|O
in	77	79		|O
children	80	88		|O
with	89	93		|O
attention	94	103	attention-deficit hyperactivity disorder	|B-DISEASE
-	103	104		|I-DISEASE
deficit	104	111		|I-DISEASE
hyperactivity	112	125		|I-DISEASE
disorder	126	134		|I-DISEASE
:	134	135		|O
rapid	136	141		|O
onset	142	147		|O
of	148	150		|O
effect	151	157		|O
.	157	158		|O
BACKGROUND	160	170		|O
:	170	171		|O
Long	172	176		|O
-	176	177		|O
acting	177	183		|O
methylphenidate	184	199		|O
formulations	200	212		|O
provide	213	220		|O
control	221	228		|O
of	229	231		|O
attention	232	241	attention-deficit hyperactivity disorder	|B-DISEASE
-	241	242		|I-DISEASE
deficit	242	249		|I-DISEASE
hyperactivity	250	263		|I-DISEASE
disorder	264	272		|I-DISEASE
(	273	274		|O
ADHD	274	278	ADHD	|B-DISEASE
)	278	279		|O
symptoms	280	288		|O
for	289	292		|O
up	293	295		|O
to	296	298		|O
12	299	301		|O
hours	302	307		|O
;	307	308		|O
however	309	316		|O
,	316	317		|O
not	318	321		|O
all	322	325		|O
formulations	326	338		|O
have	339	343		|O
rapid	344	349		|O
onset	350	355		|O
of	356	358		|O
therapeutic	359	370		|O
effect	371	377		|O
,	377	378		|O
which	379	384		|O
is	385	387		|O
essential	388	397		|O
for	398	401		|O
providing	402	411		|O
symptom	412	419		|O
control	420	427		|O
during	428	434		|O
morning	435	442		|O
hours	443	448		|O
.	448	449		|O
The	450	453		|O
primary	454	461		|O
objective	462	471		|O
of	472	474		|O
this	475	479		|O
randomized	480	490		|O
,	490	491		|O
double	492	498		|O
-	498	499		|O
blind	499	504		|O
,	504	505		|O
crossover	506	515		|O
study	516	521		|O
was	522	525		|O
to	526	528		|O
assess	529	535		|O
the	536	539		|O
efficacy	540	548		|O
of	549	551		|O
dexmethylphenidate	552	570		|O
extended	571	579		|O
release	580	587		|O
(	588	589		|O
ER	589	591		|O
)	591	592		|O
versus	593	599		|O
placebo	600	607		|O
by	608	610		|O
measuring	611	620		|O
the	621	624		|O
change	625	631		|O
from	632	636		|O
pre	637	640		|O
-	640	641		|O
dose	641	645		|O
to	646	648		|O
0.5	649	652		|O
hours	653	658		|O
post	659	663		|O
-	663	664		|O
dose	664	668		|O
on	669	671		|O
the	672	675		|O
Swanson	676	683		|O
,	683	684		|O
Kotkin	685	691		|O
,	691	692		|O
Agler	693	698		|O
,	698	699		|O
M	700	701		|O
-	701	702		|O
Flynn	702	707		|O
and	708	711		|O
Pelham	712	718		|O
(	719	720		|O
SKAMP	720	725		|O
)	725	726		|O
rating	727	733		|O
scale	734	739		|O
.	739	740		|O
METHODS	741	748		|O
:	748	749		|O
Eighty	750	756		|O
-	756	757		|O
six	757	760		|O
children	761	769		|O
(	770	771		|O
6-12	771	775		|O
years	776	781		|O
)	781	782		|O
with	783	787		|O
ADHD	788	792	ADHD	|B-DISEASE
diagnosed	793	802		|O
using	803	808		|O
the	809	812		|O
DSM	813	816		|O
-	816	817		|O
IV	817	819		|O
criteria	820	828		|O
were	829	833		|O
randomized	834	844		|O
to	845	847		|O
receive	848	855		|O
dexmethylphenidate	856	874		|O
ER	875	877		|O
20	878	880		|O
mg	881	883		|O
/	883	884		|O
day	884	887		|O
or	888	890		|O
placebo	891	898		|O
,	898	899		|O
sequentially	900	912		|O
,	912	913		|O
for	914	917		|O
7	918	919		|O
days	920	924		|O
,	924	925		|O
with	926	930		|O
the	931	934		|O
final	935	940		|O
dose	941	945		|O
administered	946	958		|O
in	959	961		|O
a	962	963		|O
laboratory	964	974		|O
classroom	975	984		|O
setting	985	992		|O
on	993	995		|O
day	996	999		|O
7	1000	1001		|O
of	1002	1004		|O
each	1005	1009		|O
treatment	1010	1019		|O
period	1020	1026		|O
.	1026	1027		|O
The	1028	1031		|O
primary	1032	1039		|O
efficacy	1040	1048		|O
comparison	1049	1059		|O
was	1060	1063		|O
change	1064	1070		|O
in	1071	1073		|O
the	1074	1077		|O
SKAMP	1078	1083		|O
-	1083	1084		|O
Combined	1084	1092		|O
score	1093	1098		|O
from	1099	1103		|O
pre	1104	1107		|O
-	1107	1108		|O
dose	1108	1112		|O
to	1113	1115		|O
0.5	1116	1119		|O
hours	1120	1125		|O
post	1126	1130		|O
-	1130	1131		|O
dose	1131	1135		|O
,	1135	1136		|O
with	1137	1141		|O
additional	1142	1152		|O
secondary	1153	1162		|O
assessments	1163	1174		|O
at	1175	1177		|O
1	1178	1179		|O
,	1179	1180		|O
2	1181	1182		|O
,	1182	1183		|O
4	1184	1185		|O
,	1185	1186		|O
6	1187	1188		|O
and	1189	1192		|O
8	1193	1194		|O
hours	1195	1200		|O
post	1201	1205		|O
-	1205	1206		|O
dose	1206	1210		|O
.	1210	1211		|O
Secondary	1212	1221		|O
efficacy	1222	1230		|O
measures	1231	1239		|O
included	1240	1248		|O
change	1249	1255		|O
from	1256	1260		|O
pre	1261	1264		|O
-	1264	1265		|O
dose	1265	1269		|O
at	1270	1272		|O
all	1273	1276		|O
timepoints	1277	1287		|O
in	1288	1290		|O
the	1291	1294		|O
SKAMP	1295	1300		|O
-	1300	1301		|O
Attention	1301	1310		|O
and	1311	1314		|O
SKAMP	1315	1320		|O
-	1320	1321		|O
Deportment	1321	1331		|O
,	1331	1332		|O
Math	1333	1337		|O
Test	1338	1342		|O
-	1342	1343		|O
Attempted	1343	1352		|O
and	1353	1356		|O
Math	1357	1361		|O
Test	1362	1366		|O
-	1366	1367		|O
Correct	1367	1374		|O
scores	1375	1381		|O
,	1381	1382		|O
and	1383	1386		|O
change	1387	1393		|O
from	1394	1398		|O
baseline	1399	1407		|O
on	1408	1410		|O
the	1411	1414		|O
Conners	1415	1422		|O
'	1422	1423		|O
ADHD	1424	1428	ADHD	|B-DISEASE
/	1428	1429		|O
DSM	1429	1432		|O
-	1432	1433		|O
IV	1433	1435		|O
Scale	1436	1441		|O
for	1442	1445		|O
Parents	1446	1453		|O
(	1454	1455		|O
CADS	1455	1459		|O
-	1459	1460		|O
P	1460	1461		|O
)	1461	1462		|O
.	1462	1463		|O
In	1464	1466		|O
an	1467	1469		|O
exploratory	1470	1481		|O
analysis	1482	1490		|O
,	1490	1491		|O
a	1492	1493		|O
daily	1494	1499		|O
diary	1500	1505		|O
card	1506	1510		|O
was	1511	1514		|O
completed	1515	1524		|O
by	1525	1527		|O
parents	1528	1535		|O
on	1536	1538		|O
the	1539	1542		|O
children	1543	1551		|O
's	1551	1553		|O
in	1554	1556		|O
-	1556	1557		|O
home	1557	1561		|O
behaviour	1562	1571		|O
before	1572	1578		|O
school	1579	1585		|O
.	1585	1586		|O
Safety	1587	1593		|O
was	1594	1597		|O
assessed	1598	1606		|O
by	1607	1609		|O
occurrence	1610	1620		|O
of	1621	1623		|O
adverse	1624	1631		|O
events	1632	1638		|O
,	1638	1639		|O
monitoring	1640	1650		|O
of	1651	1653		|O
vital	1654	1659		|O
signs	1660	1665		|O
and	1666	1669		|O
interpretation	1670	1684		|O
of	1685	1687		|O
ECGs	1688	1692		|O
.	1692	1693		|O
RESULTS	1694	1701		|O
:	1701	1702		|O
Significant	1703	1714		|O
improvements	1715	1727		|O
were	1728	1732		|O
noted	1733	1738		|O
at	1739	1741		|O
0.5	1742	1745		|O
hours	1746	1751		|O
and	1752	1755		|O
at	1756	1758		|O
all	1759	1762		|O
timepoints	1763	1773		|O
post	1774	1778		|O
-	1778	1779		|O
dose	1779	1783		|O
throughout	1784	1794		|O
the	1795	1798		|O
8	1799	1800		|O
-	1800	1801		|O
hour	1801	1805		|O
laboratory	1806	1816		|O
classroom	1817	1826		|O
day	1827	1830		|O
for	1831	1834		|O
dexmethylphenidate	1835	1853		|O
ER	1854	1856		|O
vs	1857	1859		|O
placebo	1860	1867		|O
in	1868	1870		|O
the	1871	1874		|O
primary	1875	1882		|O
outcome	1883	1890		|O
measure	1891	1898		|O
of	1899	1901		|O
the	1902	1905		|O
SKAMP	1906	1911		|O
-	1911	1912		|O
Combined	1912	1920		|O
scores	1921	1927		|O
(	1928	1929		|O
p	1929	1930		|O
<	1931	1932		|O
0.001	1933	1938		|O
)	1938	1939		|O
,	1939	1940		|O
as	1941	1943		|O
well	1944	1948		|O
as	1949	1951		|O
SKAMP	1952	1957		|O
-	1957	1958		|O
Attention	1958	1967		|O
,	1967	1968		|O
SKAMP	1969	1974		|O
-	1974	1975		|O
Deportment	1975	1985		|O
,	1985	1986		|O
Math	1987	1991		|O
Test	1992	1996		|O
-	1996	1997		|O
Attempted	1997	2006		|O
and	2007	2010		|O
Math	2011	2015		|O
Test	2016	2020		|O
-	2020	2021		|O
Correct	2021	2028		|O
scores	2029	2035		|O
(	2036	2037		|O
p	2037	2038		|O
<	2039	2040		|O
0.05	2041	2045		|O
)	2045	2046		|O
.	2046	2047		|O
The	2048	2051		|O
changes	2052	2059		|O
from	2060	2064		|O
baseline	2065	2073		|O
in	2074	2076		|O
CADS	2077	2081		|O
-	2081	2082		|O
P	2082	2083		|O
scores	2084	2090		|O
were	2091	2095		|O
significantly	2096	2109		|O
greater	2110	2117		|O
with	2118	2122		|O
dexmethylphenidate	2123	2141		|O
ER	2142	2144		|O
than	2145	2149		|O
placebo	2150	2157		|O
(	2158	2159		|O
-	2159	2160		|O
16.382	2160	2166		|O
vs	2167	2169		|O
-	2170	2171		|O
4.622	2171	2176		|O
;	2176	2177		|O
p	2178	2179		|O
<	2180	2181		|O
0.001	2182	2187		|O
)	2187	2188		|O
.	2188	2189		|O
Responses	2190	2199		|O
to	2200	2202		|O
all	2203	2206		|O
diary	2207	2212		|O
questions	2213	2222		|O
indicated	2223	2232		|O
significant	2233	2244		|O
improvement	2245	2256		|O
with	2257	2261		|O
dexmethylphenidate	2262	2280		|O
ER	2281	2283		|O
treatment	2284	2293		|O
versus	2294	2300		|O
placebo	2301	2308		|O
(	2309	2310		|O
all	2310	2313		|O
p	2314	2315		|O
<	2316	2317		|O
0.001	2318	2323		|O
)	2323	2324		|O
.	2324	2325		|O
The	2326	2329		|O
most	2330	2334		|O
common	2335	2341		|O
adverse	2342	2349		|O
events	2350	2356		|O
were	2357	2361		|O
abdominal	2362	2371	abdominal pain	|B-ADVERSE
pain	2372	2376		|I-ADVERSE
(	2377	2378		|O
dexmethylphenidate	2378	2396		|O
ER	2397	2399		|O
3.5%	2400	2404		|O
;	2404	2405		|O
placebo	2406	2413		|O
4.7%	2414	2418		|O
)	2418	2419		|O
,	2419	2420		|O
headache	2421	2429	headache	|B-ADVERSE
(	2430	2431		|O
dexmethylphenidate	2431	2449		|O
ER	2450	2452		|O
3.5%	2453	2457		|O
;	2457	2458		|O
placebo	2459	2466		|O
2.3%	2467	2471		|O
)	2471	2472		|O
and	2473	2476		|O
increased	2477	2486	increased appetite	|B-ADVERSE
appetite	2487	2495		|I-ADVERSE
(	2496	2497		|O
dexmethylphenidate	2497	2515		|O
ER	2516	2518		|O
0%	2519	2521		|O
;	2521	2522		|O
placebo	2523	2530		|O
3.5%	2531	2535		|O
)	2535	2536		|O
.	2536	2537		|O
CONCLUSION	2538	2548		|O
:	2548	2549		|O
Compared	2550	2558		|O
with	2559	2563		|O
placebo	2564	2571		|O
,	2571	2572		|O
once	2573	2577		|O
-	2577	2578		|O
daily	2578	2583		|O
dexmethylphenidate	2584	2602		|O
ER	2603	2605		|O
20	2606	2608		|O
mg	2609	2611		|O
provided	2612	2620		|O
rapid	2621	2626		|O
and	2627	2630		|O
significant	2631	2642		|O
improvement	2643	2654		|O
at	2655	2657		|O
0.5	2658	2661		|O
hours	2662	2667		|O
post	2668	2672		|O
-	2672	2673		|O
dose	2673	2677		|O
in	2678	2680		|O
attention	2681	2690		|O
,	2690	2691		|O
deportment	2692	2702		|O
and	2703	2706		|O
academic	2707	2715		|O
performance	2716	2727		|O
,	2727	2728		|O
which	2729	2734		|O
was	2735	2738		|O
sustained	2739	2748		|O
for	2749	2752		|O
8	2753	2754		|O
hours	2755	2760		|O
post	2761	2765		|O
-	2765	2766		|O
dose	2766	2770		|O
.	2770	2771		|O
Overall	2772	2779		|O
,	2779	2780		|O
once	2781	2785		|O
-	2785	2786		|O
daily	2786	2791		|O
dexmethylphenidate	2792	2810		|O
ER	2811	2813		|O
20	2814	2816		|O
mg	2817	2819		|O
was	2820	2823		|O
well	2824	2828		|O
tolerated	2829	2838		|O
.	2838	2839		|O
In	2840	2842		|O
an	2843	2845		|O
analysis	2846	2854		|O
of	2855	2857		|O
parental	2858	2866		|O
assessment	2867	2877		|O
of	2878	2880		|O
diary	2881	2886		|O
responses	2887	2896		|O
,	2896	2897		|O
children	2898	2906		|O
appeared	2907	2915		|O
more	2916	2920		|O
organized	2921	2930		|O
,	2930	2931		|O
and	2932	2935		|O
morning	2936	2943		|O
preparation	2944	2955		|O
for	2956	2959		|O
school	2960	2966		|O
was	2967	2970		|O
smoother	2971	2979		|O
and	2980	2983		|O
less	2984	2988		|O
frustrating	2989	3000		|O
with	3001	3005		|O
once	3006	3010		|O
-	3010	3011		|O
daily	3011	3016		|O
dexmethylphenidate	3017	3035		|O
ER	3036	3038		|O
compared	3039	3047		|O
with	3048	3052		|O
placebo	3053	3060		|O
.	3060	3061		|O

### 18827612
A	0	1		|O
phase	2	7		|O
II	8	10		|O
study	11	16		|O
of	17	19		|O
oxaliplatin	20	31		|O
,	31	32		|O
pemetrexed	33	43		|O
,	43	44		|O
and	45	48		|O
bevacizumab	49	60		|O
in	61	63		|O
previously	64	74		|O
treated	75	82		|O
advanced	83	91		|O
non	92	95	non-small cell lung cancer	|B-DISEASE
-	95	96		|I-DISEASE
small	96	101		|I-DISEASE
cell	102	106		|I-DISEASE
lung	107	111		|I-DISEASE
cancer	112	118		|I-DISEASE
.	118	119		|O
INTRODUCTION	121	133		|O
:	133	134		|O
Single	135	141		|O
agent	142	147		|O
chemotherapy	148	160		|O
is	161	163		|O
standard	164	172		|O
for	173	176		|O
second	177	183		|O
and	184	187		|O
third	188	193		|O
line	194	198		|O
treatment	199	208		|O
of	209	211		|O
non	212	215	non-small cell lung cancer	|B-DISEASE
-	215	216		|I-DISEASE
small	216	221		|I-DISEASE
cell	222	226		|I-DISEASE
lung	227	231		|I-DISEASE
cancer	232	238		|I-DISEASE
(	239	240		|O
NSCLC	240	245	NSCLC	|B-DISEASE
)	245	246		|O
.	246	247		|O
Combination	248	259		|O
therapy	260	267		|O
to	268	270		|O
date	271	275		|O
has	276	279		|O
not	280	283		|O
proven	284	290		|O
to	291	293		|O
be	294	296		|O
superior	297	305		|O
to	306	308		|O
single	309	315		|O
agents	316	322		|O
in	323	325		|O
this	326	330		|O
setting	331	338		|O
,	338	339		|O
often	340	345		|O
adding	346	352		|O
toxicity	353	361		|O
without	362	369		|O
any	370	373		|O
additional	374	384		|O
efficacy	385	393		|O
.	393	394		|O
We	395	397		|O
investigated	398	410		|O
the	411	414		|O
activity	415	423		|O
and	424	427		|O
tolerability	428	440		|O
of	441	443		|O
the	444	447		|O
combination	448	459		|O
of	460	462		|O
oxaliplatin	463	474		|O
,	474	475		|O
pemetrexed	476	486		|O
,	486	487		|O
and	488	491		|O
bevacizumab	492	503		|O
in	504	506		|O
patients	507	515		|O
with	516	520		|O
previously	521	531		|O
treated	532	539		|O
advanced	540	548		|O
NSCLC	549	554	NSCLC	|B-DISEASE
.	554	555		|O
METHODS	556	563		|O
:	563	564		|O
This	565	569		|O
multicenter	570	581		|O
phase	582	587		|O
II	588	590		|O
trial	591	596		|O
evaluated	597	606		|O
the	607	610		|O
safety	611	617		|O
and	618	621		|O
efficacy	622	630		|O
of	631	633		|O
the	634	637		|O
combination	638	649		|O
of	650	652		|O
pemetrexed	653	663		|O
(	664	665		|O
500	665	668		|O
mg	669	671		|O
/	671	672		|O
m	672	673		|O
)	673	674		|O
,	674	675		|O
oxaliplatin	676	687		|O
(	688	689		|O
120	689	692		|O
mg	693	695		|O
/	695	696		|O
m	696	697		|O
)	697	698		|O
,	698	699		|O
and	700	703		|O
bevacizumab	704	715		|O
(	716	717		|O
15	717	719		|O
mg	720	722		|O
/	722	723		|O
kg	723	725		|O
)	725	726		|O
,	726	727		|O
given	728	733		|O
every	734	739		|O
21	740	742		|O
days	743	747		|O
,	747	748		|O
in	749	751		|O
patients	752	760		|O
with	761	765		|O
previously	766	776		|O
treated	777	784		|O
advanced	785	793		|O
NSCLC	794	799	NSCLC	|B-DISEASE
.	799	800		|O
Eligibility	801	812		|O
criteria	813	821		|O
included	822	830		|O
performance	831	842		|O
status	843	849		|O
0	850	851		|O
to	852	854		|O
1	855	856		|O
,	856	857		|O
nonsquamous	858	869		|O
histology	870	879		|O
,	879	880		|O
and	881	884		|O
at	885	887		|O
least	888	893		|O
one	894	897		|O
prior	898	903		|O
chemotherapy	904	916		|O
regimen	917	924		|O
.	924	925		|O
Patients	926	934		|O
with	935	939		|O
treated	940	947		|O
brain	948	953	brain metastases	|B-DISEASE
metastases	954	964		|I-DISEASE
were	965	969		|O
allowed	970	977		|O
.	977	978		|O
The	979	982		|O
primary	983	990		|O
end	991	994		|O
point	995	1000		|O
was	1001	1004		|O
response	1005	1013		|O
rate	1014	1018		|O
,	1018	1019		|O
with	1020	1024		|O
secondary	1025	1034		|O
endpoints	1035	1044		|O
of	1045	1047		|O
progression	1048	1059		|O
-	1059	1060		|O
free	1060	1064		|O
survival	1065	1073		|O
and	1074	1077		|O
overall	1078	1085		|O
survival	1086	1094		|O
.	1094	1095		|O
RESULTS	1096	1103		|O
:	1103	1104		|O
Thirty	1105	1111		|O
-	1111	1112		|O
six	1112	1115		|O
patients	1116	1124		|O
were	1125	1129		|O
enrolled	1130	1138		|O
on	1139	1141		|O
this	1142	1146		|O
study	1147	1152		|O
.	1152	1153		|O
Treatment	1154	1163		|O
was	1164	1167		|O
well	1168	1172		|O
tolerated	1173	1182		|O
;	1182	1183		|O
the	1184	1187		|O
most	1188	1192		|O
common	1193	1199		|O
grade	1200	1205		|O
3	1206	1207		|O
toxicity	1208	1216		|O
was	1217	1220		|O
hypertension	1221	1233	hypertension	|B-ADVERSE
,	1233	1234		|O
which	1235	1240		|O
was	1241	1244		|O
easily	1245	1251		|O
managed	1252	1259		|O
with	1260	1264		|O
oral	1265	1269		|O
medications	1270	1281		|O
.	1281	1282		|O
The	1283	1286		|O
nine	1287	1291		|O
(	1292	1293		|O
25%	1293	1296		|O
)	1296	1297		|O
patients	1298	1306		|O
with	1307	1311		|O
treated	1312	1319		|O
brain	1320	1325	brain metastases	|B-DISEASE
metastases	1326	1336		|I-DISEASE
had	1337	1340		|O
no	1341	1343		|O
episodes	1344	1352		|O
of	1353	1355		|O
cerebral	1356	1364	cerebral hemorrhage	|B-DISEASE
hemorrhage	1365	1375		|I-DISEASE
.	1375	1376		|O
Of	1377	1379		|O
the	1380	1383		|O
34	1384	1386		|O
patients	1387	1395		|O
evaluable	1396	1405		|O
for	1406	1409		|O
tumor	1410	1415	tumor	|B-DISEASE
response	1416	1424		|O
,	1424	1425		|O
none	1426	1430		|O
had	1431	1434		|O
complete	1435	1443		|O
response	1444	1452		|O
,	1452	1453		|O
nine	1454	1458		|O
(	1459	1460		|O
27%	1460	1463		|O
)	1463	1464		|O
had	1465	1468		|O
partial	1469	1476		|O
response	1477	1485		|O
,	1485	1486		|O
15	1487	1489		|O
(	1490	1491		|O
44%	1491	1494		|O
)	1494	1495		|O
had	1496	1499		|O
stable	1500	1506		|O
disease	1507	1514		|O
,	1514	1515		|O
and	1516	1519		|O
10	1520	1522		|O
(	1523	1524		|O
29%	1524	1527		|O
)	1527	1528		|O
had	1529	1532		|O
progressive	1533	1544		|O
disease	1545	1552		|O
.	1552	1553		|O
Median	1554	1560		|O
progression	1561	1572		|O
-	1572	1573		|O
free	1573	1577		|O
survival	1578	1586		|O
was	1587	1590		|O
5.8	1591	1594		|O
months	1595	1601		|O
(	1602	1603		|O
95%	1603	1606		|O
confidence	1607	1617		|O
interval	1618	1626		|O
4.1-7.8	1627	1634		|O
months	1635	1641		|O
)	1641	1642		|O
and	1643	1646		|O
median	1647	1653		|O
overall	1654	1661		|O
survival	1662	1670		|O
was	1671	1674		|O
12.5	1675	1679		|O
months	1680	1686		|O
(	1687	1688		|O
95%	1688	1691		|O
confidence	1692	1702		|O
interval	1703	1711		|O
7.3-17	1712	1718		|O
months	1719	1725		|O
)	1725	1726		|O
.	1726	1727		|O
CONCLUSIONS	1728	1739		|O
:	1739	1740		|O
Treatment	1741	1750		|O
with	1751	1755		|O
oxaliplatin	1756	1767		|O
and	1768	1771		|O
pemetrexed	1772	1782		|O
in	1783	1785		|O
combination	1786	1797		|O
with	1798	1802		|O
the	1803	1806		|O
targeted	1807	1815		|O
antiangiogenic	1816	1830		|O
agent	1831	1836		|O
bevacizumab	1837	1848		|O
yielded	1849	1856		|O
promising	1857	1866		|O
efficacy	1867	1875		|O
with	1876	1880		|O
manageable	1881	1891		|O
toxicity	1892	1900		|O
in	1901	1903		|O
the	1904	1907		|O
previously	1908	1918		|O
treated	1919	1926		|O
advanced	1927	1935		|O
NSCLC	1936	1941	NSCLC	|B-DISEASE
population	1942	1952		|O
.	1952	1953		|O

### 18682687
EF24	0	4		|O
,	4	5		|O
a	6	7		|O
novel	8	13		|O
curcumin	14	22		|O
analog	23	29		|O
,	29	30		|O
disrupts	31	39		|O
the	40	43		|O
microtubule	44	55		|O
cytoskeleton	56	68		|O
and	69	72		|O
inhibits	73	81		|O
HIF	82	85		|O
-	85	86		|O
1	86	87		|O
.	87	88		|O
Curcumin	90	98		|O
,	98	99		|O
the	100	103		|O
yellow	104	110		|O
pigment	111	118		|O
of	119	121		|O
the	122	125		|O
spice	126	131		|O
turmeric	132	140		|O
,	140	141		|O
has	142	145		|O
emerged	146	153		|O
as	154	156		|O
a	157	158		|O
promising	159	168		|O
anticancer	169	179		|O
agent	180	185		|O
due	186	189		|O
to	190	192		|O
its	193	196		|O
antiproliferative	197	214		|O
and	215	218		|O
antiangiogenic	219	233		|O
properties	234	244		|O
.	244	245		|O
However	246	253		|O
,	253	254		|O
the	255	258		|O
molecular	259	268		|O
mechanism	269	278		|O
of	279	281		|O
action	282	288		|O
of	289	291		|O
this	292	296		|O
compound	297	305		|O
remains	306	313		|O
a	314	315		|O
subject	316	323		|O
of	324	326		|O
debate	327	333		|O
.	333	334		|O
In	335	337		|O
addition	338	346		|O
,	346	347		|O
curcumin	348	356		|O
's	356	358		|O
low	359	362		|O
bioavailability	363	378		|O
and	379	382		|O
efficacy	383	391		|O
profile	392	399		|O
in	400	402		|O
vivo	403	407		|O
further	408	415		|O
hinders	416	423		|O
its	424	427		|O
clinical	428	436		|O
development	437	448		|O
.	448	449		|O
This	450	454		|O
study	455	460		|O
focuses	461	468		|O
on	469	471		|O
the	472	475		|O
mechanism	476	485		|O
of	486	488		|O
action	489	495		|O
of	496	498		|O
EF24	499	503		|O
,	503	504		|O
a	505	506		|O
novel	507	512		|O
curcumin	513	521		|O
analog	522	528		|O
with	529	533		|O
greater	534	541		|O
than	542	546		|O
curcumin	547	555		|O
biological	556	566		|O
activity	567	575		|O
and	576	579		|O
bioavailability	580	595		|O
,	595	596		|O
but	597	600		|O
no	601	603		|O
increased	604	613		|O
toxicity	614	622		|O
.	622	623		|O
Treatment	624	633		|O
of	634	636		|O
MDA	637	640		|O
-	640	641		|O
MB231	641	646		|O
breast	647	653		|O
and	654	657		|O
PC3	658	661		|O
prostate	662	670	prostate cancer	|B-DISEASE
cancer	671	677		|I-DISEASE
cells	678	683		|O
with	684	688		|O
EF24	689	693		|O
or	694	696		|O
curcumin	697	705		|O
led	706	709		|O
to	710	712		|O
inhibition	713	723		|O
of	724	726		|O
HIF	727	730		|O
-	730	731		|O
1alpha	731	737		|O
protein	738	745		|O
levels	746	752		|O
and	753	756		|O
,	756	757		|O
consequently	758	770		|O
,	770	771		|O
inhibition	772	782		|O
of	783	785		|O
HIF	786	789		|O
transcriptional	790	805		|O
activity	806	814		|O
.	814	815		|O
This	816	820		|O
drug	821	825		|O
-	825	826		|O
induced	826	833		|O
HIF	834	837		|O
inhibition	838	848		|O
occurred	849	857		|O
in	858	860		|O
a	861	862		|O
VHL	863	866		|O
-	866	867		|O
dependent	867	876		|O
but	877	880		|O
proteasome	881	891		|O
-	891	892		|O
independent	892	903		|O
manner	904	910		|O
.	910	911		|O
We	912	914		|O
found	915	920		|O
that	921	925		|O
,	925	926		|O
while	927	932		|O
curcumin	933	941		|O
inhibited	942	951		|O
HIF	952	955		|O
-	955	956		|O
1alpha	956	962		|O
gene	963	967		|O
transcription	968	981		|O
,	981	982		|O
EF24	983	987		|O
exerted	988	995		|O
its	996	999		|O
activity	1000	1008		|O
by	1009	1011		|O
inhibiting	1012	1022		|O
HIF	1023	1026		|O
-	1026	1027		|O
1alpha	1027	1033		|O
posttranscriptionally	1034	1055		|O
.	1055	1056		|O
This	1057	1061		|O
result	1062	1068		|O
suggested	1069	1078		|O
that	1079	1083		|O
the	1084	1087		|O
two	1088	1091		|O
compounds	1092	1101		|O
are	1102	1105		|O
structurally	1106	1118		|O
similar	1119	1126		|O
but	1127	1130		|O
mechanistically	1131	1146		|O
distinct	1147	1155		|O
.	1155	1156		|O
Another	1157	1164		|O
cellular	1165	1173		|O
effect	1174	1180		|O
that	1181	1185		|O
further	1186	1193		|O
differentiated	1194	1208		|O
the	1209	1212		|O
two	1213	1216		|O
compounds	1217	1226		|O
was	1227	1230		|O
the	1231	1234		|O
ability	1235	1242		|O
of	1243	1245		|O
EF24	1246	1250		|O
,	1250	1251		|O
but	1252	1255		|O
not	1256	1259		|O
curcumin	1260	1268		|O
,	1268	1269		|O
to	1270	1272		|O
induce	1273	1279		|O
microtubule	1280	1291		|O
stabilization	1292	1305		|O
in	1306	1308		|O
cells	1309	1314		|O
.	1314	1315		|O
EF24	1316	1320		|O
had	1321	1324		|O
no	1325	1327		|O
stabilizing	1328	1339		|O
effect	1340	1346		|O
on	1347	1349		|O
tubulin	1350	1357		|O
polymerization	1358	1372		|O
in	1373	1375		|O
an	1376	1378		|O
in	1379	1381		|O
vitro	1382	1387		|O
assay	1388	1393		|O
using	1394	1399		|O
purified	1400	1408		|O
bovine	1409	1415		|O
brain	1416	1421		|O
tubulin	1422	1429		|O
,	1429	1430		|O
suggesting	1431	1441		|O
that	1442	1446		|O
the	1447	1450		|O
EF24	1451	1455		|O
-	1455	1456		|O
induced	1456	1463		|O
cytoskeletal	1464	1476		|O
disruption	1477	1487		|O
in	1488	1490		|O
cells	1491	1496		|O
may	1497	1500		|O
be	1501	1503		|O
the	1504	1507		|O
result	1508	1514		|O
of	1515	1517		|O
upstream	1518	1526		|O
signaling	1527	1536		|O
events	1537	1543		|O
rather	1544	1550		|O
than	1551	1555		|O
EF24	1556	1560		|O
direct	1561	1567		|O
binding	1568	1575		|O
to	1576	1578		|O
tubulin	1579	1586		|O
.	1586	1587		|O
In	1588	1590		|O
summary	1591	1598		|O
,	1598	1599		|O
our	1600	1603		|O
study	1604	1609		|O
identifies	1610	1620		|O
EF24	1621	1625		|O
as	1626	1628		|O
a	1629	1630		|O
novel	1631	1636		|O
curcumin	1637	1645		|O
-	1645	1646		|O
related	1646	1653		|O
compound	1654	1662		|O
possessing	1663	1673		|O
a	1674	1675		|O
distinct	1676	1684		|O
mechanism	1685	1694		|O
of	1695	1697		|O
action	1698	1704		|O
,	1704	1705		|O
which	1706	1711		|O
we	1712	1714		|O
believe	1715	1722		|O
contributes	1723	1734		|O
to	1735	1737		|O
the	1738	1741		|O
potent	1742	1748		|O
anticancer	1749	1759		|O
activity	1760	1768		|O
of	1769	1771		|O
this	1772	1776		|O
agent	1777	1782		|O
and	1783	1786		|O
can	1787	1790		|O
be	1791	1793		|O
further	1794	1801		|O
exploited	1802	1811		|O
to	1812	1814		|O
investigate	1815	1826		|O
the	1827	1830		|O
therapeutic	1831	1842		|O
potential	1843	1852		|O
of	1853	1855		|O
EF24	1856	1860		|O
.	1860	1861		|O

### 18715200
Reduced	0	7		|O
weight	8	14		|O
gain	15	19		|O
with	20	24		|O
insulin	25	32		|O
detemir	33	40		|O
compared	41	49		|O
to	50	52		|O
NPH	53	56		|O
insulin	57	64		|O
is	65	67		|O
not	68	71		|O
explained	72	81		|O
by	82	84		|O
a	85	86		|O
reduction	87	96		|O
in	97	99		|O
hypoglycemia	100	112	hypoglycemia	|B-DISEASE
.	112	113		|O
BACKGROUND	115	125		|O
:	125	126		|O
Weight	127	133		|O
gain	134	138		|O
often	139	144		|O
occurs	145	151		|O
when	152	156		|O
insulin	157	164		|O
therapy	165	172		|O
is	173	175		|O
initiated	176	185		|O
.	185	186		|O
The	187	190		|O
long	191	195		|O
-	195	196		|O
acting	196	202		|O
insulin	203	210		|O
analog	211	217		|O
insulin	218	225		|O
detemir	226	233		|O
has	234	237		|O
been	238	242		|O
shown	243	248		|O
to	249	251		|O
be	252	254		|O
effective	255	264		|O
and	265	268		|O
well	269	273		|O
tolerated	274	283		|O
when	284	288		|O
used	289	293		|O
in	294	296		|O
basal	297	302		|O
-	302	303		|O
bolus	303	308		|O
regimens	309	317		|O
or	318	320		|O
as	321	323		|O
an	324	326		|O
add	327	330		|O
-	330	331		|O
on	331	333		|O
to	334	336		|O
oral	337	341		|O
antidiabetic	342	354		|O
drugs	355	360		|O
(	361	362		|O
OADs	362	366		|O
)	366	367		|O
and	368	371		|O
causes	372	378		|O
less	379	383		|O
weight	384	390		|O
gain	391	395		|O
than	396	400		|O
other	401	406		|O
insulins	407	415		|O
.	415	416		|O
The	417	420		|O
aim	421	424		|O
of	425	427		|O
this	428	432		|O
exploratory	433	444		|O
analysis	445	453		|O
was	454	457		|O
to	458	460		|O
investigate	461	472		|O
any	473	476		|O
correlations	477	489		|O
between	490	497		|O
weight	498	504		|O
change	505	511		|O
and	512	515		|O
occurrence	516	526		|O
of	527	529		|O
hypoglycemia	530	542	hypoglycemia	|B-ADVERSE
with	543	547		|O
NPH	548	551		|O
insulin	552	559		|O
and	560	563		|O
insulin	564	571		|O
detemir	572	579		|O
.	579	580		|O
METHODS	581	588		|O
:	588	589		|O
The	590	593		|O
analysis	594	602		|O
was	603	606		|O
based	607	612		|O
on	613	615		|O
a	616	617		|O
26	618	620		|O
-	620	621		|O
week	621	625		|O
,	625	626		|O
randomized	627	637		|O
,	637	638		|O
multicenter	639	650		|O
,	650	651		|O
open	652	656		|O
-	656	657		|O
label	657	662		|O
,	662	663		|O
parallel	664	672		|O
-	672	673		|O
group	673	678		|O
trial	679	684		|O
in	685	687		|O
which	688	693		|O
glycemic	694	702		|O
control	703	710		|O
,	710	711		|O
hypoglycemia	712	724	hypoglycemia	|B-DISEASE
,	724	725		|O
and	726	729		|O
weight	730	736		|O
change	737	743		|O
were	744	748		|O
compared	749	757		|O
between	758	765		|O
insulin	766	773		|O
detemir	774	781		|O
and	782	785		|O
NPH	786	789		|O
insulin	790	797		|O
.	797	798		|O
A	799	800		|O
total	801	806		|O
of	807	809		|O
476	810	813		|O
insulin	814	821		|O
-	821	822		|O
naive	822	827		|O
patients	828	836		|O
with	837	841		|O
type	842	846	type 2 diabetes	|B-DISEASE
2	847	848		|I-DISEASE
diabetes	849	857		|I-DISEASE
treated	858	865		|O
with	866	870		|O
one	871	874		|O
or	875	877		|O
two	878	881		|O
OADs	882	886		|O
added	887	892		|O
insulin	893	900		|O
detemir	901	908		|O
(	909	910		|O
n	910	911		|O
=	911	912		|O
237	912	915		|O
)	915	916		|O
or	917	919		|O
NPH	920	923		|O
insulin	924	931		|O
(	932	933		|O
n	933	934		|O
=	934	935		|O
239	935	938		|O
)	938	939		|O
morning	940	947		|O
and	948	951		|O
evening	952	959		|O
to	960	962		|O
their	963	968		|O
current	969	976		|O
oral	977	981		|O
treatment	982	991		|O
.	991	992		|O
Weight	993	999		|O
gain	1000	1004		|O
data	1005	1009		|O
from	1010	1014		|O
this	1015	1019		|O
study	1020	1025		|O
were	1026	1030		|O
analyzed	1031	1039		|O
as	1040	1042		|O
a	1043	1044		|O
function	1045	1053		|O
of	1054	1056		|O
hypoglycemia	1057	1069	hypoglycemia	|B-DISEASE
frequency	1070	1079		|O
.	1079	1080		|O
RESULTS	1081	1088		|O
:	1088	1089		|O
Both	1090	1094		|O
groups	1095	1101		|O
achieved	1102	1110		|O
excellent	1111	1120		|O
glycosylated	1121	1133		|O
hemoglobin	1134	1144		|O
control	1145	1152		|O
(	1153	1154		|O
insulin	1154	1161		|O
detemir	1162	1169		|O
,	1169	1170		|O
6.6%	1171	1175		|O
;	1175	1176		|O
NPH	1177	1180		|O
insulin	1181	1188		|O
,	1188	1189		|O
6.5%	1190	1194		|O
[	1195	1196		|O
difference	1196	1206		|O
not	1207	1210		|O
significant	1211	1222		|O
]	1222	1223		|O
)	1223	1224		|O
.	1224	1225		|O
Weight	1226	1232		|O
gain	1233	1237		|O
with	1238	1242		|O
insulin	1243	1250		|O
detemir	1251	1258		|O
was	1259	1262		|O
less	1263	1267		|O
than	1268	1272		|O
half	1273	1277		|O
that	1278	1282		|O
of	1283	1285		|O
NPH	1286	1289		|O
insulin	1290	1297		|O
(	1298	1299		|O
1.2	1299	1302		|O
vs.	1303	1306		|O
2.8	1307	1310		|O
kg	1311	1313		|O
,	1313	1314		|O
respectively	1315	1327		|O
[	1328	1329		|O
P	1329	1330		|O
<	1330	1331		|O
0.001	1331	1336		|O
]	1336	1337		|O
)	1337	1338		|O
,	1338	1339		|O
and	1340	1343		|O
the	1344	1347		|O
overall	1348	1355		|O
risk	1356	1360		|O
of	1361	1363		|O
hypoglycemia	1364	1376	hypoglycemia	|B-ADVERSE
was	1377	1380		|O
47%	1381	1384		|O
lower	1385	1390		|O
with	1391	1395		|O
insulin	1396	1403		|O
detemir	1404	1411		|O
(	1412	1413		|O
P	1413	1414		|O
<	1414	1415		|O
0.001	1415	1420		|O
)	1420	1421		|O
.	1421	1422		|O
No	1423	1425		|O
significant	1426	1437		|O
relationship	1438	1450		|O
between	1451	1458		|O
hypoglycemia	1459	1471	hypoglycemia	|B-ADVERSE
and	1472	1475		|O
weight	1476	1482		|O
gain	1483	1487		|O
was	1488	1491		|O
seen	1492	1496		|O
with	1497	1501		|O
insulin	1502	1509		|O
detemir	1510	1517		|O
(	1518	1519		|O
P	1519	1520		|O
=	1520	1521		|O
0.2	1521	1524		|O
)	1524	1525		|O
,	1525	1526		|O
while	1527	1532		|O
a	1533	1534		|O
statistically	1535	1548		|O
significant	1549	1560		|O
correlation	1561	1572		|O
was	1573	1576		|O
found	1577	1582		|O
for	1583	1586		|O
NPH	1587	1590		|O
insulin	1591	1598		|O
(	1599	1600		|O
P	1600	1601		|O
=	1601	1602		|O
0.003	1602	1607		|O
)	1607	1608		|O
.	1608	1609		|O
CONCLUSIONS	1610	1621		|O
:	1621	1622		|O
Hypoglycemia	1623	1635	Hypoglycemia	|B-ADVERSE
is	1636	1638		|O
predictive	1639	1649		|O
of	1650	1652		|O
weight	1653	1659		|O
gain	1660	1664		|O
with	1665	1669		|O
NPH	1670	1673		|O
insulin	1674	1681		|O
,	1681	1682		|O
but	1683	1686		|O
the	1687	1690		|O
same	1691	1695		|O
relationship	1696	1708		|O
is	1709	1711		|O
not	1712	1715		|O
seen	1716	1720		|O
with	1721	1725		|O
insulin	1726	1733		|O
detemir	1734	1741		|O
.	1741	1742		|O
It	1743	1745		|O
is	1746	1748		|O
therefore	1749	1758		|O
likely	1759	1765		|O
that	1766	1770		|O
the	1771	1774		|O
weight	1775	1781		|O
-	1781	1782		|O
sparing	1782	1789		|O
effect	1790	1796		|O
of	1797	1799		|O
insulin	1800	1807		|O
detemir	1808	1815		|O
involves	1816	1824		|O
other	1825	1830		|O
mechanisms	1831	1841		|O
.	1841	1842		|O

### 18809451
Derivation	0	10		|O
of	11	13		|O
a	14	15		|O
chronic	16	23		|O
reference	24	33		|O
dose	34	38		|O
and	39	42		|O
reference	43	52		|O
concentration	53	66		|O
for	67	70		|O
trimethylbenzenes	71	88		|O
and	89	92		|O
C9	93	95		|O
aromatic	96	104		|O
hydrocarbon	105	116		|O
solvents	117	125		|O
.	125	126		|O
Trimethylbenzenes	128	145		|O
(	146	147		|O
TMBs	147	151		|O
)	151	152		|O
and	153	156		|O
C9	157	159		|O
aromatic	160	168		|O
hydrocarbon	169	180		|O
solvents	181	189		|O
are	190	193		|O
structurally	194	206		|O
similar	207	214		|O
and	215	218		|O
have	219	223		|O
similar	224	231		|O
toxicity	232	240		|O
.	240	241		|O
Based	242	247		|O
on	248	250		|O
a	251	252		|O
review	253	259		|O
of	260	262		|O
the	263	266		|O
entire	267	273		|O
TMB	274	277		|O
and	278	281		|O
C9	282	284		|O
aromatic	285	293		|O
hydrocarbon	294	305		|O
solvents	306	314		|O
toxicology	315	325		|O
database	326	334		|O
,	334	335		|O
oral	336	340		|O
and	341	344		|O
inhalation	345	355		|O
studies	356	363		|O
were	364	368		|O
identified	369	379		|O
to	380	382		|O
serve	383	388		|O
as	389	391		|O
the	392	395		|O
basis	396	401		|O
for	402	405		|O
a	406	407		|O
Reference	408	417		|O
dose	418	422		|O
(	423	424		|O
RfD	424	427		|O
)	427	428		|O
and	429	432		|O
Reference	433	442		|O
concentrations	443	457		|O
(	458	459		|O
RfC	459	462		|O
)	462	463		|O
.	463	464		|O
The	465	468		|O
RfD	469	472		|O
and	473	476		|O
RfC	477	480		|O
were	481	485		|O
derived	486	493		|O
using	494	499		|O
standard	500	508		|O
USEPA	509	514		|O
methods	515	522		|O
and	523	526		|O
assumptions	527	538		|O
.	538	539		|O
The	540	543		|O
RfD	544	547		|O
was	548	551		|O
calculated	552	562		|O
to	563	565		|O
be	566	568		|O
0.4	569	572		|O
mg	573	575		|O
/	575	576		|O
kg	576	578		|O
/	578	579		|O
day	579	582		|O
using	583	588		|O
a	589	590		|O
90	591	593		|O
-	593	594		|O
day	594	597		|O
oral	598	602		|O
study	603	608		|O
that	609	613		|O
resulted	614	622		|O
in	623	625		|O
a	626	627		|O
NOAEL	628	633		|O
of	634	636		|O
600	637	640		|O
mg	641	643		|O
/	643	644		|O
kg	644	646		|O
/	646	647		|O
day	647	650		|O
,	650	651		|O
based	652	657		|O
on	658	660		|O
a	661	662		|O
lack	663	667		|O
of	668	670		|O
adverse	671	678		|O
effects	679	686		|O
at	687	689		|O
the	690	693		|O
highest	694	701		|O
dose	702	706		|O
level	707	712		|O
(	713	714		|O
reversible	714	724		|O
effects	725	732		|O
such	733	737		|O
as	738	740		|O
increased	741	750		|O
serum	751	756		|O
phosphorus	757	767		|O
levels	768	774		|O
and	775	778		|O
liver	779	784		|O
and	785	788		|O
kidney	789	795		|O
weights	796	803		|O
)	803	804		|O
,	804	805		|O
along	806	811		|O
with	812	816		|O
a	817	818		|O
total	819	824		|O
uncertainty	825	836		|O
factor	837	843		|O
of	844	846		|O
1000	847	851		|O
.	851	852		|O
For	853	856		|O
the	857	860		|O
RfC	861	864		|O
,	864	865		|O
three	866	871		|O
studies	872	879		|O
were	880	884		|O
considered	885	895		|O
based	896	901		|O
on	902	904		|O
different	905	914		|O
study	915	920		|O
designs	921	928		|O
and	929	932		|O
toxicological	933	946		|O
endpoints	947	956		|O
,	956	957		|O
including	958	967		|O
neurotoxicity	968	981	neurotoxicity	|B-ADVERSE
,	981	982		|O
systemic	983	991	systemic toxicity	|B-ADVERSE
toxicity	992	1000		|I-ADVERSE
,	1000	1001		|O
and	1002	1005		|O
potential	1006	1015		|O
developmental	1016	1029		|O
and	1030	1033		|O
reproductive	1034	1046	reproductive toxicity	|B-ADVERSE
toxicity	1047	1055		|I-ADVERSE
.	1055	1056		|O
For	1057	1060		|O
all	1061	1064		|O
three	1065	1070		|O
studies	1071	1078		|O
,	1078	1079		|O
as	1080	1082		|O
the	1083	1086		|O
calculated	1087	1097		|O
RfCs	1098	1102		|O
were	1103	1107		|O
consistent	1108	1118		|O
(	1119	1120		|O
3-4	1120	1123		|O
mg	1124	1126		|O
/	1126	1127		|O
m3	1127	1129		|O
)	1129	1130		|O
,	1130	1131		|O
the	1132	1135		|O
most	1136	1140		|O
conservative	1141	1153		|O
RfC	1154	1157		|O
,	1157	1158		|O
3mg	1159	1162		|O
/	1162	1163		|O
m3	1163	1165		|O
,	1165	1166		|O
was	1167	1170		|O
selected	1171	1179		|O
.	1179	1180		|O
The	1181	1184		|O
C9	1185	1187		|O
aromatic	1188	1196		|O
hydrocarbon	1197	1208		|O
solvents	1209	1217		|O
referred	1218	1226		|O
to	1227	1229		|O
herein	1230	1236		|O
are	1237	1240		|O
based	1241	1246		|O
on	1247	1249		|O
chemistries	1250	1261		|O
assessed	1262	1270		|O
as	1271	1273		|O
part	1274	1278		|O
of	1279	1281		|O
the	1282	1285		|O
TSCA	1286	1290		|O
Section	1291	1298		|O
4	1299	1300		|O
Test	1301	1305		|O
Rule	1306	1310		|O
.	1310	1311		|O
These	1312	1317		|O
solvents	1318	1326		|O
contain	1327	1334		|O
primarily	1335	1344		|O
ethyl	1345	1350		|O
toluene	1351	1358		|O
and	1359	1362		|O
tri	1363	1366		|O
-	1366	1367		|O
methyl	1367	1373		|O
benzene	1374	1381		|O
isomers	1382	1389		|O
,	1389	1390		|O
but	1391	1394		|O
the	1395	1398		|O
specific	1399	1407		|O
compositions	1408	1420		|O
can	1421	1424		|O
vary	1425	1429		|O
based	1430	1435		|O
on	1436	1438		|O
feedstock	1439	1448		|O
and	1449	1452		|O
manufacturing	1453	1466		|O
process	1467	1474		|O
,	1474	1475		|O
thus	1476	1480		|O
,	1480	1481		|O
it	1482	1484		|O
is	1485	1487		|O
important	1488	1497		|O
to	1498	1500		|O
consider	1501	1509		|O
the	1510	1513		|O
composition	1514	1525		|O
of	1526	1528		|O
any	1529	1532		|O
specific	1533	1541		|O
solvent	1542	1549		|O
to	1550	1552		|O
assess	1553	1559		|O
similarity	1560	1570		|O
to	1571	1573		|O
that	1574	1578		|O
assessed	1579	1587		|O
in	1588	1590		|O
the	1591	1594		|O
TSCA	1595	1599		|O
Section	1600	1607		|O
4	1608	1609		|O
Test	1610	1614		|O
Rule	1615	1619		|O
program	1620	1627		|O
.	1627	1628		|O

### 18845239
NRF2	0	4		|O
as	5	7		|O
a	8	9		|O
determinant	10	21		|O
of	22	24		|O
cellular	25	33		|O
resistance	34	44		|O
in	45	47		|O
retinoic	48	56		|O
acid	57	61		|O
cytotoxicity	62	74	cytotoxicity	|B-ADVERSE
.	74	75		|O
Clinical	77	85		|O
use	86	89		|O
of	90	92		|O
retinoic	93	101		|O
acids	102	107		|O
(	108	109		|O
RA	109	111		|O
)	111	112		|O
is	113	115		|O
hindered	116	124		|O
by	125	127		|O
toxicity	128	136		|O
possibly	137	145		|O
related	146	153		|O
to	154	156		|O
oxidative	157	166		|O
stress	167	173		|O
.	173	174		|O
Recently	175	183		|O
,	183	184		|O
RA	185	187		|O
at	188	190		|O
relatively	191	201		|O
low	202	205		|O
concentrations	206	220		|O
was	221	224		|O
shown	225	230		|O
to	231	233		|O
inhibit	234	241		|O
NRF2	242	246		|O
and	247	250		|O
the	251	254		|O
expression	255	265		|O
of	266	268		|O
its	269	272		|O
target	273	279		|O
antioxidative	280	293		|O
genes	294	299		|O
.	299	300		|O
This	301	305		|O
raises	306	312		|O
the	313	316		|O
possibility	317	328		|O
that	329	333		|O
RA	334	336	RA toxicity	|B-ADVERSE
toxicity	337	345		|I-ADVERSE
may	346	349		|O
result	350	356		|O
from	357	361		|O
cellular	362	370		|O
inability	371	380		|O
to	381	383		|O
cope	384	388		|O
with	389	393		|O
resultant	394	403		|O
oxidative	404	413		|O
stress	414	420		|O
.	420	421		|O
Using	422	427		|O
in	428	430		|O
vitro	431	436		|O
cell	437	441		|O
and	442	445		|O
in	446	448		|O
vivo	449	453		|O
mouse	454	459		|O
models	460	466		|O
,	466	467		|O
we	468	470		|O
report	471	477		|O
that	478	482		|O
RA	483	485		|O
,	485	486		|O
specifically	487	499		|O
all	500	503		|O
-	503	504		|O
trans	504	509		|O
-	509	510		|O
RA	510	512		|O
(	513	514		|O
atRA	514	518		|O
)	518	519		|O
at	520	522		|O
concentrations	523	537		|O
implicated	538	548		|O
in	549	551		|O
toxicity	552	560		|O
,	560	561		|O
can	562	565		|O
activate	566	574		|O
NRF2	575	579		|O
and	580	583		|O
induce	584	590		|O
NRF2	591	595		|O
target	596	602		|O
genes	603	608		|O
,	608	609		|O
particularly	610	622		|O
the	623	626		|O
subunits	627	635		|O
of	636	638		|O
the	639	642		|O
rate	643	647		|O
-	647	648		|O
limiting	648	656		|O
enzyme	657	663		|O
of	664	666		|O
glutathione	667	678		|O
biosynthesis	679	691		|O
,	691	692		|O
glutamate	693	702		|O
cysteine	703	711		|O
ligase	712	718		|O
(	719	720		|O
GCLM	720	724		|O
/	724	725		|O
GCLC	725	729		|O
)	729	730		|O
.	730	731		|O
RNA	732	735		|O
interference	736	748		|O
-	748	749		|O
mediated	749	757		|O
silencing	758	767		|O
of	768	770		|O
NRF2	771	775		|O
,	775	776		|O
but	777	780		|O
not	781	784		|O
of	785	787		|O
retinoid	788	796		|O
X	797	798		|O
receptor	799	807		|O
-	807	808		|O
alpha	808	813		|O
and	814	817		|O
-	818	819		|O
beta	819	823		|O
,	823	824		|O
reduced	825	832		|O
basal	833	838		|O
and	839	842		|O
atRA	843	847		|O
-	847	848		|O
induced	848	855		|O
GCLM	856	860		|O
/	860	861		|O
GCLC	861	865		|O
gene	866	870		|O
expression	871	881		|O
.	881	882		|O
Moreover	883	891		|O
,	891	892		|O
RA	893	895		|O
increased	896	905		|O
nuclear	906	913		|O
accumulation	914	926		|O
of	927	929		|O
NRF2	930	934		|O
,	934	935		|O
antioxidant	936	947		|O
response	948	956		|O
element	957	964		|O
(	965	966		|O
ARE	966	969		|O
)	969	970		|O
reporter	971	979		|O
activity	980	988		|O
,	988	989		|O
and	990	993		|O
NRF2	994	998		|O
occupancy	999	1008		|O
at	1009	1011		|O
AREs	1012	1016		|O
.	1016	1017		|O
4	1018	1019		|O
-	1019	1020		|O
Hydroxynonenal	1020	1034		|O
,	1034	1035		|O
a	1036	1037		|O
lipid	1038	1043		|O
peroxidation	1044	1056		|O
product	1057	1064		|O
,	1064	1065		|O
was	1066	1069		|O
increased	1070	1079		|O
by	1080	1082		|O
RA	1083	1085		|O
.	1085	1086		|O
Inhibition	1087	1097		|O
of	1098	1100		|O
MEK1	1101	1105		|O
/	1105	1106		|O
ERK	1106	1109		|O
mitogen	1110	1117		|O
-	1117	1118		|O
activated	1118	1127		|O
protein	1128	1135		|O
kinases	1136	1143		|O
significantly	1144	1157		|O
suppressed	1158	1168		|O
atRA	1169	1173		|O
-	1173	1174		|O
induced	1174	1181		|O
NRF2	1182	1186		|O
activation	1187	1197		|O
and	1198	1201		|O
ARE	1202	1205		|O
-	1205	1206		|O
regulated	1206	1215		|O
gene	1216	1220		|O
expression	1221	1231		|O
,	1231	1232		|O
reducing	1233	1241		|O
cell	1242	1246		|O
resistance	1247	1257		|O
against	1258	1265		|O
toxic	1266	1271		|O
concentrations	1272	1286		|O
of	1287	1289		|O
RA	1290	1292		|O
.	1292	1293		|O
NRF2	1294	1298		|O
-	1298	1299		|O
silenced	1299	1307		|O
cells	1308	1313		|O
were	1314	1318		|O
vulnerable	1319	1329		|O
to	1330	1332		|O
atRA	1333	1337		|O
-	1337	1338		|O
induced	1338	1345		|O
mitochondrial	1346	1359	mitochondrial toxicity	|B-ADVERSE
toxicity	1360	1368		|I-ADVERSE
and	1369	1372		|O
apoptosis	1373	1382		|O
.	1382	1383		|O
In	1384	1386		|O
conclusion	1387	1397		|O
,	1397	1398		|O
toxic	1399	1404		|O
RA	1405	1407		|O
activates	1408	1417		|O
NRF2	1418	1422		|O
,	1422	1423		|O
thereby	1424	1431		|O
triggering	1432	1442		|O
an	1443	1445		|O
adaptive	1446	1454		|O
response	1455	1463		|O
against	1464	1471		|O
the	1472	1475		|O
resultant	1476	1485		|O
oxidative	1486	1495		|O
stress	1496	1502		|O
.	1502	1503		|O
NRF2	1504	1508		|O
enhancement	1509	1520		|O
as	1521	1523		|O
a	1524	1525		|O
therapeutic	1526	1537		|O
target	1538	1544		|O
of	1545	1547		|O
retinoid	1548	1556		|O
toxicity	1557	1565		|O
awaits	1566	1572		|O
further	1573	1580		|O
investigation	1581	1594		|O
.	1594	1595		|O

### 18569162
Amended	0	7		|O
final	8	13		|O
report	14	20		|O
of	21	23		|O
the	24	27		|O
safety	28	34		|O
assessment	35	45		|O
of	46	48		|O
cocamidopropylamine	49	68		|O
oxide	69	74		|O
.	74	75		|O
Cocamidopropylamine	77	96		|O
Oxide	97	102		|O
is	103	105		|O
a	106	107		|O
tertiary	108	116		|O
amine	117	122		|O
oxide	123	128		|O
which	129	134		|O
functions	135	144		|O
as	145	147		|O
a	148	149		|O
hair	150	154		|O
-	154	155		|O
conditioning	155	167		|O
agent	168	173		|O
and	174	177		|O
as	178	180		|O
a	181	182		|O
surfactant	183	193		|O
,	193	194		|O
currently	195	204		|O
used	205	209		|O
in	210	212		|O
60	213	215		|O
cosmetic	216	224		|O
formulations	225	237		|O
at	238	240		|O
concentrations	241	255		|O
between	256	263		|O
0.07%	264	269		|O
and	270	273		|O
4.0%	274	278		|O
.	278	279		|O
In	280	282		|O
an	283	285		|O
earlier	286	293		|O
safety	294	300		|O
assessment	301	311		|O
,	311	312		|O
the	313	316		|O
Cosmetic	317	325		|O
Ingredient	326	336		|O
Review	337	343		|O
(	344	345		|O
CIR	345	348		|O
)	348	349		|O
Expert	350	356		|O
Panel	357	362		|O
had	363	366		|O
determined	367	377		|O
that	378	382		|O
the	383	386		|O
available	387	396		|O
data	397	401		|O
were	402	406		|O
insufficient	407	419		|O
to	420	422		|O
support	423	430		|O
the	431	434		|O
safety	435	441		|O
of	442	444		|O
this	445	449		|O
ingredient	450	460		|O
in	461	463		|O
cosmetic	464	472		|O
products	473	481		|O
.	481	482		|O
Additional	483	493		|O
data	494	498		|O
have	499	503		|O
now	504	507		|O
been	508	512		|O
provided	513	521		|O
and	522	525		|O
reviewed	526	534		|O
.	534	535		|O
Cocamidopropylamine	536	555		|O
Oxide	556	561		|O
was	562	565		|O
determined	566	576		|O
to	577	579		|O
have	580	584		|O
an	585	587		|O
acute	588	593		|O
oral	594	598		|O
LD	599	601		|O
(	601	602		|O
50	602	604		|O
)	604	605		|O
between	606	613		|O
500	614	617		|O
and	618	621		|O
1000	622	626		|O
mg	627	629		|O
/	629	630		|O
kg	630	632		|O
day	633	636		|O
(	636	637		|O
-	637	638		|O
1	638	639		|O
)	639	640		|O
using	641	646		|O
rats	647	651		|O
.	651	652		|O
The	653	656		|O
acute	657	662		|O
dermal	663	669		|O
LD	670	672		|O
(	672	673		|O
50	673	675		|O
)	675	676		|O
in	677	679		|O
rats	680	684		|O
was	685	688		|O
>	689	690		|O
2174	691	695		|O
mg	696	698		|O
/	698	699		|O
kg	699	701		|O
day	702	705		|O
(	705	706		|O
-	706	707		|O
1	707	708		|O
)	708	709		|O
.	709	710		|O
A	711	712		|O
28	713	715		|O
-	715	716		|O
day	716	719		|O
repeated	720	728		|O
oral	729	733		|O
dose	734	738	dose toxicity	|B-ADVERSE
toxicity	739	747		|I-ADVERSE
study	748	753		|O
in	754	756		|O
rats	757	761		|O
found	762	767		|O
hemolytic	768	777	hemolytic anemia	|B-ADVERSE
anemia	778	784		|I-ADVERSE
at	785	787		|O
150	788	791		|O
and	792	795		|O
1000	796	800		|O
mg	801	803		|O
/	803	804		|O
kg	804	806		|O
day	807	810		|O
(	810	811		|O
-	811	812		|O
1	813	814		|O
)	814	815		|O
,	815	816		|O
with	817	821		|O
a	822	823		|O
no	824	826		|O
observed	827	835		|O
effect	836	842		|O
level	843	848		|O
(	849	850		|O
NOEL	850	854		|O
)	854	855		|O
of	856	858		|O
15	859	861		|O
mg	862	864		|O
/	864	865		|O
kg	865	867		|O
day	868	871		|O
(	871	872		|O
-	872	873		|O
1	874	875		|O
)	875	876		|O
.	876	877		|O
At	878	880		|O
5%	881	883		|O
,	883	884		|O
Cocamidopropylamine	885	904		|O
Oxide	905	910		|O
solution	911	919		|O
was	920	923		|O
not	924	927		|O
a	928	929		|O
primary	930	937		|O
dermal	938	944		|O
irritant	945	953		|O
.	953	954		|O
Application	955	966		|O
of	967	969		|O
81.5%	970	975		|O
Cocamidopropylamine	976	995		|O
Oxide	996	1001		|O
to	1002	1004		|O
rabbit	1005	1011		|O
skin	1012	1016		|O
caused	1017	1023		|O
moderate	1024	1032		|O
irritation	1033	1043	irritation	|B-ADVERSE
under	1044	1049		|O
Draize	1050	1056		|O
classification	1057	1071		|O
scale	1072	1077		|O
,	1077	1078		|O
but	1079	1082		|O
81.5%	1083	1088		|O
Cocamidopropylamine	1089	1108		|O
Oxide	1109	1114		|O
in	1115	1117		|O
rabbit	1118	1124		|O
eyes	1125	1129		|O
caused	1130	1136		|O
severe	1137	1143		|O
irritation	1144	1154	irritation	|B-ADVERSE
.	1154	1155		|O
A	1156	1157		|O
maximization	1158	1170		|O
study	1171	1176		|O
classified	1177	1187		|O
Cocamidopropylamine	1188	1207		|O
Oxide	1208	1213		|O
as	1214	1216		|O
a	1217	1218		|O
nonsensitizer	1219	1232		|O
to	1233	1235		|O
guinea	1236	1242		|O
pig	1243	1246		|O
skin	1247	1251		|O
.	1251	1252		|O
Cocamidopropylamine	1253	1272		|O
Oxide	1273	1278		|O
was	1279	1282		|O
not	1283	1286		|O
mutagenic	1287	1296		|O
in	1297	1299		|O
an	1300	1302		|O
Ames	1303	1307		|O
test	1308	1312		|O
,	1312	1313		|O
with	1314	1318		|O
and	1319	1322		|O
without	1323	1330		|O
metabolic	1331	1340		|O
activation	1341	1351		|O
.	1351	1352		|O
No	1353	1355		|O
evidence	1356	1364		|O
of	1365	1367		|O
increased	1368	1377		|O
chromosomal	1378	1389		|O
aberrations	1390	1401		|O
were	1402	1406		|O
noted	1407	1412		|O
in	1413	1415		|O
human	1416	1421		|O
lymphocytes	1422	1433		|O
treated	1434	1441		|O
with	1442	1446		|O
81.5%	1447	1452		|O
Cocamidopropylamine	1453	1472		|O
Oxide	1473	1478		|O
.	1478	1479		|O
In	1480	1482		|O
a	1483	1484		|O
clinical	1485	1493		|O
study	1494	1499		|O
,	1499	1500		|O
7.5%	1501	1505		|O
Cocamidopropylamine	1506	1525		|O
Oxide	1526	1531		|O
was	1532	1535		|O
not	1536	1539		|O
a	1540	1541		|O
sensitizer	1542	1552		|O
,	1552	1553		|O
although	1554	1562		|O
it	1563	1565		|O
did	1566	1569		|O
produce	1570	1577		|O
some	1578	1582		|O
reactions	1583	1592		|O
typical	1593	1600		|O
of	1601	1603		|O
mild	1604	1608		|O
irritation	1609	1619	irritation	|B-ADVERSE
.	1619	1620		|O
Although	1621	1629		|O
the	1630	1633		|O
impurities	1634	1644		|O
,	1644	1645		|O
amidoamine	1646	1656		|O
and	1657	1660		|O
dimethylaminopropylamine	1661	1685		|O
,	1685	1686		|O
have	1687	1691		|O
been	1692	1696		|O
implicated	1697	1707		|O
in	1708	1710		|O
contact	1711	1718	contact allergy	|B-ADVERSE
allergy	1719	1726		|I-ADVERSE
reactions	1727	1736		|O
to	1737	1739		|O
products	1740	1748		|O
containing	1749	1759		|O
cocamidopropylamine	1760	1779		|O
betaine	1780	1787		|O
,	1787	1788		|O
clinical	1789	1797		|O
testing	1798	1805		|O
of	1806	1808		|O
a	1809	1810		|O
product	1811	1818		|O
with	1819	1823		|O
cocamidopropylamine	1824	1843		|O
betaine	1844	1851		|O
containing	1852	1862		|O
these	1863	1868		|O
impurities	1869	1879		|O
,	1879	1880		|O
at	1881	1883		|O
levels	1884	1890		|O
comparable	1891	1901		|O
to	1902	1904		|O
those	1905	1910		|O
found	1911	1916		|O
in	1917	1919		|O
Cocamidopropylamine	1920	1939		|O
Oxide	1940	1945		|O
,	1945	1946		|O
failed	1947	1953		|O
to	1954	1956		|O
produce	1957	1964		|O
a	1965	1966		|O
reaction	1967	1975		|O
in	1976	1978		|O
10	1979	1981		|O
individuals	1982	1993		|O
known	1994	1999		|O
to	2000	2002		|O
be	2003	2005		|O
sensitive	2006	2015		|O
to	2016	2018		|O
cocamidopropylamine	2019	2038		|O
betaine	2039	2046		|O
.	2046	2047		|O
Two	2048	2051		|O
repeat	2052	2058		|O
-	2058	2059		|O
insult	2059	2065		|O
patch	2066	2071		|O
tests	2072	2077		|O
using	2078	2083		|O
a	2084	2085		|O
facial	2086	2092		|O
wash	2093	2097		|O
with	2098	2102		|O
1%	2103	2105		|O
raw	2106	2109		|O
material	2110	2118		|O
containing	2119	2129		|O
35%	2130	2133		|O
to	2134	2136		|O
36.5%	2137	2142		|O
Cocamidopropylamine	2143	2162		|O
Oxide	2163	2168		|O
did	2169	2172		|O
not	2173	2176		|O
find	2177	2181		|O
evidence	2182	2190		|O
of	2191	2193		|O
dermal	2194	2200	dermal sensitization	|B-ADVERSE
sensitization	2201	2214		|I-ADVERSE
.	2214	2215		|O
Tests	2216	2221		|O
for	2222	2225		|O
dermal	2226	2232	dermal phototoxicity	|B-ADVERSE
phototoxicity	2233	2246		|I-ADVERSE
and	2247	2250		|O
photoallergenicity	2251	2269	photoallergenicity	|B-ADVERSE
with	2270	2274		|O
the	2275	2278		|O
same	2279	2283		|O
facial	2284	2290		|O
wash	2291	2295		|O
product	2296	2303		|O
also	2304	2308		|O
did	2309	2312		|O
not	2313	2316		|O
produce	2317	2324		|O
evidence	2325	2333		|O
of	2334	2336		|O
effect	2337	2343		|O
.	2343	2344		|O
The	2345	2348		|O
CIR	2349	2352		|O
Expert	2353	2359		|O
Panel	2360	2365		|O
recognizes	2366	2376		|O
that	2377	2381		|O
there	2382	2387		|O
are	2388	2391		|O
data	2392	2396		|O
gaps	2397	2401		|O
regarding	2402	2411		|O
the	2412	2415		|O
use	2416	2419		|O
and	2420	2423		|O
concentration	2424	2437		|O
of	2438	2440		|O
this	2441	2445		|O
ingredient	2446	2456		|O
.	2456	2457		|O
However	2458	2465		|O
,	2465	2466		|O
the	2467	2470		|O
overall	2471	2478		|O
information	2479	2490		|O
available	2491	2500		|O
on	2501	2503		|O
types	2504	2509		|O
of	2510	2512		|O
products	2513	2521		|O
in	2522	2524		|O
which	2525	2530		|O
this	2531	2535		|O
ingredient	2536	2546		|O
is	2547	2549		|O
used	2550	2554		|O
and	2555	2558		|O
at	2559	2561		|O
what	2562	2566		|O
concentration	2567	2580		|O
indicate	2581	2589		|O
a	2590	2591		|O
pattern	2592	2599		|O
of	2600	2602		|O
use	2603	2606		|O
,	2606	2607		|O
which	2608	2613		|O
was	2614	2617		|O
considered	2618	2628		|O
by	2629	2631		|O
the	2632	2635		|O
Expert	2636	2642		|O
Panel	2643	2648		|O
in	2649	2651		|O
assessing	2652	2661		|O
safety	2662	2668		|O
.	2668	2669		|O
Overall	2670	2677		|O
,	2677	2678		|O
these	2679	2684		|O
data	2685	2689		|O
demonstrate	2690	2701		|O
that	2702	2706		|O
Cocamidopropylamine	2707	2726		|O
Oxide	2727	2732		|O
has	2733	2736		|O
low	2737	2740		|O
toxicity	2741	2749		|O
in	2750	2752		|O
animal	2753	2759		|O
and	2760	2763		|O
in	2764	2766		|O
vitro	2767	2772		|O
tests	2773	2778		|O
.	2778	2779		|O
Although	2780	2788		|O
there	2789	2794		|O
are	2795	2798		|O
no	2799	2801		|O
available	2802	2811		|O
carcinogenicity	2812	2827	carcinogenicity	|B-ADVERSE
data	2828	2832		|O
,	2832	2833		|O
the	2834	2837		|O
available	2838	2847		|O
genotoxicity	2848	2860	genotoxicity	|B-ADVERSE
data	2861	2865		|O
,	2865	2866		|O
combined	2867	2875		|O
with	2876	2880		|O
the	2881	2884		|O
absence	2885	2892		|O
of	2893	2895		|O
any	2896	2899		|O
structural	2900	2910		|O
alerts	2911	2917		|O
,	2917	2918		|O
suggest	2919	2926		|O
no	2927	2929		|O
carcinogenic	2930	2942		|O
potential	2943	2952		|O
.	2952	2953		|O
The	2954	2957		|O
Panel	2958	2963		|O
noted	2964	2969		|O
the	2970	2973		|O
absence	2974	2981		|O
of	2982	2984		|O
reproductive	2985	2997		|O
and	2998	3001		|O
developmental	3002	3015	developmental toxicity	|B-ADVERSE
toxicity	3016	3024		|I-ADVERSE
data	3025	3029		|O
.	3029	3030		|O
Because	3031	3038		|O
this	3039	3043		|O
ingredient	3044	3054		|O
has	3055	3058		|O
a	3059	3060		|O
highly	3061	3067		|O
polarized	3068	3077		|O
molecular	3078	3087		|O
structure	3088	3097		|O
,	3097	3098		|O
the	3099	3102		|O
Panel	3103	3108		|O
considered	3109	3119		|O
that	3120	3124		|O
it	3125	3127		|O
would	3128	3133		|O
be	3134	3136		|O
,	3136	3137		|O
at	3138	3140		|O
most	3141	3145		|O
,	3145	3146		|O
slowly	3147	3153		|O
absorbed	3154	3162		|O
.	3162	3163		|O
Given	3164	3169		|O
that	3170	3174		|O
most	3175	3179		|O
of	3180	3182		|O
the	3183	3186		|O
uses	3187	3191		|O
and	3192	3195		|O
the	3196	3199		|O
highest	3200	3207		|O
use	3208	3211		|O
concentration	3212	3225		|O
of	3226	3228		|O
4%	3229	3231		|O
is	3232	3234		|O
found	3235	3240		|O
in	3241	3243		|O
rinse	3244	3249		|O
-	3249	3250		|O
off	3250	3253		|O
products	3254	3262		|O
,	3262	3263		|O
the	3264	3267		|O
Panel	3268	3273		|O
determined	3274	3284		|O
that	3285	3289		|O
the	3290	3293		|O
available	3294	3303		|O
data	3304	3308		|O
suggest	3309	3316		|O
that	3317	3321		|O
Cocamidopropylamine	3322	3341		|O
Oxide	3342	3347		|O
is	3348	3350		|O
safe	3351	3355		|O
as	3356	3358		|O
used	3359	3363		|O
in	3364	3366		|O
rinse	3367	3372		|O
-	3372	3373		|O
off	3373	3376		|O
products	3377	3385		|O
.	3385	3386		|O
Although	3387	3395		|O
dermal	3396	3402		|O
penetration	3403	3414		|O
may	3415	3418		|O
be	3419	3421		|O
slow	3422	3426		|O
,	3426	3427		|O
data	3428	3432		|O
on	3433	3435		|O
the	3436	3439		|O
extent	3440	3446		|O
of	3447	3449		|O
dermal	3450	3456		|O
penetration	3457	3468		|O
of	3469	3471		|O
Cocamidopropylamine	3472	3491		|O
Oxide	3492	3497		|O
are	3498	3501		|O
needed	3502	3508		|O
to	3509	3511		|O
support	3512	3519		|O
the	3520	3523		|O
safety	3524	3530		|O
of	3531	3533		|O
leave	3534	3539		|O
-	3539	3540		|O
on	3540	3542		|O
uses	3543	3547		|O
.	3547	3548		|O
If	3549	3551		|O
there	3552	3557		|O
is	3558	3560		|O
significant	3561	3572		|O
dermal	3573	3579		|O
absorption	3580	3590		|O
,	3590	3591		|O
dermal	3592	3598		|O
reproductive	3599	3611		|O
and	3612	3615		|O
developmental	3616	3629	developmental toxicity	|B-ADVERSE
toxicity	3630	3638		|I-ADVERSE
data	3639	3643		|O
may	3644	3647		|O
be	3648	3650		|O
needed	3651	3657		|O
.	3657	3658		|O

### 18927542
Determinants	0	12		|O
of	13	15		|O
negative	16	24		|O
white	25	30		|O
-	30	31		|O
coat	31	35		|O
effect	36	42		|O
in	43	45		|O
treated	46	53		|O
hypertensive	54	66		|O
patients	67	75		|O
:	75	76		|O
the	77	80		|O
Jichi	81	86		|O
Morning	87	94		|O
Hypertension	95	107	Hypertension	|B-DISEASE
Research	108	116		|O
(	117	118		|O
J	118	119		|O
-	119	120		|O
MORE	120	124		|O
)	124	125		|O
study	126	131		|O
.	131	132		|O
BACKGROUND	134	144		|O
:	144	145		|O
The	146	149		|O
negative	150	158		|O
white	159	164		|O
-	164	165		|O
coat	165	169		|O
effect	170	176		|O
(	177	178		|O
WCE	178	181		|O
)	181	182		|O
,	182	183		|O
a	184	185		|O
phenomenon	186	196		|O
in	197	199		|O
which	200	205		|O
out	206	209		|O
-	209	210		|O
of	210	212		|O
-	212	213		|O
office	213	219		|O
blood	220	225		|O
pressure	226	234		|O
(	235	236		|O
BP	236	238		|O
)	238	239		|O
is	240	242		|O
higher	243	249		|O
than	250	254		|O
clinic	255	261		|O
BP	262	264		|O
,	264	265		|O
has	266	269		|O
not	270	273		|O
been	274	278		|O
well	279	283		|O
examined	284	292		|O
,	292	293		|O
unlike	294	300		|O
the	301	304		|O
WCE	305	308		|O
.	308	309		|O
METHODS	310	317		|O
:	317	318		|O
As	319	321		|O
part	322	326		|O
of	327	329		|O
the	330	333		|O
Jichi	334	339		|O
Morning	340	347		|O
Hypertension	348	360	Hypertension	|B-DISEASE
Research	361	369		|O
study	370	375		|O
,	375	376		|O
in	377	379		|O
which	380	385		|O
clinic	386	392		|O
and	393	396		|O
home	397	401		|O
BP	402	404		|O
were	405	409		|O
measured	410	418		|O
in	419	421		|O
969	422	425		|O
hypertensive	426	438		|O
outpatients	439	450		|O
,	450	451		|O
405	452	455		|O
patients	456	464		|O
with	465	469		|O
normal	470	476		|O
clinic	477	483		|O
BP	484	486		|O
were	487	491		|O
separately	492	502		|O
analyzed	503	511		|O
.	511	512		|O
Clinic	513	519		|O
BP	520	522		|O
was	523	526		|O
measured	527	535		|O
on	536	538		|O
two	539	542		|O
different	543	552		|O
occasions	553	562		|O
,	562	563		|O
and	564	567		|O
home	568	572		|O
BP	573	575		|O
was	576	579		|O
measured	580	588		|O
twice	589	594		|O
in	595	597		|O
the	598	601		|O
morning	602	609		|O
and	610	613		|O
twice	614	619		|O
in	620	622		|O
the	623	626		|O
evening	627	634		|O
for	635	638		|O
three	639	644		|O
consecutive	645	656		|O
days	657	661		|O
.	661	662		|O
Clinic	663	669		|O
and	670	673		|O
home	674	678		|O
BP	679	681		|O
were	682	686		|O
each	687	691		|O
averaged	692	700		|O
from	701	705		|O
all	706	709		|O
readings	710	718		|O
,	718	719		|O
and	720	723		|O
negative	724	732		|O
WCE	733	736		|O
was	737	740		|O
defined	741	748		|O
as	749	751		|O
clinic	752	758		|O
systolic	759	767		|O
BP	768	770		|O
(	771	772		|O
SBP	772	775		|O
)	775	776		|O
lower	777	782		|O
than	783	787		|O
home	788	792		|O
SBP	793	796		|O
.	796	797		|O
RESULTS	798	805		|O
:	805	806		|O
Negative	807	815		|O
WCE	816	819		|O
was	820	823		|O
observed	824	832		|O
in	833	835		|O
324	836	839		|O
(	840	841		|O
33%	841	844		|O
)	844	845		|O
of	846	848		|O
the	849	852		|O
patients	853	861		|O
overall	862	869		|O
and	870	873		|O
in	874	876		|O
173	877	880		|O
(	881	882		|O
42%	882	885		|O
)	885	886		|O
of	887	889		|O
the	890	893		|O
patients	894	902		|O
with	903	907		|O
controlled	908	918		|O
BP	919	921		|O
(	922	923		|O
clinic	923	929		|O
BP	930	932		|O
<	933	934		|O
140/90	935	941		|O
mm	942	944		|O
Hg	945	947		|O
)	947	948		|O
.	948	949		|O
In	950	952		|O
multiple	953	961		|O
logistic	962	970		|O
regression	971	981		|O
analysis	982	990		|O
adjusting	991	1000		|O
for	1001	1004		|O
covariates	1005	1015		|O
including	1016	1025		|O
home	1026	1030		|O
SBP	1031	1034		|O
and	1035	1038		|O
pulse	1039	1044		|O
rate	1045	1049		|O
,	1049	1050		|O
negative	1051	1059		|O
WCE	1060	1063		|O
was	1064	1067		|O
correlated	1068	1078		|O
with	1079	1083		|O
older	1084	1089		|O
age	1090	1093		|O
(	1094	1095		|O
odds	1095	1099		|O
ratio	1100	1105		|O
(	1106	1107		|O
OR	1107	1109		|O
)	1109	1110		|O
1.03	1111	1115		|O
,	1115	1116		|O
95%	1117	1120		|O
confidence	1121	1131		|O
interval	1132	1140		|O
(	1141	1142		|O
CI	1142	1144		|O
)	1144	1145		|O
1.01-1.06	1146	1155		|O
)	1155	1156		|O
and	1157	1160		|O
male	1161	1165		|O
gender	1166	1172		|O
(	1173	1174		|O
OR	1174	1176		|O
1.08	1177	1181		|O
,	1181	1182		|O
95%	1183	1186		|O
CI	1187	1189		|O
1.01-1.14	1190	1199		|O
)	1199	1200		|O
in	1201	1203		|O
overall	1204	1211		|O
subjects	1212	1220		|O
.	1220	1221		|O
Among	1222	1227		|O
patients	1228	1236		|O
with	1237	1241		|O
well	1242	1246		|O
-	1246	1247		|O
controlled	1247	1257		|O
clinic	1258	1264		|O
BP	1265	1267		|O
,	1267	1268		|O
negative	1269	1277		|O
WCE	1278	1281		|O
was	1282	1285		|O
significantly	1286	1299		|O
correlated	1300	1310		|O
with	1311	1315		|O
the	1316	1319		|O
presence	1320	1328		|O
of	1329	1331		|O
ischemic	1332	1340	ischemic heart disease	|B-DISEASE
heart	1341	1346		|I-DISEASE
disease	1347	1354		|I-DISEASE
(	1355	1356		|O
OR	1356	1358		|O
1.17	1359	1363		|O
,	1363	1364		|O
95%	1365	1368		|O
CI	1369	1371		|O
1.04-1.31	1372	1381		|O
)	1381	1382		|O
.	1382	1383		|O
The	1384	1387		|O
association	1388	1399		|O
of	1400	1402		|O
negative	1403	1411		|O
WCE	1412	1415		|O
with	1416	1420		|O
age	1421	1424		|O
and	1425	1428		|O
male	1429	1433		|O
gender	1434	1440		|O
remained	1441	1449		|O
significant	1450	1461		|O
under	1462	1467		|O
stringent	1468	1477		|O
criteria	1478	1486		|O
(	1487	1488		|O
negative	1488	1496		|O
WCE	1497	1500		|O
<	1501	1502		|O
-	1503	1504		|O
10.2	1504	1508		|O
mm	1509	1511		|O
Hg	1512	1514		|O
(	1515	1516		|O
the	1516	1519		|O
mean	1520	1524		|O
-	1525	1526		|O
1	1526	1527		|O
s	1528	1529		|O
.	1529	1530		|O
d	1530	1531		|O
.	1531	1532		|O
)	1532	1533		|O
)	1533	1534		|O
.	1534	1535		|O
CONCLUSIONS	1536	1547		|O
:	1547	1548		|O
Negative	1549	1557		|O
WCE	1558	1561		|O
remaining	1562	1571		|O
even	1572	1576		|O
after	1577	1582		|O
clinic	1583	1589		|O
BP	1590	1592		|O
is	1593	1595		|O
controlled	1596	1606		|O
may	1607	1610		|O
be	1611	1613		|O
related	1614	1621		|O
to	1622	1624		|O
cardiovascular	1625	1639		|O
risk	1640	1644		|O
factors	1645	1652		|O
such	1653	1657		|O
as	1658	1660		|O
older	1661	1666		|O
age	1667	1670		|O
,	1670	1671		|O
male	1672	1676		|O
gender	1677	1683		|O
,	1683	1684		|O
and	1685	1688		|O
a	1689	1690		|O
history	1691	1698		|O
of	1699	1701		|O
ischemic	1702	1710	ischemic heart disease	|B-DISEASE
heart	1711	1716		|I-DISEASE
disease	1717	1724		|I-DISEASE
.	1724	1725		|O

### 18765204
Amiodarone	0	10		|O
pulmonary	11	20	pulmonary toxicity	|B-ADVERSE
toxicity	21	29		|I-ADVERSE
after	30	35		|O
lung	36	40		|O
transplantation	41	56		|O
.	56	57		|O
Atrial	59	65	Atrial fibrillation	|B-ADVERSE
fibrillation	66	78		|I-ADVERSE
occurs	79	85		|O
frequently	86	96		|O
after	97	102		|O
lung	103	107		|O
transplantation	108	123		|O
and	124	127		|O
is	128	130		|O
commonly	131	139		|O
treated	140	147		|O
with	148	152		|O
amiodarone	153	163		|O
.	163	164		|O
Pulmonary	165	174	Pulmonary toxicity	|B-ADVERSE
toxicity	175	183		|I-ADVERSE
may	184	187		|O
result	188	194		|O
from	195	199		|O
amiodarone	200	210		|O
exposure	211	219		|O
and	220	223		|O
is	224	226		|O
characterized	227	240		|O
by	241	243		|O
non	244	247		|O
-	247	248		|O
specific	248	256		|O
respiratory	257	268		|O
manifestations	269	283		|O
.	283	284		|O
To	285	287		|O
our	288	291		|O
knowledge	292	301		|O
,	301	302		|O
there	303	308		|O
are	309	312		|O
no	313	315		|O
reports	316	323		|O
of	324	326		|O
this	327	331		|O
complication	332	344		|O
occurring	345	354		|O
after	355	360		|O
lung	361	365		|O
transplantation	366	381		|O
.	381	382		|O
We	383	385		|O
present	386	393		|O
a	394	395		|O
patient	396	403		|O
who	404	407		|O
developed	408	417		|O
radiologic	418	428		|O
evidence	429	437		|O
of	438	440		|O
amiodarone	441	451		|O
deposition	452	462		|O
in	463	465		|O
the	466	469		|O
lungs	470	475		|O
after	476	481		|O
bilateral	482	491		|O
lung	492	496		|O
transplantation	497	512		|O
.	512	513		|O

### 18941357
Predicting	0	10		|O
and	11	14		|O
preventing	15	25		|O
acute	26	31	acute kidney injury	|B-ADVERSE
kidney	32	38		|I-ADVERSE
injury	39	45		|I-ADVERSE
after	46	51		|O
cardiac	52	59		|O
surgery	60	67		|O
.	67	68		|O
PURPOSE	70	77		|O
OF	78	80		|O
REVIEW	81	87		|O
:	87	88		|O
Acute	89	94	Acute kidney injury	|B-ADVERSE
kidney	95	101		|I-ADVERSE
injury	102	108		|I-ADVERSE
(	109	110		|O
AKI	110	113	AKI	|B-ADVERSE
)	113	114		|O
after	115	120		|O
cardiac	121	128		|O
surgery	129	136		|O
is	137	139		|O
associated	140	150		|O
with	151	155		|O
significant	156	167		|O
morbidity	168	177		|O
and	178	181		|O
mortality	182	191		|O
.	191	192		|O
Despite	193	200		|O
the	201	204		|O
proliferation	205	218		|O
of	219	221		|O
predictive	222	232		|O
clinical	233	241		|O
scoring	242	249		|O
models	250	256		|O
of	257	259		|O
renal	260	265		|O
risk	266	270		|O
after	271	276		|O
cardiac	277	284		|O
surgery	285	292		|O
,	292	293		|O
limitations	294	305		|O
in	306	308		|O
preventing	309	319		|O
AKI	320	323		|O
through	324	331		|O
the	332	335		|O
use	336	339		|O
of	340	342		|O
pharmacological	343	358		|O
agents	359	365		|O
remain	366	372		|O
.	372	373		|O
Here	374	378		|O
we	379	381		|O
review	382	388		|O
the	389	392		|O
evolution	393	402		|O
of	403	405		|O
predictive	406	416		|O
models	417	423		|O
of	424	426		|O
renal	427	432		|O
risk	433	437		|O
after	438	443		|O
cardiac	444	451		|O
surgery	452	459		|O
,	459	460		|O
and	461	464		|O
highlight	465	474		|O
the	475	478		|O
important	479	488		|O
gains	489	494		|O
made	495	499		|O
in	500	502		|O
preventing	503	513		|O
its	514	517		|O
occurrence	518	528		|O
.	528	529		|O
RECENT	530	536		|O
FINDINGS	537	545		|O
:	545	546		|O
Simple	547	553		|O
risk	554	558		|O
indices	559	566		|O
predicting	567	577		|O
AKI	578	581		|O
after	582	587		|O
cardiac	588	595		|O
surgery	596	603		|O
have	604	608		|O
been	609	613		|O
developed	614	623		|O
and	624	627		|O
can	628	631		|O
now	632	635		|O
be	636	638		|O
readily	639	646		|O
applied	647	654		|O
clinically	655	665		|O
.	665	666		|O
However	667	674		|O
,	674	675		|O
studies	676	683		|O
focusing	684	692		|O
on	693	695		|O
preventing	696	706		|O
AKI	707	710		|O
after	711	716		|O
surgery	717	724		|O
have	725	729		|O
yet	730	733		|O
to	734	736		|O
demonstrate	737	748		|O
any	749	752		|O
consistent	753	763		|O
renoprotective	764	778		|O
effect	779	785		|O
.	785	786		|O
SUMMARY	787	794		|O
:	794	795		|O
Clinical	796	804		|O
scoring	805	812		|O
systems	813	820		|O
predicting	821	831		|O
AKI	832	835		|O
risk	836	840		|O
after	841	846		|O
cardiac	847	854		|O
surgery	855	862		|O
are	863	866		|O
available	867	876		|O
and	877	880		|O
should	881	887		|O
be	888	890		|O
employed	891	899		|O
in	900	902		|O
the	903	906		|O
preoperative	907	919		|O
assessment	920	930		|O
.	930	931		|O
Elucidation	932	943		|O
of	944	946		|O
beneficial	947	957		|O
preventive	958	968		|O
strategies	969	979		|O
of	980	982		|O
AKI	983	986		|O
after	987	992		|O
cardiac	993	1000		|O
surgery	1001	1008		|O
requires	1009	1017		|O
ongoing	1018	1025		|O
research	1026	1034		|O
.	1034	1035		|O

### 18627362
Review	0	6		|O
article	7	14		|O
:	14	15		|O
new	16	19		|O
drug	20	24		|O
formulations	25	37		|O
,	37	38		|O
chemical	39	47		|O
entities	48	56		|O
and	57	60		|O
therapeutic	61	72		|O
approaches	73	83		|O
for	84	87		|O
the	88	91		|O
management	92	102		|O
of	103	105		|O
ulcerative	106	116	ulcerative colitis	|B-DISEASE
colitis	117	124		|I-DISEASE
.	124	125		|O
BACKGROUND	127	137		|O
:	137	138		|O
Treatment	139	148		|O
options	149	156		|O
for	157	160		|O
ulcerative	161	171	ulcerative colitis	|B-DISEASE
colitis	172	179		|I-DISEASE
(	180	181		|O
UC	181	183	UC	|B-DISEASE
)	183	184		|O
are	185	188		|O
expanding	189	198		|O
with	199	203		|O
the	204	207		|O
development	208	219		|O
of	220	222		|O
novel	223	228		|O
drug	229	233		|O
formulations	234	246		|O
and	247	250		|O
dosing	251	257		|O
regimens	258	266		|O
and	267	270		|O
new	271	274		|O
chemical	275	283		|O
entities	284	292		|O
.	292	293		|O
Although	294	302		|O
the	303	306		|O
goals	307	312		|O
of	313	315		|O
medical	316	323		|O
therapy	324	331		|O
for	332	335		|O
UC	336	338	UC	|B-DISEASE
remain	339	345		|O
unchanged	346	355		|O
,	355	356		|O
that	357	361		|O
is	362	364		|O
to	365	367		|O
induce	368	374		|O
and	375	378		|O
to	379	381		|O
maintain	382	390		|O
remission	391	400		|O
,	400	401		|O
focus	402	407		|O
has	408	411		|O
also	412	416		|O
centred	417	424		|O
on	425	427		|O
improving	428	437		|O
patient	438	445		|O
compliance	446	456		|O
,	456	457		|O
modifying	458	467		|O
the	468	471		|O
natural	472	479		|O
course	480	486		|O
of	487	489		|O
disease	490	497		|O
and	498	501		|O
healing	502	509		|O
the	510	513		|O
mucosa	514	520		|O
.	520	521		|O
AIM	522	525		|O
:	525	526		|O
To	527	529		|O
examine	530	537		|O
novel	538	543		|O
formulations	544	556		|O
,	556	557		|O
new	558	561		|O
chemical	562	570		|O
entities	571	579		|O
and	580	583		|O
novel	584	589		|O
therapeutic	590	601		|O
approaches	602	612		|O
to	613	615		|O
the	616	619		|O
management	620	630		|O
of	631	633		|O
UC	634	636	UC	|B-DISEASE
.	636	637		|O
METHODS	638	645		|O
:	645	646		|O
Searches	647	655		|O
for	656	659		|O
all	660	663		|O
studies	664	671		|O
related	672	679		|O
to	680	682		|O
UC	683	685	UC	|B-DISEASE
treatment	686	695		|O
in	696	698		|O
Medline	699	706		|O
and	707	710		|O
abstracts	711	720		|O
from	721	725		|O
major	726	731		|O
national	732	740		|O
and	741	744		|O
international	745	758		|O
meetings	759	767		|O
published	768	777		|O
in	778	780		|O
the	781	784		|O
last	785	789		|O
10	790	792		|O
years	793	798		|O
.	798	799		|O
RESULTS	800	807		|O
:	807	808		|O
5	809	810		|O
-	810	811		|O
Aminosalicylic	811	825		|O
acids	826	831		|O
(	832	833		|O
5	833	834		|O
-	834	835		|O
ASA	835	838		|O
)	838	839		|O
remain	840	846		|O
the	847	850		|O
standard	851	859		|O
first	860	865		|O
-	865	866		|O
line	866	870		|O
treatment	871	880		|O
for	881	884		|O
patients	885	893		|O
with	894	898		|O
mild	899	903		|O
to	904	906		|O
moderately	907	917		|O
active	918	924		|O
UC	925	927	UC	|B-DISEASE
.	927	928		|O
New	929	932		|O
formulations	933	945		|O
with	946	950		|O
altered	951	958		|O
delivery	959	967		|O
,	967	968		|O
and	969	972		|O
new	973	976		|O
dosing	977	983		|O
regimens	984	992		|O
have	993	997		|O
demonstrated	998	1010		|O
possible	1011	1019		|O
improvements	1020	1032		|O
in	1033	1035		|O
efficacy	1036	1044		|O
compared	1045	1053		|O
with	1054	1058		|O
historically	1059	1071		|O
available	1072	1081		|O
preparations	1082	1094		|O
and	1095	1098		|O
dosing	1099	1105		|O
patterns	1106	1114		|O
.	1114	1115		|O
Once	1116	1120		|O
-	1120	1121		|O
daily	1121	1126		|O
dosing	1127	1133		|O
,	1133	1134		|O
micropellet	1135	1146		|O
formulations	1147	1159		|O
,	1159	1160		|O
and	1160	1163		|O
high	1164	1168		|O
-	1168	1169		|O
dose	1169	1173		|O
tablets	1174	1181		|O
offer	1182	1187		|O
enhanced	1188	1196		|O
efficacy	1197	1205		|O
and	1206	1209		|O
improved	1210	1218		|O
compliance	1219	1229		|O
.	1229	1230		|O
5	1231	1232		|O
-	1232	1233		|O
ASA	1233	1236		|O
is	1237	1239		|O
now	1240	1243		|O
recognized	1244	1254		|O
as	1255	1257		|O
a	1258	1259		|O
ligand	1260	1266		|O
for	1267	1270		|O
peroxisome	1271	1281		|O
proliferator	1282	1294		|O
activated	1295	1304		|O
receptor	1305	1313		|O
-	1313	1314		|O
gamma	1314	1319		|O
(	1320	1321		|O
PPAR	1321	1325		|O
-	1325	1326		|O
gamma	1326	1331		|O
)	1331	1332		|O
and	1333	1336		|O
it	1337	1339		|O
has	1340	1343		|O
a	1344	1345		|O
role	1346	1350		|O
as	1351	1353		|O
a	1354	1355		|O
chemo	1356	1361		|O
-	1361	1362		|O
preventive	1362	1372		|O
agent	1373	1378		|O
in	1379	1381		|O
long	1382	1386		|O
-	1386	1387		|O
standing	1387	1395		|O
UC	1396	1398	UC	|B-DISEASE
.	1398	1399		|O
New	1400	1403		|O
colonic	1404	1411		|O
release	1412	1419		|O
corticosteroid	1420	1434		|O
formulations	1435	1447		|O
help	1448	1452		|O
to	1453	1455		|O
limit	1456	1461		|O
systemic	1462	1470	systemic toxicity	|B-ADVERSE
toxicity	1471	1479		|I-ADVERSE
;	1479	1480		|O
turmeric	1481	1489		|O
,	1489	1490		|O
tacrolimus	1491	1501		|O
and	1502	1505		|O
infliximab	1506	1516		|O
have	1517	1521		|O
shown	1522	1527		|O
promising	1528	1537		|O
results	1538	1545		|O
.	1545	1546		|O
New	1547	1550		|O
anti	1551	1555		|O
-	1555	1556		|O
inflammatory	1556	1568		|O
targeted	1569	1577		|O
therapies	1578	1587		|O
include	1588	1595		|O
an	1596	1598		|O
anti	1599	1603		|O
-	1603	1604		|O
CD3	1604	1607		|O
antibody	1608	1616		|O
,	1616	1617		|O
selective	1618	1627		|O
integrin	1628	1636		|O
blockers	1637	1645		|O
,	1645	1646		|O
anti	1647	1651		|O
-	1651	1652		|O
IL	1652	1654		|O
-	1654	1655		|O
2	1655	1656		|O
antibody	1657	1665		|O
and	1666	1669		|O
PPAR	1670	1674		|O
-	1674	1675		|O
gamma	1675	1680		|O
agonists	1681	1689		|O
.	1689	1690		|O
CONCLUSION	1691	1701		|O
:	1701	1702		|O
The	1703	1706		|O
evolution	1707	1716		|O
of	1717	1719		|O
novel	1720	1725		|O
oral	1726	1730		|O
5	1731	1732		|O
-	1732	1733		|O
ASA	1733	1736		|O
formulations	1737	1749		|O
and	1750	1753		|O
dosage	1754	1760		|O
regimens	1761	1769		|O
,	1769	1770		|O
and	1770	1773		|O
recent	1774	1780		|O
development	1781	1792		|O
of	1793	1795		|O
new	1796	1799		|O
molecules	1800	1809		|O
have	1810	1814		|O
expanded	1815	1823		|O
the	1824	1827		|O
therapeutic	1828	1839		|O
armamentarium	1840	1853		|O
of	1854	1856		|O
UC	1857	1859	UC	|B-DISEASE
.	1859	1860		|O

### 18818699
The	0	3		|O
addition	4	12		|O
of	13	15		|O
rituximab	16	25		|O
to	26	28		|O
front	29	34		|O
-	34	35		|O
line	35	39		|O
therapy	40	47		|O
with	48	52		|O
CHOP	53	57		|O
(	58	59		|O
R	59	60		|O
-	60	61		|O
CHOP	61	65		|O
)	65	66		|O
results	67	74		|O
in	75	77		|O
a	78	79		|O
higher	80	86		|O
response	87	95		|O
rate	96	100		|O
and	101	104		|O
longer	105	111		|O
time	112	116		|O
to	117	119		|O
treatment	120	129		|O
failure	130	137		|O
in	138	140		|O
patients	141	149		|O
with	150	154		|O
lymphoplasmacytic	155	172	lymphoplasmacytic lymphoma	|B-DISEASE
lymphoma	173	181		|I-DISEASE
:	181	182		|O
results	183	190		|O
of	191	193		|O
a	194	195		|O
randomized	196	206		|O
trial	207	212		|O
of	213	215		|O
the	216	219		|O
German	220	226		|O
Low	227	230		|O
-	230	231		|O
Grade	231	236		|O
Lymphoma	237	245	Lymphoma	|B-DISEASE
Study	246	251		|O
Group	252	257		|O
(	258	259		|O
GLSG	259	263		|O
)	263	264		|O
.	264	265		|O
Lymphoplasmacytic	267	284	Lymphoplasmacytic lymphoma	|B-DISEASE
lymphoma	285	293		|I-DISEASE
(	294	295		|O
LPL	295	298	LPL	|B-DISEASE
)	298	299		|O
is	300	302		|O
an	303	305		|O
indolent	306	314		|O
lymphoma	315	323	lymphoma	|B-DISEASE
with	324	328		|O
moderate	329	337		|O
sensitivity	338	349		|O
to	350	352		|O
conventional	353	365		|O
chemotherapy	366	378		|O
.	378	379		|O
This	380	384		|O
study	385	390		|O
investigated	391	403		|O
whether	404	411		|O
the	412	415		|O
addition	416	424		|O
of	425	427		|O
rituximab	428	437		|O
to	438	440		|O
standard	441	449		|O
chemotherapy	450	462		|O
improves	463	471		|O
treatment	472	481		|O
outcome	482	489		|O
in	490	492		|O
LPL	493	496	LPL	|B-DISEASE
and	497	500		|O
the	501	504		|O
subgroup	505	513		|O
of	514	516		|O
LPL	517	520	LPL	|B-DISEASE
patients	521	529		|O
fulfilling	530	540		|O
the	541	544		|O
criteria	545	553		|O
of	554	556		|O
Waldenstroem	557	569	Waldenstroem's macroglobulinemia	|B-DISEASE
's	569	571		|I-DISEASE
macroglobulinemia	572	589		|I-DISEASE
(	590	591		|O
WM	591	593	WM	|B-DISEASE
)	593	594		|O
.	594	595		|O
A	596	597		|O
total	598	603		|O
of	604	606		|O
69	607	609		|O
patients	610	618		|O
with	619	623		|O
previously	624	634		|O
untreated	635	644		|O
LPL	645	648	LPL	|B-DISEASE
were	649	653		|O
enrolled	654	662		|O
into	663	667		|O
the	668	671		|O
trial	672	677		|O
;	677	678		|O
64	679	681		|O
patients	682	690		|O
were	691	695		|O
evaluable	696	705		|O
for	706	709		|O
treatment	710	719		|O
outcome	720	727		|O
.	727	728		|O
In	729	731		|O
all	732	735		|O
,	735	736		|O
48	737	739		|O
of	740	742		|O
the	743	746		|O
64	747	749		|O
LPL	750	753	LPL	|B-DISEASE
patients	754	762		|O
fulfilled	763	772		|O
the	773	776		|O
criteria	777	785		|O
of	786	788		|O
WM	789	791		|O
.	791	792		|O
Patients	793	801		|O
were	802	806		|O
randomly	807	815		|O
assigned	816	824		|O
to	825	827		|O
R	828	829		|O
-	829	830		|O
CHOP	830	834		|O
(	835	836		|O
rituximab	836	845		|O
,	845	846		|O
cyclophosphamide	847	863		|O
,	863	864		|O
doxorubicin	865	876		|O
,	876	877		|O
vincristine	878	889		|O
and	890	893		|O
prednisone	894	904		|O
,	904	905		|O
n	906	907		|O
=	907	908		|O
34	908	910		|O
)	910	911		|O
or	912	914		|O
CHOP	915	919		|O
(	920	921		|O
n	921	922		|O
=	922	923		|O
30	923	925		|O
)	925	926		|O
.	926	927		|O
R	928	929		|O
-	929	930		|O
CHOP	930	934		|O
resulted	935	943		|O
in	944	946		|O
significantly	947	960		|O
higher	961	967		|O
overall	968	975		|O
response	976	984		|O
(	985	986		|O
OR	986	988		|O
)	988	989		|O
rate	990	994		|O
(	995	996		|O
94	996	998		|O
vs	999	1001		|O
67%	1002	1005		|O
,	1005	1006		|O
P	1007	1008		|O
=	1008	1009		|O
0.0085	1009	1015		|O
)	1015	1016		|O
in	1017	1019		|O
the	1020	1023		|O
LPL	1024	1027	LPL	|B-DISEASE
patients	1028	1036		|O
and	1037	1040		|O
in	1041	1043		|O
the	1044	1047		|O
WM	1048	1050	WM	|B-DISEASE
subgroup	1051	1059		|O
(	1060	1061		|O
91	1061	1063		|O
vs	1064	1066		|O
60%	1067	1070		|O
,	1070	1071		|O
P	1072	1073		|O
=	1073	1074		|O
0.0188	1074	1080		|O
)	1080	1081		|O
.	1081	1082		|O
With	1083	1087		|O
a	1088	1089		|O
median	1090	1096		|O
observation	1097	1108		|O
time	1109	1113		|O
of	1114	1116		|O
42	1117	1119		|O
months	1120	1126		|O
,	1126	1127		|O
R	1128	1129		|O
-	1129	1130		|O
CHOP	1130	1134		|O
induced	1135	1142		|O
a	1143	1144		|O
significantly	1145	1158		|O
longer	1159	1165		|O
time	1166	1170		|O
to	1171	1173		|O
treatment	1174	1183		|O
failure	1184	1191		|O
(	1192	1193		|O
TTF	1193	1196		|O
)	1196	1197		|O
with	1198	1202		|O
a	1203	1204		|O
median	1205	1211		|O
of	1212	1214		|O
63	1215	1217		|O
months	1218	1224		|O
for	1225	1228		|O
R	1229	1230		|O
-	1230	1231		|O
CHOP	1231	1235		|O
vs	1236	1238		|O
22	1239	1241		|O
months	1242	1248		|O
in	1249	1251		|O
the	1252	1255		|O
CHOP	1256	1260		|O
arm	1261	1264		|O
in	1265	1267		|O
the	1268	1271		|O
LPL	1272	1275	LPL	|B-DISEASE
patients	1276	1284		|O
(	1285	1286		|O
P	1286	1287		|O
=	1287	1288		|O
0.0033	1288	1294		|O
)	1294	1295		|O
and	1296	1299		|O
in	1300	1302		|O
the	1303	1306		|O
WM	1307	1309	WM	|B-DISEASE
subgroup	1310	1318		|O
(	1319	1320		|O
P	1320	1321		|O
=	1321	1322		|O
0.0241	1322	1328		|O
)	1328	1329		|O
.	1329	1330		|O
There	1331	1336		|O
was	1337	1340		|O
no	1341	1343		|O
major	1344	1349		|O
difference	1350	1360		|O
of	1361	1363		|O
treatment	1364	1373	treatment-associated toxicity	|B-ADVERSE
-	1373	1374		|I-ADVERSE
associated	1374	1384		|I-ADVERSE
toxicity	1385	1393		|I-ADVERSE
between	1394	1401		|O
both	1402	1406		|O
treatment	1407	1416		|O
groups	1417	1423		|O
.	1423	1424		|O
These	1425	1430		|O
data	1431	1435		|O
indicate	1436	1444		|O
that	1445	1449		|O
the	1450	1453		|O
addition	1454	1462		|O
of	1463	1465		|O
rituximab	1466	1475		|O
to	1476	1478		|O
front	1479	1484		|O
-	1484	1485		|O
line	1485	1489		|O
chemotherapy	1490	1502		|O
improves	1503	1511		|O
treatment	1512	1521		|O
outcome	1522	1529		|O
in	1530	1532		|O
patients	1533	1541		|O
with	1542	1546		|O
LPL	1547	1550	LPL	|B-DISEASE
or	1551	1553		|O
WM	1554	1556	WM	|B-DISEASE
.	1556	1557		|O

### 18547273
Fluctuating	0	11		|O
functions	12	21		|O
related	22	29		|O
to	30	32		|O
quality	33	40		|O
of	41	43		|O
life	44	48		|O
in	49	51		|O
advanced	52	60		|O
Parkinson	61	70		|O
disease	71	78		|O
:	78	79		|O
effects	80	87		|O
of	88	90		|O
duodenal	91	99		|O
levodopa	100	108		|O
infusion	109	117		|O
.	117	118		|O
OBJECTIVE	120	129		|O
:	129	130		|O
To	131	133		|O
assess	134	140		|O
fluctuations	141	153		|O
in	154	156		|O
quality	157	164		|O
of	165	167		|O
life	168	172		|O
(	173	174		|O
QoL	174	177		|O
)	177	178		|O
and	179	182		|O
motor	183	188		|O
performance	189	200		|O
in	201	203		|O
patients	204	212		|O
with	213	217		|O
advanced	218	226		|O
Parkinson	227	236		|O
disease	237	244		|O
(	245	246		|O
PD	246	248		|O
)	248	249		|O
treated	250	257		|O
with	258	262		|O
continuous	263	273		|O
daytime	274	281		|O
duodenal	282	290		|O
levodopa	291	299		|O
/	299	300		|O
carbidopa	300	309		|O
infusion	310	318		|O
or	319	321		|O
conventional	322	334		|O
therapy	335	342		|O
.	342	343		|O
METHODS	344	351		|O
:	351	352		|O
Of	353	355		|O
18	356	358		|O
patients	359	367		|O
completing	368	378		|O
a	379	380		|O
6	381	382		|O
-	382	383		|O
week	383	387		|O
trial	388	393		|O
(	394	395		|O
DIREQT	395	401		|O
)	401	402		|O
,	402	403		|O
12	404	406		|O
were	407	411		|O
followed	412	420		|O
for	421	424		|O
up	425	427		|O
to	428	430		|O
6	431	432		|O
months	433	439		|O
and	440	443		|O
assessed	444	452		|O
using	453	458		|O
electronic	459	469		|O
diaries	470	477		|O
and	478	481		|O
the	482	485		|O
PD	486	488		|O
Questionnaire	489	502		|O
-	502	503		|O
39	503	505		|O
(	506	507		|O
PDQ	507	510		|O
-	510	511		|O
39	511	513		|O
)	513	514		|O
.	514	515		|O
RESULTS	516	523		|O
:	523	524		|O
During	525	531		|O
the	532	535		|O
trial	536	541		|O
and	542	545		|O
follow	546	552		|O
-	552	553		|O
up	553	555		|O
,	555	556		|O
major	557	562		|O
diurnal	563	570		|O
fluctuations	571	583		|O
were	584	588		|O
observed	589	597		|O
,	597	598		|O
especially	599	609		|O
for	610	613		|O
hyperkinesia	614	626	hyperkinesia	|B-DISEASE
,	626	627		|O
'	628	629		|O
off	629	632		|O
'	632	633		|O
time	634	638		|O
,	638	639		|O
ability	640	647		|O
to	648	650		|O
walk	651	655		|O
and	656	659		|O
depression	660	670	depression	|B-DISEASE
.	670	671		|O
Duodenal	672	680		|O
infusion	681	689		|O
was	690	693		|O
associated	694	704		|O
with	705	709		|O
significantly	710	723		|O
more	724	728		|O
favourable	729	739		|O
outcomes	740	748		|O
compared	749	757		|O
with	758	762		|O
conventional	763	775		|O
treatment	776	785		|O
for	786	789		|O
satisfaction	790	802		|O
with	803	807		|O
overall	808	815		|O
functioning	816	827		|O
,	827	828		|O
'	829	830		|O
off	830	833		|O
'	833	834		|O
time	835	839		|O
and	840	843		|O
ability	844	851		|O
to	852	854		|O
walk	855	859		|O
,	859	860		|O
with	861	865		|O
improved	866	874		|O
outcomes	875	883		|O
with	884	888		|O
PDQ	889	892		|O
-	892	893		|O
39	893	895		|O
.	895	896		|O
CONCLUSIONS	897	908		|O
:	908	909		|O
Relative	910	918		|O
to	919	921		|O
conventional	922	934		|O
treatment	935	944		|O
,	944	945		|O
infusion	946	954		|O
therapy	955	962		|O
may	963	966		|O
stabilize	967	976		|O
and	977	980		|O
significantly	981	994		|O
improve	995	1002		|O
motor	1003	1008		|O
function	1009	1017		|O
and	1018	1021		|O
patient	1022	1029		|O
's	1029	1031		|O
QoL	1032	1035		|O
.	1035	1036		|O
The	1037	1040		|O
potential	1041	1050		|O
for	1051	1054		|O
daily	1055	1060		|O
fluctuation	1061	1072		|O
in	1073	1075		|O
PD	1076	1078		|O
symptoms	1079	1087		|O
means	1088	1093		|O
single	1094	1100		|O
measures	1101	1109		|O
of	1110	1112		|O
treatment	1113	1122		|O
effectiveness	1123	1136		|O
can	1137	1140		|O
result	1141	1147		|O
in	1148	1150		|O
bias	1151	1155		|O
in	1156	1158		|O
effect	1159	1165		|O
estimates	1166	1175		|O
and	1176	1179		|O
hence	1180	1185		|O
repeated	1186	1194		|O
measures	1195	1203		|O
are	1204	1207		|O
recommended	1208	1219		|O
.	1219	1220		|O

### 18707009
Methods	0	7		|O
in	8	10		|O
safety	11	17		|O
pharmacology	18	30		|O
in	31	33		|O
focus	34	39		|O
.	39	40		|O
This	42	46		|O
focused	47	54		|O
issue	55	60		|O
of	61	63		|O
the	64	67		|O
Journal	68	75		|O
of	76	78		|O
Pharmacological	79	94		|O
and	95	98		|O
Toxicological	99	112		|O
Methods	113	120		|O
is	121	123		|O
the	124	127		|O
fifth	128	133		|O
to	134	136		|O
highlight	137	146		|O
Methods	147	154		|O
in	155	157		|O
Safety	158	164		|O
Pharmacology	165	177		|O
and	178	181		|O
includes	182	190		|O
a	191	192		|O
number	193	199		|O
of	200	202		|O
articles	203	211		|O
from	212	216		|O
the	217	220		|O
7th	221	224		|O
Annual	225	231		|O
Safety	232	238		|O
Pharmacology	239	251		|O
Society	252	259		|O
(	260	261		|O
SPS	261	264		|O
)	264	265		|O
meeting	266	273		|O
that	274	278		|O
was	279	282		|O
held	283	287		|O
in	288	290		|O
Edinburgh	291	300		|O
,	300	301		|O
Scotland	302	310		|O
,	310	311		|O
September	312	321		|O
19-21	322	327		|O
,	327	328		|O
2007	329	333		|O
.	333	334		|O
However	335	342		|O
,	342	343		|O
unlike	344	350		|O
issues	351	357		|O
of	358	360		|O
the	361	364		|O
past	365	369		|O
,	369	370		|O
in	371	373		|O
which	374	379		|O
content	380	387		|O
predominantly	388	401		|O
focused	402	409		|O
on	410	412		|O
cardiovascular	413	427		|O
issues	428	434		|O
(	435	436		|O
specifically	436	448		|O
QT	449	451		|O
interval	452	460		|O
prolongation	461	473		|O
,	473	474		|O
QT	475	477		|O
-	477	478		|O
HR	478	480		|O
correction	481	491		|O
methods	492	499		|O
and	500	503		|O
validation	504	514		|O
of	515	517		|O
non	518	521		|O
-	521	522		|O
clinical	522	530		|O
cardiovascular	531	545		|O
models	546	552		|O
)	552	553		|O
this	554	558		|O
issue	559	564		|O
is	565	567		|O
composed	568	576		|O
of	577	579		|O
a	580	581		|O
number	582	588		|O
of	589	591		|O
non	592	595		|O
-	595	596		|O
cardiovascular	596	610		|O
methods	611	618		|O
papers	619	625		|O
and	626	629		|O
review	630	636		|O
articles	637	645		|O
.	645	646		|O
Of	647	649		|O
particular	650	660		|O
interest	661	669		|O
to	670	672		|O
readers	673	680		|O
will	681	685		|O
be	686	688		|O
articles	689	697		|O
related	698	705		|O
to	706	708		|O
CNS	709	712		|O
studies	713	720		|O
,	720	721		|O
in	722	724		|O
particular	725	735		|O
neurobehavioral	736	751		|O
assessments	752	763		|O
in	764	766		|O
non	767	770		|O
-	770	771		|O
human	771	776		|O
primates	777	785		|O
and	786	789		|O
the	790	793		|O
effects	794	801		|O
of	802	804		|O
drugs	805	810		|O
in	811	813		|O
juvenile	814	822		|O
and	823	826		|O
adult	827	832		|O
rats	833	837		|O
(	838	839		|O
an	839	841		|O
article	842	849		|O
that	850	854		|O
may	855	858		|O
be	859	861		|O
relevant	862	870		|O
in	871	873		|O
light	874	879		|O
of	880	882		|O
recent	883	889		|O
EU	890	892		|O
/	892	893		|O
US	893	895		|O
pediatric	896	905		|O
legislation	906	917		|O
)	917	918		|O
.	918	919		|O
While	920	925		|O
cardiovascular	926	940		|O
function	941	949		|O
may	950	953		|O
not	954	957		|O
dominate	958	966		|O
there	967	972		|O
are	973	976		|O
several	977	984		|O
useful	985	991		|O
methodological	992	1006		|O
papers	1007	1013		|O
including	1014	1023		|O
an	1024	1026		|O
assessment	1027	1037		|O
of	1038	1040		|O
cardiovascular	1041	1055		|O
sensitivity	1056	1067		|O
of	1068	1070		|O
drugs	1071	1076		|O
in	1077	1079		|O
conscious	1080	1089		|O
and	1090	1093		|O
anesthetized	1094	1106		|O
non	1107	1110		|O
-	1110	1111		|O
human	1111	1116		|O
primates	1117	1125		|O
,	1125	1126		|O
and	1127	1130		|O
a	1131	1132		|O
mathematical	1133	1145		|O
model	1146	1151		|O
(	1152	1153		|O
fractal	1153	1160		|O
analysis	1161	1169		|O
)	1169	1170		|O
applied	1171	1178		|O
to	1179	1181		|O
canine	1182	1188		|O
heartbeat	1189	1198		|O
dynamics	1199	1207		|O
.	1207	1208		|O
A	1209	1210		|O
first	1211	1216		|O
for	1217	1220		|O
the	1221	1224		|O
journal	1225	1232		|O
is	1233	1235		|O
a	1236	1237		|O
paper	1238	1243		|O
by	1244	1246		|O
Vargas	1247	1253		|O
et	1254	1256		|O
al.	1257	1260		|O
,	1260	1261		|O
(	1262	1263		|O
2008	1263	1267		|O
-	1267	1268		|O
this	1268	1272		|O
issue	1273	1278		|O
)	1278	1279		|O
in	1280	1282		|O
which	1283	1288		|O
members	1289	1296		|O
of	1297	1299		|O
the	1300	1303		|O
SPS	1304	1307		|O
formed	1308	1314		|O
a	1315	1316		|O
working	1317	1324		|O
group	1325	1330		|O
in	1331	1333		|O
order	1334	1339		|O
to	1340	1342		|O
assess	1343	1349		|O
and	1350	1353		|O
review	1354	1360		|O
safety	1361	1367		|O
pharmacology	1368	1380		|O
testing	1381	1388		|O
of	1389	1391		|O
biological	1392	1402		|O
therapeutic	1403	1414		|O
agents	1415	1421		|O
(	1422	1423		|O
specifically	1423	1435		|O
monoclonal	1436	1446		|O
antibodies	1447	1457		|O
,	1457	1458		|O
mAbs	1459	1463		|O
)	1463	1464		|O
.	1464	1465		|O
The	1466	1469		|O
group	1470	1475		|O
provides	1476	1484		|O
recommendations	1485	1500		|O
that	1501	1505		|O
will	1506	1510		|O
likely	1511	1517		|O
shape	1518	1523		|O
regulatory	1524	1534		|O
strategy	1535	1543		|O
and	1544	1547		|O
discussions	1548	1559		|O
in	1560	1562		|O
the	1563	1566		|O
yet	1567	1570		|O
to	1571	1573		|O
be	1574	1576		|O
fully	1577	1582		|O
discussed	1583	1592		|O
area	1593	1597		|O
of	1598	1600		|O
biological	1601	1611		|O
safety	1612	1618		|O
testing	1619	1626		|O
.	1626	1627		|O
In	1628	1630		|O
the	1631	1634		|O
tradition	1635	1644		|O
of	1645	1647		|O
obtaining	1648	1657		|O
a	1658	1659		|O
perspective	1660	1671		|O
on	1672	1674		|O
industry	1675	1683		|O
safety	1684	1690		|O
pharmacology	1691	1703		|O
program	1704	1711		|O
practices	1712	1721		|O
Lindgren	1722	1730		|O
et	1731	1733		|O
al.	1734	1737		|O
,	1737	1738		|O
(	1739	1740		|O
2008	1740	1744		|O
-	1744	1745		|O
this	1745	1749		|O
issue	1750	1755		|O
)	1755	1756		|O
provide	1757	1764		|O
the	1765	1768		|O
results	1769	1776		|O
of	1777	1779		|O
a	1780	1781		|O
recent	1782	1788		|O
SPS	1789	1792		|O
survey	1793	1799		|O
that	1800	1804		|O
examines	1805	1813		|O
ICH	1814	1817		|O
S7A	1818	1821		|O
and	1822	1825		|O
S7B	1826	1829		|O
trends	1830	1836		|O
,	1836	1837		|O
aspects	1838	1845		|O
of	1846	1848		|O
early	1849	1854		|O
'	1855	1856		|O
frontloading	1856	1868		|O
'	1868	1869		|O
safety	1870	1876		|O
studies	1877	1884		|O
,	1884	1885		|O
abuse	1886	1891		|O
and	1892	1895		|O
dependence	1896	1906		|O
liability	1907	1916		|O
and	1917	1920		|O
Contract	1921	1929		|O
Research	1930	1938		|O
Organization	1939	1951		|O
(	1952	1953		|O
CRO	1953	1956		|O
)	1956	1957		|O
tests	1958	1963		|O
/	1963	1964		|O
assays	1964	1970		|O
used	1971	1975		|O
in	1976	1978		|O
safety	1979	1985		|O
assessment	1986	1996		|O
of	1997	1999		|O
core	2000	2004		|O
battery	2005	2012		|O
and	2013	2016		|O
supplementary	2017	2030		|O
organ	2031	2036		|O
systems	2037	2044		|O
.	2044	2045		|O
In	2046	2048		|O
keeping	2049	2056		|O
with	2057	2061		|O
the	2062	2065		|O
translation	2066	2077		|O
track	2078	2083		|O
aspect	2084	2090		|O
of	2091	2093		|O
the	2094	2097		|O
2007	2098	2102		|O
meeting	2103	2110		|O
is	2111	2113		|O
an	2114	2116		|O
overview	2117	2125		|O
of	2126	2128		|O
the	2129	2132		|O
Distinguished	2133	2146		|O
Service	2147	2154		|O
Award	2155	2160		|O
lecture	2161	2168		|O
to	2169	2171		|O
Dr.	2172	2175		|O
T	2176	2177		|O
.	2177	2178		|O
Hammond	2179	2186		|O
that	2187	2191		|O
discusses	2192	2201		|O
many	2202	2206		|O
aspects	2207	2214		|O
of	2215	2217		|O
safety	2218	2224		|O
pharmacology	2225	2237		|O
including	2238	2247		|O
its	2248	2251		|O
evolution	2252	2261		|O
,	2261	2262		|O
impact	2263	2269		|O
,	2269	2270		|O
value	2271	2276		|O
and	2277	2280		|O
translation	2281	2292		|O
of	2293	2295		|O
non	2296	2299		|O
-	2299	2300		|O
clinical	2300	2308		|O
findings	2309	2317		|O
to	2318	2320		|O
humans	2321	2327		|O
.	2327	2328		|O
Finally	2329	2336		|O
,	2336	2337		|O
perspectives	2338	2350		|O
are	2351	2354		|O
presented	2355	2364		|O
on	2365	2367		|O
the	2368	2371		|O
use	2372	2375		|O
of	2376	2378		|O
the	2379	2382		|O
zebrafish	2383	2392		|O
as	2393	2395		|O
an	2396	2398		|O
early	2399	2404		|O
safety	2405	2411		|O
pharmacology	2412	2424		|O
-	2424	2425		|O
screening	2425	2434		|O
assay	2435	2440		|O
.	2440	2441		|O

### 18719341
Lung	0	4	Lung fibrosis	|B-ADVERSE
fibrosis	5	13		|I-ADVERSE
10	14	16		|O
years	17	22		|O
after	23	28		|O
cessation	29	38		|O
of	39	41		|O
bleomycin	42	51		|O
therapy	52	59		|O
.	59	60		|O
Bleomycin	62	71		|O
(	72	73		|O
BLM	73	76		|O
)	76	77		|O
is	78	80		|O
a	81	82		|O
chemotherapeutic	83	99		|O
agent	100	105		|O
used	106	110		|O
for	111	114		|O
the	115	118		|O
treatment	119	128		|O
of	129	131		|O
several	132	139		|O
types	140	145		|O
of	146	148		|O
malignancy	149	159		|O
,	159	160		|O
including	161	170		|O
germ	171	175	germ cell tumors	|B-DISEASE
cell	176	180		|I-DISEASE
tumors	181	187		|I-DISEASE
,	187	188		|O
lymphoma	189	197	lymphoma	|B-DISEASE
,	197	198		|O
and	199	202		|O
certain	203	210		|O
types	211	216		|O
of	217	219		|O
squamous	220	228	squamous-cell carcinoma	|B-DISEASE
-	228	229		|I-DISEASE
cell	229	233		|I-DISEASE
carcinoma	234	243		|I-DISEASE
.	243	244		|O
The	245	248		|O
common	249	255		|O
adverse	256	263		|O
effect	264	270		|O
of	271	273		|O
BLM	274	277		|O
is	278	280		|O
interstitial	281	293	interstitial pneumonitis	|B-ADVERSE
pneumonitis	294	305		|I-ADVERSE
,	305	306		|O
followed	307	315		|O
by	316	318		|O
pulmonary	319	328	pulmonary fibrosis	|B-ADVERSE
fibrosis	329	337		|I-ADVERSE
.	337	338		|O
BLM	339	342		|O
-	342	343		|O
induced	343	350		|O
pneumonitis	351	362	pneumonitis	|B-ADVERSE
occurs	363	369		|O
in	370	372		|O
up	373	375		|O
to	376	378		|O
46%	379	382		|O
of	383	385		|O
patients	386	394		|O
treated	395	402		|O
with	403	407		|O
BLM	408	411		|O
-	411	412		|O
containing	412	422		|O
chemotherapy	423	435		|O
and	436	439		|O
lung	440	444	lung toxicity	|B-ADVERSE
toxicity	445	453		|I-ADVERSE
usually	454	461		|O
appears	462	469		|O
during	470	476		|O
treatment	477	486		|O
.	486	487		|O
Here	488	492		|O
we	493	495		|O
describe	496	504		|O
a	505	506		|O
patient	507	514		|O
with	515	519		|O
lung	520	524	lung fibrosis	|B-DISEASE
fibrosis	525	533		|I-DISEASE
,	533	534		|O
who	535	538		|O
presented	539	548		|O
with	549	553		|O
slow	554	558		|O
progressive	559	570	progressive breathlessness	|B-ADVERSE
breathlessness	571	585		|I-ADVERSE
and	586	589		|O
pneumothorax	590	602	pneumothorax	|B-ADVERSE
more	603	607		|O
than	608	612		|O
10	613	615		|O
years	616	621		|O
after	622	627		|O
cessation	628	637		|O
of	638	640		|O
BLM	641	644		|O
therapy	645	652		|O
.	652	653		|O
A	654	655		|O
15	656	658		|O
year	659	663		|O
-	663	664		|O
old	664	667		|O
girl	668	672		|O
presented	673	682		|O
with	683	687		|O
abnormal	688	696		|O
shadows	697	704		|O
on	705	707		|O
chest	708	713		|O
X	714	715		|O
-	715	716		|O
ray	716	719		|O
.	719	720		|O
The	721	724		|O
patient	725	732		|O
had	733	736		|O
a	737	738		|O
yolk	739	743	yolk sac carcinoma	|B-DISEASE
sac	744	747		|I-DISEASE
carcinoma	748	757		|I-DISEASE
in	758	760		|O
the	761	764		|O
sacral	765	771		|O
region	772	778		|O
at	779	781		|O
1	782	783		|O
year	784	788		|O
of	789	791		|O
age	792	795		|O
and	796	799		|O
obtained	800	808		|O
complete	809	817		|O
remission	818	827		|O
after	828	833		|O
being	834	839		|O
treated	840	847		|O
with	848	852		|O
tumor	853	858	tumor	|B-DISEASE
resection	859	868		|O
,	868	869		|O
radiation	870	879		|O
,	879	880		|O
and	881	884		|O
several	885	892		|O
anti	893	897		|O
-	897	898		|O
cancer	898	904		|O
drugs	905	910		|O
including	911	920		|O
BLM	921	924		|O
.	924	925		|O
There	926	931		|O
were	932	936		|O
no	937	939		|O
abnormal	940	948		|O
findings	949	957		|O
in	958	960		|O
chest	961	966		|O
X	967	968		|O
-	968	969		|O
ray	969	972		|O
until	973	978		|O
she	979	982		|O
reached	983	990		|O
3	991	992		|O
years	993	998		|O
of	999	1001		|O
age	1002	1005		|O
,	1005	1006		|O
when	1007	1011		|O
she	1012	1015		|O
had	1016	1019		|O
developed	1020	1029		|O
respiratory	1030	1041	respiratory distress	|B-ADVERSE
distress	1042	1050		|I-ADVERSE
that	1051	1055		|O
worsened	1056	1064		|O
with	1065	1069		|O
age	1070	1073		|O
.	1073	1074		|O
The	1075	1078		|O
patient	1079	1086		|O
had	1087	1090		|O
experienced	1091	1102		|O
an	1103	1105		|O
episode	1106	1113		|O
of	1114	1116		|O
pneumothorax	1117	1129	pneumothorax	|B-ADVERSE
at	1130	1132		|O
13	1133	1135		|O
years	1136	1141		|O
of	1142	1144		|O
age	1145	1148		|O
.	1148	1149		|O
Chest	1150	1155		|O
CT	1156	1158		|O
at	1159	1161		|O
the	1162	1165		|O
time	1166	1170		|O
revealed	1171	1179		|O
interstitial	1180	1192		|O
reticular	1193	1202		|O
opacities	1203	1212		|O
.	1212	1213		|O
Radiological	1214	1226		|O
findings	1227	1235		|O
and	1236	1239		|O
pathological	1240	1252		|O
examination	1253	1264		|O
of	1265	1267		|O
the	1268	1271		|O
lung	1272	1276		|O
tissue	1277	1283		|O
obtained	1284	1292		|O
during	1293	1299		|O
bullectomy	1300	1310		|O
with	1311	1315		|O
video	1316	1321		|O
-	1321	1322		|O
assisted	1322	1330		|O
thoracic	1331	1339		|O
surgery	1340	1347		|O
were	1348	1352		|O
compatible	1353	1363		|O
with	1364	1368		|O
BLM	1369	1372		|O
-	1372	1373		|O
induced	1373	1380		|O
pneumonitis	1381	1392	pneumonitis	|B-ADVERSE
.	1392	1393		|O
The	1394	1397		|O
present	1398	1405		|O
study	1406	1411		|O
suggests	1412	1420		|O
that	1421	1425		|O
lung	1426	1430	lung fibrosis	|B-DISEASE
fibrosis	1431	1439		|I-DISEASE
may	1440	1443		|O
surface	1444	1451		|O
more	1452	1456		|O
than	1457	1461		|O
10	1462	1464		|O
years	1465	1470		|O
after	1471	1476		|O
cessation	1477	1486		|O
of	1487	1489		|O
BLM	1490	1493		|O
therapy	1494	1501		|O
at	1502	1504		|O
the	1505	1508		|O
age	1509	1512		|O
of	1513	1515		|O
1	1516	1517		|O
year	1518	1522		|O
,	1522	1523		|O
with	1524	1528		|O
no	1529	1531		|O
chest	1532	1537		|O
radiographic	1538	1550		|O
findings	1551	1559		|O
1	1560	1561		|O
year	1562	1566		|O
after	1567	1572		|O
completion	1573	1583		|O
of	1584	1586		|O
chemotherapy	1587	1599		|O
.	1599	1600		|O
The	1601	1604		|O
use	1605	1608		|O
of	1609	1611		|O
BLM	1612	1615		|O
in	1616	1618		|O
infants	1619	1626		|O
requires	1627	1635		|O
strict	1636	1642		|O
supervision	1643	1654		|O
and	1655	1658		|O
observation	1659	1670		|O
and	1671	1674		|O
careful	1675	1682		|O
long	1683	1687		|O
-	1687	1688		|O
term	1688	1692		|O
follow	1693	1699		|O
up	1700	1702		|O
.	1702	1703		|O

### 18789678
Hyperthermia	0	12	Hyperthermia	|B-DISEASE
adds	13	17		|O
to	18	20		|O
chemotherapy	21	33		|O
.	33	34		|O
The	36	39		|O
hallmarks	40	49		|O
of	50	52		|O
hyperthermia	53	65	hyperthermia	|B-DISEASE
and	66	69		|O
its	70	73		|O
pleotropic	74	84		|O
effects	85	92		|O
are	93	96		|O
in	97	99		|O
favour	100	106		|O
of	107	109		|O
its	110	113		|O
combined	114	122		|O
use	123	126		|O
with	127	131		|O
chemotherapy	132	144		|O
.	144	145		|O
Preclinical	146	157		|O
research	158	166		|O
reveals	167	174		|O
that	175	179		|O
for	180	183		|O
heat	184	188		|O
killing	189	196		|O
and	197	200		|O
synergistic	201	212		|O
effects	213	220		|O
the	221	224		|O
thermal	225	232		|O
dose	233	237		|O
is	238	240		|O
most	241	245		|O
critical	246	254		|O
.	254	255		|O
Thermal	256	263		|O
enhancement	264	275		|O
of	276	278		|O
drug	279	283	drug cytotoxicity	|B-ADVERSE
cytotoxicity	284	296		|I-ADVERSE
is	297	299		|O
accompanied	300	311		|O
by	312	314		|O
cellular	315	323		|O
death	324	329		|O
and	330	333		|O
necrosis	334	342		|O
without	343	350		|O
increasing	351	361		|O
its	362	365		|O
oncogenic	366	375		|O
potential	376	385		|O
.	385	386		|O
The	387	390		|O
induction	391	400		|O
of	401	403		|O
genetically	404	415		|O
defined	416	423		|O
stress	424	430		|O
responses	431	440		|O
can	441	444		|O
deliver	445	452		|O
danger	453	459		|O
signals	460	467		|O
to	468	470		|O
activate	471	479		|O
the	480	483		|O
host	484	488		|O
's	488	490		|O
immune	491	497		|O
system	498	504		|O
.	504	505		|O
The	506	509		|O
positive	510	518		|O
results	519	526		|O
of	527	529		|O
randomised	530	540		|O
trials	541	547		|O
have	548	552		|O
definitely	553	563		|O
established	564	575		|O
hyperthermia	576	588	hyperthermia	|B-DISEASE
in	589	591		|O
combination	592	603		|O
with	604	608		|O
chemotherapy	609	621		|O
as	622	624		|O
a	625	626		|O
novel	627	632		|O
clinical	633	641		|O
modality	642	650		|O
for	651	654		|O
the	655	658		|O
treatment	659	668		|O
of	669	671		|O
cancer	672	678	cancer	|B-DISEASE
.	678	679		|O
Hyperthermia	680	692	Hyperthermia	|B-DISEASE
targets	693	700		|O
the	701	704		|O
action	705	711		|O
of	712	714		|O
chemotherapy	715	727		|O
within	728	734		|O
the	735	738		|O
heated	739	745		|O
tumour	746	752	tumour	|B-DISEASE
region	753	759		|O
without	760	767		|O
affecting	768	777		|O
systemic	778	786	systemic toxicity	|B-ADVERSE
toxicity	787	795		|I-ADVERSE
.	795	796		|O
In	797	799		|O
specific	800	808		|O
clinical	809	817		|O
settings	818	826		|O
regional	827	835	regional hyperthermia	|B-DISEASE
hyperthermia	836	848		|I-DISEASE
(	849	850		|O
RHT	850	853	RHT	|B-DISEASE
)	853	854		|O
or	855	857		|O
hyperthermic	858	870		|O
perfusion	871	880		|O
has	881	884		|O
proved	885	891		|O
its	892	895		|O
value	896	901		|O
and	902	905		|O
deserve	906	913		|O
a	914	915		|O
greater	916	923		|O
focus	924	929		|O
and	930	933		|O
investigation	934	947		|O
in	948	950		|O
other	951	956		|O
malignancies	957	969		|O
.	969	970		|O
In	971	973		|O
Europe	974	980		|O
,	980	981		|O
more	982	986		|O
specialised	987	998		|O
centres	999	1006		|O
should	1007	1013		|O
be	1014	1016		|O
created	1017	1024		|O
and	1025	1028		|O
maintained	1029	1039		|O
as	1040	1042		|O
network	1043	1050		|O
of	1051	1053		|O
excellence	1054	1064		|O
for	1065	1068		|O
hyperthermia	1069	1081	hyperthermia	|B-DISEASE
in	1082	1084		|O
the	1085	1088		|O
field	1089	1094		|O
of	1095	1097		|O
oncology	1098	1106		|O
.	1106	1107		|O

### 18709536
Breakthrough	0	12		|O
cryptococcosis	13	27	cryptococcosis	|B-ADVERSE
in	28	30		|O
a	31	32		|O
patient	33	40		|O
with	41	45		|O
systemic	46	54	systemic lupus erythematosus	|B-DISEASE
lupus	55	60		|I-DISEASE
erythematosus	61	74		|I-DISEASE
(	75	76		|O
SLE	76	79	SLE	|B-DISEASE
)	79	80		|O
receiving	81	90		|O
micafungin	91	101		|O
.	101	102		|O
A	104	105		|O
67	106	108		|O
-	108	109		|O
year	109	113		|O
-	113	114		|O
old	114	117		|O
woman	118	123		|O
with	124	128		|O
systemic	129	137	systemic lupus erythematosus	|B-DISEASE
lupus	138	143		|I-DISEASE
erythematosus	144	157		|I-DISEASE
(	158	159		|O
SLE	159	162	SLE	|B-DISEASE
)	162	163		|O
was	164	167		|O
admitted	168	176		|O
to	177	179		|O
our	180	183		|O
hospital	184	192		|O
because	193	200		|O
of	201	203		|O
lupus	204	209	lupus nephritis	|B-DISEASE
nephritis	210	219		|I-DISEASE
.	219	220		|O
Methylprednisolone	221	239		|O
minipulse	240	249		|O
therapy	250	257		|O
dramatically	258	270		|O
reduced	271	278		|O
her	279	282		|O
proteinuria	283	294	proteinuria	|B-DISEASE
;	294	295		|O
however	296	303		|O
;	303	304		|O
she	305	308		|O
then	309	313		|O
complained	314	324		|O
of	325	327		|O
general	328	335		|O
fatigue	336	343	fatigue	|B-ADVERSE
with	344	348		|O
low	349	352		|O
-	352	353		|O
grade	353	358		|O
fever	359	364	fever	|B-ADVERSE
.	364	365		|O
Radiological	366	378		|O
and	379	382		|O
culture	383	390		|O
studies	391	398		|O
revealed	399	407		|O
no	408	410		|O
infectious	411	421		|O
focus	422	427		|O
,	427	428		|O
but	429	432		|O
she	433	436		|O
was	437	440		|O
treated	441	448		|O
with	449	453		|O
meropenem	454	463		|O
and	464	467		|O
micafungin	468	478		|O
,	478	479		|O
considering	480	491		|O
her	492	495		|O
immunosuppressive	496	513		|O
state	514	519		|O
.	519	520		|O
Cytomegalovirus	521	536		|O
antigenemia	537	548		|O
was	549	552		|O
later	553	558		|O
determined	559	569		|O
and	570	573		|O
ganciclovir	574	585		|O
was	586	589		|O
added	590	595		|O
.	595	596		|O
She	597	600		|O
became	601	607		|O
afebrile	608	616		|O
,	616	617		|O
but	618	621		|O
complained	622	632		|O
of	633	635		|O
nausea	636	642	nausea	|B-ADVERSE
and	643	646		|O
headache	647	655	headache	|B-ADVERSE
,	655	656		|O
and	657	660		|O
disorientation	661	675	disorientation	|B-ADVERSE
,	675	676		|O
without	677	684		|O
meningeal	685	694	meningeal signs	|B-ADVERSE
signs	695	700		|I-ADVERSE
.	700	701		|O
Because	702	709		|O
a	710	711		|O
brain	712	717		|O
computed	718	726		|O
tomography	727	737		|O
(	738	739		|O
CT	739	741		|O
)	741	742		|O
scan	743	747		|O
showed	748	754		|O
no	755	757		|O
abnormality	758	769		|O
,	769	770		|O
we	771	773		|O
initially	774	783		|O
suspected	784	793		|O
some	794	798		|O
kind	799	803		|O
of	804	806		|O
drug	807	811		|O
interaction	812	823		|O
.	823	824		|O
Despite	825	832		|O
the	833	836		|O
discontinuation	837	852		|O
of	853	855		|O
all	856	859		|O
drugs	860	865		|O
,	865	866		|O
however	867	874		|O
,	874	875		|O
she	876	879		|O
still	880	885		|O
suffered	886	894		|O
from	895	899		|O
disturbance	900	911		|O
of	912	914		|O
consciousness	915	928		|O
.	928	929		|O
A	930	931		|O
lumbar	932	938		|O
puncture	939	947		|O
revealed	948	956		|O
yeast	957	962		|O
cells	963	968		|O
stained	969	976		|O
by	977	979		|O
India	980	985		|O
ink	986	989		|O
.	989	990		|O
A	991	992		|O
diagnosis	993	1002		|O
of	1003	1005		|O
cryptococcal	1006	1018	cryptococcal meningitis	|B-DISEASE
meningitis	1019	1029		|I-DISEASE
was	1030	1033		|O
confirmed	1034	1043		|O
.	1043	1044		|O
Though	1045	1051		|O
fluconazole	1052	1063		|O
and	1064	1067		|O
meropenem	1068	1077		|O
were	1078	1082		|O
administered	1083	1095		|O
,	1095	1096		|O
the	1097	1100		|O
patient	1101	1108		|O
died	1109	1113		|O
.	1113	1114		|O
Autopsy	1115	1122		|O
findings	1123	1131		|O
revealed	1132	1140		|O
disseminated	1141	1153	disseminated cryptococcosis	|B-DISEASE
cryptococcosis	1154	1168		|I-DISEASE
concomitant	1169	1180		|O
with	1181	1185		|O
pulmonary	1186	1195	pulmonary aspergillosis	|B-DISEASE
aspergillosis	1196	1209		|I-DISEASE
.	1209	1210		|O
Micafungin	1211	1221		|O
is	1222	1224		|O
a	1225	1226		|O
recently	1227	1235		|O
approved	1236	1244		|O
echinocandin	1245	1257		|O
-	1257	1258		|O
class	1258	1263		|O
antifungal	1264	1274		|O
agent	1275	1280		|O
that	1281	1285		|O
is	1286	1288		|O
now	1289	1292		|O
widely	1293	1299		|O
used	1300	1304		|O
in	1305	1307		|O
Japan	1308	1313		|O
because	1314	1321		|O
of	1322	1324		|O
its	1325	1328		|O
minimal	1329	1336		|O
toxicity	1337	1345		|O
and	1346	1349		|O
broadspectrum	1350	1363		|O
activity	1364	1372		|O
.	1372	1373		|O
However	1374	1381		|O
,	1381	1382		|O
such	1383	1387		|O
echinocandins	1388	1401		|O
have	1402	1406		|O
limited	1407	1414		|O
activity	1415	1423		|O
against	1424	1431		|O
a	1432	1433		|O
number	1434	1440		|O
of	1441	1443		|O
fungi	1444	1449		|O
.	1449	1450		|O
Indeed	1451	1457		|O
,	1457	1458		|O
breakthrough	1459	1471		|O
trichosporonosis	1472	1488		|O
is	1489	1491		|O
becoming	1492	1500		|O
a	1501	1502		|O
significant	1503	1514		|O
problem	1515	1522		|O
in	1523	1525		|O
patients	1526	1534		|O
with	1535	1539		|O
hematological	1540	1553	hematological malignancies	|B-DISEASE
malignancies	1554	1566		|I-DISEASE
who	1567	1570		|O
are	1571	1574		|O
receiving	1575	1584		|O
echinocandins	1585	1598		|O
.	1598	1599		|O
To	1600	1602		|O
the	1603	1606		|O
best	1607	1611		|O
of	1612	1614		|O
our	1615	1618		|O
knowledge	1619	1628		|O
,	1628	1629		|O
breakthrough	1630	1642		|O
cryptococcosis	1643	1657	cryptococcosis	|B-ADVERSE
,	1657	1658		|O
as	1659	1661		|O
seen	1662	1666		|O
in	1667	1669		|O
our	1670	1673		|O
patient	1674	1681		|O
,	1681	1682		|O
has	1683	1686		|O
not	1687	1690		|O
been	1691	1695		|O
reported	1696	1704		|O
previously	1705	1715		|O
in	1716	1718		|O
patients	1719	1727		|O
who	1728	1731		|O
were	1732	1736		|O
receiving	1737	1746		|O
micafungin	1747	1757		|O
as	1758	1760		|O
an	1761	1763		|O
empiric	1764	1771		|O
antifungal	1772	1782		|O
therapy	1783	1790		|O
.	1790	1791		|O
This	1792	1796		|O
case	1797	1801		|O
highlights	1802	1812		|O
that	1813	1817		|O
cryptococcosis	1818	1832	cryptococcosis	|B-ADVERSE
should	1833	1839		|O
be	1840	1842		|O
kept	1843	1847		|O
in	1848	1850		|O
mind	1851	1855		|O
as	1856	1858		|O
a	1859	1860		|O
possible	1861	1869		|O
breakthrough	1870	1882		|O
infection	1883	1892	infection	|B-ADVERSE
during	1893	1899		|O
the	1900	1903		|O
administration	1904	1918		|O
of	1919	1921		|O
echinocandins	1922	1935		|O
,	1935	1936		|O
especially	1937	1947		|O
in	1948	1950		|O
patients	1951	1959		|O
with	1960	1964		|O
cellular	1965	1973	cellular immunodeficiency	|B-DISEASE
immunodeficiency	1974	1990		|I-DISEASE
.	1990	1991		|O

### 18786302
Effect	0	6		|O
of	7	9		|O
ranitidine	10	20		|O
on	21	23		|O
the	24	27		|O
pharmacokinetics	28	44		|O
and	45	48		|O
pharmacodynamics	49	65		|O
of	66	68		|O
prasugrel	69	78		|O
and	79	82		|O
clopidogrel	83	94		|O
.	94	95		|O
OBJECTIVE	97	106		|O
:	106	107		|O
Clopidogrel	108	119		|O
is	120	122		|O
an	123	125		|O
oral	126	130		|O
thienopyridine	131	145		|O
antiplatelet	146	158		|O
agent	159	164		|O
indicated	165	174		|O
for	175	178		|O
the	179	182		|O
treatment	183	192		|O
of	193	195		|O
atherothrombotic	196	212		|O
events	213	219		|O
in	220	222		|O
patients	223	231		|O
with	232	236		|O
acute	237	242	acute coronary syndrome	|B-DISEASE
coronary	243	251		|I-DISEASE
syndrome	252	260		|I-DISEASE
(	261	262		|O
ACS	262	265		|O
)	265	266		|O
.	266	267		|O
Prasugrel	268	277		|O
,	277	278		|O
a	279	280		|O
novel	281	286		|O
oral	287	291		|O
thienopyridine	292	306		|O
,	306	307		|O
is	308	310		|O
under	311	316		|O
investigation	317	330		|O
for	331	334		|O
the	335	338		|O
reduction	339	348		|O
of	349	351		|O
atherothrombotic	352	368		|O
events	369	375		|O
in	376	378		|O
patients	379	387		|O
with	388	392		|O
ACS	393	396		|O
undergoing	397	407		|O
percutaneous	408	420		|O
coronary	421	429		|O
intervention	430	442		|O
.	442	443		|O
Prasugrel	444	453		|O
's	453	455		|O
solubility	456	466		|O
decreases	467	476		|O
with	477	481		|O
increasing	482	492		|O
pH	493	495		|O
,	495	496		|O
suggesting	497	507		|O
that	508	512		|O
concomitantly	513	526		|O
-	526	527		|O
administered	527	539		|O
medications	540	551		|O
that	552	556		|O
increase	557	565		|O
gastric	566	573		|O
pH	574	576		|O
may	577	580		|O
lower	581	586		|O
the	587	590		|O
rate	591	595		|O
and	596	599		|O
/	599	600		|O
or	600	602		|O
extent	603	609		|O
of	610	612		|O
prasugrel	613	622		|O
absorption	623	633		|O
.	633	634		|O
This	635	639		|O
study	640	645		|O
evaluated	646	655		|O
the	656	659		|O
influence	660	669		|O
of	670	672		|O
ranitidine	673	683		|O
coadministration	684	700		|O
on	701	703		|O
the	704	707		|O
pharmacokinetics	708	724		|O
and	725	728		|O
pharmacodynamics	729	745		|O
of	746	748		|O
the	749	752		|O
respective	753	763		|O
active	764	770		|O
metabolite	771	781		|O
of	782	784		|O
prasugrel	785	794		|O
and	795	798		|O
clopidogrel	799	810		|O
.	810	811		|O
RESEARCH	812	820		|O
DESIGN	821	827		|O
AND	828	831		|O
METHODS	832	839		|O
:	839	840		|O
In	841	843		|O
this	844	848		|O
open	849	853		|O
-	853	854		|O
label	854	859		|O
,	859	860		|O
two	861	864		|O
-	864	865		|O
period	865	871		|O
,	871	872		|O
two	873	876		|O
-	876	877		|O
treatment	877	886		|O
,	886	887		|O
crossover	888	897		|O
study	898	903		|O
,	903	904		|O
47	905	907		|O
healthy	908	915		|O
male	916	920		|O
subjects	921	929		|O
were	930	934		|O
randomized	935	945		|O
to	946	948		|O
one	949	952		|O
of	953	955		|O
two	956	959		|O
study	960	965		|O
arms	966	970		|O
,	970	971		|O
receiving	972	981		|O
either	982	988		|O
prasugrel	989	998		|O
(	999	1000		|O
60	1000	1002		|O
-	1002	1003		|O
mg	1003	1005		|O
loading	1006	1013		|O
dose	1014	1018		|O
[	1019	1020		|O
LD	1020	1022		|O
]	1022	1023		|O
,	1023	1024		|O
10	1025	1027		|O
-	1027	1028		|O
mg	1028	1030		|O
maintenance	1031	1042		|O
dose	1043	1047		|O
[	1048	1049		|O
MD	1049	1051		|O
]	1051	1052		|O
for	1053	1056		|O
7	1057	1058		|O
days	1059	1063		|O
;	1063	1064		|O
n	1065	1066		|O
=	1067	1068		|O
23	1069	1071		|O
)	1071	1072		|O
or	1073	1075		|O
clopidogrel	1076	1087		|O
(	1088	1089		|O
600	1089	1092		|O
-	1092	1093		|O
mg	1093	1095		|O
LD	1096	1098		|O
,	1098	1099		|O
75	1100	1102		|O
-	1102	1103		|O
mg	1103	1105		|O
MD	1106	1108		|O
for	1109	1112		|O
7	1113	1114		|O
days	1115	1119		|O
;	1119	1120		|O
n	1121	1122		|O
=	1123	1124		|O
24	1125	1127		|O
)	1127	1128		|O
.	1128	1129		|O
In	1130	1132		|O
one	1133	1136		|O
treatment	1137	1146		|O
period	1147	1153		|O
,	1153	1154		|O
subjects	1155	1163		|O
received	1164	1172		|O
prasugrel	1173	1182		|O
or	1183	1185		|O
clopidogrel	1186	1197		|O
alone	1198	1203		|O
,	1203	1204		|O
and	1205	1208		|O
in	1209	1211		|O
the	1212	1215		|O
alternate	1216	1225		|O
period	1226	1232		|O
received	1233	1241		|O
the	1242	1245		|O
same	1246	1250		|O
thienopyridine	1251	1265		|O
with	1266	1270		|O
ranitidine	1271	1281		|O
(	1282	1283		|O
150	1283	1286		|O
mg	1287	1289		|O
twice	1290	1295		|O
daily	1296	1301		|O
,	1301	1302		|O
starting	1303	1311		|O
1	1312	1313		|O
day	1314	1317		|O
before	1318	1324		|O
the	1325	1328		|O
LD	1329	1331		|O
)	1331	1332		|O
.	1332	1333		|O
Pharmacokinetic	1334	1349		|O
parameter	1350	1359		|O
estimates	1360	1369		|O
(	1370	1371		|O
AUC	1371	1374		|O
(	1374	1375		|O
0	1375	1376		|O
-	1376	1377		|O
t	1377	1378		|O
last	1379	1383		|O
)	1383	1384		|O
,	1384	1385		|O
C	1386	1387		|O
(	1387	1388		|O
max	1388	1391		|O
)	1391	1392		|O
,	1392	1393		|O
and	1394	1397		|O
t	1398	1399		|O
(	1399	1400		|O
max	1400	1403		|O
)	1403	1404		|O
)	1404	1405		|O
and	1406	1409		|O
inhibition	1410	1420		|O
of	1421	1423		|O
platelet	1424	1432		|O
aggregation	1433	1444		|O
(	1445	1446		|O
IPA	1446	1449		|O
)	1449	1450		|O
by	1451	1453		|O
light	1454	1459		|O
transmission	1460	1472		|O
aggregometry	1473	1485		|O
were	1486	1490		|O
assessed	1491	1499		|O
at	1500	1502		|O
multiple	1503	1511		|O
time	1512	1516		|O
points	1517	1523		|O
after	1524	1529		|O
the	1530	1533		|O
LD	1534	1536		|O
and	1537	1540		|O
final	1541	1546		|O
MD	1547	1549		|O
.	1549	1550		|O
RESULTS	1551	1558		|O
:	1558	1559		|O
Ranitidine	1560	1570		|O
had	1571	1574		|O
no	1575	1577		|O
clinically	1578	1588		|O
significant	1589	1600		|O
effect	1601	1607		|O
on	1608	1610		|O
the	1611	1614		|O
area	1615	1619		|O
under	1620	1625		|O
the	1626	1629		|O
plasma	1630	1636		|O
-	1636	1637		|O
concentration	1637	1650		|O
-	1650	1651		|O
time	1651	1655		|O
curve	1656	1661		|O
(	1662	1663		|O
AUC	1663	1666		|O
)	1666	1667		|O
and	1668	1671		|O
did	1672	1675		|O
not	1676	1679		|O
affect	1680	1686		|O
the	1687	1690		|O
time	1691	1695		|O
to	1696	1698		|O
C	1699	1700		|O
(	1700	1701		|O
max	1701	1704		|O
)	1704	1705		|O
(	1706	1707		|O
t	1707	1708		|O
(	1708	1709		|O
max	1709	1712		|O
)	1712	1713		|O
)	1713	1714		|O
for	1715	1718		|O
active	1719	1725		|O
metabolites	1726	1737		|O
of	1738	1740		|O
either	1741	1747		|O
prasugrel	1748	1757		|O
or	1758	1760		|O
clopidogrel	1761	1772		|O
.	1772	1773		|O
It	1774	1776		|O
reduced	1777	1784		|O
the	1785	1788		|O
geometric	1789	1798		|O
mean	1799	1803		|O
maximum	1804	1811		|O
concentrations	1812	1826		|O
of	1827	1829		|O
active	1830	1836		|O
metabolite	1837	1847		|O
(	1848	1849		|O
C	1849	1850		|O
(	1850	1851		|O
max	1851	1854		|O
)	1854	1855		|O
)	1855	1856		|O
after	1857	1862		|O
a	1863	1864		|O
prasugrel	1865	1874		|O
and	1875	1878		|O
clopidogrel	1879	1890		|O
LD	1891	1893		|O
by	1894	1896		|O
14%	1897	1900		|O
and	1901	1904		|O
10%	1905	1908		|O
,	1908	1909		|O
respectively	1910	1922		|O
,	1922	1923		|O
but	1924	1927		|O
these	1928	1933		|O
differences	1934	1945		|O
were	1946	1950		|O
not	1951	1954		|O
statistically	1955	1968		|O
significant	1969	1980		|O
.	1980	1981		|O
When	1982	1986		|O
coadministered	1987	2001		|O
with	2002	2006		|O
a	2007	2008		|O
60	2009	2011		|O
-	2011	2012		|O
mg	2012	2014		|O
prasugrel	2015	2024		|O
LD	2025	2027		|O
,	2027	2028		|O
ranitidine	2029	2039		|O
did	2040	2043		|O
not	2044	2047		|O
affect	2048	2054		|O
the	2055	2058		|O
time	2059	2063		|O
to	2064	2066		|O
,	2066	2067		|O
or	2068	2070		|O
magnitude	2071	2080		|O
of	2081	2083		|O
,	2083	2084		|O
peak	2085	2089		|O
IPA	2090	2093		|O
,	2093	2094		|O
but	2095	2098		|O
did	2099	2102		|O
result	2103	2109		|O
in	2110	2112		|O
a	2113	2114		|O
modest	2115	2121		|O
reduction	2122	2131		|O
at	2132	2134		|O
0.5	2135	2138		|O
h	2139	2140		|O
from	2141	2145		|O
67.4	2146	2150		|O
to	2151	2153		|O
55.1%	2154	2159		|O
(	2160	2161		|O
p	2161	2162		|O
<	2163	2164		|O
0.001	2165	2170		|O
)	2170	2171		|O
.	2171	2172		|O
Ranitidine	2173	2183		|O
did	2184	2187		|O
not	2188	2191		|O
affect	2192	2198		|O
prasugrel	2199	2208		|O
IPA	2209	2212		|O
during	2213	2219		|O
MD	2220	2222		|O
.	2222	2223		|O
For	2224	2227		|O
clopidogrel	2228	2239		|O
,	2239	2240		|O
IPA	2241	2244		|O
was	2245	2248		|O
not	2249	2252		|O
affected	2253	2261		|O
by	2262	2264		|O
ranitidine	2265	2275		|O
.	2275	2276		|O
Prasugrel	2277	2286		|O
and	2287	2290		|O
clopidogrel	2291	2302		|O
were	2303	2307		|O
both	2308	2312		|O
well	2313	2317		|O
-	2317	2318		|O
tolerated	2318	2327		|O
,	2327	2328		|O
with	2329	2333		|O
/	2333	2334		|O
without	2334	2341		|O
ranitidine	2342	2352		|O
.	2352	2353		|O
CONCLUSIONS	2354	2365		|O
:	2365	2366		|O
Results	2367	2374		|O
from	2375	2379		|O
this	2380	2384		|O
study	2385	2390		|O
suggest	2391	2398		|O
that	2399	2403		|O
there	2404	2409		|O
is	2410	2412		|O
no	2413	2415		|O
significant	2416	2427		|O
drug	2428	2432		|O
-	2432	2433		|O
drug	2433	2437		|O
interaction	2438	2449	interaction	|B-DISEASE
between	2450	2457		|O
oral	2458	2462		|O
ranitidine	2463	2473		|O
therapy	2474	2481		|O
and	2482	2485		|O
concomitantly	2486	2499		|O
-	2499	2500		|O
administered	2500	2512		|O
prasugrel	2513	2522		|O
or	2523	2525		|O
clopidogrel	2526	2537		|O
.	2537	2538		|O

### 18851690
Renin	0	5		|O
-	5	6		|O
angiotensin	6	17		|O
-	17	18		|O
aldosterone	18	29		|O
responsiveness	30	44		|O
to	45	47		|O
low	48	51		|O
sodium	52	58		|O
and	59	62		|O
blood	63	68		|O
pressure	69	77		|O
reactivity	78	88		|O
to	89	91		|O
angiotensin	92	103		|O
-	103	104		|O
II	104	106		|O
are	107	110		|O
unrelated	111	120		|O
to	121	123		|O
cholesteryl	124	135		|O
ester	136	141		|O
transfer	142	150		|O
protein	151	158		|O
mass	159	163		|O
in	164	166		|O
healthy	167	174		|O
subjects	175	183		|O
.	183	184		|O
BACKGROUND	186	196		|O
:	196	197		|O
The	198	201		|O
blood	202	207		|O
pressure	208	216		|O
increase	217	225		|O
associated	226	236		|O
with	237	241		|O
the	242	245		|O
cholesteryl	246	257		|O
ester	258	263		|O
transfer	264	272		|O
protein	273	280		|O
(	281	282		|O
CETP	282	286		|O
)	286	287		|O
inhibitor	288	297		|O
,	297	298		|O
torcetrapib	299	310		|O
is	311	313		|O
probably	314	322		|O
attributable	323	335		|O
to	336	338		|O
an	339	341		|O
off	342	345		|O
-	345	346		|O
target	346	352		|O
effect	353	359		|O
but	360	363		|O
it	364	366		|O
is	367	369		|O
unknown	370	377		|O
whether	378	385		|O
activation	386	396		|O
of	397	399		|O
the	400	403		|O
renin	404	409		|O
-	409	410		|O
angiotensin	410	421		|O
-	421	422		|O
aldosterone	422	433		|O
system	434	440		|O
(	441	442		|O
RAAS	442	446		|O
)	446	447		|O
may	448	451		|O
be	452	454		|O
related	455	462		|O
to	463	465		|O
variation	466	475		|O
in	476	478		|O
the	479	482		|O
plasma	483	489		|O
CETP	490	494		|O
level	495	500		|O
.	500	501		|O
We	502	504		|O
questioned	505	515		|O
whether	516	523		|O
the	524	527		|O
plasma	528	534		|O
CETP	535	539		|O
level	540	545		|O
would	546	551		|O
affect	552	558		|O
RAAS	559	563		|O
responsiveness	564	578		|O
to	579	581		|O
low	582	585		|O
sodium	586	592		|O
diet	593	597		|O
and	598	601		|O
the	602	605		|O
blood	606	611		|O
pressure	612	620		|O
response	621	629		|O
to	630	632		|O
angiotensin	633	644		|O
-	644	645		|O
II	645	647		|O
infusion	648	656		|O
in	657	659		|O
healthy	660	667		|O
subjects	668	676		|O
.	676	677		|O
METHODS	678	685		|O
:	685	686		|O
RAAS	687	691		|O
parameters	692	702		|O
and	703	706		|O
blood	707	712		|O
pressure	713	721		|O
were	722	726		|O
determined	727	737		|O
during	738	744		|O
liberal	745	752		|O
sodium	753	759		|O
diet	760	764		|O
(	765	766		|O
200	766	769		|O
mmol	770	774		|O
/	774	775		|O
24	775	777		|O
h	778	779		|O
)	779	780		|O
and	781	784		|O
low	785	788		|O
sodium	789	795		|O
diet	796	800		|O
(	801	802		|O
50	802	804		|O
mmol	805	809		|O
/	809	810		|O
24	810	812		|O
h	813	814		|O
)	814	815		|O
in	816	818		|O
67	819	821		|O
healthy	822	829		|O
men	830	833		|O
.	833	834		|O
Blood	835	840		|O
pressure	841	849		|O
response	850	858		|O
to	859	861		|O
incremental	862	873		|O
angiotensin	874	885		|O
-	885	886		|O
II	886	888		|O
infusion	889	897		|O
was	898	901		|O
assessed	902	910		|O
in	911	913		|O
34	914	916		|O
subjects	917	925		|O
during	926	932		|O
liberal	933	940		|O
sodium	941	947		|O
diet	948	952		|O
.	952	953		|O
Correlation	954	965		|O
analysis	966	974		|O
was	975	978		|O
performed	979	988		|O
to	989	991		|O
test	992	996		|O
whether	997	1004		|O
RAAS	1005	1009		|O
responsiveness	1010	1024		|O
and	1025	1028		|O
blood	1029	1034		|O
pressure	1035	1043		|O
were	1044	1048		|O
related	1049	1056		|O
to	1057	1059		|O
plasma	1060	1066		|O
CETP	1067	1071		|O
mass	1072	1076		|O
,	1076	1077		|O
high	1078	1082		|O
-	1082	1083		|O
density	1083	1090		|O
lipoprotein	1091	1102		|O
-	1102	1103		|O
cholesterol	1103	1114		|O
(	1115	1116		|O
HDL	1116	1119		|O
-	1119	1120		|O
C	1120	1121		|O
)	1121	1122		|O
and	1123	1126		|O
apolipoprotein	1127	1141		|O
A	1142	1143		|O
-	1143	1144		|O
I	1144	1145		|O
measured	1146	1154		|O
during	1155	1161		|O
liberal	1162	1169		|O
sodium	1170	1176		|O
diet	1177	1181		|O
.	1181	1182		|O
RESULTS	1183	1190		|O
:	1190	1191		|O
CETP	1192	1196		|O
mass	1197	1201		|O
ranged	1202	1208		|O
from	1209	1213		|O
1.29	1214	1218		|O
to	1219	1221		|O
2.95	1222	1226		|O
mg	1227	1229		|O
/	1229	1230		|O
l	1230	1231		|O
.	1231	1232		|O
No	1233	1235		|O
significant	1236	1247		|O
differences	1248	1259		|O
in	1260	1262		|O
(	1263	1264		|O
changes	1264	1271		|O
)	1271	1272		|O
in	1273	1275		|O
mean	1276	1280		|O
arterial	1281	1289		|O
pressure	1290	1298		|O
,	1298	1299		|O
aldosterone	1300	1311		|O
and	1312	1315		|O
active	1316	1322		|O
plasma	1323	1329		|O
renin	1330	1335		|O
concentration	1336	1349		|O
in	1350	1352		|O
response	1353	1361		|O
to	1362	1364		|O
low	1365	1368		|O
sodium	1369	1375		|O
were	1376	1380		|O
observed	1381	1389		|O
between	1390	1397		|O
the	1398	1401		|O
lowest	1402	1408		|O
and	1409	1412		|O
highest	1413	1420		|O
tertiles	1421	1429		|O
of	1430	1432		|O
CETP	1433	1437		|O
mass	1438	1442		|O
,	1442	1443		|O
HDL	1444	1447		|O
-	1447	1448		|O
C	1448	1449		|O
and	1450	1453		|O
apolipoprotein	1454	1468		|O
A	1469	1470		|O
-	1470	1471		|O
I	1471	1472		|O
.	1472	1473		|O
These	1474	1479		|O
outcome	1480	1487		|O
variables	1488	1497		|O
were	1498	1502		|O
also	1503	1507		|O
not	1508	1511		|O
significantly	1512	1525		|O
correlated	1526	1536		|O
with	1537	1541		|O
CETP	1542	1546		|O
,	1546	1547		|O
HDL	1548	1551		|O
-	1551	1552		|O
C	1552	1553		|O
and	1554	1557		|O
apolipoprotein	1558	1572		|O
A	1573	1574		|O
-	1574	1575		|O
I	1575	1576		|O
,	1576	1577		|O
except	1578	1584		|O
for	1585	1588		|O
a	1589	1590		|O
modest	1591	1597		|O
relation	1598	1606		|O
of	1607	1609		|O
aldosterone	1610	1621		|O
measured	1622	1630		|O
during	1631	1637		|O
low	1638	1641		|O
sodium	1642	1648		|O
with	1649	1653		|O
apolipoprotein	1654	1668		|O
A	1669	1670		|O
-	1670	1671		|O
I	1671	1672		|O
(	1673	1674		|O
r	1674	1675		|O
=	1676	1677		|O
0.28	1678	1682		|O
,	1682	1683		|O
p	1684	1685		|O
=	1686	1687		|O
0.022	1688	1693		|O
)	1693	1694		|O
.	1694	1695		|O
Blood	1696	1701		|O
pressure	1702	1710		|O
response	1711	1719		|O
to	1720	1722		|O
angiotensin	1723	1734		|O
-	1734	1735		|O
II	1735	1737		|O
was	1738	1741		|O
similar	1742	1749		|O
between	1750	1757		|O
CETP	1758	1762		|O
tertiles	1763	1771		|O
.	1771	1772		|O
CONCLUSIONS	1773	1784		|O
:	1784	1785		|O
Mineralocorticoid	1786	1803		|O
and	1804	1807		|O
blood	1808	1813		|O
pressure	1814	1822		|O
responsiveness	1823	1837		|O
to	1838	1840		|O
dietary	1841	1848		|O
salt	1849	1853		|O
intake	1854	1860		|O
are	1861	1864		|O
not	1865	1868		|O
significantly	1869	1882		|O
related	1883	1890		|O
to	1891	1893		|O
physiological	1894	1907		|O
interindividual	1908	1923		|O
differences	1924	1935		|O
in	1936	1938		|O
plasma	1939	1945		|O
CETP	1946	1950		|O
.	1950	1951		|O
We	1952	1954		|O
suggest	1955	1962		|O
that	1963	1967		|O
a	1968	1969		|O
lower	1970	1975		|O
CETP	1976	1980		|O
mass	1981	1985		|O
does	1986	1990		|O
not	1991	1994		|O
exert	1995	2000		|O
adverse	2001	2008		|O
effects	2009	2016		|O
on	2017	2019		|O
blood	2020	2025		|O
pressure	2026	2034		|O
regulation	2035	2045		|O
.	2045	2046		|O

### 18721116
Riluzole	0	8		|O
in	9	11		|O
psychiatry	12	22		|O
:	22	23		|O
a	24	25		|O
systematic	26	36		|O
review	37	43		|O
of	44	46		|O
the	47	50		|O
literature	51	61		|O
.	61	62		|O
BACKGROUND	64	74		|O
:	74	75		|O
The	76	79		|O
glutamate	80	89		|O
system	90	96		|O
seems	97	102		|O
to	103	105		|O
be	106	108		|O
an	109	111		|O
important	112	121		|O
contributor	122	133		|O
to	134	136		|O
the	137	140		|O
pathophysiology	141	156		|O
of	157	159		|O
mood	160	164		|O
and	165	168		|O
anxiety	169	176	anxiety disorders	|B-DISEASE
disorders	177	186		|I-DISEASE
.	186	187		|O
Thus	188	192		|O
,	192	193		|O
glutamatergic	194	207		|O
modulators	208	218		|O
are	219	222		|O
reasonable	223	233		|O
candidate	234	243		|O
drugs	244	249		|O
to	250	252		|O
test	253	257		|O
in	258	260		|O
patients	261	269		|O
with	270	274		|O
mood	275	279		|O
and	280	283		|O
anxiety	284	291	anxiety disorders	|B-DISEASE
disorders	292	301		|I-DISEASE
.	301	302		|O
Riluzole	303	311		|O
,	311	312		|O
a	313	314		|O
neuroprotective	315	330		|O
agent	331	336		|O
with	337	341		|O
anticonvulsant	342	356		|O
properties	357	367		|O
approved	368	376		|O
for	377	380		|O
the	381	384		|O
treatment	385	394		|O
of	395	397		|O
amyotrophic	398	409	amyotrophic lateral sclerosis	|B-DISEASE
lateral	410	417		|I-DISEASE
sclerosis	418	427		|I-DISEASE
(	428	429		|O
ALS	429	432	ALS	|B-DISEASE
)	432	433		|O
is	434	436		|O
one	437	440		|O
such	441	445		|O
agent	446	451		|O
.	451	452		|O
OBJECTIVE	453	462		|O
:	462	463		|O
To	464	466		|O
assess	467	473		|O
the	474	477		|O
potential	478	487		|O
risks	488	493		|O
and	494	497		|O
benefits	498	506		|O
of	507	509		|O
riluzole	510	518		|O
treatment	519	528		|O
in	529	531		|O
psychiatric	532	543		|O
patients	544	552		|O
.	552	553		|O
METHODS	554	561		|O
:	561	562		|O
A	563	564		|O
PubMed	565	571		|O
search	572	578		|O
was	579	582		|O
performed	583	592		|O
using	593	598		|O
the	599	602		|O
keywords	603	611		|O
'	612	613		|O
riluzole	613	621		|O
'	621	622		|O
,	622	623		|O
'	624	625		|O
inhibitor	625	634		|O
of	635	637		|O
glutamate	638	647		|O
release	648	655		|O
'	655	656		|O
and	657	660		|O
'	661	662		|O
glutamatergic	662	675		|O
modulator	676	685		|O
'	685	686		|O
to	687	689		|O
identify	690	698		|O
all	699	702		|O
clinical	703	711		|O
studies	712	719		|O
and	720	723		|O
case	724	728		|O
reports	729	736		|O
involving	737	746		|O
riluzole	747	755		|O
in	756	758		|O
psychiatric	759	770		|O
patients	771	779		|O
.	779	780		|O
RESULTS	781	788		|O
/	788	789		|O
CONCLUSION	789	799		|O
:	799	800		|O
Riluzole	801	809		|O
's	809	811		|O
side	812	816		|O
effect	817	823		|O
profile	824	831		|O
is	832	834		|O
favorable	835	844		|O
and	845	848		|O
preliminary	849	860		|O
results	861	868		|O
regarding	869	878		|O
riluzole	879	887		|O
for	888	891		|O
the	892	895		|O
treatment	896	905		|O
of	906	908		|O
severe	909	915		|O
mood	916	920		|O
,	920	921		|O
anxiety	922	929	anxiety	|B-DISEASE
and	930	933		|O
impulsive	934	943	impulsive disorders	|B-DISEASE
disorders	944	953		|I-DISEASE
are	954	957		|O
encouraging	958	969		|O
.	969	970		|O

### 18728218
Effect	0	6		|O
of	7	9		|O
calpain	10	17		|O
and	18	21		|O
proteasome	22	32		|O
inhibition	33	43		|O
on	44	46		|O
Ca2+	47	51		|O
-	51	52		|O
dependent	52	61		|O
proteolysis	62	73		|O
and	74	77		|O
muscle	78	84		|O
histopathology	85	99		|O
in	100	102		|O
the	103	106		|O
mdx	107	110		|O
mouse	111	116		|O
.	116	117		|O
Dystrophin	119	129		|O
deficiency	130	140		|O
is	141	143		|O
the	144	147		|O
underlying	148	158		|O
molecular	159	168		|O
cause	169	174		|O
of	175	177		|O
progressive	178	189	progressive muscle weakness	|B-DISEASE
muscle	190	196		|I-DISEASE
weakness	197	205		|I-DISEASE
observed	206	214		|O
in	215	217		|O
Duchenne	218	226	Duchenne muscular dystrophy	|B-DISEASE
muscular	227	235		|I-DISEASE
dystrophy	236	245		|I-DISEASE
(	246	247		|O
DMD	247	250	DMD	|B-DISEASE
)	250	251		|O
.	251	252		|O
Loss	253	257		|O
of	258	260		|O
functional	261	271		|O
dystrophin	272	282		|O
leads	283	288		|O
to	289	291		|O
elevated	292	300		|O
levels	301	307		|O
of	308	310		|O
intracellular	311	324		|O
Ca	325	327		|O
(	327	328		|O
2+	328	330		|O
)	330	331		|O
,	331	332		|O
a	333	334		|O
key	335	338		|O
step	339	343		|O
in	344	346		|O
the	347	350		|O
cellular	351	359		|O
pathology	360	369		|O
of	370	372		|O
DMD	373	376	DMD	|B-DISEASE
.	376	377		|O
The	378	381		|O
cysteine	382	390		|O
protease	391	399		|O
calpain	400	407		|O
is	408	410		|O
activated	411	420		|O
in	421	423		|O
dystrophin	424	434		|O
-	434	435		|O
deficient	435	444		|O
muscle	445	451		|O
,	451	452		|O
and	453	456		|O
its	457	460		|O
inhibition	461	471		|O
is	472	474		|O
regarded	475	483		|O
as	484	486		|O
a	487	488		|O
potential	489	498		|O
therapeutic	499	510		|O
approach	511	519		|O
.	519	520		|O
In	521	523		|O
addition	524	532		|O
,	532	533		|O
previous	534	542		|O
work	543	547		|O
has	548	551		|O
shown	552	557		|O
that	558	562		|O
the	563	566		|O
ubiquitin	567	576		|O
-	576	577		|O
proteasome	577	587		|O
system	588	594		|O
also	595	599		|O
contributes	600	611		|O
to	612	614		|O
muscle	615	621		|O
protein	622	629		|O
breakdown	630	639		|O
in	640	642		|O
dystrophic	643	653		|O
muscle	654	660		|O
and	661	664		|O
,	664	665		|O
therefore	666	675		|O
,	675	676		|O
also	677	681		|O
qualifies	682	691		|O
as	692	694		|O
a	695	696		|O
potential	697	706		|O
target	707	713		|O
for	714	717		|O
therapeutic	718	729		|O
intervention	730	742		|O
in	743	745		|O
DMD	746	749	DMD	|B-DISEASE
.	749	750		|O
The	751	754		|O
relative	755	763		|O
contribution	764	776		|O
of	777	779		|O
calpain	780	787		|O
-	787	788		|O
and	789	792		|O
proteasome	793	803		|O
-	803	804		|O
mediated	804	812		|O
proteolysis	813	824		|O
induced	825	832		|O
by	833	835		|O
increased	836	845		|O
Ca	846	848		|O
(	848	849		|O
2+	849	851		|O
)	851	852		|O
levels	853	859		|O
was	860	863		|O
characterized	864	877		|O
in	878	880		|O
cultured	881	889		|O
muscle	890	896		|O
cells	897	902		|O
and	903	906		|O
revealed	907	915		|O
initial	916	923		|O
Ca	924	926		|O
(	926	927		|O
2+	927	929		|O
)	929	930		|O
influx	931	937		|O
-	937	938		|O
dependent	938	947		|O
calpain	948	955		|O
activity	956	964		|O
and	965	968		|O
subsequent	969	979		|O
Ca	980	982		|O
(	982	983		|O
2+	983	985		|O
)	985	986		|O
-	986	987		|O
independent	987	998		|O
activity	999	1007		|O
of	1008	1010		|O
the	1011	1014		|O
ubiquitin	1015	1024		|O
-	1024	1025		|O
proteasome	1025	1035		|O
system	1036	1042		|O
.	1042	1043		|O
We	1044	1046		|O
then	1047	1051		|O
set	1052	1055		|O
out	1056	1059		|O
to	1060	1062		|O
optimize	1063	1071		|O
novel	1072	1077		|O
small	1078	1083		|O
-	1083	1084		|O
molecule	1084	1092		|O
inhibitors	1093	1103		|O
that	1104	1108		|O
inhibit	1109	1116		|O
both	1117	1121		|O
calpain	1122	1129		|O
as	1130	1132		|O
well	1133	1137		|O
as	1138	1140		|O
the	1141	1144		|O
20S	1145	1148		|O
proteasome	1149	1159		|O
in	1160	1162		|O
a	1163	1164		|O
cellular	1165	1173		|O
system	1174	1180		|O
with	1181	1185		|O
impaired	1186	1194		|O
Ca	1195	1197		|O
(	1197	1198		|O
2+	1198	1200		|O
)	1200	1201		|O
homeostasis	1202	1213		|O
.	1213	1214		|O
On	1215	1217		|O
administration	1218	1232		|O
of	1233	1235		|O
such	1236	1240		|O
inhibitors	1241	1251		|O
to	1252	1254		|O
mdx	1255	1258		|O
mice	1259	1263		|O
,	1263	1264		|O
quantitative	1265	1277		|O
histological	1278	1290		|O
parameters	1291	1301		|O
improved	1302	1310		|O
significantly	1311	1324		|O
,	1324	1325		|O
in	1326	1328		|O
particular	1329	1339		|O
with	1340	1344		|O
compounds	1345	1354		|O
strongly	1355	1363		|O
inhibiting	1364	1374		|O
the	1375	1378		|O
20S	1379	1382		|O
proteasome	1383	1393		|O
.	1393	1394		|O
To	1395	1397		|O
investigate	1398	1409		|O
the	1410	1413		|O
role	1414	1418		|O
of	1419	1421		|O
calpain	1422	1429		|O
inhibition	1430	1440		|O
without	1441	1448		|O
interfering	1449	1460		|O
with	1461	1465		|O
the	1466	1469		|O
ubiquitin	1470	1479		|O
-	1479	1480		|O
proteasome	1480	1490		|O
system	1491	1497		|O
,	1497	1498		|O
we	1499	1501		|O
crossed	1502	1509		|O
mdx	1510	1513		|O
mice	1514	1518		|O
with	1519	1523		|O
transgenic	1524	1534		|O
mice	1535	1539		|O
,	1539	1540		|O
overexpressing	1541	1555		|O
the	1556	1559		|O
endogenous	1560	1570		|O
calpain	1571	1578		|O
inhibitor	1579	1588		|O
calpastatin	1589	1600		|O
.	1600	1601		|O
Although	1602	1610		|O
our	1611	1614		|O
data	1615	1619		|O
show	1620	1624		|O
that	1625	1629		|O
proteolysis	1630	1641		|O
by	1642	1644		|O
calpain	1645	1652		|O
is	1653	1655		|O
strongly	1656	1664		|O
inhibited	1665	1674		|O
in	1675	1677		|O
the	1678	1681		|O
transgenic	1682	1692		|O
mdx	1693	1696		|O
mouse	1697	1702		|O
,	1702	1703		|O
this	1704	1708		|O
calpain	1709	1716		|O
inhibition	1717	1727		|O
did	1728	1731		|O
not	1732	1735		|O
ameliorate	1736	1746		|O
muscle	1747	1753		|O
histology	1754	1763		|O
.	1763	1764		|O
Our	1765	1768		|O
results	1769	1776		|O
indicate	1777	1785		|O
that	1786	1790		|O
inhibition	1791	1801		|O
of	1802	1804		|O
the	1805	1808		|O
proteasome	1809	1819		|O
rather	1820	1826		|O
than	1827	1831		|O
calpain	1832	1839		|O
is	1840	1842		|O
required	1843	1851		|O
for	1852	1855		|O
histological	1856	1868		|O
improvement	1869	1880		|O
of	1881	1883		|O
dystrophin	1884	1894		|O
-	1894	1895		|O
deficient	1895	1904		|O
muscle	1905	1911		|O
.	1911	1912		|O
In	1913	1915		|O
conclusion	1916	1926		|O
,	1926	1927		|O
we	1928	1930		|O
have	1931	1935		|O
identified	1936	1946		|O
novel	1947	1952		|O
proteasome	1953	1963		|O
inhibitors	1964	1974		|O
that	1975	1979		|O
qualify	1980	1987		|O
as	1988	1990		|O
potential	1991	2000		|O
candidates	2001	2011		|O
for	2012	2015		|O
pharmacological	2016	2031		|O
intervention	2032	2044		|O
in	2045	2047		|O
muscular	2048	2056	muscular dystrophy	|B-DISEASE
dystrophy	2057	2066		|I-DISEASE
.	2066	2067		|O

### 18755159
7	0	1		|O
-	1	2		|O
Deaza	2	7		|O
-	7	8		|O
6	8	9		|O
-	9	10		|O
benzylthioinosine	10	27		|O
analogues	28	37		|O
as	38	40		|O
subversive	41	51		|O
substrate	52	61		|O
of	62	64		|O
Toxoplasma	65	75		|O
gondii	76	82		|O
adenosine	83	92		|O
kinase	93	99		|O
:	99	100		|O
activities	101	111		|O
and	112	115		|O
selective	116	125		|O
toxicities	126	136		|O
.	136	137		|O
Toxoplasma	139	149		|O
gondii	150	156		|O
adenosine	157	166		|O
kinase	167	173		|O
(	174	175		|O
EC	175	177		|O
.2	177	179		|O
.7	179	181		|O
.1	181	183		|O
.20	183	186		|O
)	186	187		|O
is	188	190		|O
the	191	194		|O
major	195	200		|O
route	201	206		|O
of	207	209		|O
adenosine	210	219		|O
metabolism	220	230		|O
in	231	233		|O
this	234	238		|O
parasite	239	247		|O
.	247	248		|O
The	249	252		|O
enzyme	253	259		|O
is	260	262		|O
significantly	263	276		|O
more	277	281		|O
active	282	288		|O
than	289	293		|O
any	294	297		|O
other	298	303		|O
enzyme	304	310		|O
of	311	313		|O
the	314	317		|O
purine	318	324		|O
salvage	325	332		|O
in	333	335		|O
T	336	337		|O
.	337	338		|O
gondii	339	345		|O
and	346	349		|O
has	350	353		|O
been	354	358		|O
established	359	370		|O
as	371	373		|O
a	374	375		|O
potential	376	385		|O
chemotherapeutic	386	402		|O
target	403	409		|O
for	410	413		|O
the	414	417		|O
treatment	418	427		|O
of	428	430		|O
toxoplasmosis	431	444	toxoplasmosis	|B-DISEASE
.	444	445		|O
Certain	446	453		|O
6	454	455		|O
-	455	456		|O
benzylthioinosines	456	474		|O
act	475	478		|O
as	479	481		|O
subversive	482	492		|O
substrates	493	503		|O
of	504	506		|O
T	507	508		|O
.	508	509		|O
gondii	510	516		|O
,	516	517		|O
but	518	521		|O
not	522	525		|O
human	526	531		|O
,	531	532		|O
adenosine	533	542		|O
kinase	543	549		|O
.	549	550		|O
Therefore	551	560		|O
,	560	561		|O
these	562	567		|O
compounds	568	577		|O
are	578	581		|O
preferentially	582	596		|O
metabolized	597	608		|O
to	609	611		|O
their	612	617		|O
respective	618	628		|O
nucleotides	629	640		|O
and	641	644		|O
become	645	651		|O
selectively	652	663		|O
toxic	664	669		|O
against	670	677		|O
the	678	681		|O
parasites	682	691		|O
but	692	695		|O
not	696	699		|O
their	700	705		|O
host	706	710		|O
.	710	711		|O
Moreover	712	720		|O
,	720	721		|O
7	722	723		|O
-	723	724		|O
deazaadenosine	724	738		|O
(	739	740		|O
tubercidin	740	750		|O
)	750	751		|O
was	752	755		|O
shown	756	761		|O
to	762	764		|O
be	765	767		|O
an	768	770		|O
excellent	771	780		|O
ligand	781	787		|O
of	788	790		|O
T	791	792		|O
.	792	793		|O
gondii	794	800		|O
adenosine	801	810		|O
kinase	811	817		|O
.	817	818		|O
Therefore	819	828		|O
,	828	829		|O
we	830	832		|O
synthesized	833	844		|O
7	845	846		|O
-	846	847		|O
deaza	847	852		|O
-	852	853		|O
6	853	854		|O
-	854	855		|O
benzylthioinosine	855	872		|O
,	872	873		|O
and	874	877		|O
analogues	878	887		|O
with	888	892		|O
various	893	900		|O
substitutions	901	914		|O
at	915	917		|O
their	918	923		|O
phenyl	924	930		|O
ring	931	935		|O
,	935	936		|O
to	937	939		|O
increase	940	948		|O
the	949	952		|O
binding	953	960		|O
affinity	961	969		|O
of	970	972		|O
the	973	976		|O
6	977	978		|O
-	978	979		|O
benzylthioinosines	979	997		|O
to	998	1000		|O
T	1001	1002		|O
.	1002	1003		|O
gondii	1004	1010		|O
adenosine	1011	1020		|O
kinase	1021	1027		|O
.	1027	1028		|O
Indeed	1029	1035		|O
,	1035	1036		|O
the	1037	1040		|O
7	1041	1042		|O
-	1042	1043		|O
deaza	1043	1048		|O
-	1048	1049		|O
6	1049	1050		|O
-	1050	1051		|O
benzylthioinosine	1051	1068		|O
analogues	1069	1078		|O
were	1079	1083		|O
better	1084	1090		|O
ligands	1091	1098		|O
of	1099	1101		|O
T	1102	1103		|O
.	1103	1104		|O
gondii	1105	1111		|O
adenosine	1112	1121		|O
kinase	1122	1128		|O
than	1129	1133		|O
the	1134	1137		|O
parent	1138	1144		|O
compounds	1145	1154		|O
,	1154	1155		|O
6	1156	1157		|O
-	1157	1158		|O
benzylthioinosine	1158	1175		|O
and	1176	1179		|O
7	1180	1181		|O
-	1181	1182		|O
deazainosine	1182	1194		|O
.	1194	1195		|O
Herein	1196	1202		|O
,	1202	1203		|O
we	1204	1206		|O
report	1207	1213		|O
the	1214	1217		|O
testing	1218	1225		|O
of	1226	1228		|O
the	1229	1232		|O
metabolism	1233	1243		|O
of	1244	1246		|O
these	1247	1252		|O
newly	1253	1258		|O
synthesized	1259	1270		|O
7	1271	1272		|O
-	1272	1273		|O
deaza	1273	1278		|O
-	1278	1279		|O
6	1279	1280		|O
-	1280	1281		|O
benzylthioinosines	1281	1299		|O
,	1299	1300		|O
as	1301	1303		|O
well	1304	1308		|O
as	1309	1311		|O
their	1312	1317		|O
efficacy	1318	1326		|O
as	1327	1329		|O
anti	1330	1334		|O
-	1334	1335		|O
toxoplasmic	1335	1346		|O
agents	1347	1353		|O
in	1354	1356		|O
cell	1357	1361		|O
culture	1362	1369		|O
.	1369	1370		|O
All	1371	1374		|O
the	1375	1378		|O
7	1379	1380		|O
-	1380	1381		|O
deaza	1381	1386		|O
-	1386	1387		|O
6	1387	1388		|O
-	1388	1389		|O
benzylthioinosine	1389	1406		|O
analogues	1407	1416		|O
were	1417	1421		|O
metabolized	1422	1433		|O
to	1434	1436		|O
their	1437	1442		|O
5'	1443	1445		|O
-	1445	1446		|O
monophosphate	1446	1459		|O
derivatives	1460	1471		|O
,	1471	1472		|O
albeit	1473	1479		|O
to	1480	1482		|O
different	1483	1492		|O
degrees	1493	1500		|O
.	1500	1501		|O
These	1502	1507		|O
results	1508	1515		|O
indicate	1516	1524		|O
that	1525	1529		|O
these	1530	1535		|O
compounds	1536	1545		|O
are	1546	1549		|O
not	1550	1553		|O
only	1554	1558		|O
ligands	1559	1566		|O
but	1567	1570		|O
also	1571	1575		|O
substrates	1576	1586		|O
of	1587	1589		|O
T	1590	1591		|O
.	1591	1592		|O
gondii	1593	1599		|O
adenosine	1600	1609		|O
kinase	1610	1616		|O
.	1616	1617		|O
All	1618	1621		|O
the	1622	1625		|O
7	1626	1627		|O
-	1627	1628		|O
deaza	1628	1633		|O
-	1633	1634		|O
6	1634	1635		|O
-	1635	1636		|O
benzylthioinosine	1636	1653		|O
analogues	1654	1663		|O
showed	1664	1670		|O
a	1671	1672		|O
selective	1673	1682		|O
antitoxoplasmic	1683	1698		|O
effect	1699	1705		|O
against	1706	1713		|O
wild	1714	1718		|O
type	1719	1723		|O
parasites	1724	1733		|O
,	1733	1734		|O
but	1735	1738		|O
not	1739	1742		|O
mutants	1743	1750		|O
lacking	1751	1758		|O
adenosine	1759	1768		|O
kinase	1769	1775		|O
.	1775	1776		|O
The	1777	1780		|O
efficacy	1781	1789		|O
of	1790	1792		|O
these	1793	1798		|O
compounds	1799	1808		|O
varied	1809	1815		|O
with	1816	1820		|O
the	1821	1824		|O
position	1825	1833		|O
and	1834	1837		|O
nature	1838	1844		|O
of	1845	1847		|O
the	1848	1851		|O
substitution	1852	1864		|O
on	1865	1867		|O
their	1868	1873		|O
phenyl	1874	1880		|O
ring	1881	1885		|O
.	1885	1886		|O
Moreover	1887	1895		|O
,	1895	1896		|O
none	1897	1901		|O
of	1902	1904		|O
these	1905	1910		|O
analogues	1911	1920		|O
exhibited	1921	1930		|O
host	1931	1935		|O
toxicity	1936	1944		|O
.	1944	1945		|O
The	1946	1949		|O
best	1950	1954		|O
compounds	1955	1964		|O
were	1965	1969		|O
7	1970	1971		|O
-	1971	1972		|O
deaza	1972	1977		|O
-	1977	1978		|O
6	1978	1979		|O
-	1979	1980		|O
(	1980	1981		|O
p	1981	1982		|O
-	1982	1983		|O
methoxybenzylthio	1983	2000		|O
)	2000	2001		|O
inosine	2001	2008		|O
(	2009	2010		|O
IC	2010	2012		|O
(	2012	2013		|O
50	2013	2015		|O
)	2015	2016		|O
=	2016	2017		|O
4.6	2017	2020		|O
microM	2021	2027		|O
)	2027	2028		|O
,	2028	2029		|O
7	2030	2031		|O
-	2031	2032		|O
deaza	2032	2037		|O
-	2037	2038		|O
6	2038	2039		|O
-	2039	2040		|O
(	2040	2041		|O
p	2041	2042		|O
-	2042	2043		|O
methoxycarbonylbenzylthio	2043	2068		|O
)	2068	2069		|O
inosine	2069	2076		|O
(	2077	2078		|O
IC	2078	2080		|O
(	2080	2081		|O
50	2081	2083		|O
)	2083	2084		|O
=	2084	2085		|O
5.0	2085	2088		|O
microM	2089	2095		|O
)	2095	2096		|O
,	2096	2097		|O
and	2098	2101		|O
7	2102	2103		|O
-	2103	2104		|O
deaza	2104	2109		|O
-	2109	2110		|O
6	2110	2111		|O
-	2111	2112		|O
(	2112	2113		|O
p	2113	2114		|O
-	2114	2115		|O
cyanobenzylthio	2115	2130		|O
)	2130	2131		|O
inosine	2131	2138		|O
(	2139	2140		|O
IC	2140	2142		|O
(	2142	2143		|O
50	2143	2145		|O
)	2145	2146		|O
=	2146	2147		|O
5.3	2147	2150		|O
microM	2151	2157		|O
)	2157	2158		|O
.	2158	2159		|O
These	2160	2165		|O
results	2166	2173		|O
further	2174	2181		|O
confirm	2182	2189		|O
that	2190	2194		|O
T	2195	2196		|O
.	2196	2197		|O
gondii	2198	2204		|O
adenosine	2205	2214		|O
kinase	2215	2221		|O
is	2222	2224		|O
an	2225	2227		|O
excellent	2228	2237		|O
target	2238	2244		|O
for	2245	2248		|O
chemotherapy	2249	2261		|O
and	2262	2265		|O
that	2266	2270		|O
7	2271	2272		|O
-	2272	2273		|O
deaza	2273	2278		|O
-	2278	2279		|O
6	2279	2280		|O
-	2280	2281		|O
benzylthioinosines	2281	2299		|O
are	2300	2303		|O
potential	2304	2313		|O
antitoxoplasmic	2314	2329		|O
agents	2330	2336		|O
.	2336	2337		|O

### 18687753
Enhanced	0	8		|O
PDE4B	9	14		|O
expression	15	25		|O
augments	26	34		|O
LPS	35	38		|O
-	38	39		|O
inducible	39	48		|O
TNF	49	52		|O
expression	53	63		|O
in	64	66		|O
ethanol	67	74		|O
-	74	75		|O
primed	75	81		|O
monocytes	82	91		|O
:	91	92		|O
relevance	93	102		|O
to	103	105		|O
alcoholic	106	115	alcoholic liver disease	|B-DISEASE
liver	116	121		|I-DISEASE
disease	122	129		|I-DISEASE
.	129	130		|O
Increased	132	141		|O
plasma	142	148		|O
and	149	152		|O
hepatic	153	160		|O
TNF	161	164		|O
-	164	165		|O
alpha	165	170		|O
expression	171	181		|O
is	182	184		|O
well	185	189		|O
documented	190	200		|O
in	201	203		|O
patients	204	212		|O
with	213	217		|O
alcoholic	218	227	alcoholic hepatitis	|B-DISEASE
hepatitis	228	237		|I-DISEASE
and	238	241		|O
is	242	244		|O
implicated	245	255		|O
in	256	258		|O
the	259	262		|O
pathogenesis	263	275		|O
of	276	278		|O
alcoholic	279	288	alcoholic liver disease	|B-DISEASE
liver	289	294		|I-DISEASE
disease	295	302		|I-DISEASE
.	302	303		|O
We	304	306		|O
have	307	311		|O
previously	312	322		|O
shown	323	328		|O
that	329	333		|O
monocytes	334	343		|O
from	344	348		|O
patients	349	357		|O
with	358	362		|O
alcoholic	363	372	alcoholic hepatitis	|B-DISEASE
hepatitis	373	382		|I-DISEASE
show	383	387		|O
increased	388	397		|O
constitutive	398	410		|O
and	411	414		|O
LPS	415	418		|O
-	418	419		|O
induced	419	426		|O
NF	427	429		|O
-	429	430		|O
kappaB	430	436		|O
activation	437	447		|O
and	448	451		|O
TNF	452	455		|O
-	455	456		|O
alpha	456	461		|O
production	462	472		|O
.	472	473		|O
Our	474	477		|O
recent	478	484		|O
studies	485	492		|O
showed	493	499		|O
that	500	504		|O
chronic	505	512		|O
ethanol	513	520		|O
exposure	521	529		|O
significantly	530	543		|O
decreased	544	553		|O
cellular	554	562		|O
cAMP	563	567		|O
levels	568	574		|O
in	575	577		|O
both	578	582		|O
LPS	583	586		|O
-	586	587		|O
stimulated	587	597		|O
and	598	601		|O
unstimulated	602	614		|O
monocytes	615	624		|O
and	625	628		|O
Kupffer	629	636		|O
cells	637	642		|O
,	642	643		|O
leading	644	651		|O
to	652	654		|O
an	655	657		|O
increase	658	666		|O
in	667	669		|O
LPS	670	673		|O
-	673	674		|O
inducible	674	683		|O
TNF	684	687		|O
-	687	688		|O
alpha	688	693		|O
production	694	704		|O
by	705	707		|O
affecting	708	717		|O
NF	718	720		|O
-	720	721		|O
kappaB	721	727		|O
activation	728	738		|O
and	739	742		|O
induction	743	752		|O
of	753	755		|O
TNF	756	759		|O
mRNA	760	764		|O
expression	765	775		|O
.	775	776		|O
Accordingly	777	788		|O
,	788	789		|O
the	790	793		|O
mechanisms	794	804		|O
underlying	805	815		|O
this	816	820		|O
ethanol	821	828		|O
-	828	829		|O
induced	829	836		|O
decrease	837	845		|O
in	846	848		|O
cellular	849	857		|O
cAMP	858	862		|O
leading	863	870		|O
to	871	873		|O
an	874	876		|O
increase	877	885		|O
in	886	888		|O
TNF	889	892		|O
expression	893	903		|O
were	904	908		|O
examined	909	917		|O
in	918	920		|O
monocytes	921	930		|O
/	930	931		|O
macrophages	931	942		|O
.	942	943		|O
In	944	946		|O
this	947	951		|O
study	952	957		|O
,	957	958		|O
chronic	959	966		|O
ethanol	967	974		|O
exposure	975	983		|O
was	984	987		|O
observed	988	996		|O
to	997	999		|O
significantly	1000	1013		|O
increase	1014	1022		|O
LPS	1023	1026		|O
-	1026	1027		|O
inducible	1027	1036		|O
expression	1037	1047		|O
of	1048	1050		|O
cAMP	1051	1055		|O
-	1055	1056		|O
specific	1056	1064		|O
phosphodiesterase	1065	1082		|O
(	1083	1084		|O
PDE	1084	1087		|O
)	1087	1088		|O
4B	1088	1090		|O
that	1091	1095		|O
degrades	1096	1104		|O
cellular	1105	1113		|O
cAMP	1114	1118		|O
.	1118	1119		|O
Increased	1120	1129		|O
PDE4B	1130	1135		|O
expression	1136	1146		|O
was	1147	1150		|O
associated	1151	1161		|O
with	1162	1166		|O
enhanced	1167	1175		|O
NF	1176	1178		|O
-	1178	1179		|O
kappaB	1179	1185		|O
activation	1186	1196		|O
and	1197	1200		|O
transcriptional	1201	1216		|O
activity	1217	1225		|O
and	1226	1229		|O
subsequent	1230	1240		|O
priming	1241	1248		|O
of	1249	1251		|O
monocytes	1252	1261		|O
/	1261	1262		|O
macrophages	1262	1273		|O
leading	1274	1281		|O
to	1282	1284		|O
enhanced	1285	1293		|O
LPS	1294	1297		|O
-	1297	1298		|O
inducible	1298	1307		|O
TNF	1308	1311		|O
-	1311	1312		|O
alpha	1312	1317		|O
production	1318	1328		|O
.	1328	1329		|O
Selective	1330	1339		|O
inhibition	1340	1350		|O
of	1351	1353		|O
PDE4	1354	1358		|O
by	1359	1361		|O
rolipram	1362	1370		|O
abrogated	1371	1380		|O
LPS	1381	1384		|O
-	1384	1385		|O
mediated	1385	1393		|O
TNF	1394	1397		|O
-	1397	1398		|O
alpha	1398	1403		|O
expression	1404	1414		|O
at	1415	1417		|O
both	1418	1422		|O
protein	1423	1430		|O
and	1431	1434		|O
mRNA	1435	1439		|O
levels	1440	1446		|O
in	1447	1449		|O
control	1450	1457		|O
and	1458	1461		|O
ethanol	1462	1469		|O
-	1469	1470		|O
treated	1470	1477		|O
cells	1478	1483		|O
.	1483	1484		|O
Notably	1485	1492		|O
,	1492	1493		|O
PDE4	1494	1498		|O
inhibition	1499	1509		|O
did	1510	1513		|O
not	1514	1517		|O
affect	1518	1524		|O
LPS	1525	1528		|O
-	1528	1529		|O
inducible	1529	1538		|O
NF	1539	1541		|O
-	1541	1542		|O
kappaB	1542	1548		|O
activation	1549	1559		|O
but	1560	1563		|O
significantly	1564	1577		|O
decreased	1578	1587		|O
NF	1588	1590		|O
-	1590	1591		|O
kappaB	1591	1597		|O
transcriptional	1598	1613		|O
activity	1614	1622		|O
.	1622	1623		|O
These	1624	1629		|O
findings	1630	1638		|O
strongly	1639	1647		|O
support	1648	1655		|O
the	1656	1659		|O
pathogenic	1660	1670		|O
role	1671	1675		|O
of	1676	1678		|O
PDE4B	1679	1684		|O
in	1685	1687		|O
the	1688	1691		|O
ethanol	1692	1699		|O
-	1699	1700		|O
mediated	1700	1708		|O
priming	1709	1716		|O
of	1717	1719		|O
monocytes	1720	1729		|O
/	1729	1730		|O
macrophages	1730	1741		|O
and	1742	1745		|O
increased	1746	1755		|O
LPS	1756	1759		|O
-	1759	1760		|O
inducible	1760	1769		|O
TNF	1770	1773		|O
production	1774	1784		|O
and	1785	1788		|O
the	1789	1792		|O
subsequent	1793	1803		|O
development	1804	1815		|O
of	1816	1818		|O
alcoholic	1819	1828	alcoholic liver disease	|B-DISEASE
liver	1829	1834		|I-DISEASE
disease	1835	1842		|I-DISEASE
(	1843	1844		|O
ALD	1844	1847	ALD	|B-DISEASE
)	1847	1848		|O
.	1848	1849		|O
Since	1850	1855		|O
enhanced	1856	1864		|O
TNF	1865	1868		|O
expression	1869	1879		|O
plays	1880	1885		|O
a	1886	1887		|O
significant	1888	1899		|O
role	1900	1904		|O
in	1905	1907		|O
the	1908	1911		|O
evolution	1912	1921		|O
of	1922	1924		|O
clinical	1925	1933		|O
and	1934	1937		|O
experimental	1938	1950		|O
ALD	1951	1954	ALD	|B-DISEASE
,	1954	1955		|O
its	1956	1959		|O
downregulation	1960	1974		|O
via	1975	1978		|O
selective	1979	1988		|O
PDE4B	1989	1994		|O
inhibitors	1995	2005		|O
could	2006	2011		|O
constitute	2012	2022		|O
a	2023	2024		|O
novel	2025	2030		|O
therapeutic	2031	2042		|O
approach	2043	2051		|O
in	2052	2054		|O
the	2055	2058		|O
treatment	2059	2068		|O
of	2069	2071		|O
ALD	2072	2075	ALD	|B-DISEASE
.	2075	2076		|O

### 18776152
The	0	3		|O
safety	4	10		|O
of	11	13		|O
long	14	18		|O
-	18	19		|O
acting	19	25		|O
beta	26	30		|O
-	30	31		|O
agonists	31	39		|O
among	40	45		|O
patients	46	54		|O
with	55	59		|O
asthma	60	66	asthma	|B-DISEASE
using	67	72		|O
inhaled	73	80		|O
corticosteroids	81	96		|O
:	96	97		|O
systematic	98	108		|O
review	109	115		|O
and	116	119		|O
metaanalysis	120	132		|O
.	132	133		|O
RATIONALE	135	144		|O
:	144	145		|O
Inhaled	146	153		|O
long	154	158		|O
-	158	159		|O
acting	159	165		|O
beta	166	170		|O
-	170	171		|O
agonists	171	179		|O
(	180	181		|O
LABAs	181	186		|O
)	186	187		|O
,	187	188		|O
when	189	193		|O
used	194	198		|O
as	199	201		|O
monotherapy	202	213		|O
in	214	216		|O
asthma	217	223	asthma	|B-DISEASE
,	223	224		|O
may	225	228		|O
increase	229	237		|O
asthma	238	244		|O
-	244	245		|O
related	245	252		|O
hospitalizations	253	269		|O
,	269	270		|O
life	271	275		|O
threatening	276	287		|O
events	288	294		|O
requiring	295	304		|O
intubation	305	315		|O
/	315	316		|O
mechanical	316	326		|O
ventilation	327	338		|O
,	338	339		|O
and	340	343		|O
asthma	344	350		|O
-	350	351		|O
related	351	358		|O
deaths	359	365		|O
,	365	366		|O
but	367	370		|O
concomitant	371	382		|O
use	383	386		|O
of	387	389		|O
inhaled	390	397		|O
corticosteroids	398	413		|O
(	414	415		|O
ICS	415	418		|O
)	418	419		|O
may	420	423		|O
modify	424	430		|O
this	431	435		|O
effect	436	442		|O
.	442	443		|O
Objectives	444	454		|O
:	454	455		|O
To	456	458		|O
determine	459	468		|O
the	469	472		|O
safety	473	479		|O
of	480	482		|O
long	483	487		|O
-	487	488		|O
acting	488	494		|O
beta	495	499		|O
-	499	500		|O
agonists	500	508		|O
among	509	514		|O
patients	515	523		|O
with	524	528		|O
asthma	529	535	asthma	|B-DISEASE
using	536	541		|O
corticosteroids	542	557		|O
.	557	558		|O
METHODS	559	566		|O
:	566	567		|O
We	568	570		|O
conducted	571	580		|O
a	581	582		|O
systematic	583	593		|O
review	594	600		|O
and	601	604		|O
metaanalysis	605	617		|O
of	618	620		|O
parallel	621	629		|O
-	629	630		|O
group	630	635		|O
,	635	636		|O
blinded	637	644		|O
,	644	645		|O
randomized	646	656		|O
,	656	657		|O
controlled	658	668		|O
trials	669	675		|O
with	676	680		|O
at	681	683		|O
least	684	689		|O
12	690	692		|O
weeks	693	698		|O
of	699	701		|O
treatment	702	711		|O
addressing	712	722		|O
the	723	726		|O
impact	727	733		|O
of	734	736		|O
LABA	737	741		|O
on	742	744		|O
asthma	745	751	asthma	|B-DISEASE
-	751	752		|O
related	752	759		|O
and	760	763		|O
total	764	769		|O
morbidity	770	779		|O
and	780	783		|O
mortality	784	793		|O
in	794	796		|O
patients	797	805		|O
concomitantly	806	819		|O
using	820	825		|O
ICS	826	829		|O
.	829	830		|O
We	831	833		|O
searched	834	842		|O
MEDLINE	843	850		|O
,	850	851		|O
EMBASE	852	858		|O
,	858	859		|O
ACPJC	860	865		|O
,	865	866		|O
and	867	870		|O
Cochrane	871	879		|O
(	880	881		|O
Central	881	888		|O
)	888	889		|O
databases	890	899		|O
,	899	900		|O
and	901	904		|O
contacted	905	914		|O
authors	915	922		|O
and	923	926		|O
sponsors	927	935		|O
.	935	936		|O
MEASUREMENTS	937	949		|O
AND	950	953		|O
MAIN	954	958		|O
RESULTS	959	966		|O
:	966	967		|O
We	968	970		|O
used	971	975		|O
a	976	977		|O
random	978	984		|O
effects	985	992		|O
model	993	998		|O
to	999	1001		|O
pool	1002	1006		|O
results	1007	1014		|O
from	1015	1019		|O
different	1020	1029		|O
studies	1030	1037		|O
as	1038	1040		|O
odds	1041	1045		|O
ratios	1046	1052		|O
(	1053	1054		|O
ORs	1054	1057		|O
)	1057	1058		|O
(	1059	1060		|O
95%	1060	1063		|O
confidence	1064	1074		|O
interval	1075	1083		|O
[	1084	1085		|O
CI	1085	1087		|O
]	1087	1088		|O
)	1088	1089		|O
(	1090	1091		|O
OR	1091	1093		|O
<	1094	1095		|O
1.0	1096	1099		|O
favors	1100	1106		|O
LABA	1107	1111		|O
)	1111	1112		|O
.	1112	1113		|O
The	1114	1117		|O
search	1118	1124		|O
yielded	1125	1132		|O
62	1133	1135		|O
relevant	1136	1144		|O
studies	1145	1152		|O
included	1153	1161		|O
in	1162	1164		|O
this	1165	1169		|O
analysis	1170	1178		|O
.	1178	1179		|O
Among	1180	1185		|O
over	1186	1190		|O
29,000	1191	1197		|O
participants	1198	1210		|O
(	1211	1212		|O
15,710	1212	1218		|O
taking	1219	1225		|O
LABA	1226	1230		|O
,	1230	1231		|O
with	1232	1236		|O
over	1237	1241		|O
8,000	1242	1247		|O
patient	1248	1255		|O
-	1255	1256		|O
years	1256	1261		|O
observed	1262	1270		|O
in	1271	1273		|O
the	1274	1277		|O
LABA	1278	1282		|O
groups	1283	1289		|O
)	1289	1290		|O
,	1290	1291		|O
there	1292	1297		|O
were	1298	1302		|O
three	1303	1308		|O
asthma	1309	1315	asthma	|B-DISEASE
-	1315	1316		|O
related	1316	1323		|O
deaths	1324	1330		|O
and	1331	1334		|O
two	1335	1338		|O
asthma	1339	1345	asthma	|B-DISEASE
-	1345	1346		|O
related	1346	1353		|O
,	1353	1354		|O
nonfatal	1355	1363		|O
intubations	1364	1375		|O
(	1376	1377		|O
all	1377	1380		|O
in	1381	1383		|O
LABA	1384	1388		|O
groups	1389	1395		|O
;	1395	1396		|O
<	1397	1398		|O
or	1398	1400		|O
=	1400	1401		|O
one	1402	1405		|O
event	1406	1411		|O
per	1412	1415		|O
study	1416	1421		|O
)	1421	1422		|O
.	1422	1423		|O
Differences	1424	1435		|O
in	1436	1438		|O
asthma	1439	1445		|O
-	1445	1446		|O
related	1446	1453		|O
hospitalizations	1454	1470		|O
(	1471	1472		|O
OR	1472	1474		|O
,	1474	1475		|O
0.74	1476	1480		|O
;	1480	1481		|O
95%	1482	1485		|O
CI	1486	1488		|O
,	1488	1489		|O
0.53-1.03	1490	1499		|O
)	1499	1500		|O
and	1501	1504		|O
asthma	1505	1511		|O
-	1511	1512		|O
related	1512	1519		|O
serious	1520	1527		|O
adverse	1528	1535		|O
events	1536	1542		|O
(	1543	1544		|O
mostly	1544	1550		|O
hospitalizations	1551	1567		|O
;	1567	1568		|O
OR	1569	1571		|O
,	1571	1572		|O
0.75	1573	1577		|O
;	1577	1578		|O
95%	1579	1582		|O
CI	1583	1585		|O
,	1585	1586		|O
0.54-1.03	1587	1596		|O
)	1596	1597		|O
failed	1598	1604		|O
to	1605	1607		|O
reach	1608	1613		|O
statistical	1614	1625		|O
significance	1626	1638		|O
.	1638	1639		|O
The	1640	1643		|O
OR	1644	1646		|O
for	1647	1650		|O
total	1651	1656		|O
mortality	1657	1666		|O
was	1667	1670		|O
1.26	1671	1675		|O
(	1676	1677		|O
95%	1677	1680		|O
CI	1681	1683		|O
,	1683	1684		|O
0.58-2.74	1685	1694		|O
)	1694	1695		|O
,	1695	1696		|O
reflecting	1697	1707		|O
14	1708	1710		|O
deaths	1711	1717		|O
in	1718	1720		|O
LABA	1721	1725		|O
groups	1726	1732		|O
and	1733	1736		|O
eight	1737	1742		|O
deaths	1743	1749		|O
in	1750	1752		|O
control	1753	1760		|O
groups	1761	1767		|O
,	1767	1768		|O
respectively	1769	1781		|O
.	1781	1782		|O
CONCLUSIONS	1783	1794		|O
:	1794	1795		|O
In	1796	1798		|O
patients	1799	1807		|O
with	1808	1812		|O
asthma	1813	1819	asthma	|B-DISEASE
using	1820	1825		|O
ICS	1826	1829		|O
,	1829	1830		|O
LABA	1831	1835		|O
did	1836	1839		|O
not	1840	1843		|O
increase	1844	1852		|O
the	1853	1856		|O
risk	1857	1861		|O
of	1862	1864		|O
asthma	1865	1871		|O
-	1871	1872		|O
related	1872	1879		|O
hospitalizations	1880	1896		|O
.	1896	1897		|O
There	1898	1903		|O
were	1904	1908		|O
very	1909	1913		|O
few	1914	1917		|O
asthma	1918	1924		|O
-	1924	1925		|O
related	1925	1932		|O
deaths	1933	1939		|O
and	1940	1943		|O
intubations	1944	1955		|O
,	1955	1956		|O
and	1957	1960		|O
events	1961	1967		|O
were	1968	1972		|O
too	1973	1976		|O
infrequent	1977	1987		|O
to	1988	1990		|O
establish	1991	2000		|O
LABA	2001	2005		|O
's	2005	2007		|O
relative	2008	2016		|O
effect	2017	2023		|O
on	2024	2026		|O
these	2027	2032		|O
outcomes	2033	2041		|O
.	2041	2042		|O

### 18812062
Fatal	0	5		|O
toxic	6	11	toxic epidermal necrolysis	|B-ADVERSE
epidermal	12	21		|I-ADVERSE
necrolysis	22	32		|I-ADVERSE
and	33	36		|O
severe	37	43		|O
granulocytopenia	44	60	granulocytopenia	|B-ADVERSE
following	61	70		|O
therapy	71	78		|O
with	79	83		|O
cefuroxime	84	94		|O
.	94	95		|O
Toxic	97	102	Toxic epidermal necrolysis	|B-ADVERSE
epidermal	103	112		|I-ADVERSE
necrolysis	113	123		|I-ADVERSE
(	124	125		|O
TEN	125	128	TEN	|B-ADVERSE
)	128	129		|O
is	130	132		|O
one	133	136		|O
of	137	139		|O
the	140	143		|O
most	144	148		|O
threatening	149	160		|O
adverse	161	168		|O
reactions	169	178		|O
to	179	181		|O
various	182	189		|O
drugs	190	195		|O
.	195	196		|O
No	197	199		|O
case	200	204		|O
of	205	207		|O
concomitant	208	219		|O
occurrence	220	230		|O
TEN	231	234	TEN	|B-ADVERSE
and	235	238		|O
severe	239	245		|O
granulocytopenia	246	262	granulocytopenia	|B-ADVERSE
following	263	272		|O
the	273	276		|O
treatment	277	286		|O
with	287	291		|O
cefuroxime	292	302		|O
has	303	306		|O
been	307	311		|O
reported	312	320		|O
to	321	323		|O
date	324	328		|O
.	328	329		|O
Herein	330	336		|O
we	337	339		|O
present	340	347		|O
a	348	349		|O
case	350	354		|O
of	355	357		|O
TEN	358	361	TEN	|B-ADVERSE
that	362	366		|O
developed	367	376		|O
eighteen	377	385		|O
days	386	390		|O
of	391	393		|O
the	394	397		|O
initiation	398	408		|O
of	409	411		|O
cefuroxime	412	422		|O
axetil	423	429		|O
therapy	430	437		|O
for	438	441		|O
urinary	442	449	urinary tract infection	|B-DISEASE
tract	450	455		|I-DISEASE
infection	456	465		|I-DISEASE
in	466	468		|O
a	469	470		|O
73	471	473		|O
-	473	474		|O
year	474	478		|O
-	478	479		|O
old	479	482		|O
woman	483	488		|O
with	489	493		|O
chronic	494	501	chronic renal failure	|B-DISEASE
renal	502	507		|I-DISEASE
failure	508	515		|I-DISEASE
and	516	519		|O
no	520	522		|O
previous	523	531		|O
history	532	539		|O
of	540	542		|O
allergic	543	551	allergic diathesis	|B-DISEASE
diathesis	552	561		|I-DISEASE
.	561	562		|O
The	563	566		|O
condition	567	576		|O
was	577	580		|O
associated	581	591		|O
with	592	596		|O
severe	597	603		|O
granulocytopenia	604	620	granulocytopenia	|B-ADVERSE
and	621	624		|O
followed	625	633		|O
by	634	636		|O
gastrointestinal	637	653	gastrointestinal hemorrhage	|B-ADVERSE
hemorrhage	654	664		|I-ADVERSE
,	664	665		|O
severe	666	672		|O
sepsis	673	679	sepsis	|B-ADVERSE
and	680	683		|O
multiple	684	692	multiple organ failure syndrome	|B-ADVERSE
organ	693	698		|I-ADVERSE
failure	699	706		|I-ADVERSE
syndrome	707	715		|I-ADVERSE
development	716	727		|O
.	727	728		|O
Despite	729	736		|O
intensive	737	746		|O
medical	747	754		|O
treatment	755	764		|O
the	765	768		|O
patient	769	776		|O
died	777	781		|O
.	781	782		|O
The	783	786		|O
present	787	794		|O
report	795	801		|O
underlines	802	812		|O
the	813	816		|O
potential	817	826		|O
of	827	829		|O
cefuroxime	830	840		|O
to	841	843		|O
simultaneously	844	858		|O
induce	859	865		|O
life	866	870		|O
threatening	871	882		|O
adverse	883	890		|O
effects	891	898		|O
such	899	903		|O
as	904	906		|O
TEN	907	910	TEN	|B-ADVERSE
and	911	914		|O
severe	915	921		|O
granulocytopenia	922	938	granulocytopenia	|B-ADVERSE
.	938	939		|O
Further	940	947		|O
on	948	950		|O
,	950	951		|O
because	952	959		|O
the	960	963		|O
patient	964	971		|O
was	972	975		|O
also	976	980		|O
taking	981	987		|O
furosemide	988	998		|O
for	999	1002		|O
chronic	1003	1010	chronic renal failure	|B-DISEASE
renal	1011	1016		|I-DISEASE
failure	1017	1024		|I-DISEASE
,	1024	1025		|O
the	1026	1029		|O
possible	1030	1038		|O
unfavorable	1039	1050		|O
interactions	1051	1063		|O
between	1064	1071		|O
the	1072	1075		|O
two	1076	1079		|O
drugs	1080	1085		|O
could	1086	1091		|O
be	1092	1094		|O
hypothesized	1095	1107		|O
.	1107	1108		|O
Therefore	1109	1118		|O
,	1118	1119		|O
awareness	1120	1129		|O
of	1130	1132		|O
the	1133	1136		|O
possible	1137	1145		|O
drug	1146	1150		|O
interaction	1151	1162		|O
is	1163	1165		|O
necessary	1166	1175		|O
,	1175	1176		|O
especially	1177	1187		|O
when	1188	1192		|O
given	1193	1198		|O
in	1199	1201		|O
conditions	1202	1212		|O
of	1213	1215		|O
their	1216	1221		|O
altered	1222	1229		|O
pharmacokinetics	1230	1246		|O
as	1247	1249		|O
in	1250	1252		|O
case	1253	1257		|O
of	1258	1260		|O
chronic	1261	1268	chronic renal failure	|B-DISEASE
renal	1269	1274		|I-DISEASE
failure	1275	1282		|I-DISEASE
.	1282	1283		|O

### 18654853
Hepatic	0	7		|O
protection	8	18		|O
by	19	21		|O
noni	22	26		|O
fruit	27	32		|O
juice	33	38		|O
against	39	46		|O
CCl	47	50		|O
(	50	51		|O
4	51	52		|O
)	52	53		|O
-	53	54		|O
induced	54	61		|O
chronic	62	69	chronic liver damage	|B-ADVERSE
liver	70	75		|I-ADVERSE
damage	76	82		|I-ADVERSE
in	83	85		|O
female	86	92		|O
SD	93	95		|O
rats	96	100		|O
.	100	101		|O
Morinda	103	110		|O
citrifolia	111	121		|O
L	122	123		|O
.	123	124		|O
(	125	126		|O
noni	126	130		|O
)	130	131		|O
has	132	135		|O
been	136	140		|O
used	141	145		|O
throughout	146	156		|O
the	157	160		|O
Pacific	161	168		|O
,	168	169		|O
Southeast	170	179		|O
Asia	180	184		|O
,	184	185		|O
Central	186	193		|O
America	194	201		|O
,	201	202		|O
and	203	206		|O
the	207	210		|O
Caribbean	211	220		|O
for	221	224		|O
a	225	226		|O
variety	227	234		|O
of	235	237		|O
health	238	244		|O
conditions	245	255		|O
,	255	256		|O
including	257	266		|O
heart	267	272		|O
and	273	276		|O
liver	277	282		|O
ailments	283	291		|O
.	291	292		|O
In	293	295		|O
this	296	300		|O
study	301	306		|O
,	306	307		|O
we	308	310		|O
examined	311	319		|O
the	320	323		|O
hepatoprotective	324	340		|O
effects	341	348		|O
of	349	351		|O
TAHITIAN	352	360		|O
NONI	361	365		|O
Juice	366	371		|O
(	372	373		|O
TNJ	373	376		|O
)	376	377		|O
against	378	385		|O
CCl	386	389		|O
(	389	390		|O
4	390	391		|O
)	391	392		|O
-	392	393		|O
induced	393	400		|O
chronic	401	408	chronic liver damage	|B-ADVERSE
liver	409	414		|I-ADVERSE
damage	415	421		|I-ADVERSE
in	422	424		|O
female	425	431		|O
Sprague	432	439		|O
Dawley	440	446		|O
(	447	448		|O
SD	448	450		|O
)	450	451		|O
rats	452	456		|O
.	456	457		|O
Twelve	458	464		|O
female	465	471		|O
SD	472	474		|O
rats	475	479		|O
were	480	484		|O
divided	485	492		|O
into	493	497		|O
control	498	505		|O
,	505	506		|O
placebo	507	514		|O
and	515	518		|O
TNJ	519	522		|O
(	523	524		|O
6	524	525		|O
mL	526	528		|O
/	528	529		|O
rat	529	532		|O
/	532	533		|O
day	533	536		|O
)	536	537		|O
groups	538	544		|O
.	544	545		|O
On	546	548		|O
day	549	552		|O
15	553	555		|O
,	555	556		|O
animals	557	564		|O
in	565	567		|O
the	568	571		|O
placebo	572	579		|O
and	580	583		|O
TNJ	584	587		|O
groups	588	594		|O
received	595	603		|O
0.25	604	608		|O
mL	609	611		|O
/	611	612		|O
kg	612	614		|O
CCl	615	618		|O
(	618	619		|O
4	619	620		|O
)	620	621		|O
in	622	624		|O
corn	625	629		|O
oil	630	633		|O
once	634	638		|O
a	639	640		|O
week	641	645		|O
for	646	649		|O
12	650	652		|O
successive	653	663		|O
weeks	664	669		|O
.	669	670		|O
All	671	674		|O
animals	675	682		|O
were	683	687		|O
sacrificed	688	698		|O
at	699	701		|O
week	702	706		|O
16	707	709		|O
.	709	710		|O
Blood	711	716		|O
and	717	720		|O
liver	721	726		|O
were	727	731		|O
collected	732	741		|O
for	742	745		|O
liver	746	751		|O
function	752	760		|O
,	760	761		|O
lipid	762	767		|O
panel	768	773		|O
tests	774	779		|O
,	779	780		|O
and	781	784		|O
histological	785	797		|O
observation	798	809		|O
.	809	810		|O
Histopathological	811	828		|O
examination	829	840		|O
revealed	841	849		|O
that	850	854		|O
liver	855	860		|O
sections	861	869		|O
from	870	874		|O
the	875	878		|O
TNJ	879	882		|O
+	883	884		|O
CCl	885	888		|O
(	888	889		|O
4	889	890		|O
)	890	891		|O
appeared	892	900		|O
similar	901	908		|O
to	909	911		|O
controls	912	920		|O
,	920	921		|O
whereas	922	929		|O
typical	930	937		|O
hepatic	938	945	hepatic steatosis	|B-ADVERSE
steatosis	946	955		|I-ADVERSE
was	956	959		|O
observed	960	968		|O
in	969	971		|O
the	972	975		|O
placebo	976	983		|O
+	984	985		|O
CCl	986	989		|O
(	989	990		|O
4	990	991		|O
)	991	992		|O
group	993	998		|O
.	998	999		|O
Serum	1000	1005		|O
alkaline	1006	1014		|O
phosphatase	1015	1026		|O
(	1027	1028		|O
ALP	1028	1031		|O
)	1031	1032		|O
,	1032	1033		|O
aspartate	1034	1043		|O
aminotransferase	1044	1060		|O
(	1061	1062		|O
AST	1062	1065		|O
)	1065	1066		|O
,	1066	1067		|O
alanine	1068	1075		|O
transaminase	1076	1088		|O
(	1089	1090		|O
ALT	1090	1093		|O
)	1093	1094		|O
,	1094	1095		|O
total	1096	1101		|O
cholesterol	1102	1113		|O
(	1114	1115		|O
TC	1115	1117		|O
)	1117	1118		|O
,	1118	1119		|O
triglycerides	1120	1133		|O
(	1134	1135		|O
TG	1135	1137		|O
)	1137	1138		|O
,	1138	1139		|O
low	1140	1143		|O
-	1143	1144		|O
density	1144	1151		|O
lipoprotein	1152	1163		|O
(	1164	1165		|O
LDL	1165	1168		|O
)	1168	1169		|O
,	1169	1170		|O
and	1171	1174		|O
very	1175	1179		|O
low	1180	1183		|O
-	1183	1184		|O
density	1184	1191		|O
lipoprotein	1192	1203		|O
(	1204	1205		|O
VLDL	1205	1209		|O
)	1209	1210		|O
levels	1211	1217		|O
were	1218	1222		|O
increased	1223	1232		|O
in	1233	1235		|O
the	1236	1239		|O
placebo	1240	1247		|O
group	1248	1253		|O
compared	1254	1262		|O
with	1263	1267		|O
the	1268	1271		|O
TNJ	1272	1275		|O
group	1276	1281		|O
.	1281	1282		|O
In	1283	1285		|O
contrast	1286	1294		|O
,	1294	1295		|O
high	1296	1300		|O
-	1300	1301		|O
density	1301	1308		|O
lipoprotein	1309	1320		|O
(	1321	1322		|O
HDL	1322	1325		|O
)	1325	1326		|O
was	1327	1330		|O
increased	1331	1340		|O
in	1341	1343		|O
the	1344	1347		|O
TNJ	1348	1351		|O
group	1352	1357		|O
and	1358	1361		|O
decreased	1362	1371		|O
in	1372	1374		|O
the	1375	1378		|O
placebo	1379	1386		|O
group	1387	1392		|O
.	1392	1393		|O
Thus	1394	1398		|O
,	1398	1399		|O
TNJ	1400	1403		|O
juice	1404	1409		|O
appears	1410	1417		|O
to	1418	1420		|O
protect	1421	1428		|O
the	1429	1432		|O
liver	1433	1438		|O
from	1439	1443		|O
chronic	1444	1451		|O
exogenous	1452	1461		|O
CCl	1462	1465		|O
(	1465	1466		|O
4	1466	1467		|O
)	1467	1468		|O
exposures	1469	1478		|O
.	1478	1479		|O
Such	1480	1484		|O
protective	1485	1495		|O
mechanisms	1496	1506		|O
are	1507	1510		|O
supportive	1511	1521		|O
evidence	1522	1530		|O
for	1531	1534		|O
the	1535	1538		|O
utility	1539	1546		|O
of	1547	1549		|O
noni	1550	1554		|O
in	1555	1557		|O
traditional	1558	1569		|O
medicine	1570	1578		|O
for	1579	1582		|O
liver	1583	1588		|O
ailments	1589	1597		|O
.	1597	1598		|O

### 18815021
Occupational	0	12		|O
hazard	13	19		|O
:	19	20		|O
treating	21	29		|O
cocaine	30	37		|O
body	38	42		|O
packers	43	50		|O
in	51	53		|O
Caribbean	54	63		|O
countries	64	73		|O
.	73	74		|O
Body	76	80		|O
packing	81	88		|O
is	89	91		|O
a	92	93		|O
common	94	100		|O
method	101	107		|O
of	108	110		|O
smuggling	111	120		|O
cocaine	121	128		|O
where	129	134		|O
individuals	135	146		|O
ingest	147	153		|O
several	154	161		|O
drug	162	166		|O
-	166	167		|O
filled	167	173		|O
parcels	174	181		|O
for	182	185		|O
transport	186	195		|O
.	195	196		|O
When	197	201		|O
identified	202	212		|O
by	213	215		|O
the	216	219		|O
authorities	220	231		|O
,	231	232		|O
body	233	237		|O
packers	238	245		|O
are	246	249		|O
usually	250	257		|O
taken	258	263		|O
to	264	266		|O
hospital	267	275		|O
for	276	279		|O
evaluation	280	290		|O
.	290	291		|O
There	292	297		|O
are	298	301		|O
several	302	309		|O
points	310	316		|O
during	317	323		|O
management	324	334		|O
of	335	337		|O
these	338	343		|O
patients	344	352		|O
when	353	357		|O
the	358	361		|O
health	362	368		|O
care	369	373		|O
team	374	378		|O
may	379	382		|O
be	383	385		|O
placed	386	392		|O
at	393	395		|O
risk	396	400		|O
.	400	401		|O
We	402	404		|O
explore	405	412		|O
the	413	416		|O
hazards	417	424		|O
encountered	425	436		|O
during	437	443		|O
the	444	447		|O
management	448	458		|O
of	459	461		|O
these	462	467		|O
patients	468	476		|O
in	477	479		|O
developing	480	490		|O
Caribbean	491	500		|O
nations	501	508		|O
.	508	509		|O

### 18654747
A	0	1		|O
multi	2	7		|O
-	7	8		|O
centre	8	14		|O
dose	15	19		|O
-	19	20		|O
escalation	20	30		|O
and	31	34		|O
pharmacokinetic	35	50		|O
study	51	56		|O
of	57	59		|O
diflomotecan	60	72		|O
in	73	75		|O
patients	76	84		|O
with	85	89		|O
advanced	90	98		|O
malignancy	99	109	malignancy	|B-DISEASE
.	109	110		|O
PURPOSE	112	119		|O
:	119	120		|O
Diflomotecan	121	133		|O
,	133	134		|O
a	135	136		|O
homocamptothecin	137	153		|O
,	153	154		|O
targets	155	162		|O
DNA	163	166		|O
topoisomerase	167	180		|O
I	181	182		|O
.	182	183		|O
Previous	184	192		|O
clinical	193	201		|O
trials	202	208		|O
have	209	213		|O
demonstrated	214	226		|O
a	227	228		|O
variable	229	237		|O
degree	238	244		|O
of	245	247		|O
dose	248	252	dose limiting toxicity	|B-ADVERSE
limiting	253	261		|I-ADVERSE
toxicity	262	270		|I-ADVERSE
.	270	271		|O
The	272	275		|O
purpose	276	283		|O
of	284	286		|O
this	287	291		|O
study	292	297		|O
was	298	301		|O
to	302	304		|O
further	305	312		|O
evaluate	313	321		|O
the	322	325		|O
safety	326	332		|O
and	333	336		|O
pharmacokinetic	337	352		|O
profile	353	360		|O
of	361	363		|O
a	364	365		|O
range	366	371		|O
of	372	374		|O
diflomotecan	375	387		|O
doses	388	393		|O
administered	394	406		|O
intravenously	407	420		|O
.	420	421		|O
METHODS	422	429		|O
:	429	430		|O
Patients	431	439		|O
with	440	444		|O
advanced	445	453		|O
solid	454	459		|O
malignant	460	469	malignant tumours	|B-DISEASE
tumours	470	477		|I-DISEASE
,	477	478		|O
refractory	479	489		|O
to	490	492		|O
standard	493	501		|O
therapies	502	511		|O
,	511	512		|O
with	513	517		|O
adequate	518	526		|O
haematologic	527	539		|O
,	539	540		|O
renal	541	546		|O
and	547	550		|O
hepatic	551	558		|O
function	559	567		|O
,	567	568		|O
received	569	577		|O
diflomotecan	578	590		|O
administered	591	603		|O
as	604	606		|O
a	607	608		|O
20	609	611		|O
min	612	615		|O
intravenous	616	627		|O
infusion	628	636		|O
every	637	642		|O
21	643	645		|O
days	646	650		|O
.	650	651		|O
Cohorts	652	659		|O
of	660	662		|O
six	663	666		|O
patients	667	675		|O
were	676	680		|O
recruited	681	690		|O
sequentially	691	703		|O
to	704	706		|O
one	707	710		|O
of	711	713		|O
three	714	719		|O
fixed	720	725		|O
starting	726	734		|O
dose	735	739		|O
groups	740	746		|O
-	746	747		|O
2	747	748		|O
,	748	749		|O
4	750	751		|O
,	751	752		|O
or	753	755		|O
7	756	757		|O
mg	758	760		|O
,	760	761		|O
with	762	766		|O
drug	767	771		|O
administered	772	784		|O
by	785	787		|O
fixed	788	793		|O
-	793	794		|O
dose	794	798		|O
rather	799	805		|O
than	806	810		|O
dosing	811	817		|O
by	818	820		|O
body	821	825		|O
surface	826	833		|O
area	834	838		|O
.	838	839		|O
Pharmacokinetic	840	855		|O
analyses	856	864		|O
were	865	869		|O
performed	870	879		|O
on	880	882		|O
serial	883	889		|O
blood	890	895		|O
samples	896	903		|O
taken	904	909		|O
over	910	914		|O
the	915	918		|O
first	919	924		|O
24	925	927		|O
h	928	929		|O
after	930	935		|O
diflomotecan	936	948		|O
administration	949	963		|O
(	964	965		|O
cycles	965	971		|O
1	972	973		|O
and	974	977		|O
2	978	979		|O
)	979	980		|O
.	980	981		|O
Cytochrome	982	992		|O
P450	993	997		|O
3A4	998	1001		|O
(	1002	1003		|O
CYP3A4	1003	1009		|O
)	1009	1010		|O
activity	1011	1019		|O
was	1020	1023		|O
determined	1024	1034		|O
by	1035	1037		|O
an	1038	1040		|O
erythromycin	1041	1053		|O
breath	1054	1060		|O
test	1061	1065		|O
(	1066	1067		|O
EBT	1067	1070		|O
)	1070	1071		|O
prior	1072	1077		|O
to	1078	1080		|O
diflomotecan	1081	1093		|O
administration	1094	1108		|O
in	1109	1111		|O
cycles	1112	1118		|O
1	1119	1120		|O
and	1121	1124		|O
2	1125	1126		|O
.	1126	1127		|O
RESULTS	1128	1135		|O
:	1135	1136		|O
Thirteen	1137	1145		|O
patients	1146	1154		|O
,	1154	1155		|O
were	1156	1160		|O
treated	1161	1168		|O
with	1169	1173		|O
a	1174	1175		|O
starting	1176	1184		|O
dose	1185	1189		|O
of	1190	1192		|O
either	1193	1199		|O
2	1200	1201		|O
mg	1202	1204		|O
(	1205	1206		|O
n	1206	1207		|O
=	1208	1209		|O
8	1210	1211		|O
)	1211	1212		|O
or	1213	1215		|O
4	1216	1217		|O
mg	1218	1220		|O
(	1221	1222		|O
n	1222	1223		|O
=	1224	1225		|O
5	1226	1227		|O
)	1227	1228		|O
of	1229	1231		|O
diflomotecan	1232	1244		|O
.	1244	1245		|O
Dose	1246	1250		|O
limiting	1251	1259		|O
toxicities	1260	1270		|O
(	1271	1272		|O
DLTs	1272	1276		|O
)	1276	1277		|O
were	1278	1282		|O
observed	1283	1291		|O
in	1292	1294		|O
1	1295	1296		|O
patient	1297	1304		|O
in	1305	1307		|O
the	1308	1311		|O
2	1312	1313		|O
mg	1314	1316		|O
starting	1317	1325		|O
dose	1326	1330		|O
level	1331	1336		|O
(	1337	1338		|O
grade	1338	1343		|O
4	1344	1345		|O
neutropenia	1346	1357	neutropenia	|B-ADVERSE
which	1358	1363		|O
lasted	1364	1370		|O
for	1371	1374		|O
8	1375	1376		|O
days	1377	1381		|O
)	1381	1382		|O
,	1382	1383		|O
and	1384	1387		|O
in	1388	1390		|O
2	1391	1392		|O
of	1393	1395		|O
5	1396	1397		|O
patients	1398	1406		|O
enrolled	1407	1415		|O
at	1416	1418		|O
the	1419	1422		|O
4	1423	1424		|O
mg	1425	1427		|O
starting	1428	1436		|O
dose	1437	1441		|O
level	1442	1447		|O
(	1448	1449		|O
grade	1449	1454		|O
4	1455	1456		|O
neutropenia	1457	1468	neutropenia	|B-ADVERSE
for	1469	1472		|O
11	1473	1475		|O
days	1476	1480		|O
;	1480	1481		|O
grade	1482	1487		|O
4	1488	1489		|O
neutropenia	1490	1501	neutropenia	|B-ADVERSE
leading	1502	1509		|O
to	1510	1512		|O
withdrawal	1513	1523		|O
from	1524	1528		|O
the	1529	1532		|O
study	1533	1538		|O
)	1538	1539		|O
,	1539	1540		|O
and	1541	1544		|O
no	1545	1547		|O
further	1548	1555		|O
dose	1556	1560		|O
escalation	1561	1571		|O
was	1572	1575		|O
performed	1576	1585		|O
.	1585	1586		|O
Pharmacokinetic	1587	1602		|O
analyses	1603	1611		|O
revealed	1612	1620		|O
a	1621	1622		|O
less	1623	1627		|O
than	1628	1632		|O
dose	1633	1637		|O
-	1637	1638		|O
proportional	1638	1650		|O
increase	1651	1659		|O
in	1660	1662		|O
diflomotecan	1663	1675		|O
and	1676	1679		|O
for	1680	1683		|O
the	1684	1687		|O
two	1688	1691		|O
metabolites	1692	1703		|O
BN80942	1704	1711		|O
and	1712	1715		|O
P	1716	1717		|O
-	1717	1718		|O
20	1718	1720		|O
,	1720	1721		|O
with	1722	1726		|O
a	1727	1728		|O
magnitude	1729	1738		|O
of	1739	1741		|O
P	1742	1743		|O
-	1743	1744		|O
20	1744	1746		|O
exposure	1747	1755		|O
similar	1756	1763		|O
to	1764	1766		|O
the	1767	1770		|O
parent	1771	1777		|O
drug	1778	1782		|O
.	1782	1783		|O
There	1784	1789		|O
was	1790	1793		|O
a	1794	1795		|O
high	1796	1800		|O
inter	1801	1806		|O
-	1806	1807		|O
patient	1807	1814		|O
variability	1815	1826		|O
in	1827	1829		|O
diflomotecan	1830	1842		|O
exposure	1843	1851		|O
similar	1852	1859		|O
to	1860	1862		|O
that	1863	1867		|O
observed	1868	1876		|O
with	1877	1881		|O
other	1882	1887		|O
camptothecin	1888	1900		|O
derivatives	1901	1912		|O
.	1912	1913		|O
One	1914	1917		|O
minor	1918	1923		|O
response	1924	1932		|O
was	1933	1936		|O
observed	1937	1945		|O
in	1946	1948		|O
a	1949	1950		|O
patient	1951	1958		|O
with	1959	1963		|O
oesophageal	1964	1975	oesophageal cancer	|B-DISEASE
cancer	1976	1982		|I-DISEASE
.	1982	1983		|O
CONCLUSIONS	1984	1995		|O
:	1995	1996		|O
Diflomotecan	1997	2009		|O
administered	2010	2022		|O
as	2023	2025		|O
a	2026	2027		|O
20	2028	2030		|O
-	2030	2031		|O
min	2031	2034		|O
intravenous	2035	2046		|O
infusion	2047	2055		|O
3	2056	2057		|O
-	2057	2058		|O
weekly	2058	2064		|O
is	2065	2067		|O
characterised	2068	2081		|O
by	2082	2084		|O
a	2085	2086		|O
variable	2087	2095		|O
pharmacokinetic	2096	2111		|O
profile	2112	2119		|O
.	2119	2120		|O
Alternative	2121	2132		|O
oral	2133	2137		|O
dosing	2138	2144		|O
schedules	2145	2154		|O
of	2155	2157		|O
diflomotecan	2158	2170		|O
have	2171	2175		|O
been	2176	2180		|O
shown	2181	2186		|O
to	2187	2189		|O
display	2190	2197		|O
a	2198	2199		|O
more	2200	2204		|O
predictable	2205	2216		|O
PK	2217	2219		|O
/	2219	2220		|O
PD	2220	2222		|O
and	2223	2226		|O
safety	2227	2233		|O
profile	2234	2241		|O
and	2242	2245		|O
should	2246	2252		|O
be	2253	2255		|O
selected	2256	2264		|O
for	2265	2268		|O
further	2269	2276		|O
evaluation	2277	2287		|O
in	2288	2290		|O
Phase	2291	2296		|O
II	2297	2299		|O
clinical	2300	2308		|O
trials	2309	2315		|O
.	2315	2316		|O

### 18555912
Effect	0	6		|O
of	7	9		|O
carbocisteine	10	23		|O
on	24	26		|O
acute	27	32		|O
exacerbation	33	45		|O
of	46	48		|O
chronic	49	56	chronic obstructive pulmonary disease	|B-DISEASE
obstructive	57	68		|I-DISEASE
pulmonary	69	78		|I-DISEASE
disease	79	86		|I-DISEASE
(	87	88		|O
PEACE	88	93		|O
Study	94	99		|O
)	99	100		|O
:	100	101		|O
a	102	103		|O
randomised	104	114		|O
placebo	115	122		|O
-	122	123		|O
controlled	123	133		|O
study	134	139		|O
.	139	140		|O
BACKGROUND	142	152		|O
:	152	153		|O
Chronic	154	161	Chronic obstructive pulmonary disease	|B-DISEASE
obstructive	162	173		|I-DISEASE
pulmonary	174	183		|I-DISEASE
disease	184	191		|I-DISEASE
(	192	193		|O
COPD	193	197	COPD	|B-DISEASE
)	197	198		|O
is	199	201		|O
characterised	202	215		|O
by	216	218		|O
airflow	219	226		|O
limitation	227	237		|O
,	237	238		|O
and	239	242		|O
has	243	246		|O
many	247	251		|O
components	252	262		|O
including	263	272		|O
mucus	273	278		|O
hypersecretion	279	293		|O
,	293	294		|O
oxidative	295	304		|O
stress	305	311		|O
,	311	312		|O
and	313	316		|O
airway	317	323		|O
inflammation	324	336		|O
.	336	337		|O
We	338	340		|O
aimed	341	346		|O
to	347	349		|O
assess	350	356		|O
whether	357	364		|O
carbocisteine	365	378		|O
,	378	379		|O
a	380	381		|O
mucolytic	382	391		|O
agent	392	397		|O
with	398	402		|O
anti	403	407		|O
-	407	408		|O
inflammatory	408	420		|O
and	421	424		|O
antioxidation	425	438		|O
activities	439	449		|O
,	449	450		|O
could	451	456		|O
reduce	457	463		|O
the	464	467		|O
yearly	468	474		|O
exacerbation	475	487		|O
rate	488	492		|O
in	493	495		|O
patients	496	504		|O
with	505	509		|O
COPD	510	514	COPD	|B-DISEASE
.	514	515		|O
METHODS	516	523		|O
:	523	524		|O
We	525	527		|O
did	528	531		|O
a	532	533		|O
randomised	534	544		|O
,	544	545		|O
double	546	552		|O
-	552	553		|O
blind	553	558		|O
,	558	559		|O
placebo	560	567		|O
-	567	568		|O
controlled	568	578		|O
study	579	584		|O
of	585	587		|O
709	588	591		|O
patients	592	600		|O
from	601	605		|O
22	606	608		|O
centres	609	616		|O
in	617	619		|O
China	620	625		|O
.	625	626		|O
Participants	627	639		|O
were	640	644		|O
eligible	645	653		|O
if	654	656		|O
they	657	661		|O
were	662	666		|O
diagnosed	667	676		|O
as	677	679		|O
having	680	686		|O
COPD	687	691	COPD	|B-DISEASE
with	692	696		|O
a	697	698		|O
postbronchodilator	699	717		|O
forced	718	724		|O
expiratory	725	735		|O
volume	736	742		|O
in	743	745		|O
1	746	747		|O
s	748	749		|O
(	750	751		|O
FEV	751	754		|O
(	754	755		|O
1	755	756		|O
)	756	757		|O
)	757	758		|O
to	759	761		|O
forced	762	768		|O
vital	769	774		|O
capacity	775	783		|O
(	784	785		|O
FVC	785	788		|O
)	788	789		|O
ratio	790	795		|O
(	796	797		|O
FEV	797	800		|O
(	800	801		|O
1	801	802		|O
)	802	803		|O
/	803	804		|O
FVC	804	807		|O
)	807	808		|O
of	809	811		|O
less	812	816		|O
than	817	821		|O
0.7	822	825		|O
and	826	829		|O
an	830	832		|O
FEV	833	836		|O
(	836	837		|O
1	837	838		|O
)	838	839		|O
between	840	847		|O
25%	848	851		|O
and	852	855		|O
79%	856	859		|O
of	860	862		|O
the	863	866		|O
predicted	867	876		|O
value	877	882		|O
,	882	883		|O
were	884	888		|O
aged	889	893		|O
between	894	901		|O
40	902	904		|O
and	905	908		|O
80	909	911		|O
years	912	917		|O
,	917	918		|O
had	919	922		|O
a	923	924		|O
history	925	932		|O
of	933	935		|O
at	936	938		|O
least	939	944		|O
two	945	948		|O
COPD	949	953	COPD	|B-DISEASE
exacerbations	954	967		|O
within	968	974		|O
the	975	978		|O
previous	979	987		|O
2	988	989		|O
years	990	995		|O
,	995	996		|O
and	997	1000		|O
had	1001	1004		|O
remained	1005	1013		|O
clinically	1014	1024		|O
stable	1025	1031		|O
for	1032	1035		|O
over	1036	1040		|O
4	1041	1042		|O
weeks	1043	1048		|O
before	1049	1055		|O
the	1056	1059		|O
study	1060	1065		|O
.	1065	1066		|O
Patients	1067	1075		|O
were	1076	1080		|O
randomly	1081	1089		|O
assigned	1090	1098		|O
to	1099	1101		|O
receive	1102	1109		|O
1500	1110	1114		|O
mg	1115	1117		|O
carbocisteine	1118	1131		|O
or	1132	1134		|O
placebo	1135	1142		|O
per	1143	1146		|O
day	1147	1150		|O
for	1151	1154		|O
a	1155	1156		|O
year	1157	1161		|O
.	1161	1162		|O
The	1163	1166		|O
primary	1167	1174		|O
endpoint	1175	1183		|O
was	1184	1187		|O
exacerbation	1188	1200		|O
rate	1201	1205		|O
over	1206	1210		|O
1	1211	1212		|O
year	1213	1217		|O
,	1217	1218		|O
and	1219	1222		|O
analysis	1223	1231		|O
was	1232	1235		|O
by	1236	1238		|O
intention	1239	1248		|O
to	1249	1251		|O
treat	1252	1257		|O
.	1257	1258		|O
This	1259	1263		|O
trial	1264	1269		|O
is	1270	1272		|O
registered	1273	1283		|O
with	1284	1288		|O
the	1289	1292		|O
Japan	1293	1298		|O
Clinical	1299	1307		|O
Trials	1308	1314		|O
Registry	1315	1323		|O
(	1324	1325		|O
http://umin.ac.jp/ctr/index/htm	1325	1356		|O
)	1356	1357		|O
number	1358	1364		|O
UMIN	1365	1369		|O
-	1369	1370		|O
CRT	1370	1373		|O
C000000233	1374	1384		|O
.	1384	1385		|O
FINDINGS	1386	1394		|O
:	1394	1395		|O
354	1396	1399		|O
patients	1400	1408		|O
were	1409	1413		|O
assigned	1414	1422		|O
to	1423	1425		|O
the	1426	1429		|O
carbocisteine	1430	1443		|O
group	1444	1449		|O
and	1450	1453		|O
355	1454	1457		|O
to	1458	1460		|O
the	1461	1464		|O
placebo	1465	1472		|O
group	1473	1478		|O
.	1478	1479		|O
Numbers	1480	1487		|O
of	1488	1490		|O
exacerbations	1491	1504		|O
per	1505	1508		|O
patient	1509	1516		|O
per	1517	1520		|O
year	1521	1525		|O
declined	1526	1534		|O
significantly	1535	1548		|O
in	1549	1551		|O
the	1552	1555		|O
carbocisteine	1556	1569		|O
group	1570	1575		|O
compared	1576	1584		|O
with	1585	1589		|O
the	1590	1593		|O
placebo	1594	1601		|O
group	1602	1607		|O
(	1608	1609		|O
1.01	1609	1613		|O
[	1614	1615		|O
SE	1615	1617		|O
0.06	1618	1622		|O
]	1622	1623		|O
vs	1624	1626		|O
1.35	1627	1631		|O
[	1632	1633		|O
SE	1633	1635		|O
0.06	1636	1640		|O
]	1640	1641		|O
)	1641	1642		|O
,	1642	1643		|O
risk	1644	1648		|O
ratio	1649	1654		|O
0.75	1655	1659		|O
(	1660	1661		|O
95%	1661	1664		|O
CI	1665	1667		|O
0.62-0.92	1668	1677		|O
,	1677	1678		|O
p	1679	1680		|O
=	1680	1681		|O
0.004	1681	1686		|O
)	1686	1687		|O
.	1687	1688		|O
Non	1689	1692		|O
-	1692	1693		|O
significant	1693	1704		|O
interactions	1705	1717		|O
were	1718	1722		|O
found	1723	1728		|O
between	1729	1736		|O
the	1737	1740		|O
preventive	1741	1751		|O
effects	1752	1759		|O
and	1760	1763		|O
COPD	1764	1768	COPD	|B-DISEASE
severity	1769	1777		|O
,	1777	1778		|O
smoking	1779	1786		|O
,	1786	1787		|O
as	1788	1790		|O
well	1791	1795		|O
as	1796	1798		|O
concomitant	1799	1810		|O
use	1811	1814		|O
of	1815	1817		|O
inhaled	1818	1825		|O
corticosteroids	1826	1841		|O
.	1841	1842		|O
Carbocisteine	1843	1856		|O
was	1857	1860		|O
well	1861	1865		|O
tolerated	1866	1875		|O
.	1875	1876		|O
INTERPRETATION	1877	1891		|O
:	1891	1892		|O
Mucolytics	1893	1903		|O
,	1903	1904		|O
such	1905	1909		|O
as	1910	1912		|O
carbocisteine	1913	1926		|O
,	1926	1927		|O
should	1928	1934		|O
be	1935	1937		|O
recognised	1938	1948		|O
as	1949	1951		|O
a	1952	1953		|O
worthwhile	1954	1964		|O
treatment	1965	1974		|O
for	1975	1978		|O
prevention	1979	1989		|O
of	1990	1992		|O
exacerbations	1993	2006		|O
in	2007	2009		|O
Chinese	2010	2017		|O
patients	2018	2026		|O
with	2027	2031		|O
COPD	2032	2036	COPD	|B-DISEASE
.	2036	2037		|O

### 18589198
Altered	0	7		|O
first	8	13		|O
-	13	14		|O
pass	14	18		|O
effects	19	26		|O
in	27	29		|O
a	30	31		|O
liver	32	37		|O
transplant	38	48		|O
recipient	49	58		|O
explained	59	68		|O
intraindividual	69	84		|O
variation	85	94		|O
in	95	97		|O
calcineurin	98	109		|O
inhibitor	110	119		|O
concentrations	120	134		|O
:	134	135		|O
a	136	137		|O
case	138	142		|O
report	143	149		|O
.	149	150		|O
BACKGROUND	152	162		|O
:	162	163		|O
The	164	167		|O
significant	168	179		|O
interindividual	180	195		|O
and	196	199		|O
intraindividual	200	215		|O
variability	216	227		|O
in	228	230		|O
the	231	234		|O
blood	235	240		|O
concentrations	241	255		|O
of	256	258		|O
the	259	262		|O
most	263	267		|O
commonly	268	276		|O
used	277	281		|O
calcineurin	282	293		|O
inhibitors	294	304		|O
such	305	309		|O
as	310	312		|O
tacrolimus	313	323		|O
and	324	327		|O
cyclosporine	328	340		|O
makes	341	346		|O
the	347	350		|O
exact	351	356		|O
dosing	357	363		|O
of	364	366		|O
these	367	372		|O
agents	373	379		|O
in	380	382		|O
transplant	383	393		|O
recipients	394	404		|O
very	405	409		|O
challenging	410	421		|O
.	421	422		|O
As	423	425		|O
both	426	430		|O
of	431	433		|O
these	434	439		|O
drugs	440	445		|O
have	446	450		|O
narrow	451	457		|O
therapeutic	458	469		|O
index	470	475		|O
and	476	479		|O
are	480	483		|O
metabolized	484	495		|O
by	496	498		|O
hepatic	499	506		|O
and	507	510		|O
intestinal	511	521		|O
cytochrome	522	532		|O
P450	533	537		|O
3A	538	540		|O
,	540	541		|O
we	542	544		|O
tested	545	551		|O
the	552	555		|O
hypothesis	556	566		|O
that	567	571		|O
these	572	577		|O
variations	578	588		|O
are	589	592		|O
secondary	593	602		|O
to	603	605		|O
varying	606	613		|O
first	614	619		|O
-	619	620		|O
pass	620	624		|O
effects	625	632		|O
in	633	635		|O
the	636	639		|O
gut	640	643		|O
and	644	647		|O
the	648	651		|O
liver	652	657		|O
over	658	662		|O
a	663	664		|O
period	665	671		|O
of	672	674		|O
time	675	679		|O
.	679	680		|O
CASE	681	685		|O
REPORT	686	692		|O
:	692	693		|O
A	694	695		|O
liver	696	701		|O
transplant	702	712		|O
recipient	713	722		|O
,	722	723		|O
who	724	727		|O
had	728	731		|O
previously	732	742		|O
presented	743	752		|O
with	753	757		|O
tacrolimus	758	768	tacrolimus toxicity	|B-ADVERSE
toxicity	769	777		|I-ADVERSE
on	778	780		|O
his	781	784		|O
usual	785	790		|O
dosing	791	797		|O
regimen	798	805		|O
and	806	809		|O
intolerant	810	820		|O
to	821	823		|O
standard	824	832		|O
doses	833	838		|O
of	839	841		|O
cyclosporine	842	854		|O
,	854	855		|O
was	856	859		|O
selected	860	868		|O
to	869	871		|O
undergo	872	879		|O
the	880	883		|O
study	884	889		|O
.	889	890		|O
Oral	891	895		|O
and	896	899		|O
intravenous	900	911		|O
midazolam	912	921		|O
was	922	925		|O
used	926	930		|O
as	931	933		|O
the	934	937		|O
probe	938	943		|O
to	944	946		|O
measure	947	954		|O
hepatic	955	962		|O
and	963	966		|O
intestinal	967	977		|O
CYP3A4	978	984		|O
activities	985	995		|O
at	996	998		|O
two	999	1002		|O
different	1003	1012		|O
time	1013	1017		|O
points	1018	1024		|O
(	1025	1026		|O
phases	1026	1032		|O
one	1033	1036		|O
and	1037	1040		|O
two	1041	1044		|O
)	1044	1045		|O
.	1045	1046		|O
Small	1047	1052		|O
intestinal	1053	1063		|O
biopsies	1064	1072		|O
were	1073	1077		|O
also	1078	1082		|O
obtained	1083	1091		|O
for	1092	1095		|O
measuring	1096	1105		|O
CYP3A4	1106	1112		|O
activity	1113	1121		|O
for	1122	1125		|O
in	1126	1128		|O
vitro	1129	1134		|O
studies	1135	1142		|O
.	1142	1143		|O
On	1144	1146		|O
serially	1147	1155		|O
determining	1156	1167		|O
the	1168	1171		|O
patient	1172	1179		|O
's	1179	1181		|O
hepatic	1182	1189		|O
and	1190	1193		|O
intestinal	1194	1204		|O
CYP3A	1205	1210		|O
activities	1211	1221		|O
,	1221	1222		|O
we	1223	1225		|O
concluded	1226	1235		|O
that	1236	1240		|O
the	1241	1244		|O
variability	1245	1256		|O
in	1257	1259		|O
the	1260	1263		|O
dosing	1264	1270		|O
requirements	1271	1283		|O
is	1284	1286		|O
due	1287	1290		|O
to	1291	1293		|O
altered	1294	1301		|O
first	1302	1307		|O
-	1307	1308		|O
pass	1308	1312		|O
effects	1313	1320		|O
in	1321	1323		|O
the	1324	1327		|O
intestine	1328	1337		|O
.	1337	1338		|O
DISCUSSION	1339	1349		|O
:	1349	1350		|O
Transplant	1351	1361		|O
recipients	1362	1372		|O
receive	1373	1380		|O
multiple	1381	1389		|O
medications	1390	1401		|O
that	1402	1406		|O
may	1407	1410		|O
inhibit	1411	1418		|O
or	1419	1421		|O
induce	1422	1428		|O
these	1429	1434		|O
metabolizing	1435	1447		|O
enzymes	1448	1455		|O
,	1455	1456		|O
which	1457	1462		|O
eventually	1463	1473		|O
determine	1474	1483		|O
the	1484	1487		|O
concentrations	1488	1502		|O
of	1503	1505		|O
these	1506	1511		|O
narrow	1512	1518		|O
therapeutic	1519	1530		|O
agents	1531	1537		|O
.	1537	1538		|O
If	1539	1541		|O
no	1542	1544		|O
obvious	1545	1552		|O
etiology	1553	1561		|O
of	1562	1564		|O
intolerance	1565	1576		|O
to	1577	1579		|O
calcineurin	1580	1591		|O
inhibitors	1592	1602		|O
in	1603	1605		|O
a	1606	1607		|O
transplant	1608	1618		|O
recipient	1619	1628		|O
is	1629	1631		|O
identified	1632	1642		|O
,	1642	1643		|O
one	1644	1647		|O
should	1648	1654		|O
consider	1655	1663		|O
altered	1664	1671		|O
first	1672	1677		|O
-	1677	1678		|O
pass	1678	1682		|O
effects	1683	1690		|O
in	1691	1693		|O
the	1694	1697		|O
gut	1698	1701		|O
and	1702	1705		|O
the	1706	1709		|O
liver	1710	1715		|O
contributing	1716	1728		|O
to	1729	1731		|O
intraindividual	1732	1747		|O
variations	1748	1758		|O
in	1759	1761		|O
the	1762	1765		|O
blood	1766	1771		|O
concentrations	1772	1786		|O
.	1786	1787		|O

### 18539681
Arsenic	0	7		|O
upregulates	8	19		|O
MMP	20	23		|O
-	23	24		|O
9	24	25		|O
and	26	29		|O
inhibits	30	38		|O
wound	39	44	wound	|B-DISEASE
repair	45	51		|O
in	52	54		|O
human	55	60		|O
airway	61	67		|O
epithelial	68	78		|O
cells	79	84		|O
.	84	85		|O
As	87	89		|O
part	90	94		|O
of	95	97		|O
the	98	101		|O
innate	102	108		|O
immune	109	115		|O
defense	116	123		|O
,	123	124		|O
the	125	128		|O
polarized	129	138		|O
conducting	139	149		|O
lung	150	154		|O
epithelium	155	165		|O
acts	166	170		|O
as	171	173		|O
a	174	175		|O
barrier	176	183		|O
to	184	186		|O
keep	187	191		|O
particulates	192	204		|O
carried	205	212		|O
in	213	215		|O
respiration	216	227		|O
from	228	232		|O
underlying	233	243		|O
tissue	244	250		|O
.	250	251		|O
Arsenic	252	259		|O
is	260	262		|O
a	263	264		|O
metalloid	265	274		|O
toxicant	275	283		|O
that	284	288		|O
can	289	292		|O
affect	293	299		|O
the	300	303		|O
lung	304	308		|O
via	309	312		|O
inhalation	313	323		|O
or	324	326		|O
ingestion	327	336		|O
.	336	337		|O
We	338	340		|O
have	341	345		|O
recently	346	354		|O
shown	355	360		|O
that	361	365		|O
chronic	366	373		|O
exposure	374	382		|O
of	383	385		|O
mice	386	390		|O
or	391	393		|O
humans	394	400		|O
to	401	403		|O
arsenic	404	411		|O
(	412	413		|O
10-50	413	418		|O
ppb	419	422		|O
)	422	423		|O
in	424	426		|O
drinking	427	435		|O
water	436	441		|O
alters	442	448		|O
bronchiolar	449	460		|O
lavage	461	467		|O
or	468	470		|O
sputum	471	477		|O
proteins	478	486		|O
consistent	487	497		|O
with	498	502		|O
reduced	503	510		|O
epithelial	511	521		|O
cell	522	526		|O
migration	527	536		|O
and	537	540		|O
wound	541	546	wound	|B-DISEASE
repair	547	553		|O
in	554	556		|O
the	557	560		|O
airway	561	567		|O
.	567	568		|O
In	569	571		|O
this	572	576		|O
report	577	583		|O
,	583	584		|O
we	585	587		|O
used	588	592		|O
an	593	595		|O
in	596	598		|O
vitro	599	604		|O
model	605	610		|O
to	611	613		|O
examine	614	621		|O
effects	622	629		|O
of	630	632		|O
acute	633	638		|O
exposure	639	647		|O
of	648	650		|O
arsenic	651	658		|O
(	659	660		|O
15-290	660	666		|O
ppb	667	670		|O
)	670	671		|O
on	672	674		|O
conducting	675	685		|O
airway	686	692		|O
lung	693	697		|O
epithelium	698	708		|O
.	708	709		|O
We	710	712		|O
found	713	718		|O
that	719	723		|O
arsenic	724	731		|O
at	732	734		|O
concentrations	735	749		|O
as	750	752		|O
low	753	756		|O
as	757	759		|O
30	760	762		|O
ppb	763	766		|O
inhibits	767	775		|O
reformation	776	787		|O
of	788	790		|O
the	791	794		|O
epithelial	795	805		|O
monolayer	806	815		|O
following	816	825		|O
scrape	826	832		|O
wounds	833	839		|O
of	840	842		|O
monolayer	843	852		|O
cultures	853	861		|O
.	861	862		|O
In	863	865		|O
an	866	868		|O
effort	869	875		|O
to	876	878		|O
understand	879	889		|O
functional	890	900		|O
contributions	901	914		|O
to	915	917		|O
epithelial	918	928		|O
wound	929	934	wound	|B-DISEASE
repair	935	941		|O
altered	942	949		|O
by	950	952		|O
arsenic	953	960		|O
,	960	961		|O
we	962	964		|O
showed	965	971		|O
that	972	976		|O
acute	977	982		|O
arsenic	983	990		|O
exposure	991	999		|O
increases	1000	1009		|O
activity	1010	1018		|O
and	1019	1022		|O
expression	1023	1033		|O
of	1034	1036		|O
matrix	1037	1043		|O
metalloproteinase	1044	1061		|O
(	1062	1063		|O
MMP	1063	1066		|O
)	1066	1067		|O
-	1067	1068		|O
9	1068	1069		|O
,	1069	1070		|O
an	1071	1073		|O
important	1074	1083		|O
protease	1084	1092		|O
in	1093	1095		|O
lung	1096	1100		|O
function	1101	1109		|O
.	1109	1110		|O
Furthermore	1111	1122		|O
,	1122	1123		|O
inhibition	1124	1134		|O
of	1135	1137		|O
MMP	1138	1141		|O
-	1141	1142		|O
9	1142	1143		|O
in	1144	1146		|O
arsenic	1147	1154		|O
-	1154	1155		|O
treated	1155	1162		|O
cells	1163	1168		|O
improved	1169	1177		|O
wound	1178	1183	wound	|B-DISEASE
repair	1184	1190		|O
.	1190	1191		|O
We	1192	1194		|O
propose	1195	1202		|O
that	1203	1207		|O
arsenic	1208	1215		|O
in	1216	1218		|O
the	1219	1222		|O
airway	1223	1229		|O
can	1230	1233		|O
alter	1234	1239		|O
the	1240	1243		|O
airway	1244	1250		|O
epithelial	1251	1261		|O
barrier	1262	1269		|O
by	1270	1272		|O
restricting	1273	1284		|O
proper	1285	1291		|O
wound	1292	1297	wound	|B-DISEASE
repair	1298	1304		|O
in	1305	1307		|O
part	1308	1312		|O
through	1313	1320		|O
the	1321	1324		|O
upregulation	1325	1337		|O
of	1338	1340		|O
MMP	1341	1344		|O
-	1344	1345		|O
9	1345	1346		|O
by	1347	1349		|O
lung	1350	1354		|O
epithelial	1355	1365		|O
cells	1366	1371		|O
.	1371	1372		|O

### 18603680
Clostridium	0	11		|O
perfringens	12	23		|O
enterotoxin	24	35		|O
in	36	38		|O
antibiotic	39	49	antibiotic-associated diarrhea	|B-DISEASE
-	49	50		|I-DISEASE
associated	50	60		|I-DISEASE
diarrhea	61	69		|I-DISEASE
.	69	70		|O
Clostridium	72	83		|O
perfringens	84	95		|O
type	96	100		|O
A	101	102		|O
is	103	105		|O
associated	106	116		|O
with	117	121		|O
5-20%	122	127		|O
cases	128	133		|O
of	134	136		|O
antibiotic	137	147	antibiotic-associated diarrhea	|B-DISEASE
-	147	148		|I-DISEASE
associated	148	158		|I-DISEASE
diarrhea	159	167		|I-DISEASE
(	168	169		|O
AAD	169	172		|O
)	172	173		|O
even	174	178		|O
though	179	185		|O
Clostridium	186	197		|O
difficile	198	207		|O
is	208	210		|O
implicated	211	221		|O
in	222	224		|O
the	225	228		|O
most	229	233		|O
severe	234	240		|O
cases	241	246		|O
.	246	247		|O
Fecal	248	253		|O
specimens	254	263		|O
from	264	268		|O
one	269	272		|O
hundred	273	280		|O
hospitalized	281	293		|O
patients	294	302		|O
,	302	303		|O
who	304	307		|O
developed	308	317		|O
diarrhea	318	326	diarrhea	|B-DISEASE
regardless	327	337		|O
of	338	340		|O
antibiotic	341	351		|O
intake	352	358		|O
and	359	362		|O
who	363	366		|O
were	367	371		|O
negative	372	380		|O
for	381	384		|O
C	385	386		|O
.	386	387		|O
difficile	388	397		|O
toxin	398	403		|O
assay	404	409		|O
,	409	410		|O
were	411	415		|O
investigated	416	428		|O
for	429	432		|O
C	433	434		|O
.	434	435		|O
perfringens	436	447		|O
enterotoxin	448	459		|O
(	460	461		|O
CPE	461	464		|O
)	464	465		|O
.	465	466		|O
Simultaneously	467	481		|O
,	481	482		|O
cultures	483	491		|O
were	492	496		|O
set	497	500		|O
up	501	503		|O
for	504	507		|O
other	508	513		|O
possible	514	522		|O
aetiological	523	535		|O
factors	536	543		|O
.	543	544		|O
Ten	545	548	Ten	|B-DISEASE
healthy	549	556		|O
controls	557	565		|O
were	566	570		|O
also	571	575		|O
similarly	576	585		|O
investigated	586	598		|O
.	598	599		|O
CPE	600	603		|O
was	604	607		|O
positive	608	616		|O
in	617	619		|O
2/100	620	625		|O
(	626	627		|O
2%	627	629		|O
)	629	630		|O
of	631	633		|O
the	634	637		|O
patients	638	646		|O
and	647	650		|O
the	651	654		|O
samples	655	662		|O
were	663	667		|O
also	668	672		|O
positive	673	681		|O
for	682	685		|O
the	686	689		|O
organism	690	698		|O
in	699	701		|O
culture	702	709		|O
.	709	710		|O
Other	711	716		|O
organisms	717	726		|O
isolated	727	735		|O
were	736	740		|O
non	741	744		|O
-	744	745		|O
toxigenic	745	754		|O
C	755	756		|O
.	756	757		|O
difficile	758	767		|O
(	768	769		|O
4%	769	771		|O
)	771	772		|O
,	772	773		|O
staphylococci	774	787		|O
(	788	789		|O
6%	789	791		|O
)	791	792		|O
,	792	793		|O
Candida	794	801		|O
(	802	803		|O
18%	803	806		|O
)	806	807		|O
and	808	811		|O
Klebsiella	812	822		|O
pneumoniae	823	833		|O
(	834	835		|O
1%	835	837		|O
)	837	838		|O
.	838	839		|O
Stool	840	845		|O
samples	846	853		|O
from	854	858		|O
healthy	859	866		|O
controls	867	875		|O
grew	876	880		|O
mixed	881	886		|O
growth	887	893		|O
of	894	896		|O
no	897	899		|O
significance	900	912		|O
and	913	916		|O
CPE	917	920		|O
was	921	924		|O
negative	925	933		|O
in	934	936		|O
all	937	940		|O
of	941	943		|O
them	944	948		|O
.	948	949		|O
Detection	950	959		|O
of	960	962		|O
CPE	963	966		|O
is	967	969		|O
not	970	973		|O
part	974	978		|O
of	979	981		|O
routine	982	989		|O
laboratory	990	1000		|O
investigation	1001	1014		|O
due	1015	1018		|O
to	1019	1021		|O
resource	1022	1030		|O
implication	1031	1042		|O
.	1042	1043		|O
Criteria	1044	1052		|O
for	1053	1056		|O
initiating	1057	1067		|O
investigations	1068	1082		|O
have	1083	1087		|O
to	1088	1090		|O
be	1091	1093		|O
therefore	1094	1103		|O
established	1104	1115		|O
by	1116	1118		|O
understanding	1119	1132		|O
the	1133	1136		|O
true	1137	1141		|O
burden	1142	1148		|O
of	1149	1151		|O
C	1152	1153		|O
.	1153	1154		|O
perfringens	1155	1166		|O
-	1166	1167		|O
associated	1167	1177		|O
AAD	1178	1181		|O
by	1182	1184		|O
further	1185	1192		|O
research	1193	1201		|O
.	1201	1202		|O

### 18594001
Efficacy	0	8		|O
and	9	12		|O
safety	13	19		|O
of	20	22		|O
two	23	26		|O
doses	27	32		|O
of	33	35		|O
pemetrexed	36	46		|O
supplemented	47	59		|O
with	60	64		|O
folic	65	70		|O
acid	71	75		|O
and	76	79		|O
vitamin	80	87		|O
B12	88	91		|O
in	92	94		|O
previously	95	105		|O
treated	106	113		|O
patients	114	122		|O
with	123	127		|O
non	128	131	non-small cell lung cancer	|B-DISEASE
-	131	132		|I-DISEASE
small	132	137		|I-DISEASE
cell	138	142		|I-DISEASE
lung	143	147		|I-DISEASE
cancer	148	154		|I-DISEASE
.	154	155		|O
PURPOSE	157	164		|O
:	164	165		|O
The	166	169		|O
objective	170	179		|O
of	180	182		|O
this	183	187		|O
study	188	193		|O
was	194	197		|O
to	198	200		|O
evaluate	201	209		|O
the	210	213		|O
efficacy	214	222		|O
and	223	226		|O
safety	227	233		|O
of	234	236		|O
two	237	240		|O
doses	241	246		|O
of	247	249		|O
pemetrexed	250	260		|O
supplemented	261	273		|O
with	274	278		|O
folic	279	284		|O
acid	285	289		|O
and	290	293		|O
vitamin	294	301		|O
B	302	303		|O
(	303	304		|O
12	304	306		|O
)	306	307		|O
in	308	310		|O
pretreated	311	321		|O
Japanese	322	330		|O
patients	331	339		|O
with	340	344		|O
advanced	345	353		|O
non	354	357	non-small cell lung cancer	|B-DISEASE
-	357	358		|I-DISEASE
small	358	363		|I-DISEASE
cell	364	368		|I-DISEASE
lung	369	373		|I-DISEASE
cancer	374	380		|I-DISEASE
(	381	382		|O
NSCLC	382	387	NSCLC	|B-DISEASE
)	387	388		|O
.	388	389		|O
EXPERIMENTAL	390	402		|O
DESIGN	403	409		|O
:	409	410		|O
Patients	411	419		|O
with	420	424		|O
an	425	427		|O
Eastern	428	435		|O
Cooperative	436	447		|O
Oncology	448	456		|O
Group	457	462		|O
performance	463	474		|O
status	475	481		|O
0	482	483		|O
to	484	486		|O
2	487	488		|O
,	488	489		|O
stage	490	495		|O
III	496	499		|O
or	500	502		|O
IV	503	505		|O
,	505	506		|O
and	507	510		|O
who	511	514		|O
received	515	523		|O
previously	524	534		|O
one	535	538		|O
or	539	541		|O
two	542	545		|O
chemotherapy	546	558		|O
regimens	559	567		|O
were	568	572		|O
randomized	573	583		|O
to	584	586		|O
receive	587	594		|O
500	595	598		|O
mg	599	601		|O
/	601	602		|O
m	602	603		|O
(	603	604		|O
2	604	605		|O
)	605	606		|O
pemetrexed	607	617		|O
(	618	619		|O
P500	619	623		|O
)	623	624		|O
or	625	627		|O
1,000	628	633		|O
mg	634	636		|O
/	636	637		|O
m	637	638		|O
(	638	639		|O
2	639	640		|O
)	640	641		|O
pemetrexed	642	652		|O
(	653	654		|O
P1000	654	659		|O
)	659	660		|O
on	661	663		|O
day	664	667		|O
1	668	669		|O
every	670	675		|O
3	676	677		|O
weeks	678	683		|O
.	683	684		|O
The	685	688		|O
primary	689	696		|O
endpoint	697	705		|O
was	706	709		|O
response	710	718		|O
rate	719	723		|O
.	723	724		|O
RESULTS	725	732		|O
:	732	733		|O
Of	734	736		|O
the	737	740		|O
216	741	744		|O
patients	745	753		|O
evaluable	754	763		|O
for	764	767		|O
efficacy	768	776		|O
(	777	778		|O
108	778	781		|O
in	782	784		|O
each	785	789		|O
arm	790	793		|O
)	793	794		|O
,	794	795		|O
response	796	804		|O
rates	805	810		|O
were	811	815		|O
18.5%	816	821		|O
(	822	823		|O
90%	823	826		|O
confidence	827	837		|O
interval	838	846		|O
,	846	847		|O
12.6-25.8%	848	858		|O
)	858	859		|O
and	860	863		|O
14.8%	864	869		|O
(	870	871		|O
90%	871	874		|O
confidence	875	885		|O
interval	886	894		|O
,	894	895		|O
9.5-21.6%	896	905		|O
)	905	906		|O
,	906	907		|O
median	908	914		|O
survival	915	923		|O
times	924	929		|O
were	930	934		|O
16.0	935	939		|O
and	940	943		|O
12.6	944	948		|O
months	949	955		|O
,	955	956		|O
1	957	958		|O
-	958	959		|O
year	959	963		|O
survival	964	972		|O
rates	973	978		|O
were	979	983		|O
59.2%	984	989		|O
and	990	993		|O
53.7%	994	999		|O
,	999	1000		|O
and	1001	1004		|O
median	1005	1011		|O
progression	1012	1023		|O
-	1023	1024		|O
free	1024	1028		|O
survival	1029	1037		|O
were	1038	1042		|O
3.0	1043	1046		|O
and	1047	1050		|O
2.5	1051	1054		|O
months	1055	1061		|O
for	1062	1065		|O
the	1066	1069		|O
P500	1070	1074		|O
and	1075	1078		|O
P1000	1079	1084		|O
,	1084	1085		|O
respectively	1086	1098		|O
.	1098	1099		|O
Cox	1100	1103		|O
multiple	1104	1112		|O
regression	1113	1123		|O
analysis	1124	1132		|O
indicated	1133	1142		|O
that	1143	1147		|O
pemetrexed	1148	1158		|O
dose	1159	1163		|O
was	1164	1167		|O
not	1168	1171		|O
a	1172	1173		|O
significant	1174	1185		|O
prognostic	1186	1196		|O
factor	1197	1203		|O
.	1203	1204		|O
Drug	1205	1209	Drug-related toxicity	|B-ADVERSE
-	1209	1210		|I-ADVERSE
related	1210	1217		|I-ADVERSE
toxicity	1218	1226		|I-ADVERSE
was	1227	1230		|O
generally	1231	1240		|O
tolerable	1241	1250		|O
for	1251	1254		|O
both	1255	1259		|O
doses	1260	1265		|O
;	1265	1266		|O
however	1267	1274		|O
,	1274	1275		|O
the	1276	1279		|O
safety	1280	1286		|O
profile	1287	1294		|O
of	1295	1297		|O
P500	1298	1302		|O
showed	1303	1309		|O
generally	1310	1319		|O
milder	1320	1326		|O
toxicity	1327	1335		|O
.	1335	1336		|O
Main	1337	1341		|O
adverse	1342	1349		|O
drug	1350	1354		|O
reactions	1355	1364		|O
of	1365	1367		|O
severity	1368	1376		|O
grade	1377	1382		|O
3	1383	1384		|O
or	1385	1387		|O
4	1388	1389		|O
were	1390	1394		|O
neutrophil	1395	1405	neutrophil count decreased	|B-ADVERSE
count	1406	1411		|I-ADVERSE
decreased	1412	1421		|I-ADVERSE
(	1422	1423		|O
20.2%	1423	1428		|O
)	1428	1429		|O
and	1430	1433		|O
alanine	1434	1441	alanine aminotransferase (glutamine pyruvic transaminase) increased	|B-ADVERSE
aminotransferase	1442	1458		|I-ADVERSE
(	1459	1460		|I-ADVERSE
glutamine	1460	1469		|I-ADVERSE
pyruvic	1470	1477		|I-ADVERSE
transaminase	1478	1490		|I-ADVERSE
)	1490	1491		|I-ADVERSE
increased	1492	1501		|I-ADVERSE
(	1502	1503		|O
15.8%	1503	1508		|O
)	1508	1509		|O
in	1510	1512		|O
P500	1513	1517		|O
and	1518	1521		|O
neutrophil	1522	1532	neutrophil count decreased	|B-ADVERSE
count	1533	1538		|I-ADVERSE
decreased	1539	1548		|I-ADVERSE
(	1549	1550		|O
24.3%	1550	1555		|O
)	1555	1556		|O
,	1556	1557		|O
WBC	1558	1561	WBC count decreased	|B-ADVERSE
count	1562	1567		|I-ADVERSE
decreased	1568	1577		|I-ADVERSE
(	1578	1579		|O
20.7%	1579	1584		|O
)	1584	1585		|O
,	1585	1586		|O
and	1587	1590		|O
lymphocyte	1591	1601	lymphocyte count decreased	|B-ADVERSE
count	1602	1607		|I-ADVERSE
decreased	1608	1617		|I-ADVERSE
(	1618	1619		|O
18.0%	1619	1624		|O
)	1624	1625		|O
in	1626	1628		|O
P1000	1629	1634		|O
.	1634	1635		|O
One	1636	1639		|O
drug	1640	1644		|O
-	1644	1645		|O
related	1645	1652		|O
death	1653	1658		|O
from	1659	1663		|O
interstitial	1664	1676	interstitial lung disease	|B-ADVERSE
lung	1677	1681		|I-ADVERSE
disease	1682	1689		|I-ADVERSE
occurred	1690	1698		|O
in	1699	1701		|O
the	1702	1705		|O
P500	1706	1710		|O
.	1710	1711		|O
CONCLUSION	1712	1722		|O
:	1722	1723		|O
P500	1724	1728		|O
and	1729	1732		|O
P1000	1733	1738		|O
are	1739	1742		|O
similarly	1743	1752		|O
active	1753	1759		|O
with	1760	1764		|O
promising	1765	1774		|O
efficacy	1775	1783		|O
and	1784	1787		|O
acceptable	1788	1798		|O
safety	1799	1805		|O
outcomes	1806	1814		|O
in	1815	1817		|O
pretreated	1818	1828		|O
patients	1829	1837		|O
with	1838	1842		|O
NSCLC	1843	1848	NSCLC	|B-DISEASE
.	1848	1849		|O
These	1850	1855		|O
results	1856	1863		|O
support	1864	1871		|O
the	1872	1875		|O
use	1876	1879		|O
of	1880	1882		|O
P500	1883	1887		|O
as	1888	1890		|O
a	1891	1892		|O
second	1893	1899		|O
-	1899	1900		|O
and	1901	1904		|O
third	1905	1910		|O
-	1910	1911		|O
line	1911	1915		|O
treatment	1916	1925		|O
of	1926	1928		|O
NSCLC	1929	1934	NSCLC	|B-DISEASE
.	1934	1935		|O

### 18695260
Disparities	0	11		|O
in	12	14		|O
the	15	18		|O
use	19	22		|O
of	23	25		|O
chemotherapy	26	38		|O
and	39	42		|O
monoclonal	43	53		|O
antibody	54	62		|O
therapy	63	70		|O
for	71	74		|O
elderly	75	82		|O
advanced	83	91		|O
colorectal	92	102	colorectal cancer	|B-DISEASE
cancer	103	109		|I-DISEASE
patients	110	118		|O
in	119	121		|O
the	122	125		|O
community	126	135		|O
oncology	136	144		|O
setting	145	152		|O
.	152	153		|O
BACKGROUND	155	165		|O
:	165	166		|O
The	167	170		|O
clinical	171	179		|O
trials	180	186		|O
on	187	189		|O
which	190	195		|O
the	196	199		|O
treatment	200	209		|O
of	210	212		|O
advanced	213	221		|O
colorectal	222	232	colorectal	|B-DISEASE
(	233	234		|O
CRC	234	237	CRC	|B-DISEASE
)	237	238		|O
is	239	241		|O
based	242	247		|O
enroll	248	254		|O
few	255	258		|O
elderly	259	266		|O
patients	267	275		|O
.	275	276		|O
Furthermore	277	288		|O
,	288	289		|O
few	290	293		|O
investigations	294	308		|O
have	309	313		|O
determined	314	324		|O
the	325	328		|O
use	329	332		|O
and	333	336		|O
outcomes	337	345		|O
of	346	348		|O
the	349	352		|O
treatment	353	362		|O
of	363	365		|O
advanced	366	374		|O
CRC	375	378	CRC	|B-DISEASE
in	379	381		|O
practice	382	390		|O
.	390	391		|O
This	392	396		|O
study	397	402		|O
evaluated	403	412		|O
the	413	416		|O
treatment	417	426		|O
of	427	429		|O
advanced	430	438		|O
CRC	439	442	CRC	|B-DISEASE
in	443	445		|O
community	446	455		|O
oncology	456	464		|O
practices	465	474		|O
,	474	475		|O
focusing	476	484		|O
on	485	487		|O
age	488	491		|O
-	491	492		|O
related	492	499		|O
differences	500	511		|O
in	512	514		|O
treatment	515	524		|O
and	525	528		|O
outcome	529	536		|O
.	536	537		|O
METHODS	538	545		|O
:	545	546		|O
A	547	548		|O
national	549	557		|O
,	557	558		|O
retrospective	559	572		|O
chart	573	578		|O
review	579	585		|O
was	586	589		|O
conducted	590	599		|O
to	600	602		|O
evaluate	603	611		|O
the	612	615		|O
management	616	626		|O
of	627	629		|O
advanced	630	638		|O
CRC	639	642	CRC	|B-DISEASE
in	643	645		|O
10	646	648		|O
community	649	658		|O
practices	659	668		|O
across	669	675		|O
the	676	679		|O
U	680	681		|O
.	681	682		|O
S	682	683		|O
.	683	684		|O
All	685	688		|O
medical	689	696		|O
records	697	704		|O
of	705	707		|O
patients	708	716		|O
diagnosed	717	726		|O
with	727	731		|O
advanced	732	740		|O
CRC	741	744	CRC	|B-DISEASE
initiating	745	755		|O
chemotherapy	756	768		|O
treatment	769	778		|O
after	779	784		|O
January	785	792		|O
1	793	794		|O
,	794	795		|O
2003	796	800		|O
through	801	808		|O
2006	809	813		|O
were	814	818		|O
included	819	827		|O
.	827	828		|O
The	829	832		|O
primary	833	840		|O
aim	841	844		|O
was	845	848		|O
to	849	851		|O
compare	852	859		|O
the	860	863		|O
proportion	864	874		|O
receiving	875	884		|O
doublet	885	892		|O
chemotherapy	893	905		|O
(	906	907		|O
irinotecan	907	917		|O
or	918	920		|O
oxaliplatin	921	932		|O
with	933	937		|O
a	938	939		|O
fluoropyrimidine	940	956		|O
)	956	957		|O
as	958	960		|O
initial	961	968		|O
therapy	969	976		|O
in	977	979		|O
young	980	985		|O
(	986	987		|O
age	987	990		|O
<	991	992		|O
or	992	994		|O
=	994	995		|O
65	995	997		|O
years	998	1003		|O
)	1003	1004		|O
and	1005	1008		|O
elderly	1009	1016		|O
(	1017	1018		|O
age	1018	1021		|O
>	1022	1023		|O
65	1023	1025		|O
years	1026	1031		|O
)	1031	1032		|O
patients	1033	1041		|O
.	1041	1042		|O
Additional	1043	1053		|O
aims	1054	1058		|O
included	1059	1067		|O
age	1068	1071		|O
-	1071	1072		|O
based	1072	1077		|O
comparisons	1078	1089		|O
of	1090	1092		|O
the	1093	1096		|O
addition	1097	1105		|O
of	1106	1108		|O
bevacizumab	1109	1120		|O
to	1121	1123		|O
chemotherapy	1124	1136		|O
,	1136	1137		|O
overall	1138	1145		|O
chemotherapy	1146	1158		|O
use	1159	1162		|O
,	1162	1163		|O
all	1164	1167		|O
-	1167	1168		|O
cause	1168	1173		|O
mortality	1174	1183		|O
,	1183	1184		|O
and	1185	1188		|O
toxicity	1189	1197		|O
-	1197	1198		|O
related	1198	1205		|O
events	1206	1212		|O
.	1212	1213		|O
RESULTS	1214	1221		|O
:	1221	1222		|O
Overall	1223	1230		|O
,	1230	1231		|O
520	1232	1235		|O
patients	1236	1244		|O
(	1245	1246		|O
56%	1246	1249		|O
elderly	1250	1257		|O
)	1257	1258		|O
received	1259	1267		|O
6,253	1268	1273		|O
cycles	1274	1280		|O
of	1281	1283		|O
chemotherapy	1284	1296		|O
.	1296	1297		|O
Of	1298	1300		|O
the	1301	1304		|O
younger	1305	1312		|O
patients	1313	1321		|O
,	1321	1322		|O
84%	1323	1326		|O
received	1327	1335		|O
doublet	1336	1343		|O
chemotherapy	1344	1356		|O
first	1357	1362		|O
-	1362	1363		|O
line	1363	1367		|O
,	1367	1368		|O
compared	1369	1377		|O
with	1378	1382		|O
58%	1383	1386		|O
of	1387	1389		|O
elderly	1390	1397		|O
patients	1398	1406		|O
(	1407	1408		|O
p	1408	1409		|O
<	1410	1411		|O
.001	1412	1416		|O
)	1416	1417		|O
.	1417	1418		|O
The	1419	1422		|O
use	1423	1426		|O
of	1427	1429		|O
each	1430	1434		|O
of	1435	1437		|O
the	1438	1441		|O
medications	1442	1453		|O
-	1453	1454		|O
-	1454	1455		|O
irinotecan	1455	1465		|O
,	1465	1466		|O
oxaliplatin	1467	1478		|O
,	1478	1479		|O
and	1480	1483		|O
bevacizumab	1484	1495		|O
-	1495	1496		|O
-	1496	1497		|O
was	1497	1500		|O
lower	1501	1506		|O
in	1507	1509		|O
elderly	1510	1517		|O
patients	1518	1526		|O
(	1527	1528		|O
p	1528	1529		|O
<	1530	1531		|O
.001	1532	1536		|O
)	1536	1537		|O
.	1537	1538		|O
Independent	1539	1550		|O
predictors	1551	1561		|O
of	1562	1564		|O
a	1565	1566		|O
higher	1567	1573		|O
risk	1574	1578		|O
for	1579	1582		|O
mortality	1583	1592		|O
were	1593	1597		|O
age	1598	1601		|O
>	1602	1603		|O
65	1603	1605		|O
(	1606	1607		|O
adjusted	1607	1615		|O
hazards	1616	1623		|O
ratio	1624	1629		|O
[	1630	1631		|O
HR	1631	1633		|O
]	1633	1634		|O
,	1634	1635		|O
1.19	1635	1639		|O
;	1639	1640		|O
95%	1641	1644		|O
confidence	1645	1655		|O
interval	1656	1664		|O
[	1665	1666		|O
CI	1666	1668		|O
]	1668	1669		|O
,	1669	1670		|O
1.02-1.39	1671	1680		|O
)	1680	1681		|O
and	1682	1685		|O
performance	1686	1697		|O
status	1698	1704		|O
score	1705	1710		|O
>	1711	1712		|O
or	1712	1714		|O
=	1714	1715		|O
2	1715	1716		|O
(	1717	1718		|O
HR	1718	1720		|O
,	1720	1721		|O
1.65	1722	1726		|O
;	1726	1727		|O
95%	1728	1731		|O
CI	1732	1734		|O
,	1734	1735		|O
1.41-1.91	1736	1745		|O
)	1745	1746		|O
.	1746	1747		|O
CONCLUSION	1748	1758		|O
:	1758	1759		|O
Elderly	1760	1767		|O
patients	1768	1776		|O
are	1777	1780		|O
less	1781	1785		|O
likely	1786	1792		|O
to	1793	1795		|O
receive	1796	1803		|O
first	1804	1809		|O
-	1809	1810		|O
line	1810	1814		|O
doublet	1815	1822		|O
chemotherapy	1823	1835		|O
than	1836	1840		|O
younger	1841	1848		|O
patients	1849	1857		|O
.	1857	1858		|O
Age	1859	1862		|O
and	1863	1866		|O
performance	1867	1878		|O
status	1879	1885		|O
are	1886	1889		|O
independent	1890	1901		|O
predictors	1902	1912		|O
of	1913	1915		|O
treatment	1916	1925		|O
and	1926	1929		|O
overall	1930	1937		|O
survival	1938	1946		|O
.	1946	1947		|O

### 18598093
Effect	0	6		|O
of	7	9		|O
repeated	10	18		|O
doses	19	24		|O
of	25	27		|O
darunavir	28	37		|O
plus	38	42		|O
low	43	46		|O
-	46	47		|O
dose	47	51		|O
ritonavir	52	61		|O
on	62	64		|O
the	65	68		|O
pharmacokinetics	69	85		|O
of	86	88		|O
sildenafil	89	99		|O
in	100	102		|O
healthy	103	110		|O
male	111	115		|O
subjects	116	124		|O
:	124	125		|O
phase	126	131		|O
I	132	133		|O
randomized	134	144		|O
,	144	145		|O
open	146	150		|O
-	150	151		|O
label	151	156		|O
,	156	157		|O
two	158	161		|O
-	161	162		|O
way	162	165		|O
crossover	166	175		|O
study	176	181		|O
.	181	182		|O
BACKGROUND	184	194		|O
AND	195	198		|O
OBJECTIVES	199	209		|O
:	209	210		|O
Darunavir	211	220		|O
(	221	222		|O
DRV	222	225		|O
,	225	226		|O
TMC114	227	233		|O
)	233	234		|O
is	235	237		|O
a	238	239		|O
novel	240	245		|O
protease	246	254		|O
inhibitor	255	264		|O
administered	265	277		|O
in	278	280		|O
combination	281	292		|O
with	293	297		|O
low	298	301		|O
-	301	302		|O
dose	302	306		|O
ritonavir	307	316		|O
(	317	318		|O
DRV	318	321		|O
/	321	322		|O
r	322	323		|O
)	323	324		|O
and	325	328		|O
is	329	331		|O
highly	332	338		|O
active	339	345		|O
against	346	353		|O
both	354	358		|O
wild	359	363		|O
-	363	364		|O
type	364	368		|O
and	369	372		|O
multidrug	373	382		|O
-	382	383		|O
resistant	383	392		|O
HIV	393	396		|O
-	396	397		|O
1	397	398		|O
strains	399	406		|O
.	406	407		|O
Sildenafil	408	418		|O
is	419	421		|O
an	422	424		|O
oral	425	429		|O
therapy	430	437		|O
for	438	441		|O
erectile	442	450	erectile dysfunction	|B-DISEASE
dysfunction	451	462		|I-DISEASE
.	462	463		|O
Concomitant	464	475		|O
administration	476	490		|O
of	491	493		|O
protease	494	502		|O
inhibitors	503	513		|O
and	514	517		|O
sildenafil	518	528		|O
increases	529	538		|O
sildenafil	539	549		|O
plasma	550	556		|O
concentrations	557	571		|O
.	571	572		|O
The	573	576		|O
potential	577	586		|O
for	587	590		|O
a	591	592		|O
pharmacokinetic	593	608		|O
drug	609	613		|O
interaction	614	625		|O
exists	626	632		|O
when	633	637		|O
sildenafil	638	648		|O
and	649	652		|O
DRV	653	656		|O
/	656	657		|O
r	657	658		|O
are	659	662		|O
co	663	665		|O
-	665	666		|O
administered	666	678		|O
,	678	679		|O
as	680	682		|O
these	683	688		|O
drugs	689	694		|O
are	695	698		|O
primarily	699	708		|O
metabolized	709	720		|O
by	721	723		|O
cytochrome	724	734		|O
P450	735	739		|O
(	740	741		|O
CYP	741	744		|O
)	744	745		|O
3A	746	748		|O
,	748	749		|O
and	750	753		|O
darunavir	754	763		|O
and	764	767		|O
ritonavir	768	777		|O
are	778	781		|O
CYP3A	782	787		|O
inhibitors	788	798		|O
.	798	799		|O
The	800	803		|O
primary	804	811		|O
objective	812	821		|O
of	822	824		|O
this	825	829		|O
open	830	834		|O
-	834	835		|O
label	835	840		|O
,	840	841		|O
crossover	842	851		|O
,	851	852		|O
phase	853	858		|O
I	859	860		|O
study	861	866		|O
was	867	870		|O
to	871	873		|O
assess	874	880		|O
the	881	884		|O
effect	885	891		|O
of	892	894		|O
multiple	895	903		|O
doses	904	909		|O
of	910	912		|O
DRV	913	916		|O
/	916	917		|O
r	917	918		|O
on	919	921		|O
the	922	925		|O
pharmacokinetics	926	942		|O
of	943	945		|O
sildenafil	946	956		|O
and	957	960		|O
its	961	964		|O
active	965	971		|O
metabolite	972	982		|O
N	983	984		|O
-	984	985		|O
desmethyl	985	994		|O
sildenafil	995	1005		|O
.	1005	1006		|O
The	1007	1010		|O
secondary	1011	1020		|O
objective	1021	1030		|O
was	1031	1034		|O
to	1035	1037		|O
assess	1038	1044		|O
the	1045	1048		|O
short	1049	1054		|O
-	1054	1055		|O
term	1055	1059		|O
safety	1060	1066		|O
and	1067	1070		|O
tolerability	1071	1083		|O
of	1084	1086		|O
co	1087	1089		|O
-	1089	1090		|O
administration	1090	1104		|O
of	1105	1107		|O
sildenafil	1108	1118		|O
and	1119	1122		|O
DRV	1123	1126		|O
/	1126	1127		|O
r	1127	1128		|O
.	1128	1129		|O
METHODS	1130	1137		|O
:	1137	1138		|O
Sixteen	1139	1146		|O
HIV	1147	1150		|O
-	1150	1151		|O
negative	1151	1159		|O
healthy	1160	1167		|O
male	1168	1172		|O
subjects	1173	1181		|O
were	1182	1186		|O
randomized	1187	1197		|O
to	1198	1200		|O
one	1201	1204		|O
of	1205	1207		|O
two	1208	1211		|O
sequences	1212	1221		|O
.	1221	1222		|O
In	1223	1225		|O
two	1226	1229		|O
sessions	1230	1238		|O
each	1239	1243		|O
subject	1244	1251		|O
received	1252	1260		|O
treatments	1261	1271		|O
A	1272	1273		|O
and	1274	1277		|O
B	1278	1279		|O
.	1279	1280		|O
In	1281	1283		|O
treatment	1284	1293		|O
A	1294	1295		|O
,	1295	1296		|O
a	1297	1298		|O
single	1299	1305		|O
dose	1306	1310		|O
of	1311	1313		|O
sildenafil	1314	1324		|O
100	1325	1328		|O
mg	1329	1331		|O
was	1332	1335		|O
administered	1336	1348		|O
.	1348	1349		|O
In	1350	1352		|O
treatment	1353	1362		|O
B	1363	1364		|O
,	1364	1365		|O
the	1366	1369		|O
subjects	1370	1378		|O
received	1379	1387		|O
DRV	1388	1391		|O
/	1391	1392		|O
r	1392	1393		|O
400/100	1394	1401		|O
mg	1402	1404		|O
twice	1405	1410		|O
daily	1411	1416		|O
for	1417	1420		|O
8	1421	1422		|O
days	1423	1427		|O
and	1428	1431		|O
on	1432	1434		|O
day	1435	1438		|O
7	1439	1440		|O
a	1441	1442		|O
single	1443	1449		|O
dose	1450	1454		|O
of	1455	1457		|O
sildenafil	1458	1468		|O
25	1469	1471		|O
mg	1472	1474		|O
was	1475	1478		|O
co	1479	1481		|O
-	1481	1482		|O
administered	1482	1494		|O
.	1494	1495		|O
Full	1496	1500		|O
pharmacokinetic	1501	1516		|O
profiles	1517	1525		|O
of	1526	1528		|O
sildenafil	1529	1539		|O
,	1539	1540		|O
N	1541	1542		|O
-	1542	1543		|O
desmethyl	1543	1552		|O
sildenafil	1553	1563		|O
,	1563	1564		|O
darunavir	1565	1574		|O
and	1575	1578		|O
ritonavir	1579	1588		|O
were	1589	1593		|O
determined	1594	1604		|O
.	1604	1605		|O
Safety	1606	1612		|O
and	1613	1616		|O
tolerability	1617	1629		|O
were	1630	1634		|O
also	1635	1639		|O
assessed	1640	1648		|O
.	1648	1649		|O
RESULTS	1650	1657		|O
:	1657	1658		|O
Sildenafil	1659	1669		|O
exposure	1670	1678		|O
(	1679	1680		|O
area	1680	1684		|O
under	1685	1690		|O
the	1691	1694		|O
plasma	1695	1701		|O
concentration	1702	1715		|O
-	1715	1716		|O
time	1716	1720		|O
curve	1721	1726		|O
[	1727	1728		|O
AUC	1728	1731		|O
]	1731	1732		|O
)	1732	1733		|O
was	1734	1737		|O
comparable	1738	1748		|O
between	1749	1756		|O
the	1757	1760		|O
two	1761	1764		|O
treatments	1765	1775		|O
despite	1776	1783		|O
administration	1784	1798		|O
of	1799	1801		|O
a	1802	1803		|O
lower	1804	1809		|O
dose	1810	1814		|O
of	1815	1817		|O
sildenafil	1818	1828		|O
(	1829	1830		|O
25	1830	1832		|O
mg	1833	1835		|O
)	1835	1836		|O
with	1837	1841		|O
DRV	1842	1845		|O
/	1845	1846		|O
r	1846	1847		|O
than	1848	1852		|O
when	1853	1857		|O
sildenafil	1858	1868		|O
(	1869	1870		|O
100	1870	1873		|O
mg	1874	1876		|O
)	1876	1877		|O
was	1878	1881		|O
administered	1882	1894		|O
alone	1895	1900		|O
.	1900	1901		|O
When	1902	1906		|O
sildenafil	1907	1917		|O
25	1918	1920		|O
mg	1921	1923		|O
was	1924	1927		|O
co	1928	1930		|O
-	1930	1931		|O
administered	1931	1943		|O
with	1944	1948		|O
DRV	1949	1952		|O
/	1952	1953		|O
r	1953	1954		|O
,	1954	1955		|O
the	1956	1959		|O
sildenafil	1960	1970		|O
maximum	1971	1978		|O
plasma	1979	1985		|O
concentration	1986	1999		|O
(	2000	2001		|O
Cmax	2001	2005		|O
)	2005	2006		|O
was	2007	2010		|O
38%	2011	2014		|O
lower	2015	2020		|O
compared	2021	2029		|O
with	2030	2034		|O
Cmax	2035	2039		|O
after	2040	2045		|O
administration	2046	2060		|O
of	2061	2063		|O
sildenafil	2064	2074		|O
alone	2075	2080		|O
at	2081	2083		|O
a	2084	2085		|O
dose	2086	2090		|O
of	2091	2093		|O
100	2094	2097		|O
mg	2098	2100		|O
.	2100	2101		|O
N	2102	2103		|O
-	2103	2104		|O
desmethyl	2104	2113		|O
sildenafil	2114	2124		|O
Cmax	2125	2129		|O
and	2130	2133		|O
AUC	2134	2137		|O
from	2138	2142		|O
the	2143	2146		|O
time	2147	2151		|O
of	2152	2154		|O
administration	2155	2169		|O
until	2170	2175		|O
the	2176	2179		|O
last	2180	2184		|O
time	2185	2189		|O
point	2190	2195		|O
with	2196	2200		|O
a	2201	2202		|O
measurable	2203	2213		|O
concentration	2214	2227		|O
after	2228	2233		|O
dosing	2234	2240		|O
(	2241	2242		|O
calculated	2242	2252		|O
by	2253	2255		|O
linear	2256	2262		|O
trapezoidal	2263	2274		|O
summation	2275	2284		|O
[	2285	2286		|O
AUClast	2286	2293		|O
]	2293	2294		|O
)	2294	2295		|O
values	2296	2302		|O
decreased	2303	2312		|O
by	2313	2315		|O
approximately	2316	2329		|O
95%	2330	2333		|O
when	2334	2338		|O
sildenafil	2339	2349		|O
25	2350	2352		|O
mg	2353	2355		|O
was	2356	2359		|O
co	2360	2362		|O
-	2362	2363		|O
administered	2363	2375		|O
with	2376	2380		|O
DRV	2381	2384		|O
/	2384	2385		|O
r	2385	2386		|O
compared	2387	2395		|O
with	2396	2400		|O
sildenafil	2401	2411		|O
100	2412	2415		|O
mg	2416	2418		|O
alone	2419	2424		|O
.	2424	2425		|O
Combined	2426	2434		|O
treatment	2435	2444		|O
with	2445	2449		|O
DRV	2450	2453		|O
/	2453	2454		|O
r	2454	2455		|O
and	2456	2459		|O
sildenafil	2460	2470		|O
was	2471	2474		|O
generally	2475	2484		|O
safe	2485	2489		|O
and	2490	2493		|O
well	2494	2498		|O
tolerated	2499	2508		|O
.	2508	2509		|O
CONCLUSION	2510	2520		|O
:	2520	2521		|O
Sildenafil	2522	2532		|O
exposure	2533	2541		|O
is	2542	2544		|O
increased	2545	2554		|O
in	2555	2557		|O
the	2558	2561		|O
presence	2562	2570		|O
of	2571	2573		|O
DRV	2574	2577		|O
/	2577	2578		|O
r	2578	2579		|O
.	2579	2580		|O
In	2581	2583		|O
this	2584	2588		|O
setting	2589	2596		|O
,	2596	2597		|O
a	2598	2599		|O
dose	2600	2604		|O
adjustment	2605	2615		|O
for	2616	2619		|O
sildenafil	2620	2630		|O
is	2631	2633		|O
warranted	2634	2643		|O
;	2643	2644		|O
no	2645	2647		|O
more	2648	2652		|O
than	2653	2657		|O
25	2658	2660		|O
mg	2661	2663		|O
of	2664	2666		|O
sildenafil	2667	2677		|O
is	2678	2680		|O
recommended	2681	2692		|O
over	2693	2697		|O
a	2698	2699		|O
48	2700	2702		|O
-	2702	2703		|O
hour	2703	2707		|O
period	2708	2714		|O
when	2715	2719		|O
co	2720	2722		|O
-	2722	2723		|O
administered	2723	2735		|O
with	2736	2740		|O
DRV	2741	2744		|O
/	2744	2745		|O
r	2745	2746		|O
.	2746	2747		|O

### 18788754
Dielectrophoretic	0	17		|O
field	18	23		|O
-	23	24		|O
flow	24	28		|O
fractionation	29	42		|O
system	43	49		|O
for	50	53		|O
detection	54	63		|O
of	64	66		|O
aquatic	67	74		|O
toxicants	75	84		|O
.	84	85		|O
Dielectrophoretic	87	104		|O
field	105	110		|O
-	110	111		|O
flow	111	115		|O
fractionation	116	129		|O
(	130	131		|O
dFFF	131	135		|O
)	135	136		|O
was	137	140		|O
applied	141	148		|O
as	149	151		|O
a	152	153		|O
contact	154	161		|O
-	161	162		|O
free	162	166		|O
way	167	170		|O
to	171	173		|O
sense	174	179		|O
changes	180	187		|O
in	188	190		|O
the	191	194		|O
plasma	195	201		|O
membrane	202	210		|O
capacitances	211	223		|O
and	224	227		|O
conductivities	228	242		|O
of	243	245		|O
cultured	246	254		|O
human	255	260		|O
HL	261	263		|O
-	263	264		|O
60	264	266		|O
cells	267	272		|O
in	273	275		|O
response	276	284		|O
to	285	287		|O
toxicant	288	296		|O
exposure	297	305		|O
.	305	306		|O
A	307	308		|O
micropatterned	309	323		|O
electrode	324	333		|O
imposed	334	341		|O
electric	342	350		|O
forces	351	357		|O
on	358	360		|O
cells	361	366		|O
in	367	369		|O
suspension	370	380		|O
in	381	383		|O
a	384	385		|O
parabolic	386	395		|O
flow	396	400		|O
profile	401	408		|O
as	409	411		|O
they	412	416		|O
moved	417	422		|O
through	423	430		|O
a	431	432		|O
thin	433	437		|O
chamber	438	445		|O
.	445	446		|O
Relative	447	455		|O
changes	456	463		|O
in	464	466		|O
the	467	470		|O
dFFF	471	475		|O
peak	476	480		|O
elution	481	488		|O
time	489	493		|O
,	493	494		|O
reflecting	495	505		|O
changes	506	513		|O
in	514	516		|O
cell	517	521		|O
membrane	522	530		|O
area	531	535		|O
and	536	539		|O
ion	540	543		|O
permeability	544	556		|O
,	556	557		|O
were	558	562		|O
measured	563	571		|O
as	572	574		|O
indices	575	582		|O
of	583	585		|O
response	586	594		|O
during	595	601		|O
the	602	605		|O
first	606	611		|O
150	612	615		|O
min	616	619		|O
of	620	622		|O
exposure	623	631		|O
to	632	634		|O
eight	635	640		|O
toxicants	641	650		|O
having	651	657		|O
different	658	667		|O
single	668	674		|O
or	675	677		|O
mixed	678	683		|O
modes	684	689		|O
of	690	692		|O
action	693	699		|O
(	700	701		|O
acrylonitrile	701	714		|O
,	714	715		|O
actinomycin	716	727		|O
D	728	729		|O
,	729	730		|O
carbon	731	737		|O
tetrachloride	738	751		|O
,	751	752		|O
endosulfan	753	763		|O
,	763	764		|O
N	765	766		|O
-	766	767		|O
nitroso	767	774		|O
-	774	775		|O
N	776	777		|O
-	777	778		|O
methylurea	778	788		|O
(	789	790		|O
NMU	790	793		|O
)	793	794		|O
,	794	795		|O
paraquat	796	804		|O
dichloride	805	815		|O
,	815	816		|O
puromycin	817	826		|O
,	826	827		|O
and	828	831		|O
styrene	832	839		|O
oxide	840	845		|O
)	845	846		|O
.	846	847		|O
The	848	851		|O
dFFF	852	856		|O
method	857	863		|O
was	864	867		|O
compared	868	876		|O
with	877	881		|O
the	882	885		|O
cell	886	890		|O
viability	891	900		|O
assay	901	906		|O
for	907	910		|O
all	911	914		|O
toxicants	915	924		|O
and	925	928		|O
with	929	933		|O
the	934	937		|O
mitochondrial	938	951		|O
potentiometric	952	966		|O
dye	967	970		|O
assay	971	976		|O
or	977	979		|O
DNA	980	983		|O
alkaline	984	992		|O
comet	993	998		|O
assay	999	1004		|O
according	1005	1014		|O
to	1015	1017		|O
the	1018	1021		|O
mode	1022	1026		|O
of	1027	1029		|O
action	1030	1036		|O
of	1037	1039		|O
the	1040	1043		|O
specific	1044	1052		|O
agents	1053	1059		|O
.	1059	1060		|O
Except	1061	1067		|O
for	1068	1071		|O
low	1072	1075		|O
doses	1076	1081		|O
of	1082	1084		|O
nucleic	1085	1092		|O
acid	1093	1097		|O
-	1097	1098		|O
targeting	1098	1107		|O
agents	1108	1114		|O
(	1115	1116		|O
actinomycin	1116	1127		|O
D	1128	1129		|O
and	1130	1133		|O
NMU	1134	1137		|O
)	1137	1138		|O
,	1138	1139		|O
the	1140	1143		|O
dFFF	1144	1148		|O
method	1149	1155		|O
detected	1156	1164		|O
all	1165	1168		|O
toxicants	1169	1178		|O
more	1179	1183		|O
sensitively	1184	1195		|O
than	1196	1200		|O
other	1201	1206		|O
assays	1207	1213		|O
,	1213	1214		|O
in	1215	1217		|O
some	1218	1222		|O
cases	1223	1228		|O
up	1229	1231		|O
to	1232	1234		|O
10	1235	1237		|O
(	1238	1239		|O
5	1239	1240		|O
)	1240	1241		|O
times	1242	1247		|O
more	1248	1252		|O
sensitively	1253	1264		|O
than	1265	1269		|O
the	1270	1273		|O
viability	1274	1283		|O
approach	1284	1292		|O
.	1292	1293		|O
The	1294	1297		|O
results	1298	1305		|O
suggest	1306	1313		|O
the	1314	1317		|O
dFFF	1318	1322		|O
method	1323	1329		|O
merits	1330	1336		|O
additional	1337	1347		|O
study	1348	1353		|O
for	1354	1357		|O
possible	1358	1366		|O
applicability	1367	1380		|O
in	1381	1383		|O
toxicology	1384	1394		|O
.	1394	1395		|O

### 18566484
Application	0	11		|O
of	12	14		|O
a	15	16		|O
high	17	21		|O
-	21	22		|O
content	22	29		|O
multiparameter	30	44		|O
cytotoxicity	45	57	cytotoxicity	|B-ADVERSE
assay	58	63		|O
to	64	66		|O
prioritize	67	77		|O
compounds	78	87		|O
based	88	93		|O
on	94	96		|O
toxicity	97	105		|O
potential	106	115		|O
in	116	118		|O
humans	119	125		|O
.	125	126		|O
Prioritization	128	142		|O
of	143	145		|O
compounds	146	155		|O
based	156	161		|O
on	162	164		|O
human	165	170		|O
hepatotoxicity	171	185	hepatotoxicity	|B-ADVERSE
potential	186	195		|O
is	196	198		|O
currently	199	208		|O
a	209	210		|O
key	211	214		|O
unmet	215	220		|O
need	221	225		|O
in	226	228		|O
drug	229	233		|O
discovery	234	243		|O
,	243	244		|O
as	245	247		|O
it	248	250		|O
can	251	254		|O
become	255	261		|O
a	262	263		|O
major	264	269		|O
problem	270	277		|O
for	278	281		|O
several	282	289		|O
lead	290	294		|O
compounds	295	304		|O
in	305	307		|O
later	308	313		|O
stages	314	320		|O
of	321	323		|O
the	324	327		|O
drug	328	332		|O
discovery	333	342		|O
pipeline	343	351		|O
.	351	352		|O
The	353	356		|O
authors	357	364		|O
report	365	371		|O
the	372	375		|O
validation	376	386		|O
and	387	390		|O
implementation	391	405		|O
of	406	408		|O
a	409	410		|O
high	411	415		|O
-	415	416		|O
content	416	423		|O
multiparametric	424	439		|O
cytotoxicity	440	452	cytotoxicity	|B-ADVERSE
assay	453	458		|O
based	459	464		|O
on	465	467		|O
simultaneous	468	480		|O
measurement	481	492		|O
of	493	495		|O
8	496	497		|O
key	498	501		|O
cell	502	506		|O
health	507	513		|O
indicators	514	524		|O
associated	525	535		|O
with	536	540		|O
nuclear	541	548		|O
morphology	549	559		|O
,	559	560		|O
plasma	561	567		|O
membrane	568	576		|O
integrity	577	586		|O
,	586	587		|O
mitochondrial	588	601		|O
function	602	610		|O
,	610	611		|O
and	612	615		|O
cell	616	620		|O
proliferation	621	634		|O
.	634	635		|O
Compounds	636	645		|O
are	646	649		|O
prioritized	650	661		|O
by	662	664		|O
(	665	666		|O
a	666	667		|O
)	667	668		|O
computing	669	678		|O
an	679	681		|O
in	682	684		|O
vitro	685	690		|O
safety	691	697		|O
margin	698	704		|O
using	705	710		|O
the	711	714		|O
minimum	715	722		|O
cytotoxic	723	732		|O
concentration	733	746		|O
(	747	748		|O
IC	748	750		|O
(	750	751		|O
20	751	753		|O
)	753	754		|O
)	754	755		|O
across	756	762		|O
all	763	766		|O
8	767	768		|O
indicators	769	779		|O
and	780	783		|O
cell	784	788		|O
-	788	789		|O
based	789	794		|O
efficacy	795	803		|O
data	804	808		|O
and	809	812		|O
(	813	814		|O
b	814	815		|O
)	815	816		|O
using	817	822		|O
the	823	826		|O
minimal	827	834		|O
cytotoxic	835	844		|O
concentration	845	858		|O
alone	859	864		|O
to	865	867		|O
take	868	872		|O
into	873	877		|O
account	878	885		|O
concentration	886	899		|O
of	900	902		|O
drug	903	907		|O
in	908	910		|O
tissues	911	918		|O
.	918	919		|O
Feasibility	920	931		|O
data	932	936		|O
using	937	942		|O
selected	943	951		|O
compounds	952	961		|O
,	961	962		|O
including	963	972		|O
quinolone	973	982		|O
antibiotics	983	994		|O
,	994	995		|O
thiazolidinediones	996	1014		|O
,	1014	1015		|O
and	1016	1019		|O
statins	1020	1027		|O
,	1027	1028		|O
suggest	1029	1036		|O
the	1037	1040		|O
viability	1041	1050		|O
of	1051	1053		|O
this	1054	1058		|O
approach	1059	1067		|O
.	1067	1068		|O
To	1069	1071		|O
increase	1072	1080		|O
overall	1081	1088		|O
throughput	1089	1099		|O
of	1100	1102		|O
compound	1103	1111		|O
prioritization	1112	1126		|O
,	1126	1127		|O
the	1128	1131		|O
authors	1132	1139		|O
have	1140	1144		|O
identified	1145	1155		|O
the	1156	1159		|O
higher	1160	1166		|O
throughput	1167	1177		|O
,	1177	1178		|O
plate	1179	1184		|O
reader	1185	1191		|O
-	1191	1192		|O
based	1192	1197		|O
CyQUANT	1198	1205		|O
assay	1206	1211		|O
that	1212	1216		|O
is	1217	1219		|O
similar	1220	1227		|O
to	1228	1230		|O
the	1231	1234		|O
high	1235	1239		|O
-	1239	1240		|O
content	1240	1247		|O
screening	1248	1257		|O
(	1258	1259		|O
HCS	1259	1262		|O
)	1262	1263		|O
assay	1264	1269		|O
in	1270	1272		|O
sensitivity	1273	1284		|O
of	1285	1287		|O
measuring	1288	1297		|O
inhibition	1298	1308		|O
of	1309	1311		|O
cell	1312	1316		|O
proliferation	1317	1330		|O
.	1330	1331		|O
It	1332	1334		|O
is	1335	1337		|O
expected	1338	1346		|O
that	1347	1351		|O
the	1352	1355		|O
phenotypic	1356	1366		|O
output	1367	1373		|O
from	1374	1378		|O
the	1379	1382		|O
multiparametric	1383	1398		|O
HCS	1399	1402		|O
assay	1403	1408		|O
in	1409	1411		|O
combination	1412	1423		|O
with	1424	1428		|O
other	1429	1434		|O
highly	1435	1441		|O
sensitive	1442	1451		|O
approaches	1452	1462		|O
,	1462	1463		|O
such	1464	1468		|O
as	1469	1471		|O
microarray	1472	1482		|O
-	1482	1483		|O
based	1483	1488		|O
expression	1489	1499		|O
analysis	1500	1508		|O
of	1509	1511		|O
toxic	1512	1517		|O
signatures	1518	1528		|O
,	1528	1529		|O
will	1530	1534		|O
contribute	1535	1545		|O
to	1546	1548		|O
a	1549	1550		|O
better	1551	1557		|O
understanding	1558	1571		|O
and	1572	1575		|O
predictivity	1576	1588		|O
of	1589	1591		|O
human	1592	1597		|O
hepatotoxicity	1598	1612	hepatotoxicity	|B-ADVERSE
potential	1613	1622		|O
.	1622	1623		|O

### 18560606
Induction	0	9		|O
of	10	12		|O
the	13	16		|O
multixenobiotic	17	32		|O
/	32	33		|O
multidrug	33	42		|O
resistance	43	53		|O
system	54	60		|O
in	61	63		|O
various	64	71		|O
cell	72	76		|O
lines	77	82		|O
in	83	85		|O
response	86	94		|O
to	95	97		|O
perfluorinated	98	112		|O
carboxylic	113	123		|O
acids	124	129		|O
.	129	130		|O
The	132	135		|O
multixenobiotic	136	151		|O
resistance	152	162		|O
(	163	164		|O
closely	164	171		|O
related	172	179		|O
to	180	182		|O
multidrug	183	192		|O
resistance	193	203		|O
)	203	204		|O
system	205	211		|O
controls	212	220		|O
transport	221	230		|O
across	231	237		|O
the	238	241		|O
plasma	242	248		|O
membrane	249	257		|O
as	258	260		|O
a	261	262		|O
defense	263	270		|O
against	271	278		|O
toxic	279	284		|O
molecules	285	294		|O
.	294	295		|O
Multixenobiotic	296	311		|O
resistance	312	322		|O
system	323	329		|O
consists	330	338		|O
of	339	341		|O
an	342	344		|O
efflux	345	351		|O
pump	352	356		|O
,	356	357		|O
ABCB1	358	363		|O
(	364	365		|O
also	365	369		|O
named	370	375		|O
P	376	377		|O
-	377	378		|O
glycoprotein	378	390		|O
,	390	391		|O
P	392	393		|O
-	393	394		|O
gp	394	396		|O
)	396	397		|O
,	397	398		|O
and	399	402		|O
/	402	403		|O
or	403	405		|O
a	406	407		|O
molecule	408	416		|O
of	417	419		|O
the	420	423		|O
ABCC	424	428		|O
family	429	435		|O
(	436	437		|O
also	437	441		|O
named	442	447		|O
multiple	448	456		|O
resistance	457	467		|O
associated	468	478		|O
protein	479	486		|O
,	486	487		|O
MRP	488	491		|O
)	491	492		|O
.	492	493		|O
ABCB1	494	499		|O
is	500	502		|O
able	503	507		|O
to	508	510		|O
increase	511	519		|O
efflux	520	526		|O
of	527	529		|O
many	530	534		|O
low	535	538		|O
-	538	539		|O
molecular	539	548		|O
foreign	549	556		|O
molecules	557	566		|O
.	566	567		|O
Measuring	568	577		|O
system	578	584		|O
induction	585	594		|O
may	595	598		|O
be	599	601		|O
used	602	606		|O
as	607	609		|O
a	610	611		|O
biomarker	612	621		|O
of	622	624		|O
cell	625	629		|O
/	629	630		|O
organism	630	638		|O
exposure	639	647		|O
to	648	650		|O
foreign	651	658		|O
substances	659	669		|O
.	669	670		|O
Various	671	678		|O
established	679	690		|O
cell	691	695		|O
lines	696	701		|O
were	702	706		|O
tested	707	713		|O
for	714	717		|O
constitutive	718	730		|O
and	731	734		|O
induced	735	742		|O
multixenobiotic	743	758		|O
resistance	759	769		|O
proteins	770	778		|O
by	779	781		|O
Western	782	789		|O
blotting	790	798		|O
immunodetection	799	814		|O
.	814	815		|O
The	816	819		|O
pumping	820	827		|O
function	828	836		|O
was	837	840		|O
indirectly	841	851		|O
assayed	852	859		|O
with	860	864		|O
Rhodamine	865	874		|O
B	875	876		|O
by	877	879		|O
visualization	880	893		|O
of	894	896		|O
cell	897	901		|O
fluorescence	902	914		|O
in	915	917		|O
the	918	921		|O
presence	922	930		|O
of	931	933		|O
verapamil	934	943		|O
.	943	944		|O
Changes	945	952		|O
in	953	955		|O
ABC	956	959		|O
proteins	960	968		|O
were	969	973		|O
measured	974	982		|O
by	983	985		|O
flow	986	990		|O
cytometry	991	1000		|O
after	1001	1006		|O
exposition	1007	1017		|O
to	1018	1020		|O
various	1021	1028		|O
perfluorinated	1029	1043		|O
carboxylic	1044	1054		|O
acids	1055	1060		|O
.	1060	1061		|O
MCF7	1062	1066		|O
and	1067	1070		|O
HeLa	1071	1075		|O
cells	1076	1081		|O
were	1082	1086		|O
found	1087	1092		|O
to	1093	1095		|O
contain	1096	1103		|O
the	1104	1107		|O
highest	1108	1115		|O
constitutive	1116	1128		|O
level	1129	1134		|O
of	1135	1137		|O
both	1138	1142		|O
ABCB1	1143	1148		|O
and	1149	1152		|O
ABCC1	1153	1158		|O
.	1158	1159		|O
HEK293	1160	1166		|O
exhibited	1167	1176		|O
much	1177	1181		|O
less	1182	1186		|O
ABCB1	1187	1192		|O
and	1193	1196		|O
no	1197	1199		|O
activity	1200	1208		|O
of	1209	1211		|O
pumping	1212	1219		|O
out	1220	1223		|O
Rhodamine	1224	1233		|O
B	1234	1235		|O
.	1235	1236		|O
The	1237	1240		|O
pumping	1241	1248		|O
activity	1249	1257		|O
was	1258	1261		|O
found	1262	1267		|O
to	1268	1270		|O
be	1271	1273		|O
related	1274	1281		|O
to	1282	1284		|O
the	1285	1288		|O
amount	1289	1295		|O
of	1296	1298		|O
the	1299	1302		|O
cell	1303	1307		|O
-	1307	1308		|O
type	1308	1312		|O
specific	1313	1321		|O
170	1322	1325		|O
kDa	1326	1329		|O
ABCB1	1330	1335		|O
protein	1336	1343		|O
.	1343	1344		|O
An	1345	1347		|O
8	1348	1349		|O
-	1349	1350		|O
day	1350	1353		|O
exposure	1354	1362		|O
to	1363	1365		|O
10	1366	1368		|O
(	1368	1369		|O
-	1369	1370		|O
4	1370	1371		|O
)	1371	1372		|O
M	1373	1374		|O
perfluorononanoic	1375	1392		|O
acid	1393	1397		|O
resulted	1398	1406		|O
in	1407	1409		|O
about	1410	1415		|O
2-2.5	1416	1421		|O
-	1421	1422		|O
fold	1422	1426		|O
increase	1427	1435		|O
of	1436	1438		|O
ABCB1	1439	1444		|O
level	1445	1450		|O
.	1450	1451		|O
That	1452	1456		|O
was	1457	1460		|O
confirmed	1461	1470		|O
also	1471	1475		|O
for	1476	1479		|O
short	1480	1485		|O
times	1486	1491		|O
by	1492	1494		|O
flow	1495	1499		|O
cytometry	1500	1509		|O
of	1510	1512		|O
cells	1513	1518		|O
exposed	1519	1526		|O
to	1527	1529		|O
perfluorinated	1530	1544		|O
acids	1545	1550		|O
and	1551	1554		|O
its	1555	1558		|O
natural	1559	1566		|O
congeners	1567	1576		|O
.	1576	1577		|O
Both	1578	1582		|O
ABCB1	1583	1588		|O
-	1588	1589		|O
and	1590	1593		|O
ABCC1	1594	1599		|O
-	1599	1600		|O
related	1600	1607		|O
fluorescence	1608	1620		|O
increased	1621	1630		|O
along	1631	1636		|O
with	1637	1641		|O
the	1642	1645		|O
carbon	1646	1652		|O
chain	1653	1658		|O
in	1659	1661		|O
acids	1662	1667		|O
from	1668	1672		|O
C	1673	1674		|O
(	1674	1675		|O
6	1675	1676		|O
)	1676	1677		|O
up	1678	1680		|O
to	1681	1683		|O
C	1684	1685		|O
(	1685	1686		|O
9	1686	1687		|O
)	1687	1688		|O
and	1689	1692		|O
decreased	1693	1702		|O
for	1703	1706		|O
C	1707	1708		|O
(	1708	1709		|O
10	1709	1711		|O
)	1711	1712		|O
.	1712	1713		|O
Measuring	1714	1723		|O
of	1724	1726		|O
multixenobiotic	1727	1742		|O
resistance	1743	1753		|O
changes	1754	1761		|O
in	1762	1764		|O
vitro	1765	1770		|O
induced	1771	1778		|O
by	1779	1781		|O
chemicals	1782	1791		|O
may	1792	1795		|O
be	1796	1798		|O
a	1799	1800		|O
convenient	1801	1811		|O
test	1812	1816		|O
for	1817	1820		|O
screening	1821	1830		|O
for	1831	1834		|O
their	1835	1840		|O
potential	1841	1850		|O
toxicity	1851	1859		|O
.	1859	1860		|O

### 18936793
Capecitabine	0	12		|O
:	12	13		|O
have	14	18		|O
we	19	21		|O
got	22	25		|O
the	26	29		|O
dose	30	34		|O
right	35	40		|O
?	40	41		|O
In	43	45		|O
the	46	49		|O
past	50	54		|O
5-10	55	59		|O
years	60	65		|O
there	66	71		|O
has	72	75		|O
been	76	80		|O
a	81	82		|O
growing	83	90		|O
trend	91	96		|O
for	97	100		|O
substituting	101	113		|O
conventional	114	126		|O
5	127	128		|O
-	128	129		|O
fluorouracil	129	141		|O
with	142	146		|O
the	147	150		|O
oral	151	155		|O
prodrug	156	163		|O
of	164	166		|O
5	167	168		|O
-	168	169		|O
fluorouracil	169	181		|O
,	181	182		|O
capecitabine	183	195		|O
,	195	196		|O
in	197	199		|O
chemotherapy	200	212		|O
regimens	213	221		|O
.	221	222		|O
This	223	227		|O
regimen	228	235		|O
change	236	242		|O
is	243	245		|O
based	246	251		|O
on	252	254		|O
evidence	255	263		|O
of	264	266		|O
the	267	270		|O
efficacy	271	279		|O
equivalence	280	291		|O
of	292	294		|O
these	295	300		|O
two	301	304		|O
drugs	305	310		|O
and	311	314		|O
the	315	318		|O
lack	319	323		|O
of	324	326		|O
an	327	329		|O
increase	330	338		|O
in	339	341		|O
overall	342	349		|O
toxic	350	355		|O
effects	356	363		|O
when	364	368		|O
capecitabine	369	381		|O
is	382	384		|O
used	385	389		|O
.	389	390		|O
Many	391	395		|O
investigators	396	409		|O
in	410	412		|O
different	413	422		|O
parts	423	428		|O
of	429	431		|O
the	432	435		|O
world	436	441		|O
have	442	446		|O
determined	447	457		|O
their	458	463		|O
own	464	467		|O
starting	468	476		|O
dose	477	481		|O
for	482	485		|O
capecitabine	486	498		|O
,	498	499		|O
usually	500	507		|O
based	508	513		|O
on	514	516		|O
their	517	522		|O
experience	523	533		|O
of	534	536		|O
toxic	537	542		|O
events	543	549		|O
within	550	556		|O
the	557	560		|O
population	561	571		|O
of	572	574		|O
patients	575	583		|O
they	584	588		|O
treat	589	594		|O
.	594	595		|O
This	596	600		|O
starting	601	609		|O
dose	610	614		|O
is	615	617		|O
usually	618	625		|O
between	626	633		|O
1,000-1,250	634	645		|O
mg	646	648		|O
/	648	649		|O
m	649	650		|O
(	650	651		|O
2	651	652		|O
)	652	653		|O
,	653	654		|O
which	655	660		|O
is	661	663		|O
generally	664	673		|O
administered	674	686		|O
twice	687	692		|O
daily	693	698		|O
for	699	702		|O
14	703	705		|O
days	706	710		|O
followed	711	719		|O
by	720	722		|O
7	723	724		|O
days	725	729		|O
rest	730	734		|O
.	734	735		|O
This	736	740		|O
Review	741	747		|O
summarizes	748	758		|O
why	759	762		|O
there	763	768		|O
may	769	772		|O
indeed	773	779		|O
not	780	783		|O
be	784	786		|O
a	787	788		|O
universally	789	800		|O
applicable	801	811		|O
starting	812	820		|O
dose	821	825		|O
for	826	829		|O
capecitabine	830	842		|O
because	843	850		|O
of	851	853		|O
interpatient	854	866		|O
differences	867	878		|O
in	879	881		|O
basic	882	887		|O
physiology	888	898		|O
,	898	899		|O
pharmacogenomics	900	916		|O
and	917	920		|O
diet	921	925		|O
.	925	926		|O
This	927	931		|O
article	932	939		|O
also	940	944		|O
explores	945	953		|O
which	954	959		|O
of	960	962		|O
these	963	968		|O
factors	969	976		|O
contribute	977	987		|O
to	988	990		|O
the	991	994		|O
observed	995	1003		|O
inter	1004	1009		|O
-	1009	1010		|O
regional	1010	1018		|O
geographical	1019	1031		|O
variation	1032	1041		|O
in	1042	1044		|O
capecitabine	1045	1057		|O
toxicity	1058	1066		|O
,	1066	1067		|O
and	1068	1071		|O
explains	1072	1080		|O
why	1081	1084		|O
even	1085	1089		|O
within	1090	1096		|O
a	1097	1098		|O
region	1099	1105		|O
various	1106	1113		|O
factors	1114	1121		|O
should	1122	1128		|O
prompt	1129	1135		|O
a	1136	1137		|O
clinician	1138	1147		|O
to	1148	1150		|O
modify	1151	1157		|O
the	1158	1161		|O
starting	1162	1170		|O
dose	1171	1175		|O
.	1175	1176		|O

### 18695846
Pharmacological	0	15		|O
profile	16	23		|O
,	23	24		|O
efficacy	25	33		|O
and	34	37		|O
safety	38	44		|O
of	45	47		|O
rupatadine	48	58		|O
in	59	61		|O
allergic	62	70	allergic rhinitis	|B-DISEASE
rhinitis	71	79		|I-DISEASE
.	79	80		|O
Allergic	82	90	Allergic rhinitis	|B-DISEASE
rhinitis	91	99		|I-DISEASE
(	100	101		|O
AR	101	103	AR	|B-DISEASE
)	103	104		|O
is	105	107		|O
a	108	109		|O
disease	110	117		|O
with	118	122		|O
high	123	127		|O
prevalence	128	138		|O
.	138	139		|O
In	140	142		|O
AR	143	145	AR	|B-DISEASE
,	145	146		|O
exposure	147	155		|O
to	156	158		|O
airborne	159	167		|O
allergens	168	177		|O
elicits	178	185		|O
an	186	188		|O
allergic	189	197		|O
response	198	206		|O
which	207	212		|O
involves	213	221		|O
epithelial	222	232		|O
accumulation	233	245		|O
of	246	248		|O
effector	249	257		|O
cells	258	263		|O
-	264	265		|O
e.g.	266	270		|O
mast	271	275		|O
cells	276	281		|O
and	282	285		|O
basophils	286	295		|O
-	296	297		|O
and	298	301		|O
subsequent	302	312		|O
inflammation	313	325	inflammation	|B-DISEASE
.	325	326		|O
During	327	333		|O
the	334	337		|O
early	338	343		|O
response	344	352		|O
in	353	355		|O
AR	356	358	AR	|B-DISEASE
,	358	359		|O
histamine	360	369		|O
has	370	373		|O
been	374	378		|O
found	379	384		|O
to	385	387		|O
be	388	390		|O
the	391	394		|O
most	395	399		|O
abundant	400	408		|O
mediator	409	417		|O
and	418	421		|O
it	422	424		|O
is	425	427		|O
associated	428	438		|O
with	439	443		|O
many	444	448		|O
symptoms	449	457		|O
of	458	460		|O
this	461	465		|O
disease	466	473		|O
mediated	474	482		|O
through	483	490		|O
the	491	494		|O
histamine	495	504		|O
H1	505	507		|O
receptor	508	516		|O
.	516	517		|O
Therefore	518	527		|O
,	527	528		|O
anti	529	533		|O
-	533	534		|O
histamines	534	544		|O
have	545	549		|O
a	550	551		|O
role	552	556		|O
to	557	559		|O
play	560	564		|O
in	565	567		|O
the	568	571		|O
management	572	582		|O
of	583	585		|O
AR	586	588	AR	|B-DISEASE
.	588	589		|O
However	590	597		|O
,	597	598		|O
the	599	602		|O
available	603	612		|O
antihistamines	613	627		|O
have	628	632		|O
certain	633	640		|O
well	641	645		|O
-	645	646		|O
known	646	651		|O
side	652	656		|O
effects	657	664		|O
like	665	669		|O
sedation	670	678	sedation	|B-ADVERSE
and	679	682		|O
potential	683	692		|O
pro	693	696	pro-arrythmic effects	|B-ADVERSE
-	696	697		|I-ADVERSE
arrythmic	697	706		|I-ADVERSE
effects	707	714		|I-ADVERSE
owing	715	720		|O
to	721	723		|O
their	724	729		|O
interactions	730	742		|O
with	743	747		|O
other	748	753		|O
drugs	754	759		|O
,	759	760		|O
as	761	763		|O
well	764	768		|O
as	769	771		|O
having	772	778		|O
poor	779	783		|O
or	784	786		|O
no	787	789		|O
effect	790	796		|O
on	797	799		|O
platelet	800	808		|O
activating	809	819		|O
factor	820	826		|O
(	827	828		|O
PAF	828	831		|O
)	831	832		|O
which	833	838		|O
also	839	843		|O
plays	844	849		|O
an	850	852		|O
important	853	862		|O
role	863	867		|O
in	868	870		|O
AR	871	873	AR	|B-DISEASE
.	873	874		|O
This	875	879		|O
article	880	887		|O
is	888	890		|O
a	891	892		|O
qualitative	893	904		|O
systematic	905	915		|O
literature	916	926		|O
review	927	933		|O
on	934	936		|O
the	937	940		|O
pharmacological	941	956		|O
profile	957	964		|O
of	965	967		|O
rupatadine	968	978		|O
in	979	981		|O
order	982	987		|O
to	988	990		|O
evaluate	991	999		|O
its	1000	1003		|O
safety	1004	1010		|O
and	1011	1014		|O
efficacy	1015	1023		|O
in	1024	1026		|O
AR	1027	1029	AR	|B-DISEASE
as	1030	1032		|O
compared	1033	1041		|O
to	1042	1044		|O
other	1045	1050		|O
anti	1051	1055		|O
-	1055	1056		|O
histamines	1056	1066		|O
.	1066	1067		|O
Rupatadine	1068	1078		|O
is	1079	1081		|O
a	1082	1083		|O
once	1084	1088		|O
-	1088	1089		|O
daily	1089	1094		|O
non	1095	1098		|O
-	1098	1099		|O
sedative	1099	1107		|O
,	1107	1108		|O
selective	1109	1118		|O
,	1118	1119		|O
long	1120	1124		|O
-	1124	1125		|O
acting	1125	1131		|O
H1	1132	1134		|O
anti	1135	1139		|O
-	1139	1140		|O
histamine	1140	1149		|O
with	1150	1154		|O
antagonistic	1155	1167		|O
PAF	1168	1171		|O
effects	1172	1179		|O
through	1180	1187		|O
its	1188	1191		|O
interaction	1192	1203		|O
with	1204	1208		|O
specific	1209	1217		|O
receptors	1218	1227		|O
.	1227	1228		|O
Rupatadine	1229	1239		|O
significantly	1240	1253		|O
improves	1254	1262		|O
nasal	1263	1268		|O
symptoms	1269	1277		|O
in	1278	1280		|O
patients	1281	1289		|O
with	1290	1294		|O
AR	1295	1297	AR	|B-DISEASE
.	1297	1298		|O
It	1299	1301		|O
has	1302	1305		|O
a	1306	1307		|O
good	1308	1312		|O
safety	1313	1319		|O
profile	1320	1327		|O
and	1328	1331		|O
is	1332	1334		|O
devoid	1335	1341		|O
of	1342	1344		|O
arrythmogenic	1345	1358	arrythmogenic effects	|B-ADVERSE
effects	1359	1366		|I-ADVERSE
.	1366	1367		|O
These	1368	1373		|O
properties	1374	1384		|O
make	1385	1389		|O
rupatadine	1390	1400		|O
a	1401	1402		|O
suitable	1403	1411		|O
first	1412	1417		|O
line	1418	1422		|O
anti	1423	1427		|O
-	1427	1428		|O
histamine	1428	1437		|O
for	1438	1441		|O
the	1442	1445		|O
treatment	1446	1455		|O
of	1456	1458		|O
AR	1459	1461	AR	|B-DISEASE
.	1461	1462		|O

### 18634978
Nitrate	0	7		|O
-	7	8		|O
induced	8	15		|O
toxicity	16	24		|O
and	25	28		|O
preconditioning	29	44		|O
:	44	45		|O
a	46	47		|O
rationale	48	57		|O
for	58	61		|O
reconsidering	62	75		|O
the	76	79		|O
use	80	83		|O
of	84	86		|O
these	87	92		|O
drugs	93	98		|O
.	98	99		|O
Although	101	109		|O
organic	110	117		|O
nitrates	118	126		|O
have	127	131		|O
been	132	136		|O
clinically	137	147		|O
used	148	152		|O
for	153	156		|O
more	157	161		|O
than	162	166		|O
a	167	168		|O
century	169	176		|O
,	176	177		|O
findings	178	186		|O
in	187	189		|O
the	190	193		|O
last	194	198		|O
decade	199	205		|O
have	206	210		|O
radically	211	220		|O
challenged	221	231		|O
our	232	235		|O
traditional	236	247		|O
view	248	252		|O
concerning	253	263		|O
the	264	267		|O
mechanism	268	277		|O
(	277	278		|O
s	278	279		|O
)	279	280		|O
of	281	283		|O
their	284	289		|O
clinical	290	298		|O
effects	299	306		|O
and	307	310		|O
implications	311	323		|O
.	323	324		|O
While	325	330		|O
their	331	336		|O
hemodynamic	337	348		|O
properties	349	359		|O
are	360	363		|O
well	364	368		|O
known	369	374		|O
,	374	375		|O
the	376	379		|O
knowledge	380	389		|O
that	390	394		|O
nitrates	395	403		|O
possess	404	411		|O
previously	412	422		|O
unexpected	423	433		|O
nonhemodynamic	434	448		|O
effects	449	456		|O
is	457	459		|O
a	460	461		|O
unique	462	468		|O
opportunity	469	480		|O
of	481	483		|O
which	484	489		|O
clinicians	490	500		|O
should	501	507		|O
be	508	510		|O
aware	511	516		|O
but	517	520		|O
,	520	521		|O
at	522	524		|O
the	525	528		|O
same	529	533		|O
time	534	538		|O
,	538	539		|O
it	540	542		|O
also	543	547		|O
provides	548	556		|O
a	557	558		|O
rationale	559	568		|O
to	569	571		|O
worry	572	577		|O
about	578	583		|O
previously	584	594		|O
unanticipated	595	608		|O
clinical	609	617		|O
consequences	618	630		|O
of	631	633		|O
long	634	638		|O
-	638	639		|O
term	639	643		|O
treatment	644	653		|O
with	654	658		|O
these	659	664		|O
drugs	665	670		|O
.	670	671		|O

### 18781134
Adjuvant	0	8		|O
treatment	9	18		|O
with	19	23		|O
vindesine	24	33		|O
in	34	36		|O
comparison	37	47		|O
to	48	50		|O
observation	51	62		|O
alone	63	68		|O
in	69	71		|O
patients	72	80		|O
with	81	85		|O
metastasized	86	98	metastasized melanoma	|B-DISEASE
melanoma	99	107		|I-DISEASE
after	108	113		|O
complete	114	122		|O
metastasectomy	123	137		|O
:	137	138		|O
a	139	140		|O
randomized	141	151		|O
multicenter	152	163		|O
trial	164	169		|O
of	170	172		|O
the	173	176		|O
German	177	183		|O
Dermatologic	184	196		|O
Cooperative	197	208		|O
Oncology	209	217		|O
Group	218	223		|O
.	223	224		|O
To	226	228		|O
evaluate	229	237		|O
the	238	241		|O
efficacy	242	250		|O
and	251	254		|O
safety	255	261		|O
of	262	264		|O
vindesine	265	274		|O
in	275	277		|O
patients	278	286		|O
with	287	291		|O
metastatic	292	302	metastatic melanoma	|B-DISEASE
melanoma	303	311		|I-DISEASE
after	312	317		|O
complete	318	326		|O
metastasectomy	327	341		|O
.	341	342		|O
One	343	346		|O
hundred	347	354		|O
and	355	358		|O
forty	359	364		|O
-	364	365		|O
two	365	368		|O
patients	369	377		|O
with	378	382		|O
metastatic	383	393		|O
spread	394	400		|O
to	401	403		|O
regional	404	412		|O
sites	413	418		|O
,	418	419		|O
lymph	420	425		|O
nodes	426	431		|O
,	431	432		|O
and	433	436		|O
distant	437	444		|O
sites	445	450		|O
after	451	456		|O
complete	457	465		|O
metastasectomy	466	480		|O
were	481	485		|O
randomized	486	496		|O
to	497	499		|O
receive	500	507		|O
either	508	514		|O
treatment	515	524		|O
with	525	529		|O
vindesine	530	539		|O
for	540	543		|O
2	544	545		|O
years	546	551		|O
or	552	554		|O
observation	555	566		|O
alone	567	572		|O
.	572	573		|O
Vindesine	574	583		|O
3	584	585		|O
mg	586	588		|O
/	588	589		|O
m	589	590		|O
intravenously	591	604		|O
was	605	608		|O
administered	609	621		|O
biweekly	622	630		|O
for	631	634		|O
the	635	638		|O
first	639	644		|O
26	645	647		|O
weeks	648	653		|O
following	654	663		|O
3	664	665		|O
-	665	666		|O
week	666	670		|O
intervals	671	680		|O
for	681	684		|O
an	685	687		|O
additional	688	698		|O
26	699	701		|O
weeks	702	707		|O
and	708	711		|O
thereafter	712	722		|O
every	723	728		|O
4	729	730		|O
weeks	731	736		|O
for	737	740		|O
52	741	743		|O
weeks	744	749		|O
.	749	750		|O
One	751	754		|O
hundred	755	762		|O
and	763	766		|O
thirty	767	773		|O
-	773	774		|O
nine	774	778		|O
patients	779	787		|O
were	788	792		|O
eligible	793	801		|O
for	802	805		|O
intent	806	812		|O
-	812	813		|O
to	813	815		|O
-	815	816		|O
treat	816	821		|O
analysis	822	830		|O
.	830	831		|O
Median	832	838		|O
follow	839	845		|O
-	845	846		|O
up	846	848		|O
time	849	853		|O
was	854	857		|O
46	858	860		|O
months	861	867		|O
.	867	868		|O
Median	869	875		|O
recurrence	876	886		|O
free	887	891		|O
survival	892	900		|O
was	901	904		|O
7.9	905	908		|O
months	909	915		|O
in	916	918		|O
the	919	922		|O
vindesine	923	932		|O
group	933	938		|O
and	939	942		|O
7.6	943	946		|O
months	947	953		|O
in	954	956		|O
the	957	960		|O
observational	961	974		|O
group	975	980		|O
(	981	982		|O
P	982	983		|O
=	983	984		|O
0.40	984	988		|O
)	988	989		|O
.	989	990		|O
Three	991	996		|O
-	996	997		|O
year	997	1001		|O
overall	1002	1009		|O
survival	1010	1018		|O
rate	1019	1023		|O
was	1024	1027		|O
54.9%	1028	1033		|O
(	1034	1035		|O
37	1035	1037		|O
patients	1038	1046		|O
)	1046	1047		|O
for	1048	1051		|O
patients	1052	1060		|O
receiving	1061	1070		|O
vindesine	1071	1080		|O
in	1081	1083		|O
comparison	1084	1094		|O
to	1095	1097		|O
43.6%	1098	1103		|O
(	1104	1105		|O
31	1105	1107		|O
patients	1108	1116		|O
)	1116	1117		|O
in	1118	1120		|O
the	1121	1124		|O
observation	1125	1136		|O
arm	1137	1140		|O
(	1141	1142		|O
P	1142	1143		|O
=	1143	1144		|O
0.07	1144	1148		|O
)	1148	1149		|O
.	1149	1150		|O
No	1151	1153		|O
grade	1154	1159		|O
IV	1160	1162		|O
toxicity	1163	1171		|O
was	1172	1175		|O
observed	1176	1184		|O
.	1184	1185		|O
The	1186	1189		|O
two	1190	1193		|O
major	1194	1199		|O
side	1200	1204		|O
effects	1205	1212		|O
in	1213	1215		|O
the	1216	1219		|O
vindesine	1220	1229		|O
group	1230	1235		|O
were	1236	1240		|O
alopecia	1241	1249	alopecia	|B-ADVERSE
and	1250	1253		|O
peripheral	1254	1264	peripheral neuropathy	|B-ADVERSE
neuropathy	1265	1275		|I-ADVERSE
.	1275	1276		|O
Ten	1277	1280		|O
patients	1281	1289		|O
went	1290	1294		|O
off	1295	1298		|O
treatment	1299	1308		|O
because	1309	1316		|O
of	1317	1319		|O
grade	1320	1325		|O
III	1326	1329		|O
toxicity	1330	1338		|O
.	1338	1339		|O
Adjuvant	1340	1348		|O
treatment	1349	1358		|O
with	1359	1363		|O
vindesine	1364	1373		|O
did	1374	1377		|O
not	1378	1381		|O
significantly	1382	1395		|O
prolong	1396	1403		|O
disease	1404	1411		|O
free	1412	1416		|O
or	1417	1419		|O
overall	1420	1427		|O
survival	1428	1436		|O
in	1437	1439		|O
high	1440	1444		|O
-	1444	1445		|O
risk	1445	1449		|O
melanoma	1450	1458	melanoma	|B-DISEASE
patients	1459	1467		|O
.	1467	1468		|O
Thus	1469	1473		|O
,	1473	1474		|O
this	1475	1479		|O
randomized	1480	1490		|O
trial	1491	1496		|O
did	1497	1500		|O
not	1501	1504		|O
confirm	1505	1512		|O
earlier	1513	1520		|O
reports	1521	1528		|O
of	1529	1531		|O
beneficial	1532	1542		|O
effects	1543	1550		|O
of	1551	1553		|O
adjuvant	1554	1562		|O
vindesine	1563	1572		|O
and	1573	1576		|O
can	1577	1580		|O
therefore	1581	1590		|O
not	1591	1594		|O
be	1595	1597		|O
recommended	1598	1609		|O
.	1609	1610		|O

### 18690886
The	0	3		|O
molecular	4	13		|O
basis	14	19		|O
of	20	22		|O
class	23	28		|O
side	29	33		|O
effects	34	41		|O
due	42	45		|O
to	46	48		|O
treatment	49	58		|O
with	59	63		|O
inhibitors	64	74		|O
of	75	77		|O
the	78	81		|O
VEGF	82	86		|O
/	86	87		|O
VEGFR	87	92		|O
pathway	93	100		|O
.	100	101		|O
Vascular	103	111		|O
Endothelial	112	123		|O
Growth	124	130		|O
Factor	131	137		|O
(	138	139		|O
VEGF	139	143		|O
)	143	144		|O
is	145	147		|O
considered	148	158		|O
to	159	161		|O
be	162	164		|O
one	165	168		|O
of	169	171		|O
the	172	175		|O
most	176	180		|O
important	181	190		|O
regulators	191	201		|O
of	202	204		|O
angiogenesis	205	217		|O
and	218	221		|O
a	222	223		|O
new	224	227		|O
key	228	231		|O
target	232	238		|O
in	239	241		|O
anti	242	246		|O
-	246	247		|O
cancer	247	253		|O
treatment	254	263		|O
.	263	264		|O
Various	265	272		|O
clinical	273	281		|O
trials	282	288		|O
have	289	293		|O
validated	294	303		|O
the	304	307		|O
clinical	308	316		|O
importance	317	327		|O
of	328	330		|O
anti	331	335		|O
-	335	336		|O
VEGF	336	340		|O
or	341	343		|O
anti	344	348		|O
-	348	349		|O
VEGF	349	353		|O
receptor	354	362		|O
(	363	364		|O
VEGFR	364	369		|O
)	369	370		|O
therapy	371	378		|O
.	378	379		|O
Currently	380	389		|O
the	390	393		|O
humanized	394	403		|O
monoclonal	404	414		|O
antibody	415	423		|O
bevacizumab	424	435		|O
(	436	437		|O
blocks	437	443		|O
VEGF	444	448		|O
-	448	449		|O
A	449	450		|O
)	450	451		|O
,	451	452		|O
and	453	456		|O
the	457	460		|O
tyrosine	461	469		|O
kinase	470	476		|O
inhibitors	477	487		|O
sunitinib	488	497		|O
and	498	501		|O
sorafenib	502	511		|O
(	512	513		|O
inhibit	513	520		|O
VEGFRs	521	527		|O
)	527	528		|O
are	529	532		|O
approved	533	541		|O
for	542	545		|O
patients	546	554		|O
with	555	559		|O
various	560	567		|O
malignancies	568	580	malignancies	|B-DISEASE
and	581	584		|O
several	585	592		|O
others	593	599		|O
are	600	603		|O
expected	604	612		|O
in	613	615		|O
the	616	619		|O
coming	620	626		|O
years	627	632		|O
.	632	633		|O
Unfortunately	634	647		|O
,	647	648		|O
anti	649	653		|O
-	653	654		|O
VEGF	654	658		|O
/	658	659		|O
VEGFR	659	664		|O
treatment	665	674		|O
is	675	677		|O
not	678	681		|O
void	682	686		|O
of	687	689		|O
side	690	694		|O
effects	695	702		|O
.	702	703		|O
An	704	706		|O
array	707	712		|O
of	713	715		|O
unexpected	716	726		|O
side	727	731		|O
effects	732	739		|O
is	740	742		|O
now	743	746		|O
seen	747	751		|O
in	752	754		|O
clinical	755	763		|O
practice	764	772		|O
.	772	773		|O
Management	774	784		|O
of	785	787		|O
these	788	793		|O
side	794	798		|O
effects	799	806		|O
is	807	809		|O
extremely	810	819		|O
important	820	829		|O
in	830	832		|O
the	833	836		|O
development	837	848		|O
of	849	851		|O
the	852	855		|O
various	856	863		|O
anti	864	868		|O
-	868	869		|O
VEGF	869	873		|O
/	873	874		|O
VEGFR	874	879		|O
therapies	880	889		|O
and	890	893		|O
their	894	899		|O
optimal	900	907		|O
use	908	911		|O
.	911	912		|O
This	913	917		|O
review	918	924		|O
provides	925	933		|O
an	934	936		|O
overview	937	945		|O
of	946	948		|O
the	949	952		|O
toxicity	953	961		|O
profile	962	969		|O
of	970	972		|O
this	973	977		|O
class	978	983		|O
of	984	986		|O
agents	987	993		|O
,	993	994		|O
the	995	998		|O
molecular	999	1008		|O
basis	1009	1014		|O
behind	1015	1021		|O
these	1022	1027		|O
side	1028	1032		|O
effects	1033	1040		|O
and	1041	1044		|O
indicates	1045	1054		|O
potential	1055	1064		|O
options	1065	1072		|O
for	1073	1076		|O
management	1077	1087		|O
.	1087	1088		|O
VEGF	1089	1093		|O
and	1094	1097		|O
its	1098	1101		|O
receptors	1102	1111		|O
play	1112	1116		|O
an	1117	1119		|O
important	1120	1129		|O
role	1130	1134		|O
in	1135	1137		|O
normal	1138	1144		|O
tissues	1145	1152		|O
and	1153	1156		|O
are	1157	1160		|O
widely	1161	1167		|O
expressed	1168	1177		|O
.	1177	1178		|O
It	1179	1181		|O
is	1182	1184		|O
likely	1185	1191		|O
that	1192	1196		|O
interference	1197	1209		|O
with	1210	1214		|O
this	1215	1219		|O
pathway	1220	1227		|O
induces	1228	1235		|O
an	1236	1238		|O
array	1239	1244		|O
of	1245	1247		|O
side	1248	1252		|O
effects	1253	1260		|O
due	1261	1264		|O
to	1265	1267		|O
the	1268	1271		|O
lack	1272	1276		|O
of	1277	1279		|O
normal	1280	1286		|O
function	1287	1295		|O
of	1296	1298		|O
VEGF	1299	1303		|O
.	1303	1304		|O
A	1305	1306		|O
consistent	1307	1317		|O
pattern	1318	1325		|O
of	1326	1328		|O
side	1329	1333		|O
effects	1334	1341		|O
is	1342	1344		|O
now	1345	1348		|O
emerging	1349	1357		|O
.	1357	1358		|O
Hypertension	1359	1371	Hypertension	|B-ADVERSE
,	1371	1372		|O
gastro	1373	1379	gastro-intestinal toxicity	|B-ADVERSE
-	1379	1380		|I-ADVERSE
intestinal	1380	1390		|I-ADVERSE
toxicity	1391	1399		|I-ADVERSE
,	1399	1400		|O
hypothyroidism	1401	1415	hypothyroidism	|B-ADVERSE
,	1415	1416		|O
proteinuria	1417	1428	proteinuria	|B-ADVERSE
,	1428	1429		|O
coagulation	1430	1441	coagulation disorders	|B-ADVERSE
disorders	1442	1451		|I-ADVERSE
and	1452	1455		|O
neurotoxicity	1456	1469	neurotoxicity	|B-ADVERSE
are	1470	1473		|O
side	1474	1478		|O
effects	1479	1486		|O
observed	1487	1495		|O
with	1496	1500		|O
both	1501	1505		|O
anti	1506	1510		|O
-	1510	1511		|O
VEGF	1511	1515		|O
and	1516	1519		|O
anti	1520	1524		|O
-	1524	1525		|O
VEGFR	1525	1530		|O
inhibitors	1531	1541		|O
.	1541	1542		|O
For	1543	1546		|O
these	1547	1552		|O
side	1553	1557		|O
effects	1558	1565		|O
the	1566	1569		|O
role	1570	1574		|O
of	1575	1577		|O
VEGF	1578	1582		|O
/	1582	1583		|O
VEGFR	1583	1588		|O
pathway	1589	1596		|O
in	1597	1599		|O
normal	1600	1606		|O
tissue	1607	1613		|O
was	1614	1617		|O
reviewed	1618	1626		|O
in	1627	1629		|O
order	1630	1635		|O
to	1636	1638		|O
provide	1639	1646		|O
a	1647	1648		|O
molecular	1649	1658		|O
mechanism	1659	1668		|O
that	1669	1673		|O
linked	1674	1680		|O
side	1681	1685		|O
effect	1686	1692		|O
with	1693	1697		|O
physiological	1698	1711		|O
activity	1712	1720		|O
of	1721	1723		|O
VEGF	1724	1728		|O
/	1728	1729		|O
VEGFR	1729	1734		|O
.	1734	1735		|O
Insight	1736	1743		|O
into	1744	1748		|O
the	1749	1752		|O
molecular	1753	1762		|O
basis	1763	1768		|O
may	1769	1772		|O
aid	1773	1776		|O
specific	1777	1785		|O
supportive	1786	1796		|O
care	1797	1801		|O
measures	1802	1810		|O
to	1811	1813		|O
ensure	1814	1820		|O
optimal	1821	1828		|O
use	1829	1832		|O
of	1833	1835		|O
this	1836	1840		|O
class	1841	1846		|O
of	1847	1849		|O
agents	1850	1856		|O
.	1856	1857		|O
Conclusion	1858	1868		|O
:	1868	1869		|O
Inhibiting	1870	1880		|O
the	1881	1884		|O
VEGF	1885	1889		|O
/	1889	1890		|O
VEGFR	1890	1895		|O
pathway	1896	1903		|O
is	1904	1906		|O
an	1907	1909		|O
effective	1910	1919		|O
approach	1920	1928		|O
to	1929	1931		|O
treat	1932	1937		|O
cancer	1938	1944	cancer	|B-DISEASE
.	1944	1945		|O
It	1946	1948		|O
has	1949	1952		|O
also	1953	1957		|O
provided	1958	1966		|O
new	1967	1970		|O
insight	1971	1978		|O
into	1979	1983		|O
the	1984	1987		|O
physiological	1988	2001		|O
role	2002	2006		|O
of	2007	2009		|O
this	2010	2014		|O
pathway	2015	2022		|O
in	2023	2025		|O
various	2026	2033		|O
organs	2034	2040		|O
.	2040	2041		|O
Integrating	2042	2053		|O
the	2054	2057		|O
knowledge	2058	2067		|O
in	2068	2070		|O
daily	2071	2076		|O
oncological	2077	2088		|O
practice	2089	2097		|O
will	2098	2102		|O
be	2103	2105		|O
a	2106	2107		|O
challenge	2108	2117		|O
for	2118	2121		|O
the	2122	2125		|O
future	2126	2132		|O
.	2132	2133		|O

### 18675256
Novel	0	5		|O
roles	6	11		|O
for	12	15		|O
ceramides	16	25		|O
,	25	26		|O
calpains	27	35		|O
and	36	39		|O
caspases	40	48		|O
in	49	51		|O
kidney	52	58		|O
proximal	59	67		|O
tubule	68	74		|O
cell	75	79		|O
apoptosis	80	89		|O
:	89	90		|O
lessons	91	98		|O
from	99	103		|O
in	104	106		|O
vitro	107	112		|O
cadmium	113	120	cadmium toxicity	|B-ADVERSE
toxicity	121	129		|I-ADVERSE
studies	130	137		|O
.	137	138		|O
Apoptosis	140	149		|O
is	150	152		|O
a	153	154		|O
tightly	155	162		|O
regulated	163	172		|O
physiological	173	186		|O
process	187	194		|O
,	194	195		|O
which	196	201		|O
can	202	205		|O
be	206	208		|O
initiated	209	218		|O
by	219	221		|O
toxic	222	227		|O
stimuli	228	235		|O
,	235	236		|O
such	237	241		|O
as	242	244		|O
cadmium	245	252		|O
(	253	254		|O
Cd2+	254	258		|O
)	258	259		|O
.	259	260		|O
Cd2+	261	265		|O
(	266	267		|O
10-50	267	272		|O
microM	273	279		|O
)	279	280		|O
induces	281	288		|O
a	289	290		|O
rapid	291	296		|O
increase	297	305		|O
in	306	308		|O
reactive	309	317		|O
oxygen	318	324		|O
species	325	332		|O
(	333	334		|O
ROS	334	337		|O
)	337	338		|O
(	339	340		|O
>	340	341		|O
or	342	344		|O
=	345	346		|O
30	347	349		|O
min	350	353		|O
)	353	354		|O
in	355	357		|O
a	358	359		|O
cell	360	364		|O
line	365	369		|O
derived	370	377		|O
from	378	382		|O
the	383	386		|O
S1	387	389		|O
segment	390	397		|O
of	398	400		|O
rat	401	404		|O
kidney	405	411		|O
proximal	412	420		|O
tubule	421	427		|O
,	427	428		|O
without	429	436		|O
any	437	440		|O
apparent	441	449		|O
mitochondrial	450	463		|O
dysfunction	464	475		|O
.	475	476		|O
The	477	480		|O
sphingolipid	481	493		|O
ceramide	494	502		|O
is	503	505		|O
an	506	508		|O
important	509	518		|O
second	519	525		|O
messenger	526	535		|O
in	536	538		|O
apoptosis	539	548		|O
.	548	549		|O
Short	550	555		|O
exposure	556	564		|O
to	565	567		|O
Cd2+	568	572		|O
(	573	574		|O
3h	574	576		|O
)	576	577		|O
causes	578	584		|O
an	585	587		|O
increase	588	596		|O
in	597	599		|O
ceramides	600	609		|O
,	609	610		|O
which	611	616		|O
occurs	617	623		|O
downstream	624	634		|O
of	635	637		|O
ROS	638	641		|O
formation	642	651		|O
,	651	652		|O
and	653	656		|O
may	657	660		|O
interact	661	669		|O
with	670	674		|O
cellular	675	683		|O
components	684	694		|O
,	694	695		|O
such	696	700		|O
as	701	703		|O
endoplasmic	704	715		|O
reticulum	716	725		|O
and	726	729		|O
mitochondria	730	742		|O
.	742	743		|O
Following	744	753		|O
apoptosis	754	763		|O
initiation	764	774		|O
,	774	775		|O
execution	776	785		|O
must	786	790		|O
take	791	795		|O
place	796	801		|O
.	801	802		|O
The	803	806		|O
classical	807	816		|O
executioners	817	829		|O
of	830	832		|O
apoptosis	833	842		|O
are	843	846		|O
caspases	847	855		|O
,	855	856		|O
a	857	858		|O
family	859	865		|O
of	866	868		|O
cysteine	869	877		|O
proteases	878	887		|O
.	887	888		|O
However	889	896		|O
,	896	897		|O
increasing	898	908		|O
studies	909	916		|O
report	917	923		|O
caspase	924	931		|O
-	931	932		|O
independent	932	943		|O
apoptosis	944	953		|O
,	953	954		|O
which	955	960		|O
questions	961	970		|O
the	971	974		|O
essentiality	975	987		|O
of	988	990		|O
caspases	991	999		|O
for	1000	1003		|O
apoptosis	1004	1013		|O
implementation	1014	1028		|O
.	1028	1029		|O
With	1030	1034		|O
low	1035	1038		|O
micromolar	1039	1049		|O
Cd2+	1050	1054		|O
concentrations	1055	1069		|O
(	1070	1071		|O
<	1071	1072		|O
10	1073	1075		|O
microM	1076	1082		|O
)	1082	1083		|O
,	1083	1084		|O
caspases	1085	1093		|O
are	1094	1097		|O
only	1098	1102		|O
activated	1103	1112		|O
after	1113	1118		|O
24h	1119	1122		|O
and	1123	1126		|O
not	1127	1130		|O
at	1131	1133		|O
earlier	1134	1141		|O
time	1142	1146		|O
points	1147	1153		|O
,	1153	1154		|O
which	1155	1160		|O
supports	1161	1169		|O
the	1170	1173		|O
notion	1174	1180		|O
of	1181	1183		|O
caspase	1184	1191		|O
-	1191	1192		|O
independent	1192	1203		|O
apoptosis	1204	1213		|O
.	1213	1214		|O
Due	1215	1218		|O
to	1219	1221		|O
increased	1222	1231		|O
cytosolic	1232	1241		|O
Ca	1242	1244		|O
(	1244	1245		|O
2+	1245	1247		|O
)	1247	1248		|O
under	1249	1254		|O
pathological	1255	1267		|O
conditions	1268	1278		|O
,	1278	1279		|O
a	1280	1281		|O
role	1282	1286		|O
for	1287	1290		|O
the	1291	1294		|O
Ca2+	1295	1299		|O
-	1299	1300		|O
dependent	1300	1309		|O
proteases	1310	1319		|O
,	1319	1320		|O
calpains	1321	1329		|O
,	1329	1330		|O
has	1331	1334		|O
emerged	1335	1342		|O
.	1342	1343		|O
Calpain	1344	1351		|O
activation	1352	1362		|O
by	1363	1365		|O
Cd2+	1366	1370		|O
(	1371	1372		|O
3-6	1372	1375		|O
h	1375	1376		|O
)	1376	1377		|O
seems	1378	1383		|O
to	1384	1386		|O
be	1387	1389		|O
regulated	1390	1399		|O
by	1400	1402		|O
ceramide	1403	1411		|O
levels	1412	1418		|O
,	1418	1419		|O
in	1420	1422		|O
order	1423	1428		|O
to	1429	1431		|O
induce	1432	1438		|O
apoptosis	1439	1448		|O
.	1448	1449		|O
Calpain	1450	1457		|O
and	1458	1461		|O
caspase	1462	1469		|O
substrates	1470	1480		|O
overlap	1481	1488		|O
but	1489	1492		|O
yield	1493	1498		|O
different	1499	1508		|O
fragments	1509	1518		|O
,	1518	1519		|O
which	1520	1525		|O
may	1526	1529		|O
explain	1530	1537		|O
their	1538	1543		|O
diverse	1544	1551		|O
downstream	1552	1562		|O
targets	1563	1570		|O
.	1570	1571		|O
Furthermore	1572	1583		|O
,	1583	1584		|O
calpains	1585	1593		|O
and	1594	1597		|O
caspases	1598	1606		|O
may	1607	1610		|O
interact	1611	1619		|O
with	1620	1624		|O
one	1625	1628		|O
another	1629	1636		|O
to	1637	1639		|O
enhance	1640	1647		|O
,	1647	1648		|O
as	1649	1651		|O
seen	1652	1656		|O
by	1657	1659		|O
Cd2+	1660	1664		|O
,	1664	1665		|O
or	1666	1668		|O
diminish	1669	1677		|O
apoptosis	1678	1687		|O
.	1687	1688		|O
In	1689	1691		|O
this	1692	1696		|O
review	1697	1703		|O
,	1703	1704		|O
we	1705	1707		|O
discuss	1708	1715		|O
novel	1716	1721		|O
roles	1722	1727		|O
for	1728	1731		|O
ceramides	1732	1741		|O
,	1741	1742		|O
calpains	1743	1751		|O
and	1752	1755		|O
caspases	1756	1764		|O
as	1765	1767		|O
part	1768	1772		|O
of	1773	1775		|O
Cd2+	1776	1780		|O
-	1780	1781		|O
induced	1781	1788		|O
apoptotic	1789	1798		|O
signalling	1799	1809		|O
pathways	1810	1818		|O
in	1819	1821		|O
the	1822	1825		|O
kidney	1826	1832		|O
proximal	1833	1841		|O
tubule	1842	1848		|O
and	1849	1852		|O
their	1853	1858		|O
in	1859	1861		|O
vivo	1862	1866		|O
relevance	1867	1876		|O
to	1877	1879		|O
Cd2+	1880	1884		|O
-	1884	1885		|O
induced	1885	1892		|O
nephrotoxicity	1893	1907	nephrotoxicity	|B-ADVERSE
.	1907	1908		|O

### 18773144
Phase	0	5		|O
I	6	7		|O
study	8	13		|O
of	14	16		|O
capecitabine	17	29		|O
in	30	32		|O
combination	33	44		|O
with	45	49		|O
cisplatin	50	59		|O
and	60	63		|O
irinotecan	64	74		|O
in	75	77		|O
patients	78	86		|O
with	87	91		|O
advanced	92	100		|O
solid	101	106	solid malignancies	|B-DISEASE
malignancies	107	119		|I-DISEASE
.	119	120		|O
PURPOSE	122	129		|O
:	129	130		|O
This	131	135		|O
phase	136	141		|O
I	142	143		|O
trial	144	149		|O
assessed	150	158		|O
the	159	162		|O
safety	163	169		|O
and	170	173		|O
the	174	177		|O
maximum	178	185		|O
tolerated	186	195		|O
dose	196	200		|O
of	201	203		|O
capecitabine	204	216		|O
given	217	222		|O
for	223	226		|O
10	227	229		|O
days	230	234		|O
prior	235	240		|O
to	241	243		|O
a	244	245		|O
combination	246	257		|O
of	258	260		|O
cisplatin	261	270		|O
and	271	274		|O
irinotecan	275	285		|O
in	286	288		|O
patients	289	297		|O
with	298	302		|O
advanced	303	311		|O
solid	312	317	solid malignancies	|B-DISEASE
malignancies	318	330		|I-DISEASE
.	330	331		|O
It	332	334		|O
also	335	339		|O
evaluated	340	349		|O
the	350	353		|O
changes	354	361		|O
in	362	364		|O
cisplatin	365	374		|O
DNA	375	378		|O
adducts	379	386		|O
induced	387	394		|O
by	395	397		|O
capecitabine	398	410		|O
.	410	411		|O
PATIENTS	412	420		|O
AND	421	424		|O
METHODS	425	432		|O
:	432	433		|O
Patients	434	442		|O
with	443	447		|O
refractory	448	458		|O
solid	459	464		|O
tumors	465	471		|O
who	472	475		|O
had	476	479		|O
not	480	483		|O
failed	484	490		|O
5	491	492		|O
-	492	493		|O
fluorouracil	493	505		|O
(	506	507		|O
5	507	508		|O
-	508	509		|O
FU	509	511		|O
)	511	512		|O
analogs	513	520		|O
or	521	523		|O
topoisomerase	524	537		|O
I	538	539		|O
inhibitors	540	550		|O
were	551	555		|O
eligible	556	564		|O
.	564	565		|O
All	566	569		|O
cohorts	570	577		|O
of	578	580		|O
patients	581	589		|O
first	590	595		|O
received	596	604		|O
a	605	606		|O
28	607	609		|O
-	609	610		|O
day	610	613		|O
cycle	614	619		|O
of	620	622		|O
cisplatin	623	632		|O
and	633	636		|O
irinotecan	637	647		|O
.	647	648		|O
Both	649	653		|O
drugs	654	659		|O
were	660	664		|O
given	665	670		|O
at	671	673		|O
a	674	675		|O
dose	676	680		|O
of	681	683		|O
50	684	686		|O
mg	687	689		|O
/	689	690		|O
m	690	691		|O
(	691	692		|O
2	692	693		|O
)	693	694		|O
intravenously	695	708		|O
on	709	711		|O
day	712	715		|O
1	716	717		|O
,	717	718		|O
followed	719	727		|O
by	728	730		|O
irinotecan	731	741		|O
on	742	744		|O
days	745	749		|O
8	750	751		|O
and	752	755		|O
15	756	758		|O
at	759	761		|O
the	762	765		|O
same	766	770		|O
dose	771	775		|O
.	775	776		|O
The	777	780		|O
first	781	786		|O
cycle	787	792		|O
served	793	799		|O
as	800	802		|O
an	803	805		|O
internal	806	814		|O
control	815	822		|O
.	822	823		|O
Starting	824	832		|O
from	833	837		|O
the	838	841		|O
second	842	848		|O
cycle	849	854		|O
,	854	855		|O
patients	856	864		|O
received	865	873		|O
increasing	874	884		|O
doses	885	890		|O
per	891	894		|O
cohort	895	901		|O
of	902	904		|O
capecitabine	905	917		|O
from	918	922		|O
day	923	926		|O
1	927	928		|O
to	929	931		|O
10	932	934		|O
of	935	937		|O
each	938	942		|O
cycle	943	948		|O
,	948	949		|O
followed	950	958		|O
by	959	961		|O
cisplatin	962	971		|O
on	972	974		|O
day	975	978		|O
11	979	981		|O
and	982	985		|O
irinotecan	986	996		|O
on	997	999		|O
days	1000	1004		|O
11	1005	1007		|O
,	1007	1008		|O
18	1009	1011		|O
and	1012	1015		|O
25	1016	1018		|O
,	1018	1019		|O
both	1020	1024		|O
at	1025	1027		|O
same	1028	1032		|O
doses	1033	1038		|O
as	1039	1041		|O
the	1042	1045		|O
first	1046	1051		|O
cycle	1052	1057		|O
.	1057	1058		|O
Cycles	1059	1065		|O
were	1066	1070		|O
repeated	1071	1079		|O
every	1080	1085		|O
38	1086	1088		|O
days	1089	1093		|O
.	1093	1094		|O
The	1095	1098		|O
starting	1099	1107		|O
dose	1108	1112		|O
of	1113	1115		|O
capecitabine	1116	1128		|O
was	1129	1132		|O
500	1133	1136		|O
mg	1137	1139		|O
/	1139	1140		|O
m	1140	1141		|O
(	1141	1142		|O
2	1142	1143		|O
)	1143	1144		|O
/	1144	1145		|O
day	1145	1148		|O
which	1149	1154		|O
was	1155	1158		|O
escalated	1159	1168		|O
by	1169	1171		|O
250	1172	1175		|O
mg	1176	1178		|O
/	1178	1179		|O
m	1179	1180		|O
(	1180	1181		|O
2	1181	1182		|O
)	1182	1183		|O
/	1183	1184		|O
day	1184	1187		|O
in	1188	1190		|O
the	1191	1194		|O
subsequent	1195	1205		|O
cohort	1206	1212		|O
of	1213	1215		|O
patients	1216	1224		|O
to	1225	1227		|O
reach	1228	1233		|O
the	1234	1237		|O
maximum	1238	1245		|O
tolerated	1246	1255		|O
dose	1256	1260		|O
(	1261	1262		|O
MTD	1262	1265		|O
)	1265	1266		|O
.	1266	1267		|O
Later	1268	1273		|O
,	1273	1274		|O
additional	1275	1285		|O
patients	1286	1294		|O
were	1295	1299		|O
treated	1300	1307		|O
at	1308	1310		|O
the	1311	1314		|O
MTD	1315	1318		|O
of	1319	1321		|O
capecitabine	1322	1334		|O
to	1335	1337		|O
further	1338	1345		|O
evaluate	1346	1354		|O
the	1355	1358		|O
safety	1359	1365		|O
,	1365	1366		|O
pharmacodynamics	1367	1383		|O
,	1383	1384		|O
and	1385	1388		|O
tumor	1389	1394		|O
response	1395	1403		|O
.	1403	1404		|O
Patients	1405	1413		|O
blood	1414	1419		|O
was	1420	1423		|O
tested	1424	1430		|O
for	1431	1434		|O
cisplatin	1435	1444		|O
-	1444	1445		|O
DNA	1445	1448		|O
adducts	1449	1456		|O
to	1457	1459		|O
determine	1460	1469		|O
the	1470	1473		|O
impact	1474	1480		|O
of	1481	1483		|O
capecitabine	1484	1496		|O
on	1497	1499		|O
cisplatin	1500	1509		|O
-	1509	1510		|O
based	1510	1515		|O
therapy	1516	1523		|O
.	1523	1524		|O
RESULTS	1525	1532		|O
:	1532	1533		|O
Fifteen	1534	1541		|O
patients	1542	1550		|O
received	1551	1559		|O
at	1560	1562		|O
least	1563	1568		|O
2	1569	1570		|O
cycles	1571	1577		|O
of	1578	1580		|O
treatment	1581	1590		|O
.	1590	1591		|O
At	1592	1594		|O
1,250	1595	1600		|O
mg	1601	1603		|O
/	1603	1604		|O
m	1604	1605		|O
(	1605	1606		|O
2	1606	1607		|O
)	1607	1608		|O
,	1608	1609		|O
two	1610	1613		|O
DLT	1614	1617		|O
of	1618	1620		|O
prolonged	1621	1630		|O
neutropenia	1631	1642	neutropenia	|B-ADVERSE
of	1643	1645		|O
grade	1646	1651		|O
>	1652	1653		|O
or	1654	1656		|O
=	1657	1658		|O
3	1658	1659		|O
were	1660	1664		|O
observed	1665	1673		|O
.	1673	1674		|O
The	1675	1678		|O
MTD	1679	1682		|O
for	1683	1686		|O
capecitabine	1687	1699		|O
was	1700	1703		|O
thus	1704	1708		|O
determined	1709	1719		|O
to	1720	1722		|O
be	1723	1725		|O
1000	1726	1730		|O
mg	1731	1733		|O
/	1733	1734		|O
m	1734	1735		|O
(	1735	1736		|O
2	1736	1737		|O
)	1737	1738		|O
/	1738	1739		|O
day	1739	1742		|O
.	1742	1743		|O
Fatigue	1744	1751	Fatigue	|B-ADVERSE
and	1752	1755		|O
diarrhea	1756	1764	diarrhea	|B-ADVERSE
of	1765	1767		|O
grade	1768	1773		|O
1	1774	1775		|O
or	1776	1778		|O
2	1779	1780		|O
were	1781	1785		|O
the	1786	1789		|O
most	1790	1794		|O
frequent	1795	1803		|O
toxicities	1804	1814		|O
at	1815	1817		|O
this	1818	1822		|O
dose	1823	1827		|O
level	1828	1833		|O
.	1833	1834		|O
No	1835	1837		|O
significant	1838	1849		|O
hematologic	1850	1861	hematologic toxicity	|B-ADVERSE
toxicity	1862	1870		|I-ADVERSE
was	1871	1874		|O
observed	1875	1883		|O
at	1884	1886		|O
the	1887	1890		|O
MTD	1891	1894		|O
.	1894	1895		|O
Two	1896	1899		|O
complete	1900	1908		|O
and	1909	1912		|O
three	1913	1918		|O
partial	1919	1926		|O
remissions	1927	1937		|O
were	1938	1942		|O
observed	1943	1951		|O
.	1951	1952		|O
Four	1953	1957		|O
of	1958	1960		|O
the	1961	1964		|O
responders	1965	1975		|O
had	1976	1979		|O
received	1980	1988		|O
a	1989	1990		|O
platinum	1991	1999		|O
agent	2000	2005		|O
and	2006	2009		|O
/	2009	2010		|O
or	2010	2012		|O
5	2013	2014		|O
-	2014	2015		|O
FU	2015	2017		|O
in	2018	2020		|O
the	2021	2024		|O
past	2025	2029		|O
.	2029	2030		|O
CONCLUSIONS	2031	2042		|O
:	2042	2043		|O
A	2044	2045		|O
sequential	2046	2056		|O
treatment	2057	2066		|O
with	2067	2071		|O
capecitabine	2072	2084		|O
followed	2085	2093		|O
by	2094	2096		|O
cisplatin	2097	2106		|O
and	2107	2110		|O
irinotecan	2111	2121		|O
is	2122	2124		|O
well	2125	2129		|O
tolerated	2130	2139		|O
and	2140	2143		|O
demonstrates	2144	2156		|O
clinical	2157	2165		|O
activity	2166	2174		|O
in	2175	2177		|O
patients	2178	2186		|O
with	2187	2191		|O
advanced	2192	2200		|O
solid	2201	2206	solid malignancies	|B-DISEASE
malignancies	2207	2219		|I-DISEASE
.	2219	2220		|O
The	2221	2224		|O
influence	2225	2234		|O
of	2235	2237		|O
capecitabine	2238	2250		|O
,	2250	2251		|O
if	2252	2254		|O
any	2255	2258		|O
,	2258	2259		|O
on	2260	2262		|O
the	2263	2266		|O
efficacy	2267	2275		|O
of	2276	2278		|O
the	2279	2282		|O
cisplatin	2283	2292		|O
-	2292	2293		|O
irinotecan	2293	2303		|O
combination	2304	2315		|O
is	2316	2318		|O
not	2319	2322		|O
related	2323	2330		|O
to	2331	2333		|O
a	2334	2335		|O
variation	2336	2345		|O
in	2346	2348		|O
cisplatin	2349	2358		|O
-	2358	2359		|O
DNA	2359	2362		|O
adducts	2363	2370		|O
.	2370	2371		|O

### 18673438
Endogenous	0	10		|O
alpha	11	16		|O
-	16	17		|O
calcitonin	17	27		|O
gene	28	32		|O
-	32	33		|O
related	33	40		|O
peptide	41	48		|O
mitigates	49	58		|O
liver	59	64	liver fibrosis	|B-DISEASE
fibrosis	65	73		|I-DISEASE
in	74	76		|O
chronic	77	84	chronic hepatitis	|B-DISEASE
hepatitis	85	94		|I-DISEASE
induced	95	102		|O
by	103	105		|O
repeated	106	114		|O
administration	115	129		|O
of	130	132		|O
concanavalin	133	145		|O
A	146	147		|O
.	147	148		|O
BACKGROUND	150	160		|O
:	160	161		|O
Alpha	162	167		|O
-	167	168		|O
calcitonin	168	178		|O
gene	179	183		|O
-	183	184		|O
related	184	191		|O
peptide	192	199		|O
(	200	201		|O
alphaCGRP	201	210		|O
)	210	211		|O
is	212	214		|O
a	215	216		|O
37	217	219		|O
-	219	220		|O
amino	220	225		|O
acid	226	230		|O
pleiotropic	231	242		|O
peptide	243	250		|O
that	251	255		|O
we	256	258		|O
previously	259	269		|O
showed	270	276		|O
to	277	279		|O
exert	280	285		|O
a	286	287		|O
hepatoprotective	288	304		|O
effect	305	311		|O
during	312	318		|O
concanavalin	319	331		|O
A	332	333	A (Con A)-induced acute hepatitis	|B-DISEASE
(	334	335		|I-DISEASE
Con	335	338		|I-DISEASE
A	339	340		|I-DISEASE
)	340	341		|I-DISEASE
-	341	342		|I-DISEASE
induced	342	349		|I-DISEASE
acute	350	355		|I-DISEASE
hepatitis	356	365		|I-DISEASE
.	365	366		|O
In	367	369		|O
the	370	373		|O
present	374	381		|O
study	382	387		|O
,	387	388		|O
we	389	391		|O
used	392	396		|O
alphaCGRP	397	406		|O
(	406	407		|O
-	407	408		|O
/	408	409		|O
-	409	410		|O
)	410	411		|O
mice	412	416		|O
to	417	419		|O
further	420	427		|O
investigate	428	439		|O
the	440	443		|O
antifibrogenic	444	458		|O
and	459	462		|O
hepatoprotective	463	479		|O
effects	480	487		|O
of	488	490		|O
endogenous	491	501		|O
alphaCGRP	502	511		|O
in	512	514		|O
Con	515	518		|O
A	519	520		|O
-	520	521		|O
induced	521	528		|O
chronic	529	536	chronic hepatitis	|B-DISEASE
hepatitis	537	546		|I-DISEASE
.	546	547		|O
METHODS	548	555		|O
:	555	556		|O
Chronic	557	564	Chronic hepatitis	|B-DISEASE
hepatitis	565	574		|I-DISEASE
was	575	578		|O
induced	579	586		|O
in	587	589		|O
alphaCGRP	590	599		|O
(	599	600		|O
-	600	601		|O
/	601	602		|O
-	602	603		|O
)	603	604		|O
and	605	608		|O
wild	609	613		|O
-	613	614		|O
type	614	618		|O
mice	619	623		|O
by	624	626		|O
repeated	627	635		|O
administration	636	650		|O
of	651	653		|O
Con	654	657		|O
A	658	659		|O
.	659	660		|O
Serum	661	666		|O
transaminases	667	680		|O
were	681	685		|O
measured	686	694		|O
to	695	697		|O
assess	698	704		|O
hepatic	705	712		|O
injury	713	719	injury	|B-DISEASE
.	719	720		|O
The	721	724		|O
severity	725	733		|O
of	734	736		|O
fibrosis	737	745	fibrosis	|B-DISEASE
and	746	749		|O
the	750	753		|O
activation	754	764		|O
of	765	767		|O
hepatic	768	775		|O
stellate	776	784		|O
cells	785	790		|O
(	791	792		|O
HSCs	792	796		|O
)	796	797		|O
were	798	802		|O
analysed	803	811		|O
by	812	814		|O
Masson	815	821		|O
trichrome	822	831		|O
staining	832	840		|O
and	841	844		|O
immunohistochemical	845	864		|O
staining	865	873		|O
of	874	876		|O
alpha	877	882		|O
-	882	883		|O
smooth	883	889		|O
muscle	890	896		|O
actin	897	902		|O
(	903	904		|O
alpha	904	909		|O
-	909	910		|O
SMA	910	913		|O
)	913	914		|O
respectively	915	927		|O
.	927	928		|O
Altered	929	936		|O
expression	937	947		|O
of	948	950		|O
fibrosis	951	959		|O
-	959	960		|O
and	961	964		|O
inflammation	965	977		|O
-	977	978		|O
related	978	985		|O
genes	986	991		|O
was	992	995		|O
evaluated	996	1005		|O
using	1006	1011		|O
a	1012	1013		|O
quantitative	1014	1026		|O
real	1027	1031		|O
-	1031	1032		|O
time	1032	1036		|O
polymerase	1037	1047		|O
chain	1048	1053		|O
reaction	1054	1062		|O
.	1062	1063		|O
Activation	1064	1074		|O
and	1075	1078		|O
proliferation	1079	1092		|O
of	1093	1095		|O
HSCs	1096	1100		|O
were	1101	1105		|O
analysed	1106	1114		|O
using	1115	1120		|O
both	1121	1125		|O
primary	1126	1133		|O
cultured	1134	1142		|O
HSCs	1143	1147		|O
from	1148	1152		|O
the	1153	1156		|O
mice	1157	1161		|O
and	1162	1165		|O
the	1166	1169		|O
LI90	1170	1174		|O
HSC	1175	1178		|O
cell	1179	1183		|O
line	1184	1188		|O
.	1188	1189		|O
RESULTS	1190	1197		|O
:	1197	1198		|O
alphaCGRP	1199	1208		|O
(	1208	1209		|O
-	1209	1210		|O
/	1210	1211		|O
-	1211	1212		|O
)	1212	1213		|O
mice	1214	1218		|O
showed	1219	1225		|O
more	1226	1230		|O
severe	1231	1237		|O
liver	1238	1243	liver fibrosis	|B-DISEASE
fibrosis	1244	1252		|I-DISEASE
than	1253	1257		|O
wild	1258	1262		|O
-	1262	1263		|O
type	1263	1267		|O
mice	1268	1272		|O
in	1273	1275		|O
a	1276	1277		|O
Con	1278	1281		|O
A	1282	1283		|O
-	1283	1284		|O
induced	1284	1291		|O
chronic	1292	1299	chronic hepatitis	|B-DISEASE
hepatitis	1300	1309		|I-DISEASE
model	1310	1315		|O
.	1315	1316		|O
In	1317	1319		|O
histological	1320	1332		|O
and	1333	1336		|O
gene	1337	1341		|O
expression	1342	1352		|O
analyses	1353	1361		|O
,	1361	1362		|O
alphaCGRP	1363	1372		|O
(	1372	1373		|O
-	1373	1374		|O
/	1374	1375		|O
-	1375	1376		|O
)	1376	1377		|O
mice	1378	1382		|O
showed	1383	1389		|O
greater	1390	1397		|O
inflammatory	1398	1410		|O
and	1411	1414		|O
fibrotic	1415	1423		|O
changes	1424	1431		|O
,	1431	1432		|O
greater	1433	1440		|O
HSC	1441	1444		|O
activation	1445	1455		|O
and	1456	1459		|O
a	1460	1461		|O
higher	1462	1468		|O
incidence	1469	1478		|O
of	1479	1481		|O
apoptosis	1482	1491	apoptosis	|B-DISEASE
among	1492	1497		|O
nonparenchymal	1498	1512		|O
cells	1513	1518		|O
than	1519	1523		|O
wild	1524	1528		|O
-	1528	1529		|O
type	1529	1533		|O
mice	1534	1538		|O
.	1538	1539		|O
CONCLUSIONS	1540	1551		|O
:	1551	1552		|O
Endogenous	1553	1563		|O
alphaCGRP	1564	1573		|O
mitigates	1574	1583		|O
liver	1584	1589	liver fibrosis	|B-DISEASE
fibrosis	1590	1598		|I-DISEASE
in	1599	1601		|O
chronic	1602	1609	chronic hepatitis	|B-DISEASE
hepatitis	1610	1619		|I-DISEASE
induced	1620	1627		|O
by	1628	1630		|O
repeated	1631	1639		|O
administration	1640	1654		|O
of	1655	1657		|O
Con	1658	1661		|O
A	1662	1663		|O
.	1663	1664		|O
alphaCGRP	1665	1674		|O
could	1675	1680		|O
be	1681	1683		|O
a	1684	1685		|O
useful	1686	1692		|O
therapeutic	1693	1704		|O
target	1705	1711		|O
for	1712	1715		|O
the	1716	1719		|O
treatment	1720	1729		|O
of	1730	1732		|O
chronic	1733	1740	chronic hepatitis	|B-DISEASE
hepatitis	1741	1750		|I-DISEASE
.	1750	1751		|O

### 18921966
D	0	1		|O
-	1	2		|O
chiro	2	7		|O
-	7	8		|O
inositol	8	16		|O
-	16	17		|O
enriched	17	25		|O
tartary	26	33		|O
buckwheat	34	43		|O
bran	44	48		|O
extract	49	56		|O
lowers	57	63		|O
the	64	67		|O
blood	68	73		|O
glucose	74	81		|O
level	82	87		|O
in	88	90		|O
KK	91	93		|O
-	93	94		|O
Ay	94	96		|O
mice	97	101		|O
.	101	102		|O
D	104	105		|O
-	105	106		|O
chiro	106	111		|O
-	111	112		|O
inositol	112	120		|O
(	121	122		|O
DCI	122	125		|O
)	125	126		|O
is	127	129		|O
an	130	132		|O
active	133	139		|O
compound	140	148		|O
in	149	151		|O
tartary	152	159		|O
buckwheat	160	169		|O
[	170	171		|O
Fagopyrum	171	180		|O
tataricum	181	190		|O
(	191	192		|O
L	192	193		|O
.	193	194		|O
)	194	195		|O
Gaench	196	202		|O
]	202	203		|O
with	204	208		|O
an	209	211		|O
insulin	212	219		|O
-	219	220		|O
like	220	224		|O
bioactivity	225	236		|O
.	236	237		|O
The	238	241		|O
present	242	249		|O
study	250	255		|O
was	256	259		|O
performed	260	269		|O
to	270	272		|O
(	273	274		|O
i	274	275		|O
)	275	276		|O
prepare	277	284		|O
DCI	285	288		|O
-	288	289		|O
enriched	289	297		|O
tartary	298	305		|O
buckwheat	306	315		|O
bran	316	320		|O
extract	321	328		|O
(	329	330		|O
TBBE	330	334		|O
)	334	335		|O
,	335	336		|O
(	337	338		|O
ii	338	340		|O
)	340	341		|O
evaluate	342	350		|O
its	351	354		|O
acute	355	360	acute toxicity	|B-ADVERSE
toxicity	361	369		|I-ADVERSE
in	370	372		|O
mice	373	377		|O
,	377	378		|O
and	379	382		|O
(	383	384		|O
iii	384	387		|O
)	387	388		|O
examine	389	396		|O
its	397	400		|O
blood	401	406		|O
glucose	407	414		|O
lowering	415	423		|O
activity	424	432		|O
in	433	435		|O
diabetic	436	444		|O
mice	445	449		|O
.	449	450		|O
It	451	453		|O
was	454	457		|O
found	458	463		|O
that	464	468		|O
steaming	469	477		|O
buckwheat	478	487		|O
bran	488	492		|O
in	493	495		|O
an	496	498		|O
autoclave	499	508		|O
at	509	511		|O
1.6	512	515		|O
MPa	516	519		|O
and	520	523		|O
120	524	527		|O
degrees	528	535		|O
C	536	537		|O
for	538	541		|O
60	542	544		|O
min	545	548		|O
could	549	554		|O
significantly	555	568		|O
enrich	569	575		|O
the	576	579		|O
DCI	580	583		|O
level	584	589		|O
in	590	592		|O
TBBE	593	597		|O
from	598	602		|O
0.03	603	607		|O
to	608	610		|O
0.22%	611	616		|O
and	617	620		|O
further	621	628		|O
to	629	631		|O
22%	632	635		|O
after	636	641		|O
passage	642	649		|O
of	650	652		|O
the	653	656		|O
TBBE	657	661		|O
through	662	669		|O
activated	670	679		|O
carbon	680	686		|O
and	687	690		|O
ion	691	694		|O
exchange	695	703		|O
resins	704	710		|O
.	710	711		|O
An	712	714		|O
acute	715	720	acute toxicity	|B-ADVERSE
toxicity	721	729		|I-ADVERSE
test	730	734		|O
demonstrated	735	747		|O
that	748	752		|O
the	753	756		|O
LD	757	759		|O
50	760	762		|O
of	763	765		|O
TBBE	766	770		|O
was	771	774		|O
>	775	776		|O
20	776	778		|O
g	779	780		|O
/	780	781		|O
kg	781	783		|O
of	784	786		|O
body	787	791		|O
weight	792	798		|O
in	799	801		|O
mice	802	806		|O
,	806	807		|O
suggesting	808	818		|O
that	819	823		|O
TBBE	824	828		|O
was	829	832		|O
in	833	835		|O
general	836	843		|O
nontoxic	844	852		|O
and	853	856		|O
safe	857	861		|O
in	862	864		|O
mice	865	869		|O
.	869	870		|O
Male	871	875		|O
KK	876	878		|O
-	878	879		|O
A	879	880		|O
(	880	881		|O
y	881	882		|O
)	882	883		|O
mice	884	888		|O
(	889	890		|O
type	890	894	type 2 diabetic	|B-DISEASE
2	895	896		|I-DISEASE
diabetic	897	905		|I-DISEASE
)	905	906		|O
and	907	910		|O
C57BL	911	916		|O
/	916	917		|O
6	917	918		|O
mice	919	923		|O
(	924	925		|O
the	925	928		|O
control	929	936		|O
)	936	937		|O
were	938	942		|O
used	943	947		|O
to	948	950		|O
investigate	951	962		|O
the	963	966		|O
antidiabetic	967	979		|O
activity	980	988		|O
of	989	991		|O
TBBE	992	996		|O
.	996	997		|O
In	998	1000		|O
KK	1001	1003		|O
-	1003	1004		|O
A	1004	1005		|O
(	1005	1006		|O
y	1006	1007		|O
)	1007	1008		|O
mice	1009	1013		|O
,	1013	1014		|O
the	1015	1018		|O
blood	1019	1024		|O
glucose	1025	1032		|O
,	1032	1033		|O
plasma	1034	1040		|O
C	1041	1042		|O
-	1042	1043		|O
peptide	1043	1050		|O
,	1050	1051		|O
glucagon	1052	1060		|O
,	1060	1061		|O
total	1062	1067		|O
cholesterol	1068	1079		|O
,	1079	1080		|O
triglyceride	1081	1093		|O
,	1093	1094		|O
and	1095	1098		|O
blood	1099	1104		|O
urea	1105	1109		|O
nitrogen	1110	1118		|O
(	1119	1120		|O
BUN	1120	1123		|O
)	1123	1124		|O
levels	1125	1131		|O
were	1132	1136		|O
significantly	1137	1150		|O
higher	1151	1157		|O
than	1158	1162		|O
those	1163	1168		|O
in	1169	1171		|O
the	1172	1175		|O
C57BL	1176	1181		|O
/	1181	1182		|O
6	1182	1183		|O
mice	1184	1188		|O
.	1188	1189		|O
In	1190	1192		|O
addition	1193	1201		|O
,	1201	1202		|O
KK	1203	1205		|O
-	1205	1206		|O
A	1206	1207		|O
(	1207	1208		|O
y	1208	1209		|O
)	1209	1210		|O
mice	1211	1215		|O
showed	1216	1222		|O
an	1223	1225		|O
obvious	1226	1233		|O
decrease	1234	1242		|O
in	1243	1245		|O
insulin	1246	1253		|O
immunoreactivity	1254	1270		|O
in	1271	1273		|O
the	1274	1277		|O
pancreas	1278	1286		|O
.	1286	1287		|O
The	1288	1291		|O
present	1292	1299		|O
study	1300	1305		|O
clearly	1306	1313		|O
demonstrated	1314	1326		|O
that	1327	1331		|O
oral	1332	1336		|O
administration	1337	1351		|O
of	1352	1354		|O
DCI	1355	1358		|O
-	1358	1359		|O
enriched	1359	1367		|O
TBBE	1368	1372		|O
could	1373	1378		|O
lower	1379	1384		|O
plasma	1385	1391		|O
glucose	1392	1399		|O
,	1399	1400		|O
C	1401	1402		|O
-	1402	1403		|O
peptide	1403	1410		|O
,	1410	1411		|O
glucagon	1412	1420		|O
,	1420	1421		|O
triglyceride	1422	1434		|O
,	1434	1435		|O
and	1436	1439		|O
BUN	1440	1443		|O
,	1443	1444		|O
improve	1445	1452		|O
glucose	1453	1460		|O
tolerance	1461	1470	tolerance	|B-DISEASE
,	1470	1471		|O
and	1472	1475		|O
enhance	1476	1483		|O
insulin	1484	1491		|O
immunoreactivity	1492	1508		|O
in	1509	1511		|O
KK	1512	1514		|O
-	1514	1515		|O
A	1515	1516		|O
(	1516	1517		|O
y	1517	1518		|O
)	1518	1519		|O
mice	1520	1524		|O
.	1524	1525		|O

### 18692119
Evidence	0	8		|O
for	9	12		|O
altered	13	20		|O
hippocampal	21	32		|O
volume	33	39		|O
and	40	43		|O
brain	44	49		|O
metabolites	50	61		|O
in	62	64		|O
workers	65	72		|O
occupationally	73	87		|O
exposed	88	95		|O
to	96	98		|O
lead	99	103		|O
:	103	104		|O
a	105	106		|O
study	107	112		|O
by	113	115		|O
magnetic	116	124		|O
resonance	125	134		|O
imaging	135	142		|O
and	143	146		|O
(	147	148		|O
1	148	149		|O
)	149	150		|O
H	150	151		|O
magnetic	152	160		|O
resonance	161	170		|O
spectroscopy	171	183		|O
.	183	184		|O
Environmental	186	199		|O
and	200	203		|O
occupational	204	216		|O
exposure	217	225		|O
to	226	228		|O
lead	229	233		|O
(	234	235		|O
Pb	235	237		|O
)	237	238		|O
remains	239	246		|O
to	247	249		|O
be	250	252		|O
a	253	254		|O
major	255	260		|O
public	261	267		|O
health	268	274		|O
issue	275	280		|O
.	280	281		|O
The	282	285		|O
purpose	286	293		|O
of	294	296		|O
this	297	301		|O
cross	302	307		|O
-	307	308		|O
sectional	308	317		|O
study	318	323		|O
was	324	327		|O
to	328	330		|O
use	331	334		|O
non	335	338		|O
-	338	339		|O
invasive	339	347		|O
magnetic	348	356		|O
resonance	357	366		|O
imaging	367	374		|O
(	375	376		|O
MRI	376	379		|O
)	379	380		|O
and	381	384		|O
proton	385	391		|O
magnetic	392	400		|O
resonance	401	410		|O
spectroscopy	411	423		|O
(	424	425		|O
(	425	426		|O
1	426	427		|O
)	427	428		|O
H	428	429		|O
MRS	430	433		|O
)	433	434		|O
techniques	435	445		|O
to	446	448		|O
investigate	449	460		|O
whether	461	468		|O
chronic	469	476		|O
exposure	477	485		|O
to	486	488		|O
Pb	489	491		|O
in	492	494		|O
an	495	497		|O
occupational	498	510		|O
setting	511	518		|O
altered	519	526		|O
brain	527	532		|O
structure	533	542		|O
and	543	546		|O
function	547	555		|O
of	556	558		|O
Pb	559	561		|O
-	561	562		|O
exposed	562	569		|O
workers	570	577		|O
.	577	578		|O
The	579	582		|O
Pb	583	585		|O
-	585	586		|O
exposed	586	593		|O
group	594	599		|O
consisted	600	609		|O
of	610	612		|O
15	613	615		|O
workers	616	623		|O
recruited	624	633		|O
from	634	638		|O
either	639	645		|O
a	646	647		|O
Pb	648	650		|O
-	650	651		|O
smelting	651	659		|O
factory	660	667		|O
or	668	670		|O
a	671	672		|O
Pb	673	675		|O
-	675	676		|O
battery	676	683		|O
manufacturer	684	696		|O
.	696	697		|O
The	698	701		|O
control	702	709		|O
group	710	715		|O
had	716	719		|O
19	720	722		|O
healthy	723	730		|O
volunteers	731	741		|O
who	742	745		|O
had	746	749		|O
no	750	752		|O
history	753	760		|O
of	761	763		|O
Pb	764	766		|O
exposure	767	775		|O
in	776	778		|O
working	779	786		|O
environment	787	798		|O
or	799	801		|O
at	802	804		|O
home	805	809		|O
.	809	810		|O
The	811	814		|O
average	815	822		|O
airborne	823	831		|O
Pb	832	834		|O
concentrations	835	849		|O
in	850	852		|O
fume	853	857		|O
and	858	861		|O
dust	862	866		|O
were	867	871		|O
0.43	872	876		|O
and	877	880		|O
0.44	881	885		|O
mg	886	888		|O
/	888	889		|O
m	889	890		|O
(	890	891		|O
3	891	892		|O
)	892	893		|O
,	893	894		|O
respectively	895	907		|O
,	907	908		|O
in	909	911		|O
the	912	915		|O
smeltery	916	924		|O
,	924	925		|O
and	926	929		|O
0.10	930	934		|O
and	935	938		|O
1.06	939	943		|O
mg	944	946		|O
/	946	947		|O
m	947	948		|O
(	948	949		|O
3	949	950		|O
)	950	951		|O
,	951	952		|O
respectively	953	965		|O
,	965	966		|O
in	967	969		|O
the	970	973		|O
Pb	974	976		|O
battery	977	984		|O
workshop	985	993		|O
.	993	994		|O
The	995	998		|O
average	999	1006		|O
blood	1007	1012		|O
Pb	1013	1015		|O
concentrations	1016	1030		|O
(	1031	1032		|O
BPb	1032	1035		|O
)	1035	1036		|O
in	1037	1039		|O
Pb	1040	1042		|O
-	1042	1043		|O
exposed	1043	1050		|O
and	1051	1054		|O
control	1055	1062		|O
workers	1063	1070		|O
were	1071	1075		|O
63.5	1076	1080		|O
and	1081	1084		|O
8.7	1085	1088		|O
microg	1089	1095		|O
/	1095	1096		|O
dL	1096	1098		|O
,	1098	1099		|O
respectively	1100	1112		|O
.	1112	1113		|O
The	1114	1117		|O
MRI	1118	1121		|O
examination	1122	1133		|O
showed	1134	1140		|O
that	1141	1145		|O
brain	1146	1151		|O
hippocampal	1152	1163		|O
volume	1164	1170		|O
among	1171	1176		|O
Pb	1177	1179		|O
-	1179	1180		|O
exposed	1180	1187		|O
workers	1188	1195		|O
was	1196	1199		|O
significantly	1200	1213		|O
diminished	1214	1224		|O
in	1225	1227		|O
comparison	1228	1238		|O
to	1239	1241		|O
age	1242	1245		|O
-	1245	1246		|O
matched	1246	1253		|O
control	1254	1261		|O
subjects	1262	1270		|O
(	1271	1272		|O
p	1272	1273		|O
<	1274	1275		|O
0.01	1276	1280		|O
)	1280	1281		|O
,	1281	1282		|O
although	1283	1291		|O
the	1292	1295		|O
extent	1296	1302		|O
of	1303	1305		|O
this	1306	1310		|O
reduction	1311	1320		|O
was	1321	1324		|O
relatively	1325	1335		|O
small	1336	1341		|O
(	1342	1343		|O
5-6%	1343	1347		|O
of	1348	1350		|O
the	1351	1354		|O
control	1355	1362		|O
values	1363	1369		|O
)	1369	1370		|O
.	1370	1371		|O
Linear	1372	1378		|O
regression	1379	1389		|O
analyses	1390	1398		|O
revealed	1399	1407		|O
significant	1408	1419		|O
inverse	1420	1427		|O
associations	1428	1440		|O
between	1441	1448		|O
BPb	1449	1452		|O
and	1453	1456		|O
the	1457	1460		|O
decreased	1461	1470		|O
hippocampal	1471	1482		|O
volume	1483	1489		|O
on	1490	1492		|O
both	1493	1497		|O
sides	1498	1503		|O
of	1504	1506		|O
brain	1507	1512		|O
hemisphere	1513	1523		|O
.	1523	1524		|O
Among	1525	1530		|O
five	1531	1535		|O
brain	1536	1541		|O
metabolites	1542	1553		|O
investigated	1554	1566		|O
by	1567	1569		|O
MRS	1570	1573		|O
,	1573	1574		|O
i.e.	1575	1579		|O
,	1579	1580		|O
N	1581	1582		|O
-	1582	1583		|O
acetyl	1583	1589		|O
-	1589	1590		|O
aspartate	1590	1599		|O
(	1600	1601		|O
NAA	1601	1604		|O
)	1604	1605		|O
,	1605	1606		|O
creatine	1607	1615		|O
(	1616	1617		|O
Cr	1617	1619		|O
)	1619	1620		|O
,	1620	1621		|O
choline	1622	1629		|O
(	1630	1631		|O
Cho	1631	1634		|O
)	1634	1635		|O
,	1635	1636		|O
inosine	1637	1644		|O
(	1645	1646		|O
mI	1646	1648		|O
)	1648	1649		|O
,	1649	1650		|O
glutamate	1651	1660		|O
/	1660	1661		|O
glutamine	1661	1670		|O
(	1671	1672		|O
Glx	1672	1675		|O
)	1675	1676		|O
and	1677	1680		|O
lipids	1681	1687		|O
(	1688	1689		|O
Lip	1689	1692		|O
)	1692	1693		|O
,	1693	1694		|O
a	1695	1696		|O
significant	1697	1708		|O
decrease	1709	1717		|O
in	1718	1720		|O
NAA	1721	1724		|O
/	1724	1725		|O
Cr	1725	1727		|O
ratio	1728	1733		|O
(	1734	1735		|O
7%	1735	1737		|O
of	1738	1740		|O
controls	1741	1749		|O
,	1749	1750		|O
p	1751	1752		|O
<	1753	1754		|O
0.05	1755	1759		|O
)	1759	1760		|O
and	1761	1764		|O
a	1765	1766		|O
remarkable	1767	1777		|O
increase	1778	1786		|O
in	1787	1789		|O
Lip	1790	1793		|O
/	1793	1794		|O
Cr	1794	1796		|O
ratio	1797	1802		|O
(	1803	1804		|O
40%	1804	1807		|O
,	1807	1808		|O
p	1809	1810		|O
<	1811	1812		|O
0.01	1813	1817		|O
)	1817	1818		|O
were	1819	1823		|O
observed	1824	1832		|O
in	1833	1835		|O
the	1836	1839		|O
brains	1840	1846		|O
of	1847	1849		|O
Pb	1850	1852		|O
-	1852	1853		|O
exposed	1853	1860		|O
workers	1861	1868		|O
as	1869	1871		|O
compared	1872	1880		|O
to	1881	1883		|O
controls	1884	1892		|O
.	1892	1893		|O
Furthermore	1894	1905		|O
,	1905	1906		|O
the	1907	1910		|O
increased	1911	1920		|O
Lip	1921	1924		|O
/	1924	1925		|O
Cr	1925	1927		|O
ratio	1928	1933		|O
was	1934	1937		|O
significantly	1938	1951		|O
associated	1952	1962		|O
with	1963	1967		|O
BPb	1968	1971		|O
(	1972	1973		|O
r	1973	1974		|O
=	1975	1976		|O
0.46	1977	1981		|O
,	1981	1982		|O
p	1983	1984		|O
<	1985	1986		|O
0.01	1987	1991		|O
)	1991	1992		|O
.	1992	1993		|O
Taken	1994	1999		|O
together	2000	2008		|O
,	2008	2009		|O
this	2010	2014		|O
study	2015	2020		|O
suggests	2021	2029		|O
that	2030	2034		|O
occupational	2035	2047		|O
exposure	2048	2056		|O
to	2057	2059		|O
Pb	2060	2062		|O
may	2063	2066		|O
cause	2067	2072		|O
subtle	2073	2079		|O
structural	2080	2090		|O
and	2091	2094		|O
functional	2095	2105		|O
alteration	2106	2116		|O
in	2117	2119		|O
human	2120	2125		|O
brains	2126	2132		|O
.	2132	2133		|O
The	2134	2137		|O
MRI	2138	2141		|O
and	2142	2145		|O
MRS	2146	2149		|O
brain	2150	2155		|O
imaging	2156	2163		|O
techniques	2164	2174		|O
can	2175	2178		|O
be	2179	2181		|O
used	2182	2186		|O
as	2187	2189		|O
the	2190	2193		|O
non	2194	2197		|O
-	2197	2198		|O
invasive	2198	2206		|O
means	2207	2212		|O
to	2213	2215		|O
evaluate	2216	2224		|O
Pb	2225	2227		|O
-	2227	2228		|O
induced	2228	2235		|O
neurotoxicity	2236	2249	neurotoxicity	|B-ADVERSE
.	2249	2250		|O

### 18843413
Synthesis	0	9		|O
and	10	13		|O
biological	14	24		|O
evaluation	25	35		|O
of	36	38		|O
bile	39	43		|O
acid	44	48		|O
dimers	49	55		|O
linked	56	62		|O
with	63	67		|O
1,2,3	68	73		|O
-	73	74		|O
triazole	74	82		|O
and	83	86		|O
bis	87	90		|O
-	90	91		|O
beta	91	95		|O
-	95	96		|O
lactam	96	102		|O
.	102	103		|O
We	105	107		|O
report	108	114		|O
herein	115	121		|O
the	122	125		|O
synthesis	126	135		|O
and	136	139		|O
biological	140	150		|O
evaluation	151	161		|O
of	162	164		|O
bile	165	169		|O
acid	170	174		|O
dimers	175	181		|O
linked	182	188		|O
through	189	196		|O
1,2,3	197	202		|O
-	202	203		|O
triazole	203	211		|O
and	212	215		|O
bis	216	219		|O
-	219	220		|O
beta	220	224		|O
-	224	225		|O
lactam	225	231		|O
.	231	232		|O
The	233	236		|O
dimers	237	243		|O
were	244	248		|O
synthesized	249	260		|O
using	261	266		|O
1,3	267	270		|O
-	270	271		|O
dipolar	271	278		|O
cycloaddition	279	292		|O
reaction	293	301		|O
of	302	304		|O
diazido	305	312		|O
bis	313	316		|O
-	316	317		|O
beta	317	321		|O
-	321	322		|O
lactams	322	329		|O
,	330	331		|O
and	332	335		|O
terminal	336	344		|O
alkynes	345	352		|O
derived	353	360		|O
from	361	365		|O
cholic	366	372		|O
acid	373	377		|O
/	377	378		|O
deoxycholic	378	389		|O
acid	390	394		|O
in	395	397		|O
the	398	401		|O
presence	402	410		|O
of	411	413		|O
Cu	414	416		|O
(	416	417		|O
i	417	418		|O
)	418	419		|O
catalyst	420	428		|O
(	429	430		|O
click	430	435		|O
chemistry	436	445		|O
)	445	446		|O
.	446	447		|O
These	448	453		|O
novel	454	459		|O
molecules	460	469		|O
were	470	474		|O
evaluated	475	484		|O
in	485	487		|O
vitro	488	493		|O
for	494	497		|O
their	498	503		|O
antifungal	504	514		|O
and	515	518		|O
antibacterial	519	532		|O
activity	533	541		|O
.	541	542		|O
Most	543	547		|O
of	548	550		|O
the	551	554		|O
compounds	555	564		|O
exhibited	565	574		|O
significant	575	586		|O
antifungal	587	597		|O
as	598	600		|O
well	601	605		|O
as	606	608		|O
antibacterial	609	622		|O
activity	623	631		|O
against	632	639		|O
all	640	643		|O
the	644	647		|O
tested	648	654		|O
fungal	655	661		|O
and	662	665		|O
bacterial	666	675		|O
strains	676	683		|O
.	683	684		|O
Moreover	685	693		|O
,	693	694		|O
their	695	700		|O
in	701	703		|O
vitro	704	709		|O
cytotoxicities	710	724	cytotoxicities	|B-ADVERSE
towards	725	732		|O
HEK	733	736		|O
-	736	737		|O
293	737	740		|O
and	741	744		|O
MCF	745	748		|O
-	748	749		|O
7	749	750		|O
cells	751	756		|O
were	757	761		|O
also	762	766		|O
established	767	778		|O
.	778	779		|O

### 18541199
Stem	0	4		|O
cell	5	9		|O
mobilization	10	22		|O
with	23	27		|O
cyclophosphamide	28	44		|O
overcomes	45	54		|O
the	55	58		|O
suppressive	59	70		|O
effect	71	77		|O
of	78	80		|O
lenalidomide	81	93		|O
therapy	94	101		|O
on	102	104		|O
stem	105	109		|O
cell	110	114		|O
collection	115	125		|O
in	126	128		|O
multiple	129	137	multiple myeloma	|B-DISEASE
myeloma	138	145		|I-DISEASE
.	145	146		|O
A	148	149		|O
total	150	155		|O
of	156	158		|O
28	159	161		|O
treatment	162	171		|O
-	171	172		|O
na	172	174		|O
?	174	175		|O
ve	175	177		|O
patients	178	186		|O
with	187	191		|O
stage	192	197		|O
II	198	200		|O
or	201	203		|O
III	204	207		|O
multiple	208	216	multiple myeloma	|B-DISEASE
myeloma	217	224		|I-DISEASE
(	225	226		|O
MM	226	228	MM	|B-DISEASE
)	228	229		|O
were	230	234		|O
treated	235	242		|O
with	243	247		|O
the	248	251		|O
combination	252	263		|O
of	264	266		|O
clarithromycin	267	281		|O
,	281	282		|O
lenalidomide	283	295		|O
,	295	296		|O
and	297	300		|O
dexamethasone	301	314		|O
(	315	316		|O
BiRD	316	320		|O
)	320	321		|O
.	321	322		|O
Stem	323	327		|O
cells	328	333		|O
were	334	338		|O
collected	339	348		|O
following	349	358		|O
granulocyte	359	370		|O
-	370	371		|O
colony	371	377		|O
stimulating	378	389		|O
factor	390	396		|O
(	397	398		|O
G	398	399		|O
-	399	400		|O
CSF	400	403		|O
)	403	404		|O
or	405	407		|O
cyclophosphamide	408	424		|O
(	425	426		|O
Cy	426	428		|O
)	428	429		|O
plus	430	434		|O
G	435	436		|O
-	436	437		|O
CSF	437	440		|O
mobilization	441	453		|O
at	454	456		|O
maximum	457	464		|O
response	465	473		|O
.	473	474		|O
Sufficient	475	485		|O
stem	486	490		|O
cells	491	496		|O
for	497	500		|O
2	501	502		|O
autologous	503	513		|O
stem	514	518		|O
cell	519	523		|O
transplants	524	535		|O
were	536	540		|O
collected	541	550		|O
from	551	555		|O
all	556	559		|O
patients	560	568		|O
mobilized	569	578		|O
with	579	583		|O
Cy	584	586		|O
plus	587	591		|O
G	592	593		|O
-	593	594		|O
CSF	594	597		|O
,	597	598		|O
versus	599	605		|O
33%	606	609		|O
mobilized	610	619		|O
with	620	624		|O
G	625	626		|O
-	626	627		|O
CSF	627	630		|O
alone	631	636		|O
(	637	638		|O
P	638	639		|O
<	640	641		|O
.0001	642	647		|O
)	647	648		|O
.	648	649		|O
The	650	653		|O
duration	654	662		|O
of	663	665		|O
prior	666	671		|O
lenalidomide	672	684		|O
therapy	685	692		|O
did	693	696		|O
not	697	700		|O
correlate	701	710		|O
with	711	715		|O
success	716	723		|O
of	724	726		|O
stem	727	731		|O
cell	732	736		|O
harvests	737	745		|O
(	746	747		|O
P	747	748		|O
=	749	750		|O
.91	751	754		|O
)	754	755		|O
.	755	756		|O
In	757	759		|O
conclusion	760	770		|O
,	770	771		|O
Cy	772	774		|O
can	775	778		|O
be	779	781		|O
added	782	787		|O
to	788	790		|O
G	791	792		|O
-	792	793		|O
CSF	793	796		|O
for	797	800		|O
stem	801	805		|O
cell	806	810		|O
mobilization	811	823		|O
to	824	826		|O
successfully	827	839		|O
overcome	840	848		|O
the	849	852		|O
suppressive	853	864		|O
effect	865	871		|O
of	872	874		|O
prior	875	880		|O
treatment	881	890		|O
with	891	895		|O
lenalidomide	896	908		|O
.	908	909		|O

### 18669463
Chemoimmunotherapy	0	18		|O
reinduction	19	30		|O
with	31	35		|O
epratuzumab	36	47		|O
in	48	50		|O
children	51	59		|O
with	60	64		|O
acute	65	70	acute lymphoblastic leukemia	|B-DISEASE
lymphoblastic	71	84		|I-DISEASE
leukemia	85	93		|I-DISEASE
in	94	96		|O
marrow	97	103		|O
relapse	104	111		|O
:	111	112		|O
a	113	114		|O
Children	115	123		|O
's	123	125		|O
Oncology	126	134		|O
Group	135	140		|O
Pilot	141	146		|O
Study	147	152		|O
.	152	153		|O
PURPOSE	155	162		|O
:	162	163		|O
To	164	166		|O
determine	167	176		|O
the	177	180		|O
tolerability	181	193		|O
and	194	197		|O
serum	198	203		|O
concentration	204	217		|O
of	218	220		|O
epratuzumab	221	232		|O
,	232	233		|O
a	234	235		|O
humanized	236	245		|O
monoclonal	246	256		|O
antibody	257	265		|O
targeting	266	275		|O
CD22	276	280		|O
,	280	281		|O
administered	282	294		|O
alone	295	300		|O
and	301	304		|O
in	305	307		|O
combination	308	319		|O
with	320	324		|O
reinduction	325	336		|O
chemotherapy	337	349		|O
in	350	352		|O
children	353	361		|O
with	362	366		|O
relapsed	367	375		|O
acute	376	381	acute lymphoblastic leukemia	|B-DISEASE
lymphoblastic	382	395		|I-DISEASE
leukemia	396	404		|I-DISEASE
(	405	406		|O
ALL	406	409	ALL	|B-DISEASE
)	409	410		|O
,	410	411		|O
and	412	415		|O
to	416	418		|O
preliminarily	419	432		|O
assess	433	439		|O
tumor	440	445		|O
targeting	446	455		|O
and	456	459		|O
efficacy	460	468		|O
.	468	469		|O
PATIENTS	470	478		|O
AND	479	482		|O
METHODS	483	490		|O
:	490	491		|O
Therapy	492	499		|O
consisted	500	509		|O
of	510	512		|O
a	513	514		|O
single	515	521		|O
-	521	522		|O
agent	522	527		|O
phase	528	533		|O
(	534	535		|O
epratuzumab	535	546		|O
360	547	550		|O
mg	551	553		|O
/	553	554		|O
m	554	555		|O
(	555	556		|O
2	556	557		|O
)	557	558		|O
/	558	559		|O
dose	559	563		|O
intravenously	564	577		|O
twice	578	583		|O
weekly	584	590		|O
x	591	592		|O
four	593	597		|O
doses	598	603		|O
)	603	604		|O
,	604	605		|O
followed	606	614		|O
by	615	617		|O
four	618	622		|O
weekly	623	629		|O
doses	630	635		|O
of	636	638		|O
epratuzumab	639	650		|O
in	651	653		|O
combination	654	665		|O
with	666	670		|O
standard	671	679		|O
reinduction	680	691		|O
chemotherapy	692	704		|O
.	704	705		|O
Morphologic	706	717		|O
and	718	721		|O
minimal	722	729		|O
residual	730	738		|O
disease	739	746		|O
(	747	748		|O
MRD	748	751		|O
)	751	752		|O
responses	753	762		|O
were	763	767		|O
determined	768	778		|O
at	779	781		|O
the	782	785		|O
end	786	789		|O
of	790	792		|O
this	793	797		|O
6	798	799		|O
-	799	800		|O
week	800	804		|O
period	805	811		|O
.	811	812		|O
Serum	813	818		|O
concentrations	819	833		|O
of	834	836		|O
epratuzumab	837	848		|O
were	849	853		|O
determined	854	864		|O
before	865	871		|O
and	872	875		|O
30	876	878		|O
minutes	879	886		|O
after	887	892		|O
infusions	893	902		|O
,	902	903		|O
and	904	907		|O
CD22	908	912		|O
targeting	913	922		|O
efficiency	923	933		|O
was	934	937		|O
determined	938	948		|O
by	949	951		|O
quantifying	952	963		|O
changes	964	971		|O
in	972	974		|O
CD22	975	979		|O
expression	980	990		|O
after	991	996		|O
epratuzumab	997	1008		|O
administration	1009	1023		|O
.	1023	1024		|O
RESULTS	1025	1032		|O
:	1032	1033		|O
Fifteen	1034	1041		|O
patients	1042	1050		|O
(	1051	1052		|O
12	1052	1054		|O
fully	1055	1060		|O
assessable	1061	1071		|O
for	1072	1075		|O
toxicity	1076	1084		|O
)	1084	1085		|O
with	1086	1090		|O
first	1091	1096		|O
or	1097	1099		|O
later	1100	1105		|O
CD22	1106	1110		|O
-	1110	1111		|O
positive	1111	1119		|O
ALL	1120	1123	ALL	|B-DISEASE
marrow	1124	1130		|O
relapse	1131	1138		|O
enrolled	1139	1147		|O
on	1148	1150		|O
the	1151	1154		|O
feasibility	1155	1166		|O
portion	1167	1174		|O
of	1175	1177		|O
this	1178	1182		|O
study	1183	1188		|O
from	1189	1193		|O
December	1194	1202		|O
2005	1203	1207		|O
to	1208	1210		|O
June	1211	1215		|O
2006	1216	1220		|O
.	1220	1221		|O
Two	1222	1225		|O
dose	1226	1230		|O
-	1230	1231		|O
limiting	1231	1239		|O
toxicities	1240	1250		|O
occurred	1251	1259		|O
:	1259	1260		|O
one	1261	1264		|O
grade	1265	1270		|O
4	1271	1272		|O
seizure	1273	1280	seizure	|B-DISEASE
of	1281	1283		|O
unclear	1284	1291		|O
etiology	1292	1300		|O
and	1301	1304		|O
one	1305	1308		|O
asymptomatic	1309	1321		|O
grade	1322	1327		|O
3	1328	1329		|O
ALT	1330	1333		|O
elevation	1334	1343		|O
.	1343	1344		|O
In	1345	1347		|O
all	1348	1351		|O
but	1352	1355		|O
one	1356	1359		|O
patient	1360	1367		|O
,	1367	1368		|O
surface	1369	1376		|O
CD22	1377	1381		|O
was	1382	1385		|O
not	1386	1389		|O
detected	1390	1398		|O
by	1399	1401		|O
flow	1402	1406		|O
cytometry	1407	1416		|O
on	1417	1419		|O
peripheral	1420	1430		|O
blood	1431	1436		|O
leukemic	1437	1445		|O
blasts	1446	1452		|O
within	1453	1459		|O
24	1460	1462		|O
hours	1463	1468		|O
of	1469	1471		|O
drug	1472	1476		|O
administration	1477	1491		|O
,	1491	1492		|O
indicating	1493	1503		|O
effective	1504	1513		|O
targeting	1514	1523		|O
of	1524	1526		|O
leukemic	1527	1535		|O
cells	1536	1541		|O
by	1542	1544		|O
epratuzumab	1545	1556		|O
.	1556	1557		|O
Nine	1558	1562		|O
patients	1563	1571		|O
achieved	1572	1580		|O
a	1581	1582		|O
complete	1583	1591		|O
remission	1592	1601		|O
after	1602	1607		|O
chemoimmunotherapy	1608	1626		|O
,	1626	1627		|O
seven	1628	1633		|O
of	1634	1636		|O
whom	1637	1641		|O
were	1642	1646		|O
MRD	1647	1650		|O
negative	1651	1659		|O
.	1659	1660		|O
CONCLUSION	1661	1671		|O
:	1671	1672		|O
Treatment	1673	1682		|O
with	1683	1687		|O
epratuzumab	1688	1699		|O
plus	1700	1704		|O
standard	1705	1713		|O
reinduction	1714	1725		|O
chemotherapy	1726	1738		|O
is	1739	1741		|O
feasible	1742	1750		|O
and	1751	1754		|O
acceptably	1755	1765		|O
tolerated	1766	1775		|O
in	1776	1778		|O
children	1779	1787		|O
with	1788	1792		|O
relapsed	1793	1801		|O
CD22	1802	1806		|O
-	1806	1807		|O
positive	1807	1815		|O
ALL	1816	1819	ALL	|B-DISEASE
.	1819	1820		|O
CD22	1821	1825		|O
targeting	1826	1835		|O
was	1836	1839		|O
efficient	1840	1849		|O
,	1849	1850		|O
and	1851	1854		|O
the	1855	1858		|O
majority	1859	1867		|O
of	1868	1870		|O
patients	1871	1879		|O
achieved	1880	1888		|O
favorable	1889	1898		|O
early	1899	1904		|O
responses	1905	1914		|O
.	1914	1915		|O

### 18942772
Transient	0	9		|O
gene	10	14		|O
delivery	15	23		|O
for	24	27		|O
functional	28	38		|O
enrichment	39	49		|O
of	50	52		|O
differentiating	53	68		|O
embryonic	69	78		|O
stem	79	83		|O
cells	84	89		|O
.	89	90		|O
There	92	97		|O
is	98	100		|O
a	101	102		|O
critical	103	111		|O
need	112	116		|O
for	117	120		|O
new	121	124		|O
sources	125	132		|O
of	133	135		|O
hepatocytes	136	147		|O
,	147	148		|O
both	149	153		|O
clinically	154	164		|O
to	165	167		|O
provide	168	175		|O
support	176	183		|O
for	184	187		|O
patients	188	196		|O
with	197	201		|O
liver	202	207	liver failure	|B-DISEASE
failure	208	215		|I-DISEASE
and	216	219		|O
in	220	222		|O
drug	223	227		|O
discovery	228	237		|O
for	238	241		|O
toxicity	242	250		|O
,	250	251		|O
metabolic	252	261		|O
and	262	265		|O
pharmacokinetic	266	281		|O
screening	282	291		|O
of	292	294		|O
new	295	298		|O
drug	299	303		|O
entities	304	312		|O
.	312	313		|O
We	314	316		|O
have	317	321		|O
reported	322	330		|O
previously	331	341		|O
a	342	343		|O
variety	344	351		|O
of	352	354		|O
methods	355	362		|O
for	363	366		|O
differentiating	367	382		|O
murine	383	389		|O
embryonic	390	399		|O
stem	400	404		|O
(	405	406		|O
ES	406	408		|O
)	408	409		|O
cells	410	415		|O
into	416	420		|O
hepatocyte	421	431		|O
-	431	432		|O
like	432	436		|O
cells	437	442		|O
.	442	443		|O
One	444	447		|O
major	448	453		|O
challenge	454	463		|O
of	464	466		|O
our	467	470		|O
work	471	475		|O
and	476	479		|O
others	480	486		|O
in	487	489		|O
the	490	493		|O
field	494	499		|O
has	500	503		|O
been	504	508		|O
the	509	512		|O
ability	513	520		|O
to	521	523		|O
selectively	524	535		|O
purify	536	542		|O
and	543	546		|O
enrich	547	553		|O
these	554	559		|O
cells	560	565		|O
from	566	570		|O
a	571	572		|O
heterogeneous	573	586		|O
population	587	597		|O
.	597	598		|O
Traditional	599	610		|O
approaches	611	621		|O
for	622	625		|O
inserting	626	635		|O
new	636	639		|O
genes	640	645		|O
(	646	647		|O
e.g.	647	651		|O
,	651	652		|O
stable	653	659		|O
transfection	660	672		|O
,	672	673		|O
knock	674	679		|O
-	679	680		|O
in	680	682		|O
,	682	683		|O
retroviral	684	694		|O
transduction	695	707		|O
)	707	708		|O
involve	709	716		|O
permanent	717	726		|O
alterations	727	738		|O
in	739	741		|O
the	742	745		|O
genome	746	752		|O
.	752	753		|O
These	754	759		|O
approaches	760	770		|O
can	771	774		|O
lead	775	779		|O
to	780	782		|O
mutations	783	792		|O
and	793	796		|O
involve	797	804		|O
the	805	808		|O
extra	809	814		|O
costs	815	820		|O
and	821	824		|O
time	825	829		|O
of	830	832		|O
developing	833	843		|O
,	843	844		|O
validating	845	855		|O
and	856	859		|O
maintaining	860	871		|O
new	872	875		|O
cell	876	880		|O
lines	881	886		|O
.	886	887		|O
We	888	890		|O
have	891	895		|O
developed	896	905		|O
a	906	907		|O
transient	908	917		|O
gene	918	922		|O
delivery	923	931		|O
system	932	938		|O
that	939	943		|O
uses	944	948		|O
fluorescent	949	960		|O
gene	961	965		|O
reporters	966	975		|O
for	976	979		|O
purification	980	992		|O
of	993	995		|O
the	996	999		|O
cells	1000	1005		|O
.	1005	1006		|O
Following	1007	1016		|O
a	1017	1018		|O
transient	1019	1028		|O
transfection	1029	1041		|O
,	1041	1042		|O
the	1043	1046		|O
cells	1047	1052		|O
are	1053	1056		|O
purified	1057	1065		|O
through	1066	1073		|O
a	1074	1075		|O
fluorescence	1076	1088		|O
-	1088	1089		|O
activated	1089	1098		|O
cell	1099	1103		|O
sorter	1104	1110		|O
(	1111	1112		|O
FACS	1112	1116		|O
)	1116	1117		|O
,	1117	1118		|O
re	1119	1121		|O
-	1121	1122		|O
plated	1122	1128		|O
in	1129	1131		|O
secondary	1132	1141		|O
culture	1142	1149		|O
and	1150	1153		|O
subsequent	1154	1164		|O
phenotypic	1165	1175		|O
analysis	1176	1184		|O
is	1185	1187		|O
performed	1188	1197		|O
.	1197	1198		|O
In	1199	1201		|O
an	1202	1204		|O
effort	1205	1211		|O
to	1212	1214		|O
test	1215	1219		|O
the	1220	1223		|O
ability	1224	1231		|O
of	1232	1234		|O
the	1235	1238		|O
reporters	1239	1248		|O
to	1249	1251		|O
work	1252	1256		|O
in	1257	1259		|O
a	1260	1261		|O
transient	1262	1271		|O
environment	1272	1283		|O
for	1284	1287		|O
our	1288	1291		|O
differentiation	1292	1307		|O
system	1308	1314		|O
,	1314	1315		|O
we	1316	1318		|O
engineered	1319	1329		|O
two	1330	1333		|O
non	1334	1337		|O
-	1337	1338		|O
viral	1338	1343		|O
plasmid	1344	1351		|O
reporters	1352	1361		|O
,	1361	1362		|O
the	1363	1366		|O
first	1367	1372		|O
driven	1373	1379		|O
by	1380	1382		|O
the	1383	1386		|O
mouse	1387	1392		|O
albumin	1393	1400		|O
enhancer	1401	1409		|O
/	1409	1410		|O
promoter	1410	1418		|O
and	1419	1422		|O
the	1423	1426		|O
second	1427	1433		|O
by	1434	1436		|O
the	1437	1440		|O
mouse	1441	1446		|O
cytochrome	1447	1457		|O
P450	1458	1462		|O
7A1	1463	1466		|O
(	1467	1468		|O
Cyp7A1	1468	1474		|O
)	1474	1475		|O
promoter	1476	1484		|O
.	1484	1485		|O
We	1486	1488		|O
optimized	1489	1498		|O
the	1499	1502		|O
transfection	1503	1515		|O
efficiency	1516	1526		|O
of	1527	1529		|O
delivering	1530	1540		|O
these	1541	1546		|O
genes	1547	1552		|O
into	1553	1557		|O
spontaneously	1558	1571		|O
differentiated	1572	1586		|O
ES	1587	1589		|O
cells	1590	1595		|O
and	1596	1599		|O
sorted	1600	1606		|O
independent	1607	1618		|O
fractions	1619	1628		|O
positive	1629	1637		|O
for	1638	1641		|O
each	1642	1646		|O
reporter	1647	1655		|O
17	1656	1658		|O
days	1659	1663		|O
after	1664	1669		|O
inducing	1670	1678		|O
differentiation	1679	1694		|O
.	1694	1695		|O
We	1696	1698		|O
found	1699	1704		|O
that	1705	1709		|O
cells	1710	1715		|O
sorted	1716	1722		|O
based	1723	1728		|O
on	1729	1731		|O
the	1732	1735		|O
Cyp7A1	1736	1742		|O
promoter	1743	1751		|O
showed	1752	1758		|O
significant	1759	1770		|O
enrichment	1771	1781		|O
in	1782	1784		|O
terms	1785	1790		|O
of	1791	1793		|O
albumin	1794	1801		|O
secretion	1802	1811		|O
,	1811	1812		|O
urea	1813	1817		|O
secretion	1818	1827		|O
and	1828	1831		|O
cytochrome	1832	1842		|O
P450	1843	1847		|O
1A2	1848	1851		|O
detoxification	1852	1866		|O
activity	1867	1875		|O
as	1876	1878		|O
compared	1879	1887		|O
to	1888	1890		|O
enrichment	1891	1901		|O
garnered	1902	1910		|O
by	1911	1913		|O
the	1914	1917		|O
albumin	1918	1925		|O
promoter	1926	1934		|O
-	1934	1935		|O
based	1935	1940		|O
cell	1941	1945		|O
sort	1946	1950		|O
.	1950	1951		|O
Development	1952	1963		|O
of	1964	1966		|O
gene	1967	1971		|O
reporter	1972	1980		|O
systems	1981	1988		|O
that	1989	1993		|O
allow	1994	1999		|O
us	2000	2002		|O
to	2003	2005		|O
identify	2006	2014		|O
,	2014	2015		|O
purify	2016	2022		|O
and	2023	2026		|O
assess	2027	2033		|O
homogeneous	2034	2045		|O
populations	2046	2057		|O
of	2058	2060		|O
cells	2061	2066		|O
is	2067	2069		|O
important	2070	2079		|O
in	2080	2082		|O
better	2083	2089		|O
understanding	2090	2103		|O
stem	2104	2108		|O
cell	2109	2113		|O
differentiation	2114	2129		|O
pathways	2130	2138		|O
.	2138	2139		|O
And	2140	2143		|O
engineering	2144	2155		|O
cellular	2156	2164		|O
systems	2165	2172		|O
without	2173	2180		|O
making	2181	2187		|O
permanent	2188	2197		|O
gene	2198	2202		|O
changes	2203	2210		|O
will	2211	2215		|O
be	2216	2218		|O
critical	2219	2227		|O
for	2228	2231		|O
the	2232	2235		|O
generation	2236	2246		|O
of	2247	2249		|O
clinically	2250	2260		|O
acceptable	2261	2271		|O
cellular	2272	2280		|O
material	2281	2289		|O
in	2290	2292		|O
the	2293	2296		|O
future	2297	2303		|O
.	2303	2304		|O

### 18623605
Pentachlorophenol	0	17		|O
decreases	18	27		|O
ATP	28	31		|O
levels	32	38		|O
in	39	41		|O
human	42	47		|O
natural	48	55		|O
killer	56	62		|O
cells	63	68		|O
.	68	69		|O
Pentachlorophenol	71	88		|O
(	89	90		|O
PCP	90	93		|O
)	93	94		|O
is	95	97		|O
used	98	102		|O
as	103	105		|O
a	106	107		|O
wood	108	112		|O
preservative	113	125		|O
and	126	129		|O
is	130	132		|O
found	133	138		|O
in	139	141		|O
human	142	147		|O
blood	148	153		|O
and	154	157		|O
urine	158	163		|O
.	163	164		|O
PCP	165	168		|O
causes	169	175		|O
significant	176	187		|O
decreases	188	197		|O
in	198	200		|O
the	201	204		|O
tumor	205	210		|O
-	210	211		|O
killing	211	218		|O
(	219	220		|O
lytic	220	225		|O
)	225	226		|O
function	227	235		|O
of	236	238		|O
human	239	244		|O
natural	245	252		|O
killer	253	259		|O
(	260	261		|O
NK	261	263		|O
)	263	264		|O
cells	265	270		|O
,	270	271		|O
a	272	273		|O
critical	274	282		|O
immune	283	289		|O
defense	290	297		|O
.	297	298		|O
The	299	302		|O
current	303	310		|O
study	311	316		|O
examined	317	325		|O
the	326	329		|O
association	330	341		|O
between	342	349		|O
decreased	350	359		|O
lytic	360	365		|O
function	366	374		|O
and	375	378		|O
decreased	379	388		|O
ATP	389	392		|O
levels	393	399		|O
,	399	400		|O
as	401	403		|O
well	404	408		|O
as	409	411		|O
the	412	415		|O
ability	416	423		|O
of	424	426		|O
antioxidants	427	439		|O
(	440	441		|O
vitamin	441	448		|O
E	449	450		|O
and	451	454		|O
reduced	455	462		|O
glutathione	463	474		|O
)	474	475		|O
to	476	478		|O
prevent	479	486		|O
PCP	487	490		|O
-	490	491		|O
induced	491	498		|O
decreases	499	508		|O
in	509	511		|O
either	512	518		|O
ATP	519	522		|O
levels	523	529		|O
or	530	532		|O
lytic	533	538		|O
function	539	547		|O
.	547	548		|O
Exposure	549	557		|O
of	558	560		|O
NK	561	563		|O
cells	564	569		|O
to	570	572		|O
10	573	575		|O
microm	576	582		|O
PCP	583	586		|O
decreased	587	596		|O
ATP	597	600		|O
levels	601	607		|O
by	608	610		|O
15%	611	614		|O
at	615	617		|O
24	618	620		|O
h	621	622		|O
,	622	623		|O
and	624	627		|O
exposure	628	636		|O
to	637	639		|O
5	640	641		|O
microm	642	648		|O
PCP	649	652		|O
decreased	653	662		|O
ATP	663	666		|O
levels	667	673		|O
by	674	676		|O
32%	677	680		|O
at	681	683		|O
48	684	686		|O
h	687	688		|O
.	688	689		|O
No	690	692		|O
effects	693	700		|O
were	701	705		|O
seen	706	710		|O
with	711	715		|O
0.5	716	719		|O
microm	720	726		|O
at	727	729		|O
48	730	732		|O
h	733	734		|O
or	735	737		|O
with	738	742		|O
5	743	744		|O
microm	745	751		|O
at	752	754		|O
24	755	757		|O
h	758	759		|O
.	759	760		|O
However	761	768		|O
,	768	769		|O
10	770	772		|O
microm	773	779		|O
PCP	780	783		|O
decreased	784	793		|O
lytic	794	799		|O
function	800	808		|O
by	809	811		|O
69%	812	815		|O
at	816	818		|O
24	819	821		|O
h	822	823		|O
and	824	827		|O
5	828	829		|O
microm	830	836		|O
decreased	837	846		|O
it	847	849		|O
by	850	852		|O
90%	853	856		|O
at	857	859		|O
48	860	862		|O
h	863	864		|O
.	864	865		|O
Even	866	870		|O
0.5	871	874		|O
microm	875	881		|O
PCP	882	885		|O
decreased	886	895		|O
lytic	896	901		|O
function	902	910		|O
by	911	913		|O
46%	914	917		|O
at	918	920		|O
48	921	923		|O
h	924	925		|O
.	925	926		|O
None	927	931		|O
of	932	934		|O
these	935	940		|O
effects	941	948		|O
were	949	953		|O
prevented	954	963		|O
by	964	966		|O
pretreatment	967	979		|O
with	980	984		|O
1	985	986		|O
mm	987	989		|O
vitamin	990	997		|O
E	998	999		|O
or	1000	1002		|O
reduced	1003	1010		|O
glutathione	1011	1022		|O
.	1022	1023		|O

### 18843743
Blood	0	5		|O
pressure	6	14	pressure	|B-DISEASE
lowering	15	23		|O
efficacy	24	32		|O
of	33	35		|O
renin	36	41		|O
inhibitors	42	52		|O
for	53	56		|O
primary	57	64	primary hypertension	|B-DISEASE
hypertension	65	77		|I-DISEASE
.	77	78		|O
BACKGROUND	80	90		|O
:	90	91		|O
Hypertension	92	104	Hypertension	|B-DISEASE
is	105	107		|O
a	108	109		|O
chronic	110	117		|O
condition	118	127		|O
associated	128	138		|O
with	139	143		|O
an	144	146		|O
increased	147	156		|O
risk	157	161		|O
of	162	164		|O
mortality	165	174		|O
and	175	178		|O
morbidity	179	188		|O
.	188	189		|O
The	190	193		|O
renin	194	199		|O
-	199	200		|O
angiotensin	200	211		|O
-	211	212		|O
aldosterone	212	223		|O
system	224	230		|O
is	231	233		|O
an	234	236		|O
important	237	246		|O
target	247	253		|O
site	254	258		|O
for	259	262		|O
five	263	267		|O
antihypertensive	268	284		|O
drug	285	289		|O
classes	290	297		|O
:	297	298		|O
beta	299	303		|O
blockers	304	312		|O
,	312	313		|O
renin	314	319		|O
inhibitors	320	330		|O
,	330	331		|O
ACE	332	335		|O
inhibitors	336	346		|O
,	346	347		|O
angiotensin	348	359		|O
receptor	360	368		|O
blockers	369	377		|O
(	378	379		|O
ARBs	379	383		|O
)	383	384		|O
and	385	388		|O
aldosterone	389	400		|O
inhibitors	401	411		|O
.	411	412		|O
Renin	413	418		|O
is	419	421		|O
the	422	425		|O
enzyme	426	432		|O
responsible	433	444		|O
for	445	448		|O
converting	449	459		|O
angiotensinogen	460	475		|O
to	476	478		|O
angiotensin	479	490		|O
I	491	492		|O
,	492	493		|O
which	494	499		|O
is	500	502		|O
then	503	507		|O
converted	508	517		|O
to	518	520		|O
angiotensin	521	532		|O
II	533	535		|O
.	535	536		|O
Renin	537	542		|O
inhibitors	543	553		|O
prevent	554	561		|O
the	562	565		|O
formation	566	575		|O
of	576	578		|O
both	579	583		|O
angiotensin	584	595		|O
I	596	597		|O
and	598	601		|O
angiotensin	602	613		|O
II	614	616		|O
.	617	618		|O
Renin	619	624		|O
inhibitors	625	635		|O
do	636	638		|O
not	639	642		|O
affect	643	649		|O
kinin	650	655		|O
metabolism	656	666		|O
and	667	670		|O
may	671	674		|O
produce	675	682		|O
fewer	683	688		|O
adverse	689	696		|O
effects	697	704		|O
than	705	709		|O
ACE	710	713		|O
inhibitors	714	724		|O
such	725	729		|O
as	730	732		|O
dry	733	736	dry cough	|B-DISEASE
cough	737	742		|I-DISEASE
or	743	745		|O
angioedema	746	756	angioedema	|B-DISEASE
.	756	757		|O
OBJECTIVES	758	768		|O
:	768	769		|O
To	770	772		|O
quantify	773	781		|O
the	782	785		|O
dose	786	790		|O
-	790	791		|O
related	791	798		|O
blood	799	804		|O
pressure	805	813	pressure	|B-DISEASE
lowering	814	822		|O
efficacy	823	831		|O
of	832	834		|O
renin	835	840		|O
inhibitors	841	851		|O
versus	852	858		|O
placebo	859	866		|O
in	867	869		|O
the	870	873		|O
treatment	874	883		|O
of	884	886		|O
primary	887	894	primary hypertension	|B-DISEASE
hypertension	895	907		|I-DISEASE
.	907	908		|O
SEARCH	909	915		|O
STRATEGY	916	924		|O
:	924	925		|O
We	926	928		|O
searched	929	937		|O
the	938	941		|O
following	942	951		|O
databases	952	961		|O
for	962	965		|O
randomised	966	976		|O
,	976	977		|O
double	978	984		|O
blind	985	990	blind	|B-DISEASE
,	990	991		|O
placebo	992	999		|O
-	999	1000		|O
controlled	1000	1010		|O
trials	1011	1017		|O
of	1018	1020		|O
renin	1021	1026		|O
inhibitors	1027	1037		|O
:	1037	1038		|O
Medline	1039	1046		|O
(	1047	1048		|O
1966	1048	1052		|O
-	1052	1053		|O
March	1053	1058		|O
2008	1059	1063		|O
)	1063	1064		|O
,	1064	1065		|O
EMBASE	1066	1072		|O
(	1073	1074		|O
1988	1074	1078		|O
-	1078	1079		|O
March	1079	1084		|O
2008	1085	1089		|O
)	1089	1090		|O
,	1090	1091		|O
Cochrane	1092	1100		|O
CENTRAL	1101	1108		|O
,	1108	1109		|O
and	1110	1113		|O
bibliographic	1114	1127		|O
citations	1128	1137		|O
from	1138	1142		|O
retrieved	1143	1152		|O
references	1153	1163		|O
.	1163	1164		|O
No	1165	1167		|O
language	1168	1176		|O
restrictions	1177	1189		|O
were	1190	1194		|O
applied	1195	1202		|O
.	1202	1203		|O
SELECTION	1204	1213		|O
CRITERIA	1214	1222		|O
:	1222	1223		|O
Study	1224	1229		|O
design	1230	1236		|O
had	1237	1240		|O
to	1241	1243		|O
meet	1244	1248		|O
the	1249	1252		|O
following	1253	1262		|O
criteria	1263	1271		|O
:	1271	1272		|O
double	1273	1279		|O
-	1279	1280		|O
blinded	1280	1287		|O
,	1287	1288		|O
placebo	1289	1296		|O
-	1296	1297		|O
controlled	1297	1307		|O
;	1307	1308		|O
random	1309	1315		|O
allocation	1316	1326		|O
to	1327	1329		|O
a	1330	1331		|O
specific	1332	1340		|O
dose	1341	1345		|O
of	1346	1348		|O
renin	1349	1354		|O
inhibitor	1355	1364		|O
group	1365	1370		|O
and	1371	1374		|O
parallel	1375	1383		|O
placebo	1384	1391		|O
group	1392	1397		|O
;	1397	1398		|O
duration	1399	1407		|O
of	1408	1410		|O
follow	1411	1417		|O
-	1417	1418		|O
up	1418	1420		|O
of	1421	1423		|O
at	1424	1426		|O
least	1427	1432		|O
three	1433	1438		|O
weeks	1439	1444		|O
.	1444	1445		|O
DATA	1446	1450		|O
COLLECTION	1451	1461		|O
AND	1462	1465		|O
ANALYSIS	1466	1474		|O
:	1474	1475		|O
Two	1476	1479		|O
reviewers	1480	1489		|O
independently	1490	1503		|O
extracted	1504	1513		|O
data	1514	1518		|O
and	1519	1522		|O
assessed	1523	1531		|O
trial	1532	1537		|O
quality	1538	1545		|O
using	1546	1551		|O
risk	1552	1556		|O
of	1557	1559		|O
bias	1560	1564		|O
tables	1565	1571		|O
.	1571	1572		|O
Disagreements	1573	1586		|O
were	1587	1591		|O
resolved	1592	1600		|O
by	1601	1603		|O
discussion	1604	1614		|O
or	1615	1617		|O
a	1618	1619		|O
third	1620	1625		|O
reviewer	1626	1634		|O
.	1634	1635		|O
Data	1636	1640		|O
synthesis	1641	1650		|O
and	1651	1654		|O
analyses	1655	1663		|O
were	1664	1668		|O
done	1669	1673		|O
using	1674	1679		|O
the	1680	1683		|O
Cochrane	1684	1692		|O
Review	1693	1699		|O
Manager	1700	1707		|O
software	1708	1716		|O
,	1716	1717		|O
RevMan	1718	1724		|O
5	1725	1726		|O
.	1726	1727		|O
Data	1728	1732		|O
for	1733	1736		|O
continuous	1737	1747		|O
variables	1748	1757		|O
were	1758	1762		|O
combined	1763	1771		|O
using	1772	1777		|O
a	1778	1779		|O
weighted	1780	1788		|O
mean	1789	1793		|O
difference	1794	1804		|O
method	1805	1811		|O
.	1811	1812		|O
Dichotomous	1813	1824		|O
variables	1825	1834		|O
were	1835	1839		|O
analysed	1840	1848		|O
using	1849	1854		|O
relative	1855	1863		|O
risk	1864	1868		|O
.	1868	1869		|O
MAIN	1870	1874		|O
RESULTS	1875	1882		|O
:	1882	1883		|O
Six	1884	1887		|O
trials	1888	1894		|O
(	1895	1896		|O
N	1896	1897		|O
=	1897	1898		|O
3694	1898	1902		|O
)	1902	1903		|O
met	1904	1907		|O
the	1908	1911		|O
inclusion	1912	1921		|O
criteria	1922	1930		|O
for	1931	1934		|O
this	1935	1939		|O
review	1940	1946		|O
.	1946	1947		|O
Aliskiren	1948	1957		|O
was	1958	1961		|O
the	1962	1965		|O
only	1966	1970		|O
renin	1971	1976		|O
inhibitor	1977	1986		|O
studied	1987	1994		|O
in	1995	1997		|O
these	1998	2003		|O
studies	2004	2011		|O
.	2011	2012		|O
The	2013	2016		|O
meta	2017	2021		|O
-	2021	2022		|O
analysis	2022	2030		|O
shows	2031	2036		|O
that	2037	2041		|O
aliskiren	2042	2051		|O
has	2052	2055		|O
a	2056	2057		|O
dose	2058	2062		|O
-	2062	2063		|O
related	2063	2070		|O
both	2071	2075		|O
systolic	2076	2084		|O
/	2084	2085		|O
diastolic	2085	2094		|O
blood	2095	2100		|O
pressure	2101	2109	pressure	|B-DISEASE
lowering	2110	2118		|O
effect	2119	2125		|O
as	2126	2128		|O
compared	2129	2137		|O
to	2138	2140		|O
placebo	2141	2148		|O
:	2148	2149		|O
aliskiren	2150	2159		|O
75	2160	2162		|O
mg	2163	2165		|O
-	2166	2167		|O
2.9	2167	2170		|O
/	2170	2171		|O
-	2171	2172		|O
2.3	2172	2175		|O
mmHg	2176	2180		|O
,	2180	2181		|O
aliskiren	2182	2191		|O
150	2192	2195		|O
mg	2196	2198		|O
-	2199	2200		|O
5.5	2200	2203		|O
/	2203	2204		|O
-	2204	2205		|O
3.0	2205	2208		|O
mmHg	2209	2213		|O
,	2213	2214		|O
aliskiren	2215	2224		|O
300	2225	2228		|O
mg	2229	2231		|O
-	2232	2233		|O
8.7	2233	2236		|O
/	2236	2237		|O
-	2237	2238		|O
5.0	2238	2241		|O
,	2241	2242		|O
aliskiren	2243	2252		|O
600	2253	2256		|O
mg	2257	2259		|O
-	2260	2261		|O
11.4	2261	2265		|O
/	2265	2266		|O
-	2266	2267		|O
6.6	2267	2270		|O
mmHg	2271	2275		|O
.	2275	2276		|O
Aliskiren	2277	2286		|O
300	2287	2290		|O
mg	2291	2293		|O
significantly	2294	2307		|O
lowered	2308	2315		|O
both	2316	2320		|O
SBP	2321	2324		|O
and	2325	2328		|O
DBP	2329	2332		|O
as	2333	2335		|O
compared	2336	2344		|O
to	2345	2347		|O
aliskiren	2348	2357		|O
150	2358	2361		|O
mg	2362	2364		|O
(	2365	2366		|O
SBP	2366	2369		|O
:	2369	2370		|O
-	2370	2371		|O
2.97	2371	2375		|O
(	2376	2377		|O
95%	2377	2380		|O
CI	2381	2383		|O
-	2384	2385		|O
3.99	2385	2389		|O
,	2389	2390		|O
-	2391	2392		|O
1.95	2392	2396		|O
)	2396	2397		|O
and	2398	2401		|O
DBP	2402	2405		|O
:	2405	2406		|O
-	2407	2408		|O
1.66	2408	2412		|O
(	2413	2414		|O
95%	2414	2417		|O
CI	2418	2420		|O
-	2421	2422		|O
2.32	2422	2426		|O
,	2426	2427		|O
-	2428	2429		|O
1.0	2429	2432		|O
)	2432	2433		|O
.	2433	2434		|O
Aliskiren	2435	2444		|O
has	2445	2448		|O
no	2449	2451		|O
effect	2452	2458		|O
on	2459	2461		|O
blood	2462	2467		|O
pressure	2468	2476	pressure	|B-DISEASE
variability	2477	2488		|O
.	2488	2489		|O
No	2490	2492		|O
data	2493	2497		|O
was	2498	2501		|O
available	2502	2511		|O
to	2512	2514		|O
assess	2515	2521		|O
the	2522	2525		|O
effect	2526	2532		|O
of	2533	2535		|O
aliskiren	2536	2545		|O
on	2546	2548		|O
heart	2549	2554		|O
rate	2555	2559		|O
and	2560	2563		|O
pulse	2564	2569		|O
pressure	2570	2578	pressure	|B-DISEASE
.	2578	2579		|O
This	2580	2584		|O
review	2585	2591		|O
found	2592	2597		|O
weak	2598	2602		|O
evidence	2603	2611		|O
that	2612	2616		|O
with	2617	2621		|O
short	2622	2627		|O
-	2627	2628		|O
term	2629	2633		|O
use	2634	2637		|O
,	2637	2638		|O
aliskiren	2639	2648		|O
does	2649	2653		|O
not	2654	2657		|O
increase	2658	2666		|O
withdrawals	2667	2678		|O
due	2679	2682		|O
to	2683	2685		|O
adverse	2686	2693		|O
effects	2694	2701		|O
as	2702	2704		|O
compared	2705	2713		|O
to	2714	2716		|O
placebo	2717	2724		|O
.	2724	2725		|O
AUTHORS	2726	2733		|O
'	2733	2734		|O
CONCLUSIONS	2735	2746		|O
:	2746	2747		|O
Aliskiren	2748	2757		|O
has	2758	2761		|O
a	2762	2763		|O
dose	2764	2768		|O
-	2768	2769		|O
related	2769	2776		|O
blood	2777	2782		|O
pressure	2783	2791	pressure	|B-DISEASE
lowering	2792	2800		|O
effect	2801	2807		|O
better	2808	2814		|O
than	2815	2819		|O
placebo	2820	2827		|O
.	2827	2828		|O
This	2829	2833		|O
effect	2834	2840		|O
is	2841	2843		|O
similar	2844	2851		|O
to	2852	2854		|O
that	2855	2859		|O
determined	2860	2870		|O
for	2871	2874		|O
ACE	2875	2878		|O
inhibitors	2879	2889		|O
and	2890	2893		|O
ARBs	2894	2898		|O
.	2898	2899		|O

### 18751431
Influence	0	9		|O
of	10	12		|O
valproic	13	21		|O
acid	22	26		|O
on	27	29		|O
outcome	30	37		|O
of	38	40		|O
high	41	45		|O
-	45	46		|O
grade	46	51		|O
gliomas	52	59		|O
in	60	62		|O
children	63	71		|O
.	71	72		|O
BACKGROUND	74	84		|O
:	84	85		|O
Chemotherapy	86	98		|O
has	99	102		|O
limited	103	110		|O
effects	111	118		|O
in	119	121		|O
the	122	125		|O
treatment	126	135		|O
of	136	138		|O
high	139	143		|O
-	143	144		|O
grade	144	149		|O
gliomas	150	157	gliomas	|B-DISEASE
(	158	159		|O
HGGs	159	163	HGGs	|B-DISEASE
)	163	164		|O
.	164	165		|O
Valproic	166	174		|O
acid	175	179		|O
(	180	181		|O
VPA	181	184		|O
)	184	185		|O
,	185	186		|O
a	187	188		|O
histone	189	196		|O
deacetylase	197	208		|O
(	209	210		|O
HDAC	210	214		|O
)	214	215		|O
inhibitor	216	225		|O
,	225	226		|O
may	227	230		|O
sensitize	231	240		|O
HGGs	241	245		|O
to	246	248		|O
radiochemotherapy	249	266		|O
.	266	267		|O
As	268	270		|O
the	271	274		|O
drug	275	279		|O
has	280	283		|O
been	284	288		|O
given	289	294		|O
frequently	295	305		|O
as	306	308		|O
an	309	311		|O
antiepileptic	312	325		|O
drug	326	330		|O
,	330	331		|O
a	332	333		|O
retrospective	334	347		|O
analysis	348	356		|O
was	357	360		|O
conducted	361	370		|O
to	371	373		|O
ensure	374	380		|O
relevant	381	389		|O
information	390	401		|O
was	402	405		|O
not	406	409		|O
missed	410	416		|O
before	417	423		|O
a	424	425		|O
prospective	426	437		|O
study	438	443		|O
was	444	447		|O
launched	448	456		|O
.	456	457		|O
MATERIALS	458	467		|O
AND	468	471		|O
METHODS	472	479		|O
:	479	480		|O
An	481	483		|O
analysis	484	492		|O
of	493	495		|O
66	496	498		|O
pediatric	499	508		|O
patients	509	517		|O
(	518	519		|O
range	519	524		|O
,	524	525		|O
1-19	526	530		|O
years	531	536		|O
of	537	539		|O
age	540	543		|O
)	543	544		|O
with	545	549		|O
glioblastoma	550	562	glioblastoma multiforme	|B-DISEASE
multiforme	563	573		|I-DISEASE
(	574	575		|O
GBM	575	578	GBM	|B-DISEASE
)	578	579		|O
(	580	581		|O
n	581	582		|O
=	582	583		|O
40	583	585		|O
)	585	586		|O
or	587	589		|O
anaplastic	590	600	anaplastic astrocytoma	|B-DISEASE
astrocytoma	601	612		|I-DISEASE
(	613	614		|O
AA	614	616	AA	|B-DISEASE
)	616	617		|O
(	618	619		|O
n	619	620		|O
=	620	621		|O
26	621	623		|O
)	623	624		|O
was	625	628		|O
retrospectively	629	644		|O
conducted	645	654		|O
for	655	658		|O
predictors	659	669		|O
of	670	672		|O
survival	673	681		|O
and	682	685		|O
response	686	694		|O
and	695	698		|O
for	699	702		|O
effects	703	710		|O
of	711	713		|O
VPA	714	717		|O
on	718	720		|O
outcome	721	728		|O
or	729	731		|O
toxicity	732	740		|O
.	740	741		|O
RESULTS	742	749		|O
:	749	750		|O
The	751	754		|O
overall	755	762		|O
survival	763	771		|O
(	772	773		|O
OS	773	775		|O
)	775	776		|O
was	777	780		|O
better	781	787		|O
for	788	791		|O
AA	792	794	AA	|B-DISEASE
(	795	796		|O
p	796	797		|O
=	797	798		|O
0.0114	798	804		|O
)	804	805		|O
and	806	809		|O
complete	810	818		|O
resection	819	828		|O
(	829	830		|O
p	830	831		|O
<	831	832		|O
0.00005	832	839		|O
)	839	840		|O
and	841	844		|O
event	845	850		|O
-	850	851		|O
free	851	855		|O
survival	856	864		|O
(	865	866		|O
EFS	866	869		|O
)	869	870		|O
was	871	874		|O
better	875	881		|O
for	882	885		|O
complete	886	894		|O
resection	895	904		|O
(	905	906		|O
p	906	907		|O
=	907	908		|O
0.0049	908	914		|O
)	914	915		|O
.	915	916		|O
Nine	917	921		|O
patients	922	930		|O
received	931	939		|O
VPA	940	943		|O
(	944	945		|O
for	945	948		|O
seizure	949	956	seizure	|B-DISEASE
)	956	957		|O
plus	958	962		|O
further	963	970		|O
oncological	971	982		|O
treatment	983	992		|O
.	992	993		|O
The	994	997		|O
most	998	1002		|O
severe	1003	1009		|O
adverse	1010	1017		|O
effect	1018	1024		|O
was	1025	1028		|O
a	1029	1030		|O
pulmonary	1031	1040	pulmonary embolism	|B-ADVERSE
embolism	1041	1049		|I-ADVERSE
(	1050	1051		|O
n	1051	1052		|O
=	1052	1053		|O
1	1053	1054		|O
)	1054	1055		|O
;	1055	1056		|O
no	1057	1059		|O
other	1060	1065		|O
severe	1066	1072		|O
side	1073	1077		|O
-	1077	1078		|O
effects	1078	1085		|O
were	1086	1090		|O
noted	1091	1096		|O
.	1096	1097		|O
The	1098	1101		|O
response	1102	1110		|O
to	1111	1113		|O
nonsurgical	1114	1125		|O
treatment	1126	1135		|O
after	1136	1141		|O
8	1142	1143		|O
weeks	1144	1149		|O
was	1150	1153		|O
:	1153	1154		|O
complete	1155	1163		|O
response	1164	1172		|O
(	1173	1174		|O
CR	1174	1176		|O
)	1176	1177		|O
:	1177	1178		|O
0	1179	1180		|O
,	1180	1181		|O
partial	1182	1189		|O
response	1190	1198		|O
(	1199	1200		|O
PR	1200	1202		|O
)	1202	1203		|O
:	1203	1204		|O
3	1205	1206		|O
,	1206	1207		|O
stable	1208	1214		|O
disease	1215	1222		|O
(	1223	1224		|O
SD	1224	1226		|O
)	1226	1227		|O
:	1227	1228		|O
4	1229	1230		|O
,	1230	1231		|O
progressive	1232	1243		|O
disease	1244	1251		|O
(	1252	1253		|O
PD	1253	1255		|O
)	1255	1256		|O
:	1256	1257		|O
2	1258	1259		|O
.	1259	1260		|O
Some	1261	1265		|O
of	1266	1268		|O
the	1269	1272		|O
patients	1273	1281		|O
with	1282	1286		|O
SD	1287	1289		|O
responded	1290	1299		|O
later	1300	1305		|O
resulting	1306	1315		|O
in	1316	1318		|O
best	1319	1323		|O
response	1324	1332		|O
:	1332	1333		|O
CR	1334	1336		|O
:	1336	1337		|O
0	1337	1338		|O
,	1338	1339		|O
PR	1340	1342		|O
:	1342	1343		|O
5	1343	1344		|O
,	1344	1345		|O
SD	1346	1348		|O
:	1348	1349		|O
2	1349	1350		|O
,	1350	1351		|O
PD	1352	1354		|O
:	1354	1355		|O
2	1355	1356		|O
.	1356	1357		|O
CONCLUSION	1358	1368		|O
:	1368	1369		|O
Treatment	1370	1379		|O
with	1380	1384		|O
VPA	1385	1388		|O
plus	1389	1393		|O
radiochemotherapy	1394	1411		|O
is	1412	1414		|O
well	1415	1419		|O
tolerated	1420	1429		|O
with	1430	1434		|O
an	1435	1437		|O
encouraging	1438	1449		|O
response	1450	1458		|O
rate	1459	1463		|O
.	1463	1464		|O

### 18692326
Anemia	0	6	Anemia	|B-ADVERSE
during	7	13		|O
sequential	14	24		|O
induction	25	34		|O
chemotherapy	35	47		|O
and	48	51		|O
chemoradiation	52	66		|O
for	67	70		|O
head	71	75	head and neck cancer	|B-DISEASE
and	76	79		|I-DISEASE
neck	80	84		|I-DISEASE
cancer	85	91		|I-DISEASE
:	91	92		|O
the	93	96		|O
impact	97	103		|O
of	104	106		|O
blood	107	112		|O
transfusion	113	124		|O
on	125	127		|O
treatment	128	137		|O
outcome	138	145		|O
.	145	146		|O
PURPOSE	148	155		|O
:	155	156		|O
Sequential	157	167		|O
treatment	168	177		|O
(	178	179		|O
chemotherapy	179	191		|O
followed	192	200		|O
by	201	203		|O
concomitant	204	215		|O
chemoradiation	216	230		|O
;	230	231		|O
CCRT	232	236		|O
)	236	237		|O
is	238	240		|O
increasingly	241	253		|O
being	254	259		|O
used	260	264		|O
for	265	268		|O
radical	269	276		|O
treatment	277	286		|O
of	287	289		|O
squamous	290	298	squamous cell cancer of the head and neck	|B-DISEASE
cell	299	303		|I-DISEASE
cancer	304	310		|I-DISEASE
of	311	313		|I-DISEASE
the	314	317		|I-DISEASE
head	318	322		|I-DISEASE
and	323	326		|I-DISEASE
neck	327	331		|I-DISEASE
(	332	333		|O
SCCHN	333	338	SCCHN	|B-DISEASE
)	338	339		|O
,	339	340		|O
which	341	346		|O
results	347	354		|O
in	355	357		|O
increased	358	367		|O
myelosuppression	368	384	myelosuppression	|B-ADVERSE
.	384	385		|O
In	386	388		|O
this	389	393		|O
study	394	399		|O
,	399	400		|O
we	401	403		|O
review	404	410		|O
the	411	414		|O
incidence	415	424		|O
of	425	427		|O
anemia	428	434	anemia	|B-ADVERSE
and	435	438		|O
the	439	442		|O
effect	443	449		|O
of	450	452		|O
a	453	454		|O
policy	455	461		|O
of	462	464		|O
hemoglobin	465	475		|O
(	476	477		|O
Hb	477	479		|O
)	479	480		|O
maintenance	481	492		|O
by	493	495		|O
blood	496	501		|O
transfusion	502	513		|O
on	514	516		|O
disease	517	524		|O
outcomes	525	533		|O
in	534	536		|O
these	537	542		|O
patients	543	551		|O
.	551	552		|O
METHODS	553	560		|O
AND	561	564		|O
MATERIALS	565	574		|O
:	574	575		|O
Retrospective	576	589		|O
review	590	596		|O
of	597	599		|O
the	600	603		|O
records	604	611		|O
of	612	614		|O
patients	615	623		|O
with	624	628		|O
SCCHN	629	634	SCCHN	|B-DISEASE
treated	635	642		|O
with	643	647		|O
sequential	648	658		|O
CCRT	659	663		|O
formed	664	670		|O
the	671	674		|O
basis	675	680		|O
of	681	683		|O
this	684	688		|O
study	689	694		|O
.	694	695		|O
The	696	699		|O
incidence	700	709		|O
of	710	712		|O
anemia	713	719	anemia	|B-ADVERSE
and	720	723		|O
statistics	724	734		|O
on	735	737		|O
blood	738	743		|O
transfusion	744	755		|O
were	756	760		|O
documented	761	771		|O
.	771	772		|O
For	773	776		|O
the	777	780		|O
purpose	781	788		|O
of	789	791		|O
outcome	792	799		|O
analyses	800	808		|O
,	808	809		|O
patients	810	818		|O
were	819	823		|O
divided	824	831		|O
into	832	836		|O
four	837	841		|O
categories	842	852		|O
by	853	855		|O
(	856	857		|O
1	857	858		|O
)	858	859		|O
transfusion	860	871		|O
status	872	878		|O
,	878	879		|O
(	880	881		|O
2	881	882		|O
)	882	883		|O
nadir	884	889		|O
Hb	890	892		|O
concentration	893	906		|O
,	906	907		|O
(	908	909		|O
3	909	910		|O
)	910	911		|O
number	912	918		|O
of	919	921		|O
transfusion	922	933		|O
episodes	934	942		|O
,	942	943		|O
and	944	947		|O
(	948	949		|O
4	949	950		|O
)	950	951		|O
number	952	958		|O
of	959	961		|O
units	962	967		|O
of	968	970		|O
blood	971	976		|O
transfused	977	987		|O
(	988	989		|O
NOUT	989	993		|O
)	993	994		|O
.	994	995		|O
Data	996	1000		|O
on	1001	1003		|O
3	1004	1005		|O
-	1005	1006		|O
year	1006	1010		|O
locoregional	1011	1023		|O
control	1024	1031		|O
(	1032	1033		|O
LRC	1033	1036		|O
)	1036	1037		|O
,	1037	1038		|O
relapse	1039	1046		|O
-	1046	1047		|O
free	1047	1051		|O
survival	1052	1060		|O
(	1061	1062		|O
RFS	1062	1065		|O
)	1065	1066		|O
,	1066	1067		|O
disease	1068	1075		|O
-	1075	1076		|O
specific	1076	1084		|O
survival	1085	1093		|O
(	1094	1095		|O
DSS	1095	1098		|O
)	1098	1099		|O
,	1099	1100		|O
and	1101	1104		|O
overall	1105	1112		|O
survival	1113	1121		|O
(	1122	1123		|O
OS	1123	1125		|O
)	1125	1126		|O
were	1127	1131		|O
analyzed	1132	1140		|O
.	1140	1141		|O
RESULTS	1142	1149		|O
:	1149	1150		|O
One	1151	1154		|O
hundred	1155	1162		|O
and	1163	1166		|O
sixty	1167	1172		|O
-	1172	1173		|O
nine	1173	1177		|O
patients	1178	1186		|O
were	1187	1191		|O
identified	1192	1202		|O
.	1202	1203		|O
The	1204	1207		|O
median	1208	1214		|O
follow	1215	1221		|O
-	1221	1222		|O
up	1222	1224		|O
was	1225	1228		|O
23.6	1229	1233		|O
months	1234	1240		|O
.	1240	1241		|O
The	1242	1245		|O
RFS	1246	1249		|O
(	1250	1251		|O
52%	1251	1254		|O
vs.	1255	1258		|O
41%	1259	1262		|O
,	1262	1263		|O
p	1264	1265		|O
=	1266	1267		|O
0.03	1268	1272		|O
)	1272	1273		|O
,	1273	1274		|O
DSS	1275	1278		|O
(	1279	1280		|O
71%	1280	1283		|O
vs.	1284	1287		|O
66%	1288	1291		|O
,	1291	1292		|O
p	1293	1294		|O
=	1295	1296		|O
0.02	1297	1301		|O
)	1301	1302		|O
,	1302	1303		|O
and	1304	1307		|O
OS	1308	1310		|O
(	1311	1312		|O
58%	1312	1315		|O
vs.	1316	1319		|O
42%	1320	1323		|O
p	1324	1325		|O
=	1326	1327		|O
0.005	1328	1333		|O
)	1333	1334		|O
were	1335	1339		|O
significantly	1340	1353		|O
better	1354	1360		|O
for	1361	1364		|O
patients	1365	1373		|O
who	1374	1377		|O
did	1378	1381		|O
not	1382	1385		|O
have	1386	1390		|O
a	1391	1392		|O
transfusion	1393	1404		|O
vs.	1405	1408		|O
those	1409	1414		|O
who	1415	1418		|O
did	1419	1422		|O
.	1422	1423		|O
The	1424	1427		|O
LRC	1428	1431		|O
,	1431	1432		|O
RFS	1433	1436		|O
,	1436	1437		|O
DSS	1438	1441		|O
,	1441	1442		|O
and	1443	1446		|O
OS	1447	1449		|O
were	1450	1454		|O
also	1455	1459		|O
significantly	1460	1473		|O
better	1474	1480		|O
for	1481	1484		|O
patients	1485	1493		|O
with	1494	1498		|O
nadir	1499	1504		|O
Hb	1505	1507		|O
level	1508	1513		|O
>	1514	1515		|O
12	1515	1517		|O
vs.	1518	1521		|O
<	1522	1523		|O
12	1523	1525		|O
g	1526	1527		|O
/	1527	1528		|O
dL	1528	1530		|O
and	1531	1534		|O
NOUT	1535	1539		|O
1-4	1540	1543		|O
vs.	1544	1547		|O
>	1548	1549		|O
4	1549	1550		|O
.	1550	1551		|O
CONCLUSION	1552	1562		|O
:	1562	1563		|O
Our	1564	1567		|O
study	1568	1573		|O
seems	1574	1579		|O
to	1580	1582		|O
suggest	1583	1590		|O
that	1591	1595		|O
blood	1596	1601		|O
transfusion	1602	1613		|O
during	1614	1620		|O
radical	1621	1628		|O
treatment	1629	1638		|O
for	1639	1642		|O
SCCHN	1643	1648	SCCHN	|B-DISEASE
might	1649	1654		|O
be	1655	1657		|O
detrimental	1658	1669		|O
.	1669	1670		|O
Further	1671	1678		|O
research	1679	1687		|O
should	1688	1694		|O
be	1695	1697		|O
undertaken	1698	1708		|O
into	1709	1713		|O
the	1714	1717		|O
complex	1718	1725		|O
interactions	1726	1738		|O
among	1739	1744		|O
tumor	1745	1750	tumor hypoxia	|B-DISEASE
hypoxia	1751	1758		|I-DISEASE
,	1758	1759		|O
anemia	1760	1766	anemia	|B-DISEASE
,	1766	1767		|O
and	1768	1771		|O
the	1772	1775		|O
treatment	1776	1785		|O
of	1786	1788		|O
anemia	1789	1795	anemia	|B-DISEASE
before	1796	1802		|O
making	1803	1809		|O
treatment	1810	1819		|O
recommendations	1820	1835		|O
.	1835	1836		|O

### 18707827
Intensity	0	9		|O
-	9	10		|O
modulated	10	19		|O
radiotherapy	20	32		|O
in	33	35		|O
postoperative	36	49		|O
treatment	50	59		|O
of	60	62		|O
oral	63	67	oral cavity cancers	|B-DISEASE
cavity	68	74		|I-DISEASE
cancers	75	82		|I-DISEASE
.	82	83		|O
PURPOSE	85	92		|O
:	92	93		|O
To	94	96		|O
present	97	104		|O
our	105	108		|O
single	109	115		|O
-	115	116		|O
institution	116	127		|O
experience	128	138		|O
of	139	141		|O
intensity	142	151		|O
-	151	152		|O
modulated	152	161		|O
radiotherapy	162	174		|O
(	175	176		|O
IMRT	176	180		|O
)	180	181		|O
for	182	185		|O
oral	186	190	oral cavity cancer	|B-DISEASE
cavity	191	197		|I-DISEASE
cancer	198	204		|I-DISEASE
.	204	205		|O
METHODS	206	213		|O
AND	214	217		|O
MATERIALS	218	227		|O
:	227	228		|O
Between	229	236		|O
September	237	246		|O
2000	247	251		|O
and	252	255		|O
December	256	264		|O
2006	265	269		|O
,	269	270		|O
35	271	273		|O
patients	274	282		|O
with	283	287		|O
histologically	288	302		|O
confirmed	303	312		|O
squamous	313	321	squamous cell carcinoma of the oral cavity	|B-DISEASE
cell	322	326		|I-DISEASE
carcinoma	327	336		|I-DISEASE
of	337	339		|I-DISEASE
the	340	343		|I-DISEASE
oral	344	348		|I-DISEASE
cavity	349	355		|I-DISEASE
underwent	356	365		|O
surgery	366	373		|O
followed	374	382		|O
by	383	385		|O
postoperative	386	399		|O
IMRT	400	404		|O
.	404	405		|O
The	406	409		|O
sites	410	415		|O
included	416	424		|O
were	425	429		|O
buccal	430	436		|O
mucosa	437	443		|O
in	444	446		|O
8	447	448		|O
,	448	449		|O
oral	450	454		|O
tongue	455	461		|O
in	462	464		|O
11	465	467		|O
,	467	468		|O
floor	469	474		|O
of	475	477		|O
the	478	481		|O
mouth	482	487		|O
in	488	490		|O
9	491	492		|O
,	492	493		|O
gingiva	494	501		|O
in	502	504		|O
4	505	506		|O
,	506	507		|O
hard	508	512		|O
palate	513	519		|O
in	520	522		|O
2	523	524		|O
,	524	525		|O
and	526	529		|O
retromolar	530	540		|O
trigone	541	548		|O
in	549	551		|O
1	552	553		|O
.	553	554		|O
Most	555	559		|O
patients	560	568		|O
had	569	572		|O
Stage	573	578		|O
III	579	582		|O
-	582	583		|O
IV	583	585		|O
disease	586	593		|O
(	594	595		|O
80%	595	598		|O
)	598	599		|O
.	599	600		|O
Ten	601	604		|O
patients	605	613		|O
(	614	615		|O
29%	615	618		|O
)	618	619		|O
also	620	624		|O
received	625	633		|O
concurrent	634	644		|O
postoperative	645	658		|O
chemotherapy	659	671		|O
with	672	676		|O
IMRT	677	681		|O
.	681	682		|O
The	683	686		|O
median	687	693		|O
prescribed	694	704		|O
radiation	705	714		|O
dose	715	719		|O
was	720	723		|O
60	724	726		|O
Gy	727	729		|O
.	729	730		|O
RESULTS	731	738		|O
:	738	739		|O
The	740	743		|O
median	744	750		|O
follow	751	757		|O
-	757	758		|O
up	758	760		|O
for	761	764		|O
surviving	765	774		|O
patients	775	783		|O
was	784	787		|O
28.1	788	792		|O
months	793	799		|O
(	800	801		|O
range	801	806		|O
,	806	807		|O
11.9-85.1	808	817		|O
)	817	818		|O
.	818	819		|O
Treatment	820	829		|O
failure	830	837		|O
occurred	838	846		|O
in	847	849		|O
11	850	852		|O
cases	853	858		|O
as	859	861		|O
follows	862	869		|O
:	869	870		|O
local	871	876		|O
in	877	879		|O
4	880	881		|O
,	881	882		|O
regional	883	891		|O
in	892	894		|O
2	895	896		|O
,	896	897		|O
and	898	901		|O
distant	902	909		|O
metastases	910	920		|O
in	921	923		|O
5	924	925		|O
.	925	926		|O
Of	927	929		|O
the	930	933		|O
5	934	935		|O
patients	936	944		|O
with	945	949		|O
distant	950	957		|O
metastases	958	968		|O
,	968	969		|O
2	970	971		|O
presented	972	981		|O
with	982	986		|O
dermal	987	993		|O
metastases	994	1004		|O
.	1004	1005		|O
The	1006	1009		|O
2	1010	1011		|O
-	1011	1012		|O
and	1013	1016		|O
3	1017	1018		|O
-	1018	1019		|O
year	1019	1023		|O
estimates	1024	1033		|O
of	1034	1036		|O
locoregional	1037	1049		|O
progression	1050	1061		|O
-	1061	1062		|O
free	1062	1066		|O
survival	1067	1075		|O
,	1075	1076		|O
distant	1077	1084		|O
metastasis	1085	1095		|O
-	1095	1096		|O
free	1096	1100		|O
survival	1101	1109		|O
,	1109	1110		|O
disease	1111	1118		|O
-	1118	1119		|O
free	1119	1123		|O
survival	1124	1132		|O
,	1132	1133		|O
and	1134	1137		|O
overall	1138	1145		|O
survival	1146	1154		|O
were	1155	1159		|O
84%	1160	1163		|O
and	1164	1167		|O
77%	1168	1171		|O
,	1171	1172		|O
85%	1173	1176		|O
and	1177	1180		|O
85%	1181	1184		|O
,	1184	1185		|O
70%	1186	1189		|O
and	1190	1193		|O
64%	1194	1197		|O
,	1197	1198		|O
and	1199	1202		|O
74%	1203	1206		|O
and	1207	1210		|O
74%	1211	1214		|O
,	1214	1215		|O
respectively	1216	1228		|O
.	1228	1229		|O
Acute	1230	1235		|O
Grade	1236	1241		|O
2	1242	1243		|O
or	1244	1246		|O
greater	1247	1254		|O
dermatitis	1255	1265	dermatitis	|B-ADVERSE
,	1265	1266		|O
mucositis	1267	1276	mucositis	|B-ADVERSE
,	1276	1277		|O
and	1278	1281		|O
esophageal	1282	1292	esophageal reactions	|B-ADVERSE
reactions	1293	1302		|I-ADVERSE
were	1303	1307		|O
experienced	1308	1319		|O
by	1320	1322		|O
54%	1323	1326		|O
,	1326	1327		|O
66%	1328	1331		|O
,	1331	1332		|O
and	1333	1336		|O
40%	1337	1340		|O
of	1341	1343		|O
the	1344	1347		|O
patients	1348	1356		|O
,	1356	1357		|O
respectively	1358	1370		|O
.	1370	1371		|O
Documented	1372	1382		|O
late	1383	1387		|O
complications	1388	1401		|O
included	1402	1410		|O
trismus	1411	1418	trismus	|B-ADVERSE
(	1419	1420		|O
17%	1420	1423		|O
)	1423	1424		|O
and	1425	1428		|O
osteoradionecrosis	1429	1447	osteoradionecrosis	|B-ADVERSE
(	1448	1449		|O
5%	1449	1451		|O
)	1451	1452		|O
.	1452	1453		|O
CONCLUSION	1454	1464		|O
:	1464	1465		|O
IMRT	1466	1470		|O
as	1471	1473		|O
an	1474	1476		|O
adjuvant	1477	1485		|O
treatment	1486	1495		|O
after	1496	1501		|O
surgical	1502	1510		|O
resection	1511	1520		|O
for	1521	1524		|O
oral	1525	1529	oral cavity tumors	|B-DISEASE
cavity	1530	1536		|I-DISEASE
tumors	1537	1543		|I-DISEASE
is	1544	1546		|O
feasible	1547	1555		|O
and	1556	1559		|O
effective	1560	1569		|O
,	1569	1570		|O
with	1571	1575		|O
promising	1576	1585		|O
results	1586	1593		|O
and	1594	1597		|O
acceptable	1598	1608		|O
toxicity	1609	1617		|O
.	1617	1618		|O

### 18805679
Selenium	0	8		|O
nanoparticles	9	22		|O
fabricated	23	33		|O
in	34	36		|O
Undaria	37	44		|O
pinnatifida	45	56		|O
polysaccharide	57	71		|O
solutions	72	81		|O
induce	82	88		|O
mitochondria	89	101		|O
-	101	102		|O
mediated	102	110		|O
apoptosis	111	120		|O
in	121	123		|O
A375	124	128		|O
human	129	134		|O
melanoma	135	143		|O
cells	144	149		|O
.	149	150		|O
Selenium	152	160		|O
nanoparticle	161	173		|O
(	174	175		|O
Nano	175	179		|O
-	179	180		|O
Se	180	182		|O
)	182	183		|O
is	184	186		|O
a	187	188		|O
novel	189	194		|O
Se	195	197		|O
species	198	205		|O
with	206	210		|O
novel	211	216		|O
biological	217	227		|O
activities	228	238		|O
and	239	242		|O
low	243	246		|O
toxicity	247	255		|O
.	255	256		|O
In	257	259		|O
the	260	263		|O
present	264	271		|O
study	272	277		|O
,	277	278		|O
we	279	281		|O
demonstrated	282	294		|O
a	295	296		|O
simple	297	303		|O
method	304	310		|O
for	311	314		|O
synthesis	315	324		|O
of	325	327		|O
size	328	332		|O
-	332	333		|O
controlled	333	343		|O
Nano	344	348		|O
-	348	349		|O
Se	349	351		|O
by	352	354		|O
adding	355	361		|O
Undaria	362	369		|O
pinnatifida	370	381		|O
polysaccharides	382	397		|O
to	398	400		|O
the	401	404		|O
redox	405	410		|O
system	411	417		|O
of	418	420		|O
selenite	421	429		|O
and	430	433		|O
ascorbic	434	442		|O
acid	443	447		|O
.	447	448		|O
A	449	450		|O
panel	451	456		|O
of	457	459		|O
four	460	464		|O
human	465	470		|O
cancer	471	477		|O
cell	478	482		|O
lines	483	488		|O
was	489	492		|O
shown	493	498		|O
to	499	501		|O
be	502	504		|O
susceptible	505	516		|O
to	517	519		|O
Nano	520	524		|O
-	524	525		|O
Se	525	527		|O
,	527	528		|O
with	529	533		|O
IC	534	536		|O
(	536	537		|O
50	537	539		|O
)	539	540		|O
values	541	547		|O
ranging	548	555		|O
from	556	560		|O
3.0	561	564		|O
to	565	567		|O
14.1	568	572		|O
microM	573	579		|O
.	579	580		|O
Treatment	581	590		|O
of	591	593		|O
A375	594	598		|O
human	599	604		|O
melanoma	605	613		|O
cells	614	619		|O
with	620	624		|O
the	625	628		|O
Nano	629	633		|O
-	633	634		|O
Se	634	636		|O
resulted	637	645		|O
in	646	648		|O
dose	649	653		|O
-	653	654		|O
dependent	654	663		|O
cell	664	668		|O
apoptosis	669	678		|O
as	679	681		|O
indicated	682	691		|O
by	692	694		|O
DNA	695	698		|O
fragmentation	699	712		|O
and	713	716		|O
phosphatidylserine	717	735		|O
translocation	736	749		|O
.	749	750		|O
Further	751	758		|O
investigation	759	772		|O
on	773	775		|O
intracellular	776	789		|O
mechanisms	790	800		|O
found	801	806		|O
that	807	811		|O
Nano	812	816		|O
-	816	817		|O
Se	817	819		|O
treatment	820	829		|O
triggered	830	839		|O
apoptotic	840	849		|O
cell	850	854		|O
death	855	860		|O
in	861	863		|O
A375	864	868		|O
cells	869	874		|O
with	875	879		|O
the	880	883		|O
involvement	884	895		|O
of	896	898		|O
oxidative	899	908		|O
stress	909	915		|O
and	916	919		|O
mitochondrial	920	933		|O
dysfunction	934	945		|O
.	945	946		|O
Our	947	950		|O
results	951	958		|O
suggest	959	966		|O
that	967	971		|O
Nano	972	976		|O
-	976	977		|O
Se	977	979		|O
may	980	983		|O
be	984	986		|O
a	987	988		|O
candidate	989	998		|O
for	999	1002		|O
further	1003	1010		|O
evaluation	1011	1021		|O
as	1022	1024		|O
a	1025	1026		|O
chemopreventive	1027	1042		|O
and	1043	1046		|O
chemotherapeutic	1047	1063		|O
agent	1064	1069		|O
for	1070	1073		|O
human	1074	1079		|O
cancers	1080	1087		|O
,	1087	1088		|O
especially	1089	1099		|O
melanoma	1100	1108	melanoma cancer	|B-DISEASE
cancer	1109	1115		|I-DISEASE
.	1115	1116		|O

### 18936500
Addition	0	8		|O
of	9	11		|O
sildenafil	12	22		|O
to	23	25		|O
long	26	30		|O
-	30	31		|O
term	31	35		|O
intravenous	36	47		|O
epoprostenol	48	60		|O
therapy	61	68		|O
in	69	71		|O
patients	72	80		|O
with	81	85		|O
pulmonary	86	95	pulmonary arterial hypertension	|B-DISEASE
arterial	96	104		|I-DISEASE
hypertension	105	117		|I-DISEASE
:	117	118		|O
a	119	120		|O
randomized	121	131		|O
trial	132	137		|O
.	137	138		|O
BACKGROUND	140	150		|O
:	150	151		|O
Oral	152	156		|O
sildenafil	157	167		|O
and	168	171		|O
intravenous	172	183		|O
epoprostenol	184	196		|O
have	197	201		|O
independently	202	215		|O
been	216	220		|O
shown	221	226		|O
to	227	229		|O
be	230	232		|O
effective	233	242		|O
in	243	245		|O
patients	246	254		|O
with	255	259		|O
pulmonary	260	269	pulmonary arterial hypertension	|B-DISEASE
arterial	270	278		|I-DISEASE
hypertension	279	291		|I-DISEASE
.	291	292		|O
OBJECTIVE	293	302		|O
:	302	303		|O
To	304	306		|O
investigate	307	318		|O
the	319	322		|O
effect	323	329		|O
of	330	332		|O
adding	333	339		|O
oral	340	344		|O
sildenafil	345	355		|O
to	356	358		|O
long	359	363		|O
-	363	364		|O
term	364	368		|O
intravenous	369	380		|O
epoprostenol	381	393		|O
in	394	396		|O
patients	397	405		|O
with	406	410		|O
pulmonary	411	420	pulmonary arterial hypertension	|B-DISEASE
arterial	421	429		|I-DISEASE
hypertension	430	442		|I-DISEASE
.	442	443		|O
DESIGN	444	450		|O
:	450	451		|O
A	452	453		|O
16	454	456		|O
-	456	457		|O
week	457	461		|O
,	461	462		|O
double	463	469		|O
-	469	470		|O
blind	470	475		|O
,	475	476		|O
placebo	477	484		|O
-	484	485		|O
controlled	485	495		|O
,	495	496		|O
parallel	497	505		|O
-	505	506		|O
group	506	511		|O
study	512	517		|O
.	517	518		|O
SETTING	519	526		|O
:	526	527		|O
Multinational	528	541		|O
study	542	547		|O
at	548	550		|O
41	551	553		|O
centers	554	561		|O
in	562	564		|O
11	565	567		|O
countries	568	577		|O
from	578	582		|O
3	583	584		|O
July	585	589		|O
2003	590	594		|O
to	595	597		|O
27	598	600		|O
January	601	608		|O
2006	609	613		|O
.	613	614		|O
PATIENTS	615	623		|O
:	623	624		|O
267	625	628		|O
patients	629	637		|O
with	638	642		|O
pulmonary	643	652	pulmonary arterial hypertension	|B-DISEASE
arterial	653	661		|I-DISEASE
hypertension	662	674		|I-DISEASE
(	675	676		|O
idiopathic	676	686		|O
,	686	687		|O
associated	688	698		|O
anorexigen	699	709		|O
use	710	713		|O
or	714	716		|O
connective	717	727	connective tissue disease	|B-DISEASE
tissue	728	734		|I-DISEASE
disease	735	742		|I-DISEASE
,	742	743		|O
or	744	746		|O
corrected	747	756		|O
congenital	757	767	congenital heart disease	|B-DISEASE
heart	768	773		|I-DISEASE
disease	774	781		|I-DISEASE
)	781	782		|O
who	783	786		|O
were	787	791		|O
receiving	792	801		|O
long	802	806		|O
-	806	807		|O
term	807	811		|O
intravenous	812	823		|O
epoprostenol	824	836		|O
therapy	837	844		|O
.	844	845		|O
INTERVENTION	846	858		|O
:	858	859		|O
Patients	860	868		|O
were	869	873		|O
randomly	874	882		|O
assigned	883	891		|O
to	892	894		|O
receive	895	902		|O
placebo	903	910		|O
or	911	913		|O
sildenafil	914	924		|O
,	924	925		|O
20	926	928		|O
mg	929	931		|O
three	932	937		|O
times	938	943		|O
daily	944	949		|O
,	949	950		|O
titrated	951	959		|O
to	960	962		|O
40	963	965		|O
mg	966	968		|O
and	969	972		|O
80	973	975		|O
mg	976	978		|O
three	979	984		|O
times	985	990		|O
daily	991	996		|O
,	996	997		|O
as	998	1000		|O
tolerated	1001	1010		|O
,	1010	1011		|O
at	1012	1014		|O
4	1015	1016		|O
-	1016	1017		|O
week	1017	1021		|O
intervals	1022	1031		|O
.	1031	1032		|O
Of	1033	1035		|O
265	1036	1039		|O
patients	1040	1048		|O
who	1049	1052		|O
received	1053	1061		|O
treatment	1062	1071		|O
,	1071	1072		|O
256	1073	1076		|O
(	1077	1078		|O
97%	1078	1081		|O
)	1081	1082		|O
patients	1083	1091		|O
(	1092	1093		|O
123	1093	1096		|O
in	1097	1099		|O
the	1100	1103		|O
placebo	1104	1111		|O
group	1112	1117		|O
and	1118	1121		|O
133	1122	1125		|O
in	1126	1128		|O
the	1129	1132		|O
sildenafil	1133	1143		|O
group	1144	1149		|O
)	1149	1150		|O
completed	1151	1160		|O
the	1161	1164		|O
study	1165	1170		|O
.	1170	1171		|O
MEASUREMENTS	1172	1184		|O
:	1184	1185		|O
Change	1186	1192		|O
from	1193	1197		|O
baseline	1198	1206		|O
in	1207	1209		|O
exercise	1210	1218		|O
capacity	1219	1227		|O
measured	1228	1236		|O
by	1237	1239		|O
6	1240	1241		|O
-	1241	1242		|O
minute	1242	1248		|O
walk	1249	1253		|O
distance	1254	1262		|O
(	1263	1264		|O
primary	1264	1271		|O
end	1272	1275		|O
point	1276	1281		|O
)	1281	1282		|O
and	1283	1286		|O
hemodynamic	1287	1298		|O
measurements	1299	1311		|O
,	1311	1312		|O
time	1313	1317		|O
to	1318	1320		|O
clinical	1321	1329		|O
worsening	1330	1339		|O
,	1339	1340		|O
and	1341	1344		|O
Borg	1345	1349		|O
dyspnea	1350	1357	dyspnea	|B-DISEASE
score	1358	1363		|O
(	1364	1365		|O
secondary	1365	1374		|O
end	1375	1378		|O
points	1379	1385		|O
)	1385	1386		|O
.	1386	1387		|O
RESULTS	1388	1395		|O
:	1395	1396		|O
A	1397	1398		|O
placebo	1399	1406		|O
-	1406	1407		|O
adjusted	1407	1415		|O
increase	1416	1424		|O
of	1425	1427		|O
28.8	1428	1432		|O
meters	1433	1439		|O
(	1440	1441		|O
95%	1441	1444		|O
CI	1445	1447		|O
,	1447	1448		|O
13.9	1449	1453		|O
to	1454	1456		|O
43.8	1457	1461		|O
meters	1462	1468		|O
)	1468	1469		|O
in	1470	1472		|O
the	1473	1476		|O
6	1477	1478		|O
-	1478	1479		|O
minute	1479	1485		|O
walk	1486	1490		|O
distance	1491	1499		|O
occurred	1500	1508		|O
in	1509	1511		|O
patients	1512	1520		|O
in	1521	1523		|O
the	1524	1527		|O
sildenafil	1528	1538		|O
group	1539	1544		|O
;	1544	1545		|O
these	1546	1551		|O
improvements	1552	1564		|O
were	1565	1569		|O
most	1570	1574		|O
prominent	1575	1584		|O
among	1585	1590		|O
patients	1591	1599		|O
with	1600	1604		|O
baseline	1605	1613		|O
distances	1614	1623		|O
of	1624	1626		|O
325	1627	1630		|O
meters	1631	1637		|O
or	1638	1640		|O
more	1641	1645		|O
.	1645	1646		|O
Relative	1647	1655		|O
to	1656	1658		|O
epoprostenol	1659	1671		|O
monotherapy	1672	1683		|O
,	1683	1684		|O
addition	1685	1693		|O
of	1694	1696		|O
sildenafil	1697	1707		|O
resulted	1708	1716		|O
in	1717	1719		|O
a	1720	1721		|O
greater	1722	1729		|O
change	1730	1736		|O
in	1737	1739		|O
mean	1740	1744		|O
pulmonary	1745	1754		|O
arterial	1755	1763		|O
pressure	1764	1772		|O
by	1773	1775		|O
-	1776	1777		|O
3.8	1777	1780		|O
mm	1781	1783		|O
Hg	1784	1786		|O
(	1787	1788		|O
CI	1788	1790		|O
,	1790	1791		|O
-	1792	1793		|O
5.6	1793	1796		|O
to	1797	1799		|O
-	1800	1801		|O
2.1	1801	1804		|O
mm	1805	1807		|O
Hg	1808	1810		|O
)	1810	1811		|O
;	1811	1812		|O
cardiac	1813	1820		|O
output	1821	1827		|O
by	1828	1830		|O
0.9	1831	1834		|O
L	1835	1836		|O
/	1836	1837		|O
min	1837	1840		|O
(	1841	1842		|O
CI	1842	1844		|O
,	1844	1845		|O
0.5	1846	1849		|O
to	1850	1852		|O
1.2	1853	1856		|O
L	1857	1858		|O
/	1858	1859		|O
min	1859	1862		|O
)	1862	1863		|O
;	1863	1864		|O
and	1865	1868		|O
longer	1869	1875		|O
time	1876	1880		|O
to	1881	1883		|O
clinical	1884	1892		|O
worsening	1893	1902		|O
,	1902	1903		|O
with	1904	1908		|O
a	1909	1910		|O
smaller	1911	1918		|O
proportion	1919	1929		|O
of	1930	1932		|O
patients	1933	1941		|O
experiencing	1942	1954		|O
a	1955	1956		|O
worsening	1957	1966		|O
event	1967	1972		|O
in	1973	1975		|O
the	1976	1979		|O
sildenafil	1980	1990		|O
group	1991	1996		|O
(	1997	1998		|O
0.062	1998	2003		|O
)	2003	2004		|O
than	2005	2009		|O
in	2010	2012		|O
the	2013	2016		|O
placebo	2017	2024		|O
group	2025	2030		|O
(	2031	2032		|O
0.195	2032	2037		|O
)	2037	2038		|O
by	2039	2041		|O
week	2042	2046		|O
16	2047	2049		|O
(	2050	2051		|O
P	2051	2052		|O
=	2053	2054		|O
0.002	2055	2060		|O
)	2060	2061		|O
.	2061	2062		|O
Health	2063	2069		|O
-	2069	2070		|O
related	2070	2077		|O
quality	2078	2085		|O
of	2086	2088		|O
life	2089	2093		|O
also	2094	2098		|O
improved	2099	2107		|O
in	2108	2110		|O
patients	2111	2119		|O
who	2120	2123		|O
received	2124	2132		|O
combined	2133	2141		|O
therapy	2142	2149		|O
compared	2150	2158		|O
with	2159	2163		|O
those	2164	2169		|O
who	2170	2173		|O
received	2174	2182		|O
epoprostenol	2183	2195		|O
monotherapy	2196	2207		|O
.	2207	2208		|O
There	2209	2214		|O
was	2215	2218		|O
no	2219	2221		|O
effect	2222	2228		|O
on	2229	2231		|O
the	2232	2235		|O
Borg	2236	2240		|O
dyspnea	2241	2248		|O
score	2249	2254		|O
.	2254	2255		|O
Of	2256	2258		|O
the	2259	2262		|O
side	2263	2267		|O
effects	2268	2275		|O
generally	2276	2285		|O
associated	2286	2296		|O
with	2297	2301		|O
sildenafil	2302	2312		|O
treatment	2313	2322		|O
,	2322	2323		|O
the	2324	2327		|O
most	2328	2332		|O
commonly	2333	2341		|O
reported	2342	2350		|O
in	2351	2353		|O
the	2354	2357		|O
placebo	2358	2365		|O
and	2366	2369		|O
sildenafil	2370	2380		|O
groups	2381	2387		|O
,	2387	2388		|O
respectively	2389	2401		|O
,	2401	2402		|O
were	2403	2407		|O
headache	2408	2416	headache	|B-ADVERSE
(	2417	2418		|O
34%	2418	2421		|O
and	2422	2425		|O
57%	2426	2429		|O
;	2429	2430		|O
difference	2431	2441		|O
,	2441	2442		|O
23	2443	2445		|O
percentage	2446	2456		|O
points	2457	2463		|O
[	2464	2465		|O
CI	2465	2467		|O
,	2467	2468		|O
12	2469	2471		|O
to	2472	2474		|O
35	2475	2477		|O
percentage	2478	2488		|O
points	2489	2495		|O
]	2495	2496		|O
)	2496	2497		|O
,	2497	2498		|O
dyspepsia	2499	2508	dyspepsia	|B-ADVERSE
(	2509	2510		|O
2%	2510	2512		|O
and	2513	2516		|O
16%	2517	2520		|O
;	2520	2521		|O
difference	2522	2532		|O
,	2532	2533		|O
13	2534	2536		|O
percentage	2537	2547		|O
points	2548	2554		|O
[	2555	2556		|O
CI	2556	2558		|O
,	2558	2559		|O
7	2560	2561		|O
to	2562	2564		|O
20	2565	2567		|O
percentage	2568	2578		|O
points	2579	2585		|O
]	2585	2586		|O
)	2586	2587		|O
,	2587	2588		|O
pain	2589	2593	pain	|B-ADVERSE
in	2594	2596		|O
extremity	2597	2606		|O
(	2607	2608		|O
18%	2608	2611		|O
and	2612	2615		|O
25%	2616	2619		|O
;	2619	2620		|O
difference	2621	2631		|O
,	2631	2632		|O
8	2633	2634		|O
percentage	2635	2645		|O
points	2646	2652		|O
[	2653	2654		|O
CI	2654	2656		|O
,	2656	2657		|O
-	2658	2659		|O
2	2659	2660		|O
to	2661	2663		|O
18	2664	2666		|O
percentage	2667	2677		|O
points	2678	2684		|O
]	2684	2685		|O
)	2685	2686		|O
,	2686	2687		|O
and	2688	2691		|O
nausea	2692	2698	nausea	|B-ADVERSE
(	2699	2700		|O
18%	2700	2703		|O
and	2704	2707		|O
25%	2708	2711		|O
;	2711	2712		|O
difference	2713	2723		|O
,	2723	2724		|O
8	2725	2726		|O
percentage	2727	2737		|O
points	2738	2744		|O
[	2745	2746		|O
CI	2746	2748		|O
,	2748	2749		|O
-	2750	2751		|O
2	2751	2752		|O
to	2753	2755		|O
18	2756	2758		|O
percentage	2759	2769		|O
points	2770	2776		|O
]	2776	2777		|O
)	2777	2778		|O
.	2778	2779		|O
LIMITATIONS	2780	2791		|O
:	2791	2792		|O
The	2793	2796		|O
study	2797	2802		|O
excluded	2803	2811		|O
patients	2812	2820		|O
with	2821	2825		|O
pulmonary	2826	2835	pulmonary arterial hypertension	|B-DISEASE
arterial	2836	2844		|I-DISEASE
hypertension	2845	2857		|I-DISEASE
associated	2858	2868		|O
with	2869	2873		|O
other	2874	2879		|O
causes	2880	2886		|O
.	2886	2887		|O
There	2888	2893		|O
was	2894	2897		|O
an	2898	2900		|O
imbalance	2901	2910		|O
in	2911	2913		|O
missing	2914	2921		|O
data	2922	2926		|O
between	2927	2934		|O
groups	2935	2941		|O
,	2941	2942		|O
with	2943	2947		|O
8	2948	2949		|O
placebo	2950	2957		|O
recipients	2958	2968		|O
having	2969	2975		|O
no	2976	2978		|O
postbaseline	2979	2991		|O
walk	2992	2996		|O
assessment	2997	3007		|O
compared	3008	3016		|O
with	3017	3021		|O
1	3022	3023		|O
sildenafil	3024	3034		|O
recipient	3035	3044		|O
.	3044	3045		|O
These	3046	3051		|O
patients	3052	3060		|O
were	3061	3065		|O
excluded	3066	3074		|O
from	3075	3079		|O
the	3080	3083		|O
analysis	3084	3092		|O
.	3092	3093		|O
CONCLUSION	3094	3104		|O
:	3104	3105		|O
In	3106	3108		|O
some	3109	3113		|O
patients	3114	3122		|O
with	3123	3127		|O
pulmonary	3128	3137	pulmonary arterial hypertension	|B-DISEASE
arterial	3138	3146		|I-DISEASE
hypertension	3147	3159		|I-DISEASE
,	3159	3160		|O
the	3161	3164		|O
addition	3165	3173		|O
of	3174	3176		|O
sildenafil	3177	3187		|O
to	3188	3190		|O
long	3191	3195		|O
-	3195	3196		|O
term	3196	3200		|O
intravenous	3201	3212		|O
epoprostenol	3213	3225		|O
therapy	3226	3233		|O
improves	3234	3242		|O
exercise	3243	3251		|O
capacity	3252	3260		|O
,	3260	3261		|O
hemodynamic	3262	3273		|O
measurements	3274	3286		|O
,	3286	3287		|O
time	3288	3292		|O
to	3293	3295		|O
clinical	3296	3304		|O
worsening	3305	3314		|O
,	3314	3315		|O
and	3316	3319		|O
quality	3320	3327		|O
of	3328	3330		|O
life	3331	3335		|O
,	3335	3336		|O
but	3337	3340		|O
not	3341	3344		|O
Borg	3345	3349		|O
dyspnea	3350	3357	dyspnea	|B-DISEASE
score	3358	3363		|O
.	3363	3364		|O
Increased	3365	3374		|O
rates	3375	3380		|O
of	3381	3383		|O
headache	3384	3392	headache	|B-ADVERSE
and	3393	3396		|O
dyspepsia	3397	3406	dyspepsia	|B-ADVERSE
occurred	3407	3415		|O
with	3416	3420		|O
the	3421	3424		|O
addition	3425	3433		|O
of	3434	3436		|O
sildenafil	3437	3447		|O
.	3447	3448		|O

### 18577998
Drug	0	4		|O
insight	5	12		|O
:	12	13		|O
aggrecanases	14	26		|O
as	27	29		|O
therapeutic	30	41		|O
targets	42	49		|O
for	50	53		|O
osteoarthritis	54	68	osteoarthritis	|B-DISEASE
.	68	69		|O
In	71	73		|O
healthy	74	81		|O
cartilage	82	91		|O
,	91	92		|O
effective	93	102		|O
weight	103	109		|O
-	109	110		|O
bearing	110	117		|O
requires	118	126		|O
a	127	128		|O
high	129	133		|O
concentration	134	147		|O
of	148	150		|O
intact	151	157		|O
aggrecan	158	166		|O
.	166	167		|O
Degradation	168	179		|O
and	180	183		|O
loss	184	188		|O
of	189	191		|O
aggrecan	192	200		|O
are	201	204		|O
features	205	213		|O
of	214	216		|O
osteoarthritis	217	231	osteoarthritis	|B-DISEASE
(	232	233		|O
OA	233	235	OA	|B-DISEASE
)	235	236		|O
.	236	237		|O
It	238	240		|O
is	241	243		|O
unclear	244	251		|O
whether	252	259		|O
ADAMTS	260	266		|O
-	266	267		|O
4	267	268		|O
,	268	269		|O
ADAMTS	270	276		|O
-	276	277		|O
5	277	278		|O
,	278	279		|O
or	280	282		|O
both	283	287		|O
of	288	290		|O
these	291	296		|O
aggrecanases	297	309		|O
from	310	314		|O
the	315	318		|O
ADAMTS	319	325		|O
(	326	327		|O
a	327	328		|O
disintegrin	329	340		|O
and	341	344		|O
metalloproteinase	345	362		|O
with	363	367		|O
thrombospondin	368	382		|O
motifs	383	389		|O
)	389	390		|O
enzyme	391	397		|O
family	398	404		|O
,	404	405		|O
are	406	409		|O
responsible	410	421		|O
for	422	425		|O
aggrecanolysis	426	440		|O
in	441	443		|O
human	444	449		|O
OA	450	452	OA	|B-DISEASE
,	452	453		|O
and	454	457		|O
at	458	460		|O
what	461	465		|O
stage	466	471		|O
of	472	474		|O
disease	475	482		|O
these	483	488		|O
enzymes	489	496		|O
are	497	500		|O
active	501	507		|O
.	507	508		|O
Several	509	516		|O
potential	517	526		|O
disease	527	534		|O
-	534	535		|O
modifying	535	544		|O
agents	545	551		|O
for	552	555		|O
OA	556	558	OA	|B-DISEASE
include	559	566		|O
glucosamine	567	578		|O
and	579	582		|O
chondroitin	583	594		|O
sulfate	595	602		|O
,	602	603		|O
diacerhein	604	614		|O
,	614	615		|O
and	616	619		|O
pentosan	620	628		|O
polysulfate	629	640		|O
;	640	641		|O
although	642	650		|O
their	651	656		|O
mechanisms	657	667		|O
of	668	670		|O
action	671	677		|O
in	678	680		|O
vivo	681	685		|O
are	686	689		|O
unknown	690	697		|O
,	697	698		|O
data	699	703		|O
from	704	708		|O
in	709	711		|O
vitro	712	717		|O
studies	718	725		|O
and	726	729		|O
animal	730	736		|O
models	737	743		|O
suggest	744	751		|O
that	752	756		|O
their	757	762		|O
efficacy	763	771		|O
might	772	777		|O
be	778	780		|O
partly	781	787		|O
due	788	791		|O
to	792	794		|O
inhibition	795	805		|O
of	806	808		|O
proinflammatory	809	824		|O
pathways	825	833		|O
that	834	838		|O
lead	839	843		|O
to	844	846		|O
downregulation	847	861		|O
of	862	864		|O
ADAMTS	865	871		|O
enzymes	872	879		|O
.	879	880		|O
Some	881	885		|O
histone	886	893		|O
deacetylase	894	905		|O
inhibitors	906	916		|O
that	917	921		|O
are	922	925		|O
successfully	926	938		|O
used	939	943		|O
to	944	946		|O
treat	947	952		|O
cancer	953	959	cancer	|B-DISEASE
can	960	963		|O
block	964	969		|O
ADAMTS	970	976		|O
-	976	977		|O
5	977	978		|O
expression	979	989		|O
;	989	990		|O
however	991	998		|O
,	998	999		|O
these	1000	1005		|O
inhibitors	1006	1016		|O
will	1017	1021		|O
only	1022	1026		|O
be	1027	1029		|O
considered	1030	1040		|O
as	1041	1043		|O
potential	1044	1053		|O
therapies	1054	1063		|O
for	1064	1067		|O
OA	1068	1070	OA	|B-DISEASE
if	1071	1073		|O
their	1074	1079		|O
toxicity	1080	1088		|O
is	1089	1091		|O
markedly	1092	1100		|O
reduced	1101	1108		|O
.	1108	1109		|O
ADAMTS	1110	1116		|O
inhibitors	1117	1127		|O
currently	1128	1137		|O
in	1138	1140		|O
development	1141	1152		|O
are	1153	1156		|O
expected	1157	1165		|O
to	1166	1168		|O
show	1169	1173		|O
excellent	1174	1183		|O
specificity	1184	1195		|O
now	1196	1199		|O
that	1200	1204		|O
crystal	1205	1212		|O
structures	1213	1223		|O
for	1224	1227		|O
several	1228	1235		|O
ADAMTS	1236	1242		|O
enzymes	1243	1250		|O
are	1251	1254		|O
available	1255	1264		|O
to	1265	1267		|O
guide	1268	1273		|O
drug	1274	1278		|O
design	1279	1285		|O
.	1285	1286		|O
ADAMTS	1287	1293		|O
-	1293	1294		|O
4	1294	1295		|O
and	1296	1299		|O
ADAMTS	1300	1306		|O
-	1306	1307		|O
5	1307	1308		|O
are	1309	1312		|O
appropriate	1313	1324		|O
targets	1325	1332		|O
for	1333	1336		|O
OA	1337	1339	OA	|B-DISEASE
therapies	1340	1349		|O
,	1349	1350		|O
but	1351	1354		|O
ultimately	1355	1365		|O
,	1365	1366		|O
inhibitors	1367	1377		|O
of	1378	1380		|O
these	1381	1386		|O
enzymes	1387	1394		|O
will	1395	1399		|O
form	1400	1404		|O
only	1405	1409		|O
part	1410	1414		|O
of	1415	1417		|O
a	1418	1419		|O
larger	1420	1426		|O
arsenal	1427	1434		|O
of	1435	1437		|O
therapies	1438	1447		|O
.	1447	1448		|O

### 18570172
Intravenous	0	11		|O
fat	12	15		|O
emulsion	16	24		|O
:	24	25		|O
a	26	27		|O
potential	28	37		|O
novel	38	43		|O
antidote	44	52		|O
.	52	53		|O
Intravenous	55	66		|O
fat	67	70		|O
emulsions	71	80		|O
(	81	82		|O
IFE	82	85		|O
)	85	86		|O
are	87	90		|O
traditionally	91	104		|O
used	105	109		|O
as	110	112		|O
a	113	114		|O
component	115	124		|O
of	125	127		|O
parenteral	128	138		|O
nutrition	139	148		|O
therapy	149	156		|O
.	156	157		|O
Recently	158	166		|O
,	166	167		|O
IFE	168	171		|O
was	172	175		|O
used	176	180		|O
to	181	183		|O
resuscitate	184	195		|O
severe	196	202		|O
local	203	208	local anesthetic drug toxicity	|B-ADVERSE
anesthetic	209	219		|I-ADVERSE
drug	220	224		|I-ADVERSE
toxicity	225	233		|I-ADVERSE
.	233	234		|O
This	235	239		|O
review	240	246		|O
focuses	247	254		|O
on	255	257		|O
the	258	261		|O
potential	262	271		|O
role	272	276		|O
of	277	279		|O
IFE	280	283		|O
in	284	286		|O
treatment	287	296		|O
of	297	299		|O
toxicity	300	308		|O
due	309	312		|O
to	313	315		|O
local	316	321		|O
anesthetics	322	333		|O
and	334	337		|O
other	338	343		|O
lipid	344	349		|O
-	349	350		|O
soluble	350	357		|O
drugs	358	363		|O
.	363	364		|O
The	365	368		|O
general	369	376		|O
properties	377	387		|O
of	388	390		|O
IFE	391	394		|O
,	394	395		|O
metabolic	396	405		|O
fate	406	410		|O
,	410	411		|O
and	412	415		|O
associated	416	426		|O
adverse	427	434		|O
events	435	441		|O
are	442	445		|O
described	446	455		|O
.	455	456		|O
Cases	457	462		|O
of	463	465		|O
local	466	471	local anesthetic toxicity	|B-ADVERSE
anesthetic	472	482		|I-ADVERSE
toxicity	483	491		|I-ADVERSE
treated	492	499		|O
with	500	504		|O
IFE	505	508		|O
are	509	512		|O
presented	513	522		|O
along	523	528		|O
with	529	533		|O
a	534	535		|O
discussion	536	546		|O
of	547	549		|O
the	550	553		|O
possible	554	562		|O
antidotal	563	572		|O
mechanisms	573	583		|O
.	583	584		|O
Initial	585	592		|O
investigations	593	607		|O
into	608	612		|O
the	613	616		|O
antidotal	617	626		|O
use	627	630		|O
of	631	633		|O
IFE	634	637		|O
for	638	641		|O
lipophilic	642	652		|O
central	653	660		|O
nervous	661	668		|O
and	669	672		|O
cardiovascular	673	687	cardiovascular drug toxicity	|B-ADVERSE
drug	688	692		|I-ADVERSE
toxicity	693	701		|I-ADVERSE
are	702	705		|O
also	706	710		|O
reviewed	711	719		|O
.	719	720		|O

### 18565883
Phase	0	5		|O
I	6	7		|O
/	7	8		|O
II	8	10		|O
study	11	16		|O
of	17	19		|O
biweekly	20	28		|O
paclitaxel	29	39		|O
and	40	43		|O
radiation	44	53		|O
in	54	56		|O
androgen	57	65		|O
-	65	66		|O
ablated	66	73		|O
locally	74	81		|O
advanced	82	90		|O
prostate	91	99	prostate cancer	|B-DISEASE
cancer	100	106		|I-DISEASE
.	106	107		|O
PURPOSE	109	116		|O
:	116	117		|O
To	118	120		|O
determine	121	130		|O
the	131	134		|O
maximum	135	142		|O
-	142	143		|O
tolerated	143	152		|O
dose	153	157		|O
(	158	159		|O
MTD	159	162		|O
)	162	163		|O
of	164	166		|O
concurrent	167	177		|O
paclitaxel	178	188		|O
and	189	192		|O
radiation	193	202		|O
therapy	203	210		|O
(	211	212		|O
RT	212	214		|O
)	214	215		|O
in	216	218		|O
patients	219	227		|O
with	228	232		|O
locally	233	240		|O
advanced	241	249		|O
prostate	250	258	prostate cancer	|B-DISEASE
cancer	259	265		|I-DISEASE
.	265	266		|O
MATERIALS	267	276		|O
AND	277	280		|O
METHODS	281	288		|O
:	288	289		|O
Eligible	290	298		|O
patients	299	307		|O
had	308	311		|O
T2	312	314		|O
-	314	315		|O
4	315	316		|O
tumors	317	323	tumors	|B-DISEASE
with	324	328		|O
Gleason	329	336		|O
scores	337	343		|O
greater	344	351		|O
than	352	356		|O
7	357	358		|O
and	359	362		|O
/	362	363		|O
or	363	365		|O
PSA	366	369		|O
levels	370	376		|O
greater	377	384		|O
than	385	389		|O
10	390	392		|O
ng	393	395		|O
/	395	396		|O
mL	396	398		|O
and	399	402		|O
/	402	403		|O
or	403	405		|O
had	406	409		|O
tumors	410	416	tumors	|B-DISEASE
with	417	421		|O
pathologic	422	432		|O
stage	433	438		|O
TxN1	439	443		|O
.	443	444		|O
Hormonal	445	453		|O
ablation	454	462		|O
was	463	466		|O
initiated	467	476		|O
3	477	478		|O
months	479	485		|O
before	486	492		|O
RT	493	495		|O
and	496	499		|O
was	500	503		|O
given	504	509		|O
for	510	513		|O
9	514	515		|O
months	516	522		|O
.	522	523		|O
RT	524	526		|O
was	527	530		|O
delivered	531	540		|O
daily	541	546		|O
(	547	548		|O
1.8	548	551		|O
Gy	552	554		|O
)	554	555		|O
with	556	560		|O
concurrent	561	571		|O
twice	572	577		|O
-	577	578		|O
weekly	578	584		|O
paclitaxel	585	595		|O
(	596	597		|O
30	597	599		|O
mg	600	602		|O
/	602	603		|O
m	603	604		|O
(	604	605		|O
2	605	606		|O
)	606	607		|O
)	607	608		|O
.	608	609		|O
The	610	613		|O
whole	614	619		|O
pelvis	620	626		|O
was	627	630		|O
irradiated	631	641		|O
to	642	644		|O
39.6	645	649		|O
Gy	650	652		|O
.	652	653		|O
The	654	657		|O
radiation	658	667		|O
dose	668	672		|O
was	673	676		|O
escalated	677	686		|O
as	687	689		|O
follows	690	697		|O
:	697	698		|O
63	699	701		|O
Gy	702	704		|O
,	704	705		|O
66.6	706	710		|O
Gy	711	713		|O
,	713	714		|O
70.2	715	719		|O
Gy	720	722		|O
,	722	723		|O
and	724	727		|O
73.8	728	732		|O
Gy	733	735		|O
.	735	736		|O
The	737	740		|O
last	741	745		|O
RT	746	748		|O
dose	749	753		|O
level	754	759		|O
was	760	763		|O
fixed	764	769		|O
at	770	772		|O
73.8	773	777		|O
Gy	778	780		|O
.	780	781		|O
RESULTs	782	789		|O
:	789	790		|O
Between	791	798		|O
January	799	806		|O
2000	807	811		|O
and	812	815		|O
October	816	823		|O
2006	824	828		|O
,	828	829		|O
22	830	832		|O
patients	833	841		|O
were	842	846		|O
enrolled	847	855		|O
.	855	856		|O
The	857	860		|O
median	861	867		|O
age	868	871		|O
was	872	875		|O
59	876	878		|O
years	879	884		|O
(	885	886		|O
range	886	891		|O
,	891	892		|O
48	893	895		|O
to	896	898		|O
72	899	901		|O
years	902	907		|O
)	907	908		|O
;	908	909		|O
the	910	913		|O
median	914	920		|O
PSA	921	924		|O
level	925	930		|O
was	931	934		|O
22.4	935	939		|O
ng	940	942		|O
/	942	943		|O
mL	943	945		|O
(	946	947		|O
range	947	952		|O
,	952	953		|O
2.8	954	957		|O
to	958	960		|O
113	961	964		|O
ng	965	967		|O
/	967	968		|O
mL	968	970		|O
)	970	971		|O
.	971	972		|O
The	973	976		|O
number	977	983		|O
of	984	986		|O
patients	987	995		|O
per	996	999		|O
stage	1000	1005		|O
was	1006	1009		|O
as	1010	1012		|O
follows	1013	1020		|O
:	1020	1021		|O
three	1022	1027		|O
with	1028	1032		|O
T1	1033	1035		|O
,	1035	1036		|O
eight	1037	1042		|O
with	1043	1047		|O
T2	1048	1050		|O
,	1050	1051		|O
11	1052	1054		|O
with	1055	1059		|O
T3	1060	1062		|O
,	1062	1063		|O
and	1064	1067		|O
five	1068	1072		|O
with	1073	1077		|O
pN1	1078	1081		|O
=	1082	1083		|O
5	1084	1085		|O
.	1085	1086		|O
No	1087	1089		|O
grade	1090	1095		|O
3	1096	1097		|O
toxicities	1098	1108		|O
occurred	1109	1117		|O
at	1118	1120		|O
63	1121	1123		|O
Gy	1124	1126		|O
.	1126	1127		|O
Grade	1128	1133		|O
3	1134	1135		|O
diarrhea	1136	1144	diarrhea	|B-ADVERSE
occurred	1145	1153		|O
in	1154	1156		|O
three	1157	1162		|O
patients	1163	1171		|O
at	1172	1174		|O
66.6	1175	1179		|O
Gy	1180	1182		|O
.	1182	1183		|O
The	1184	1187		|O
protocol	1188	1196		|O
then	1197	1201		|O
was	1202	1205		|O
amended	1206	1213		|O
to	1214	1216		|O
treat	1217	1222		|O
the	1223	1226		|O
prostate	1227	1235		|O
volume	1236	1242		|O
first	1243	1248		|O
followed	1249	1257		|O
by	1258	1260		|O
the	1261	1264		|O
whole	1265	1270		|O
pelvis	1271	1277		|O
.	1277	1278		|O
No	1279	1281		|O
grade	1282	1287		|O
3	1288	1289		|O
toxicities	1290	1300		|O
were	1301	1305		|O
observed	1306	1314		|O
at	1315	1317		|O
70.2	1318	1322		|O
Gy	1323	1325		|O
.	1325	1326		|O
One	1327	1330		|O
patient	1331	1338		|O
experienced	1339	1350		|O
grade	1351	1356		|O
3	1357	1358		|O
diarrhea	1359	1367	diarrhea	|B-ADVERSE
at	1368	1370		|O
73.8	1371	1375		|O
Gy	1376	1378		|O
.	1378	1379		|O
Five	1380	1384		|O
additional	1385	1395		|O
patients	1396	1404		|O
were	1405	1409		|O
treated	1410	1417		|O
to	1418	1420		|O
73.8	1421	1425		|O
Gy	1426	1428		|O
without	1429	1436		|O
grade	1437	1442		|O
3	1443	1444		|O
toxicity	1445	1453		|O
,	1453	1454		|O
which	1455	1460		|O
established	1461	1472		|O
the	1473	1476		|O
MTD	1477	1480		|O
for	1481	1484		|O
combined	1485	1493		|O
paclitaxel	1494	1504		|O
and	1505	1508		|O
RT	1509	1511		|O
at	1512	1514		|O
73.8	1515	1519		|O
Gy	1520	1522		|O
.	1522	1523		|O
At	1524	1526		|O
38	1527	1529		|O
months	1530	1536		|O
median	1537	1543		|O
follow	1544	1550		|O
-	1550	1551		|O
up	1551	1553		|O
(	1554	1555		|O
range	1555	1560		|O
,	1560	1561		|O
9	1562	1563		|O
to	1564	1566		|O
87	1567	1569		|O
months	1570	1576		|O
)	1576	1577		|O
,	1577	1578		|O
21	1579	1581		|O
(	1582	1583		|O
95%	1583	1586		|O
)	1586	1587		|O
of	1588	1590		|O
22	1591	1593		|O
patients	1594	1602		|O
are	1603	1606		|O
alive	1607	1612		|O
.	1612	1613		|O
Six	1614	1617		|O
(	1618	1619		|O
27%	1619	1622		|O
)	1622	1623		|O
of	1624	1626		|O
22	1627	1629		|O
experienced	1630	1641		|O
recurrence	1642	1652		|O
.	1652	1653		|O
CONCLUSION	1654	1664		|O
:	1664	1665		|O
Concurrent	1666	1676		|O
biweekly	1677	1685		|O
paclitaxel	1686	1696		|O
with	1697	1701		|O
RT	1702	1704		|O
is	1705	1707		|O
feasible	1708	1716		|O
,	1716	1717		|O
with	1718	1722		|O
an	1723	1725		|O
MTD	1726	1729		|O
of	1730	1732		|O
73.8	1733	1737		|O
Gy	1738	1740		|O
.	1740	1741		|O
Recovery	1742	1750		|O
of	1751	1753		|O
gonadal	1754	1761		|O
function	1762	1770		|O
occurs	1771	1777		|O
in	1778	1780		|O
the	1781	1784		|O
majority	1785	1793		|O
of	1794	1796		|O
patients	1797	1805		|O
.	1805	1806		|O
These	1807	1812		|O
results	1813	1820		|O
encourage	1821	1830		|O
testing	1831	1838		|O
in	1839	1841		|O
a	1842	1843		|O
phase	1844	1849		|O
III	1850	1853		|O
setting	1854	1861		|O
.	1861	1862		|O

### 18477617
Prolactin	0	9		|O
and	10	13		|O
dopamine	14	22		|O
:	22	23		|O
what	24	28		|O
is	29	31		|O
the	32	35		|O
connection	36	46		|O
?	46	47		|O
A	48	49		|O
review	50	56		|O
article	57	64		|O
.	64	65		|O
Dopamine	67	75		|O
(	76	77		|O
DA	77	79		|O
)	79	80		|O
holds	81	86		|O
a	87	88		|O
predominant	89	100		|O
role	101	105		|O
in	106	108		|O
the	109	112		|O
regulation	113	123		|O
of	124	126		|O
prolactin	127	136		|O
(	137	138		|O
PRL	138	141		|O
)	141	142		|O
secretion	143	152		|O
.	152	153		|O
Through	154	161		|O
a	162	163		|O
direct	164	170		|O
effect	171	177		|O
on	178	180		|O
anterior	181	189		|O
pituitary	190	199		|O
lactotrophs	200	211		|O
,	211	212		|O
DA	213	215		|O
inhibits	216	224		|O
the	225	228		|O
basally	229	236		|O
high	237	241		|O
-	241	242		|O
secretory	242	251		|O
tone	252	256		|O
of	257	259		|O
the	260	263		|O
cell	264	268		|O
.	268	269		|O
It	270	272		|O
accomplishes	273	285		|O
this	286	290		|O
by	291	293		|O
binding	294	301		|O
to	302	304		|O
D2	305	307		|O
receptors	308	317		|O
expressed	318	327		|O
on	328	330		|O
the	331	334		|O
cell	335	339		|O
membrane	340	348		|O
of	349	351		|O
the	352	355		|O
lactotroph	356	366		|O
,	366	367		|O
activation	368	378		|O
of	379	381		|O
which	382	387		|O
results	388	395		|O
in	396	398		|O
a	399	400		|O
reduction	401	410		|O
of	411	413		|O
PRL	414	417		|O
exocytosis	418	428		|O
and	429	432		|O
gene	433	437		|O
expression	438	448		|O
by	449	451		|O
a	452	453		|O
variety	454	461		|O
of	462	464		|O
intracellular	465	478		|O
signalling	479	489		|O
mechanisms	490	500		|O
.	500	501		|O
The	502	505		|O
hypothalamic	506	518		|O
dopaminergic	519	531		|O
neurons	532	539		|O
,	539	540		|O
which	541	546		|O
provide	547	554		|O
DA	555	557		|O
to	558	560		|O
the	561	564		|O
anterior	565	573		|O
pituitary	574	583		|O
gland	584	589		|O
,	589	590		|O
are	591	594		|O
themselves	595	605		|O
regulated	606	615		|O
by	616	618		|O
feedback	619	627		|O
from	628	632		|O
PRL	633	636		|O
through	637	644		|O
a	645	646		|O
's	647	649		|O
hort	649	653		|O
-	653	654		|O
loop	654	658		|O
feedback	659	667		|O
mechanism	668	677		|O
'	677	678		|O
.	678	679		|O
A	680	681		|O
variety	682	689		|O
of	690	692		|O
other	693	698		|O
modulators	699	709		|O
of	710	712		|O
prolactin	713	722		|O
secretion	723	732		|O
act	733	736		|O
at	737	739		|O
the	740	743		|O
hypothalamic	744	756		|O
level	757	762		|O
by	763	765		|O
either	766	772		|O
disinhibition	773	786		|O
of	787	789		|O
the	790	793		|O
dopaminergic	794	806		|O
tone	807	811		|O
(	812	813		|O
e.g.	813	817		|O
serotonin	818	827		|O
,	827	828		|O
GABA	829	833		|O
,	833	834		|O
oestrogens	835	845		|O
and	846	849		|O
opioids	850	857		|O
)	857	858		|O
or	859	861		|O
by	862	864		|O
reinforcing	865	876		|O
it	877	879		|O
(	880	881		|O
e.g.	881	885		|O
substance	886	895		|O
P	896	897		|O
)	897	898		|O
.	898	899		|O
All	900	903		|O
typical	904	911		|O
antipsychotic	912	925		|O
medications	926	937		|O
are	938	941		|O
associated	942	952		|O
with	953	957		|O
sustained	958	967	sustained hyperprolactinaemia	|B-ADVERSE
hyperprolactinaemia	968	987		|I-ADVERSE
due	988	991		|O
to	992	994		|O
their	995	1000		|O
high	1001	1005		|O
affinity	1006	1014		|O
for	1015	1018		|O
the	1019	1022		|O
D2	1023	1025		|O
receptor	1026	1034		|O
and	1035	1038		|O
their	1039	1044		|O
slow	1045	1049		|O
dissociation	1050	1062		|O
from	1063	1067		|O
the	1068	1071		|O
receptor	1072	1080		|O
once	1081	1085		|O
bound	1086	1091		|O
,	1091	1092		|O
but	1093	1096		|O
atypicals	1097	1106		|O
differ	1107	1113		|O
quite	1114	1119		|O
dramatically	1120	1132		|O
in	1133	1135		|O
their	1136	1141		|O
propensity	1142	1152		|O
to	1153	1155		|O
cause	1156	1161		|O
prolonged	1162	1171		|O
high	1172	1176		|O
prolactin	1177	1186		|O
levels	1187	1193		|O
.	1193	1194		|O
Of	1195	1197		|O
those	1198	1203		|O
atypicals	1204	1213		|O
that	1214	1218		|O
are	1219	1222		|O
associated	1223	1233		|O
with	1234	1238		|O
prolactin	1239	1248		|O
elevation	1249	1258		|O
,	1258	1259		|O
the	1260	1263		|O
main	1264	1268		|O
causative	1269	1278		|O
factor	1279	1285		|O
appears	1286	1293		|O
to	1294	1296		|O
be	1297	1299		|O
a	1300	1301		|O
higher	1302	1308		|O
peripheral	1309	1319		|O
-	1319	1320		|O
to	1320	1322		|O
-	1322	1323		|O
central	1323	1330		|O
dopamine	1331	1339		|O
receptor	1340	1348		|O
potency	1349	1356		|O
of	1357	1359		|O
either	1360	1366		|O
the	1367	1370		|O
parent	1371	1377		|O
drug	1378	1382		|O
or	1383	1385		|O
its	1386	1389		|O
active	1390	1396		|O
metabolite	1397	1407		|O
(	1408	1409		|O
e.g.	1409	1413		|O
risperidone	1414	1425		|O
,	1425	1426		|O
9	1427	1428		|O
-	1428	1429		|O
hydroxy	1429	1436		|O
-	1436	1437		|O
risperidone	1437	1448		|O
and	1449	1452		|O
amisulpride	1453	1464		|O
)	1464	1465		|O
.	1465	1466		|O
Antipsychotics	1467	1481		|O
that	1482	1486		|O
easily	1487	1493		|O
cross	1494	1499		|O
the	1500	1503		|O
blood	1504	1509		|O
-	1509	1510		|O
brain	1510	1515		|O
barrier	1516	1523		|O
and	1524	1527		|O
exhibit	1528	1535		|O
fast	1536	1540		|O
dissociation	1541	1553		|O
from	1554	1558		|O
the	1559	1562		|O
dopamine	1563	1571		|O
receptor	1572	1580		|O
once	1581	1585		|O
bound	1586	1591		|O
do	1592	1594		|O
not	1595	1598		|O
result	1599	1605		|O
in	1606	1608		|O
sustained	1609	1618	sustained hyperprolactinaemia	|B-ADVERSE
hyperprolactinaemia	1619	1638		|I-ADVERSE
.	1638	1639		|O

### 18633129
Dietary	0	7		|O
flavonoids	8	18		|O
inhibit	19	26		|O
the	27	30		|O
anticancer	31	41		|O
effects	42	49		|O
of	50	52		|O
the	53	56		|O
proteasome	57	67		|O
inhibitor	68	77		|O
bortezomib	78	88		|O
.	88	89		|O
Dietary	91	98		|O
flavonoids	99	109		|O
have	110	114		|O
many	115	119		|O
health	120	126		|O
-	126	127		|O
promoting	127	136		|O
actions	137	144		|O
,	144	145		|O
including	146	155		|O
anticancer	156	166		|O
activity	167	175		|O
via	176	179		|O
proteasome	180	190		|O
inhibition	191	201		|O
.	201	202		|O
Bor	203	206		|O
-	206	207		|O
tezomib	207	214		|O
is	215	217		|O
a	218	219		|O
dipeptide	220	229		|O
boronate	230	238		|O
proteasome	239	249		|O
inhibitor	250	259		|O
that	260	264		|O
has	265	268		|O
activity	269	277		|O
in	278	280		|O
the	281	284		|O
treatment	285	294		|O
of	295	297		|O
multiple	298	306	multiple myeloma	|B-DISEASE
myeloma	307	314		|I-DISEASE
but	315	318		|O
is	319	321		|O
not	322	325		|O
effective	326	335		|O
in	336	338		|O
chronic	339	346	chronic lymphocytic leukemia	|B-DISEASE
lymphocytic	347	358		|I-DISEASE
leukemia	359	367		|I-DISEASE
(	368	369		|O
CLL	369	372	CLL	|B-DISEASE
)	372	373		|O
.	373	374		|O
Although	375	383		|O
CLL	384	387	CLL	|B-DISEASE
cells	388	393		|O
are	394	397		|O
sensitive	398	407		|O
in	408	410		|O
vitro	411	416		|O
to	417	419		|O
bortezomib	420	430		|O
-	430	431		|O
induced	431	438		|O
apoptosis	439	448	apoptosis	|B-DISEASE
when	449	453		|O
cultured	454	462		|O
in	463	465		|O
medium	466	472		|O
,	472	473		|O
the	474	477		|O
killing	478	485		|O
activity	486	494		|O
was	495	498		|O
blocked	499	506		|O
when	507	511		|O
cultured	512	520		|O
in	521	523		|O
50%	524	527		|O
fresh	528	533		|O
autologous	534	544		|O
plasma	545	551		|O
.	551	552		|O
Dietary	553	560		|O
flavonoids	561	571		|O
,	571	572		|O
quercetin	573	582		|O
and	583	586		|O
myricetin	587	596		|O
,	596	597		|O
which	598	603		|O
are	604	607		|O
abundant	608	616		|O
in	617	619		|O
plasma	620	626		|O
,	626	627		|O
inhibited	628	637		|O
bortezomib	638	648		|O
-	648	649		|O
induced	649	656		|O
apoptosis	657	666	apoptosis	|B-DISEASE
of	667	669		|O
primary	670	677		|O
CLL	678	681	CLL	|B-DISEASE
and	682	685		|O
malignant	686	695		|O
B	696	697		|O
-	697	698		|O
cell	698	702		|O
lines	703	708		|O
in	709	711		|O
a	712	713		|O
dose	714	718		|O
-	718	719		|O
dependent	719	728		|O
manner	729	735		|O
.	735	736		|O
This	737	741		|O
inhibitory	742	752		|O
effect	753	759		|O
was	760	763		|O
associated	764	774		|O
with	775	779		|O
chemical	780	788		|O
reactions	789	798		|O
between	799	806		|O
quercetin	807	816		|O
and	817	820		|O
the	821	824		|O
boronic	825	832		|O
acid	833	837		|O
group	838	843		|O
,	843	844		|O
-	845	846		|O
RB	846	848		|O
(	848	849		|O
OH	849	851		|O
)	851	852		|O
2	852	853		|O
,	853	854		|O
in	855	857		|O
bortezomib	858	868		|O
.	868	869		|O
The	870	873		|O
addition	874	882		|O
of	883	885		|O
boric	886	891		|O
acid	892	896		|O
diminished	897	907		|O
the	908	911		|O
inhibitory	912	922		|O
effect	923	929		|O
of	930	932		|O
both	933	937		|O
quercetin	938	947		|O
and	948	951		|O
plasma	952	958		|O
on	959	961		|O
bortezomib	962	972		|O
-	972	973		|O
induced	973	980		|O
apoptosis	981	990	apoptosis	|B-DISEASE
.	990	991		|O
The	992	995		|O
protective	996	1006		|O
effect	1007	1013		|O
was	1014	1017		|O
also	1018	1022		|O
reduced	1023	1030		|O
when	1031	1035		|O
myeloma	1036	1043	myeloma	|B-DISEASE
cell	1044	1048		|O
lines	1049	1054		|O
,	1054	1055		|O
but	1056	1059		|O
not	1060	1063		|O
B	1064	1065		|O
-	1065	1066		|O
cell	1066	1070		|O
lines	1071	1076		|O
,	1076	1077		|O
were	1078	1082		|O
preincubated	1083	1095		|O
with	1096	1100		|O
quercetin	1101	1110		|O
,	1110	1111		|O
indicating	1112	1122		|O
a	1123	1124		|O
direct	1125	1131		|O
effect	1132	1138		|O
of	1139	1141		|O
quercetin	1142	1151		|O
on	1152	1154		|O
myeloma	1155	1162	myeloma	|B-DISEASE
cells	1163	1168		|O
.	1168	1169		|O
At	1170	1172		|O
high	1173	1177		|O
doses	1178	1183		|O
,	1183	1184		|O
quercetin	1185	1194		|O
itself	1195	1201		|O
induced	1202	1209		|O
tumor	1210	1215		|O
cell	1216	1220	cell death	|B-DISEASE
death	1221	1226		|I-DISEASE
.	1226	1227		|O
These	1228	1233		|O
data	1234	1238		|O
indicate	1239	1247		|O
that	1248	1252		|O
dietary	1253	1260		|O
flavonoids	1261	1271		|O
limit	1272	1277		|O
the	1278	1281		|O
efficacy	1282	1290		|O
of	1291	1293		|O
bortezomib	1294	1304		|O
,	1304	1305		|O
whereas	1306	1313		|O
supplemental	1314	1326		|O
inorganic	1327	1336		|O
boric	1337	1342		|O
acid	1343	1347		|O
is	1348	1350		|O
able	1351	1355		|O
to	1356	1358		|O
reverse	1359	1366		|O
this	1367	1371		|O
.	1371	1372		|O
The	1373	1376		|O
complex	1377	1384		|O
interactions	1385	1397		|O
between	1398	1405		|O
quercetin	1406	1415		|O
,	1415	1416		|O
tumor	1417	1422		|O
cells	1423	1428		|O
,	1428	1429		|O
and	1430	1433		|O
bortezomib	1434	1444		|O
mean	1445	1449		|O
caution	1450	1457		|O
is	1458	1460		|O
required	1461	1469		|O
when	1470	1474		|O
giving	1475	1481		|O
dietary	1482	1489		|O
advice	1490	1496		|O
to	1497	1499		|O
patients	1500	1508		|O
.	1508	1509		|O

### 18598753
Paternal	0	8		|O
exposure	9	17		|O
and	18	21		|O
counselling	22	33		|O
:	33	34		|O
experience	35	45		|O
of	46	48		|O
a	49	50		|O
Teratology	51	61		|O
Information	62	73		|O
Service	74	81		|O
.	81	82		|O
We	84	86		|O
describe	87	95		|O
paternal	96	104		|O
exposure	105	113		|O
and	114	117		|O
counselling	118	129		|O
in	130	132		|O
a	133	134		|O
selected	135	143		|O
population	144	154		|O
calling	155	162		|O
to	163	165		|O
an	166	168		|O
Italian	169	176		|O
Teratology	177	187		|O
Information	188	199		|O
Service	200	207		|O
(	208	209		|O
TIS	209	212		|O
)	212	213		|O
.	213	214		|O
The	215	218		|O
majority	219	227		|O
of	228	230		|O
callers	231	238		|O
asked	239	244		|O
for	245	248		|O
paternal	249	257		|O
drug	258	262		|O
exposure	263	271		|O
(	272	273		|O
76%	273	276		|O
,	276	277		|O
drugs	278	283		|O
except	284	290		|O
chemotherapy	291	303		|O
)	303	304		|O
and	305	308		|O
treatment	309	318		|O
for	319	322		|O
cancer	323	329	cancer	|B-DISEASE
(	330	331		|O
17%	331	334		|O
,	334	335		|O
chemotherapy	336	348		|O
and	349	352		|O
/	352	353		|O
or	353	355		|O
radiotherapy	356	368		|O
)	368	369		|O
.	369	370		|O
Others	371	377		|O
asked	378	383		|O
for	384	387		|O
exposure	388	396		|O
to	397	399		|O
diagnostic	400	410		|O
radiations	411	421		|O
(	422	423		|O
4%	423	425		|O
)	425	426		|O
,	426	427		|O
recreational	428	440		|O
drugs	441	446		|O
(	447	448		|O
2%	448	450		|O
)	450	451		|O
and	452	455		|O
occupational	456	468		|O
chemicals	469	478		|O
(	479	480		|O
1%	480	482		|O
)	482	483		|O
.	483	484		|O
Among	485	490		|O
paternal	491	499		|O
drugs	500	505		|O
neurological	506	518		|O
compounds	519	528		|O
,	528	529		|O
immunosuppressive	530	547		|O
drugs	548	553		|O
and	554	557		|O
antiviral	558	567		|O
agents	568	574		|O
were	575	579		|O
the	580	583		|O
main	584	588		|O
reasons	589	596		|O
for	597	600		|O
calling	601	608		|O
.	608	609		|O
In	610	612		|O
humans	613	619		|O
,	619	620		|O
there	621	626		|O
are	627	630		|O
no	631	633		|O
evidences	634	643		|O
of	644	646		|O
birth	647	652	birth defects	|B-ADVERSE
defects	653	660		|I-ADVERSE
after	661	666		|O
paternal	667	675		|O
exposures	676	685		|O
,	685	686		|O
but	687	690		|O
to	691	693		|O
minimize	694	702		|O
any	703	706		|O
possible	707	715		|O
risk	716	720		|O
,	720	721		|O
counselling	722	733		|O
in	734	736		|O
men	737	740		|O
exposed	741	748		|O
to	749	751		|O
radio	752	757		|O
and	758	761		|O
chemotherapy	762	774		|O
should	775	781		|O
recommend	782	791		|O
delaying	792	800		|O
conception	801	811		|O
for	812	815		|O
at	816	818		|O
least	819	824		|O
3	825	826		|O
months	827	833		|O
after	834	839		|O
the	840	843		|O
end	844	847		|O
of	848	850		|O
the	851	854		|O
therapy	855	862		|O
.	862	863		|O
Male	864	868		|O
patients	869	877		|O
treated	878	885		|O
with	886	890		|O
drugs	891	896		|O
,	896	897		|O
whose	898	903		|O
teratogenic	904	915		|O
potential	916	925		|O
has	926	929		|O
been	930	934		|O
well	935	939		|O
assessed	940	948		|O
or	949	951		|O
suspected	952	961		|O
for	962	965		|O
maternal	966	974		|O
exposure	975	983		|O
,	983	984		|O
should	985	991		|O
be	992	994		|O
advised	995	1002		|O
to	1003	1005		|O
practice	1006	1014		|O
effective	1015	1024		|O
birth	1025	1030		|O
control	1031	1038		|O
during	1039	1045		|O
therapy	1046	1053		|O
and	1054	1057		|O
up	1058	1060		|O
to	1061	1063		|O
one	1064	1067		|O
or	1068	1070		|O
two	1071	1074		|O
cycles	1075	1081		|O
of	1082	1084		|O
spermatogenesis	1085	1100		|O
and	1101	1104		|O
to	1105	1107		|O
avoid	1108	1113		|O
semen	1114	1119		|O
contact	1120	1127		|O
with	1128	1132		|O
vaginal	1133	1140		|O
walls	1141	1146		|O
during	1147	1153		|O
first	1154	1159		|O
trimester	1160	1169		|O
of	1170	1172		|O
pregnancy	1173	1182		|O
.	1182	1183		|O

### 18608299
Iatrogenic	0	10		|O
intravenous	11	22		|O
medication	23	33		|O
errors	34	40		|O
reported	41	49		|O
to	50	52		|O
the	53	56		|O
PIC	57	60		|O
Erfurt	61	67		|O
.	67	68		|O
BACKGROUND	70	80		|O
:	80	81		|O
We	82	84		|O
investigated	85	97		|O
the	98	101		|O
iatrogenic	102	112		|O
intravenous	113	124		|O
medication	125	135		|O
errors	136	142		|O
(	143	144		|O
IIME	144	148		|O
)	148	149		|O
reported	150	158		|O
to	159	161		|O
the	162	165		|O
Poisons	166	173		|O
Information	174	185		|O
Center	186	192		|O
(	193	194		|O
PIC	194	197		|O
)	197	198		|O
Erfurt	199	205		|O
.	205	206		|O
METHODS	207	214		|O
:	214	215		|O
All	216	219		|O
IIME	220	224		|O
over	225	229		|O
a	230	231		|O
ten	232	235		|O
year	236	240		|O
period	241	247		|O
were	248	252		|O
analyzed	253	261		|O
retrospectively	262	277		|O
and	278	281		|O
categorized	282	293		|O
into	294	298		|O
error	299	304		|O
types	305	310		|O
,	310	311		|O
age	312	315		|O
groups	316	322		|O
,	322	323		|O
drugs	324	329		|O
involved	330	338		|O
,	338	339		|O
and	340	343		|O
estimated	344	353		|O
risk	354	358		|O
of	359	361		|O
toxicity	362	370		|O
.	370	371		|O
RESULTS	372	379		|O
:	379	380		|O
From	381	385		|O
1997	386	390		|O
to	391	393		|O
2006	394	398		|O
the	399	402		|O
PIC	403	406		|O
Erfurt	407	413		|O
registered	414	424		|O
132	425	428		|O
cases	429	434		|O
of	435	437		|O
IIME	438	442		|O
.	442	443		|O
They	444	448		|O
increased	449	458		|O
from	459	463		|O
7	464	465		|O
in	466	468		|O
1997	469	473		|O
to	474	476		|O
31	477	479		|O
in	480	482		|O
2006	483	487		|O
.	487	488		|O
Children	489	497		|O
accounted	498	507		|O
for	508	511		|O
31.1%	512	517		|O
of	518	520		|O
the	521	524		|O
patients	525	533		|O
affected	534	542		|O
and	543	546		|O
adults	547	553		|O
for	554	557		|O
68.9%	558	563		|O
.	563	564		|O
The	565	568		|O
drug	569	573		|O
classes	574	581		|O
(	582	583		|O
ATC	583	586		|O
classification	587	601		|O
)	601	602		|O
involved	603	611		|O
most	612	616		|O
frequently	617	627		|O
were	628	632		|O
antipsychotics	633	647		|O
(	648	649		|O
9.8%	649	653		|O
)	653	654		|O
and	655	658		|O
antihistamines	659	673		|O
for	674	677		|O
systemic	678	686		|O
use	687	690		|O
(	691	692		|O
7.5%	692	696		|O
)	696	697		|O
.	697	698		|O
The	699	702		|O
main	703	707		|O
types	708	713		|O
of	714	716		|O
IIME	717	721		|O
were	722	726		|O
overdose	727	735		|O
(	736	737		|O
53.1%	737	742		|O
)	742	743		|O
and	744	747		|O
incorrect	748	757		|O
route	758	763		|O
of	764	766		|O
administration	767	781		|O
(	782	783		|O
29.7%	783	788		|O
)	788	789		|O
.	789	790		|O
The	791	794		|O
estimated	795	804		|O
risk	805	809		|O
of	810	812		|O
toxicity	813	821		|O
was	822	825		|O
:	825	826		|O
14.4%	827	832		|O
none	833	837		|O
,	837	838		|O
71.2%	839	844		|O
risk	845	849		|O
of	850	852		|O
toxicity	853	861		|O
,	861	862		|O
and	863	866		|O
14.4%	867	872		|O
unpredictable	873	886		|O
risk	887	891		|O
.	891	892		|O
Medical	893	900		|O
treatment	901	910		|O
was	911	914		|O
recommended	915	926		|O
in	927	929		|O
82%	930	933		|O
.	933	934		|O
The	935	938		|O
outcome	939	946		|O
of	947	949		|O
104	950	953		|O
of	954	956		|O
the	957	960		|O
132	961	964		|O
(	965	966		|O
78.8%	966	971		|O
)	971	972		|O
courses	973	980		|O
was	981	984		|O
unknown	985	992		|O
.	992	993		|O
In	994	996		|O
the	997	1000		|O
28	1001	1003		|O
cases	1004	1009		|O
followed	1010	1018		|O
to	1019	1021		|O
a	1022	1023		|O
known	1024	1029		|O
outcome	1030	1037		|O
,	1037	1038		|O
9	1039	1040		|O
(	1041	1042		|O
32%	1042	1045		|O
)	1045	1046		|O
were	1047	1051		|O
asymptomatic	1052	1064		|O
and	1065	1068		|O
19	1069	1071		|O
(	1072	1073		|O
68%	1073	1076		|O
)	1076	1077		|O
symptomatic	1078	1089		|O
with	1090	1094		|O
minor	1095	1100		|O
(	1101	1102		|O
9	1102	1103		|O
cases	1104	1109		|O
)	1109	1110		|O
,	1110	1111		|O
moderate	1112	1120		|O
(	1121	1122		|O
1	1122	1123		|O
case	1124	1128		|O
)	1128	1129		|O
,	1129	1130		|O
and	1131	1134		|O
severe	1135	1141		|O
features	1142	1150		|O
(	1151	1152		|O
6	1152	1153		|O
cases	1154	1159		|O
)	1159	1160		|O
but	1161	1164		|O
mostly	1165	1171		|O
complete	1172	1180		|O
recovery	1181	1189		|O
.	1189	1190		|O
Two	1191	1194		|O
IIME	1195	1199		|O
resulted	1200	1208		|O
in	1209	1211		|O
hypoxia	1212	1219		|O
-	1219	1220		|O
induced	1220	1227		|O
brain	1228	1233	brain damage	|B-ADVERSE
damage	1234	1240		|I-ADVERSE
and	1241	1244		|O
one	1245	1248		|O
in	1249	1251		|O
death	1252	1257		|O
despite	1258	1265		|O
of	1266	1268		|O
resuscitation	1269	1282		|O
.	1282	1283		|O
CONCLUSION	1284	1294		|O
:	1294	1295		|O
Approximately	1296	1309		|O
0.1%	1310	1314		|O
of	1315	1317		|O
all	1318	1321		|O
calls	1322	1327		|O
registered	1328	1338		|O
by	1339	1341		|O
the	1342	1345		|O
PIC	1346	1349		|O
Erfurt	1350	1356		|O
from	1357	1361		|O
1997	1362	1366		|O
to	1367	1369		|O
2006	1370	1374		|O
concerned	1375	1384		|O
IIME	1385	1389		|O
.	1389	1390		|O
Thirty	1391	1397		|O
-	1397	1398		|O
two	1398	1401		|O
percent	1402	1409		|O
of	1410	1412		|O
IIME	1413	1417		|O
followed	1418	1426		|O
to	1427	1429		|O
a	1430	1431		|O
known	1432	1437		|O
outcome	1438	1445		|O
resulted	1446	1454		|O
in	1455	1457		|O
severe	1458	1464		|O
symptoms	1465	1473		|O
.	1473	1474		|O
These	1475	1480		|O
data	1481	1485		|O
show	1486	1490		|O
that	1491	1495		|O
IIME	1496	1500		|O
can	1501	1504		|O
be	1505	1507		|O
harmful	1508	1515		|O
.	1515	1516		|O

